PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lee, SSJ; Appelbaum, PS; Chung, WK				Lee, Sandra Soo-Jin; Appelbaum, Paul S.; Chung, Wendy K.			Challenges and potential solutions to health disparities in genomic medicine	CELL			English	Editorial Material								Significant disparities in the clinical usefulness of genomic information across diverse groups are due to underrepresentation in genetic databases and inequitable access to genetic services. Remedying disparities is immediately needed to ensure that genomic medicine is more equitable but will take a long-term commitment and active engagement of diverse communities.	[Lee, Sandra Soo-Jin] Columbia Univ, Div Eth, Dept Med Human & Eth, New York, NY USA; [Appelbaum, Paul S.] Columbia Univ, Dept Psychiat, New York, NY USA; [Chung, Wendy K.] Columbia Univ, Dept Pediat, New York, NY USA; [Chung, Wendy K.] Columbia Univ, Dept Med, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University	Chung, WK (corresponding author), Columbia Univ, Dept Pediat, New York, NY USA.; Chung, WK (corresponding author), Columbia Univ, Dept Med, New York, NY USA.	wkc15@columbia.edu			National Institutes of Health [R01-HG010365, RM1HG007257, R01-HG010330]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the National Institutes of Health (R01-HG010365, RM1HG007257, R01-HG010330).	AlShebli BK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07634-8; Armstrong K, 2022, NEW ENGL J MED, V386, P203, DOI 10.1056/NEJMp2115621; Bedeker A, 2022, BMJ GLOB HEALTH, V7, DOI 10.1136/bmjgh-2021-008096; Claw KG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05188-3; Collins FS, 2021, CELL, V184, P3075, DOI 10.1016/j.cell.2021.05.014; Garland-Thomson R, 2012, J BIOETHIC INQ, V9, P339, DOI 10.1007/s11673-012-9380-0; Jeske M, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0263750; Lee SSJ, 2019, SCIENCE, V364, P941, DOI 10.1126/science.aaw8299; Richter S, 2013, ANN ONCOL, V24, P69, DOI 10.1093/annonc/mdt312; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048	10	0	0	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2022	185	12					2007	2010		10.1016/j.cell.2022.05.010	http://dx.doi.org/10.1016/j.cell.2022.05.010			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	6L4LP	35688129				2023-01-03	WOS:000888155900001
J	Stephenson, A; Howes, S; Murphy, PJ; Deutsch, JE; Stokes, M; Pedlow, K; McDonough, SM				Stephenson, Aoife; Howes, Sarah; Murphy, Paul J.; Deutsch, Judith E.; Stokes, Maria; Pedlow, Katy; McDonough, Suzanne M.			Factors influencing the delivery of telerehabilitation for stroke: A systematic review	PLOS ONE			English	Review							RANDOMIZED CLINICAL-TRIAL; VIRTUAL-REALITY; PHYSICAL FUNCTION; HEALTH-CARE; INTERVENTION; PROGRAM; REHABILITATION; TELEPHONE; SURVIVORS; BALANCE	Objective Despite the available evidence regarding effectiveness of stroke telerehabilitation, there has been little focus on factors influencing its delivery or translation from the research setting into practice. There are complex challenges to embedding telerehabilitation into stroke services and generating transferable knowledge about scaling up and routinising this service model. This review aimed to explore factors influencing the delivery of stroke telerehabilitation interventions, including platforms, technical requirements, training, support, access, cost, usability and acceptability. Methods MEDLINE, EMBASE, CINAHL, Web of Science and Cochrane Library and Central Registry of Clinical Trials were searched to identify full-text articles of randomised controlled trials (RCTs) and protocols for RCTs published since a Cochrane review on stroke telerehabilitation services. A narrative synthesis was conducted, providing a comprehensive description of the factors influencing stroke telerehabilitation intervention delivery. Results Thirty-one studies and ten protocols of ongoing studies were included. Interventions were categorised as synchronous telerehabilitation (n = 9), asynchronous telerehabilitation (n = 11) and tele-support (n = 11). Telephone and videoconference were the most frequently used modes of delivery. Usability and acceptability with telerehabilitation were high across all platforms, although access issues and technical challenges may be potential barriers to the use of telerehabilitation in service delivery. Costs of intervention delivery and training requirements were poorly reported. Conclusions This review synthesises the evidence relating to factors that may influence stroke telerehabilitation intervention delivery at a crucial timepoint given the rapid deployment of telerehabilitation in response to the COVID-19 pandemic. It recommends strategies, such as ensuring adequate training and technical infrastructure, shared learning and consistent reporting of cost and usability and acceptability outcomes, to overcome challenges in embedding and routinising this service model and priorities for research in this area.	[Stephenson, Aoife; McDonough, Suzanne M.] Royal Coll Surgeons Ireland, Sch Physiotherapy, Dublin, Ireland; [Stephenson, Aoife; Howes, Sarah; Pedlow, Katy; McDonough, Suzanne M.] Ulster Univ, Ctr Hlth & Rehabil Technol, Newtownabbey, North Ireland; [Stephenson, Aoife; Howes, Sarah; McDonough, Suzanne M.] Ulster Univ, Sch Hlth Sci, Newtownabbey, North Ireland; [Murphy, Paul J.] Royal Coll Surgeons Ireland, RCSI Lib, Dublin, Ireland; [Deutsch, Judith E.] Rutgers State Univ, Sch Hlth Profess, Dept Rehabil & Movement Sci, Rivers Lab, New Brunswick, NJ USA; [Stokes, Maria] Univ Southampton, Sch Hlth Sci, Southampton, Hants, England; [Stokes, Maria] Ctr Sport Exercise & Osteoarthrit, Res Versus Arthrit, Chesterfield, England; [McDonough, Suzanne M.] Univ Otago, Sch Physiotherapy, Dunedin, New Zealand	Royal College of Surgeons - Ireland; Ulster University; Ulster University; Royal College of Surgeons - Ireland; Rutgers State University New Brunswick; University of Southampton; University of Otago	Pedlow, K (corresponding author), Ulster Univ, Ctr Hlth & Rehabil Technol, Newtownabbey, North Ireland.	k.pedlow@ulster.ac.uk	; Murphy, Paul/E-2305-2011	Howes, Sarah/0000-0001-9314-5281; Murphy, Paul/0000-0001-5056-1971; McDonough, Suzanne/0000-0003-3758-3302	Royal College of Surgeons in Ireland (School of Physiotherapy); European Union [687228]	Royal College of Surgeons in Ireland (School of Physiotherapy); European Union(European Commission)	AS's time was co-funded by Royal College of Surgeons in Ireland (School of Physiotherapy) and the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 687228, MAGIC PCP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegue DR, 2020, JMIR RES PROTOC, V9, DOI 10.2196/14629; Appleby E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225150; Asano M, 2021, J TELEMED TELECARE, V27, P231, DOI 10.1177/1357633X19868905; Australian Physiotherapy Association, 2020, ANN PERM TEL FUND; Aydin GO, 2015, WORLD CONFERENCE ON TECHNOLOGY, INNOVATION AND ENTREPRENEURSHIP, P1683, DOI 10.1016/j.sbspro.2015.06.252; Bagot KL, 2017, J TELEMED TELECARE, V23, P850, DOI 10.1177/1357633X17734004; Bakhtiar M, 2020, J AM ACAD DERMATOL, V83, pE345, DOI 10.1016/j.jaad.2020.07.043; Bettger JP, 2020, PHYS THER, V100, P1913, DOI 10.1093/ptj/pzaa151; Bishop D, 2014, TOP STROKE REHABIL, V21, pS63, DOI 10.1310/tsr21S1-S63; Blanton S, 2019, PILOT FEASIBILITY ST, V5, DOI 10.1186/s40814-019-0439-0; Boter H, 2004, STROKE, V35, P2867, DOI 10.1161/01.STR.0000147717.57531.e5; Bowen A, 2016, ROYAL COLL PHYS 2016; Brennan DM, 2009, STUD HEALTH TECHNOL, V145, P231, DOI 10.3233/978-1-60750-018-6-231; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Caughlin S, 2020, TELEMED E-HEALTH, V26, P710, DOI 10.1089/tmj.2019.0097; Chaparro D, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2410-9; Chartered Society of Physiotherapy, 2020, DIG PHYS; Chau JPC, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026500; Chen J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009605; Chen J, 2017, AM J PHYS MED REHAB, V96, P152, DOI 10.1097/PHM.0000000000000559; Chen J, 2015, J STROKE CEREBROVASC, V24, P2660, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.014; Chumbler NR, 2012, STROKE, V43, P2168, DOI 10.1161/STROKEAHA.111.646943; Cieza A, 2020, LANCET, V396, P2006, DOI 10.1016/S0140-6736(20)32340-0; Cramer SC, 2019, JAMA NEUROL, V76, P1079, DOI 10.1001/jamaneurol.2019.1604; DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008; Deng HQ, 2012, PHYS THER, V92, P197, DOI 10.2522/ptj.20110018; European GNSS Agency, 2020, TEL GUID, DOI 10.2878/581340.https://www.gsc-europa.eu/sites/default/files/sites/all/files/Galileo_HAS_Info_Note.pdf; Eysenbach G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1923; Forducey PG, 2012, PSYCHOL SERV, V9, P144, DOI 10.1037/a0028112; Gauthier LV, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0888-0; Grau-Pellicer M, 2020, TOP STROKE REHABIL, V27, P354, DOI [10.1080/10749357.2019.1605751, 10.1080/10749357.2019.1691816]; Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998; Greenhalgh T, 2018, PUBLIC HEALTH RES PR, V28, DOI 10.17061/phrp2831815; Guillaumier A, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3604-0; Hansen CR, 2017, EUR J ENDOCRINOL, V176, P727, DOI 10.1530/EJE-16-0811; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; HSE, 2020, GUID SETT VIRT PULM; Huijgen BCH, 2008, J TELEMED TELECARE, V14, P249, DOI 10.1258/jtt.2008.080104; Irish Society of Chartered Physiotherapists, 2020, TEL PHYS; Joubert J, 2020, INT J STROKE, V15, P438, DOI 10.1177/1747493019830582; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Khilnani A, 2020, J INF COMMUN ETHICS, V18, P393, DOI 10.1108/JICES-04-2020-0052; Kirkness Catherine J, 2017, BMC Res Notes, V10, P500, DOI 10.1186/s13104-017-2819-y; Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3; Li L, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/17219; Lin KH, 2014, SENSORS-BASEL, V14, P12451, DOI 10.3390/s140712451; Llorens R, 2015, ARCH PHYS MED REHAB, V96, P418, DOI 10.1016/j.apmr.2014.10.019; Lyden P, 2020, STROKE, V51, P1910, DOI 10.1161/STROKEAHA.120.030023; Maresca G, 2019, J STROKE CEREBROVASC, V28, DOI 10.1016/j.jstrokecerebrovasdis.2019.104303; Mayo NE, 2008, AGE AGEING, V37, P32, DOI 10.1093/ageing/afm133; McIntyre M, 2020, AM J PHYS MED REHAB, V99, P464, DOI 10.1097/PHM.0000000000001453; Meltzer JA, 2018, APHASIOLOGY, V32, P290, DOI 10.1080/02687038.2017.1355440; Murray E, 2016, AM J PREV MED, V51, P843, DOI 10.1016/j.amepre.2016.06.008; National Institute For Health And Care Excellence [NICE], 2013, STROKE REHABILITATIO; Nawaz A, 2016, HEALTH INFORM J, V22, P911, DOI 10.1177/1460458215598638; Ora HP, 2020, CLIN REHABIL, V34, P369, DOI 10.1177/0269215519896616; Peretti Alessandro, 2017, JMIR Rehabil Assist Technol, V4, pe7, DOI 10.2196/rehab.7511; Piron L, 2008, J TELEMED TELECARE, V14, P257, DOI 10.1258/jtt.2008.080304; Piron L, 2009, J REHABIL MED, V41, P1016, DOI 10.2340/16501977-0459; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Rochette A, 2013, CIRC-CARDIOVASC QUAL, V6, P674, DOI 10.1161/CIRCOUTCOMES.113.000375; Rodgers H, 2019, STROKE, V50, P3561, DOI 10.1161/STROKEAHA.119.024876; Royal College of Physicians, 2015, SENT STROK NAT AUD P; Saal S, 2015, TOP STROKE REHABIL, V22, P429, DOI 10.1179/1074935714Z.0000000047; Sakakibara BM, 2017, ARCH PHYS MED REHAB, V98, P1195, DOI 10.1016/j.apmr.2017.01.019; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Seah KTM, 2020, INT J SURG, V79, P127, DOI 10.1016/j.ijsu.2020.05.057; Sheehy L, 2018, INT J STROKE, V13, P207; Smith GC, 2012, REHABIL PSYCHOL, V57, P196, DOI 10.1037/a0029587; Sureshkumar K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020098; Svaerke KW, 2019, J STROKE CEREBROVASC, V28, DOI 10.1016/j.jstrokecerebrovasdis.2019.104356; The Physiotherapy Board New Zealand, TEL STAND; The Stroke Association, 2018, STATE NATION STROKE; Torrisi M, 2019, INT J REHABIL RES, V42, P344, DOI 10.1097/MRR.0000000000000369; Totten AM, 2016, TECHNICAL BRIEFS, V26; U.S. Centers for Medicare & Medicaid Services, 2020, LIST TEL SERV; Wan LH, 2016, J STROKE CEREBROVASC, V25, P2259, DOI 10.1016/j.jstrokecerebrovasdis.2016.05.010; Wang MY, 2020, J CARDIOVASC NURS, V35, P156, DOI 10.1097/JCN.0000000000000631; Withiel TD, 2019, J REHABIL MED, V51, P343, DOI 10.2340/16501977-2540	81	0	0	9	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2022	17	5							e0265828	10.1371/journal.pone.0265828	http://dx.doi.org/10.1371/journal.pone.0265828			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1VP	35544471	Green Published, gold			2023-01-03	WOS:000818854500010
J	Okereke, OI; Mischoulon, D; Manson, JE				Okereke, Olivia, I; Mischoulon, David; Manson, JoAnn E.			Mediterranean Diet or Mindfulness-Based Stress Reduction and Prevention of Small-for-Gestational-Age Birth Weights in Newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Okereke, Olivia, I; Mischoulon, David] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Okereke, OI (corresponding author), Massachusetts Gen Hosp, One Bowdoin Sq,Seventh Floor, Boston, MA 02114 USA.	olivia.okereke@mgh.harvard.edu						Bublitz M, 2021, JAMA-J AM MED ASSOC, V326, P2137, DOI 10.1001/jama.2021.19923; Crovetto F, 2021, JAMA-J AM MED ASSOC, V326, P2150, DOI 10.1001/jama.2021.20178; Ramos-Lopez O, 2021, INFLAMM RES, V70, P29, DOI 10.1007/s00011-020-01425-y; Sadeghi O, 2021, NUTR NEUROSCI, V24, P248, DOI 10.1080/1028415X.2019.1620425; Szegda K, 2014, J MATERN-FETAL NEO M, V27, P960, DOI 10.3109/14767058.2013.845157	5	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13					1292	1293		10.1001/jama.2022.2164	http://dx.doi.org/10.1001/jama.2022.2164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35380587				2023-01-03	WOS:000783965500029
J	dos Reis, EC; Rodrigues, P; de Jesus, TR; Monteiro, ELD; Virtuoso, JS; Bianchi, L				dos Reis, Erika Cardoso; Rodrigues, Phillipe; de Jesus, Tatielle Rocha; de Freitas Monteiro, Elma Lucia; Virtuoso Junior, Jair Sindra; Bianchi, Lucas			Risk of hospitalization and mortality due to COVID-19 in people with obesity: An analysis of data from a Brazilian state	PLOS ONE			English	Article							OUTCOMES	The aim of this article is to assess the odds ratio of hospitalization and mortality due to COVID-19 in people with obesity using data from residents of Espirito Santo, Brazil. An observational, quantitative, cross-sectional study was carried out from the database available on the official channel of the State Health Secretariat of Espirito Santo. Crude odds ratio estimates (ORs) referring to the association between variables were calculated, as well as adjusted odds ratios (adjusted odds ratios-OR adj.) and their respective 95% confidence intervals (CI 95%). The results indicate that men, non-white, no education or with lower education level and age over 40 years old were more likely to be hospitalized and died of COVID-19. People with obesity are at risk of hospitalization and death due to COVID-19 54% and 113% higher than people who do not have obesity. People with obesity had a higher chance of hospitalization when they were over 40 years old, had breathing difficulty, and the comorbidities diabetes (2.18 higher) and kidney disease (4.10 higher). The odds ratio of death for people with obesity over 60 years old was 12.51 higher, and those who were hospitalized was 17.9 higher compared to those who were not hospitalized.	[dos Reis, Erika Cardoso] Univ Fed Ouro Preto, Sch Nutr, Dept Clin & Social Nutr, Ouro Preto, MG, Brazil; [Rodrigues, Phillipe] Univ Fed Rio de Janeiro, Sch Phys Educ & Sports, Rio De Janeiro, Brazil; [de Jesus, Tatielle Rocha] Univ Fed Espirito Santo, Dept Integrated Hlth Educ, Vitoria, ES, Brazil; [de Freitas Monteiro, Elma Lucia; Virtuoso Junior, Jair Sindra] Univ Fed Triangulo Mineiro, Grad Program Hlth Care, Uberaba, MG, Brazil; [Bianchi, Lucas] Natl Sch Publ Hlth ENSP Fiocruz, Rio De Janeiro, Brazil	Universidade Federal de Ouro Preto; Universidade Federal do Rio de Janeiro; Universidade Federal do Espirito Santo; Universidade Federal do Triangulo Mineiro; Fundacao Oswaldo Cruz	dos Reis, EC (corresponding author), Univ Fed Ouro Preto, Sch Nutr, Dept Clin & Social Nutr, Ouro Preto, MG, Brazil.	erika.careis@gmail.com	Reis, Erika/C-4375-2019	Reis, Erika/0000-0003-4459-9345; Rocha de Jesus, Tatielle/0000-0002-2002-3096; Monteiro Bianchi, Lucas/0000-0001-7160-1143	Pan American Health Organization (PAHO)	Pan American Health Organization (PAHO)	The project received financial support from the Pan American Health Organization (PAHO).	Abate BB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040129; Abdi A, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108347; Apostolopoulos V, 2016, MOL NUTR FOOD RES, V60, P43, DOI 10.1002/mnfr.201500272; Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598; Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Borges GM., 2020, CAD SA DE P BLICA IN, V36; Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X; Carneiro RAVD, ARCH ENDOCRIN METAB; Chang TH, 2020, OBES REV, V21, DOI 10.1111/obr.13089; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Codeco CT., 2020, AN LISE RISCO DISSEM, V3; de Souza FSH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248580; Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117; Esprito Santo, 2021, NOTA TCNICA COVID 19; Ghanim H, 2004, CIRCULATION, V110, P1564, DOI 10.1161/01.CIR.0000142055.53122.FA; Klang E, 2020, OBESITY, V28, P1595, DOI 10.1002/oby.22913; Kuruvilla ME, 2019, CLIN REV ALLERG IMMU, V56, P219, DOI 10.1007/s12016-018-8712-1; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Soares RDM, 2020, AM J TROP MED HYG, V103, P1184, DOI 10.4269/ajtmh.20-0483; Miller J, 2021, CLIN INFECT DIS, V72, pE704, DOI 10.1093/cid/ciaa1420; Nobel YR, 2020, GASTROENTEROLOGY, V159, P373, DOI 10.1053/j.gastro.2020.04.017; Noor FM, 2020, J COMMUN HEALTH, V45, P1270, DOI 10.1007/s10900-020-00920-x; Ong SWX, 2020, CLIN INFECT DIS, V71, P2300, DOI 10.1093/cid/ciaa548; Parameswaran Krishnan, 2006, Can Respir J, V13, P203; Patel AP, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01227-y; Pranata R, 2021, DIABETES METAB, V47, DOI 10.1016/j.diabet.2020.07.005; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Rezende LFM, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002596; Rod JE, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002481; Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843; Szwarcwald CL, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.1590/S1679-49742020000500018, 10.1590/s1679-49742020000500018]; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Tavares FF, 2021, WORLD DEV, V139, DOI 10.1016/j.worlddev.2020.105307; Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wang D, 2020, J AEROSPACE ENG, V33, DOI 10.1061/(ASCE)AS.1943-5525.0001149; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; Webster RK, 2020, PUBLIC HEALTH, V182, P163, DOI 10.1016/j.puhe.2020.03.007; Wolff D, 2021, INFECTION, V49, P15, DOI 10.1007/s15010-020-01509-1; Bello-Chavolla OY, 2020, J CLIN ENDOCR METAB, V105, P2752, DOI 10.1210/clinem/dgaa346; Zhang FQ, 2020, J MED VIROL, V92, P2536, DOI 10.1002/jmv.26039; Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9; Zhou Y, 2020, INT J INFECT DIS, V99, P47, DOI 10.1016/j.ijid.2020.07.029	43	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2022	17	3							e0263723	10.1371/journal.pone.0263723	http://dx.doi.org/10.1371/journal.pone.0263723			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M2JD	35245299	Green Published, gold			2023-01-03	WOS:000799799100005
J	Gomes, T; Campbell, TJ; Kitchen, SA; Garg, R; Bozinoff, N; Men, SY; Tadrous, M; Munro, C; Antoniou, T; Werb, D; Wyman, J				Gomes, Tara; Campbell, Tonya J.; Kitchen, Sophie A.; Garg, Ria; Bozinoff, Nikki; Men, Siyu; Tadrous, Mina; Munro, Charlotte; Antoniou, Tony; Werb, Dan; Wyman, Jennifer			Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METHADONE; BUPRENORPHINE	IMPORTANCE During the COVID-19 pandemic, modified guidance for opioid agonist therapy (OAT) allowed prescribers to increase the number of take-home doses to promote treatment retention. Whether this was associated with an increased risk of overdose is unclear. OBJECTIVE To evaluate whether increased take-home doses of OAT early in the COVID-19 pandemic was associated with treatment retention and opioid-related harm. DESIGN, SETTING, AND PARTICIPANTS A retrospective propensity-weighted cohort study of 21 297 people actively receiving OAT on March 21, 2020, in Ontario, Canada. Changes in OAT take-home dose frequency were assessed between March 22, 2020, and April 21, 2020, and individuals were observed for up to 180 days to assess outcomes (last date of follow-up, October 18, 2020). EXPOSURES Exposure was defined as extended take-home doses in the first month of the pandemic within each of 4 cohorts based on OAT type and baseline take-home dose frequency (daily dispensed methadone, 5-6 take-home doses of methadone, daily dispensed buprenorphine/naloxone, and 5-6 take-home doses of buprenorphine/naloxone). MAIN OUTCOMES AND MEASURES Primary outcomes were opioid overdose, interruption in OAT, and OAT discontinuation. RESULTS Among 16 862 methadone and 4435 buprenorphine/naloxone recipients, the median age ranged between 38 and 42 years, and 29.1% to 38.2% were women. Among individuals receiving daily dispensed methadone (n = 5852), initiation of take-home doses was significantly associated with lower risks of opioid overdose (6.9% vs 9.5%/person-year; weighted hazard ratio [HR], 0.73 [95% CI, 0.56-0.96]), treatment discontinuation (51.0% vs 63.6%/person-year; weighted HR, 0.80 [95% CI, 0.72-0.90]), and treatment interruption (19.0% vs 23.9%/person-year; weighted HR, 0.80 [95% CI, 0.67-0.95]) compared with no change in take-home doses. Among individuals receiving daily dispensed buprenorphine/naloxone (n = 662), there was no significant difference in any outcomes between exposure groups. Among individuals receiving weekly dispensed OAT (n = 11 010 for methadone; n = 3773 for buprenorphine/naloxone), extended take-home methadone doses were significantly associated with lower risks of OAT discontinuation (14.1% vs 19.6%/person-year; weighted HR, 0.72 [95% CI, 0.62-0.84]) and interruption in therapy (5.1% vs 7.4%/person-year; weighted HR, 0.69 [95% CI, 0.53-0.90]), and extended take-home doses of buprenorphine/naloxone were significantly associated with lower risk of interruption in therapy (9.5% vs 12.9%/person-year; weighted HR, 0.74 [95% CI, 0.56-0.99]) compared with no change in take-home doses. Other primary outcomes were not significantly different between groups. CONCLUSIONS AND RELEVANCE In Ontario, Canada, during the COVID-19 pandemic, dispensing of increased take-home doses of opioid agonist therapy was significantly associated with lower rates of treatment interruption and discontinuation among some subsets of patients receiving opioid agonist therapy, and there were no statistically significant increases in opioid-related overdoses over 6 months of follow-up. These findings may be susceptible to residual confounding and should be interpreted cautiously.	[Gomes, Tara; Campbell, Tonya J.; Antoniou, Tony; Werb, Dan] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Gomes, Tara; Kitchen, Sophie A.; Men, Siyu; Tadrous, Mina; Antoniou, Tony] ICES, Toronto, ON, Canada; [Gomes, Tara; Tadrous, Mina] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Gomes, Tara; Werb, Dan] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Garg, Ria] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Garg, Ria] Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada; [Bozinoff, Nikki] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada; [Bozinoff, Nikki; Antoniou, Tony; Wyman, Jennifer] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Tadrous, Mina; Wyman, Jennifer] Womens Coll Hosp, Toronto, ON, Canada; [Munro, Charlotte] Ontario Drug Policy Res Network, Lived Experience Advisory Grp, Toronto, ON, Canada; [Antoniou, Tony] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada; [Werb, Dan] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, La Jolla, CA USA	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of British Columbia; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of California System; University of California San Diego	Gomes, T (corresponding author), St Michaers Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	tara.gomes@unityhealth.to	Tadrous, Mina/E-9136-2018	Tadrous, Mina/0000-0003-1911-6129	Ontario MOH [0691]; CIHR [153070]; ICES - Ontario MOH; ICES - Ministry of Long-Term Care [MLTC]	Ontario MOH; CIHR(Canadian Institutes of Health Research (CIHR)); ICES - Ontario MOH; ICES - Ministry of Long-Term Care [MLTC]	This study was funded by grants from the Ontario MOH (0691) and the CIHR (153070); and supported by ICES (funded by an annual grant from the Ontario MOH and the Ministry of Long-Term Care [MLTC]). Parts of this material are based on data and information compiled and provided by the Ontario MOH and the Canadian Institute for Health Information.	Amram O, 2021, AM J DRUG ALCOHOL AB, V47, P722, DOI 10.1080/00952990.2021.1979991; Bell J, 2020, BIOL PSYCHIAT, V87, P82, DOI 10.1016/j.biopsych.2019.06.020; Bruneau J, 2018, CAN MED ASSOC J, V190, pE247, DOI 10.1503/cmaj.170958; Centre for Addiction and Mental Health, 2020, COVID 19 OP AG TREAT; Frank D, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00535-y; Hickman M, 2018, ADDICTION, V113, P1461, DOI 10.1111/add.14188; IAU, 2022, RISK MIT CONT DUAL H; Levander XA, 2021, ADDICT SCI CLIN PRAC, V16, DOI 10.1186/s13722-021-00281-3; Levander XA, 2022, SUBST ABUS, V43, P633, DOI 10.1080/08897077.2021.1986768; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Nunes EV, 2021, J SUBST ABUSE TREAT, V122, DOI 10.1016/j.jsat.2020.108196; Pearce LA, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m772; Priest KC, 2019, INT J DRUG POLICY, V74, P257, DOI 10.1016/j.drugpo.2019.01.020; Proctor SL, 2014, EXP CLIN PSYCHOPHARM, V22, P424, DOI 10.1037/a0037550; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Stone AC, 2020, J SUBST ABUSE TREAT, V115, DOI 10.1016/j.jsat.2020.108031; Substance Abuse and Mental Health Services Administration, 2015, FED GUID OP TREATM P; Substance Abuse & Mental Health Services Administration, 2020, OP TREATM PROGR OTP; Timko C, 2016, J ADDICT DIS, V35, P22, DOI 10.1080/10550887.2016.1100960; Williams AR, 2018, J SUBST ABUSE TREAT, V91, P57, DOI 10.1016/j.jsat.2018.06.001; Yarborough BJH, 2016, DRUG ALCOHOL DEPEN, V160, P112, DOI 10.1016/j.drugalcdep.2015.12.031	21	11	11	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2022	327	9					846	855		10.1001/jama.2022.1271	http://dx.doi.org/10.1001/jama.2022.1271			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZO9OI	35230394	Green Published			2023-01-03	WOS:000766056100018
J	Branch-Elliman, W; Ferguson, R; Doros, G; Woods, P; Leatherman, S; Strymish, J; Datta, R; Goswami, R; Jankowich, MD; Shah, NR; Taylor, TH; Page, ST; Schiller, SJ; Shannon, C; Hau, C; Flynn, M; Holmberg, E; Visnaw, K; Dhond, R; Brophy, M; Monach, PA				Branch-Elliman, Westyn; Ferguson, Ryan; Doros, Gheorghe; Woods, Patricia; Leatherman, Sarah; Strymish, Judith; Datta, Rupak; Goswami, Rekha; Jankowich, Matthew D.; Shah, Nishant R.; Taylor, Thomas H.; Page, Sarah T.; Schiller, Sara J.; Shannon, Colleen; Hau, Cynthia; Flynn, Maura; Holmberg, Erika; Visnaw, Karen; Dhond, Rupali; Brophy, Mary; Monach, Paul A.			Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial	PLOS ONE			English	Article								Importance and objective The aim of this pragmatic, embedded, adaptive trial was to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of inpatients with moderate to severe COVID-19 disease. Design Two-arm, randomized, open-label controlled trial comparing SOC alone to SOC plus sarilumab. The trial used a randomized play-the-winner design and was fully embedded within the electronic health record (EHR) system. Setting 5 VA Medical Centers. Participants Hospitalized patients with clinical criteria for moderate to severe COVID-19 but not requiring mechanical ventilation, and a diagnostic test positive for SARS-CoV-2. Interventions Sarilumab, 200 or 400 mg subcutaneous injection. SOC was not pre-specified and could vary over time, e.g., to include antiviral or other anti-inflammatory drugs. Main outcomes and measures The primary outcome was intubation or death within 14 days of randomization. All data were extracted remotely from the EHR. Results Among 162 eligible patients, 53 consented, and 50 were evaluated for the primary endpoint of intubation or death. This occurred in 5/20 and 1/30 of participants in the sarilumab and SOC arms respectively, with the majority occurring in the initial 9 participants (3/4 in the sarilumab and 1/5 in the SOC) before the sarilumab dose was increased to 400 mg and before remdesivir and dexamethasone were widely adopted. After interim review, the unblinded Data Monitoring Committee recommended that the study be stopped due to concern for safety: a high probability that rates of intubation or death were higher with addition of sarilumab to SOC (92.6%), and a very low probability (3.4%) that sarilumab would be found to be superior. Conclusions and relevance This randomized trial of patients hospitalized due to respiratory compromise from COVID-19 but not mechanical ventilation found no benefit from subcutaneous sarilumab when added to an evolving SOC. The numbers of patients and events were too low to allow definitive conclusions to be drawn, but this study contributes valuable information about the role of subcutaneous IL-6R inhibition in the treatment of hospitalized COVID-19 patients. Methods developed and piloted during this trial will be useful in conducting future studies more efficiently.	[Branch-Elliman, Westyn; Ferguson, Ryan; Doros, Gheorghe; Woods, Patricia; Leatherman, Sarah; Strymish, Judith; Page, Sarah T.; Schiller, Sara J.; Shannon, Colleen; Hau, Cynthia; Flynn, Maura; Holmberg, Erika; Visnaw, Karen; Dhond, Rupali; Brophy, Mary; Monach, Paul A.] VA Boston Healthcare Syst, Boston, MA 02115 USA; [Branch-Elliman, Westyn] Harvard Med Sch, Boston, MA 02115 USA; [Ferguson, Ryan; Dhond, Rupali] Boston Univ, Evans Dept Med, Sect Gen Internal Med, Sch Med, Boston, MA 02215 USA; [Doros, Gheorghe] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02215 USA; [Datta, Rupak] VA Connecticut Healthcare Syst, Hosp Epidemiol & Infect Prevent Program, West Haven, CT USA; [Datta, Rupak] Yale Sch Med, Sect Infect Dis, New Haven, CT USA; [Goswami, Rekha] VA Maine Healthcare Syst, Sect Infect Dis, Togus, ME USA; [Jankowich, Matthew D.] Brown Univ, Alpert Med Sch, Providence VA Med Ctr, Div Pulm & Crit Care Med,Dept Med, Providence, RI 02912 USA; [Shah, Nishant R.] Brown Univ, Providence VA Med Ctr, Dept Med, Div Cardiol,Alpert Med Sch, Providence, RI 02912 USA; [Taylor, Thomas H.] White River Jct VA Med Ctr, Infect Dis & Rheumatol, Hartford, VT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Boston University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Branch-Elliman, W (corresponding author), VA Boston Healthcare Syst, Boston, MA 02115 USA.; Branch-Elliman, W (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	wbranche@bidmc.harvard.edu		Woods, Patricia/0000-0001-5646-4216; Dhond, Rupali/0000-0002-8186-1296; /0000-0003-3816-7407; Branch-Elliman, Westyn/0000-0002-9658-5124	NIH NHLBI [1K12HL138049-01]	NIH NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	WBE was supported by NIH NHLBI 1K12HL138049-01. This material is the result of work supported with resources and the use of facilities the VISN-1 Clinical Trials Network and the VA Boston Healthcare System. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2021, OPEN FORUM INFECT DI; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Branch-Elliman W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa490; Branch-Elliman W, 2020, CONT CLIN TRIAL COMM, V19, DOI 10.1016/j.conctc.2020.100614; Chambers DA, 2016, JAMA-J AM MED ASSOC, V315, P1941, DOI 10.1001/jama.2016.3867; Fiore LD, 2011, CLIN TRIALS, V8, P183, DOI [10.1177/1740774510395635, 10.1177/1740774511398368]; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Grieve AP, 2017, PHARM STAT, V16, P64, DOI 10.1002/pst.1778; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Morris G, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155593; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Schulert GS, 2018, ARTHRIT CARE RES, V70, P409, DOI 10.1002/acr.23277; Si S, 2020, THER CLIN RISK MANAG, V16, P705, DOI 10.2147/TCRM.S223468; Snow TAC, 2021, INTENS CARE MED, V47, P641, DOI 10.1007/s00134-021-06416-z; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; US Food and Drug Administration, 2020, FDA GUID COND CLIN T; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Woods P, 2021, CONT CLIN TRIAL COMM, V23, DOI 10.1016/j.conctc.2021.100804; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117	27	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0263591	10.1371/journal.pone.0263591	http://dx.doi.org/10.1371/journal.pone.0263591			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0U7EE	35213547	Green Published, gold			2023-01-03	WOS:000787811000025
J	Sallehuddin, H; Ong, T; Said, SM; Tarmizi, NAA; Loh, SP; Lim, WC; Nadarajah, R; Lim, HT; Zambri, NHM; Ho, YY; Ghazali, SS				Sallehuddin, Hakimah; Ong, Terence; Said, Salmiah Md.; Tarmizi, Noor Azleen Ahmad; Loh, Siew Ping; Lim, Wan Chieh; Nadarajah, Reena; Lim, Hong Tak; Zambri, Nurul Huda Mohd; Ho, Yun Ying; Ghazali, Sazlina Shariff			Non-pharmacological interventions for bone health after stroke: A systematic review	PLOS ONE			English	Review							MINERAL DENSITY; EXERCISE PROGRAM; MUSCLE STRENGTH; HIP FRACTURE; OSTEOPOROSIS; RISK; TURNOVER; GEOMETRY	Objective To examine the effectiveness and safety of non-pharmacological interventions to reduce bone loss among post-stroke adult patients. Data sources Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database for Systematic Reviews, MEDLINE, CINAHL, ScienceDirect, Scopus, PubMed and PeDRO databases were searched from inception up to 31st August 2021. Methods A systematic review of randomized controlled trials, experimental studies without randomization and prospective cohort studies with concurrent control of non-pharmacological interventions for adult stroke patients compared with placebo or other stroke care. The review outcomes were bone loss, fall and fracture. The Cochrane Risk of Bias Tools were used to assess methodological quality, and Grading of Recommendations, Assessment, Development and Evaluations Framework to assess outcome quality. Synthesis Without Meta-Analysis (SWIM) was used for result synthesis. Results Seven studies (n = 453) were included. The methodological and outcome qualities varied from low to moderate. There were statistically significant changes between the intervention and parallel/placebo group in bone mineral density, bone mineral content, cortical thickness and bone turnover markers with specific physical and vibration therapies (p<0.05). Falls were higher in the intervention group, but no fracture was reported. Conclusion There was low to moderate evidence that physical and vibration therapies significantly reduced bone loss in post-stroke patients at the expense of a higher falls rate. The sample size was small, and the interventions were highly heterogeneous with different duration, intensities and frequencies. Despite osteoporosis occurring with ageing and accelerated by stroke, there were no studies on vitamin D or protein supplementation to curb the ongoing loss. Effective, high-quality non-pharmacological intervention to improve post-stroke bone health is required.	[Sallehuddin, Hakimah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Geriatr Med Unit, Seri Kembangan, Selangor, Malaysia; [Sallehuddin, Hakimah; Ghazali, Sazlina Shariff] Univ Putra Malaysia, Malaysian Res Inst Ageing MyAgeingTM, Seri Kembangan, Selangor, Malaysia; [Ong, Terence] Univ Malaya, Div Geriatr Med, Dept Med, Fac Med, Kuala Lumpur, Malaysia; [Said, Salmiah Md.] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Community Hlth, Seri Kembangan, Selangor, Malaysia; [Tarmizi, Noor Azleen Ahmad] Univ Teknol MARA, Fac Med, Dept Med, Shah Alam, Selangor, Malaysia; [Loh, Siew Ping] Malacca Hosp, Dept Internal Med, Malacca, Malaysia; [Lim, Wan Chieh] Taiping Hosp, Dept Internal Med, Taiping, Perak, Malaysia; [Nadarajah, Reena] Selayang Hosp, Dept Internal Med, Batu Caves, Selangor, Malaysia; [Lim, Hong Tak] Tuanku Jaafar Hosp, Dept Internal Med, Seremban, Negeri Sembilan, Malaysia; [Zambri, Nurul Huda Mohd] Kuala Lumpur Hosp, Dept Internal Med, Kuala Lumpur, Malaysia; [Ho, Yun Ying] Tengku Ampuan Rahimah Hosp, Dept Internal Med, Klang, Selangor, Malaysia; [Ghazali, Sazlina Shariff] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Seri Kembangan, Selangor, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Malaya; Universiti Putra Malaysia; Universiti Teknologi MARA; Universiti Putra Malaysia	Sallehuddin, H (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Geriatr Med Unit, Seri Kembangan, Selangor, Malaysia.; Sallehuddin, H (corresponding author), Univ Putra Malaysia, Malaysian Res Inst Ageing MyAgeingTM, Seri Kembangan, Selangor, Malaysia.	drhakimah@upm.edu.my	Ong, Terence/AAJ-6357-2020	Ong, Terence/0000-0001-7473-446X; Lim, Hong Tak/0000-0002-5808-4978; Lim, Wan Chieh/0000-0002-1061-9291	Universiti Putra Malaysia Publication Fund	Universiti Putra Malaysia Publication Fund	There is no financial support or funding for this review. The publication of this manuscript is partially funded by the Universiti Putra Malaysia Publication Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aquilani R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/964365; Aziz ZA, 2017, ANN REPORT MALAYSIAN; Berghout BP, 2019, STROKE, V50, P2293, DOI 10.1161/STROKEAHA.119.025449; Brown DL, 2008, CEREBROVASC DIS, V25, P95, DOI 10.1159/000111997; Campbell M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6890; Dolan E, 2020, EXERC SPORT SCI REV, V48, P49, DOI 10.1249/JES.0000000000000215; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HAMDY RC, 1995, AM J PHYS MED REHAB, V74, P351; Han L, 2017, EXP THER MED, V13, P961, DOI 10.3892/etm.2017.4078; Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Kapoor E, 2019, STROKE, V50, P1564, DOI 10.1161/STROKEAHA.118.024685; Lau EMC, 2001, J BONE MINER RES, V16, P572, DOI 10.1359/jbmr.2001.16.3.572; Lee SB, 2013, INT J STROKE, V8, P68, DOI 10.1111/j.1747-4949.2011.00714.x; Leiu KH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228803; Levendoglu F, 2004, AM J PHYS MED REHAB, V83, P835, DOI 10.1097/01.PHM.0000140802.91648.57; Liu MG, 1999, ARCH PHYS MED REHAB, V80, P1219, DOI 10.1016/S0003-9993(99)90019-9; Liu Pei-Yang, 2011, J Aging Res, V2011, P379674, DOI 10.4061/2011/379674; Marin-Cascales E, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011918; Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE-15-0118; MULLEY G, 1979, POSTGRAD MED J, V55, P264, DOI 10.1136/pgmj.55.642.264; Pang MYC, 2006, OSTEOPOROSIS INT, V17, P1615, DOI 10.1007/s00198-006-0168-0; Pang MYC, 2013, EUR J PHYS REHAB MED, V49, P439; Pang MYC, 2010, NEUROREHAB NEURAL RE, V24, P368, DOI 10.1177/1545968309353326; Pang MYC, 2005, J AM GERIATR SOC, V53, P1667, DOI 10.1111/j.1532-5415.2005.53521.x; PESZCZYNSKI M, 1957, Geriatrics, V12, P687; Pinheiro MB, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-01040-4; Ramasamy DK, 2021, NUTR NEUROSCI, V24, P426, DOI 10.1080/1028415X.2019.1641295; Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053; Ramnemark A, 2000, STROKE, V31, P1572, DOI 10.1161/01.STR.31.7.1572; Sherrington C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012424.pub2; Shimizu Michele Eisemann, 2002, Hiroshima Journal of Medical Sciences, V51, P15; SIGN118 SIGN, 2010, MAN PAT STROK NAT CL, P48; Sozen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048; Stroke Council M, 2020, CLIN PRACTICE GUIDEL, V3; Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198-017-4082-4; TAKAMOTO S, 1995, CALCIFIED TISSUE INT, V56, P259, DOI 10.1007/BF00318043; Turner S, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/710387; Wang HP, 2021, J NEUROL SCI, V427, DOI 10.1016/j.jns.2021.117512; Wei WE, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1377-7; Yang FZ, 2020, OSTEOPOROSIS INT, V31, P211, DOI 10.1007/s00198-019-05175-4; Yang ZH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80526-4; Yao P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.17789; Zhang L, 2019, STROKE OSTEOPOROSIS, P6	44	0	0	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2022	17	2							e0263935	10.1371/journal.pone.0263935	http://dx.doi.org/10.1371/journal.pone.0263935			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0QE	35196338	Green Published, gold			2023-01-03	WOS:000835161600021
J	Ma, JK; Leese, J; Therrien, S; Hoens, AM; Tsui, K; Li, LC				Ma, Jasmin K.; Leese, Jennifer; Therrien, Stephanie; Hoens, Alison M.; Tsui, Karen; Li, Linda C.			A scoping review of interventions to improve strength training participation	PLOS ONE			English	Article							PHYSICAL-ACTIVITY INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; BEHAVIOR-CHANGE TECHNIQUES; SPINAL-CORD-INJURY; RESISTANCE EXERCISE; PUBLIC-HEALTH; OLDER-ADULTS; PEOPLE; METAANALYSIS; INTENSITY	Background Low participation rates (1-31%) and unique barriers to strength training (e.g., specialized knowledge, equipment, perceived complexity) suggest effective strength training interventions may differ from effective aerobic or general physical activity interventions. The purpose of this scoping review was to examine interventions used to improve strength training participation through mapping theory, intervention characteristics, prescription parameters, and behaviour change techniques. Methods Recommendations by Levac et al. (2010) and PRISMA-ScR were followed in the conduct and reporting of this review, respectively. Patients and exercise professionals participated in developing the research question and data extraction form, interpreting the findings, and drafting the manuscript. Medline, Embase, PsycINFO, CINAHL, SPORTDiscus, and PubMed databases (inception-December 2020) were searched. The inclusion criteria were (a) original peer-reviewed articles and grey literature, (b) intervention study design, and (c) behavioural interventions targeted towards improving strength training participation. Two reviewers performed data screening, extraction, and coding. The interventions were coded using the Behaviour Change Technique Taxonomy version 1. Data were synthesized using descriptive and frequency reporting. Results Twenty-seven unique interventions met the inclusion criteria. Social cognitive theory (n = 9), the transtheoretical model (n = 4), and self-determination theory (n = 2) were the only behaviour change theories used. Almost all the interventions were delivered face-to-face (n = 25), with the majority delivered by an exercise specialist (n = 23) in community or home settings (n = 24), with high variability in exercise prescription parameters. Instructions on how to perform the behaviour, behavioural practice, graded tasks, goal setting, adding objects to the environment (e.g., providing equipment), and using a credible source (e.g., exercise specialist delivery) comprised the most common behaviour change techniques. Conclusions Our results highlight gaps in theory, intervention delivery, exercise prescription parameters, and behaviour change techniques for future interventions to examine and improve our understanding of how to most effectively influence strength training participation.	[Ma, Jasmin K.; Leese, Jennifer; Therrien, Stephanie; Hoens, Alison M.; Tsui, Karen; Li, Linda C.] Arthrit Res Canada, Richmond, BC, Canada; [Ma, Jasmin K.; Leese, Jennifer; Hoens, Alison M.; Li, Linda C.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada; [Hoens, Alison M.] Univ British Columbia, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada	Arthritis Research Canada; University of British Columbia; University of British Columbia	Ma, JK (corresponding author), Arthrit Res Canada, Richmond, BC, Canada.; Ma, JK (corresponding author), Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada.	Jasmin.ma@ubc.ca		Li, Linda/0000-0001-6280-0511; Ma, Jasmin/0000-0002-0193-4820	Michael Smith Foundation for Health Research Trainee Award [17936]; Arthritis Society Post-Doctoral Fellowship [TPF-18-0209]; Canadian Institute of Health Research Post-Doctoral Fellowship [201910MFE-430114-231890]; Harold Robinson/Arthritis Society Chair in Arthritic Diseases award; Canada Research Chair Program; Michael Smith Foundation for Health Research	Michael Smith Foundation for Health Research Trainee Award(Michael Smith Foundation for Health Research); Arthritis Society Post-Doctoral Fellowship; Canadian Institute of Health Research Post-Doctoral Fellowship(Canadian Institutes of Health Research (CIHR)); Harold Robinson/Arthritis Society Chair in Arthritic Diseases award; Canada Research Chair Program(Canada Research Chairs); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	JM is supported by the Michael Smith Foundation for Health Research Trainee Award (#17936), the Arthritis Society Post-Doctoral Fellowship (TPF-18-0209), and the Canadian Institute of Health Research Post-Doctoral Fellowship (201910MFE-430114-231890). LL is supported by the Harold Robinson/Arthritis Society Chair in Arthritic Diseases award, the Canada Research Chair Program, and the Michael Smith Foundation for Health Research. Funding bodies did not play a role in the study collection, analysis, interpretation of the data, or writing of the manuscript. Funder websites: https://cihr-irsc.gc.ca/e/193.html https://www.msfhr.org https://arthritis.ca.	Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Ashton RE, 2020, BRIT J SPORT MED, V54, P341, DOI 10.1136/bjsports-2017-098970; AuYoung M, 2016, AM J MED, V129, P1022, DOI 10.1016/j.amjmed.2016.02.008; Baker K, 2020, ARTHRIT CARE RES, V72, P982, DOI 10.1002/acr.23921; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bartlett YK, 2014, BRIT J HEALTH PSYCH, V19, P181, DOI 10.1111/bjhp.12071; Bauman AE, 2012, LANCET, V380, P258, DOI 10.1016/S0140-6736(12)60735-1; Bennie JA, 2020, SPORTS MED-OPEN, V6, DOI 10.1186/s40798-020-00271-w; Bennie JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153225; Burton E, 2017, J AGING PHYS ACTIV, V25, P311, DOI 10.1123/japa.2015-0289; Copeland JL, 2019, AGING CLIN EXP RES, V31, P1257, DOI 10.1007/s40520-018-1079-6; Davies CA, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-52; Davies DSC., 2019, UK CHIEF MED OFFICER; Falck RS, 2019, NEUROBIOL AGING, V79, P119, DOI 10.1016/j.neurobiolaging.2019.03.007; Falcon A, 2016, DISSERT ABSTR; Fetherman DL, 2011, J WOMEN AGING, V23, P58, DOI 10.1080/08952841.2011.540487; Fragala MS, 2019, J STRENGTH COND RES, V33, P2019, DOI 10.1519/JSC.0000000000003230; Gainforth HL, 2021, ARCH PHYS MED REHAB, V102, P656, DOI 10.1016/j.apmr.2020.09.393; Gainforth HL, 2019, ARCH PHYS MED REHAB, V100, P1916, DOI 10.1016/j.apmr.2019.04.019; Garrett S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X561249; Ginis KAM, 2016, HEALTH PSYCHOL REV, V10, P478, DOI 10.1080/17437199.2016.1198240; Gordon BR, 2018, JAMA PSYCHIAT, V75, P566, DOI 10.1001/jamapsychiatry.2018.0572; Gordon BR, 2017, SPORTS MED, V47, P2521, DOI 10.1007/s40279-017-0769-0; Greaves CJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-119; Grgic J, 2020, SPORTS MED, V50, P1983, DOI 10.1007/s40279-020-01331-7; Grontved A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001587; Grontved A, 2012, ARCH INTERN MED, V172, P1306, DOI 10.1001/archinternmed.2012.3138; Hamilton CB, 2018, HEALTH EXPECT, V21, P396, DOI 10.1111/hex.12635; Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; JOP Diclemente, 2005, HDB PSYCHOTHERPAY IN, P147, DOI [10.1093/med:psych/9780195165791.001.0001, 10.1093/med:psych/9780195165791.003.0007, DOI 10.1093/MED:PSYCH/9780195165791.003.0007]; Kamada M, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0242-0; Kazuhiro H., 2008, International Journal of Sport and Health Science, V6, P66, DOI 10.5432/ijshs.6.66; Latimer-Cheung AE, 2013, REHABIL PSYCHOL, V58, P307, DOI 10.1037/a0032816; Letts L, 2011, REHABIL PSYCHOL, V56, P128, DOI 10.1037/a0023624; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Loustalot F, 2013, RES Q EXERCISE SPORT, V84, P30, DOI 10.1080/02701367.2013.762289; Loveless MS, 2015, CURR SPORT MED REP, V14, P221, DOI 10.1249/JSR.0000000000000149; Lubans DR, 2013, J AGING PHYS ACTIV, V21, P20, DOI 10.1123/japa.21.1.20; Lubans DR, 2013, INT J SPORT PSYCHOL, V44, P252, DOI 10.7352/IJSP2013.44.252; Ma JK, 2018, PSYCHOL SPORT EXERC, V37, P262, DOI 10.1016/j.psychsport.2018.01.006; Macridis S, 2020, J PHYS ACT HEALTH, V17, P995, DOI 10.1123/jpah.2019-0646; Maillart E, 2020, INFECT DIS-NOR, V52, P659, DOI 10.1080/23744235.2020.1774644; Marinik EL, 2014, CONTEMP CLIN TRIALS, V37, P19, DOI 10.1016/j.cct.2013.11.006; Michie S., 2014, ABC BEHAV CHANGE THE; Michie S, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19990; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136; Millen JA, 2009, J CARDIOVASC NURS, V24, P316, DOI 10.1097/JCN.0b013e3181a0d256; MILLER KA, 1988, CONTEMP SOCIOL, V17, P253, DOI 10.2307/2070638; Mullane SL, 2017, FAM COMMUNITY HEALTH, V40, P183, DOI [10.1097/FCH.0000000000000157, 10.1097/fch.0000000000000157]; Muntaner A, 2016, HEALTH INFORM J, V22, P451, DOI 10.1177/1460458214567004; Nakamura Y., 2015, PHYS ACTIVITY EXERCI, P29; Olander EK, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-29; Ott Carol D, 2004, Orthop Nurs, V23, P45, DOI 10.1097/00006416-200401000-00013; Phillips SM, 2010, CURR SPORT MED REP, V9, P208, DOI 10.1249/JSR.0b013e3181e7da73; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Plotnikoff RC, 2010, INT J OBESITY, V34, P1733, DOI 10.1038/ijo.2010.109; Rhodes RE, 2017, BRIT J SPORT MED, V51, P1466, DOI 10.1136/bjsports-2016-096950; Rhodes RE, 2019, PSYCHOL SPORT EXERC, V42, P100, DOI 10.1016/j.psychsport.2018.11.010; Richards EA, 2016, WESTERN J NURS RES, V38, P484, DOI 10.1177/0193945915581861; Saeidifard F, 2019, EUR J PREV CARDIOL, V26, P1647, DOI 10.1177/2047487319850718; Schmitz KH, 2007, AM J CLIN NUTR, V86, P566, DOI 10.1093/ajcn/86.3.566; Schoenfeld BJ, 2021, SPORTS, V9, DOI 10.3390/sports9020032; Schwartz AL, 2009, PHYSICIAN SPORTSMED, V37, P62, DOI 10.3810/psm.2009.10.1730; Sparrow D, 2011, J GERONTOL A-BIOL, V66, P1251, DOI 10.1093/gerona/glr138; Stamatakis E, 2018, AM J EPIDEMIOL, V187, P1102, DOI 10.1093/aje/kwx345; Steele J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4209-8; Strain T, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3774-6; Sylvester BD, 2018, ADV MOTIV SCI, V5, P169, DOI 10.1016/bs.adms.2017.11.001; Tambalis K, 2009, ANGIOLOGY, V60, P614, DOI 10.1177/0003319708324927; Teychenne M, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0266-5; Tremblay MS, 2011, APPL PHYSIOL NUTR ME, V36, P36, DOI [10.1139/H11-009, 10.1139/H11-010]; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Vanroy J, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1060-z; Viera AJ, 2005, FAM MED, V37, P360; Webb TL, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1376; Westcott WL, 2009, PHYSICIAN SPORTSMED, V37, P51, DOI 10.3810/psm.2009.06.1709; Winett RA, 2009, BRIT J SPORT MED, V43, P114, DOI 10.1136/bjsm.2008.049361; Winett RA, 2001, PREV MED, V33, P503, DOI 10.1006/pmed.2001.0909; World Health Organization, 2010, Global recommendations on physical activity for health	81	2	2	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2022	17	2							e0263218	10.1371/journal.pone.0263218	http://dx.doi.org/10.1371/journal.pone.0263218			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2V2QB	35113954	Green Published, gold			2023-01-03	WOS:000823694700061
J	Schindel, D; Mandl, L; Schilling, R; Meisel, A; Schenk, L				Schindel, Daniel; Mandl, Lena; Schilling, Ralph; Meisel, Andreas; Schenk, Liane			Guideline adherence in speech and language therapy in stroke aftercare. A health insurance claims data analysis	PLOS ONE			English	Article							CLINICAL GUIDELINES; SOCIAL-PARTICIPATION; PATHOLOGY SERVICES; APHASIA; CARE; REHABILITATION; PREDICTORS; RECOVERY; OUTCOMES; DISEASE	Background Impairments to comprehension and production of speech (aphasia, dysarthria) and swallowing disorders (dysphagia) are common sequelae of stroke, reducing patients' quality of life and social participation. Treatment oriented on evidence-based guidelines seems likely to improve outcomes. Currently, little is known about guideline adherence in stroke aftercare for the above-mentioned sequelae. This study aims to analyse guideline adherence in the treatment of aphasia, dysarthria and dysphagia after stroke, based on suitable test parameters, and to determine factors that influence the implementation of recommended therapies. Methods Six test parameters were defined, based on systematic study of guidelines for the treatment of speech impairments and swallowing disorders (e.g. comprehensive diagnostics, early initiation and continuity). Guideline adherence in treatment was tested using claims data from four statutory health insurance companies. Multivariate logistic and linear regression analyses were performed in order to test the outcomes. Results 4,486 stroke patients who were diagnosed with specific disorders or received speech therapy were included in the study. The median age was 78 years; the proportion of women was 55.9%. Within the first year after the stroke, 90.3% of patients were diagnosed with speech impairments and swallowing disorders. Overall, 44.1% of patients received outpatient speech and language therapy aftercare. Women were less frequently diagnosed with specific disorders (OR 0.70 [95%CI:0.55/0.88], p = 0.003) and less frequently received longer PLOS therapy sessions (OR 0.64 [95%CI:0.43/0.94], p = 0.022). Older age and longer hospitalization duration increased the likelihood of guideline recommendations being implemented and of earlier initiation of stroke aftercare measures. Conclusions Our observations indicate deficits in the implementation of guideline recommendations in stroke aftercare. At the same time, they underscore the need for regular monitoring of implementation measures in stroke aftercare to address group-based disparities in care.	[Schindel, Daniel; Mandl, Lena; Schenk, Liane] Charite Univ Med Berlin, Inst Med Sociol & Rehabil Sci, Berlin, Germany; [Schindel, Daniel; Mandl, Lena; Schilling, Ralph; Meisel, Andreas; Schenk, Liane] Free Univ Berlin, Berlin, Germany; [Schindel, Daniel; Mandl, Lena; Schilling, Ralph; Meisel, Andreas; Schenk, Liane] Humboldt Univ, Berlin, Germany; [Schilling, Ralph] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany; [Schilling, Ralph] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Meisel, Andreas] Charite Unv Med Berlin, NeuroCure Clin Res Ctr, Ctr Stroke Res Berlin, Berlin, Germany; [Meisel, Andreas] Charite Unv Med Berlin, Dept Neurol Expt Neurol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schindel, D (corresponding author), Charite Univ Med Berlin, Inst Med Sociol & Rehabil Sci, Berlin, Germany.; Schindel, D (corresponding author), Free Univ Berlin, Berlin, Germany.; Schindel, D (corresponding author), Humboldt Univ, Berlin, Germany.	daniel.schindel@charite.de		Schindel, Daniel/0000-0003-3351-8378	German Federal Ministry of Education and Research [01GY1601]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	LS recieved funding for this study through the German Federal Ministry of Education and Research [Project NAVICARE, 01GY1601, https://www.bmbf.de/].The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, BERLIN STROKE REGIST; [Anonymous], 2015, EVALUATION 2014; [Anonymous], 1999, EPIDEMIOLOGIC METHOD; Ayerbe L, 2011, STROKE, V42, P1907, DOI 10.1161/STROKEAHA.110.605808; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Brady MC, 2011, DISABIL REHABIL, V33, P178, DOI 10.3109/09638288.2010.517897; Bushnell CD, 2018, J CEREBR BLOOD F MET, V38, P2179, DOI 10.1177/0271678X18793324; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cherney LR, 2012, INT J SPEECH-LANG PA, V14, P424, DOI 10.3109/17549507.2012.686629; Code C, 2003, DISABIL REHABIL, V25, P1231, DOI 10.1080/09638280310001599961; Code C, 2011, INT J SPEECH-LANG PA, V13, P3, DOI 10.3109/17549507.2010.520090; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Duncan PW, 2002, STROKE, V33, P167, DOI 10.1161/hs0102.101014; Ferro JM, 1999, CEREBROVASC DIS, V9, P6, DOI 10.1159/000047571; Field MJ, 1990, CLIN PRACTICE GUIDEL; Flowers HL, 2013, J COMMUN DISORD, V46, P238, DOI 10.1016/j.jcomdis.2013.04.001; Fridriksson J, 2012, NEUROIMAGE, V60, P854, DOI 10.1016/j.neuroimage.2011.12.057; Gall SL, 2012, STROKE, V43, P1982, DOI 10.1161/STROKEAHA.111.632547; Gonzalez-Fernandez M, 2009, DYSPHAGIA, V24, P398, DOI 10.1007/s00455-009-9216-1; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Guo YE, 2014, DISABIL REHABIL, V36, P691, DOI 10.3109/09638288.2013.804597; Heuschmann PU, 2010, AKTUEL NEUROL, V37, P333, DOI 10.1055/s-0030-1248611; Hoffmann F, 2012, GESUNDHEITSWESEN, V74, P291, DOI 10.1055/s-0031-1275711; Hotter B, 2018, EUR STROKE J, V3, P237, DOI 10.1177/2396987318771174; Hotter B, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0989-9; Hubbard IJ, 2012, ARCH PHYS MED REHAB, V93, P965, DOI 10.1016/j.apmr.2012.01.011; Caballero PEJ, 2013, J STROKE CEREBROVASC, V22, pE214, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.014; Katz RC, 2000, INT J LANG COMM DIS, V35, P303; Koennecke HC, 2011, NEUROLOGY, V77, P965, DOI 10.1212/WNL.0b013e31822dc795; Lam JMC, 2010, MED CARE, V48, P380, DOI 10.1097/MLR.0b013e3181ca2647; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Linder R, 2018, EUR J HEALTH ECON, V19, P821, DOI 10.1007/s10198-017-0924-4; Mackenzie C, 1992, Disabil Rehabil, V14, P146; Mandl L, 2019, REHABILITATION, V58, P331, DOI 10.1055/a-0651-9838; McNaughton H, 2014, NEW ZEAL MED J, V127, P10; Mitchell C, 2021, APHASIOLOGY, V35, P950, DOI 10.1080/02687038.2020.1759772; Nelson Michelle L A, 2016, J Comorb, V6, P35, DOI 10.15256/joc.2016.6.63; Nishimura A, 2019, CIRC J, V83, P2292, DOI 10.1253/circj.CJ-19-0089; Ostwald SK, 2009, TOP STROKE REHABIL, V16, P80, DOI 10.1310/tsr1601-80; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Phan HT, 2019, STROKE, V50, P2299, DOI 10.1161/STROKEAHA.118.024437; Pindus DM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192533; Plowman E, 2012, J EVAL CLIN PRACT, V18, P689, DOI 10.1111/j.1365-2753.2011.01650.x; Reinecke H, 2015, EUR HEART J, V36, P932, DOI 10.1093/eurheartj/ehv006; Reker DM, 2002, ARCH PHYS MED REHAB, V83, P750, DOI 10.1053/apmr.2002.99736; Rohde A, 2013, J EVAL CLIN PRACT, V19, P994, DOI 10.1111/jep.12023; Rose M, 2014, INT J SPEECH-LANG PA, V16, P169, DOI 10.3109/17549507.2013.794474; Rudberg AS, 2021, TOP STROKE REHABIL, V28, P153, DOI 10.1080/10749357.2020.1789829; Schindel D, 2021, DISABIL REHABIL, V43, P2332, DOI 10.1080/09638288.2019.1699173; Schubert I, 2017, Z EVIDENZ FORTBILD Q, V126, P66, DOI 10.1016/j.zefq.2017.06.008; Shrubsole K, 2017, APHASIOLOGY, V31, P1, DOI 10.1080/02687038.2016.1143083; Stark BC, 2018, NEUROPSYCHOL REHABIL, V28, P818, DOI 10.1080/09602011.2016.1146150; Statistics, 2021, BOTTL AN; Sung SF, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1769-8; Sung SF, 2016, PHARMACOEPIDEM DR S, V25, P438, DOI 10.1002/pds.3944; Tenforde AS, 2020, AM J PHYS MED REHAB, V99, P977, DOI 10.1097/PHM.0000000000001571; Thomas L, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000349, DOI 10.1002/14651858.CD000349]; Tyson S, 2000, CLIN REHABIL, V14, P381, DOI 10.1191/0269215500cr331oa; van den Bussche H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-101; Verna A, 2009, INT J SPEECH-LANG PA, V11, P191, DOI 10.1080/17549500902726059; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796	66	2	2	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2022	17	2							e0263397	10.1371/journal.pone.0263397	http://dx.doi.org/10.1371/journal.pone.0263397			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2V2QB	35113968	Green Published, gold			2023-01-03	WOS:000823694700091
J	Bang, HJ; Park, KN; Youn, CS; Kim, HJ; Oh, SH; Lim, JY; Song, H; Kim, SH; Jeong, WJ; Kim, HJK				Bang, Hyo Jin; Park, Kyu Nam; Youn, Chun Song; Kim, Han Joon; Oh, Sang Hoon; Lim, Jee Yong; Song, Hwan; Kim, Soo Hyun; Jeong, Won Jung; Kim, Hyo Joon		Korean Hypothermia Network Investi	The relationship between body mass index and neurologic outcomes in survivors of out-of-hospital cardiac arrest treated with targeted temperature management	PLOS ONE			English	Article							OBESITY; MORTALITY; ASSOCIATION; OVERWEIGHT; PROGNOSIS; IMPACT	BackgroundThe association of body mass index with outcome in patients treated with targeted temperature management (TTM) after out-of-hospital cardiac arrest (OHCA) is unclear. The purpose of this study was to examine the effect of body mass index (BMI) on neurological outcomes and mortality in resuscitated patients treated with TTM after OHCA. MethodsThis multicenter, prospective, observational study was performed with data from 22 hospitals included in the Korean Hypothermia Network KORHN-PRO registry. Comatose adult patients treated with TTM after OHCA between October 2015 and December 2018 were enrolled. The BMI of each patient was calculated and classified according to the criteria of the World Health Organization (WHO). Each group was analyzed in terms of demographic characteristics and associations with six-month neurologic outcomes and mortality after cardiac arrest (CA). ResultsOf 1,373 patients treated with TTM identified in the registry, 1,315 were included in this study. One hundred two patients were underweight (BMI <18.5 kg/m(2)), 798 were normal weight (BMI 18.5-24.9 kg/m(2)), 332 were overweight (BMI 25-29.9 kg/m(2)), and 73 were obese (BMI >= 30 kg/m(2)). The higher BMI group had younger patients and a greater incidence of diabetes and hypertension. Six-month neurologic outcomes and mortality were not different among the BMI groups (p = 0.111, p = 0.234). Univariate and multivariate analyses showed that BMI classification was not associated with six-month neurologic outcomes or mortality. In the subgroup analysis, the underweight group treated with TTM at 33 degrees C was associated with poor neurologic outcomes six months after CA (OR 2.090, 95% CI 1.010-4.325, p = 0.047), whereas the TTM at 36 degrees C group was not (OR 0.88, 95% CI 0.249-3.112, p = 0.843). ConclusionsBMI was not associated with six-month neurologic outcomes or mortality in patients surviving OHCA. However, in the subgroup analysis, underweight patients were associated with poor neurologic outcomes when treated with TTM at 33 degrees C.	[Bang, Hyo Jin; Park, Kyu Nam; Youn, Chun Song; Kim, Han Joon; Oh, Sang Hoon; Lim, Jee Yong; Song, Hwan; Kim, Hyo Joon] Catholic Univ Korea, Seoul St Mary Hosp, Coll Med, Dept Emergency Med, Seoul, South Korea; [Kim, Soo Hyun] Catholic Univ Korea, Eunpyeong St Mary Hosp, Coll Med, Dept Emergency Med, Seoul, South Korea; [Jeong, Won Jung] Catholic Univ Korea, St Vincents Hosp, Dept Emergency Med, Coll Med, Suwon, South Korea	Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea	Kim, HJK (corresponding author), Catholic Univ Korea, Seoul St Mary Hosp, Coll Med, Dept Emergency Med, Seoul, South Korea.	khjoon0110@gmail.com		BANG, Hyo Jin/0000-0002-1818-4667; /0000-0003-3141-9413; Kim, Hyo Joon/0000-0002-2673-2950				Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; Antonopoulos AS, 2017, CARDIOVASC RES, V113, P1074, DOI 10.1093/cvr/cvx106; Birmingham AR, 2018, AM J EMERG MED, V36, P1242, DOI 10.1016/j.ajem.2018.03.079; Breathett K, 2016, AM J EMERG MED, V34, P722, DOI 10.1016/j.ajem.2015.12.077; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Geri G, 2016, RESUSCITATION, V109, P49, DOI 10.1016/j.resuscitation.2016.09.011; Grimaldi D, 2014, CRIT CARE MED, V42, P2350, DOI 10.1097/CCM.0000000000000512; Gupta T, 2016, AM J CARDIOL, V118, P662, DOI 10.1016/j.amjcard.2016.06.019; Hales Craig M, 2020, NCHS Data Brief, P1; Jung YH, 2017, AM J EMERG MED, V35, P268, DOI 10.1016/j.ajem.2016.10.070; Lavie CJ, 2016, PROG CARDIOVASC DIS, V58, P537, DOI 10.1016/j.pcad.2016.01.008; Lavie CJ, 2013, JACC-HEART FAIL, V1, P93, DOI 10.1016/j.jchf.2013.01.006; Leary M, 2014, RESUSCITATION, V85, P244, DOI 10.1016/j.resuscitation.2013.10.027; Lee H, 2021, SCAND J TRAUMA RESUS, V29, DOI 10.1186/s13049-021-00837-x; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Mewes C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010046; Min JY, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-09789-w; Ortega-Loubon C, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3135; Pepper DJ, 2019, CRIT CARE MED, V47, P643, DOI 10.1097/CCM.0000000000003692; Sakr Y, 2012, J CRIT CARE, V27, P714, DOI 10.1016/j.jcrc.2012.08.013; Speakman JR, 2018, HAND CLINIC, V156, P431, DOI 10.1016/B978-0-444-63912-7.00026-6; Veronese N, 2015, OBES REV, V16, P1001, DOI 10.1111/obr.12309; Zeve D, 2009, CELL STEM CELL, V5, P472, DOI 10.1016/j.stem.2009.10.014	24	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265656	10.1371/journal.pone.0265656	http://dx.doi.org/10.1371/journal.pone.0265656			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P0IK	35349593	Green Published, gold			2023-01-03	WOS:000783906500008
J	Bushen, G; Merga, H; Tessema, F				Bushen, Gedamu; Merga, Hailu; Tessema, Fasil			Effects of community-led total sanitation and hygiene implementation on diarrheal diseases prevention in children less than five years of age in South Western Ethiopia: A quasi- experimental study	PLOS ONE			English	Article							HEALTH; WATER; PREVALENCE; PREDICTORS; GROWTH	BackgroundLack of improved sanitation is the most important contributing factor to diarrheal disease among under-five children in low and middle-income countries. There was no study to identify the effect of Community-Led Total Sanitation and Hygiene intervention on diarrheal diseases in the study area. Hence, this study was designed with the aim of finding the effects of Community-led Total Sanitation and Hygiene implementation for preventing diarrhea among under-five children. MethodsA community-based Quasi-Experimental study was conducted among a sample of 846 households selected from intervention (kersa) and comparison (mana) districts using the four-stage random cluster-sampling method. A Semi-structured questionnaire was used to collect data. The collected data was cleaned, coded, and entered into EpiData version 3.1 and exported to SPSS version 20 for analysis. Difference-in Difference method with McNemar's tests was used to compare the prevalence of diarrhea between the intervention and comparison districts, and the significance of change between the pre-test and post-test was declared at p-value less than 0.05 with 95% confidence interval. ResultsThe intervention led to decreased diarrhea prevalence [pp = -8.2, 95% CI: -15.9, -0.5], increased latrine ownership [pp = 5.6, 95% CI: 0.5, 10.8], and increased latrine utilization [pp = 10.7, 95% CI: 4.7, 16.6] in intervention district at post-test compared to the baseline; while the presence of handwashing facility near the latrine, home-based water treatment, and proper water storage and handling practice were decreased at post-test compared to the baseline. ConclusionImplementation of Community-Led Total Sanitation improved sanitation and hygiene status of community that resulted in the reduction of diarrhea diseases in under-five children. Further implementation, evaluation, and scale-up of the interventions are needed to reduce diarrheal disease in under-five children.	[Bushen, Gedamu] South West Sewa Hlth Dept, MPH Filed Epidemiol, Oromia Region, Waliso, Ethiopia; [Merga, Hailu; Tessema, Fasil] Jimma Univ, Inst Hlth, Dept Epidemiol, Jimma, Ethiopia	Jimma University	Merga, H (corresponding author), Jimma Univ, Inst Hlth, Dept Epidemiol, Jimma, Ethiopia.	hailu.merga2014@gmail.com		Merga, Hailu/0000-0001-7536-4755				[Anonymous], 2017, WORLD HLTH STAT 2017; Anteneh ZA, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4021-5; Anthonj C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102112; Azage M, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0090-z; Bitew BD, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0412-6; Central Statistical Agency, 2008, 2007 NAT CENS PREL R; Cha S, 2017, AM J TROP MED HYG, V97, P460, DOI 10.4269/ajtmh.16-0361; Crocker J, 2017, INT J HYG ENVIR HEAL, V220, P551, DOI 10.1016/j.ijheh.2017.02.011; Danquah Leslie., 2014, SCI J PUBLIC HLTH, V2, P119, DOI [10.11648/j.sjph.20140202.21, DOI 10.11648/J.SJPH.20140202.21]; Degebasa MZ, 2018, PEDIATR HEALTH MED T, V9, P109, DOI 10.2147/PHMT.S159366; Dreibelbis R, 2014, AM J PUBLIC HEALTH, V104, pE91, DOI 10.2105/AJPH.2013.301412; Eshete N, 2015, SCI J PUBLIC HLTH, V3, P669, DOI DOI 10.11648/j.sjph.20150305.22; Florence Nwaoha Adanma, 2017, Cuadernos de Investigación UNED, V9, P7; Gebremariam B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203458; Gebru T, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-395; Geremew A, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0737-9; Gizaw Z, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199-019-0801-0; Harris M, 2017, ENVIRON SCI TECHNOL, V51, P7219, DOI 10.1021/acs.est.7b00178; Harter M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5287-y; Hurlimann E, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2642-x; Jung S, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1319-z; Jung YT, 2017, PLOS ONE, V12, DOI [10.1371/Journal.pone.0173808, 10.1371/journal.pone.0173808]; Kakulu RemidiusKamuhabwa., 2012, MUHIMBILI U HLTH ALL; Kar K, 2008, HDB COMMUNITY LED TO; Larsen DA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005591; Mihrete TS, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-102; Ministry of Health of Uganda, 2018, COMM LED TOT SAN FAC, P128; Ayalew AM, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/4271915; Patil SR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001709; Pickering AJ, 2015, LANCET GLOB HEALTH, V3, pE701, DOI 10.1016/S2214-109X(15)00144-8; Roushdy R., 2012, IMPACT WATER SUPPLY, P1, DOI [10.23846/wss1.4-egypt-gfr, DOI 10.23846/WSS1.4-EGYPT-GFR]; Solomon Islands Government Ministry of Health, 2016, COMM LED TOT SAN CLT, P170; Tadesse A, 2022, BMC HEALTH SERV RES, V22, DOI 10.1186/s12913-022-07565-7; UNICEF, 2016, COMM LED TOT SAN TRA, P1104; Walker CLF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-220; Warsame HA, 2016, MORBIDITY DIARRHEAL, P192; World Health Organization and United Nations Childrens Fund Joint Monitoring Programme for Water Supply and Sanitation (JMP), 2008, PROGR DRINKING WATER; World Health Organization (WHO), 2018, GUID SAN HLTH	38	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0265804	10.1371/journal.pone.0265804	http://dx.doi.org/10.1371/journal.pone.0265804			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D9PO	35468143	Green Submitted, Green Published, gold			2023-01-03	WOS:000794129600017
J	de Lima, FF; Silva, CR; Kohn, AF				de Lima, Felipe Fava; Silva, Cristiano Rocha; Kohn, Andre Fabio			Transcutaneous spinal direct current stimulation (tsDCS) does not affect postural sway of young and healthy subjects during quiet upright standing	PLOS ONE			English	Article							DC-STIMULATION; H-REFLEX; DEPENDENT MODULATION; MULTISCALE ENTROPY; ELECTRICAL NOISE; TRICEPS SURAE; LIGHT TOUCH; BALANCE; TDCS; INTENSITY	Transcutaneous spinal direct current stimulation (tsDCS) is an effective non-invasive spinal cord electrical stimulation technique to induce neuromodulation of local and distal neural circuits of the central nervous system (CNS). Applied to the spinal cord lumbosacral region, tsDCS changes electrophysiological responses of the motor, proprioceptive and nociceptive pathways, alters the performance of some lower limb motor tasks and can even modulate the behavior of supramedullary neuronal networks. In this study an experimental protocol was conducted to verify if tsDCS (5 mA, 20 minutes) of two different polarizations, applied over the lumbosacral region (tenth thoracic vertebrae (T10)), can induce changes in postural sway oscillations of young healthy individuals during quiet standing. A novel initialization of the electrical stimulation was developed to improve subject blinding to the different stimulus conditions including the sham trials. Measures of postural sway, both global and structural, were computed before, during and following the DC stimulation period. The results indicated that, for the adopted conditions, tsDCS did not induce statistically significant changes in postural sway of young healthy individuals during quiet standing.	[de Lima, Felipe Fava; Silva, Cristiano Rocha; Kohn, Andre Fabio] Univ Sao Paulo, Biomed Engn Lab, Escola Politecn, Sao Paulo, Brazil	Universidade de Sao Paulo	de Lima, FF (corresponding author), Univ Sao Paulo, Biomed Engn Lab, Escola Politecn, Sao Paulo, Brazil.	felipefavadelima@usp.br	Silva, Cristiano Rocha/P-1183-2016	Silva, Cristiano Rocha/0000-0001-8545-3321; Fava de Lima, Felipe/0000-0002-7102-8532	Sao Paulo Research Foundation (FAPESP) [2016/10614-4]; Brazilian Council of Science and Technology (CNPq) [311223/2021-4]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian Council of Science and Technology (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Sao Paulo Research Foundation (FAPESP grant #2016/10614-4 from CRS) (https://fapesp.br/) Brazilian Council of Science and Technology (CNPq grant #311223/2021-4 from AFK) (https://www.gov.br/cnpq/pt-br) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed Z, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12157; Albuquerque PL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195276; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Asslander L, 2014, J NEUROPHYSIOL, V111, P1852, DOI 10.1152/jn.00669.2013; Awosika OO, 2019, BRAIN STIMUL, V12, P628, DOI 10.1016/j.brs.2019.01.017; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bear M., 2020, NEUROSCIENCE EXPLORI; Berry HR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173846; Bocci T, 2015, NEUROMODULATION, V18, P686, DOI 10.1111/ner.12298; Bocci T, 2015, J NEUROSCI METH, V254, P18, DOI 10.1016/j.jneumeth.2015.07.012; Bocci T, 2015, J NEUROPHYSIOL, V114, P440, DOI 10.1152/jn.00490.2014; Bocci T, 2014, NEUROSCI LETT, V578, P75, DOI 10.1016/j.neulet.2014.06.037; Bosco G, 2001, PHYSIOL REV, V81, P539, DOI 10.1152/physrev.2001.81.2.539; Busa MA, 2016, J SPORT HEALTH SCI, V5, P44, DOI 10.1016/j.jshs.2016.01.018; Chen YS, 2011, GAIT POSTURE, V33, P169, DOI 10.1016/j.gaitpost.2010.12.008; Cogiamanian Filippo, 2012, Front Psychiatry, V3, P63, DOI 10.3389/fpsyt.2012.00063; Cogiamanian F, 2011, PAIN, V152, P370, DOI 10.1016/j.pain.2010.10.041; Cogiamanian F, 2008, CLIN NEUROPHYSIOL, V119, P2636, DOI 10.1016/j.clinph.2008.07.249; COLLINS JJ, 1993, EXP BRAIN RES, V95, P308, DOI 10.1007/BF00229788; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; de Lima F., 2022, TRANSCUTANEOUS SPINA; de Lima FF, 2020, EFEITO ESTIMULAO TRA; DIENER HC, 1984, ELECTROEN CLIN NEURO, V57, P134, DOI 10.1016/0013-4694(84)90172-X; Donges SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172333; Duarte M, 2010, REV BRAS FISIOTER, V14, P183, DOI 10.1590/S1413-35552010000300003; Elias LA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003944; Esmaeilpour Z, 2018, BRAIN STIMUL, V11, P310, DOI 10.1016/j.brs.2017.12.002; Fernandes SR, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaac38; Field A.P., 2007, DISCOVERING STAT USI, V2; FITZPATRICK R, 1994, J PHYSIOL-LONDON, V478, P173, DOI 10.1113/jphysiol.1994.sp020240; FITZPATRICK R, 1994, J PHYSIOL-LONDON, V480, P395, DOI 10.1113/jphysiol.1994.sp020369; Gandevia SC., 2012, SENSORIMOTOR CONTROL, V508; Gera G, 2020, ARCH PHYS MED REHAB, V101, P258, DOI 10.1016/j.apmr.2019.07.011; Gilfriche P, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00293; Gordon Robertson JHGKSW Graham Caldwell., 2004, RES METHODS BIOMECHA, P90; Hanna-Boutros B, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12276; Hansen C, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00206; Heckman CJ, 2008, NEUROSCIENTIST, V14, P264, DOI 10.1177/1073858408314986; Heide AC, 2014, BRAIN STIMUL, V7, P636, DOI 10.1016/j.brs.2014.06.008; Hodgson CI, 2014, EFFECTS ACUTE COLD E; Hoy KE, 2013, NEUROPSYCHOLOGIA, V51, P1777, DOI 10.1016/j.neuropsychologia.2013.05.018; Hubli M, 2013, CLIN NEUROPHYSIOL, V124, P1187, DOI 10.1016/j.clinph.2012.11.021; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Jamil A, 2017, J PHYSIOL-LONDON, V595, P1273, DOI 10.1113/JP272738; Jankowska E, 2001, J PHYSIOL-LONDON, V533, P31, DOI 10.1111/j.1469-7793.2001.0031b.x; Jorgensen MG, 2012, GAIT POSTURE, V35, P653, DOI 10.1016/j.gaitpost.2011.12.018; Kabakov AY, 2012, J NEUROPHYSIOL, V107, P1881, DOI 10.1152/jn.00715.2011; KATZ R, 1988, BRAIN, V111, P417, DOI 10.1093/brain/111.2.417; Knotkova H., 2019, PRACTICAL GUIDE TRAN, P81; Krishnamoorthy V, 2002, EXP BRAIN RES, V147, P71, DOI 10.1007/s00221-002-1206-6; Kuck A, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa7960; Kuck A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00151; Lafond D, 2004, J BIOMECH, V37, P1421, DOI 10.1016/S0021-9290(03)00251-3; Lamy JC, 2013, J NEUROPHYSIOL, V110, P109, DOI 10.1152/jn.00116.2013; Lamy JC, 2012, J NEUROPHYSIOL, V108, P906, DOI 10.1152/jn.10898.2011; Leach JM, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00126; Learmonth G, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00664; Lenoir C, 2018, NEUROSCIENCE, V393, P150, DOI 10.1016/j.neuroscience.2018.10.007; Li L, 2019, J SPORT HEALTH SCI, V8, P218, DOI 10.1016/j.jshs.2018.09.010; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2009, CLIN NEUROPHYSIOL, V120, P1161, DOI 10.1016/j.clinph.2009.01.022; Lim CY, 2011, NEUROREPORT, V22, P819, DOI 10.1097/WNR.0b013e32834b939d; Magalhaes FH, 2014, EUR J APPL PHYSIOL, V114, P1129, DOI 10.1007/s00421-014-2846-5; Magalhaes FH, 2012, EXP BRAIN RES, V217, P175, DOI 10.1007/s00221-011-2983-6; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53, DOI 10.1016/0957-4271(95)00014-3; Marangolo P, 2020, BRAIN RES, V1727, DOI 10.1016/j.brainres.2019.146564; Martinelli AR, 2015, EXP BRAIN RES, V233, P1399, DOI 10.1007/s00221-015-4214-z; Maurer C, 2000, NEUROSCI LETT, V281, P99, DOI 10.1016/S0304-3940(00)00814-4; Meyer PF, 2004, EXP BRAIN RES, V156, P505, DOI 10.1007/s00221-003-1804-y; Meyer-Friessem CH, 2015, NEUROSCI LETT, V589, P153, DOI 10.1016/j.neulet.2015.01.029; Mochizuki L, 2006, FISIOT MOV, V19, P11; Murray LM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18872-z; Nierat MC, 2014, J NEUROSCI, V34, P14420, DOI 10.1523/JNEUROSCI.1288-14.2014; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Paillard T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/891390; Palm U, 2013, BRAIN STIMUL, V6, P690, DOI 10.1016/j.brs.2013.01.005; Paulus W., 2019, PRACTICAL GUIDE TRAN, P115; Pereira M, 2018, CLIN NEUROPHYSIOL, V129, P1999, DOI 10.1016/j.clinph.2018.07.002; Perrotta A, 2016, CLIN NEUROPHYSIOL, V127, P755, DOI 10.1016/j.clinph.2015.01.031; Peterka RJ, 2000, BIOL CYBERN, V82, P335, DOI 10.1007/s004220050587; PierrotDeseilligny E, 2012, CIRCUITRY OF THE HUMAN SPINAL CORD: SPINAL AND CORTICOSPINAL MECHANISMS OF MOVEMENT, P1, DOI 10.1017/CBO9781139026727; PierrotDeseilligny E, 2005, CIRCUITRY OF THE HUMAN SPINAL CORD: ITS ROLE IN MOTOR CONTROL AND MOVEMENT DISORDERS, P1, DOI 10.1017/CBO9780511545047; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Poppele R, 2003, TRENDS NEUROSCI, V26, P269, DOI 10.1016/S0166-2236(03)00073-0; Pradat PF., 2014, NEUROPROTECTIVE STRA; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Priplata A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.238101; Rekling JC, 2000, PHYSIOL REV, V80, P767, DOI 10.1152/physrev.2000.80.2.767; Roman-Liu D, 2018, ARCH GERONTOL GERIAT, V77, P68, DOI 10.1016/j.archger.2018.04.007; Ruhe A, 2010, GAIT POSTURE, V32, P436, DOI 10.1016/j.gaitpost.2010.09.012; Siedlecka B, 2015, ACTA BIOENG BIOMECH, V17, P95, DOI 10.5277/ABB-00150-2014-03; Silva CR, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01072; Smith SS, 2012, EXP BRAIN RES, V221, P329, DOI 10.1007/s00221-012-3175-8; Taube W, 2006, J APPL PHYSIOL, V101, P420, DOI 10.1152/japplphysiol.01447.2005; Therkildsen ER, 2022, EXP BRAIN RES, V240, P159, DOI 10.1007/s00221-021-06243-0; Tokuno CD, 2007, ACTA PHYSIOL, V191, P229, DOI 10.1111/j.1748-1716.2007.01727.x; Tokuno CD, 2008, J APPL PHYSIOL, V104, P1359, DOI 10.1152/japplphysiol.00857.2007; Truini A, 2011, EUR J PAIN, V15, P1023, DOI 10.1016/j.ejpain.2011.04.009; Vignaud P, 2018, NEUROPHYSIOL CLIN, V48, P89, DOI 10.1016/j.neucli.2018.02.001; Vitkovic J, 2016, AUDIOL NEURO-OTOL, V21, P195, DOI 10.1159/000445100; Winkler T, 2010, CLIN NEUROPHYSIOL, V121, P957, DOI 10.1016/j.clinph.2010.01.014; Winter D. A, 1995, GAIT POSTURE, V3, P193; Yamaguchi T, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14531; Yamaguchi T, 2013, I IEEE EMBS C NEUR E, P275, DOI 10.1109/NER.2013.6695925; Yamamoto T, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12329; Zatsiorsky VM, 1999, MOTOR CONTROL, V3, P28, DOI 10.1123/mcj.3.1.28	107	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267718	10.1371/journal.pone.0267718	http://dx.doi.org/10.1371/journal.pone.0267718			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482798	gold, Green Published			2023-01-03	WOS:000794035700061
J	Eroglu, TE; Blom, MT; Souverein, PC; Yasmina, A; de Boer, A; Tan, HL				Eroglu, Talip E.; Blom, Marieke T.; Souverein, Patrick C.; Yasmina, Alfi; de Boer, Anthonius; Tan, Hanno L.		ESCAPE-NET Investigators	Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study	PLOS ONE			English	Article							ACUTE CORONARY SYNDROMES; CALCIUM; ASPIRIN; ARRHYTHMIAS; ISCHEMIA; INSIGHTS; DRUGS	Aim Activated blood platelet products facilitate myocardial intracellular Ca2+ overload, thereby provoking afterdepolarizations and increasing susceptibility of ischemic myocardium to ventricular fibrillation (VF). These effects are counteracted in vitro by acetylsalicylic acid (ASA), but no prior study investigated whether ASA is associated with decreased out-of-hospital cardiac arrest (OHCA) risk on a population level. Therefore, we studied whether ASA and other antiplatelet drugs (carbasalate calcium, clopidogrel) are associated with decreased risk of OHCA. Methods We conducted a population-based case-control study among individuals (772 OHCA-cases with documented VT/VF, 2444 non-OHCA-controls) who had used antiplatelet drugs in the year before index-date (OHCA-date), and studied the association between current antiplatelet drug use and OHCA-risk with multivariable logistic regression analysis. Results ASA use was associated with reduced OHCA-risk (adjusted odds ratio (ORadj) 0.6 [0.5-0.8]), and more so in women (ORadi 0.3 [0.2-0.6]) than in men (ORadi 0.7 [0.5-0.95], P-interaction 0.021). Carbasalate calcium was associated with decreased OHCA-risk in women (ORadj 0.5 [0.3-0.9]), but not in men (OR(adj )1.3 [0.96-1.7], P-interaction 0.005). Clopidogrel was not associated with reduction in OHCA-risk. Risk reduction associated with ASA in patients with OHCA was similar in the presence of acute myocardial infarction (AMI) (OR(adj )0.6 [0.4-0.9]) and in the absence of AMI (ORadi 0.7 [0.4-1.2]). Conclusion ASA use was associated with reduced OHCA-risk in both sexes, and more so in women, while carbasalate calcium only protected women. Clopidogrel was not associated with reduced OHCA-risk.	[Eroglu, Talip E.; Blom, Marieke T.; Tan, Hanno L.] Univ Amsterdam, Acad Med Ctr, Heart Ctr, Dept Cardiol, Amsterdam, Netherlands; [Eroglu, Talip E.; Souverein, Patrick C.; de Boer, Anthonius] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Eroglu, Talip E.] Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Copenhagen, Denmark; [Yasmina, Alfi] Lambung Mangkurat Univ, Fac Med, Dept Pharmacol, Banjarmasin, Indonesia; [Tan, Hanno L.] Netherlands Heart Inst, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Universitas Lambung Mangkurat	Tan, HL (corresponding author), Univ Amsterdam, Acad Med Ctr, Heart Ctr, Dept Cardiol, Amsterdam, Netherlands.; Tan, HL (corresponding author), Netherlands Heart Inst, Utrecht, Netherlands.	h.l.tan@amc.nl		Tan, Hanno/0000-0002-7905-5818	European Union's Horizon 2020 research and innovation programme under acronym ESCAPENET [733381]; Dutch Heart Foundation [CVON2017-15 RESCUED, CVON2018-30 Predict-2]	European Union's Horizon 2020 research and innovation programme under acronym ESCAPENET; Dutch Heart Foundation(Netherlands Heart Foundation)	This project has received funding from the European Union's Horizon 2020 research and innovation programme under acronym ESCAPENET, registered under grant agreement No 733381 (T.E.E., M.T.B., H.L.T. URL: https://ec.europa.eu/programmes/horizon2020/en), and the Dutch Heart Foundation (CVON2017-15 RESCUED and CVON2018-30 Predict-2; M.T.B., H.L.T. URL: https://www.vo.eu/home/about-vo/sponsoring/hartstichting-the-dutch-heart-foundation/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bardai A, 2013, EUR HEART J, V34, P1506, DOI 10.1093/eurheartj/eht054; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Blom MT, 2014, OPEN HEART, V1, DOI 10.1136/openhrt-2014-000112; Buurma H, 2008, J CLIN PHARM THER, V33, P17, DOI 10.1111/j.1365-2710.2008.00878.x; Coronel R, 1997, CIRCULATION, V96, P3985; de Jong JSSG, 2011, J MOL CELL CARDIOL, V51, P347, DOI 10.1016/j.yjmcc.2011.05.016; Dhanjal TS, 2013, CIRC-ARRHYTHMIA ELEC, V6, P995, DOI 10.1161/CIRCEP.113.000591; FAGBEMI SO, 1984, EUR J PHARMACOL, V97, P283, DOI 10.1016/0014-2999(84)90461-8; GOLDSTEIN JA, 1994, CIRCULATION, V90, P139, DOI 10.1161/01.CIR.90.1.139; Hall R, 2011, ANESTH ANALG, V112, P292, DOI 10.1213/ANE.0b013e318203f38d; Herings R., 2012, PHARMACOEPIDEM DR S, P270, DOI [10.1002/9781119959946.ch18, DOI 10.1002/9781119959946.CH18]; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Jneid H, 2003, ARCH INTERN MED, V163, P1145, DOI 10.1001/archinte.163.10.1145; Kalik ZM, 2017, EXP PHYSIOL, V102, P804, DOI 10.1113/EP085977; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Li Q, 2013, CARDIOLOGY, V126, P27, DOI 10.1159/000353365; Li YY, 1997, PROSTAGLANDINS, V54, P511, DOI 10.1016/S0090-6980(97)00122-6; MOSCHOS CB, 1978, CIRCULATION, V57, P681, DOI 10.1161/01.CIR.57.4.681; Myerburg RJ., 2007, BRAUNWALDS HEART DIS, P933; Pham TV, 2002, CARDIOVASC RES, V53, P752, DOI 10.1016/S0008-6363(01)00449-7; Rang HP., 2012, RANG DALES PHARM, V7th ed., P318; Schafer AI, 1996, AM J MED, V101, P199, DOI 10.1016/S0002-9343(96)80077-5; Straus SMJM, 2005, EUR HEART J, V26, P2007, DOI 10.1093/eurheartj/ehi312; Van Hoeijen DA, 2015, EUROPACE, V17, P753, DOI 10.1093/europace/euv014; Verkerk AO, 2005, INT HEART J, V46, P1105, DOI 10.1536/ihj.46.1105; Wang X, 2011, J VET PHARMACOL THER, V34, P410, DOI 10.1111/j.1365-2885.2010.01250.x; Woosley R. L., QTDRUGS LIST; Zakhrabova-Zwiauer OM, 2013, INT J CARDIOL, V167, P303, DOI 10.1016/j.ijcard.2012.09.188; Zorginstituut Nederland, AANTAL GEBRUIKERS 20	30	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0267016	10.1371/journal.pone.0267016	http://dx.doi.org/10.1371/journal.pone.0267016			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35675268	Green Published, gold			2023-01-03	WOS:000843619700065
J	Hammerschmidt, J; Heier, L; Ernstmann, N				Hammerschmidt, Judith; Heier, Lina; Ernstmann, Nicole			Enablement of nursing home residents in infection prevention during general practitioner visits: A qualitative study	PLOS ONE			English	Article							HEALTH-CARE; HAND HYGIENE; RISK-FACTORS; PREVALENCE; RESISTANCE	Introduction Hand hygiene measures are essential to protect nursing home residents against nosocomial infections. Evidence on the prevention of nosocomial infections for nursing home residents by general practitioners during their medical visits in nursing homes or how they enable nursing home residents to perform hand hygiene measures is lacking. This study aimed to explore hand hygiene behaviors of general practitioners in nursing homes, their attitudes toward infection prevention measures, and the enablement of nursing home residents in performing hand hygiene measures. Materials and methods Semi-structured interviews were conducted with general practitioners and nursing home residents in Germany. Interviews were audio-recorded and transcribed. Data were analyzed using thematic content analysis. Results Overall, 12 general practitioners and 12 nursing home residents participated in the study. The general practitioners expressed the fact that the possibilities for practicing hand hygiene differ in individual nursing homes. For nursing home residents, the availability of hand rub solutions was limited. Instructions for residents on hand disinfection from general practitioners was not described. Due to the lack of enablement, the residents' knowledge on how to correctly perform hand hygiene was low, although some of the nursing home residents have experience with multidrug-resistant organisms. The nursing home residents varied in their needs for active participation and enablement during the general practitioners visit. Conclusion Nursing home residents require continuous enablement by their general practitioners to maintain adequate hand hygiene. Therefore, general practitioners should consider the different needs of nursing home residents to ensure adequate individual hand hygiene and safety for the residents. Existing guidelines for infection prevention and control do not adequately cover the nursing home care setting for the enablement of residents to enquire about hand hygiene.	[Hammerschmidt, Judith; Heier, Lina; Ernstmann, Nicole] Univ Hosp Bonn, Inst Patient Safety, Bonn, Germany; [Heier, Lina; Ernstmann, Nicole] Univ Hosp Bonn, Ctr Hlth Commun & Hlth Serv Res, Dept Psychosomat Med & Psychotherapy, Bonn, Germany	University of Bonn; University of Bonn	Ernstmann, N (corresponding author), Univ Hosp Bonn, Inst Patient Safety, Bonn, Germany.; Ernstmann, N (corresponding author), Univ Hosp Bonn, Ctr Hlth Commun & Hlth Serv Res, Dept Psychosomat Med & Psychotherapy, Bonn, Germany.	nicole.ernstmann@ukbonn.de		Ernstmann, Nicole/0000-0001-7685-6110	Bundesministerium fur Gesundheit [IIA5-2512FSB105]	Bundesministerium fur Gesundheit	The present study was supported by Bundesministerium fur Gesundheit in the form of a grant (No. IIA5-2512FSB105); the funding from this source was received by JH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegranzi B, 2009, J HOSP INFECT, V73, P305, DOI 10.1016/j.jhin.2009.04.019; [Anonymous], 1994, BGBL S, V1014, P2797; [Anonymous], OFFICIAL J EUROPEAN; [Anonymous], 2018, FNFTE BUCH SOZIALGES; Augurzky Boris., 2020, SCHRIFTENREIHE GESUN; Barr PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126553; Bundesamt S., 2015, PFLEGESTATISTIK PFLE; Denzin NK, 2017, RES ACT THEORETICAL, DOI DOI 10.4324/9781315134543; Fleischmann N, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0522-z; Gould D., 2021, PROBLEMMY 5 MOMENTS; Gould Dinah, 2018, J Infect Prev, V19, P108, DOI 10.1177/1757177417751285; Gould DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005186.pub3; Hammerschmidt J, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4347-z; Hudon C, 2011, J EVAL CLIN PRACT, V17, P143, DOI 10.1111/j.1365-2753.2010.01413.x; Hughes C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006354.pub4; Hughes C, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006354.pub3; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Loeb MB, 2003, AM J EPIDEMIOL, V157, P40, DOI 10.1093/aje/kwf173; Mayring P., 2015, QUALITATIVE INHALTSA, Vtwelfth; McClean P, 2012, J HOSP INFECT, V81, P264, DOI 10.1016/j.jhin.2012.05.005; McGuckin M, 2013, J HOSP INFECT, V84, P191, DOI 10.1016/j.jhin.2013.01.014; Mitchell SL, 2014, JAMA INTERN MED, V174, P1660, DOI 10.1001/jamainternmed.2014.3918; Mody L, 2015, INFECT CONT HOSP EP, V36, P1155, DOI 10.1017/ice.2015.143; Pellino T, 1998, Orthop Nurs, V17, P48; Petrignani M, 2015, J HOSP INFECT, V89, P163, DOI 10.1016/j.jhin.2014.11.015; Pittet D, 2009, INFECT CONT HOSP EP, V30, P611, DOI 10.1086/600379; Ricchizzi Enrico, 2018, Euro Surveill, V23, DOI 10.2807/1560-7917.ES.2018.23.46.1800394; Robert Koch-Institut (RKI), STAND PRAX; Robert Koch-Institut (RKI), PRVENT MAN COVID 19; Roghmann MC, 2015, INFECT CONT HOSP EP, V36, P1050, DOI 10.1017/ice.2015.119; Rooney PJ, 2009, J ANTIMICROB CHEMOTH, V64, P635, DOI 10.1093/jac/dkp220; Ruscher C, 2012, BUNDESGESUNDHEITSBLA, V55, P1444, DOI 10.1007/s00103-012-1555-7; Ruscher C, 2015, BUNDESGESUNDHEITSBLA, V58, P436, DOI 10.1007/s00103-015-2126-5; Sak G, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0448-x; Smith PW, 2008, INFECT CONT HOSP EP, V29, P785, DOI 10.1086/592416; Stone ND, 2012, INFECT CONT HOSP EP, V33, P965, DOI 10.1086/667743; Strausbaugh LJ, 2000, INFECT CONT HOSP EP, V21, P674, DOI 10.1086/501712; Tacconelli E, 2019, LANCET INFECT DIS, V19, P4, DOI 10.1016/S1473-3099(18)30648-0; Theile G, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-24; Valensi P, 2008, INT J CLIN PRACT, V62, P1809, DOI 10.1111/j.1742-1241.2008.01917.x; van den Dool C, 2016, INFECT CONT HOSP EP, V37, P761, DOI 10.1017/ice.2016.59; Who, 2015, GUID START ANT THER; Wieler LH, 2018, BUNDESGESUNDHEITSBLA, V61, P495, DOI 10.1007/s00103-018-2732-0; World Health Organization, 2012, SAV LIV CLEAN YOUR H	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266502	10.1371/journal.pone.0266502	http://dx.doi.org/10.1371/journal.pone.0266502			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390089	gold, Green Published			2023-01-03	WOS:000795077200084
J	Jemth, AS; Scaletti, ER; Homan, E; Stenmark, P; Helleday, T; Michel, M				Jemth, Ann-Sofie; Scaletti, Emma Rose; Homan, Evert; Stenmark, Pal; Helleday, Thomas; Michel, Maurice			Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGO HEMORRHAGIC-FEVER; MTH1; EFFICACY	Remdesivir and molnupiravir have gained considerable interest because of their demonstrated activity against SARS-CoV-2. These antivirals are converted intracellularly to their active triphosphate forms remdesivir-TP and molnupiravir-TP. Cellular hydrolysis of these active metabolites would consequently decrease the efficiency of these drugs; however, whether endogenous enzymes that can catalyze this hydrolysis exist is unknown. Here, we tested remdesivir-TP as a substrate against a panel of human hydrolases and found that only Nudix hydrolase (NUDT) 18 catalyzed the hydrolysis of remdesivir-TP with notable activity. The k(cat)/K-m value of NUDT18 for remdesivir-TP was determined to be 17,700 s(-1)M(-1), suggesting that NUDT18-catalyzed hydrolysis of remdesivir-TP may occur in cells. Moreover, we demonstrate that the triphosphates of the antivirals ribavirin and molnupiravir are also hydrolyzed by NUDT18, albeit with lower efficiency than Remdesivir-TP. Low activity was also observed with the triphosphate forms of sofosbuvir and aciclovir. This is the first report showing that NUDT18 hydrolyzes triphosphates of nucleoside analogs of exogenous origin, suggesting that NUDT18 can act as a cellular sanitizer of modified nucleotides and may influence the antiviral efficacy of remdesivir, molnupiravir, and ribavirin. As NUDT18 is expressed in respiratory epithelial cells, it may limit the antiviral efficacy of remdesivir and molnupiravir against SARS-CoV-2 replication by decreasing the intracellular concentration of their active metabolites at their intended site of action.	[Jemth, Ann-Sofie; Homan, Evert; Helleday, Thomas; Michel, Maurice] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Solna, Sweden; [Scaletti, Emma Rose; Stenmark, Pal] Stockholm Univ, Dept Biochem & Biophys, Stockholm, Sweden; [Helleday, Thomas] Univ Sheffield, Med Sch, Dept Oncol & Metab, Weston Pk Canc Ctr, Sheffield, S Yorkshire, England	Karolinska Institutet; Stockholm University; University of Sheffield	Jemth, AS; Michel, M (corresponding author), Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Solna, Sweden.	ann-sofie.jemth@ki.se; maurice.michel@ki.se		Scaletti, Emma Rose/0000-0002-8741-8981	European Research Council, European Union (TAROX Program) [ERC-695376]; Swedish Research Council, Sweden [2015-00162, 2017-06095, 2018-03406]; Torsten and Ragnar Soderberg Foundation, Sweden; Knut and Alice Wallenberg Foundation, Sweden [KAW2014.0273]; Swedish Cancer Society, Sweden [CAN2018/0658, 20 1287 PjF]; KI funds [2020-02211]; Alfred Osterlund foundation, Sweden; Ake Olsson foundation for hematological research [2020-00306]; Innovative Medicines Initiative 2 Joint Undertaking (JU) [875510]; European Union; EFPIA; Royal Institution for the Advancement of Learning McGill University; Kungliga Tekniska Hoegskolan; Diamond Light Source Limited; Swedish Research Council	European Research Council, European Union (TAROX Program); Swedish Research Council, Sweden(Swedish Research Council); Torsten and Ragnar Soderberg Foundation, Sweden; Knut and Alice Wallenberg Foundation, Sweden(Knut & Alice Wallenberg Foundation); Swedish Cancer Society, Sweden(Swedish Cancer Society); KI funds; Alfred Osterlund foundation, Sweden; Ake Olsson foundation for hematological research; Innovative Medicines Initiative 2 Joint Undertaking (JU); European Union(European Commission); EFPIA; Royal Institution for the Advancement of Learning McGill University; Kungliga Tekniska Hoegskolan; Diamond Light Source Limited; Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by the European Research Council, European Union (TAROX Program, ERC-695376 to T. H.), the Swedish Research Council, Sweden (2015-00162, 2017-06095 to T. H. and 2018-03406 to P. S.), the Torsten and Ragnar Soderberg Foundation, Sweden (to T. H.), the Knut and Alice Wallenberg Foundation, Sweden (KAW2014.0273 to T. H.), the Swedish Cancer Society, Sweden (CAN2018/0658 to T. H. and 20 1287 PjF to P. S.), KI funds (2020-02211 to A. S. J), the Alfred Osterlund foundation, Sweden (to P. S.), the Ake Olsson foundation for hematological research (2020-00306 to M. M.). This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan, Diamond Light Source Limited. This communication reflects the views of the authors and the JU is not liable for any use that may be made of the information contained herein. Funding for open access charge: The Swedish Research Council.	Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18; Artese A, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100721; Ascioglu S, 2011, J ANTIMICROB CHEMOTH, V66, P1215, DOI 10.1093/jac/dkr136; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Carreras-Puigvert J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01642-w; de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117; Debing Y, 2013, CURR OPIN VIROL, V3, P217, DOI 10.1016/j.coviro.2013.03.001; Dokuzoguz B, 2013, CLIN INFECT DIS, V57, P1270, DOI 10.1093/cid/cit527; Fellay J, 2010, NATURE, V464, P405, DOI 10.1038/nature08825; Fischer WA., 2021, MEDRXIV, DOI [DOI 10.1101/2021.06.17.21258639, 10.1101/2021.06.17.21258639]; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Hashiguchi K, 2018, MUTAT RES-FUND MOL M, V808, P10, DOI 10.1016/j.mrfmmm.2018.01.002; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840; Jemth AS, 2018, NUCLEIC ACIDS RES, V46, P10888, DOI 10.1093/nar/gky896; Kabinger F, 2021, NAT STRUCT MOL BIOL, V28, P740, DOI 10.1038/s41594-021-00651-0; Kamar N, 2014, NEW ENGL J MED, V370, P1111, DOI 10.1056/NEJMoa1215246; Loving KA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003741; Michel M, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00443; Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128; Ngo BT, 2021, EXPERT OPIN INV DRUG, V30, P505, DOI 10.1080/13543784.2021.1901883; Nystrom K, 2018, J VIROL, V92, DOI 10.1128/JVI.01087-18; Painter GR, 2019, ANTIVIR RES, V171, DOI 10.1016/j.antiviral.2019.104597; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Scaletti ER, 2020, J BIOL CHEM, V295, P4761, DOI 10.1074/jbc.RA120.012636; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; Takagi Y, 2012, J BIOL CHEM, V287, P21541, DOI 10.1074/jbc.M112.363010; Tempestilli M, 2020, J ANTIMICROB CHEMOTH, V75, P2977, DOI 10.1093/jac/dkaa239; Teoh SL, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01857; Ting Wang J. F., 2020, J BIOANAL BIOMED, DOI [10.37421/Jbabm.2020.12.237, DOI 10.37421/JBABM.2020.12.237]; Toots M, 2020, TRANSL RES, V218, P16, DOI 10.1016/j.trsl.2019.12.002; Valerie NCK, 2016, CANCER RES, V76, P5501, DOI 10.1158/0008-5472.CAN-16-0584; Waz S, 2017, J BIOL CHEM, V292, P2785, DOI 10.1074/jbc.M116.749713; Zhang SM, 2021, CELL CHEM BIOL, V28, P1693, DOI 10.1016/j.chembiol.2021.06.001; Zhang SM, 2020, NAT CHEM BIOL, V16, P1120, DOI 10.1038/s41589-020-0592-z	41	1	1	3	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG	2022	298	8							102169	10.1016/j.jbc.2022.102169	http://dx.doi.org/10.1016/j.jbc.2022.102169			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	3S2WH	35732208	gold, Green Accepted, Green Published			2023-01-03	WOS:000839461200004
J	Halasa, NB; Olson, SM; Staat, MA; Newhams, MM; Price, AM; Pannaraj, PS; Boom, JA; Sahni, LC; Chiotos, K; Cameron, MA; Bline, KE; Hobbs, CV; Maddux, AB; Coates, BM; Michelson, KN; Heidemann, SM; Irby, K; Nofziger, RA; Mack, EH; Smallcomb, L; Schwartz, SP; Walker, TC; Gertz, SJ; Schuster, JE; Kamidani, S; Tarquinio, KM; Bhumbra, SS; Maamari, M; Hume, JR; Crandall, H; Levy, ER; Zinter, MS; Bradford, TT; Flori, HR; Cullimore, ML; Kong, MCL; Cvijanovich, NZ; Gilboa, SM; Polen, KN; Campbell, AP; Randolph, AG; Patel, MM				Halasa, Natasha B.; Olson, Samantha M.; Staat, Mary A.; Newhams, Margaret M.; Price, Ashley M.; Pannaraj, Pia S.; Boom, Julie A.; Sahni, Leila C.; Chiotos, Kathleen; Cameron, Melissa A.; Bline, Katherine E.; Hobbs, Charlotte V.; Maddux, Aline B.; Coates, Bria M.; Michelson, Kelly N.; Heidemann, Sabrina M.; Irby, Katherine; Nofziger, Ryan A.; Mack, Elizabeth H.; Smallcomb, Laura; Schwartz, Stephanie P.; Walker, Tracie C.; Gertz, Shira J.; Schuster, Jennifer E.; Kamidani, Satoshi; Tarquinio, Keiko M.; Bhumbra, Samina S.; Maamari, Mia; Hume, Janet R.; Crandall, Hillary; Levy, Emily R.; Zinter, Matt S.; Bradford, Tamara T.; Flori, Heidi R.; Cullimore, Melissa L.; Kong, Michele; Cvijanovich, Natalie Z.; Gilboa, Suzanne M.; Polen, Kara N.; Campbell, Angela P.; Randolph, Adrienne G.; Patel, Manish M.		Overcoming Covid 19 Investigators	Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MESSENGER-RNA VACCINATION; PREGNANT-WOMEN; UNITED-STATES; CHILDREN	BACKGROUND Infants younger than 6 months of age are at high risk for complications of coronavirus disease 2019 (Covid-19) and are not eligible for vaccination. Transplacental transfer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection against Covid-19 in infants. METHODS We used a case-control test-negative design to assess the effectiveness of maternal vaccination during pregnancy against hospitalization for Covid-19 among infants younger than 6 months of age. Between July 1, 2021, and March 8, 2022, we enrolled infants hospitalized for Covid-19 (case infants) and infants hospitalized without Covid-19 (control infants) at 30 hospitals in 22 states. We estimated vaccine effectiveness by comparing the odds of full maternal vaccination (two doses of mRNA vaccine) among case infants and control infants during circulation of the B.1.617.2 (delta) variant (July 1, 2021, to December 18, 2021) and the B.1.1.259 (omicron) variant (December 19, 2021, to March 8, 2022). RESULTS A total of 537 case infants (181 of whom had been admitted to a hospital during the delta period and 356 during the omicron period; median age, 2 months) and 512 control infants were enrolled and included in the analyses; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against Covid-19 during pregnancy. Among the case infants, 113 (21%) received intensive care (64 [12%] received mechanical ventilation or vasoactive infusions). Two case infants died from Covid-19; neither infant's mother had been vaccinated during pregnancy. The effectiveness of maternal vaccination against hospitalization for Covid-19 among infants was 52% (95% confidence interval [CI], 33 to 65) overall, 80% (95% CI, 60 to 90) during the delta period, and 38% (95% CI, 8 to 58) during the omicron period. Effectiveness was 69% (95% CI, 50 to 80) when maternal vaccination occurred after 20 weeks of pregnancy and 38% (95% CI, 3 to 60) during the first 20 weeks of pregnancy. CONCLUSIONS Maternal vaccination with two doses of mRNA vaccine was associated with a reduced risk of hospitalization for Covid-19, including for critical illness, among infants younger than 6 months of age.	[Halasa, Natasha B.] Vanderbilt Univ, Div Pediat Infect Dis, Dept Pediat, Med Ctr, Nashville, TN USA; [Olson, Samantha M.; Price, Ashley M.; Gilboa, Suzanne M.; Polen, Kara N.; Campbell, Angela P.; Patel, Manish M.] Emory Univ, Sch Med, Covid19 Response Team Ctrs Dis Control & Prevent, Atlanta, GA USA; [Kamidani, Satoshi] Emory Univ, Ctr Childhood Infect & Vaccines Childrens Healthc, Atlanta, GA USA; [Kamidani, Satoshi] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA USA; [Tarquinio, Keiko M.] Emory Univ, Div Crit Care Med, Dept Pediat, Childrens Healthcare Atlanta,Sch Med, Atlanta, GA USA; [Staat, Mary A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Coll Med, Cincinnati, OH USA; [Bline, Katherine E.] Nationwide Childrens Hosp, Div Pediat Crit Care Med, Columbus, OH USA; [Nofziger, Ryan A.] Akron Childrens Hosp, Div Crit Care Med, Dept Pediat, Akron, OH USA; [Newhams, Margaret M.; Randolph, Adrienne G.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA; [Randolph, Adrienne G.] Harvard Med Sch, Dept Anaesthesia & Pediat, Boston, MA 02115 USA; [Pannaraj, Pia S.] Childrens Hosp Los Angeles, Div Infect Dis, Los Angeles, CA USA; [Pannaraj, Pia S.] Univ Southern Calif, Dept Pediat & Molr Microbiol & Immunol, Los Angeles, CA 90007 USA; [Cameron, Melissa A.] Univ Calif San Diego, Div Pediat Hosp Med, Rady Childrens Hosp, San Diego, CA USA; [Zinter, Matt S.] Univ Calif San Francisco, Div Crit Care Med & Allergy Immunol & Bone Marrow, Dept Pediat, San Francisco, CA USA; [Cvijanovich, Natalie Z.] UCSF Benioff Childrens Hosp, Div Crit Care Med, Oakland, CA USA; [Boom, Julie A.; Sahni, Leila C.] Texas Childrens Hosp, Dept Pediat, Baylor Coll Med, Immunizat Project, Houston, TX USA; [Chiotos, Kathleen] Childrens Hosp Philadelphia, Div Crit Care Med, Dept Anesthesiol & Crit Care, Philadelphia, PA USA; [Hobbs, Charlotte V.] Univ Mississippi, Div Infect Dis, Dept Pediat, Med Ctr, Jackson, MS USA; [Maddux, Aline B.] Univ Colorado, Sect Crit Care Med, Dept Pediat, Sch Med, Aurora, CO USA; [Maddux, Aline B.] Univ Colorado, Hosp Colorado, Sch Med, Aurora, CO USA; [Coates, Bria M.; Michelson, Kelly N.] Northwestern Univ, Div Crit Care Med, Dept Pediat, Feinberg Sch Med, Chicago, IL USA; [Coates, Bria M.; Michelson, Kelly N.] Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Heidemann, Sabrina M.] Cent Michigan Univ, Childrens Hosp Michigan, Div Pediat Crit Care Med, Detroit, MI USA; [Flori, Heidi R.] Mott Childrens Hosp, Dept Pediat, Div Pediat Crit Care Med, Ann Arbor, MI USA; [Flori, Heidi R.] Univ Michigan, Ann Arbor, MI USA; [Irby, Katherine] Arkansas Childrens Hosp, Pediat Crit Care Sect, Dept Pediat, Little Rock, AR USA; [Mack, Elizabeth H.] Med Univ South Carolina, Div Pediat Crit Care Med, Charleston, SC USA; [Smallcomb, Laura] Med Univ South Carolina, Dept Pediat, Charleston, SC USA; [Schwartz, Stephanie P.; Walker, Tracie C.] Univ N Carolina, Chapel Hill Childrens Hosp, Dept Pediat, Chapel Hill, NC USA; [Gertz, Shira J.] Cooperman Barnabas Med Ctr, Div Pediat Crit Care, Dept Pediat rics, Livingston, NJ USA; [Schuster, Jennifer E.] Childrens Mercy Kansas City, Div Pediat Infect Dis, Dept Pediatr, Kansas City, MO USA; [Bhumbra, Samina S.] Indiana Univ Sch Med, Dept Pediat, Ryan White Ctr Pediat Infect Dis & Global Hlth, Indianapolis, IN USA; [Maamari, Mia] Univ Texas SouthWestern, Div Crit Care Med, Dept Pediat, Childrens Med Ctr, Dallas, TX USA; [Hume, Janet R.] Univ Minnesota, Div Pediat Crit Care, Mason Childrens Hosp, Minneapolis, MN USA; [Levy, Emily R.] Mayo Clin, Div Pediat Infect Dis & Pediat Crit Care Med, Dept Pediat & Adolescent Med, Rochester, MN USA; [Hobbs, Charlotte V.] Univ Utah, Div Pediat Crit Care, Dept Pediat, Salt Lake City, UT USA; [Bradford, Tamara T.] Louisiana State Univ, Div Cardiol, Dept Pediatr, Hlth Sci Ctr, New Orleans, LA USA; [Cullimore, Melissa L.] Childrens Hosp & Med Ctr, Div Pediat Crit Care, Dept Pediat, Omaha, NE USA; [Kong, Michele] Univ Alabama Birmingham, Div Pediat Crit Care Med, Dept Pediat, Birmingham, AL USA	Vanderbilt University; Emory University; Emory University; Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Akron Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Children's Hospital Los Angeles; University of Southern California; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Mississippi; University of Mississippi Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Central Michigan University; Children's Hospital of Michigan; University of Michigan System; University of Michigan; Arkansas Children's Hospital; Medical University of South Carolina; Medical University of South Carolina; University of North Carolina; University of North Carolina Chapel Hill; Children's Mercy Hospital; Indiana University System; Indiana University Bloomington; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Utah System of Higher Education; University of Utah; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Alabama System; University of Alabama Birmingham	Patel, MM (corresponding author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,H24 7, Atlanta, GA 30329 USA.	Aul3@cdc.gov	Bhumbra, Samina/AAX-8266-2020	Bhumbra, Samina/0000-0002-4036-0479; Olson, Samantha/0000-0003-0589-5766; Hume, Janet/0000-0002-8891-6800	Centers for Disease Control and Prevention; Boston Children's Hospital	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Boston Children's Hospital	Supported by the Centers for Disease Control and Prevention under a contract with Boston Children's Hospital.	Abu Raya B, 2017, LANCET INFECT DIS, V17, pE209, DOI 10.1016/S1473-3099(17)30190-1; [Anonymous], 2002, Bull World Health Organ, V80, P983; Azziz-Baumgartner E, 2021, JAMA-J AM MED ASSOC, V325, P2257, DOI 10.1001/jama.2021.7776; Baird JK, 2021, J HUM LACT, V37, P492, DOI 10.1177/08903344211030168; BEHARIER O, 2021, J CLIN INVEST, V131, DOI [DOI 10.1172/JCI150319, 10.1172/JCI150319]; Butt AA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI153662; Carlsen EO, 2022, JAMA INTERN MED, V182, P825, DOI 10.1001/jamainternmed.2022.2442; Centers for Disease Control and Prevention, COVID DAT TRACK VAR; Centers for Disease Control and Prevention, COVID 19 VACC PREGN; Chua HY, 2020, EPIDEMIOLOGY, V31, P43, DOI 10.1097/EDE.0000000000001116; Dagan N, 2021, NAT MED, V27, P1693, DOI 10.1038/s41591-021-01490-8; DeSisto CL, 2021, MMWR-MORBID MORTAL W, V70, P1640, DOI 10.15585/mmwr.mm7047e1; Gray Kathryn J, 2021, medRxiv, DOI 10.1101/2021.03.07.21253094; Halasa NB, 2022, MMWR-MORBID MORTAL W, V71, P264, DOI 10.15585/mmwr.mm7107e3; Hobbs CV, 2022, PEDIATR INFECT DIS J, V41, pE81, DOI 10.1097/INF.0000000000003435; Klein NP, 2022, MMWR-MORBID MORTAL W, V71, P352, DOI 10.15585/mmwr.mm7109e3; Lauring AS, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-069761; Lipkind HS, 2022, MMWR-MORBID MORTAL W, V7, P26, DOI 10.15585/mmwr.mm7101e1; Magnus MC, 2021, NEW ENGL J MED, V385, P2008, DOI 10.1056/NEJMc2114466; Marks KJ, 2022, MMWR-MORBID MORTAL W, V71, P429, DOI 10.15585/mmwr.mm7111e2; Mithal LB, 2021, AM J OBSTET GYNECOL, V225, P192, DOI 10.1016/j.ajog.2021.03.035; Molgaard-Nielsen D, 2019, J INTERN MED, V286, P469, DOI 10.1111/joim.12947; Nemet I, 2022, NEW ENGL J MED, V386, P492, DOI 10.1056/NEJMc2119358; Nir O, 2022, AM J OBST GYNEC MFM, V4, DOI 10.1016/j.ajogmf.2021.100492; Office of the Federal Register, CODE FEDERAL REGULAT; Olson SM, 2022, NEW ENGL J MED, V386, P713, DOI 10.1056/NEJMoa2117995; Olson Samantha M, 2021, MMWR Morb Mortal Wkly Rep, V70, P1483, DOI 10.15585/mmwr.mm7042e1; Olson SM., 2022, CLIN INFECT DIS; Omer SB, 2017, NEW ENGL J MED, V376, P1256, DOI 10.1056/NEJMra1509044; Patel MK, 2021, VACCINE, V39, P4013, DOI 10.1016/j.vaccine.2021.05.099; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Prabhu M, 2021, OBSTET GYNECOL, V138, P278, DOI 10.1097/AOG.0000000000004438; Razzaghi H, 2021, MMWR-MORBID MORTAL W, V70, P895, DOI [10.15585/mmwr.mm7024e2, 10.1101/2021.03.26.21254402v1]; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Shook LL, 2022, JAMA-J AM MED ASSOC, V327, P1087, DOI 10.1001/jama.2022.1206; Thompson Mark G, 2022, MMWR Morb Mortal Wkly Rep, V71, P139, DOI 10.15585/mmwr.mm7104e3; Trostle ME, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100481; Yang Yawei J, 2022, Obstet Gynecol, V139, P373, DOI 10.1097/AOG.0000000000004693; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3; Zauche LH, 2021, NEW ENGL J MED, V385, P1533, DOI 10.1056/NEJMc2113891	40	18	18	10	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	2022	387	2					109	119		10.1056/NEJMoa2204399	http://dx.doi.org/10.1056/NEJMoa2204399		JUN 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2V6ZG	35731908	Bronze, Green Published			2023-01-03	WOS:000814817600001
J	Mourad, O; Chagla, Z				Mourad, Omar; Chagla, Zain			In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Mourad, Omar; Chagla, Zain] McMaster Univ, Hamilton, ON, Canada	McMaster University	Mourad, O (corresponding author), McMaster Univ, Hamilton, ON, Canada.							Bhimraj A, IDSA GUIDELINES TREA; Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1002/nla.2362, 10.1038/s41586-021-04385-3]; COVID-19 Treatment Guidelines Panel, THER MAN NONH AD COV; Li PF, 2022, CELL RES, V32, P322, DOI 10.1038/s41422-022-00618-w	4	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2022	175	5					JC50	JC50		10.7326/J22-0026	http://dx.doi.org/10.7326/J22-0026		MAY 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2U5RH	35500263				2023-01-03	WOS:000796986800001
J	Zhu, ZH; Cao, PH; Lin, LJ				Zhu, Zhaohua; Cao, Peihua; Lin, Lijun			Regional vs General Anesthesia and Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Zhu, Zhaohua; Lin, Lijun] Southern Med Univ, Dept Joint & Orthoped, Zhujiang Hosp, 253 Ind Ave, Guangzhou 510280, Peoples R China; [Cao, Peihua] Southern Med Univ, Clin Res Ctr, Zhujiang Hosp, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhu, ZH (corresponding author), Southern Med Univ, Dept Joint & Orthoped, Zhujiang Hosp, 253 Ind Ave, Guangzhou 510280, Peoples R China.	zhaohua.zhu@utas.edu.au	Cao, Peihua/GYU-4280-2022					Li T, 2022, JAMA-J AM MED ASSOC, V327, P50, DOI 10.1001/jama.2021.22647	1	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2022	327	17					1708	1708						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D3AC	35503351				2023-01-03	WOS:000793675300026
J	Mahase, E				Mahase, Elisabeth			York eating disorders hospital is placed in special measures after care judged unsafe	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		CQC, SCHOEN CLIN YORK	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2022	377								o1022	10.1136/bmj.o1022	http://dx.doi.org/10.1136/bmj.o1022			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H7OU	35450925	Bronze			2023-01-03	WOS:000796729200009
J	Rocha-Filho, CR; Martins, JWL; Lucchetta, RC; Ramalho, GS; Trevisani, GFM; da Rocha, AP; Pinto, ACPN; Reis, FSD; Ferla, LJ; Mastroianni, PD; Correa, L; Saconato, H; Trevisani, VFM				Rocha-Filho, Cesar Ramos; Leite Martins, Johnny Wallef; Lucchetta, Rosa Camila; Ramalho, Gabriel Sodre; Moca Trevisani, Giulia Fernandes; da Rocha, Aline Pereira; Pereira Nunes Pinto, Ana Carolina; de Assis Reis, Felipe Sebastiao; Ferla, Laura Jantsch; Mastroianni, Patricia de Carvalho; Correa, Luci; Saconato, Humberto; Moca Trevisani, Virginia Fernandes			Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review	PLOS ONE			English	Review							TOOL	Background COVID-19, SARS and MERS are diseases that present an important health burden worldwide. This situation demands resource allocation to the healthcare system, affecting especially middle- and low-income countries. Thus, identifying the main cost drivers is relevant to optimize patient care and resource allocation. Objective To systematically identify and summarize the current status of knowledge on direct medical hospitalization costs of SARS, MERS, or COVID-19 in Upper-Middle-Income Countries. Methods We conducted a systematic review across seven key databases (PubMed, EMBASE, BVS Portal, CINAHL, CRD library, MedRxiv and Research Square) from database inception to February 2021. Costs extracted were converted into 2021 International Dollars using the Purchasing Power Parity-adjusted. The assessment of quality was based on the protocol by the BMJ and CHEERS. PROSPERO 2020: CRD42020225757. Results No eligible study about SARS or MERS was recovered. For COVID-19, five studies presented cost analysis performed in Brazil, China, Iran, and Turkey. Regarding total direct medical costs, the lowest cost per patient at ward was observed in Turkey ($900.08), while the highest in Brazil ($5,093.38). At ICU, the lowest was in Turkey ($2,984.78), while the highest was in China ($52,432.87). Service care was the most expressive (58% to 88%) cost driver of COVID-19 patients at ward. At ICU, there was no consensus between service care (54% to 87%) and treatment (72% to 81%) as key burdens of total cost. Conclusion Our findings elucidate the importance of COVID-19 on health-economic outcomes. The marked heterogeneity among studies leaded to substantially different results and made challenging the comparison of data to estimate pooled results for single countries or regions. Further studies concerning cost estimates from standardized analysis may provide clearer data for a more substantial analysis. This may help care providers and policy makers to organize care for patients in the most efficient way.	[Rocha-Filho, Cesar Ramos; da Rocha, Aline Pereira; Pereira Nunes Pinto, Ana Carolina; Moca Trevisani, Virginia Fernandes] Univ Fed Sao Paulo, Escola Paulista Med, Evidence Based Hlth Program, Sao Paulo, SP, Brazil; [Leite Martins, Johnny Wallef; Mastroianni, Patricia de Carvalho] Univ Estadual Sao Paulo, Sch Pharmaceut Sci, Pharmaceut Sci Program, Araraquara, SP, Brazil; [Lucchetta, Rosa Camila; Mastroianni, Patricia de Carvalho] Univ Estadual Sao Paulo, Sch Pharmaceut Sci, Dept Drugs & Med, Araraquara, SP, Brazil; [Lucchetta, Rosa Camila] Hosp Alemao Oswaldo Cruz, Dept Sustainabil & Social Responsibil, Sao Paulo, SP, Brazil; [Ramalho, Gabriel Sodre; Ferla, Laura Jantsch] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil; [Moca Trevisani, Giulia Fernandes; Moca Trevisani, Virginia Fernandes] Univ Santo Amaro, Fac Med, Sao Paulo, SP, Brazil; [Pereira Nunes Pinto, Ana Carolina] Univ Fed Amapa, Dept Biol & Hlth Sci, Macapa, AP, Brazil; [de Assis Reis, Felipe Sebastiao] Beneficencia Portuguesa Sao Paulo, Dept Med Practices, Sao Paulo, SP, Brazil; [Correa, Luci] Univ Fed Sao Paulo, Escola Paulista Med, Discipline Infectiol, Sao Paulo, SP, Brazil; [Saconato, Humberto; Moca Trevisani, Virginia Fernandes] Univ Fed Sao Paulo, Escola Paulista Med, Discipline Emergency & Evidence Based Med, Sao Paulo, SP, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Santo Amaro (UNISA); Fundacao Universidade Federal do Amapa; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Saconato, H (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Discipline Emergency & Evidence Based Med, Sao Paulo, SP, Brazil.	hsaconato@unifesp.br	Lucchetta, Rosa C/L-4557-2013; Trevisani, Virginia/I-1137-2013	Lucchetta, Rosa C/0000-0002-4004-1320; Leite Martins, Johnny Wallef/0000-0002-0391-8656; Ramos Rocha-Filho, Cesar/0000-0002-7190-0263; Trevisani, Virginia/0000-0002-7180-6285	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001, 88887.505900/2020-00]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	CRRF had financial support from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001 -Number 88887.505900/2020-00 (URL: https://www.gov.br/capes/pt-br).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Chaiyakunapruk N, 2018, INFLUENZA OTHER RESP, V12, P13, DOI 10.1111/irv.12491; Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x; COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1; Oliveira LND, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211401; Dahham J, 2021, PHARMACOECONOMICS, V39, P789, DOI 10.1007/s40273-021-01032-7; Darab MG, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06126-8; de Broucker G, 2020, PHARMACOECONOMICS, V38, P1071, DOI 10.1007/s40273-020-00940-4; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Gedik H, 2020, ACTA MEDICA MEDITERR, V36, DOI 10.19193/0393-6384_2020_6_520; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Jin HJ, 2021, B WORLD HEALTH ORGAN, V99, P112, DOI 10.2471/BLT.20.267112; Kiertiburanakul S, 2020, INQUIRY-J HEALTH CAR, V57, DOI 10.1177/0046958020982925; Kolbin AS., 2020, KACHESTVENNAYA KLIN, P35, DOI [10.37489/2588-0519-2020-1-35-44, DOI 10.37489/2588-0519-2020-1-35-44]; Lee K, 2009, GLOB INST, P1; Lefebvre C., 2019, COCHRANE HDB SYSTEMA, P67, DOI [10.1002/9781119536604.ch4, DOI 10.1002/9781119536604.CH4]; Liang X., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-79298/v1, DOI 10.21203/RS.3.RS-79298/V1]; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411; Miethke-Morais A., 2020, MEDRXIV, DOI [10.1101/2020.12.24.20248633, DOI 10.1101/2020.12.24.20248633]; Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Rocha-Filho CR., 2020, MEDRXIV, DOI [10.1101/2020.12.14.20248198, DOI 10.1101/2020.12.14.20248198]; Shemilt I, 2010, EVID POLICY, V6, P51, DOI 10.1332/174426410X482999; The World Bank, WORLD BANK COUNTR LE; WHO, 2017, ACC MED MAK MARK FOR; Xiao Feng, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P312; Zhu ZX, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01479-w	30	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2022	17	3							e0265003	10.1371/journal.pone.0265003	http://dx.doi.org/10.1371/journal.pone.0265003			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4H6NN	35275935	Green Published, gold			2023-01-03	WOS:000849994500040
J	Kaka, AS; MacDonald, R; Linskens, EJ; Langsetmo, L; Vela, K; Duan-Porter, W; Wilt, TJ				Kaka, Anjum S.; MacDonald, Roderick; Linskens, Eric J.; Langsetmo, Lisa; Vela, Kathryn; Duan-Porter, Wei; Wilt, Timothy J.			Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points	ANNALS OF INTERNAL MEDICINE			English	Review								Background: Remdesivir is approved for the treatment of adults hospitalized with COVID-19. Purpose: To update a living review of remdesivir for adults with COVID-19. Data Sources: Several electronic U.S. Food and Drug Administration, company, and journal websites from 1 January 2020 through 19 October 2021. Study Selection: English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19. Data Extraction: One reviewer abstracted, and a second reviewer verified data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used. Data Synthesis: Since the last update (search date 9 August 2021), 1 new RCT and 1 new subtrial comparing a 10-day course of remdesivir with control (placebo or standard care) were identified. This review summarizes and updates the evidence on the cumulative 5 RCTs and 2 subtrials for this comparison. Our updated results confirm a 10-day course of remdesivir, compared with control, probably results in little to no mortality reduction (5 RCTs). Updated results also confirm that remdesivir probably results in a moderate increase in the proportion of patients recovered by day 29 (4 RCTs) and may reduce time to clinical improvement (2 RCTs) and hospital length of stay (4 RCTs). New RCTs, by increasing the strength of evidence, lead to an updated conclusion that remdesivir probably results in a small reduction in the proportion of patients receiving ventilation or extracorporeal membrane oxygenation at specific follow-up times (4 RCTs). New RCTs also alter the conclusions for harms-remdesivir, compared with control, may lead to a small reduction in serious adverse events but may lead to a small increase in any adverse event. Limitation: The RCTs differed in definitions of COVID-19 severity and outcomes reported. Conclusion: In hospitalized adults with COVID- 19, the findings confirm that remdesivir probably results in little to no difference in mortality and increases the proportion of patients recovered. Remdesivir may reduce time to clinical improvement and may lead to small reductions in serious adverse events but may result in a small increase in any adverse event.	[Kaka, Anjum S.] Minneapolis VA Sect Infect Dis, Minneapolis, MN USA; [Kaka, Anjum S.; Duan-Porter, Wei; Wilt, Timothy J.] Univ Minnesota, Sch Med, Minneapolis, MN USA; [MacDonald, Roderick; Linskens, Eric J.; Langsetmo, Lisa; Duan-Porter, Wei; Wilt, Timothy J.] Ctr Care Delivery & Outcomes Res, Minneapolis VA Evidence Synth Program, Minneapolis, MN USA; [Vela, Kathryn] Portland VA Hlth Care Syst, Portland, OR USA	University of Minnesota System; University of Minnesota Twin Cities	Kaka, AS (corresponding author), Minneapolis VA Hlth Care Syst, One Vet Dr 111-0, Minneapolis, MN 55417 USA.	Anjum.Kaka@va.gov; Roderick.macdonald@va.gov	; Langsetmo, Lisa/T-2619-2017	Kaka, Anjum/0000-0003-1817-8950; Langsetmo, Lisa/0000-0003-2245-1657; Vela, Kathryn/0000-0003-0221-2800				Abd-Elsalam S, 2022, AM J TROP MED HYG, V106, P886, DOI 10.4269/ajtmh.21-0606; Ader Florence, 2022, Lancet Infect Dis, V22, P209, DOI 10.1016/S1473-3099(21)00485-0; Baracco GJ, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.16057; Barratt-Due A, 2021, ANN INTERN MED, V174, P1261, DOI 10.7326/M21-0653; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bimonte S, 2020, IN VIVO, V34, P1597, DOI 10.21873/invivo.11949; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Institute for Clinical and Economic Review, ICER PROV 2 UPD PRIC; Kaka AS, 2021, ANN INTERN MED, V174, pW114, DOI 10.7326/L21-0600; Kaka AS, 2021, ANN INTERN MED, V174, pW65, DOI 10.7326/L21-0375; Kaka AS, 2021, ANN INTERN MED, V174, P663, DOI 10.7326/M20-8148; Kaka AS, SURVEILLANCE UPDATE, DOI [10.7326/M20-8148, DOI 10.7326/M20-8148]; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mahajan L, 2021, INDIAN J ANAESTH, V65, pS41, DOI 10.4103/ija.IJA_149_21; National Institutes of Health, COVID 19 TREATM GUID; Ohl ME, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14741; Sax, HIV ID OBSERVATIONS; Schunemann H, 2013, GRADE HDB; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; U.S. Food and Drug Administration, FDAS APPR VEKL REMD; U.S. National Library of Medicine, CLIN GOV; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wilt TJ, 2021, ANN INTERN MED, V174, P209, DOI 10.7326/M20-5752; Wilt TJ, 2020, 09009 VA ESP HLTH SE	30	10	10	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2022	175	5					701	+		10.7326/M21-4784	http://dx.doi.org/10.7326/M21-4784		MAR 2022	16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2U5RH	35226522	Green Published			2023-01-03	WOS:000823217200024
J	Simon, GE; Shortreed, SM; Rossom, RC; Beck, A; Clarke, GN; Whiteside, U; Richards, JE; Penfold, RB; Boggs, JM; Smith, J				Simon, Gregory E.; Shortreed, Susan M.; Rossom, Rebecca C.; Beck, Arne; Clarke, Gregory N.; Whiteside, Ursula; Richards, Julie E.; Penfold, Robert B.; Boggs, Jennifer M.; Smith, Julia			Effect of Offering Care Management or Online Dialectical Behavior Therapy Skills Training vs Usual Care on Self-harm Among Adult Outpatients With Suicidal Ideation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTION; PREVENTION; RISK	This randomized trial assesses the effect of offering care management or online dialectical behavior therapy skills training vs usual care on risk of self-harm among adult outpatients with suicidal ideation. Question Can low-intensity outreach programs, based on effective clinical interventions but delivered primarily online, prevent self-harm or suicidal behavior among outpatients reporting frequent suicidal ideation? Findings In this pragmatic randomized clinical trial that included 18 882 outpatients with frequent suicidal ideation, the percentage with nonfatal or fatal self-harm over 18 months was 3.3% among those offered care management, 3.9% among those offered online dialectical behavior therapy skills training, and 3.1% among those receiving usual care, respectively. Compared with usual care, the risk of self-harm was not significantly different for care management but was significantly increased for those offered skills training. Meaning Compared with usual care, offering care management did not significantly reduce the risk of self-harm, and offering brief online dialectical behavior therapy skills training increased the risk of self-harm among at-risk adults. IMPORTANCE People at risk of self-harm or suicidal behavior can be accurately identified, but effective prevention will require effective scalable interventions. OBJECTIVE To compare 2 low-intensity outreach programs with usual care for prevention of suicidal behavior among outpatients who report recent frequent suicidal thoughts. DESIGN, SETTING, AND PARTICIPANTS Pragmatic randomized clinical trial including outpatients reporting frequent suicidal thoughts identified using routine Patient Health Questionnaire depression screening at 4 US integrated health systems. A total of 18 882 patients were randomized between March 2015 and September 2018, and ascertainment of outcomes continued through March 2020. INTERVENTIONS Patients were randomized to a care management intervention (n = 6230) that included systematic outreach and care, a skills training intervention (n = 6227) that introduced 4 dialectical behavior therapy skills (mindfulness, mindfulness of current emotion, opposite action, and paced breathing), or usual care (n = 6187). Interventions, lasting up to 12 months, were delivered primarily through electronic health record online messaging and were intended to supplement ongoing mental health care. MAIN OUTCOMES AND MEASURES The primary outcome was time to first nonfatal or fatal self-harm. Nonfatal self-harm was ascertained from health system records, and fatal self-harm was ascertained from state mortality data. Secondary outcomes included more severe self-harm (leading to death or hospitalization) and a broader definition of self-harm (selected injuries and poisonings not originally coded as self-harm). RESULTS A total of 18 644 patients (9009 [48%] aged 45 years or older; 12 543 [67%] female; 9222 [50%] from mental health specialty clinics and the remainder from primary care) contributed at least 1 day of follow-up data and were included in analyses. Thirty-one percent of participants offered care management and 39% offered skills training actively engaged in intervention programs. A total of 540 participants had a self-harm event (including 45 deaths attributed to self-harm and 495 nonfatal self-harm events) over 18 months following randomization: 172 (3.27%) in care management, 206 (3.92%) in skills training, and 162 (3.27%) in usual care. Risk of fatal or nonfatal self-harm over 18 months did not differ significantly between the care management and usual care groups (hazard ratio [HR], 1.07; 97.5% CI, 0.84-1.37) but was significantly higher in the skills training group than in usual care (HR, 1.29; 97.5% CI, 1.02-1.64). For severe self-harm, care management vs usual care had an HR of 1.03 (97.5% CI, 0.71-1.51); skills training vs usual care had an HR of 1.34 (97.5% CI, 0.94-1.91). For the broader self-harm definition, care management vs usual care had an HR of 1.10 (97.5% CI, 0.92-1.33); skills training vs usual care had an HR of 1.17 (97.5% CI, 0.97-1.41). CONCLUSIONS AND RELEVANCE Among adult outpatients with frequent suicidal ideation, offering care management did not significantly reduce risk of self-harm, and offering brief dialectical behavior therapy skills training significantly increased risk of self-harm, compared with usual care. These findings do not support implementation of the programs tested in this study.	[Simon, Gregory E.; Shortreed, Susan M.; Richards, Julie E.; Penfold, Robert B.; Smith, Julia] Kaiser Permanente Washington Hlth Res Inst, 1730 Minor Ave 1600, Seattle, WA 98112 USA; [Rossom, Rebecca C.] HealthPartners Inst, Minneapolis, MN USA; [Beck, Arne; Boggs, Jennifer M.] Kaiser Permanente Colorado Inst Hlth Res, Denver, CO USA; [Clarke, Gregory N.] Kaiser Permanente Northwest Ctr Hlth Res, Portland, OR USA; [Whiteside, Ursula] NowMattersNow Org, Seattle, WA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Simon, GE (corresponding author), Kaiser Permanente Washington Hlth Res Inst, 1730 Minor Ave 1600, Seattle, WA 98112 USA.	gregory.e.simon@kp.org			National Institute of Mental Health (NIMH) [UH3 MH007755]	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This trial was funded by National Institute of Mental Health (NIMH) cooperative agreement UH3 MH007755.	Ahmedani BK, 2015, MED CARE, V53, P430, DOI 10.1097/MLR.0000000000000335; Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; Archer J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006525.pub2; Beautrais AL, 2010, BRIT J PSYCHIAT, V197, P55, DOI 10.1192/bjp.bp.109.075754; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Carter GL, 2007, BRIT J PSYCHIAT, V191, P548, DOI 10.1192/bjp.bp.107.038406; Coffey CE, 2013, PSYCHIAT SERV, V64, P396, DOI 10.1176/appi.PS.640422; Coleman KJ, 2016, PSYCHIAT SERV, V67, P749, DOI 10.1176/appi.ps.201500217; Comtois KA, 2019, JAMA PSYCHIAT, V76, P474, DOI 10.1001/jamapsychiatry.2018.4530; Cwik MF, 2016, AM J PUBLIC HEALTH, V106, P2183, DOI 10.2105/AJPH.2016.303453; DeCou CR, 2019, BEHAV THER, V50, P60, DOI 10.1016/j.beth.2018.03.009; Fleischmann A, 2008, B WORLD HEALTH ORGAN, V86, P703, DOI 10.2471/BLT.07.046995; Katon W, 2010, GEN HOSP PSYCHIAT, V32, P456, DOI 10.1016/j.genhosppsych.2010.04.001; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Linehan MM, 2006, ARCH GEN PSYCHIAT, V63, P757, DOI 10.1001/archpsyc.63.7.757; Linehan MM, 2015, JAMA PSYCHIAT, V72, P475, DOI 10.1001/jamapsychiatry.2014.3039; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; National Action Alliance for Suicide Prevention Transforming Health Systems Initiative Work Group, 2018, REC STAND CAR PEOPL; Neacsiu AD, 2010, BEHAV RES THER, V48, P832, DOI 10.1016/j.brat.2010.05.017; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Ralston JD, 2009, J GEN INTERN MED, V24, P349, DOI 10.1007/s11606-008-0899-z; Shortreed SM, 2019, CLIN TRIALS, V16, P273, DOI 10.1177/1740774519833679; Simon GE, 2018, AM J PSYCHIAT, V175, P434, DOI [10.1176/appi.ajp.2017.17080844, 10.1176/appi.ajp.2018.17101167]; Simon GE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1566-z; Simon GE, 2016, J CLIN PSYCHIAT, V77, P221, DOI 10.4088/JCP.15m09776; Simon GE, 2011, J GEN INTERN MED, V26, P698, DOI 10.1007/s11606-011-1679-8; The Joint Commission Patient Safety Advisory Group, 2016, DET TREAT SUIC ID AL; Whiteside U, 2021, JMIR FORM RES, V5, DOI 10.2196/21127; Woltmann E, 2012, AM J PSYCHIAT, V169, P790, DOI 10.1176/appi.ajp.2012.11111616; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	33	12	12	17	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2022	327	7					630	638		10.1001/jama.2022.0423	http://dx.doi.org/10.1001/jama.2022.0423			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD5SM	35166800	Green Published			2023-01-03	WOS:000758259800018
J	Ovtcharenko, N; Oczkowski, S				Ovtcharenko, Natalia; Oczkowski, Simon			In critically ill adults, IV fluid bolus infused at slower vs. faster rates did not differ for 90-d mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MANAGEMENT; SEPSIS		[Ovtcharenko, Natalia; Oczkowski, Simon] McMaster Univ, Hamilton, ON, Canada	McMaster University	Ovtcharenko, N (corresponding author), McMaster Univ, Hamilton, ON, Canada.							Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; Evans L, 2021, CRIT CARE MED, V49, pE1063, DOI 10.1097/CCM.0000000000005337; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3	5	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2022	175	2					JC23	JC23		10.7326/J21-0015	http://dx.doi.org/10.7326/J21-0015		FEB 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE4HR	35099988				2023-01-03	WOS:000750883100001
J	Billah, SM; Ali, NB; Khan, ANS; Raynes-Greenow, C; Kelly, PJ; Siraj, MS; Askari, S; Menon, P; El Arifeen, S; Dibley, MJ; Nguyen, PH				Billah, Sk Masum; Ali, Nazia Binte; Khan, Abdullah Nurus Salam; Raynes-Greenow, Camille; Kelly, Patrick John; Siraj, Md Shahjahan; Askari, Sufia; Menon, Purnima; El Arifeen, Shams; Dibley, Michael John; Nguyen, Phuong Hong			Factors influencing quality nutrition service provision at antenatal care contacts: Findings from a public health facility-based observational study in 21 districts of Bangladesh	PLOS ONE			English	Article							OF-CARE	Malnutrition during pregnancy is associated with increased maternal morbidity and mortality and has a long-term negative impact on child growth and development. Antenatal care (ANC) is the formal point of contact for pregnant women to receive preventive health and nutrition services. We assessed the quality of nutrition service delivery during ANC and examined its influencing factors related to the health facility, health care provider (HCP) and client characteristics. We conducted a cross-sectional assessment in 179 facilities, including 1,242 ANC observations and exit interviews of pregnant women from 21 districts in Bangladesh. We considered four essential nutrition services at each ANC contact including maternal weight measurement, anaemia assessment, nutrition counselling and iron-folic acid (IFA) supplement provision. We defined a composite 'quality nutrition service' outcome by counting the number of services (out of four) provided at each ANC from observation data. We explored both the supply-side and the client-level factors of quality nutrition service using multilevel Poisson regression. Overall, only 15% of clients received all four nutrition services. Performance of weight measurement (79%) was higher than IFA provision (56%), anaemia assessment (52%) and nutrition counselling (52%). The multivariable analysis showed that quality nutrition service delivery is positively associated with good logistical readiness of the facilities (aIRR: 1.23, 95% CI: 1.08-1.39), consultation by paramedics (aIRR 1.23, 95% CI: 1.06-1.42) and community health care providers (aIRR 1.32, 95% CI: 1.12-1.57), HCPs' knowledge on maternal nutrition (aIRR 1.04; 95% CI: 1.01-1.08), better HCP-client communication (aIRR 1.14; 95% CI: 1.04-1.26) and use visual aids or ANC card (aIRR 1.18; 95% CI: 1.11-1.27). We found limited associations between HCP training and external supervision with the quality of nutrition services. In conclusion, the quality of nutrition service provision during ANC is suboptimal. Public health nutrition programmers should ensure the facilities' logistical readiness, and revisit and reinforce the content and modality of training and supportive supervision of the HCPs. They should also emphasize positive HCP-client communication and the use of job aids to improve the quality of nutrition service provision during ANC.	[Billah, Sk Masum; Ali, Nazia Binte; Khan, Abdullah Nurus Salam; Siraj, Md Shahjahan; El Arifeen, Shams] Int Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh; [Billah, Sk Masum; Raynes-Greenow, Camille; Kelly, Patrick John; Dibley, Michael John] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Askari, Sufia] Childrens Investment Fund Fdn, London, England; [Menon, Purnima; Nguyen, Phuong Hong] Int Food Policy Res Inst, Washington, DC USA	International Centre for Diarrhoeal Disease Research (ICDDR); University of Sydney; CGIAR; International Food Policy Research Institute (IFPRI)	Billah, SM (corresponding author), Int Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh.; Billah, SM (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia.	billah@icddrb.org	Khan, Abdullah Nurus Salam/J-1661-2018	Khan, Abdullah Nurus Salam/0000-0002-8694-4349; Siraj, Md Shahjahan/0000-0001-6925-324X; Raynes-Greenow, Camille/0000-0002-8802-6226	Children's Investment Fund Foundation (CIFF) [G-1612-00805]	Children's Investment Fund Foundation (CIFF)	The lead author, SMB, received funding from Children's Investment Fund Foundation (CIFF) for conducting the initial assessment for the Evaluation of Accelerating Implementation of the National Nutritional Service (AINNS) project in Bangladesh (Grant number G-1612-00805). This paper uses the data from the initial assessment. Sufia Askari from the funding agency has contributed to the conception of the paper and provided inputs to the manuscript draft. The funding agency had no other role in original study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abera SF, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09313-0; Afulani PA, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4476-4; Ajeani J, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1345497; Alam A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1697-2; Amoakoh-Coleman M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157542; Arsenault JE, 2013, J NUTR, V143, P197, DOI 10.3945/jn.112.169524; Billah SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178121; Billah SM, 2016, EVALUATION ACCELERAT; Billah SM., CIFF INITIATIVE FACI, DOI [10.23846/ridie0902016, DOI 10.23846/RIDIE0902016]; Bintabara D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216520; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; Campbell SM, 2000, SOC SCI MED, V51, P1611, DOI 10.1016/S0277-9536(00)00057-5; Christian P, 2015, SEMIN PERINATOL, V39, P361, DOI 10.1053/j.semperi.2015.06.009; Di Renzo GC, 2015, WOMENS HEALTH, V11, P891, DOI 10.2217/whe.15.35; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Emiru AA, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037085; GoB, 2017, 4 HLTH POO NUTR SECT; Goudet S, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12699; Gross K, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-36; Haileslassie K, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-28; Harris T, 2012, STATA J, V12, P736, DOI 10.1177/1536867X1201200412; Hoque DME, 2014, HEALTH POLICY PLANN, V29, P753, DOI 10.1093/heapol/czt059; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Jennings L, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-75; Joarder T, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035183; Kanyangarara M, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.021101; Karuga RN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216444; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Mansur Ahmed M S A, 2014, J Family Reprod Health, V8, P175; MOH&FW, 2015, MAT HLTH STAND OP PR, V1; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; Nguyen PH, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-040109; NIPORT ACPR ICF International, 2016, BANGL HLTH FAC SURV; NIPORT. & ICF, 2019, BANGL HLTH FAC SURV; Omer AM, 2020, HEALTH POLICY PLANN, V35, P65, DOI 10.1093/heapol/czaa101; Organization WH, 2015, BANGLADESH HLTH SYST; Oswald D, 2014, REV SOCIAL STUDIES, V1, P53; Owili PO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177756; Phommachanh S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2345-0; Rahman A, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-016-0078-5; Saha K.K., 2015, BANGLADESH NATL NUTR; Siekmans K, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12532; Singh L, 2019, BJOG-INT J OBSTET GY, V126, P7, DOI 10.1111/1471-0528.15825; Stelfox HT, 2013, J CLIN EPIDEMIOL, V66, P1320, DOI 10.1016/j.jclinepi.2013.05.018; Berehe TT, 2020, ADV PUBLIC HLTH, V2020, DOI 10.1155/2020/5436324; Victora CG, 2021, LANCET, V397, P1388, DOI 10.1016/S0140-6736(21)00394-9; WHO, 2016, WHO TECH REP SER, V997, P1; WHO, 2016, STANDARDS IMPROVING; Wynne SJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229852	49	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262867	10.1371/journal.pone.0262867	http://dx.doi.org/10.1371/journal.pone.0262867			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085319	Green Published, gold			2023-01-03	WOS:000779379600090
J	Fung, KW; Baik, SH; Baye, F; Zheng, ZN; Huser, V; McDonald, CJ				Fung, Kin Wah; Baik, Seo H.; Baye, Fitsum; Zheng, Zhaonian; Huser, Vojtech; McDonald, Clement J.			Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients	PLOS ONE			English	Article							RECEPTOR BLOCKERS; CORONAVIRUS; ACE2; INHIBITION; INFECTION; THERAPY; RAAS	BackgroundMaintenance drugs are used to treat chronic conditions. Several classes of maintenance drugs have attracted attention because of their potential to affect susceptibility to and severity of COVID-19. MethodsUsing claims data on 20% random sample of Part D Medicare enrollees from April to December 2020, we identified patients diagnosed with COVID-19. Using a nested case-control design, non-COVID-19 controls were identified by 1:5 matching on age, race, sex, dual-eligibility status, and geographical region. We identified usage of angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), statins, warfarin, direct factor Xa inhibitors, P2Y12 inhibitors, famotidine and hydroxychloroquine based on Medicare prescription claims data. Using extended Cox regression models with time-varying propensity score adjustment we examined the independent effect of each study drug on contracting COVID-19. For severity of COVID-19, we performed extended Cox regressions on all COVID-19 patients, using COVID-19-related hospitalization and all-cause mortality as outcomes. Covariates included gender, age, race, geographic region, low-income indicator, and co-morbidities. To compensate for indication bias related to the use of hydroxychloroquine for the prophylaxis or treatment of COVID-19, we censored patients who only started on hydroxychloroquine in 2020. ResultsUp to December 2020, our sample contained 374,229 Medicare patients over 65 who were diagnosed with COVID-19. Among the COVID-19 patients, 278,912 (74.6%) were on at least one study drug. The three most common study drugs among COVID-19 patients were statins 187,374 (50.1%), ACEI 97,843 (26.2%) and ARB 83,290 (22.3%). For all three outcomes (diagnosis, hospitalization and death), current users of ACEI, ARB, statins, warfarin, direct factor Xa inhibitors and P2Y12 inhibitors were associated with reduced risks, compared to never users. Famotidine did not show consistent significant effects. Hydroxychloroquine did not show significant effects after censoring of recent starters. ConclusionMaintenance use of ACEI, ARB, warfarin, statins, direct factor Xa inhibitors and P2Y12 inhibitors was associated with reduction in risk of acquiring COVID-19 and dying from it.	[Fung, Kin Wah; Baik, Seo H.; Baye, Fitsum; Zheng, Zhaonian; Huser, Vojtech; McDonald, Clement J.] NIH, Lister Hill Natl Ctr Biomed Commun, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Fung, KW (corresponding author), NIH, Lister Hill Natl Ctr Biomed Commun, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.	kfung@mail.nih.gov		Fung, Kin Wah/0000-0003-0593-5377	Intramural Research Program of the NIH, National Library of Medicine	Intramural Research Program of the NIH, National Library of Medicine	This research was supported in part by the Intramural Research Program of the NIH, National Library of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administration on AgingU.S. Department of Health and Human Services, 2018, PROF OLD AM; An J, 2021, INT J CARDIOL HYPER, V9, DOI 10.1016/j.ijchy.2021.100088; Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099; Azzato EM, 2009, BRIT J CANCER, V100, P1806, DOI 10.1038/sj.bjc.6605062; Barochiner J, 2020, J CLIN PHARM THER, V45, P1244, DOI 10.1111/jcpt.13246; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Bourinbaiar Aldar S., 1996, Life Sciences, V59, pPL365, DOI 10.1016/S0024-3205(96)00553-X; Bozkurt B, 2020, J CARD FAIL, V26, P370, DOI 10.1016/j.cardfail.2020.04.013; Centers for Disease Control and Prevention, 2020, COVID 19 RESP COVID; Csizmadi I, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P791; Cubeddu LX, 2006, PHARMACOTHERAPY, V26, P1288, DOI 10.1592/phco.26.9.1288; Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830; Elshafei A, 2021, SAUDI J BIOL SCI, V28, P6465, DOI 10.1016/j.sjbs.2021.07.003; ERNSTER VL, 1994, PREV MED, V23, P587, DOI 10.1006/pmed.1994.1093; Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461; Fontelo Paul, 2021, Thromb J, V19, P47, DOI 10.1186/s12959-021-00298-3; Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301; Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053; Guo XM, 2020, HYPERTENSION, V76, pE13, DOI 10.1161/HYPERTENSIONAHA.120.15572; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Inama G, 2020, J CARDIOVASC MED, V21, P765, DOI 10.2459/JCM.0000000000001066; Janowitz T, 2020, GUT, V69, P1592, DOI 10.1136/gutjnl-2020-321852; Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923; Pal R, 2022, POSTGRAD MED J, V98, P354, DOI 10.1136/postgradmedj-2020-139172; Pawlos A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084177; Permana H, 2021, PHARMACOL REP, V73, P769, DOI 10.1007/s43440-021-00233-3; Pourhoseingholi Mohamad Amin, 2012, Gastroenterol Hepatol Bed Bench, V5, P79; Research Data Assistance Center (ResDAC), CMS VRDC; Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975; Rico-Mesa JS, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01328-8; Rodrigues-Diez RR, 2020, BRIT J PHARMACOL, V177, P4873, DOI 10.1111/bph.15166; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rossi R, 2020, EUR J INTERN MED, V77, P158, DOI 10.1016/j.ejim.2020.06.006; Russo V, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104965; Sinha N, 2020, POSTGRAD MED J, V96, P550, DOI 10.1136/postgradmedj-2020-137785; Sivaloganathan H, 2020, BRIT J HAEMATOL, V190, pE192, DOI 10.1111/bjh.16968; Soler MJ, 2008, CURR HYPERTENS REP, V10, P410, DOI 10.1007/s11906-008-0076-0; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; The Chronic Condition Warehouse, CHRON COND DAT WAR C; Tremblay D, 2020, BLOOD, V136, P144, DOI 10.1182/blood.2020006941; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2020, COVID 19 US ANG CONV; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Wyss R, 2020, EPIDEMIOLOGY, V31, P82, DOI 10.1097/EDE.0000000000001107; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575	52	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266922	10.1371/journal.pone.0266922	http://dx.doi.org/10.1371/journal.pone.0266922			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z7MW	35436293	Green Submitted, Green Published, gold			2023-01-03	WOS:000791258900008
J	Gong, XW; Yuan, BY; Yuan, YD				Gong, Xiaowei; Yuan, Boyun; Yuan, Yadong			Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review							HOSPITALIZED-PATIENTS; COMPLICATIONS; PNEUMONIA	BackgroundPulmonary embolisms are frequently and prognostically in individuals infected by coronavirus disease 2019 (COVID-19); the incidence of pulmonary embolisms is varied across numerous studies. This study aimed to assess the pooled incidence of pulmonary embolic events and the prognostic value of such events in intensive care unit (ICU) admissions of patients with COVID-19. MethodsThe Cochrane Library, PubMed, and EmBase were systematically searched for eligible studies published on or before October 20, 2021. The pooled incidence of pulmonary embolism was calculated using the random-effects model. Moreover, the prognostic value was assessed by measuring the sensitivity, specificity, positive and negative likelihood ratio (PLR and NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curve (AUC). ResultsThirty-six studies involving 10,367 COVID-19 patients were selected for the final meta-analysis. The cumulative incidence of pulmonary embolism in patients with COVID-19 was 21% (95% confidence interval [95%CI]: 18-24%; P<0.001), and the incidence of pulmonary embolism in ICU and non-ICU patients was 26% (95%CI: 22-31%; P<0.001) and 17% (95%CI: 14-20%; P<0.001), respectively. The predictive role of pulmonary embolism in ICU admission was also assessed, and the sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.31 (95%CI: 0.21-0.42), 0.84 (95%CI: 0.75-0.90), 1.88 (95%CI: 1.45-2.45), 0.83 (95%CI: 0.75-0.91), 2.25 (95%CI: 1.64-3.08), and 0.61 (95%CI: 0.57-0.65), respectively. ConclusionThis study found that the incidence of pulmonary embolism was relatively high in COVID-19 patients, and the incidence of pulmonary embolism in ICU patients was higher than that in non-ICU patients.	[Gong, Xiaowei; Yuan, Boyun; Yuan, Yadong] Hebei Med Univ, Dept Resp & Crit Care Med, Hosp 2, Shijiazhuang, Hebei, Peoples R China	Hebei Medical University	Yuan, YD (corresponding author), Hebei Med Univ, Dept Resp & Crit Care Med, Hosp 2, Shijiazhuang, Hebei, Peoples R China.	yuanyd1108@163.com			Hebei Province Science and Technology Support Program [20277706D]; Scientific Research Fund project of Hebei Provincial Health and Family Planning Commission [20170091]	Hebei Province Science and Technology Support Program; Scientific Research Fund project of Hebei Provincial Health and Family Planning Commission	This study was supported by Hebei Province Science and Technology Support Program (20277706D) and Scientific Research Fund project of Hebei Provincial Health and Family Planning Commission (20170091). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Alonso-Fernandez A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238216; Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z; Badr OI, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18147645; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Benito N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00557; Bompard F, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01365-2020; Bruggemann RAG, 2020, THROMB RES, V196, P486, DOI 10.1016/j.thromres.2020.10.012; Cerda P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243533; Contou D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238413; DeOliveira ML, 2006, ANN SURG, V244, P931, DOI 10.1097/01.sla.0000246856.03918.9a; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diehl JL, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00716-1; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fauvel C, 2020, EUR HEART J, V41, P3058, DOI 10.1093/eurheartj/ehaa500; Filippi L, 2021, THROMB RES, V206, P29, DOI 10.1016/j.thromres.2021.08.003; Fraisse M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03025-y; Freund Y, 2020, ACAD EMERG MED, V27, P811, DOI 10.1111/acem.14096; Galeano-Valle F, 2020, THROMB RES, V192, P113, DOI 10.1016/j.thromres.2020.05.017; Garcia-Ortega A, 2021, J INFECTION, V82, P261, DOI 10.1016/j.jinf.2021.01.003; Gervaise A, 2020, EUR RADIOL, V30, P6170, DOI 10.1007/s00330-020-06977-5; Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hekimian G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02931-5; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jefferson T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000975.pub2; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Lavu H, 2014, ANN SURG, V260, P445, DOI 10.1097/SLA.0000000000000872; Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561; Liao SC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03175-z; Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Longchamp A, 2020, RES PRACT THROMB HAE, V4, P842, DOI 10.1002/rth2.12376; Lu YF, 2020, INT J INFECT DIS, V100, P34, DOI 10.1016/j.ijid.2020.08.023; Malas MB, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100639; Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825; Marone EM, 2020, ANN VASC SURG, V68, P83, DOI 10.1016/j.avsg.2020.07.007; Mestre-Gomez B, 2021, J THROMB THROMBOLYS, V51, P40, DOI 10.1007/s11239-020-02190-9; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nordberg M, 2021, INFECT DIS-NOR, V53, P513, DOI 10.1080/23744235.2021.1896030; Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430; Roncon L, 2020, EUR J INTERN MED, V82, P29, DOI 10.1016/j.ejim.2020.09.006; Schmidt M, 2021, INTENS CARE MED, V47, P60, DOI 10.1007/s00134-020-06294-x; Scudiero F, 2021, THROMB RES, V198, P34, DOI 10.1016/j.thromres.2020.11.017; Soumagne Thibaud, 2020, Crit Care Explor, V2, pe0166, DOI 10.1097/CCE.0000000000000166; Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018; Stoneham SM, 2020, CLIN MED, V20, pE76, DOI 10.7861/clinmed.2020-0228; Suh YJ, 2021, RADIOLOGY, V298, pE70, DOI 10.1148/radiol.2020203557; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028; Valle C, 2021, EUR J RADIOL, V137, DOI 10.1016/j.ejrad.2021.109613; van Dam LF, 2020, THROMB RES, V196, P435, DOI 10.1016/j.thromres.2020.10.006; Walter SD, 2002, STAT MED, V21, P1237, DOI 10.1002/sim.1099; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Whyte MB, 2020, THROMB RES, V195, P95, DOI 10.1016/j.thromres.2020.07.025; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zochios V., 2013, JICS, V14, P36	61	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0263580	10.1371/journal.pone.0263580	http://dx.doi.org/10.1371/journal.pone.0263580			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3NO	35286316	Green Published, gold			2023-01-03	WOS:000799880200010
J	Luisana, E; Saker, K; Jaykus, LA; Getty, C				Luisana, Emily; Saker, Korinn; Jaykus, Lee-Ann; Getty, Caitlyn			Survey evaluation of dog owners' feeding practices and dog bowls' hygiene assessment in domestic settings	PLOS ONE			English	Article							RAW MEAT; CONTAMINATION	In-home pet food handling and food dish hygiene practices can have adverse health impacts for both humans and pets. Safe food and dish handling guidelines are not easily evidenced for pet owners. The study was designed to investigate dog owners' feeding habits and evaluate the impact of the Food and Drug Association (FDA) hygiene protocols on dog food dish contamination. Procedures and surveys were approved by North Carolina State University Institutional Animal Care and Use Committee and Institutional Review Board. Pet feeding and food dish hygiene data were collected from 417 dog owner surveys and 68 food dish swabs. Total aerobic plate counts (APC) were performed on 68 dishes and randomly assigned into Group A (FDA pet food handling and dish hygiene guidelines), Group B (FDA pet and human food handling and dish hygiene guidelines), or Group C (no guidelines). Hygiene protocols were instituted in-home for 1 week, followed by a second APC and follow-up survey. Survey from dog owners-households indicated: 4.7% were aware of FDA pet food handling and dish hygiene guidelines; 36% have individuals <= 13 years old and/or immunocompromised; 43% stored dog food 0-5 feet from human food; 34% washed their hands after feeding; and 33% prepared their dog food on human food preparation surfaces. The hygiene protocols followed by Groups A and B resulted in significant decreases in food dish APC (p<0.001; 1.4; (0.9, 2.0); p<0.05; 0.604 (0.02, 1.2), respectively), as compared to Group C (p >= 0.05). Hot water (>160 degrees F or 71.1 degrees C) washing decreased APC (p<0.01; 1.5 (0.4, 2.6)) over cold/lukewarm water. In the follow-up survey, 8% of Group A and B respondents reported likely to adhere to protocols long-term. This study suggests a need for pet food handling and dish hygiene guideline education to minimize bacterial contamination of dishes, especially for high-risk populations.	[Luisana, Emily; Saker, Korinn; Getty, Caitlyn] North Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27695 USA; [Jaykus, Lee-Ann] North Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC USA; [Luisana, Emily] BluePearl Vet Specialty Hosp, Cary, NC 27518 USA; [Getty, Caitlyn] NomNomNow Inc, Nashville, TN USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Luisana, E (corresponding author), North Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27695 USA.; Luisana, E (corresponding author), BluePearl Vet Specialty Hosp, Cary, NC 27518 USA.	ektownse@gmail.com		Luisana, Emily/0000-0003-4380-7798				[Anonymous], 2018, CDC GUIDELINE DISINF; [Anonymous], 2017, FDA FOOD CODE 2017; Bischoff K, 2018, VET CLIN N AM-SMALL, V48, P917, DOI 10.1016/j.cvsm.2018.07.005; CDC One Health Initiative, 2021, ABOUTUS; Contzen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136445; Deasy M., 2008, Morbidity and Mortality Weekly Report, V57, P1200; Donofrio RS, 2012, J ENVIRON HEALTH, V75, P12; FDA, 2019, PET FOOD; Holda K, 2016, J THERM ANAL CALORIM, V126, P91, DOI 10.1007/s10973-016-5543-2; Kiel RC, 2018, J FOOD PROTECT, V81, P1364, DOI [10.4315/0362-028X.JFP-17-344, 10.4315/0362-028x.jfp-17-344]; Leite-Martins L, 2015, J VET BEHAV, V10, P549, DOI 10.1016/j.jveb.2015.07.040; R Development Core Team, BOOK R LANG ENV STAT, P2021; Scott E, 2009, AM J INFECT CONTROL, V37, P447, DOI 10.1016/j.ajic.2008.12.001; Strohmeyer RA, 2006, JAVMA-J AM VET MED A, V228, P537, DOI 10.2460/javma.228.4.537; Weese JS, 2010, EPIDEMIOL INFECT, V138, P1100, DOI 10.1017/S0950268809991312; Weese JS, 2006, CAN VET J, V47, P887; Wernersson ES, 2004, J HOSP INFECT, V56, P312, DOI 10.1016/j.jhin.2004.01.002; Zupancic J, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1674-5	18	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0259478	10.1371/journal.pone.0259478	http://dx.doi.org/10.1371/journal.pone.0259478			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6KL	35385485	gold, Green Published			2023-01-03	WOS:000804836900067
J	Stickles, SA; Kane, DSM; Kraus, C; Strony, R; Ablordeppey, ER; Doering, M; Theodoro, D; Lee, JS; Carpenter, C				Stickles, Sean A.; Kane, Deborah Shipley M.; Kraus, Chadd; Strony, Robert; Ablordeppey, Enyo R.; Doering, Michelle; Theodoro, Daniel; Lee, Jacques Simon; Carpenter, Christopher			Adverse events related to ultrasound-guided regional anesthesia performed by Emergency Physicians: Systematic review protocol	PLOS ONE			English	Review							NERVE BLOCKS; HIP	The use of ultrasound-guided regional anesthesia for pain management has become increasingly prevalent in Emergency Medicine, with studies noting excellent pain control while sparing opioid use. However, the use of ultrasound-guided regional anesthesia may be hampered by concern about risks for patient harm. This systematic review protocol describes our approach to evaluate the incidence of adverse events from the use of ultrasound-guided regional anesthesia by Emergency Physicians as described in the literature. This project will also seek to document the scope of ultrasound-guided regional anesthesia applications being performed in Emergency Medicine literature, and potentially serve as a framework for future systematic reviews evaluating adverse events in Emergency Medicine.	[Stickles, Sean A.; Kane, Deborah Shipley M.; Ablordeppey, Enyo R.; Theodoro, Daniel; Carpenter, Christopher] Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63130 USA; [Kraus, Chadd; Strony, Robert] Geisinger Hlth Syst, Dept Emergency Med, Danville, PA USA; [Doering, Michelle] Washington Univ, Sch Med St Louis, Bernard Becker Med Lib, St Louis, MO USA; [Lee, Jacques Simon] Mt Sinai Hosp, Schwartz Reisman Emergency Ctr, Dept Family & Community Med, Toronto, ON, Canada	Saint Louis University; Washington University (WUSTL); Geisinger Health System; Saint Louis University; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stickles, SA (corresponding author), Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63130 USA.	spstickles@gmail.com						Aamodt M, 2019, EVID BASED LIB INF P, V14, P103, DOI 10.18438/eblip29601; Amini R, 2016, J ULTRAS MED, V35, P731, DOI 10.7863/ultra.15.05095; Balk EM, 2013, ASSESSING ACCURACY G; Berkman ND, 2015, J CLIN EPIDEMIOL, V68, P1312, DOI 10.1016/j.jclinepi.2014.11.023; Bhoi Sanjeev, 2010, J Emerg Trauma Shock, V3, P82, DOI 10.4103/0974-2700.58655; Counselman FL, 2017, J EMERG MED, V52, P846, DOI 10.1016/j.jemermed.2017.01.040; Herring AA, 2017, AEM EDUC TRAIN, V1, P165, DOI 10.1002/aet2.10027; Hopewell S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000010.pub3; Leung A, 2018, CONTROVERSIES SURROU; Liberati A, 2009, PLOS MED, V6; Loke YK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-32; Moola S., 2017, CHAPTER 7 SYSTEMATIC, V5, DOI DOI 10.46658/JBIMES-20-08; Morrison RS, 2016, J AM GERIATR SOC, V64, P2433, DOI 10.1111/jgs.14386; Mullan RJ, 2009, J CLIN EPIDEMIOL, V62, P138, DOI 10.1016/j.jclinepi.2008.08.002; Munn Z, 2020, JBI EVID SYNTH, V18, P2127, DOI 10.11124/JBISRIR-D-19-00099; Ritcey B, 2016, CAN J EMERG MED, V18, P37, DOI 10.1017/cem.2015.75; Schmucker CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176210; Shokoohi H, 2020, JACEP OPEN, V1, P1326, DOI 10.1002/emp2.12279; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; TING PL, 1989, BRIT J ANAESTH, V63, P326, DOI 10.1093/bja/63.3.326; Wahl Daniel J, 2019, Spartan Med Res J, V3, P7402; Wells G.A., 2000, NEWCASTLE OTTAWA SCA; Wilson CL, 2017, AEM EDUC TRAIN, V1, P158, DOI 10.1002/aet2.10014	23	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269697	10.1371/journal.pone.0269697	http://dx.doi.org/10.1371/journal.pone.0269697			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3F0KH	35749370	gold, Green Published			2023-01-03	WOS:000830362700051
J	Tejada, D; Juanbeltz, R; Rivero, M; San Miguel, R; Capdevila, F; Beloqui, JJ; Sarobe, M				Tejada, Diana; Juanbeltz, Regina; Rivero, Maria; San Miguel, Ramon; Capdevila, Ferran; Jose Beloqui, Juan; Sarobe, Maite			Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study	PLOS ONE			English	Article								BackgroundThere is currently much uncertainty regarding the most optimal treatment for COVID-19. This study analyze the change in the clinical condition of patients hospitalized for severe COVID-19 pneumonia and treated with remdesivir in a real-life setting, based on the WHO Ordinal Scale. Clinical complications, treatment safety, and impact of other associated drugs were also analyzed. MethodsWe conducted an observational, retrospective study including patients treated with remdesivir. The need for admission to the ICU, the length of ICU and hospital stay, and the need for ventilatory support were analyzed. The laboratory parameters, drugs administered concomitantly, and difference in the length of hospital stay according to the concomitant treatment received were also evaluated. A univariate and multivariate Cox regression analysis was performed to analyze associated factors. ResultsA total of 92 patients were included. The mean length of hospital stay was 15 days, and 90% of the patients had been discharged from the hospital 28 days after starting treatment with remdesivir. The likelihood of hospital discharge among patients not presenting with hypertension as a comorbidity was significantly higher than that of those with this condition (HR = 3.19, P = 0.008). Nineteen patients had to be admitted to the ICU (mean of 18 days). Approximately 11% required invasive mechanical ventilation (mean of 22 days). Almost 37% of the patients received high-flow oxygen therapy and 14% non-invasive mechanical ventilation. Four deaths were recorded within the first week. Main adverse events were increases in transaminase and creatinine levels. Nosocomial infections were more frequent when remdesivir was combined with immunosuppressive drugs. ConclusionsPatients with severe COVID-19 pneumonia and treated with remdesivir require relatively prolonged hospital stays, many with a need for ventilatory support and, in a considerable proportion of cases, admission to the ICU. However, the observed survival rate is high, and the drug is well tolerated.	[Tejada, Diana; Juanbeltz, Regina; San Miguel, Ramon; Capdevila, Ferran; Jose Beloqui, Juan; Sarobe, Maite] Hosp Univ Navarra, Dept Hosp Pharm, Navarra, Spain; [Tejada, Diana; Juanbeltz, Regina; Rivero, Maria; San Miguel, Ramon; Capdevila, Ferran; Sarobe, Maite] Navarre Inst Hlth Res IdiSNA, Navarra, Spain; [Juanbeltz, Regina] CIBER Epidemiol & Salud Publ CIBERESP, Navarra, Spain; [Rivero, Maria] Complejo Hosp Navarra, Infect Dis Unit, Navarra, Spain; [Jose Beloqui, Juan] Ctr Invest Med Navarrabiomed, Navarra, Spain	Servicio Navarro de Salud - Osasunbidea; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Servicio Navarro de Salud - Osasunbidea; Navarrabiomed	Juanbeltz, R (corresponding author), Hosp Univ Navarra, Dept Hosp Pharm, Navarra, Spain.; Juanbeltz, R (corresponding author), Navarre Inst Hlth Res IdiSNA, Navarra, Spain.; Juanbeltz, R (corresponding author), CIBER Epidemiol & Salud Publ CIBERESP, Navarra, Spain.	regina.juanbeltz.zurbano@navarra.es		Capdevila Bastons, Ferran/0000-0002-7970-3213; Sarobe, Maite/0000-0002-2375-0053; BELOQUI LIZASO, JUAN JOSE/0000-0003-1290-4050	Spanish AIDS Research Network (Red Espanola de Investigacion en SIDA) [RD16/0025/0044]; Carlos III Institute of Health; European Regional Development Fund [JR19/00044]	Spanish AIDS Research Network (Red Espanola de Investigacion en SIDA); Carlos III Institute of Health(Instituto de Salud Carlos III); European Regional Development Fund(European Commission)	This study was funded by the Spanish AIDS Research Network (Red Espanola de Investigacio ' n en SIDA), RD16/0025/0044. Regina Juanbeltz received research grant from Carlos III Institute of Health with the European Regional Development Fund, during the conduct of the study (JR19/00044). These institutions played no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	[Anonymous], 2022, AEMPS WEBSITE; Antinori S, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104899; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Berenguer J, 2020, CLIN MICROBIOL INFEC, V26, P1525, DOI 10.1016/j.cmi.2020.07.024; Cancer Therapy Evaluation Program (CTEP), 2017, CANC THER EVAL PROGR, P155; Cucchiari D, 2020, MED CLIN-BARCELONA, V155, P502, DOI [10.1016/j.medcli.2020.05.022, 10.1016/j.medcle.2020.05.028]; Deeks ED, 2021, DRUGS, V81, P2047, DOI 10.1007/s40265-021-01620-z; Fung M, 2021, CLIN INFECT DIS, V72, P340, DOI 10.1093/cid/ciaa863; Garcia-Vidal C, 2021, LANCET REG HEALTH-EU, V3, DOI 10.1016/j.lanepe.2021.100041; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Kooshkaki O, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.572329; Lee TC, 2021, INT J INFECT DIS, V104, P671, DOI 10.1016/j.ijid.2021.01.065; Malin JJ, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00162-20; Ministerio de Sanidad, 2020, AEMPS WEBSITE; Regas VHL, 2020, MED CLIN-BARCELONA, V155, P448, DOI 10.1016/j.medcli.2020.06.019; Solimando AG, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.625176; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Terap IDEP, 2015, INFORME POSICIONAMIE, V223, P1; Vu CA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05701-4; Wang B, 2020, EUR J CLIN MICROBIOL, V39, P2309, DOI 10.1007/s10096-020-03927-3; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5	26	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267283	10.1371/journal.pone.0267283	http://dx.doi.org/10.1371/journal.pone.0267283			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482685	Green Published, gold			2023-01-03	WOS:000794035700052
J	Israeli, E				Israeli, Eitan			Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer	ISRAEL MEDICAL ASSOCIATION JOURNAL			English	Editorial Material														Wong, Rachel/0000-0002-4926-5689					0	47	47	14	14	ISRAEL MEDICAL ASSOC JOURNAL	RAMAT GAN	2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136, ISRAEL	1565-1088			ISR MED ASSOC J	Isr. Med. Assoc. J.	JUL	2022	24	7					481	481		10.1056/NEJMoa2200075	http://dx.doi.org/10.1056/NEJMoa2200075			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2Y7UV	35657320	Green Accepted			2023-01-03	WOS:000826097900031
J	Myles, PS; Bui, T				Myles, Paul S.; Bui, Thuy			Opioid-free analgesia after surgery	LANCET			English	Editorial Material							PRESCRIPTION		[Myles, Paul S.] Alfred Hosp, Dept Anaesthesiol & Perioperat Med, Melbourne, Vic 3004, Australia; [Myles, Paul S.] Monash Univ, Melbourne, Vic 3004, Australia; [Bui, Thuy] Alfred Hlth, Pharm Dept, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Myles, PS (corresponding author), Alfred Hosp, Dept Anaesthesiol & Perioperat Med, Melbourne, Vic 3004, Australia.; Myles, PS (corresponding author), Monash Univ, Melbourne, Vic 3004, Australia.	p.myles@alfred.org.au						Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Bui Thuy, 2020, J Opioid Manag, V16, P167, DOI 10.5055/jom.2020.0565; Fiore Jr JF, LANCET, V399, P2280; Gan TJ, 2004, BRIT J ANAESTH, V92, P681, DOI 10.1093/bja/aeh123; Hill MV, 2018, ANN SURG, V267, P468, DOI 10.1097/SLA.0000000000002198; Hopkins RE, 2020, MED J AUSTRALIA, V213, P417, DOI 10.5694/mja2.50812; Hopkins RE, 2019, PAIN PHYSICIAN, V22, pE551; Kaafarani HMA, 2020, ANN SURG, V272, P879, DOI 10.1097/SLA.0000000000004225; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Myles PS, 2018, BRIT J ANAESTH, V120, P705, DOI 10.1016/j.bja.2017.12.037; Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466; Neuman MD, 2019, LANCET, V393, P1547, DOI 10.1016/S0140-6736(19)30428-3	12	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2022	399	10343					2245	2247						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L5CA	35717974				2023-01-03	WOS:000817033100003
J	Padron, LJ; Maurer, DM; O'Hara, MH; O'Reilly, EM; Wolff, RA; Wainberg, ZA; Ko, AH; Fisher, G; Rahma, O; Lyman, JP; Cabanski, CR; Yu, JX; Pfeiffer, SM; Spasic, M; Xu, JY; Gherardini, PF; Karakunnel, J; Mick, R; Alanio, C; Byrne, KT; Hollmann, TJ; Moore, JS; Jones, DD; Tognetti, M; Chen, RO; Yang, XD; Salvador, L; Wherry, EJ; Dugan, U; O'Donnell-Tormey, J; Butterfield, LH; Hubbard-Lucey, VM; Ibrahim, R; Fairchild, J; Bucktrout, S; LaVallee, TM; Vonderheide, RH				Padron, Lacey J.; Maurer, Deena M.; O'Hara, Mark H.; O'Reilly, Eileen M.; Wolff, Robert A.; Wainberg, Zev A.; Ko, Andrew H.; Fisher, George; Rahma, Osama; Lyman, Jaclyn P.; Cabanski, Christopher R.; Yu, Jia Xin; Pfeiffer, Shannon M.; Spasic, Marko; Xu, Jingying; Gherardini, Pier Federico; Karakunnel, Joyson; Mick, Rosemarie; Alanio, Cecile; Byrne, Katelyn T.; Hollmann, Travis J.; Moore, Jonni S.; Jones, Derek D.; Tognetti, Marco; Chen, Richard O.; Yang, Xiaodong; Salvador, Lisa; Wherry, E. John; Dugan, Ute; O'Donnell-Tormey, Jill; Butterfield, Lisa H.; Hubbard-Lucey, Vanessa M.; Ibrahim, Ramy; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M.; Vonderheide, Robert H.			Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial	NATURE MEDICINE			English	Article							T-CELL IMMUNITY; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; NAB-PACLITAXEL; SURVIVAL; ADENOCARCINOMA; FRAMEWORK; SUBSETS; SAFETY	Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (NCT03214250). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.	[Padron, Lacey J.; Maurer, Deena M.; Lyman, Jaclyn P.; Cabanski, Christopher R.; Yu, Jia Xin; Pfeiffer, Shannon M.; Spasic, Marko; Xu, Jingying; Gherardini, Pier Federico; Karakunnel, Joyson; Dugan, Ute; Butterfield, Lisa H.; Ibrahim, Ramy; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M.] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA; [O'Hara, Mark H.; Mick, Rosemarie; Alanio, Cecile; Byrne, Katelyn T.; Moore, Jonni S.; Jones, Derek D.; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [O'Reilly, Eileen M.; Hollmann, Travis J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Wolff, Robert A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Wainberg, Zev A.] Univ Calif Los Angeles, Los Angeles, CA USA; [Ko, Andrew H.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Fisher, George] Stanford Univ, Stanford, CA 94305 USA; [Rahma, Osama] Dana Farber Canc Inst, Boston, MA 02115 USA; [Alanio, Cecile; Byrne, Katelyn T.; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Alanio, Cecile; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Alanio, Cecile; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA; [Tognetti, Marco] Biognosys AG, Schlieren, Switzerland; [Chen, Richard O.] Personalis Inc, Menlo Pk, CA USA; [Yang, Xiaodong] Apexigen Inc, San Carlos, CA USA; [Salvador, Lisa] Bristol Myers Squibb, New York, NY USA; [O'Donnell-Tormey, Jill; Hubbard-Lucey, Vanessa M.] Canc Res Inst, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Stanford University; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Bristol-Myers Squibb	Padron, LJ (corresponding author), Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA.; Vonderheide, RH (corresponding author), Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.; Vonderheide, RH (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.; Vonderheide, RH (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.	lpadron@parkerici.org; rhv@upenn.edu		Chen, Richard/0000-0002-2842-4476	Parker Institute for Cancer Immunotherapy (PICI); Cancer Research Institute; Bristol Myers Squibb; PICI	Parker Institute for Cancer Immunotherapy (PICI); Cancer Research Institute; Bristol Myers Squibb(Bristol-Myers Squibb); PICI	This study was sponsored by the Parker Institute for Cancer Immunotherapy (PICI) and funded by the Cancer Research Institute, Bristol Myers Squibb and PICI. Study drugs were provided by Bristol Myers Squibb and Apexigen. We extend our gratitude to the patients, their families, the clinical investigators and their site staff members who are making this trial possible. We would also like to thank S. Nawabi at PICI for operations leadership of the trial. We thank C. Spencer, M. Travers and R. Kageyama at PICI for aiding in data analysis review and figure formatting; D. DaSilva at PICI for writing and collaborating with the authors on the Methods section of the manuscript; and the Research Operations team at PICI for sample management. We thank S. M. Domchek from the Basser Center of the University of Pennsylvania for expertise and discussion on genomic alterations in patients with mPDAC. We thank R. Schretzenmair, J. Jakobowski and G. Brake-Silla from the University of Pennsylvania Flow Core for handling and running X50 analysis on patient PBMC samples. We thank A. Ruiz and Y. Li from Memorial Sloan Kettering Cancer Center for handling and tissue preparation and analysis of patient tumor biopsies for Vectra analysis. We thank C. Abbott, L. McDaniel and S. Boyle at Personalis for whole-exome sequencing and transcriptomics analyses of patient biopsies and thoughtful discussions. We thank K. Sklodowski, R. Bruderer and L. Reiter from Biognosys for their contributions in mass spectrometry proteomic data. We thank Sean Parker for his support and helpful scientific discussions. We thank Bristol Myers Squibb and Apexigen for collaboration and study drugs.	[Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Byrne KT, 2021, CLIN CANCER RES, V27, P4574, DOI 10.1158/1078-0432.CCR-21-1047; Byrne KT, 2016, CELL REP, V15, P2719, DOI 10.1016/j.celrep.2016.05.058; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Cohn L, 2013, J EXP MED, V210, P1049, DOI 10.1084/jem.20121251; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Diamond MS, 2021, CANCER IMMUNOL RES, V9, P877, DOI 10.1158/2326-6066.CIR-20-0785; Ding CL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3813; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Filbert EL, 2021, CANCER IMMUNOL IMMUN, V70, P1853, DOI 10.1007/s00262-020-02814-2; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Hartmann FJ, 2019, CELL REP, V28, P819, DOI 10.1016/j.celrep.2019.06.049; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Lyman JP, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.528; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; O'Hara MH, 2021, LANCET ONCOL, V22, P118, DOI 10.1016/S1470-2045(20)30532-5; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; Patnaik A, 2015, CLIN CANCER RES, V21, P4286, DOI 10.1158/1078-0432.CCR-14-2607; Patwardhan A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0197-4; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Romero P, 2007, J IMMUNOL, V178, P4112, DOI 10.4049/jimmunol.178.7.4112; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Spitzer MH, 2015, SCIENCE, V349, DOI 10.1126/science.1259425; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Stromnes IM, 2017, CANCER IMMUNOL RES, V5, P978, DOI 10.1158/2326-6066.CIR-16-0322; Tempero M, 2021, ANN ONCOL, V32, P600, DOI 10.1016/j.annonc.2021.01.070; Tokito T, 2016, EUR J CANCER, V55, P7, DOI 10.1016/j.ejca.2015.11.020; Upadhaya S, 2021, NAT REV DRUG DISCOV, V20, P168, DOI 10.1038/d41573-020-00204-y; van Hooren L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24347-7; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wainberg ZA, 2020, CLIN CANCER RES, V26, P4814, DOI 10.1158/1078-0432.CCR-20-0099; Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326-6066.CIR-14-0215; Yang ZY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.695006	43	13	13	5	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1167	+		10.1038/s41591-022-01829-9	http://dx.doi.org/10.1038/s41591-022-01829-9		JUN 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35662283	hybrid, Green Published			2023-01-03	WOS:000805744500001
J	Hamieh, M; Themeli, M				Hamieh, Mohamad; Themeli, Maria			Synthetic circuits suited for the clinic	NATURE			English	Editorial Material							T-CELLS	Synthetic receptor proteins can enable customized and flexible control of immune cells called T lymphocytes. A defined framework for the proteins' design now improves their potential for use in cancer immunotherapy.	[Hamieh, Mohamad] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10065 USA; [Hamieh, Mohamad] Sloan Kettering Inst, Program Immunol, New York, NY USA; [Themeli, Maria] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands; [Themeli, Maria] Canc Ctr Amsterdam, Amsterdam, Netherlands	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	Themeli, M (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands.; Themeli, M (corresponding author), Canc Ctr Amsterdam, Amsterdam, Netherlands.	m.themeli@amsterdamumc.nl						Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Roybal KT, 2016, CELL, V167, P419, DOI 10.1016/j.cell.2016.09.011; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Zhu I, 2022, CELL, V185, P1431, DOI 10.1016/j.cell.2022.03.023	6	0	0	8	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2022	606	7916					868	869		10.1038/d41586-022-01528-y	http://dx.doi.org/10.1038/d41586-022-01528-y		JUN 2022	2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2L9AU	35654967				2023-01-03	WOS:000805092700001
J	Muwema, M; Kaye, DK; Edwards, G; Nalwadda, G; Nangendo, J; Okiring, J; Mwanjaid, W; Ekong, EN; Kalyango, JN; Nankabirwa, JI				Muwema, Mercy; Kaye, Dan K.; Edwards, Grace; Nalwadda, Gorrette; Nangendo, Joanita; Okiring, Jaffer; Mwanjaid, Wilson; Ekong, Elizabeth N.; Kalyango, Joan N.; Nankabirwa, Joaniter I.			Perinatal care in Western Uganda: Prevalence and factors associated with appropriate care among women attending three district hospitals	PLOS ONE			English	Article							SAVING MOTHERS	Background Perinatal mortality remains high globally and remains an important indicator of the quality of a health care system. To reduce this mortality, it is important to provide the recommended care during the perinatal period. We assessed the prevalence and factors associated with appropriate perinatal care (antenatal, intrapartum, and postpartum) in Bunyoro region, Uganda. Results from this study provide valuable information on the perinatal care services and highlight areas of improvement for better perinatal outcomes. Methods A cross sectional survey was conducted among postpartum mothers attending care at three district hospitals in Bunyoro. Following consent, a questionnaire was administered to capture the participants' demographics and data on care received was extracted from their antenatal, labour, delivery, and postpartum records using a pre-tested structured tool. The care received by women was assessed against the standard protocol established by World Health Organization (WHO). Poisson regression with robust standard errors was used to assess factors associated with appropriate postpartum care. Results A total of 872 mothers receiving care at the participating hospitals between March and June 2020 were enrolled in the study. The mean age of the mothers was 25 years (SD = 5.95). None of the mothers received appropriate antenatal or intrapartum care, and only 3.8% of the participants received appropriate postpartum care. Factors significantly associated with appropriate postpartum care included mothers being >35 years of age (adjusted prevalence ratio [aPR] = 11.9, 95% confidence interval [CI] 2.8-51.4) and parity, with low parity (2-3) and multiparous (>3) mothers less likely to receive appropriate care than prime gravidas (aPR = 0.3, 95% CI 0.1-0.9 and aPR = 0.3, 95% CI 0.1-0.8 respectively). Conclusions Antenatal, intrapartum, and postpartum care received by mothers in this region remains below the standard recommended by WHO, and innovative strategies across the continuum of perinatal care need to be devised to prevent mortality among the mothers. The quality of care also needs to be balanced for all mothers irrespective of the age and parity.	[Muwema, Mercy; Nangendo, Joanita; Okiring, Jaffer; Kalyango, Joan N.; Nankabirwa, Joaniter I.] Makerere Univ, Sch Med, Clin Epidemiol Unit, Coll Hlth Sci, Kampala, Uganda; [Kaye, Dan K.] Makerere Univ, Sch Med, Dept Obstet & Gynecol, Coll Hlth Sci, Kampala, Uganda; [Edwards, Grace] Aga Khan Univ, Sch Nursing & Midwifery, Kampala, Uganda; [Nalwadda, Gorrette] Makerere Univ, Sch Hlth Sci, Dept Nursing, Coll Hlth Sci, Kampala, Uganda; [Mwanjaid, Wilson] Whale Consult Ltd, Kampala, Uganda; [Ekong, Elizabeth N.] Uganda Christian Univ, Dept Nursing, Fac Hlth Sci, Mukono Town, Uganda; [Kalyango, Joan N.] Makerere Univ, Sch Hlth Sci, Dept Pharm, Coll Hlth Sci, Kampala, Uganda; [Nankabirwa, Joaniter I.] Infect Dis Res Collaborat, Kampala, Uganda	Makerere University; Makerere University; Aga Khan University; Makerere University; Makerere University	Muwema, M (corresponding author), Makerere Univ, Sch Med, Clin Epidemiol Unit, Coll Hlth Sci, Kampala, Uganda.	muwecy@gmail.com		Muwema, Mercy/0000-0001-9181-3055; Mwanja, Wilson/0000-0003-4055-1328				Agaba P, 2021, SOC SCI-BASEL, V10, DOI 10.3390/socsci10120474; Akibu M, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/8625437; Beraki GG, 2020, BMC PREGNANCY CHILDB, P20; Chou VB, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002990; Clinton Health Access Initiative (CHAI), ANN REP 2018; Dey T, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004230; Duysburgh E, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0562-8; Jolivet RR, 2018, BMC PREGNANCY CHILDB, P18; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kassa GM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218259; Kassaw A, 2020, J PREGNANCY, V2020, DOI 10.1155/2020/9592124; Kigenyi O, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-162; Kyaddondo D, 2017, INT J GYNECOL OBSTET, V139, P38, DOI 10.1002/ijgo.12405; Leslie HH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002151; Manzi A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2939-7; Martinez-Galiano JM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47881-3; Ministry of Health, RES POL FRAM UG REPR; Morof D, 2019, GLOB HEALTH-SCI PRAC, V7, pS85, DOI 10.9745/GHSP-D-18-00272; Mukisa J, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3934-3; Muyunda B, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00127; Secretariat of Health Care, 2011, GUID COLL AN ANTHR D, V76; Sensalire S, 2019, GLOB HEALTH-SCI PRAC, V7, pS168, DOI 10.9745/GHSP-D-18-00263; Serbanescu F, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1222-y; Sharma G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S2; Sheen JJ, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.08.034; Sserwanja Q, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-07179-5; Ssetaala A, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05739-9; Tetui M, 2012, PAN AFR MED J, V13; UBOS Icf, 2018, UGANDA DEMOGRAPHIC H; Uganda Bureau of Statistics (UBOS), 2017, NAT POP HOUS CENS 20; Uganda Bureau of Statistics (UBOS), 2020 STAT ABSTR 2020; Uganda Bureau of Statistics (UBOS), 2017, THEMATIC REPORT SERI; Walker Dilys, 2020, Lancet Glob Health, V8, pe1061, DOI 10.1016/S2214-109X(20)30232-1; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2014, EV NEWB ACT PLAN END; WHO, MAT MORT 2019; Wilunda C, 2015, REPROD HEALTH, P12; World Health Organization, 2018, RECOMMENDATIONS INTR; World Health Organization, NEWB IMPR SURV WELL; World Health Organization Department of Maternal N, 2013, WHO REC POSTN CAR MO	40	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2022	17	5							e0267015	10.1371/journal.pone.0267015	http://dx.doi.org/10.1371/journal.pone.0267015			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3V2EB	35639711	gold, Green Published			2023-01-03	WOS:000841472800005
J	Guan, XN; Polesso, F; Wang, CJ; Sehrawat, A; Hawkins, RM; Murray, SE; Thomas, GV; Caruso, B; Thompson, RF; Wood, MA; Hipfinger, C; Hammond, SA; Graff, JN; Xia, Z; Moran, AE				Guan, Xiangnan; Polesso, Fanny; Wang, Chaojie; Sehrawat, Archana; Hawkins, Reed M.; Murray, Susan E.; Thomas, George, V; Caruso, Breanna; Thompson, Reid F.; Wood, Mary A.; Hipfinger, Christina; Hammond, Scott A.; Graff, Julie N.; Xia, Zheng; Moran, Amy E.			Androgen receptor activity in T cells limits checkpoint blockade efficacy	NATURE			English	Article							RESISTANT PROSTATE-CANCER; CTLA-4 BLOCKADE; PD-1 BLOCKADE; DOUBLE-BLIND; SEX; EXPRESSION; IPILIMUMAB; IMMUNOTHERAPY; MAINTAINS; RESPONSES	Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-tumour immunity in solid tumours. In patients with advanced prostate cancer, immunotherapy treatments have largely failed(1-5). Androgen deprivation therapy is classically administered in these patients to inhibit tumour cell growth, and we postulated that this therapy also affects tumour-associated T cells. Here we demonstrate that androgen receptor (AR) blockade sensitizes tumour-bearing hosts to effective checkpoint blockade by directly enhancing CD8 T cell function. Inhibition of AR activity in CD8 T cells prevented T cell exhaustion and improved responsiveness to PD-1 targeted therapy via increased IFN gamma expression. AR bound directly to Ifng and eviction of AR with a small molecule significantly increased cytokine production in CD8 T cells. Together, our findings establish that T cell intrinsic AR activity represses IFN gamma expression and represents a novel mechanism of immunotherapy resistance.	[Guan, Xiangnan; Thompson, Reid F.; Xia, Zheng] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA; [Guan, Xiangnan; Murray, Susan E.; Xia, Zheng] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR USA; [Polesso, Fanny; Wang, Chaojie; Sehrawat, Archana; Hawkins, Reed M.; Caruso, Breanna; Hipfinger, Christina; Moran, Amy E.] Oregon Hlth & Sci Univ, Cell Dev & Canc Biol, Portland, OR 97201 USA; [Murray, Susan E.] Univ Portland, Dept Biol, Portland, OR USA; [Thomas, George, V; Thompson, Reid F.; Graff, Julie N.; Xia, Zheng; Moran, Amy E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Thomas, George, V] Oregon Hlth & Sci Univ, Dept Pathol & Lab Med, Portland, OR USA; [Thompson, Reid F.] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR USA; [Thompson, Reid F.; Wood, Mary A.; Graff, Julie N.] VA Portland Hlth Care Syst, Portland, OR USA; [Hammond, Scott A.] AstraZeneca, Oncol R&D, Crin IO Discovery, Gaithersburg, MD USA; [Guan, Xiangnan] Genentech Inc, San Francisco, CA 94080 USA; [Wang, Chaojie] Bristol Myers Squibb, New Brunswick, NJ USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Portland; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; AstraZeneca; Roche Holding; Genentech; Bristol-Myers Squibb	Moran, AE (corresponding author), Oregon Hlth & Sci Univ, Cell Dev & Canc Biol, Portland, OR 97201 USA.; Moran, AE (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.	moranam@ohsu.edu		Thomas, George V/0000-0001-7416-8840; Caruso, Breanna/0000-0002-1519-8131; Murray, Susan/0000-0002-6470-3827	Collins Medical Trust; OHSU Foundation; Prostate Cancer Foundation; Pacific Northwest Prostate Cancer SPORE NCI [5P50CA097186]; NIH [1R37 CA263592-01, 5K01LM012877, 1R21HL145426]; M.J. Murdock Charitable Trust [NS-201812034]; MedImmune; Medical Research Foundation at Oregon; Massively Parallel Sequencing Shared Resource (MPSSR)	Collins Medical Trust; OHSU Foundation; Prostate Cancer Foundation; Pacific Northwest Prostate Cancer SPORE NCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); M.J. Murdock Charitable Trust; MedImmune(AstraZenecaMedimmune); Medical Research Foundation at Oregon; Massively Parallel Sequencing Shared Resource (MPSSR)	We thank A. Adey and R. Searle for sharing expertise as we developed protocols for single-cell RNA-seq. We are grateful to the OHSU Department of Comparative Medicine for outstanding animal husbandry, the Massively Parallel Sequencing Shared Resource (MPSSR) for their support, and the Knight Cancer Institute Prostate Programs outstanding clinical research team. This work is funded in part by the Collins Medical Trust, OHSU Foundation, Prostate Cancer Foundation, Pacific Northwest Prostate Cancer SPORE NCI 5P50CA097186, NIH 1R37 CA263592-01 (to A.E.M.), M.J. Murdock Charitable Trust NS-201812034 (to S.E.M.), and a sponsored research agreement with MedImmune (to A.E.M.). This work is also supported by Medical Research Foundation at Oregon, NIH 5K01LM012877 and NIH 1R21HL145426 (to Z.X.). The resources of the Exacloud high performance computing environment developed jointly by OHSU and Intel and the technical support of the OHSU Advanced Computing Center are gratefully acknowledged. BioRender.com software was used for the creation of some figures.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638; ASHLEY DJB, 1969, BRIT J CANCER, V23, P313, DOI 10.1038/bjc.1969.41; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bebo BF, 1999, J IMMUNOL, V162, P35; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Bupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01269; Cartwright RA, 2002, BRIT J HAEMATOL, V118, P1071, DOI 10.1046/j.1365-2141.2002.03750.x; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Conforti F, 2018, LANCET ONCOL, V19, P737, DOI 10.1016/S1470-2045(18)30261-4; Cook MB, 2009, BRIT J CANCER, V101, P855, DOI 10.1038/sj.bjc.6605246; Edgren G, 2012, EUR J EPIDEMIOL, V27, P187, DOI 10.1007/s10654-011-9647-5; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; FONG PCC, 2019, J CLIN ONCOL, V37; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Graff JN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000642; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Gruner BM, 2016, NAT METHODS, V13, P883, DOI 10.1038/nmeth.3992; He MX, 2021, NAT MED, V27, P426, DOI 10.1038/s41591-021-01244-6; Higano CS, 2019, CANCER-AM CANCER SOC, V125, P4172, DOI 10.1002/cncr.32445; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hwang SS, 2020, SCIENCE, V367, P1255, DOI 10.1126/science.aax0194; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; Kersh EN, 2006, J IMMUNOL, V176, P4083, DOI 10.4049/jimmunol.176.7.4083; Kissick HT, 2014, P NATL ACAD SCI USA, V111, P9887, DOI 10.1073/pnas.1402468111; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lin AA, 2010, J NEUROIMMUNOL, V226, P8, DOI 10.1016/j.jneuroim.2010.05.026; Liva SM, 2001, J IMMUNOL, V167, P2060, DOI 10.4049/jimmunol.167.4.2060; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Moran AE, 2016, J IMMUNOL, V197, P2509, DOI 10.4049/jimmunol.1502659; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Murray SE, 2017, J EXP MED, V214, P1889, DOI 10.1084/jem.20161988; Northrop JK, 2006, J IMMUNOL, V177, P1062, DOI 10.4049/jimmunol.177.2.1062; Nussing S, 2020, J IMMUNOL, V204, P2308, DOI 10.4049/jimmunol.1901396; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Pavese J, 2013, JOVE-J VIS EXP, DOI 10.3791/50873; Pernigoni N, 2021, SCIENCE, V374, P216, DOI 10.1126/science.abf8403; Polesso F, 2021, EUR J IMMUNOL, V51, P1473, DOI 10.1002/eji.202048960; Polesso F, 2019, J IMMUNOL, V203, P2011, DOI 10.4049/jimmunol.1900696; Polesso F, 2019, CANCER IMMUNOL RES, V7, P269, DOI 10.1158/2326-6066.CIR-18-0222; Prat A, 2017, CANCER RES, V77, P3540, DOI 10.1158/0008-5472.CAN-16-3556; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Rayford W, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02140-y; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Schofield DJ, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1857100; Sharma P, 2020, CANCER CELL, V38, P489, DOI 10.1016/j.ccell.2020.08.007; Small EJ, 2007, CLIN CANCER RES, V13, P1810, DOI 10.1158/1078-0432.CCR-06-2318; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valkenburg KC, 2016, JOVE-J VIS EXP, DOI 10.3791/53984; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Walecki M, 2015, MOL BIOL CELL, V26, P2845, DOI 10.1091/mbc.E14-08-1323; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Zediak VP, 2011, J IMMUNOL, V186, P2705, DOI 10.4049/jimmunol.1003741	69	33	33	43	70	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 23	2022	606	7915					791	+		10.1038/s41586-022-04522-6	http://dx.doi.org/10.1038/s41586-022-04522-6		MAR 2022	23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2J7WG	35322234				2023-01-03	WOS:000772363100002
J	Saul, H; Gursul, D; Cassidy, S; Vinogradova, Y				Saul, Helen; Gursul, Deniz; Cassidy, Samantha; Vinogradova, Yana			Risk of breast cancer with HRT depends on therapy type and duration	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Saul, Helen; Gursul, Deniz; Cassidy, Samantha] NIHR Ctr Engagement & Disseminat, Twickenham, England; [Vinogradova, Yana] Univ Nottingham, Nottingham, England	University of Nottingham	Saul, H (corresponding author), NIHR Ctr Engagement & Disseminat, Twickenham, England.	NIHRAlerts@nihr.ac.uk						Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bithell C., BLOG POSTINSTITUTE C; Breast Cancer Now, BREAST CANC NOW GEN; Collaborative Group on Hormonal Factors in Breast Cancer, 2019, LANCET, V394, P10204; Institute of Cancer Research, EFF COMB HRT BREAST; National Institute for Health and Care Excellence, 2019, NICE GUID NG23	6	1	1	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 8	2022	376								o485	10.1136/bmj.o485	http://dx.doi.org/10.1136/bmj.o485			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ8QM	35260385				2023-01-03	WOS:000767362700011
J	Xu, S; Arnetz, JE; Arnetz, BB				Xu, Sonnet; Arnetz, Judith E.; Arnetz, Bengt B.			Applying machine learning to explore the association between biological stress and near misses in emergency medicine residents	PLOS ONE			English	Article							CORTISOL; DHEA; DEHYDROEPIANDROSTERONE; METABOLISM; BURNOUT	Physician stress is associated with near misses and adverse medical events. However, little is known about physiological mechanisms linking stress to such events. We explored the utility of machine learning to determine whether the catabolic stress hormone cortisol and the anabolic, anti-stress hormone dehydroepiandrosterone sulfate (DHEA-S), as well as the cortisol to DHEA-S ratio relate to near misses in emergency medicine residents during active duty in a trauma 1 emergency department. Compared to statistical models better suited for inference, machine learning models allow for prediction in situations that have not yet occurred, and thus better suited for clinical applications. This exploratory study used multiple machine learning models to determine possible relationships between biomarkers and near misses. Of the various models tested, support vector machine with radial bias function kernels and support vector machine with linear kernels performed the best, with training accuracies of 85% and 79% respectively. When evaluated on a test dataset, both models had prediction accuracies of around 80%. The pre-shift cortisol to DHEA-S ratio was shown to be the most important predictor in interpretable models tested. Results suggest that interventions that help emergency room physicians relax before they begin their shift could reduce risk of errors and improve patient and physician outcomes. This pilot demonstrates promising results regarding using machine learning to better understand the stress biology of near misses. Future studies should use larger groups and relate these variables to information in electronic medical records, such as objective and patient-reported quality measures.	[Xu, Sonnet] Troy High Sch, Troy, MI 48098 USA; [Arnetz, Judith E.; Arnetz, Bengt B.] Michigan State Univ, Coll Human Med, Dept Family Med, Grand Rapids, MI USA	Michigan State University; Michigan State University College of Human Medicine	Xu, S (corresponding author), Troy High Sch, Troy, MI 48098 USA.	sonnet.xu@gmail.com	Arnetz, Bengt/G-1685-2011	Arnetz, Bengt/0000-0001-7173-4333; Xu, Sonnet/0000-0003-2891-937X	Blue Cross Blue Shield of Michigan Foundation	Blue Cross Blue Shield of Michigan Foundation	BBA, grant numbers - N/A, Blue Cross Blue Shield of Michigan Foundation, https://www.bcbsm.com/The sponsors played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arlt W, 2006, J CLIN ENDOCR METAB, V91, P2548, DOI 10.1210/jc.2005-2258; Arnetz BB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016479; Bakker A., 2014, BURNOUT RES, V1, P112, DOI [10.1016/j.burn.2014.04.003, DOI 10.1016/J.BURN.2014.04.003]; Batista P., 2016, J MOL BIOMARKERS DIA, V07; Bozorgmehr A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250842; Butcher SK, 2005, AGING CELL, V4, P319, DOI 10.1111/j.1474-9726.2005.00178.x; Bzdok Danilo, 2018, Nat Methods, V15, P233, DOI 10.1038/nmeth.4642; Cay M., 2017, NORTH CLIN ISTANB; Cruz JA, 2006, CANCER INFORM, V2, P59; Deo RC, 2015, CIRCULATION, V132, P1920, DOI 10.1161/CIRCULATIONAHA.115.001593; Elliott ML, 2021, MOL PSYCHIATR, V26, P3829, DOI 10.1038/s41380-019-0626-7; Farago E, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19153309; Golpour P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186449; Hastie T, 2013, ELEMENTS STAT LEARNI; Heaney JLJ, 2014, J AGING PHYS ACTIV, V22, P465, DOI [10.1123/JAPA.2012-0082, 10.1123/japa.2012-0082]; Hirotsu C, 2015, SLEEP SCI, V8, P143, DOI 10.1016/j.slsci.2015.09.002; Kaczor Eric E, 2020, Proc Annu Hawaii Int Conf Syst Sci, V2020, P3729; Kamin HS, 2017, HORM BEHAV, V89, P69, DOI 10.1016/j.yhbeh.2016.11.018; Kourou K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/j.csbj.2014.11.005; Kroboth PD, 2003, J CLIN PSYCHOPHARM, V23, P96, DOI 10.1097/00004714-200302000-00014; Langarizadeh Mostafa, 2016, Acta Inform Med, V24, P364, DOI 10.5455/aim.2016.24.364-369; Majd Tahereh Mohammadi, 2018, Iranian Biomedical Journal, V22, P374, DOI 10.29252/.22.6.374; Morales J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214858; Parry RM, 2010, PHARMACOGENOMICS J, V10, P292, DOI 10.1038/tpj.2010.56; Rotenstein LS, 2018, JAMA-J AM MED ASSOC, V320, P1131, DOI 10.1001/jama.2018.12777; Schafer KM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249833; Shayan Zahra, 2015, Glob J Health Sci, V8, P41, DOI 10.5539/gjhs.v8n7p41; SIMES RJ, 1985, J CHRON DIS, V38, P171, DOI 10.1016/0021-9681(85)90090-6; Sprague J, 2011, EMOTION, V11, P61, DOI 10.1037/a0021788; Stehman CR, 2019, WEST J EMERG MED, V20, P485, DOI 10.5811/westjem.2019.4.40970; Toker S., 2017, HDB STRESS HLTH, P168, DOI [https://doi.org/10.1002/9781118993811.ch10, DOI 10.1002/9781118993811.CH10]; Toren Orly, 2021, Int J Qual Health Care, V33, DOI 10.1093/intqhc/mzab031; van der Heijden M, 2014, J BIOMED INFORM, V48, P94, DOI 10.1016/j.jbi.2013.12.007; West CP, 2018, J INTERN MED, V283, P516, DOI 10.1111/joim.12752; Zwain IH, 1999, ENDOCRINOLOGY, V140, P880, DOI 10.1210/en.140.2.880	35	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2022	17	3							e0264957	10.1371/journal.pone.0264957	http://dx.doi.org/10.1371/journal.pone.0264957			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0II	35259166	Green Published, gold			2023-01-03	WOS:000835141200034
J	Bibi, F; Abbas, Z; Harun, N; Perveen, B; Bussmann, RW				Bibi, Fozia; Abbas, Zaheer; Harun, Nidaa; Perveen, Bushra; Bussmann, Rainer W.			Indigenous knowledge and quantitative ethnobotany of the Tanawal area, Lesser Western Himalayas, Pakistan	PLOS ONE			English	Article							MEDICINAL-PLANTS; TRADITIONAL KNOWLEDGE; ETHNOMEDICINAL PLANTS; TRIBAL COMMUNITIES; KAGHAN VALLEY; DISTRICT; WOMEN	Ethnobotanical field surveys were carried out in the Tanawal area of the Lesser Himalayan Region, Khyber Pakhtunkhawa, Province from April 2016 to October 2017. The area is located between 34.36 (34 degrees 21' 30 N) latitude and 73.07 (73 degrees 4' 0 E) longitude with an average elevation of 1374 meters above sea level. Ethnomedicinal data were collected through Participatory Rural Appraisal (PRA), and participants were selected through the snow-boll technique. Semi-structured, in-depth and open-ended interviews were conducted. The data were quantitatively evaluated using ethnomedicinal indices i.e. Relative frequency of citation (RFCs), Fidelity level (FL), and Use Value (UV). The ethnobotanical data were also comparatively analyzed through the Jaccard Index (JI). The study yielded 66 medicinal plants in 62 genera and 43 families. Asteraceae and Solanaceae were the most important families with five medicinal taxa each. Regarding medicinal plant part utilization, leaves (43.28%) were used predominantly, followed by whole plant (14.92%) and fruits (14.92%). Decoction was the main drug formulation applied to 21 species (31.15%) and the oral route was most common (56.1%) while 31.2% of medicinal plants were used for both oral and topical applications. Fifty health disorders were recorded and grouped in 15 categories. Maximum species were used to treat gastrointestinal disorders i.e. 13 species, dermal problems (12 species), and respiratory tract ailments (9). The calculated RFCs ranged between 81 to 31. The most important medicinal plants were Acacia modesta, Citrullus vulgaris, Tamarindus indica, and Momordica charantia with an RGFC of 81 each. The UV ranged between 0.58 and 3.6. Medicinal taxa with the highest UV were Dioscorea deltoidea (3.6), Withania coagulans (3.3), Momordica charantia (3.5), Silybum marianum and Pyrus pashia (3.2). FL values showed that 28 (41.79%) species had a FL value below 50 (74.62%) while 39 (58.20%) had higher FL values. Momordica charantia, Tamarindus indica, Acacia modesta and Citrullus vulgaris were 95.2 each. The Jaccard Index (JI) values ranged from16.77 to 0.98. The current study also reported 16 medicinal plants, commonly used around the globe, have been rarely documented for their medicinal values in the local ethnomedicinal literature i.e. Althaea officinalis, Plantanus orientalis, Jasminum sombac, Maytenus royleana, Cucurbita maxima, Phyllanthus emblica, Citrullus vulgaris. Polygonatum verticilliatum, Caseria tomentosa, Cistanche tubulosa, Bambusa arundinacea, Schinus molle, Tamarindus indica, Pongamia pinnata, Citrus limon and Catharanthus roseus. However, 48 medicinal plants had been reported in the literature but the current study reported their novel medicinal uses. Important taxa should be established in botanical gardens for in-situ conservation, chemical investigation and sustainable utilization. It would also be effective to improve the livelihoods of the local population.	[Bibi, Fozia; Perveen, Bushra] Rawalpindi Women Univ, Dept Bot, Rawalpindi, Pakistan; [Abbas, Zaheer] Univ Educ, Dept Bot, Div Sci & Technol, Lahore, Pakistan; [Harun, Nidaa] Univ Okara, Fac Life Sci, Dept Bot, Okara, Pakistan; [Bussmann, Rainer W.] Ilia State Univ, Inst Bot, Dept Ethnobot, Tbilisi, Georgia	Ilia State University	Harun, N (corresponding author), Univ Okara, Fac Life Sci, Dept Bot, Okara, Pakistan.	nidaadr@uo.edu.pk		nidaa, Dr./0000-0002-5387-0785				Abbas Z, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0172-9; Abbas Z, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0114-y; Abbasi AM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-66; Abbasi AM, 2013, J ETHNOPHARMACOL, V148, P528, DOI 10.1016/j.jep.2013.04.050; Abbasi AM, 2010, INDIAN J TRADIT KNOW, V9, P175; Abidullah S., 2019, INT J BIOORG CHEM, V4, P70, DOI DOI 10.11648/J.IJBC.20190401.20; Adnan M, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-16; Ahmad I, 2011, J INEQUAL APPL, DOI 10.1186/1029-242X-2011-75; Ahmad KS, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0196-1; Ahmed E, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-13; Alexiades MN., 1996, SELECTED GUIDELINES; Ali S.I, 1972, FLORA W PAKISTAN ANN; Anwar Ali, 2020, Sarhad Journal of Agriculture, V36, P236, DOI 10.17582/journal.sja/2020/36.1.236.244; Aziz MA, 2017, J ETHNOPHARMACOL, V198, P268, DOI 10.1016/j.jep.2017.01.024; Bano A, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-43; CHAMBERS R, 1994, WORLD DEV, V22, P953, DOI 10.1016/0305-750X(94)90141-4; Ehlers E., 2000, HIGH MOUNTAIN PASTOR; Farooq A, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0323-2; Farooq M., 2019, ACTA ECOL SIN, V39, P267, DOI [10.1016/j.chnaes.2018.09.014, DOI 10.1016/J.CHNAES.2018.09.014]; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Gonzalez-Tejero MR, 2008, J ETHNOPHARMACOL, V116, P341, DOI 10.1016/j.jep.2007.11.045; Haston E, 2009, BOT J LINN SOC, V161, P128, DOI 10.1111/j.1095-8339.2009.00996.x; JAIN S K, 1977, P157; KAINER KA, 1992, ECON BOT, V46, P408, DOI 10.1007/BF02866513; Kayani S, 2015, J ETHNOPHARMACOL, V164, P186, DOI 10.1016/j.jep.2015.02.004; Kent M, 1992, VEGETATION DESCRIPTI; Khalid M, 2017, J RADIAT RES APPL SC, V10, P152, DOI 10.1016/j.jrras.2017.03.005; Khan N, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-122; Khan SM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-4; Korner C, 2004, AMBIO, P11; Korner C, 2021, ALPINE BOT, V131, P213, DOI 10.1007/s00035-021-00265-8; Korner C, 2017, ALPINE BOT, V127, P1, DOI 10.1007/s00035-016-0182-6; Ladio A, 2007, J ARID ENVIRON, V69, P695, DOI 10.1016/j.jaridenv.2006.11.008; Leonti M, 2003, J ETHNOPHARMACOL, V88, P119, DOI 10.1016/S0378-8741(03)00188-0; Maden K, 2004, OUR NAT, V2, P53, DOI [DOI 10.3126/on.v2i1.327, 10.3126/on.v2i1.327, DOI 10.3126/ON.V2I1.327]; Majid A, 2019, REV BRAS FARMACOGN, V29, P785, DOI 10.1016/j.bjp.2019.03.005; Martin G.A., 2004, ETHNOBOTANY METHODS; Moerman DE., 1998, NATIVE AM ETHNOBOTAN; Murad W, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-77; Nasir E, 1970, FLORA W PAKISTAN; PHILLIPS O, 1993, ECON BOT, V47, P33, DOI 10.1007/BF02862204; Rahman IU, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120581; Reyes-Garcia V, 2013, EVOL HUM BEHAV, V34, P249, DOI 10.1016/j.evolhumbehav.2013.03.002; Shah G.M., 2006, ETHNOBOTANICAL LEAFL, V2006, P63; Shah GM, 2014, J ETHNOPHARMACOL, V155, P450, DOI 10.1016/j.jep.2014.05.047; Shah GM, 2013, PAK J BOT, V45, P253; Shoaib G., 2017, J APPL ENVIRON BIOL, V7, P21; Shoaib G, 2021, REV BIOL TROP, V69, P1, DOI 10.15517/rbt.v69i1.42021; Sulaiman, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9081001; Tardio J, 2008, ECON BOT, V62, P24, DOI 10.1007/s12231-007-9004-5; Tariq F., 2019, J MED PLANT ST, V7, P24; Tounekti T, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/3190670; ul Haq N, 2022, GEOJOURNAL, V87, P3307, DOI 10.1007/s10708-021-10437-y; Ullah S, 2020, PLANT SCI TODAY, V7, P17, DOI 10.14719/pst.2020.7.1.625; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Voeks RA, 2007, SINGAPORE J TROP GEO, V28, P7, DOI 10.1111/j.1467-9493.2006.00273.x; Yabesh JEM, 2014, J ETHNOPHARMACOL, V154, P774, DOI 10.1016/j.jep.2014.05.004; Zenderland J, 2019, ECON BOT, V73, P293, DOI 10.1007/s12231-019-09480-1	58	3	3	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2022	17	2							e0263604	10.1371/journal.pone.026360	http://dx.doi.org/10.1371/journal.pone.026360			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E9PM	35192648				2023-01-03	WOS:000812552500025
J	Polizzotto, MN; Nordwall, J; Babiker, AG; Phillips, A; Vock, DM; Eriobu, N; Kwaghe, V; Paredes, R; Mateu, L; Ramachandruni, S; Narang, R; Jain, MK; Lazarte, SM; Baker, JV; Frosch, AEP; Poulakou, G; Syrigos, KN; Amoczy, GS; McBride, NA; Robinson, PA; Sarafian, F; Bhagani, S; Taha, ILS; Benfield, T; Liu, STH; Antoniadou, A; Jensen, JUS; Kalomenidis, I; Susilo, A; Hariadi, P; Jensen, TO; Morales-Rull, JL; Helleberg, M; Meegada, S; Johansen, IS; Canario, D; Fernandez-Cruz, E; Metallidis, S; Shah, A; Sakurai, A; Koulouris, NG; Trounan, R; Weintrob, AC; Podlekareva, D; Hadi, U; Lloyd, KM; Roge, BT; Saito, S; Sweenis, K; Malin, JJ; Lubbert, C; Munoz, J; Cummings, MJ; Losso, MH; Turner, D; Shaw-Saliba, K; Dewar, R; Highbarger, H; Lallemand, P; Rehman, T; Gerry, N; Arlinda, D; Chang, CC; Grund, B; Holbrook, MR; Holley, HP; Hudson, F; McNay, LA; Murray, DD; Pett, SL; Shaughnessy, M; Smolslcis, MC; Touloumi, G; Wright, MF; Doyle, MK; Popik, S; Hall, C; Ramanathan, R; Cao, HY; Mondou, E; Willis, T; Thakuria, JV; Yel, L; Liggs, EI; Kan, VL; Lundgren, JD; Neaton, JD; Lane, HC				Polizzotto, Mark N.; Nordwall, Jacqueline; Babiker, Abdel G.; Phillips, Andrew; Vock, David M.; Eriobu, Nnakelu; Kwaghe, Vivian; Paredes, Roger; Mateu, Lourdes; Ramachandruni, Srikanth; Narang, Rajeev; Jain, Manua K.; Lazarte, Susana M.; Baker, Jason, V; Frosch, Anne E. P.; Poulakou, Garyfallia; Syrigos, Konstantinos N.; Amoczy, Gretchen S.; McBride, Natalie A.; Robinson, Philip A.; Sarafian, Farjad; Bhagani, Sanjay; Taha, I. Lassan S.; Benfield, Thomas; Liu, Sean T. H.; Antoniadou, Anastasia; Jensen, Jens Ulrik Staehr; Kalomenidis, Ioannis; Susilo, Adityo; Hariadi, Prasetyo; Jensen, Tomas O.; Morales-Rull, Jose Luis; Helleberg, Marie; Meegada, Sreenath; Johansen, Isik S.; Canario, Daniel; Fernandez-Cruz, Eduardo; Metallidis, Simeon; Shah, Amish; Sakurai, Aki; Koulouris, Nikolaus G.; Trounan, Robin; Weintrob, Amy C.; Podlekareva, Dania; Hadi, Usman; Lloyd, Kathryn M.; Roge, Birgit Thorup; Saito, Sho; Sweenis, Kelly; Malin, Jakob J.; Luebbert, Christoph; Munoz, Jose; Cummings, Matthew J.; Losso, Marcelo H.; Turner, Dan; Shaw-Saliba, Kathryn; Dewar, Robin; Highbarger, Helene; Lallemand, Pertine; Rehman, Tauseef; Gerry, Norman; Arlinda, Dona; Chang, Christina C.; Grund, Birgit; Holbrook, Michael R.; Holley, Horace P.; Hudson, Fleur; McNay, Laura A.; Murray, Daniel D.; Pett, Sarah L.; Shaughnessy, Megan; Smolslcis, Mary C.; Touloumi, Giota; Wright, Mary F.; Doyle, Mittie K.; Popik, Sharon; Hall, Christine; Ramanathan, Roshan; Cao, Huyen; Mondou, Elsa; Willis, Todd; Thakuria, Joseph, V; Yel, Leman; Liggs, Elizabeth, I; Kan, Virginia L.; Lundgren, Jens D.; Neaton, James D.; Lane, H. Clifford		ITAC INSIGHT 013 Study Grp	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial	LANCET			English	Article								Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of COVID-19 are limited. Methods In this international randomised, double-blind, placebo-controlled trial, hospitalised patients with COVID-19 who had been symptomatic for up to 12 days and did not have acute end-organ failure were randomly assigned (1:1) to receive either hIVIG or an equivalent volume of saline as placebo, in addition to remdesivir, when not contraindicated, and other standard clinical care. Randomisation was stratified by site pharmacy; schedules were prepared using a mass-weighted urn design. Infusions were prepared and masked by trial pharmacists; all other investigators, research staff, and trial participants were masked to group allocation. Follow-up was for 28 days. The primary outcome was measured at day 7 by a seven-category ordinal endpoint that considered pulmonary status and extrapulmonary complications and ranged from no limiting symptoms to death. Deaths and adverse events, including organ failure and serious infections, were used to define composite safety outcomes at days 7 and 28. Prespecified subgroup analyses were carried out for efficacy and safety outcomes by duration of symptoms, the presence of antispike neutralising antibodies, and other baseline factors. Analyses were done on a modified intention-to-treat (mITT) population, which included all randomly assigned participants who met eligibility criteria and received all or part of the assigned study product infusion. This study is registered with ClinicalTrials.gov, NCT04546581. Findings From Oct 8, 2020, to Feb 10, 2021, 593 participants (n=301 hIVIG, n=292 placebo) were enrolled at 63 sites in 11 countries; 579 patients were included in the mITT analysis. Compared with placebo, the hIVIG group did not have significantly greater odds of a more favourable outcome at day 7; the adjusted OR was 1.06 (95% CI 0.77-1.45; p=0.72). Infusions were well tolerated, although infusion reactions were more common in the hIVIG group (18.6% vs 9.5% for placebo; p=0.002). The percentage with the composite safety outcome at day 7 was similar for the hIVIG (24%) and placebo groups (25%; OR 0.98, 95% CI 0.66-1.46; p=0.91). The ORs for the day 7 ordinal outcome did not vary for subgroups considered, but there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome: risk was greater for hIVIG compared with placebo for patients who were antibody positive (OR 2.21, 95% CI 1.14-4.29); for patients who were antibody negative, the OR was 0.51 (0.29-0.90; p(interaction)=0.001). Interpretation When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure. The safety of hIVIG might vary by the presence of endogenous neutralising antibodies at entry. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Polizzotto, Mark N.] Australian Natl Univ, Clin Hub Intervent Res, Canberra, ACT 2600, Australia	Australian National University	Polizzotto, MN (corresponding author), Australian Natl Univ, Clin Hub Intervent Res, Canberra, ACT 2600, Australia.	mark.polizzotto@anu.edu.au	Hadi, Usman/ABE-9657-2020; Jensen, Tomas/AFN-5759-2022; Malin, Jakob J./L-7935-2019; Lundgren, Jens/AAE-6876-2019	Hadi, Usman/0000-0001-9348-7046; Jensen, Tomas/0000-0003-0398-4431; Malin, Jakob J./0000-0002-2989-0436; Paredes, Roger/0000-0002-6553-691X; Jain, Mamta/0000-0003-2292-6544; Bhagani, Sanjay/0000-0003-2557-4337; ERIOBU, NNAKELU/0000-0003-2528-8082; Podlekareva, Daria/0000-0003-3187-0597; Benfield, Thomas/0000-0003-0698-9385; Jensen, Jens Ulrik/0000-0003-4036-0521; Mateu, Lourdes/0000-0001-7223-7611; Vock, David M/0000-0002-5459-9579	US National Institutes of Health	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	US National Institutes of Health.	AALEN OO, 1978, SCAND J STAT, V5, P141; ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Aitken AE, 2007, DRUG METAB DISPOS, V35, P1687, DOI 10.1124/dmd.107.015511; Ali S, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100926; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Avendano-Sola C, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152740; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Begin P, 2021, NAT MED, V27, P2012, DOI 10.1038/s41591-021-01488-2; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X; Enria DA, 2008, ANTIVIR RES, V78, P132, DOI 10.1016/j.antiviral.2007.10.010; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015; Gharbharan A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23469-2; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Griffin DO, 2021, AIDS REV, V23, P40, DOI 10.24875/AIDSRev.200001261; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Janiaud P, 2021, JAMA-J AM MED ASSOC, V325, P1185, DOI 10.1001/jama.2021.2747; Joyner MJ, 2021, NEW ENGL J MED, V384, P1015, DOI 10.1056/NEJMoa2031893; Korley FK, 2021, NEW ENGL J MED, V385, P1951, DOI 10.1056/NEJMoa2103784; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lopardo G, 2021, ECLINICALMEDICINE, V34, DOI 10.1016/j.eclinm.2021.100843; Lundgren JD, 2022, ANN INTERN MED, V175, P234, DOI 10.7326/M21-3507; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; RECOVERY Collaborative group, 2021, LANCET, DOI [10.1101/2021.06.15.21258542, DOI 10.1101/2021.06.15.21258542V1]; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Vandeberg P, 2021, TRANSFUSION, V61, P1705, DOI 10.1111/trf.16378; Vanderen HA, 2018, J INFECT DIS, V218, P1383, DOI 10.1093/infdis/jiy328; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Zhao WL, 2015, CONTEMP CLIN TRIALS, V43, P209, DOI 10.1016/j.cct.2015.06.008; Zhou BQ, 2011, BIOMETRICS, V67, P661, DOI 10.1111/j.1541-0420.2010.01493.x	36	17	17	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10324					530	540		10.1016/S0140-6736(22)00101-5	http://dx.doi.org/10.1016/S0140-6736(22)00101-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY9ZX	35093205	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000755144500026
J	Almulla, L; Al-Naib, I; Ateeq, IS; Althobaiti, M				Almulla, Latifah; Al-Naib, Ibraheem; Ateeq, Ijlal Shahrukh; Althobaiti, Murad			Observation and motor imagery balance tasks evaluation: An fNIRS feasibility study	PLOS ONE			English	Article							NEAR-INFRARED SPECTROSCOPY; FALSE DISCOVERY RATE; PREFRONTAL CORTEX; CORTICAL ACTIVATION; PRECISION GAIT; BRAIN ACTIVITY; CHRONIC STROKE; WALKING; MIRROR	In this study, we aimed at exploring the feasibility of functional near-infrared spectroscopy (fNIRS) for studying the observation and/or motor imagination of various postural tasks. Thirteen healthy adult subjects followed five trials of static and dynamic standing balance tasks, throughout three different experimental setups of action observation (AO), a combination of action observation and motor imagery (AO+MI), and motor imagery (MI). During static and dynamic standing tasks, both the AO+MI and MI experiments revealed that many channels in prefrontal or motor regions are significantly activated while the AO experiment showed almost no significant increase in activations in most of the channels. The contrast between static and dynamic standing tasks showed that with more demanding balance tasks, relative higher activation patterns were observed, particularly during AO and in AO+MI experiments in the frontopolar area. Moreover, the AO+MI experiment revealed a significant difference in premotor and supplementary motor cortices that are related to balance control. Furthermore, it has been observed that the AO+MI experiment induced relatively higher activation patterns in comparison to AO or MI alone. Remarkably, the results of this work match its counterpart from previous functional magnetic resonance imaging studies. Therefore, they may pave the way for using the fNIRS as a diagnostic tool for evaluating the performance of the non-physical balance training during the rehabilitation period of temporally immobilized patients.	[Almulla, Latifah; Al-Naib, Ibraheem; Ateeq, Ijlal Shahrukh; Althobaiti, Murad] Imam Abdulrahman Bin Faisal Univ, Coll Engn, Biomed Engn Dept, Dammam, Saudi Arabia; [Almulla, Latifah] King Abdullah Univ Sci & Technol, Biol & Environm Sci & Engn Div, Organ Bioelect Lab, Thuwal, Saudi Arabia	Imam Abdulrahman Bin Faisal University; King Abdullah University of Science & Technology	Althobaiti, M (corresponding author), Imam Abdulrahman Bin Faisal Univ, Coll Engn, Biomed Engn Dept, Dammam, Saudi Arabia.	mmalthobaiti@iau.edu.sa	; Althobaiti, Murad/K-4708-2018	Al-Naib, Ibraheem/0000-0002-7499-0655; Almulla, Latifah/0000-0003-3165-8561; Ateeq, Ijlal Shahrukh/0000-0002-3404-0508; Althobaiti, Murad/0000-0002-8084-6916	Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University, Saudi Arabia [2019-013-Eng]	Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University, Saudi Arabia	This work was supported by the Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University, Saudi Arabia under project number 2019-013-Eng. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalmalak A, 2020, NEUROSCI LETT, V714, DOI 10.1016/j.neulet.2019.134607; Al-Shargie F, 2016, BIOMED OPT EXPRESS, V7, P3882, DOI 10.1364/BOE.7.003882; Almulla L, 2020, BIOMED PHYS ENG EXPR, V6, DOI 10.1088/2057-1976/aba102; Arenth PM, 2007, CLIN NEUROPSYCHOL, V21, P38, DOI 10.1080/13854040600878785; Babiloni C, 2009, INT REV NEUROBIOL, V86, P67, DOI 10.1016/S0074-7742(09)86005-4; Bang DH, 2013, CLIN REHABIL, V27, P1118, DOI 10.1177/0269215513501528; Barker JW, 2013, BIOMED OPT EXPRESS, V4, P1366, DOI 10.1364/BOE.4.001366; Batula AM, 2017, COMPUT INTEL NEUROSC, V2017, DOI 10.1155/2017/5491296; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brassard P, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00204; Chiarelli AM, 2017, NEUROPHOTONICS, V4, DOI [10.1117/1.NPh.4.4.041411, 10.1117/1.NPh.4.4.041411]]; Cho HY, 2013, CLIN REHABIL, V27, P675, DOI 10.1177/0269215512464702; Chul J, 2009, NEUROIMAGE, V44, P428, DOI 10.1016/j.neuroimage.2008.08.036; Condy EE, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.627983; Crosson B, 2010, J REHABIL RES DEV, V47, pVII, DOI 10.1682/JRRD.2010.02.0017; Ferrari M, 2014, BRAIN TOPOGR, V27, P353, DOI 10.1007/s10548-013-0320-z; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Fujimoto H, 2014, NEUROIMAGE, V85, P547, DOI 10.1016/j.neuroimage.2013.05.014; Gatti Roberto, 2019, Arch Physiother, V9, P1, DOI 10.1186/s40945-018-0053-0; Granacher U, 2011, GERONTOLOGY, V57, P304, DOI 10.1159/000320250; Grezes J, 2003, NEUROIMAGE, V18, P928, DOI 10.1016/S1053-8119(03)00042-9; Hamel MF, 2005, AGING CLIN EXP RES, V17, P223; HE B., 2013, NEURAL ENG; He B, 2011, IEEE T BIO-MED ENG, V58, P1918, DOI 10.1109/TBME.2011.2139210; Herold F, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120466; Herold F, 2017, HUM MOVEMENT SCI, V51, P51, DOI 10.1016/j.humov.2016.11.002; Higuchi S, 2012, NEUROIMAGE, V59, P1668, DOI 10.1016/j.neuroimage.2011.09.021; Holper L, 2011, EUR J NEUROSCI, V33, P2318, DOI 10.1111/j.1460-9568.2011.07720.x; Hoppes CW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193710; Huppert TJ, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.1.010401; Ihme K, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00327; Irani F, 2007, CLIN NEUROPSYCHOL, V21, P9, DOI 10.1080/13854040600910018; Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Karim H, 2012, GAIT POSTURE, V35, P367, DOI 10.1016/j.gaitpost.2011.10.007; Kempny AM, 2016, NEUROIMAGE-CLIN, V12, P312, DOI 10.1016/j.nicl.2016.07.013; Kim JC, 2018, J MOTOR BEHAV, V50, P373, DOI 10.1080/00222895.2017.1363697; Koenraadt KLM, 2014, NEUROIMAGE, V85, P415, DOI 10.1016/j.neuroimage.2013.04.070; Kotegawa K, 2021, BEHAV BRAIN RES, V399, DOI 10.1016/j.bbr.2020.113046; Kotegawa K, 2020, EXP BRAIN RES, V238, P221, DOI 10.1007/s00221-019-05706-9; Lin CC, 2017, EXP BRAIN RES, V235, P1247, DOI 10.1007/s00221-017-4893-8; Mahoney JR, 2016, BRAIN RES, V1633, P126, DOI 10.1016/j.brainres.2015.10.053; Malouin F, 2003, HUM BRAIN MAPP, V19, P47, DOI 10.1002/hbm.10103; Menant JC, 2020, GAIT POSTURE, V82, P254, DOI 10.1016/j.gaitpost.2020.09.012; Mihara M, 2008, NEUROIMAGE, V43, P329, DOI 10.1016/j.neuroimage.2008.07.029; Miyai I, 2001, NEUROIMAGE, V14, P1186, DOI 10.1006/nimg.2001.0905; Moro SB, 2014, NEUROIMAGE, V85, P451, DOI 10.1016/j.neuroimage.2013.05.031; Mouthon A, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/1598178; Mouthon A, 2015, NEUROSCIENCE, V303, P535, DOI 10.1016/j.neuroscience.2015.07.031; Nicholson V, 2019, J PHYSIOTHER, V65, P200, DOI 10.1016/j.jphys.2019.08.007; Obrig H, 2003, J CEREBR BLOOD F MET, V23, P1, DOI 10.1097/01.WCB.0000043472.45775.29; Olsson CJ, 2008, SCAND J PSYCHOL, V49, P133, DOI 10.1111/j.1467-9450.2008.00625.x; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Rahimpour A, 2020, J NEUROSCI METH, V341, DOI 10.1016/j.jneumeth.2020.108790; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rosso AL, 2017, GAIT POSTURE, V57, P193, DOI 10.1016/j.gaitpost.2017.06.013; Santosa H, 2018, ALGORITHMS, V11, DOI 10.3390/a11050073; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Singh AK, 2006, NEUROIMAGE, V33, P542, DOI 10.1016/j.neuroimage.2006.06.047; St George RJ, 2021, NEUROSCIENCE, V452, P208, DOI 10.1016/j.neuroscience.2020.10.027; Suzuki M, 2004, NEUROIMAGE, V23, P1020, DOI 10.1016/j.neuroimage.2004.07.002; Taroni P, 2003, PHOTOCH PHOTOBIO SCI, V2, P124, DOI 10.1039/b209651j; Taube W, 2015, CORTEX, V64, P102, DOI 10.1016/j.cortex.2014.09.022; Taube W, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00972; Tia B, 2010, NEUROSCI LETT, V480, P138, DOI 10.1016/j.neulet.2010.06.026; Vanzella P, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00164; Visschedijk J, 2010, J AM GERIATR SOC, V58, P1739, DOI 10.1111/j.1532-5415.2010.03036.x; Morais GAZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21716-z	69	0	0	7	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265898	10.1371/journal.pone.0265898	http://dx.doi.org/10.1371/journal.pone.0265898			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P5DL	35320324	Green Published, gold			2023-01-03	WOS:000784240600008
J	Guthrie, DM; Williams, N; Beach, C; Buzath, E; Cohen, J; Declercq, A; Fisher, K; Fries, BE; Goodridge, D; Hermans, K; Hirdes, JP; Seow, H; Silveira, M; Sinnarajah, A; Stevens, S; Tanuseputro, P; Taylor, D; Vadeboncoeur, C; Martin, TLW				Guthrie, Dawn M.; Williams, Nicole; Beach, Cheryl; Buzath, Emma; Cohen, Joachim; Declercq, Anja; Fisher, Kathryn; Fries, Brant E.; Goodridge, Donna; Hermans, Kirsten; Hirdes, John P.; Seow, Hsien; Silveira, Maria; Sinnarajah, Aynharan; Stevens, Susan; Tanuseputro, Peter; Taylor, Deanne; Vadeboncoeur, Christina; Martin, Tracy Lyn Wityk			A multi-stage process to develop quality indicators for community-based palliative care using interRAI data	PLOS ONE			English	Article							END-OF-LIFE; CANCER-PATIENTS; HOME-CARE; ADMINISTRATIVE DATABASES; NURSING-HOMES; IN-HOME; HEALTH; SYSTEM; OUTCOMES; ONTARIO	Background Individuals receiving palliative care (PC) are generally thought to prefer to receive care and die in their homes, yet little research has assessed the quality of home- and community-based PC. This project developed a set of valid and reliable quality indicators (QIs) that can be generated using data that are already gathered with interRAI assessments-an internationally validated set of tools commonly used in North America for home care clients. The QIs can serve as decision-support measures to assist providers and decision makers in delivering optimal care to individuals and their families. Methods The development efforts took part in multiple stages, between 2017-2021, including a workshop with clinicians and decision-makers working in PC, qualitative interviews with individuals receiving PC, families and decision makers and a modified Delphi panel, based on the RAND/ULCA appropriateness method. Results Based on the workshop results, and qualitative interviews, a set of 27 candidate QIs were defined. They capture issues such as caregiver burden, pain, breathlessness, falls, constipation, nausea/vomiting and loneliness. These QIs were further evaluated by clinicians/decision makers working in PC, through the modified Delphi panel, and five were removed from further consideration, resulting in 22 QIs. Conclusions Through in-depth and multiple-stakeholder consultations we developed a set of QIs generated with data already collected with interRAI assessments. These indicators provide a feasible basis for quality benchmarking and improvement systems for care providers aiming to optimize PC to individuals and their families.	[Guthrie, Dawn M.; Williams, Nicole] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON, Canada; [Guthrie, Dawn M.] Wilfrid Laurier Univ, Dept Hlth Sci, Waterloo, ON, Canada; [Beach, Cheryl] Fraser Hlth, Integrated Community Serv, Surrey, BC, Canada; [Buzath, Emma; Martin, Tracy Lyn Wityk] Alberta Hlth Serv, Prov Palliat & End Of Life Care, Seniors Hlth & Continuing Care, Calgary, AB, Canada; [Cohen, Joachim] Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Declercq, Anja; Hermans, Kirsten] Katholieke Univ Leuven, LUCAS Ctr Care Res & Consultancy, Leuven, Belgium; [Declercq, Anja] Katholieke Univ Leuven, CESO Ctr Sociol Res, Leuven, Belgium; [Fisher, Kathryn] McMaster Univ, Sch Nursing, Hamilton, ON, Canada; [Fries, Brant E.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Fries, Brant E.] Univ Michigan, Dept Geriatr & Palliat Med, Ann Arbor, MI 48109 USA; [Goodridge, Donna] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada; [Hirdes, John P.] Univ Waterloo, Sch Publ Hlth Sci, Waterloo, ON, Canada; [Seow, Hsien] McMaster Univ, Dept Oncol, Hamilton, ON, Canada; [Silveira, Maria] Univ Michigan, Dept Internal Med, Div Geriatr & Palliat Med, Ann Arbor, MI 48109 USA; [Sinnarajah, Aynharan] Queens Univ, Dept Med, Kingston, ON, Canada; [Stevens, Susan] Nova Scotia Hlth, Halifax, NS, Canada; [Tanuseputro, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Taylor, Deanne] Interior Hlth Author, Res Dept, Kelowna, BC, Canada; [Taylor, Deanne] Rural Coordinat Ctr BC, Penticton, BC, Canada; [Vadeboncoeur, Christina] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada; [Vadeboncoeur, Christina] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Vadeboncoeur, Christina] Roger Neilson House, Ottawa, ON, Canada	Wilfrid Laurier University; Wilfrid Laurier University; Alberta Health Services (AHS); University of Calgary; Vrije Universiteit Brussel; KU Leuven; KU Leuven; McMaster University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Saskatchewan; University of Waterloo; McMaster University; University of Michigan System; University of Michigan; Queens University - Canada; University of Ottawa; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	Guthrie, DM (corresponding author), Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON, Canada.; Guthrie, DM (corresponding author), Wilfrid Laurier Univ, Dept Hlth Sci, Waterloo, ON, Canada.	dguthrie@wlu.ca	Declercq, Anja/AGS-7441-2022; Seow, Hsien/AAQ-1438-2021	Declercq, Anja/0000-0003-3136-124X; Seow, Hsien/0000-0001-6701-1714; Guthrie, Dawn/0000-0003-3241-6580	Canadian Institutes of Health Research (CIHR) [PJT156359]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	DG received an award from the Canadian Institutes of Health Research (CIHR; grant #PJT156359). CIHR web site:https://cihr-irsc.gc.ca/e/193.html.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahluwalia SC, 2018, J PAIN SYMPTOM MANAG, V56, P831, DOI 10.1016/j.jpainsymman.2018.09.008; Alberta Health Services, 2014, PALL END LIF CAR ALB; Barbera L, 2006, J PALLIATIVE CARE, V22, P12, DOI 10.1177/082585970602200103; Barbera L, 2015, CURR ONCOL, V22, P341, DOI 10.3747/co.22.2636; Berg K, 2002, HEALTH CARE FINANC R, V23, P19; Bjorkgren MA, 2000, CAN J AGING, V19, P106, DOI 10.1017/S0714980800013921; Bone AE, 2019, EUR J PUBLIC HEALTH, V29, P67, DOI 10.1093/eurpub/cky241; Canadian Institute for Health Information, 2019, YOUR HLTH SYST POT I; Canadian Institute for Health Information, 2021, PROF CLIENTS HOM CAR; Carpenter I., 2013, OECD HLTH POLICY STU, V17, P93; Chartier LB, 2021, ANN EMERG MED, V77, P193, DOI 10.1016/j.annemergmed.2020.09.449; Claessen SJJ, 2011, J PAIN SYMPTOM MANAG, V42, P169, DOI 10.1016/j.jpainsymman.2010.10.267; Cohen J., 2014, EUROPEAN J PALLIATIV, V21, P228; Cohen J, 2021, PALLIATIVE MED, V35, P1525, DOI 10.1177/02692163211019881; Cohen SR, 2002, J PALLIATIVE CARE, V18, P48, DOI 10.1177/082585970201800108; Currow DC, 2015, SUPPORT CARE CANCER, V23, P307, DOI 10.1007/s00520-014-2351-8; D'Angelo D, 2012, SUPPORT CARE CANCER, V20, P1983, DOI 10.1007/s00520-011-1301-y; Dalby Dawn M, 2008, Home Health Care Serv Q, V27, P59, DOI 10.1300/J027v27n01_04; Dalby DM, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-7; De Schreye R, 2017, PALLIATIVE MED, V31, P932, DOI 10.1177/0269216317705099; Dy SM, 2015, J PAIN SYMPTOM MANAG, V49, P773, DOI 10.1016/j.jpainsymman.2015.01.012; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Ettorchi-Tardy Amina, 2012, Healthc Policy, V7, pe101; Foebel AD, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0146-5; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Fries BE, 2001, GERONTOLOGIST, V41, P173, DOI 10.1093/geront/41.2.173; Fries BE, 2019, HEALTH SERV INSIGHTS, V12, DOI 10.1177/1178632919856011; Gagnon B, 2015, J PAIN SYMPTOM MANAG, V50, P48, DOI 10.1016/j.jpainsymman.2014.12.012; Grunfeld E, 2006, PALLIATIVE MED, V20, P769, DOI 10.1177/0269216306072553; Guthrie DM, 2021, J APPL GERONTOL, V40, P731, DOI 10.1177/0733464820920102; Guthrie DM, 2019, J PALLIAT MED, V22, P1346, DOI 10.1089/jpm.2019.0022; Guthrie DM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-137; Harman LE, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-018-0389-y; Health Quality Ontario, 2016, PALL CAR END LIF; Heckman GA, 2013, CAN GERIATR SOC J, V3, P8; Hirdes JP, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00926; Hirdes JP, 2004, GERONTOLOGIST, V44, P665, DOI 10.1093/geront/44.5.665; Hogeveen SE, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0547-9; Iezzoni LI, 2004, AM J PHYS MED REHAB, V83, P316, DOI 10.1097/01.PHM.0000118041.17739.BB; Jensdottir A B, 2003, Int Nurs Rev, V50, P79, DOI 10.1046/j.1466-7657.2003.00163.x; Jones RN, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-96; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Karon SL, 1999, MED CARE, V37, P570, DOI 10.1097/00005650-199906000-00006; Leemans K, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-6; Lorenz KA, 2007, J AM GERIATR SOC, V55, pS318, DOI 10.1111/j.1532-5415.2007.01338.x; Luymes N, 2021, BMC PALLIAT CARE, V20, DOI 10.1186/s12904-021-00843-x; Lynn J, 2005, HASTINGS CENT REP, V35, pS14, DOI 10.1353/hcr.2005.0096; Martin L, 2008, AGE AGEING, V37, P51, DOI 10.1093/ageing/afm162; McDonnell J., 2001, RANDUCLA APPROPRIATE; Meier DE, 2011, MILBANK Q, V89, P343, DOI 10.1111/j.1468-0009.2011.00632.x; Mor V, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-20; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Morris JN, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0842-z; Nakazawa Y, 2016, J PAIN SYMPTOM MANAG, V51, P652, DOI 10.1016/j.jpainsymman.2015.11.011; National Consensus Project for Quality Palliative Care, 2013, CLIN PRACT GUID QUAL; Norton PG, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004488; Paap JV, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-396; Pasman HRW, 2009, J PAIN SYMPTOM MANAG, V38, P145, DOI 10.1016/j.jpainsymman.2008.07.008; Perlman CM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-15; Poss J, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-67; Raijmakers N, 2012, J PALLIAT MED, V15, P308, DOI 10.1089/jpm.2011.0393; Rocker G, 2016, CAN MED ASSOC J, V188, pE493, DOI 10.1503/cmaj.151454; Roulston E., 2016, CANADIANS VIEW PALLI; Schang L., 2021, INT J QUAL HEALTH C, V33, DOI [10.1093/intqhc/mzab107, DOI 10.1093/INTQHC/MZAB107]; Schenck AP, 2014, J PALLIAT MED, V17, P769, DOI 10.1089/jpm.2013.0652; Seow H, 2016, J PALLIAT MED, V19, P712, DOI 10.1089/jpm.2015.0366; Seow H, 2016, J PALLIAT MED, V19, P263, DOI 10.1089/jpm.2015.0229; Seow H, 2009, J PAIN SYMPTOM MANAG, V38, P903, DOI 10.1016/j.jpainsymman.2009.04.024; Steel K., 1999, T AM CLIN CLIMATOLOG, V110, P30; Sussman J, 2012, PALLIATIVE MED, V26, P322, DOI 10.1177/0269216311416697; van der Roest HG, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4109-y; Walker H, 2011, J PALLIAT CARE, V27, P79, DOI 10.1177/082585971102700203; Williams N, 2022, PALLIAT SUPPORT CARE, V20, P226, DOI 10.1017/S1478951521000791; Woitha K, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-381; Worldwide Palliative Care Alliance, 2014, GLOBAL ATLAS PALLIAT; Yabroff KR, 2004, PALLIATIVE MED, V18, P202, DOI 10.1191/0269216304pm880oa; Zimmerman D. R., 1995, HLTH CARE FINANCING, V16, P104; Zimmerman DR, 2003, INT J GERIATR PSYCH, V18, P250, DOI 10.1002/gps.820	78	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266569	10.1371/journal.pone.0266569	http://dx.doi.org/10.1371/journal.pone.0266569			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390091	Green Published, gold			2023-01-03	WOS:000795077200094
J	Li, A; Cove, ME; Phua, J; Puah, SH; Ng, V; Kansal, A; Tan, QL; Sahagun, JT; Taculod, J; Tan, AYH; Mukhopadhyay, A; Tay, CK; Ramanathan, K; Chia, YW; Sewa, DW; Chew, M; Lew, SJW; Goh, S; Dhanvijay, S; Tan, JJE; See, KC				Li, Andrew; Cove, Matthew Edward; Phua, Jason; Puah, Ser Hon; Ng, Vicky; Kansal, Amit; Tan, Qiao Li; Sahagun, Juliet Tolentino; Taculod, Juvel; Tan, Addy Yong-Hui; Mukhopadhyay, Amartya; Tay, Chee Kiang; Ramanathan, Kollengode; Chia, Yew Woon; Sewa, Duu Wen; Chew, Meiying; Lew, Sennen J. W.; Goh, Shirley; Dhanvijay, Shekhar; Tan, Jonathan Jit-Ern; See, Kay Choong		SICM-NICER Grp	Expanding the utility of the ROX index among patients with acute hypoxemic respiratory failure	PLOS ONE			English	Article							FLOW NASAL CANNULA; OXYGEN-THERAPY; IMMUNOCOMPROMISED PATIENTS; EMERGENCY-DEPARTMENT; COPD; CARE; DISTRESS	BackgroundDelaying intubation in patients who fail high-flow nasal cannula (HFNC) may result in increased mortality. The ROX index has been validated to predict HFNC failure among pneumonia patients with acute hypoxemic respiratory failure (AHRF), but little information is available for non-pneumonia causes. In this study, we validate the ROX index among AHRF patients due to both pneumonia or non-pneumonia causes, focusing on early prediction. MethodsThis was a retrospective observational study in eight Singapore intensive care units from 1 January 2015 to 30 September 2017. All patients >18 years who were treated with HFNC for AHRF were eligible and recruited. Clinical parameters and arterial blood gas values at HFNC initiation and one hour were recorded. HFNC failure was defined as requiring intubation post-HFNC initiation. ResultsHFNC was used in 483 patients with 185 (38.3%) failing HFNC. Among pneumonia patients, the ROX index was most discriminatory in pneumonia patients one hour after HFNC initiation [AUC 0.71 (95% CI 0.64-0.79)], with a threshold value of <6.06 at one hour predicting HFNC failure (sensitivity 51%, specificity 80%, positive predictive value 61%, negative predictive value 73%). The discriminatory power remained moderate among pneumonia patients upon HFNC initiation [AUC 0.65 (95% CI 0.57-0.72)], non-pneumonia patients at HFNC initiation [AUC 0.62 (95% CI 0.55-0.69)] and one hour later [AUC 0.63 (95% CI 0.56-0.70)]. ConclusionThe ROX index demonstrated moderate discriminatory power among patients with either pneumonia or non-pneumonia-related AHRF at HFNC initiation and one hour later.	[Li, Andrew; Cove, Matthew Edward; Phua, Jason; Mukhopadhyay, Amartya; Chew, Meiying; See, Kay Choong] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Resp & Crit Care Med, Singapore, Singapore; [Li, Andrew] Woodlands Hlth, Dept Intens Care Med, Singapore, Singapore; [Phua, Jason] Natl Univ Hlth Syst, Alexandra Hosp, Fast & Chron Programmes, Singapore, Singapore; [Puah, Ser Hon; Lew, Sennen J. W.] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; [Ng, Vicky; Goh, Shirley; Tan, Jonathan Jit-Ern] Tan Tock Seng Hosp, Dept Anaesthesiol Intens Care & Pain Med, Singapore, Singapore; [Kansal, Amit; Dhanvijay, Shekhar] Natl Univ Hlth Syst, Ng Teng Fong Gen Hosp, Dept Intens Care Med, Singapore, Singapore; [Tan, Qiao Li; Tay, Chee Kiang; Sewa, Duu Wen] Singapore Gen Hosp, Dept Resp Med & Crit Care Med, Singapore, Singapore; [Sahagun, Juliet Tolentino; Taculod, Juvel] Natl Univ Hlth Syst, Natl Univ Hosp, Div Crit Care, Singapore, Singapore; [Tan, Addy Yong-Hui] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Anaesthesia, Singapore, Singapore; [Ramanathan, Kollengode] Natl Univ Singapore Hosp, Natl Univ Heart Ctr, Dept Cardiac Thorac & Vasc Surg, Singapore, Singapore; [Chia, Yew Woon] Tan Tock Seng Hosp, Dept Cardiol, Singapore, Singapore	National University of Singapore; National University of Singapore; Tan Tock Seng Hospital; Tan Tock Seng Hospital; National University of Singapore; Singapore General Hospital; National University of Singapore; National University of Singapore; National University of Singapore; Tan Tock Seng Hospital	Li, A (corresponding author), Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Resp & Crit Care Med, Singapore, Singapore.; Li, A (corresponding author), Woodlands Hlth, Dept Intens Care Med, Singapore, Singapore.	Andrew_yunkai_li@nuhs.edu.sg		Chia, Yew Woon/0000-0002-4635-3333; Cove, Matthew/0000-0003-3805-4680; Li, Andrew/0000-0003-1516-3454	Medtronic; GE Healthcare; Baxter	Medtronic(Medtronic); GE Healthcare(General ElectricGE Healthcare); Baxter	Author KCS has received honoraria and travel support from Medtronic and GE Healthcare. MC acknowledges travel support and honorarium from Baxter and Medtronic. JP and KR have received travel support from Medtronic. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azoulay E, 2019, LANCET RESP MED, V7, P173, DOI 10.1016/S2213-2600(18)30345-X; Azoulay E, 2018, JAMA-J AM MED ASSOC, V320, P2099, DOI 10.1001/jama.2018.14282; Azoulay E, 2017, INTENS CARE MED, V43, P1808, DOI 10.1007/s00134-017-4947-1; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Braunlich J, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S104616; Braunlich J, 2013, RESPIRATION, V85, P319, DOI 10.1159/000342027; Cho WH, 2015, INTERNAL MED, V54, P2307, DOI 10.2169/internalmedicine.54.4266; Fraser JF, 2016, THORAX, V71, P759, DOI 10.1136/thoraxjnl-2015-207962; Frat JP, 2016, LANCET RESP MED, V4, P646, DOI 10.1016/S2213-2600(16)30093-5; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Gaunt KA, 2015, RESP CARE, V60, P1383, DOI 10.4187/respcare.04016; Goh KJ, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00458-z; Goligher EC, 2017, AM J RESP CRIT CARE, V195, P1128, DOI 10.1164/rccm.201701-0006ED; Jones PG, 2016, RESP CARE, V61, P291, DOI 10.4187/respcare.04252; Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5; Lemiale Virginie, 2017, Crit Care Med, V45, pe274, DOI 10.1097/CCM.0000000000002085; Liew MF, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2828-4; Makdee O, 2017, ANN EMERG MED, V70, P465, DOI 10.1016/j.annemergmed.2017.03.028; Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC; Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423; Pilcher J, 2017, RESPIROLOGY, V22, P1149, DOI 10.1111/resp.13050; Ricard JD, 2020, INTENS CARE MED, V46, P2238, DOI 10.1007/s00134-020-06228-7; Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC; Roca O, 2016, J CRIT CARE, V35, P200, DOI 10.1016/j.jcrc.2016.05.022; Rodriguez M, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0578-8; Schwabbauer N, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-66; Sotello D, 2015, AM J MED SCI, V350, P308, DOI 10.1097/MAJ.0000000000000557; Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6	28	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0261234	10.1371/journal.pone.0261234	http://dx.doi.org/10.1371/journal.pone.0261234			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2K2KP	35472205	Green Published, gold			2023-01-03	WOS:000816171900016
J	Dyer, O				Dyer, Owen			Covid-19: Doctor who sold hydroxychloroquine as "magic bullet" treatment is jailed	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	2022	377								o1395	10.1136/bmj.o1395	http://dx.doi.org/10.1136/bmj.o1395			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2D7JI	35667680	Bronze			2023-01-03	WOS:000811718000004
J	Meersch, M; Weiss, R; Kullmar, M; Bergmann, L; Thompson, A; Griep, L; Kusmierz, D; Buchholz, A; Wolf, A; Nowak, H; Rahmel, T; Adamzik, M; Haaker, JG; Goettker, C; Gruendel, M; Hemping-Bovenkerk, A; Goebel, U; Braumann, J; Wisudanto, I; Wenk, M; Flores-Bergmann, D; Bohmer, A; Cleophas, S; Hohn, A; Houben, A; Ellerkmann, RK; Larmann, J; Sander, J; Weigand, MA; Eick, N; Ziemann, S; Bormann, E; Gerss, J; Sessler, DI; Wempe, C; Massoth, C; Zarbock, A				Meersch, Melanie; Weiss, Raphael; Kuellmar, Mira; Bergmann, Lars; Thompson, Astrid; Griep, Leonore; Kusmierz, Desiree; Buchholz, Annika; Wolf, Alexander; Nowak, Hartmuth; Rahmel, Tim; Adamzik, Michael; Haaker, Jan Gerrit; Goettker, Carina; Gruendel, Matthias; Hemping-Bovenkerk, Andre; Goebel, Ulrich; Braumann, Julius; Wisudanto, Irawan; Wenk, Manuel; Flores-Bergmann, Darius; Boehmer, Andreas; Cleophas, Sebastian; Hohn, Andreas; Houben, Anne; Ellerkmann, Richard K.; Larmann, Jan; Sander, Julia; Weigand, Markus A.; Eick, Nicolas; Ziemann, Sebastian; Bormann, Eike; Gerss, Joachim; Sessler, Daniel, I; Wempe, Carola; Massoth, Christina; Zarbock, Alexander			Effect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults The HandiCAP Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-SURGERY; COMMUNICATION; TRANSITIONS; ASSOCIATION; IMPLEMENTATION; MORBIDITY; OUTCOMES; HEALTH; RISK	IMPORTANCE Intraoperative handovers of anesthesia care are common. Handovers might improve care by reducing physician fatigue, but there is also an inherent risk of losing critical information. Large observational analyses report associations between handover of anesthesia care and adverse events, including higher mortality. OBJECTIVE To determine the effect of handovers of anesthesia care on postoperative morbidity and mortality. DESIGN, SETTING, AND PARTICIPANTS This was a parallel-group, randomized clinical trial conducted in 12 German centers with patients enrolled between June 2019 and June 2021 (final follow-up, July 31, 2021). Eligible participants had an American Society of Anesthesiologists physical status 3 or 4 and were scheduled for major inpatient surgery expected to last at least 2 hours. INTERVENTIONS A total of 1817 participants were randomized to receive either a complete handover to receive anesthesia care by another clinician (n = 908) or no handover of anesthesia care (n = 909). None of the participating institutions used a standardized handover protocol. MAIN OUTCOMES AND MEASURES The primary outcome was a 30-day composite of all-cause mortality, hospital readmission, or serious postoperative complications. There were 19 secondary outcomes, including the components of the primary composite, along with intensive care unit and hospital lengths of stay. RESULTS Among 1817 randomized patients, 1772 (98%; mean age, 66 [SD, 12] years; 997 men [56%]; and 1717 [97%] with an American Society of Anesthesiologists physical status of 3) completed the trial. The median total duration of anesthesia was 267 minutes (IQR. 206-351 minutes), and the median time from start of anesthesia to first handover was 144 minutes in the handover group (IQR, 105-213 minutes). The composite primary outcome occurred in 268 of 891 patients (30%) in the handover group and in 284 of 881(33%) in the no handover group (absolute risk difference [RD], -2.5%; 95% CI, -6.8% to 1.9%; odds ratio [OR], 0.89; 95% CI, 0.72 to 1.10; P = .27). Nineteen of 889 patients (2.1%) in the handover group and 30 of 873 (3.4%) in the no handover group experienced all-cause 30-day mortality (absolute RD, -1.3%; 95% CI, -2.8% to 0.2%; OR, 0.61; 95% CI, 0.34 to 1.10; P = .11); 115 of 888 (13%) vs 136 of 872 (16%) were readmitted to the hospital (absolute RD, -2.7%; 95% CI, -5 .9% to 0.6%; OR, 0.80; 95% CI, 0.61 to 1.05; P = .12); and 195 of 890 (22%) vs 189 of 874 (22%) experienced serious postoperative complications (absolute RD, 0.3%; 95% CI, -3.6% to 4.1%; odds ratio, 1.02; 95% CI, 0.81 to 128; P = .91). None of the 19 prespecified secondary end points differed significantly. CONCLUSIONS AND RELEVANCE Among adults undergoing extended surgical procedures, there was no significant difference between the patients randomized to receive handover of anesthesia care from one clinician to another, compared with the no handover group, in the composite primary outcome of mortality, readmission, or serious postoperative complications within 30 days.	[Meersch, Melanie; Weiss, Raphael; Kuellmar, Mira; Wempe, Carola; Massoth, Christina; Zarbock, Alexander] Univ Hosp Munster, Dept Anesthesiol Intens Care & Pain Med, Albert Schweitzer Campus 1,Bldg A1, D-48149 Munster, Germany; [Bergmann, Lars; Thompson, Astrid; Griep, Leonore; Kusmierz, Desiree; Buchholz, Annika; Wolf, Alexander; Nowak, Hartmuth; Rahmel, Tim; Adamzik, Michael; Haaker, Jan Gerrit] Univ Hosp Knappschaftskrankenhaus Bochum, Dept Anesthesiol Intens Care & Pain Med, Bochum, Germany; [Goettker, Carina; Gruendel, Matthias; Hemping-Bovenkerk, Andre; Goebel, Ulrich] Franziskus Hosp Munster, Dept Anesthesiol, Dept Anesthesiol & Crit Care, Munster, Germany; [Braumann, Julius; Wisudanto, Irawan; Wenk, Manuel] Florence Nightingale Hosp, Dept Anesthesiol Intens Care & Pain Med, Dusseldorf, Germany; [Flores-Bergmann, Darius; Boehmer, Andreas] Kliniken Koln, Dept Anesthesiol & Operat Intens Care Med, Cologne, Germany; [Flores-Bergmann, Darius; Boehmer, Andreas] Witten Herdecke Univ, Sch Med, Fac Hlth, Witten, Germany; [Cleophas, Sebastian; Hohn, Andreas] Kliniken Maria Hilf, Dept Anesthesiol & Intens Care Med, Monchengladbach, Germany; [Cleophas, Sebastian; Hohn, Andreas] Univ Cologne, Fac Med, Dept Anesthesiol & Intens Care Med, Cologne, Germany; [Cleophas, Sebastian; Hohn, Andreas] Univ Cologne, Univ Hosp Cologne, Dept Anesthesiol & Intens Care Med, Cologne, Germany; [Houben, Anne; Ellerkmann, Richard K.] Klinikum Dortmund, Dept Anesthesiol Intens Care & Pain Med, Dortmund, Germany; [Ellerkmann, Richard K.] Univ Hosp Bonn, Dept Anesthesiol & Intens Care Med, Bonn, Germany; [Larmann, Jan; Sander, Julia; Weigand, Markus A.] Univ Hosp Heidelberg, Dept Anesthesiol, Heidelberg, Germany; [Eick, Nicolas] Dept Anesthesiol Intens Care & Pain Med, Dortmund, Germany; [Ziemann, Sebastian] Rhein Westfal TH Aachen, Med Fac, Dept Anesthesiol, Aachen, Germany; [Bormann, Eike; Gerss, Joachim] Univ Munster, Inst Biostat & Clin Res, Munster, Germany; [Sessler, Daniel, I] Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res, Cleveland, OH USA	University of Munster; Ruhr University Bochum; St. Franziskus-Hospital; University of Cologne; University of Cologne; Klinikum Dortmund; University of Bonn; Ruprecht Karls University Heidelberg; RWTH Aachen University; University of Munster; Cleveland Clinic Foundation	Meersch, M (corresponding author), Univ Hosp Munster, Dept Anesthesiol Intens Care & Pain Med, Albert Schweitzer Campus 1,Bldg A1, D-48149 Munster, Germany.	meersch@uni-muenster.de	Goebel, Ulrich M./AGG-1495-2022; Adamzik, Michael/HGE-9286-2022; Wolf, Alexander/AAR-5797-2021	Wolf, Alexander/0000-0001-8875-586X; Ziemann, Sebastian/0000-0003-4485-6030	Else-Kroner-Fresenius Stiftung German Research Foundation [2018_A96, KFO342-1, ZA428/18-1, ZA428/21-1, ME5413/1-1]	Else-Kroner-Fresenius Stiftung German Research Foundation	The trial was funded by Else-Kroner-Fresenius Stiftung German Research Foundation (grants 2018_A96, KFO342-1, ZA428/18-1, ZA428/21-1, and ME5413/1-1).	[Anonymous], 1998, Fed Regist, V63, P49583; [Anonymous], 2017, Sentinel Event Alert, P1; Bagian JP, 2018, JAMA-J AM MED ASSOC, V319, P125, DOI 10.1001/jama.2017.20602; Boet S, 2020, BRIT J ANAESTH, V125, P605, DOI 10.1016/j.bja.2020.05.062; Douglas RN, 2021, BRIT J ANAESTH, V127, P470, DOI 10.1016/j.bja.2021.05.030; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Haig KM, 2006, JT COMM J QUAL PATIE, V32, P167, DOI 10.1016/S1553-7250(06)32022-3; Hannan EL, 2020, ANESTH ANALG, V131, P1883, DOI 10.1213/ANE.0000000000005221; Hudson CCC, 2015, J CARDIOTHOR VASC AN, V29, P11, DOI 10.1053/j.jvca.2014.05.018; Hyder JA, 2016, ANESTH ANALG, V122, P134, DOI 10.1213/ANE.0000000000000692; Jones PM, 2018, JAMA-J AM MED ASSOC, V319, P143, DOI 10.1001/jama.2017.20040; Keller S, 2016, ERGONOMICS, V59, P1541, DOI 10.1080/00140139.2016.1159736; Kotz S., 1983, ENCY STAT SCI; Liu GY, 2019, J ANESTH, V33, P295, DOI 10.1007/s00540-019-02627-3; Massoth C, 2021, ANAESTHESIST, V70, P320, DOI 10.1007/s00101-021-00940-9; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Mistry KP, 2005, CRIT CARE MED, V33, pA12, DOI 10.1097/00003246-200512002-00047; O'Reilly-Shah VN, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0858-8; Olejniczak MJ, 2017, ANESTH ANALG, V125, P380, DOI 10.1213/ANE.0000000000002265; Saager L, 2014, ANESTHESIOLOGY, V121, P695, DOI 10.1097/ALN.0000000000000401; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Starmer AJ, 2014, NEW ENGL J MED, V371, P1803, DOI 10.1056/NEJMsa1405556; Starmer AJ, 2014, ACAD MED, V89, P876, DOI 10.1097/ACM.0000000000000264; Sun LY, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.48161; Terekhov MA, 2016, ANESTHESIOLOGY, V125, P690, DOI 10.1097/ALN.0000000000001246; Thackray NM, 2011, ANESTHESIOLOGY, V114, P467, DOI 10.1097/ALN.0b013e3182065c88; Weiser TG, 2015, LANCET, V385, P11, DOI 10.1016/S0140-6736(15)60806-6; Yang D., 2012, SAS GLOBAL FORUM, V335, P1	28	4	4	7	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2022	327	24					2403	2412		10.1001/jama.2022.9451	http://dx.doi.org/10.1001/jama.2022.9451		JUN 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2S1QA	35665794	Green Published			2023-01-03	WOS:000809216600001
J	Vollenweider, R; Manettas, AI; Hani, N; de Bruin, ED; Knols, RH				Vollenweider, Rahel; Manettas, Anastasios, I; Hani, Nathalie; de Bruin, Eling D.; Knols, Ruud H.			Passive motion of the lower extremities in sedated and ventilated patients in the ICU - a systematic review of early effects and replicability of Interventions	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; NEUROMUSCULAR ELECTRICAL-STIMULATION; UNIT-ACQUIRED WEAKNESS; CRITICAL ILLNESS; METHODOLOGICAL QUALITY; MUSCLE STRENGTH; EXERCISE; REHABILITATION; PHYSIOTHERAPY; MOBILIZATION	Early mobilization, which includes active / passive motion in bed along with mobilization out of bed, is recommended to prevent the development of intensive care unit acquired-weakness (ICU-AW) for patients with critical illness on the intensive care unit. To date, the impact of passive motion of the lower extremities in sedated and ventilated patients remains unclear. The aim of the study is to systematically review and summarize the currently available randomized controlled trials in English or German language on the impact of passive motion of the lower extremities in sedated and ventilated patients >= 18 years in the intensive care unit on musculature, inflammation and immune system and the development of intensive care unit-acquired weakness and to evaluate the replicability of interventions and the methodological quality of included studies. A systematic literature search was performed up to 20th February 2022 in the databases Medline, Embase, Cochrane Library, CINAHL and PEDro. The description of the intervention (TIDieR checklist) and the methodological quality (Downs and Black checklist) were assessed. Five studies were included in the qualitative syntheses. On average, the studies were rated with 6.8 out of 12 points according to the TIDieR checklist. For the methodological quality an average of 19.8 out of 27 points on the Downs and Black checklist was reported. The results of included studies indicated that muscle loss may be reduced by passive manual movement, passive cycling and passive motion on a continuous passive motion-unit. In addition, positive effects were reported on the reduction of nitrosative stress and the immune response. The impact on the development of ICU-AW remains unclear. In conclusion, passive movement show a slight tendency for beneficial changes on cellular level in sedated and ventilated patients in the ICU within the first days of admission, which may indicate a reduction of muscle wasting and could prevent the development of ICU-AW. Future randomized controlled trials should use larger samples, use complete intervention description, use a comparable set of outcome measures, use rigorous methodology and examine the effect of passive motion on the development of ICU-AW.	[Vollenweider, Rahel; Manettas, Anastasios, I; Hani, Nathalie] Univ Hosp Zurich, Physiotherapy Occupat Therapy, Nursing & Allied Hlth Profess Off, Zurich, Switzerland; [de Bruin, Eling D.; Knols, Ruud H.] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Inst Human Movement Sci & Sport, Zurich, Switzerland; [de Bruin, Eling D.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, Solna, Sweden; [de Bruin, Eling D.] OST Eastern Swiss Univ Appl Sci, Dept Hlth, St Gallen, Switzerland; [Knols, Ruud H.] Univ Hosp Zurich, Physiotherapy Occupat Therapy Res Ctr, Directorate Res & Educ, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Karolinska Institutet; University of Zurich; University Zurich Hospital	de Bruin, ED (corresponding author), Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Inst Human Movement Sci & Sport, Zurich, Switzerland.; de Bruin, ED (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, Solna, Sweden.; de Bruin, ED (corresponding author), OST Eastern Swiss Univ Appl Sci, Dept Hlth, St Gallen, Switzerland.	eling.debruin@hest.ethz.ch	de Bruin, Eling D./A-4751-2011	de Bruin, Eling D./0000-0002-6542-7385				Alaparthi GK, 2020, CRIT CARE RES PRACT, V2020, DOI 10.1155/2020/7840743; Altman DG, 1991, PRACTICAL STAT MED R; Amidei C, 2013, AM J CRIT CARE, V22, P337, DOI 10.4037/ajcc2013284; Appleton Richard Td, 2015, J Intensive Care Soc, V16, P126, DOI 10.1177/1751143714563016; Barbalho M, 2019, CLIN REHABIL, V33, P233, DOI 10.1177/0269215518801440; Barreiro E, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.12; Bein T, 2015, ANAESTHESIST, V64, pS1, DOI 10.1007/s00101-015-0071-1; Brower Roy G, 2009, Crit Care Med, V37, pS422, DOI 10.1097/CCM.0b013e3181b6e30a; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Carvalho Maurício Tatsch Ximenes, 2019, Fisioter. Pesqui., V26, P227, DOI 10.1590/1809-2950/17025126032019; Castro-Avila AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130722; Connolly B, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2678-4; De Backer D, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2433-6; Ding NN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223151; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Fossat G, 2018, JAMA-J AM MED ASSOC, V320, P368, DOI 10.1001/jama.2018.9592; Franca EET, 2020, BRAZ J MED BIOL RES, V53, DOI [10.1590/1414-431X20208770, 10.1590/1414-431x20208770]; Friedrich O, 2015, PHYSIOL REV, V95, P1025, DOI 10.1152/physrev.00028.2014; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Griffiths RD, 1995, NUTRITION, V11, P428; Grouven U, 2007, Dtsch Med Wochenschr, V132 Suppl 1, pe65, DOI 10.1055/s-2007-959046; Hacke C, 2018, INT J SPORTS MED, V39, P902, DOI 10.1055/a-0649-1040; Hayes K, 2018, J CRIT CARE, V48, P1, DOI 10.1016/j.jcrc.2018.08.002; Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7; Hickmann CE, 2018, CRIT CARE MED, V46, P1436, DOI 10.1097/CCM.0000000000003263; Higgins Jpt T. J., 2019, COCHRANE HDB SYSTEMA, V2nd; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hughes L, 2017, BRIT J SPORT MED, V51, P1003, DOI 10.1136/bjsports-2016-097071; Judemann K, 2011, ANAESTHESIST, V60, P887, DOI 10.1007/s00101-011-1951-7; Kayambu G, 2013, CRIT CARE MED, V41, P1543, DOI 10.1097/CCM.0b013e31827ca637; Kho ME, 2015, J CRIT CARE, V30, DOI 10.1016/j.jcrc.2015.07.025; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knols RH, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00946; Knols RH, 2016, GAMES HEALTH J, V5, P224, DOI 10.1089/g4h.2015.0067; Kramer CL, 2017, NEUROL CLIN, V35, P723, DOI 10.1016/j.ncl.2017.06.008; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Liu M, 2020, INT J NURS SCI, V7, P228, DOI 10.1016/j.ijnss.2020.03.002; Llano-Diez M, 2012, CRIT CARE, V16, DOI 10.1186/cc11841; Machado AD, 2017, J BRAS PNEUMOL, V43, P134, DOI [10.1590/S1806-37562016000000170, 10.1590/s1806-37562016000000170]; Medrinal C, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2030-0; Menges D, 2021, CRIT CARE, V25, DOI 10.1186/s13054-020-03446-9; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Nickels MR, 2020, AUST CRIT CARE, V33, P236, DOI 10.1016/j.aucc.2020.02.007; Nydahl P, 2017, ANN AM THORAC SOC, V14, P766, DOI 10.1513/AnnalsATS.201611-843SR; Pardo E, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0647-9; Parry SM, 2018, NUTR CLIN PRACT, V33, P772, DOI 10.1002/ncp.10213; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Reid JC, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0349-x; Renaud G, 2013, J PHYSIOL-LONDON, V591, P1385, DOI 10.1113/jphysiol.2012.248724; Santos PMR, 2017, PHYSIOTHERAPY, V103, P1, DOI 10.1016/j.physio.2016.08.003; Schefold JC, 2010, J CACHEXIA SARCOPENI, V1, P147, DOI 10.1007/s13539-010-0010-6; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Senger D, 2017, MED KLIN-INTENSIVMED, V112, P589, DOI 10.1007/s00063-017-0339-0; Sundstrom-Rehal M, 2019, CURR OPIN CLIN NUTR, V22, P146, DOI 10.1097/MCO.0000000000000548; Takaoka A, 2020, ANN AM THORAC SOC, V17, P1289, DOI 10.1513/AnnalsATS.202001-059OC; Thelandersson A, 2012, CLIN PHYSIOL FUNCT I, V32, P338, DOI 10.1111/j.1475-097X.2012.01132.x; Tourel C, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2638; Van Aerde N, 2020, INTENS CARE MED, V46, P2083, DOI 10.1007/s00134-020-06244-7; Wageck B, 2014, MED INTENSIVA, V38, P444, DOI 10.1016/j.medin.2013.12.003; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Wiles L, 2010, J CRIT CARE, V25, P501, DOI 10.1016/j.jcrc.2009.07.003; Wollersheim T, 2019, J CACHEXIA SARCOPENI, V10, P734, DOI 10.1002/jcsm.12428; Yamato TP, 2016, J PHYSIOTHER, V62, P57, DOI 10.1016/j.jphys.2016.02.015; Yang T, 2018, ACTA NEUROL SCAND, V138, P104, DOI 10.1111/ane.12964; Zayed Y, 2020, AUST CRIT CARE, V33, P203, DOI 10.1016/j.aucc.2019.04.003; Zhang L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223185; Zhou WD, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021282	68	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2022	17	5							e0267255	10.1371/journal.pone.0267255	http://dx.doi.org/10.1371/journal.pone.0267255			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5I1ZV	35552550	gold, Green Published			2023-01-03	WOS:000868164600021
J	Androga, LA; Amundson, RH; Hickson, LJ; Thorsteinsdottir, B; Garovic, VD; Manohar, S; Viehman, JK; Zoghby, Z; Norby, SM; Kattah, AG; Albright, RC				Androga, Lagu A.; Amundson, Rachel H.; Hickson, LaTonya J.; Thorsteinsdottir, Bjoerg; Garovic, Vesna D.; Manohar, Sandhya; Viehman, Jason K.; Zoghby, Ziad; Norby, Suzanne M.; Kattah, Andrea G.; Albright, Robert C., Jr.			Telehealth versus face-to-face visits: A comprehensive outpatient perspective-based cohort study of patients with kidney disease	PLOS ONE			English	Article							SATISFACTION; CARE	Background Telenephrology has become an important health care delivery modality during the COVID-19 pandemic. However, little is known about patient perspectives on the quality of care provided via telenephrology compared to face-to-face visits. We aimed to use objective data to study patients' perspectives on outpatient nephrology care received via telenephrology (phone and video) versus face-to-face visits. Methods We retrospectively studied adults who received care in the outpatient Nephrology & Hypertension division at Mayo Clinic, Rochester, from March to July 2020. We used a standardized survey methodology to evaluate patient satisfaction. The primary outcome was the percent of patients who responded with a score of good (4) or very good (5) on a 5-point Likert scale on survey questions that asked their perspectives on access to their nephrologist, relationship with care provider, their opinions on the telenephrology technology, and their overall assessment of the care received. Wilcoxon rank sum tests and chi-square tests were used as appropriate to compare telenephrology versus face-to-face visits. Results 3,486 of the patient encounters were face-to-face, 808 phone and 317 video visits. 443 patients responded to satisfaction surveys, and 21% of these had telenephrology encounters. Established patients made up 79.6% of telenephrology visits and 60.9% of face-to-face visits. There was no significant difference in patient perceived access to health care, satisfaction with their care provider, or overall quality of care between patients cared for via telenephrology versus face-to-face. Patient satisfaction was also equally high. Conclusions Patient satisfaction was equally high amongst those patients seen face-to-face or via telenephrology.	[Androga, Lagu A.; Amundson, Rachel H.; Hickson, LaTonya J.; Garovic, Vesna D.; Manohar, Sandhya; Zoghby, Ziad; Norby, Suzanne M.; Kattah, Andrea G.; Albright, Robert C., Jr.] Mayo Clin, Nephrol & Hypertens Div, Coll Med, Rochester, MN 55905 USA; [Thorsteinsdottir, Bjoerg] Mayo Clin, Community Internal Med, Coll Med, Rochester, MN USA; [Viehman, Jason K.] Mayo Clin, Quantitat Hlth Sci, Coll Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Albright, RC (corresponding author), Mayo Clin, Nephrol & Hypertens Div, Coll Med, Rochester, MN 55905 USA.	albright.robert@mayo.edu	Androga, Lagu/HCH-8463-2022	Androga, Lagu/0000-0002-8215-6951	Mayo Clinic, Nephrology & Hypertension Research Committee	Mayo Clinic, Nephrology & Hypertension Research Committee	Mayo Clinic, Nephrology & Hypertension Research Committee -$5,000 funding for statistical personnel support for their time. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, TRANSPARENCY STRATEG; [Anonymous], 2017, PRESS GANEY WEBSITE; Bestsenny O, 2020, TELEHEALTH Q TRILLIO; Centers for Disease Control and Prevention, 2020, US TEL EXP ACC ESS H; Centers for Medicare & Medicaid Services, 2020, MED TEL HLTH CAR PRO; Presson AP, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0610-3; Ryan T, 2016, OTOLARYNG HEAD NECK, V155, P411, DOI 10.1177/0194599816652386; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Schers H, 2005, FAM PRACT, V22, P15, DOI 10.1093/fampra/cmh721; Schwartz TM, 2014, ANN EMERG MED, V64, P469, DOI 10.1016/j.annemergmed.2014.02.010; VA Telehealth Services Fact Sheet, 2016, VA TEL SERV FACT SHE; Wells William C, 2007, Perm J, V11, P30	12	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2022	17	3							e0265073	10.1371/journal.pone.0265073	http://dx.doi.org/10.1371/journal.pone.0265073			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4H6NN	35275958	Green Published, gold			2023-01-03	WOS:000849994500045
J	Lam, B; Stepanova, M; Venkatesan, C; Garcia, I; Reyes, M; Mannan, A; Groves, S; Desai, M; Racila, A; Kolacevski, A; Henry, L; Gerber, LH; Younossi, ZM				Lam, Brian; Stepanova, Maria; Venkatesan, Chapy; Garcia, Ivan; Reyes, Mary; Mannan, Ashiq; Groves, Soleyah; Desai, Mehul; Racila, Andrei; Kolacevski, Andrej; Henry, Linda; Gerber, Lynn H.; Younossi, Zobair M.			Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system	PLOS ONE			English	Article							MORTALITY	Background Given the rapid spread of COVID-19 and its associated morbidity and mortality, healthcare providers throughout the world have been forced to constantly update and change their care delivery models. Objective To assess the outcomes of COVID-19 hospitalized patients during the course of the pandemic in a well-integrated health system. Methods The study used data from the electronic health medical records to assess trends in clinical profile and outcomes of hospitalized adult COVID-19 patients hospitalized in our 5-hospital health system from March 2020-May 2021 (n = 6865). Integration of the health system began in February 2020 and was fully actualized by March 30, 2020. Results Mortality decreased from 15% during first peak (March-May 2020; the rate includes 19% in March-April and 10% in May 2020) to 6% in summer-fall 2020, increased to 13% during the second peak (November 2020-January 2021), and dropped to 7% during the decline period (February-May 2021) (p<0.01). Resource utilization followed a similar pattern including a decrease in ICU use from 35% (first peak) to 16% (decline period), mechanical ventilation from 16% (first peak, including 45% in March 2020) to 9-11% in subsequent periods (p<0.01). Independent predictors of inpatient mortality across multiple study periods included older age, male sex, higher multi-morbidity scores, morbid obesity, and indicators of severe illness on admission such as oxygen saturation <90% and high qS0FA score (all p<0.05). However, admission during the first peak remained independently associated with increased mortality even after adjustment for patient-related factors: odds ratio = 1.8 (1.4-2.4) (p<0.0001). Conclusions The creation of a fully integrated health system allowed us to dynamically respond to the everchanging COVID-19 landscape. In this context, despite the increasing patient acuity, our mortality and resource utilization rates have improved during the pandemic.	[Lam, Brian; Stepanova, Maria; Racila, Andrei; Henry, Linda; Gerber, Lynn H.; Younossi, Zobair M.] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA 22042 USA; [Lam, Brian; Kolacevski, Andrej; Gerber, Lynn H.; Younossi, Zobair M.] Inova Hlth Syst, Inova Off Res, Falls Church, VA 22042 USA; [Lam, Brian; Stepanova, Maria; Venkatesan, Chapy; Garcia, Ivan; Reyes, Mary; Mannan, Ashiq; Groves, Soleyah; Desai, Mehul; Racila, Andrei; Henry, Linda; Gerber, Lynn H.; Younossi, Zobair M.] Inova Hlth Syst, Dept Med, Falls Church, VA 22042 USA	Inova Health System; Inova Health System; Inova Health System	Younossi, ZM (corresponding author), Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA 22042 USA.; Younossi, ZM (corresponding author), Inova Hlth Syst, Inova Off Res, Falls Church, VA 22042 USA.; Younossi, ZM (corresponding author), Inova Hlth Syst, Dept Med, Falls Church, VA 22042 USA.	Zobair.Younossi@inova.org						cdc, ASSESSING RISK FACTO; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Fernando SM, 2018, ANN INTERN MED, V168, P266, DOI 10.7326/M17-2820; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Mannan A, 2022, AM J MANAG CARE, V28, pE80, DOI 10.37765/ajmc.2022.88731; nih, CORONAVIRUS DIS 2019; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; U.S. Census Bureau, QUICKFACTS FAIRFAX C; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Wang XH, 2020, RESEARCH-CHINA, V2020, DOI 10.34133/2020/2402961; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	14	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0263417	10.1371/journal.pone.0263417	http://dx.doi.org/10.1371/journal.pone.0263417			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0U7EE	35213553	Green Published, gold			2023-01-03	WOS:000787811000022
J	Hwang, S; Lee, B				Hwang, Soyun; Lee, Bongjin			Machine learning-based prediction of critical illness in children visiting the emergency department	PLOS ONE			English	Article							EARLY WARNING SCORE; PEDIATRIC RISK; ADMISSION SCORE; SEVERITY; SYSTEM; TRIAGE	Objectives Triage is an essential emergency department (ED) process designed to provide timely management depending on acuity and severity; however, the process may be inconsistent with clinical and hospitalization outcomes. Therefore, studies have attempted to augment this process with machine learning models, showing advantages in predicting critical conditions and hospitalization outcomes. The aim of this study was to utilize nationwide registry data to develop a machine learning-based classification model to predict the clinical course of pediatric ED visits. Methods This cross-sectional observational study used data from the National Emergency Department Information System on emergency visits of children under 15 years of age from January 1, 2016, to December 31, 2017. The primary and secondary outcomes were to identify critically ill children and predict hospitalization from triage data, respectively. We developed and tested a random forest model with the under sampled dataset and validated the model using the entire dataset. We compared the model's performance with that of the conventional triage system. Results A total of 2,621,710 children were eligible for the analysis and included 12,951 (0.5%) critical outcomes and 303,808 (11.6%) hospitalizations. After validation, the area under the receiver operating characteristic curve was 0.991 (95% confidence interval [CI] 0.991-0.992) for critical outcomes and 0.943 (95% CI 0.943-0.944) for hospitalization, which were higher than those of the conventional triage system. Conclusions The machine learning-based model using structured triage data from a nationwide database can effectively predict critical illness and hospitalizations among children visiting the ED.	[Hwang, Soyun] Yonsei Univ, Severance Childrens Hosp, Dept Pediat, Coll Med, Seoul, South Korea; [Lee, Bongjin] Seoul Natl Univ Hosp, Dept Pediat, Seoul, South Korea	Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University Hospital	Lee, B (corresponding author), Seoul Natl Univ Hosp, Dept Pediat, Seoul, South Korea.	pedbjl@snu.ac.kr		Hwang, Soyun/0000-0002-4290-0213; Lee, Bongjin/0000-0001-7878-9644				Akre M, 2010, PEDIATRICS, V125, pE763, DOI 10.1542/peds.2009-0338; Barak-Corren Y, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2785; Becker JB, 2015, REV ESC ENFERM USP, V49, P779, DOI 10.1590/S0080-623420150000500011; Breslin K, 2014, PEDIATR EMERG CARE, V30, P97, DOI 10.1097/PEC.0000000000000063; Chamberlain JM, 2004, ANN EMERG MED, V43, P461, DOI 10.1016/j.annemergmed.2003.08.001; Chamberlain JM, 1998, ANN EMERG MED, V32, P161, DOI 10.1016/S0196-0644(98)70132-5; Choi SW, 2019, HEALTHC INFORM RES, V25, P305, DOI 10.4258/hir.2019.25.4.305; Churpek MM, 2016, CRIT CARE MED, V44, P368, DOI 10.1097/CCM.0000000000001571; Duncan H, 2006, J CRIT CARE, V21, P271, DOI 10.1016/j.jcrc.2006.06.007; Egdell P, 2008, EMERG MED J, V25, P745, DOI 10.1136/emj.2007.054965; Gold DL, 2014, ACAD EMERG MED, V21, P1249, DOI 10.1111/acem.12514; Goto T, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6937; Goto Y, 2013, CRIT CARE, V17, DOI 10.1186/cc12812; Gravel J, 2003, ANN EMERG MED, V41, P630, DOI 10.1067/mem.2003.139; Green NA, 2012, PEDIATR EMERG CARE, V28, P753, DOI 10.1097/PEC.0b013e3182621813; Hong WS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201016; Horng S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174708; Ji Hyouck Kim M.D., 2016, [Journal of The Korean Society of Emergency Medicine, 대한응급의학회지], V27, P436; Kim J, 2020, J CRIT CARE, V55, P163, DOI 10.1016/j.jcrc.2019.09.024; Kim JS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072284; Kim TH, 2019, AM J EMERG MED, V37, P183, DOI 10.1016/j.ajem.2018.05.007; Klug M, 2020, J GEN INTERN MED, V35, P220, DOI 10.1007/s11606-019-05512-7; Kwon JM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205836; Lemaitre G, 2017, J MACH LEARN RES, V18; Levin S, 2018, ANN EMERG MED, V71, P565, DOI 10.1016/j.annemergmed.2017.08.005; Lim YD, 2020, EUR J TRAUMA EMERG S, V46, P895, DOI 10.1007/s00068-018-1048-y; Lucini FR, 2017, INT J MED INFORM, V100, P1, DOI 10.1016/j.ijmedinf.2017.01.001; Murray Michael, 2004, CJEM, V6, P421; Ong MEH, 2012, CRIT CARE, V16, DOI 10.1186/cc11396; PARK JOONBUM, 2017, [Journal of The Korean Society of Emergency Medicine, 대한응급의학회지], V28, P547; Patel SJ, 2018, ACAD EMERG MED, V25, P1463, DOI 10.1111/acem.13655; Pedregosa F, 2011, JMLR, V12, P2825; Raita Y, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2351-7; Rudin C., 2019, HARV DATA SCI REV, V1, DOI [10.1162/99608f99692.99605a99608a99603a99603d, DOI 10.1162/99608F92.5A8A3A3D]; Rudin C, 2019, NAT MACH INTELL, V1, P206, DOI 10.1038/s42256-019-0048-x; Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432; Seiger N, 2013, PEDIATRICS, V132, pE841, DOI 10.1542/peds.2012-3594; Shapiro NI, 2003, CRIT CARE MED, V31, P670, DOI 10.1097/01.CCM.0000054867.01688.D1; Shillan D, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2564-9; Vistisen ST, 2019, J CLIN MONIT COMPUT, V33, P949, DOI 10.1007/s10877-019-00343-7; Williams RM, 1996, ANN EMERG MED, V27, P506, DOI 10.1016/S0196-0644(96)99999-0	41	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0264184	10.1371/journal.pone.0264184	http://dx.doi.org/10.1371/journal.pone.0264184			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176113	Green Published, gold			2023-01-03	WOS:000777505200090
J	Islam, MR; Beni, MS; Ng, CY; Miyake, M; Rahman, M; Ito, S; Gotoh, S; Yamaya, T; Watabe, H				Islam, M. Rafiqul; Beni, Mehrdad Shahmohammadi; Ng, Chor-Yi; Miyake, Masayasu; Rahman, Mahabubur; Ito, Shigeki; Gotoh, Shinichi; Yamaya, Taiga; Watabe, Hiroshi			Proton range monitoring using N-13 peak for proton therapy applications	PLOS ONE			English	Article							QUALITY-ASSURANCE; PET; TOMOGRAPHY; PARTICLE; PATIENT	The Monte Carlo method is employed in this study to simulate the proton irradiation of a water-gel phantom. Positron-emitting radionuclides such as C-11, O-15, and N-13 are scored using the Particle and Heavy Ion Transport Code System Monte Carlo code package. Previously, it was reported that as a result of O-16(p,2p2n)N-13 nuclear reaction, whose threshold energy is relatively low (5.660 MeV), a N-13 peak is formed near the actual Bragg peak. Considering the generated N-13 peak, we obtain offset distance values between the N-13 peak and the actual Bragg peak for various incident proton energies ranging from 45 to 250 MeV, with an energy interval of 5 MeV. The offset distances fluctuate between 1.0 and 2.0 mm. For example, the offset distances between the N-13 peak and the Bragg peak are 2.0, 2.0, and 1.0 mm for incident proton energies of 80, 160, and 240 MeV, respectively. These slight fluctuations for different incident proton energies are due to the relatively stable energy-dependent cross-section data for the (160)(p,2p2n)N-13 nuclear reaction. Hence, we develop an open-source computer program that performs linear and non-linear interpolations of offset distance data against the incident proton energy, which further reduces the energy interval from 5 to 0.1 MeV. In addition, we perform spectral analysis to reconstruct the N-13 Bragg peak, and the results are consistent with those predicted from Monte Carlo computations. Hence, the results are used to generate three-dimensional scatter plots of the N-13 radionuclide distribution in the modeled phantom. The obtained results and the developed methodologies will facilitate future investigations into proton range monitoring for therapeutic applications.	[Islam, M. Rafiqul; Watabe, Hiroshi] Tohoku Univ, Grad Sch Biomed Engn, Sendai, Miyagi, Japan; [Islam, M. Rafiqul] Bangladesh Atom Energy Commiss, Inst Nucl Med Phys, AERE, Dhaka, Bangladesh; [Beni, Mehrdad Shahmohammadi; Miyake, Masayasu; Watabe, Hiroshi] Tohoku Univ, Div Radiat Protect & Safety Control, CYRIC, Sendai, Miyagi, Japan; [Beni, Mehrdad Shahmohammadi] City Univ Hong Kong, Dept Phys, Kowloon Tong, Hong Kong, Peoples R China; [Ng, Chor-Yi] Queen Mary Hosp, Pok Fu Lam, Hong Kong, Peoples R China; [Rahman, Mahabubur] Bangladesh Atom Energy Regular Author, Nucl Safety Secur Safeguard Div, Dhaka, Bangladesh; [Ito, Shigeki] Mirai Imaging Inc, Iwaki, Fukushima, Japan; [Gotoh, Shinichi] GO Proton Japan Inc, Tokyo, Japan; [Yamaya, Taiga] Natl Inst Quantum & Radiol Sci & Technol, Chiba, Japan	Tohoku University; Tohoku University; City University of Hong Kong; University of Hong Kong; National Institutes for Quantum Science & Technology	Watabe, H (corresponding author), Tohoku Univ, Grad Sch Biomed Engn, Sendai, Miyagi, Japan.; Watabe, H (corresponding author), Tohoku Univ, Div Radiat Protect & Safety Control, CYRIC, Sendai, Miyagi, Japan.	watabe@cyric.tohoku.ac.jp	miyake, masayasu/GQR-5788-2022	Watabe, Hiroshi/0000-0001-6257-7735; ISLAM, MD Rafiqul/0000-0003-4230-665X	Agency for Medical Research and Development (AMED) [20he2202004h0402]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) [21F21103]	Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research work was funded by Agency for Medical Research and Development (AMED) under Grant Number 20he2202004h0402 and Ministry of Education, Culture, Sports, Science and Technology (MEXT) under Grant Number 21F21103. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared	Beebe-Wang J, 2004, IEEE NUCL SCI CONF R, P2496, DOI 10.1109/NSSMIC.2003.1352399; Beni M.S., 2019, SCI REP-UK, V9, P1, DOI DOI 10.1038/S41598-018-37186-2; Beni MS, 2021, OPEN PHYS, V19, P454, DOI 10.1515/phys-2021-0055; Beni MS, 2021, OPEN PHYS, V19, P277, DOI 10.1515/phys-2021-0026; Beni MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248300; Beni MS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193575; Beni MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181281; Carson R. E., 1981, Proceedings of the Fifth Annual Symposium on Computer Applications in Medical Care, P562; Cherry SR, 2018, J NUCL MED, V59, P3, DOI 10.2967/jnumed.116.184028; Cho JM, 2017, MED PHYS, V44, P1734, DOI 10.1002/mp.12191; CUNNINGHAM VJ, 1993, J CEREBR BLOOD F MET, V13, P15, DOI 10.1038/jcbfm.1993.5; Del Guerra A., 9310TRA9 TERA; Draeger E, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aaa203; Enghardt W, 1999, NUCL PHYS A, V654, p1047C, DOI 10.1016/S0375-9474(00)88597-8; Espana S, 2011, PHYS MED BIOL, V56, P2687, DOI 10.1088/0031-9155/56/9/003; Geissel H, 1998, NUCL INSTRUM METH B, V136, P114, DOI 10.1016/S0168-583X(97)00660-5; Guo SY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260374; Hayakawa Y., 1995, RADIAT ONCOL INVEST, V3, P42, DOI DOI 10.1002/roi.2970030107; Held KD, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20209004; ICRU, 2000, 63 ICRU; Jones KC, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aa9d16; Knopf AC, 2013, PHYS MED BIOL, V58, DOI 10.1088/0031-9155/58/15/R131; Litzenberg D., 1997, THESIS U MICHIGAN; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; Min CH, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2378561; NIITA K, 1995, PHYS REV C, V52, P2620, DOI 10.1103/PhysRevC.52.2620; Niita K, 2001, NUCL INSTRUM METH B, V184, P406, DOI 10.1016/S0168-583X(01)00784-4; Nikezic D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157627; Oelfke U, 1996, PHYS MED BIOL, V41, P177, DOI 10.1088/0031-9155/41/1/013; PAANS AMJ, 1993, IEEE T NUCL SCI, V40, P1041, DOI 10.1109/23.256709; Paganetti H, 2012, PHYS MED BIOL, V57, pR99, DOI 10.1088/0031-9155/57/11/R99; Parodi K, 2000, PHYS MED BIOL, V45, pN151, DOI 10.1088/0031-9155/45/11/403; Parodi K, 2002, PHYS MED BIOL, V47, P21, DOI 10.1088/0031-9155/47/1/302; Poludniowski G, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150134; Sato T, 2018, J NUCL SCI TECHNOL, V55, P684, DOI 10.1080/00223131.2017.1419890; Schneider U, 2012, MED PHYS, V39, P798, DOI 10.1118/1.3676739; Testa M, 2013, PHYS MED BIOL, V58, P8215, DOI 10.1088/0031-9155/58/22/8215; Watabe H, 2006, ANN NUCL MED, V20, P583, DOI 10.1007/BF02984655; Yamaguchi M, 2016, NUCL INSTRUM METH A, V833, P199, DOI 10.1016/j.nima.2016.07.034; Yamaguchi M, 2012, PHYS MED BIOL, V57, P2843, DOI 10.1088/0031-9155/57/10/2843; Zhu XP, 2011, PHYS MED BIOL, V56, P4041, DOI 10.1088/0031-9155/56/13/019; Ziegler JF, 2010, NUCL INSTRUM METH B, V268, P1818, DOI 10.1016/j.nimb.2010.02.091	42	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2022	17	2							e0263521	10.1371/journal.pone.0263521	http://dx.doi.org/10.1371/journal.pone.0263521			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P8AU	35167589	Green Published, gold			2023-01-03	WOS:000802227200009
J	Boddaert, MS; Douma, J; Dijxhoorn, AFQ; Heman, RACL; van der Rijt, CCD; Teunissen, SSCM; Huijgens, PC; Vissers, KCP				Boddaert, Manon S.; Douma, Joep; Dijxhoorn, Anne-Floor Q.; Heman, Rene A. C. L.; van der Rijt, Carin C. D.; Teunissen, Saskia S. C. M.; Huijgens, Peter C.; Vissers, Kris C. P.			Development of a national quality framework for palliative care in a mixed generalist and specialist care model: A whole-sector approach and a modified Delphi technique	PLOS ONE			English	Article							OF-LIFE CARE; ADVANCED CANCER; END; INTEGRATION; BARRIERS; ELEMENTS; SOCIETY; PEOPLE; NEED	In a predominantly biomedical healthcare model focused on cure, providing optimal, person-centred palliative care is challenging. The general public, patients, and healthcare professionals are often unaware of palliative care's benefits. Poor interdisciplinary teamwork and limited communication combined with a lack of early identification of patients with palliative care needs contribute to sub-optimal palliative care provision. We aimed to develop a national quality framework to improve availability and access to high-quality palliative care in a mixed generalist-specialist palliative care model. We hypothesised that a whole-sector approach and a modified Delphi technique would be suitable to reach this aim. Analogous to the international AGREE guideline criteria and employing a whole-sector approach, an expert panel comprising mandated representatives for patients and their families, various healthcare associations, and health insurers answered the main question: 'What are the elements defining high-quality palliative care in the Netherlands?'. For constructing the quality framework, a bottleneck analysis of palliative care provision and a literature review were conducted. Six core documents were used in a modified Delphi technique to build the framework with the expert panel, while stakeholder organisations were involved and informed in round-table discussions. In the entire process, preparing and building relationships took one year and surveying, convening, discussing content, consulting peers, and obtaining final consent from all stakeholders took 18 months. A quality framework, including a glossary of terms, endorsed by organisations representing patients and their families, general practitioners, elderly care physicians, medical specialists, nurses, social workers, psychologists, spiritual caregivers, and health insurers was developed and annexed with a summary for patients and families. We successfully developed a national consensus-based patient-centred quality framework for high-quality palliative care in a mixed generalist-specialist palliative care model. A whole-sector approach and a modified Delphi technique are feasible structures to achieve this aim. The process we reported may guide other countries in their initiatives to enhance palliative care.	[Boddaert, Manon S.; Douma, Joep; Dijxhoorn, Anne-Floor Q.; Huijgens, Peter C.] Netherlands Comprehens Canc Org IKNL, Utrecht, Netherlands; [Boddaert, Manon S.; Dijxhoorn, Anne-Floor Q.] Leiden Univ, Ctr Expertise Palliat Care, Med Ctr, Leiden, Netherlands; [Douma, Joep; van der Rijt, Carin C. D.; Vissers, Kris C. P.] Dutch Soc Profess Palliat Care, Palliactief, Delft, Netherlands; [Heman, Rene A. C. L.] Royal Dutch Med Assoc, Utrecht, Netherlands; [van der Rijt, Carin C. D.] Erasmus Univ, Med Ctr, Inst Canc, Dept Med Oncol, Rotterdam, Netherlands; [Teunissen, Saskia S. C. M.] Netherlands Assoc Palliat Care PZNL, Utrecht, Netherlands; [Vissers, Kris C. P.] Radboud Univ Nijmegen, Dept Anesthesiol Pain & Palliat Med, Med Ctr, Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen	Boddaert, MS (corresponding author), Netherlands Comprehens Canc Org IKNL, Utrecht, Netherlands.; Boddaert, MS (corresponding author), Leiden Univ, Ctr Expertise Palliat Care, Med Ctr, Leiden, Netherlands.	m.boddaert@iknl.nl		Boddaert, Manon/0000-0003-2158-8221				Ahluwalia SC, 2018, J PAIN SYMPTOM MANAG, V56, P831, DOI 10.1016/j.jpainsymman.2018.09.008; American Academy of Hospice and Palliative Medicine, 2004, J Palliat Med, V7, P611; [Anonymous], 2015, AUST J EMERG MANAG, V30, P9; [Anonymous], 2009, EUR J PALLIAT CARE; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Boddaert MS, 2022, BMJ SUPPORT PALLIAT, V12, pE137, DOI 10.1136/bmjspcare-2020-002302; Brinkman-Stoppelenburg A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1770-2; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Canadian Agency for Drugs and Technologies in Health (CADTH), 2015, GREY MATT PRACT TOOL; Cardona-Morrell M, 2016, INT J QUAL HEALTH C, V28, P456, DOI 10.1093/intqhc/mzw060; CBO, 2013, ZORGMODULE PALLIATIE; Chen AY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76707-w; Cohen J., 2012, GLOBALIZATION SOVERE; Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894; Dalgaard KM, 2014, PALLIAT SUPPORT CARE, V12, P495, DOI 10.1017/S1478951513001338; de Bruin J, 2018, PERSPECT MED EDUC, V7, P325, DOI 10.1007/s40037-018-0447-4; De Korte-Verhoef MC, 2014, PALLIATIVE MED, V28, P949, DOI 10.1177/0269216314528742; Dijxhoorn AFQ, 2021, J PAIN SYMPTOM MANAG, V62, pE38, DOI 10.1016/j.jpainsymman.2021.04.004; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Dumanovsky T, 2015, J PALLIAT MED, V18, P998, DOI 10.1089/jpm.2015.0436; Etkind SN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0860-2; Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474; Gardiner C, 2011, AGE AGEING, V40, P233, DOI 10.1093/ageing/afq172; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Goris P., 2019, DESIGNING INTEGRATED, P67; Gott M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1773; Grant MS, 2021, J PALLIAT MED, V24, P46, DOI 10.1089/jpm.2020.0111; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Haun MW, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011129.pub2; Heida JP HJ., 2016, NEXT LEVEL GEZONDHEI; Henderson JD, 2019, J PALLIAT MED, V22, P1318, DOI 10.1089/jpm.2019.0314; Hill Andrea D, 2019, CMAJ Open, V7, pE306, DOI 10.9778/cmajo.20180097; Hillman KM, 2011, AUST HEALTH REV, V35, P176, DOI 10.1071/AH10963; Hospice New Zealand, 2012, HOSP NZ STAND PALL; Hui D, 2020, J CLIN ONCOL, V38, P852, DOI 10.1200/JCO.18.02123; Hui D, 2018, CA-CANCER J CLIN, V68, P356, DOI 10.3322/caac.21490; IKNL/Palliactief, 2015, PALL ZORG NED ZIEK; IKNL/Palliactief, 2017, KNELP PALL ZORG EERS; Inst Med, 2015, DYING IN AMERICA: IMPROVING QUALITY AND HONORING INDIVIDUAL PREFERENCES NEAR THE END OF LIFE, P1; Jordan K, 2018, ANN ONCOL, V29, P36, DOI 10.1093/annonc/mdx757; Junger S, 2012, J PAIN SYMPTOM MANAG, V44, P192, DOI 10.1016/j.jpainsymman.2011.09.009; Kaasa S, 2018, LANCET ONCOL, V19, pE588, DOI 10.1016/S1470-2045(18)30415-7; Kerngroep Palliatieve Zorg, 2011, WITBOEK PALLIATIEVE; Maetens A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025180; Meier DE, 2017, HEALTH AFFAIR, V36, P1265, DOI 10.1377/hlthaff.2017.0164; Mitchell S, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1827; Morin L, 2017, PALLIATIVE MED, V31, P526, DOI 10.1177/0269216316671280; Murtagh FEM, 2014, PALLIATIVE MED, V28, P49, DOI 10.1177/0269216313489367; National Consensus Project for Quality Palliative Care, 2013, CLIN PRACT GUID QUAL; National Consensus Project for Quality Palliative Care, 2009, CLIN PRACT GUID QUAL; National Institute for Health and Care Excellence, 2011, [No title captured]; National Quality Forum, 2006, NAT FRAM PREF PRACT; Oosterveld-Vlug MG, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0485-7; Optimaliseren Onderwijs Palliatieve Zorg (O2PZ), 2020, OND FRAM PALL CAR 2; Ozier W, 1998, DELPHI MODIFIED DELP; Paap JV, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0130-z; Palliatieve Zorg Nederland (PZNL), 2020, HANDR FIN PALL ZORG; Palliative Care Australia, 2005, STAND PROV QUAL PALL; Patientenfederatie Nederland, 2019, HOE MOET PALL ZORG N; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Quinn KL, 2020, JAMA-J AM MED ASSOC, V324, P1439, DOI 10.1001/jama.2020.14205; Radbruch L, 2010, EUR J PALLIAT CARE, V17, P22; Radbruch L, 2020, LANCET, V395, P1467, DOI 10.1016/S0140-6736(20)30964-8; Regieraad Kwaliteit van Zorg, 2012, RICHTLIJN RICHTLIJNE; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Sinclair C, 2020, INTERN MED J, V50, P918, DOI 10.1111/imj.14937; Sleeman KE, 2019, LANCET GLOB HEALTH, V7, pE883, DOI 10.1016/S2214-109X(19)30172-X; Steering Committee for Appropriate End-of-Life Care, 2015, JUST WE CAN; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P713, DOI 10.1016/S0885-3924(01)00336-0; The Choice in End of Life Care Programme Board, 2015, WHATS IMPORTANT ME; van der Velden A, 2018, J PAIN SYMPTOM MANAG, V56, pE107, DOI 10.1016/j.jpainsymman.2018.10.358; Vanbutsele G, 2018, LANCET ONCOL, V19, P394, DOI 10.1016/S1470-2045(18)30060-3; Virdun Claudia, 2020, BMJ Support Palliat Care, DOI 10.1136/bmjspcare-2020-002645; Virdun C, 2017, PALLIATIVE MED, V31, P587, DOI 10.1177/0269216316673547; Virdun C, 2015, PALLIATIVE MED, V29, P774, DOI 10.1177/0269216315583032; World Health Assembly, 2014, STRENGTH PALL CAR AS; Ziegler LE, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018284; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	79	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265726	10.1371/journal.pone.0265726	http://dx.doi.org/10.1371/journal.pone.0265726			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0P5DL	35320315	Green Published, gold			2023-01-03	WOS:000784240600016
J	Unoki, T; Kitayama, M; Sakuramoto, H; Ouchi, A; Kuribara, T; Yamaguchi, T; Uemura, S; Fukuda, Y; Haruna, J; Tsujimoto, T; Hino, M; Shiba, Y; Nagao, T; Shirasaka, M; Satoi, Y; Toyoshima, M; Masuda, Y				Unoki, Takeshi; Kitayama, Mio; Sakuramoto, Hideaki; Ouchi, Akira; Kuribara, Tomoki; Yamaguchi, Takako; Uemura, Sakura; Fukuda, Yuko; Haruna, Junpei; Tsujimoto, Takahiro; Hino, Mayumi; Shiba, Yuko; Nagao, Takumi; Shirasaka, Masako; Satoi, Yosuke; Toyoshima, Miki; Masuda, Yoshiki		SMAP HoPe Study Project	Employment status and its associated factors for patients 12 months after intensive care: Secondary analysis of the SMAP-HoPe study	PLOS ONE			English	Article							HOSPITAL ANXIETY; CRITICAL ILLNESS; SURVIVORS; RETURN; WORK; JAPAN	BackgroundReturning to work is a serious issue that affects patients who are discharged from the intensive care unit (ICU). This study aimed to clarify the employment status and the perceived household financial status of ICU patients 12 months following ICU discharge. Additionally, we evaluated whether there exists an association between depressive symptoms and subsequent unemployment status. MethodsThis study was a subgroup analysis of the published Survey of Multicenter Assessment with Postal questionnaire for Post-Intensive Care Syndrome for Home Living Patients (the SMAP-HoPe study) in Japan. Eligible patients were those who were employed before ICU admission, stayed in the ICU for at least three nights between October 2019 and July 2020, and lived at home for 12 months after discharge. We assessed the employment status, subjective cognitive functions, household financial status, Hospital Anxiety and Depression Scale, and EuroQOL-5 dimensions of physical function at 12 months following intensive care. ResultsThis study included 328 patients, with a median age of 64 (interquartile range [IQR], 52-72) years. Of these, 79 (24%) were unemployed 12 months after ICU discharge. The number of patients who reported worsened financial status was significantly higher in the unemployed group (p<0.01) than in the employed group. Multivariable analysis showed that higher age (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.03-1.08]) and greater severity of depressive symptoms (OR, 1.13 [95% CI, 1.05-1.23]) were independent factors for unemployment status at 12 months after ICU discharge. ConclusionsWe found that 24.1% of our patients who had been employed prior to ICU admission were subsequently unemployed following ICU discharge and that depressive symptoms were associated with unemployment status. The government and the local municipalities should provide medical and financial support to such patients. Additionally, community and workplace support for such patients are warranted.	[Unoki, Takeshi; Kuribara, Tomoki] Sapporo City Univ, Sch Nursing, Dept Acute & Crit Care Nursing, Chuo Ku, Sapporo, Hokkaido, Japan; [Kitayama, Mio] Kanazawa Med Univ Hosp, Dept Nursing, Ctr Heart, Uchinada, Ishikawa, Japan; [Sakuramoto, Hideaki; Ouchi, Akira] Ibaraki Christian Univ, Coll Nursing, Dept Adult Hlth Nursing, Hitachi, Ibaraki, Japan; [Ouchi, Akira; Shiba, Yuko] Univ Tsukuba Hosp, Intens Care Unit, Tsukuba, Ibaraki, Japan; [Kuribara, Tomoki] Japanese Red Cross Maebashi Hosp, Adv Emergency Med Serv Ctr, Intens Care Unit, Maebahi, Japan; [Yamaguchi, Takako] Musashikosugi Hosp, Nippon Med Sch, Intens Care Unit, Kawasaki, Kanagawa, Japan; [Uemura, Sakura; Toyoshima, Miki] Osaka City Gen Hosp, Emergency & Crit Care Med Ctr, Osaka, Japan; [Fukuda, Yuko] Jichi Med Univ Hosp, Intens Care Unit, Yakushiji, Shimotsuke, Japan; [Haruna, Junpei] Sapporo Med Univ Hosp, Intens Care Unit, Sapporo, Hokkaido, Japan; [Tsujimoto, Takahiro] Nara Med Univ Hosp, Nursing Practice & Career Support Ctr, Kashihara, Nara, Japan; [Hino, Mayumi] Tohoku Med & Pharmaceut Univ Hosp, Intens Care Unit, Sendai, Miyagi, Japan; [Nagao, Takumi] Sakakibara Heart Inst, Intens Care Unit, Fuchu, Tokyo, Japan; [Shirasaka, Masako] Japanese Red Cross Fukuoka Hosp, Intens Care Unit, Fukuoka, Japan; [Shirasaka, Masako] Japanese Red Cross Fukuoka Hosp, Cardiac Care Unit, Fukuoka, Japan; [Satoi, Yosuke] Naha City Hosp, Intens Care Unit, Naha, Japan; [Masuda, Yoshiki] Sapporo Med Univ, Sch Med, Dept Intens Care Med, Sapporo, Hokkaido, Japan	Kanazawa Medical University; University of Tsukuba; Nippon Medical School; Osaka City General Hospital; Sapporo Medical University; Nara Medical University; Tohoku Medical & Pharmaceutical University; Sapporo Medical University	Unoki, T (corresponding author), Sapporo City Univ, Sch Nursing, Dept Acute & Crit Care Nursing, Chuo Ku, Sapporo, Hokkaido, Japan.	iwhyh1029@gmail.com	Ouchi, Akira/GRR-7032-2022	Ouchi, Akira/0000-0003-4740-0098; Sakuramoto, Hideaki/0000-0002-2370-2588; Unoki, Takeshi/0000-0002-7778-4355	JSPS KAKENHI [19K10929]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The following SMAP-HoPe Study Project investigators were involved in the protocol: Ryuta Indo, Hiroomi Tatsumi, Atsuko Handa, Kazuyo Koori, Ayano Kudo, Kayo Kitaura, Etsuko Moro, Shin Nunomiya, Akira Ouchi, Masako Sato, Yoshiaki Inoue, Etsuko Tsukioka, Yasuhiro Kishi, Chiaki Fujii, Kohei Matsuba, Hiroki Isonishi, Ikumi Kobashi, Miki Toyoshima, Masahiro Yamane, Yumi Kajiyama, and Yoshifumi Heshiki.	Bell Melanie L, 2016, BMC Res Notes, V9, P479; Cullen KL, 2018, J OCCUP REHABIL, V28, P1, DOI 10.1007/s10926-016-9690-x; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Hatta H., 1998, JAPANESE J PSYCHOSOM, V38, P309; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hodgson CL, 2018, J CRIT CARE, V48, P21, DOI 10.1016/j.jcrc.2018.08.005; Irie H, 2020, J CRIT CARE, V55, P86, DOI 10.1016/j.jcrc.2019.09.004; Kamdar BB, 2020, THORAX, V75, P17, DOI 10.1136/thoraxjnl-2019-213803; Kawakami D, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03501-z; Ministry of Health Labour and Welfare., 2017, OV RES COMPR SURV WO; Mortensen M, 2022, SCAND J CARING SCI, V36, P893, DOI 10.1111/scs.13006; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Nakamura K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10143044; Norman BC, 2016, CRIT CARE MED, V44, P2003, DOI 10.1097/CCM.0000000000001849; OECD, 2010, SICKN DIS WORK BREAK; Ono H, 2010, J JPN INT ECON, V24, P1, DOI 10.1016/j.jjie.2009.11.003; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sirio CA, 2002, CHEST, V121, P539, DOI 10.1378/chest.121.2.539; Su H, 2021, J ADV NURS, V77, P653, DOI 10.1111/jan.14631; Unoki T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252167; Vlasveld MC, 2012, J OCCUP REHABIL, V22, P118, DOI 10.1007/s10926-011-9326-0; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zisopoulos G, 2020, HEALTH PSYCHOL RES, V8, P131, DOI 10.4081/hpr.2020.8852	23	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0263441	10.1371/journal.pone.0263441	http://dx.doi.org/10.1371/journal.pone.0263441			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0P4VV	35302991	Green Published, gold			2023-01-03	WOS:000784220200052
J	Slomski, A				Slomski, Anita			Mediterranean Diet vs Low-fat Diet for Patients With Heart Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2022	327	24					2386	2386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2S1QA	35762998				2023-01-03	WOS:000821573300005
J	Lin, YP; Chen, YS				Lin, Yen-Po; Chen, Yu-Syuan			Effect of Intra-arrest Transport and Extracorporeal Cardiopulmonary Resuscitation on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Lin, Yen-Po; Chen, Yu-Syuan] Chung Shan Med Univ, Sch Med, Taichung, Taiwan	Chung Shan Medical University	Lin, YP (corresponding author), Chung Shan Med Univ, 110 Jianguo N Rd,Sect 1, Taichung 40201, Taiwan.	dante44442@gmail.com						Belohlavek J, 2022, JAMA-J AM MED ASSOC, V327, P737, DOI 10.1001/jama.2022.1025; Daubert JP, 2021, J AM COLL CARDIOL, V77, P372, DOI 10.1016/j.jacc.2020.11.052; Martinell L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1677-2; Reynolds JC, 2016, CIRCULATION, V134, P2084, DOI 10.1161/CIRCULATIONAHA.116.023309	4	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2022	327	23					2356	2357		10.1001/jama.2022.6545	http://dx.doi.org/10.1001/jama.2022.6545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L3ZC	35727282				2023-01-03	WOS:000816956000025
J	Kim, JH; Na, CS; Cho, MR; Park, GC; Lee, JS				Kim, Jae-Hong; Na, Chang-Su; Cho, Myoung-Rae; Park, Gwang-Cheon; Lee, Jeong-Soon			Efficacy of invasive laser acupuncture in treating chronic non-specific low back pain: A randomized controlled trial	PLOS ONE			English	Article							CROSS-CULTURAL ADAPTATION; KOREAN VERSION; VALIDATION; GUIDELINES; MANAGEMENT; CARE	This study aimed to provide preliminary evidence for the efficacy of invasive laser acupuncture (ILA) for chronic non-specific low back pain (CNLBP). This was a single-center, randomized, patient and assessor-blinded, placebo-controlled, parallel-arm, clinical trial with a 1:1:1 allocation ratio that included a full analysis set. Forty-five participants with CNLBP were randomly assigned to the control group (sham laser), 650 group (650 nm-wavelength ILA), or 830 group (830 nm-wavelength ILA) (n = 15/group). All participants received ILA for 10 min, followed by electroacupuncture for 10 min on the same day. The treatment was performed once per day, twice per week for 4 weeks at bilateral BL23, BL24, BL25, and GB30. The primary outcome was the among-group difference of changes in the visual analog scale (VAS) scores at intervention endpoint (week 4). The secondary outcomes were the among-group difference of changes in VAS at 4 weeks after intervention completion (week 8), those in the Korean version of the Oswestry Disability Index (ODI) and the European Quality of Life Five-Dimension- Five-Level (EQ-5D-5L) at intervention endpoint (week 4) and 4 weeks after intervention completion (week 8). The VAS scores of the 650 group decreased significantly compared with those of the control group (p = 0.047; week 4 vs. week 0). The ODI scores of the 650 group (p = 0.018, week 4 vs. week 0; p = 0.006, week 8 vs. week 0) and 830 group (p = 0.014, week 4 vs. week 0) decreased significantly compared with those of the control group. There was no adverse event related to ILA and no significant difference in changes in vital signs among the three groups. The 650 group showed significant improvements in pain intensity and functional disability. The 830 group showed significant improvements in functional disability. Therefore, ILA therapy at 650 nm and 830 nm wavelengths can be used to treat CNLBP.	[Kim, Jae-Hong; Cho, Myoung-Rae] Dongshin Univ, Coll Korean Med, Dept Acupuncture & Moxibust Med, Naju, South Korea; [Kim, Jae-Hong; Park, Gwang-Cheon] Dongshin Univ, Gwangju Korean Med Hosp, Clin Res Ctr, Gwangju, South Korea; [Na, Chang-Su] Dongshin Univ, Coll Korean Med, Dept Acupoint & Meridian, Naju, South Korea; [Lee, Jeong-Soon] Christian Coll Nursing, Dept Nursing, Gwangju, South Korea	Dongshin University; Dongshin University; Dongshin University	Kim, JH (corresponding author), Dongshin Univ, Coll Korean Med, Dept Acupuncture & Moxibust Med, Naju, South Korea.; Kim, JH (corresponding author), Dongshin Univ, Gwangju Korean Med Hosp, Clin Res Ctr, Gwangju, South Korea.	nahonga@hanmail.net			Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HF21C0044]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HF21C0044). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; [Anonymous], 2014, KOREAN J ACUPUNCTURE, V31, P195, DOI [10.14406/acu.2014.038, DOI 10.14406/ACU.2014.038]; Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1; Bogduk N, 2004, MED J AUSTRALIA, V180, P79, DOI 10.5694/j.1326-5377.2004.tb05805.x; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Chiarotto A, 2019, J PAIN, V20, P245, DOI 10.1016/j.jpain.2018.07.009; Chon TY, 2019, MED ACUPUNCT, V31, P164, DOI 10.1089/acu.2019.1343; Delitto A, 2012, J ORTHOP SPORT PHYS, V42, pA1, DOI 10.2519/jospt.2012.42.4.A1; Edit V, 2013, RHEUMATOL INT, V33, P587, DOI 10.1007/s00296-012-2398-0; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Glazov G, 2016, ACUPUNCT MED, V34, P328, DOI 10.1136/acupmed-2015-011036; Glazov G, 2014, ACUPUNCT MED, V32, P116, DOI 10.1136/acupmed-2013-010456; Glazov G, 2009, ACUPUNCT MED, V27, P94, DOI 10.1136/aim.2009.000521; Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864; Hamblin MR, 2013, HDB PHOTOMEDICINE, P591; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Huang ZY, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0882-0; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; In-Seon Lee, 2012, Korean Journal of Acupuncture, V29, P519; Jeon CH, 2006, J KOREAN MED SCI, V21, P1092, DOI 10.3346/jkms.2006.21.6.1092; Johanson GA, 2010, EDUC PSYCHOL MEAS, V70, P394, DOI 10.1177/0013164409355692; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kim JH, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05038-6; Kim MH, 2005, QUAL LIFE RES, V14, P1401, DOI 10.1007/s11136-004-5681-z; Kim MR, 2019, KOREAN J ACUPUNCTURE, V36, P189, DOI [10.14406/acu.2019.023, DOI 10.14406/ACU.2019.023]; Law D, 2015, J ACUPUNCT MERIDIAN, V8, P2, DOI 10.1016/j.jams.2014.06.015; Lim JA, 2011, KOREAN J ACUPUNCTURE, V28, P37; Lim Tiaw-Kee, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030063; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140-6736(16)30970-9; Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2; Rubinstein SM, 2010, EUR SPINE J, V19, P1213, DOI 10.1007/s00586-010-1356-3; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Shin JY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/808425; Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8; WHO western Pacific region, 2009, WHO STAND AC POINT L, P190; Yeum Hyewon, 2021, Journal of Acupuncture Research, V38, P8, DOI 10.13045/jar.2020.00283; Ypusefi-Nooraie R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005107.pub4	38	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2022	17	5							e0269282	10.1371/journal.pone.0269282	http://dx.doi.org/10.1371/journal.pone.0269282			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3V2EB	35639723	gold, Green Published			2023-01-03	WOS:000841472800039
J							WHO Solidarity Trial Consortium	Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses	LANCET			English	Article								Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-beta 1a were discontinued for futility but randomisation to remdesivir continued. Here, we report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date. Methods Solidarity enrolled consenting adults (aged >= 18 years) recently hospitalised with, in the view of their doctor, definite COVID-19 and no contraindication to any of the study drugs, regardless of any other patient characteristics. Participants were randomly allocated, in equal proportions between the locally available options, to receive whichever of the four study drugs (lopinavir, hydroxychloroquine, IFN-beta 1a, or remdesivir) were locally available at that time or no study drug (controls). All patients also received the local standard of care. No placebos were given. The protocol specified primary endpoint was in-hospital mortality, subdivided by disease severity. Secondary endpoints were progression to ventilation if not already ventilated, and time-to-discharge from hospital. Final log-rank and Kaplan Meier analyses are presented for remdesivir, and are appended for all four study drugs. Meta-analyses give weighted averages of the mortality findings in this and all other randomised trials of these drugs among hospital inpatients. Solidarity is registered with ISRCTN, ISRCTN83971151, and ClinicalTrials.gov, NCT04315948. Findings Between March 22, 2020, and Jan 29, 2021, 14 304 potentially eligible patients were recruited from 454 hospitals in 35 countries in all six WHO regions. After the exclusion of 83 (0.6%) patients with a refuted COVID-19 diagnosis or encrypted consent not entered into the database, Solidarity enrolled 14 221 patients, including 8275 randomly allocated (1:1) either to remdesivir (ten daily infusions, unless discharged earlier) or to its control (allocated no study drug although remdesivir was locally available). Compliance was high in both groups. Overall, 602 (14.5%) of 4146 patients assigned to remdesivir died versus 643 (15.6%) of 4129 assigned to control (mortality rate ratio [RR] 0.91 [95% CI 0.82-1.02], p=0.12). Of those already ventilated, 151 (42.1%) of 359 assigned to remdesivir died versus 134 (38.6%) of 347 assigned to control (RR 1.13 [0.89-1.42], p=0.32). Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76-0.99], p=0.03). Of 1730 not on oxygen initially, 2.9% assigned to remdesivir died versus 3.8% assigned to control (RR 0.76 [0.46-1.28], p=0.30). Combining all those not ventilated initially, 11.9% assigned to remdesivir died versus 13.5% assigned to control (RR 0.86 [0.76-0.98], p=0.02) and 14.1% versus 15.7% progressed to ventilation (RR 0.88 [0.77-1.00], p=0.04). The non-prespecified composite outcome of death or progression to ventilation occurred in 19.6% assigned to remdesivir versus 22.5% assigned to control (RR 0.84 [0.75-0.93], p=0.001). Allocation to daily remdesivir infusions (vs open-label control) delayed discharge by about 1 day during the 10-day treatment period. A meta-analysis of mortality in all randomised trials of remdesivir versus no remdesivir yielded similar findings. Interpretation Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both). Copyright (C) 2022 World Health Organization; licensee Elsevier.					Meregildo-Rodriguez, Edinson Dante/AAH-5720-2020; Portolés, Antonio/AAE-5451-2020; Barry, Mazin/AAJ-7615-2020; Azañero, Johan/AAV-5606-2021; Guijarro, Carlos/B-3003-2008; Villegas-Chiroque, Miguel/AAK-8016-2021; Marwah, Vikas/ABC-4319-2020; , Felipe/F-4242-2014; Díaz Pollán, Beatriz/ABA-9452-2021; Zaky, Samy/AAB-6469-2021	Meregildo-Rodriguez, Edinson Dante/0000-0003-1814-5593; Portolés, Antonio/0000-0002-5646-5275; Barry, Mazin/0000-0003-2274-007X; Azañero, Johan/0000-0003-3385-1891; Guijarro, Carlos/0000-0001-8132-9366; Villegas-Chiroque, Miguel/0000-0002-8090-8224; Marwah, Vikas/0000-0002-7033-6090; , Felipe/0000-0001-7658-5832; Díaz Pollán, Beatriz/0000-0002-7241-4208; Zaky, Samy/0000-0003-4123-9221; Hakamifard, Atousa/0000-0001-9456-2239; Kildal, Anders Benjamin/0000-0002-1319-6511; Sterne, Jonathan/0000-0001-8496-6053; Lamminmaki, Satu/0000-0002-3791-2121; Perez-Macias, Natalia/0000-0002-9216-8438; Moorthy, Vasee/0000-0002-6535-2854; Bingi, Thrilok Chander/0000-0002-6151-3868; Jarvinen, Petrus/0000-0002-3751-4609; Barreto Rocchetti, Luis Guillermo/0000-0002-2851-0219; Fanjul, Francisco/0000-0003-1852-0330; McCarthy, Cormac/0000-0003-2896-5210; de Pablo Esteban, Antonio/0000-0001-6017-609X	WHO	WHO(World Health Organization)	WHO.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ader Florence, 2022, Lancet Infect Dis, V22, P209, DOI 10.1016/S1473-3099(21)00485-0; Ali K, 2022, CAN MED ASSOC J, V194, pE242, DOI 10.1503/cmaj.211698; Barratt-Due A, 2021, ANN INTERN MED, V174, P1261, DOI 10.7326/M21-0653; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Boutron I, COVID NMA PROJECT LI; Chokkalingam A, 2021, WORLD MICROBE FORUM; Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; FDA Center for Drug Evaluation and Research, 2020, FDAS APPR VEKL REMD; Gilead Sciences, 2021, GIL VEKL REMD ASS RE; Go AS, 2021, WORLD MICROBE FORUM; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Heil EL, 2022, NEW ENGL J MED, V386, P385, DOI 10.1056/NEJMe2118579; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Horby PW, 2022, LANCET, V399, P665, DOI 10.1016/S0140-6736(22)00163-5; Institute for Clinical and Economic Review (ICER), 2020, ICER COMM GIL PRIC R; Krause P, 2020, LANCET, V396, P741, DOI 10.1016/S0140-6736(20)31821-3; Mozaffari E, 2022, CLIN INFECT DIS, V75, pE450, DOI 10.1093/cid/ciab875; O'Brien MP, 2021, NEW ENGL J MED, V385, P1184, DOI 10.1056/NEJMoa2109682; ODay D, 2020, OPEN LETT DANIEL ODA; Peto R, 2011, BRIT J CANCER, V104, P1057, DOI 10.1038/bjc.2011.79; Rubin D, 2020, NEW ENGL J MED, V383, P2598, DOI 10.1056/NEJMp2032369; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; U.S. Department of Health & Human Services, 2022, COR COVID 19 UPD FDA; US Food and Drug Administration, 2021, PRESS REL COR COVID; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	30	32	32	15	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2022	399	10339					1941	1953		10.1016/S0140-6736(22)00519-0	http://dx.doi.org/10.1016/S0140-6736(22)00519-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1T7VQ	35512728	Green Published, hybrid			2023-01-03	WOS:000804936100017
J	Lin, ZS; Zhang, ZC; Ye, XJ; Zhu, M; Li, ZH; Chen, Y; Huang, SP				Lin, Zesen; Zhang, Zechao; Ye, Xuejin; Zhu, Min; Li, Zhihong; Chen, Yu; Huang, Shuping			Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer	PLOS ONE			English	Article							ASTRAGALUS-MEMBRANACEUS; CELL-CYCLE; APOPTOSIS; P53; PROGRESSION; EXPRESSION; FLAVONOIDS; THERAPY; PATHWAY; ACID	Background As a kind of traditional Chinese medicine, HQ is widely mentioned in the treatment of cancerous diseases in China, which has been proven to have a therapeutic effect on cancerous diseases, such as prostate cancer. To predict the specific mechanism of HQ in the treatment of CRPC, we will conduct preliminary verification and discussion based on a comprehensive consideration of network pharmacology and molecular docking. Methods TCMSP was used to obtain the compounds and reach the effective targets of HQ. The targets of CRPC were reached based on GeneCards database and CTD database. GO and KEGG were utilized for the analysis of overlapping targets. The software of Openbabel was used to convert the formats of ligands and reporters. In addition, molecular docking studies were performed by using the software of Autodock Vina. Result It can be seen from the database results that there were 87 active compounds (20 key active compounds) in HQ, and 33 targets were screened out for CRPC treatment. GO and KEGG pathway enrichment analyses identified 81 significant GO terms and 24 significant KEGG pathways. There is a difference in terms of the expression of core protein between cancer patients and healthy people. The expression of core protein in patients also has an impact on the life cycle. The results of molecular docking showed that the docking activity of drug molecules and core proteins was better. Conclusions It is concluded from the results of this network pharmacology and molecular docking that HQ makes a multi-target and multi-biological process, and results in the multi-channel synergistic effect on the treatment of CRPC by regulating cell apoptosis, proliferation and metastasis, which still needs further verification by experimental research.	[Lin, Zesen] Second Peoples Hosp Zhaoqing, Zhaoqing, Peoples R China; [Zhang, Zechao; Ye, Xuejin; Zhu, Min; Li, Zhihong; Chen, Yu; Huang, Shuping] Guangxi Univ Chinese Med, Ruikang Hosp, Nanning, Peoples R China	Guangxi University of Chinese Medicine	Zhu, M (corresponding author), Guangxi Univ Chinese Med, Ruikang Hosp, Nanning, Peoples R China.	chao616317728@foxmail.com			Fundamental Research Ability Improvement Project for Young and Middle aged Teachers in Guangxi Universities (Natural Science) [2022KY0300]; Administration of Traditional Chinese Medicine of Guangxi Zhuang Autonomous Region Self-funded Scientific Research Project (Natural Science) [GXZYZ20210346]; Health Commission of Guangxi Zhuang Autonomous Region self-funded scientific research project (Youth Fund) [Z20211659]; Science Research Project of Guangxi University of Traditional Chinese Medicine (Youth Fund) [2021QN029]	Fundamental Research Ability Improvement Project for Young and Middle aged Teachers in Guangxi Universities (Natural Science); Administration of Traditional Chinese Medicine of Guangxi Zhuang Autonomous Region Self-funded Scientific Research Project (Natural Science); Health Commission of Guangxi Zhuang Autonomous Region self-funded scientific research project (Youth Fund); Science Research Project of Guangxi University of Traditional Chinese Medicine (Youth Fund)	The authors received funding, staff, and equipment support for the following research projects: Fundamental Research Ability Improvement Project for Young and Middle aged Teachers in Guangxi Universities (Natural Science), Agreement No. 2022KY0300. Administration of Traditional Chinese Medicine of Guangxi Zhuang Autonomous Region Self-funded Scientific Research Project (Natural Science), Agreement No. GXZYZ20210346. Health Commission of Guangxi Zhuang Autonomous Region self-funded scientific research project (Youth Fund), Agreement No. Z20211659. Natural Science Research Project of Guangxi University of Traditional Chinese Medicine (Youth Fund), Agreement No. 2021QN029.	[Anonymous], OPEN BABEL PACKAGE; Auyeung KK, 2016, AM J CHINESE MED, V44, P1, DOI 10.1142/S0192415X16500014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Bu Weizhen, 2019, CHINESE REMEDIES CLI, V19, P2707; Cai FZ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192826; Cao HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160253; Chappell WH, 2012, CELL CYCLE, V11, P4579, DOI 10.4161/cc.22852; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Chen W, 2020, EUR J CANCER PREV, V29, P357, DOI 10.1097/CEJ.0000000000000549; Deng Ying, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P1174, DOI 10.3736/jcim20091216; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; El-Amm J, 2019, CLIN MED INSIGHTS-ON, V13, DOI 10.1177/1179554919833927; Elix C, 2018, ASIAN J ANDROL, V20, P238, DOI 10.4103/aja.aja_15_17; Eroglu C, 2015, TUMOR BIOL, V36, P9437, DOI 10.1007/s13277-015-3689-3; Ezzati M, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117463; Fang EH, 2017, CANCER BIOMARK, V20, P553, DOI 10.3233/CBM-170362; Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706; Fu W, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109374; Gao H, 2014, CELL BIOCHEM BIOPHYS, V69, P27, DOI 10.1007/s12013-013-9762-x; Greasley RU, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4527-y; Guo YL, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193396; Handy CE, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0438-9; HERTOG MGL, 1994, NUTR CANCER, V22, P175, DOI 10.1080/01635589409514342; Hong B, 2014, CURR DRUG TARGETS, V15, P80, DOI 10.2174/1389450114666140106101412; King L, 2020, PROSTATE INT, V8, P34, DOI 10.1016/j.prnil.2019.10.004; Li JL, 2020, MOL MED REP, V22, P155, DOI 10.3892/mmr.2020.11121; Li SZ, 2019, CANCER RES, V79, P2580, DOI 10.1158/0008-5472.CAN-18-2812; Li SS, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112797; Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342; Lin Shin-Jen, 2015, Oncoscience, V2, P142; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Lowrance WT, 2018, J UROLOGY, V200, P1264, DOI 10.1016/j.juro.2018.07.090; Masliah-Planchon J, 2016, ONCOTARGET, V7, P38892, DOI 10.18632/oncotarget.6476; Mateo J, 2019, EUR UROL, V75, P285, DOI 10.1016/j.eururo.2018.07.035; Maughan BL, 2018, PROSTATE CANCER P D, V21, P260, DOI 10.1038/s41391-017-0027-4; Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003; Na D, 2009, WORLD J GASTROENTERO, V15, P570, DOI 10.3748/wjg.15.570; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; Peng HS, 2017, CHIN MED-UK, V12, DOI 10.1186/s13020-017-0135-z; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Shankar E, 2017, MOLECULES, V22, DOI 10.3390/molecules22020264; Shankar S, 2008, CLIN CANCER RES, V14, P6855, DOI 10.1158/1078-0432.CCR-08-0903; Shappell SB, 2001, NEOPLASIA, V3, P287, DOI 10.1038/sj.neo.7900166; Tian J, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0625-y; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Wang KS, 2018, ONCOTARGETS THER, V11, P3167, DOI 10.2147/OTT.S159777; Wang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1243-7; Wang YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066999; Xu JK, 2017, ONCOL REP, V37, P1555, DOI 10.3892/or.2017.5364; Ye Y, 2012, HORM METAB RES, V44, P263, DOI 10.1055/s-0032-1301922; Yin MZ, 2019, J AOAC INT, V102, P734, DOI 10.5740/jaoacint.18-0308; Zhang J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02885-9; Zhao X, 2019, CURR PHARM DESIGN, V25, P4919, DOI 10.2174/1381612825666191212105145; Zhou Y, 2015, J MOL ENDOCRINOL, V54, pR15, DOI 10.1530/JME-14-0203	60	0	0	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2022	17	5							e0263291	10.1371/journal.pone.0263291	http://dx.doi.org/10.1371/journal.pone.0263291			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6Y3BV	35594510	Green Published, gold			2023-01-03	WOS:000896974400001
J	Delgado-Lista, J; Alcala-Diaz, JF; Torres-Pena, JD; Quintana-Navarro, GM; Fuentes, F; Garcia-Rios, A; Ortiz-Morales, AM; Gonzalez-Requero, AI; Perez-Caballero, AI; Yubero-Serrano, EM; Rangel-Zuniga, OA; Camargo, A; Rodriguez-Cantalejo, F; Lopez-Segura, F; Badimon, L; Ordovas, JM; Perez-Jimenez, F; Perez-Martinez, P; Lopez-Miranda, J				Delgado-Lista, Javier; Alcala-Diaz, Juan F.; Torres-Pena, Jose; Quintana-Navarro, Gracia M.; Fuentes, Francisco; Garcia-Rios, Antonio; Ortiz-Morales, Ana M.; Gonzalez-Requero, Ana, I; Perez-Caballero, Ana, I; Yubero-Serrano, Elena M.; Rangel-Zuniga, Oriol A.; Camargo, Antonio; Rodriguez-Cantalejo, Fernando; Lopez-Segura, Fernando; Badimon, Lina; Ordovas, Jose M.; Perez-Jimenez, Francisco; Perez-Martinez, Pablo; Lopez-Miranda, Jose		CORDIOPREV Investigators	Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV) a randomised controlled trial	LANCET			English	Article							CORONARY-ARTERY DISEASE; HEART-DISEASE; RISK-FACTORS; STYLE DIET; INTERVENTION; ADHERENCE; PROGRESSION; RICH	Background Mediterranean and low-fat diets are effective in the primary prevention of cardiovascular disease. We did a long-term randomised trial to compare the effects of these two diets in secondary prevention of cardiovascular disease. Methods The CORDIOPREV study was a single-centre, randomised clinical trial done at the Reina Sofia University Hospital in Cordoba, Spain. Patients with established coronary heart disease (aged 20-75 years) were randomly assigned in a 1:1 ratio by the Andalusian School of Public Health to receive a Mediterranean diet or a low-fat diet intervention, with a follow-up of 7 years. Clinical investigators (physicians, investigators, and clinical endpoint committee members) were masked to treatment assignment; participants were not. A team of dietitians did the dietary interventions. The primary outcome (assessed by intention to treat) was a composite of major cardiovascular events, including myocardial infarction, revascularisation, ischaemic stroke, peripheral artery disease, and cardiovascular death. This study is registered with ClinicalTrials.gov, NCT00924937. Findings From Oct 1, 2009, to Feb 28, 2012, a total of 1002 patients were enrolled, 500 (49.9%) in the low-fat diet group and 502 (50.1%) in the Mediterranean diet group. The mean age was 59.5 years (SD 8.7) and 827 (82.5%) of 1002 patients were men. The primary endpoint occurred in 198 participants: 87 in the Mediterranean diet group and 111 in the low-fat group (crude rate per 1000 person-years: 28.1 [95% CI 27.9-28.3] in the Mediterranean diet group vs 37.7 [37.5-37.9] in the low-fat group, log-rank p=0.039). Multivariable-adjusted hazard ratios (HRs) of the different models ranged from 0.719 (95% CI 0.541-0.957) to 0.753 (0.568-0.998) in favour of the Mediterranean diet. These effects were more evident in men, with primary endpoints occurring in 67 (16.2%) of 414 men in the Mediterranean diet group versus 94 (22.8%) of 413 men in the low-fat diet group (multiadjusted HR 0.669 [95% CI 0.489-0.915], log-rank p=0.013), than in 175 women for whom no difference was found between groups. Interpretation In secondary prevention, the Mediterranean diet was superior to the low-fat diet in preventing major cardiovascular events. Our results are relevant to clinical practice, supporting the use of the Mediterranean diet in secondary prevention. Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Delgado-Lista, Javier; Alcala-Diaz, Juan F.; Torres-Pena, Jose; Quintana-Navarro, Gracia M.; Fuentes, Francisco; Garcia-Rios, Antonio; Ortiz-Morales, Ana M.; Gonzalez-Requero, Ana, I; Perez-Caballero, Ana, I; Yubero-Serrano, Elena M.; Rangel-Zuniga, Oriol A.; Camargo, Antonio; Lopez-Segura, Fernando; Perez-Jimenez, Francisco; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Hosp Univ Reina Sofia, Dept Internal Med, Lipids & Atherosclerosis Unit, Cordoba, Spain; [Delgado-Lista, Javier; Alcala-Diaz, Juan F.; Fuentes, Francisco; Garcia-Rios, Antonio; Perez-Jimenez, Francisco; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Univ Cordoba, Dept Med & Surg Sci, Cordoba, Spain; [Delgado-Lista, Javier; Alcala-Diaz, Juan F.; Torres-Pena, Jose; Quintana-Navarro, Gracia M.; Fuentes, Francisco; Garcia-Rios, Antonio; Yubero-Serrano, Elena M.; Rangel-Zuniga, Oriol A.; Camargo, Antonio; Lopez-Segura, Fernando; Perez-Jimenez, Francisco; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain; [Delgado-Lista, Javier; Alcala-Diaz, Juan F.; Torres-Pena, Jose; Fuentes, Francisco; Garcia-Rios, Antonio; Yubero-Serrano, Elena M.; Rangel-Zuniga, Oriol A.; Camargo, Antonio; Lopez-Segura, Fernando; Perez-Jimenez, Francisco; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Inst Salud Carlos III, CIBER, Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain; [Rodriguez-Cantalejo, Fernando] Reina Sofia Univ Hosp, Biochem Lab, Cordoba, Spain; [Badimon, Lina] Hosp Santa Creu & Sant Pau Res Inst, IIB Sant Pau, Cardiovasc Program ICCC, Barcelona, Spain; [Badimon, Lina] Inst Salud Carlos III, CIBER CV, Madrid, Spain; [Ordovas, Jose M.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr & Genom Lab, Boston, MA USA; [Ordovas, Jose M.] IMDEA Food Inst, Madrid, Spain	Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Hospital Universitario Reina Sofia - Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Instituto de Salud Carlos III; Tufts University; United States Department of Agriculture (USDA)	Delgado-Lista, J; Lopez-Miranda, J (corresponding author), Hosp Univ Reina Sofia, Dept Internal Med, Lipids & Atherosclerosis Res Unit, Cordoba 14004, Spain.	md1delij@uco.es; jlopezmir@uco.es	Visioli, Francesco/J-9356-2013; Caballero-Villarraso, Javier/AAC-3434-2019; FUENTES JIMENEZ, FRANCISCO/G-4311-2016; HARO, CARMEN/P-3104-2016	Visioli, Francesco/0000-0002-1756-1723; Caballero-Villarraso, Javier/0000-0003-0571-5147; QUINTANA-NAVARRO, GRACIA MARIA/0000-0003-4413-4062; Alcala-Diaz, Juan Francisco/0000-0002-4572-3611; Yubero-Serrano, Elena M/0000-0002-2733-5359; FUENTES JIMENEZ, FRANCISCO/0000-0002-4584-7366; HARO, CARMEN/0000-0002-1355-8359	Fundacion Patrimonio Comunal Olivarero; CEAS (Centro de Excelencia en Investigacion sobre Aceite de Oliva); Junta de Andalucia (Consejeria de Salud, Consejeria de Agricultura y Pesca, Consejeria de Innovacion, Ciencia y Empresa); Diputaciones de Jaen y Cordoba, y Salud; Ministerio de Medio Ambiente, Medio Rural y Marino; Spanish Government; Ministerio de Ciencia e Innovacion [FIS PI10/01041, FIS PI13/00023, PIE14/00005, PIE 14/00031, PI15/00733, PI16/01777, PI18/01822, PI19/00299, DTS19/00007, PID2019-104362RB-I00, PI10/02412, PI13/00619]; Ministerio de Economia y Competitividad [AGL2009-122270, AGL2012/39615, PCIN-2016-084, AGL201567896-P]; Consejeria de Salud, Junta de Andalucia [PI0193/09, PI-0058/10, PI-0206-2013, PC0283/2017, PI-0170-2018-FIB]; Proyecto de Excelencia, Consejeria de Economia, Innovacion, Ciencia y Empleo [CVI-7450, P20_00256]; Seven Framework Programme NutriTech [289511]; Nicolas Monardes Programme from the Servicio Andaluz de Salud, Junta de Andalucia, Spain [C1-0005-2019]; ISCIII research contract [CP14/00114, CPII19/00007, CP19/00142, CM12/00202]; Servicio Andaluz de Salud research contract [B-00009-2017]; Institute of Health Carlos III, ISCIII [TerCel-RD16/0011/0018]; Spanish Ministry of Economy and Competitiveness of Science [PID2019107160RB-I00]; FEDER Una Manera de Hacer Europa; US Department of Agriculture [8050-51000-098-00D]	Fundacion Patrimonio Comunal Olivarero; CEAS (Centro de Excelencia en Investigacion sobre Aceite de Oliva); Junta de Andalucia (Consejeria de Salud, Consejeria de Agricultura y Pesca, Consejeria de Innovacion, Ciencia y Empresa); Diputaciones de Jaen y Cordoba, y Salud; Ministerio de Medio Ambiente, Medio Rural y Marino; Spanish Government(Spanish GovernmentEuropean Commission); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Ministerio de Economia y Competitividad(Spanish Government); Consejeria de Salud, Junta de Andalucia(Junta de Andalucia); Proyecto de Excelencia, Consejeria de Economia, Innovacion, Ciencia y Empleo; Seven Framework Programme NutriTech; Nicolas Monardes Programme from the Servicio Andaluz de Salud, Junta de Andalucia, Spain(Junta de Andalucia); ISCIII research contract; Servicio Andaluz de Salud research contract; Institute of Health Carlos III, ISCIII; Spanish Ministry of Economy and Competitiveness of Science(Spanish Government); FEDER Una Manera de Hacer Europa; US Department of Agriculture(United States Department of Agriculture (USDA))	The CORDIOPREV study was supported by the Fundacion Patrimonio Comunal Olivarero. The main sponsor agreed to participate in the study because when it started, there were no full-length studies evaluating the effect of an olive oil-based Mediterranean diet on coronary secondary prevention, although there were many observational studies and studies evaluating risk factors that indicated that it could have a favourable effect. The sponsor was not involved in the design or carrying out the study, and its participation was limited to funding and providing the olive oil used in the study. We also received additional funding from CEAS (Centro de Excelencia en Investigacion sobre Aceite de Oliva), Junta de Andalucia (Consejeria de Salud, Consejeria de Agricultura y Pesca, Consejeria de Innovacion, Ciencia y Empresa), Diputaciones de Jaen y Cordoba, y Salud and Ministerio de Medio Ambiente, Medio Rural y Marino, and the Spanish Government. The study was also partly supported by research grants from the Ministerio de Ciencia e Innovacion (FIS PI10/01041 to PP-M; FIS PI13/00023 to JD-L; PIE14/00005 and PIE 14/00031 to JL-M; PI15/00733 to OAR-Z; PI16/01777 to PP-M; PI18/01822 to EY-S; PI19/00299 to AC; DTS19/00007 to AC; PID2019-104362RB-I00 to JL-M; and PI10/02412 and PI13/00619 to FP-J); Ministerio de Economia y Competitividad (AGL2009-122270, AGL2012/39615, and PCIN-2016-084 [JPI HDHL] to JL-M, and AGL201567896-P to JL-M and AC); Consejeria de Salud, Junta de Andalucia (PI0193/09 to JL-M; PI-0058/10 to PP-M; PI-0206-2013 to AG-R; PC0283/2017 to EMY-S; and PI-0170-2018-FIB to OAR-Z); Proyecto de Excelencia, Consejeria de Economia, Innovacion, Ciencia y Empleo (CVI-7450 and P20_00256 to JL-M; and Seven Framework Programme NutriTech (289511). The study was also cofinanced by the Fondo Europeo de Desarrollo Regional (FEDER). EY-S was the recipient of the Nicolas Monardes Programme from the Servicio Andaluz de Salud, Junta de Andalucia, Spain (C1-0005-2019). AC is supported by an ISCIII research contract (Programa Miguel-Servet CP14/00114 and CPII19/00007). OAR-Z is supported by an ISCIII research contract (Programa MiguelServet CP19/00142). JFA-D was supported by an ISCIII research contract (Rio-Hortega Program CM12/00202) and is supported by a Servicio Andaluz de Salud research contract (Accion B-Clinicos investigadores B-00009-2017). LB is funded by the Institute of Health Carlos III, ISCIII (CIBERCV; Red Terapia Celular TerCel-RD16/0011/0018); the Spanish Ministry of Economy and Competitiveness of Science (PID2019107160RB-I00); and cofunded by FEDER Una Manera de Hacer Europa. JMO is funded by the US Department of Agriculture, under agreement number 8050-51000-098-00D. The CIBEROBN and CIBERCV are initiatives of the Instituto de Salud Carlos III, Madrid, Spain. There are no ties with industry regarding this Article. We want to thank Miguel Angel Martinez Gonzalez for his valuable help in the statistical approach. We also want to thank to the cardiology unit at IMIBIC, University Hospital Reina Sofia, for their valuable help in the recruitment for this study. We want to thank the external advisory board and the clinical endpoint committee for their excellent work. We would like to thank the Escuela Andaluza de Salud Publica for performing the randomisation process. We especially want to thank the participants of the CORDIOPREV study.; The low abandonment rate of the dietary intervention (and the high percentage of these patients who allowed the follow-up of their data by electronic medical record or by telephone) and the high level of adherence during the study clearly indicate their level of personal involvement.	Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Babio N, 2009, NUTR METAB CARDIOVAS, V19, P563, DOI 10.1016/j.numecd.2008.10.007; BURR ML, 1989, LANCET, V2, P757; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Delgado-Lista J, 2016, AM HEART J, V177, P42, DOI 10.1016/j.ahj.2016.04.011; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Diez-Espino J, 2011, ANN NUTR METAB, V58, P74, DOI 10.1159/000324718; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Estruch R, 2010, P NUTR SOC, V69, P333, DOI 10.1017/S0029665110001539; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HJERMANN I, 1981, LANCET, V2, P1303; Lara J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-60; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.1093/eurheartj/ehz455, 10.15829/1560-4071-2020-3826]; Martinez-Gonzalez MA, 2004, EUR J CLIN NUTR, V58, P1550, DOI 10.1038/sj.ejcn.1602004; Martinez-Gonzalez MA, 2019, CIRC RES, V124, P779, DOI 10.1161/CIRCRESAHA.118.313348; Murphy KJ, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0732-z; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Quintana-Navarro GM, 2020, EUR J NUTR, V59, P2099, DOI 10.1007/s00394-019-02059-5; Rees K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub3; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Sanchez Fernandez JJ, 2019, REV ESP CARDIOL ENGL, V72, P827; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WATTS GF, 1994, AM J CARDIOL, V73, P328, DOI 10.1016/0002-9149(94)90003-5; Zazpe I, 2008, J AM DIET ASSOC, V108, P1134, DOI 10.1016/j.jada.2008.04.011	34	22	22	33	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2022	399	10338					1876	1885		10.1016/S0140-6736(22)00122-2	http://dx.doi.org/10.1016/S0140-6736(22)00122-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1V8AR	35525255				2023-01-03	WOS:000806306700018
J	Reis, G; Silva, EASM; Silva, DCM; Thabane, L; Milagres, AC; Ferreira, TS; dos Santos, CVQ; Campos, VHS; Nogueira, AMR; de Almeida, APFG; Callegari, ED; Neto, ADF; Savassi, LCM; Simplicio, MIC; Ribeiro, LB; Oliveira, R; Harari, O; Forrest, JI; Ruton, H; Sprague, S; McKay, P; Guo, CM; Rowland-Yeo, K; Guyatt, GH; Boulware, DR; Rayner, CR; Mills, EJ				Reis, G.; Silva, E. A. S. M.; Silva, D. C. M.; Thabane, L.; Milagres, A. C.; Ferreira, T. S.; dos Santos, C. V. Q.; Campos, V. H. S.; Nogueira, A. M. R.; de Almeida, A. P. F. G.; Callegari, E. D.; Neto, A. D. F.; Savassi, L. C. M.; Simplicio, M. I. C.; Ribeiro, L. B.; Oliveira, R.; Harari, O.; Forrest, J., I; Ruton, H.; Sprague, S.; McKay, P.; Guo, C. M.; Rowland-Yeo, K.; Guyatt, G. H.; Boulware, D. R.; Rayner, C. R.; Mills, E. J.		TOGETHER Investigators	Effect of Early Treatment with Ivermectin among Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access								Background: The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear. Methods: We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2-positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 mu g per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for > 6 hours) within 28 days after randomization. Results: A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Findings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events. Conclusions: Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424).	[Reis, G.; Silva, E. A. S. M.; Silva, D. C. M.; Ferreira, T. S.; dos Santos, C. V. Q.; Simplicio, M. I. C.; Ribeiro, L. B.; Oliveira, R.] Cardres Cardiol Assistencial & Pesquisa, Res Div, Rua Domingos Vieira 300,Sala 606, BR-30150242 Belo Horizonte, MG, Brazil; [Reis, G.; Silva, E. A. S. M.; Silva, D. C. M.; dos Santos, C. V. Q.; Campos, V. H. S.] Pontificia Univ Catolica Minas Gerais, Dept Med, Belo Horizonte, MG, Brazil; [Milagres, A. C.; Savassi, L. C. M.] Univ Fed Ouro Preto, Dept Publ Hlth & Mental & Family Med, Ouro Preto, Brazil; [Milagres, A. C.] Publ Hlth Care Div, Ibirite, Brazil; [Nogueira, A. M. R.; de Almeida, A. P. F. G.] UNIFIPMoc, Dept Publ Hlth, Montes Claros, MG, Brazil; [Nogueira, A. M. R.; de Almeida, A. P. F. G.] UNIFIPMoc, Family Med Fellowship Program, Montes Claros, MG, Brazil; [Callegari, E. D.] Publ Hlth Care Div, Brumadinho, Brazil; [Neto, A. D. F.] Governador Valadares Publ Hlth Author, Publ Hlth Fellowship Program, Governador Valadares, Brazil; [Thabane, L.; Sprague, S.; McKay, P.; Guyatt, G. H.; Mills, E. J.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Harari, O.; Ruton, H.; Mills, E. J.] Cytel, Vancouver, BC, Canada; [Forrest, J., I; Guo, C. M.; Mills, E. J.] Platform Life Sci, Vancouver, BC, Canada; [Rowland-Yeo, K.; Rayner, C. R.] Certara, Princeton, NJ USA; [Boulware, D. R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN USA; [Rayner, C. R.] Monash Univ, Monash Inst Pharmaceut Sci, Melbourne, Vic, Australia	Pontificia Universidade Catolica de Minas Gerais; Universidade Federal de Ouro Preto; McMaster University; University of Minnesota System; University of Minnesota Twin Cities; Monash University	Reis, G (corresponding author), Cardres Cardiol Assistencial & Pesquisa, Res Div, Rua Domingos Vieira 300,Sala 606, BR-30150242 Belo Horizonte, MG, Brazil.; Rayner, CR (corresponding author), Monash Inst Pharmaceut Sci, 381 Royal Parade, Melbourne, Vic 3052, Australia.	thetogethertrial@gmail.com	SAVASSI, LEONARDO CANCADO MONTEIRO/Z-4310-2019; Savassi, Leonardo CM/I-4733-2013; Boulware, David R/GRS-0999-2022; Reis, Gilmar/I-4500-2013	SAVASSI, LEONARDO CANCADO MONTEIRO/0000-0001-6780-0377; Savassi, Leonardo CM/0000-0001-6780-0377; Boulware, David R/0000-0002-4715-0060; Reis, Gilmar/0000-0002-4847-1034				Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; Bryant A, 2021, AM J THER, V28, pE434, DOI 10.1097/MJT.0000000000001402; Chua KP, 2022, JAMA-J AM MED ASSOC, V327, P584, DOI 10.1001/jama.2021.24352; Department of Health and Human Services, 2017, DIV AIDS DAIDS TABL; Forrester SG, 2002, BIOCHEM PHARMACOL, V63, P1061, DOI 10.1016/S0006-2952(02)00852-3; Heidary F, 2020, J ANTIBIOT, V73, P593, DOI 10.1038/s41429-020-0336-z; Hill A, 2022, OPEN FORUM INFECT DI, V9, DOI 10.1093/ofid/ofab645; Kim MS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003501; Kow CS, 2021, PHARMACOL REP, V73, P1473, DOI 10.1007/s43440-021-00245-z; Lee K, 2009, GLOB INST, P1; Mahani AS, 2019, J STAT SOFTW, V89, DOI 10.18637/jss.v089.i09; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; Rayner CR, 2020, AM J TROP MED HYG, V103, P1364, DOI 10.4269/ajtmh.20-0995; Reardon S, 2021, NATURE, V596, P173, DOI 10.1038/d41586-021-02081-w; Reis G., 2021, GATES OPEN RESE, V5, P117; Reis G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.6468; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8; Torres I, 2020, LANCET GLOB HEALTH, V8, pE1355, DOI 10.1016/S2214-109X(20)30415-0; Zein AFMZ, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102186	22	41	41	3	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2115869	http://dx.doi.org/10.1056/NEJMoa2115869		MAR 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1L2BH	35353979	Bronze, Green Published			2023-01-03	WOS:000799096500001
J	Bradbury, CA; Lawler, PR; Stanworth, SJ; McVerry, BJ; McQuilten, Z; Higgins, AM; Mouncey, PR; Al-Beidh, F; Rowan, KM; Berry, LR; Lorenzi, E; Zarychanski, R; Arabi, YM; Annane, D; Beane, A; Van Bentum-Puijk, W; Bhimani, Z; Bihari, S; Bonten, MJM; Brunkhorst, FM; Buzgau, A; Buxton, M; Carrier, M; Cheng, AC; Cove, M; Detry, MA; Estcourt, LJ; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Haniffa, R; Hills, T; Huang, DT; Horvat, CM; Hunt, BJ; Ichihara, N; Lamontagne, F; Leavis, HL; Linstrum, KM; Litton, E; Marshall, JC; McAuley, DF; McGlothlin, A; McGuinness, SP; Middeldorp, S; Montgomery, SK; Morpeth, SC; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Reyes, L; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Singh, V; Tolppa, T; Turgeon, AF; Turner, AM; van de Veerdonk, FL; Green, C; Lewis, RJ; Angus, DC; McArthur, CJ; Berry, S; Derde, LPG; Webb, SA; Gordon, AC				Bradbury, Charlotte A.; Lawler, Patrick R.; Stanworth, Simon J.; McVerry, Bryan J.; McQuilten, Zoe; Higgins, Alisa M.; Mouncey, Paul R.; Al-Beidh, Farah; Rowan, Kathryn M.; Berry, Lindsay R.; Lorenzi, Elizabeth; Zarychanski, Ryan; Arabi, Yaseen M.; Annane, Djillali; Beane, Abi; Van Bentum-Puijk, Wilma; Bhimani, Zahra; Bihari, Shailesh; Bonten, Marc J. M.; Brunkhorst, Frank M.; Buzgau, Adrian; Buxton, Meredith; Carrier, Marc; Cheng, Allen C.; Cove, Matthew; Detry, Michelle A.; Estcourt, Lise J.; Fitzgerald, Mark; Girard, Timothy D.; Goligher, Ewan C.; Goossens, Herman; Haniffa, Rashan; Hills, Thomas; Huang, David T.; Horvat, Christopher M.; Hunt, Beverley J.; Ichihara, Nao; Lamontagne, Francois; Leavis, Helen L.; Linstrum, Kelsey M.; Litton, Edward; Marshall, John C.; McAuley, Daniel F.; McGlothlin, Anna; McGuinness, Shay P.; Middeldorp, Saskia; Montgomery, Stephanie K.; Morpeth, Susan C.; Murthy, Srinivas; Neal, Matthew D.; Nichol, Alistair D.; Parke, Rachael L.; Parker, Jane C.; Reyes, Luis; Saito, Hiroki; Santos, Marlene S.; Saunders, Christina T.; Serpa-Neto, Ary; Seymour, Christopher W.; Shankar-Hari, Manu; Singh, Vanessa; Tolppa, Timo; Turgeon, Alexis F.; Turner, Anne M.; van de Veerdonk, Frank L.; Green, Cameron; Lewis, Roger J.; Angus, Derek C.; McArthur, Colin J.; Berry, Scott; Derde, Lennie P. G.; Webb, Steve A.; Gordon, Anthony C.		REMAP-CAP Investigators	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COAGULOPATHY; INFECTION	IMPORTANCE The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. OBJECTIVE To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing adaptive platform trial (RE MAP-CAP) testing multiple interventions within multiple therapeutic domains, 1557 critically ill adult patients with COVID-19 were enrolled between October 30, 2020, and June 23, 2021, from 105 sites in 8 countries and followed up for 90 days (final follow-up date: July 26, 2021). INTERVENTIONS Patients were randomized to receive either open-label aspirin (n = 565). a P2Y12 inhibitor (n = 455), or no antiplatelet therapy (control; n = 529). Interventions were continued in the hospital for a maximum of 14 days and were in addition to anticoagulation thromboprophylaxis. MAIN OUTCOMES AND MEASURES The primary end point was organ support-free days (days alive and free of intensive care unit-based respiratory or cardiovascular organ support) within 21 days, ranging from -1 for any death in hospital (censored at 90 days) to 22 for survivors with no organ support. There were 13 secondary outcomes, including survival to discharge and major bleeding to 14 days. The primary analysis was a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented improved survival, more organ support-free days, or both. Efficacy was defined as greater than 99% posterior probability of an OR greater than 1. Futility was defined as greater than 95% posterior probability of an OR less than 1.2 vs control. Intervention equivalence was defined as greater than 90% probability that the OR (compared with each other) was between 1/1.2 and 1.2 for 2 noncontrol interventions. RESULTS The aspirin and P2Y12 inhibitor groups met the predefined criteria for equivalence at an adaptive analysis and were statistically pooled for further analysis. Enrollment was discontinued after the prespecified criterion for futility was met for the pooled antiplatelet group compared with control. Among the 1557 critically ill patients randomized, 8 patients withdrew consent and 1549 completed the trial (median age. 57 years; 521 [33.6%] female). The median for organ support-free days was 7 (IQR. -1 to 16) in both the antiplatelet and control groups (median-adjusted OR, 1.02 [95% credible interval {Crl}, 0.86-1.23]; 95.7% posterior probability of futility). The proportions of patients surviving to hospital discharge were 71.5% (723/1011) and 67.9% (354/521) in the antiplatelet and control groups, respectively (median-adjusted OR, 1.27 [95% Crl, 0.99-1.62]; adjusted absolute difference, 5% [95% Crl, -0.2% to 9.5%]; 97% posterior probability of efficacy). Among survivors, the median for organ support-free days was 14 in both groups. Major bleeding occurred in 2.1% and 0.4% of patients in the antiplatelet and control groups (adjusted OR, 2.97 [95% Crl, 1.23-8.28]; adjusted absolute risk increase, 0.8% [95% Crl, 0.1%-2.7%]: 99.4% probability of harm). CONCLUSIONS AND RELEVANCE Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days. (C) 2022 American Medical Association. All rights reserved.	[Bradbury, Charlotte A.] Univ Bristol, Bristol, Avon, England; [Lawler, Patrick R.; Goligher, Ewan C.] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Lawler, Patrick R.; Goligher, Ewan C.] Univ Toronto, Toronto, ON, Canada; [Stanworth, Simon J.; Beane, Abi] Univ Oxford, Oxford, England; [Stanworth, Simon J.; Estcourt, Lise J.] NHS Blood & Transplant, Oxford, England; [McVerry, Bryan J.; Girard, Timothy D.; Huang, David T.; Linstrum, Kelsey M.; Montgomery, Stephanie K.; Neal, Matthew D.; Seymour, Christopher W.; Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA; [McQuilten, Zoe; Higgins, Alisa M.; Buzgau, Adrian; Cheng, Allen C.; McGuinness, Shay P.; Nichol, Alistair D.; Parker, Jane C.; Serpa-Neto, Ary; Singh, Vanessa; Green, Cameron; Webb, Steve A.] Monash Univ, Melbourne, Vic, Australia; [McQuilten, Zoe] Monash Hlth, Melbourne, Vic, Australia; [Mouncey, Paul R.; Rowan, Kathryn M.] Intens Care Natl Audit & Res Ctr ICNARC, London, England; [Al-Beidh, Farah; Gordon, Anthony C.] Imperial Coll London, London, England; [Berry, Lindsay R.; Lorenzi, Elizabeth; Detry, Michelle A.; Fitzgerald, Mark; McGlothlin, Anna; Saunders, Christina T.; Lewis, Roger J.; Berry, Scott] Berry Consultants, Austin, TX USA; [Zarychanski, Ryan] Univ Manitoba, Winnipeg, MB, Canada; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen M.] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Annane, Djillali] Hop Raymond Poincare, Assistance Publ Hop Paris, Garches, France; [Annane, Djillali] Univ Versailles SQY Univ Paris Saclay, Montigny Le Bretonneux, France; [Van Bentum-Puijk, Wilma; Bonten, Marc J. M.; Leavis, Helen L.; Derde, Lennie P. G.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Bhimani, Zahra; Marshall, John C.; Santos, Marlene S.] St Michaels Hosp Unity Hlth, Toronto, ON, Canada; [Bihari, Shailesh] Flinders Univ S Australia, Bedford Pk, SA, Australia; [Brunkhorst, Frank M.] Jena Univ Hosp, Jena, Germany; [Buxton, Meredith] Global Coalit Adapt Res, Los Angeles, CA USA; [Carrier, Marc] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Carrier, Marc] Inst Savoir Montfort, Ottawa, ON, Canada; [Cheng, Allen C.] Alfred Hlth, Melbourne, Vic, Australia; [Cove, Matthew] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Goossens, Herman] Univ Antwerp, Antwerp, Belgium; [Haniffa, Rashan] Univ Oxford, Bangkok, Thailand; [Haniffa, Rashan; Tolppa, Timo] Natl Intens Care Surveillance NICST, Colombo, Sri Lanka; [Hills, Thomas; Turner, Anne M.] Med Res Inst New Zealand MRINZ, Wellington, New Zealand; [Horvat, Christopher M.] UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Hunt, Beverley J.] Kings Healthcare Partners, London, England; [Ichihara, Nao] Univ Tokyo, Tokyo, Japan; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Litton, Edward] Fiona Stanley Hosp, Perth, WA, Australia; [Litton, Edward] Univ Western Australia, Perth, WA, Australia; [McAuley, Daniel F.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [McGuinness, Shay P.; Parke, Rachael L.; McArthur, Colin J.] Auckland City Hosp, Auckland, New Zealand; [Middeldorp, Saskia; van de Veerdonk, Frank L.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Morpeth, Susan C.] Middlemore Hosp, Auckland, New Zealand; [Murthy, Srinivas] Univ British Columbia, Vancouver, BC, Canada; [Nichol, Alistair D.] Univ Coll Dublin, Dublin, Ireland; [Parke, Rachael L.] Univ Auckland, Auckland, New Zealand; [Reyes, Luis] Univ La Sabana, Chia, Colombia; [Reyes, Luis] Clin Univ La Sabana, Chia, Colombia; [Saito, Hiroki] St Marianna Univ, Sch Med, Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan; [Serpa-Neto, Ary] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Shankar-Hari, Manu] Kings Coll London, London, England; [Shankar-Hari, Manu] Guys & St Thomas NHS Fdn Trust, London, England; [Turgeon, Alexis F.] Univ Laval, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval Res Ctr, CHU Quebec, Quebec City, PQ, Canada; [Berry, Lindsay R.; Lorenzi, Elizabeth; Detry, Michelle A.; Fitzgerald, Mark; McGlothlin, Anna; Saunders, Christina T.; Lewis, Roger J.; Berry, Scott] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Webb, Steve A.] St John God Hosp, Subiaco, WA, Australia; [Gordon, Anthony C.] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England	University of Bristol; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Oxford; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Monash University; Intensive Care National Audit & Research Centre; Imperial College London; University of Manitoba; King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Utrecht University; Utrecht University Medical Center; Flinders University South Australia; Friedrich Schiller University of Jena; University of Ottawa; Ottawa Hospital Research Institute; National University of Singapore; University of Antwerp; University of Oxford; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tokyo; University of Sherbrooke; University of Western Australia; Queens University Belfast; Auckland City Hospital; Radboud University Nijmegen; University of British Columbia; University College Dublin; University of Auckland; Universidad de La Sabana; Universidad de La Sabana; Saint Marianna University; Hospital Israelita Albert Einstein; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Laval University; Laval University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; St John of God Health Care; Imperial College London	Bradbury, CA (corresponding author), Bristol Haematol & Oncol Ctr, Horfield Rd, Bristol BS2 8ED, Avon, England.	c.bradbury@bristol.ac.uk	Dushianthan, Ahilanandan/T-8390-2019; Derde, Lennie/AAF-2725-2021; Neal, Matthew/GMW-5601-2022; Leaf, David/AAO-8977-2021; Middeldorp, Saskia/ABI-8197-2020; Veenith, Tonny/A-9948-2010; Gordon, Anthony/A-3472-2012; Presneill, Jeffrey/B-4894-2012; Summers, Charlotte/A-6973-2012; litton, edward/C-5384-2017	Dushianthan, Ahilanandan/0000-0002-0165-3359; Derde, Lennie/0000-0002-3577-5629; Neal, Matthew/0000-0001-8931-6236; Leaf, David/0000-0001-7875-090X; Middeldorp, Saskia/0000-0002-1006-6420; Veenith, Tonny/0000-0002-4125-8804; Gordon, Anthony/0000-0002-0419-547X; Duffy, Eamon/0000-0002-4515-5116; Rowan, Kathryn/0000-0001-8217-5602; Hills, Thomas/0000-0003-0322-5822; Dark, Paul/0000-0003-3309-0164; Jayakumar, Devachandran/0000-0001-7134-3746; Presneill, Jeffrey/0000-0001-7177-7667; Summers, Charlotte/0000-0002-7269-2873; Ustianowski, Andrew/0000-0002-6134-7855; Malley, Brian/0000-0002-1731-1046; Lamontagne, Francois/0000-0002-0360-3427; Young, Paul/0000-0002-3428-3083; Waite, Alicia/0000-0001-8734-994X; Mouncey, Paul/0000-0002-8510-8517; Ichihara, Nao/0000-0002-6902-2342; Hormis, Anil/0000-0001-5510-7639; Binnie, Alexandra/0000-0003-2969-8177; Vodovar, Dominique/0000-0002-8196-5511; Nichol, Alistair/0000-0002-4689-1238; Murthy, Srinivas/0000-0002-9476-839X; Beane, Abigail/0000-0001-7046-1580; Acquah, Ronald/0000-0002-5375-6106; Hunt, Beverley Jane/0000-0002-4709-0774; litton, edward/0000-0002-5125-6829; Jhanji, Shaman/0000-0002-1116-628X	Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) consortium of the European Union, FP7-HEALTH-2013-INNOVATION-1 [602525]; Rapid European COVID-19 Emergency Research Response (RECOVER) consortium of the European Union's Horizon 2020 Research and Innovation Programme [101003589]; Australian National Health and Medical Research Council [APP1101719]; Health Research Council of New Zealand [16/631]; Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program [158584]; NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland [CTN 2014-012]; University of Pittsburgh Medical Center (UPMC) Learning While Doing Program; Translational Breast Cancer Research Consortium; French Ministry of Health [PHRC-20-0147]; Minderoo Foundation; Wellcome Trust Innovations Project [215522]; NIHR clinician scientist fellowship [CS-2016-16-011]; NIHR [RP-2015-06-18]	Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) consortium of the European Union, FP7-HEALTH-2013-INNOVATION-1; Rapid European COVID-19 Emergency Research Response (RECOVER) consortium of the European Union's Horizon 2020 Research and Innovation Programme; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program(Canadian Institutes of Health Research (CIHR)); NIHR(National Institute for Health Research (NIHR)); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; University of Pittsburgh Medical Center (UPMC) Learning While Doing Program; Translational Breast Cancer Research Consortium; French Ministry of Health; Minderoo Foundation; Wellcome Trust Innovations Project(Wellcome Trust); NIHR clinician scientist fellowship; NIHR(National Institute for Health Research (NIHR))	This study was funded by the following: the Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) consortium of the European Union, FP7-HEALTH-2013-INNOVATION-1 (grant 602525), the Rapid European COVID-19 Emergency Research Response (RECOVER) consortium of the European Union's Horizon 2020 Research and Innovation Programme (grant 101003589), the Australian National Health and Medical Research Council (grant APP1101719), the Health Research Council of New Zealand (grant 16/631), the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program (grant 158584), the NIHR and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (grant CTN 2014-012), the University of Pittsburgh Medical Center (UPMC) Learning While Doing Program, the Translational Breast Cancer Research Consortium, the French Ministry of Health (grant PHRC-20-0147), the Minderoo Foundation, and theWellcome Trust Innovations Project (grant 215522). Dr Shankar-Hari is funded by an NIHR clinician scientist fellowship (grant CS-2016-16-011) and Dr Gordon is funded by an NIHR research professorship (grant RP-2015-06-18).	Akinosoglou K, 2014, THROMB RES, V133, P131, DOI 10.1016/j.thromres.2013.07.002; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD; Arabi YM, 2021, INTENS CARE MED, V47, P867, DOI 10.1007/s00134-021-06448-5; Berger JS, 2022, JAMA-J AM MED ASSOC, V327, P227, DOI 10.1001/jama.2021.23605; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Bilaloglu S, 2020, JAMA-J AM MED ASSOC, V324, P799, DOI 10.1001/jama.2020.13372; Chow JH, 2021, ANESTH ANALG, V132, P930, DOI 10.1213/ANE.0000000000005292; Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014; Estcourt LJ, 2021, JAMA-J AM MED ASSOC, V326, P1690, DOI 10.1001/jama.2021.18178; Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002; Godoy LC, 2020, CAN MED ASSOC J, V192, pE1156, DOI 10.1503/cmaj.201240; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gomez K, 2021, BRIT J HAEMATOL, V192, P459, DOI 10.1111/bjh.17241; Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Morris G, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118617; O'Sullivan JM, 2020, LANCET HAEMATOL, V7, pE553, DOI 10.1016/S2352-3026(20)30215-5; Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850; Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854; Rapkiewicz AV, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100434; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Shah A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03260-3; Shaw RJ, 2021, BRIT J HAEMATOL, V194, P518, DOI 10.1111/bjh.17664; Sholzberg M, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2400; Spaetgens B, 2022, JAMA-J AM MED ASSOC, V327, P223, DOI 10.1001/jama.2021.23866; Spyropoulos AC, 2021, JAMA INTERN MED, V181, P1612, DOI 10.1001/jamainternmed.2021.6203; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703	42	26	26	5	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13					1247	1259		10.1001/jama.2022.2910	http://dx.doi.org/10.1001/jama.2022.2910		MAR 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35315874	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000772989300002
J	Vos, R; Boesten, J; van den Akker, M				Vos, Rein; Boesten, Jos; van den Akker, Marjan			Fifteen-year trajectories of multimorbidity and polypharmacy in Dutch primary care-A longitudinal analysis of age and sex patterns	PLOS ONE			English	Article							GENERAL-PRACTICE; REGISTRATION NETWORK; MEDICAL-EDUCATION; HEALTH; EPIDEMIOLOGY	Objective After stratifying for age, sex and multimorbidity at baseline, our aim is to analyse time trends in incident multimorbidity and polypharmacy in the 15-year clinical trajectories of individual patients in a family medicine setting. Methods This study was carried out using data from the Registration Network Family Medicine in the South of the Netherlands. The clinical trajectories of 10037 subjects during the 15-year period (2000-2014) were analyzed in a repeated measurement of using a generalized estimating equations model as well as a multilevel random intercept model with repeated measurements to determine patterns of incident multimorbidity and polypharmacy. Hierarchical age-period-cohort models were used to generate age and cohort trajectories for comparison with prevalence trends in multimorbidity literature. Results Multimorbidity was more common in females than in males throughout the duration of the 15-year trajectory (females: 39.6%; males: 33.5%). With respective ratios of 11.7 and 5.9 between the end and the beginning of the 15-year period, the youngest female and male groups showed a substantial increase in multimorbidity prevalence. Ratios in the oldest female and male groups were 2.2 and 1.9 respectively. Females had higher levels of multimorbidity than males in the 0-24-year and 25-44-year age groups, but the levels converged to a prevalence of 92.2% in the oldest male and 90.7% in the oldest female group. Similar, albeit, moderate differences were found in polypharmacy patterns. Conclusions We sought to specify the progression of multimorbidity from an early age. As a result, our study adds to the multimorbidity literature by specifying changes in chronic disease accumulation with relation to polypharmacy, and by tracking differences in patient trajectories according to age and sex. Multimorbidity and polypharmacy are common and their prevalence is accelerating, with a relatively rapid increase in younger groups. From the point of view of family medicine, this underlines the need for a longitudinal approach and a life course perspective in patient care.	[Vos, Rein] Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands; [Boesten, Jos; van den Akker, Marjan] Maastricht Univ, Care & Publ Hlth Res Inst, Dept Family Med, Maastricht, Netherlands; [van den Akker, Marjan] Goethe Univ Frankfurt, Inst Gen Practice, Frankfurt, Germany; [van den Akker, Marjan] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Acad Ctr Gen Practice, Leuven, Belgium	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Goethe University Frankfurt; KU Leuven	van den Akker, M (corresponding author), Maastricht Univ, Care & Publ Hlth Res Inst, Dept Family Med, Maastricht, Netherlands.; van den Akker, M (corresponding author), Goethe Univ Frankfurt, Inst Gen Practice, Frankfurt, Germany.; van den Akker, M (corresponding author), Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Acad Ctr Gen Practice, Leuven, Belgium.	m.vandenAkker@allgemeinmedizin.uni-frankfurt.de						Allison PD, 2014, QUANTITATIVE APPL SO, V2; Ashworth Mark, 2019, BMJ Open, V9, pe031649, DOI 10.1136/bmjopen-2019-031649; Bakaki PM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208047; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bell A, 2014, SOC SCI MED, V120, P21, DOI 10.1016/j.socscimed.2014.09.008; Bjur Kara A, 2019, Hosp Pediatr, V9, P281, DOI 10.1542/hpeds.2018-0091; Canizares M, 2018, J GERONTOL B-PSYCHOL, V73, P1303, DOI 10.1093/geronb/gbx004; Department of Family Medicine Maastricht University The Netherlands, RES NETW FAM MED RNF; Department of General Practice KU Leuven Belgium, INT PROJ; Falster MO, 2021, BRIT J CLIN PHARMACO, V87, P1264, DOI 10.1111/bcp.14504; Feng X, 2018, POPUL HEALTH MANAG, V21, P123, DOI 10.1089/pop.2017.0065; Ferro MA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-034544; Guisado-Clavero M, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0705-7; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Heck RH, 2012, QUANT METH SER, P1; Heck RH, 2010, QUANT METH SER, P1; Horace AE, 2020, PEDIATR DRUGS, V22, P85, DOI 10.1007/s40272-019-00372-4; Gonzalez AI, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-034485; Kendir C, 2017, EUR J GEN PRACT, V24, P45, DOI 10.1080/13814788.2017.1398318; Kostev K, 2018, EUR J INTERN MED, V55, P66, DOI 10.1016/j.ejim.2018.07.014; Kudesia Prtha, 2021, J Multimorb Comorb, V11, p26335565211032880, DOI 10.1177/26335565211032880; Lash TL., 2021, MODERN EPIDEMIOLOGY, V4th; Leitliniengruppe Hessen DEGAM, 2021, S3 LEITL MULT; Makovski TT, 2019, AGEING RES REV, V53, DOI 10.1016/j.arr.2019.04.005; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Maxwell CJ, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250567; McGrail K, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1312; Meinow B, 2015, EUR J AGEING, V12, P285, DOI 10.1007/s10433-015-0351-2; Melis R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103120; Metsemakers JFM, 1996, INT J BIOMED COMPUT, V42, P43, DOI 10.1016/0020-7101(96)01180-4; METSEMAKERS JFM, 1992, BRIT J GEN PRACT, V42, P102; Muth C, 2019, J INTERN MED, V285, P272, DOI 10.1111/joim.12842; Nguyen TN, 2019, FAM PRACT, V36, P706, DOI 10.1093/fampra/cmz023; Oktora MP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214240; Romano I, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043124; Scottish Government Polypharmacy Model of Care Group, 2018, POL GUID REAL PRESCR, V3rd; Shi Xi., 2020, J GERONTOL A, V20, P1; Singh-Manoux A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002571; Sinnott Carol, 2015, J Comorb, V5, P29, DOI 10.15256/joc.2015.5.51; Soysal P, 2019, EXP GERONTOL, V120, P62, DOI 10.1016/j.exger.2019.02.019; St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006413; Truyers C, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-48; Uijen Annemarie A, 2008, Eur J Gen Pract, V14 Suppl 1, P28, DOI 10.1080/13814780802436093; van den Akker M, 1998, J CLIN EPIDEMIOL, V51, P367, DOI 10.1016/S0895-4356(97)00306-5; van den Akker M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212046; Van der Akker M, 1996, EUR J GEN PRACT, V2, P65, DOI 10.3109/13814789609162146; van Oostrom SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160264; Vetrano DL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16780-x; Vetrano DL, 2018, J AM MED DIR ASSOC, V19, P710, DOI 10.1016/j.jamda.2018.04.008; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Vos R, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-014-0213-6; Ware D, 2019, AIDS PATIENT CARE ST, V33, P354, DOI 10.1089/apc.2019.0057; Westergaard D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08475-9; Westert GP, 2005, EUR J PUBLIC HEALTH, V15, P59, DOI 10.1093/eurpub/cki116; WHO Collaborating Drug Statistics Methodology, 1997, AN THER CHEM ATC CLA; Zemedikun DT, 2018, MAYO CLIN PROC, V93, P857, DOI 10.1016/j.mayocp.2018.02.012	56	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0264343	10.1371/journal.pone.0264343	http://dx.doi.org/10.1371/journal.pone.0264343			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0U7EE	35213615	Green Published, gold			2023-01-03	WOS:000787811000078
J	Dahl, D; Onishi, Y; Norwood, P; Huh, R; Bray, R; Patel, H; Rodriguez, A				Dahl, Dominik; Onishi, Yukiko; Norwood, Paul; Huh, Ruth; Bray, Ross; Patel, Hiren; Rodriguez, Angel			Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEPTIDE-1 RECEPTOR AGONIST; THERAPY; EFFICACY; SAFETY	IMPORTANCE The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described. OBJECTIVE To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control. DESIGN, SETTING, AND PARTICIPANTS Randomized phase 3 clinical trial conducted at 45 medical research centers and hospitals in 8 countries (enrollment from August 30, 2019, to March 20, 2020; follow-up completed January 13, 2021) in 475 adults with type 2 diabetes and inadequate glycemic control while treated with once-daily insulin glargine with or without metformin. INTERVENTIONS Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg (n = 116), 10-mg (n = 119), or 15-mg (n = 120) tirzepatide or volume-matched placebo (n = 120) over 40 weeks. Tirzepatide was initiated at 2.5mg/week and escalated by 2.5mg every 4 weeks until the assigned dose was achieved. MAIN OUTCOMES AND MEASURES The primary end pointwas mean change from baseline in glycated hemoglobin A1c (HbA1c) at week 40. The 5 key secondary end points included mean change in body weight and percentage of patients achieving prespecified HbA1c levels. RESULTS Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group. At week 40, mean HbA1c change from baseline was -2.40% with 10-mg tirzepatide and -2.34% with 15-mg tirzepatide vs -0.86% with placebo (10mg: difference vs placebo, -1.53%[97.5% CI, -1.80% to -1.27%]; 15mg: difference vs placebo, -1.47%[97.5% CI, -1.75% to -1.20%]; P<.001 for both). Mean HbA1c change from baseline was -2.11% with 5-mg tirzepatide (difference vs placebo, -1.24%[95% CI, -1.48% to -1.01%]; P<.001]). Mean body weight change from baseline was -5.4 kg with 5-mg tirzepatide, -7.5 kg with 10-mg tirzepatide, -8.8 kg with 15-mg tirzepatide and 1.6 kg with placebo (5mg: difference, -7.1 kg [95% CI, -8.7 to -5.4]; 10mg: difference, -9.1 kg [95% CI, -10.7 to -7.5]; 15mg: difference, -10.5 kg [95% CI, -12.1 to -8.8]; P<.001 for all). Higher percentages of patients treated with tirzepatide vs those treated with placebo had HbA1c less than 7%(85%-90% vs 34%; P<.001 for all). The most common treatment-emergent adverse events in the tirzepatide groups vs placebo group were diarrhea (12%-21% vs 10%) and nausea (13%-18% vs 3%). CONCLUSIONS AND RELEVANCE Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks.	[Dahl, Dominik] Gemeinschaftspraxis Innere Med & Diabetol, Hamburg, Germany; [Onishi, Yukiko] Asahi Life Fdn, Inst Med Sci, Tokyo, Japan; [Norwood, Paul] Valley Endocrine & Res, Fresno, CA USA; [Huh, Ruth; Bray, Ross; Patel, Hiren] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Rodriguez, Angel] Lilly Spain, Ave Ind 30, Madrid 28108, Spain	Asahi Life Foundation; Eli Lilly	Rodriguez, A (corresponding author), Lilly Spain, Ave Ind 30, Madrid 28108, Spain.	rodriguez_angel@lilly.com			Eli Lilly and Company	Eli Lilly and Company(Eli Lilly)	This study was sponsored by Eli Lilly and Company.	Baggio LL, 2020, MOL METAB, V46, DOI 10.1016/j.molmet.2020.101090; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Del Prato S, 2021, LANCET, V398, P1811, DOI 10.1016/S0140-6736(21)02188-7; Frias JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519; Frias JP, 2018, LANCET, V392, P2180, DOI 10.1016/S0140-6736(18)32260-8; Gasbjerg LS, 2019, DIABETES, V68, P906, DOI 10.2337/db18-1123; Huthmacher JA, 2020, DIABETES CARE, V43, P2303, DOI 10.2337/dc20-0498; Ludvik B, 2021, LANCET, V398, P583, DOI 10.1016/S0140-6736(21)01443-4; Nauck MA, 2018, DIABETES OBES METAB, V20, P5, DOI 10.1111/dom.13129; Pozzilli P, 2017, DIABETES OBES METAB, V19, P1024, DOI 10.1111/dom.12937; Rodbard HW, 2018, J CLIN ENDOCR METAB, V103, P2291, DOI 10.1210/jc.2018-00070; Rosenstock J, 2021, LANCET, V398, P143, DOI 10.1016/S0140-6736(21)01324-6; Rosenstock J, 2020, DIABETES CARE, V43, P2509, DOI 10.2337/dc19-2316; Swinnen SG, 2009, DIABETES CARE, V32, pS253, DOI 10.2337/dc09-S318; Yu M, 2017, CLIN THER, V39, P2399, DOI 10.1016/j.clinthera.2017.11.001; Zinman B, 2019, DIABETES CARE, V42, P2262, DOI 10.2337/dc19-0898	16	38	38	12	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2022	327	6					534	545		10.1001/jama.2022.0078	http://dx.doi.org/10.1001/jama.2022.0078			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD5RT	35133415	Bronze, Green Published			2023-01-03	WOS:000758257900012
J	O'Regan, A; O'Doherty, J; O'Connor, R; Cullen, W; Niranjan, V; Glynn, L; Hannigan, A				O'Regan, Andrew; O'Doherty, Jane; O'Connor, Ray; Cullen, Walter; Niranjan, Vikram; Glynn, Liam; Hannigan, Ailish			How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations	PLOS ONE			English	Article							HEALTH-CARE UTILIZATION; MULTIMORBIDITY; PREVALENCE; WORKLOAD; PRACTITIONERS; ENGLAND; WORKING; BURNOUT	Background As prevalence of multimorbidity and polypharmacy rise, health care systems must respond to these challenges. Data is needed from general practice regarding the impact of age, number of chronic illnesses and medications on specific metrics of healthcare utilisation. Methods This was a retrospective study of general practices in a university-affiliated education and research network, consisting of 72 practices. Records from a random sample of 100 patients aged 50 years and over who attended each participating practice in the previous two years were analysed. Through manual record searching, data were collected on patient demographics, number of chronic illnesses and medications, numbers of attendances to the general practitioner (GP), practice nurse, home visits and referrals to a hospital doctor. Attendance and referral rates were expressed per person-years for each demographic variable and the ratio of attendance to referral rate was also calculated. Results Of the 72 practices invited to participate, 68 (94%) accepted, providing complete data on a total of 6603 patients' records and 89,667 consultations with the GP or practice nurse; 50.1% of patients had been referred to hospital in the previous two years. The attendance rate to general practice was 4.94 per person per year and the referral rate to the hospital was 0.6 per person per year, giving a ratio of over eight attendances for every referral. Increasing age, number of chronic illnesses and number of medications were associated with increased attendance rates to the GP and practice nurse and home visits but did not significantly increase the ratio of attendance to referral rate. Discussion As age, morbidity and number of medications rise, so too do all types of consultations in general practice. However, the rate of referral remains relatively stable. General practice must be supported to provide person centred care to an ageing population with rising rates of multi-morbidity and polypharmacy.	[O'Regan, Andrew; O'Doherty, Jane; O'Connor, Ray; Glynn, Liam; Hannigan, Ailish] Univ Limerick, Fac Educ & Hlth Sci, Sch Med, Hlth Res Inst, Limerick, Ireland; [Cullen, Walter] Univ Coll Dublin, Hlth Sci Ctr, Sch Med, Dublin, Ireland; [Niranjan, Vikram] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Sports Sci, Dublin, Ireland; [Glynn, Liam] Hlth Res Board Primary Care Clin Trial Network, Galway, Ireland	University of Limerick; University College Dublin; University College Dublin	O'Regan, A (corresponding author), Univ Limerick, Fac Educ & Hlth Sci, Sch Med, Hlth Res Inst, Limerick, Ireland.	andrew.oregan@ul.ie		Glynn, Liam/0000-0002-6153-9363; Cullen, Walter/0000-0003-1838-5052; O'Regan, Andrew/0000-0001-8470-2736; Niranjan, Vikram/0000-0003-2202-8250				Avery AJ, 2017, BRIT J GEN PRACT, V67, P390, DOI 10.3399/bjgp17X692201; Baird B, 2016, UNDERSTANDING PRESSU; Cassell A, 2018, BRIT J GEN PRACT, V68, pE245, DOI 10.3399/bjgp18X695465; Cohen J., 2013, STAT POWER ANAL BEHA; Croxson CHD, 2017, BRIT J GEN PRACT, V67, pE138, DOI 10.3399/bjgp17X688849; Curry N, 2016, FACT FICTION DEMAND; Dinsdale E, 2020, FAM PRACT, V37, P63, DOI 10.1093/fampra/cmz037; Fortin M, 2005, ANN FAM MED, V3, P223, DOI 10.1370/afm.272; Glynn LG, 2011, FAM PRACT, V28, P516, DOI 10.1093/fampra/cmr013; Hobbs FDR, 2016, LANCET, V387, P2323, DOI 10.1016/S0140-6736(16)00620-6; Hopman P, 2015, EUR J INTERN MED, V26, P190, DOI 10.1016/j.ejim.2015.02.006; Iacobucci G, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l531; Le Reste JY, 2013, J AM MED DIR ASSOC, V14, P319, DOI 10.1016/j.jamda.2013.01.001; Loeb DF, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0433-z; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; McInnes S, 2015, J ADV NURS, V71, P1973, DOI 10.1111/jan.12647; National Collaborating Centre for Mental Health (UK), 2010, DEPR AD CHRON PHYS H; O'Dea B, 2017, IRISH J MED SCI, V186, P447, DOI 10.1007/s11845-016-1407-9; O'Dowd T T, 2016, STRUCTURE GEN PRACTI; O'Regan A, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-020-1100-y; O'Regan A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3800-8; Palladino R, 2016, AGE AGEING, V45, P431, DOI 10.1093/ageing/afw044; Pedersen AF, 2020, BRIT J GEN PRACT, V70, pE95, DOI 10.3399/bjgp20X707837; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Ramage-Morin Pamela L, 2009, Health Rep, V20, P37; Reason B, 2012, FAM PRACT, V29, P427, DOI 10.1093/fampra/cmr124; Roland M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i942; Roland M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2510; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Sinnott C, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0322-1; Sinnott C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003610; Smith SM, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X514756; Svedahl ER, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0952-5; Sweeney AM, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-017-0523-x; Theile G, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-24; TILDA, DESIGN IRISH LONGITU, P53; van Oostrom SH, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-61; Vyas Ami, 2012, Int J Family Med, V2012, P193168, DOI 10.1155/2012/193168; Wallace E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h176	39	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2022	17	2							e0263258	10.1371/journal.pone.0263258	http://dx.doi.org/10.1371/journal.pone.0263258			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2V2QB	35113926	Green Published, gold			2023-01-03	WOS:000823694700069
J	Santos, A; Colaco, AR; Nielsen, AB; Niu, LL; Strauss, M; Geyer, PE; Coscia, F; Albrechtsen, NJW; Mundt, F; Jensen, LJ; Mann, M				Santos, Alberto; Colaco, Ana R.; Nielsen, Annelaura B.; Niu, Lili; Strauss, Maximilian; Geyer, Philipp E.; Coscia, Fabian; Albrechtsen, Nicolai J. Wewer; Mundt, Filip; Jensen, Lars Juhl; Mann, Matthias			A knowledge graph to interpret clinical proteomics data	NATURE BIOTECHNOLOGY			English	Article							PEPTIDE IDENTIFICATION; GENE; INHIBITION; EXPRESSION; SIGNATURES; MEDICINE; SCALE	A knowledge graph platform integrates proteomics with other omics data and biomedical databases. Implementing precision medicine hinges on the integration of omics data, such as proteomics, into the clinical decision-making process, but the quantity and diversity of biomedical data, and the spread of clinically relevant knowledge across multiple biomedical databases and publications, pose a challenge to data integration. Here we present the Clinical Knowledge Graph (CKG), an open-source platform currently comprising close to 20 million nodes and 220 million relationships that represent relevant experimental data, public databases and literature. The graph structure provides a flexible data model that is easily extendable to new nodes and relationships as new databases become available. The CKG incorporates statistical and machine learning algorithms that accelerate the analysis and interpretation of typical proteomics workflows. Using a set of proof-of-concept biomarker studies, we show how the CKG might augment and enrich proteomics data and help inform clinical decision-making.	[Santos, Alberto; Colaco, Ana R.; Nielsen, Annelaura B.; Niu, Lili; Strauss, Maximilian; Geyer, Philipp E.; Coscia, Fabian; Albrechtsen, Nicolai J. Wewer; Mundt, Filip; Jensen, Lars Juhl; Mann, Matthias] Univ Copenhagen, Fac Hlth Sci, NNF Ctr Prot Res, Copenhagen, Denmark; [Santos, Alberto] Univ Oxford, Li Ka Shing Big Data Inst, Oxford, England; [Santos, Alberto] Univ Copenhagen, Fac Hlth Sci, Ctr Hlth Data Sci, Copenhagen, Denmark; [Strauss, Maximilian; Geyer, Philipp E.] OmicEra Diagnost GmbH, Planegg, Germany; [Geyer, Philipp E.; Coscia, Fabian; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany; [Albrechtsen, Nicolai J. Wewer] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark; [Albrechtsen, Nicolai J. Wewer] Univ Copenhagen, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark	University of Copenhagen; University of Oxford; University of Copenhagen; Max Planck Society; University of Copenhagen; Rigshospitalet; University of Copenhagen	Santos, A; Mann, M (corresponding author), Univ Copenhagen, Fac Hlth Sci, NNF Ctr Prot Res, Copenhagen, Denmark.; Santos, A (corresponding author), Univ Oxford, Li Ka Shing Big Data Inst, Oxford, England.; Santos, A (corresponding author), Univ Copenhagen, Fac Hlth Sci, Ctr Hlth Data Sci, Copenhagen, Denmark.; Mann, M (corresponding author), Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany.	alberto.santos@sund.ku.dk; mmann@biochem.mpg.de	Strauss, Maximilian/GRR-3068-2022	Strauss, Maximilian/0000-0003-3320-6833; Santos, Alberto/0000-0002-9163-7730; Jensen, Lars Juhl/0000-0001-7885-715X; Wewer Albrechtsen, Nicolai/0000-0003-4230-5753; Coscia, Fabian/0000-0002-2244-5081	Max Planck Society	Max Planck Society(Max Planck SocietyFoundation CELLEX)	Open access funding provided by Max Planck Society.	Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Ahrens M, 2013, CELL METAB, V18, P296, DOI 10.1016/j.cmet.2013.07.004; Albrechtsen NJW, 2018, CELL SYST, V7, P601, DOI 10.1016/j.cels.2018.10.012; [Anonymous], 2016, NATURE, V533, P437, DOI 10.1038/533437a; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004; Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a; Balaur I, 2017, BIOINFORMATICS, V33, P1096, DOI 10.1093/bioinformatics/btw731; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Brisimi TS, 2018, INT J MED INFORM, V112, P59, DOI 10.1016/j.ijmedinf.2018.01.007; Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305; Chami I., 2022, J MACH LEARN RES, V23, P1; Chen FX, 2020, APSIPA TRANS SIGNAL, V9, DOI 10.1017/ATSIP.2020.13; Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5; Choi M, 2014, BIOINFORMATICS, V30, P2524, DOI 10.1093/bioinformatics/btu305; Cook HV, 2019, METHODS MOL BIOL, V1939, P73, DOI 10.1007/978-1-4939-9089-4_5; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; Coscia F, 2018, CELL, V175, P159, DOI 10.1016/j.cell.2018.08.065; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Demichev V, 2020, NAT METHODS, V17, P41, DOI 10.1038/s41592-019-0638-x; Deshmukh AS, 2019, CELL METAB, V30, P963, DOI 10.1016/j.cmet.2019.10.001; Doll S, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201800113; Doll S, 2018, MOL ONCOL, V12, P1296, DOI 10.1002/1878-0261.12326; Eichner H., 2019, PROC MACH LEARN SYST; Fabregat A, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005968; Filbin MR, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100287; Geyer PE, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910427; Geyer PE, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20156297; Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200; Giurgiu M, 2019, NUCLEIC ACIDS RES, V47, pD559, DOI 10.1093/nar/gky973; Griss J, 2014, MOL CELL PROTEOMICS, V13, P2765, DOI 10.1074/mcp.O113.036681; Grover A, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P855, DOI 10.1145/2939672.2939754; Hagberg Aric A., 2008, P 7 PYTHON SCI C, P11; Halu A, 2019, NPJ SYST BIOL APPL, V5, DOI 10.1038/s41540-019-0092-5; Han JF, 2015, AM J CANCER RES, V5, P945; Have CT, 2013, BIOINFORMATICS, V29, P3107, DOI 10.1093/bioinformatics/btt549; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Henke E, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00160; Himmelstein DS, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004259; Himmelstein DS, 2017, ELIFE, V6, DOI 10.7554/eLife.26726; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Kalin JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02242-4; Kong AT, 2017, NAT METHODS, V14, P513, DOI [10.1038/NMETH.4256, 10.1038/nmeth.4256]; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lazar C, 2016, J PROTEOME RES, V15, P1116, DOI 10.1021/acs.jproteome.5b00981; Lee JSH, 2018, CELL, V174, P1045, DOI 10.1016/j.cell.2018.08.012; Lehmann J, 2015, SEMANT WEB, V6, P167, DOI 10.3233/SW-140134; Leopold JA, 2018, CIRC RES, V122, P1302, DOI 10.1161/CIRCRESAHA.117.310782; Liben-Nowell D., 2004, LINK PREDICTION PROB; Mann M, 2021, CELL SYST, V12, P759, DOI 10.1016/j.cels.2021.06.006; Mendez KM, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1588-0; Mimasu S, 2010, BIOCHEMISTRY-US, V49, P6494, DOI 10.1021/bi100299r; Muller JB, 2020, NATURE, V582, P592, DOI 10.1038/s41586-020-2402-x; Mughal S, 2017, BIOINFORMATICS, V33, P3317, DOI 10.1093/bioinformatics/btx397; Nahnsen S, 2013, MOL CELL PROTEOMICS, V12, P549, DOI 10.1074/mcp.R112.025163; Nickel M, 2016, P IEEE, V104, P11, DOI 10.1109/JPROC.2015.2483592; Niu L, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188793; Nowak-Sliwinska P, 2019, BBA-REV CANCER, V1871, P434, DOI 10.1016/j.bbcan.2019.04.005; Pafilis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065390; Pan J, 2020, NATURE, V578, P559, DOI 10.1038/s41586-020-2016-3; Pei G, 2017, METHOD ENZYMOL, V585, P135, DOI 10.1016/bs.mie.2016.09.016; Perez-Riverol Y, 2020, J PROTEOME RES, V19, P3906, DOI 10.1021/acs.jproteome.0c00376; Perfetto L, 2016, NUCLEIC ACIDS RES, V44, pD548, DOI 10.1093/nar/gkv1048; Perkel JM, 2018, NATURE, V563, P145, DOI 10.1038/d41586-018-07196-1; Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021; Pletscher-Frankild S, 2015, METHODS, V74, P83, DOI 10.1016/j.ymeth.2014.11.020; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Rafehi Haloom, 2016, Non-Coding RNA, V2, P4, DOI 10.3390/ncrna2020004; Rule A, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007007; Sarvari J, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.8351; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shirakami Y, 2012, BBA-MOL CELL BIOL L, V1821, P124, DOI 10.1016/j.bbalip.2011.06.023; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Vashishta A, 2014, NEUROMOL MED, V16, P727, DOI 10.1007/s12017-014-8322-x; Veselkov K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45349-y; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Wang XQ, 2013, MOL CARCINOGEN, V52, P218, DOI 10.1002/mc.21846; Wilkinson Mark D, 2016, Sci Data, V3, P160018, DOI 10.1038/sdata.2016.18; Wittenbecher C, 2019, DIABETES, V68, P188, DOI 10.2337/db18-0620; Yoon Byoung-Ha, 2017, Genomics & Informatics, V15, P19, DOI 10.5808/GI.2017.15.1.19	85	12	12	41	70	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2022	40	5					692	+		10.1038/s41587-021-01145-6	http://dx.doi.org/10.1038/s41587-021-01145-6		JAN 2022	14	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	1L7FB	35102292	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000750630900002
J	Doherty, Z; Kippen, R; Bevan, D; Duke, G; Williams, S; Wilson, A; Pilcher, D				Doherty, Zakary; Kippen, Rebecca; Bevan, David; Duke, Graeme; Williams, Sharon; Wilson, Andrew; Pilcher, David			Long-term outcomes of hospital survivors following an ICU stay: A multi-centre retrospective cohort study	PLOS ONE			English	Article							CARDIAC-SURGERY; CRITICAL ILLNESS; INTENSIVE-CARE; POPULATION; PREDICTORS; MORTALITY; RISK	BackgroundThe focus of much Intensive Care research has been on short-term survival, which has demonstrated clear improvements over time. Less work has investigated long-term survival, and its correlates. This study describes long-term survival and identifies factors associated with time to death, in patients who initially survived an Intensive Care admission in Victoria, Australia. MethodsWe conducted a retrospective cohort study of adult patients discharged alive from hospital following admission to all Intensive Care Units (ICUs) in the state of Victoria, Australia between July 2007 and June 2018. Using the Victorian Death Registry, we determined survival of patients beyond hospital discharge. Comparisons between age matched cohorts of the general population were made. Cox regression was employed to investigate factors associated with long-term survival. ResultsA total of 130,775 patients from 23 ICUs were included (median follow-up 3.6 years post-discharge). At 1-year post-discharge, survival was 90% compared to the age-matched cohort of 98%. All sub-groups had worse long-term survival than their age-matched general population cohort, apart from elderly patients admitted following cardiac surgery who had better or equal survival. Multiple demographic, socio-economic, diagnostic, acute and chronic illness factors were associated with long-term survival. ConclusionsAustralian patients admitted to ICU who survive to discharge have worse long-term survival than the general population, except for the elderly admitted to ICU following cardiac surgery. These findings may assist during goal-of-care discussions with patients during an ICU admission.	[Doherty, Zakary; Kippen, Rebecca] Monash Univ, Sch Rural Hlth, Melbourne, Vic, Australia; [Doherty, Zakary; Pilcher, David] Alfred Hlth, Melbourne, Vic, Australia; [Bevan, David; Williams, Sharon] Dept Hlth & Human Serv, Melbourne, Vic, Australia; [Duke, Graeme] Eastern Hlth, Melbourne, Vic, Australia; [Wilson, Andrew; Pilcher, David] Safer Care Victoria, Melbourne, Vic, Australia; [Pilcher, David] Ctr Outcome & Resource Evaluat, Australian & New Zealand Intens Care Soc ANZICS, Melbourne, Vic, Australia; [Pilcher, David] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia	Monash University; Monash University	Doherty, Z (corresponding author), Monash Univ, Sch Rural Hlth, Melbourne, Vic, Australia.; Doherty, Z (corresponding author), Alfred Hlth, Melbourne, Vic, Australia.	zak.doherty@monash.edu		Doherty, Zakary/0000-0001-6433-5123; Kippen, Rebecca/0000-0002-4823-5832				[Anonymous], 2020, REG POP AG SEX; ANZICS, 2018, CTR OUTC RES EV 2018; ANZICS, 2018, AD PAT DAT ACT REP 2; Australian Bureau of Statistics, 2020, AUSTR STAT GEOGR STA; Australian Bureau of Statistics, 2018, CENSUS POPULATION HO; Australian Bureau of Statistics, 2020, LIF TABL STAT TERR A; Brennan JM, 2012, CIRCULATION, V126, P1621, DOI 10.1161/CIRCULATIONAHA.112.091371; Cuthbertson BH, 2016, AM J RESP CRIT CARE, V194, P132, DOI 10.1164/rccm.201602-0257ED; Cuthbertson BH, 2013, CRIT CARE, V17, DOI 10.1186/cc12616; Department of Health, 2020, CTR VICT DAT LINK; Department of Health, 2020, VICT ADM EP DAT; Gabbe BJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002322; Ghanta RK, 2011, ANN THORAC SURG, V92, P851, DOI 10.1016/j.athoracsur.2011.04.083; Ghelani D, 2009, J EVAL CLIN PRACT, V15, P425, DOI 10.1111/j.1365-2753.2008.01030.x; Higgins AM, 2019, CRIT CARE MED, V47, P765, DOI 10.1097/CCM.0000000000003762; Hill AD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1248-y; Hodgson CL, 2018, J CRIT CARE, V48, P21, DOI 10.1016/j.jcrc.2018.08.005; Hodgson CL, 2017, INTENS CARE MED, V43, P992, DOI 10.1007/s00134-017-4830-0; Iwashyna TJ, 2016, LANCET RESP MED, V4, P566, DOI 10.1016/S2213-2600(16)30098-4; Jones JRA, 2019, CRIT CARE MED, V47, pE512, DOI 10.1097/CCM.0000000000003727; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Krane M, 2011, ANN THORAC SURG, V91, P506, DOI 10.1016/j.athoracsur.2010.10.041; Lokhandwala S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197226; Lone NI, 2016, AM J RESP CRIT CARE, V194, P198, DOI 10.1164/rccm.201511-2234OC; Moitra VK, 2016, CRIT CARE MED, V44, P655, DOI 10.1097/CCM.0000000000001480; Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735; Paul E, 2016, CRIT CARE RESUSC, V18, P25; Szakmany A, 2019, CRIT CARE MED, V47, P15, DOI 10.1097/CCM.0000000000003424; Ulvik A, 2007, ACTA ANAESTH SCAND, V51, P171, DOI 10.1111/j.1399-6576.2006.01207.x; Victorian State Government, 2020, VICT DEATH REG; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405	31	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0266038	10.1371/journal.pone.0266038	http://dx.doi.org/10.1371/journal.pone.0266038			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0V0SA	35344543	gold, Green Published			2023-01-03	WOS:000788055200015
J	Louw, A; Puentedura, EJ; Denninger, TR; Lutz, AD; Cox, T; Zimney, K; Landers, MR				Louw, Adriaan; Puentedura, Emilio J.; Denninger, Thomas R.; Lutz, Adam D.; Cox, Terry; Zimney, Kory; Landers, Merrill R.			The clinical impact of pain neuroscience continuing education on physical therapy outcomes for patients with low back and neck pain	PLOS ONE			English	Article							DISABILITY QUESTIONNAIRE; PREDICTION RULE; PRACTICE-GUIDELINES; IDENTIFY PATIENTS; RATING-SCALE; NUMERIC PAIN; MANAGEMENT; INDEX; RESPONSIVENESS; INTERVENTIONS	ObjectivesResearch suggests that attendance by physical therapists at continuing education (CE) targeting the management of low back pain (LBP) and neck pain does not result in positive impacts on clinical outcomes. The aim of this study was to determine if therapists attending a self-paced 3-hour online Pain Neuroscience Education (PNE) program was associated with any observed changes to patient outcomes and also clinical practice. MethodsParticipants were 25 different physical therapists who treated 3,705 patients with low back pain (LBP) or neck pain before and after they had completed an online PNE CE course. Change in outcomes measures of pain and disability at discharge were compared for the patients treated before and after the therapist training. Clinical practice patterns of the therapists, including total treatment visits, duration of care, total units billed, average units billed per visit, percentage of 'active' billing units and percentage of 'active and manual' billing units, were also compared for the patient care episodes before and after the therapist training. ResultsThere was no significant difference for change in pain scores at discharge for patients treated after therapist CE training compared to those treated before regardless of the condition (LBP or neck pain). However, patients with LBP who were treated after therapist CE training did report greater improvement in their disability scores. Also after CE training, for each episode of care, therapists tended to use less total visits, billed fewer units per visit, and billed a greater percentage of more 'active' and 'active and manual' billing units. DiscussionAttending an online 3-hour CE course on PNE resulted in improved disability scores for patients with LBP, but not for those with neck pain. Changes in clinical behavior by the therapists included using less visits, billing fewer total units, and shifting to more active and manual therapy interventions. Further prospective studies with control groups should investigate the effect of therapist CE on patient outcomes and clinical practice.	[Louw, Adriaan] Evidence Mot, Story City, IA USA; [Puentedura, Emilio J.] Baylor Univ, Robbins Coll Hlth & Human Sci, Dept Phys Therapy, Waco, TX 76798 USA; [Denninger, Thomas R.; Lutz, Adam D.] ATI Phys Therapy, Greenville, SC USA; [Cox, Terry] Southwest Baptist Univ, Dept Phys Therapy, Bolivar, MO USA; [Zimney, Kory] Univ South Dakota, Sch Hlth Sci, Dept Phys Therapy, Vermillion, SD USA; [Landers, Merrill R.] Univ Nevada, Sch Integrated Hlth Sci, Dept Phys Therapy, Las Vegas, NV 89154 USA	Baylor University; University of South Dakota; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Puentedura, EJ (corresponding author), Baylor Univ, Robbins Coll Hlth & Human Sci, Dept Phys Therapy, Waco, TX 76798 USA.	louie_puentedura@baylor.edu		Zimney, Kory/0000-0002-7513-2126; Puentedura, Emilio/0000-0003-4771-4732				[Anonymous], 1998, PHYSIOTHERAPY, V84, P27, DOI DOI 10.1016/S0031-9406(05)65900-7; Avins AL, 2007, CONTEMP CLIN TRIALS, V28, P557, DOI 10.1016/j.cct.2007.02.004; Bahreini M, 2020, AM J EMERG MED, V38, P1641, DOI 10.1016/j.ajem.2019.158489; Blanpied Peter R, 2017, J Orthop Sports Phys Ther, V47, pA1, DOI 10.2519/jospt.2017.0302; Brennan GP, 2006, PHYS THER, V86, P1251, DOI 10.2522/ptj.20050382; Brooks JM., 2021, CISC VIS NETW IND GL; Campbell P, 2017, J PAIN RES, V10, P2331, DOI 10.2147/JPR.S139445; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Chipchase LS, 2016, MANUAL THER, V25, P87, DOI 10.1016/j.math.2016.06.010; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Cleland JA, 2009, PHYS THER, V89, P38, DOI 10.2522/ptj.20080033; Cox T., 2017, ABBREVIATED THERAPEU, V25, P11; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Frost Helen, 2008, Spine (Phila Pa 1976), V33, P2450, DOI 10.1097/BRS.0b013e31818916fd; George SZ, 2021, J ORTHOP SPORT PHYS, V51, pCPG1, DOI 10.2519/jospt.2021.0304; Glasgow RE, 2013, JAIDS-J ACQ IMM DEF, V63, pS26, DOI 10.1097/QAI.0b013e3182920286; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Jorritsma W, 2012, EUR SPINE J, V21, P2550, DOI 10.1007/s00586-012-2407-8; Keedy Nicole H, 2014, Iowa Orthop J, V34, P158; Kleinsinger F, 2015, JAMA-J AM MED ASSOC, V314, P1073, DOI 10.1001/jama.2015.10220; Kovacs FM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-43; Leahy E, 2020, PHYS THER, V100, P1469, DOI 10.1093/ptj/pzaa107; Louw A., 2018, PAIN NEUROSCIENCE ED, V2nd, DOI [10.1097/j.pain.0000000000001198, DOI 10.1097/J.PAIN.0000000000001198]; Louw A, 2019, PAIN REHABILITATION, V46, P24; Louw A., 2013, WHY DO I HURT NEUROS; Louw A, 2020, PSYCHOL DISORDERS RE, V3, P1; Louw A, 2019, CLIN J PAIN, V35, P901, DOI 10.1097/AJP.0000000000000756; Louw A, 2016, PHYSIOTHER THEOR PR, V32, P385, DOI 10.1080/09593985.2016.1194652; Louw A, 2016, PHYSIOTHER THEOR PR, V32, P328, DOI 10.1080/09593985.2016.1194669; Louw A, 2014, PHYSIOTHER THEOR PR, V30, P588, DOI 10.3109/09593985.2014.912255; Louw A, 2013, AM J PHYS MED REHAB, V92, P446, DOI 10.1097/PHM.0b013e3182876aa4; Louw A, 2011, ARCH PHYS MED REHAB, V92, P2041, DOI 10.1016/j.apmr.2011.07.198; Lutz AD, 2020, PHYS THER, V100, P609, DOI 10.1093/ptj/pzaa019; Malfliet A, 2018, JAMA NEUROL, V75, P808, DOI 10.1001/jamaneurol.2018.0492; McMahon GT, 2018, JAMA-J AM MED ASSOC, V319, P545, DOI 10.1001/jama.2017.19954; Moseley GL, 2007, PHYS THER REV, V12, P169, DOI 10.1179/108331907X223010; Moseley L, 2003, J PAIN, V4, P184, DOI 10.1016/S1526-5900(03)00488-7; Nissen SE, 2015, JAMA-J AM MED ASSOC, V313, P1813, DOI 10.1001/jama.2015.4138; Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2; Puentedura EJ, 2012, J ORTHOP SPORT PHYS, V42, P577, DOI 10.2519/jospt.2012.4243; Ryynanen K, 2021, SCAND J WORK ENV HEA, V47, P367, DOI 10.5271/sjweh.3959; Schwartz LM, 2013, JAMA-J AM MED ASSOC, V310, P2507, DOI 10.1001/jama.2013.281640; Shraim MA, 2020, CLIN J PAIN, V36, P793, DOI 10.1097/AJP.0000000000000860; Stevenson K, 2006, J EVAL CLIN PRACT, V12, P365, DOI 10.1111/j.1365-2753.2006.00565.x; Takasaki H, 2012, SPINE J, V12, P912, DOI 10.1016/j.spinee.2012.09.053; Watson JA, 2019, J PAIN; Wood L, 2019, EUR J PAIN, V23, P234, DOI 10.1002/ejp.1314; Young BA, 2009, SPINE J, V9, P802, DOI 10.1016/j.spinee.2009.06.002; Young IA, 2019, PHYSIOTHER THEOR PR, V35, P1328, DOI 10.1080/09593985.2018.1471763; Zimney Kory, 2018, S D Med, V71, P506; Zimney K, 2014, PHYSIOTHER THEOR PR, V30, P202, DOI 10.3109/09593985.2013.856508	53	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267157	10.1371/journal.pone.0267157	http://dx.doi.org/10.1371/journal.pone.0267157			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482780	Green Published, gold			2023-01-03	WOS:000794035700062
J	Park, HJ; Choi, D; Park, HA; Lee, CA				Park, Hye Ji; Choi, Daun; Park, Hang A.; Lee, Choung Ah			Nurse evaluation of stress levels during CPR training with heart rate variability using smartwatches according to their personality: A prospective, observational study	PLOS ONE			English	Article							UNIVERSITY	Background Cardiopulmonary resuscitation (CPR) is a very critical phenomenon, and to prepare for it, most nurses undertake simulation training, during which learners' stress levels should be managed. This study aims to evaluate nurses' stress levels during CPR simulation training using heart rate variability (HRV) measured with a smartwatch and to determine the correlation between individual personality traits and stress levels. Methods This prospective observational study was conducted from July 2020 to December 2021. For nurses participating in advanced life support training with more than six months of clinical experience, their stress levels while performing as a CPR team leader were measured. Regarding stress levels, heart rate data measured with a smartwatch were processed using Kubios HRV Standard software to generate HRV parameters. The personality of participants was evaluated using the Big Five personality test. The degree of stress according to personality was determined using HRV parameters. Consequently, the correlation between personality and stress according to the clinical experience of cardiac arrest was analyzed. Results Of the 132 participants, 91.7% were female, and the median age of the sample was 27 years. Agreeable personality had the highest score (32.84 +/- 3.83). LF power (r = 0.18, p = 0.04) and HF power (r = 0.20, p = 0.02) showed a significant positive correlation with the agreeableness trait. In subgroup analysis according to the cardiac arrest experience, the agreeableness trait had a positive correlation with a standard deviation of NN intervals (r = 0.24, p = 0.01), root-mean-square of successive differences (r = 0.23, p = 0.02), LF Power (r = 0.26, p = 0.01), and HF power (r = 0.23, p = 0.02), but a negative correlation with mean HR (r = -0.22, p = 0.03). Conclusion The clinical experience in cardiac arrest and agreeableness were related to acute stress during training. In the future, it is necessary to apply a scenario of a level suitable for individual personality and experience, and evaluate the level and achievement of students.	[Park, Hye Ji; Park, Hang A.; Lee, Choung Ah] Hallym Univ, Dongtan Sacred Heart Hosp, Dept Emergency Med, Hwaseong Si, Gyeonggi Do, South Korea; [Choi, Daun; Lee, Choung Ah] Hallym Dongtan Simulat Ctr, Hwaseong Si, Gyeonggi Do, South Korea	Hallym University	Lee, CA (corresponding author), Hallym Univ, Dongtan Sacred Heart Hosp, Dept Emergency Med, Hwaseong Si, Gyeonggi Do, South Korea.; Lee, CA (corresponding author), Hallym Dongtan Simulat Ctr, Hwaseong Si, Gyeonggi Do, South Korea.	cuccum@hanmail.net		LEE, Choung Ah/0000-0003-2487-8988; Park, Hang A/0000-0002-8714-0828				Akoglu H, 2018, TURK J EMERG MED, V18, P91, DOI 10.1016/j.tjem.2018.08.001; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Brugnera A, 2018, INT J PSYCHOPHYSIOL, V127, P17, DOI 10.1016/j.ijpsycho.2018.02.016; Caminal P, 2018, EUR J APPL PHYSIOL, V118, P669, DOI 10.1007/s00421-018-3808-0; Camm AJ, 1996, CIRCULATION, V93, P1043; Chalmers T, 2022, SENSORS-BASEL, V22, DOI 10.3390/s22010151; Cheng A, 2018, CIRCULATION, V138, pE82, DOI 10.1161/CIR.0000000000000583; Demirtas A, 2021, AUSTRALAS EMERG CARE, V24, P4, DOI 10.1016/j.auec.2020.08.005; Eden SK, 2022, BIOMETRICS, V78, P421, DOI 10.1111/biom.13453; Einspruch EL, 2007, RESUSCITATION, V74, P476, DOI 10.1016/j.resuscitation.2007.01.030; Hendrickse A D, 2001, J R Army Med Corps, V147, P173; Hengartner MP, 2017, STRESS HEALTH, V33, P35, DOI 10.1002/smi.2671; Hunziker S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-8; Ireland S, 2020, AUSTRALAS EMERG CARE, V23, P77, DOI 10.1016/j.auec.2019.11.001; Kim HG, 2018, PSYCHIAT INVEST, V15, P235, DOI 10.30773/pi.2017.08.17; 김선영, 2010, [Journal of Korean Society of Biological Psychiatry, 생물정신의학], V17, P15; LeBlanc VR, 2009, ACAD MED, V84, pS25, DOI 10.1097/ACM.0b013e3181b37b8f; Lin X, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252430; Okutsu Ayako, 2019, J Rural Med, V14, P236, DOI 10.2185/jrm.3020; Pervin L., 1999, HDB PERSONALITY THEO, V2nd; Power RA, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.96; Pryjmachuk S, 2008, MIDWIFERY, V24, P108, DOI 10.1016/j.midw.2006.07.006; Reevy G., 2011, PERSONALITY STRESS C; Salonen Anne H, 2007, J Nurs Manag, V15, P792, DOI 10.1111/j.1365-2934.2007.00768.x; Shaffer F, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01040; Siddiqui F, 2020, J PAK MED ASSOC, V70, P447, DOI 10.5455/JPMA.6674; Streiff S, 2011, SIMUL HEALTHC, V6, P78, DOI 10.1097/SIH.0b013e318209382b; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Tramer L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233155; Turki Ahmad, 2021, PETRA 2021: The 14th PErvasive Technologies Related to Assistive Environments Conference, P565, DOI 10.1145/3453892.3462647; Vincent A, 2021, J CRIT CARE, V63, P223, DOI 10.1016/j.jcrc.2020.09.020; Wan QF, 2019, NURSE EDUC PRACT, V38, P66, DOI 10.1016/j.nepr.2019.06.005; Yao YC, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3478-y; Yazdanian Arsalan, 2016, Iran J Nurs Midwifery Res, V21, P9, DOI 10.4103/1735-9066.174758; Yoo HH, 2021, MED PRIN PRACT, V30, P193, DOI 10.1159/000513781	35	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268928	10.1371/journal.pone.0268928	http://dx.doi.org/10.1371/journal.pone.0268928			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35675277	Green Published, gold			2023-01-03	WOS:000832307900067
J	Wasay, SA; Jan, SU; Akhtar, M; Noreen, S; Gul, R				Wasay, Syed Abdul; Jan, Syed Umer; Akhtar, Muhammad; Noreen, Sobia; Gul, Rahman			Developed meloxicam loaded microparticles for colon targeted delivery: Statistical optimization, physicochemical characterization, and in-vivo toxicity study	PLOS ONE			English	Article							POLYMETHACRYLATE MICROSPHERES; DRUG-DELIVERY; RS 100; RELEASE; VITRO; POLYMER; SYSTEM; CANCER; NANOPARTICLES; FORMULATIONS	The study aimed to fabricate and evaluate Meloxicam (MLX) loaded Hydroxypropyl Methylcellulose (HPMC) microparticles for colon targeting because MLX is a potent analgesic used in the treatment of pain and inflammation associated with colorectal cancer (CRC). Nevertheless, its efficiency is limited by poor solubility and gastrointestinal tracts (GIT) associated side effects. Seventeen formulations of MLX loaded HPMC microparticles were fabricated by the oil-in-oil (O/O)/ emulsion solvent evaporation (ESE) technique. A 3-factor, 3-level Box Behnken (BBD) statistical design was used to estimate the combined effects of the independent variables on the dependent variables (responses), such as the percent yield (R-1), the entrapment efficiency (EE) (R-2), mean particle size (R-3) and in vitro percentage of cumulative drug release (R-4). For physicochemical characterization FTIR, XRD, DSC, and SEM analyses were performed. Biocompatibility and non-toxicity were confirmed by in-vivo acute oral toxicity determination. The percentage yield and EE were 65.75-90.71%, and 70.62-88.37%, respectively. However, the mean particle size was 62.89-284.55 mu m, and the in vitro cumulative drug release percentage was 74.25-92.64% for 24 hours. FTIR analysis showed that the composition of the particles was completely compatible, while XRD analysis confirmed the crystalline nature of the pure drug and its transition into an amorphous state after formulation. DSC analysis revealed the thermal stability of the formulations. The SEM analysis showed dense spherical particles. The toxicity study in albino rabbits showed no toxicity and was found biocompatible. The histopathological evaluation showed no signs of altered patterns. Results of this study highlighted a standard colonic drug delivery system with the ability to improve patient adherence and reduce GIT drug-associated side effects in CRC treatment.	[Wasay, Syed Abdul; Jan, Syed Umer; Gul, Rahman] Univ Balochistan, Fac Pharm & Hlth Sci, Dept Pharmaceut, Quetta, Pakistan; [Akhtar, Muhammad; Noreen, Sobia] Islamia Univ Bahawalpur, Fac Pharm, Dept Pharmaceut, Bahawalpur, Pakistan; [Akhtar, Muhammad] Islamia Univ Bahawalpur, Fac Med & Allied Hlth Sci, Dept Med Lab Technol, Bahawalpur, Pakistan	University of Balochistan; Islamia University of Bahawalpur; Islamia University of Bahawalpur	Jan, SU (corresponding author), Univ Balochistan, Fac Pharm & Hlth Sci, Dept Pharmaceut, Quetta, Pakistan.	umer.pharm@um.uob.edu.pk	Noreen, Sobia/AAT-8296-2021	Noreen, Sobia/0000-0002-4407-6002; Jan, Syed Umer/0000-0002-7584-5740; Akhtar, Muhammad/0000-0003-1759-8224				Abadi SAH, 2022, INT J ENVIRON AN CH, V102, P546, DOI 10.1080/03067319.2020.1724983; Abd Elbary A, 2012, B FACULTY PHARM, V50, P89; Abdalla M. E., 2012, Journal of Biology, Agriculture and Healthcare, V2, P6; Al Hussein SM, 2017, REV CHIM-BUCHAREST, V68, P937; Ali L, 2015, CELL CHEM TECHNOL, V49, P143; Alvi Z, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13244350; Ambrus R, 2009, INT J PHARMACEUT, V381, P153, DOI 10.1016/j.ijpharm.2009.07.009; Behera BC, 2008, TROP J PHARM RES, V7, P879; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cardoso CG, 2020, RES VET SCI, V128, P177, DOI 10.1016/j.rvsc.2019.11.016; Chaisri Wasana, 2009, Current Drug Delivery, V6, P69; Chime S.A., 2013, RES J PHARM BIO CHEM, V4, P97, DOI DOI 10.1517/17425241003602259; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; da Silveira LM, 2018, EUR J PHARM SCI, V112, P146, DOI 10.1016/j.ejps.2017.11.015; Deshmukh RK, 2014, MAT SCI ENG C-MATER, V36, P320, DOI 10.1016/j.msec.2013.12.024; El-Badry M, 2008, B PHARM SCI, V31, P123; El-Bagory IM., 2007, SAUDI PHARM J, V15, P213; Emam MF, 2021, DRUG DEV IND PHARM, V47, P163, DOI 10.1080/03639045.2020.1862175; Eroglu H., 2009, HACETTEPE U J FACULT, P115; Fathanah Ana, 2019, J Basic Clin Physiol Pharmacol, V30, DOI 10.1515/jbcpp-2019-0249; Floyd JA, 2015, ADV DRUG DELIVER REV, V91, P23, DOI 10.1016/j.addr.2015.04.008; Freitas MN, 2005, INT J PHARMACEUT, V295, P201, DOI 10.1016/j.ijpharm.2005.03.003; Fu XC, 2004, J CONTROL RELEASE, V95, P209, DOI 10.1016/j.jconrel.2003.11.007; Gomez-Gaete C, 2017, EUR J PHARM SCI, V96, P390, DOI 10.1016/j.ejps.2016.10.010; Govender S, 2005, INT J PHARMACEUT, V306, P24, DOI 10.1016/j.ijpharm.2005.07.026; Hnatyszyn A, 2019, HERED CANCER CLIN PR, V17, DOI 10.1186/s13053-019-0118-4; Hong Y, 2005, POLYM ADVAN TECHNOL, V16, P622, DOI 10.1002/pat.629; Hussain Z, 2021, J CONTROL RELEASE, V335, P130, DOI 10.1016/j.jconrel.2021.05.018; Jayaramudu T, 2021, CARBOHYD POLYM, V254, DOI 10.1016/j.carbpol.2020.117302; Jose S., 2011, BIOINTERFACES, DOI [10.1016/j.colsurfb.2010.11.033, DOI 10.1016/J.COLSURFB.2010.11.033]; Kashif PM, 2017, AAPS PHARMSCITECH, V18, P1810, DOI 10.1208/s12249-016-0653-5; Khalil NY, 2020, PROF DRUG SUB EXCIP, V45, P159, DOI 10.1016/bs.podrm.2019.10.006; Khan KU, 2021, DRUG DEV IND PHARM, V47, P465, DOI 10.1080/03639045.2021.1892738; Kilicarslan M, 2003, INT J PHARM, V252, P99, DOI 10.1016/S0378-5173(02)00630-0; Kim BK, 2002, J MICROENCAPSUL, V19, P811, DOI 10.1080/0265204021000022770; Krishnamachari Y, 2007, INT J PHARM, V338, P238, DOI 10.1016/j.ijpharm.2007.02.015; Li CL, 2005, J PHARM PHARMACOL, V57, P533, DOI 10.1211/0022357055957; LIPMAN NS, 1990, LAB ANIM SCI, V40, P395; Maqbool I, 2020, EUR J PHARM SCI, V146, DOI 10.1016/j.ejps.2020.105254; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Martindale W., 2009, COMPLETE DRUG REFERE, V36 Edn.; Maskova E, 2020, J CONTROL RELEASE, V324, P695, DOI 10.1016/j.jconrel.2020.05.045; Meng FB, 2017, POWDER TECHNOL, V320, P405, DOI 10.1016/j.powtec.2017.07.073; Montejo C, 2010, INT J PHARMACEUT, V387, P223, DOI 10.1016/j.ijpharm.2009.11.036; Mujtaba A, 2014, CHEM ENG RES DES, V92, P156, DOI 10.1016/j.cherd.2013.05.032; Nagai N, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040313; Naidu NB, 2004, J PHARMACEUT BIOMED, V35, P75, DOI 10.1016/j.jpba.2004.01.003; Nanaki SG, 2012, CARBOHYD POLYM, V87, P1286, DOI 10.1016/j.carbpol.2011.09.013; Nandy BC, 2014, CURR DRUG DELIV, V11, P621, DOI 10.2174/1567201811666140519161628; Nhire N., 2014, PHARMA INNOVATION, V2; Nidhi, 2016, SAUDI PHARM J, V24, P458, DOI 10.1016/j.jsps.2014.10.001; Nielsen SS, 2020, EFSA J, V18, DOI 10.2903/j.efsa.2020.5943; Nohemann L, 2017, BRAZ J PHARM SCI, V53, DOI 10.1590/s2175-97902017000115218; Noreen S, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14060557; Oecd O, 2004, SECTION, V1, P1, DOI [10.1177/026119290403200304, DOI 10.1177/026119290403200304]; Osmani RAM, 2015, ASIAN J PHARM SCI, V10, P442, DOI 10.1016/j.ajps.2015.06.003; Padmavathy J., 2011, INT J PHARM PHARM SC, V3, P170; Patel MM, 2017, DRUG DELIV TRANSL RE, V7, P312, DOI 10.1007/s13346-017-0358-7; Patel MM, 2011, CARBOHYD POLYM, V86, P536, DOI 10.1016/j.carbpol.2011.04.068; Patel MM, 2009, PHARM DEV TECHNOL, V14, P62, DOI 10.1080/10837450802409412; Perumal D, 2001, INT J PHARM, V218, P1, DOI 10.1016/S0378-5173(00)00686-4; Prabu PC, 2013, PHYTOTHER RES, V27, P1169, DOI 10.1002/ptr.4854; Rai G, 2016, DRUG DELIV, V23, P328, DOI 10.3109/10717544.2014.913733; Raj, 2016, RES REV J DRUG FORMU, V3, P15; Reverchon E, 2008, J SUPERCRIT FLUID, V46, P185, DOI 10.1016/j.supflu.2008.04.010; Sadaquat H, 2021, INT J PHARMACEUT, V598, DOI 10.1016/j.ijpharm.2021.120363; Sadeghi M, 2010, TURK J CHEM, V34, P739, DOI 10.3906/kim-0910-21; Sanche L, 2016, RADIAT PHYS CHEM, V128, P36, DOI 10.1016/j.radphyschem.2016.05.008; Shahzad Y, 2018, INT J BIOL MACROMOL, V109, P963, DOI 10.1016/j.ijbiomac.2017.11.089; Shi YL, 2017, MAT SCI ENG C-MATER, V76, P975, DOI 10.1016/j.msec.2017.03.163; Sienel W, 2007, EUR J CARDIO-THORAC, V31, P522, DOI 10.1016/j.ejcts.2006.12.018; Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004; Sun L, 2017, ASIAN J PHARM SCI, V12, P418, DOI 10.1016/j.ajps.2017.04.002; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Thakkar H, 2004, J DRUG TARGET, V12, P549, DOI 10.1080/10611860400010630; Tuynman JB, 2004, CRIT REV ONCOL HEMAT, V52, P81, DOI 10.1016/j.critrevonc.2004.08.004; Udeh NE, 2018, AM J RES MED SCI, V3, P7; Vilos C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/672760; Wahab AA., 2013, INT J PHARM SCI REV, V21, P38; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Yu Q, 2018, ASIAN J PHARM SCI, V13, P518, DOI 10.1016/j.ajps.2017.10.004; Zhang L, 2011, J MICROENCAPSUL, V28, P659, DOI 10.3109/02652048.2011.604436	83	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267306	10.1371/journal.pone.0267306	http://dx.doi.org/10.1371/journal.pone.0267306			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D9PO	35468155	gold, Green Published			2023-01-03	WOS:000794129600027
J	Wang, ML; Jurczak, W; Jerkeman, M; Trotman, J; Zinzani, PL; Belada, D; Boccomini, C; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Hermine, O; Hernandez-Rivas, JA; Hong, XN; Kim, SJ; Lewis, D; Mishima, Y; Ozcan, M; Perini, GF; Pocock, C; Song, YQ; Spurgeon, SE; Storring, JM; Walewski, J; Zhu, J; Qin, R; Henninger, T; Deshpande, S; Howes, A; Le Gouill, S; Dreyling, M				Wang, Michael L.; Jurczak, Wojciech; Jerkeman, Mats; Trotman, Judith; Zinzani, Pier L.; Belada, David; Boccomini, Carola; Flinn, Ian W.; Giri, Pratyush; Goy, Andre; Hamlin, Paul A.; Hermine, Olivier; Hernandez-Rivas, Jose-Angel; Hong, Xiaonan; Kim, Seok Jin; Lewis, David; Mishima, Yuko; Ozcan, Muhit; Perini, Guilherme F.; Pocock, Christopher; Song, Yuqin; Spurgeon, Stephen E.; Storring, John M.; Walewski, Jan; Zhu, Jun; Qin, Rui; Henninger, Todd; Deshpande, Sanjay; Howes, Angela; Le Gouill, Steven; Dreyling, Martin		SHINE Investigators	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; TRANSPLANTATION; CHOP	BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma. METHODS We randomly assigned patients 65 years of age or older to receive ibrutinib (560 mg, administered orally once daily until disease progression or unacceptable toxic effects) or placebo, plus six cycles of bendamustine (90 mg per square meter of body-surface area) and rituximab (375 mg per square meter). Patients with an objective response (complete or partial response) received rituximab maintenance therapy, administered every 8 weeks for up to 12 additional doses. The primary end point was progression-free survival as assessed by the investigators. Overall survival and safety were also assessed. RESULTS Among 523 patients, 261 were randomly assigned to receive ibrutinib and 262 to receive placebo. At a median follow-up of 84.7 months, the median progression-free survival was 80.6 months in the ibrutinib group and 52.9 months in the placebo group (hazard ratio for disease progression or death, 0.75; 95% confidence interval, 0.59 to 0.96; P=0.01). The percentage of patients with a complete response was 65.5% in the ibrutinib group and 57.6 degrees Io in the placebo group (P=0.06). Overall survival was similar in the two groups. The incidence of grade 3 or 4 adverse events during treatment was 81.5% in the ibrutinib group and 77.3% in the placebo group. CONCLUSIONS Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs.	[Wang, Michael L.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA; [Jurczak, Wojciech] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland; [Walewski, Jan] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland; [Jerkeman, Mats] Skane Univ Hosp, Lund, Sweden; [Jerkeman, Mats] Lund Univ, Lund, Sweden; [Trotman, Judith] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia; [Giri, Pratyush] Royal Adelaide Hosp, Adelaide, SA, Australia; [Zinzani, Pier L.] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Ist Emarol Seagnoli, IRCCS Azienda Osped Univ Bologna, Bologna, Italy; [Boccomini, Carola] Azienda Osped Univ Cita Salute & Sci Torino, SC Ematol, Turin, Italy; [Belada, David] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic; [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA; [Flinn, Ian W.] Tennessee Oncol, Nashville, TN USA; [Goy, Andre] John Theurer Canc Ctr, Hackensack, NJ USA; [Qin, Rui; Henninger, Todd; Deshpande, Sanjay; Howes, Angela] Janssen Res & Dev, Raritan, NJ USA; [Hamlin, Paul A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Hermine, Olivier] Univ Paris, Hop Necker, AP HP, Dept Hematol, Paris, France; [Hermine, Olivier] Univ Paris, Inst Imagine, INSEAM Unite Mixte Rech 1183, Paris, France; [Le Gouill, Steven] Inst Curie Comprehens Canc Ctr, Paris, France; [Le Gouill, Steven] Univ Nantes, Hosp Univ Nantes, Ctr Rech Cancerol & Immunol Nantes Angers, INSERM, Nantes, France; [Hernandez-Rivas, Jose-Angel] Univ Complutense, Hosp Univ Infanta Leonor, Dept Hematol, Madrid, Spain; [Hong, Xiaonan] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Song, Yuqin; Zhu, Jun] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Kim, Seok Jin] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; [Lewis, David] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England; [Pocock, Christopher] Kent & Canterbury Hosp, Canterbury, New Zealand; [Mishima, Yuko] Canc Inst Hosp Japanese Fdn Canc Res, Dept Hematol Oncol, Tokyo, Japan; [Ozcan, Muhit] Ankara Univ, Sch Med, Ankara, Turkey; [Perini, Guilherme F.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil; [Spurgeon, Stephen E.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Storring, John M.] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Dreyling, Martin] Ludwig Maximilian Univ Munich, Klinikum Univ Munchen, Munich, Germany	University of Texas System; UTMD Anderson Cancer Center; Lund University; Skane University Hospital; Lund University; Concord Repatriation General Hospital; University of Sydney; Royal Adelaide Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; A.O.U. Citta della Salute e della Scienza di Torino; Charles University Prague; Sarah Cannon Research Institute; Tennessee Oncology; Johnson & Johnson; Janssen Pharmaceuticals; Memorial Sloan Kettering Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Complutense University of Madrid; Hospital Universitario Infanta Leonor; Fudan University; Sungkyunkwan University (SKKU); Samsung Medical Center; Japanese Foundation for Cancer Research; Ankara University; Hospital Israelita Albert Einstein; Oregon Health & Science University; McGill University; University of Munich	Wang, ML (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA.	miwang@mdanderson.org	Walewski, Jan/ABC-9523-2020; Hernandez-Rivas, Jose-Angel/ADF-6441-2022; Jurczak, Wojciech/ABB-2136-2020	Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Jurczak, Wojciech/0000-0003-1879-8084	Janssen Research and Development; Pharmacyclics	Janssen Research and Development; Pharmacyclics	Supported by Janssen Research and Development and Pharmacyclics.	Albertsson-Lindblad A, 2022, HAEMATOLOGICA, V107, P740, DOI 10.3324/haematol.2021.279037; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx289, 10.1093/annonc/mdx223]; Flinn IW, 2019, J CLIN ONCOL, V37, P984, DOI 10.1200/JCO.18.00605; Hermine O, 2016, LANCET, V388, P565, DOI 10.1016/S0140-6736(16)00739-X; Hill BT, 2019, HEMATOL ONCOL, V37, P405; Hlubocky FJ, 2013, LYMPHOMA, V54, P1, DOI DOI 10.1155/2013/1471766; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Jain P, 2019, AM J HEMATOL, V94, P710, DOI 10.1002/ajh.25487; Kluin-Nelemans HC, 2020, J CLIN ONCOL, V38, P248, DOI 10.1200/JCO.19.01294; Le Gouill S, 2017, NEW ENGL J MED, V377, P1250, DOI 10.1056/NEJMoa1701769; Maddocks K, 2015, BLOOD, V125, P242, DOI 10.1182/blood-2014-08-597914; Martin P, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.7504; McKay P, 2018, BRIT J HAEMATOL, V182, P46, DOI 10.1111/bjh.15283; Monga N, 2021, CRIT REV ONCOL HEMAT, V158, DOI 10.1016/j.critrevonc.2020.103212; National Comprehensive Cancer Network (NCCN), 2021, NCCN CLIN PRACTICE G; Robak T, 2019, LEUKEMIA LYMPHOMA, V60, P2622, DOI 10.1080/10428194.2019.1605511; Robak T, 2018, LANCET ONCOL, V19, P1449, DOI 10.1016/S1470-2045(18)30685-5; Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096; Rule S, 2018, LEUKEMIA, V32, P1799, DOI 10.1038/s41375-018-0023-2; Rule S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124691; Rummel MJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.7503; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220	24	8	8	3	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2022	386	26					2482	2494		10.1056/NEJMoa2201817	http://dx.doi.org/10.1056/NEJMoa2201817		JUN 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D8GD	35657079				2023-01-03	WOS:000806766100001
J	O'Dowd, A				O'Dowd, Adrian			All neighbourhoods need "single, urgent care teams" offering same day access, says review	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Fuller C, 2022, NEXT STEPS INTEGRATI	1	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2022	377								o1342	10.1136/bmj.o1342	http://dx.doi.org/10.1136/bmj.o1342			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3H7ZL	35623650				2023-01-03	WOS:000832250600011
J	Bradley, MC; Perez-Vilar, S; Chillarige, Y; Dong, D; Martinez, AI; Weckstein, AR; Dal Pan, GJ				Bradley, Marie C.; Perez-Vilar, Silvia; Chillarige, Yoganand; Dong, Diane; Martinez, Ashley I.; Weckstein, Andrew R.; Dal Pan, Gerald J.			Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Bradley, Marie C.; Perez-Vilar, Silvia; Dal Pan, Gerald J.] US FDA, Off Surveillance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA; [Chillarige, Yoganand] Acumen LLC, Burlingame, CA USA; [Dong, Diane] Dept Vet Affairs Ctr Medicat Safety, Hines, IL USA; [Martinez, Ashley I.] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Weckstein, Andrew R.] Aetion Inc, New York, NY USA	US Food & Drug Administration (FDA); Harvard University; Harvard Medical School	Bradley, MC (corresponding author), US FDA, Off Surveillance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA.	marie.bradley@fda.hhs.gov		Bradley, Marie/0000-0002-6266-4414	US Food and Drug Administration (FDA) [21-182]; Centers for Medicare & Medicaid Services (CMS) [75FCMC21F0067]; FDA; Centers for Drug Evaluation and Research [75F40119D10037]; US Department of Health and Human Services (DHHS) [75F40119F19001]	US Food and Drug Administration (FDA)(United States Department of Health & Human Services); Centers for Medicare & Medicaid Services (CMS); FDA(United States Department of Health & Human Services); Centers for Drug Evaluation and Research; US Department of Health and Human Services (DHHS)	This study was funded through interagency agreement 21-182 between the US Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) (task order 75FCMC21F0067) for which Acumen LLC is the contractor, with additional funding from the FDA and the Centers for Drug Evaluation and Research (contract 75F40119D10037). The Sentinel System Initiative is funded by the FDA through contract 75F40119F19001 from the US Department of Health and Human Services (DHHS).	Centers for Medicare and Medicaid Services, MED PROGR GEN INF; Cocoros NM, 2021, PHARMACOEPIDEM DR S, V30, P827, DOI 10.1002/pds.5240; Crothers K, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02532-2021; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; National Institutes of Health, THER MAN NONH COVID; RECOVERY, RAND EVAL COVID 19 T	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2022	327	20					2015	2018						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1Y7GZ	35394487	Bronze, Green Published			2023-01-03	WOS:000808309800028
J	Uraki, R; Kiso, M; Iida, S; Imai, M; Takashita, E; Kuroda, M; Halfmann, PJ; Loeber, S; Maemura, T; Yamayoshi, S; Fujisaki, S; Wang, ZD; Ito, M; Ujie, M; Iwatsuki-Horimoto, K; Furusawa, Y; Wright, R; Chong, ZL; Ozono, S; Yasuhara, A; Ueki, H; Sakai-Tagawa, Y; Li, R; Liu, YN; Larson, D; Koga, M; Tsutsumi, T; Adachi, E; Saito, M; Yamamoto, S; Hagihara, M; Mitamura, K; Sato, T; Hojo, M; Hattori, SI; Maeda, K; Valdez, R; Okuda, M; Murakami, J; Duong, C; Godbole, S; Douek, DC; Maeda, K; Watanabe, S; Gordon, A; Ohmagari, N; Yotsuyanagi, H; Diamond, MS; Hasegawa, H; Mitsuya, H; Suzuki, T; Kawaoka, Y				Uraki, Ryuta; Kiso, Maki; Iida, Shun; Imai, Masaki; Takashita, Emi; Kuroda, Makoto; Halfmann, Peter J.; Loeber, Samantha; Maemura, Tadashi; Yamayoshi, Seiya; Fujisaki, Seiichiro; Wang, Zhongde; Ito, Mutsumi; Ujie, Michiko; Iwatsuki-Horimoto, Kiyoko; Furusawa, Yuri; Wright, Ryan; Chong, Zhenlu; Ozono, Seiya; Yasuhara, Atsuhiro; Ueki, Hiroshi; Sakai-Tagawa, Yuko; Li, Rong; Liu, Yanan; Larson, Deanna; Koga, Michiko; Tsutsumi, Takeya; Adachi, Eisuke; Saito, Makoto; Yamamoto, Shinya; Hagihara, Masao; Mitamura, Keiko; Sato, Tetsuro; Hojo, Masayuki; Hattori, Shin-ichiro; Maeda, Kenji; Valdez, Riccardo; Okuda, Moe; Murakami, Jurika; Duong, Calvin; Godbole, Sucheta; Douek, Daniel C.; Maeda, Ken; Watanabe, Shinji; Gordon, Aubree; Ohmagari, Norio; Yotsuyanagi, Hiroshi; Diamond, Michael S.; Hasegawa, Hideki; Mitsuya, Hiroaki; Suzuki, Tadaki; Kawaoka, Yoshihiro		IASO Study Team	Characterization and antiviral susceptibility ofSARS-CoV-2 Omicron BA.2	NATURE			English	Article							SARS-COV-2; INFECTION	The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these variants(1,2). The original Omicron lineage, BA.1, prevailed in many countries, but more recently, BA.2 has become dominant in at least 68 countries(3). Here we evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters. In contrast to recent data with chimeric, recombinant SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an ancestral WK-521 backbone(4), we observed similar infectivity and pathogenicity in mice and hamsters for BA.2 and BA.1, and less pathogenicity compared with early SARS-CoV-2 strains. We also observed a marked and significant reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 compared to ancestral and Delta variant strains. In addition, we found that some therapeutic monoclonal antibodies (REGN10987 plus REGN10933, COV2-2196 plus COV2-2130, and S309) and antiviral drugs (molnupiravir, nirmatrelvir and S-217622) can restrict viral infection in the respiratory organs of BA.2-infected hamsters. These findings suggest that the replication and pathogenicity of BA.2 is similar to that of BA.1 in rodents and that several therapeutic monoclonal antibodies and antiviral compounds are effective against Omicron BA.2 variants.	[Uraki, Ryuta; Kiso, Maki; Imai, Masaki; Yamayoshi, Seiya; Ito, Mutsumi; Ujie, Michiko; Iwatsuki-Horimoto, Kiyoko; Furusawa, Yuri; Yasuhara, Atsuhiro; Ueki, Hiroshi; Sakai-Tagawa, Yuko; Yamamoto, Shinya; Okuda, Moe; Murakami, Jurika; Duong, Calvin; Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Div Virol, Tokyo, Japan; [Uraki, Ryuta; Imai, Masaki; Yamayoshi, Seiya; Ujie, Michiko; Furusawa, Yuri; Ueki, Hiroshi; Kawaoka, Yoshihiro] Natl Ctr Global Hlth, Med Res Inst, Res Ctr Global Viral Dis, Tokyo, Japan; [Iida, Shun; Ozono, Seiya; Suzuki, Tadaki] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan; [Takashita, Emi; Fujisaki, Seiichiro; Watanabe, Shinji; Hasegawa, Hideki] Natl Inst Infect Dis, Ctr Influenza & Resp Virus Res, Tokyo, Japan; [Kuroda, Makoto; Halfmann, Peter J.; Maemura, Tadashi; Wright, Ryan; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53705 USA; [Loeber, Samantha] Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI USA; [Wang, Zhongde; Li, Rong; Liu, Yanan; Larson, Deanna] Utah State Univ, Coll Agr & Appl Sci, Dept Anim Dairy & Vet Sci, Logan, UT USA; [Furusawa, Yuri] Kyoto Univ, Inst Frontier Life & Med Sci, Lab UltraStruct Virol, Kyoto, Japan; [Chong, Zhenlu; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO USA; [Koga, Michiko; Tsutsumi, Takeya; Saito, Makoto; Yamamoto, Shinya; Yotsuyanagi, Hiroshi] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Infect Dis, Tokyo, Japan; [Koga, Michiko; Tsutsumi, Takeya; Adachi, Eisuke; Saito, Makoto; Yotsuyanagi, Hiroshi] Univ Tokyo, IMSUT Hosp Inst Med Sci, Dept Infect Dis & Appl Immunol, Tokyo, Japan; [Hagihara, Masao] Eiju Gen Hosp, Dept Hematol, Tokyo, Japan; [Mitamura, Keiko] Eiju Gen Hosp, Div Infect Control, Tokyo, Japan; [Sato, Tetsuro; Ohmagari, Norio] Natl Ctr Global Hlth & Med Hosp, Dis Control & Prevent Ctr, Tokyo, Japan; [Hojo, Masayuki] Natl Ctr Global Hlth & Med Hosp, Dept Resp Med, Tokyo, Japan; [Hattori, Shin-ichiro; Maeda, Kenji; Mitsuya, Hiroaki] Natl Ctr Global Hlth, Dept Refractory Viral Infect, Tokyo, Japan; [Hattori, Shin-ichiro; Maeda, Kenji; Mitsuya, Hiroaki] Natl Ctr Global Hlth, Med Res Inst, Tokyo, Japan; [Valdez, Riccardo] Univ Michigan, Dept Pathol, Ann Arbor, MI USA; [Godbole, Sucheta; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD USA; [Maeda, Ken] Natl Inst Infect Dis, Dept Vet Sci, Tokyo, Japan; [Gordon, Aubree] Univ Michigan, Sch Publ Hlth, Dept Epidmiol, Ann Arbor, MI USA; [Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Diamond, Michael S.] Washington Univ, Dept Mol MicroBiol, Sch Med, St Louis, MO USA; [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO USA; [Mitsuya, Hiroaki] NCI, Expl Retrovirol Sect HIV & AIDS Malignancy Branch, NIH, Bethesda, MD USA	University of Tokyo; National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; Utah State University; Kyoto University; Washington University (WUSTL); University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institute of Infectious Diseases (NIID); University of Michigan System; University of Michigan; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kawaoka, Y (corresponding author), Univ Tokyo, Inst Med Sci, Div Virol, Tokyo, Japan.; Kawaoka, Y (corresponding author), Natl Ctr Global Hlth, Med Res Inst, Res Ctr Global Viral Dis, Tokyo, Japan.; Kawaoka, Y (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53705 USA.	yoshihiro.kawaoka@wisc.edu	Saito, Makoto/O-7383-2019; Hasegawa, Hideki/C-7978-2014	Saito, Makoto/0000-0002-1667-9287; Loeber, Samantha/0000-0003-4921-2357; Takashita, Emi/0000-0002-9064-4699; Uraki, Ryuta/0000-0003-0890-1922	Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) [JP20fk0108412, JP20fk0108502, JP21fk0108615, JP20fk0108472, JP21fk0108104, JP20nk0101632, JP22wm0125002]; Project Promoting Support for Drug Discovery from the Japan Agency for Medical Research and Development (AMED) [JP20nk0101632]; Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development (AMED) [JP22wm0125002]; National Institutes of Allergy and Infectious Diseases Center for Research on Influenza Pathogenesis [HHSN272201400008C]; NIAID [R01 AI157155]; Center for Research on Influenza Pathogenesis and Transmission (CRIPT) [75N93021C00014]; Collaborative Influenza Vaccine Innovation Center [75N93019C00051]; Ministry of Health, Labour and Welfare, Japan [JPMH20HA1006, JPMH 20HA2007]; Intramural Research Program of National Center for Global Health and Medicine; Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health	Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Project Promoting Support for Drug Discovery from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development (AMED); National Institutes of Allergy and Infectious Diseases Center for Research on Influenza Pathogenesis; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Center for Research on Influenza Pathogenesis and Transmission (CRIPT); Collaborative Influenza Vaccine Innovation Center; Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Intramural Research Program of National Center for Global Health and Medicine; Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Shionogi for providing S-217622; S. Watson for scientific editing; S. Matsubara, K. Yokota, N. Mizutani, H. Morita, H. Miura, S. Nagata and Y. Sato for technical assistance along with the IASO study team for their efforts with the organization and collection of blood samples from individuals after immunization. This work was supported by a Research Program on Emerging and Re-emerging Infectious Diseases (JP20fk0108412, JP20fk0108502, JP21fk0108615, JP20fk0108472 and JP21fk0108104), a Project Promoting Support for Drug Discovery (JP20nk0101632), the Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002) from the Japan Agency for Medical Research and Development (AMED), the National Institutes of Allergy and Infectious Diseases Center for Research on Influenza Pathogenesis (HHSN272201400008C), R01 AI157155 (NIAID), the Center for Research on Influenza Pathogenesis and Transmission (CRIPT) (75N93021C00014), the Collaborative Influenza Vaccine Innovation Center (75N93019C00051), and a Grant-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan (JPMH20HA1006, JPMH 20HA2007). This work was also supported in part by the Intramural Research Program of National Center for Global Health and Medicine, and in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], 2022, 36 UK HLTH SEC AG; Callaway E, 2021, NATURE, V600, P197, DOI 10.1038/d41586-021-03614-z; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1002/nla.2362, 10.1038/s41586-021-04385-3]; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Case, 2022, BIORXIV, DOI 10.1101/2022.03.17.484787; Case JB, 2020, VIROLOGY, V548, P39, DOI 10.1016/j.virol.2020.05.015; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Cheng SMS, 2022, NAT MED, V28, P486, DOI 10.1038/s41591-022-01704-7; Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]; Corbett KS, 2021, NAT IMMUNOL, V22, P1306, DOI 10.1038/s41590-021-01021-0; Dinnon Kenneth H, 2020, bioRxiv, DOI 10.1101/2020.05.06.081497; Elliott P., 2022, PREPRINT, DOI 10.1101/2022.02.03.22270365; Ferren M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26096-z; Flemming A, 2022, NAT REV IMMUNOL, V22, P75, DOI 10.1038/s41577-022-00676-6; Gilliland T., 2021, BIORXIV, DOI 10.1101/2021.07.26.453840; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Halfmann PJ, 2022, NATURE, V603, P687, DOI 10.1038/s41586-022-04441-6; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Imai M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2106535118; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Itokawa K., NCOV 2019 SEQUENCING; Itokawa K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239403; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; Liu LJ, 2022, NUTR NEUROSCI, V25, P2302, DOI 10.1080/1028415X.2021.1959099; Liu Y, 2022, NATURE, V602, P294, DOI 10.1038/s41586-021-04245-0; Lubinski B, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103589; Lyngse F., PREPRINT, DOI 10.1101/2022.01.28.22270044(2022; Majumdar S, 2022, J MED VIROL, V94, P1777, DOI 10.1002/jmv.27558; Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117; McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06; Meng B, 2022, NATURE, V603, P706, DOI 10.1038/s41586-022-04474-x; Muruato A, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001284; Owen DR, 2021, SCIENCE, V374, P1586, DOI 10.1126/science.abl4784; Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z; Quick J., 2020, NCOV 2019 SEQUENCING; Rossler A, 2022, NEW ENGL J MED, V386, P698, DOI 10.1056/NEJMc2119236; Saito A, 2022, NATURE, V602, P300, DOI 10.1038/s41586-021-04266-9; Shuai HP, 2022, NATURE, V603, P693, DOI 10.1038/s41586-022-04442-5; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Simpson Scott, 2020, J Thorac Imaging, V35, P219, DOI [10.1148/ryct.2020200152, 10.1097/RTI.0000000000000524]; Suzuki R, 2022, NATURE, V603, P700, DOI 10.1038/s41586-022-04462-1; Takashita E, 2022, NEW ENGL J MED, V386, P995, DOI 10.1056/NEJMc2119407; Tomris I, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1010340; Unoh Y, 2022, J MED CHEM, V65, P6499, DOI 10.1021/acs.jmedchem.2c00117; Uraki R., 2022, RES SQUARE, DOI 10.21203/rs.3.rs-1240227/v1; Vieillard-Baron A., 2022, PREPRINT, DOI 10.1101/2022.01.25.22269839; Wahl A, 2021, NATURE, V591, P451, DOI 10.1038/s41586-021-03312-w; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Yamasoba D., 2022, CELL, DOI 10.1101/2022.02.14.480335v1; Yamayoshi S, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100734; Yasuhara A, 2019, NAT MICROBIOL, V4, P1024, DOI 10.1038/s41564-019-0401-1; ZOU J, 2022, NAT COMMUN, V13	59	40	40	19	30	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 7	2022	607	7917					119	+		10.1038/s41586-022-04856-1	http://dx.doi.org/10.1038/s41586-022-04856-1		MAY 2022	23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S3FB	35576972	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000818664600001
J	Chou, YH; Cheng, YY; Nfor, ON; Chen, PH; Chen, CH; Chen, HL; Chang, BJ; Tantoh, DM; Huang, CN; Liaw, YP				Chou, Ying-Hsiang; Cheng, Yung-Yin; Nfor, Oswald Ndi; Chen, Pei-Hsin; Chen, Che-Hong; Chen, Hsin-Lin; Chang, Bo-Jiun; Tantoh, Disline Manli; Huang, Chien-Ning; Liaw, Yung-Po			Effects of aerobic and resistance exercise on glycosylated hemoglobin (HbA1c) concentrations in non-diabetic Taiwanese individuals based on the waist-hip ratio	PLOS ONE			English	Article							GLYCATED HEMOGLOBIN; CARDIOVASCULAR RISK; ADULTS; DIAGNOSIS; DISEASE	Background Glycosylated hemoglobin (HbA1c) reflects the average blood sugar over the past eight to twelve weeks. Several demographic and lifestyle factors are known to affect HbA1c levels. We evaluated the association of HbA1c with aerobic and resistance exercise in non-diabetic Taiwanese adults based on the waist-hip ratio (WHR). Methods We conducted this study based on TWB data collected from 90,958 individuals between 2008 and 2019. We estimated the Beta (beta) coefficient and 95% confidence intervals (CI) for HbA1c using multivariate regression models. Results Based on the multivariate analysis, lower HbA1c levels were associated with both resistance exercise (beta-coefficient = -0.027, 95% CI -0.037 to -0.017) and aerobic exercise (beta-coefficient = 0.018, 95% CI, -0.023 to -0.013). Higher HbA1c levels were associated with abnormal WHR compared to normal WHR (beta-coefficient = 0.091, 95% CI, 0.086 to 0.096). We detected an interaction between exercise and WHR (p for interaction = 0.0181). To determine the magnitude of the interaction, we performed additional analyses (with the reference group being 'abnormal WHR with no exercise') and observed substantial decreases in HbA1c regardless of the WHR and exercise category. However, the largest reduction occurred in the 'normal WHR and resistance exercise' group (beta = -0.121, 95% CI, -0.132 to -0.109). Conclusions We found that normal resistance exercise, coupled with a normal WHR was significantly associated with lower HbA1c levels among non-diabetic individuals in Taiwan.	[Chou, Ying-Hsiang; Chen, Hsin-Lin; Chang, Bo-Jiun] Chung Shan Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Chou, Ying-Hsiang; Cheng, Yung-Yin] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Chou, Ying-Hsiang; Cheng, Yung-Yin] Chung Shan Med Univ, Sch Med Imaging & Radiol Sci, Taichung, Taiwan; [Cheng, Yung-Yin; Tantoh, Disline Manli; Liaw, Yung-Po] Chung Shan Med Univ Hosp, Dept Med Imaging, Taichung, Taiwan; [Nfor, Oswald Ndi; Chen, Pei-Hsin; Tantoh, Disline Manli; Liaw, Yung-Po] Chung Shan Med Univ, Dept Publ Hlth & Inst Publ Hlth, Taichung, Taiwan; [Chen, Che-Hong] Stanford Univ, Dept Chem & Syst Biol, Sch Med, Stanford, CA USA; [Huang, Chien-Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Huang, Chien-Ning] Chung Shan Med Univ, Inst Med, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Stanford University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University	Liaw, YP (corresponding author), Chung Shan Med Univ Hosp, Dept Med Imaging, Taichung, Taiwan.; Liaw, YP (corresponding author), Chung Shan Med Univ, Dept Publ Hlth & Inst Publ Hlth, Taichung, Taiwan.; Huang, CN (corresponding author), Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan.; Huang, CN (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.	cshy049@csh.org.tw; Liawyp@csmu.edu.tw			Ministry of Science and Technology [MOST1102121-M-040-002, MOST110-2811-M-040-001, CSH-2022-D-008]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This project was supported by the Ministry of Science and Technology (MOST1102121-M-040-002; MOST110-2811-M-040-001; CSH-2022-D-008).	Anderson TJ, 2013, CAN J CARDIOL, V29, P151, DOI 10.1016/j.cjca.2012.11.032; [Anonymous], WILLIAMS TXB ENDOCRI, V12th ed.; Arora E, 2009, INDIAN J MED RES, V129, P515; Bala Manju, 2019, EJIFCC, V30, P317; Balducci S, 2010, NUTR METAB CARDIOVAS, V20, P608, DOI 10.1016/j.numecd.2009.04.015; Baltadjiev A., 2017, CORRELATIONS SOME AN; Bweir S, 2009, DIABETOL METAB SYNDR, V1, DOI 10.1186/1758-5996-1-27; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Dey SSS., 2020, HBA1C ITS ASS ANTHR; Dubowitz N, 2014, DIABETIC MED, V31, P927, DOI 10.1111/dme.12459; Fonseca VA, 2009, DIABETES CARE, V32, P1, DOI [10.2337/dc09-9033, 10.2337/dc09-S301]; Ghari Arab A., 2018, J CLIN BASIC RES, V2, P26; Greenland P, 2010, J AM COLL CARDIOL, V56, pE50, DOI 10.1016/j.jacc.2010.09.001; Li A., 2019, WORLD J PUBLIC HLTH, V4, P1; Liu YB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16010140; Ma JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091972; Mellergard E, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-00585-6; Nakagami T., 2017, DIABETES ENDOCRINOLO; Nitin S, 2010, SINGAP MED J, V51, P616; Araya MR, 2020, ENDOCRINOL DIAB NUTR, V67, P155, DOI 10.1016/j.endinu.2019.07.007; Sekgala MD, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19063224; Selvin E, 2010, NEW ENGL J MED, V362, P800, DOI 10.1056/NEJMoa0908359; Sherwani SI, 2016, BIOMARK INSIGHTS, V11, P95, DOI [10.4137/BMI.S38440, 10.4137/BMIMI.S38440]; Silbernagel G, 2011, DIABETES CARE, V34, P1355, DOI 10.2337/dc10-2010; Skogberg N, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6698-0; Tatsumi Y, 2019, AM J HYPERTENS, V32, P1178, DOI 10.1093/ajh/hpz123; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; Vlassopoulos A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1013; White HD, 2020, AM HEART J, V225, P97, DOI 10.1016/j.ahj.2020.04.004; Yang ZY, 2014, SPORTS MED, V44, P487, DOI 10.1007/s40279-013-0128-8	30	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0267387	10.1371/journal.pone.0267387	http://dx.doi.org/10.1371/journal.pone.0267387			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511934	gold, Green Published			2023-01-03	WOS:000892294900041
J	Davis, JC; Hsu, CL; Barha, C; Jehu, DA; Chan, P; Ghag, C; Jacova, P; Adjetey, C; Dian, L; Parmar, N; Madden, K; Liu-Ambrose, T				Davis, Jennifer C.; Hsu, Chun Liang; Barha, Cindy; Jehu, Deborah A.; Chan, Patrick; Ghag, Cheyenne; Jacova, Patrizio; Adjetey, Cassandra; Dian, Larry; Parmar, Naaz; Madden, Kenneth; Liu-Ambrose, Teresa			Comparing the cost-effectiveness of the Otago Exercise Programme among older women and men: A secondary analysis of a randomized controlled trial	PLOS ONE			English	Article							HOME-BASED EXERCISE; PREVENT FALLS; ECONOMIC EVALUATIONS; NONFATAL FALLS; ADULTS; COMMUNITY; FRAILTY; PEOPLE; INJURIES; STRENGTH	Objective Using stratified analyses, we examined the cost-effectiveness of the Otago Exercise Programme (OEP), from a health care system perspective, among older women and men who have previously fallen. Methods This study was a secondary stratified analysis (by women and men), of a 12-month prospective economic evaluation of a randomized clinical trial (OEP compared with usual care). Three hundred and forty four community-dwelling older adults (>= 70; 172 OEP (110 women; 62 men), 172 usual care (119 women; 53 men)) who sustained a fall in the past 12 months and received a baseline assessment at the Vancouver Falls Prevention Clinic, Canada were included. A gender by OEP/usual care interaction was examined for the falls incidence rate ratio (IRR). Outcome measures stratified by gender included: falls IRR, incremental cost-per fall prevented (ICER), incremental cost per quality adjusted life year (QALY, ICUR) gained, and mean total health care resource utilization costs. Results Men were frailer than women at baseline. Men incurred higher mean total healthcare costs $6794 (SD: $11906)). There was no significant gender by OEP/usual care interaction on falls IRR. The efficacy of the OEP did not vary by gender. The adjusted IRR for the OEP group demonstrated a 39% (IRR: 0.61, CI: 0.40-0.93) significant reduction in falls among men but not women (32% reduction (IRR: 0.69, CI: 0.47-1.02)). The ICER showed the OEP was effective in preventing falls and less costly for men, while it was costlier for women by $42. The ICUR showed the OEP did not impact quality of life. Conclusion Future studies should explore gender factors (i.e., health seeking behaviours, gender related frailty) that may explain observed variation in the cost-effectiveness of the OEP as a secondary falls prevention strategy.	[Davis, Jennifer C.; Hsu, Chun Liang; Barha, Cindy; Chan, Patrick; Ghag, Cheyenne; Jacova, Patrizio; Liu-Ambrose, Teresa] Univ British Columbia, Dept Phys Therapy, Aging Mobil & Cognit Neurosci Lab, Vancouver, BC, Canada; [Davis, Jennifer C.; Hsu, Chun Liang; Barha, Cindy; Chan, Patrick; Ghag, Cheyenne; Jacova, Patrizio; Liu-Ambrose, Teresa] Vancouver Coastal Hlth Res Inst, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada; [Davis, Jennifer C.; Hsu, Chun Liang; Barha, Cindy; Chan, Patrick; Ghag, Cheyenne; Jacova, Patrizio; Liu-Ambrose, Teresa] Vancouver Coastal Hlth Res Inst, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada; [Davis, Jennifer C.; Adjetey, Cassandra] Univ British Columbia, Fac Management, Social & Econ Change Lab, Kelowna, BC, Canada; [Hsu, Chun Liang] Hebrew SeniorLife, Hinda & Arthur Marcus Inst Aging Res, Roslindale, MA USA; [Jehu, Deborah A.] Augusta Univ, Interdisciplinary Hlth Sci Dept, Augusta, GA USA; [Dian, Larry; Parmar, Naaz; Madden, Kenneth] Univ British Columbia, Fac Med, Dept Med, Div Geriatr Med, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health Research Institute; University of British Columbia; Harvard University; Hebrew SeniorLife; University System of Georgia; Augusta University; University of British Columbia	Davis, JC (corresponding author), Univ British Columbia, Dept Phys Therapy, Aging Mobil & Cognit Neurosci Lab, Vancouver, BC, Canada.; Davis, JC (corresponding author), Vancouver Coastal Hlth Res Inst, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada.; Davis, JC (corresponding author), Vancouver Coastal Hlth Res Inst, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada.; Davis, JC (corresponding author), Univ British Columbia, Fac Management, Social & Econ Change Lab, Kelowna, BC, Canada.	jennifer.davis@ubc.ca		Hsu, Chun Liang/0000-0003-2090-1001; Davis, Jennifer/0000-0002-5274-4293	Canadian Institutes of Health Research (CIHR) [MOP110954, MAT_92025]; CIHR; MSFHR; Alzheimer's Associated; Brain Canada Postdoctoral Award; CIHR Postdoctoral Award	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); MSFHR(Michael Smith Foundation for Health Research); Alzheimer's Associated; Brain Canada Postdoctoral Award; CIHR Postdoctoral Award(Canadian Institutes of Health Research (CIHR))	This study is funded by the Canadian Institutes of Health Research to TLA (CIHR, MOP110954, CIHR, MAT_92025). TLA is a Canada Research Chair in Physical Activity, Mobility, and Cognitive Neuroscience. JCD was funded by a CIHR and MSFHR Postdoctoral Fellowship for part of this trial. JCD is a MSFHR Career Scholar and a Canada Research Chair in Applied Health Economics. CB is funded by the Alzheimer's Associated and Brain Canada Postdoctoral Award. CLH was funded by a CIHR Postdoctoral Award.	Aging PHAoCDo Seniors, 2005, REP SEM FALLS CAN DI; Albornos-Munoz L, 2018, J ADV NURS, V74, P1700, DOI 10.1111/jan.13583; ALEXANDER BH, 1992, AM J PUBLIC HEALTH, V82, P1020, DOI 10.2105/AJPH.82.7.1020; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Briggs AH, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/HTA3020; Burns ER, 2016, J SAFETY RES, V58, P99, DOI 10.1016/j.jsr.2016.05.001; Butler AA, 2015, J GERONTOL A-BIOL, V70, P628, DOI 10.1093/gerona/glu201; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Davis JC, 2010, OSTEOPOROSIS INT, V21, P1295, DOI 10.1007/s00198-009-1162-0; Davis JC, 2010, BRIT J SPORT MED, V44, P80, DOI 10.1136/bjsm.2008.060988; Davis JC, 2020, J AM GERIATR SOC, V68, P1988, DOI 10.1111/jgs.16476; Drummond M, 2005, INT J TECHNOL ASSESS, V21, P165, DOI 10.1017/S0266462305050221; Florence CS, 2018, J AM GERIATR SOC, V66, P693, DOI 10.1111/jgs.15304; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gill TM, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i245; Gillespie LD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007146.pub3; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hartholt KA, 2011, J TRAUMA, V71, P255, DOI 10.1097/TA.0b013e31821c36e7; Hendrie Delia, 2004, Aust Health Rev, V28, P363; Jehu DA, 2022, GERONTOLOGY, V68, P272, DOI 10.1159/000516260; Johnson Shanthi, 2015, Inj Epidemiol, V2, P24; Kane AE, 2021, MECH AGEING DEV, V198, DOI 10.1016/j.mad.2021.111546; Laska EM, 1997, HEALTH ECON, V6, P229, DOI 10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.3.CO;2-D; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leurent B, 2018, HEALTH ECON, V27, P1024, DOI 10.1002/hec.3654; Liu-Ambrose T, 2008, J AM GERIATR SOC, V56, P1821, DOI [10.1111/j.1532-5415.2008.01931.x, 10.1111/j.1532-5415.2008.01984.x]; Liu-Ambrose T, 2019, JAMA-J AM MED ASSOC, V321, P2092, DOI 10.1001/jama.2019.5795; Liu-Ambrose T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0648-7; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Lord S., 2001, FALLS OLDER PEOPLE R, P221; Ma LN, 2018, J AM GERIATR SOC, V66, P559, DOI 10.1111/jgs.15214; Manca A, 2005, APPL HEALTH ECON HEA, V4, P65, DOI 10.2165/00148365-200504020-00001; Miyamoto J M, 1985, Med Decis Making, V5, P191, DOI 10.1177/0272989X8500500208; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Oostenbrink JB, 2003, PHARMACOECONOMICS, V21, P1103, DOI 10.2165/00019053-200321150-00004; Oostenbrink JB, 2005, HEALTH ECON, V14, P763, DOI 10.1002/hed.966; Patton S, 2022, HEALTH PROMOT PRACT, V23, P785, DOI 10.1177/15248399211009783; Redondo-Sendino A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-155; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Robertson MC, 2001, BRIT MED J, V322, P701, DOI 10.1136/bmj.322.7288.701; Screen W., ROLE NUTR EXERCISE M; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; Stevens JA, 2006, INJURY PREV, V12, P290, DOI 10.1136/ip.2005.011015; Stevens J.A., 2015, CDC COMPENDIUM EFFEC; Towne SD, 2022, J AGING SOC POLICY, V34, P515, DOI 10.1080/08959420.2020.1740639; VANMARWIJK HWJ, 1995, BRIT J GEN PRACT, V45, P195; Whitney JC, 2005, AGE AGEING, V34, P567, DOI 10.1093/ageing/afi178; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	54	1	1	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2022	17	4							e0267247	10.1371/journal.pone.0267247	http://dx.doi.org/10.1371/journal.pone.0267247			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2T6VD	35442974	gold, Green Published			2023-01-03	WOS:000822608900046
J	Childers, JW				Childers, Julie W.			Goals of Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Childers, Julie W.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Palliat Care & Med Eth, 200 Lothrop St,9W, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Childers, JW (corresponding author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Palliat Care & Med Eth, 200 Lothrop St,9W, Pittsburgh, PA 15213 USA.	childersjw2@upmc.edu		Childers, Julie/0000-0001-6876-7660					0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2022	327	15					1449	1450						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1C3PR	35438726				2023-01-03	WOS:000793035800025
J	Bruel, T; Hadjadj, J; Maes, P; Planas, D; Seve, A; Staropoli, I; Guivel-Benhassine, F; Porrot, F; Bolland, WH; Nguyen, Y; Casadevall, M; Charre, C; Pere, H; Veyer, D; Prot, M; Baidaliuk, A; Cuypers, L; Planchais, C; Mouquet, H; Baele, G; Mouthon, L; Hocqueloux, L; Simon-Loriere, E; Andre, E; Terrier, B; Prazuck, T; Schwartz, O				Bruel, Timothee; Hadjadj, Jerome; Maes, Piet; Planas, Delphine; Seve, Aymeric; Staropoli, Isabelle; Guivel-Benhassine, Florence; Porrot, Francoise; Bolland, William-Henry; Nguyen, Yann; Casadevall, Marion; Charre, Caroline; Pere, Helene; Veyer, David; Prot, Matthieu; Baidaliuk, Artem; Cuypers, Lize; Planchais, Cyril; Mouquet, Hugo; Baele, Guy; Mouthon, Luc; Hocqueloux, Laurent; Simon-Loriere, Etienne; Andre, Emmanuel; Terrier, Benjamin; Prazuck, Thierry; Schwartz, Olivier			Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	NATURE MEDICINE			English	Article								Therapeutic antibodies, and sera from immunocompromised individuals prophylactically treated with therapeutic antibodies, differ in neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, which could have implications for pre-exposure and post-exposure treatment. The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients' sera.	[Bruel, Timothee; Planas, Delphine; Staropoli, Isabelle; Guivel-Benhassine, Florence; Porrot, Francoise; Bolland, William-Henry; Schwartz, Olivier] Univ Paris Cite, Inst Pasteur, Virus & Immun Unit, CNRS,UMR3569, Paris, France; [Bruel, Timothee; Planas, Delphine; Schwartz, Olivier] Vaccine Res Inst, Creteil, France; [Hadjadj, Jerome; Nguyen, Yann; Casadevall, Marion; Mouthon, Luc; Terrier, Benjamin] Hop Cochin, AP HP, Natl Reference Ctr Rare Syst Autoimmune Dis, Dept Internal Med,AP HP CUP, Paris, France; [Maes, Piet; Baele, Guy] Katholieke Univ Leuven, Lab Clin & Epidemiol Virol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium; [Seve, Aymeric; Hocqueloux, Laurent; Prazuck, Thierry] CHR Orleans, Serv Malad Infect, Orleans, France; [Bolland, William-Henry] Univ Paris Cite, Bcole Doctorale BioSPC 562, Paris, France; [Charre, Caroline] Univ Paris Cite, Fac Med, Paris, France; [Charre, Caroline] Inst Cochin, CNRS UMR8104, INSERM U1016, Paris, France; [Charre, Caroline] CHU Cochin, AP HP, Lab Virol, Paris, France; [Pere, Helene; Veyer, David] Univ Paris, Ctr Rech Cordeliers, INSERM, Funct Genom Solid Tumors FunGeST, Paris, France; [Pere, Helene; Veyer, David] Sorbonne Univ, Paris, France; [Pere, Helene; Veyer, David] Hop Europeen Georges Pompidou, AP HP, Serv Microbiol, Lab Virol, Paris, France; [Prot, Matthieu; Baidaliuk, Artem; Simon-Loriere, Etienne] Univ Paris Cite, Inst Pasteur, Evolutionary Genom RNA Viruses G5, Paris, France; [Cuypers, Lize; Andre, Emmanuel] Univ Hosp Leuven, Natl Reference Ctr Resp Pathogens, Dept Lab Med, Leuven, Belgium; [Planchais, Cyril; Mouquet, Hugo] Univ Paris Cite, Inst Pasteur, Humoral Immunol Lab, INSERM U1222, Paris, France; [Andre, Emmanuel] Katholieke Univ Leuven, Lab Clin Microbiol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; Centre Hospitalier Regional d'Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven; University Hospital Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven	Bruel, T; Schwartz, O (corresponding author), Univ Paris Cite, Inst Pasteur, Virus & Immun Unit, CNRS,UMR3569, Paris, France.; Bruel, T; Schwartz, O (corresponding author), Vaccine Res Inst, Creteil, France.	timothee.bruel@pasteur.fr; olivier.schwartz@pasteur.fr	Bruel, Timothée/AAI-4632-2020; Hadjadj, Jerome/AGY-3817-2022; Charre, Caroline/AAY-9326-2020; Mouquet, Hugo/M-2750-2014; Maes, Piet/P-7782-2017	Charre, Caroline/0000-0002-4356-5146; Mouquet, Hugo/0000-0002-4230-610X; Maes, Piet/0000-0002-4571-5232; Nguyen, Yann/0000-0002-0866-3824; Andre, Emmanuel/0000-0001-8321-3770	European Health Emergency Preparedness and Response Authority (HERA); Institut Pasteur; Region.le-de-France (DIM1Health); KU Leuven University; Sciensano; Urgence COVID-19 Fundraising Campaign of Institut Pasteur; Fondation pour la Recherche Medicale (FRM); ANRS; Vaccine Research Institute [ANR-10-LABX-77]; Labex IBEID [ANR-10-LABX-62-IBEID]; ANR/FRM Flash Covid PROTEO-SARS-CoV-2; ANR Coronamito; ANR IDISCOVR; Region.le-de-France program DIM1Health; Vaccine Research Institute; Internal Funds KU Leuven [C14/18/094, 3M170314]; Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen) [G0E1420N, G098321N]; COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]; 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]; INCEPTION program (Investissements d'Avenir grant) [ANR-16-CONV-0005];  [ANR10-INSB-04-01]	European Health Emergency Preparedness and Response Authority (HERA); Institut Pasteur(European Commission); Region.le-de-France (DIM1Health); KU Leuven University(KU Leuven); Sciensano; Urgence COVID-19 Fundraising Campaign of Institut Pasteur; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); ANRS(ANRSFrench National Research Agency (ANR)); Vaccine Research Institute; Labex IBEID; ANR/FRM Flash Covid PROTEO-SARS-CoV-2; ANR Coronamito(French National Research Agency (ANR)); ANR IDISCOVR(French National Research Agency (ANR)); Region.le-de-France program DIM1Health; Vaccine Research Institute; Internal Funds KU Leuven; Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen)(FWO); COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders; 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders; INCEPTION program (Investissements d'Avenir grant)(French National Research Agency (ANR)); 	We thank the European Health Emergency Preparedness and Response Authority (HERA) for supporting the work being done at Institut Pasteur and UK Leuven. We thank J. Buchrieser, J. Puech and F. Gambaro for their help with the sequencing data analysis. We thank the patients who participated to this study. We thank Y. Yazdanpanah, members of the Virus and Immunity Unit and other teams for discussions and help, N. Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis. The Opera system was co-funded by Institut Pasteur and the Region.le-de-France (DIM1Health). We thank the KU Leuven University authorities and J. Arnout, B. Lambrecht, C. Van Geet and L. Sels for their support. We thank F. Peira, V. Legros and L. Courtellemont for their help with the cohorts. UZ Leuven, as national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged. Work in the O.S. lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito and IDISCOVR. Work in the UPBI facility is funded by grant ANR10-INSB-04-01 and the Region.le-de-France program DIM1Health. D.P. is supported by the Vaccine Research Institute. G.B. acknowledges support from the Internal Funds KU Leuven under grant agreement C14/18/094 and the Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, G0E1420N and G098321N). P.M. acknowledges support from a COVID-19 research grant of `Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N). P.M. acknowledges support of a COVID-19 research grant from `Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N) and `Internal Funds KU Leuven' (grant 3M170314). E.S.L. acknowledges funding from the INCEPTION program (Investissements d'Avenir grant ANR-16-CONV-0005). The funders of this study had no role in study design, data collection, analysis and interpretation or writing of the article.	Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Buchrieser J, 2020, EMBO J, V39, DOI 10.15252/embj.2020106267; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1002/nla.2362, 10.1038/s41586-021-04385-3]; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Cathcart A. L., 2021, DUAL FUNCTION MONOCL, DOI [10.1101/2021.03.09.434607v10, DOI 10.1101/2021.03.09.434607V10]; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Crowe JE, 2022, ANNU REV IMMUNOL, V40, P349, DOI 10.1146/annurev-immunol-042718-041309; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Grzelak L, 2021, J INFECT DIS, V224, P983, DOI 10.1093/infdis/jiab127; Hadjadj J, 2022, ANN RHEUM DIS, V81, P720, DOI 10.1136/annrheumdis-2021-221508; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Haute Autorite de Sante, 2021, EVUSHELD TIXAGEVIMAB; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Liu LJ, 2022, NUTR NEUROSCI, V25, P2302, DOI 10.1080/1028415X.2021.1959099; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1109/TKDE.2020.3004939, 10.1101/2020.06.17.153486]; Loo YM, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl8124; Mykytyn AZ., BIORXIV2022022348164, V2022; National Institutes of Health, 2022, ALL VAR REP IN VITR; O'Brien Meagan P, 2021, medRxiv, DOI 10.1101/2021.06.14.21258567; Pelleau S, 2021, J INFECT DIS, V224, P1489, DOI 10.1093/infdis/jiab375; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Simon-Loriere E, 2022, NAT REV MICROBIOL, V20, P187, DOI 10.1038/s41579-022-00708-x; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Viana R, 2022, NATURE, V603, P679, DOI 10.1038/s41586-022-04411-y; Westendorf K., 2022, LY COV1404 BEBTELOVI, DOI [10.1101/2021.04.30.442182v5, DOI 10.1101/2021.04.30.442182V5]; Yamasoba D., 2022, CELL, DOI 10.1101/2022.02.14.480335v1; Yu JY, 2022, NEW ENGL J MED, V386, DOI 10.1056/NEJMc2201849; Zhou H., 2022, NEUTRALIZATION SARS, DOI [10.1101/2022.02.15.480166v2, DOI 10.1101/2022.02.15.480166V2]; Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005	40	81	82	11	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1297	+		10.1038/s41591-022-01792-5	http://dx.doi.org/10.1038/s41591-022-01792-5		MAR 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35322239	Green Submitted, Bronze			2023-01-03	WOS:000782318100001
J	Alhakamy, NA; Okbazghi, SZ; Alfaleh, MA; Abdulaal, WH; Bakhaidar, RB; Alselami, MO; Al Zahrani, M; Alqarni, HM; Alghaith, AF; Alshehri, S; Badr-Eldin, SM; Aldawsari, HM; Al-hejaili, OD; Aldhabi, BM; Mahdi, WA				Alhakamy, Nabil A.; Okbazghi, Solomon Z.; Alfaleh, Mohamed A.; Abdulaal, Wesam H.; Bakhaidar, Rana B.; Alselami, Mohammed O.; Al Zahrani, Majed; Alqarni, Hani M.; Alghaith, Adel F.; Alshehri, Sultan; Badr-Eldin, Shaimaa M.; Aldawsari, Hibah M.; Al-hejaili, Omar D.; Aldhabi, Bander M.; Mahdi, Wael A.			Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells	PLOS ONE			English	Article							ORAL BISPHOSPHONATES; CYCLE ARREST; CHEMOTHERAPY; NANOPARTICLES; THYMOQUINONE; APOPTOSIS; DELIVERY; EPIDEMIOLOGY; FORMULATION; LIPOSOMES	Background Lung cancer in men and women is considered the leading cause for cancer-related mortality worldwide. Anti-cancer peptides represent a potential untapped reservoir of effective cancer therapy. Methodology Box-Behnken response surface design was applied for formulating Alendronate sodium (ALS)-mastoparan peptide (MP) nanoconjugates using Design-Expert software. The optimization process aimed at minimizing the size of the prepared ALS-MP nanoconjugates. ALS-MP nanoconjugates' particle size, encapsulation efficiency and the release profile were determined. Cytotoxicity, cell cycle, annexin V staining and caspase 3 analyses on A549 cells were carried out for the optimized formula. Results The results revealed that the optimized formula was of 134.915.1 nm particle size. The novel ALS-MP demonstrated the lowest IC50 (1.3 +/- 0.34 mu M) in comparison to ALS-Raw (37.6 +/- 1.79 mu M). Thus, the results indicated that when optimized ALS-MP nanoconjugate was used, the IC50 of ALS was also reduced by half. Cell cycle analysis demonstrated a significantly higher percentage of cells in the G2-M phase following the treatment with optimized ALS-MP nanoconjugates. Conclusion The optimized ALS-MP formula had significantly improved the parameters related to the cytotoxic activity towards A549 cells, compared to control, MP and ALS-Raw.	[Alhakamy, Nabil A.; Bakhaidar, Rana B.; Alselami, Mohammed O.; Al Zahrani, Majed; Alqarni, Hani M.; Badr-Eldin, Shaimaa M.; Aldawsari, Hibah M.; Al-hejaili, Omar D.; Aldhabi, Bander M.] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia; [Alhakamy, Nabil A.; Aldawsari, Hibah M.] King Abdulaziz Univ, Fac Pharm, Adv Drug Delivery Res Grp, Jeddah, Saudi Arabia; [Alhakamy, Nabil A.; Aldawsari, Hibah M.] King Abdulaziz Univ, Ctr Excellence Drug Res & Pharmaceut Ind, Jeddah, Saudi Arabia; [Alhakamy, Nabil A.] King Abdulaziz Univ, Mohamed Saeed Tamer Chair Pharmaceut Ind, Jeddah, Saudi Arabia; [Okbazghi, Solomon Z.] Alexion Pharmaceut, Global Analyt & Pharmaceut Dev, New Haven, CT USA; [Alfaleh, Mohamed A.] King Abdulaziz Univ, King Fahd Med Res Ctr, Vaccines & Mmunotherapy Unit, Jeddah, Saudi Arabia; [Abdulaal, Wesam H.] King Abdulaziz Univ, Fac Sci, King Fahd Med Res Ctr, Dept Biochem,Canc & Mutagenesis Unit, Jeddah, Saudi Arabia; [Abdulaal, Wesam H.] King Abdulaziz Univ, Ctr Artificial Intelligence Precis Med, Jeddah, Saudi Arabia; [Alghaith, Adel F.; Alshehri, Sultan; Mahdi, Wael A.] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh, Saudi Arabia; [Alshehri, Sultan] Almaarefa Univ, Coll Pharm, Dept Pharmaceut Sci, Ad Diriyah, Saudi Arabia; [Badr-Eldin, Shaimaa M.] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt	King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Saud University; Almaarefa University; Egyptian Knowledge Bank (EKB); Cairo University	Alhakamy, NA (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia.; Alhakamy, NA (corresponding author), King Abdulaziz Univ, Fac Pharm, Adv Drug Delivery Res Grp, Jeddah, Saudi Arabia.; Alhakamy, NA (corresponding author), King Abdulaziz Univ, Ctr Excellence Drug Res & Pharmaceut Ind, Jeddah, Saudi Arabia.; Alhakamy, NA (corresponding author), King Abdulaziz Univ, Mohamed Saeed Tamer Chair Pharmaceut Ind, Jeddah, Saudi Arabia.	nalhakamy@kau.edu.sa	Aldawsari, Hibah/U-1571-2019; Badr-Eldin, Shaimaa M./J-7681-2012; MAHDI, WAEL/ABD-1707-2020	Aldawsari, Hibah/0000-0002-9067-8565; Badr-Eldin, Shaimaa M./0000-0003-1034-1653; MAHDI, WAEL/0000-0002-7083-1753; Alhakamy, Nabil/0000-0002-3826-1519	Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah [RG-10-16642]	Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah	This project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under grant no. (RG-10-16642). The authors, therefore, acknowledge with thanks DSR for technical and financial support. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	Agardan NBM, 2016, AAPS PHARMSCITECH, V17, P968, DOI 10.1208/s12249-015-0429-3; Ahmed OAA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020140; Al-Asmari AK, 2018, J EVID-BASED INTEGR, V23, DOI 10.1177/2156587217751796; Alhakamy NA, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14080729; Alhakamy NA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080761; Alhakamy NA, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050419; Alhakamy NA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040346; Alhakamy NA, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120685; Awan ZA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070597; Badr-Eldin SM, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.642171; Balwan W.K., 2021, SAUDI J MED PHARM SC, DOI [10.36348/sjmps.2021.v07i04.003, DOI 10.36348/SJMPS.2021.V07I04.003]; Banerjee S, 2010, NUTR CANCER, V62, P938, DOI 10.1080/01635581.2010.509832; Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890; Budreviciute A, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.574111; Caraglia M, 2006, ENDOCR-RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; Czarnomysy R, 2018, J ENZYM INHIB MED CH, V33, P1006, DOI 10.1080/14756366.2018.1471687; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; El-Helw ARM, 2015, INT J NANOMED, V10, P5797, DOI 10.2147/IJN.S91556; Fahmy UA, 2020, INT J NANOMED, V15, P5253, DOI 10.2147/IJN.S258791; Fahmy UA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060485; Faramarzi L, 2019, ARTIF CELL NANOMED B, V47, P737, DOI 10.1080/21691401.2019.1573737; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097/00001813-200404000-00012; Ghaderi S, 2014, ADV PHARM BULL, V4, P549, DOI 10.5681/apb.2014.081; Gilad S, 2012, J MOL DIAGN, V14, P510, DOI 10.1016/j.jmoldx.2012.03.004; Herve Jean Claude, 2015, Small GTPases, V6, P43, DOI 10.1080/21541248.2015.1044811; Hilchie AL, 2016, BBA-BIOMEMBRANES, V1858, P3195, DOI 10.1016/j.bbamem.2016.09.021; Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008; Hosny KM, 2013, EXPERT OPIN DRUG DEL, V10, P741, DOI 10.1517/17425247.2013.799136; Hu GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27669; Huang WF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31070-9; Jain AS, 2014, BIOMED PHARMACOTHER, V68, P429, DOI 10.1016/j.biopha.2014.03.004; Lam WK, 2004, INT J TUBERC LUNG D, V8, P1045; Lason E, 2013, ACTA BIOCHIM POL, V60, P773; Mangal S, 2017, ACTA PHARMACOL SIN, V38, P782, DOI 10.1038/aps.2017.34; Md S, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13070152; Nagai H, 2017, J THORAC DIS, V9, P448, DOI 10.21037/jtd.2017.02.75; Naguib MJ, 2020, INT J PHARMACEUT, V582, DOI 10.1016/j.ijpharm.2020.119302; Naseri MH, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0204-2; Park EJ, 2016, ONCOL REP, V36, P2261, DOI 10.3892/or.2016.5019; Rennert G, 2017, CLIN CANCER RES, V23, P1684, DOI 10.1158/1078-0432.CCR-16-0547; Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011; Schirrmacher V, 2019, INT J ONCOL, V54, P407, DOI 10.3892/ijo.2018.4661; Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059; Sharma N, 2016, ASIAN J PHARM SCI, V11, P404, DOI 10.1016/j.ajps.2015.09.004; Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37; Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Taratula O, 2011, J DRUG TARGET, V19, P900, DOI 10.3109/1061186X.2011.622404; TATSUMURA T, 1993, BRIT J CANCER, V68, P1146, DOI 10.1038/bjc.1993.495; Veiga LHS, 2013, THYROID, V23, P748, DOI 10.1089/thy.2012.0532; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239; Wong VCL, 2012, CELL CYCLE, V11, P2526, DOI 10.4161/cc.20905; Yoo JH, 2018, J DAIRY SCI, V101, P3758, DOI 10.3168/jds.2017-13872; Zarogoulidis P, 2012, THER DELIV, V3, P1021, DOI 10.4155/tde.12.77; Zarogoulidis P, 2012, INT J NANOMED, V7, P1551, DOI 10.2147/IJN.S29997	59	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2022	17	2							e0264093	10.1371/journal.pone.0264093	http://dx.doi.org/10.1371/journal.pone.0264093			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ4EP	35202419	gold, Green Published			2023-01-03	WOS:000773224600020
J	Feldman, WB; Avorn, J; Kesselheim, AS				Feldman, William B.; Avorn, Jerry; Kesselheim, Aaron S.			Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Feldman, William B.; Avorn, Jerry; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Phannacoecon, Program Regulat Therapeut & Law PORTAL, Boston, MA 02115 USA; [Feldman, William B.; Avorn, Jerry; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Feldman, WB (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	wbfeldman@bwh.harvard.edu			National Institutes of Health; FDA Sentinel Initiative; Arnold Ventures grants	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FDA Sentinel Initiative; Arnold Ventures grants	National Institutes of Health and FDA Sentinel Initiative grants support Dr Feldman and Arnold Ventures grants support Dr Kesselheim. Role of the Funder/Sponsor: The sponsors had no	Crossingham I, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013518.pub2; Gardiner J, 2021, J LAW MED ETHICS, V49, P321, DOI 10.1017/jme.2021.46; Gerald Joe K, 2014, Ann Am Thorac Soc, V11, P969, DOI [10.1513/AnnalsATS.201407-318LE, 10.1513/AnnalsATS.201404-139OI]; Global Initiative for Asthma (GINA),, 2021 GIN REP GLOB ST; Karst, 2010, HAS FDA ALREADY RESO; Mondal P, 2014, J ALLER CL IMM-PRACT, V2, P575, DOI 10.1016/j.jaip.2014.02.014; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stein SW, 2017, J AEROSOL MED PULM D, V30, P20, DOI 10.1089/jamp.2016.1297; Sullivan MG., 2018, CHEST PHYS; US Food and Drug Administration, 2018, INNOVATIVE APPROACHE	10	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2022	327	11					1021	1022		10.1001/jama.2022.1160	http://dx.doi.org/10.1001/jama.2022.1160		FEB 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY1GU	35188561				2023-01-03	WOS:000760972800001
J	Paneerselvam, GS; Aftab, RA; Sirisinghe, RG; Lai, PSM; Lim, SK				Paneerselvam, Ganesh Sritheran; Aftab, Raja Ahsan; Sirisinghe, Roland Gamini; Lai, Pauline Siew Mei; Lim, Soo Kun			Study protocol: Effectiveness of patient centered pharmacist care in improving medication adherence, clinical parameters and quality of life among hemodialysis patients	PLOS ONE			English	Article							DIALYSIS PATIENTS; KIDNEY-DISEASE; POLYPHARMACY; VALIDATION; MANAGEMENT; MORTALITY; OUTCOMES	Background Patients requiring hemodialysis (HD) often have several chronic comorbidities, which necessitate the use of several medications and hence put them at high risk of polypharmacy. Medication-related problems (MRPs) among HD patients are a serious issue as they can increase morbidity and nonadherence with medications. To overcome this issue, a unique pharmacy practice model including medication review (MR) and motivational interviewing (MI) is needed to improve medication adherence, by reducing MRPs and optimizing therapeutic outcomes. The present study aims to assess the effectiveness of MR and MI in improving medication adherence, quality of life (QOL) and clinical outcomes among end-stage renal disease (ESRD) patients who are on dialysis. Method and design This pre-post study will be conducted prospectively among patients with ESRD who have been on dialysis at the Hemodialysis Unit, Hospital Kuala Lumpur and the Hemodialysis Affiliated Centers of the University Malaya Medical Centre, from August 2020 till August 2021. Medication adherence will be assessed using the General Medication Adherence Scale (GMAS), whilst patients' HRQOL will be assessed using the Kidney Disease Quality of Life Short Form 36 (KDQOL-36). Clinical parameters such as blood glucose level, calcium, phosphate, hemoglobin and serum low-density lipoprotein (LDL) levels will be obtained from medical records. A total of 70 patients will be recruited. Discussion We hypothesize that the implementation of pharmacy-based MR and MI may expect an increase in medication adherence scores and increase in HRQOL scores from baseline as well as achieving the clinical lab parameters within the desired range. This would indicate a need for a pharmacist to be involved in the multidisciplinary team to achieve a positive impact on medication adherence among hemodialysis patients.	[Paneerselvam, Ganesh Sritheran; Aftab, Raja Ahsan; Sirisinghe, Roland Gamini] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Selangor, Malaysia; [Lai, Pauline Siew Mei] Univ Malaya, Dept Primary Care Med, Fac Med, Kuala Lumpur, Malaysia; [Lim, Soo Kun] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia	Taylor's University; Universiti Malaya; Universiti Malaya	Paneerselvam, GS (corresponding author), Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Selangor, Malaysia.	ganesh_alei@hotmail.com	Lim, Soo Kun/Q-2012-2019; Lai, Pauline Siew Mei/B-1031-2012	Lim, Soo Kun/0000-0001-7589-5150; Lai, Pauline Siew Mei/0000-0002-9940-9644; PANEERSELVAM, GANESH SRITHERAN/0000-0002-9062-5092				Al Salmi I, 2021, INT J NEPHROL, V2021, DOI 10.1155/2021/8876559; Atreja Ashish, 2005, MedGenMed, V7, P4; Berhe KK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240839; Catley D, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-456; Ferreira ED, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02135-7; Fukuhara S, 2003, KIDNEY INT, V64, P1903, DOI 10.1046/j.1523-1755.2003.00289.x; Ghimire S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144119; Goh KKK, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1397-8; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Jin Jing, 2008, Ther Clin Risk Manag, V4, P269; Karuppannan Mahmathi., 2019, ARCH PHAR PHARM RES, V2, DOI [10.33552/APPR.2019.02.000528, DOI 10.33552/APPR.2019.02.000528]; Korevaar JC, 2000, PERITON DIALYSIS INT, V20, P69; Lai DTC, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006936.pub2, 10.1002/14651858.CD006936.pub3]; Lee WWM, 2016, INT J NURS STUD, V53, P331, DOI 10.1016/j.ijnurstu.2015.09.010; Lundahl BW, 2010, RES SOCIAL WORK PRAC, V20, P137, DOI 10.1177/1049731509347850; Mair A, 2017, EUR J HOSP PHARM, V24, P5, DOI 10.1136/ejhpharm-2016-001044; Manley HJ, 2005, AM J KIDNEY DIS, V46, P669, DOI 10.1053/j.ajkd.2005.07.001; Miller WR, 2002, MOTIVATIONAL INTERVI, V2nd, DOI DOI 10.1097/01445442-200305000-00013; Msaad R, 2019, PAN AFR MED J, V33, DOI 10.11604/pamj.2019.33.61.18083; Naqvi AA, 2020, SAUDI PHARM J, V28, P1055, DOI 10.1016/j.jsps.2020.07.005; Nayana SA, 2017, CLIN EPIDEMIOL GLOB, V5, P148, DOI 10.1016/j.cegh.2016.08.005; Osthus TBH, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-46; Pagels AA, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-71; Pai AB, 2009, PHARMACOTHERAPY, V29, P1433, DOI 10.1592/phco.29.12.1433; Patricia Nicholas J., 2016, Pharmacy Pract (Granada), V14, DOI 10.18549/PharmPract.2016.03.785; PCNE, 2016, POS PAP PCNE DEF MED; Pharmaceutical Care Network Europe (PCNE), 2018, PCNE CLASS V8 02; Ramadaniati HU, 2016, INT J PHARM PHARM SC, V8, P298, DOI [10.22159/ijpps.2016v8i12.15193, DOI 10.22159/IJPPS.2016V8I12.15193]; Ramatillah DL, 2017, J PHARM BIOALLIED SC, V9, P229, DOI 10.4103/jpbs.JPBS_191_17; Rodrigues P.A., 2019, INT J PHARM SCI, V11, P131, DOI [10.22159/ijpps.2019v11i7.31305, DOI 10.22159/IJPPS.2019V11I7.31305]; Sabat E, 2003, ADHERENCE LONG TERM; Sampling P., 2012, CHOOSING TYPE SAMPLI, P74, DOI [10.1007/s11095-012-0705-9, DOI 10.1007/S11095-012-0705-9]; St Peter WL, 2015, SEMIN DIALYSIS, V28, P427, DOI 10.1111/sdi.12377; Taherdoost H., 2016, INT J ACAD RES MANAG, V5, P28, DOI [10.2139/ssrn.3205040, DOI 10.2139/SSRN.3205040]; Urbaniak GC., 1997, RES RANDOMIZER; van Loon IN, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0621-7; Vellone E, 2017, CONTEMP CLIN TRIALS, V55, P34, DOI 10.1016/j.cct.2017.02.003; Watzke B, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1429-5	39	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2022	17	2							e0263412	10.1371/journal.pone.0263412	http://dx.doi.org/10.1371/journal.pone.0263412			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H3HL	35180236	Green Published, gold			2023-01-03	WOS:000796435800017
J	Teshale, AB				Teshale, Achamyeleh Birhanu			Factors associated with unmet need for family planning in sub-Saharan Africa: A multilevel multinomial logistic regression analysis	PLOS ONE			English	Article								Background More than one out of every ten married women in the world, and one out of every five women in Africa, have unmet family planning needs. Despite this, studies concerning sub-Saharan Africa as well as the community-level factors that may influence the unmet need for family planning are scarce. Objective To assess factors associated with unmet need for family planning in sub-Saharan Africa. Methods This study used the nineteen demographic and health surveys (DHS) conducted between 2015 and 2020 in sub-Saharan Africa. A total weighted sample of 175, 820 women of reproductive age who were married during the survey was used for this study. To assess the factors associated with unmet need for family planning, I have employed a multilevel multinomial logistic regression model. After selecting variables using the bivariable analysis, a multivariable model was fitted. Finally, an adjusted relative risk ratio with its 95% Confidence Interval was reported and variables with a p-value less than 0.05 were declared to be significant predictors of unmet need for family planning. Result The overall prevalence of unmet need for family planning in sub-Saharan Africa was 23.70%, of which unmet need for spacing and limiting was 15.81% and 7.90% respectively. In the multivariable multilevel multinomial model, women's age, women's education, age at cohabitation, heard about family planning through media, parity, number of under-five children, and knowledge about modern contraceptive methods were among the individual-level factors that were associated with both the unmet need for spacing and limiting. Place of residence, community level of women illiteracy, and region were among the community-level factors that were associated with both unmet needs for spacing and limiting. Household size and visiting the health facility in the last 12 months were associated with unmet need for spacing only and husband education was associated with unmet need for limiting only. Conclusion Unmet need for family planning in sub-Saharan Africa was high. Both individual and community level factors were associated with both unmet need for spacing and limiting. Therefore, it is better to consider interventions at both individual and community levels.	[Teshale, Achamyeleh Birhanu] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia	University of Gondar	Teshale, AB (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia.	achambir08@gmail.com	Teshale, Achamyeleh/HHN-8416-2022	Teshale, Achamyeleh/0000-0002-7572-9993				Adebowale S. A., 2014, African Population Studies, V28, P499, DOI 10.11564/28-1-503; Affairs S, 2017, WORLD FAM PLANN 2017; Ajmal S., 2018, DHS Working Papers; Ali AAA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-102; Anita Pal JY., 2018, INT J REPROD CONTRAC, V7, P3638, DOI [10.18203/2320-1770.ijrcog20183768, DOI 10.18203/2320-1770.IJRCOG20183768]; Asif MF., 2019, BMC PUBLIC HEALTH, V19, P1, DOI [10.1186/s12889-018-6343-3, DOI 10.1186/S12889-018-6343-3]; Ayele W, 2013, TRENDS DETERMINANTS; Bahk J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0505-4; Bhusal Chet Kant, 2018, Int J Reprod Med, V2018, P9312687, DOI 10.1155/2018/9312687; Bishwajit G, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1379-4; Bradley S.E.K., 2012, DHS ANAL STUDIES; Bradley SarahE.K., 2012, DHS ANAL STUDIES; Brown S.S., 1995, BEST INTENTIONS UNIN; Dejene H, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250297; Fagbamigbe AF, 2018, SAGE OPEN, V8, DOI 10.1177/2158244017754023; Gebre G, 2016, PAN AFR MED J, V23, DOI 10.11604/pamj.2016.23.195.8386; Gebreselassie T, 2013, LEVELS TRENDS UNMET; Guure C, 2019, ARCH PUBLIC HEALTH, V77, DOI 10.1186/s13690-019-0340-6; Hailemariam A, 2011, ETHIOP J HEALTH SCI, V21, P77; Khan SM., 2008, UNMET NEED DEMAND FA; Klima CS, 1998, J NURSE-MIDWIFERY, V43, P483, DOI 10.1016/S0091-2182(98)00063-9; Korra A., 2002, ATTITUDES FAMILY PLA; Mekonnen W, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-37; Nkoka O, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08885-1; Nzokirishaka A, 2018, CONTRACEP REPROD MED, V3, DOI 10.1186/s40834-018-0062-0; Pradhan J., 2015, J WOMENS HLTH CARE, V4, P1; Solanke BL, 2019, CONTRACEP REPROD MED, V4, DOI 10.1186/s40834-019-0093-1; Stephenson R, 2006, AM J PUBLIC HEALTH, V96, P84, DOI 10.2105/AJPH.2004.057422; Tadele A, 2019, CONTRACEP REPROD MED, V4, DOI 10.1186/s40834-019-0087-z; Teshale AB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09550-3; The Alan Guttmacher Institute, 1999, SHARING RESPONSIBILI; The DHS Program, DHS METH; United Nations Department of Economic and Social Affairs Population Division, 2014, POPDBCPREV2014; Wafula SW, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0240-z; Waqas Hameed, 2011, Pakistan Journal of Public Health, V1, P21; Westoff CF., 2006, DHS COMP REPORTS; Worku SA, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4180-9; Wulifan JK, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1614-z; Yalew M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08653-1; Yaya S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209801	40	1	1	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2022	17	2							e0263885	10.1371/journal.pone.0263885	http://dx.doi.org/10.1371/journal.pone.0263885			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1J1AU	35143584	Green Published, gold			2023-01-03	WOS:000797657800089
J	Chin, LF; Rosbergen, ICM; Hayward, KS; Brauer, SG				Chin, Lay Fong; Rosbergen, Ingrid C. M.; Hayward, Kathryn S.; Brauer, Sandra G.			A self-directed upper limb program during early post-stroke rehabilitation: A qualitative study of the perspective of nurses, therapists and stroke survivors	PLOS ONE			English	Article								Introduction This study aimed to explore the perspective of nurses, therapists and stroke survivors on the performance of upper limb self-exercise and use outside therapy during early inpatient stroke rehabilitation. Methods A descriptive qualitative approach was used in focus groups with nurses (n = 21) and therapists (n = 8), as well as in-depth semi-structured interviews with stroke survivors (n = 8) who were undergoing subacute inpatient stroke rehabilitation. Inductive thematic analysis of data was performed according to participant group. Results Nurses and therapists perceived that stroke survivors played a central role in determining the success of a self-directed upper limb program. Nurses perceived that stroke survivors needed a lot of prompting to be motivated to perform self-directed upper limb therapy outside therapy. Therapists perceived that not all stroke survivors would be able to perform self-directed upper limb therapy and deemed it important to consider stroke survivor factors before commencing a program. Although some stroke survivors expressed initial reservations with performing self-practice, many indicated that they would participate in the selfdirected upper limb program because they wanted to recover faster. Conclusion A difference between the perspective of nurses/therapists and stroke survivors towards self-directed upper limb performance outside therapy was found. Deeper stroke survivor engagement and a shift in rehabilitation culture to encourage stroke survivor autonomy are important considerations for a self-directed upper limb program. Teamwork amongst healthcare professionals and families is essential to support stroke survivors to participate in a self-directed upper limb program during early inpatient stroke rehabilitation.	[Chin, Lay Fong] Tan Tock Seng Hosp, Rehabil Ctr, Singapore, Singapore; [Chin, Lay Fong; Rosbergen, Ingrid C. M.; Hayward, Kathryn S.; Brauer, Sandra G.] Univ Queensland, Sch Hlth & Rehabil Sci, Physiotherapy, Brisbane, Qld, Australia; [Rosbergen, Ingrid C. M.] Univ Queensland, STARS Surg Treatment & Rehabil Serv, Brisbane, Qld, Australia; [Rosbergen, Ingrid C. M.] Metro North Hlth, STARS Surg Treatment & Rehabil Serv, Brisbane, Qld, Australia; [Hayward, Kathryn S.] Univ Melbourne, Melbourne Sch Hlth Sci, Physiotherapy, Parkville, Vic, Australia; [Hayward, Kathryn S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Stroke Theme, Melbourne, Vic, Australia; [Hayward, Kathryn S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, NHMRC Ctr Res Excellence Stroke Rehabil & Brain R, Melbourne, Australia	Tan Tock Seng Hospital; University of Queensland; University of Queensland; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Chin, LF (corresponding author), Tan Tock Seng Hosp, Rehabil Ctr, Singapore, Singapore.; Chin, LF (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Physiotherapy, Brisbane, Qld, Australia.	Lay_Fong_CHIN@ttsh.com.sg		Chin, Lay Fong/0000-0002-5795-7554				Barker RN, 2005, DISABIL REHABIL, V27, P1213, DOI 10.1080/09638280500075717; Batalden M, 2016, BMJ QUAL SAF, V25, P509, DOI 10.1136/bmjqs-2015-004315; Bernhardt J, 2007, J REHABIL MED, V39, P43, DOI 10.2340/16501977-0013; Bleijenberg N, 2018, INT J NURS STUD, V79, P86, DOI 10.1016/j.ijnurstu.2017.12.001; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chin LF, 2021, NEUROREHAB NEURAL RE, V35, P836, DOI 10.1177/15459683211032967; Chin LF, 2021, AM J PHYS MED REHAB, V100, P153, DOI 10.1097/PHM.0000000000001539; Eng XW, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/626538; Galvin R, 2009, DISABIL REHABIL, V31, P898, DOI 10.1080/09638280802356369; Harris JE, 2010, PHYS THER, V90, P1302, DOI 10.2522/ptj.20090349; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Hayward KS, 2015, CLIN REHABIL, V29, P1234, DOI 10.1177/0269215514565395; Janssen J, 2020, PHYS THER, V100, P307, DOI 10.1093/ptj/pzz159; Kimberley TJ, 2010, J REHABIL RES DEV, V47, P851, DOI 10.1682/JRRD.2010.02.0019; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; Luker J, 2015, ARCH PHYS MED REHAB, V96, P1698, DOI 10.1016/j.apmr.2015.03.017; Luker JA, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0156-9; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; O'Cathain A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029954; Rosbergen ICM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018226; Schneider EJ, 2016, J PHYSIOTHER, V62, P182, DOI 10.1016/j.jphys.2016.08.006; Scrivener K, 2017, STROKE RES TREAT, V2017, DOI 10.1155/2017/4574385; Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201; Taub E, 2006, Eura Medicophys, V42, P241; Tinson D J, 1989, Int Disabil Stud, V11, P45; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Turakhia Puja, 2017, AMA J Ethics, V19, P1125, DOI 10.1001/journalofethics.2017.19.11.pfor1-1711; Vloothuis J, 2020, DISABIL REHABIL, V42, P698, DOI 10.1080/09638288.2018.1507048; West T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/438679; Woodbury ML, 2013, ARCH PHYS MED REHAB, V94, P1527, DOI 10.1016/j.apmr.2013.03.007	32	0	0	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2022	17	2							e0263413	10.1371/journal.pone.0263413	http://dx.doi.org/10.1371/journal.pone.0263413			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0W8MA	35120167	gold, Green Published			2023-01-03	WOS:000789273600041
J	Gregg, J				Gregg, Jessica			The Care I Needed	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gregg, Jessica] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Gregg, J (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2022	386	5					411	413		10.1056/NEJMp2112526	http://dx.doi.org/10.1056/NEJMp2112526		JAN 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR1JU	35089663				2023-01-03	WOS:000748300400001
J	Alamneh, TS; Teshale, AB; Yeshaw, Y; Alem, AZ; Ayalew, HG; Liyew, AM; Tessema, ZT; Tesema, GA; Worku, MG				Alamneh, Tesfa Sewunet; Teshale, Achamyeleh Birhanu; Yeshaw, Yigizie; Alem, Adugnaw Zeleke; Ayalew, Hiwotie Getaneh; Liyew, Alemneh Mekuriaw; Tessema, Zemenu Tadesse; Tesema, Getayeneh Antehunegn; Worku, Misganaw Gebrie			Barriers for health care access affects maternal continuum of care utilization in Ethiopia; spatial analysis and generalized estimating equation	PLOS ONE			English	Article							3 DELAYS; PAKISTAN; TRENDS	BackgroundAlthough Ethiopia had made a significant change in maternal morbidity and mortality over the past decades, it remains a major public health concern. World Health Organization designed maternal continuum of care to reduce maternal morbidity and mortality. However, majority of the mothers didn't utilize the maternal continuum of care. Therefore, this study aimed to assess the spatial distribution of incomplete utilization of maternal continuum of care and its associated factors in Ethiopia. MethodsThis study was based on 2016 Demographic and Health Survey data of Ethiopia. A total weighted sample of 4,772 reproductive aged women were included. The study used ArcGIS and SaTScan software to explore the spatial distribution of incomplete utilization of maternal continuum of care. Besides, multivariable Generalized Estimating Equation was fitted to identify the associated factors of incomplete utilization of maternal continuum of care using STATA software. Model comparison was made based on Quasi Information Criteria. An adjusted odds ratio with 95% confidence interval of the selected model was reported to identify significantly associated factors of incomplete utilization of maternal continuum of care. ResultsThe spatial analysis revealed that incomplete utilization of maternal continuum of care had significant spatial variation across the country. Primary clusters were detected at Somali, North-Eastern part of Oromia, and East part of Southern Nation Nationalities while secondary clusters were detected in the Central Amhara region. In multivariate GEE, rural residency, secondary education, higher education, Protestant religious follower's, Muslim religious follower's, poorer wealth index, richer wealth index, richest wealth index, currently working, having barriers for accessing health care, and exposure for mass media were significantly associated with incomplete utilization maternal continuum of care. ConclusionIncomplete utilization of maternal continuum of care had significant spatial variations in Ethiopia. Residence, wealth index, education, religion, and barriers for health care access, mass media exposure, and currently working were significantly associated with incomplete utilization of maternal continuum of care. Therefore, public health interventions targeted to enhance maternal service utilization and women empowerment in hotspot areas of incomplete utilization of maternal continuum of care are crucial for reducing maternal morbidity and mortality.	[Alamneh, Tesfa Sewunet; Teshale, Achamyeleh Birhanu; Yeshaw, Yigizie; Alem, Adugnaw Zeleke; Liyew, Alemneh Mekuriaw; Tessema, Zemenu Tadesse; Tesema, Getayeneh Antehunegn] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia; [Yeshaw, Yigizie] Univ Gondar, Coll Med & Hlth Sci, Sch Med, Dept Physiol, Gondar, Ethiopia; [Ayalew, Hiwotie Getaneh] Wollo Univ, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Dept Midwifery, Dessie, Ethiopia; [Worku, Misganaw Gebrie] Univ Gondar, Coll Med & Hlth Sci, Sch Med, Dept Human Anat, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Alamneh, TS (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia.	tesfasewunet23@gmail.com	Teshale, Achamyeleh/HHN-8416-2022	Alemneh, Tesfa Sewunet/0000-0002-4830-931X				Adedini SA, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.23499; Akinyemi JO, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1083-9; Alkema Leontine, 2016, Lancet, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Amare NS, 2019, BIORXIV; ANSELIN L, 1992, ANN REGIONAL SCI, V26, P19, DOI 10.1007/BF01581478; Assembly, 2015, SDGS TRANSFORM OUR W, DOI DOI 10.1186/S12916-015-0342-3; Atnafu A, 2020, J PREGNANCY, V2020, DOI 10.1155/2020/4318197; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P137, DOI 10.4314/ejhs.v24i0.12S; Bhunia G. S., 2018, Journal of the Saudi Society of Agricultural Sciences, V17, P114, DOI 10.1016/j.jssas.2016.02.001; Chaka EE, 2019, INT J PREVENTIVE MED, V10, DOI 10.4103/ijpvm.IJPVM_26_19; Croft TN, 2018, GUIDE DHS STAT; Defar A, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1079-y; Directorate for Sub-Saharan Africa, 2021, GEN COUNTR OR INF RE; Emiru AA, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02953-5; Esscher A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-141; Estimation UNIGfCM, 2017, LEVELS TRENDS CHILD; Haile D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0221670; Hamed A. F., 2018, International Journal of Medical Science and Public Health, V7, P417; Haque A., 2016, INT J BUS SOC SCI, V7, P78; Iqbal S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2111-9; Joliat GR, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3824-0; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Kulldorff M, 2018, SATSCANTM USER GUIDE; Lipsitz S, 2017, J COMPUT GRAPH STAT, V26, P734, DOI 10.1080/10618600.2017.1321552; Liu X., 2015, APPL ORDINAL LOGISTI; Macro O: Central Statistical Agency, 2006, ETH DEM HLTH SURV 20; Mainuddin Akm, 2015, J Family Reprod Health, V9, P65; McMaughan DJ, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00231; MOH E, 2014, FED DEM REP ETH MIN; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Muluneh AG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234741; Okwaraji YB, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1161-0; Organization WH, 2019, TRENDS MAT MORT 2000; Sakuma S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215635; Saxena D, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.19652; Shah N, 2009, JCPSP-J COLL PHYSICI, V19, P95, DOI 02.2009/JCPSP.9598; Shaikh BT, 2005, J PUBLIC HEALTH-UK, V27, P49, DOI 10.1093/pubmed/fdh207; Shibanuma A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000786; Singh K, 2016, MATERN CHILD HLTH J, V20, P281, DOI 10.1007/s10995-015-1827-6; Singh R, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0173-5; Tamang TM, 2017, INT POP C; Tamirat KS, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05485-y; Waldhor T, 1996, STAT MED, V15, P887, DOI 10.1002/(SICI)1097-0258(19960415)15:7/9<887::AID-SIM257>3.3.CO;2-5; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; Wieczorek WF, 2009, WILEY INTERDISCIP RE, V1, P167, DOI 10.1002/wics.21; World Health Organization, 2019, POL BRIEF HLTH RED I; Wulandari RD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232550; wwwworldometersinfo, ETHIOPIA POPULATION; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	50	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266490	10.1371/journal.pone.0266490	http://dx.doi.org/10.1371/journal.pone.0266490			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1C1KV	35452475	Green Published, gold			2023-01-03	WOS:000792887700040
J	Barrett, LA; Xing, AW; Sheffler, J; Steidley, E; Adam, TJ; Zhang, R; He, Z				Barrett, Laura A.; Xing, Aiwen; Sheffler, Julia; Steidley, Elizabeth; Adam, Terrence J.; Zhang, Rui; He, Zhe			Assessing the use of prescription drugs and dietary supplements in obese respondents in the National Health and Nutrition Examination Survey	PLOS ONE			English	Article							BODY-MASS INDEX; UNITED-STATES; OVERWEIGHT; MORTALITY; TRENDS	Introduction Obesity is a common disease and a known risk factor for many other conditions such as hypertension, type 2 diabetes, and cancer. Treatment options for obesity include lifestyle changes, pharmacotherapy, and surgical interventions such as bariatric surgery. In this study, we examine the use of prescription drugs and dietary supplements by the individuals with obesity. Methods We conducted a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2003-2018. We used multivariate logistic regression to analyze the correlations of demographics and obesity status with the use of prescription drugs and dietary supplement use. We also built machine learning models to classify prescription drug and dietary supplement use using demographic data and obesity status. Results Individuals with obesity are more likely to take cardiovascular agents (OR = 2.095, 95% CI 1.989-2.207) and metabolic agents (OR = 1.658, 95% CI 1.573-1.748) than individuals without obesity. Gender, age, race, poverty income ratio, and insurance status are significantly correlated with dietary supplement use. The best performing model for classifying prescription drug use had the accuracy of 74.3% and the AUROC of 0.82. The best performing model for classifying dietary supplement use had the accuracy of 65.3% and the AUROC of 0.71. Conclusions This study can inform clinical practice and patient education of the use of prescription drugs and dietary supplements and their correlation with obesity.	[Barrett, Laura A.; Steidley, Elizabeth; He, Zhe] Florida State Univ, Sch Informat, Tallahassee, FL 32306 USA; [Xing, Aiwen] Florida State Univ, Dept Stat, Tallahassee, FL 32306 USA; [Sheffler, Julia; He, Zhe] Florida State Univ, Coll Med, Dept Behav Sci & Social Med, Tallahassee, FL 32306 USA; [Adam, Terrence J.; Zhang, Rui] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN USA; [Adam, Terrence J.; Zhang, Rui] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	He, Z (corresponding author), Florida State Univ, Sch Informat, Tallahassee, FL 32306 USA.; He, Z (corresponding author), Florida State Univ, Coll Med, Dept Behav Sci & Social Med, Tallahassee, FL 32306 USA.	zhe@fsu.edu	; He, Zhe/J-2336-2014	Xing, Aiwen/0000-0003-4901-7025; He, Zhe/0000-0003-3608-0244	National Institute on Aging (NIA) of the National Institutes of Health (NIH) [R21AG061431]; University of Florida Clinical and Translational Science Institute; NIH National Center for Advancing Translational Sciences [UL1TR001427]; National Center for Complementary and Integrative Medicine (NCCIH) of NIH [R01AT009457]	National Institute on Aging (NIA) of the National Institutes of Health (NIH); University of Florida Clinical and Translational Science Institute; NIH National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Medicine (NCCIH) of NIH	This study was supported in part by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) under Award Number R21AG061431 (ZH); and the University of Florida Clinical and Translational Science Institute, which is supported in part by the NIH National Center for Advancing Translational Sciences under award number UL1TR001427 (ZH); and National Center for Complementary and Integrative Medicine (NCCIH) of NIH under Award Number R01AT009457 (RZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19430; [Anonymous], NHANES SURVEY METHOD; [Anonymous], OFFICE DIETARY SUPPL; Ashman Jill J, 2015, NCHS Data Brief, P1; Batsis JA, 2016, INT J OBESITY, V40, P761, DOI 10.1038/ijo.2015.243; Casillas A, 2022, J GEN INTERN MED, V37, P258, DOI 10.1007/s11606-021-06608-9; Centers for Disease Control and Prevention, 2021, DEFINING ADULT OVERW; de Wit L, 2010, PSYCHIAT RES, V178, P230, DOI 10.1016/j.psychres.2009.04.015; Doerrmann C, 2020, AM J HEALTH PROMOT, V34, P359, DOI 10.1177/0890117119897189; Dong L, 2022, J AFFECT DISORDERS, V296, P183, DOI 10.1016/j.jad.2021.09.075; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Frank E, 2004, BIOINFORMATICS, V20, P2479, DOI 10.1093/bioinformatics/bth261; Gadde KM, 2018, J AM COLL CARDIOL, V71, P69, DOI 10.1016/j.jacc.2017.11.011; Gahche JJ, 2018, J NUTR, V148, p1436S, DOI 10.1093/jn/nxy093; Gelfand A, 2018, EUR J PREV CARDIOL, V25, P40, DOI 10.1177/2047487317736390; Gill T, 2005, P NUTR SOC, V64, P255, DOI 10.1079/PNS2005425; Gu Qiuping, 2010, NCHS Data Brief, P1; He Zhe, 2020, AMIA Jt Summits Transl Sci Proc, V2020, P231; He Z, 2016, J BIOMED INFORM, V60, P66, DOI 10.1016/j.jbi.2016.01.007; He Z, 2016, 2016 3RD IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS, P136, DOI 10.1109/BHI.2016.7455853; He Z, 2015, STUD HEALTH TECHNOL, V216, P569, DOI 10.3233/978-1-61499-564-7-569; Hodish I, 2018, DIABETES OBES METAB, V20, P2085, DOI 10.1111/dom.13367; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Khalil H, 2020, ANN PHARMACOTHER, V54, P691, DOI 10.1177/1060028019898912; Kim D, 2019, PREV CHRONIC DIS, V16, DOI 10.5888/pcd16.180220; Kirby JB, 2006, MED CARE, V44, P64; Knudsen N, 2005, J CLIN ENDOCR METAB, V90, P4019, DOI 10.1210/jc.2004-2225; Li MF, 2011, WORLD J DIABETES, V2, P19, DOI 10.4239/wjd.v2.i2.19; Li R, 1999, INT J OBESITY, V23, P926, DOI 10.1038/sj.ijo.0801020; Liao SE, 2020, ECOTOX ENVIRON SAFE, V201, DOI 10.1016/j.ecoenv.2020.110785; Lubowiecki-Vikuk A, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0191-3; Perez-Lasierra JL, 2022, EXP GERONTOL, V158, DOI 10.1016/j.exger.2021.111656; Martin Cresent B, 2019, NCHS Data Brief, P1; Palmer MK, 2019, OBESITY, V27, P309, DOI 10.1002/oby.22370; Pillitteri JL, 2008, OBESITY, V16, P790, DOI 10.1038/oby.2007.136; Randhawa AK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184089; Ruban A, 2019, CLIN MED, V19, P205, DOI 10.7861/clinmedicine.19-3-205; Sharretts J, 2020, NEW ENGL J MED, V383, P1000, DOI 10.1056/NEJMp2003873; Singh AK, 2020, EXPERT REV CLIN PHAR, V13, P53, DOI 10.1080/17512433.2020.1698291; Squadrito F, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110320; Srivastava SB, 2020, AM J LIFESTYLE MED, V14, P36, DOI 10.1177/1559827619881095; Stessman J, 2009, J AM GERIATR SOC, V57, P2232, DOI 10.1111/j.1532-5415.2009.02567.x; Stokes A, 2020, AM J PREV MED, V58, P766, DOI 10.1016/j.amepre.2019.12.018; Suh E, 2021, AGE MAJORITY STATE 2; Uche UI, 2020, ENVIRON RES, V191, DOI 10.1016/j.envres.2020.110109; Wang L, 2022, ECOTOX ENVIRON SAFE, V230, DOI 10.1016/j.ecoenv.2022.113161; Wu BS, 2020, ENVIRON HEALTH-GLOB, V19, DOI 10.1186/s12940-020-00642-6; Wurtman RJ, 1995, OBES RES, V3, pS477, DOI 10.1002/j.1550-8528.1995.tb00215.x; Xu ZX, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-04109-7; Yanovski SZ, 2021, JAMA-J AM MED ASSOC, V326, P129, DOI 10.1001/jama.2021.9486; Yanovski SZ, 2014, JAMA-J AM MED ASSOC, V311, P74, DOI 10.1001/jama.2013.281361; Yu X., 2022, SSM-POPUL HLTH, V17, DOI [10.1016/j.ssmph.2021.100989, DOI 10.1016/J.SSMPH.2021.100989]; Zhang YQ, 2019, ENVIRON INT, V123, P325, DOI 10.1016/j.envint.2018.11.076	55	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269241	10.1371/journal.pone.0269241	http://dx.doi.org/10.1371/journal.pone.0269241			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35657782	Green Published, gold			2023-01-03	WOS:000843567600010
J	Jiang, X; Dahmani, S; Bronshteyn, M; Yang, FN; Ryan, JP; Gallagher, RC; Damera, SR; Kumar, PN; Moore, DJ; Ellis, RJ; Turkeltaub, PE				Jiang, Xiong; Dahmani, Sophia; Bronshteyn, Margarita; Yang, Fan Nils; Ryan, John Paul; Gallagher, R. Craig, Jr.; Damera, Srikanth R.; Kumar, Princy N.; Moore, David J.; Ellis, Ronald J.; Turkeltaub, Peter E.			Cingulate transcranial direct current stimulation in adults with HIV	PLOS ONE			English	Article							FUNCTIONAL CONNECTIVITY; ANTIRETROVIRAL THERAPY; MAGNETIC STIMULATION; CORTEX; BRAIN; PERFORMANCE; ACTIVATION; DISORDERS; COGNITION; SAFETY	Background Neuronal dysfunction plays an important role in the high prevalence of HIV-associated neurocognitive disorders (HAND) in people with HIV (PWH). Transcranial direct current stimulation (tDCS)-with its capability to improve neuronal function-may have the potential to serve as an alternative therapeutic approach for HAND. Brain imaging and neurobehavioral studies provide converging evidence that injury to the anterior cingulate cortex (ACC) is highly prevalent and contributes to HAND in PWH, suggesting that ACC may serve as a potential neuromodulation target for HAND. Here we conducted a randomized, doubleblind, placebo-controlled, partial crossover pilot study to test the safety, tolerability, and potential efficacy of anodal tDCS over cingulate cortex in adults with HIV, with a focus on the dorsal ACC (dACC). Methods Eleven PWH (47-69 years old, 2 females, 100% African Americans, disease duration 1636 years) participated in the study, which had two phases, Phase 1 and Phase 2. During Phase 1, participants were randomized to receive ten sessions of sham (n = 4) or cingulate tDCS (n = 7) over the course of 2-3 weeks. Treatment assignments were unknown to the participants and the technicians. Neuropsychology and MRI data were collected from four additional study visits to assess treatment effects, including one baseline visit (BL, prior to treatment) and three follow-up visits (FU1, FU2, and FU3, approximately 1 week, 3 weeks, and 3 months after treatment, respectively). Treatment assignment was unblinded after FU3. Participants in the sham group repeated the study with open-label cingulate tDCS during Phase 2. Statistical analysis was limited to data from Phase 1. Results Compared to sham tDCS, cingulate tDCS led to a decrease in Perseverative Errors in Wisconsin Card Sorting Test (WCST), but not Non-Perseverative Errors, as well as a decrease in the ratio score of Trail Making Test-Part B (TMT-B) to TMT-Part A (TMT-A). Seed-tovoxel analysis with resting state functional MRI data revealed an increase in functional connectivity between the bilateral dACC and a cluster in the right dorsal striatum after cingulate tDCS. There were no differences in self-reported discomfort ratings between sham and cingulate tDCS. Conclusions Cingulate tDCS is safe and well-tolerated in PWH, and may have the potential to improve cognitive performance and brain function. A future study with a larger sample is warranted.	[Jiang, Xiong; Dahmani, Sophia; Bronshteyn, Margarita; Yang, Fan Nils; Ryan, John Paul; Gallagher, R. Craig, Jr.; Damera, Srikanth R.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Kumar, Princy N.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; [Moore, David J.; Ellis, Ronald J.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Ellis, Ronald J.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Turkeltaub, Peter E.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; [Turkeltaub, Peter E.] Georgetown Univ, Med Ctr, Ctr Brain Plast & Recovery, Washington, DC 20007 USA	Georgetown University; Georgetown University; University of California System; University of California San Diego; University of California System; University of California San Diego; Georgetown University; Georgetown University	Jiang, X (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA.	Xiong.Jiang@georgetown.edu	Ellis, Ronald/K-3543-2015	Ellis, Ronald/0000-0003-4931-752X	Georgetown University Partners In Research Award; Georgetown University; NIH [R56NS124422-01, 1R01MH108466]; Georgetown University Lisa J. Raines Summer Research Fellowship	Georgetown University Partners In Research Award; Georgetown University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgetown University Lisa J. Raines Summer Research Fellowship	This research was supported in part by Georgetown University Partners In Research Award, Georgetown University Lisa J. Raines Summer Research Fellowship, NIH 1R01MH108466, and NIH R56NS124422-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests:	Abidin AZ, 2020, J NEUROVIROL, V26, P188, DOI 10.1007/s13365-019-00823-1; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Auvichayapat P, 2018, J PAIN RES, V11, P2301, DOI 10.2147/JPR.S172920; Beckmann M, 2009, J NEUROSCI, V29, P1175, DOI 10.1523/JNEUROSCI.3328-08.2009; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Bladowska J, 2013, EUR J RADIOL, V82, P686, DOI 10.1016/j.ejrad.2012.11.029; Boban J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56330-0; Brockett AT, 2020, P NATL ACAD SCI USA, V117, P6196, DOI 10.1073/pnas.1919303117; Bronshteyn M, 2021, HUM BRAIN MAPP, V42, P3750, DOI 10.1002/hbm.25451; Brunner E, 2001, STAT PAP, V42, P1, DOI 10.1007/s003620000039; Buchanan DM, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11020212; Buchsbaum BR, 2005, HUM BRAIN MAPP, V25, P35, DOI 10.1002/hbm.20128; CARROLL RM, 1975, EDUC PSYCHOL MEAS, V35, P541, DOI 10.1177/001316447503500304; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Chhabra H, 2020, PSYCHIAT RES, V284, DOI 10.1016/j.psychres.2020.112744; Choi EY, 2017, NEUROIMAGE, V146, P821, DOI 10.1016/j.neuroimage.2016.09.037; Cody SL, 2020, APPL NEUROPSYCH-ADUL, V27, P267, DOI 10.1080/23279095.2018.1534736; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Csifcsak G, 2021, ENEURO, V8, DOI 10.1523/ENEURO.0041-21.2021; Dahmani S, 2021, NEUROLOGY, V97, pE1085, DOI 10.1212/WNL.0000000000012394; De Ridder D, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.10.046; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; DeMarco AT, 2021, COGN BEHAV NEUROL, V34, P96, DOI 10.1097/WNN.0000000000000270; Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040; Fazeli PL, 2019, APPL NEUROPSYCH-ADUL, V26, P36, DOI 10.1080/23279095.2017.1357037; Fregni F, 2015, Clin Res Regul Aff, V32, P22; Fregni F, 2021, INT J NEUROPSYCHOPH, V24, P256, DOI 10.1093/ijnp/pyaa051; Garvey LJ, 2014, AIDS, V28, P67, DOI 10.1097/01.aids.0000432467.54003.f7; Glascher J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07912-5; Haber SN, 2016, DIALOGUES CLIN NEURO, V18, P7; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; Hayward G, 2004, EXP BRAIN RES, V154, P355, DOI 10.1007/s00221-003-1665-4; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heilbronner SR, 2016, ANNU REV NEUROSCI, V39, P149, DOI 10.1146/annurev-neuro-070815-013952; Hoare J, 2016, NEUROLOGY, V87, P86, DOI 10.1212/WNL.0000000000002669; Hoffstaedter F, 2014, HUM BRAIN MAPP, V35, P2741, DOI 10.1002/hbm.22363; Hohenfeld C, 2018, NEUROIMAGE-CLIN, V18, P849, DOI 10.1016/j.nicl.2018.03.013; Irollo E, 2021, CELL MOL LIFE SCI, V78, P4283, DOI 10.1007/s00018-021-03785-y; Israel SM, 2019, HUM BRAIN MAPP, V40, P3010, DOI 10.1002/hbm.24577; Jackson MP, 2016, CLIN NEUROPHYSIOL, V127, P3425, DOI 10.1016/j.clinph.2016.08.016; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jiang X, 2016, AIDS CARE, V28, P436, DOI 10.1080/09540121.2015.1112347; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Khan A, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.584136; Knotkova Helena, 2012, Front Psychiatry, V3, P59, DOI 10.3389/fpsyt.2012.00059; Konietschke F, 2015, J STAT SOFTW, V64; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Lacey EH, 2015, BRAIN STIMUL, V8, P305, DOI 10.1016/j.brs.2014.10.019; Le Heron C, 2018, NEUROPSYCHOLOGIA, V118, P54, DOI 10.1016/j.neuropsychologia.2017.07.003; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Modirrousta M, 2015, DEPRESS ANXIETY, V32, P445, DOI 10.1002/da.22363; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mohamed M, 2018, AM J NEURORADIOL, V39, P704, DOI 10.3174/ajnr.A5547; Nikolin S, 2018, BRAIN STIMUL, V11, P278, DOI 10.1016/j.brs.2017.10.020; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Noguchi K, 2012, J STAT SOFTW, V50, P1, DOI 10.18637/jss.v050.i12; Ownby RL, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.766311; Ownby RL, 2016, NEUROPSYCH DIS TREAT, V12, P2745, DOI 10.2147/NDT.S120282; Pope CN, 2018, TRANSPORT RES F-TRAF, V58, P1061, DOI 10.1016/j.trf.2018.08.002; Popov M, 2020, BRAIN IMAGING BEHAV, V14, P821, DOI 10.1007/s11682-018-0026-7; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Scarpina F, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00557; Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007; Stagg CJ, 2018, J ECT, V34, P144, DOI 10.1097/YCT.0000000000000510; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Taylor MJ, 2007, J NEUROVIROL, V13, P150, DOI 10.1080/13550280701194230; Tomiyama H, 2019, NEUROIMAGE-CLIN, V24, DOI 10.1016/j.nicl.2019.102004; Towgood KJ, 2013, HUM BRAIN MAPP, V34, P2484, DOI 10.1002/hbm.22078; Verveer I, 2021, BRAIN RES, V1756, DOI 10.1016/j.brainres.2021.147282; Walker KA, 2018, J CLIN EXP NEUROPSYC, V40, P357, DOI 10.1080/13803395.2017.1349879; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Yang FN, 2021, AIDS, V35, P727, DOI 10.1097/QAD.0000000000002840; Zheng HR, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv059	75	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269491	10.1371/journal.pone.026949	http://dx.doi.org/10.1371/journal.pone.026949			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35658059				2023-01-03	WOS:000843567600130
J	Li, QH; Tan, XR; Li, XQ; Tang, WX; Mei, L; Cheng, G; Zou, YR				Li, Qiaohong; Tan, Xuerong; Li, Xueqing; Tang, Wenxiu; Mei, Lin; Cheng, Gang; Zou, Yongrong			Efficacy and safety of combined oral sucrose and nonnutritive sucking in pain management for infants: A systematic review and meta-analysis	PLOS ONE			English	Review							PROCEDURAL PAIN; PRETERM INFANTS; NEONATAL PAIN; BREAST-MILK; HEEL LANCE; SCHOOL-AGE; RELIEF; PREMATURITY; RETINOPATHY; PROFILE	BackgroundPain management is currently important in neonatal intensive care unit (NICU). The superiority in pain relief of the combined oral sucrose (OS) and nonnutritive sucking (NNS) to other single intervention has not been well established. The administration of sucrose has been considered to potentially induce adverse events, which has been controversial. This study aims to investigate the combined effects and safety in comparison with other single intervention methods, including NNS, OS alone, breast milk and oral glucose. MethodsWe searched databases including Medline (via Pubmed), Embase (via Ovid), web of science, and Cochrane Library for randomized controlled trials from Jan 1, 2000 to Mar 31, 2021. The data were analyzed in the meta-analysis using Review manager Version 5.3. Pain score was the primary outcome in this meta-analysis. The adverse events were assessed qualitatively. ResultsA total of 16 studies were eligible in the meta-analysis. The results demonstrated a significant reduction in pain score in the NNS+OS group compared with NNS alone (SMD = -1.69, 95%CI, -1.69,-0.65) or sucrose alone (SMD = -1.39, 95% CI, -2.21,-0.57) during the painful procedures. When compared NNS+OS with breast milk, no significant difference was detected (SMD = -0.19, 95% CI: -0.5, 0.11). ConclusionThe combined effects of NNS and OS might be superior to other single intervention method. However, the effects might be mild for moderate-to-severe pain.	[Li, Qiaohong; Tan, Xuerong; Tang, Wenxiu; Mei, Lin; Cheng, Gang; Zou, Yongrong] Yaan Peoples Hosp, Dept Neonatol, Yaan, Sichuan, Peoples R China; [Li, Xueqing] Yaan Peoples Hosp, Dept Pediat, Yaan, Sichuan, Peoples R China		Zou, YR (corresponding author), Yaan Peoples Hosp, Dept Neonatol, Yaan, Sichuan, Peoples R China.	zwj135678@126.com			Project of Sichuan Provincial Health Commission [140108]	Project of Sichuan Provincial Health Commission	Our paper is supported by Project of Sichuan Provincial Health Commission in 2014 (NO: 140108). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asmerom Y, 2013, J PEDIATR-US, V163, P29, DOI 10.1016/j.jpeds.2012.12.088; Ballantyne M, 1999, CLIN J PAIN, V15, P297, DOI 10.1097/00002508-199912000-00006; Benoit B, 2021, EARLY HUM DEV, V154, DOI 10.1016/j.earlhumdev.2021.105308; Bland M., 2015, INT J STAT MED RES, V4, P57, DOI [10.6000/1929-6029.2015.04.01.6, DOI 10.6000/1929-6029.2015.04.01.6]; Bouza H, 2009, J MATERN-FETAL NEO M, V22, P722, DOI [10.1080/14767050902926962, 10.3109/14767050902926962]; Boyle EM, 2006, ARCH DIS CHILD-FETAL, V91, pF166, DOI 10.1136/adc.2005.087668; Bueno M, 2013, PAIN RES MANAG, V18, P153, DOI 10.1155/2013/956549; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Collados-Gomez L, 2018, ACTA PAEDIATR, V107, P436, DOI 10.1111/apa.14151; Cullas Ilarslan N., 2012, ARCH DIS CHILD, V97, pA55, DOI [10.1136/archdischild-2012-302724.0190, DOI 10.1136/ARCHDISCHILD-2012-302724.0190]; De Bernardo G, 2019, J PAIN RES, V12, P299, DOI 10.2147/JPR.S184504; de Freitas RL, 2012, PHARMACOL BIOCHEM BE, V101, P265, DOI 10.1016/j.pbb.2011.12.005; Dilli D, 2014, ACTA PAEDIATR, V103, pE76, DOI 10.1111/apa.12454; Doesburg SM, 2013, PAIN, V154, P1946, DOI 10.1016/j.pain.2013.04.009; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; Elserafy FA, 2009, ANN SAUDI MED, V29, P184, DOI 10.5144/0256-4947.52821; Gao HX, 2018, INT J NURS STUD, V83, P25, DOI 10.1016/j.ijnurstu.2018.04.006; Gibbins S, 2002, NURS RES, V51, P375, DOI 10.1097/00006199-200211000-00005; Gibbins S, 2001, Pain Res Manag, V6, P21; Gibbins Sharyn, 2003, Adv Neonatal Care, V3, P241, DOI 10.1016/j.adnc.2003.08.004; Grabska Joanna, 2005, J Perinatol, V25, P33, DOI 10.1038/sj.jp.7211199; Hall RW, 2014, CLIN PERINATOL, V41, P895, DOI 10.1016/j.clp.2014.08.010; Hatfield LA, 2019, J PEDIATR NURS, V44, P22, DOI 10.1016/j.pedn.2018.10.004; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Hummel P, 2010, J PERINATOL, V30, P474, DOI 10.1038/jp.2009.185; Jeong IS, 2014, ASIAN NURS RES, V8, P261, DOI 10.1016/j.anr.2014.05.008; Johnston C, 2011, CLIN J PAIN, V27, P225, DOI 10.1097/AJP.0b013e3181fe14cf; Kyololo OM, 2014, ARCH DIS CHILD-FETAL, V99, pF464, DOI 10.1136/archdischild-2014-306003; Lawrence J, 1993, Neonatal Netw, V12, P59; Leng HY, 2016, EUR J PAIN, V20, P989, DOI 10.1002/ejp.824; Liaw JJ, 2011, J PAIN SYMPTOM MANAG, V42, P918, DOI 10.1016/j.jpainsymman.2011.02.016; Lim Y, 2017, ARCH DIS CHILDHOOD-E, V102, P254, DOI 10.1136/archdischild-2016-311066; Liu Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006108; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mandee S, 2021, EUR J PEDIATR SURG, V31, P439, DOI 10.1055/s-0040-1716883; McNair C, 2019, CLIN PERINATOL, V46, P709, DOI 10.1016/j.clp.2019.08.006; Meesters N, 2017, ARCH DIS CHILD-FETAL, V102, pF167, DOI 10.1136/archdischild-2016-310841; Metres O, 2019, J PEDIATR NURS, V49, pE81, DOI 10.1016/j.pedn.2019.08.013; Miller HD., 2009, ADV NEONAT CARE, P142, DOI [10.1097/01.ANC.0000360173.97702.0d, DOI 10.1097/01.ANC.0000360173.97702.0D]; Mitchell AJ, 2016, ACTA PAEDIATR, V105, P1434, DOI 10.1111/apa.13581; Neto MG, 2020, EUR J PEDIATR, V179, P699, DOI 10.1007/s00431-020-03640-5; O'Sullivan A, 2010, ARCH DIS CHILD-FETAL, V95, pF419, DOI 10.1136/adc.2009.180943; Olsen EA, 2013, CURR OPIN ANESTHESIO, V26, P535, DOI 10.1097/01.aco.0000433061.59939.b7; Peng HF, 2018, INT J NURS STUD, V77, P162, DOI 10.1016/j.ijnurstu.2017.10.001; Perry M, 2018, CRIT CARE NURS CLIN, V30, P549, DOI 10.1016/j.cnc.2018.07.013; Peters JWB, 2003, CLIN J PAIN, V19, P353, DOI 10.1097/00002508-200311000-00003; Pirelli A, 2019, ACTA PAEDIATR, V108, P593, DOI 10.1111/apa.14523; Qiu J, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0755-y; Review Manager (RevMan), 2014, REV MAN REVMAN VERS; Shah PS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004950.pub3; Shah SR, 2017, J PEDIATR-US, V190, P153, DOI 10.1016/j.jpeds.2017.08.003; Shah Vibhuti, 2015, Clin J Pain, V31, pS38, DOI 10.1097/AJP.0000000000000281; Squillaro A, 2019, CLIN THER, V41, P1701, DOI 10.1016/j.clinthera.2019.07.014; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Stevens B, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1026-x; Stevens B, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001069.pub5; Stevens BJ, 2014, CLIN J PAIN, V30, P238, DOI 10.1097/AJP.0b013e3182906aed; Thakkar P, 2016, J PERINATOL, V36, P67, DOI 10.1038/jp.2015.122; Thrane SE, 2016, J PEDIATR NURS, V31, pE23, DOI 10.1016/j.pedn.2015.09.002; Ucar S., 2014, ARCH DIS CHILD, V2, pA182, DOI [10.1136/archdischild-2014-307384.491, DOI 10.1136/ARCHDISCHILD-2014-307384.491]; Uematsu H, 2019, PAED CHILD HEALT-CAN, V24, pE33, DOI 10.1093/pch/pxy072; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Zeller B, 2014, NEONATAL NETW, V33, P336, DOI 10.1891/0730-0832.33.6.336	63	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5								10.1371/journal.pone.0268033	http://dx.doi.org/10.1371/journal.pone.0268033			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M1MQ	35522649	gold, Green Published			2023-01-03	WOS:000835222600021
J	Tsutsue, S; Makita, S; Yi, JB; Crawford, B				Tsutsue, Saaya; Makita, Shinichi; Yi, Jingbo; Crawford, Bruce			Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis	PLOS ONE			English	Article							TRANSPLANTATION; RITUXIMAB; OUTCOMES	Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma of increasing prevalence in Japan. However, patients with relapsed or refractory disease to first line treatment (rrDLBCL) have been found to shoulder greater economic burden and have poor survival with subsequent lines of therapy. The relative impact of individual patient attributes on total medical cost among patients with rrDLBCL receiving second or third line (2L/3L) therapy was assessed. Structural equation modelling was used to identify potential cost drivers of total medical costs incurred by treatment and procedures in a Japanese retrospective claims database. From the database, rrDLBCL patients on 2L or 3L of treatment were grouped into respective cohorts. The mean [median] (SD) total medical cost of care for the 2L cohort was 73,296.40 [58,223.11] (58,409.79) US dollars (USD) and 75,238.35 [60,477.31] (59,583.66) USD for the 3L cohort. The largest total effect on medical cost in both cohorts was length of hospital stay (LOS) (beta: 0.750 [95%CI: 0.728, 0.772] vs beta: 0.762 [95%CI: 0.729, 0.794]). Length of hospital stay and potential heart disease complications due to line of treatment were the primary drivers of total cost for patients who had received at least 2L or 3L therapy for rrDLBCL.	[Tsutsue, Saaya] Celgene KK Bristol Myers Squibb Co, Tokyo, Japan; [Makita, Shinichi] Natl Canc Ctr, Tokyo, Japan; [Yi, Jingbo; Crawford, Bruce] Syneos Hlth, Tokyo, Japan	National Cancer Center - Japan	Tsutsue, S (corresponding author), Celgene KK Bristol Myers Squibb Co, Tokyo, Japan.	saayatsutsue@13.alumni.u-tokyo.ac.jp	Tsutsué, Saaya/ABC-6731-2020	Tsutsué, Saaya/0000-0002-8412-8778	Celgene KK; Bristol Myers Squibb Company	Celgene KK(Bristol-Myers SquibbCelgene Corporation); Bristol Myers Squibb Company(Bristol-Myers Squibb)	This study was sponsored by Celgene KK., Bristol Myers Squibb Company.	BENTLER PM, 1983, PSYCHOMETRIKA, V48, P493, DOI 10.1007/BF02293875; Bryan A, 2007, AIDS BEHAV, V11, P365, DOI 10.1007/s10461-006-9150-2; Chihara D, 2015, INT J CANCER, V137, P1217, DOI 10.1002/ijc.29477; Chihara D, 2014, BRIT J HAEMATOL, V164, P536, DOI 10.1111/bjh.12659; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Gisselbrecht C, 2012, J CLIN ONCOL, V30, P4462, DOI 10.1200/JCO.2012.41.9416; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Huntington S, 2018, LEUKEMIA LYMPHOMA, V59, P2880, DOI 10.1080/10428194.2018.1459613; Javaugue V, 2019, KIDNEY INT, V96, P94, DOI 10.1016/j.kint.2019.01.027; Kondo E, 2016, J CLIN EXP HEMATOP, V56, P100; Lai K, 2019, STRUCT EQU MODELING, V26, P260, DOI 10.1080/10705511.2018.1505522; Lee RC, 2008, VALUE HEALTH, V11, P221, DOI 10.1111/j.1524-4733.2007.00227.x; Miyoshi H, 2018, INT J HEMATOL, V107, P420, DOI 10.1007/s12185-018-2430-6; Mizia-Stec K, 2018, MED ONCOL, V35, DOI 10.1007/s12032-017-1075-2; Morrison VA, 2018, FUTURE ONCOL, V14, P2627, DOI 10.2217/fon-2018-0267; Nagaura T, 1991, PROG BATTERIES BATTE, V10, P218; Nagle SJ, 2013, AM J HEMATOL, V88, P890, DOI 10.1002/ajh.23524; Oki Y, 2008, CANCER SCI, V99, P179, DOI 10.1111/j.1349-7006.2007.00662.x; Orimo Hajime, 2017, Osteoporos Sarcopenia, V3, P174, DOI 10.1016/j.afos.2017.10.002; Purdum A, 2019, ONCOLOGIST, V24, P1229, DOI 10.1634/theoncologist.2018-0490; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Radford J, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123664; Rijnhart JJM, 2017, CONT CLIN TRIAL COMM, V7, P130, DOI 10.1016/j.conctc.2017.06.005; Rosseel Y., 2021, LAVAAN LATENT VARIAB; Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02; Shi Q, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7960907; Sruamsiri R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011491; Statistical Bureau of Japan, 2015, BAS EXPL CONS PRIC I; Tsutsue S, 2021, FUTURE ONCOL, V17, P4511, DOI 10.2217/fon-2021-0400; Tsutsue S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237509; Zelenetz AD, 2019, J NATL COMPR CANC NE, V17, P651, DOI 10.6004/jnccn.2019.0029	31	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5							e0269169	10.1371/journal.pone.0269169	http://dx.doi.org/10.1371/journal.pone.0269169			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L8PY	35622820	gold, Green Published			2023-01-03	WOS:000835025800001
J	Uneda, K; Kawai, Y; Yamada, T; Kaneko, A; Saito, R; Chen, L; Ishigami, T; Namiki, T; Mitsuma, T				Uneda, Kazushi; Kawai, Yuki; Yamada, Takayuki; Kaneko, Akira; Saito, Ryuji; Chen, Lin; Ishigami, Tomoaki; Namiki, Takao; Mitsuma, Tadamichi			Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis	PLOS ONE			English	Review							BOFU-TSUSHO-SAN; ORIENTAL HERBAL MEDICINE; WEIGHT-LOSS; CONTROLLED-TRIAL; RISK-FACTORS; OVERWEIGHT; ADULTS; MORTALITY; EFFICACY; INTERVENTIONS	BackgroundThe number of people with obesity is rapidly increasing worldwide. Since obesity is a critical risk factor for cardiovascular diseases and mortality, the management of obesity is an urgent issue. However, anti-obesity drugs are insufficient in current clinical settings. Bofutsushosan (BTS, Fang-Feng-Tong-Sheng-San in China) is a traditional Japanese Kampo formula for patients with obesity. Recent basic studies have indicated that BTS potentially improves the pathophysiology of obesity. However, it is still unknown whether BTS clinically reduces body mass index (BMI) in patients with obesity. MethodsWe searched electronic databases, including the Medline, EMBASE, Cochrane Library, and Japanese/Chinese/Korean databases, on June 15, 2021. We conducted a meta-analysis of randomized controlled trials to evaluate the effects of BTS on BMI, waist circumference, glycolipid metabolism, and blood pressure in participants with obesity. The primary outcome was change in BMI. ResultsWe included seven studies and 679 participants (351 in the BTS group and 328 in the control group). In participants with obesity, BTS significantly reduced BMI relative to controls (mean difference, MD [95% confidence interval]: -0.52 kg/m(2) [-0.86, -0.18], P = 0.003). There was no significant difference in waist circumference, glycolipid parameters, or blood pressure. Sensitivity analyses showed robust outcomes for the primary endpoint, although the heterogeneity was considerable. Moreover, no serious adverse events were observed in the BTS group. ConclusionBTS showed a potential benefit in safely and tolerably improving BMI in participants with obesity.	[Uneda, Kazushi; Kaneko, Akira; Saito, Ryuji; Mitsuma, Tadamichi] Fukushima Med Univ, Aizu Med Ctr, Dept Kampo Med, Sch Med, Aizu Wakamatsu, Fukushima, Japan; [Uneda, Kazushi; Kawai, Yuki; Yamada, Takayuki; Chen, Lin; Ishigami, Tomoaki] Yokohama City Univ, Dept Med Sci & Cardiorenal Med, Grad Sch Med, Yokohama, Kanagawa, Japan; [Yamada, Takayuki] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA; [Chen, Lin] Nanjing Med Univ, Sir Run Run Hosp, Dept Cardiol, Nanjing, Peoples R China; [Namiki, Takao] Chiba Univ, Grad Sch Med, Dept Japanese Oriental Kampo Med, Chiba, Japan	Yokohama City University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nanjing Medical University; Chiba University	Uneda, K (corresponding author), Fukushima Med Univ, Aizu Med Ctr, Dept Kampo Med, Sch Med, Aizu Wakamatsu, Fukushima, Japan.; Uneda, K (corresponding author), Yokohama City Univ, Dept Med Sci & Cardiorenal Med, Grad Sch Med, Yokohama, Kanagawa, Japan.	uneda@fmu.ac.jp		Uneda, Kazushi/0000-0002-9660-142X				Akaki J., 2019, J NEW REM CLIN, V68, P766; Akaki J, 2018, J ETHNOPHARMACOL, V220, P1, DOI 10.1016/j.jep.2018.03.028; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS100, DOI 10.2337/dc21-S008; Apovian CM, 2013, OBESITY, V21, P935, DOI 10.1002/oby.20309; Azushima K, 2015, ATHEROSCLEROSIS, V240, P297, DOI 10.1016/j.atherosclerosis.2015.01.025; Azushima K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075560; Beiroa D, 2014, DIABETES, V63, P3346, DOI 10.2337/db14-0302; Benotti PN, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005126; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Csige I, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/3407306; Davies MJ, 2015, JAMA-J AM MED ASSOC, V314, P687, DOI 10.1001/jama.2015.9676; Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Finer N, 2021, EUR J INTERN MED, V93, P13, DOI 10.1016/j.ejim.2021.04.024; Fujisaka S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62506-w; Garvey WT, 2012, AM J CLIN NUTR, V95, P297, DOI 10.3945/ajcn.111.024927; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hioki C, 2004, CLIN EXP PHARMACOL P, V31, P614, DOI 10.1111/j.1440-1681.2004.04056.x; Hoshino N, 2018, INT J CLIN ONCOL, V23, P434, DOI 10.1007/s10147-017-1229-4; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Kim Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018507; Kobayashi S, 2018, YAKUGAKU ZASSHI, V138, P389, DOI 10.1248/yakushi.17-00168; Kobayashi S, 2017, CHIN MED-UK, V12, DOI 10.1186/s13020-017-0129-x; Koliaki C, 2019, METABOLISM, V92, P98, DOI 10.1016/j.metabol.2018.10.011; La Sala L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218178; Liu JH, 2007, NEUROCHEM INT, V51, P361, DOI 10.1016/j.neuint.2007.04.021; Lucchetta RC, 2017, CLINICS, V72, P317, DOI 10.6061/clinics/2017(05)10; Ma CH, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4849; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Murase K, 2013, AM J RESP CRIT CARE, V187; Namiki T., 2007, UEHARA KINEN SEIMEI, V21, P60; Nishiyama M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030839; Nissen SE, 2016, JAMA-J AM MED ASSOC, V315, P990, DOI 10.1001/jama.2016.1558; Park J, 2014, J MED FOOD, V17, P558, DOI 10.1089/jmf.2013.2836; Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892; Rucker D, 2007, BMJ-BRIT MED J, V335, P1194, DOI 10.1136/bmj.39385.413113.25; Shimada T, 2008, BIOL PHARM BULL, V31, P1362, DOI 10.1248/bpb.31.1362; Singh AK, 2020, EXPERT REV CLIN PHAR, V13, P53, DOI 10.1080/17512433.2020.1698291; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Uneda K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89620-7; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; WHO, WHO INT NEWS FACT SH; Wu Y., 2011, HUBEI J TRADITIONAL, V33, P23; Xu FH., 2012, E MED, V28, P37; YOSHIDA T, 1995, INT J OBESITY, V19, P717; Yoshino T, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2474-z; Yumuk V, 2015, OBESITY FACTS, V8, P402, DOI 10.1159/000442721	48	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266917	10.1371/journal.pone.0266917	http://dx.doi.org/10.1371/journal.pone.0266917			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1A8IV	35417488	gold, Green Published			2023-01-03	WOS:000791994200030
J	Srivastava, D				Srivastava, Deepak			Cellular cross-talk in heart repair	SCIENCE			English	Editorial Material								The cytokine meteorin-like (METRNL) improves cardiac function after heart attack in mice	[Srivastava, Deepak] Gladstone Inst, San Francisco, CA 94158 USA; [Srivastava, Deepak] Roddenberry Stem Cell Ctr Gladstone, San Francisco, CA 94158 USA; [Srivastava, Deepak] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Srivastava, Deepak] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Srivastava, D (corresponding author), Gladstone Inst, San Francisco, CA 94158 USA.; Srivastava, D (corresponding author), Roddenberry Stem Cell Ctr Gladstone, San Francisco, CA 94158 USA.; Srivastava, D (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.; Srivastava, D (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	dsrivastava@gladstone.ucsf.edu						Collen A, 2022, NAT REV DRUG DISCOV, V21, P79, DOI 10.1038/s41573-021-00355-6; Kim KL, 2019, ARTERIOSCL THROM VAS, V39, P2120, DOI 10.1161/ATVBAHA.119.313179; Reboll MR, 2022, SCIENCE, V376, P1343, DOI 10.1126/science.abn3027; Ruperez C, 2021, J EXP MED, V218, DOI 10.1084/jem.20201206; Swirski FK, 2018, NAT REV IMMUNOL, V18, P733, DOI 10.1038/s41577-018-0065-8; Ushach I, 2018, J IMMUNOL, V201, P3669, DOI 10.4049/jimmunol.1800435; Yla-Herttuala S, 2017, MOL THER, V25, P1095, DOI 10.1016/j.ymthe.2017.03.027	7	0	0	14	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2022	376	6599					1271	1272		10.1126/science.adc8698	http://dx.doi.org/10.1126/science.adc8698			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2I5YE	35709257				2023-01-03	WOS:000815052900028
J	Heesakkers, H; van den Boogaard, M; Zegers, M				Heesakkers, Hidde; van den Boogaard, Mark; Zegers, Marieke			Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19 Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VALIDATION		[Heesakkers, Hidde; van den Boogaard, Mark; Zegers, Marieke] Radboud Univ Nijmegen Med Ctr, Dept Intens Care Med, Nijmegen, Netherlands	Radboud University Nijmegen	Heesakkers, H (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Intens Care Med, POB 9101, NL-6500 HB Nijmegen, Netherlands.	hidde.heesakkers@radboudumc.nl	van den Boogaard, M./N-5857-2014	van den Boogaard, M./0000-0003-4233-2903; Zegers, Marieke/0000-0002-7472-6184				Heesakkers H, 2022, JAMA-J AM MED ASSOC, V327, P559, DOI 10.1001/jama.2022.0040; Latronico N, 2017, INTENS CARE MED, V43, P1270, DOI 10.1007/s00134-017-4757-5; Needham DM, 2017, AM J RESP CRIT CARE, V196, P1122, DOI 10.1164/rccm.201702-0372OC; Ponds R., 2006, TIJDSCHRIFT NEUROPSY, V2, P37; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2022	327	21								10.1001/jama.2022.5895	http://dx.doi.org/10.1001/jama.2022.5895			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E5JY	35670789				2023-01-03	WOS:000812264900031
J	Dusetzina, SB				Dusetzina, Stacie B.			Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The High Cost of Cancer Drugs under Medicare Part D The financial burden associated with orally administered anticancer drugs can be overwhelming for Medicare beneficiaries. Policies adding an out-of-pocket spending cap to Part D have been proposed, and Congress could permit price negotiation for anticancer drugs.	[Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Dusetzina, Stacie B.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Dusetzina, SB (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA.; Dusetzina, SB (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.							[Anonymous], 2022, FACT SHEET PRESIDENT; [Anonymous], 2021, PROFILE OLDER AMERIC; [Anonymous], FINANCIAL TOXICITY C; Ma CX., 2022, UPTODATE; Schott AF, 2021, UPTODATE	5	4	4	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2022	386	23					2164	2167		10.1056/NEJMp2202726	http://dx.doi.org/10.1056/NEJMp2202726		MAY 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E5LO	35507526				2023-01-03	WOS:000793800400001
J	Dobashi, Y; Yao, D; Petel, Y; Nguyen, TN; Sarwar, MS; Thabet, Y; Ng, CLW; Glitz, ES; Nguyen, GTM; Plesse, C; Vidal, F; Michal, CA; Madden, JDW				Dobashi, Yuta; Yao, Dickson; Petel, Yael; Tan Ngoc Nguyen; Sarwar, Mirza Saquib; Thabet, Yacine; Ng, Cliff L. W.; Glitz, Ettore Scabeni; Giao Tran Minh Nguyen; Plesse, Cedric; Vidal, Frederic; Michal, Carl A.; Madden, John D. W.			Piezoionic mechanoreceptors: Force-induced current generation in hydrogels	SCIENCE			English	Article							POLYMER ELECTROLYTES; PROPYLENE CARBONATE; TRANSPORT; SOFT; SENSORS; CONDUCTIVITY; TRANSDUCTION; TRANSPARENT; MECHANISMS; VISCOSITY	The human somatosensory network relies on ionic currents to sense, transmit, and process tactile information. We investigate hydrogels that similarly transduce pressure into ionic currents, forming a piezoionic skin. As in rapid- and slow-adapting mechanoreceptors, piezoionic currents can vary widely in duration, from milliseconds to hundreds of seconds. These currents are shown to elicit direct neuromodulation and muscle excitation, suggesting a path toward bionic sensory interfaces. The signal magnitude and duration depend on cationic and anionic mobility differences. Patterned hydrogel films with gradients of fixed charge provide voltage offsets akin to cell potentials. The combined effects enable the creation of self-powered and ultrasoft piezoionic mechanoreceptors that generate a charge density four to six orders of magnitude higher than those of triboelectric and piezoelectric devices.	[Dobashi, Yuta; Yao, Dickson; Tan Ngoc Nguyen; Sarwar, Mirza Saquib; Thabet, Yacine; Ng, Cliff L. W.; Glitz, Ettore Scabeni; Madden, John D. W.] Univ British Columbia, Adv Mat & Proc Engn Lab, Vancouver, BC, Canada; [Dobashi, Yuta; Madden, John D. W.] Univ British Columbia, Fac Appl Sci, Sch Biomed Engn, Vancouver, BC, Canada; [Dobashi, Yuta] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Petel, Yael; Ng, Cliff L. W.; Michal, Carl A.] Univ British Columbia, Dept Chem, Vancouver, BC, Canada; [Tan Ngoc Nguyen; Sarwar, Mirza Saquib; Madden, John D. W.] Univ British Columbia, Dept Elect & Comp Engn, Vancouver, BC, Canada; [Giao Tran Minh Nguyen; Plesse, Cedric; Vidal, Frederic] CY Cergy Paris Univ, LPPI, CY Adv Studies, 5 Mail Gay Lussac, F-95031 Neuville Sur Oise, Cerg Pontoise, France; [Michal, Carl A.] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of Toronto; University of British Columbia; University of British Columbia; CY Cergy Paris Universite; University of British Columbia	Madden, JDW (corresponding author), Univ British Columbia, Adv Mat & Proc Engn Lab, Vancouver, BC, Canada.; Madden, JDW (corresponding author), Univ British Columbia, Fac Appl Sci, Sch Biomed Engn, Vancouver, BC, Canada.; Madden, JDW (corresponding author), Univ British Columbia, Dept Elect & Comp Engn, Vancouver, BC, Canada.	jmadden@ece.ubc.ca	; Michal, Carl/G-5288-2012	Petel, Yael/0000-0002-2834-373X; Dobashi, Yuta/0000-0002-6040-2197; Plesse, Cedric/0000-0001-9227-9544; Thabet, Yacine/0000-0002-5167-4617; Michal, Carl/0000-0002-5764-3221	Natural Sciences and Engineering Research Council of Canada (NSERC); Collaborative Research and Development Grant; Institute of Advanced Studies at CY Cergy Paris Universite through the Visiting Scholar program	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Collaborative Research and Development Grant; Institute of Advanced Studies at CY Cergy Paris Universite through the Visiting Scholar program	This study was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant and a Collaborative Research and Development Grant. J.D.W.M. was supported by the Institute of Advanced Studies at CY Cergy Paris Universite through the Visiting Scholar program.	Allegretto G, 2018, SMART MATER STRUCT, V27, DOI 10.1088/1361-665X/aac134; Bard A.J., 1980, ELECTROCHEMICAL METH; Chortos A, 2016, NAT MATER, V15, P937, DOI [10.1038/nmat4671, 10.1038/NMAT4671]; Dagdeviren C, 2014, P NATL ACAD SCI USA, V111, P1927, DOI 10.1073/pnas.1317233111; de Gennes PG, 2000, EUROPHYS LETT, V50, P513, DOI 10.1209/epl/i2000-00299-3; DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902; Delmas P, 2011, NAT REV NEUROSCI, V12, P139, DOI 10.1038/nrn2993; Dobashi Y., 2017, US patent, Patent No. [10,401,241, 10401241 10401241]; Dobashi Y, 2016, MRS ADV, V1, P63, DOI 10.1557/adv.2016.74; Fiumefreddo A, 2010, MACROMOLECULES, V43, P5814, DOI 10.1021/ma100565s; FRANK EH, 1987, J BIOMECH, V20, P615, DOI 10.1016/0021-9290(87)90282-X; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1; Jiang HT, 2019, PHYS CHEM CHEM PHYS, V21, P10417, DOI 10.1039/c8cp07552b; Kapur V, 1997, J MEMBRANE SCI, V131, P143, DOI 10.1016/S0376-7388(97)00037-9; Keplinger C, 2013, SCIENCE, V341, P984, DOI 10.1126/science.1240228; Kim CC, 2016, SCIENCE, V353, P682, DOI 10.1126/science.aaf8810; Kim DH, 2011, SCIENCE, V333, P838, DOI 10.1126/science.1206157; Klinkenberg L J, 1941, DRILLING PRODUCTION, DOI [10.5510/OGP20120200114, DOI 10.5510/OGP20120200114]; Kosto KB, 2005, BIOPHYS J, V88, P277, DOI 10.1529/biophysj.104.050302; Lee W, 2016, ADV MATER, V28, P9722, DOI 10.1002/adma.201602237; Liu Y, 2016, SMALL, V12, P5074, DOI 10.1002/smll.201600553; Liu YX, 2019, NAT BIOMED ENG, V3, P58, DOI 10.1038/s41551-018-0335-6; Madden J. D. W., 2018, US patent, Patent No. [10,663,358, 10663358 10663358]; Madden J. D. W., 2000, THESIS MIT; Mannsfeld SCB, 2010, NAT MATER, V9, P859, DOI [10.1038/NMAT2834, 10.1038/nmat2834]; MCCREERY DB, 1990, IEEE T BIO-MED ENG, V37, P996, DOI 10.1109/10.102812; MENDELSON M, 1964, SCIENCE, V144, P554, DOI 10.1126/science.144.3618.554; Michal CA, 2002, REV SCI INSTRUM, V73, P453, DOI 10.1063/1.1433950; MILLER ML, 1956, J PHYS CHEM-US, V60, P186, DOI 10.1021/j150536a012; Mirfakhrai T, 2011, IEEE-ASME T MECH, V16, P90, DOI 10.1109/TMECH.2010.2091420; Othman L, 2017, MATER TODAY-PROC, V4, P5122, DOI 10.1016/j.matpr.2017.05.017; PEI QB, 1993, SOLID STATE IONICS, V60, P161, DOI 10.1016/0167-2738(93)90291-A; Prudnikova K, 2010, MACROMOLECULES, V43, P511, DOI 10.1021/ma901899m; Pu X, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700015; Rohtlaid K, 2021, ADV MATER TECHNOL-US, V6, DOI 10.1002/admt.202001063; Ruch PW, 2009, ELECTROCHIM ACTA, V54, P4451, DOI 10.1016/j.electacta.2009.03.022; Sarwar M. S. us, 2015, SPIE SMART STRUCTURE; Sarwar MS, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602200; SAWAHATA K, 1995, MACROMOL RAPID COMM, V16, P713, DOI 10.1002/marc.1995.030161002; Sekhon SS, 2003, B MATER SCI, V26, P321, DOI 10.1007/BF02707454; Shoa TN, 2010, SENSOR ACTUAT A-PHYS, V161, P127, DOI 10.1016/j.sna.2010.04.024; Someya T, 2013, IEEE SPECTRUM, V50, P50, DOI 10.1109/MSPEC.2013.6587191; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun JY, 2014, ADV MATER, V26, P7608, DOI 10.1002/adma.201403441; Takalloo SE, 2019, ROBOTICS, V8, DOI 10.3390/robotics8030060; Takashima W, 2007, ELECTROCHEM COMMUN, V9, P2056, DOI 10.1016/j.elecom.2007.05.019; TOBISHIMA SI, 1985, ELECTROCHIM ACTA, V30, P1715, DOI 10.1016/0013-4686(85)87019-5; Torop J, 2011, CARBON, V49, P3113, DOI 10.1016/j.carbon.2011.03.034; UE M, 1994, J ELECTROCHEM SOC, V141, P3336, DOI 10.1149/1.2059336; Villa SM, 2019, ACS MACRO LETT, V8, P414, DOI 10.1021/acsmacrolett.8b01011; Vohrer U, 2004, CARBON, V42, P1159, DOI 10.1016/j.carbon.2003.12.044; Woehling V., 2019, MULTIFUNCT MAT, V2, DOI DOI 10.1088/2399-7532/AB56A2; Wu Y, 2007, ADV FUNCT MATER, V17, P3216, DOI 10.1002/adfm.200700060; Yuk H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12028; Zarrinkoob L, 2015, J CEREBR BLOOD F MET, V35, P648, DOI 10.1038/jcbfm.2014.241; Zhang SW, 2020, NANO LETT, V20, P4580, DOI 10.1021/acs.nanolett.0c01434	56	18	18	202	381	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	2022	376	6592					502	+		10.1126/science.aaw1974	http://dx.doi.org/10.1126/science.aaw1974			79	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z7IN	35482868				2023-01-03	WOS:000791247600072
J	Shepherd, A				Shepherd, Alison			Africa's lifesaving medical drones fly into action	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	2022	377								o1035	10.1136/bmj.o1035	http://dx.doi.org/10.1136/bmj.o1035			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H2FP	35477694				2023-01-03	WOS:000796361600007
J	Liu, SS; Lin, CC; Wei, JCC				Liu, Shu-Tsen; Lin, Chieh-Chung; Wei, James Cheng-Chung			Mediterranean Diet or Mindfulness-Based Stress Reduction and Prevention of Small-for-Gestational-Age Birth Weights in Newborns-Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Liu, Shu-Tsen] China Med Univ, Dept Child & Adolescent Psychiat, Childrens Hosp, Taichung, Taiwan; [Lin, Chieh-Chung] Taichung Vet Gen Hosp, Childrens Med Ctr, Taichung, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ, Chung Shan Med Univ Hosp, Taichung, Taiwan	China Medical University Taiwan; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Dept Med, 110 Jianguo N Rd,Sect 1, Taichung 40201, Taiwan.	jccwei@gmail.com			Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras; Hospital Clinic/Institut d'Investigacions Biomediques August Pi i Sunyer La Caixa Foundation; Cerebra Foundation; Agencia de Gestio d'Ajudes Universitaries i de Investigacio (AGAUR) [LCF/PR/GN18/10310003]; Cerebra Foundation for the Brain Injured Child; AGAUR Catalonian government [1531]; Editorial Medica Panamericana; Roche Diagnostics International	Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras; Hospital Clinic/Institut d'Investigacions Biomediques August Pi i Sunyer La Caixa Foundation; Cerebra Foundation; Agencia de Gestio d'Ajudes Universitaries i de Investigacio (AGAUR); Cerebra Foundation for the Brain Injured Child; AGAUR Catalonian government; Editorial Medica Panamericana; Roche Diagnostics International	Dr Crovetto reported receiving personal fees from the Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras for support for investigation (until July 2019) during the conduct of the study. Dr Crispi reported receiving grants from the Hospital Clinic/Institut d'Investigacions Biomediques August Pi i Sunyer La Caixa Foundation, Cerebra Foundation, and Agencia de Gestio d'Ajudes Universitaries i de Investigacio (AGAUR) during the conduct of the study. Dr Gratacos reported receiving grants from CaixaResearch (LCF/PR/GN18/10310003), the Cerebra Foundation for the Brain Injured Child, and AGAUR Catalonian government (2017 SGR No. 1531) during the conduct of the study and book royalties from Columna Edicions and Editorial Medica Panamericana and grants from Roche Diagnostics International (paid to his institution).	[Anonymous], 2018, PREGN MON PROT CAT, V3rd; Crovetto F, 2021, JAMA-J AM MED ASSOC, V326, P2150, DOI 10.1001/jama.2021.20178; Sevild CH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09111-8	3	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13								10.1001/jama.2022.2167	http://dx.doi.org/10.1001/jama.2022.2167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35380584				2023-01-03	WOS:000783965500030
J	Rubin, R				Rubin, Rita			Physicians in Ukraine: Caring for Patients in the Middle of a War	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2022	327	14					1318	1320		10.1001/jama.2022.4680	http://dx.doi.org/10.1001/jama.2022.4680		MAR 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1FH	35293959	Bronze			2023-01-03	WOS:000770397800001
J	Wammes, JD; Nakanishi, M; Van der Steen, JT; Vroomen, JLM				Wammes, Joost D.; Nakanishi, Miharu; van der Steen, Jenny T.; Vroomen, Janet L. MacNeil			The Revised Medical Care Act is associated with a decrease in hospital death for the total Japanese older adult population regardless of dementia status: An interrupted time series analysis	PLOS ONE			English	Article							OF-LIFE CARE; NURSING-HOMES; END; PLACE; PREVALENCE; PROGRAM; PEOPLE; IMPACT; POLICY	Background In 2006, Japan introduced the Revised Medical Care Act aimed to shift end-of-life care from hospitals to communities. For patients and families, dying in hospital can be highly distressing. Persons with dementia are especially susceptible to negative hospital-related outcomes. This study aims to evaluate whether the Revised Medical Care Act is associated with a decrease in the proportion of hospital deaths for older adults and persons with dementia over a 20-year period covering the reform. Methods and findings This is a population-level, repeated cross-sectional study using mortality data from Vital Statistics Japan. Participants were Japanese older adults 65 years or older with and without dementia who died between 1996 and 2016. The policy intervention was the 2006 Revised Medical Care Act that increased community care infrastructure. The primary outcome was location of death in hospital, nursing home, home, or elsewhere. The trend in the proportion of location of death, before and after the reforms was estimated using an interrupted time-series analysis. All analyses were adjusted for sex and seasonality. Of the 19,307,104 older adult decedents, 216,442 had dementia identified on their death certificate. Death in nursing home (1.10, 95% CI 1.10-1.10), home (1.08, 95% CI 1.08-1.08), and elsewhere (1.07, 95% CI 1.07-1.07) increased over time compared to hospital deaths for the total population after reform implementation. Nursing home (1.04, 95% CI 1.03-1.05) and home death (1.11, 95% CI 1.10-1.12) increased after reform implementation for persons with dementia. Conclusion This study provides evidence that the 2006 Revised Medical Care Act was associated with decreased older adults dying in hospital regardless of dementia status; however, hospital continues as the primary location of death.	[Wammes, Joost D.; Vroomen, Janet L. MacNeil] Univ Amsterdam, Dept Internal Med, Sect Geriatr Med, Amsterdam UMC, Amsterdam, Netherlands; [Nakanishi, Miharu] Tohoku Univ, Dept Psychiat Nursing, Grad Sch Med, Sendai, Miyagi, Japan; [van der Steen, Jenny T.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [van der Steen, Jenny T.] Radboud Univ Nijmegen, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands	University of Amsterdam; Tohoku University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	Wammes, JD (corresponding author), Univ Amsterdam, Dept Internal Med, Sect Geriatr Med, Amsterdam UMC, Amsterdam, Netherlands.	j.d.wammes@amsterdamumc.nl		Nakanishi, Miharu/0000-0001-6200-9279; Wammes, Joost/0000-0003-3260-2199	Netherlands Organization for Health Research and Development (NWO-ZonMw Veni) [091.619.060]	Netherlands Organization for Health Research and Development (NWO-ZonMw Veni)	J.L. MacNeil-Vroomen, the Netherlands Organization for Health Research and Development (NWO-ZonMw Veni, Grant number 091.619.060). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama A, 2012, ARCH GERONTOL GERIAT, V54, pE383, DOI 10.1016/j.archger.2012.01.004; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Broad JB, 2013, INT J PUBLIC HEALTH, V58, P257, DOI 10.1007/s00038-012-0394-5; Dodge Hiroko H, 2012, Int J Alzheimers Dis, V2012, P956354, DOI 10.1155/2012/956354; Fukui S, 2013, J PALLIAT CARE, V29, P22, DOI 10.1177/082585971302900104; Gao W, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6030107; Hayashi T, 2011, ARCH GERONTOL GERIAT, V53, P242, DOI 10.1016/j.archger.2010.12.005; Ikegami N, 2013, J AM MED DIR ASSOC, V14, P718, DOI 10.1016/j.jamda.2013.02.008; Ikegami N, 2012, HEALTH POLICY, V105, P303, DOI 10.1016/j.healthpol.2012.01.009; International Longevity Center Japan, 2020, OV REV LONG TERM CAR; Jandoc R, 2015, J CLIN EPIDEMIOL, V68, P950, DOI 10.1016/j.jclinepi.2014.12.018; Kalseth J, 2017, PALLIATIVE MED, V31, P964, DOI 10.1177/0269216317691259; Lee CY, 2010, ASIAN NURS RES, V4, P163, DOI 10.1016/S1976-1317(11)60001-7; Lehmann J, 2018, J ALZHEIMERS DIS, V64, P735, DOI 10.3233/JAD-171128; MacNeil Vroomen J, 2020, JAMDA; Martina D, 2021, J AM MED DIR ASSOC, V22, DOI 10.1016/j.jamda.2020.12.018; Martinsson L, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00639-5; Meeussen K, 2011, J PAIN SYMPTOM MANAG, V42, P565, DOI 10.1016/j.jpainsymman.2011.01.011; Ministry of Health Labor and Welfare, 2021, ELD CAR EST CAR SUPP; Ministry of Health Labor and Welfare, 2020, NUMB PERS WAIT LIST; Ministry of Health LaW, 2022, OV DYN SURV MED I HO; Ministry of Health LaW, 2010, FIN REP LONG TERM CA; Mukadam N, 2011, INT PSYCHOGERIATR, V23, P344, DOI 10.1017/S1041610210001717; Nakanishi M, 2019, GERIATR GERONTOL INT, V19, P829, DOI 10.1111/ggi.13729; Nakanishi M, 2015, AGEING INT, V40, P248, DOI 10.1007/s12126-014-9215-x; Nakanishi M, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.04.024; Nakanishi M, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2015.10.018; Nakanishi M, 2012, J AM MED DIR ASSOC, V13, P794, DOI 10.1016/j.jamda.2012.08.010; Ohmachi I, 2015, INT J GERONTOL, V9, P24, DOI 10.1016/j.ijge.2014.03.008; Okamura H, 2013, DEMENT GERIATR COGN, V36, P111, DOI 10.1159/000353444; Paddy Miranda, 2011, Nurs Stand, V26, P33; Phelan EA, 2012, JAMA-J AM MED ASSOC, V307, P165, DOI 10.1001/jama.2011.1964; Pivodic L, 2021, PALLIATIVE MED, V35, P369, DOI 10.1177/0269216320972036; Romero JP, 2014, J ALZHEIMERS DIS, V41, P213, DOI 10.3233/JAD-132765; Sakamoto H, 2018, JAPAN HLTH SYSTEM RE; Sato M, 2021, J AM MED DIR ASSOC, V22, P329, DOI 10.1016/j.jamda.2020.09.021; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Teno JM, 2016, JAMA ONCOL, V2, P957, DOI 10.1001/jamaoncol.2016.0441; Tsutsui T, 2014, INT J INTEGR CARE, V14; Vroomen JLM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241132; Worldbank, 2019, LOW MIDDL INC POP	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264624	10.1371/journal.pone.0264624	http://dx.doi.org/10.1371/journal.pone.0264624			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0D4YH	35239744	Green Published, gold			2023-01-03	WOS:000776002200052
J	Wang, ZJ; Zhang, Y; Lu, SS; Tan, LL; Guo, W; Lown, M; Hu, XY; Liu, JP				Wang, Zhijie; Zhang, Yu; Lu, Shanshan; Tan, Linlin; Guo, Wei; Lown, Mark; Hu, Xiaoyang; Liu, Jianping			Horticultural therapy for general health in the older adults: A systematic review and meta-analysis	PLOS ONE			English	Review							STRESS; ISSUES; IMPACT	Background With a pronounced and historically unprecedented tendency of population ageing, research on ageing and related disorders has been increasingly brought into focus. Horticultural therapy (HT), as an important role of social prescribing, has been an integrative for decades. This systematic review and meta-analysis aimed to evaluate HT for general health in older adults. Methods Electronic databases including PubMed, Web of Science, ScienceDirect, the Cochrane Library, MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCO), China National Knowledge Infrastructure (CNKI), and the Wanfang database, grey literature databases and clinical trials registers were searched from inception to March 2021. Randomized controlled trials (RCTs), quasi-RCTs (QRCTs) and the cohort studies about HT for adults aged over 60 were included in this study. Outcome measures were physical function, quality of life, BMI, mood tested by self-reported questionnaire and the expression of the immune cells. The study was registered under PROSPERO (CRD42019146184). Results Totally, fifteen studies (thirteen RCTs and two cohort studies) involving 1046 older participants were included. Meta-analysis showed that HT resulted in better quality of life (MD 2.09, 95% CI [1.33, 2.85], P<0. 01) and physical function (SMD 0.82, 95% [0.36, 1.29], P<0.01) compared with no-gardener; the similar findings showed in BMI (SMD -0.30, 95% [-0.57, -0.04], P = 0.02) and mood tested by self-reported questionnaire (SMD 2.80, 95% CI [1.82, 3.79], P<0. 01). And HT might be conducive on blood pressure and immunity, while all the evidence were moderate-quality judged by GRADE. Conclusions HT may improve physical function and quality of life in older adults, reduce BMI and enhance positive mood. A suitable duration of HT may be between 60 to 120 minutes per week lasting 1.5 to 12 months. However, it remains unclear as to what constitutes an optimal recommendation.	[Wang, Zhijie; Tan, Linlin] Shanxi Prov Hosp Tradit Chinese Med, Dept Oncol, Taiyuan, Shanxi, Peoples R China; [Zhang, Yu] Anhui Univ Chinese Med, Dept Tuina, Affiliated Hosp 1, Hefei, Anhui, Peoples R China; [Lu, Shanshan] Beijing Floriculture Engn Technol Res Ctr, Beijing Lab Urban & Rural Ecol Environm, Beijing Bot Garden, Beijing, Peoples R China; [Guo, Wei] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Lown, Mark; Hu, Xiaoyang] Univ Southampton, Fac Med, Primary Care Populat Sci & Med Educ, Southampton, Hants, England; [Liu, Jianping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China	Anhui University of Chinese Medicine; Guangzhou University of Chinese Medicine; University of Southampton; Beijing University of Chinese Medicine	Wang, ZJ (corresponding author), Shanxi Prov Hosp Tradit Chinese Med, Dept Oncol, Taiyuan, Shanxi, Peoples R China.; Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	wang15244616809@126.com; liujp@bucm.edu.cn	Hu, Xiao-Yang/AGD-5115-2022	Hu, Xiao-Yang/0000-0002-3143-7999; Wang, Zhijie/0000-0002-9361-6570; Lown, Mark/0000-0001-8309-568X	Scientific Research Project of Shanxi Provincial Health Commission [2020050]; Youth Basic Research Program of Shanxi Province [20210302124087]	Scientific Research Project of Shanxi Provincial Health Commission; Youth Basic Research Program of Shanxi Province	This study was supported by Scientific Research Project of Shanxi Provincial Health Commission (No. 2020050), and Youth Basic Research Program of Shanxi Province (20210302124087) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alderson P, 2004, COCHRANE LIB; American Horticultural Therapy Association, 2011, US; Andrews GR, 2001, J RURAL HEALTH, V17, P323; Bazzano Lydia A, 2003, Curr Atheroscler Rep, V5, P492, DOI 10.1007/s11883-003-0040-z; Blake Marianne, 2016, Nurs Stand, V30, P41, DOI 10.7748/ns.30.21.41.s44; Bloom DE, 2015, LANCET, V385, P649, DOI 10.1016/S0140-6736(14)61464-1; Bloom DE, 2011, SCIENCE, V333, P562, DOI 10.1126/science.1209290; Carnes D, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2778-y; Charles L.G., 2014, NCT02225847; Chen Y.J., 2018, HLTH ED HLTH PROMOTI, V13, P555, DOI [10.16117/j.cnki.31-1974/r.201806024, DOI 10.16117/J.CNKI.31-1974/R.201806024]; Demark-Wahnefried W, 2018, J ACAD NUTR DIET, V118, P689, DOI 10.1016/j.jand.2017.11.001; Detweiler MB, 2015, ALTERN THER HEALTH M, V21, P36; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fahy N, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3815; FLOURNOY RL, 1975, HOSP COMMUNITY PSYCH, V26, P75; Frostick C, 2019, BRIT J GEN PRACT, V69, P538, DOI 10.3399/bjgp19X706157; Gonzalez Marianne Thorsen, 2009, Res Theory Nurs Pract, V23, P312; Graybill EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102705; Han AR, 2018, COMPLEMENT THER MED, V38, P19, DOI 10.1016/j.ctim.2018.03.011; Jarrott SE, 2010, AM J ALZHEIMERS DIS, V25, P657, DOI 10.1177/1533317510385810; Julian P.T.H., 2011, MANUAL COCHRANE REVI; Leng CHH, 2016, CLIN INTERV AGING, V11, P947, DOI 10.2147/CIA.S107197; Liu Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009413.pub2; Loftus AM, 2017, PUBLIC HEALTH, V148, P96, DOI 10.1016/j.puhe.2017.03.010; Lombard Kevin A, 2006, Rural Remote Health, V6, P640; Luk KY, 2011, INT J GERIATR PSYCH, V26, P435, DOI 10.1002/gps.2493; McPhail SM, 2016, RISK MANAG HEALTHC P, V9, P143, DOI 10.2147/RMHP.S97248; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; MORLEY JE, 1995, ANN INTERN MED, V123, P850, DOI 10.7326/0003-4819-123-11-199512010-00008; Ng KST, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081705; OECD, 2011, PENS GLANC 2011 RET; Park SA, 2016, KOREAN J HORTIC SCI, V34, P513, DOI 10.12972/kjhst.20160053; Public Health England, 2019, SOC PRESCR APPL ALL; Raju MSVK, 2018, INDIAN J PSYCHIAT, V60, P295, DOI 10.4103/0019-5545.224466; Russell K, 2008, LANCET, V371, P2056, DOI 10.1016/S0140-6736(08)60877-6; Santoni C, 2019, EDUC PRIM CARE, V30, P361, DOI 10.1080/14739879.2019.1669223; Shellman JM, 2014, J NURS MEAS, V22, P500, DOI 10.1891/1061-3749.22.3.500; Shiue I, 2016, SCAND J OCCUP THER, V23, P320, DOI 10.3109/11038128.2015.1085596; Soderback Ingrid, 2004, Pediatr Rehabil, V7, P245, DOI 10.1080/13638490410001711416; Soga M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14010071; Tavares Beatriz, 2006, Allergol Immunopathol (Madr), V34, P73, DOI 10.1157/13086751; Teig E, 2009, HEALTH PLACE, V15, P1115, DOI 10.1016/j.healthplace.2009.06.003; Verra ML, 2012, ALTERN THER HEALTH M, V18, P44; Wakefield S, 2007, HEALTH PROMOT INT, V22, P92, DOI 10.1093/heapro/dam001; Wang Z, 2019, CRD42019146184 PROSP; Watson DLB, 2011, PERSPECT PUBLIC HEAL, V131, P163, DOI 10.1177/1757913911412475; Wichrowski Matthew, 2005, J Cardiopulm Rehabil, V25, P270, DOI 10.1097/00008483-200509000-00008; Yang S, 2015, MENTAL HLTH STATUS I; Yao YF, 2017, QUAL LIFE RES, V26, P1007, DOI 10.1007/s11136-016-1425-0	49	2	2	8	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2022	17	2							e0263598	10.1371/journal.pone.0263598	http://dx.doi.org/10.1371/journal.pone.0263598			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1J1AU	35143551	Green Published, gold, Green Accepted			2023-01-03	WOS:000797657800061
J	Rzhevskiy, A; Popov, A; Pavlov, C; Anissimov, Y; Zvyagin, A; Levin, Y; Kochba, E				Rzhevskiy, Alexey; Popov, Andrei; Pavlov, Chavdar; Anissimov, Yuri; Zvyagin, Andrei; Levin, Yotam; Kochba, Efrat			Intradermal injection of lidocaine with a microneedle device to provide rapid local anaesthesia for peripheral intravenous cannulation: A randomised open-label placebo-controlled clinical trial	PLOS ONE			English	Article							VISUAL ANALOG SCALE; INFLUENZA VACCINE; JET-INJECTION; IMMUNOGENICITY; DELIVERY; SAFETY; PAIN; CHILDREN; COMPARE; SYSTEM	Background Peripheral venous cannulation is one of the most common procedures in medicine. It is associated with noticeable pain and apprehension, although in most cases it is performed without any anesthesia due to lack of a painless, cost-effective option, which would provide rapid local anesthesia with subsequent significant reduction in the experienced pain. We conducted an open-label placebo-controlled clinical trial to evaluate the efficacy and safety of a 2% lidocaine injection using the commercially available microneedle device Minron-Jet600 (NanoPass Technologies Ltd, Israel) to achieve rapid local anesthesia prior to peripheral venous cannulation. Methods One hundred and two subjects were randomly allocated into two groups. In the first group, 100 mu L of lidocaine hydrochloride (2%) was injected intradermally to subjects using the MicronJet600 device in the left arm (MJ-Lido) and 100 mu L of saline was injected intradermally using the device in the right arm (MJ-Saline). In the second group, 100 mu L of lidocaine hydrochloride (2%) was injected using the MicronJet600 device into the left arm (MJ-Lido), with no injection into the right arm of subjects (No pretreatment). In both groups the intradermal injection was performed at the cannulation site prior to insertion of a 18G cannula into a median cubital vein in both arms. As a primary variable, a score of cannulation-induced pain was indicated by subjects using a 100-point visual analog scale immediately after cannulation. As a secondary variable, subjects in Group 2 also indicated their preference to receive the anaesthetic injection with MicronJet600 in the future by using the 5-point Likert scale. Also, as a secondary variable, the duration of skin numbness after lidocaine injection was indicated by performing a superficial pin-prick with a 27G needle at 15, 30 and 45 minutes, at distances of 1, 2 and 3 centimeters from the injection site. Results A significant pain reduction (11.0-fold) was achieved due to the lidocaine injection compared to the cannulation without any pretreatment (p< 0.005). After the lidocaine injection the anesthesia was effective up to 2 centimeters from the injection site and remained for up to 30 minutes. Eighty percent of subjects from the second group preferred cannulation after the lidocaine injection over cannulation without any pretreatment. No significant side effects were identified. Conclusion Intradermal injection of anaesthetic with Micronjet600 was found to be a safe and effective option for providing rapid local anesthesia for peripheral intravenous cannulation.	[Rzhevskiy, Alexey; Popov, Andrei; Zvyagin, Andrei] Sechenov First Moscow State Med Univ, Ctr Biomed Engn, Moscow, Russia; [Pavlov, Chavdar] Sechenov First Moscow State Med Univ, Clin Internal Dis Propedeut, Moscow, Russia; [Anissimov, Yuri] Griffith Univ, Sch Nat Sci, Gold Coast, Qld, Australia; [Levin, Yotam; Kochba, Efrat] NanoPass Technol, Ness Ziona, Israel	Sechenov First Moscow State Medical University; Sechenov First Moscow State Medical University; Griffith University	Rzhevskiy, A (corresponding author), Sechenov First Moscow State Med Univ, Ctr Biomed Engn, Moscow, Russia.	rzhevskiy01@gmail.com	Rzehvskiy, Alexey Sergey/T-4939-2017	Rzehvskiy, Alexey Sergey/0000-0002-4042-7813	Ministry of Education and Science of the Russian Federation [075-15-2019-192]; NanoPass Technologies Ltd.	Ministry of Education and Science of the Russian Federation(Ministry of Education and Science, Russian Federation); NanoPass Technologies Ltd.	The work was supported by the Ministry of Education and Science of the Russian Federation, grant No. 075-15-2019-192. NanoPass Technologies Ltd. provided support in the form of salary for authors EK and YL. A payment for labour of the nurse who participated in the study was covered by NanoPass Technologies Ltd. as well. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the `author contributions' section.	Anand A, 2015, VACCINE, V33, P6816, DOI 10.1016/j.vaccine.2015.09.039; Azagury A, 2014, ADV DRUG DELIVER REV, V72, P127, DOI 10.1016/j.addr.2014.01.007; Beals CR, 2016, LANCET INFECT DIS, V16, P915, DOI 10.1016/S1473-3099(16)00133-X; Bond M, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0252-8; Della Cioppa G, 2014, HUM VACC IMMUNOTHER, V10, P1701, DOI 10.4161/hv.28618; Houck Constance S, 2005, Expert Rev Neurother, V5, P625, DOI 10.1586/14737175.5.5.625; Hung IFN, 2012, VACCINE, V30, P6427, DOI 10.1016/j.vaccine.2012.08.014; Hung IFN, 2012, VACCINE, V30, P2707, DOI 10.1016/j.vaccine.2011.12.069; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Kochba E, 2016, DIABETES TECHNOL THE, V18, P525, DOI 10.1089/dia.2016.0156; LANGLEY GB, 1985, RHEUMATOL INT, V5, P145, DOI 10.1007/BF00541514; Levin Y, 2016, VACCINE, V34, P5262, DOI 10.1016/j.vaccine.2016.09.008; Levin Y, 2014, VACCINE, V32, P4249, DOI 10.1016/j.vaccine.2014.03.024; Lysakowski C, 2003, ANESTH ANALG, V96, P215, DOI 10.1097/00000539-200301000-00044; Murthy SN, 2010, J CONTROL RELEASE, V148, P197, DOI 10.1016/j.jconrel.2010.08.015; Oni G, 2012, LASER SURG MED, V44, P168, DOI 10.1002/lsm.21130; Reis EC, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.6.e5; Rzhevskiy AS, 2018, J CONTROL RELEASE, V270, P184, DOI 10.1016/j.jconrel.2017.11.048; Spanos S, 2008, PEDIATR EMERG CARE, V24, P511, DOI 10.1097/PEC.0b013e31816a8d5b; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Troy SB, 2015, J INFECT DIS, V211, P1969, DOI 10.1093/infdis/jiu841; Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077; Zempsky WT, 2004, CLIN THER, V26, P1110, DOI 10.1016/S0149-2918(04)90183-X	23	0	0	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2022	17	1							e0261641	10.1371/journal.pone.0261641	http://dx.doi.org/10.1371/journal.pone.0261641			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P3UI	35100279	Green Published, gold			2023-01-03	WOS:000801937600009
J	Chen, C; Liu, J; Liu, BY; Cao, X; Liu, ZS; Zhao, TY; Lv, XY; Guo, SN; Li, Y; He, LY; Ai, YK				Chen, Chao; Liu, Jia; Liu, Baoyan; Cao, Xue; Liu, Zhishun; Zhao, Tianyi; Lv, Xiaoying; Guo, Shengnan; Li, Yang; He, Liyun; Ai, Yanke			Efficacy of acupuncture in subpopulations with functional constipation: A protocol for a systematic review and individual patient data meta-analysis	PLOS ONE			English	Review							PARTICIPANT DATA; IPD; PREVALENCE; MANAGEMENT; IDENTIFY; CRITERIA; QUALITY; BIAS	Background & nbsp;Several systematic reviews have suggested that acupuncture is effective against functional constipation, but it is unknown whether variations in treatment effect across subgroups remain consistent. Our purpose of this study is to explore the heterogeneity of treatment effect of acupuncture on functional constipation across subgroups.& nbsp;Methods & nbsp;We will search eleven English and Chinese electronic databases and three clinical trial registries from inception to December 2021. Randomized controlled trials that evaluate acupuncture compared with sham acupuncture or no treatment for functional constipation will be eligible if they report at least one primary outcome. The primary outcomes will include the change in weekly complete spontaneous bowel movements or spontaneous bowel movements from baseline. Two authors will independently identify the relevant studies, assess the risk of bias using the Cochrane RoB 2 tool and contact the primary researchers of the eligible trials for individual patient data. Individual patient data obtained from the original trial author will be standardized and all trial data will be combined into a single database. Generalized linear mixed effects model will be used to determine possible subgroup effects by adding an interaction term for predefined subgroup and treatment.& nbsp;	[Chen, Chao; Liu, Jia; Cao, Xue; Zhao, Tianyi; Lv, Xiaoying; He, Liyun; Ai, Yanke] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China; [Chen, Chao] China Astronaut Res & Training Ctr, Beijing, Peoples R China; [Liu, Baoyan] China Acad Chinese Med Sci, Beijing, Peoples R China; [Liu, Zhishun] China Acad Chinese Med Sci, Guangan Men Hosp, Beijing, Peoples R China; [Guo, Shengnan] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Li, Yang] Beijing Fengtai Youanmen Hosp, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS	He, LY; Ai, YK (corresponding author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.	hely3699@163.com; aiyanke@163.com		Chen, Chao/0000-0002-9089-2860	Seedling Fund Special Cultivation Fund; China Academy of Chinese Medical Sciences [ZZ11-112]; National Natural Science Foundation of China [81703950]; National Major Science and Technology Projects; Ministry of Science and Technology of China [2017ZX10106001]	Seedling Fund Special Cultivation Fund; China Academy of Chinese Medical Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Science and Technology Projects; Ministry of Science and Technology of China(Ministry of Science and Technology, China)	Funding: YA received Seedling Fund Special Cultivation Fund, from China Academy of Chinese Medical Sciences (ZZ11-112); XL received Young Scientists Fund, from National Natural Science Foundation of China (81703950); YA received National Major Science and Technology Projects, from the Ministry of Science and Technology of China(2017ZX10106001). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the	Amatya AK, 2021, CLIN CANCER RES, V27, P5753, DOI 10.1158/1078-0432.CCR-20-4912; American Gastroenterological Association, 2013, Gastroenterology, V144, P211, DOI 10.1053/j.gastro.2012.10.029; [Anonymous], 2010, CONSTIPATION GLOBAL; Barberio B, 2021, LANCET GASTROENTEROL, V6, P638, DOI 10.1016/S2468-1253(21)00111-4; Belias M, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0817-6; Bytzer P, 2001, GUT, V49, P66, DOI 10.1136/gut.49.1.66; Chan AOO, 2007, CLIN GASTROENTEROL H, V5, P197, DOI 10.1016/j.cgh.2006.10.009; Debray TPA, 2015, RES SYNTH METHODS, V6, P293, DOI 10.1002/jrsm.1160; Dukas L, 2003, AM J GASTROENTEROL, V98, P1790, DOI [10.1016/S0002-9270(03)00442-8, 10.1111/j.1572-0241.2003.07591.x]; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1998, BRIT MED J, V316, P470; EVERHART JE, 1989, DIGEST DIS SCI, V34, P1153, DOI 10.1007/BF01537261; Fanshawe TR, 2019, BMJ EVID-BASED MED, V24, P190, DOI 10.1136/bmjebm-2018-111127; Fisher DJ, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j573; Goldstein H, 2002, STAT MED, V21, P3291, DOI 10.1002/sim.1264; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hyams Jeffrey S, 2016, Gastroenterology, DOI 10.1053/j.gastro.2016.02.015; Hyman PE, 2006, GASTROENTEROLOGY, V130, P1519, DOI [10.1053/j.gastro.2005.11.065, 10.1053/j.gastro.2016.02.016]; Imran A, 2020, EXPERT REV GASTROENT, V14, P39, DOI 10.1080/17474124.2020.1708718; Johanson JF, 2007, ALIMENT PHARM THER, V25, P599, DOI 10.1111/j.1365-2036.2006.03238.x; Johanson JF, 1998, AM J GASTROENTEROL, V93, P188, DOI 10.1111/j.1572-0241.1998.00188.x; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kontopantelis E, 2018, RES SYNTH METHODS, V9, P417, DOI 10.1002/jrsm.1303; Koopman L, 2008, AM J EPIDEMIOL, V167, P540, DOI 10.1093/aje/kwm341; Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118; Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208; Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583; Mayor David F, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030085; Mearin Fermin, 2016, Gastroenterology, DOI 10.1053/j.gastro.2016.02.031; Mounsey A, 2015, AM FAM PHYSICIAN, V92, P500; Mueller-Lissner S, 2010, AM J GASTROENTEROL, V105, P897, DOI 10.1038/ajg.2010.41; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Riley RD, 2020, STAT MED, V39, P2536, DOI 10.1002/sim.8555; Sanchez Maria Ines Pinto, 2011, Can J Gastroenterol, V25 Suppl B, p11B; Serra J, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13762; Simmonds M, 2015, CONTEMP CLIN TRIALS, V45, P76, DOI 10.1016/j.cct.2015.06.012; Skardoon GR, 2017, ALIMENT PHARM THER, V46, P410, DOI 10.1111/apt.14174; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; Stewart LA, 2002, EVAL HEALTH PROF, V25, P76, DOI 10.1177/0163278702025001006; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Talley NJ, 1996, AM J GASTROENTEROL, V91, P19; Thompson WG, 1999, GUT, V45, P43; Vale CL, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1088; Wong RK, 2010, AM J GASTROENTEROL, V105, P2228, DOI 10.1038/ajg.2010.200; Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493; Zheng H, 2019, NEUROGASTROENT MOTIL, V31, DOI 10.1111/nmo.13441; Zhou SL, 2017, ACUPUNCT MED, V35, P324, DOI 10.1136/acupmed-2016-011127	49	0	0	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266075	10.1371/journal.pone.0266075	http://dx.doi.org/10.1371/journal.pone.0266075			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Y6SQ	35413064	gold, Green Published			2023-01-03	WOS:000790519000024
J	Pinho, RH; Luna, SPL; Trindade, PHE; Justo, AA; Cima, DS; Fonseca, MW; Minto, BW; Rocha, FDC; Miller, A; Flecknell, P; Leach, M				Haddad Pinho, Renata; Luna, Stelio Pacca Loureiro; Trindade, Pedro Henrique Esteves; Justo, Andre Augusto; Cima, Daniela Santilli; Fonseca, Mariana Werneck; Minto, Bruno Watanabe; Rocha, Fabiana Del Lama C.; Miller, Amy; Flecknell, Paul; Leach, Matthew			Validation of the rabbit pain behaviour scale (RPBS) to assess acute postoperative pain in rabbits (Oryctolagus cuniculus)	PLOS ONE			English	Article							VETERINARY STUDENTS; WEIGHTED KAPPA; GUINEA-PIGS; BUPRENORPHINE; AGREEMENT; CARPROFEN; ANESTHESIOLOGISTS; RESPONSIVENESS; QUESTIONNAIRE; STATISTICS	Considering the widespread use of rabbits in research that potentially causes pain and discomfort and the limited number of pain assessment validated tools in this species, we aimed to develop and validate a scale of acute postoperative pain in rabbits (RPBS). Footage of 58 rabbits from previous studies were used, recorded at 'baseline' (before orthopaedic and soft tissue surgeries), 'pain' (after surgery), 'analgesia' (after analgesic), and '24h post' (24 hours after surgery). The videos were randomised and assessed twice by four evaluators, within one-month interval between evaluations. After content validation, RBPS was further refined using the criteria from the validation. According to the principal component analysis, RPBS was considered unidimensional. The intra- and inter-observer reliability was excellent (ICC>0.80) for all evaluators. There was a high Spearman's correlation of the RPBS with unidimensional scales (>0.80) and a moderate correlation with the Rabbit Grimace Scale (0.68), confirming criterion validity. According to the mixed linear model, the scale was responsive, shown by the increase in pain scores after surgery. Construct validity was confirmed by known-group approach and internal relationships among items. Adequate item-total correlation (>0.3) was observed for all items, except for the attention to the affected area (0.04). The internal consistency was very good (Cronbach's alpha coefficient = 0.78; Mcdonald's omega coefficient = 0.83). The cut-off score for rescue analgesia was >= 3, with an area under the curve >0.95, demonstrating a high discriminatory capacity of the instrument. Scores 3 and 4 were within the uncertainty diagnostic zone. Specificity was 87% and sensitivity was 90%. It was concluded that the RPBS presented content, criterion, and construct validities, responsiveness, and reliability to assess acute pain in rabbits submitted to orthopaedic and soft tissue surgeries. The cut-off for rescue analgesia serves as a basis for the administration of analgesics to rabbits submitted to painful procedures.	[Haddad Pinho, Renata; Cima, Daniela Santilli; Fonseca, Mariana Werneck] Sao Paulo State Univ Unesp, Botucatu Med Sch, Dept Surg Specialties & Anesthesiol, Botucatu, SP, Brazil; [Luna, Stelio Pacca Loureiro; Trindade, Pedro Henrique Esteves] Sao Paulo State Univ Unesp, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Botucatu, SP, Brazil; [Justo, Andre Augusto] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Surg, Sao Paulo, SP, Brazil; [Minto, Bruno Watanabe; Rocha, Fabiana Del Lama C.] Sao Paulo State Univ Unesp, Sch Agr & Vet Sci, Dept Vet Clin & Surg, Jaboticabal, SP, Brazil; [Miller, Amy] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough, England; [Flecknell, Paul; Leach, Matthew] Newcastle Univ, Sch Nat & Environm Sci, Newcastle Upon Tyne, England	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade Estadual Paulista; University of Teesside; Newcastle University - UK	Luna, SPL (corresponding author), Sao Paulo State Univ Unesp, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Botucatu, SP, Brazil.	stelio.pacca@unesp.br	Luna, Stelio/C-4527-2013; Esteves Trindade, Pedro Henrique/K-1178-2017	Luna, Stelio/0000-0001-5312-9076; Esteves Trindade, Pedro Henrique/0000-0002-8522-5553; Pinho, Renata/0000-0001-5625-9538	FAPESP (Sao Paulo Research Foundation) [2018/17839-7, 2017/12815-0]; National Centre for 3Rs (NC3Rs Grant) [G1100563]; Boehringer Ingelheim Vetmedica GmbH, Germany	FAPESP (Sao Paulo Research Foundation)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Centre for 3Rs (NC3Rs Grant); Boehringer Ingelheim Vetmedica GmbH, Germany(Boehringer Ingelheim)	RHP -sponsored by FAPESP (Sao Paulo Research Foundation) -M.Sc. grant 2018/17839-7 SPLL-Financial support by FAPESP (Sao Paulo Research Foundation) -thematic project 2017/12815-0 (http://www.fapesp.br/en/) This study used videos from previous funded research; Miller et al. 2021 was funded by the National Centre for 3Rs (NC3Rs Grant/Award No. G1100563), Leach et al 2009, was funded by Boehringer Ingelheim Vetmedica GmbH, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman DG, 1991, PRACTICAL STAT MED R; [Anonymous], 2006, MEASURING HLTH GUIDE, DOI [10.1002/sim.4780081017, DOI 10.1002/SIM.4780081017]; Banchi P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0221377; Barletta M, 2016, VET ANAESTH ANALG, V43, P91, DOI 10.1111/vaa.12269; Barter LS, 2013, J AM ASSOC LAB ANIM, V52, P44; Belshaw Z, 2015, VET J, V206, P203, DOI 10.1016/j.tvjl.2015.07.016; Benato L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252417; Benato L, 2020, VET REC, V186, DOI 10.1136/vr.105071; Benato L, 2019, VET ANAESTH ANALG, V46, P151, DOI 10.1016/j.vaa.2018.10.007; Boateng GO, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00149; Bollen K.A., 1989, STRUCTURAL EQUATIONS, V210; Brondani JT, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-143; Cannesson M, 2011, ANESTHESIOLOGY, V115, P231, DOI 10.1097/ALN.0b013e318225b80a; de Oliveira MGC, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.671330; Celeita-Rodriguez N, 2019, VET ANAESTH ANALG, V46, P276, DOI 10.1016/j.vaa.2018.12.004; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Cooper CS, 2009, J AM ASSOC LAB ANIM, V48, P279; Coulter CA, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-12; d'Ovidio D, 2016, J VET BEHAV, V15, P37, DOI 10.1016/j.jveb.2016.08.072; de Oliveira FA, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0200-0; DeVon HA, 2007, J NURS SCHOLARSHIP, V39, P155, DOI 10.1111/j.1547-5069.2007.00161.x; DEYO RA, 1991, CONTROL CLIN TRIALS, V12, pS142, DOI 10.1016/S0197-2456(05)80019-4; DiVincenti L, 2016, JAVMA-J AM VET MED A, V248, P795, DOI 10.2460/javma.248.7.795; Doodnaught GM, 2017, CAN VET J, V58, P805; Dunbar ML, 2016, J AM ASSOC LAB ANIM, V55, P29; Trindade PHE, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11061629; Evangelista MC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84696-7; Farnworth MJ, 2011, ANIM WELFARE, V20, P225; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Gavish M, 2014, IEEE T INFORM THEORY, V60, P5040, DOI 10.1109/TIT.2014.2323359; Glick M, 2017, J AM DENT ASSOC, V148, P131, DOI 10.1016/j.adaj.2017.01.009; HajianTilaki KO, 1997, MED DECIS MAKING, V17, P94, DOI 10.1177/0272989X9701700111; Hawkins P, 2002, LAB ANIM-UK, V36, P378, DOI 10.1258/002367702320389044; Hedenqvist P, 2016, RES VET SCI, V107, P123, DOI 10.1016/j.rvsc.2016.05.010; Jensen MP, 2003, CLIN J PAIN, V19, P345, DOI 10.1097/00002508-200311000-00002; Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kalkbrenner M.T., 2021, COUNS OUTCOME RES EV, V13, P1, DOI [10.1080/21501378.2021.1940118, DOI 10.1080/21501378.2021.1940118]; Keating SCJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044437; Kim J, 2014, ANN REHABIL MED-ARM, V38, P665, DOI 10.5535/arm.2014.38.5.665; Klune CB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209467; Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langenecker M, 2009, TIERAERZTL PRAX K H, V37, P326, DOI 10.1055/s-0038-1622807; Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]; Leach MC, 2009, RES VET SCI, V87, P336, DOI 10.1016/j.rvsc.2009.02.001; Luna SPL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233552; Luna SPL, 2022, PEERJ, V10, DOI 10.7717/peerj.13134; Martin P., 1986, MEASURING BEHAV; McDowell I., 2006, MEASURING HLTH GUIDE, DOI [10.1093/acprof:oso/9780195165678.001.0001, DOI 10.1093/ACPROF:OSO/9780195165678.001.0001]; Merola I, 2016, J FELINE MED SURG, V18, P60, DOI 10.1177/1098612X15578725; Miller AL, 2022, FRONT VET SCI, V9, DOI 10.3389/fvets.2022.782486; Mokkink L, 2018, COSMIN METHODOLOGY S; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Peacher K.J., 2003, UNDERSTANDING STAT, V2, P13, DOI DOI 10.1207/S15328031US0201_02; Pinho RH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240605; Prinsen CAC, 2018, QUAL LIFE RES, V27, P1147, DOI 10.1007/s11136-018-1798-3; Quarterone C., 2017, CAN VET J; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Roughan JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002; Roughan JV, 2003, EUR J PAIN, V7, P397, DOI 10.1016/S1090-3801(02)00140-4; Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0; RStudio Team, 2016, RSTUDIO TEAM; RUSSELL W. M. S., 1959; Schnellbacher RW, 2017, AM J VET RES, V78, P1359, DOI 10.2460/ajvr.78.12.1359; Schuster C, 2004, EDUC PSYCHOL MEAS, V64, P243, DOI 10.1177/0013164403260197; Silva NEOF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239622; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Streiner D, 2008, HLTH MEASUREMENT SCA; Streiner D. L., 2015, HLTH MEASUREMENT SCA, V1, DOI [10.1093/med/9780199685219.001.0001, DOI 10.1093/MED/9780199685219.001.0001]; Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210; Streiner DL, 2003, J PERS ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01; Streiner DL., 2008, HLTH MEASUREMENT SCA, DOI DOI 10.1093/ACPROF:OSO/9780199231881.001.0001; Suraseranivongse S, 2001, BRIT J ANAESTH, V87, P400, DOI 10.1093/bja/87.3.400; Taffarel MO, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0395-8; Uhlig C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134205; Weaver LA, 2010, J AM ASSOC LAB ANIM, V49, P845; Zhang EQ, 2019, J AM ASSOC LAB ANIM, V58, P178, DOI [10.30802/AALAS-JAALAS-18-000044, 10.30802/aalas-jaalas-18-000044]	79	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5								10.1371/journal.pone.0268973	http://dx.doi.org/10.1371/journal.pone.0268973			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L8YU	35617348	Green Published, gold			2023-01-03	WOS:000835048800060
J	Kiputa, M; Salim, N; Kunambi, PP; Massawe, A				Kiputa, Mpokigwa; Salim, Nahya; Kunambi, Peter P.; Massawe, Augustine			Referral challenges and outcomes of neonates received at Muhimbili National Hospital, Dar es Salaam, Tanzania	PLOS ONE			English	Article							TRANSPORT; MORTALITY; MORBIDITY; NEWBORN	Background Functional referral system including pre referral care, access to emergency transport and ensuring continuity of care between facilities is critical for improved newborn health outcome. The neonatal transport system is quite undervalued in many sub Saharan countries, Tanzania included. This study assessed the pre referral care, transport process, ambulance characteristics, admission clinical status and outcomes of referred neonates at Muhimbili National Hospital Upanga, a tertiary facility in Dar es Salaam, Tanzania. Methods A descriptive cross sectional study with a longitudinal follow up was conducted from September 2020 to February 2021 including neonates referred to Muhimbili National Hospital. A structured questionnaire was used to collect demographic characteristics and transport factors including pre referral care extracted from the referral documents and through interviewing caregivers or escorting person/nurse. Ambulances were directly observed using a structured checklist on presence, absence and functionality of supportive equipment. All enrolled neonates had a clinical assessment at admission and 48 hours post admission to determine admission clinical status and 48 hours' clinical outcome as either survived/died. Results Out of the 348 neonates assessed during the study period, the median gestation age was 38 weeks (IQR 32, 39) with the mean birth weight of 2455 +/- 938 g. Pre referral documentation showed that temperature was measured in 176 (57.1%), oxygen saturation and random blood glucose in only 143 (46.6%) and 116 (36.2%) neonates respectively. Ambulance was used as a means of transportation in 308 (88.5%) neonates. While no ambulance had an incubator only 7 (2.0%) neonates were kept on a Kangaroo Mother Care position. Monitoring enroute was done to only 94 (27%) of the transferred neonates with 169 (54.9%) of health care professionals escorting the neonates lacking training on essential newborn care. On arrival, 115 (33%) were hypothermic, 74 (21.3%) hypoxic, 30 (8.6%) with poor perfusion and 49 (14.1%) hypoglycemic. Hypothermic neonates had an increased chance of dying compared to those who were normothermic (OR = 2.09, 95% CI (1.05-4.20), p = 0.037). The chance of dying among those presenting with hypoxia was almost three times (OR = 2.88, 95%CI (1.44-5.74), p = 0.003) while those with poor perfusion was almost five times (OR = 4.76, 95%CI (1.80-12.58), p = 0.002). Additionally, neonates who had hyperglycemia (RBG > 8.3mmol/l) on arrival had a higher probability of dying compared to those who were euglycemic [(OR = 3.10, 95% CI (1.19-8.09) p = 0.021]. Overall mortality was 22.4% within 48 hours of admission and risk of dying increased as the presence of poor clinical status added on. Conclusion Neonatal transportation in Dar es Salaam, Tanzania was observed to be challenging. Pre transfer care and monitoring during transportation was inadequate and this contributed to poor clinical status on admission. Hypothermia, hypoglycemia, hyperglycemia, hypoxia and poor perfusion on admission were associated with increased mortality. Effective referral network is needed for improved neonatal health outcomes. Pre referral supportive care, training of health care professionals, transportation with improved monitoring, clear communication protocol and referral documentation should be invested and effectively utilized.	[Kiputa, Mpokigwa; Salim, Nahya; Massawe, Augustine] Muhimbili Univ Hlth & Allied Sci, Dept Paediat & Child Hlth, Dar Es Salaam, Tanzania; [Kunambi, Peter P.] Muhimbili Univ Hlth & Allied Sci, Dept Clin Pharmacol, Dar Es Salaam, Tanzania	Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences	Kiputa, M; Salim, N (corresponding author), Muhimbili Univ Hlth & Allied Sci, Dept Paediat & Child Hlth, Dar Es Salaam, Tanzania.	mpokigwakiputa@gmail.com; nsalim@ihi.or.tz		masoud, nahya salim/0000-0002-3784-6478; KIPUTA, MPOKIGWA/0000-0001-5627-6725	Government of Tanzania through the Ministry of Health, Community Development, Gender, Elderly and Children at Muhimbili University of Health and Allied Sciences, MUHAS	Government of Tanzania through the Ministry of Health, Community Development, Gender, Elderly and Children at Muhimbili University of Health and Allied Sciences, MUHAS	This study received no financial support, it was part of the academic completion requirement supported by the Government of Tanzania through the Ministry of Health, Community Development, Gender, Elderly and Children at Muhimbili University of Health and Allied Sciences, MUHAS.	Abdulraheem MA, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.216.8651; Agostino R, 1999, PRENAT NEONAT MED, V4, P20; Ashokcoomar P, 2016, SAMJ, S. Afr. med. j., V106, P514, DOI [10.7196/SAMJ.2016.v106i5.8554, 10.7196/samj.2016v106i5.8554]; Baidya M., 2018, BANGLADESH J CHILD H, V41, P159; Begum A, 2016, IOSR J DENT MED SCI, V15, P53; BRITTO J, 1995, BRIT MED J, V311, P836, DOI 10.1136/bmj.311.7009.836; Care EN., 2013, NORMS STAND ESSENT N, P7; CHANCE GW, 1978, J PEDIATR-US, V93, P662, DOI 10.1016/S0022-3476(78)80913-5; Dedeke I., 2011, NIGER J PAEDIAT, V38, P90; GUNN T, 1978, CAN MED ASSOC J, V118, P646; Harahap Nabila Clydea, 2019, Informatics in Medicine Unlocked, V15, P39, DOI 10.1016/j.imu.2019.100184; Henry S, 2017, J TROP PEDIATRICS, V63, P307, DOI 10.1093/tropej/fmw095; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Kumar PP, 2010, INDIAN J PEDIATR, V77, P151, DOI 10.1007/s12098-009-0336-2; Kumar PP, 2008, INDIAN PEDIATR, V45, P920; Laptook AR, 2007, PEDIATRICS, V119, pE643, DOI 10.1542/peds.2006-0943; Lunze K, 2012, J PERINATOL, V32, P317, DOI 10.1038/jp.2012.11; Manji K P, 2003, Cent Afr J Med, V49, P23; Martinez Veronica R, 2011, B M D HOSP INFANT M, V68, P34; Mathur NB, 2007, ACTA PAEDIATR, V96, P172, DOI 10.1111/j.1651-2227.2007.00006.x; McCall EM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004210.pub3; Mehta N, 2018, INDIAN J CHILD HLTH, V5, P280; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) Ministry of Health (MoH) National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2016, TANZ DEM HLTH SURV M; MIR N A, 1989, Indian Pediatrics, V26, P755; Morgan MC, 2017, ARCH DIS CHILD-FETAL, V102, pF266, DOI 10.1136/archdischild-2016-311813; Narang Manish, 2013, Indian J Public Health, V57, P100, DOI 10.4103/0019-557X.115003; Pan P., 2017, JPNC, V6, P00235, DOI [10.15406/jpnc.2017.06.00235, DOI 10.15406/JPNC.2017.06.00235]; Rathod D, 2015, TROP DOCT, V45, P96, DOI 10.1177/0049475514564270; Sampathkumar PS, 2018, INT J CONT PEDIAT, V5, P1040; SEGAL S, 1966, PEDIATR CLIN N AM, V13, P1195; Tette EMA, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7030022; WHO . World Health Organization, 2003, MAN NEWB PROBL GUID; World Health Organization, 2018, NETW IMPR QUAL CAR M	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269479	10.1371/journal.pone.0269479	http://dx.doi.org/10.1371/journal.pone.0269479			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35704624	gold, Green Published			2023-01-03	WOS:000843567600123
J	Wang, CC; Lo, J; Geraghty, S; Yang, AWH				Wang, Carol Chunfeng; Lo, Johnny; Geraghty, Sadie; Yang, Angela Wei Hong			Effects of Tai Chi on the quality of life, mental wellbeing, and physical function of adults with chronic diseases: Protocol for a single-blind, two-armed, randomised controlled trial	PLOS ONE			English	Article							MCGILL PAIN QUESTIONNAIRE; FORM HEALTH SURVEY; VISUAL ANALOG; RELIABILITY; VALIDITY; SF-36; OUTCOMES	Introduction Quality of life (QoL), mental wellbeing, and physical function are often diminished among people with chronic disease. Tai Chi is a moderate form of exercise that may be effective in improving chronic disease management. This protocol paper outlines a trial to determine the therapeutic effects of a Tai Chi program on chronic disease management. Methods and analysis This study will be a pilot, interventional, single-blind, two-armed, randomised, parallel, and controlled trial involving a 12-week Tai Chi program for Australian adults. Forty people aged 18 years and older, diagnosed with one or more chronic disease from general community will be recruited. All participants will be randomised to either a 12-week Tai Chi program or a waiting list control group. The Tai Chi program will involve 12 weeks of group Tai Chi sessions, with 45 minutes per session, twice a week. The primary outcome will be QoL as measured by mean scores on the 12-item Short Form Health Survey (SF-12v2) and the EuroQoL (EQ-5D). The secondary outcomes will include anxiety as measured by mean score on the generalised anxiety disorder 7 (GAD-7) survey; depression as measured by mean score on the patient health questionnaire (PHQ-9); work productivity and activity assessment (WPAI:SHP); pain (if any) as measured by mean scores on the visual analogue scale (VAS) and the McGill pain questionnaire (MPQ). These primary and secondary outcomes will be self-administered via two online assessments prior to (T0) and post-intervention (T1). Objective measures as additional secondary outcomes, will also be carried out by the research team including flexibility as measured by the finger to floor distance (FFD); obesity as measured by mean scores on body mass index (BMI); vital signs (blood pressure, heart rate, respiratory rate, temperate, and oxygen saturation) as measured by a blood pressure monitor, tympanic, and pulse oximetry device, and these outcomes will be measured at T0 and T1 in the ECU Holistic Health Research Clinic. People diagnosed with pre-diabetes or diabetes, their glycosylated haemoglobin (HbA1C) and fasting (before breakfast) blood glucose level (BGL) will also be measured via test kits at T0 and T1 in the clinic. Linear mixed modelling will be conducted to assess changes in outcomes. Statistical significance will be set at an alpha level of 0.05 with a medium effect size. All analyses will be conducted using R version 4.1. Qualitative data will be analysed using template thematic analysis. Ethics and dissemination Ethical approval has been obtained from the Edith Cowan University (ECU) Human Research Ethics Committee (2021-03042-WANG). Research findings will be disseminated to the public, health professionals, researchers, and healthcare providers through conference presentations, lay summaries, and peer-reviewed publications. This study will provide an updated evidence on a safe, sustainable, and inexpensive non-pharmacological approach in the management of chronic disease, the number one burden of disease in Australia.	[Wang, Carol Chunfeng; Geraghty, Sadie] Univ Notre Dame Australia, Sch Nursing Midwifery Hlth Sci & Physiotherapy, Perth, WA, Australia; [Wang, Carol Chunfeng] Edith Cowan Univ, Sch Nursing & Midwifery, Perth, WA, Australia; [Lo, Johnny] Edith Cowan Univ, Sch Sci, Perth, WA, Australia; [Yang, Angela Wei Hong] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia	University of Notre Dame Australia; Edith Cowan University; Edith Cowan University; Royal Melbourne Institute of Technology (RMIT)	Wang, CC (corresponding author), Univ Notre Dame Australia, Sch Nursing Midwifery Hlth Sci & Physiotherapy, Perth, WA, Australia.; Wang, CC (corresponding author), Edith Cowan Univ, Sch Nursing & Midwifery, Perth, WA, Australia.	carol.wang@nd.edu.au	Geraghty, Sadie/L-3029-2016	Geraghty, Sadie/0000-0001-6920-6013; Wang, Dr Carol Chunfeng/0000-0002-6672-7187				Australian Health Ministers' Advisory Council, 2017, NATL STRATEGIC FRAME; Brooks J, 2015, QUAL RES PSYCHOL, V12, P202, DOI 10.1080/14780887.2014.955224; Care RH, 12 ITEM SHORT FORM S; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Diabetesaustralia, WHAT IS DIAB 2021; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Feng YS, 2021, QUAL LIFE RES, V30, P647, DOI 10.1007/s11136-020-02688-y; Foundation H, 2022, WHATS YOUR BMI; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Janssen MF, 2013, QUAL LIFE RES, V22, P1717, DOI 10.1007/s11136-012-0322-4; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; Jiang Y, 2013, J SPORT HEALTH SCI, V2, P204, DOI 10.1016/j.jshs.2013.03.008; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Lough ME, 2015, HEMODYNAMIC MONITORI; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Ministry of Health. Chilean Government, 2018, DEVELOPER SURVEY RES; NHMRC, 2016, STATEMENT CONSUMER C; Oh B, 2010, ANN ONCOL, V21, P608, DOI 10.1093/annonc/mdp479; Painaustralia, 2021, PAINF FACTS; Preedy VR., 2010, HDB DIS BURDENS QUAL; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Reilly M., 2018, WORK PRODUCTIVITY AC; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Revicki DA, 2000, QUAL LIFE RES, V9, P887, DOI 10.1023/A:1008996223999; Strand LI, 2008, EUR J PAIN, V12, P917, DOI 10.1016/j.ejpain.2007.12.013; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Wayne P, 2013, HARVARD MED SCH GUID; Wright KD, 2001, EUR J PAIN, V5, P279, DOI 10.1053/eujp.2001.0243; Yeh Gloria Y, 2008, Prev Cardiol, V11, P82	37	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2022	17	6							e0270212	10.1371/journal.pone.0270212	http://dx.doi.org/10.1371/journal.pone.0270212			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4E6MG	35749413	gold, Green Published			2023-01-03	WOS:000847936900001
J	Fiore, JF; El-Kefraoui, C; Chay, MA; Nguyen-Powanda, P; Do, U; Olleik, G; Rajabiyazdi, F; Kouyoumdjian, A; Derksen, A; Landry, T; Amar-Zifkin, A; Bergeron, A; Ramanakumar, AV; Martel, M; Lee, LC; Baldini, G; Feldman, LS				Fiore, Julio F., Jr.; El-Kefraoui, Charbel; Chay, Marc-Aurele; Nguyen-Powanda, Philip; Do, Uyen; Olleik, Ghadeer; Rajabiyazdi, Fateme; Kouyoumdjian, Araz; Derksen, Alexa; Landry, Tara; Amar-Zifkin, Alexandre; Bergeron, Amy; Ramanakumar, Agnihotram, V; Martel, Marc; Lee, Lawrence; Baldini, Gabriele; Feldman, Liane S.			Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials	LANCET			English	Review							CLINICALLY IMPORTANT DIFFERENCE; 3RD MOLAR SURGERY; POSTOPERATIVE PAIN; PLUS CODEINE; ANESTHESIA OUTCOMES; PATIENT PREFERENCES; OPERATIVE TREATMENT; DOUBLE-BLIND; EFFICACY; IBUPROFEN	Background Excessive opioid prescribing after surgery has contributed to the current opioid crisis; however, the value of prescribing opioids at surgical discharge remains uncertain. We aimed to estimate the extent to which opioid prescribing after discharge affects self-reported pain intensity and adverse events in comparison with an opioid-free analgesic regimen. Methods In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Library, Scopus, AMED, Biosis, and CINAHL from Jan 1, 1990, until July 8, 2021. We included multidose randomised controlled trials comparing opioid versus opioid-free analgesia in patients aged 15 years or older, discharged after undergoing a surgical procedure according to the Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity definition (minor, moderate, major, and major complex). We screened articles, extracted data, and assessed risk of bias (Cochrane's risk-of-bias tool for randomised trials) in duplicate. The primary outcomes of interest were self-reported pain intensity on day 1 after discharge (standardised to 0-10 cm visual analogue scale) and vomiting up to 30 days. Pain intensity at further timepoints, pain interference, other adverse events, risk of dissatisfaction, and health-care reutilisation were also assessed. We did random-effects meta-analyses and appraised evidence certainty using the Grading of Recommendations, Assessment, Development, and Evaluations scoring system. The review was registered with PROSPERO (ID CRD42020153050). Findings 47 trials (n=6607 patients) were included. 30 (64%) trials involved elective minor procedures (63% dental procedures) and 17 (36%) trials involved procedures of moderate extent (47% orthopaedic and 29% general surgery procedures). Compared with opioid-free analgesia, opioid prescribing did not reduce pain on the first day after discharge (weighted mean difference 0.01cm, 95% CI -0.26 to 0.27; moderate certainty) or at other postoperative timepoints (moderate-to-very-low certainty). Opioid prescribing was associated with increased risk of vomiting (relative risk 4.50, 95% CI 1.93 to 10.51; high certainty) and other adverse events, including nausea, constipation, dizziness, and drowsiness (high-to-moderate certainty). Opioids did not affect other outcomes. Interpretation Findings from this meta-analysis support that opioid prescribing at surgical discharge does not reduce pain intensity but does increase adverse events. Evidence relied on trials focused on elective surgeries of minor and moderate extent, suggesting that clinicians can consider prescribing opioid-free analgesia in these surgical settings. Data were largely derived from low-quality trials, and none involved patients having major or major-complex procedures. Given these limitations, there is a great need to advance the quality and scope of research in this field. Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Fiore, Julio F., Jr.; Kouyoumdjian, Araz; Lee, Lawrence; Feldman, Liane S.] McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada; [Fiore, Julio F., Jr.; El-Kefraoui, Charbel; Nguyen-Powanda, Philip; Olleik, Ghadeer; Kouyoumdjian, Araz; Lee, Lawrence; Baldini, Gabriele; Feldman, Liane S.] McGill Univ, Div Expt Surg, Montreal, PQ, Canada; [Chay, Marc-Aurele] McGill Univ, Fac Med, Montreal, PQ, Canada; [Martel, Marc] McGill Univ, Fac Dent, Montreal, PQ, Canada; [Martel, Marc; Baldini, Gabriele] McGill Univ, Dept Anaesthesia, Montreal, PQ, Canada; [Fiore, Julio F., Jr.; El-Kefraoui, Charbel; Nguyen-Powanda, Philip; Olleik, Ghadeer; Rajabiyazdi, Fateme; Lee, Lawrence; Feldman, Liane S.] McGill Univ, Hlth Ctr, Steinberg Bernstein Ctr Minimally Invas Surg & In, Montreal, PQ, Canada; [Landry, Tara; Amar-Zifkin, Alexandre; Bergeron, Amy] McGill Univ, Hlth Ctr, Med Libraries, Montreal, PQ, Canada; [Fiore, Julio F., Jr.; El-Kefraoui, Charbel; Nguyen-Powanda, Philip; Olleik, Ghadeer; Ramanakumar, Agnihotram, V; Lee, Lawrence; Feldman, Liane S.] McGill Univ, Ctr Outcomes Res & Evaluat, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Rajabiyazdi, Fateme] Carleton Univ, Dept Syst & Comp Engn, Ottawa, ON, Canada; [Derksen, Alexa] Univ Montreal, Patient Representat, Montreal, PQ, Canada; [Landry, Tara] Univ Montreal, Bibliotheque Sante, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; Carleton University; Universite de Montreal; Universite de Montreal	Fiore, JF (corresponding author), McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada.	julio.fiorejunior@mcgill.ca		Amar-Zifkin, Alexandre/0000-0002-1196-5209; Rajabiyazdi, Fateme/0000-0002-8710-865X; Bergeron, Amy/0000-0002-4224-0307; Landry, Tara/0000-0003-1930-9529	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The Canadian Institutes of Health Research.	Akinbade AO, 2019, NIGER J CLIN PRACT, V22, P796, DOI 10.4103/njcp.njcp_544_18; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; [Anonymous], 2017, LANCET, V390, P2016, DOI 10.1016/S0140-6736(17)32808-8; [Anonymous], 2021, PILOT TRIAL POSTOPER; Beauregard L, 1998, CAN J ANAESTH, V45, P304, DOI 10.1007/BF03012019; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bernstein DN, 2019, J HAND SURG-AM, V44, P635, DOI 10.1016/j.jhsa.2019.04.004; Best AD, 2017, J ORAL MAXIL SURG, V75, P2063, DOI 10.1016/j.joms.2017.04.045; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Boretsky K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071472; Brady JT, 2021, SURGERY, V169, P202, DOI 10.1016/j.surg.2020.03.027; Breivik EK, 1998, EUR J PAIN, V2, P179, DOI 10.1016/S1090-3801(98)90010-6; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Brown JD, 2013, CLIN J PAIN, V29, P492, DOI 10.1097/AJP.0b013e318260c144; Bugada D, 2015, J CLIN ANESTH, V27, P658, DOI 10.1016/j.jclinane.2015.06.008; Buia Alexander, 2015, World J Methodol, V5, P238, DOI 10.5662/wjm.v5.i4.238; Busse JW, 2015, J RHEUMATOL, V42, P1962, DOI 10.3899/jrheum.141440; Carvalho B, 2005, ANESTH ANALG, V101, P1182, DOI 10.1213/01.ane.0000167774.36833.99; Casey R, 1997, CURR MED RES OPIN, V13, P555, DOI 10.1185/03007999709113329; Chen T, 2009, J OTOLARYNGOL-HEAD N, V38, P580, DOI 10.2310/7070.2009.080265; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Christensen GJ, 2005, J AM DENT ASSOC, V136, P1563, DOI 10.14219/jada.archive.2005.0088; Church CA, 2006, LARYNGOSCOPE, V116, P602, DOI 10.1097/01.MLG.0000208341.30628.16; Citardi MJ, 2021, ARE NSAIDS EFFECTIVE; Clarke HA, 2020, CAN J PAIN, V4, P67, DOI 10.1080/24740527.2020.1724775; Collins M, 1997, BRIT J ORAL MAX SURG, V35, P54, DOI 10.1016/S0266-4356(97)90012-7; Comfort MB, 2002, AUST DENT J, V47, P327, DOI 10.1111/j.1834-7819.2002.tb00546.x; Copeland GP, 2002, ARCH SURG-CHICAGO, V137, P15, DOI 10.1001/archsurg.137.1.15; Curtis HJ, 2019, LANCET PSYCHIAT, V6, P140, DOI 10.1016/S2215-0366(18)30471-1; da Silva PB, 2021, CLIN ORAL INVEST, V25, P875, DOI 10.1007/s00784-020-03374-6; Davies B, 2020, ANN SURG, V271, P37, DOI 10.1097/SLA.0000000000003379; Debas HT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1245; Desjardins P, 2020, PAIN MED, V21, P2447, DOI 10.1093/pm/pnaa124; Dinis J, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.12.001; Eden J, 2011, FINDING WHAT WORKS IN HEALTH CARE: STANDARDS FOR SYSTEMATIC REVIEWS, P1; El-Kefraoui C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035443; Fiore JF, 2019, BRIT J ANAESTH, V123, P627, DOI 10.1016/j.bja.2019.08.014; Fischer B, 2019, LANCET PUBLIC HEALTH, V4, pE81, DOI 10.1016/S2468-2667(18)30232-9; Frants A, 2021, PLAST RECONSTR SURG, V147, P56, DOI 10.1097/PRS.0000000000007427; Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5; Gan TJ, 2004, BRIT J ANAESTH, V92, P681, DOI 10.1093/bja/aeh123; Garibaldi JA, 2002, INT J ORAL MAX SURG, V31, P276, DOI 10.1054/ijom.2002.0216; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gewandter JS, 2021, PAIN, V162, P2669, DOI 10.1097/j.pain.0000000000002283; Gewandter JS, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000621; Gilron I, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000647; Gimbel JS, 2001, CLIN THER, V23, P228, DOI 10.1016/S0149-2918(01)80005-9; Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140-6736(19)30352-6; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Han TH, 1998, KOREAN J PAIN, V11, P74; Harbaugh CM, 2018, JAMA-J AM MED ASSOC, V320, P504, DOI 10.1001/jama.2018.9023; Helmerhorst GTT, 2017, J BONE JOINT SURG AM, V99, P1908, DOI 10.2106/JBJS.17.00149; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; Hopewell S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000010.pub3; Howard DH, 2018, JAMA INTERN MED, V178, P1557, DOI 10.1001/jamainternmed.2018.4175; Howard R, 2019, JAMA SURG, V154, DOI 10.1001/jamasurg.2018.4234; Ilyas AM, 2019, ORTHOPEDICS, V42, P110, DOI 10.3928/01477447-20190221-02; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jammer I, 2015, EUR J ANAESTH, V32, P88, DOI 10.1097/EJA.0000000000000118; Jildeh TR, 2021, J SHOULDER ELB SURG, V30, P2445, DOI 10.1016/j.jse.2021.07.008; Jildeh TR, 2021, ARTHROSCOPY, V37, P2237, DOI 10.1016/j.arthro.2021.02.043; Jildeh TR, 2021, NONOPIOID ANALGESIA; Jildeh TR, 2019, NONOPIOID ANALGESIA; Kaafarani HMA, 2020, ANN SURG, V272, P879, DOI 10.1097/SLA.0000000000004225; Kang R, 2020, J AM COLL SURGEONS, V230, P975, DOI 10.1016/j.jamcollsurg.2020.03.025; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kim JB, 2005, KOREAN J OTOLARYNGOL, V48, P506; Kim SI, 2019, CLIN SPINE SURG, V32, pE311, DOI 10.1097/BSD.0000000000000761; La Monaca G, 2021, J EVID-BASED DENT PR, V21, DOI 10.1016/j.jebdp.2021.101611; Ladha KS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10734; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larach DB, 2021, ANN SURG, V273, P507, DOI 10.1097/SLA.0000000000003509; Larance B, 2018, DRUG ALCOHOL REV, V37, pS203, DOI 10.1111/dar.12617; Lawal OD, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7367; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Li RJ, 2018, JAMA OTOLARYNGOL, V144, P1060, DOI 10.1001/jamaoto.2018.1787; Li Zhan, 2005, Yan Ke Xue Bao, V21, P114; Lindenhovious ALC, 2009, J TRAUMA, V67, P160, DOI 10.1097/TA.0b013e31818c12ee; Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952; Lorenc T, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0366-6; Lownie J F, 1992, J Dent Assoc S Afr, V47, P403; LYSELL L, 1992, SWED DENT J, V16, P151; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; Marin-Martinez F, 2010, EDUC PSYCHOL MEAS, V70, P56, DOI 10.1177/0013164409344534; Meader N, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-82; Mitchell A, 2008, J AM COLL SURGEONS, V206, P472, DOI 10.1016/j.jamcollsurg.2007.09.006; Mitchell A, 2012, ANN SURG ONCOL, V19, P3792, DOI 10.1245/s10434-012-2447-7; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moo TA, 2020, ANN SURG ONCOL, V27, P4637, DOI 10.1245/s10434-020-08886-9; Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011407.pub2; Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008242.pub3; Motonobu A, 2017, ORAL DIS, V23, P78, DOI 10.1111/odi.12576; Murad MH, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k4817; Myles PS, 2018, BRIT J ANAESTH, V120, P705, DOI 10.1016/j.bja.2017.12.037; Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466; Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158; Neuman MD, 2019, LANCET, V393, P1547, DOI 10.1016/S0140-6736(19)30428-3; Nielsen S, 2016, PHARMACOEPIDEM DR S, V25, P733, DOI 10.1002/pds.3945; Page MJ, 2021, INT J SURG, V88, DOI 10.1016/j.ijsu.2021.105906; Paice JA, 2005, J PAIN, V6, P639, DOI 10.1016/j.jpain.2005.04.007; Papoian V, 2020, SURGERY, V167, P957, DOI 10.1016/j.surg.2020.01.011; Petrikovets A, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.06.002; Pildal J, 2007, INT J EPIDEMIOL, V36, P847, DOI 10.1093/ije/dym087; Probst P, 2016, ANN SURG, V264, P87, DOI 10.1097/SLA.0000000000001372; Raeder JC, 2001, ANESTH ANALG, V92, P1470, DOI 10.1097/00000539-200106000-00023; Salm-Reifferscheidt L, 2018, LANCET, V391, P1982, DOI 10.1016/S0140-6736(18)31073-0; Samieirad S, 2017, J CRANIO MAXILL SURG, V45, P1614, DOI 10.1016/j.jcms.2017.06.014; Schunemann HJ, 2005, HEALTH SERV RES, V40, P593, DOI 10.1111/j.1475-6773.2005.0k375.x; Shah I, 2008, PAK ORAL DENT J, V28, P241; Sirintawat Nattapong, 2017, J Dent Anesth Pain Med, V17, P253, DOI 10.17245/jdapm.2017.17.4.253; Smith SM, 2020, PAIN, V161, P2446, DOI 10.1097/j.pain.0000000000001952; Spagnoli AM, 2011, IN VIVO, V25, P291; Srivastava D, 2021, BRIT J ANAESTH, V126, P1208, DOI 10.1016/j.bja.2021.02.030; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stessel Bjorn, 2014, Curr Ther Res Clin Exp, V76, P120, DOI 10.1016/j.curtheres.2014.10.001; Suda KJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.4303; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Thibaudeau S., 2019, ACETAMINOPHEN CODEIN; Thorlund K, 2011, RES SYNTH METHODS, V2, P188, DOI 10.1002/jrsm.46; TORABINEJAD M, 1994, J ENDODONT, V20, P427, DOI 10.1016/S0099-2399(06)80031-2; Vallecillo C, 2021, J EVID-BASED DENT PR, V21, DOI 10.1016/j.jebdp.2021.101618; van Amsterdam Jan, 2015, Curr Drug Abuse Rev, V8, P3; Vasilopoulos T, 2021, ANESTHESIOLOGY, V134, P421, DOI 10.1097/ALN.0000000000003681; WALTON GM, 1990, BRIT DENT J, V169, P245, DOI 10.1038/sj.bdj.4807341; Weinheimer K, 2019, J HAND SURG-AM, V44, P387, DOI 10.1016/j.jhsa.2018.10.014; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Wong M, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.10.022; Yang MMH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025091; Zuniga JR, 2019, PAIN MED, V20, P2528, DOI 10.1093/pm/pny294	132	3	3	11	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2022	399	10343					2280	2293						14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L5CA	35717988				2023-01-03	WOS:000817033100015
J	Tsay, SV; Bartoces, M; Gouin, K; Kabbani, S; Hicks, LA				Tsay, Sharon V.; Bartoces, Monina; Gouin, Katryna; Kabbani, Sarah; Hicks, Lauri A.			Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Tsay, Sharon V.; Bartoces, Monina; Gouin, Katryna; Kabbani, Sarah; Hicks, Lauri A.] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Tsay, SV (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE, Atlanta, GA 30329 USA.	lxq1@cdc.gov			CDC	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was funded by the CDC.	Bosworth ARJ., 2020, MEDICARE BENEFICIARY; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Gerber JS, 2013, PEDIATRICS, V131, P677, DOI 10.1542/peds.2012-2500; King Laura M, 2021, Antimicrob Steward Healthc Epidemiol, V1, P1, DOI 10.1017/ash.2021.230; Kow CS, 2020, CLIN DRUG INVEST, V40, P989, DOI 10.1007/s40261-020-00961-z; Oldenburg CE, 2021, JAMA-J AM MED ASSOC, V326, P490, DOI 10.1001/jama.2021.11517	6	3	3	2	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2022	327	20					2018	2019						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1Y7GZ	35394497	Green Published, Bronze			2023-01-03	WOS:000808309800029
J	Phimister, EG				Phimister, Elizabeth G.			Tumor-Infiltrating T Cells - A Portrait	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Braun, David/0000-0003-4543-5553				Braun DA, 2021, CANCER CELL, V39, P632, DOI 10.1016/j.ccell.2021.02.013; Combes AJ, 2022, CELL, V185, P184, DOI 10.1016/j.cell.2021.12.004; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Oliveira G, 2021, NATURE, V596, P119, DOI 10.1038/s41586-021-03704-y; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; ZHENG L, 2021, SCIENCE NEW YORK NY, V0374	6	1	1	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2022	386	10					992	994		10.1056/NEJMcibr2119477	http://dx.doi.org/10.1056/NEJMcibr2119477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP3BU	35263526				2023-01-03	WOS:000766299000018
J	Sachs, RE; Kyle, MA				Sachs, Rachel E.; Kyle, Michael Anne			Step Therapy's Balancing Act - Protecting Patients while Addressing High Drug Prices	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sachs, Rachel E.] Washington Univ, Sch Law, St Louis, MO 63110 USA; [Kyle, Michael Anne] Harvard Med Sch, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Harvard Medical School	Sachs, RE (corresponding author), Washington Univ, Sch Law, St Louis, MO 63110 USA.							[Anonymous], 2021, SAFE STEP ACT 2021, P464; Centers for Medicare and Medicaid Services, 2018, CMS EMP PAT MOR CHOI; Lenahan KL, 2021, HEALTH AFFAIR, V40, P1749, DOI 10.1377/hlthaff.2021.00822; Nayak RK, 2014, HEALTH AFFAIR, V33, P1779, DOI 10.1377/hlthaff.2014.0516; Tharp L, 2022, HEALTH ECON POLICY L, V17, P282, DOI 10.1017/S1744133121000153	5	4	4	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2022	386	10					901	904		10.1056/NEJMp2117582	http://dx.doi.org/10.1056/NEJMp2117582		MAR 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP3BU	35245014				2023-01-03	WOS:000764894200001
J	Limenie, AA; Dugul, TT; Eshetu, EM				Limenie, Abebaye Aragaw; Dugul, Tesfaye Tolessa; Eshetu, Eyasu Mekonnen			Effects of Catha Edulis Forsk on spatial learning, memory and correlation with serum electrolytes in wild-type male white albino rats	PLOS ONE			English	Article							KHAT; HYPONATREMIA; AMPHETAMINE; STRESS; IMPAIRMENT; DEPRESSION; POTASSIUM; ANXIETY; WOMEN	Background The burdens of psychostimulant use disorders are becoming a worldwide problem. One of the psychostimulants widely consumed in Ethiopia and East African countries is Catha adults Forsk (khat). However, no studies have been conducted on the cognitive effects of khat and its correlation with serum electrolytes. The present study was aimed to evaluate the effects of khat on spatial learning and memory and their correlation with serum electrolytes. Materials and methods Diethyl ether and chloroform (3:1v/v ratio) were solvents used to obtain the crude khat extract in this study. T80W was used to prepare the khat juice, fresh khat leave extract. The rats were received crude khat extract subchronically (KESC) (100 mg/kg, 200 mg/kg and 300 mg/kg b.w), khat juice (KHJ 2.5 mUkg), 2% tween 80 in distilled water (T80W- v/v, vehicle) and khat extract subacutely (KESA) (300 mg/kg). For subchronic treatment, each rat was administered for twelve weeks before Morris water maze experiment has been started, while it was administered for a week for acute treatment. Spatial learning and memory were measured using the Morris water maze model and serum sodium, calcium, potassium, and chloride were evaluated using Cobas 6000. Results Spatial learning was improved with trials across the groups, while average escape latency (s) of rats received KESC 200 mg/kg (p<0.001), KESC 300 mg/kg (p<0.01) and KHJ 2.5 mUkg (p<0.05) was significantly greater than rats that received vehicle. There was no significant difference in the latency between rats that received KESA 300mg/kg and vehicle (p>0.05). Thigmotaxis was significantly higher in rats that received all doses of khat extract (p<0.001). The time spent in the target quadrant in rats that received KESC 300 mg/kg was significantly reduced (p<0.05). Serum calcium level was inversely correlated with the escape latency (R = -0.417, p<0.05) in rats that received khat. Conclusions Khat extract and juice administered subchronically, but not subacutely, impaired learning and memory and was associated with serum calcium reduction. The neuronal basis for such alteration should be investigated.	[Limenie, Abebaye Aragaw; Dugul, Tesfaye Tolessa] Addis Ababa Univ, Dept Physiol, Coll Hlth Sci, Addis Ababa, Ethiopia; [Eshetu, Eyasu Mekonnen] Addis Ababa Univ, Coll Hlth Sci, Dept Pharmacol, Addis Ababa, Ethiopia	Addis Ababa University; Addis Ababa University	Limenie, AA (corresponding author), Addis Ababa Univ, Dept Physiol, Coll Hlth Sci, Addis Ababa, Ethiopia.	abebaye.aragaw@aau.edu.et		Makonnen, Eyasu/0000-0002-9259-5288				Abidin I, 2004, INT J NEUROSCI, V114, P683, DOI 10.1080/00207450490430543; Ageely HMA, 2008, J FAM COMMUNITY MED, V15, P3; Al-Habori Molham, 2005, Expert Opin Drug Saf, V4, P1145, DOI 10.1517/14740338.4.6.1145; Alfaifi H, 2017, PHCOG MAG, V13, P354; Alsalahi A, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/829401; Atlabachew M, 2013, B CHEM SOC ETHIOPIA, V27, P347, DOI 10.4314/bcse.v27i3.3; Bae YJ, 2012, NUTR RES PRACT, V6, P527, DOI 10.4162/nrp.2012.6.6.527; Bolton S, 2017, LEARN MEMORY, V24, P532, DOI 10.1101/lm.045187.117; Bora F, 2016, IRAN J BASIC MED SCI, V19, P1151; Colzato LS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020602; Cox G., 2003, ADV PSYCHIAT TREATME, V9, P456, DOI [10.1192/apt.9.6.456, DOI 10.1192/APT.9.6.456]; Echoru I., 2018, ANAT J AFR, V7, P1121, DOI [10.4314/aja.v7i1.169485, DOI 10.4314/AJA.V7I1.169485]; El-Sayed M. I. K., 2012, American Journal of Biochemistry and Biotechnology, V8, P157; Engidawork, 2014, ETHIOP PHARM J, V30, P77, DOI [10.4314/epj.v30i2, DOI 10.4314/EPJ.V30I2.2]; Fitri FI, 2018, EARTH ENV SCI, V25, P1; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Fujisawa H, 2016, J AM SOC NEPHROL, V27, P766, DOI 10.1681/ASN.2014121196; Gebrehanna E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1198; Hassan NA, 2002, SAUDI MED J, V23, P850; Henckens MJAG, 2009, J NEUROSCI, V29, P10111, DOI 10.1523/JNEUROSCI.1184-09.2009; KALIX P, 1990, PHARMACOL THERAPEUT, V48, P397, DOI 10.1016/0163-7258(90)90057-9; Kassa A, 2017, AFR HEALTH SCI, V17, P175, DOI 10.4314/ahs.v17i1.22; Kimani ST, 2016, METAB BRAIN DIS, V31, P45, DOI 10.1007/s11011-015-9738-1; Kimani ST, 2008, BEHAV BRAIN RES, V195, P192, DOI 10.1016/j.bbr.2008.05.022; Kiunga J, 2016, INT J ETHNOBIOLOGY E, V3, P1; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; Lee S, 2012, BMC MED INFORM DECIS, V12, DOI [10.1186/1472-6947-12-S1-S1, 10.1186/1472-6947-12-S1]; LEONARD BE, 1971, BRIT J PHARMACOL, V41, P198, DOI 10.1111/j.1476-5381.1971.tb08022.x; Ljomone Omamuyovwi M, 2011, J NEUROSCIENCE BEHAV, V3, P107; Lourida I, 2015, PARATHYROID HORMONE, V10, P1; Luethi M, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.005.2008; Macuchova E, 2013, PHYSIOL RES, V62, pS89, DOI 10.33549/physiolres.932598; Manzar MD, 2017, ANN THORAC MED, V12, P247, DOI [10.4103/atm.ATM_24_17, 10.4103/atm.atm_24_17]; Mendez IA, 2008, NEUROBIOL LEARN MEM, V89, P185, DOI 10.1016/j.nlm.2007.08.005; Miller M, 2006, J AM GERIATR SOC, V54, P345, DOI 10.1111/j.1532-5415.2005.00609.x; Mirzaei F, 2013, ANATOMICAL SCI, V10, P24; Moritz ML, 2013, NEPHROL DIAL TRANSPL, V28, P2206, DOI 10.1093/ndt/gft192; Muela HCS, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004579; Mwaniki DM, 2014, E AFR MED J, V9, P1; National academies press, 2010, GUIDE CARE USE LAB A, V8th; Perez V, 2014, ADV NUTR, V5, P712, DOI 10.3945/an.114.006783; Sathi MM, 2014, J ETHNOPHARMACOL, V156, P102, DOI 10.1016/j.jep.2014.08.004; Shewamene Z, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-66; Siedlecka-Kroplewska K, 2014, J PHYSIOL PHARMACOL, V65, P241; Sivaraman S, 2016, J PSYCHOL PSYCHOTHER, V6, P1; Thanos PK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155457; Thouri A, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1751-y; Veetil PK., 2014, INDIAN J PHYSIOL PH, V58, P239; Vintimilla RM, 2018, DEMENT GER COGN D EX, V8, P151, DOI 10.1159/000488483; Wabe Nasir Tajure, 2011, Addict Health, V3, P137; Whiteford H, 2016, HEALTH AFFAIR, V35, P1114, DOI 10.1377/hlthaff.2016.0082; Wood S, 2009, PSYCHOPHARMACOLOGY, V202, P197, DOI 10.1007/s00213-008-1185-9; Yamaguchi Kiyoshi, 2015, Clin Calcium, V25, P189, DOI CliCa1502189194; Yates JW, 2007, NEUROSCI LETT, V427, P66, DOI 10.1016/j.neulet.2007.09.011	54	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2022	17	2							e0257932	10.1371/journal.pone.0257932	http://dx.doi.org/10.1371/journal.pone.0257932			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0U9YZ	35157725	gold, Green Published			2023-01-03	WOS:000788004500001
J	Tenaw, LA				Tenaw, Lebeza Alemu			Practice and determinants of emergency contraceptive utilization among women seeking termination of pregnancy in Northwest Ethiopia-A mixed quantitative and qualitative study	PLOS ONE			English	Article							ABORTION	Background Emergency contraceptives are used within 72 hours after unprotected sexual intercourse to prevent unwanted pregnancy. Although emergency contraceptives are widely available in Ethiopia, termination of pregnancy remains a public health problem indicating low uptake of emergency contraceptives after unprotected sexual intercourse. This study aimed to assess utilization and determinants of emergency contraceptives among women seeking termination of pregnancy in Northwest Ethiopia. Methods An institutional-based cross-sectional study was carried out, supplemented by phenomenologically approached in-depth interviews. Systematic random sampling was used to select study participants. A structured questionnaire and an in-depth interview guide were used to collect data. Data were entered by EPI-info and analyzed through SPSS version 23 to conduct logistic regressions. Thematic analysis was used to conduct qualitative interpretation. Results Almost one-fifth (78; 19.2%) of the study participants used emergency contraceptives to prevent their index pregnancy. Women who had secondary education (aOR 3.28; 95% CI 1.59, 6.79) and women who had no living children (aOR 4.52; 95% CI 1.40, 14.57) had a positive significant association with emergency contraceptive utilization. On the other hand, women who did not discuss contraceptives with their sexual partner (aOR 0.49; 95% CI 0.27-0.91) and women without a history of abortion (aOR 0.45; 95% CI 0.24-0.97) had a negative significant association with emergency contraceptive utilization. Conclusion and recommendation There is relatively low utilization of emergency contraception among pregnancy terminating women. Reproductive health programs should encourage women discussion with their partners about emergency contraceptives to decrease occurrence of unwanted pregnancy and termination of pregnancy.	[Tenaw, Lebeza Alemu] Woldia Univ, Coll Hlth Sci, Dept Reprod Hlth, Woldia, Ethiopia		Tenaw, LA (corresponding author), Woldia Univ, Coll Hlth Sci, Dept Reprod Hlth, Woldia, Ethiopia.	lebezaa@gmail.com		tenaw, Lebeza/0000-0003-0144-4968				Abate M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110008; Abraha D, 2019, KNOWLEDGE UTILIZATIO, V2019; Amalba A, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-114; [Anonymous], 2012, EMERGENCY CONTRACEPT; Anteneh A., 2009, ETHIOP J REPROD HLTH, V3, P16; Baird DT, 2015, HUM REPROD, V30, P751, DOI 10.1093/humrep/dev019; Bearak J, 2018, LANCET GLOB HEALTH, V6, pE380, DOI 10.1016/S2214-109X(18)30029-9; Bertrand J., 1994, HDB INDICATORS FAMIL; Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026; Demographic E., 2012, HLTH SURVEY 2011 CEN; Eyal N, 2011, SCALING CHANGES DOCT; Feleke AE, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4707-0; Hatcher R, 1997, CHINESE VERSION; IPAS, 2017, IND AB POST CAR ETH; Kathpalia S K, 2016, Med J Armed Forces India, V72, P116, DOI 10.1016/j.mjafi.2015.09.012; Keesbury J, 2007, POPULATION COUNCIL E; Meng CX, 2009, HUM REPROD, V24, P1612, DOI 10.1093/humrep/dep064; Mohammed A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-13; Oluwole EO, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i1.1094; Prata N., 2013, AFR J REPROD HEALTH, V17; Raymond E, 2004, EMERGENCY CONTRACEPT, VSecond; Sahu Monalisha, 2019, Niger Med J, V60, P117, DOI 10.4103/nmj.NMJ_121_17; Singh S, 2010, INT PERSPECT SEX R H, V36, P16, DOI 10.1363/ipsrh.36.016.10; Smit J, 2001, CONTRACEPTION, V64, P333, DOI 10.1016/S0010-7824(01)00272-4; Tafesse L., 2014, J BIOL AGR HEALTHCAR, V4; Tesfa Endalamaw, 2018, BMC Res Notes, V11, P926, DOI 10.1186/s13104-018-4031-0; Tesfaye T, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-3; Tolossa K, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-32; Workie N.W, 2013, HLTH EXTENSION PROGR; Zareba K, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183413	30	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2022	17	2							e0263776	10.1371/journal.pone.0263776	http://dx.doi.org/10.1371/journal.pone.0263776			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M6VZ	35148342	gold, Green Published			2023-01-03	WOS:000800108800028
J	Jayes, LT; Fitzsimmons, G; Weal, MJ; Kaakinen, JK; Drieghe, D				Jayes, Lewis T.; Fitzsimmons, Gemma; Weal, Mark J.; Kaakinen, Johanna K.; Drieghe, Denis			The impact of hyperlinks, skim reading and perceived importance when reading on the Web	PLOS ONE			English	Article							EYE-MOVEMENTS; WRAP-UP; TEXT; INFORMATION; ATTENTION; RECALL; COMPREHENSION; FIXATIONS; HEADINGS; TIME	It has previously been shown that readers spend a great deal of time skim reading on the Web and that this type of reading can affect comprehension of text. Across two experiments, we examine how hyperlinks influence perceived importance of sentences and how perceived importance in turn affects reading behaviour. In Experiment 1, participants rated the importance of sentences across passages of Wikipedia text. In Experiment 2, a different set of participants read these passages while their eye movements were tracked, with the task being either reading for comprehension or skim reading. Reading times of sentences were analysed in relation to the type of task and the importance ratings from Experiment 1. Results from Experiment 1 show readers rated sentences without hyperlinks as being of less importance than sentences that did feature hyperlinks, and this effect is larger when sentences are lower on the page. It was also found that short sentences with more links were rated as more important, but only when they were presented at the top of the page. Long sentences with more links were rated as more important regardless of their position on the page. In Experiment 2, higher importance scores resulted in longer sentence reading times, measured as fixation durations. When skim reading, however, importance ratings had a lesser impact on online reading behaviour than when reading for comprehension. We suggest readers are less able to establish the importance of a sentence when skim reading, even though importance could have been assessed by information that would be fairly easy to extract (i.e. presence of hyperlinks, length of sentences, and position on the screen).	[Jayes, Lewis T.] Univ Surrey, Sch Psychol, Guildford, Surrey, England; [Fitzsimmons, Gemma; Drieghe, Denis] Univ Southampton, Sch Psychol, Southampton, Hants, England; [Weal, Mark J.] Univ Southampton, Sch Elect & Comp Sci, Southampton, Hants, England; [Kaakinen, Johanna K.] Univ Turku, Finland INVEST Res, Dept Psychol, Turku, Finland; [Kaakinen, Johanna K.] Univ Turku, Flagship, Turku, Finland	University of Surrey; University of Southampton; University of Southampton; University of Turku; University of Turku	Fitzsimmons, G (corresponding author), Univ Southampton, Sch Psychol, Southampton, Hants, England.	gemma.fitzsimmons@soton.ac.uk	; Fitzsimmons, Gemma/J-2509-2016	Drieghe, Denis/0000-0001-9630-8410; Fitzsimmons, Gemma/0000-0002-4519-0499	EPSRC [EP/G036926/1]	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	GF was funded by an EPSRC grant for the Doctoral Training Centre in Web Science: EP/G036926/1. This work formed a part of a PhD completed in the Web Science DTC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1988, STAT POWER SOCIAL SC; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Carr N., 2010, THE SHALLOWS; CARVER RP, 1984, READ RES QUART, V19, P205, DOI 10.2307/747363; Cashen V. M., 1970, J EDUC PSYCHOL, V61, P484, DOI [10.1037/h0030286, DOI 10.1037/H0030286]; Cauchard F, 2010, DISCOURSE PROCESS, V47, P617, DOI 10.1080/01638531003628791; CROUSE JH, 1972, J EDUC PSYCHOL, V63, P309, DOI 10.1037/h0033574; Duggan GB, 2009, J EXP PSYCHOL-APPL, V15, P228, DOI 10.1037/a0016995; Fitzsimmons G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239134; Fitzsimmons G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210900; FOWLER RL, 1974, J APPL PSYCHOL, V59, P358, DOI 10.1037/h0036750; Gagl B, 2016, PEERJ, V4, DOI 10.7717/peerj.2467; Green P, 2016, METHODS ECOL EVOL, V7, P493, DOI 10.1111/2041-210X.12504; HABERLANDT KF, 1985, J EXP PSYCHOL GEN, V114, P357, DOI 10.1037/0096-3445.114.3.357; Haselgrove, 2000, J RES READ, V23, P210, DOI [DOI 10.1111/1467-9817.00115, 10.1111/1467-9817.00115]; HENDERSON JM, 1990, J EXP PSYCHOL LEARN, V16, P417, DOI 10.1037/0278-7393.16.3.417; Hyona J, 2004, LEARN INSTR, V14, P131, DOI 10.1016/j.learninstruc.2004.01.001; Hyona J, 2003, MIND'S EYE: COGNITIVE AND APPLIED ASPECTS OF EYE MOVEMENT RESEARCH, P313, DOI 10.1016/B978-044451020-4/50018-9; INHOFF AW, 1986, PERCEPT PSYCHOPHYS, V40, P431, DOI 10.3758/BF03208203; Josephson S, 2002, BEHAV RES METH INS C, V34, P539, DOI 10.3758/BF03195483; Just M.A., 1987, PSYCHOL READING LANG; Just M. A., 1982, WHAT EYE FIXATIONS T; JUST MA, 1980, PSYCHOL REV, V87, P329, DOI 10.1037/0033-295X.87.4.329; Kaakinen JK, 2010, J EXP PSYCHOL LEARN, V36, P1561, DOI 10.1037/a0020693; Lemarie J, 2008, EDUC PSYCHOL-US, V43, P27, DOI 10.1080/00461520701756321; Lenhard W, 2017, DISCOURSE PROCESS, V54, P427, DOI 10.1080/0163853X.2017.1319653; Lim D.J., 2021, J INTERACTIVE ADVERT, V21, P1, DOI [10.1080/15252019.2021.1921084, DOI 10.1080/15252019.2021.1921084]; Liu ZM, 2005, J DOC, V61, P700, DOI 10.1108/00220410510632040; Liversedge SP, 2000, TRENDS COGN SCI, V4, P6, DOI 10.1016/S1364-6613(99)01418-7; LORCH RF, 1995, CONTEMP EDUC PSYCHOL, V20, P51; Lorch RF, 2012, J EXP PSYCHOL-APPL, V18, P265, DOI 10.1037/a0029547; Lorch RF, 2011, DISCOURSE PROCESS, V48, P139, DOI 10.1080/0163853X.2010.503526; Lorch RF, 1989, EDUC PSYCHOL REV, V1, P209, DOI 10.1007/BF01320135; Macmillan N., 2005, DETECTION THEORY, V2; MASSON MEJ, 1982, J EXP PSYCHOL LEARN, V8, P400, DOI 10.1037/0278-7393.8.5.400; Morkes J., 1997, CONCISE SCANNABLE OB; Nikolova OR, 2004, APPRENTISSAGE LANGUE, V07, P29, DOI [10.4000/alsic.2279, DOI 10.4000/ALSIC.2279]; Nuzzolese AG, 2011, LECT NOTES COMPUT SC, V7031, P520, DOI 10.1007/978-3-642-25073-6_33; R Core Development Team, 2009, R LANG ENV STAT COMP; Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372; Rayner K, 2000, Q J EXP PSYCHOL-A, V53, P1061, DOI 10.1080/02724980050156290; Rayner K, 1996, PERCEPT PSYCHOPHYS, V58, P734, DOI 10.3758/BF03213106; Rayner K, 2009, Q J EXP PSYCHOL, V62, P1457, DOI 10.1080/17470210902816461; Reader WR, 2007, HUM-COMPUT INTERACT, V22, P263; SADOSKI M, 1990, READ RES QUART, V25, P256, DOI 10.2307/747691; Salmeron L, 2017, J COMPUT ASSIST LEAR, V33, P222, DOI 10.1111/jcal.12152; Salmeron L, 2013, COMPUT HUM BEHAV, V29, P2161, DOI 10.1016/j.chb.2013.04.034; Salmeron L, 2011, COMPUT HUM BEHAV, V27, P1143, DOI 10.1016/j.chb.2010.12.008; Scanlan C., 2003, WRITING TOP PROS CON; Schotter ER, 2019, TRENDS COGN SCI, V23, P811, DOI 10.1016/j.tics.2019.06.005; Singer LM, 2017, REV EDUC RES, V87, P1007, DOI 10.3102/0034654317722961; Stine-Morrow EAL, 2010, PSYCHOL AGING, V25, P168, DOI 10.1037/a0018127; Tiffin-Richards SP, 2018, J EXP PSYCHOL LEARN, V44, P1051, DOI 10.1037/xlm0000506; WADE SE, 1990, J READING BEHAV, V22, P331, DOI 10.1080/10862969009547717; Warren T, 2009, COGNITION, V111, P132, DOI 10.1016/j.cognition.2008.12.011; Wu YY, 2021, J COGN PSYCHOL, V33, P146, DOI 10.1080/20445911.2021.1879817	57	0	0	5	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263669	10.1371/journal.pone.0263669	http://dx.doi.org/10.1371/journal.pone.0263669			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139122	Green Published, Green Accepted, gold			2023-01-03	WOS:000821499100042
J	Jeske, M; Vasquez, E; Fullerton, SM; Saperstein, A; Bentz, M; Foti, N; Shim, JK; Lee, SSJ				Jeske, Melanie; Vasquez, Emily; Fullerton, Stephanie M.; Saperstein, Aliya; Bentz, Michael; Foti, Nicole; Shim, Janet K.; Lee, Sandra Soo-Jin			Beyond inclusion: Enacting team equity in precision medicine research	PLOS ONE			English	Article							SYSTEMIC RACISM; WORKFORCE; SCIENCE; HEALTH	Purpose To identify meanings of and challenges to enacting equitable diversification of genomics research, and specifically precision medicine research (PMR), teams. Methods We conducted in-depth interviews with 102 individuals involved in three U.S.-based precision medicine research consortia and conducted over 400 observation hours of their working group meetings, consortium-wide meetings, and conference presentations. We also reviewed published reports on genomic workforce diversity (WFD), particularly those relevant to the PMR community. Results Our study finds that many PMR teams encounter challenges as they strive to achieve equitable diversification on scientific teams. Interviewees articulated that underrepresented team members were often hired to increase the study's capacity to recruit diverse research participants, but are limited to on-the-ground staff positions with little influence over study design. We find existing hierarchies and power structures in the academic research ecosystem compound challenges for equitable diversification. Conclusion Our results suggest that meaningful diversification of PMR teams will only be possible when team equity is prioritized as a core value in academic research communities.	[Jeske, Melanie; Foti, Nicole; Shim, Janet K.] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA USA; [Vasquez, Emily] Univ Illinois, Dept Sociol, Chicago, IL 60680 USA; [Fullerton, Stephanie M.] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA USA; [Saperstein, Aliya] Stanford Univ, Dept Sociol, Stanford, CA 94305 USA; [Bentz, Michael; Lee, Sandra Soo-Jin] Columbia Univ, Dept Med Humanities & Eth, Div Eth, New York, NY 10027 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle; Stanford University; Columbia University	Lee, SSJ (corresponding author), Columbia Univ, Dept Med Humanities & Eth, Div Eth, New York, NY 10027 USA.	sandra.lee@columbia.edu	Saperstein, Aliya/E-8403-2013	Saperstein, Aliya/0000-0002-6429-1172	NHGRI [1R01HG010330-01]	NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was funded by NHGRI Award 1R01HG010330-01 (SSL, JKS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AlShebli BK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07634-8; American Society of Human Genetics, 2020, US; [Anonymous], 2017, NEW NIH APPROACH GRA; Barber PH, 2020, SCIENCE, V369, P1440, DOI 10.1126/science.abd7140; Bonham VL, 2021, AM J HUM GENET, V108, P3, DOI 10.1016/j.ajhg.2020.12.013; Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254; Braveman P, 2014, PUBLIC HEALTH REP, V129, P5, DOI 10.1177/00333549141291S203; Charmaz K., 2014, CONSTRUCTING GROUNDE, Vsecond; Collins FS, 2021, CELL, V184, P3075, DOI 10.1016/j.cell.2021.05.014; Dzirasa K, 2020, CELL, V183, P576, DOI 10.1016/j.cell.2020.09.026; Eaton AA, 2020, SEX ROLES, V82, P127, DOI 10.1007/s11199-019-01052-w; Flores GM, 2011, QUAL SOCIOL, V34, P313, DOI 10.1007/s11133-011-9189-x; Fryer CS, 2016, QUAL HEALTH RES, V26, P830, DOI 10.1177/1049732315575708; Gibbs KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114736; Gibbs KD, 2013, CBE-LIFE SCI EDUC, V12, P711, DOI 10.1187/cbe.13-02-0021; Ginther DK, 2011, SCIENCE, V333, P1015, DOI 10.1126/science.1196783; Green ED, 2020, NATURE, V586, P683, DOI 10.1038/s41586-020-2817-4; Heggeness ML, 2017, NATURE, V541, P21, DOI 10.1038/541021a; Hofstra B, 2020, P NATL ACAD SCI USA, V117, P9284, DOI 10.1073/pnas.1915378117; Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238; Jackson PB, 1995, SOC FORCES, V74, P543, DOI 10.2307/2580491; Jimenez MF, 2019, NAT ECOL EVOL, V3, P1030, DOI 10.1038/s41559-019-0911-5; Lee SSJ, 2019, SCIENCE, V364, P941, DOI 10.1126/science.aaw8299; Lee SS-J., 2020, SOC STUD SCI; National Human Genome Research Insititute, 2020, BUILD DIV GEN WORKF; National Institutes of Health, 2021, US; National Society of Genetic Counselors, 2020, US; Olsen LD, 2019, J HEALTH SOC BEHAV, V60, P55, DOI 10.1177/0022146518821388; Puritty C, 2017, SCIENCE, V357, P1101, DOI 10.1126/science.aai9054; Smith-Doerr L, 2017, ENGAG SCI TECHNOL SO, V3, P139, DOI 10.17351/ests2017.142; Stevens KR, 2021, CELL, V184, P561, DOI 10.1016/j.cell.2021.01.011; Thomson RA, 2021, ETHNIC RACIAL STUD, V44, P1250, DOI 10.1080/01419870.2020.1786144	32	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2022	17	2							e0263750	10.1371/journal.pone.0263750	http://dx.doi.org/10.1371/journal.pone.0263750			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1U6OX	35130331	gold, Green Published			2023-01-03	WOS:000805530700050
J	Torres-Prunonosa, J; Raya, JM; Crespo-Sogas, P; Mur-Gimeno, E				Torres-Prunonosa, Jose; Maria Raya, Josep; Crespo-Sogas, Patricia; Mur-Gimeno, Esther			The economic and social value of spa tourism: The case of balneotherapy in Maresme, Spain	PLOS ONE			English	Article							LOW-BACK-PAIN; COST-EFFECTIVENESS; HOT-SPRINGS; THERAPY; IMPACT; EFFICIENCY; OSTEOARTHRITIS; SEGMENTATION; EVENTS; BANKS	The aim of this article is to assess both the economic and social value of balneotherapy and spa tourism, being the first paper in carrying out this analysis. The study has been conducted in Maresme, a region of Catalonia, Spain. On the one hand, an Input-Output (IO) model with a Social Accounting Matrix (SAM) has been carried out to assess the economic value. On the other hand, a Cost-Benefit Analysis (CBA) has been used to monetise the social value in this region, taking into account, among other concepts, direct and indirect health profits, given that balneotherapy helps to alleviate various diseases. The results show that whereas the economic multiplier is 1.529 considering the direct and indirect effects and 1.712 taking into account also the induced effects, which are similar to health and medical tourism multipliers, social value generates additional positive value, given that the cost-benefit ratio is 1.858. The theoretical implications of the paper as well as the findings' implications for policy so as to encourage investments in spa tourism are discussed.	[Torres-Prunonosa, Jose] Univ Int La Rioja UNIR, Logrono, La Rioja, Spain; [Maria Raya, Josep; Crespo-Sogas, Patricia] Univ Pompeu Fabra, Escola Super Ciencies Socials & Empresa Tecnocamp, Mataro, Spain; [Mur-Gimeno, Esther] Univ Pompeu Fabra, Res Grp Attent Chronic & Innovat Hlth GRACIS, Escola Super Ciencies Salut Tecnocampus, Mataro, Spain	Universidad Internacional de La Rioja (UNIR); Pompeu Fabra University; Pompeu Fabra University	Torres-Prunonosa, J (corresponding author), Univ Int La Rioja UNIR, Logrono, La Rioja, Spain.	jose.torresprunonosa@unir.net	Torres-Pruñonosa, Jose/P-8785-2015	Torres-Pruñonosa, Jose/0000-0003-2276-1655; Mur, Esther/0000-0001-7742-1880	Universidad Internacional de la Rioja; Fundacio Tecnocampus Mataro -Maresme	Universidad Internacional de la Rioja; Fundacio Tecnocampus Mataro -Maresme	JTP. Universidad Internacional de la Rioja. www.unir.net JMR, PCS & EMG. Fundacio Tecnocampus Mataro -Maresme. www.tecnocampus.cat The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akkemik KA, 2012, TOURISM MANAGE, V33, P790, DOI 10.1016/j.tourman.2011.09.002; Allard P, 1998, REV RHUM, V65, P173; Alonso-Alvarez L, 2012, J TOUR HIST, V4, P15, DOI 10.1080/1755182X.2012.671373; [Anonymous], 2009, REV SOC ESPA OLA DOL, V16, P417; [Anonymous], SPRING CALDES DESTRA; Argandoa A, 2011, BEIM COMN DOCUMENTO; Aza Conejo R., 2007, International Journal of Sport Management and Marketing, V2, P459, DOI 10.1504/IJSMM.2007.013961; Bai RX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017092; Balogh Z, 2005, FORSCH KOMP KLAS NAT, V12, P196, DOI 10.1159/000086305; Barajas A, 2014, TOURISM ECON, V20, P279, DOI 10.5367/te.2013.0270; Batlle E., 2005, REV ESPA OLA REUMATO, V32, P22; Butler RW, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11236711; Carneiro MJ., 2013, SOCIOECONOMIC IMPACT, P46; Carrera Percivil M, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P447, DOI 10.1586/14737167.6.4.447; Cheleschi S, 2020, INT J BIOMETEOROL, V64, P1247, DOI 10.1007/s00484-020-01890-4; Chen KH, 2013, INT J HOSP MANAG, V35, P122, DOI 10.1016/j.ijhm.2013.05.013; Cheung H., 2012, STUDIES UNDERGRADUAT, V6, DOI [10.21083/surg.v6i1.2019, DOI 10.21083/SURG.V6I1.2019]; Ciani O, 2017, ARTHRIT CARE RES, V69, P966, DOI 10.1002/acr.23116; Crompton J. L., 2006, Journal of Travel Research, V45, P67, DOI 10.1177/0047287506288870; Daniels M. J., 2003, Journal of Sport Tourism, V8, P214, DOI 10.1080/1477508032000161528; Demsetz Harold, 1993, NATURE FIRM ORIGINS; Dimitrovski D, 2015, TOUR MANAG PERSPECT, V16, P259, DOI 10.1016/j.tmp.2015.09.004; Drakakis P, 2021, TOURISM ECON, V27, P527, DOI 10.1177/1354816620902328; Dryglas D., 2020, International Journal of Spa and Wellness, V3, P69, DOI 10.1080/24721735.2020.1857207; Dunets AN, 2020, ENTREP SUSTAIN ISS, V7, P2213, DOI 10.9770/jesi.2020.7.3(50); Eusebio C., 2012, QUANTITATIVE METHODS, P153, DOI [10.1007/978-3-7908-2879-5_9, DOI 10.1007/978-3-7908-2879-5_9]; Fernandez-de-las-Penas C, 2011, SPINE, V36, pE213, DOI 10.1097/BRS.0b013e3181d952c2; Fioravanti A, 2003, PANMINERVA MED, V45, P211; Fioravanti A, 2017, EUR J INTEGR MED, V9, P148, DOI 10.1016/j.eujim.2017.01.001; FLETCHER JE, 1989, ANN TOURISM RES, V16, P514, DOI 10.1016/0160-7383(89)90006-6; Florio M., 2014, APPL WELFARE EC COST; Freeman RE, 2004, ORGAN SCI, V15, P364, DOI 10.1287/orsc.1040.0066; Freeman RE, 2010, STRATEG MANAG; Gassenheimer JB, 1998, J ACAD MARKET SCI, V26, P322, DOI 10.1177/0092070398264005; Gati T, 2018, INT J BIOMETEOROL, V62, P897, DOI 10.1007/s00484-017-1491-1; Gomez Rodriguez N, 2003, An Med Interna, V20, P111; Gonzalez-Escalada Castellon JR, 2006, C TEDRA EXTRAORDINAR, P111; Goodrich J. N., 1993, Journal of Travel Research, V32, P36, DOI 10.1177/004728759303200106; Goodrich J.N., 1987, TOUR MANAG, V8, P217, DOI [10.1016/0261-5177(87)90053-7, DOI 10.1016/0261-5177(87)90053-7]; Gratton C, 2006, SOCIOL REV, V54, P41, DOI 10.1111/j.1467-954X.2006.00652.x; Guo YY, 2016, ASIA PAC J TOUR RES, V21, P118, DOI 10.1080/10941665.2015.1025085; Gutenbrunner C, 2010, INT J BIOMETEOROL, V54, P495, DOI 10.1007/s00484-010-0321-5; Haji Y, 2021, J PAIN RES, V14, P2491, DOI 10.2147/JPR.S322603; Hernandez-Torres A., 2016, B SOC ESPA OLA HIDRO, V31, P157; INE, 2015, DECIL SAL EMPL PRINC; Jensen MC, 2000, BREAKING THE CODE OF CHANGE, P37; Jeong JY, 2016, J TRAVEL RES, V55, P874, DOI 10.1177/0047287515605932; Jimenez-Naranjo HV, 2016, EUR RES MANAG BUS EC, V22, P131, DOI 10.1016/j.iedee.2015.04.001; Kim H, 2015, TOUR REV, V70, P132, DOI 10.1108/TR-11-2014-0056; Kirkby CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013015; Klijs J, 2015, TOURISM ECON, V21, P931, DOI 10.5367/te.2014.0398; Kroeger A, 2014, ACAD MANAGE REV, V39, P513, DOI 10.5465/amr.2012.0344; Kronenberg K, 2018, TOUR REV, V73, P94, DOI [10.1108/tr-03-2017-0044, 10.1108/TR-03-2017-0044]; Kucukusta D, 2016, ASIA PAC J TOUR RES, V21, P239, DOI 10.1080/10941665.2015.1025087; Laws E., 1996, HLTH INT TOURIST, P199; Lazcano L., 2019, SOCIAL ACCOUNTING SO, P132, DOI [10.4018/978-1-5225-8482-7, DOI 10.4018/978-1-5225-8482-7]; Ledesma R, 2005, MORBILIDAD DISCAPACI; Lee CK, 2017, LEISURE STUD, V36, P138, DOI 10.1080/02614367.2015.1040828; Lingane A, 2004, CALIF MANAGE REV, V46, P116, DOI 10.2307/41166224; Llop M, 2012, ANN REGIONAL SCI, V48, P339, DOI 10.1007/s00168-010-0403-7; Llor JL., 2008, MED NATURISTA, V3, P76; Retolaza JL, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00077; Carbajo JM, 2018, INT J BIOMETEOROL, V62, P1345, DOI 10.1007/s00484-018-1545-z; Maraver F, 2010, VADEMECUM 2 AGUAS MI; Raya JM, 2018, J TRAVEL TOUR MARK, V35, P148, DOI 10.1080/10548408.2017.1350252; Matsumoto S, 2018, J NIPPON MED SCH, V85, P196, DOI 10.1272/jnms.JNMS.2018_85-30; Mayer M, 2014, J SUSTAIN TOUR, V22, P561, DOI 10.1080/09669582.2013.871020; Mennuni G, 2021, Clin Ter, V172, P372, DOI 10.7417/CT.2021.2343; Morer C., 2016, TALASOTERAPIA B SOC, V31, DOI [10.23853/bsehm.2017.0209, DOI 10.23853/BSEHM.2017.0209]; Morer C, 2017, INT J BIOMETEOROL, V61, P2159, DOI 10.1007/s00484-017-1421-2; Mourgues C, 2014, EUR J ONCOL NURS, V18, P505, DOI 10.1016/j.ejon.2014.04.008; Mueller H., 2001, Journal of Vacation Marketing, V7, P5, DOI 10.1177/135676670100700101; Mulgan G., 2010, STANFORD SOCIAL INNO, P38, DOI DOI 10.1257/AER.97.2.433; Nelson R.R., 1982, EVOL THEOR, DOI DOI 10.2307/2232409; Olabe-Sanchez PJ, 2004, REV FISIOTERAPIA, V5; Olsen S., 2008, CATALOG APPROACHES I; Oosterhaven J., 2006, International Journal of Tourism Research, V8, P347, DOI 10.1002/jtr.582; Pittler MH, 2006, RHEUMATOLOGY, V45, P880, DOI 10.1093/rheumatology/kel018; Polo C, 2008, TOURISM ECON, V14, P615, DOI 10.5367/000000008785633604; Novo JP, 2015, REV CUBA REUMATOL, V17, P147; PYATT G, 1979, ECON J, V89, P850, DOI 10.2307/2231503; Retolaza J. L., 2015, NEW CHALLENGES ENTRE, P259, DOI [10.1007/978-3-319-08888, DOI 10.1007/978-3-319-08888, 10.1007/978-3-319-08888-4_19]; Retolaza J.L., 2016, SOCIAL ACCOUNTING SU, DOI [10.1016/j.aprim.2015.06.013, DOI 10.1016/J.APRIM.2015.06.013, 10.1007/978-3-319-13377-5.pdf, DOI 10.1007/978-3-319-13377-5.PDF]; Retolaza JL., 2018, LEGITIMIZING DELEGIT, P159, DOI [10.1007/978-3-319-75990-6_10, DOI 10.1007/978-3-319-75990-6_10]; Salgado-Barandela J, 2021, TOURISM ECON, V27, P436, DOI 10.1177/1354816619884448; San-Jose L., 2012, SOFT COMPUTING MANAG, P153, DOI [10.1007/978-3-642-30451-4_11, DOI 10.1007/978-3-642-30451-4_11]; San-Jose L, 2020, TRIMEST ECON, V87, P759, DOI 10.20430/ete.v87i347.882; San-Jose L, 2014, J INT FINANC MARK I, V32, P240, DOI 10.1016/j.intfin.2014.06.005; Schumpeter J, 1909, Q J ECON, V23, P213, DOI 10.2307/1882798; Silovska HC, 2019, ECON RES-EKON ISTRAZ, V32, P2063, DOI 10.1080/1331677X.2019.1642777; Smith C., 2000, Travel & Tourism Analyst, P41; Smith M.K, 2014, HLTH TOURISM HOSPITA, DOI 10.4324/9780203083772; Snyder J, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-2; Speier Amy R, 2011, Anthropol Med, V18, P55, DOI 10.1080/13648470.2010.525879; Szromek A.R., 2021, J OPEN INNOV-TECHNOL, V7, P73, DOI [10.3390/joitmc7010073, DOI 10.3390/JOITMC7010073, https://doi.org/10.3390/joitmc7010073]; Szromek AR, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11133598; Szromek AR, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11102880; Szymanska E, 2017, MODERN TENDENCIES SP; Thorbecke E., 1998, SOCIAL ACCOUNTING MA; Prunonosa JT, 2012, REVESCO-REV ESTUD CO, P152, DOI 10.5209/rev_REVE.2012.v18.39591; Torres-Prunonosa J, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.629951; Torres-Prunonosa J, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.632600; Van Tubergen A, 2002, ARTHRIT RHEUM-ARTHR, V47, P459, DOI 10.1002/art.10658; Vanhove N, 2013, HANDBOOK OF TOURISM ECONOMICS: ANALYSIS, NEW APPLICATIONS AND CASE STUDIES, P393; Verhagen AP, 2005, BALNEOTERAPIA ARTRIT; Weaver D, 2006, TOURISM MANAGE; West S, 2002, Evid Rep Technol Assess (Summ), P1; Wood J, 2021, TOURISM ECON, V27, P1303, DOI 10.1177/1354816620921577; Zhu Y, 2011, J TOURISM MANAG RES, V15; Zijlstra TR, 2007, RHEUMATOLOGY, V46, P1454, DOI 10.1093/rheumatology/kem157	110	1	1	8	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2022	17	1							e0262428	10.1371/journal.pone.0262428	http://dx.doi.org/10.1371/journal.pone.0262428			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P3UI	35100293	gold, Green Published			2023-01-03	WOS:000801937600013
J	Iacovides, S; Maloney, SK; Bhana, S; Angamia, Z; Meiring, RM				Iacovides, Stella; Maloney, Shane K.; Bhana, Sindeep; Angamia, Zareena; Meiring, Rebecca M.			Could the ketogenic diet induce a shift in thyroid function and support a metabolic advantage in healthy participants? A pilot randomized-controlled-crossover trial	PLOS ONE			English	Article							LOW-CARBOHYDRATE-DIET; LOW-FAT DIET; CARDIOVASCULAR RISK-FACTORS; BROWN ADIPOSE-TISSUE; WEIGHT-LOSS; HIGH-PROTEIN; ENERGY-EXPENDITURE; FAVORABLE IMPACT; BODY-WEIGHT; BILE-ACIDS	Background The ketogenic diet (KD) has been shown to result in body mass loss in people with disease as well as healthy people, yet the effect of the KD on thyroid function and metabolism are unknown. Objective We aimed to determine the effects of a KD, compared with an isocaloric high-carbohydrate low-fat (HCLF) diet, on resting metabolic rate and thyroid function in healthy individuals. Design Eleven healthy, normal-weight participants (mean(SD) age: 30(9) years) completed this randomized crossover-controlled study. For a minimum of three weeks on each, participants followed two isocaloric diets: a HCLF diet (55%carbohydrate, 20%fat, 25%protein) and a KD (15%carbohydrate, 60%fat, 25% protein), with a one-week washout period in-between. Importantly, while on the KD, the participants were required to remain in a state of nutritional ketosis for three consecutive weeks. Crossover analyses and linear mixed models were used to assess effect of diet on body mass, thyroid function and resting metabolic rate. Results Both dietary interventions resulted in significant body mass loss (p<0.05) however three weeks of sustained ketosis (KD) resulted in a greater loss of body mass (mean (95%CI): -2.9 (-3.5, -2.4) kg) than did three weeks on the HCLF diet (-0.4 (-1.0, 0.1) kg, p < 0.0001). Compared to pre-diet levels, the change in plasma T3 concentration was significantly different between the two diets (p = 0.003), such that plasma T3 concentration was significantly lower following the KD diet (4.1 (3.8, 4.4) pmol/L, p<0.0001) but not different following the HCLF diet (4.8 (4.5, 5.2) pmol/L, p = 0.171. There was a significant increase in T4 concentration from pre-diet levels following the KD diet (19.3 (17.8, 20.9) pmol/L, p < 0.0001), but not following the HCLF diet (17.3 (15.7, 18.8) pmol.L, p = 0.28). The magnitude of change in plasma T4 concentration was not different between the two diets (p = 0.4). There was no effect of diet on plasma thyroid stimulating hormone concentration (p = 0.27). There was a significantly greater T3:T4 ratio following the HCLF diet (0.41 (0.27, 0.55), p < 0.0001) compared to pre-diet levels but not following the KD diet (0.25 (0.12, 0.39), p = 0.80). Conclusions Although the diets were isocaloric and physical activity and resting metabolic rate remained constant, the participants lost more mass after the KD than after the HCLF diet. The observed significant changes in triiodothyronine concentration suggest that unknown metabolic changes occur in nutritional ketosis, changes that warrant further investigation.	[Iacovides, Stella; Maloney, Shane K.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Brain Funct Res Grp, Johannesburg, South Africa; [Maloney, Shane K.] Univ Western Australia, Sch Human Sci, Crawley, Australia; [Bhana, Sindeep; Angamia, Zareena] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Dept Endocrinol & Metab, Div Endocrinol, Johannesburg, South Africa; [Meiring, Rebecca M.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Movement Physiol Res Lab, Johannesburg, South Africa; [Meiring, Rebecca M.] Univ Auckland, Dept Exercise Sci, Auckland, New Zealand	University of Witwatersrand; University of Western Australia; University of Witwatersrand; University of Witwatersrand; University of Auckland	Iacovides, S (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Brain Funct Res Grp, Johannesburg, South Africa.	Stella.Iacovides@wits.ac.za		Iacovides, Stella/0000-0003-2807-9139	Faculty Research council (FRC), SEED Funding from the Faculty of Health Sciences, University of the Witwatersrand; Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand; Movement Physiology Research Laboratory, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand	Faculty Research council (FRC), SEED Funding from the Faculty of Health Sciences, University of the Witwatersrand; Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand; Movement Physiology Research Laboratory, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand	SI: The Faculty Research council (FRC), SEED Funding from the Faculty of Health Sciences, University of the Witwatersrand. SI also received funds from the Brain Function Research Group and the Movement Physiology Research Laboratory, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla SM, 2014, CLIN ENDOCRINOL, V81, P633, DOI 10.1111/cen.12538; Deluis DA, 2010, METABOLISM, V59, P1387, DOI 10.1016/j.metabol.2009.12.029; ARASE K, 1988, AM J PHYSIOL, V255, pR974, DOI 10.1152/ajpregu.1988.255.6.R974; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Brinkworth GD, 2009, ARCH INTERN MED, V169, P1873, DOI 10.1001/archinternmed.2009.329; Brinkworth GD, 2009, AM J CLIN NUTR, V90, P23, DOI 10.3945/ajcn.2008.27326; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Buysse D J, 1989, Psychiatry Res, V28, P193; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cardillo S, 2006, Eur Rev Med Pharmacol Sci, V10, P99; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Din MU, 2018, CELL METAB, V28, P207, DOI 10.1016/j.cmet.2018.05.020; Feinman RD, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-9; Feinman RD, 2003, METAB SYNDR RELAT D, V1, P209, DOI 10.1089/154041903322716688; FERY F, 1982, DIABETES METAB, V8, P299; Forsythe CE, 2008, LIPIDS, V43, P65, DOI 10.1007/s11745-007-3132-7; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Frisch S, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-36; GARBER AJ, 1974, J CLIN INVEST, V54, P981, DOI 10.1172/JCI107839; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Gereben B, 2008, CELL MOL LIFE SCI, V65, P570, DOI 10.1007/s00018-007-7396-0; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; Guldbrand H, 2012, DIABETOLOGIA, V55, P2118, DOI 10.1007/s00125-012-2567-4; Halyburton AK, 2007, AM J CLIN NUTR, V86, P580, DOI 10.1093/ajcn/86.3.580; Haugen BR, 2004, ENDOCRINOLOGY, V145, P3679, DOI 10.1210/en.2003-1401; Hernandez TL, 2010, AM J CLIN NUTR, V91, P578, DOI 10.3945/ajcn.2009.27909; Iacovides S, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2462-5; JOHANNESSEN A, 1981, J CLIN ENDOCR METAB, V52, P56, DOI 10.1210/jcem-52-1-56; Johnston CS, 2004, J NUTR, V134, P586, DOI 10.1093/jn/134.3.586; Jonasson L, 2014, ANN MED, V46, P182, DOI 10.3109/07853890.2014.894286; Keogh JB, 2008, AM J CLIN NUTR, V87, P567, DOI 10.1093/ajcn/87.3.567; Kim HJ, 2016, ENDOCRINOL METAB, V31, P311, DOI 10.3803/EnM.2016.31.2.311; Kozak LP, 2010, CELL METAB, V11, P263, DOI 10.1016/j.cmet.2010.03.009; Krauss RM, 2006, AM J CLIN NUTR, V83, P1025, DOI 10.1093/ajcn/83.5.1025; Krebs NF, 2010, J PEDIATR-US, V157, P252, DOI 10.1016/j.jpeds.2010.02.010; Li PP, 2011, CELL, V147, P815, DOI 10.1016/j.cell.2011.09.050; McClernon FJ, 2007, OBESITY, V15, P182, DOI 10.1038/oby.2007.516; Melzer K., 2011, e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, V6, pe45, DOI 10.1016/j.eclnm.2011.01.005; Minami Y, 2015, J CLIN BIOCHEM NUTR, V57, P121, DOI 10.3164/jcbn.15-24; Morgan LM, 2009, PUBLIC HEALTH NUTR, V12, P799, DOI 10.1017/S1368980008003236; Mullur R, 2014, PHYSIOL REV, V94, P355, DOI 10.1152/physrev.00030.2013; Nickols-Richardson SM, 2005, J AM DIET ASSOC, V105, P1433, DOI 10.1016/j.jada.2005.06.025; Noakes M, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-7; Ockenga J, 2012, J CLIN ENDOCR METAB, V97, P535, DOI 10.1210/jc.2011-2329; Orava J, 2011, CELL METAB, V14, P272, DOI 10.1016/j.cmet.2011.06.012; OWEN OE, 1971, J CLIN INVEST, V50, P1536, DOI 10.1172/JCI106639; Peterson CM, 2017, OBESITY, V25, P502, DOI 10.1002/oby.21721; PHINNEY SD, 1983, METABOLISM, V32, P769, DOI 10.1016/0026-0495(83)90106-3; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; SHERWIN RS, 1975, J CLIN INVEST, V55, P1382, DOI 10.1172/JCI108057; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Svensson PA, 2013, BIOCHEM BIOPH RES CO, V433, P563, DOI 10.1016/j.bbrc.2013.03.031; Tarcin O, 2012, METAB SYNDR RELAT D, V10, P137, DOI 10.1089/met.2011.0098; Tay J, 2008, J AM COLL CARDIOL, V51, P59, DOI 10.1016/j.jacc.2007.08.050; Trexler ET, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-7; ULLRICH IH, 1985, J AM COLL NUTR, V4, P451, DOI 10.1080/07315724.1985.10720087; Volek JS, 2015, EUR J SPORT SCI, V15, P13, DOI 10.1080/17461391.2014.959564; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Volek Js, 2004, Nutr Metab (Lond), V1, P13, DOI 10.1186/1743-7075-1-13; Volek JS, 2002, METABOLISM, V51, P864, DOI 10.1053/meta.2002.32037; Volek JS, 2000, J AM COLL NUTR, V19, P383, DOI 10.1080/07315724.2000.10718935; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Westerterp-Plantenga MS, 2004, INT J OBESITY, V28, P57, DOI 10.1038/sj.ijo.0802461; Westman EC, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-36; Wolffenbuttel BHR, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/s12902-017-0215-1; Yancy WS, 2010, ARCH INTERN MED, V170, P136, DOI 10.1001/archinternmed.2009.492; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006; You SH, 2010, MOL ENDOCRINOL, V24, P1359, DOI 10.1210/me.2009-0501	70	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269440	10.1371/journal.pone.0269440	http://dx.doi.org/10.1371/journal.pone.0269440			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35658056	gold, Green Published			2023-01-03	WOS:000843567600098
J	Rabinowitz, JA; Jin, J; Kuo, SIC; Campos, AI; Renteria, ME; Huhn, AS; Thrul, J; Reboussin, BA; Benke, K; Domingue, B; Ialongo, NS; Maher, BS; Kertes, D; Troiani, V; Uhl, G				Rabinowitz, Jill A.; Jin, Jin; Kuo, Sally I-Chun; Campos, Adrian, I; Renteria, Miguel E.; Huhn, Andrew S.; Thrul, Johannes; Reboussin, Beth A.; Benke, Kelly; Domingue, Benjamin; Ialongo, Nicholas S.; Maher, Brion S.; Kertes, Darlene; Troiani, Vanessa; Uhl, George			Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans	PLOS ONE			English	Article							SUBSTANCE USE DISORDERS; HEALTH; TRAJECTORIES; DEPRESSION; LIABILITY; ABUSE; YOUTH; SCANS	BackgroundThis study examined whether polygenic risk scores (PRS) for lifetime cannabis and alcohol use were associated with misusing opioids, and whether sex differences existed in these relations in an urban, African-American sample. MethodsData were drawn from three cohorts of participants (N = 1,103; 45% male) who were recruited in first grade as part of a series of elementary school-based, universal preventive intervention trials conducted in a Mid-Atlantic region of the U.S. In young adulthood, participants provided a DNA sample and reported on whether they had used heroin or misused prescription opioids in their lifetime. Three substance use PRS were computed based on prior GWAS: lifetime cannabis use from Pasman et al. (2018), heavy drinking indexed via maximum number of drinks from Gelernter et al. (2019), and alcohol consumption from Kranzler et al. (2019). ResultsHigher PRS for lifetime cannabis use, greater heavy drinking, and greater alcohol consumption were associated with heightened risk for misusing opioids among the whole sample. Significant sex by PRS interactions were also observed such that higher PRS for heavy drinking and alcohol consumption were associated with a greater likelihood of opioid misuse among males, but not females. ConclusionOur findings further elucidate the genetic contributions to misusing opioids by showing that the genetics of cannabis and alcohol consumption are associated with lifetime opioid misuse among young adults, though replication of our findings is needed.	[Rabinowitz, Jill A.; Thrul, Johannes; Benke, Kelly; Ialongo, Nicholas S.; Maher, Brion S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA; [Jin, Jin] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Kuo, Sally I-Chun] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA; [Campos, Adrian, I; Renteria, Miguel E.] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia; [Huhn, Andrew S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Thrul, Johannes] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Thrul, Johannes] La Trobe Univ, Ctr Alcohol Policy Res, Melbourne, Vic, Australia; [Reboussin, Beth A.] Wake Forest Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27101 USA; [Domingue, Benjamin] Stanford Univ, Grad Sch Educ, Stanford, CA 94305 USA; [Kertes, Darlene] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA; [Troiani, Vanessa] Geisinger, Lewisburg, PA USA; [Uhl, George] New Mexico VA HealthCare Syst, Albuquerque, NM USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Virginia Commonwealth University; QIMR Berghofer Medical Research Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; La Trobe University; Wake Forest University; Stanford University; State University System of Florida; University of Florida	Rabinowitz, JA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA.	jrabino3@jhmi.edu	Rentería, Miguel E./M-6671-2017	Rentería, Miguel E./0000-0003-4626-7248; Rabinowitz, Jill/0000-0002-3674-8032	National Institute on Drug Abuse Research [R01DA044184-02S1, DA11796 MH57005, DA 04392, DA 09897]; National Institute of Mental Health [P50 MH 38725, R01 MH 42968]	National Institute on Drug Abuse Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors would like to acknowledge support from the following National Institute on Drug Abuse Research grants (R01DA044184-02S1; DA11796 MH57005; DA 04392; DA 09897) and National Institute of Mental Health grants (P50 MH 38725; R01 MH 42968). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Affymetrix Inc, GEN WID HUM SNP NSP; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Arterberry BJ, 2016, DRUG ALCOHOL DEPEN, V159, P86, DOI 10.1016/j.drugalcdep.2015.11.029; Cai R, 2010, J Pain Palliat Care Pharmacother, V24, P293, DOI 10.3109/15360288.2010.503730; Caille S, 2006, NEUROPSYCHOPHARMACOL, V31, P804, DOI 10.1038/sj.npp.1300848; Carmon J, 2020, J ADOLESCENT HEALTH, V66, P536, DOI 10.1016/j.jadohealth.2019.11.306; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Crist RC, 2019, CURR OPIN PSYCHOL, V27, P31, DOI 10.1016/j.copsyc.2018.07.014; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Dolan L.J., 1993, J APPL DEV PSYCHOL, V14, P317, DOI [DOI 10.1016/0193-3973(93)90013-L, 10.1016/0193-3973(93)90013-l]; DuPont RL, 2018, PREV MED, V113, P68, DOI 10.1016/j.ypmed.2018.05.015; Esser MB, 2021, AM J PREV MED, V60, P169, DOI 10.1016/j.amepre.2020.08.025; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Gelernter J, 2019, NAT NEUROSCI, V22, P1394, DOI 10.1038/s41593-019-0447-7; Gelernter J, 2019, BIOL PSYCHIAT, V86, P365, DOI 10.1016/j.biopsych.2019.03.984; Gillespie NA, 2019, ADDICTION, V114, P2229, DOI 10.1111/add.14750; Girgis J, 2020, J ADOLESCENT HEALTH, V67, P26, DOI 10.1016/j.jadohealth.2020.01.015; Gostin LO, 2017, JAMA-J AM MED ASSOC, V318, P1539, DOI 10.1001/jama.2017.13358; Hagemeier NE, 2018, AM J MANAG CARE, V24, pS200; Hood LE, 2020, EXPERT OPIN PHARMACO, V21, P823, DOI 10.1080/14656566.2020.1732349; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Huhn AS, 2020, CURR PSYCHIAT REP, V22, DOI 10.1007/s11920-020-01201-z; Huhn AS, 2019, AM J ADDICTION, V28, P246, DOI 10.1111/ajad.12921; Huhn AS, 2018, INT REV PSYCHIATR, V30, P107, DOI 10.1080/09540261.2018.1514295; Ialongo NS, 1999, AM J COMMUN PSYCHOL, V27, P599, DOI 10.1023/A:1022137920532; Iob E, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12944; Jones CM, 2020, MMWR-MORBID MORTAL W, V69, P38, DOI 10.15585/mmwr.su6901a5; Katz J., 2017, DRUG DEATHS AM ARE R; Kendler KS, 2014, AM J PSYCHIAT, V171, P209, DOI 10.1176/appi.ajp.2013.12101300; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Kranzler HR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09480-8; Lake S, 2016, J ADDICT DIS, V35, P73, DOI 10.1080/10550887.2015.1127712; Marsh JC, 2018, J SUBST ABUSE TREAT, V87, P79, DOI 10.1016/j.jsat.2018.01.001; Martin AR, 2017, AM J HUM GENET, V100, P635, DOI 10.1016/j.ajhg.2017.03.004; Nicholson HL, 2019, SUBST USE MISUSE, V54, P639, DOI 10.1080/10826084.2018.1531427; Pasman JA, 2018, NAT NEUROSCI, V21, P1161, DOI 10.1038/s41593-018-0206-1; Price AL, 2008, AM J HUM GENET, V83, P132, DOI 10.1016/j.ajhg.2008.06.005; Reboussin BA, 2020, DRUG ALCOHOL DEPEN, V215, DOI 10.1016/j.drugalcdep.2020.108182; Roughan WH, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.643609; Schwantes-An TH, 2016, BEHAV GENET, V46, P151, DOI 10.1007/s10519-015-9737-3; Storr CL, 2002, DRUG ALCOHOL DEPEN, V66, P51, DOI 10.1016/S0376-8716(01)00184-3; Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210; Thrul J, 2021, SUBST ABUS, V42, P873, DOI 10.1080/08897077.2021.1890675; Vanyukov M., 2021, WHY SUBSTANCE USE PR, DOI [10.31234/osf.io/tkm5u, DOI 10.31234/OSF.IO/TKM5U]; Vanyukov MM, 2003, NEUROSCI BIOBEHAV R, V27, P507, DOI 10.1016/j.neubiorev.2003.08.002; Wang TY, 2013, BEHAV BRAIN RES, V250, P285, DOI 10.1016/j.bbr.2013.05.015; Wiese B, 2018, CANNABIS CANNABINOID, V3, P179, DOI 10.1089/can.2018.0022; Yang BZ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53560-0; Zhou H, 2020, JAMA PSYCHIAT, V77, P1072, DOI 10.1001/jamapsychiatry.2020.1206	49	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266384	10.1371/journal.pone.0266384	http://dx.doi.org/10.1371/journal.pone.0266384			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0X7AZ	35395044	Green Published, gold			2023-01-03	WOS:000789855700005
J	Yang, L; Wang, Z; Dong, HX; Wang, Q; Cheng, L; Yi, P; Huang, DM				Yang Li; Wang Zhi; Dong Haoxu; Wang Qing; Cheng Ling; Yi Ping; Huang Dongmei			Effects of electroacupuncture on the expression of hypothalamic neuropeptide Y and ghrelin in pubertal rats with polycystic ovary syndrome	PLOS ONE			English	Article							GONADOTROPIN-RELEASING-HORMONE; LUTEINIZING-HORMONE; BETA-ENDORPHIN; FEMALE RATS; IN-VITRO; GALANIN; INSULIN; SECRETION; KISSPEPTIN; OBESE	Background Polycystic ovary syndrome often starts in puberty, and its pathogenesis is not clear. This study aimed to explore the pathogenesis of pubertal polycystic ovary syndrome (PCOS) and assess the therapeutic effect of electroacupuncture on pubertal PCOS. Methods Dihydrotestosterone (DHT) was used to induce rat models of pubertal PCOS. pubertal rats with PCOS were randomly divided into a model group (M), an electroacupuncture group (EA), and a sham acupuncture group (SA). Age-matched normal rats were regarded as normal controls (N). Rats were treated with EA or SA five times a week for 25 minutes during their 6th-7th week. At the end of the experiment, we observed any changes in ovarian morphology; detected levels of metabolic indices in serum, the hypothalamus and pancreas. Results EA significantly improved estrous cycle disorders and the ovarian polycystic morphology in pubertal rats with PCOS, but SA only improved disorders of the estrous cycle. The serum levels of insulin, neuropeptide Y(NPY) and fasting blood glucose(FBG) increased significantly (both p <0.01), while the serum levels of ghrelin(GHRL) decreased in the model group (p < 0.01). After treatment with EA, the levels of NPY (p < 0.01) and FBG (p < 0.05) went into decrease, whereas the levels of GHRL (p < 0.05) and insulin (p < 0.01) increased. There was few differences in the hypothalamic expression of galanin (GAL), galanin-like peptide (GALP) and ghrelin receptor(GHSR) between the four groups. The upregulation of NPY mRNA and neuropeptide Y2 receptor(NPY2R) mRNA and the downregulation of GHRL protein and mRNA in the hypothalamus, and the increased expression of NPY and NPY2R as well as the decreased expression of GHRL in the arcuate nucleus (ARC) can be rescued by EA. But, surprisingly, SA seem to make no difference to the levels of FBG and insulin, and the protein expression of ghrelin in the hypothalamus and ARC. Co-expression of kisspeptin and GHSR, and co-expression of gonadotrophin releasing hormone(GnRH) and NPY2R were observed in ARC. No differences were found between groups in protein of GAL, GALP and GHRL expression in the pancreas. Neither EA nor SA can attenuate the upregulated kisspeptin protein expression in the pancreas of PCOS model rats. Conclusions EA and SA improved the symptoms of pubertal PCOS rats, and the mechanism might be associated with regulating hypothalamic NPY and ghrelin levels.	[Yang Li; Huang Dongmei] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China; [Wang Zhi; Dong Haoxu; Yi Ping] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China; [Wang Qing] Wuhan Univ Sci & Technol, Dept Rehabil Ctr Wuhan Puren Hosp, Affiliated Hosp, Wuhan, Peoples R China; [Cheng Ling] Tongji Univ, East Hosp, Dept Acupuncture & Moxibust, Shanghai, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Wuhan University of Science & Technology; Tongji University	Huang, DM (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China.	905244619@qq.com			National Natural Science Foundation of China (NSFC) [81573787, 81673757, 81803913, PDZYXK-1-2014005]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This study is funded by a research grant from the National Natural Science Foundation of China (NSFC) (nos. 81573787 awarded to H.D.M., grant no. 81673757 awarded to Y. P. and grant no. 81803913 awarded to D.H.X.) and Special specialties of acupuncture and moxibustion treatment for menstrual disorders (grant no. PDZYXK-1-2014005, awarded to C.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baldani DP, 2019, GYNECOL ENDOCRINOL, V35, P401, DOI 10.1080/09513590.2018.1534096; Baranowska B, 1999, GYNECOL ENDOCRINOL, V13, P344, DOI 10.3109/09513599909167578; Celi F, 2005, CLIN ENDOCRINOL, V63, P139, DOI 10.1111/j.1365-2265.2005.02313.x; Chang SL, 1999, DIABETOLOGIA, V42, P250, DOI 10.1007/s001250051146; Chen H, 2019, CURR OPIN OBSTET GYN, V31, P428, DOI 10.1097/GCO.0000000000000582; Chiavaroli V, 2010, EUR J ENDOCRINOL, V163, P55, DOI 10.1530/EJE-09-1102; Conde K, 2020, NEUROENDOCRINOLOGY, V110, P582, DOI 10.1159/000503146; Coutinho EA, 2020, NEUROENDOCRINOLOGY, V110, P671, DOI 10.1159/000504225; Coyle C, 2019, MOL CELL ENDOCRINOL, V498, DOI 10.1016/j.mce.2019.110561; Dezaki K, 2013, ENDOCR DEV, V25, P135, DOI 10.1159/000346064; Dhillon SS, 2009, REGUL PEPTIDES, V156, P96, DOI 10.1016/j.regpep.2009.04.005; Dudek M, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00145; Esparza LA, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa018; Feng Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006638; Fernandez-Fernandez R, 2005, NEUROENDOCRINOLOGY, V82, P245, DOI 10.1159/000092753; Gunes M, 2015, GYNECOL ENDOCRINOL, V31, P903, DOI 10.3109/09513590.2015.1068285; Herbison AE, 2016, NAT REV ENDOCRINOL, V12, P452, DOI 10.1038/nrendo.2016.70; Ibanez L, 2017, HORM RES PAEDIAT, V88, P371, DOI 10.1159/000479371; Kim GL, 2010, ENDOCRINOLOGY, V151, P5038, DOI 10.1210/en.2010-0521; Li Y, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/5595478; Lin JG, 2002, NEUROSCI LETT, V326, P17, DOI 10.1016/S0304-3940(02)00331-2; LOPEZ FJ, 1991, P NATL ACAD SCI USA, V88, P4508, DOI 10.1073/pnas.88.10.4508; Manneras L, 2009, AM J PHYSIOL-REG I, V296, pR1124, DOI 10.1152/ajpregu.90947.2008; MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008; Merchenthaler I, 2005, ENDOCRINOLOGY, V146, P2760, DOI 10.1210/en.2004-1562; Mills EG, 2021, NAT REV ENDOCRINOL, V17, P97, DOI 10.1038/s41574-020-00438-1; Mohr MA, 2012, J NEUROENDOCRINOL, V24, P1412, DOI 10.1111/j.1365-2826.2012.02351.x; Morales AJ, 1996, J CLIN ENDOCR METAB, V81, P2854, DOI 10.1210/jc.81.8.2854; Navarro VM, 2020, NAT REV ENDOCRINOL, V16, P407, DOI 10.1038/s41574-020-0363-7; Ots T, 2020, ACUPUNCT MED, V38, P211, DOI 10.1177/0964528419889636; PAU KYF, 1991, NEUROENDOCRINOLOGY, V53, P396; Paxinos G., 2007, RAT BRAIN STEROTAXIC, V6th; Pinilla L, 2007, AM J PHYSIOL-ENDOC M, V293, pE1385, DOI 10.1152/ajpendo.00274.2007; Ronnekleiv OK, 2015, NEUROENDOCRINOLOGY, V102, P184, DOI 10.1159/000370311; Ronnekleiv OK, 2013, ADV EXP MED BIOL, V784, P113, DOI 10.1007/978-1-4614-6199-9_6; Seth A, 2004, ENDOCRINOLOGY, V145, P743, DOI 10.1210/en.2003-0873; Shen Ling-Yu, 2021, Zhen Ci Yan Jiu, V46, P106, DOI 10.13702/j.1000-0607.200497; Splett CL, 2003, ENDOCRINOLOGY, V144, P484, DOI 10.1210/en.2002-220855; SUTTON SW, 1988, ENDOCRINOLOGY, V123, P2152, DOI 10.1210/endo-123-4-2152; Terasawa E, 2019, MOL CELL ENDOCRINOL, V498, DOI 10.1016/j.mce.2019.110578; Wang Z, 2021, ACUPUNCT MED, V39, P491, DOI 10.1177/0964528420971299; Xu Dong-Sheng, 2019, Zhen Ci Yan Jiu, V44, P62, DOI 10.13702/j.1000-0607.180396; Yoo RY, 2006, FERTIL STERIL, V85, P1049, DOI 10.1016/j.fertnstert.2005.09.037; Zhang LL, 2016, CHIN J INTEGR MED, V22, P483, DOI 10.1007/s11655-016-2458-5; Zhang ZH, 2012, NEUROPEPTIDES, V46, P133, DOI 10.1016/j.npep.2012.03.002	45	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0259609	10.1371/journal.pone.0259609	http://dx.doi.org/10.1371/journal.pone.0259609			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35704659	Green Published, gold, Green Submitted			2023-01-03	WOS:000843619700008
J	Yasmin, F; Najeeb, H; Moeed, A; Hassan, W; Khatri, M; Asghar, MS; Naveed, AK; Ullah, W; Surani, S				Yasmin, Farah; Najeeb, Hala; Moeed, Abdul; Hassan, Wardah; Khatri, Mahima; Asghar, Muhammad Sohaib; Naveed, Ahmed Kunwer; Ullah, Waqas; Surani, Salim			Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials	PLOS ONE			English	Review								BackgroundColchicine has been used an effective anti-inflammatory drug to treat gout diseases. Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials. MethodsElectronic databases (Pubmed, Google Scholar, and Cochrane) were systematically searched until June 2021 and RCTs were extracted. Outcomes of interest included all-cause mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through the generic inverse variance formula while weighted mean differences were calculated using the Wan's method. P-values < 0.05 were considered statistically significant for all outcomes. ResultsA total population of 16,048 from five RCTs were included in the analysis. Of this, 7957 were randomized to colchicine, and 8091 received standard care, with an average age of 60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, 1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; I-2 = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = 0.84) among patients receiving colchicine or standard care. ConclusionColchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected. Thus, clinical trials need to be carried out that allow effective evaluation of colchicine in COVID-19 patients.	[Yasmin, Farah; Najeeb, Hala; Moeed, Abdul; Hassan, Wardah; Khatri, Mahima; Naveed, Ahmed Kunwer] Dow Univ Hlth Sci, Dow Med Coll, Dept Internal Med, Karachi, Pakistan; [Asghar, Muhammad Sohaib] Dow Ojha Univ Hosp, Dept Internal Med, Karachi, Pakistan; [Ullah, Waqas] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Surani, Salim] Texas A&M Univ, Med & Pharmacol, College Stn, TX 77843 USA; [Surani, Salim] Univ Houston Voluntary, Houston, TX 77004 USA	Dow University of Health Sciences; Jefferson University; Texas A&M University System; Texas A&M University College Station	Surani, S (corresponding author), Texas A&M Univ, Med & Pharmacol, College Stn, TX 77843 USA.; Surani, S (corresponding author), Univ Houston Voluntary, Houston, TX 77004 USA.	srsurani@hotmail.com	Asghar, Muhammad Sohaib/ABB-7824-2020	Asghar, Muhammad Sohaib/0000-0001-6705-2030; Kunwer Naveed, Ahmed/0000-0002-4215-0600; Najeeb, Hala/0000-0001-7075-4674; , Abdul Moeed/0000-0003-4429-1391; Surani, Salim/0000-0001-7105-4266				Ali N, 2020, J MED VIROL, V92, P2409, DOI 10.1002/jmv.26097; [Anonymous], CLIN SPECTRUM COVID; [Anonymous], WHO CORONAVIRUS COVI; Atal S, 2020, PHARM MED, V34, P223, DOI 10.1007/s40290-020-00342-z; Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Brunetti L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092961; CRONSTEIN BN, 1995, J CLIN INVEST, V96, P994, DOI 10.1172/JCI118147; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218612]; Della-Torre E, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108490; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175, DOI 10.55563/clinexprheumatol/r3k9l6; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013; Hariyanto TI, 2021, CLIN EXP PHARMACOL P, V48, P823, DOI 10.1111/1440-1681.13488; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013; Li XM, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03374-8; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lopes MI, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen-2020-001455; Mareev VY, 2021, KARDIOLOGIYA, V61, P15, DOI 10.18087/cardio.2021.2.n1560; Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; Parra-Medina R, 2020, CLIN RHEUMATOL, V39, P2485, DOI 10.1007/s10067-020-05247-5; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; RECOVERY Collaborative Group, 2021, MEDRXIV, DOI [10.1101/2021.05.18.21257267, DOI 10.1101/2021.05.18.21257267]; Reyes AZ, 2021, ANN RHEUM DIS, V80, P550, DOI 10.1136/annrheumdis-2020-219174; Scarsi M, 2020, ANN RHEUM DIS, V79, P1286, DOI 10.1136/annrheumdis-2020-217712; Schlesinger Naomi, 2020, Curr Pharmacol Rep, V6, P137, DOI 10.1007/s40495-020-00225-6; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Tardif JC, 2021, LANCET RESP MED, V9, P924, DOI 10.1016/S2213-2600(21)00222-8; Tayer-Shifiman OE, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.017; Turk C, 2020, EUR REV MED PHARMACO, V24, P8606, DOI 10.26355/eurrev_202008_22660; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Wang GY, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa153; Yao YM, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00466-z; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954; Zhang Shengyu, 2020, Clin Drug Investig, V40, P511, DOI 10.1007/s40261-020-00917-3; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	45	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266245	10.1371/journal.pone.0266245	http://dx.doi.org/10.1371/journal.pone.0266245			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6EQ	35381033	Green Published, gold			2023-01-03	WOS:000804820900006
J	Zhou, WD; Yu, LL; Fan, YY; Shi, BS; Wang, XH; Chen, TL; Yu, HX; Liu, J; Wang, XZ; Liu, CH; Zheng, HJ				Zhou, Wendie; Yu, Lili; Fan, Yuying; Shi, Baisheng; Wang, Xiaohui; Chen, Tianling; Yu, Haixia; Liu, Jie; Wang, Xizhen; Liu, Caihong; Zheng, Huijia			Effect of early mobilization combined with early nutrition on acquired weakness in critically ill patients (EMAS): A dual-center, randomized controlled trial	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CRITICAL ILLNESS; PARALLEL-GROUP; REHABILITATION; THERAPY; IMPACT; MUSCLE; STANDARD; ICU	AimThe study aimed to investigate the effect of early mobilization combined with early nutrition (EMN) on intensive care unit-acquired weakness (ICU-AW) in intensive care unit (ICU) settings compared with early mobilization (EM) or routine care. MethodsA prospective, dual-center, randomized controlled trial was conducted. The control group underwent standard care without a pre-established routine for mobilization and nutrition. The EM group underwent early, individualized, progressive mobilization within 24 h of ICU admission. The EMN group underwent early mobilization, similar to the EM group plus guideline-based early nutrition (within 48 h of ICU admission). The primary outcome was the occurrence of ICU-AW at discharge from the ICU. Secondary outcomes included muscle strength, functional independence, organ failure, nutritional status, duration of mechanical ventilation (MV), length of ICU stay, and ICU mortality at ICU discharge. ResultsA total of 150 patients were enrolled and equally distributed into the three groups. Patients undergoing routine care only were more susceptible to ICU-AW upon ICU discharge than those in the EM or EMN groups (16% vs. 2%; p = 0.014 for both), and had a lower Barthel Index than others (control vs. EM/EMN: 57.5 vs 70.0; p = 0.022). The EMN group had improved muscle strength (p = 0.028) and better nutritional status than the control group (p = 0.031). Both interventions were associated with a lower ICU-AW (EM vs. control: p = 0.027, OR [95% CI] = 0.066 [0.006-0.739]; EMN vs. control: p = 0.016, OR [95% CI] = 0.065 [0.007-0.607]). ConclusionEM and EMN had positive effects. There was little difference between the effects of EM and EMN, except for muscle strength improvement. Both EM and EMN may lead to a lower occurrence of ICU-AW and better functional independence than standard care. EMN might benefit nutritional status more than usual care and promote improvement in muscle strength.	[Zhou, Wendie; Yu, Lili] Harbin Med Univ, Clin Nursing Teaching Dept, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Zhou, Wendie; Yu, Lili; Fan, Yuying] Harbin Med Univ, Sch Nursing, Harbin, Heilongjiang, Peoples R China; [Yu, Lili] Heilongjiang Acad Tradit Chinese Med, Nursing Dept, Harbin, Heilongjiang, Peoples R China; [Shi, Baisheng] Harbin Med Univ, Dept Rehabil, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Wang, Xiaohui; Yu, Haixia; Liu, Jie; Wang, Xizhen; Liu, Caihong; Zheng, Huijia] Harbin Med Univ, Dept Intens Care Unit, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Chen, Tianling] First Hosp Qiqihar, Dept Intens Care Unit, Qiqihar, Heilongjiang, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Fan, YY (corresponding author), Harbin Med Univ, Sch Nursing, Harbin, Heilongjiang, Peoples R China.	fanfanfensituan@126.com			National Natural Science Foundation of China [71704040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We acknowledge the medical staff of the ICUs of the Second Affiliated Hospital of Harbin Medical University and the First Hospital of Qiqihar, who made this research possible. We thank every patient and his or her proxy who consented to study participation.	Allingstrup MJ, 2017, INTENS CARE MED, V43, P1637, DOI 10.1007/s00134-017-4880-3; [Anonymous], 2020, INT C HARM ICH E9 R1; Bendavid I, 2017, CLIN NUTR, V36, P1122, DOI 10.1016/j.clnu.2016.07.012; Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0; Casaer MP, 2013, CRIT CARE MED, V41, P2298, DOI 10.1097/CCM.0b013e31828cef02; Chen X., 2017, ZHEJIANG CLIN MED J, V19, P1733; Cherry-Bukowiec JR, 2013, CRIT CARE NURS Q, V36, P28, DOI 10.1097/CNQ.0b013e31827507d7; Cheung K., 2021, J APPL PHYSL BETHESD; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; DETSKY AS, 1984, JPEN-PARENTER ENTER, V8, P153, DOI 10.1177/0148607184008002153; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Dres M, 2017, AM J RESP CRIT CARE, V195, P57, DOI 10.1164/rccm.201602-0367OC; Hegerova P, 2015, NUTRITION, V31, P166, DOI 10.1016/j.nut.2014.07.010; Hermans G, 2013, LANCET RESP MED, V1, P621, DOI 10.1016/S2213-2600(13)70183-8; Heyland DK, 2016, CLIN NUTR, V35, P1196, DOI 10.1016/j.clnu.2015.07.003; Hodgson CL, 2016, CRIT CARE MED, V44, P1145, DOI 10.1097/CCM.0000000000001643; Juszczak E, 2019, JAMA-J AM MED ASSOC, V321, P1610, DOI 10.1001/jama.2019.3087; Kou Keitoku, 2019, Journal of UOEH, V41, P303, DOI 10.7888/juoeh.41.303; Lad H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217840; Liu Y, 2020, J INTENSIVE CARE MED, V35, P1053, DOI 10.1177/0885066618809893; MAHONEY F I, 1965, Md State Med J, V14, P61; Moss M, 2016, AM J RESP CRIT CARE, V193, P1101, DOI 10.1164/rccm.201505-1039OC; Orem D., 2001, NURSING CONCEPTS PRA; Parry SM, 2017, INTENS CARE MED, V43, P531, DOI 10.1007/s00134-017-4685-4; Parry SM, 2015, INTENS CARE MED, V41, P744, DOI 10.1007/s00134-015-3672-x; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schujmann DS, 2020, CRIT CARE MED, V48, P491, DOI 10.1097/CCM.0000000000004181; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Simpson F, 2016, CURR OPIN CRIT CARE, V22, P303, DOI 10.1097/MCC.0000000000000324; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Stevens Robert D, 2009, Crit Care Med, V37, pS299, DOI 10.1097/CCM.0b013e3181b6ef67; Talbot D, 2019, EUR J EPIDEMIOL, V34, P725, DOI 10.1007/s10654-019-00529-y; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wakabayashi H, 2014, J CACHEXIA SARCOPENI, V5, P269, DOI 10.1007/s13539-014-0162-x; Wang WK, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.559789; Weng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035; Wright SE, 2018, THORAX, V73, P213, DOI 10.1136/thoraxjnl-2016-209858; Xing J, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2159-x; Zang K, 2020, NURS CRIT CARE, V25, P360, DOI 10.1111/nicc.12455; Zhang L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223185; Zhou WD, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021282	42	1	1	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5								10.1371/journal.pone.0268599	http://dx.doi.org/10.1371/journal.pone.0268599			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L8YU	35617287	gold, Green Published			2023-01-03	WOS:000835048800020
J	Li, YY; Chen, XY; Liu, ZD; Yang, JH				Li, Yingying; Chen, Xinying; Liu, Zhengduo; Yang, Jinghua			Chinese herbal medicine for children with idiopathic short stature (ISS): A systematic review and meta-analysis	PLOS ONE			English	Article							GROWTH-HORMONE	Background Idiopathic short stature (ISS) describes a heterogeneous group of children of many unidentified causes of short stature presently without definitive therapy. Chinese herbal medicine (CHM) is an alternative and complementary treatment for children with ISS and has been widely used for ISS while the evidence of its effectiveness is controversial. We conducted this systematic review and meta-analysis in order to evaluate the efficacy of CHM for ISS. Methods PubMed, Embase, Web of science, Sino-Med, Cochrane, CNKI, VIP, and Wangfang Data were electronically searched to collect randomized controlled trials (RCTs) of CHM treatment of ISS from inception to May 2021. Two researchers independently scanned the literature and extracted information on general characteristics, including patient, study design, interventions, and side effects, assessing the CHM intervention's efficacy and the risk of bias. Height, bone age, growth velocity, and IGF-1 level are the main consequences. Height standard deviations score (HtSDS), change in HtSDS (.HtSDS), osteocalcin, the peak level of growth hormones (GHP), and predicted adult height (PAH) are the secondary outcomes. Meta-analysis was then performed by using RevMan 5.3 (Cochrane Collaboration). Results Seven articles (569 participants) were included. The Meta-analysis indicated that herbal medicine was associated with increased height (MD 2.16 points; 95%CI, 0.22 to 4.10; P = 0.03), growth velocity (MD 1.47 points; 95%CI, 0.28 to 2.67; P = 0.02), IGF-1 level (MD 28.13 points; 95%CI, 22.80 to 33.46; P< 0.00001) and GHP (MD 3.29 points; 95%CI, 1.54 to 5.04; P = 0.0002). Conclusion According to current research, CHM appears to be useful for children with ISS. Due to the limited quality and number of studies included, more high-quality studies are needed to corroborate the above conclusions.	[Li, Yingying; Liu, Zhengduo] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou, Guangdong, Peoples R China; [Chen, Xinying; Yang, Jinghua] Guangdong Prov Hosp Chinese Med, Dept Pediat, Guangzhou, Guangdong, Peoples R China; [Chen, Xinying; Yang, Jinghua] Lingnan Pediat Wen Ziyuan Sch Studio Tradit Chine, Guangzhou, Guangdong, Peoples R China; [Chen, Xinying; Yang, Jinghua] Luo Xiaorong Natl Famous Tradit Chinese Med Exper, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Yang, JH (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Pediat, Guangzhou, Guangdong, Peoples R China.; Yang, JH (corresponding author), Lingnan Pediat Wen Ziyuan Sch Studio Tradit Chine, Guangzhou, Guangdong, Peoples R China.; Yang, JH (corresponding author), Luo Xiaorong Natl Famous Tradit Chinese Med Exper, Guangzhou, Guangdong, Peoples R China.	doumiaomama@126.com						[Anonymous], 2003, ADM FADFDA APPR HUM, P24003; Cianfarani S, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.811846; cochrane.org, 2014, REV MAN REVMAN VERS; Cohen P, 2008, J CLIN ENDOCR METAB, V93, P4210, DOI 10.1210/jc.2008-0509; Deodati A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7157; Feng B, 2014, INNER MONGOLIA J TRA, V33, P4; Grimberg A, 2019, J ENDOCR SOC, V3, P2023, DOI 10.1210/js.2019-00246; Grimberg A, 2016, HORM RES PAEDIAT, V86, P361, DOI 10.1159/000452150; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Huang AD, 2015, CHINA MED HERALD, V12, P137; LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2; Murray PG, 2018, LANCET DIABETES ENDO, V6, P564, DOI 10.1016/S2213-8587(18)30034-2; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n160; Pan DP, 2020, J NEW CHINESE MED, V52, P91; Pedicelli Stefania, 2009, J Clin Res Pediatr Endocrinol, V1, P105, DOI 10.4008/jcrpe.v1i3.53; Ranke MB, 2018, NAT REV ENDOCRINOL, V14, P285, DOI 10.1038/nrendo.2018.22; Rogol AD, 2014, J PEDIATR-US, V164, pS1, DOI 10.1016/j.jpeds.2014.02.027; Sun FP, 2020, ACTA CHINESE MED PHA, V48, P22; Sun FP, 2017, J PEDIAT TRADIT CHIN, V13, P57; Wang SK, 2020, HENAN MED RES, V29, P4936; Xu, 2015, COMMONLY CULTIVATED, P1; Zhou F, 2012, CHIN J TRADIT MED SC, V19, P204; 冯斌, 2020, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V31, P1852	23	0	0	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2022	17	6							e0270511	10.1371/journal.pone.0270511	http://dx.doi.org/10.1371/journal.pone.0270511			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5E7GI	35749540	Green Published, gold			2023-01-03	WOS:000865789500001
J	Boehnke, KF; Dean, O; Haffajee, RL; Hosanagar, A				Boehnke, Kevin F.; Dean, Owen; Haffajee, Rebecca L.; Hosanagar, Avinash			US Trends in Registration for Medical Cannabis and Reasons for Use From 2016 to 2020 An Observational Study	ANNALS OF INTERNAL MEDICINE			English	Article							OPIOIDS	Background: Cannabis policy liberalization has increased cannabis availability for medical or recreational purposes. Up-to-date trends in medical cannabis licensure can inform clinical policy and care. Objective: To describe recent trends in medical cannabis licensure in the United States. Design: Ecological study with repeated measures. Setting: State registry data via state reports and data requests on medical cannabis licensure from 2016 to 2020. Participants: Medical cannabis patients (persons with medical cannabis licenses) in the United States. Measurements: Total patient volume, patients per 10 000 of total population, and patient-reported qualifying conditions (that is, symptoms or conditions qualifying patients for licensure)-including whether these symptoms align with current therapeutic evidence of cannabis-cannabinoid efficacy. Results: In 2020, 26 states and Washington, DC reported patient numbers, and 19 states reported patient-reported qualifying conditions. Total enrolled patients increased approximately 4.5-fold from 678 408 in 2016 to 2 974 433 in 2020. Patients per 10 000 total population generally increased from 2016 to 2020, most dramatically in Oklahoma (927.1 patients per 10000 population). However, enrollment increased in states without recreational legalization (that is, medical-only states), whereas enrollment decreased in 5 of 7 with recreational legalization (that is, recreational states). In 2020, 68.2% of patient-reported qualifying conditions had substantial or conclusive evidence of therapeutic value versus 84.6% in 2016. Chronic pain was the most common patient-reported qualifying condition in 2020 (60.6%), followed by posttraumatic stress disorder (10.6%). Limitation: Missing state data; lack of rationale for discontinuing medical cannabis licensure. Conclusion: Enrollment in medical cannabis programs approximately increased 4.5-fold from 2016 to 2020, although enrollment decreased in recreational states. Use for conditions or symptoms without a strong evidence basis increased from 15.4% (2016) to 31.8% (2020). Thoughtful regulatory and clinical strategies are needed to effectively manage this rapidly changing landscape.	[Boehnke, Kevin F.] Univ Michigan, Med Sch, Chron Pain & Fatigue Res Ctr, Anesthesiol Dept, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA; [Dean, Owen] Univ Michigan, Coll Literature Sci & Arts, Ann Arbor, MI 48109 USA; [Haffajee, Rebecca L.] US Dept Hlth & Human Serv, Off Assistant Secretary Planning & Evaluat, Washington, DC USA; [Hosanagar, Avinash] Univ Michigan, Med Sch, Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA; [Hosanagar, Avinash] Univ Michigan, Dept Psychiat, Med Sch, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Boehnke, KF (corresponding author), Univ Michigan, Med Sch, Chron Pain & Fatigue Res Ctr, Anesthesiol Dept, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA.	kboehnke@med.umich.edu		Boehnke, Kevin/0000-0003-3696-3979; Hosanagar, Avinash/0000-0002-2056-1097	National Institute on Drug Abuse of the National Institutes of Health	National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	National Institute on Drug Abuse of the National Institutes of Health.	Anderson SP, 2019, J ONCOL PRACT, V15, P202, DOI 10.1200/JOP.18.00562; Bachhuber M, 2019, J PSYCHOACTIVE DRUGS, V51, P400, DOI 10.1080/02791072.2019.1626953; Boehnke KF, 2021, J PAIN, V22, P1418, DOI 10.1016/j.jpain.2021.04.011; Boehnke KF, 2021, INT J DRUG POLICY, V92, DOI 10.1016/j.drugpo.2020.103053; Boehnke KF, 2019, HEALTH AFFAIR, V38, P295, DOI 10.1377/hlthaff.2018.05266; Boehnke KF, 2019, J PAIN, V20, P830, DOI 10.1016/j.jpain.2019.01.010; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]; Brown JD, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041166; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Earp BD, 2021, AM J BIOETHICS, V21, P4, DOI 10.1080/15265161.2020.1861364; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Hauser W, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4441; Haffajee R., 2021, HLTH AFFAIRS POLICY, DOI [10.1377/hpb20210518.36548/full, DOI 10.1377/HPB20210518.36548/FULL, 10.1377/hpb20210518.36548/full/]; Haffajee RL, 2018, NEW ENGL J MED, V379, P501, DOI 10.1056/NEJMp1804408; Lucas P, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-019-0278-6; Merlin JS, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.24511; Natl Acad Sci Engn Med, 2017, HEALTH EFFECTS OF CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH, P1, DOI 10.17226/24625; Okey SA, 2022, INT J DRUG POLICY, V100, DOI 10.1016/j.drugpo.2021.103531; Richard EL, 2021, INT J DRUG POLICY, V94, DOI 10.1016/j.drugpo.2021.103202; Ronne ST, 2021, BMC FAM PRACT, V22, DOI 10.1186/s12875-021-01559-w; Sacirbey O., 2021, MJBIZDAILY 0315; Shover CL, 2019, AM J DRUG ALCOHOL AB, V45, P698, DOI 10.1080/00952990.2019.1569669; Van Green T., 2021, AM OVERWHELMINGLY SA; Vidot DC, 2020, J ADDICT DIS, V39, P26, DOI 10.1080/10550887.2020.1811455; Williams AR, 2016, HEALTH AFFAIR, V35, P480, DOI 10.1377/hlthaff.2015.0528; Zelaya Carla E, 2020, NCHS Data Brief, P1	27	1	1	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2022	175	7					945	+		10.7326/M22-0217	http://dx.doi.org/10.7326/M22-0217		JUN 2022	8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3F4ZO	35696691				2023-01-03	WOS:000813393600001
J	Neuman, MD; Feng, R; Ellenberg, SS; Sieber, F; Sessler, DI; Magaziner, J; Elkassabany, N; Schwenk, ES; Dillane, D; Marcantonio, ER; Menio, D; Ayad, S; Hassan, M; Stone, T; Papp, S; Donegan, D; Marshall, M; Jaffe, JD; Luke, C; Sharma, B; Azim, S; Hymes, R; Chin, KJ; Sheppard, R; Perlman, B; Sappenfield, J; Hauck, E; Hoeft, MA; Tierney, A; Gaskins, LJ; Horan, AD; Brown, T; Dattilo, J; Carson, JL				Neuman, Mark D.; Feng, Rui; Ellenberg, Susan S.; Sieber, Frederick; Sessler, Daniel I.; Magaziner, Jay; Elkassabany, Nabil; Schwenk, Eric S.; Dillane, Derek; Marcantonio, Edward R.; Menio, Diane; Ayad, Sabry; Hassan, Manal; Stone, Trevor; Papp, Steven; Donegan, Derek; Marshall, Mitchell; Jaffe, J. Douglas; Luke, Charles; Sharma, Balram; Azim, Syed; Hymes, Robert; Chin, Ki-Jinn; Sheppard, Richard; Perlman, Barry; Sappenfield, Joshua; Hauck, Ellen; Hoeft, Mark A.; Tierney, Ann; Gaskins, Lakisha J.; Horan, Annamarie D.; Brown, Trina; Dattilo, James; Carson, Jeffrey L.		REGAIN Regional Versus General	Pain, Analgesic Use, and Patient Satisfaction With Spinal Versus General Anesthesia for Hip Fracture Surgery A Randomized Clinical Trial	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPY AMERICAN-SOCIETY; REGIONAL-ANESTHESIA; MORTALITY; MODERATE; MILD	Background: The REGAIN (Regional versus General Anesthesia for Promoting Independence after Hip Fracture) trial found similar ambulation and survival at 60 days with spinal versus general anesthesia for hip fracture surgery. Trial outcomes evaluating pain, prescription analgesic use, and patient satisfaction have not yet been reported. Objective: To compare pain, analgesic use, and satisfaction after hip fracture surgery with spinal versus general anesthesia. Design: Preplanned secondary analysis of a pragmatic randomized trial. (ClinicalTrials.gov: NCT02507505) Setting: 46 U.S. and Canadian hospitals. Participants: Patients aged 50 years or older undergoing hip fracture surgery. Intervention: Spinal or general anesthesia. Measurements: Pain on postoperative days 1 through 3; 60-, 180-, and 365-day pain and prescription analgesic use; and satisfaction with care. Results: A total of 1600 patients were enrolled. The average age was 78 years, and 77% were women. A total of 73.5% (1050 of 1428) of patients reported severe pain during the first 24 hours after surgery. Worst pain over the first 24 hours after surgery was greater with spinal anesthesia (rated from 0 [no pain] to 10 [worst pain imaginable]; mean difference, 0.40 [95% CI, 0.12 to 0.68]). Pain did not differ across groups at other time points. Prescription analgesic use at 60 days occurred in 25% (141 of 563) and 18.8% (108 of 574) of patients assigned to spinal and general anesthesia, respectively (relative risk, 1.33 [CI, 1.06 to 1.65]). Satisfaction was similar across groups. Limitation: Missing outcome data and multiple outcomes assessed. Conclusion: Severe pain is common after hip fracture. Spinal anesthesia was associated with more pain in the first 24 hours after surgery and more prescription analgesic use at 60 days compared with general anesthesia.	[Neuman, Mark D.; Elkassabany, Nabil; Gaskins, Lakisha J.; Horan, Annamarie D.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 308 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19106 USA; [Neuman, Mark D.; Elkassabany, Nabil; Gaskins, Lakisha J.] Univ Penn, Perelman Sch Med, Ctr Perioperat Outcomes Res & Transformat, Philadelphia, PA 19104 USA; [Feng, Rui; Ellenberg, Susan S.] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Feng, Rui; Ellenberg, Susan S.; Tierney, Ann; Brown, Trina; Dattilo, James] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Sieber, Frederick] Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Sessler, Daniel I.; Ayad, Sabry; Hassan, Manal] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA; [Magaziner, Jay] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Schwenk, Eric S.] Thomas Jefferson Univ, Dept Anesthesiol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Dillane, Derek] Univ Alberta Hosp, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada; [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Menio, Diane] Ctr Advocacy Rights & Interests Elderly, Philadelphia, PA USA; [Stone, Trevor] Univ British Columbia, Dept Orthopaed, Vancouver, BC, Canada; [Papp, Steven] Ottawa Hosp, Div Orthopaed, Civ Campus, Ottawa, ON, Canada; [Donegan, Derek] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Marshall, Mitchell] NYU Langone, Med Ctr, Dept Anesthesiol, New York, NY USA; [Jaffe, J. Douglas] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27101 USA; [Luke, Charles] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA USA; [Sharma, Balram] Lahey Hosp & Med Ctr, Dept Anesthesiol, Burlington, MA USA; [Azim, Syed] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA; [Hymes, Robert] Inova Fairfax Med Campus, Dept Orthoped Surg, Falls Church, VA USA; [Chin, Ki-Jinn] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada; [Sheppard, Richard] Hartford Hosp, Dept Anesthesiol, Hartford, CT 06115 USA; [Perlman, Barry] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Sappenfield, Joshua] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA; [Hauck, Ellen] Temple Univ, Dept Anesthesiol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Hoeft, Mark A.] Univ Vermont, Dept Anesthesiol, Larner Coll Med, Burlington, VT USA; [Horan, Annamarie D.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Carson, Jeffrey L.] Rutgers Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Medicine; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore; Jefferson University; University of Alberta; Harvard University; Beth Israel Deaconess Medical Center; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; University of Pennsylvania; Pennsylvania Medicine; NYU Langone Medical Center; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Lahey Hospital & Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Inova Fairfax Hospital; University of Toronto; Hartford Hospital; Oregon Health & Science University; State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Vermont; University of Pennsylvania; Pennsylvania Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Neuman, MD (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 308 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19106 USA.	neumanm@pennmedicine.upenn.edu	Marcantonio, Edward R/U-3929-2017; Bryson, Gregory Lyle/AAG-5108-2019	Marcantonio, Edward R/0000-0002-2911-4250; Bryson, Gregory Lyle/0000-0003-3583-9802	Patient-Centered Outcomes Research Institute Award [1406-18876]	Patient-Centered Outcomes Research Institute Award(Patient-Centered Outcomes Research Institute - PCORI)	By a Patient-Centered Outcomes Research Institute Award (1406-18876).	Abou-Setta AM, 2011, ANN INTERN MED, V155, P234, DOI 10.7326/0003-4819-155-4-201108160-00346; Aoyagi K, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.31271; Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526-4637.2009.00774.x; Bauer M, 2001, ACTA ANAESTH SCAND, V45, P65, DOI 10.1034/j.1399-6576.2001.450111.x; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Casati A, 2003, EUR J ANAESTH, V20, P640, DOI 10.1097/00003643-200308000-00009; Centers for Medicaid and Medicare Services, OP OR MORPH MILL EQ; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Guay J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000521.pub3; Haghighi M, 2017, ARCH BONE JT SURG-AB, V5, P226; Heidari SM, 2011, J RES MED SCI, V16, P323; Hogan JW, 2004, STAT METHODS MED RES, V13, P17, DOI 10.1191/0962280204sm351ra; Horlocker TT, 2018, REGION ANESTH PAIN M, V43, P263, DOI 10.1097/AAP.0000000000000763; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Hruslinski J, 2021, BRIT J ANAESTH, V126, P395, DOI 10.1016/j.bja.2020.09.052; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KAWAS C, 1995, J GERIATR PSYCH NEUR, V8, P238, DOI 10.1177/089198879500800408; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P365, DOI 10.1016/0197-2456(88)90049-9; Li KK, 2007, J PALLIAT MED, V10, P1338, DOI 10.1089/jpm.2007.0087; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; Maxwell BG, 2020, JAMA SURG, V155, P167, DOI 10.1001/jamasurg.2019.4471; Neuman MD, 2021, NEW ENGL J MED, V385, P2025, DOI 10.1056/NEJMoa2113514; Neuman MD, 2018, CLIN TRIALS, V15, P107, DOI 10.1177/1740774517735536; Neuman MD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013473; Neuman MD, 2010, MED CARE, V48, P314, DOI 10.1097/MLR.0b013e3181ca4126; NHS England, REV FRIENDS FAM T; Palos GR, 2006, J PAIN, V7, P49, DOI 10.1016/j.jpain.2005.07.012; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Walker EMK, 2016, BRIT J ANAESTH, V117, P758, DOI 10.1093/bja/aew381; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6	32	1	1	3	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2022	175	7					952	+		10.7326/M22-0320	http://dx.doi.org/10.7326/M22-0320		JUN 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3F4ZO	35696684				2023-01-03	WOS:000830679100013
J	Lu, ZH; Wang, JY; Shu, YQ; Liu, LK; Kong, L; Yang, L; Wang, BH; Sun, GG; Ji, YH; Cao, GC; Liu, H; Cui, TJ; Li, N; Qiu, WS; Li, GF; Hou, XF; Luo, H; Xue, LY; Zhang, YQ; Yue, WB; Liu, Z; Wang, XW; Gao, SG; Pan, YY; Galais, MP; Zaanan, A; Ma, Z; Li, HY; Wang, Y; Shen, L				Lu, Zhihao; Wang, Junye; Shu, Yongqian; Liu, Lianke; Kong, Li; Yang, Lei; Wang, Buhai; Sun, Guogui; Ji, Yinghua; Cao, Guochun; Liu, Hu; Cui, Tongjian; Li, Na; Qiu, Wensheng; Li, Gaofeng; Hou, Xinfang; Luo, Hui; Xue, Liying; Zhang, Yanqiao; Yue, Wenbin; Liu, Zheng; Wang, Xiuwen; Gao, Shegan; Pan, Yueyin; Galais, Marie-Pierre; Zaanan, Aziz; Ma, Zhuo; Li, Haoyu; Wang, Yan; Shen, Lin		ORIENT-15 Study Grp	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OPEN-LABEL; 1ST-LINE TREATMENT; PLUS; CAMRELIZUMAB; PLATINUM; NSCLC	OBJECTIVE To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. DESIGN Multicentre, randomised, double blind, phase 3 trial. SETTING 66 sites in China and 13 sites outside of China between 14 December 2018 and 9 April 2021. PARTICIPANTS 659 adults (aged >= 18 years) with advanced or metastatic oesophageal squamous cell carcinoma who had not received systemic treatment. INTERVENTION Participants were randomised 1:1 to receive sintilimab or placebo (3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing >= 60 kg) in combination with cisplatin 75 mg/m(2) plus paclitaxel 175 mg/m(2) every three weeks. The trial was amended to allow investigators to choose the chemotherapy regimen: cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil (800 mg/m(2) continuous infusion on days 1-5). MAIN OUTCOME MEASURES Overall survival in all patients and in patients with combined positive scores of >= 10 for expression of programmed cell death ligand 1. RESULTES 659 patients were randomly assigned to sintilimab (n=327) or placebo (n=332) with chemotherapy. 616 of 659 patients (93%) received sintilimab or placebo in combination with cisplatin plus paclitaxel and 43 of 659 patients (7%) received sintilimab or placebo in combination with cisplatin plus 5-fluorouracil. At the interim analysis, sintilimab with chemotherapy showed better overall survival compared with placebo and chemotherapy in all patients (median 16.7 v 12.5 months, hazard ratio 0.63, 95% confidence interval 0.51 to 0.78, P<0.001) and in patients with combined positive scores of (17.2 v 13.6 months, 0.64, 0.48 to 0.85, P=0.002). Sintilimab and chemotherapy significantly improved progression free survival compared with placebo and chemotherapy in all patients (7.2 v 5.7 months, 0.56, 0.46 to 0.68, P<0.001) and in patients with combined positive scores of >= 10 (8.3 v 6.4 months, 0.58, 0.45 to 0.75, P<0.001). Adverse events related to treatment occurred in 321 of 327 patients (98%) in the sintilimab-chemotherapy group versus 326 of 332 (98%) patients in the placebo-chemotherapy group. Rates of adverse events related to treatment, grade were 60% (196/327) and 55% (181/332) in the sintilimab-chemotherapy and placebo-chemotherapy groups, respectively. CONCLUSION Compared with placebo, sintilimab in combination with cisplatin plus paclitaxel showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma. Similar benefits of sintilimab with cisplatin plus 5-fluorouracil seem promising.	[Lu, Zhihao] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp & Inst, Beijing, Peoples R China; [Wang, Junye] Jining Med Coll, Dept Oncol, Affiliated Hosp, Jining, Peoples R China; [Shu, Yongqian; Liu, Lianke] Nanjing Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanjing, Peoples R China; [Kong, Li] Shandong First Med Univ, Shandong Canc Hosp & Inst, Special Needs Ward, Jinan, Peoples R China; [Kong, Li] Shandong Acad Med Sci, Jinan, Peoples R China; [Yang, Lei] Nantong Tumour Hosp, Dept Med Oncol, Nantong, Peoples R China; [Wang, Buhai] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Dept Med Oncol, Affiliated Hosp, Yangzhou, Jiangsu, Peoples R China; [Sun, Guogui] Tangshan Peoples Hosp, Dept Radiotherapy & Chemotherapy, Tangshan, Peoples R China; [Ji, Yinghua] Xinxiang Med Univ, Dept Med Oncol, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China; [Cao, Guochun] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Oncol, Nanjing, Peoples R China; [Liu, Hu] Univ Sci & Technol China, Anhui Prov Canc Hosp, Dept Med Oncol, Hefei, Peoples R China; [Cui, Tongjian] Fujian Prov Hosp, Dept Oncol, Fuzhou, Peoples R China; [Li, Na] Suining Cent Hosp, Dept Med Oncol, Suining, Peoples R China; [Qiu, Wensheng] Qingdao Univ, Dept Med Oncol, Affiliated Hosp, Qingdao, Peoples R China; [Li, Gaofeng] Yunnan Canc Hosp, Dept Thorac Surg Ward 2, Kunming, Yunnan, Peoples R China; [Hou, Xinfang] Henan Tumour Hosp, Dept Med Oncol, Zhengzhou, Peoples R China; [Luo, Hui] Jiangxi Canc Hosp, Dept Thorac Tumour Radiotherapy Ward 2, Nanchang, Jiangxi, Peoples R China; [Xue, Liying] Inner Mongolia Peoples Hosp, Dept Med Oncol, Hohhot, Peoples R China; [Zhang, Yanqiao] Harbin Med Univ, Dept Digest Oncol Ward 2, Canc Hosp, Harbin, Peoples R China; [Yue, Wenbin] Puyang Oilfield Gen Hosp, Dept Med Oncol, Puyang, Peoples R China; [Liu, Zheng] Handan Cent Hosp, Dept Med Oncol 3, Handan, Peoples R China; [Wang, Xiuwen] Shandong Univ, Dept Oncol, Qilu Hosp, Jinan, Peoples R China; [Gao, Shegan] Henan Univ Sci & Technol, Oncol Dept, Affiliated Hosp 1, Luoyang, Peoples R China; [Pan, Yueyin] Anhui Prov Hosp, Dept Tumour Chemotherapy, Hefei, Peoples R China; [Galais, Marie-Pierre] Ctr Francois Baclesse, Dept Med Oncol, Caen, France; [Zaanan, Aziz] Hop Europeen Georges Pompidou, Dept Gastroenterol & Digest Oncol, Paris, France; [Ma, Zhuo; Wang, Yan] Innovent Biol, Med Sci & Strategy Oncol, Suzhou, Peoples R China; [Li, Haoyu] Innovent Biol, Dept Stat, Suzhou, Peoples R China; [Shen, Lin] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China	Peking University; Jining Medical University; Nanjing Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Yangzhou University; Xinxiang Medical University; Nanjing Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Fujian Provincial Hospital; Qingdao University; Harbin Medical University; Shandong University; Henan University of Science & Technology; UNICANCER; Centre Francois Baclesse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Peking University	Shen, L (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China.	linshenpku@163.com		Gu, Kangsheng/0000-0002-5800-5256	Innovent Biologics (Suzhou, Jiangsu, China); Eli Lilly	Innovent Biologics (Suzhou, Jiangsu, China); Eli Lilly(Eli Lilly)	Funded by Innovent Biologics (Suzhou, Jiangsu, China) and co-funded by Eli Lilly. This trial was designed by the authors in collaboration with Innovent Biologics. The authors and Innovent Biologics were involved in data analysis and interpretation, verification of data accuracy and completeness, writing of the clinical report, and the decision to submit the manuscript for publication.	Ajani JA, 2019, J NATL COMPR CANC NE, V17, P855, DOI 10.6004/jnccn.2019.0033; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chan OTM, 2000, CANCER IMMUNOL IMMUN, V49, P181, DOI 10.1007/s002620000122; CHAU I, 2021, J CLIN ONCOL, V39, DOI DOI 10.1200/JCO.2021.39.15_SUPPL.LBA4001; Emancipator K, 2021, AAPS J, V23, DOI 10.1208/s12248-020-00525-1; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao SG, 2020, J THORAC ONCOL, V15, P816, DOI 10.1016/j.jtho.2020.01.017; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Kamangar F, 2020, LANCET GASTROENTEROL, V5, P582, DOI 10.1016/S2468-1253(20)30007-8; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Luo HY, 2021, JAMA-J AM MED ASSOC, V326, P916, DOI 10.1001/jama.2021.12836; Muro K, 2019, ANN ONCOL, V30, P34, DOI 10.1093/annonc/mdy498; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Ren ZG, 2021, LANCET ONCOL, V22, P977, DOI 10.1016/S1470-2045(21)00252-7; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shi YK, 2019, LANCET HAEMATOL, V6, pE12, DOI 10.1016/S2352-3026(18)30192-3; Sun JM, 2021, LANCET, V398, P759, DOI 10.1016/S0140-6736(21)01234-4; Xu JM, 2020, J CLIN ONCOL, V38; Xu RH, 2021, ANN ONCOL, V32, pS1041, DOI 10.1016/j.annonc.2021.08.1482; Yang YP, 2020, J THORAC ONCOL, V15, P1636, DOI 10.1016/j.jtho.2020.07.014; Zhou CC, 2021, J THORAC ONCOL, V16, P1501, DOI 10.1016/j.jtho.2021.04.011	28	20	20	13	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2022	377								e068714	10.1136/bmj-2021-068714	http://dx.doi.org/10.1136/bmj-2021-068714			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H2DR	35440464	Green Published, hybrid			2023-01-03	WOS:000796356300007
J	Liew, BXW; Ford, JJ; Briganti, G; Hahne, AJ				Liew, Bernard X. W.; Ford, Jon J.; Briganti, Giovanni; Hahne, Andrew J.			Understanding how individualised physiotherapy or advice altered different elements of disability for people with low back pain using network analysis	PLOS ONE			English	Article							TREATMENT PROTOCOL; FUNCTIONAL RESTORATION; DISORDERS; CLASSIFICATION; MANAGEMENT; CENTRALITY; PROGNOSIS; RECOVERY; ADULTS	Purpose The Oswestry Disability Index (ODI) is a common aggregate measure of disability for people with Low Back Pain (LBP). Scores on individual items and the relationship between items of the ODI may help understand the complexity of low back disorders and their response to treatment. In this study, we present a network analysis to explore how individualised physiotherapy or advice might influence individual items of the ODI, and the relationship between those items, at different time points for people with LBP. Methods Data from a randomised controlled trial (n = 300) comparing individualised physiotherapy versus advice for low back pain were used. A network analysis was performed at baseline, 5, 10, 26 and 52 weeks, with the 10 items of the Oswestry Disability Index modelled as continuous variables and treatment group (Individualised Physiotherapy or Advice) modelled as a dichotomous variable. A Mixed Graphical Model was used to estimate associations between variables in the network, while centrality indices (Strength, Closeness and Betweenness) were calculated to determine the importance of each variable. Results Individualised Physiotherapy was directly related to lower Sleep and Pain scores at all follow-up time points relative to advice, as well as a lower Standing score at 10-weeks, and higher Lifting and Travelling scores at 5-weeks. The strongest associations in the network were between Sitting and Travelling at weeks 5 and 26, between Walking and Standing at week 10, and between Sitting and Standing scores at week 52. ODI items with the highest centrality measures were consistently found to be Pain, Work and Social Life. Conclusion This study represents the first to understand how individualised physiotherapy or advice differentially altered disability in people with LBP. Individualised Physiotherapy directly reduced Pain and Sleep more effectively than advice, which in turn may have facilitated improvements in other disability items. Through their high centrality measures, Pain may be considered as a candidate therapeutic target for optimising LBP management, while Work and Socialising may need to be addressed via intermediary improvements in lifting, standing, walking, travelling or sleep. Slower (5-week follow-up) improvements in Lifting and Travelling as an intended element of the Individualised Physiotherapy approach did not negatively impact any longer-term outcomes.	[Liew, Bernard X. W.] Univ Essex, Sch Sport Rehabil & Exercise Sci, Colchester, Essex, England; [Ford, Jon J.; Hahne, Andrew J.] La Trobe Univ, Sch Allied Hlth Human Serv & Sport, Discipline Physiotherapy, Melbourne, Vic, Australia; [Briganti, Giovanni] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA	University of Essex; La Trobe University; Harvard University	Liew, BXW (corresponding author), Univ Essex, Sch Sport Rehabil & Exercise Sci, Colchester, Essex, England.	bl19622@essex.ac.uk	Briganti, Giovanni/C-2094-2018	Briganti, Giovanni/0000-0002-4038-3363; Ford, Jon/0000-0001-5524-190X; Liew, Bernard/0000-0002-7057-7548				Bailly F, 2015, JOINT BONE SPINE, V82, P437, DOI 10.1016/j.jbspin.2015.02.019; Blanken TF, 2019, PSYCHOTHER PSYCHOSOM, V88, P52, DOI 10.1159/000495045; Borgatti S. P., 2006, Computational & Mathematical Organization Theory, V12, P21, DOI 10.1007/s10588-006-7084-x; Borgatti SP, 2005, SOC NETWORKS, V27, P55, DOI 10.1016/j.socnet.2004.11.008; Borsboom D, 2013, ANNU REV CLIN PSYCHO, V9, P91, DOI 10.1146/annurev-clinpsy-050212-185608; Brodke DS, 2017, SPINE J, V17, P321, DOI 10.1016/j.spinee.2016.09.020; Burgess HJ, 2019, CLIN J PAIN, V35, P569, DOI 10.1097/AJP.0000000000000711; Carroll LJ, 2016, PHYS THER, V96, P797, DOI 10.2522/ptj.20150229; Corponi F, 2020, EUR NEUROPSYCHOPHARM, V35, P49, DOI 10.1016/j.euroneuro.2020.03.017; Costantini G, 2015, J RES PERS, V54, P13, DOI 10.1016/j.jrp.2014.07.003; Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005; Davidson M, 2002, PHYS THER, V82, P8, DOI 10.1093/ptj/82.1.8; Davidson M, 2008, MANUAL THER, V13, P222, DOI 10.1016/j.math.2007.01.008; Edwards JR, 2000, PSYCHOL METHODS, V5, P155, DOI 10.1037//1082-989X.5.2.155; Epskamp S, 2021, MULTIVAR BEHAV RES, V56, P314, DOI [10.1080/00273171.2018.1489771, 10.1080/00273171.2018.1454823]; Epskamp S, 2018, PSYCHOL METHODS, V23, P617, DOI 10.1037/met0000167; Epskamp S, 2018, BEHAV RES METHODS, V50, P195, DOI 10.3758/s13428-017-0862-1; Epskamp S, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i04; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Finan PH, 2013, J PAIN, V14, P1539, DOI 10.1016/j.jpain.2013.08.007; Ford JJ, 2012, PHYS THER REV, V17, P322, DOI 10.1179/1743288X12Y.0000000034; Ford JJ, 2012, PHYS THER REV, V17, P55, DOI 10.1179/1743288X11Y.0000000037; Ford JJ, 2011, PHYS THER REV, V16, P423, DOI 10.1179/1743288X11Y.0000000033; Ford JJ, 2011, PHYS THER REV, V16, P168, DOI 10.1179/1743288X11Y.0000000005; Ford JJ, 2016, BRIT J SPORT MED, V50, P237, DOI 10.1136/bjsports-2015-095058; Ford JJ, 2013, MANUAL THER, V18, P438, DOI 10.1016/j.math.2013.01.007; Fordham B, 2017, SPINE, V42, pE1031, DOI 10.1097/BRS.0000000000002066; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; FREEMAN LC, 1979, SOC NETWORKS, V1, P215, DOI 10.1016/0378-8733(78)90021-7; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Froud R, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-50; Gluck TM, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1372543; Penedo JMG, 2020, CLIN J PAIN, V36, P249, DOI 10.1097/AJP.0000000000000797; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P740, DOI 10.1136/bmj.315.7110.740; Guzman J, 2001, BMJ-BRIT MED J, V322, P1511, DOI 10.1136/bmj.322.7301.1511; Hahne AJ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-104; Hansson EK, 2005, EUR SPINE J, V14, P337, DOI 10.1007/s00586-004-0731-3; Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X; Haslbeck JMB, 2020, J STAT SOFTW, V93, DOI 10.18637/jss.v093.i08; Hush JM, 2009, ARTHRIT RHEUM-ARTHR, V61, P124, DOI 10.1002/art.24162; INDAHL A, 1995, SPINE, V20, P473, DOI 10.1097/00007632-199502001-00011; Itz CJ, 2013, EUR J PAIN, V17, P5, DOI 10.1002/j.1532-2149.2012.00170.x; Kossakowski JJ, 2016, QUAL LIFE RES, V25, P781, DOI 10.1007/s11136-015-1127-z; Lambeek LC, 2011, SPINE, V36, P1050, DOI 10.1097/BRS.0b013e3181e70488; Liu H, 2009, J MACH LEARN RES, V10, P2295; MacNeela P, 2015, HEALTH PSYCHOL REV, V9, P63, DOI 10.1080/17437199.2013.840951; Makris UE, 2017, PAIN MED, V18, P1225, DOI 10.1093/pm/pnw196; Mansell G, 2016, J PAIN, V17, P1237, DOI 10.1016/j.jpain.2016.08.005; Masferrer L, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.566785; McWilliams LA, 2017, CLIN J PAIN, V33, P899, DOI 10.1097/AJP.0000000000000477; Costa LDM, 2012, CAN MED ASSOC J, V184, pE613, DOI 10.1503/cmaj.111271; Neuberg LG, 2003, ECONOMET THEOR, V19, P675, DOI 10.1017/S026646603004109; Newman MEJ, 2004, PHYS REV E, V70, DOI [10.1103/PhysRevE.70.056131, 10.1103/PhysRevE.69.026113]; O'Neill A, 2020, EUR J PAIN, V24, P1765, DOI 10.1002/ejp.1624; O'Sullivan PB, 2018, PHYS THER, V98, P408, DOI 10.1093/ptj/pzy022; R Core Team, 2021, R LANG ENV STAT COMP; Saltychev M, 2017, INT J REHABIL RES, V40, P202, DOI 10.1097/MRR.0000000000000226; Valente TW, 2012, SCIENCE, V337, P49, DOI 10.1126/science.1217330; Van Borkulo C. D., 2017, COMP NETWORK STRUCTU, P10; Vitoula K, 2018, PAIN THER, V7, P1, DOI 10.1007/s40122-018-0099-4; White LJ, 2002, ARCH PHYS MED REHAB, V83, P822, DOI 10.1053/apmr.2002.32685; Wu AM, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.175	62	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2022	17	2							e0263574	10.1371/journal.pone.0263574	http://dx.doi.org/10.1371/journal.pone.0263574			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1J1AU	35143552	Green Published, gold			2023-01-03	WOS:000797657800057
J	Engelberg, AB; Avorn, J; Kesselheim, AS				Engelberg, Alfred B.; Avorn, Jerry; Kesselheim, Aaron S.			A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material; Early Access								Existing laws could be used to help make many drugs more affordable. One gives the government a royalty-free license to use patented inventions that were discovered using federal funding; the other gives the government immunity from being sued for patent infringement.	[Engelberg, Alfred B.] Engelberg Fdn, Palm Beach, FL 33480 USA; [Avorn, Jerry; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Avorn, Jerry; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Engelberg, AB (corresponding author), Engelberg Fdn, Palm Beach, FL 33480 USA.		Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Abinader LG., 2021, US GOVT RIGHTS PATEN; Department of Health and Human Services, 2016, COMMUNICATION 0620; Struver Z., 2016, BIOLYSE PHARMA OFFER; U.S. General Accounting Office, 2003, AG RIGHTS FED SPONS	4	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMp2117102	http://dx.doi.org/10.1056/NEJMp2117102		FEB 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW0NR	35139270				2023-01-03	WOS:000753118900001
J	Rigotti, NA; Kruse, GR; Livingstone-Banks, J; Hartmann-Boyce, J				Rigotti, Nancy A.; Kruse, Gina R.; Livingstone-Banks, Jonathan; Hartmann-Boyce, Jamie			Treatment of Tobacco Smoking A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NICOTINE REPLACEMENT THERAPY; UNITED-STATES; PRODUCT USE; CESSATION; VARENICLINE; ADULTS; CIGARETTE; CYTISINE; DEPENDENCE; BUPROPION	IMPORTANCE More deaths in the US are attributed to cigarette smoking each year than to any other preventable cause. Approximately 34 million people and an estimated 14% of adults in the US smoke cigarettes. If they stopped smoking, they could reduce their risk of tobacco-related morbidity and mortality and potentially gain up to 10 years of life. OBSERVATIONS Tobacco smoking is a chronic disorder maintained by physical nicotine dependence and learned behaviors. Approximately 70% of people who smoke cigarettes want to quit smoking. However, individuals who attempt to quit smoking make an average of approximately 6 quit attempts before achieving long-term abstinence. Both behavioral counseling and pharmacotherapy while using nicotine replacement therapy (NRT) products, varenicline, or bupropion are effective treatments when used individually, but they are most effective when combined. In ameta-analysis including 19 488 people who smoked cigarettes, the combination of medication and behavioral counseling was associated with a quit rate of 15.2% over 6 months compared with a quit rate of 8.6% with brief advice or usual care. The EAGLES trial, a randomized double-blind clinical trial of 8144 people who smoked, directly compared the efficacy and safety of varenicline, bupropion, nicotine patch, and placebo and found a significantly higher 6-month quit rate for varenicline (21.8%) than for bupropion (16.2%) and the nicotine patch (15.7%). Each therapy was more effective than placebo (9.4%). Combining a nicotine patch with other NRT products is more effective than use of a single NRT product. Combining drugs with different mechanisms of action, such as varenicline and NRT, has increased quit rates in some studies compared with use of a single product. Brief or intensive behavioral support can be delivered effectively in person or by telephone, textmessages, or the internet. The combination of a clinician's brief advice to quit and assistance to obtain tobacco cessation treatment is effective when routinely administered to tobacco users in virtually all health care settings. CONCLUSIONS AND RELEVANCE Approximately 34 million people in the US smoke cigarettes and could potentially gain up to a decade of life expectancy by stopping smoking. First-line therapy should include both pharmacotherapy and behavioral support, with varenicline or combination NRT as preferred initial interventions.	[Rigotti, Nancy A.; Kruse, Gina R.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Mongan Inst, Dept Med,Div Gen Internal Med, Boston, MA 02114 USA; [Rigotti, Nancy A.; Kruse, Gina R.] Harvard Med Sch, Boston, MA 02115 USA; [Livingstone-Banks, Jonathan; Hartmann-Boyce, Jamie] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Oxford	Rigotti, NA (corresponding author), Massachusetts Gen Hosp, 100 Cambridge St,Ste 1600, Boston, MA 02114 USA.	rigotti.nancy@mgh.harvard.edu		Livingstone-Banks, Jonathan/0000-0002-3757-5591	NIHR via Cochrane Infrastructure	NIHR via Cochrane Infrastructure	Dr Livingstone-Banks is funded by the NIHR, via Cochrane Infrastructure funding to the Cochrane Tobacco Addiction Group.	[Anonymous], Cigarette labeling and health warning requirements; [Anonymous], FDA commits to evidence-based actions aimed at saving lives and preventing future generations of smokers; [Anonymous], 2014, HLTH CONS SMOK 50 YE; [Anonymous], Patients not ready to make a quit attempt now (the "5 R's; [Anonymous], 2020, SMOK CESS REP SURG G; Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Asfar T, 2021, NICOTINE TOB RES, V23, P1308, DOI 10.1093/ntr/ntaa277; Babb S, 2017, MMWR-MORBID MORTAL W, V65, P1457, DOI 10.15585/mmwr.mm6552a1; Baker TB, 2021, ANNU REV CLIN PSYCHO, V17, P1, DOI 10.1146/annurev-clinpsy-081219-090343; Baker TB, 2016, JAMA-J AM MED ASSOC, V315, P371, DOI 10.1001/jama.2015.19284; Barnes J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001008.pub3; Barua RS, 2018, J AM COLL CARDIOL, V72, P3332, DOI 10.1016/j.jacc.2018.10.027; Benowitz NL, 2010, NEW ENGL J MED, V362, P2295, DOI 10.1056/NEJMra0809890; Byaruhanga J, 2021, J SUBST ABUSE TREAT, V131, DOI 10.1016/j.jsat.2021.108448; Byaruhanga J, 2020, DRUG ALCOHOL DEPEN, V217, DOI 10.1016/j.drugalcdep.2020.108296; Cahill K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub7; Chaiton M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011045; Chang PH, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2055-0; Clancy CM, 2021, ANN INTERN MED, V174, P116, DOI 10.7326/M20-5593; Cornelius ME, 2020, MMWR-MORBID MORTAL W, V69, P1736, DOI 10.15585/mmwr.mm6946a4; Courtney RJ, 2021, JAMA-J AM MED ASSOC, V326, P56, DOI 10.1001/jama.2021.7621; Creamer MR, 2019, MMWR-MORBID MORTAL W, V68, P1013, DOI 10.15585/mmwr.mm6845a2; Ebbert JO, 2015, JAMA-J AM MED ASSOC, V313, P687, DOI 10.1001/jama.2015.280; Ebbert JO, 2014, JAMA-J AM MED ASSOC, V311, P155, DOI 10.1001/jama.2013.283185; Evins AE, 2019, J CLIN PSYCHOPHARM, V39, P108, DOI 10.1097/JCP.0000000000001015; Fiore MC, 2008, AM J PREV MED, V35, P158, DOI 10.1016/j.amepre.2008.04.009; Fiore MC, 2014, NEW ENGL J MED, V370, P297, DOI 10.1056/NEJMp1314942; Hajek P, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-140; Hartmann-Boyce J, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013229.pub2; Hartmann-Boyce J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009670.pub4; Hartmann-Boyce J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub5; Hartmann-Boyce J, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010216.pub4, 10.1002/14651858.CD010216.pub3]; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Howes S, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000031.pub5; Hughes JR, 2014, NICOTINE TOB RES, V16, P1190, DOI 10.1093/ntr/ntu052; Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128; Kalkhoran S, 2018, J AM COLL CARDIOL, V72, P1030, DOI 10.1016/j.jacc.2018.06.036; Koegelenberg CFN, 2014, JAMA-J AM MED ASSOC, V312, P155, DOI 10.1001/jama.2014.7195; Kotsen C, 2021, TELEMED E-HEALTH, V27, P20, DOI 10.1089/tmj.2020.0194; Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P265, DOI 10.1001/jama.2020.25019; Lancaster T, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001292.pub3; Leone FT, 2020, AM J RESP CRIT CARE, V202, pE5, DOI 10.1164/rccm.202005-1982ST; Lindson N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013183.pub2; Lindson N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006936.pub4; Lindson N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013308; Lindson-Hawley N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005231.pub3; Livingstone-Banks J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001118.pub4; Matkin W, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub4; McNeill A, 2021, VAPING ENGLAND EVIDE; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Nash SH, 2017, AM J PREV MED, V52, P276, DOI 10.1016/j.amepre.2016.09.036; National Academies of Sciences Engineering and Medicine, 2018, PUBLIC HLTH CONSEQUE; Notley C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004307.pub6; Patnode CD, 2021, JAMA-J AM MED ASSOC, V325, P280, DOI 10.1001/jama.2020.23541; Piper ME, 2015, NICOTINE TOB RES, V17, P1405, DOI 10.1093/ntr/ntv048; Ramon JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0172-8; Rice VH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001188.pub5; Rigotti NA, 2019, J AM COLL CARDIOL, V74, P508, DOI 10.1016/j.jacc.2019.06.003; Royal College of Physicians, 2016, NIC SMOK TOB HARM RE; Sheffer CE, 2016, J SMOK CESS, V11, P229, DOI 10.1017/jsc.2014.30; Sherman SE, 2008, AM J MANAG CARE, V14, P141; Stead LF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001007.pub3; Stead LF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub3; Stead LF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub4; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Taylor GMJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007078.pub5; Thomas KH, 2022, ADDICTION, V117, P861, DOI 10.1111/add.15675; Tindle HA, 2016, AM J PREV MED, V51, P522, DOI 10.1016/j.amepre.2016.05.024; Tzelepis F, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012659.pub2; US Food and Drug Administration, YOUTH TOB; VanFrank B, 2021, JAMA-J AM MED ASSOC, V325, P232, DOI 10.1001/jama.2020.23608; Vidrine JI, 2013, JAMA INTERN MED, V173, P458, DOI 10.1001/jamainternmed.2013.3751; Walker N, 2021, ADDICTION, V116, P2847, DOI 10.1111/add.15489; Walker N, 2014, NEW ENGL J MED, V371, P2353, DOI 10.1056/NEJMoa1407764; West R, 2011, NEW ENGL J MED, V365, P1193, DOI 10.1056/NEJMoa1102035; White AR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub4; Whittaker R, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006611.pub5; WHO, 2021, TOBACCO	78	14	14	5	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2022	327	6					566	577		10.1001/jama.2022.0395	http://dx.doi.org/10.1001/jama.2022.0395			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD5RT	35133411				2023-01-03	WOS:000758257900015
J	Muhammadzai, J; Haider, K; Moser, M; Chalchal, H; Shaw, J; Gardiner, D; Dueck, DA; Ahmed, O; Brunet, B; Iqbal, M; Luo, YG; Beck, G; Zaidi, A; Ahmed, S				Muhammadzai, Javeria; Haider, Kamal; Moser, Michael; Chalchal, Haji; Shaw, John; Gardiner, Donald; Dueck, Dorie-Anna; Ahmed, Osama; Brunet, Bryan; Iqbal, Mussawar; Luo, Yigang; Beck, Gavin; Zaidi, Adnan; Ahmed, Shahid			Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study	PLOS ONE			English	Article							DEFINITIVE SURGERY; FOLINIC ACID; GEMCITABINE; RESECTION; INITIATION; IMPACT; CHEMORADIOTHERAPY; DIAGNOSIS; OUTCOMES; TIME	Background The current study aimed to determine the association between timing and completion of adjuvant chemotherapy and outcomes in real-world patients with early-stage pancreatic cancer. Methods In this multi-center cohort study patients with early-stage pancreatic cancer who were diagnosed from 2007-2017 and underwent complete resection in the province of Saskatchewan were examined. Cox proportional multivariate analyses were performed for correlation with recurrence and survival. Results Of 168 patients, 71 eligible patients with median age of 69 years and M:F of 37:34 were identified. Median time to the start of adjuvant therapy from surgery was 73 days. Of all patients, 49 (69%) patients completed adjuvant chemotherapy and 22 (31%) required early treatment discontinuation. Median recurrence-free survival of patients who completed treatment was 22 months (95%CI:15.8-28.2) vs. 9 months (3.3-14.7) if treatment was discontinued early (P<0.001). Median overall survival of those who completed treatment was 33 (17.5-48.5) vs. 16 months (17.5-48.5) with early treatment discontinuation (P<0.001). In the multivariate analysis, treatment discontinuation was significantly correlated with recurrent disease, hazard ratio (HR), 2.57 (1.41-4.68), P = 0.002 and inferior survival, HR, 2.55 (1.39-4.68), P = 0.003. No correlation between treatment timing and survival was noted. Conclusions Early discontinuation but not the timing of adjuvant chemotherapy correlates with inferior outcomes.	[Muhammadzai, Javeria; Haider, Kamal; Moser, Michael; Chalchal, Haji; Shaw, John; Gardiner, Donald; Dueck, Dorie-Anna; Ahmed, Osama; Brunet, Bryan; Iqbal, Mussawar; Luo, Yigang; Beck, Gavin; Zaidi, Adnan; Ahmed, Shahid] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada; [Haider, Kamal; Dueck, Dorie-Anna; Ahmed, Osama; Zaidi, Adnan; Ahmed, Shahid] Univ Saskatchewan, Saskatoon Canc Ctr, Med Oncol, Saskatoon, SK, Canada; [Moser, Michael; Shaw, John; Luo, Yigang; Beck, Gavin] Univ Saskatchewan, Dept Surg, Saskatoon, SK, Canada; [Chalchal, Haji; Iqbal, Mussawar] Allan Blair Canc Ctr, Med Oncol, Regina, SK, Canada; [Gardiner, Donald; Brunet, Bryan] Univ Saskatchewan, Saskatoon Canc Ctr, Radiat Oncol, Saskatoon, SK, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Ahmed, S (corresponding author), Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada.; Ahmed, S (corresponding author), Univ Saskatchewan, Saskatoon Canc Ctr, Med Oncol, Saskatoon, SK, Canada.	shahid.ahmed@saskcancer.ca	Ahmed, Shahid/GPK-2366-2022	Ahmed, Osama/0000-0001-9241-7695	Mach-Gaensslen Foundation of Canada; University of Saskatchewan College of Medicine	Mach-Gaensslen Foundation of Canada; University of Saskatchewan College of Medicine	JM, SA. 2019-DPCOM The MachGaensslen Foundation of Canada and the University of Saskatchewan College of Medicine http://machgaensslen.ca/https://medicine.usask.ca/index.php The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chu CK, 2010, J AM COLL SURGEONS, V210, P463, DOI 10.1016/j.jamcollsurg.2009.12.029; Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775; Des Guetz G, 2010, EUR J CANCER, V46, P1049, DOI 10.1016/j.ejca.2010.01.020; Ducreux M, 2015, ANN ONCOL, V26, pV56, DOI 10.1093/annonc/mdv295; Khorana AA, 2019, J CLIN ONCOL, V37, P2082, DOI 10.1200/JCO.19.00946; Lohrisch C, 2006, J CLIN ONCOL, V24, P4888, DOI 10.1200/JCO.2005.01.6089; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Mirkin KA, 2016, CANCER-AM CANCER SOC, V122, P2979, DOI 10.1002/cncr.30163; Neoptolemos JP, 2009, BRIT J CANCER, V100, P246, DOI 10.1038/sj.bjc.6604838; Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Petrelli F, 2019, CANCERS, V11, DOI 10.3390/cancers11040550; Sanchez CJ, 2007, BREAST CANCER RES TR, V101, P215, DOI 10.1007/s10549-006-9282-0; Valle JW, 2014, J CLIN ONCOL, V32, P504, DOI 10.1200/JCO.2013.50.7657; World Cancer Research Fund International, CANC FACTS FIG PANCR	20	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2022	17	2							e0263250	10.1371/journal.pone.0263250	http://dx.doi.org/10.1371/journal.pone.0263250			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0D3HO	35108323	Green Published, gold			2023-01-03	WOS:000775890100054
J	Adiasto, K; Beckers, DGJ; van Hooff, MLM; Roelofs, K; Geurts, SAE				Adiasto, Krisna; Beckers, Debby G. J.; van Hooff, Madelon L. M.; Roelofs, Karin; Geurts, Sabine A. E.			Music listening and stress recovery in healthy individuals: A systematic review with meta-analysis of experimental studies	PLOS ONE			English	Review							RELAXING MUSIC; BLOOD-PRESSURE; HEART-RATE; CARDIOVASCULAR RECOVERY; META-REGRESSION; CORTISOL; RUMINATION; RESPONSES; ADAPTATION; EMOTIONS	Effective stress recovery is crucial to prevent the long-term consequences of stress exposure. Studies have suggested that listening to music may be beneficial for stress reduction. Thus, music listening stands to be a promising method to promote effective recovery from exposure to daily stressors. Despite this, empirical support for this opinion has been largely equivocal. As such, to clarify the current literature, we conducted a systematic review with meta-analysis of randomized, controlled experimental studies investigating the effects of music listening on stress recovery in healthy individuals. In fourteen experimental studies, participants (N = 706) were first exposed to an acute laboratory stressor, following which they were either exposed to music or a control condition. A random-effects meta-regression with robust variance estimation demonstrated a non-significant cumulative effect of music listening on stress recovery g = 0.15, 95% CI [-0.21, 0.52], t(13) = 0.92, p = 0.374. In healthy individuals, the effects of music listening on stress recovery seemed to vary depending on musical genre, who selects the music, musical tempo, and type of stress recovery outcome. However, considering the significant heterogeneity between the modest number of included studies, no definite conclusions may currently be drawn about the effects of music listening on the short-term stress recovery process of healthy individuals. Suggestions for future research are discussed.	[Adiasto, Krisna; Beckers, Debby G. J.; van Hooff, Madelon L. M.; Roelofs, Karin; Geurts, Sabine A. E.] Radboud Univ Nijmegen, Behav Sci Inst, Nijmege, Netherlands; [Roelofs, Karin] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmege, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Adiasto, K (corresponding author), Radboud Univ Nijmegen, Behav Sci Inst, Nijmege, Netherlands.	k.adiasto@bsi.ru.nl		Adiasto, Krisna/0000-0001-6557-4900				Ali N, 2020, INT J BEHAV MED, V27, P337, DOI 10.1007/s12529-019-09843-x; Allen AP, 2017, NEUROBIOL STRESS, V6, P113, DOI 10.1016/j.ynstr.2016.11.001; Ardizzi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60832-7; Baltazar M., 2019, MUSICAE SCIANTIAE, V2, P1, DOI [10.1177/2059204319844161, DOI 10.1177/2059204319844161]; Baltazar M, 2019, MUSIC SCI, V23, P177, DOI 10.1177/1029864917715061; Bernardi L, 2009, CIRCULATION, V119, P3171, DOI 10.1161/CIRCULATIONAHA.108.806174; Bishop NC, 2009, FRONT BIOSCI-LANDMRK, V14, P4444, DOI 10.2741/3540; Borenstein M., 2021, INTRO META ANAL; Boyle NB, 2016, PSYCHONEUROENDOCRINO, V63, P119, DOI 10.1016/j.psyneuen.2015.09.025; Bradt J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006577.pub3; Brattico E, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00308; Bretherton B., 2019, MUSIC SCI, V2, DOI [https://doi.org/10.1177/2059204319858281, DOI 10.1177/2059204319858281]; Burns JL, 2002, J MUSIC THER, V39, P101, DOI 10.1093/jmt/39.2.101; Carroll D, 2017, NEUROSCI BIOBEHAV R, V77, P74, DOI 10.1016/j.neubiorev.2017.02.025; Chafin S, 2004, BRIT J HEALTH PSYCH, V9, P393, DOI 10.1348/1359107041557020; Chanda ML, 2013, TRENDS COGN SCI, V17, P179, DOI 10.1016/j.tics.2013.02.007; Chapados C, 2008, COGNITION, V108, P639, DOI 10.1016/j.cognition.2008.05.008; Chojnowska S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030517; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; de la Torre-Luque A, 2017, PSYCHOL MUSIC, V45, P795, DOI 10.1177/0305735617689953; de la Torre-Luque A, 2017, NORD J MUSIC THER, V26, P124, DOI 10.1080/08098131.2015.1131186; de Witte M, 2022, ART PSYCHOTHER, V77, DOI 10.1016/j.aip.2021.101872; de Witte M, 2020, HEALTH PSYCHOL REV, V14, P294, DOI 10.1080/17437199.2019.1627897; Del Re AC, 2014, MAD METAANALYSIS MEA; Demerouti E, 2009, RES OCCUP STRESS WEL, V7, P85, DOI 10.1108/S1479-3555(2009)0000007006; Denson TF, 2009, MOTIV EMOTION, V33, P42, DOI 10.1007/s11031-008-9114-0; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellis RJ, 2010, MUSIC PERCEPT, V27, P317, DOI 10.1525/MP.2010.27.4.317; Etzel JA, 2006, INT J PSYCHOPHYSIOL, V61, P57, DOI 10.1016/j.ijpsycho.2005.10.025; Fallon VT, 2020, PSYCHOMUSICOLOGY, V30, P20, DOI 10.1037/pmu0000246; Finn S, 2018, PROG BRAIN RES, V237, P173, DOI 10.1016/bs.pbr.2018.03.007; Fisher ZF, 2015, ARXIV; Fukui H, 2003, NEUROENDOCRINOL LETT, V24, P173; Gaab J, 2005, PSYCHONEUROENDOCRINO, V30, P599, DOI 10.1016/j.psyneuen.2005.02.001; Gan SKE, 2016, PSYCHOL MUSIC, V44, P730, DOI 10.1177/0305735615590430; Geurts SA, 2006, SPECIAL ISSUE RECOVE, V32; Gingras B, 2014, Q J EXP PSYCHOL, V67, P1428, DOI 10.1080/17470218.2013.863954; Glynn LM, 2002, PSYCHOSOM MED, V64, P714, DOI 10.1097/01.PSY.0000031574.42041.23; Groarke JM, 2020, APPL PSYCHOL-HLTH WE, V12, P288, DOI 10.1111/aphw.12185; Groarke JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218017; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hedges LV, 2010, RES SYNTH METHODS, V1, P39, DOI 10.1002/jrsm.5; Hermans EJ, 2014, TRENDS NEUROSCI, V37, P304, DOI 10.1016/j.tins.2014.03.006; Hernandez-Ruiz E, 2020, PSYCHOL MUSIC, V48, P327, DOI 10.1177/0305735618798027; Hirokawa E, 2003, J MUSIC THER, V40, P189, DOI 10.1093/jmt/40.3.189; Holzman JB, 2017, NEUROSCI BIOBEHAV R, V74, P233, DOI 10.1016/j.neubiorev.2016.12.032; Hunt AM, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.588788; Jiang J, 2016, ART PSYCHOTHER, V48, P62, DOI 10.1016/j.aip.2016.02.002; Joels M, 2009, NAT REV NEUROSCI, V10, P459, DOI 10.1038/nrn2632; Juslin P.N., 2010, HDB MUSIC EMOTION; Juslin PN, 2013, PHYS LIFE REV, V10, P235, DOI 10.1016/j.plrev.2013.05.008; Kalisch R, 2017, NAT HUM BEHAV, V1, P784, DOI 10.1038/s41562-017-0200-8; Key BL, 2008, J BEHAV MED, V31, P237, DOI 10.1007/s10865-008-9152-9; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Knight WEJ, 2001, J MUSIC THER, V38, P254, DOI 10.1093/jmt/38.4.254; Koelsch S, 2016, SCI REP-UK, V6, DOI 10.1038/srep23008; Konvalinka I, 2011, P NATL ACAD SCI USA, V108, P8514, DOI 10.1073/pnas.1016955108; Labbe C, 2014, MUSIC PERCEPT, V32, P170, DOI 10.1525/MP.2014.32.2.170; Labbe E, 2007, APPL PSYCHOPHYS BIOF, V32, P163, DOI 10.1007/s10484-007-9043-9; Lartillot O, 2008, ST CLASS DAT ANAL, P261, DOI 10.1007/978-3-540-78246-9_31; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leman M, 2005, J NEW MUSIC RES, V34, P39, DOI 10.1080/09298210500123978; Leubner D, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01109; Levitin DJ, 2018, ANNU REV PSYCHOL, V69, P51, DOI 10.1146/annurev-psych-122216-011740; Linnemann A, 2016, PSYCHONEUROENDOCRINO, V72, P97, DOI 10.1016/j.psyneuen.2016.06.003; Linnemann A, 2015, PSYCHONEUROENDOCRINO, V60, P82, DOI 10.1016/j.psyneuen.2015.06.008; Lovallo W.R., 2005, STRESS HLTH BIOL PSY; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Marwan N, 2002, PHYS LETT A, V302, P299, DOI 10.1016/S0375-9601(02)01170-2; McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006; McPherson T, 2019, J MUSIC THER, V56, P240, DOI 10.1093/jmt/thz007; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Morgan ES, 2014, PSYCHOL ASSESSMENT, V26, P90, DOI 10.1037/a0034714; Mutze H, 2020, MUSIC SCI, V24, P377, DOI 10.1177/1029864918817805; Nakajima Y, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/5965894; Ottaviani C, 2016, PSYCHOL BULL, V142, P231, DOI 10.1037/bul0000036; Peck K, 2021, INT J STRESS MANAGE, V28, P154, DOI 10.1037/str0000217; Pelletier CL, 2004, J MUSIC THER, V41, P192, DOI 10.1093/jmt/41.3.192; Pereira CS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027241; R Core Team, R LANG ENV STAT COMP; Radstaak M, 2014, PSYCHOSOM MED, V76, P529, DOI 10.1097/PSY.0000000000000094; Radstaak M, 2011, INT J PSYCHOPHYSIOL, V81, P237, DOI 10.1016/j.ijpsycho.2011.06.017; RAUDENBUSH SW, 1988, PSYCHOL BULL, V103, P111, DOI 10.1037/0033-2909.103.1.111; Rentfrow PJ, 2012, SOC PERSONAL PSYCHOL, V6, P402, DOI 10.1111/j.1751-9004.2012.00434.x; Rohatgi A, WEBPLOTDIGITIZER WEB; Sandstrom G.M., 2010, MUSIC MED, V2, P137, DOI [10.1177/1943862110371486, DOI 10.1177/1943862110371486, 10.47513/mmd.v2i3.243]; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schafer T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151634; Scheufele PM, 2000, J BEHAV MED, V23, P207, DOI 10.1023/A:1005542121935; Schwabe L, 2008, PSYCHONEUROENDOCRINO, V33, P890, DOI 10.1016/j.psyneuen.2008.03.001; Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00258; Sharman L, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00272; Shockley K, 2002, PHYS LETT A, V305, P59, DOI 10.1016/S0375-9601(02)01411-1; Sokhadze EM, 2007, APPL PSYCHOPHYS BIOF, V32, P31, DOI 10.1007/s10484-007-9033-y; Sonnentag S, 2022, ANNU REV ORGAN PSYCH, V9, P33, DOI 10.1146/annurev-orgpsych-012420-091355; Stanley TD, 2014, RES SYNTH METHODS, V5, P60, DOI 10.1002/jrsm.1095; STRATTON VN, 1992, PERCEPT MOTOR SKILL, V75, P334, DOI 10.2466/PMS.75.4.334-334; Sutoo D, 2004, BRAIN RES, V1016, P255, DOI 10.1016/j.brainres.2004.05.018; Thaut M.H., 2005, RHYTHM MUSIC BRAIN S, P113; Thoma MV, 2012, PSYCHOL HEALTH, V27, P227, DOI 10.1080/08870446.2011.575225; Thoma MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070156; Tipton MJ, 2017, J PHYSIOL-LONDON, V595, P5729, DOI 10.1113/JP274596; Trost W., 2013, EMOTIONAL POWER MUSI, P213, DOI [https://doi.org/10.1093/acprof, DOI 10.1093/ACPROF:OSO/9780199654888.003.0016, 10.1093/acprof:oso/9780199654888.003.0016]; Tsujita S, 1999, Environ Health Prev Med, V4, P1, DOI 10.1007/BF02931243; Tugade MM, 2004, J PERS, V72, P1161, DOI 10.1111/j.1467-6494.2004.00294.x; Van den Tol AJM, 2015, PSYCHOL MUSIC, V43, P473, DOI 10.1177/0305735613517410; van Dyck E, 2017, MUSIC SCI, V21, P390, DOI 10.1177/1029864917700706; Verkuil B, 2009, INT J PSYCHOPHYSIOL, V74, P220, DOI 10.1016/j.ijpsycho.2009.09.003; Vickers K, 2012, CLIN PSYCHOL REV, V32, P153, DOI 10.1016/j.cpr.2011.12.004; Viechtbauer W, 2007, Z PSYCHOL, V215, P104, DOI 10.1027/0044-3409.215.2.104; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Vos T, 2020, LANCET, V396, P1562; Wood SK, 2017, NEUROSCI BIOBEHAV R, V74, P393, DOI 10.1016/j.neubiorev.2016.04.018; Woody A, 2018, PSYCHONEUROENDOCRINO, V97, P149, DOI 10.1016/j.psyneuen.2018.07.009; Wuttke-Linnemann A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40056-0; Yamamoto M., 2007, PSYCHOL MUSIC, V35, P249, DOI [10.1177/0305735607070375, DOI 10.1177/0305735607070375]; Zavoyskiy S., 2016, PSYCHOMUSICOLOGY A, V26, P247, DOI [10.1037/pmu0000156, DOI 10.1037/PMU0000156]; Zoccola PM, 2014, HEALTH PSYCHOL, V33, P1606, DOI 10.1037/hea0000019	121	0	0	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0270031	10.1371/journal.pone.0270031	http://dx.doi.org/10.1371/journal.pone.0270031			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D4TG	35714120	Green Published, gold			2023-01-03	WOS:000829295700031
J	Mallik, A; Russo, FA				Mallik, Adiel; Russo, Frank A.			The effects of music & auditory beat stimulation on anxiety: A randomized clinical trial	PLOS ONE			English	Article							STATE-TRAIT INVENTORY; SALIVARY CORTISOL LEVEL; NEGATIVE AFFECT; RELAXING MUSIC; BINAURAL BEATS; PSYCHOMETRIC PROPERTIES; PREOPERATIVE ANXIETY; THERAPY; DISORDERS; REDUCTION	Background and objectivesMusic and auditory beat stimulation (ABS) in the theta frequency range (4-7 Hz) are sound-based anxiety treatments that have been independently investigated in prior studies. Here, the anxiety-reducing potential of calm music combined with theta ABS was examined in a large sample of participants. MethodsAn open-label randomized controlled trial was conducted with participants taking anxiolytics (n = 163). Participants were randomly assigned using the Qualtrics randomizer algorithm, to a single session of sound-based treatment in one of four parallel arms: combined (music & ABS; n = 39), music-alone (n = 36), ABS-alone (n = 41), or pink noise (control; n = 47). Pre- and post-intervention somatic and cognitive state anxiety measures were collected along with trait anxiety, personality measures and musical preferences. The study was completed online using a custom application. ResultsBased on trait anxiety scores participants were separated into moderate and high trait anxiety sub-groups. Among participants with moderate trait anxiety, we observed reductions in somatic anxiety that were greater in combined and music-alone conditions than in the pink noise condition; and reductions in cognitive state anxiety that were greater in the combined condition than in the music-alone, ABS-alone, and pink noise conditions. While we also observed reductions in somatic and cognitive state anxiety in participants with high trait anxiety, the conditions were not well differentiated. ConclusionsSound-based treatments are effective in reducing somatic and cognitive state anxiety. For participants with moderate trait anxiety, combined conditions were most efficacious.	[Mallik, Adiel; Russo, Frank A.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada	Toronto Metropolitan University	Mallik, A (corresponding author), Ryerson Univ, Dept Psychol, Toronto, ON, Canada.	adiel.mallik@ryerson.ca		Russo, Frank/0000-0002-2939-6358; Mallik, Adiel/0000-0002-6792-1061	Mitacs Accelerate [IT16618]; Mitacs Industrial Accelerate [IT17123]	Mitacs Accelerate; Mitacs Industrial Accelerate	Funding: Dr. Adiel Mallik would like to acknowledge the support of the Mitacs Accelerate (IT16618) and Mitacs Industrial Accelerate (IT17123) grants. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ala TS, 2018, BIOMED SIGNAL PROCES, V42, P242, DOI 10.1016/j.bspc.2018.01.022; Altshuler IM., 1948, PSYCHIATRISTS EXPERI; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; Bachhuber MA, 2016, AM J PUBLIC HEALTH, V106, P686, DOI 10.2105/AJPH.2016.303061; Bados A, 2010, J PERS ASSESS, V92, P560, DOI 10.1080/00223891.2010.513295; Baldwin D, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1199; Baldwin DS, 2010, CURR TOP BEHAV NEURO, V2, P453, DOI 10.1007/7854_2009_2; Bernardi L, 2009, CIRCULATION, V119, P3171, DOI 10.1161/CIRCULATIONAHA.108.806174; Brett J, 2015, AUST PRESCR, V38, P152, DOI 10.18773/austprescr.2015.055; Bringman H, 2009, ACTA ANAESTH SCAND, V53, P759, DOI 10.1111/j.1399-6576.2009.01969.x; Buffum MD, 2006, J VASC NURS, V24, P68, DOI 10.1016/j.jvn.2006.04.001; Bulfone T, 2009, HOLIST NURS PRACT, V23, P238, DOI 10.1097/HNP.0b013e3181aeceee; Camargo A, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-15; Chaieb L., 2017, BINAURAL BEAT STIMUL, P167; Chaieb L, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00070; Chanda ML, 2013, TRENDS COGN SCI, V17, P179, DOI 10.1016/j.tics.2013.02.007; Chapados C, 2008, COGNITION, V108, P639, DOI 10.1016/j.cognition.2008.05.008; Coan J. A., 2007, HDB EMOTION ELICITAT; Crespo A, 2013, ARCH ACOUST, V38, P517, DOI 10.2478/aoa-2013-0061; DAVIS WB, 1989, J MUSIC THER, V26, P168, DOI 10.1093/jmt/26.4.168; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; DuPont RL, 1996, ANXIETY, V2, P167, DOI 10.1002/(SICI)1522-7154(1996)2:4<167::AID-ANXI2>3.0.CO;2-L; Fredenburg HA, 2014, ART PSYCHOTHER, V41, P174, DOI 10.1016/j.aip.2014.01.007; Frossard J., 2019, PERMUCO PERMUTATION; Garcia-Argibay M, 2019, PSYCHOL RES-PSYCH FO, V83, P357, DOI 10.1007/s00426-018-1066-8; Garza-Villarreal EA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01051; Garza-Villarreal EA, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00090; Goldbeck L, 2012, J MUSIC THER, V49, P395, DOI 10.1093/jmt/49.4.395; Good P, 1994, PERMUTATION TESTS PR; Greaves-Lord K, 2007, ACTA PSYCHIAT SCAND, V116, P137, DOI 10.1111/j.1600-0447.2007.01001.x; Green JG, 2010, ARCH GEN PSYCHIAT, V67, P113, DOI 10.1001/archgenpsychiatry.2009.186; Greenberg PE, 1999, J CLIN PSYCHIAT, V60, P427, DOI 10.4088/JCP.v60n0702; Gros DF, 2007, PSYCHOL ASSESSMENT, V19, P369, DOI 10.1037/1040-3590.19.4.369; Gunter RW, 2010, CLIN PSYCHOL REV, V30, P194, DOI 10.1016/j.cpr.2009.11.001; HANSER SB, 1985, J MUSIC THER, V22, P193, DOI 10.1093/jmt/22.4.193; Heiderscheit A, 2015, MUSIC THER PERSPECT, V33, P45, DOI 10.1093/mtp/miu042; Helsing M., 2016, MUSIC MED, V8, P187, DOI [10.47513/mmd.v8i4.442, DOI 10.47513/MMD.V8I4.442]; Isik BK, 2017, BRIT J ORAL MAX SURG, V55, P571, DOI 10.1016/j.bjoms.2017.02.014; Joormann J, 2005, COGNITIVE THER RES, V29, P569, DOI 10.1007/s10608-005-3340-5; Juruena MF, 2020, ADV EXP MED BIOL, V1191, P141, DOI 10.1007/978-981-32-9705-0_9; Kendall PC, 2001, J AM ACAD CHILD PSY, V40, P787, DOI 10.1097/00004583-200107000-00013; Kennel S, 2010, J PEDIATR NURS, V25, P3, DOI 10.1016/j.pedn.2008.06.010; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; Kuehl R, 2000, DESIGNS EXPT STAT PR, V2nd; Lane JD, 1998, PHYSIOL BEHAV, V63, P249, DOI 10.1016/S0031-9384(97)00436-8; Le Scouarnec RP, 2001, ALTERN THER HEALTH M, V7, P58; Lenze EJ, 2001, DEPRESS ANXIETY, V14, P86, DOI 10.1002/da.1050; Longo LP, 2000, AM FAM PHYSICIAN, V61, P2121; Lopez-Caballero F, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00557; Mallik A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41952; Martin LJ, 2015, CURR BIOL, V25, P326, DOI 10.1016/j.cub.2014.11.028; McConnell PA, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01248; Merry M, 2021, ART PSYCHOTHER, V72, DOI 10.1016/j.aip.2020.101739; Miranda D., 2012, MUSIC HLTH WELLBEING, P513, DOI [10.1093/acprof:oso/9780199586974.003.0034, DOI 10.1093/ACPROF:OSO/9780199586974.003.0034]; Moore B.C.J., 2012, INTRO PSYCHOL HEARIN, V6th; Onder H, 2007, J APPL ANIM RES, V32, P69; On FR, 2013, 2013 IEEE 9TH INTERNATIONAL COLLOQUIUM ON SIGNAL PROCESSING AND ITS APPLICATIONS (CSPA), P339, DOI 10.1109/CSPA.2013.6530068; Opbroek A, 2002, INT J NEUROPSYCHOPH, V5, P147, DOI 10.1017/S1461145702002870; Otte Christian, 2011, Dialogues Clin Neurosci, V13, P413; Padmanabhan R, 2005, ANAESTHESIA, V60, P874, DOI 10.1111/j.1365-2044.2005.04287.x; Panteleeva Y, 2018, PSYCHOL MUSIC, V46, P473, DOI 10.1177/0305735617712424; Parodi A, 2021, J PSYCHOSOM OBST GYN, V42, P147, DOI 10.1080/0167482X.2020.1751607; Pastor MA, 2002, J NEUROSCI, V22, P10501; Phillips SP, 2021, J AFFECT DISORDERS, V282, P141, DOI 10.1016/j.jad.2020.12.178; Pluck G., 2019, PSYCHOL NEUROSCIENCE, V12, P53, DOI [10.1037/pne0000166, DOI 10.1037/PNE0000166]; RAMMSAYER T, 1993, PERS INDIV DIFFER, V14, P701, DOI 10.1016/0191-8869(93)90118-M; Ree MJ, 2008, BEHAV COGN PSYCHOTH, V36, P313, DOI 10.1017/S1352465808004232; Reedijk SA, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00082; Reedijk SA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00786; Rentfrow PJ, 2003, J PERS SOC PSYCHOL, V84, P1236, DOI 10.1037/0022-3514.84.6.1236; RIDER MS, 1985, J MUSIC THER, V22, P183, DOI 10.1093/jmt/22.4.183; Ridley M, 2020, SCIENCE, V370, P1289, DOI 10.1126/science.aay0214; Roberts KE, 2016, PSYCHOL ASSESSMENT, V28, P134, DOI 10.1037/pas0000155; ROCKLIN T, 1981, BRIT J SOC PSYCHOL, V20, P279, DOI 10.1111/j.2044-8309.1981.tb00498.x; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; Sandstrom G.M., 2010, MUSIC MED, V2, P137, DOI [10.1177/1943862110371486, DOI 10.1177/1943862110371486, 10.47513/mmd.v2i3.243]; Schwarz DWF, 2005, CLIN NEUROPHYSIOL, V116, P658, DOI 10.1016/j.clinph.2004.09.014; Solca M, 2016, HEARING RES, V332, P233, DOI 10.1016/j.heares.2015.09.011; South African Department of Science and Technology, 2019, WHITE PAPER SCI TECH; Stewart RE, 2009, J CONSULT CLIN PSYCH, V77, P595, DOI 10.1037/a0016032; SUZUKI S, 1991, J SOUND VIB, V151, P407, DOI 10.1016/0022-460X(91)90537-T; Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983; Twenge JM, 2020, DEPRESS ANXIETY, V37, P954, DOI 10.1002/da.23077; Uedo N, 2004, HEPATO-GASTROENTEROL, V51, P451; Vernon D, 2014, INT J PSYCHOPHYSIOL, V93, P134, DOI 10.1016/j.ijpsycho.2012.10.008; Vreeburg SA, 2010, PSYCHOSOM MED, V72, P340, DOI 10.1097/PSY.0b013e3181d2f0c8; Wahbeh H, 2007, J ALTERN COMPLEM MED, V13, P199, DOI 10.1089/acm.2006.6201; Wahbeh H, 2007, J ALTERN COMPLEM MED, V13, P25, DOI 10.1089/acm.2006.6196; Wang SM, 2002, ANESTH ANALG, V94, P1489, DOI 10.1097/00000539-200206000-00021; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Will U, 2007, NEUROSCI LETT, V424, P55, DOI 10.1016/j.neulet.2007.07.036; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wiwatwongwana D, 2016, EYE, V30, P1407, DOI 10.1038/eye.2016.160; Wu PY, 2017, COMPLEMENT THER MED, V32, P56, DOI 10.1016/j.ctim.2017.03.007; Yusim A, 2020, J NERV MENT DIS, V208, P155, DOI 10.1097/NMD.0000000000001070; Zhou JH, 2012, J THEOR BIOL, V306, P68, DOI 10.1016/j.jtbi.2012.04.006; Zoteyeva V, 2016, PSYCHOL MUSIC, V44, P307, DOI 10.1177/0305735614566841	98	0	0	8	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0259312	10.1371/journal.pone.0259312	http://dx.doi.org/10.1371/journal.pone.0259312			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T3NB	35263341	gold, Green Published, Green Submitted			2023-01-03	WOS:000804638700038
J	Mason, S; Ezechi, OC; Obiezu-Umeh, C; Nwaozuru, U; BeLue, R; Airhihenbuwa, C; Gbaja-Biamila, T; Oladele, D; Musa, AZ; Modi, K; Parker, J; Uzoaru, F; Engelhart, A; Tucker, J; Iwelunmor, J				Mason, Stacey; Ezechi, Oliver C.; Obiezu-Umeh, Chisom; Nwaozuru, Ucheoma; BeLue, Rhonda; Airhihenbuwa, Collins; Gbaja-Biamila, Titilola; Oladele, David; Musa, Adesola Z.; Modi, Karan; Parker, Jessica; Uzoaru, Florida; Engelhart, Alexis; Tucker, Joseph; Iwelunmor, Juliet			Understanding factors that promote uptake of HIV self-testing among young people in Nigeria: Framing youth narratives using the PEN-3 cultural model	PLOS ONE			English	Article							HEALTH RESEARCH; ACCEPTABILITY; INTERVENTIONS; ADOLESCENTS; ATTITUDES; STIGMA; WOMEN	It is important to understand how to frame the formats for promoting HIV self-testing to increase uptake among young people. In this study, we used a culture-centered model to understand the narratives of HIV self-testing preferences among young people in Nigeria. We conducted a crowdsourcing contest to solicit ideas surrounding HIV self-testing promotion among young people (10-24 years) in Nigeria from October to November 2018 as part of the 2018 World AIDS Day event. We received 903 submissions and employed thematic content analysis to evaluate 769 eligible youth narratives. Thematic content analysis of the statements from the youth narratives was guided by the PEN-3 cultural model to examine the positive, existential, and negative perceptions (beliefs and values), enablers (resources), and nurturers (roles of friends and family) of HIV self-testing promotion among young people in Nigeria. Several themes emerged as factors that influence the uptake of HIV self-testing among young people in Nigeria. Specifically, seven themes emerged as perceptions: HIV testing accessibility, stigma reduction, and autonomy (positive); HIV self-testing kit packaging and advertisements (existential); lack of knowledge and increased stigma (negative). Seven themes emerged as enablers: social media, school, and government promotion (positive); gamification and animation (existential); high cost and access to linkage to care services (negative); And seven themes emerged as nurturers: peer, families, and faith-based communities (positive); parents and family-centered approach (existential); and partners and family (negative). Our data suggests that increased awareness around HIV self-testing on current youth-friendly platforms, de-stigmatization of HIV and HIV self-testing, decreased prices for HIV self-testing kits, reliability of testing kits, increased linkage to care services, and promotion of self-testing among family members and the community will be beneficial for HIV self-testing scale-up measures among young people in Nigeria.	[Mason, Stacey; Obiezu-Umeh, Chisom; Nwaozuru, Ucheoma; Gbaja-Biamila, Titilola; Oladele, David; Uzoaru, Florida; Engelhart, Alexis; Iwelunmor, Juliet] St Louis Univ, Dept Behav Sci & Hlth Educ, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA; [Ezechi, Oliver C.; Musa, Adesola Z.] Nigerian Inst Med Res, Clin Sci Div, Lagos, Nigeria; [BeLue, Rhonda] St Louis Univ, Dept Hlth Management & Policy, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA; [Airhihenbuwa, Collins] Georgia State Univ, Sch Publ Hlth, Global Res Noncommunicable Dis Grand, Atlanta, GA 30303 USA; [Modi, Karan; Parker, Jessica] St Louis Univ, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA; [Tucker, Joseph] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA	Saint Louis University; Saint Louis University; University System of Georgia; Georgia State University; Saint Louis University; University of North Carolina; University of North Carolina Chapel Hill	Mason, S (corresponding author), St Louis Univ, Dept Behav Sci & Hlth Educ, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA.	stacey.mason@slu.edu						Airhihenbuwa CO, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200245; Airhihenbuwa C, 2009, J BLACK PSYCHOL, V35, P407, DOI 10.1177/0095798408329941; Airhihenbuwa CO, 2014, HEALTH EDUC BEHAV, V41, P78, DOI 10.1177/1090198113487199; Ajayi AI, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233368; Angotti N, 2009, SOC SCI MED, V68, P2263, DOI 10.1016/j.socscimed.2009.02.041; Asuquo SE, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25666; Barr-DiChiara M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049673; Choko AT, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001873; Choko AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001102; Clinton Health Access Initiative (CHAI), 2021, HIV MARKET REPORT ST; Dowshen N, 2015, AIDS BEHAV, V19, pS106, DOI 10.1007/s10461-014-0991-9; Drew SE, 2010, QUAL HEALTH RES, V20, P1677, DOI 10.1177/1049732310377455; Erwin DO, 2010, SOC SCI MED, V71, P693, DOI 10.1016/j.socscimed.2010.05.005; Federal Ministry of Health (FMoH), GUID YOUNG PERS PART; Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8; Fox K., 2013, HIV ADOLESCENTS GUID; Galbraith-Gyan KV, 2019, ETHNIC HEALTH, V24, P323, DOI 10.1080/13557858.2017.1332758; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Harichund C, 2018, AIDS BEHAV, V22, P560, DOI 10.1007/s10461-017-1848-9; Hatzold K, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25244; Hieftje K, 2014, HEALTH PROMOT PRACT, V15, P714, DOI 10.1177/1524839914521211; Hilton LG, 2019, AM J EVAL, V40, P575, DOI 10.1177/1098214019836674; Indravudh PP, 2017, AIDS, V31, pS203, DOI 10.1097/QAD.0000000000001516; Iwelunmor J, 2022, CONTEMP CLIN TRIALS, V114, DOI 10.1016/j.cct.2021.106628; Iwelunmor J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233698; Iwelunmor J, 2014, ETHNIC HEALTH, V19, P20, DOI 10.1080/13557858.2013.857768; Jatho A, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1004; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594; Joint United Nations Programme on HIV/AIDS, 2021, YOUNG PEOPL HIV; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, AMB TREATM TARG HELP; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2021, 2021 UNAIDS GLOB AID; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2018, YOUTH HIV MAINSTR 3; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2021, PREL UNAIDS 2021 EP; Kalembo FW, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2046-2; Kumwenda MK, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25251; Kurth AE, 2015, J INT AIDS SOC, V18, P23, DOI 10.7448/IAS.18.2.19433; Lippman SA, 2016, AIDS BEHAV, V20, P928, DOI 10.1007/s10461-015-1236-2; Lyons CE, 2019, AIDS BEHAV, V23, pS130, DOI 10.1007/s10461-019-02552-2; MacPhail CL, 2008, HEALTH EDUC BEHAV, V35, P87, DOI 10.1177/1090198106286442; Mathews A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08582-z; Musheke M, 2013, BMC PUBLIC HEALTH, V13, DOI [10.1186/1471-2458-13-220, 10.1186/1472-6963-13-97]; Neary J, 2019, AIDS CARE, V31, P105, DOI 10.1080/09540121.2018.1524563; Nieuwenhuys O., 1996, PLA NOTES, V25, P52; Nwaozuru U, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4847-x; Obiezu-Umeh C, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10072-1; Pettifor A, 2020, ECLINICALMEDICINE, V21, DOI 10.1016/j.eclinm.2020.100327; Qin YL, 2018, AIDS, V32, P371, DOI 10.1097/QAD.0000000000001705; Ramaiya MK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165936; Ritchwood TD, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6402-4; Shahbazi H, 2018, INT J ENDOCRINOL MET, V16, DOI 10.5812/ijem.62582; Sibanda EL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25245; Thirumurthy H, 2016, LANCET HIV, V3, pE266, DOI 10.1016/S2352-3018(16)00041-2; Tonen-Wolyec S, 2019, PAN AFR MED J, V33, DOI 10.11604/pamj.2019.33.83.18586; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; United Nations Children's Fund (UNICEF), 2021, AD HIV PREV; United Nations Educational Scientific and Cultural Organization (UNESCO), HLTH ED RES CTR NAT; Wazny K, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010502; Wazny K, 2017, J GLOB HEALTH, V7, DOI [10.7189/jogh.07.020601, 10.7189/jogh.07.020602]; Winskell K, 2011, SOC SCI MED, V73, P1257, DOI 10.1016/j.socscimed.2011.07.007; Winskell K, 2011, SOC SCI MED, V72, P953, DOI 10.1016/j.socscimed.2011.01.014; World Health Organization (WHO), 2016, WHO REC HIV SELF TES; World Health Organization (WHO), 2018, CIRC EC HLTH OPP RIS, P26	62	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268945	10.1371/journal.pone.0268945	http://dx.doi.org/10.1371/journal.pone.0268945			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35657809	Green Published, gold, Green Accepted			2023-01-03	WOS:000832307900034
J	Wang, PJ; Li, GY; Liu, SR; Wei, XX				Wang, Pingjun; Li, Gangyan; Liu, Sirui; Wei, Xiaoxu			Structure design method of new balanced vibration reduction gear for the three cylinder engine	PLOS ONE			English	Article							OPTIMIZATION	Aiming at the engineering requirements of reducing the volume and improving the vibration characteristics of gears in the three-cylinder engine balanced system, a design and optimization method of gear structure is proposed based on the Design of Experiments (DOE) and proxy models. The paper analyzes the structure improvement process based on the gear design model and technical index requirements. By designing the plane characteristics of the weight-increasing module, the weight-reducing module and the elastic module, the calculation model of balance performance indices such as mass, moment of inertia and unbalance of new balanced vibration reduction gear are constructed. Then, a more efficient design method is proposed based on dynamic simulation and multidisciplinary optimization design platform (Isight). The results show that the new design method of gear structure can effectively reduce the structure improvement cycle. At the same time, the improved structure can reduce the thickness of the weight-increasing module by 6.3 mm and the vibration attenuation by more than 90%.	[Wang, Pingjun; Li, Gangyan; Liu, Sirui; Wei, Xiaoxu] Wuhan Univ Technol, Coll Mech & Elect Engn, Wuhan, Peoples R China; [Wang, Pingjun] Xinyang Vocat & Tech Coll, Coll Automot & Electromech Engn, Xinyang, Peoples R China	Wuhan University of Technology	Wang, PJ (corresponding author), Wuhan Univ Technol, Coll Mech & Elect Engn, Wuhan, Peoples R China.; Wang, PJ (corresponding author), Xinyang Vocat & Tech Coll, Coll Automot & Electromech Engn, Xinyang, Peoples R China.	wpj156@126.com			key scientific research project plan of the Henan education department [22A460032]	key scientific research project plan of the Henan education department	The authors thank Professor Gangyan Li for his helpful suggestion of this paper. We also thank Sirui Liu for her helpful analysis of methodology. We also thank Xiaoxu Wei for her helpful collaboration and correction of this paper.	Blair RW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218768; Gao F., 1989, MECH MACH THEORY, V4, P275, DOI [10.1016/0094-114X(89)90047-5, DOI 10.1016/0094-114X(89)90047-5]; Geng ZB, 2022, J VIB CONTROL, V28, P2212, DOI 10.1177/10775463211013245; Gent A. N., 2001, ENG RUBBER DESIGN RU; Grioli Giuseppe, 2020, United States patent, Patent No. [US20200063827, 20200063827 20200063827]; Guan NX, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11125647; Han L, 2020, MATH PROBL ENG, V2020, DOI 10.1155/2020/3197395; Hatami M, 2015, ENERG CONVERS MANAGE, V106, P1057, DOI 10.1016/j.enconman.2015.10.040; Ishikawa M, 2002, JSAE REV, V23, P27, DOI 10.1016/S0389-4304(01)00164-3; Jin ZY, 2018, ACTA METALL SIN-ENGL, V31, P82, DOI 10.1007/s40195-017-0669-1; Kim J, 2020, J KOREAN SOC AERONA, V48, P953, DOI 10.5139/JKSAS.2020.48.12.953; Kumar SM, 2021, MATER TODAY-PROC, V45, P6822, DOI 10.1016/j.matpr.2020.12.1005; Lucay FA, 2021, MIN PROC EXT MET REV, V42, P285, DOI 10.1080/08827508.2020.1728265; Mathan G., 2021, IOP C SERIES MAT SCI, V1128, article 012045, DOI [10.1088/1757-899x/1128/1/012045, DOI 10.1088/1757-899X/1128/1/012045]; Moetakef M A, 2019, United States patent, Patent No. [US20190085763, 20190085763 20190085763]; Mohammadi S, 2018, SAE INT J ENGINES, V11, P557, DOI 10.4271/03-11-05-0038; Monkova K, 2019, MATEC WEB CONF, V299, DOI 10.1051/matecconf/201929903002; Morelli M, 2021, J COMPUT APPL MATH, V392, DOI 10.1016/j.cam.2021.113492; Namazizadeh M, 2020, J APPL FLUID MECH, V13, P89, DOI 10.29252/jafm.13.01.29856; Pandiyan GK, 2020, MATER TODAY-PROC, V33, P2686, DOI 10.1016/j.matpr.2020.01.369; Qi ZC, 2019, INT J ADV MANUF TECH, V100, P3167, DOI 10.1007/s00170-018-2862-4; Shao RP, 2017, J VIB CONTROL, V23, P1548, DOI 10.1177/1077546315596482; Singh OP, 2013, APPL ACOUST, V75, P17, DOI 10.1016/j.apacoust.2013.07.007; Trieschmann J, 2014, United States patent, Patent No. [USUS20140013888A1, 20140013888 20140013888]; Wang S, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11121469; Wehrle E, 2019, MECH MACH SCI, V66, P395, DOI 10.1007/978-3-030-00365-4_47; Wen F, 2013, ADV MATER RES-SWITZ, V655-657, P537, DOI 10.4028/www.scientific.net/AMR.655-657.537; Xie ZF, 2018, SCI CHINA TECHNOL SC, V61, P879, DOI 10.1007/s11431-017-9184-x; Xu L, 2020, STRUCT INFRASTRUCT E, V16, P1286, DOI 10.1080/15732479.2019.1703760; Yue C, 2015, SHOCK VIB, V2015, DOI 10.1155/2015/934231	30	1	1	14	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266560	10.1371/journal.pone.0266560	http://dx.doi.org/10.1371/journal.pone.0266560			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1A8IV	35417472	Green Published, gold			2023-01-03	WOS:000791994200015
J	Rome, BN; Egilman, AC; Kesselheim, AS				Rome, Benjamin N.; Egilman, Alexander C.; Kesselheim, Aaron S.			Trends in Prescription Drug Launch Prices, 2008-2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Rome, Benjamin N.; Egilman, Alexander C.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital	Rome, BN (corresponding author), Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	brome@bwh.harvard.edu			Arnold Ventures	Arnold Ventures	This work was funded by a grant from Arnold Ventures.	Feldman WB, 2021, JAMA-HEALTH FORUM, V2, DOI 10.1001/jamahealthforum.2021.0626; Hartman Micah, 2022, Health Aff (Millwood), V41, P13, DOI 10.1377/hlthaff.2021.01763; Hernandez I, 2020, JAMA-J AM MED ASSOC, V323, P854, DOI 10.1001/jama.2020.1012; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Prevention AFfS, 2017, NAT IN RED ANN RAT S; Rand LZ, 2020, J LAW MED ETHICS, V48, P583, DOI 10.1177/1073110520958885	6	8	8	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2022	327	21					2145	2147		10.1001/jama.2022.5542	http://dx.doi.org/10.1001/jama.2022.5542			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E5JY	35670795	Green Published			2023-01-03	WOS:000812264900025
J	Sevin, CM; Ely, EW				Sevin, Carla M.; Ely, E. Wesley			Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sevin, Carla M.] Vanderbilt Univ, ICU Recovery Ctr, Med Ctr, Nashville, TN 37235 USA; [Ely, E. Wesley] Vanderbilt Univ, Tennessee Valley Vet Affairs Geriatr Res Educ Cli, Med Ctr, Nashville, TN USA	Vanderbilt University; Geriatric Research Education & Clinical Center; Vanderbilt University	Sevin, CM (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, 1161 21st Ave S,T-1218 Med Ctr North, Nashville, TN 37232 USA.	carla.sevin@vumc.org						Heesakkers H, 2022, JAMA-J AM MED ASSOC, V327, P559, DOI 10.1001/jama.2022.0040; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Soriano JB, 2022, LANCET INFECT DIS, V22, pE102, DOI 10.1016/S1473-3099(21)00703-9	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2022	327	21								10.1001/jama.2022.5892	http://dx.doi.org/10.1001/jama.2022.5892			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E5JY	35670791				2023-01-03	WOS:000812264900030
J	Marcus, JL; Killelea, A; Krakower, DS				Marcus, Julia L.; Killelea, Amy; Krakower, Douglas S.			Perverse Incentives - HIV Prevention and the 340B Drug Pricing Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material; Early Access								HIV Prevention and the 340B Drug Pricing Program A decade after preexposure prophylaxis against HIV became available, less than a quarter of people in the United States who could benefit from PrEP are taking it. The failure is a perverse outcome of a system that relies on high drug prices to fund HIV prevention.	[Marcus, Julia L.; Krakower, Douglas S.] Harvard Pilgrim Hlth Care Inst, Harvard Med Sch, Dept Populat Med, Boston, MA 02215 USA; [Krakower, Douglas S.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Killelea, Amy] Killelea Consulting, Arlington, VA 22204 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Marcus, JL (corresponding author), Harvard Pilgrim Hlth Care Inst, Harvard Med Sch, Dept Populat Med, Boston, MA 02215 USA.							D'Angelo AB, 2021, AIDS PATIENT CARE ST, V35, P327, DOI 10.1089/apc.2021.0033; Johns Hopkins Bloomberg School of Public Health, 2022, NEW POL PROP SEEKS I; Walensky RP, 2020, ANN INTERN MED, V172, P583, DOI [10.7326/M19-3478, 10.7326/L20-0693]	3	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMp2200601	http://dx.doi.org/10.1056/NEJMp2200601		MAY 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1T8KP	35621521				2023-01-03	WOS:000804975100001
J	Milanini, J; Magdeleine, M; Fuggetta, N; Ikhlef, S; Brau, F; Abelanet, S; Alpy, F; Tomasetto, C; Drin, G				Milanini, Julie; Magdeleine, Maud; Fuggetta, Nicolas; Ikhlef, Souade; Brau, Frederic; Abelanet, Sophie; Alpy, Fabien; Tomasetto, Catherine; Drin, Guillaume			In situ artificial contact sites (ISACS) between synthetic and endogenous organelle membranes allow for quantification of protein-tethering activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; FFAT MOTIF; GOLGI-APPARATUS; BINDING PROTEIN; LIPID TRANSFER; VAP; ER; REQUIRES; STARD3	Membrane contact sites are specialized areas where the membranes of two distinct organelles are physically connected and allow for the exchange of molecules and for signaling processes. Understanding the mechanisms whereby proteins localize to and function in these structures is of special interest; however, methods allowing for reconstitution of these contact sites are few and only based on synthetic membranes and recombinant proteins. Here, we devised a strategy to create in situ artificial contact sites between synthetic and endogenous organelle membranes. Liposomes functionalized with a peptide containing a two phenylalanines in an acidic tract (FFAT) motif were added to adherent cells whose plasma membrane was perforated. Confocal and super-resolution microscopy revealed that these liposomes associated with the endoplasmic reticulum via the specific interaction of the FFAT motif with endoplasmic reticulum-resident vesicle-associated membrane protein-associated proteins. This approach allowed for quantification of the attachment properties of peptides corresponding to FFAT motifs derived from distinct proteins and of a protein construct derived from steroidogenic acute regulatory protein-related lipid transfer domain-3. Collectively, these data indicate that the creation of in situ artificial contact sites represents an efficient approach for studying the membranet-ethering activity of proteins and for designing membrane contact site reconstitution assays in cellular contexts.	[Milanini, Julie; Magdeleine, Maud; Fuggetta, Nicolas; Ikhlef, Souade; Brau, Frederic; Abelanet, Sophie; Drin, Guillaume] Univ Cote Azur, CNRS, Inst Pharmacol Mol & Cellulaire IPMC, Valbonne, France; [Alpy, Fabien; Tomasetto, Catherine] Univ Strasbourg, CNRS, Inst Genet & Biol Mol & Cellulaire IGBMC, U1258,INSERM,UMR7104, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Drin, G (corresponding author), Univ Cote Azur, CNRS, Inst Pharmacol Mol & Cellulaire IPMC, Valbonne, France.	drin@ipmc.cnrs.fr	Tomasetto, Catherine Laure/J-2783-2014	Tomasetto, Catherine Laure/0000-0002-1811-5848; FUGGETTA, Nicolas/0000-0002-8508-3188	CNRS, France; Universite Cote d'Azur, France; Agence Nationale de la Recherche, France [ANR-19-CE44-0003]	CNRS, France(Centre National de la Recherche Scientifique (CNRS)); Universite Cote d'Azur, France; Agence Nationale de la Recherche, France(French National Research Agency (ANR))	We acknowledge the flow cytometry and microscopy facility from the Institut de Pharmacologie Moleculaire et Cellulaire, which is part of the GIS IBiSA platform MICA (Microscopie Imagerie Cote d'Azur). We thank P. Eberling (IGBMC [Institut de Genetique et de Biologie Moleculaire et Cellulaire] peptide synthesis facility) for the peptide syntheses. This work was supported by the CNRS, France; Universite Cote d'Azur, France; and by a grant from the Agence Nationale de la Recherche, France (grant no.: ANR-19-CE44-0003).	Alpy F, 2013, J CELL SCI, V126, P5500, DOI 10.1242/jcs.139295; Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Bian X, 2019, NAT CHEM BIOL, V15, P830, DOI 10.1038/s41589-019-0325-3; Cabukusta B, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108475; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Delfosse V., 2020, CONTACT, V3, DOI DOI 10.1177/2515256420946627; Di Mattia T, 2020, EMBO J, V39, DOI 10.15252/embj.2019104369; Di Mattia T, 2018, EMBO REP, V19, DOI 10.15252/embr.201745453; Eden ER, 2016, DEV CELL, V37, P473, DOI 10.1016/j.devcel.2016.05.005; James C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071780; Janikiewicz J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0105-5; Johnson B, 2019, CHANNELS, V13, P88, DOI 10.1080/19336950.2019.1568824; Kabashi E, 2013, HUM MOL GENET, V22, P2350, DOI 10.1093/hmg/ddt080; Kaiser SE, 2005, STRUCTURE, V13, P1035, DOI 10.1016/j.str.2005.04.010; Kamemura K, 2019, J BIOCHEM, V165, P391, DOI 10.1093/jb/mvz011; Kawano M, 2006, J BIOL CHEM, V281, P30279, DOI 10.1074/jbc.M605032200; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; Li CL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627700; Lipp NF, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00663; Loewen CJR, 2005, J BIOL CHEM, V280, P14097, DOI 10.1074/jbc.M500147200; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Maeda S, 2019, ELIFE, V8, DOI 10.7554/eLife.45777; Magdeleine M, 2016, ELIFE, V5, DOI 10.7554/eLife.16988; Mesmin B, 2013, CELL, V155, P830, DOI 10.1016/j.cell.2013.09.056; Murphy SE, 2016, BBA-MOL CELL BIOL L, V1861, P952, DOI 10.1016/j.bbalip.2016.02.009; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; Osawa T, 2019, NAT STRUCT MOL BIOL, V26, P281, DOI 10.1038/s41594-019-0203-4; Peretti D, 2008, MOL BIOL CELL, V19, P3871, DOI 10.1091/mbc.E08-05-0498; Petkovic M, 2021, GENE DEV, V35, P449, DOI 10.1101/gad.346759.120; Petkovic M, 2014, NAT CELL BIOL, V16, P434, DOI 10.1038/ncb2937; Prinz WA, 2020, NAT REV MOL CELL BIO, V21, P7, DOI 10.1038/s41580-019-0180-9; Saheki Y, 2016, NAT CELL BIOL, V18, P504, DOI 10.1038/ncb3339; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scorrano L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09253-3; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Valverde DP, 2019, J CELL BIOL, V218, P1787, DOI 10.1083/jcb.201811139; Wilhelm LP, 2017, EMBO J, V36, P1412, DOI 10.15252/embj.201695917; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Yadav S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.207985	42	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY	2022	298	5							101780	10.1016/j.jbc.2022.101780	http://dx.doi.org/10.1016/j.jbc.2022.101780			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	4W8EX	35231443	Green Published, gold			2023-01-03	WOS:000860390500002
J	Bernstock, JD; Kang, KD; Klinger, NV; Olsen, HE; Gary, S; Totsch, SK; Ghajar-Rahimi, G; Segar, D; Thompson, EM; Darley-Usmar, V; Mott, BT; Peruzzotti-Jametti, L; Friedman, GK				Bernstock, Joshua D.; Kang, Kyung-Don; Klinger, Neil, V; Olsen, Hannah E.; Gary, Sam; Totsch, Stacie K.; Ghajar-Rahimi, Gelare; Segar, David; Thompson, Eric M.; Darley-Usmar, Victor; Mott, Bryan T.; Peruzzotti-Jametti, Luca; Friedman, Gregory K.			Targeting oncometabolism to maximize immunotherapy in malignant brain tumors	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; ADJUVANT TEMOZOLOMIDE; EMERGING HALLMARKS; GLIOBLASTOMA CELLS; IMMUNE RESISTANCE; POLY-ICLC; IN-VIVO; GLUCOSE; METABOLISM	Brain tumors result in significant morbidity and mortality in both children and adults. Recent data indicate that immunotherapies may offer a survival benefit after standard of care has failed for malignant brain tumors. Modest results from several late phase clinical trials, however, underscore the need for more refined, comprehensive strategies that incorporate new mechanistic and pharmacologic knowledge. Recently, oncometabolism has emerged as an adjunct modality for combinatorial treatment approaches necessitated by the aggressive, refractory nature of high-grade glioma and other progressive malignant brain tumors. Manipulation of metabolic processes in cancer and immune cells that comprise the tumor microenvironment through controlled targeting of oncogenic pathways may be utilized to maximize the efficacy of immunotherapy and improve patient outcomes. Herein, we summarize preclinical and early phase clinical trial research of oncometabolism-based therapeutics that may augment immunotherapy by exploiting the biochemical and genetic underpinnings of brain tumors. We also examine metabolic pathways related to immune cells that target tumor cells, termed "tumor immunometabolism". Specifically, we focus on glycolysis and altered glucose metabolism, including glucose transporters, hexokinase, pyruvate dehydrogenase, and lactate dehydrogenase, glutamine, and we discuss targeting arginase, adenosine, and indoleamine 2,3-dioxygenase, and toll-like receptors. Lastly, we summarize future directions targeting metabolism in combination with emerging therapies such as oncolytic virotherapy, vaccines, and chimeric antigen receptor T cells.	[Bernstock, Joshua D.; Klinger, Neil, V; Olsen, Hannah E.; Segar, David] Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Kang, Kyung-Don; Totsch, Stacie K.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Gary, Sam; Ghajar-Rahimi, Gelare] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA; [Thompson, Eric M.] Duke Univ, Dept Neurosurg, Durham, NC USA; [Darley-Usmar, Victor] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Mott, Bryan T.] Wake Forest Baptist Med Ctr, Dept Neurosurg, Winston Salem, NC USA; [Peruzzotti-Jametti, Luca] Univ Cambridge, Dept Clin Neurosci, Cambridge, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University; University of Alabama System; University of Alabama Birmingham; Wake Forest University; Wake Forest Baptist Medical Center; University of Cambridge	Bernstock, JD (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.	jbernstock@partners.org; gfriedman@peds.uab.edu		Bernstock, Joshua/0000-0002-7814-3867; Ghajar-Rahimi, Gelare/0000-0001-5089-7176; Friedman, Gregory/0000-0002-6653-7420	U.S. Food and Drug Administration [R01FD005379, R01FD006368]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod [2017/B/5]; "5 per mille" public funding; Wellcome Trust CRCD Fellowship [RG G105713]; Addenbrooke's Charitable Trust [RG 97519]; Department of Defense [CA171067]; Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	U.S. Food and Drug Administration; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod(Fondazione Italiana Sclerosi Multipla (FISM)); "5 per mille" public funding; Wellcome Trust CRCD Fellowship(Wellcome Trust); Addenbrooke's Charitable Trust; Department of Defense(United States Department of Defense); Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	GKF is supported by grants from the U.S. Food and Drug Administration (R01FD005379 and R01FD006368), the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, Andrew McDonough B+ Foundation, and Cannonball Kids' cancer Foundation. LP-J has been supported by a senior research fellowship FISM-Fondazione Italiana Sclerosi Multipla-cod. 2017/B/5 and financed or co financed with the "5 per mille" public funding, a Wellcome Trust CRCD Fellowship (RG G105713), and the Addenbrooke's Charitable Trust (RG 97519). EMT is supported by the Department of Defense (CA171067), The Musella Foundation for Brain Tumor Research and Information, and the Pediatric Brain Tumor Foundation. We thank Adam A. Dmytriw for reviewing the manuscript.	Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Bavaresco L, 2008, MOL CELL BIOCHEM, V319, P61, DOI 10.1007/s11010-008-9877-3; Bernstock JD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1678921; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Certo M, 2021, NAT REV IMMUNOL, V21, P151, DOI 10.1038/s41577-020-0406-2; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Cosset E, 2017, CANCER CELL, V32, P856, DOI 10.1016/j.ccell.2017.10.016; Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; DANIELE S, 2015, SCI REP-UK, V5; De Waele J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1407899; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Galluzzi L, 2014, METHOD ENZYMOL, V542, pXIX, DOI 10.1016/B978-0-12-416618-9.10000-7; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grzywa TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00938; GUPTA S, 2017, CANCER RES, V77; Hanihara M, 2016, J NEUROSURG, V124, P1594, DOI 10.3171/2015.5.JNS141901; Hermans D, 2020, P NATL ACAD SCI USA, V117, P6047, DOI 10.1073/pnas.1920413117; Hill BG, 2020, BIOL CHEM, V401, P3, DOI 10.1515/hsz-2019-0268; Huang L, 2018, CELL MOL IMMUNOL, V15, P428, DOI 10.1038/cmi.2018.4; Jiang J, 2019, CANCERS, V11, DOI 10.3390/cancers11060804; Kareva I, 2013, CANCER RES, V73, P2737, DOI 10.1158/0008-5472.CAN-12-3696; Kathagen-Buhmann A, 2016, NEURO-ONCOLOGY, V18, P1219, DOI 10.1093/neuonc/now024; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kees T, 2012, NEURO-ONCOLOGY, V14, P64, DOI 10.1093/neuonc/nor182; Kohanbash G, 2017, J CLIN INVEST, V127, P1425, DOI 10.1172/JCI90644; Krzak G, 2021, TRENDS IMMUNOL, V42, P45, DOI 10.1016/j.it.2020.11.004; Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815; Kyi C, 2018, CLIN CANCER RES, V24, P4937, DOI 10.1158/1078-0432.CCR-17-1866; Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526; Libby CJ, 2018, ACS CHEM BIOL, V13, P2048, DOI 10.1021/acschembio.8b00251; Libby CJ, 2018, BBA-REV CANCER, V1869, P175, DOI 10.1016/j.bbcan.2018.01.004; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Liu FK, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1085-6; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Mehta MM, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0184-5; Mellinghoff I, 2018, NEURO-ONCOLOGY, V20, P234; Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mitsuka K, 2013, NEUROSURGERY, V72, P1031, DOI 10.1227/NEU.0b013e31828cf945; Moesta AK, 2020, NAT REV IMMUNOL, V20, P739, DOI 10.1038/s41577-020-0376-4; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Mooney J, 2019, WORLD NEUROSURG, V129, P90, DOI 10.1016/j.wneu.2019.05.205; Muller S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98791; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Nayak L, 2021, CLIN CANCER RES, V27, P1048, DOI 10.1158/1078-0432.CCR-20-2500; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00304; Olsen Hannah E, 2021, Neurooncol Adv, V3, pvdab027, DOI 10.1093/noajnl/vdab027; Oshima N, 2020, CELL REP, V30, P1798, DOI 10.1016/j.celrep.2020.01.039; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Ott M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134386; PAPADOPOULOS KP, 2017, J CLIN ONCOL, V35; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PEREZ RP, 2017, J CLIN ONCOL, V35; Pollack IF, 2016, NEURO-ONCOLOGY, V18, P1157, DOI 10.1093/neuonc/now026; Rai G, 2020, J MED CHEM, V63, P10984, DOI 10.1021/acs.jmedchem.0c00916; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1; Rogers TW, 2018, J NEURO-ONCOL, V137, P181, DOI 10.1007/s11060-017-2710-7; Rosenfeld MR, 2010, NEURO-ONCOLOGY, V12, P1071, DOI 10.1093/neuonc/noq071; Sanzey M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123544; Sciacovelli M, 2017, CELL DEATH DIFFER, V24, P1, DOI 10.1038/cdd.2016.137; Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247; Sheth S, 2014, INT J MOL SCI, V15, P2024, DOI 10.3390/ijms15022024; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Siu L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001095; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tejera Dalissa, 2020, CNS Oncol, V9, pCNS62, DOI 10.2217/cns-2020-0014; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Totsch SK, 2019, ONCOGENE, V38, P6159, DOI 10.1038/s41388-019-0870-y; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Velpula KK, 2017, ONCOTARGET, V8, P35639, DOI 10.18632/oncotarget.16767; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wicks RT, 2015, NEURO-ONCOLOGY, V17, P70, DOI 10.1093/neuonc/nou143; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Xu S, 2013, NEURO-ONCOLOGY, V15, P1160, DOI 10.1093/neuonc/not067; Yan A, 2019, J NEUROSCI, V39, P4387, DOI 10.1523/JNEUROSCI.1118-18.2019; Yuen Carlen A, 2016, CNS Oncol, V5, P101, DOI 10.2217/cns-2015-0006; Zappasodi R, 2021, NATURE, V591, P652, DOI 10.1038/s41586-021-03326-4; Zhai LJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01185; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou WH, 2019, CANCERS, V11, DOI 10.3390/cancers11091231; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	105	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2663	2671		10.1038/s41388-022-02312-y	http://dx.doi.org/10.1038/s41388-022-02312-y		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35430605	Green Accepted			2023-01-03	WOS:000782888200001
J	Sirois, C; Cullis, P				Sirois, Cheri; Cullis, Pieter			Learning lessons from lipids to make COVID-19 vaccines	CELL			English	Editorial Material								A game-changing intervention in the COVID-19 pandemic has been the rapid implementation of highly effective vaccines against SARS-CoV-2. The 2022 Canada Gairdner International Award recognizes Pieter Cullis, Katalin Kariko, and Drew Weissman "for their pioneering work developing nucleoside-modified mRNA and lipid nanoparticle (LNP) drug delivery: the foundational technologies for the highly effective COVID-19 mRNA vaccines.'' Cell editor Cheri Sirois caught up with Pieter to discuss how a long interest in basic and applied questions in lipid biology led to this fortuitous collaboration. Excerpts of the conversation are presented below.	[Cullis, Pieter] Univ British Columbia, Vancouver, BC, Canada	University of British Columbia									0	1	1	8	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2022	185	8					1279	1282						4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	1V8JR	35385689	Green Published, Bronze			2023-01-03	WOS:000806331300005
J	Moriyama, Y; Yamada, T; Shimamura, R; Ohmi, T; Hirosawa, M; Yamauchi, T; Tazawa, T; Kato, J				Moriyama, Yoshinao; Yamada, Takumi; Shimamura, Ryota; Ohmi, Takehiro; Hirosawa, Masaki; Yamauchi, Tomoyuki; Tazawa, Tomohiro; Kato, Junpei			Movement patterns of the functional reach test do not reflect physical function in healthy young and older participants	PLOS ONE			English	Article							PERFORMANCE-MEASURES; PREDICTIVE-VALIDITY; POSTURAL CONTROL; ELDERLY-WOMEN; FALLS RISK; STRATEGIES; BALANCE; MOBILITY; ADULTS; INDIVIDUALS	The relationship of the Functional Reach Test (FRT) value with the Center of Pressure Excursion (COPE) and physical function remains unclear, and would be influenced by different population characteristics and movement patterns used in the FRT. Therefore, we explored the relationship between the FRT value and the COPE and physical function in healthy young and older individuals classified according to movement patterns. In 21 healthy young participants (42 sides) and 20 older participants (40 sides), three-dimensional motion analysis was performed during the FRT and physical function assessments. The participants were assigned to two clusters after performing a motion analysis during the FRT. Kinematic and kinetic parameters during the FRT and physical function assessment results were compared between the clusters for both groups. Correlation analysis was performed to investigate the relationships of the FRT value with COPE and physical function parameters in each cluster, in young and older individuals separately. The results showed that the hip strategies could be divided into two groups according to the degree of use (Small Hip Strategy, SHS Group; Large Hip Strategy, LHS Group). In the older SHS group, the FRT values were significantly correlated with the COPE (r = 0.75), toe grip strength (r = 0.62), and the five-times sit-to-stand test time (r = -0.52). In the older LHS group and in both groups of young individuals, there were no significant correlations of the FRT value with any parameters. The FRT value reflects the COPE and physical function only in older individuals using the SHS. This could explain previous discrepant results. As there is no simple relationship between the FRT value and physical function, it is important to include movement strategy assessment when using the FRT in clinical evaluations.	[Moriyama, Yoshinao; Shimamura, Ryota; Hirosawa, Masaki] Tokyo Metropolitan Rehabil Hosp, Dept Rehabil, Div Phys Therapy, Tokyo, Japan; [Yamada, Takumi] Tokyo Metropolitan Univ, Fac Hlth Sci, Dept Phys Therapy, Tokyo, Japan; [Ohmi, Takehiro] Tokyo Med & Dent Univ, Clin Ctr Sports Med & Sports Dent, Tokyo, Japan; [Yamauchi, Tomoyuki] Nihon Univ Hosp, Dept Rehabil, Tokyo, Japan; [Tazawa, Tomohiro] Sonodakai Joint Replacement Ctr Hosp, Dept Rehabil, Tokyo, Japan; [Kato, Junpei] NEC Livex Ltd, Karadacare Business Dev Off, Tokyo, Japan	Tokyo Metropolitan University; Tokyo Medical & Dental University (TMDU); Nihon University	Moriyama, Y (corresponding author), Tokyo Metropolitan Rehabil Hosp, Dept Rehabil, Div Phys Therapy, Tokyo, Japan.	moriyamayoshinao2020@gmail.com		Moriyama, Yoshinao/0000-0001-7924-2827; Yamauchi, Tomoyuki/0000-0003-3000-8946				Abiko T., 2018, JPN J HLTH PROMOT PH, V8, P7, DOI [10.9759/hppt.8.7, DOI 10.9759/HPPT.8.7]; ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; Arai T., 2011, J JPN PHYS THER ASS, V38, P489; Behrman AL, 2002, ARCH PHYS MED REHAB, V83, P538, DOI 10.1053/apmr.2002.30934; Bergland A, 2004, INJURY PREV, V10, P308, DOI 10.1136/ip.2003.004721; Bohannon RW, 2006, PERCEPT MOTOR SKILL, V103, P215, DOI 10.2466/PMS.103.1.215-222; Buatois S, 2010, PHYS THER, V90, P550, DOI 10.2522/ptj.20090158; Dai J., 2007, JPN J TEST MEAS HLTH, V7, P37; de Waroquier-Leroy L., 2014, Annals of Physical and Rehabilitation Medicine, V57, P452, DOI 10.1016/j.rehab.2014.03.003; DUNCAN PW, 1992, J GERONTOL, V47, pM93, DOI 10.1093/geronj/47.3.M93; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Fujimoto A, 2015, GERONTOLOGY, V61, P109, DOI 10.1159/000363571; Fujisawa H., 2005, J JPN PHYS THER ASS, V32, P416; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369, DOI 10.1152/jn.1986.55.6.1369; HORAK FB, 1989, NEUROBIOL AGING, V10, P727, DOI 10.1016/0197-4580(89)90010-9; Huang HC, 2003, PUBLIC HEALTH NURS, V20, P399, DOI 10.1046/j.1525-1446.2003.20508.x; Jonsson E, 2003, J REHABIL MED, V35, P26, DOI 10.1080/16501970306099; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Koda H., 2014, JPN J CLIN BIOMECH, V35, P285; Kojima S., 1998, RIGAKURYOHO KAGAKU, V13, P85, DOI [10.1589/rika.13.85, DOI 10.1589/RIKA.13.85]; Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; Maeoka H., 2006, RIGAKURYOHO KAGAKU, V21, P197, DOI [10.1589/rika.21.197, DOI 10.1589/RIKA.21.197]; Makizako H., 2008, SPORTS SCI RES, V5, P71; Maranesi E, 2014, GAIT POSTURE, V39, P501, DOI 10.1016/j.gaitpost.2013.08.035; Mitani Y., 2012, J ALLIED HLTH SCI, V3, P25; Morita M, 2005, AGING CLIN EXP RES, V17, P211; Mourey F, 2000, J GERONTOL A-BIOL, V55, pB425, DOI 10.1093/gerona/55.9.B425; Nakamura I., 2006, RIGAKURYOHO KAGAKU, V21, P335, DOI [10.1589/rika.21.335, DOI 10.1589/RIKA.21.335]; Nakatani T., 2002, JPN J PHYS ED HLTH S, V47, P451, DOI DOI 10.5432/jjpehss.KJ00003390725; OBrien K, 1997, J GERONTOL A-BIOL, V52, pB221, DOI 10.1093/gerona/52A.4.B221; Papa E, 2000, J BIOMECH, V33, P1113, DOI 10.1016/S0021-9290(00)00046-4; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Portnoy S, 2017, EUR J PHYS REHAB MED, V53, P685, DOI 10.23736/S1973-9087.17.04522-1; Rosa MV, 2019, ARCH GERONTOL GERIAT, V81, P149, DOI 10.1016/j.archger.2018.11.015; Sasaki K., 2009, RIGAKURYOHO KAGAKU, V24, P813, DOI [10.1589/rika.24.813, DOI 10.1589/RIKA.24.813]; Satoh Yoshinao, 2019, J Phys Ther Sci, V31, P498, DOI 10.1589/jpts.31.498; SCHENKMAN M, 1990, PHYS THER, V70, P638, DOI 10.1093/ptj/70.10.638; SCHULTZ AB, 1992, J BIOMECH, V25, P1383, DOI 10.1016/0021-9290(92)90052-3; Shumway-Cook A., 2013, MOTOR CONTROL TRANSL; Soma M, 2014, J PHYS THER SCI, V26, P1955, DOI 10.1589/jpts.26.1955; Takasaki K, 2011, J PHYS THER SCI, V23, P773; THAPA PB, 1994, J AM GERIATR SOC, V42, P493, DOI 10.1111/j.1532-5415.1994.tb04970.x; Thomas JI, 2005, ARCH PHYS MED REHAB, V86, P1636, DOI 10.1016/j.apmr.2005.03.004; Tsujino A., 2007, RIGAKURYOHO KAGAKU, V22, P245, DOI [10.1589/rika.22.245, DOI 10.1589/RIKA.22.245]; Tsushima E., 2001, RIGAKURYOHO KAGAKU, V16, P159, DOI [10.1589/rika.16.159, DOI 10.1589/RIKA.16.159]; Uritani D, 2016, J AGING PHYS ACTIV, V24, P459, DOI 10.1123/japa.2015-0123; VELLAS B, 1987, AGE AGEING, V16, P189, DOI 10.1093/ageing/16.3.189; Wallmann HW, 2001, J GERONTOL A-BIOL, V56, pM580, DOI 10.1093/gerona/56.9.M580; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WEINER DK, 1992, J AM GERIATR SOC, V40, P203, DOI 10.1111/j.1532-5415.1992.tb02068.x; Wernick-Robinson M, 1999, ARCH PHYS MED REHAB, V80, P262, DOI 10.1016/S0003-9993(99)90136-3	53	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2022	17	3							e0266195	10.1371/journal.pone.0266195	http://dx.doi.org/10.1371/journal.pone.0266195			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M2UI	35358272	gold, Green Published			2023-01-03	WOS:000799828800077
J	Edwards, AM; Baric, RS; Saphire, EO; Ulmer, JB				Edwards, Aled M.; Baric, Ralph S.; Saphire, Erica Ollmann; Ulmer, Jeffrey B.			Stopping pandemics before they start: Lessons learned from SARS-CoV-2	SCIENCE			English	Review							ACUTE RESPIRATORY SYNDROME; COVID-19; DRUG	The vaccine and drug discovery responses to COVID-19 have worked far better than could have been imagined. Yet by the end of 2021, more than 5 million people had died, and the pandemic continues to evolve and rage globally. This Review will describe how each of the vaccines, antibody therapies, and antiviral drugs that have been approved to date were built on decades of investment in technology and basic science. We will caution that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has so far proven a straightforward test of our pandemic preparedness, and we will recommend steps we should undertake now to prepare for, to minimize the effects of, and ideally to prevent future pandemics. Other Reviews in this series describe the interactions of SARS-CoV-2 with the immune system and those therapies that target the host response to infection.	[Edwards, Aled M.] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada; [Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Rapidly Emerging Antiviral Drug Dev Initiat READD, Chapel Hill, NC 27599 USA; [Saphire, Erica Ollmann] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, 9420 Athena Circle, La Jolla, CA 92037 USA; [Saphire, Erica Ollmann] Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; [Ulmer, Jeffrey B.] TechImmune, Newport Beach, CA 92660 USA; [Ulmer, Jeffrey B.] Immorna Biotherapeut, Durham, NC 27703 USA	University of Toronto; Structural Genomics Consortium; University of North Carolina; University of North Carolina Chapel Hill; La Jolla Institute for Immunology; University of California System; University of California San Diego	Edwards, AM (corresponding author), Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada.	aled.edwards@utoronto.ca		Edwards, Aled/0000-0002-4782-6016; Saphire, Erica Ollmann/0000-0002-1206-7451; Baric, Ralph/0000-0001-6827-8701	NIH [CA260530]; Genome Canada	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genome Canada(Genome Canada)	We acknowledge H. Li and M. Sirvinskas in the preparation of the figures. R.S.B. and A.M.E. acknowledge funding from NIH grant CA260530 and Genome Canada, respectively.	Abramowicz M, 2022, JAMA-J AM MED ASSOC, V327, P384, DOI 10.1001/jama.2021.24931; Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Boras B., 2021, BIORXIV 293498 PREPR; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Changrob S, 2021, MBIO, V12, DOI 10.1128/mBio.02975-21; Choi A, 2021, J VIROL, V95, DOI 10.1128/JVI.01313-21; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1101/2020.06.11.145920, 10.1038/s41586-020-2622-0]; Deeks ED, 2021, DRUGS, V81, P2047, DOI 10.1007/s40265-021-01620-z; DiPiazza AT, 2021, IMMUNITY, V54, P1869, DOI 10.1016/j.immuni.2021.06.018; Dong JH, 2021, NAT MICROBIOL, V6, P1233, DOI 10.1038/s41564-021-00972-2; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Duncan JD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010090; Dunmire G. B, 1893, JAMA-J AM MED ASSOC, V23, P853; Edwards A, 2020, J CHEM INF MODEL, V60, P5727, DOI 10.1021/acs.jcim.0c00861; Fischer WA, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl7430; Garcia-Beltran W. F, CELL, V185; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Gordon CJ, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100770; Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056; Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Hastie KM, 2021, SCIENCE, V374, P472, DOI 10.1126/science.abh2315; Hsieh Ching-Lin, 2020, Science, V369, P1501, DOI [10.1101/2020.05.30.125484, 10.1126/science.abd0826]; Hull MW, 2011, ANN MED, V43, P375, DOI 10.3109/07853890.2011.572905; Jette CA, 2021, CELL REP, V36, DOI [10.1101/2021.04.23.441195, 10.1016/j.celrep.2021.109760]; Kolahchi Z, 2021, ADV EXP MED BIOL, V1318, P825, DOI 10.1007/978-3-030-63761-3_46; Kumar R, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00405-2020; Lee JH, 2021, SEMIN IMMUNOL, V51, DOI 10.1016/j.smim.2021.101470; Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9; Liu Hejun, 2020, Immunity, V53, P1272, DOI [10.1101/2020.08.02.233536, 10.1016/j.immuni.2020.10.023]; Mannar D, 2022, SCIENCE, V375, P760, DOI 10.1126/science.abn7760; Merad M., 2022, SCIENCE, V375, pXXXX; Morris A, 2021, CHEM COMMUN, V57, P5909, DOI 10.1039/d1cc00050k; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nabel K. G., 2022, SCIENCE, V375; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; O'Brien Meagan P, 2021, medRxiv, DOI 10.1101/2021.06.14.21258567; O'Sullivan O, 2021, CLIN MED, V21, pE68, DOI 10.7861/clinmed.2020-0204; Owen DR, 2021, SCIENCE, V374, P1586, DOI 10.1126/science.abl4784; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pavel AB, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.706902; Phetsouphanh C, 2022, NAT IMMUNOL, V23, P210, DOI 10.1038/s41590-021-01113-x; Pinto D, 2021, SCIENCE, V373, P1109, DOI 10.1126/science.abj3321; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Schafer A., 2021, BIORXIV 460111 PREPR; Servellita V, 2022, NAT MICROBIOL, V7, P277, DOI 10.1038/s41564-021-01041-4; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; STOKES J, 1945, JAMA-J AM MED ASSOC, V127, P144, DOI 10.1001/jama.1945.02860030016004; Stuyver LJ, 2003, ANTIMICROB AGENTS CH, V47, P244, DOI 10.1128/AAC.47.1.244-254.2003; Syed YY, 2021, DRUGS, V81, P2133, DOI 10.1007/s40265-021-01626-7; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Thompson Mark G, 2022, MMWR Morb Mortal Wkly Rep, V71, P139, DOI 10.15585/mmwr.mm7104e3; Tonkin-Hill G, 2021, ELIFE, V10, DOI 10.7554/eLife.66857; Tortorici MA, 2021, NATURE, V597, P103, DOI 10.1038/s41586-021-03817-4; Ulmer J. B., 2021, MOL FRONT J, V5, P1; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; von Delft F, 2021, NATURE, V594, P330, DOI 10.1038/d41586-021-01571-1; Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.928996; Ward H, 2021, LANCET, V398, P2057, DOI 10.1016/S0140-6736(21)02444-2; Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; WHO, 2020, WHO TARG PROD PROF C; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0084-5	68	11	11	8	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	2022	375	6585			SI		1133	1139		10.1126/science.abn1900	http://dx.doi.org/10.1126/science.abn1900			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV2SO	35271333				2023-01-03	WOS:000770385500054
J	Bazirete, O; Nzayirambaho, M; Umubyeyi, A; Karangwa, I; Evans, M				Bazirete, Oliva; Nzayirambaho, Manasse; Umubyeyi, Aline; Karangwa, Innocent; Evans, Marilyn			Risk factors for postpartum haemorrhage in the Northern Province of Rwanda: A case control study	PLOS ONE			English	Article							RELATIVE RISK; MANAGEMENT; PREVENTION; OUTCOMES; WOMEN; REGRESSION; DELIVERY; ANEMIA; LABOR; PREVALENCE	Background Postpartum haemorrhage (PPH) remains a major global burden contributing to high maternal mortality and morbidity rates. Assessment of PPH risk factors should be undertaken during antenatal, intrapartum and postpartum periods for timely prevention of maternal morbidity and mortality associated with PPH. The aim of this study is to investigate and model risk factors for primary PPH in Rwanda. Methods We conducted an observational case-control study of 430 (108 cases: 322 controls) pregnant women with gestational age of 32 weeks and above who gave birth in five selected health facilities of Rwanda between January and June 2020. By visual estimation of blood loss, cases of Primary PPH were women who changed the blood-soaked vaginal pads 2 times or more within the first hour after birth, or women requiring a blood transfusion for excessive bleeding after birth. Controls were randomly selected from all deliveries without primary PPH from the same source population. Poisson regression, a generalized linear model with a log link and a Poisson distribution was used to estimate the risk ratio of factors associated with PPH. Results The overall prevalence of primary PPH was 25.2%. Our findings for the following risk factors were: antepartum haemorrhage (RR 3.36, 95% CI 1.80-6.26, P<0.001); multiple pregnancy (RR 1.83; 95% CI 1.11-3.01, P = 0.02) and haemoglobin level <11 gr/dL (RR 1.51, 95% CI 1.00-2.30, P= 0.05). During the intrapartum and immediate postpartum period, the main causes of primary PPH were: uterine atony (RR 6.70, 95% CI 4.78-9.38, P<0.001), retained tissues (RR 4.32, 95% CI 2.87-6.51, P<0.001); and lacerations of genital organs after birth (RR 2.14, 95% CI 1.49-3.09, P<0.001). Coagulopathy was not prevalent in primary PPH. Conclusion Based on our findings, uterine atony remains the foremost cause of primary PPH. As well as other established risk factors for PPH, antepartum haemorrhage and intra uterine fetal death should be included as risk factors in the development and validation of prediction models for PPH. Large scale studies are needed to investigate further potential PPH risk factors.	[Bazirete, Oliva; Nzayirambaho, Manasse; Umubyeyi, Aline] Univ Rwanda, Coll Med & Hlth Sci, Kigali, Rwanda; [Karangwa, Innocent] Univ Cape Town, Cape Town, South Africa; [Evans, Marilyn] Western Univ, London, ON, Canada	University of Rwanda; University of Cape Town; Western University (University of Western Ontario)	Bazirete, O (corresponding author), Univ Rwanda, Coll Med & Hlth Sci, Kigali, Rwanda.	baziretoliva@gmail.com	; Umubyeyi, Aline/G-9485-2019	Bazirete, Oliva/0000-0002-8476-3448; Umubyeyi, Aline/0000-0002-0960-5220	University of Rwanda; Western University through Training Support Access Model Project	University of Rwanda; Western University through Training Support Access Model Project	We acknowledge the University of Rwanda and Western University through Training Support Access Model Project for supporting this research. We would like to thank the administration of Byumba, Nemba, Ruli, Rutongo district hospitals and the in charge of Rutare medicalized health centre for granting us permission to conduct this study. We also acknowledge the research assistants for their support in data collection. Our sincere gratitude goes to Dr. Andrea Nove, technical director at Novametrics in UK for her professional guidance and English editing of the present paper.	Abdul-Kadir R, 2014, TRANSFUSION, V54, P1756, DOI 10.1111/trf.12550; Abera K., 2014, THESIS ADDIS ABABA U; Al-beity FA, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001214; [Anonymous], 2011, ANT HAEM; Atukunda EC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152408; Bazirete O., 2020, J NURSING ED PRACTIC, V11, P66; Bazirete O., 2020, J NURSING ED PRACTIC, V11, P62; Bazirete O, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03389-7; Bishanga DR, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1873-3; Briley A, 2014, BJOG-INT J OBSTET GY, V121, P876, DOI 10.1111/1471-0528.12588; Carter RE, 2005, BIOSTATISTICS, V6, P39, DOI 10.1093/biostatistics/kxh016; Diaz V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010980.pub2; Dildy GA, 2018, CONTEMP OBSTET GYNEC, V63, P22; Dunning T, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0870-7; Edie G., 2016, INT J TROP DIS HLTH, V13, P1; Edwards HM, 2017, AETIOLOGY TREATMENT; Fawcus S, 2019, BEST PRACT RES CL OB, V61, P143, DOI 10.1016/j.bpobgyn.2019.03.009; Frass KA, 2015, ALEX J MED, V51, P333, DOI 10.1016/j.ajme.2014.12.002; Gani N, 2013, J Ayub Med Coll Abbottabad, V25, P81; Gold KJ, 2016, J OBSTET GYNAECOL, V36, P208, DOI 10.3109/01443615.2015.1050646; Goueslard K., 2017, QUALITY PRIMARY CARE, V25, P55; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Hancock A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0653-6; Huang YY, 2016, INT J CLIN EXP MED, V9, P16675; I-Tuporn N., 2019, Siriraj Medical Journal, V71, P110; Ifeadike CO., 2018, J PREGNANCY NEONATAL, V02, P34; Jabbar S, 2019, ANN ABBASI SHAHEED H, V24, P38; James AH, 2012, AM J HEMATOL, V87, pS16, DOI 10.1002/ajh.23156; Kavle JA, 2008, J HEALTH POPUL NUTR, V26, P232; Kebede BA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224579; Kellar S.P., 2013, MUNROS STAT METHODS, V6th; Keller SP., 2013, MUNROS STAT METHODS; Kolola T, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-032960; Kramer MS, 2011, J OBSTET GYNAECOL CA, V33, P810, DOI 10.1016/S1701-2163(16)34984-2; Leduc D, 2018, J OBSTET GYNAECOL CA, V40, pE841, DOI 10.1016/j.jogc.2018.09.024; Lindquist K., 2020, CAN ESTIMATE RELATIV; Lutomski JE, 2012, BJOG-INT J OBSTET GY, V119, P306, DOI 10.1111/j.1471-0528.2011.03198.x; Main EK, 2015, JOGNN-J OBST GYN NEO, V44, P462, DOI 10.1111/1552-6909.12723; Malik A., 2019, CHATTOGRAM MAA O SHI, V18, P23; Marschner IC, 2015, AUST NZ J STAT, V57, P437, DOI 10.1111/anzs.12131; Maslovich MM., 2020, STATPEARLS INTERNET; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mgaya AH, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-241; Milman N, 2011, ANN HEMATOL, V90, P1247, DOI 10.1007/s00277-011-1279-z; Mousa HA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003249.pub3; Muin DA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30687-0; Munshi KS, 2017, INT J REPROD CONTRAC, V7, P205, DOI [10.18203/2320-1770.ijrcog20175846, DOI 10.18203/2320-1770.IJRCOG20175846]; Nakagawa K., 2016, CRITICAL CARE OBSTET, V2, P1; National Institute of Statistics of Rwanda (NISR) [Rwanda] Ministry of Health (MOH) [Rwanda] ICF International, 2020, RWAND DEM HLTH SURV; Nelissen E, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1481-7; Ngwenya S, 2016, INT J WOMENS HEALTH, V8, P647, DOI 10.2147/IJWH.S119232; NISR Ministry of Finance Economic Planning/Rwanda Ministry of Health/Rwanda ICF International, 2016, RWAND DEM HLTH SURV; Nyflot LT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175306; Nyflot LT, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-016-1217-0; Ononge S, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0154-8; Organization WH, 2016, WHO REC SYMPH FUND H; Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9; PPH CPG Work Group Association of Ontario Midwives, 2016, CLIN PRACTICE GUIDEL; Reinebrant HE, 2018, BJOG-INT J OBSTET GY, V125, P212, DOI 10.1111/1471-0528.14971; Rocha EA, 2015, INT J GYNECOL OBSTET, V128, P131, DOI 10.1016/j.ijgo.2014.08.023; Rodrigo MRR, 2016, J EVOL MED DENT SCI-, V5, P3345, DOI 10.14260/jemds/2016/753; Rwanda Association of Midwives International Confederation of Midwives Novametrics, 2020, 50000 HAPP BIRTHD PR; Rwanda Biomedical Center, 2020, EM OBS NEWB CAR EMON; Rwanda Ministry of Health, 2016, FORM CONT SOINS OBST, P1; Rwanda Ministry of Health, 2015, KWIT KU MUG UTW UW N; Rwanda Ministry of Health, 2019, SERV PACK UPGR HLTH; Sayinzoga F, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009734; Sedgwick P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1185; Setia MS, 2016, INDIAN J DERMATOL, V61, P146, DOI 10.4103/0019-5154.177773; Sheldon WR, 2014, BJOG-INT J OBSTET GY, V121, P5, DOI 10.1111/1471-0528.12636; Silver RM, 2007, AM J OBSTET GYNECOL, V196, P433, DOI 10.1016/j.ajog.2006.11.041; Sittiparn Wanicha, 2017, Journal of the Medical Association of Thailand, V100, P382; Song JW, 2010, PLAST RECONSTR SURG, V126, P2234, DOI 10.1097/PRS.0b013e3181f44abc; StataCorp, 2017, STATA STAT SOFTWARE, DOI DOI 10.2307/2234838; Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9; Strutz KL, 2012, J ADOLESCENT HEALTH, V51, P629, DOI 10.1016/j.jadohealth.2012.03.013; Temesgen MA., 2017, J WOMENS HLTH CARE, V6, P391, DOI [10.4172/2167-0420.1000391, DOI 10.4172/2167-0420.1000391]; Tenaw Z, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1480-8; Tidy C, 2019, GRAVIDITY PARITY DEF; Tort J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0669-y; Traore Y., 2018, OPEN J OBSTET GYNECO, V8, P1; United Nations, 2019, WORLD POP AG 2019, DOI 10.18356/9df3caed-en; United Nations, ARES7012016ARES701 U; Vogel JP, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001466; Weeks A, 2015, BJOG-INT J OBSTET GY, V122, P202, DOI 10.1111/1471-0528.13098; Weir C.B., 2022, STATPEARLS; Wemakor A, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2644-5; WHO, 2016, WHO TECH REP SER, V997, P1; World Health Organization, 2019, MAT MORT; World Health Organization, 2014, ACT MAN 3 STAG LAB N; World Health Organization, 2012, WHO REC PREV TREATM; World Health Organization (WHO), 2011, EV QUAL CAR SEV PREG; YENIPINAR A., 2019, BSJ ENG SCI, V2, P16; Yeung SW, 2012, AUST NZ J OBSTET GYN, V52, P167, DOI 10.1111/j.1479-828X.2011.01401.x; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	95	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2022	17	2							e0263731	10.1371/journal.pone.0263731	http://dx.doi.org/10.1371/journal.pone.0263731			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P8AU	35167600	gold, Green Published			2023-01-03	WOS:000802227200017
J	Marshall, V; Jewett-Tennant, J; Shell-Boyd, J; Stevenson, L; Hearns, R; Gee, J; Schaub, K; LaForest, S; Taveira, TH; Cohen, L; Parent, M; Dev, S; Barrette, A; Oliver, K; Wu, WC; Ball, SL				Marshall, Vanessa; Jewett-Tennant, Jeri; Shell-Boyd, Jeneen; Stevenson, Lauren; Hearns, Rene; Gee, Julie; Schaub, Kimberley; LaForest, Sharon; Taveira, Tracey H.; Cohen, Lisa; Parent, Melanie; Dev, Sandesh; Barrette, Amy; Oliver, Karen; Wu, Wen-Chih; Ball, Sherry L.			Healthcare providers experiences with shared medical appointments for heart failure	PLOS ONE			English	Article							MANAGEMENT	Shared medical appointments (SMAs) offer a means for providing knowledge and skills needed for chronic disease management to patients. However, SMAs require a time and attention investment from health care providers, who must understand the goals and potential benefits of SMAs from the perspective of patients and providers. To better understand how to gain provider engagement and inform future SMA implementation, qualitative inquiry of provider experience based on a knowledge-attitude-practice model was explored. Semistructured interviews were conducted with 24 health care providers leading SMAs for heart failure at three Veterans Administration Medical Centers. Rapid matrix analysis process techniques including team-based qualitative inquiry followed by stakeholder validation was employed. The interview guide followed a knowledge-attitude-practice model with a priori domains of knowledge of SMA structure and content (understanding of how SMAs were structured), SMA attitude/beliefs (general expectations about SMA use), attitudes regarding how leading SMAs affected patients, and providers. Data regarding the patient referral process (organizational processes for referring patients to SMAs) and suggested improvements were collected to further inform the development of SMA implementation best practices. Providers from all three sites reported similar knowledge, attitude and beliefs of SMAs. In general, providers reported that the multi-disciplinary structure of SMAs was an effective strategy towards improving clinical outcomes for patients. Emergent themes regarding experiences with SMAs included improved self-efficacy gained from real-time collaboration with providers from multiple disciplines, perceived decrease in patient re-hospitalizations, and promotion of self-management skills for patients with HF. Most providers reported that the SMA-setting facilitated patient learning by providing opportunities for the sharing of experiences and knowledge. This was associated with the perception of increased comradery and support among patients. Future research is needed to test suggested improvements and to develop best practices for training additional sites to implement HF SMA.	[Marshall, Vanessa; Shell-Boyd, Jeneen; Stevenson, Lauren; Hearns, Rene; Gee, Julie; Schaub, Kimberley; LaForest, Sharon; Ball, Sherry L.] VA Northeast Ohio Healthcare Syst, Res, Cleveland, OH 44106 USA; [Marshall, Vanessa] Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA; [Marshall, Vanessa] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Jewett-Tennant, Jeri] Ctr Hlth Affairs, Hlth Syst Educ Opioid Data Act 2, Cleveland, OH USA; [Taveira, Tracey H.; Cohen, Lisa; Parent, Melanie; Barrette, Amy; Oliver, Karen; Wu, Wen-Chih] Providence VA Med Ctr, Med, Providence, RI USA; [Taveira, Tracey H.; Cohen, Lisa; Wu, Wen-Chih] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA; [Taveira, Tracey H.; Wu, Wen-Chih] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA; [Dev, Sandesh; Wu, Wen-Chih] Southern Arizona VA Hlth Care Syst, Med, Tucson, AZ USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; University of Rhode Island; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Ball, SL (corresponding author), VA Northeast Ohio Healthcare Syst, Res, Cleveland, OH 44106 USA.	sherry.ball@va.gov		Milfred-LaForest, Sherry/0000-0003-4076-186X	VA HSRD [IIR 14-293]	VA HSRD	This work was supported by the VA HSRD https://www.hsrd.research.va.gov/Merit Review Grant IIR 14-293 to W-CW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alzghoul Bashar I, 2015, Glob J Health Sci, V8, P154, DOI 10.5539/gjhs.v8n6p154; Averill JB, 2002, QUAL HEALTH RES, V12, P855, DOI 10.1177/104973230201200611; Beebe J., 2001, RAPID ASSESSMENT PRO; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Cohen Lisa B, 2017, J Patient Exp, V4, P169, DOI 10.1177/2374373517714452; De Vries B, 2008, J AM ACAD NURSE PRAC, V20, P163, DOI 10.1111/j.1745-7599.2007.00300.x; Dickman K, 2012, J AM ACAD NURSE PRAC, V24, P43, DOI 10.1111/j.1745-7599.2011.00660.x; Edelman D, 2015, J GEN INTERN MED, V30, P99, DOI 10.1007/s11606-014-2978-7; Egger G, 2015, AUST FAM PHYSICIAN, V44, P674; Higuita-Gutierrez LF, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09971-0; Gale RC, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0853-y; Halatchev IG, 2020, OPEN HEART, V7, DOI 10.1136/openhrt-2019-001221; Hanailton AB, 2019, PSYCHIAT RES, V280, DOI 10.1016/j.psychres.2019.112516; Herrman JW, 2012, MCN-AM J MATERN-CHIL, V37, P19, DOI 10.1097/NMC.0b013e3182385204; Jonkman NH, 2016, CIRCULATION, V133, P1189, DOI 10.1161/CIRCULATIONAHA.115.018006; Kelly F, 2019, CHRONIC ILLN, V15, P3, DOI 10.1177/1742395317731608; Kirsh S, 2007, QUAL SAF HEALTH CARE, V16, P349, DOI 10.1136/qshc.2006.019158; Kirsh SR, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2064-z; Noffsinger EB, 2000, PERM J, V4, P99; Nuti SV, 2016, JAMA-J AM MED ASSOC, V315, P582, DOI 10.1001/jama.2016.0278; Nwosu N, 2020, West Afr J Med, V37, P783; Quinones AR, 2014, PATIENT EDUC COUNS, V95, P3, DOI 10.1016/j.pec.2013.12.021; Thompson-Lastad Ariana, 2020, Glob Adv Health Med, V9, p2164956120973979, DOI 10.1177/2164956120973979; Trento M, 2004, DIABETES CARE, V27, P670, DOI 10.2337/diacare.27.3.670; Tsiamparlis-Wildeboer AHC, 2020, PATIENT EDUC COUNS, V103, P1667, DOI 10.1016/j.pec.2020.03.006; Wadsworth KH, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0972-1; Wu WC, 2018, CONTEMP CLIN TRIALS, V71, P140, DOI 10.1016/j.cct.2018.06.015	27	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2022	17	2							e0263498	10.1371/journal.pone.0263498	http://dx.doi.org/10.1371/journal.pone.0263498			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1U6OX	35130320	gold, Green Published			2023-01-03	WOS:000805530700033
J	Shiba, M; Kato, T; Morimoto, T; Yaku, H; Inuzuka, Y; Tamaki, Y; Ozasa, N; Seko, Y; Yamamoto, E; Yoshikawa, Y; Kitai, T; Yamashita, Y; Iguchi, M; Nagao, K; Kawase, Y; Morinaga, T; Toyofuku, M; Furukawa, Y; Ando, K; Kadota, K; Sato, Y; Nakagawa, Y; Kuwahara, K; Kimura, T				Shiba, Masayuki; Kato, Takao; Morimoto, Takeshi; Yaku, Hidenori; Inuzuka, Yasutaka; Tamaki, Yodo; Ozasa, Neiko; Seko, Yuta; Yamamoto, Erika; Yoshikawa, Yusuke; Kitai, Takeshi; Yamashita, Yugo; Iguchi, Moritake; Nagao, Kazuya; Kawase, Yuichi; Morinaga, Takashi; Toyofuku, Mamoru; Furukawa, Yutaka; Ando, Kenji; Kadota, Kazushige; Sato, Yukihito; Nakagawa, Yasuaki; Kuwahara, Koichiro; Kimura, Takeshi			Changes in BNP levels from discharge to 6-month visit predict subsequent outcomes in patients with acute heart failure	PLOS ONE			English	Article							BRAIN NATRIURETIC PEPTIDE; STATE	Background This study aimed to investigate the association between changes in brain natriuretic peptide (BNP) from discharge to 6-month visit and subsequent clinical outcomes in patients with acute heart failure (AHF). Methods Among 1246 patients enrolled in the prospective longitudinal follow-up study nested from the Kyoto Congestive Heart Failure registry, this study population included 446 patients with available paired BNP data at discharge and 6-month index visit. This study population was classified into 3 groups by percent change in BNP from discharge to 6-month visit; the low tertile (<= -44%, N = 149), the middle tertile (>-44% and <= 22%, N = 149) and the high tertile (>22%, N = 148). Findings The cumulative 180-day incidence after the index visit of the primary outcome measure (a composite endpoint of all-cause death or hospitalization for HF) was significantly higher in the high and middle tertiles than in the low tertile (26.8% and 14.4% versus 6.9%, log-rank P<0.0001). The adjusted excess risk of the high tertile relative to the low tertile remained significant for the primary outcome measure (hazard ratio: 3.43, 95% confidence interval: 1.51-8.46, P = 0.003). Conclusions Percent change in BNP was associated with a subsequent risk for a composite of all-cause death and hospitalization for HF after adjustment of the absolute BNP values, suggesting that observing the change in BNP levels, in addition to absolute BNP levels themselves, helps us to manage patient with HF.	[Shiba, Masayuki; Kato, Takao; Ozasa, Neiko; Seko, Yuta; Yamamoto, Erika; Yoshikawa, Yusuke; Yamashita, Yugo; Nakagawa, Yasuaki; Kimura, Takeshi] Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan; [Yaku, Hidenori] Mitsubishi Kyoto Hosp, Dept Cardiol, Kyoto, Japan; [Inuzuka, Yasutaka] Shiga Gen Hosp, Cardiovasc Med, Moriyama, Japan; [Tamaki, Yodo] Tenri Hosp, Div Cardiol, Tenri, Nara, Japan; [Kitai, Takeshi] Natl Cerebral & Cardiovasc Ctr, Div Heart Failure, Suita, Osaka, Japan; [Iguchi, Moritake] Natl Hosp Org Kyoto Med Ctr, Dept Cardiol, Kyoto, Japan; [Nagao, Kazuya] Osaka Red Cross Hosp, Dept Cardiol, Osaka, Japan; [Kawase, Yuichi; Kadota, Kazushige] Kurashiki Cent Hosp, Dept Cardiol, Kurashiki, Okayama, Japan; [Morinaga, Takashi; Ando, Kenji] Kokura Mem Hosp, Dept Cardiol, Kokura, Japan; [Toyofuku, Mamoru] Japanese Red Cross Wakayama Med Ctr, Dept Cardiol, Wakayama, Japan; [Furukawa, Yutaka] Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Med, Kobe, Hyogo, Japan; [Sato, Yukihito] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Cardiol, Amagasaki, Hyogo, Japan; [Kuwahara, Koichiro] Shinshu Univ, Dept Cardiovasc Med, Grad Sch Med, Nagano, Japan	Kyoto University; Hyogo College of Medicine; Tenri Hospital; National Cerebral & Cardiovascular Center - Japan; Osaka Red Cross Hospital; Kurashiki Central Hospital; Kokura Memorial Hospital; Kobe City Medical Center General Hospital; Shinshu University	Kato, T (corresponding author), Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan.	tkato75@kuhp.kyoto-u.ac.jp	Kuwahara, Koichiro/AFK-1723-2022	Kuwahara, Koichiro/0000-0003-2670-7170; Kato, Takao/0000-0001-8213-7999; Yoshikawa, Yusuke/0000-0001-8082-2036				Bettencourt P, 2021, JACEP OPEN, V2, DOI 10.1002/emp2.12448; Cioffi G, 2005, EUR J HEART FAIL, V7, P1040, DOI 10.1016/j.ejheart.2004.11.003; Clerico A, 2015, CLIN CHIM ACTA, V443, P17, DOI 10.1016/j.cca.2014.06.003; Farmakis D, 2020, EUR HEART J, V41, P4050, DOI 10.1093/eurheartj/ehaa083; Franzini M, 2013, CLIN CHIM ACTA, V424, P287, DOI 10.1016/j.cca.2013.07.001; Gheorghiade M, 2005, CIRCULATION, V112, P3958, DOI 10.1161/CIRCULATIONAHA.105.590091; Grodin JL, 2019, J CARD FAIL, V25, P703, DOI 10.1016/j.cardfail.2019.04.002; Hamatani Y, 2018, AM J CARDIOL, V121, P731, DOI 10.1016/j.amjcard.2017.12.012; Kagiyama N, 2019, J CARD FAIL, V25, P712, DOI 10.1016/j.cardfail.2019.04.004; Khanam SS, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0632-0; Madamanchi C, 2014, INT J CARDIOL, V176, P611, DOI 10.1016/j.ijcard.2014.08.007; Maeda K, 1998, AM HEART J, V135, P825, DOI 10.1016/S0002-8703(98)70041-9; Maisel A, 2008, EUR J HEART FAIL, V10, P824, DOI 10.1016/j.ejheart.2008.07.014; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Perez-Rodon J, 2018, J CARDIOL, V71, P505, DOI 10.1016/j.jjcc.2017.10.019; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Pugliese NR, 2017, AM J CARDIOL, V119, P71, DOI 10.1016/j.amjcard.2016.09.018; Roberts E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h910; Salah K, 2019, HEART, V105, P1182, DOI 10.1136/heartjnl-2018-314173; Seko Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24875-1; Tsutsui H, 2019, CIRC J, V83, P2084, DOI 10.1253/circj.CJ-19-0342; Yaku H, 2018, CIRC J, V82, P2811, DOI 10.1253/circj.CJ-17-1386; Yamamoto E, 2017, ESC HEART FAIL, V4, P216, DOI 10.1002/ehf2.12138; Zhang J, 2018, INT J CARDIOL, V269, P196, DOI 10.1016/j.ijcard.2018.06.070; Zile MR, 2016, J AM COLL CARDIOL, V68, P2425, DOI 10.1016/j.jacc.2016.09.931	25	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2022	17	1							e0263165	10.1371/journal.pone.0263165	http://dx.doi.org/10.1371/journal.pone.0263165			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT4WP	35089974	Green Published, gold			2023-01-03	WOS:000769158400042
J	Kapuy, O; Korcsmaros, T				Kapuy, Orsolya; Korcsmaros, Tamas			Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; MAMMALIAN AUTOPHAGY; SIGNALING PATHWAYS; HYDROXYCHLOROQUINE; INHIBITION; INDUCTION; MECHANISM; DYNAMICS	The COVID-19 pandemic caused by SARS-CoV-2 has resulted in an urgent need for identifying potential therapeutic drugs. In the first half of 2020 tropic antimalarial drugs, such as chloroquine (CQ) or hydroxochloroquine (HCQ) were the focus of tremendous public attention. In the initial periods of the pandemic, many scientific results pointed out that CQ/HCQ could be very effective for patients with severe COVID. While CQ and HCQ have successfully been used against several diseases (such as malaria, autoimmune disease and rheumatic illnesses); long term use of these agents are associated with serious adverse effects (i.e. inducing acute kidney injury, among many others) due to their role in blocking autophagy-dependent self-degradation. Recent experimental and clinical trial data also confirmed that there is no sufficient evidence about the efficient usage of CQ/HCQ against COVID-19. By using systems biology techniques, here we show that the cellular effect of CQ/HCQ on autophagy during endoplasmic reticulum (ER) stress or following SARS-CoV-2 infection results in upregulation of ER stress. By presenting a simple mathematical model, we claim that although CQ/HCQ might be able to ameliorate virus infection, the permanent inhibition of autophagy by CQ/HCQ has serious negative effects on the cell. Since CQ/HCQ promotes apoptotic cell death, here we confirm that addition of CQ/HCQ cannot be really effective even in severe cases. Only a transient treatment seemed to be able to avoid apoptotic cell death, but this type of therapy could not limit virus replication in the infected host. The presented theoretical analysis clearly points out the utility and applicability of systems biology modelling to test the cellular effect of a drug targeting key major processes, such as autophagy and apoptosis. Applying these approaches could decrease the cost of pre-clinical studies and facilitate the selection of promising clinical trials in a timely fashion.	[Kapuy, Orsolya] Semmelweis Univ, Inst Biochem & Mol Biol, Dept Mol Biol, Budapest, Hungary; [Korcsmaros, Tamas] Norwich Res Pk, Earlham Inst, Norwich, Norfolk, England; [Korcsmaros, Tamas] Norwich Res Pk, Quadram Inst Biosci, Norwich, Norfolk, England	Semmelweis University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Earlham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute	Kapuy, O (corresponding author), Semmelweis Univ, Inst Biochem & Mol Biol, Dept Mol Biol, Budapest, Hungary.	kapuy.orsolya@med.semmelweis-univ.hu	Korcsmaros, Tamas/C-3526-2015	Korcsmaros, Tamas/0000-0003-1717-996X	National Research, Development and Innovation Fund of Hungary [FK 134267]; Earlham Institute (Norwich, UK); Quadram Institute (Norwich, UK); UKRI BBSRC UK [BB/CSP17270/1]; BBSRC [BB/R012490/1, BBS/E/F/000PR10353, BBS/E/F/000PR10355]	National Research, Development and Innovation Fund of Hungary; Earlham Institute (Norwich, UK); Quadram Institute (Norwich, UK); UKRI BBSRC UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The work of O.K. was financially supported by the National Research, Development and Innovation Fund of Hungary under Grant FK 134267. The work of T.K. was supported by the Earlham Institute (Norwich, UK) in partnership with the Quadram Institute (Norwich, UK) and strategically supported by a UKRI BBSRC UK grant (BB/CSP17270/1). T.K. was also supported by a BBSRC ISP grant for Gut Microbes and Health BB/R012490/1 and its constituent projects, BBS/E/F/000PR10353 and BBS/E/F/000PR10355. The authors thank Dr. John Thomas for critical reading of the revised version of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7; Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; [Anonymous], 1994, NONLINEAR DYNAMICS C, V11; Aoe T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01095; Banerjee A, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117842; Bansal P, 2021, ANN MED, V53, P117, DOI 10.1080/07853890.2020.1839959; Bonam SR, 2020, AUTOPHAGY, V16, P2260, DOI 10.1080/15548627.2020.1779467; Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887; Calabrese LH, 2020, CLEV CLIN J MED, V87, P389, DOI 10.3949/ccjm.87a.ccc008; Ceriello A, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108151; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Chen Y, 2021, INT J BIOL SCI, V17, P1538, DOI 10.7150/ijbs.59547; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Cortegiani A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02932-4; Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005; Demeter A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67780-2; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Eskelinen EL, 2019, INT J BIOCHEM CELL B, V111, P1, DOI 10.1016/j.biocel.2019.03.010; FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5; Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Hashem AM, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101735; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Holczer M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/319589; Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kamat S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.576093; Kapuy O., 2014, COMPUTATIONAL MOL BI, V4, P28, DOI [10.4236/cmb.2014.41003, DOI 10.4236/CMB.2014.41003]; Kapuy O, 2014, FEBS OPEN BIO, V4, P704, DOI 10.1016/j.fob.2014.07.006; Khuroo MS, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106101; Lai YJ, 2020, J CHIN MED ASSOC, V83, P812, DOI 10.1097/JCMA.0000000000000362; Legido-Quigley H, 2020, LANCET, V395, P848, DOI 10.1016/S0140-6736(20)30551-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li SF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00334-0; Marton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010058; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Miller K, 2020, AUTOPHAGY, V16, P2131, DOI 10.1080/15548627.2020.1817280; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Ratre YK, 2021, 3 BIOTECH, V11, DOI 10.1007/s13205-021-02657-3; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Sargazi S, 2021, CELL BIOL INT, V45, P1598, DOI 10.1002/cbin.11609; Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x; Schrezenmeier EV, 2020, CURR OPIN RHEUMATOL, V32, P449, DOI 10.1097/BOR.0000000000000731; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Stamenkovic M, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172540; Strogatz SH, 2015, NONLINEAR DYNAMICS C, Vsecond, DOI DOI 10.1201/9780429492563; Tarighi P, 2021, EUR J PHARMACOL, V895, DOI 10.1016/j.ejphar.2021.173890; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; Tyson JJ, 2010, ANNU REV PHYS CHEM, V61, P219, DOI 10.1146/annurev.physchem.012809.103457; Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Varisli L, 2020, IMMUNOLOGY, V159, P257, DOI 10.1111/imm.13160; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	62	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266337	10.1371/journal.pone.0266337	http://dx.doi.org/10.1371/journal.pone.0266337			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390060	Green Published, gold			2023-01-03	WOS:000795077200058
J	Kanjanabuch, T; Nopsopon, T; Chatsuwan, T; Purisinsith, S; Johnson, DW; Udomsantisuk, N; Halue, G; Lorvinitnun, P; Puapatanakul, P; Pongpirul, K; Poonvivatchaikarn, U; Tatiyanupanwong, S; Chowpontong, S; Chieochanthanakij, R; Thamvichitkul, O; Treamtrakanpon, W; Saikong, W; Parinyasiri, U; Chuengsaman, P; Dandecha, P; Perl, J; Tungsanga, K; Eiam-Ong, S; Sritippayawan, S; Kantachuvesiri, S				Kanjanabuch, Talerngsak; Nopsopon, Tanawin; Chatsuwan, Tanittha; Purisinsith, Sirirat; Johnson, David W.; Udomsantisuk, Nibondh; Halue, Guttiga; Lorvinitnun, Pichet; Puapatanakul, Pongpratch; Pongpirul, Krit; Poonvivatchaikarn, Ussanee; Tatiyanupanwong, Sajja; Chowpontong, Saowalak; Chieochanthanakij, Rutchanee; Thamvichitkul, Oranan; Treamtrakanpon, Worapot; Saikong, Wadsamon; Parinyasiri, Uraiwan; Chuengsaman, Piyatida; Dandecha, Phongsak; Perl, Jeffrey; Tungsanga, Kriang; Eiam-Ong, Somchai; Sritippayawan, Suchai; Kantachuvesiri, Surasak		Advisory Board Peritoneal Dialysis; Nephrology Soc Thailand	Predictors and outcomes of peritoneal dialysis-related infections due to filamentous molds (MycoPDICS)	PLOS ONE			English	Article							FUNGAL PERITONITIS; MICROBIOLOGY; EXPERIENCE	Introduction We sought to evaluate the predictors and outcomes of mold peritonitis in patients with peritoneal dialysis (PD). Methods This cohort study included PD patients from the MycoPDICS database who had fungal peritonitis between July 2015-June 2020. Patient outcomes were analyzed by Kaplan Meier curves and the Log-rank test. Multivariable Cox proportional hazards model regression was used to estimating associations between fungal types and patients' outcomes. Results The study included 304 fungal peritonitis episodes (yeasts n = 129, hyaline molds n = 122, non-hyaline molds n = 44, and mixed fungi n = 9) in 303 patients. Fungal infections were common during the wet season (p < 0.001). Mold peritonitis was significantly more frequent in patients with higher hemoglobin levels, presentations with catheter problems, and positive galactomannan (a fungal cell wall component) tests. Patient survival rates were lowest for non-hyaline mold peritonitis. A higher hazard of death was significantly associated with leaving the catheter in-situ (adjusted hazard ratio [HR] = 6.15, 95%confidence interval [CI]: 2.86-13.23) or delaying catheter removal after the diagnosis of fungal peritonitis (HR = 1.56, 95%CI: 1.00-2.44), as well as not receiving antifungal treatment (HR = 2.23, 95%CI: 1.25-4.01) or receiving it for less than 2 weeks (HR = 2.13, 95%CI: 1.33-3.43). Each additional day of antifungal therapy beyond the minimum 14-day duration was associated with a 2% lower risk of death (HR = 0.98, 95%CI: 0.95-0.999). Conclusion Non-hyaline-mold peritonitis had worse survival. Longer duration and higher daily dosage of antifungal treatment were associated with better survival. Deviations from the 2016 ISPD Peritonitis Guideline recommendations concerning treatment duration and catheter removal timing were independently associated with higher mortality.	[Kanjanabuch, Talerngsak; Puapatanakul, Pongpratch; Tungsanga, Kriang; Eiam-Ong, Somchai] Dept Med, Div Nephrol, Bangkok, Thailand; [Kanjanabuch, Talerngsak] Ctr Excellence Kidney Metab Disorders, Bangkok, Thailand; [Kanjanabuch, Talerngsak; Puapatanakul, Pongpratch] King Chulalongkorn Mem Hosp, Peritoneal Dialysis Excellent Ctr, Bangkok, Thailand; [Kanjanabuch, Talerngsak] Dialysis Policy & Practice Program Di3P, Bangkok, Thailand; [Nopsopon, Tanawin; Pongpirul, Krit] Dept Prevent & Social Med, Bangkok, Thailand; [Chatsuwan, Tanittha; Udomsantisuk, Nibondh] Dept Microbiol, Bangkok, Thailand; [Chatsuwan, Tanittha] Chulalongkorn Univ, Fac Med, Antimicrobial Resistance & Stewardship Res Unit, Bangkok, Thailand; [Purisinsith, Sirirat] Bangkok Metropolitan Adm, Hlth Dept, Bangkok, Thailand; [Johnson, David W.] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia; [Johnson, David W.] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia; [Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia; [Halue, Guttiga] Phayao Hosp, Dept Med, Phayao, Thailand; [Lorvinitnun, Pichet] Sunpasitthiprasong Hosp, Dept Med, Ubon Ratchathani, Thailand; [Poonvivatchaikarn, Ussanee] Nakhon Pathom Hosp, Nephrol Clin, Nakhon Pathom, Thailand; [Tatiyanupanwong, Sajja] Chaiyaphum Hosp, Dept Internal Med, Nephrol Div, Chaiyaphum, Thailand; [Chowpontong, Saowalak] Phra Nakhon Si Ayutthaya Hosp, Dept Med, Div Nephrol, Phra Nakhon Si Ayutthaya, Thailand; [Chieochanthanakij, Rutchanee] Sawanpracharak Hosp, Dialysis Unit, Nakhon Sawan, Thailand; [Thamvichitkul, Oranan] Sisaket Hosp, Dialysis Unit, Sisaket, Thailand; [Treamtrakanpon, Worapot] Chaophraya Abhaibhubejhr Hosp, Dept Med, Prachin Buri, Thailand; [Saikong, Wadsamon] Mukdahan Hosp, Continuous Ambulatory Peritoneal Dialysis Clin, Mukdahan, Thailand; [Parinyasiri, Uraiwan] Songkhla Hosp, Dept Internal Med, Kidney Dis Clin, Songkhla, Thailand; [Chuengsaman, Piyatida] Banphaeo Hosp Publ Org, Banphaeo Dialysis Grp Bangkok, Bangkok, Thailand; [Dandecha, Phongsak] Prince Songkla Univ, Fac Med, Dept Internal Med, Div Nephrol, Hat Yai, Thailand; [Perl, Jeffrey] St Michaels Hosp, Toronto, ON, Canada; [Sritippayawan, Suchai] Mahidol Univ, Siriraj Hosp, Fac Med, Div Nephrol, Bangkok, Thailand; [Kantachuvesiri, Surasak] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Nephrol, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; University of Queensland; Prince of Songkla University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Mahidol University; Mahidol University	Kanjanabuch, T (corresponding author), Dept Med, Div Nephrol, Bangkok, Thailand.; Kanjanabuch, T (corresponding author), Ctr Excellence Kidney Metab Disorders, Bangkok, Thailand.; Kanjanabuch, T (corresponding author), King Chulalongkorn Mem Hosp, Peritoneal Dialysis Excellent Ctr, Bangkok, Thailand.; Kanjanabuch, T (corresponding author), Dialysis Policy & Practice Program Di3P, Bangkok, Thailand.	Talerngsak.K@chula.ac.th	Nopsopon, Tanawin/GOJ-7774-2022; Pongpirul, Krit/H-4064-2019; Johnson, David/F-2897-2011	Nopsopon, Tanawin/0000-0003-0428-973X; Pongpirul, Krit/0000-0003-3818-9761; Johnson, David/0000-0001-5491-3460	Thailand Science research and Innovation Fund Chulalongkorn University [CU_FRB65_hea (19) _026_30_07]; Chulalongkorn University, Thailand; National Research Council of Thailand [156/2560]; Thailand Research Foundation [IRG5780017]	Thailand Science research and Innovation Fund Chulalongkorn University; Chulalongkorn University, Thailand(Chulalongkorn University); National Research Council of Thailand(National Research Council of Thailand (NRCT)); Thailand Research Foundation	This study was supported by the Thailand Science research and Innovation Fund Chulalongkorn University CU_FRB65_hea (19) _026_30_07, Chulalongkorn University, Thailand, the National Research Council of Thailand (156/2560), and Thailand Research Foundation (IRG5780017).	Abbott KC, 2001, NEPHRON, V89, P426, DOI 10.1159/000046115; Auricchio S, 2018, CLIN KIDNEY J, V11, P874, DOI 10.1093/ckj/sfy045; Boudville N, 2019, NEPHROL DIAL TRANSPL, V34, P2118, DOI 10.1093/ndt/gfy204; Caring for Australians with Renal Impairment (CARI), 2004, Nephrology (Carlton), V9 Suppl 3, pS78; Chamroensakchai T, 2020, KIDNEY INT REP, V5, P530, DOI 10.1016/j.ekir.2019.12.008; Chang TI, 2011, PERITON DIALYSIS INT, V31, P60, DOI 10.3747/pdi.2009.00057; Cho Y, 2017, SEMIN NEPHROL, V37, P66, DOI 10.1016/j.semnephrol.2016.10.008; Cho YJ, 2012, NEPHROL DIAL TRANSPL, V27, P2028, DOI 10.1093/ndt/gfr582; Dabas Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196196; Ghali JR, 2011, PERITON DIALYSIS INT, V31, P651, DOI 10.3747/pdi.2010.00131; Goldie SJ, 1996, AM J KIDNEY DIS, V28, P86, DOI 10.1016/S0272-6386(96)90135-3; Hu SC, 2019, INFECTION, V47, P35, DOI 10.1007/s15010-018-1204-7; Hussain N, 2017, CURR CLIN MICROBIOL, V4, P106, DOI 10.1007/s40588-017-0062-x; Jacobson ES, 2000, CLIN MICROBIOL REV, V13, P708, DOI 10.1128/CMR.13.4.708-717.2000; Kanjanabuch T, 2021, KIDNEY INT REP, V6, P1118, DOI 10.1016/j.ekir.2021.01.010; Kanjanabuch T, 2022, PERITON DIALYSIS INT, V42, P83, DOI 10.1177/0896860821993950; Khan FY, 2011, J INFECT DEV COUNTR, V5, P646, DOI 10.3855/jidc.1519; Leelahavanichkul A, 2016, PERITON DIALYSIS INT, V36, P402, DOI 10.3747/pdi.2014.00235; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Lo SHK, 2003, PERITON DIALYSIS INT, V23, pS123; MICHEL C, 1994, AM J NEPHROL, V14, P113, DOI 10.1159/000168699; Miles R, 2009, KIDNEY INT, V76, P622, DOI 10.1038/ki.2009.202; Mujais S, 2006, KIDNEY INT, V70, pS55, DOI 10.1038/sj.ki.5001916; Murray P.R., 2020, MED MICROBIOLOGY; Nadeau-Fredette AC, 2015, PERITON DIALYSIS INT, V35, P78, DOI 10.3747/pdi.2013.00179; Perl J, 2020, AM J KIDNEY DIS, V76, P42, DOI 10.1053/j.ajkd.2019.09.016; Prasad KN, 2004, J INFECTION, V48, P96, DOI 10.1016/S0163-4453(03)00119-1; Prasad N, 2005, PERITON DIALYSIS INT, V25, P207; Ram R, 2008, NEPHRON CLIN PRACT, V110, pC207, DOI 10.1159/000167867; Taskapan H, 2000, PERITON DIALYSIS INT, V20, P338; Wang AYM, 2000, AM J KIDNEY DIS, V36, P1183, DOI 10.1053/ajkd.2000.19833	31	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2022	17	5							e0268823	10.1371/journal.pone.0268823	http://dx.doi.org/10.1371/journal.pone.0268823			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4W7AX	35609049	gold, Green Published			2023-01-03	WOS:000860312000001
J	Naeem, AH; Davis, CS; Samuels, EA				Naeem, Aneeqah H.; Davis, Corey S.; Samuels, Elizabeth A.			The Importance of Federal Action Supporting Overdose-Prevention Centers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Federal Action Supporting Overdose-Prevention CentersThere is mounting interest among state and local officials in the United States in opening overdose-prevention centers, but there remains one fundamental barrier: the interpretation and enforcement of federal law.	[Naeem, Aneeqah H.] Brown Univ, Warren Alpert Med Sch, Providence, RI USA; [Samuels, Elizabeth A.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI USA; [Davis, Corey S.] Network Publ Hlth Law, Los Angeles, CA USA; [Davis, Corey S.] NYU Grossman Sch Med, Dept Populat Hlth, New York, NY USA	Brown University; Brown University	Naeem, AH (corresponding author), Brown Univ, Warren Alpert Med Sch, Providence, RI USA.		Samuels, Elizabeth/E-6302-2018	Samuels, Elizabeth/0000-0003-2414-110X				[Anonymous], 2021, OV PREV CTR; [Anonymous], 2021, BID HARR ADM STAT DR; Burris S, 2020, NEW ENGL J MED, V382, P4, DOI 10.1056/NEJMp1913448; Levengood TW, 2021, AM J PREV MED, V61, P738, DOI 10.1016/j.amepre.2021.04.017; Mays Jeffery C., 2021, NEW YORK TIMES	5	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2022	386	21					1965	1967		10.1056/NEJMp2119764	http://dx.doi.org/10.1056/NEJMp2119764		MAY 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	1M5KE	35593724				2023-01-03	WOS:000799232000001
J	Rubin, R				Rubin, Rita			Not a Panacea	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	4	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2022	327	16					1534	1534		10.1001/jama.2022.4017	http://dx.doi.org/10.1001/jama.2022.4017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0W7TZ	35385054				2023-01-03	WOS:000789226500005
J	Uchida, Y; Nakao, M; Yamada, S; Tsuji, S; Uemura, H; Kouyama, Ji; Naiki, K; Sugawara, K; Nakayama, N; Imai, Y; Tomiya, T; Mochida, S				Uchida, Yoshihito; Nakao, Masamitsu; Yamada, Shunsuke; Tsuji, Shohei; Uemura, Hayato; Kouyama, Jun-ichi; Naiki, Kayoko; Sugawara, Kayoko; Nakayama, Nobuaki; Imai, Yukinori; Tomiya, Tomoaki; Mochida, Satoshi			Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog	PLOS ONE			English	Article							DISOPROXIL FUMARATE; SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; RISK	Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods A total of 103 patients with serum HBsAg levels of >= 100 IU/mL who had received ETV were enrolled. The nucleos(t)ide analog used for the treatment was switched from ETV to TAF, and the changes in serum HBsAg levels during the 144-week period before and after the drug switching were compared in 74 patients who had received ETV at least for 192 weeks. Results Significant decreases of serum HBsAg levels were observed during both the ETV and the TAF administration period, although the degree of reduction was greater during the latter period than during the former period (P<0.001). Significant decreases of serum HBsAg levels were seen in both patients with genotype B HBV infection and genotype C HBV infection, irrespective of the serum HBsAg and HBcrAg levels at the time of the drug switching. Conclusion Switching of the nucleos(t)ide analog used for treatment from ETV to TAF merits consideration in patients with chronic HBV infection, since the extent of reduction of the serum HBsAg level was greater during the TAF treatment period than during the ETV treatment period.	[Uchida, Yoshihito; Nakao, Masamitsu; Yamada, Shunsuke; Tsuji, Shohei; Uemura, Hayato; Kouyama, Jun-ichi; Naiki, Kayoko; Sugawara, Kayoko; Nakayama, Nobuaki; Imai, Yukinori; Tomiya, Tomoaki; Mochida, Satoshi] Saitama Med Univ, Dept Gastroenterol Hepatol, Fac Med, Saitama, Japan	Saitama Medical University	Mochida, S (corresponding author), Saitama Med Univ, Dept Gastroenterol Hepatol, Fac Med, Saitama, Japan.	smochida@saitama-med.ac.jp		Uchida, Yoshihito/0000-0002-6012-0915	Abbvie GK; EA Pharma Co., Ltd.; EPS International Holdings Co., Ltd; Gilead Sciences Inc.; Janssen Pharmaceutical K.K.; Eisai Co., Ltd.; Dainihon-Sumitomo Pharma Co. Ltd.; Torey Medical Co,. Ltd.	Abbvie GK(AbbVie); EA Pharma Co., Ltd.; EPS International Holdings Co., Ltd; Gilead Sciences Inc.(Gilead Sciences); Janssen Pharmaceutical K.K.; Eisai Co., Ltd.(Eisai Co Ltd); Dainihon-Sumitomo Pharma Co. Ltd.; Torey Medical Co,. Ltd.	Satoshi MOCHIDA has received speaking fees or honoraria from Abbvie GK, Gilead Sciences Inc., MSD K.K., Asuka Pharmaceutical Co. Ltd., Eisai Co., Ltd. Ohtsuka Parmaceutical Co. Ltd., Dainihon-Sumitomo Pharma Co. Ltd., Torey Medical Co. Ltd, has received research grants from Abbvie GK, EA Pharma Co., Ltd., EPS International Holdings Co., Ltd, Gilead Sciences Inc., Janssen Pharmaceutical K.K., has received scholarship grants from Abbvie GK, EA Pharma Co., Ltd., Asuka Pharmaceutical Co. Ltd., Eisai Co., Ltd. Dainihon-Sumitomo Pharma Co. Ltd., Torey Medical Co,. Ltd. The funders had no role in study design, data collection and analysis, decision to publis h, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Agarwal K, 2018, J HEPATOL, V68, P672, DOI 10.1016/j.jhep.2017.11.039; [Anonymous], 2021, JSH GUIDELINES MANAG; Buti M, 2016, LANCET GASTROENTEROL, V1, P90, DOI [10.1016/S2468-1253(16)30020-6, 10.1016/S2468-1253(16)30107-8]; Chan HLY, 2016, LANCET GASTROENTEROL, V1, P185, DOI 10.1016/S2468-1253(16)30024-3; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chu CM, 2007, INT J OBESITY, V31, P871, DOI 10.1038/sj.ijo.0803479; Hagiwara S, 2021, HEPATOL RES, V51, P767, DOI 10.1111/hepr.13650; Hagiwara S, 2019, J MED VIROL, V91, P1804, DOI 10.1002/jmv.25515; Itokawa N, 2021, JGH OPEN, V5, P34, DOI 10.1002/jgh3.12443; Kimura T, 2002, J CLIN MICROBIOL, V40, P439, DOI 10.1128/JCM.40.2.439-445.2002; Koike K, 2018, HEPATOL RES, V48, P59, DOI 10.1111/hepr.12902; Kumada T, 2021, EUR J GASTROEN HEPAT, V33, P255, DOI 10.1097/MEG.0000000000001733; Li ZB, 2021, LIVER INT, V41, P1254, DOI 10.1111/liv.14786; Marcellin P, 2016, GASTROENTEROLOGY, V150, P134, DOI 10.1053/j.gastro.2015.09.043; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Murata K, 2020, HEPATOLOGY, V71, P1533, DOI 10.1002/hep.30956; Murata K, 2018, GUT, V67, P362, DOI 10.1136/gutjnl-2016-312653; National Cancer Center Cancer Information Service, CANC INC INC RAT JAP; Ogawa E, 2020, LIVER INT, V40, P1578, DOI 10.1111/liv.14482; Schwarze-Zander C, 2020, HIV MED, V21, P378, DOI 10.1111/hiv.12840; Squillace N, 2020, DRUG DES DEV THER, V14, P5515, DOI 10.2147/DDDT.S274307; Surial B, 2021, ANN INTERN MED, V174, P758, DOI 10.7326/M20-4853; Suzuki F, 2019, J GASTROENTEROL, V54, P182, DOI 10.1007/s00535-018-1502-y; Suzuki K, 2021, J GASTROENTEROL, V56, P168, DOI 10.1007/s00535-020-01750-3; Tamaki N, 2020, JGH OPEN, V4, P429, DOI 10.1002/jgh3.12273; Tateishi R, 2019, J GASTROENTEROL, V54, P367, DOI 10.1007/s00535-018-1532-5; Tseng TC, 2012, GASTROENTEROLOGY, V142, P1140, DOI 10.1053/j.gastro.2012.02.007; Uchida Y, 2020, J MED VIROL, V92, P329, DOI 10.1002/jmv.25644; Yip TCF, 2020, GASTROENTEROLOGY, V158, P215, DOI 10.1053/j.gastro.2019.09.025	29	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2022	17	2							e0262764	10.1371/journal.pone.0262764	http://dx.doi.org/10.1371/journal.pone.0262764			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H3HL	35180213	Green Published, gold			2023-01-03	WOS:000796435800006
J	Coffin, PO; Barreveld, AM				Coffin, Phillip O.; Barreveld, Antje M.			Inherited Patients Taking Opioids for Chronic Pain - Considerations for Primary Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Coffin, Phillip O.] Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; [Coffin, Phillip O.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Barreveld, Antje M.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Barreveld, Antje M.] Newton Wellesley Hosp, Dept Anesthesiol, Newton, MA USA	University of California System; University of California San Francisco; Tufts University; Newton Wellesley Hospital	Coffin, PO (corresponding author), Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.; Coffin, PO (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Agnoli A, 2021, JAMA-J AM MED ASSOC, V326, P411, DOI 10.1001/jama.2021.11013; California Department of Health Care Services, 2021, PROV AL LAGS MED CTR; Coffin PO, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232538; Mark TL, 2019, J SUBST ABUSE TREAT, V103, P58, DOI 10.1016/j.jsat.2019.05.001; Oliva EM, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m283	5	2	2	2	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2022	386	7					611	613		10.1056/NEJMp2115244	http://dx.doi.org/10.1056/NEJMp2115244		FEB 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA1QN	35148038	Green Accepted			2023-01-03	WOS:000754321100001
J	Zhou, S; Zhang, SS; Crowley-McHattan, ZJ				Zhou, Shi; Zhang, Shuang-Shuang; Crowley-McHattan, Zachary J.			A scoping review of the contralateral effects of unilateral peripheral stimulation on neuromuscular function	PLOS ONE			English	Review							ELECTRICAL NERVE-STIMULATION; COOPERATIVE HAND MOVEMENTS; CROSS-EDUCATION; MUSCLE STRENGTH; WRIST EXTENSOR; VIBRATION EXERCISE; SYSTEMATIC REVIEWS; ACUPUNCTURE; VOLUNTARY; QUADRICEPS	It is known that resistance exercise using one limb can affect motor function of both the exercised limb and the unexercised contralateral limb, a phenomenon termed cross-education. It has been suggested that cross-education has clinical implications, e.g. in rehabilitation for orthopaedic conditions or post-stroke paresis. Much of the research on the contralateral effect of unilateral intervention on motor output is based on voluntary exercise. This scoping review aimed to map the characteristics of current literature on the cross-education caused by three most frequently utilised peripheral neuromuscular stimulation modalities in this context: electrical stimulation, mechanical vibration and percutaneous needling, that may direct future research and translate to clinical practice. A systematic search of relevant databases (Ebsco, ProQuest, PubMed, Scopus, Web of Science) through to the end of 2020 was conducted following the PRISMA Extension for Scoping Review. Empirical studies on human participants that applied a unilateral peripheral neuromuscular stimulation and assessed neuromuscular function of the stimulated and/or the unstimulated side were selected. By reading the full text, the demographic characteristics, context, design, methods and major findings of the studies were synthesised. The results found that 83 studies were eligible for the review, with the majority (53) utilised electrical stimulation whilst those applied vibration (18) or needling (12) were emerging. Although the contralateral effects appeared to be robust, only 31 studies claimed to be in the context of cross-education, and 25 investigated on clinical patients. The underlying mechanism for the contralateral effects induced by unilateral peripheral stimulation remains unclear. The findings suggest a need to enhance the awareness of cross-education caused by peripheral stimulation, to help improve the translation of theoretical concepts to clinical practice, and aid in developing well-designed clinical trials to determine the efficacy of cross-education therapies.	[Zhou, Shi; Zhang, Shuang-Shuang; Crowley-McHattan, Zachary J.] Southern Cross Univ, Fac Hlth, Discipline Sport & Exercise Sci, Lismore, NSW, Australia; [Zhang, Shuang-Shuang] Beijing Sport Univ, Sch Sport Sci, Beijing, Peoples R China	Southern Cross University; Beijing Sport University	Zhou, S (corresponding author), Southern Cross Univ, Fac Hlth, Discipline Sport & Exercise Sci, Lismore, NSW, Australia.	shi.zhou@scu.edu.au	Crowley-McHattan, Zachary J/W-1288-2018; Zhang, Shuangshuang/GVS-0109-2022; Zhou, Shi/B-8884-2009	Crowley-McHattan, Zachary J/0000-0002-5691-3752; Zhou, Shi/0000-0001-9038-5984				ABDELMOTY E, 1994, ARCH PHYS MED REHAB, V75, P680, DOI 10.1016/0003-9993(94)90194-5; Andrade SF., 2016, J EXERC PHYSL ONLINE, V19, P59; Audette JF, 2004, AM J PHYS MED REHAB, V83, P368, DOI 10.1097/01.PHM.0000118037.61143.7C; Aydin T, 2020, SOMATOSENS MOT RES, V37, P51, DOI 10.1080/08990220.2020.1720635; Bandeira JS, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00200; Barss TS, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14406; Bemben MG, 2001, J SPORT MED PHYS FIT, V41, P291; Ben Othman A, 2019, APPL PHYSIOL NUTR ME, V44, P973, DOI 10.1139/apnm-2018-0766; Benito-Martinez E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17239028; Beyer KS, 2016, J STRENGTH COND RES, V30, P1213, DOI 10.1519/JSC.0000000000001219; Bezerra P, 2009, MUSCLE NERVE, V40, P430, DOI 10.1002/mus.21329; Blickenstorfer A, 2009, HUM BRAIN MAPP, V30, P963, DOI 10.1002/hbm.20559; Butts R, 2021, J BODYW MOV THER, V26, P353, DOI 10.1016/j.jbmt.2020.12.003; Cabibel V, 2020, J NEUROPHYSIOL, V123, P2090, DOI 10.1152/jn.00064.2020; CABRIC M, 1987, INT J SPORTS MED, V8, P256, DOI 10.1055/s-2008-1025665; CANNON RJ, 1987, J APPL PHYSIOL, V63, P2396, DOI 10.1152/jappl.1987.63.6.2396; [曹龙军 CAO Longjun], 2009, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V24, P103; Cattagni T, 2018, J ELECTROMYOGR KINES, V38, P111, DOI 10.1016/j.jelekin.2017.11.013; Chen SQ, 2020, CHIN J INTEGR MED, V26, P20, DOI 10.1007/s11655-019-3079-6; Chen X, 2015, BRAIN RES, V1601, P64, DOI 10.1016/j.brainres.2015.01.011; Christova M, 2010, J ELECTROMYOGR KINES, V20, P627, DOI 10.1016/j.jelekin.2010.03.001; Cochrane DJ, 2011, INT J SPORTS MED, V32, P75, DOI 10.1055/s-0030-1268010; Coombs TA, 2016, EUR J APPL PHYSIOL, V116, P1757, DOI 10.1007/s00421-016-3436-5; Couto BP., 2012, MOTRICIDADE, V8, P393; de Souza LL, 2016, J ACUPUNCT MERIDIAN, V9, P250, DOI 10.1016/j.jams.2016.07.004; Delkhoush CT, 2020, J BODYW MOV THER, V24, P293, DOI 10.1016/j.jbmt.2020.02.027; Dickerson C, 2012, INT J SPORTS PHYS TH, V7, P381; Dietz V, 2015, CEREB CORTEX, V25, P948, DOI 10.1093/cercor/bht285; Dupler D., 2013, GALE ENCY NURSING AL; Ehrensberger M, 2016, TOP STROKE REHABIL, V23, P126, DOI 10.1080/10749357.2015.1112062; Einhorn J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076940; Farthing JP, 2014, EXERC SPORT SCI REV, V42, P70, DOI 10.1249/JES.0000000000000009; Farthing JP, 2009, EXERC SPORT SCI REV, V37, P179, DOI 10.1097/JES.0b013e3181b7e882; Filipovic A, 2011, J STRENGTH COND RES, V25, P3218, DOI 10.1519/JSC.0b013e318212e3ce; Fowler DE, 2010, J SPORT MED PHYS FIT, V50, P336; Francis S, 2009, NEUROIMAGE, V44, P469, DOI 10.1016/j.neuroimage.2008.09.017; Frazer AK, 2018, EUR J APPL PHYSIOL, V118, P1751, DOI 10.1007/s00421-018-3937-5; Garcia-de-Miguel S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061665; Garcia-Gutierrez MT, 2018, J MUSCULOSKEL NEURON, V18, P262; GIBSON JNA, 1989, EUR J CLIN INVEST, V19, P206, DOI 10.1111/j.1365-2362.1989.tb00219.x; Goodwill AM, 2012, SCI WORLD J, DOI 10.1100/2012/504837; Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x; Green LA, 2018, PHYS THER REV, V23, P238, DOI 10.1080/10833196.2018.1499272; Gueugneau N, 2017, J NEUROPHYSIOL, V117, P467, DOI 10.1152/jn.00355.2016; Han BS, 2003, AM J PHYS MED REHAB, V82, P17, DOI 10.1097/01.PHM.0000043516.69441.15; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; He XK, 2019, BEHAV NEUROL, V2019, DOI 10.1155/2019/9278270; Hendy AM, 2012, J SCI MED SPORT, V15, P94, DOI 10.1016/j.jsams.2011.07.007; Hollman JE, 1997, PHYS THER, V77, P28, DOI 10.1093/ptj/77.1.28; Hortobagyi T, 2003, J NEUROPHYSIOL, V90, P2451, DOI 10.1152/jn.01001.2002; Hortobagyi T, 1999, MOTOR CONTROL, V3, P205, DOI 10.1123/mcj.3.2.205; Huang LP, 2007, J ALTERN COMPLEM MED, V13, P539, DOI 10.1089/acm.2007.6250; Huang LP, 2015, J EXERC SCI FIT, V13, P86, DOI 10.1016/j.jesf.2015.07.001; Huang Z-J., 2018, J CLIN ACUPUNCT MOXI, V34, P67; Jackson SW, 2003, EUR J APPL PHYSIOL, V88, P380, DOI 10.1007/s00421-002-0701-6; Jang SH, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00432; Joa KL, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-48; Kadri MA, 2017, EUR J APPL PHYSIOL, V117, P1799, DOI 10.1007/s00421-017-3676-z; Karacan I, 2012, TURK KLIN TIP BILIM, V32, P1673, DOI 10.5336/medsci.2011-27910; Kim MK, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-41; Kurobe K, 2015, CLIN PHYSIOL FUNCT I, V35, P197, DOI 10.1111/cpf.12147; Kwong PWH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007341; Lagerquist O, 2012, EXP BRAIN RES, V222, P41, DOI 10.1007/s00221-012-3194-5; Lai H S, 1988, Aust J Physiother, V34, P151, DOI 10.1016/S0004-9514(14)60607-3; Langevin HM, 2018, J ALTERN COMPLEM MED, V24, P200, DOI 10.1089/acm.2017.0366; Lapole T, 2013, EUR J APPL PHYSIOL, V113, P2223, DOI 10.1007/s00421-013-2651-6; LAUGHMAN RK, 1983, PHYS THER, V63, P494, DOI 10.1093/ptj/63.4.494; Lazcorreta JEG., 2006, REHABIL, V40, P25; Lee B, 2015, HUM FACTORS, V57, P1348, DOI 10.1177/0018720815599284; Lee M, 2007, SPORTS MED, V37, P1, DOI 10.2165/00007256-200737010-00001; Lepley LK, 2015, CLIN BIOMECH, V30, P738, DOI 10.1016/j.clinbiomech.2015.04.011; Levin O, 2017, EUR REV AGING PHYS A, V14, DOI 10.1186/s11556-017-0189-z; Li W, 2019, NEUROREPORT, V30, P1081, DOI 10.1097/WNR.0000000000001319; Li W, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/9167028; Lin CC, 2000, NEUROREHAB NEURAL RE, V14, P199, DOI 10.1177/154596830001400305; Lin SI, 2012, ARCH PHYS MED REHAB, V93, P1027, DOI 10.1016/j.apmr.2012.01.019; Liu G., 2017, CHIN J INTEGR MED, V15, P2666; [刘小燮 Liu Xiaoxie], 2013, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V28, P97; Maffiuletti NA, 2010, EUR J APPL PHYSIOL, V110, P223, DOI 10.1007/s00421-010-1502-y; Magnus CRA, 2013, ARCH PHYS MED REHAB, V94, P1247, DOI 10.1016/j.apmr.2013.03.005; Manca A, 2021, SPORTS MED, V51, P11, DOI 10.1007/s40279-020-01377-7; Marin PJ, 2014, J MUSCULOSKEL NEURON, V14, P58; Marqueste T, 2003, MUSCLE NERVE, V28, P181, DOI 10.1002/mus.10408; Mayor DF., 2007, ELECTROACUPUNCTURE P; MILNERBROWN HS, 1988, ARCH PHYS MED REHAB, V69, P20; Minetto MA, 2018, EUR J PHYS REHAB MED, V54, P911, DOI 10.23736/S1973-9087.18.05004-9; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Munn J, 2004, J APPL PHYSIOL, V96, P1861, DOI 10.1152/japplphysiol.00541.2003; Muthalib M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131951; Ni M., 1995, YELLOW EMPERORS CLAS; Onigbinde AT, 2014, TECHNOL HEALTH CARE, V22, P759, DOI 10.3233/THC-140849; Paquet N, 1996, NEUROSCI LETT, V209, P215, DOI 10.1016/0304-3940(96)12649-5; Peters Micah D. J., 2017, Medical Reference Services Quarterly, V36, P19, DOI 10.1080/02763869.2017.1259891; Pietrosimone Brian G, 2010, N Am J Sports Phys Ther, V5, P111; Pittaccio S, 2011, HUM BRAIN MAPP, V32, P60, DOI 10.1002/hbm.20998; Popa L, 2013, CNS NEUROL DISORD-DR, V12, P265; Popa L, 2012, MED-SURG J, V116, P436; Power GA, 2013, J SPORT HEALTH SCI, V2, P215, DOI 10.1016/j.jshs.2013.07.001; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; Russell W, 2018, DISABIL REHABIL, V40, P2644, DOI 10.1080/09638288.2017.1356382; Sariyildiz M, 2011, SCAND J MED SCI SPOR, V21, pE359, DOI 10.1111/j.1600-0838.2011.01311.x; Schrafl-Altermatt M, 2016, CLIN NEUROPHYSIOL, V127, P748, DOI 10.1016/j.clinph.2015.07.004; Segers J, 2021, J CRIT CARE, V62, P65, DOI 10.1016/j.jcrc.2020.11.018; SEIB TP, 1994, ARCH PHYS MED REHAB, V75, P746; Singer K P, 1986, Aust J Physiother, V32, P31, DOI 10.1016/S0004-9514(14)60641-3; Sions JM, 2012, J GERIATR PHYS THER, V35, P155, DOI 10.1519/JPT.0b013e318236db92; Souron R, 2017, J APPL PHYSIOL, V122, P1504, DOI 10.1152/japplphysiol.00793.2016; Stephen JM, 2003, CLIN NEUROPHYSIOL, V114, P1781, DOI 10.1016/S1388-2457(03)00150-0; Suetta C, 2010, GROWTH HORM IGF RES, V20, P134, DOI 10.1016/j.ghir.2009.11.005; Sun Y, 2019, J NEUROPHYSIOL, V122, P2085, DOI 10.1152/jn.00324.2019; Suzuki S, 2016, EXP BRAIN RES, V234, P617, DOI 10.1007/s00221-015-4463-x; TACHINO K, 1989, SCAND J REHABIL MED, V21, P147; TAKAKURA N, 1992, AM J CHINESE MED, V20, P115, DOI 10.1142/S0192415X92000126; Talbot LA, 2003, J RHEUMATOL, V30, P1571; Toca-Herrera JL, 2008, J STRENGTH COND RES, V22, P614, DOI 10.1519/JSC.0b013e3181660830; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Wang PY, 2019, ARCH PHYS MED REHAB, V100, P2046, DOI 10.1016/j.apmr.2019.03.021; White A, 2009, ACUPUNCT MED, V27, P33, DOI 10.1136/aim.2008.000372; [肖娜 Xiao Na], 2014, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V36, P16; Yang CY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6085961; [于俊海 YU Junhai], 2008, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V23, P777; Yurdakul OV, 2020, NEUROL SCI, V41, P3667, DOI 10.1007/s10072-020-04506-2; Zanin MS, 2014, J ACUPUNCT MERIDIAN, V7, P231, DOI 10.1016/j.jams.2014.02.005; Zhang S, 2018, J PAIN RES, V11, P505, DOI 10.2147/JPR.S152550; Zhang Y, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/765413; Zhou KH, 2015, ACUPUNCT MED, V33, P485, DOI 10.1136/acupmed-2015-010911; Zhou S, 2000, Exerc Sport Sci Rev, V28, P177; Zhou S., 2002, HONG KONG J SPORTS M, V14, P1; Zhou S, 2012, ARCH PHYS MED REHAB, V93, P50, DOI 10.1016/j.apmr.2011.08.010; Zult T, 2019, KNEE SURG SPORT TR A, V27, P478, DOI 10.1007/s00167-018-5116-y; Zult T, 2018, EUR J APPL PHYSIOL, V118, P1609, DOI 10.1007/s00421-018-3892-1	131	1	1	7	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263662	10.1371/journal.pone.0263662	http://dx.doi.org/10.1371/journal.pone.0263662			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139128	Green Published, gold			2023-01-03	WOS:000821499100040
J	Du, RJ; Qu, YJ; Zhao, M; Liu, YH; Qi, PX; Sun, XB				Du, Renjie; Qu, Yuejun; Zhao, Min; Liu, Yanhong; Qi, Phoebe X.; Sun, Xingbin			Logistic modeling to predict the minimum inhibitory concentration (MIC) of olive leaf extract (OLE) against Listeria monocytogenes	PLOS ONE			English	Article							MICROBIAL-GROWTH; CURVES	Olive leaf extract (OLE) has been increasingly recognized as a natural and effective antimicrobial against a host of foodborne pathogens. This study attempts to predict the minimum inhibitory concentration (MIC) of OLE against Listeria monocytogenes F2365 by utilizing the asymptotic deceleration point (PDA) in a logistic model (LM), namely MIC-PDA. The experimental data obtained from the inhibitory rate (IR) versus OLE concentration against L. monocytogenes were sufficiently fitted (R-2 = 0.88957). Five significant critical points were derived by taking the multi-order derivatives of the LM function: the inflection point (PI), the maximum acceleration point (PAM), the maximum deceleration point (PDM), the absolute acceleration point (PAA), and the asymptotic deceleration point (PDA). The PDA ([OLE] = 37.055 mg/mL) was employed to approximate the MIC-PDA. This MIC value was decreased by over 42% compared to the experimental MIC of 64.0 mg/mL, obtained using the conventional 2-fold dilution method (i.e., MIC-2fold). The accuracy of MIC-PDA was evaluated by an in vitro L. monocytogenes growth inhibition assay. Finally, the logistic modeling method was independently validated using our previously published inhibition data of OLE against the growths of Escherichia coli O157:H7 and Salmonella enteritidis. The MIC-PDA (for [OLE]) values were estimated to be 41.083 and 35.313 mg/mL, respectively, compared to the experimental value of 62.5 mg/mL. Taken together, MIC-PDA, as estimated from the logistic modeling, holds the potential to shorten the time and reduce cost when OLE is used as an antimicrobial in the food industry.	[Du, Renjie; Zhao, Min; Sun, Xingbin] Northeast Forestry Univ, Coll Life Sci, Harbin, Heilongjiang, Peoples R China; [Du, Renjie; Qu, Yuejun] Mudanjiang Branch Heilongjiang Acad Forestry Sci, Mudanjiang, Heilongjiang, Peoples R China; [Liu, Yanhong] USDA, ARS, Mol Characterizat Foodborne Pathogens Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA USA; [Qi, Phoebe X.] United States Dept Agr, Agr Res Serv, Dairy & Funct Foods Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA USA	Northeast Forestry University - China; United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Zhao, M (corresponding author), Northeast Forestry Univ, Coll Life Sci, Harbin, Heilongjiang, Peoples R China.; Liu, YH (corresponding author), USDA, ARS, Mol Characterizat Foodborne Pathogens Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA USA.; Qi, PX (corresponding author), United States Dept Agr, Agr Res Serv, Dairy & Funct Foods Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA USA.	82191513@163.com; Yanhong.Liu@usda.gov; Phoebe.Qi@usda.gov	liu, yan/HGV-1365-2022; liu, yan/HCI-5542-2022	Qi, Phoebe/0000-0003-1276-0878				Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5; Balouiri M, 2016, J PHARM ANAL, V6, P71, DOI 10.1016/j.jpha.2015.11.005; Passos JRD, 2012, SCI AGR, V69, P308, DOI 10.1590/S0103-90162012000500004; Difonzo G, 2019, FOODS, V8, DOI 10.3390/foods8040138; Draper NR., 2014, WILEY SERIES PROBABI, V326, P736; Du RJ, 2020, NANOSCALE, V12, P5627, DOI 10.1039/c9nr10095d; Erdohan ZO., 2011, SCI MICROBIAL PATHOG, P1094; Haghighi H, 2020, FOOD HYDROCOLLOID, V100, DOI 10.1016/j.foodhyd.2019.105419; Han J. H., 2003, Novel food packaging techniques, P50, DOI 10.1533/9781855737020.1.50; Kakaei S, 2016, LWT-FOOD SCI TECHNOL, V72, P432, DOI 10.1016/j.lwt.2016.05.021; Korkmaz M., 2018, TURK J MATH COMPUT S, V10, P33; Kranz P, 2010, J FOOD SCI, V75, pS308, DOI 10.1111/j.1750-3841.2010.01698.x; Lagerweij M., 2019, IMPACT NUTR DIET ORA, P68; Liu YH, 2018, ACS SYM SER, V1287, P119; Liu YH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00113; Marcos B, 2014, FOOD PACKAGING SHELF, V1, P140, DOI 10.1016/j.fpsl.2014.04.002; Marroki A., 2021, REFERENCE MODULE BIO, DOI [10.1007/s12602-021-09755-x, DOI 10.1007/S12602-021-09755-X]; Menard S, 2000, AM STAT, V54, P17, DOI 10.2307/2685605; Ozcan MM, 2017, EUR FOOD RES TECHNOL, V243, P89, DOI 10.1007/s00217-016-2726-9; Pan YC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0220084; Peleg M, 2011, CRIT REV FOOD SCI, V51, P917, DOI 10.1080/10408398.2011.570463; Rychter AM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030814; Senol H, 2020, BIORESOURCE TECHNOL, V300, DOI 10.1016/j.biortech.2019.122660; SKINNER GE, 1994, J FOOD SAFETY, V14, P175, DOI 10.1111/j.1745-4565.1994.tb00594.x; Stanhope KL, 2016, CRIT REV CL LAB SCI, V53, P52, DOI 10.3109/10408363.2015.1084990; Sudjana AN, 2009, INT J ANTIMICROB AG, V33, P461, DOI 10.1016/j.ijantimicag.2008.10.026; Tovissode CF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240578; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; Zhang FY, 2020, ACS OMEGA, V5, P7537, DOI 10.1021/acsomega.0c00352	29	0	0	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2022	17	1							e0263359	10.1371/journal.pone.0263359	http://dx.doi.org/10.1371/journal.pone.0263359			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT4WP	35089984	Green Published, gold			2023-01-03	WOS:000769158400059
J	Khami, MR; Zadeh, AG; Rahi, D				Khami, Mohammad Reza; Zadeh, Armin Gholamhossein; Rahi, Dorsa			A cross-sectional study on COVID-19-related changes in self-medication with antibiotics	PLOS ONE			English	Article							VALIDITY	Background and aim Dental treatments have been limited to emergency care in many countries worldwide due to the global rapid spread of coronavirus disease-2019 (COVID-19). Fear of contracting the disease in dental clinics has also altered the pattern of dental visits and self-medication. The present study compared self-medication with antibiotics (SMA) and the pattern of dental visits before and after the emergence of COVID-19 pandemic in a referral dental clinic in the north of Iran. Materials and methods The data for the present cross-sectional study was collected from 756 patient records retrieved from the archives of the Faculty Clinic of Rasht School of Dentistry during two separate periods: before the COVID-19 pandemic from mid-November 2019 to mid-February 2020, and after the pandemic emergence from mid-April to mid-July 2020. In addition to demographic variables namely age, gender, and place of residence of patients, their smoking status, chief complaint, and SMA were also extracted from patient records. The Chisquare test and binary logistic regression models with 95% confidence interval served for statistical analysis. Results In total, 756 patient records (412 records from the pre-pandemic period and 344 records from the post-pandemic period) were evaluated. SMA was significantly more prevalent after the pandemic compared to that before pandemic (OR = 3.39, 95% CI = 2.43-4.73, P<0.001). The number of patients who smoke significantly decreased after the pandemic by 6.6% compared to that in pre-pandemic period. Dental pain, pus discharge, and abscess as the chief complaints of patients were significantly more prevalent during the post-pandemic period; while, dental checkups, tooth hypersensitivity, and esthetic dental problems were significantly more frequent as the chief complaints of patients during the pre-pandemic period. Conclusion There is indication that during the COVID-19 pandemic, SMA and prevalence of acute dental problems in patients have increased. With regard to the consequences of SMA, there is a need to raise public awareness on this matter.	[Khami, Mohammad Reza] Univ Tehran Med Sci, Res Ctr Caries Prevent, Dent Res Inst, Tehran, Iran; [Khami, Mohammad Reza] Univ Tehran Med Sci, Sch Dent, Dept Community Oral Hlth, Tehran, Iran; [Zadeh, Armin Gholamhossein; Rahi, Dorsa] Guilan Univ Med Sci, Dent Res Ctr, Sch Dent, Rasht, Iran	Tehran University of Medical Sciences; Tehran University of Medical Sciences	Rahi, D (corresponding author), Guilan Univ Med Sci, Dent Res Ctr, Sch Dent, Rasht, Iran.	rahi.dorsa@gmail.com		rahi, dorsa/0000-0002-1342-2873				AlQahtani HA, 2019, J TAIBAH UNIV MED SC, V14, P370, DOI 10.1016/j.jtumed.2019.06.006; Aslam A, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020097; Ateshim Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7020-x; Ather A, 2020, J ENDODONT, V46, P584, DOI 10.1016/j.joen.2020.03.008; Brkic H, 2020, ACTA STOMATOL CROAT, V54, P118; Campagnaro R, 2020, CHILD YOUTH SERV REV, V118, DOI 10.1016/j.childyouth.2020.105469; da Silva CF, 2021, INFECT CONT HOSP EP, V42, P1170, DOI 10.1017/ice.2020.1227; Dar-Odeh N, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093151; El-Kholey KE, 2018, IMPLANT DENT, V27, P317, DOI 10.1097/ID.0000000000000748; Elka NR., 2022, INT J SCI RES PUBLIC, V10; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Falahati S., 2019, VILLAGE DEV, V22, P125; Goodson JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170437; Guerrini L, 2019, OPEN DENT J, V13, P383, DOI 10.2174/1874210601913010383; Guo HQ, 2020, J DENT SCI, V15, P564, DOI 10.1016/j.jds.2020.02.002; HELOE LA, 1972, SCAND J DENT RES, V80, P495; Jafari Faranak, 2015, Glob J Health Sci, V7, P360, DOI 10.5539/gjhs.v7n2p360; Karimi M., 2019, J RAFSANJAN U MED SC, V18, P753; Malik M, 2020, DRUGS THER PERSPECT, V36, P565, DOI 10.1007/s40267-020-00785-z; Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246; Meshkat S, 2020, TRANSL NEUROSCI, V11, P294, DOI [10.1515/tnscl-2020-0141, 10.1515/tnsci-2020-0141]; Nicola DG., 2019, FOWLERS ZOO WILD ANI, V9; Organization WH., 2000, GUIDELINES REGULATOR; Reynolds-Campbell Glendee, 2017, Dent Clin North Am, V61, P305, DOI 10.1016/j.cden.2016.12.003; Sabrina N, 2019, PHARMACOEPIDEMIOLOGY; Siljak S, 2019, INT DENT J, V69, P200, DOI 10.1111/idj.12449; Sjostrom O, 1999, ACTA ODONTOL SCAND, V57, P242, DOI 10.1080/000163599428643; Spagnuolo G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062094; Staub MB, 2021, INFECT CONT HOSP EP, V42, P810, DOI 10.1017/ice.2020.1291; Sultan A, 2020, J INT CLIN DENT RES, V12, P94, DOI 10.4103/jicdro.jicdro_27_20; Xu RX, 2019, J INFECT DEV COUNTR, V13, P678, DOI 10.3855/jidc.11359; Zhang AR, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10030232; Zhang DY, 2020, FINANC RES LETT, V36, DOI 10.1016/j.frl.2020.101528	33	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269782	10.1371/journal.pone.0269782	http://dx.doi.org/10.1371/journal.pone.0269782			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2RM	35700193	Green Published, gold			2023-01-03	WOS:000843575700102
J	Kim, YJ; Yoon, SJ; Suh, SY; Hiratsuka, Y; Kang, B; Lee, SW; Ahn, HY; Suh, KJ; Kim, JW; Kim, SH; Kim, JW; Lee, KW; Kim, JH; Lee, JS				Kim, Yu Jung; Yoon, Seok Joon; Suh, Sang-Yeon; Hiratsuka, Yusuke; Kang, Beodeul; Lee, Si Won; Ahn, Hong-Yup; Suh, Koung Jin; Kim, Ji-Won; Kim, Se Hyun; Kim, Jin Won; Lee, Keun-Wook; Kim, Jee Hyun; Lee, Jong Seok			Performance of clinician prediction of survival in oncology outpatients with advanced cancer	PLOS ONE			English	Article							TERMINAL CANCER; ACCURACY	BackgroundWe aimed to investigate the performance of clinician prediction of survival (CPS) and the association between CPS and the prognostic confidence of clinicians in ambulatory medical oncology outpatients. MethodsEight medical oncologists estimated the expected survival of their patients in a prospective cohort study. They were asked to provide a temporal type of CPS in weeks, together with their level of confidence for each prediction (0-100%). We analyzed the accuracy of CPS, the association between CPS and the prognostic confidence, and the characteristics of patients showing inaccurate CPS. ResultsA total of 200 advanced cancer patients were enrolled and the median overall survival was 7.6 months. CPS was accurate in 67 (33.5%) patients, underestimated in 87 (43.5%), and overestimated in 46 (23.0%). The overall accuracy of CPS for 12-week, 24-week, 36-week, and 48-week survival was 83.0%, 72.0%, 75.5%, and 74.0%, respectively. The specificity was highest for 12-week survival (90.2%) and the sensitivity was highest for 48-week survival (96.1%). The sensitivity of 12-week CPS was 51.4% and the area under the receiver operating characteristic (AUROC) curve was 0.79 (95% confidence interval [CI] 0.71-0.87). The prognostic confidence of clinicians was not significantly associated with the accuracy of prediction (P = 0.359). Patients with overestimated survival had significantly poorer global health status and physical/role/emotional functioning in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Additionally, they showed significantly higher levels of fatigue, nausea/vomiting, pain, dyspnea, and loss of appetite. ConclusionThe overall accuracy of CPS in predicting 12-week to 48-week survival was high in medical oncology outpatients. However the sensitivity of 12-week CPS was low and prognostic confidence was not associated with the accuracy of CPS. Patients with overestimated CPS showed poorer quality of life and higher symptom burden.	[Kim, Yu Jung; Suh, Koung Jin; Kim, Ji-Won; Kim, Se Hyun; Kim, Jin Won; Lee, Keun-Wook; Kim, Jee Hyun; Lee, Jong Seok] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematol & Med Oncol,Coll Med, Seongnam, South Korea; [Yoon, Seok Joon] Chungnam Natl Univ Hosp, Dept Family Med, Daejeon, South Korea; [Suh, Sang-Yeon] Dongguk Univ, Dept Family Med, Ilsan Hosp, Goyang, South Korea; [Suh, Sang-Yeon] Dongguk Univ, Dept Med, Med Sch, Seoul, South Korea; [Hiratsuka, Yusuke] Takeda Gen Hosp, Dept Palliat Med, Aizu Wakamatsu, Fukushima, Japan; [Hiratsuka, Yusuke] Tohoku Univ, Dept Palliat Med, Sch Med, Sendai, Miyagi, Japan; [Kang, Beodeul] CHA Univ, Bundang Med Ctr, Div Med Oncol, Seongnam, South Korea; [Lee, Si Won] Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea; [Ahn, Hong-Yup] Dongguk Univ, Dept Stat, Med Sch, Seoul, South Korea	Seoul National University (SNU); Chungnam National University; Chungnam National University Hospital; Dongguk University; NHIS Ilsan Hospital; Dongguk University; Tohoku University; Pochon Cha University; Yonsei University; Yonsei University Health System; Dongguk University	Suh, SY (corresponding author), Dongguk Univ, Dept Family Med, Ilsan Hosp, Goyang, South Korea.; Suh, SY (corresponding author), Dongguk Univ, Dept Med, Med Sch, Seoul, South Korea.	lisasuhmd@hotmail.com	; Ahn, Hongyup/M-5043-2017	Kim, Yu Jung/0000-0002-5037-0523; Suh, Koung Jin/0000-0002-1881-8738; Hiratsuka, Yusuke/0000-0003-2334-3893; Ahn, Hongyup/0000-0001-8149-6981; Kim, Se Hyun/0000-0002-2292-906X	National Research Foundation of Korea (NRF) - Korean Government (Ministry of Science, Informatics, Communication and Technology) [2015R1C1A2A01053357]	National Research Foundation of Korea (NRF) - Korean Government (Ministry of Science, Informatics, Communication and Technology)	We thank the participating patients and clinical research nurses (Jin Suk Kim and Esther Jeon) for supporting this study.	Amano K, 2015, J PAIN SYMPTOM MANAG, V50, P139, DOI 10.1016/j.jpainsymman.2015.03.004; Butow PN, 2020, J CLIN ONCOL, V38, P877, DOI 10.1200/JCO.18.02112; Cheon S, 2016, ANN PALLIAT MED, V5, P22, DOI 10.3978/j.issn.2224-5820.2015.08.04; Chow E., 2010, J PAIN MANAG, V3, P73; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Hui D, 2019, SUPPORT CARE CANCER, V27, P1973, DOI 10.1007/s00520-019-04727-y; Hui D, 2011, ONCOLOGIST, V16, P1642, DOI 10.1634/theoncologist.2011-0173; Kiely BE, 2013, J CLIN ONCOL, V31, P3565, DOI 10.1200/JCO.2012.44.7821; Kim YJ, 2022, CANCER RES TREAT, V54, P621, DOI 10.4143/crt.2021.483; Kondziolka D, 2014, J NEUROSURG, V120, P24, DOI 10.3171/2013.9.JNS13788; Llobera J, 2000, EUR J CANCER, V36, P2036, DOI 10.1016/S0959-8049(00)00291-4; Maltoni M, 2005, J CLIN ONCOL, V23, P6240, DOI 10.1200/JCO.2005.06.866; Stone PC, 2007, ANN ONCOL, V18, P971, DOI 10.1093/annonc/mdl343; Tavares T, 2018, PALLIATIVE MED, V32, P413, DOI 10.1177/0269216317705788; Vigano A, 2004, CANCER, V101, P1090, DOI 10.1002/cncr.20472; White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407; Yun YH, 2004, QUAL LIFE RES, V13, P863, DOI 10.1023/B:QURE.0000021692.81214.70	19	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267467	10.1371/journal.pone.0267467	http://dx.doi.org/10.1371/journal.pone.0267467			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F9GM	35446910	gold, Green Published			2023-01-03	WOS:000795468200030
J	Mussig, M; Pfeiler, TM; Egloff, B				Muessig, Markus; Pfeiler, Tamara M.; Egloff, Boris			Minor and inconsistent differences in Big Five personality traits between vegetarians and vegans	PLOS ONE			English	Article							MEAT; VALIDATION; INVENTORY; PROFILES; VALIDITY; POWER; DIET	Most research examining individuals who follow different diets has combined vegetarians and vegans into a single group. To investigate whether this consolidation is justified, we analyzed possible differences between vegetarians and vegans for the Big Five personality traits in two studies. In our pre-study, we used data from a German convenience sample of 400 vegetarians and 749 vegans and found that vegans reported slightly higher scores in Openness compared to vegetarians (d = 0.22). In the preregistered main study, we used data provided by 1203 vegetarians and 128 vegans from the German Socio-Economic Panel Study; we found that vegetarians reported slightly higher scores in Neuroticism compared to vegans (d = 0.18) but did not differ in Openness. We found no differences in Conscientiousness, Extraversion, or Agreeableness in either study. Controlling for the socio-demographic variables of age, gender, and socio-economic status did not alter the pattern of results. Overall, these results suggest that there are no or only small differences in Openness or Neuroticism between vegetarians and vegans. Further studies utilizing very large, representative samples are needed to better understand the relationship between personality and diet groups.	[Muessig, Markus; Pfeiler, Tamara M.; Egloff, Boris] Johannes Gutenberg Univ Mainz, Mainz, Germany; [Muessig, Markus] Leibniz Inst Resilience Res Mainz, Mainz, Germany	Johannes Gutenberg University of Mainz	Mussig, M (corresponding author), Johannes Gutenberg Univ Mainz, Mainz, Germany.; Mussig, M (corresponding author), Leibniz Inst Resilience Res Mainz, Mainz, Germany.	m.muessig@uni-mainz.de	Egloff, Boris/G-2503-2013	Egloff, Boris/0000-0002-5736-9912; Birkenbach, Markus/0000-0001-5403-3121				Appinio, 2020, APP FMCG REP KONS VE; Bagci SC, 2019, APPETITE, V143, DOI 10.1016/j.appet.2019.104441; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; de Boer J, 2017, APPETITE, V113, P387, DOI 10.1016/j.appet.2017.03.007; Dorard G, 2021, APPETITE, V156, DOI 10.1016/j.appet.2020.104972; Eating Better Alliance, 2018, EAT BETT YOUG SURV Q; Forestell CA, 2018, ECOL FOOD NUTR, V57, P246, DOI 10.1080/03670244.2018.1455675; Gallup News Service, 2018, GALLUP POLL SOCIAL S; Ganzeboom H., 2010, ANN C INT SOCIAL SUR; Gignac GE, 2016, PERS INDIV DIFFER, V102, P74, DOI 10.1016/j.paid.2016.06.069; Goebel J, 2019, JAHRB NATL STAT, V239, P345, DOI 10.1515/jbnst-2018-0022; Gotz FM, 2022, PERSPECT PSYCHOL SCI, V17, P205, DOI 10.1177/1745691620984483; Greenwald AG, 2015, J PERS SOC PSYCHOL, V108, P553, DOI 10.1037/pspa0000016; Hahn E, 2012, J RES PERS, V46, P355, DOI 10.1016/j.jrp.2012.03.008; Hemphill JF, 2003, AM PSYCHOL, V58, P78, DOI 10.1037/0003-066X.58.1.78; Holler S, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.579700; Huang T, 2012, ANN NUTR METAB, V60, P233, DOI 10.1159/000337301; Keller C, 2015, APPETITE, V84, P128, DOI 10.1016/j.appet.2014.10.003; Kessler CS, 2016, FORSCH KOMPLEMENTMED, V23, P95, DOI 10.1159/000445369; Kirsten H, 2020, FOOD QUAL PREFER, V86, DOI 10.1016/j.foodqual.2020.103988; Kovac L, 2022, CURR ISS PERSONAL PS, V10, P147, DOI 10.5114/CIPP.2021.107172; Lund TB, 2016, ANTHROZOOS, V29, P89, DOI 10.1080/08927936.2015.1083192; MacInnis CC, 2021, APPETITE, V164, DOI 10.1016/j.appet.2021.105246; Malek L, 2021, FOOD QUAL PREFER, V88, DOI 10.1016/j.foodqual.2020.104081; MCCRAE RR, 1987, J PERS SOC PSYCHOL, V52, P81, DOI 10.1037/0022-3514.52.1.81; Mottus R, 2012, HEALTH PSYCHOL, V31, P806, DOI 10.1037/a0027041; North M, 2021, FOOD QUAL PREFER, V93, DOI 10.1016/j.foodqual.2021.104246; Ozer DJ, 2006, ANNU REV PSYCHOL, V57, P401, DOI 10.1146/annurev.psych.57.102904.190127; Pfeiler TM, 2020, APPETITE, V149, DOI 10.1016/j.appet.2020.104607; Pfeiler TM, 2018, APPETITE, V121, P294, DOI 10.1016/j.appet.2017.11.098; Pfeiler TM, 2018, APPETITE, V120, P246, DOI 10.1016/j.appet.2017.09.005; Povey R, 2001, APPETITE, V37, P15, DOI 10.1006/appe.2001.0406; Rammstedt B, 2005, DIAGNOSTICA, V51, P195, DOI 10.1026/0012-1924.51.4.195; Roberts BW, 2007, PERSPECT PSYCHOL SCI, V2, P313, DOI 10.1111/j.1745-6916.2007.00047.x; Rosenfeld DL, 2019, FOOD QUAL PREFER, V72, P40, DOI 10.1016/j.foodqual.2018.09.008; Rosenfeld DL, 2018, APPETITE, V131, P125, DOI 10.1016/j.appet.2018.09.011; Rosenfeld DL, 2017, APPETITE, V116, P456, DOI 10.1016/j.appet.2017.05.039; Ruby MB, 2012, APPETITE, V58, P141, DOI 10.1016/j.appet.2011.09.019; Schupp J., 2014, ZUSAMMENSTELLUNG SOZ, DOI [10.6102/zis54, DOI 10.6102/ZIS54]; Soto CJ, 2019, PSYCHOL SCI, V30, P711, DOI 10.1177/0956797619831612; Tan NP, 2021, APPETITE, V163, DOI 10.1016/j.appet.2021.105195; Thomas MA, 2016, APPETITE, V97, P79, DOI 10.1016/j.appet.2015.11.021; UNESCO Institute for Statistics, 2012, COMP SOCIAL RES	43	1	1	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268896	10.1371/journal.pone.0268896	http://dx.doi.org/10.1371/journal.pone.0268896			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35675342	gold, Green Published			2023-01-03	WOS:000832307900054
J	Wassihun, B; Alemayehu, Y; Gultie, T; Tekabe, B; Gebeyehu, B				Wassihun, Biresaw; Alemayehu, Yosef; Gultie, Teklemariam; Tekabe, Beemnet; Gebeyehu, Birhaneselasie			Non-pharmacological labor pain management practice and associated factors among skilled attendants working in public health facilities in Gamo and Gofa zone, Southern Ethiopia: A cross-sectional study	PLOS ONE			English	Article							EPIDURAL ANALGESIA; CHILDBIRTH; RELIEF; BIRTH	BackgroundLabor pain management is crucial to ensure the quality of obstetric care but it is one of the neglected areas in obstetrics. This study aimed to assess the practice of labor pain management and associated factors among skilled attendants working in public health facilities in Southern, Ethiopia from November 1-January 26, 2019. MethodsAn Institution-based cross-sectional study design was conducted from November 1-January 26, 2019. A simple random sampling technique was used to select a total of 272 obstetric care providers. Data were collected using pretested, and structured questionnaires. Data were entered to Epi data version 3.1 statistical software and exported to SPSS 22 for analysis. Bivariate and multivariate logistic regression analyses were performed to identify associated factors. P-value ResultOverall, 37.5% (95%CI: 32%, 43%) of health care providers had a good practice on non-pharmacological labor pain management. Clinical experience of 5 years and above (AOR = 2.91, 95%CI: 1.60, 5.42), favorable attitude (AOR = 2.82, 95%CI: 1.56, 5.07), midwife profession (AOR = 1.45, 95%CI: 1.98, 4.27), and working in satisfactory delivery rooms (AOR = 3.45, 95%CI: 2.09, 7.43), were significantly associated with a health professional good practice of labor pain management. ConclusionThis study showed that the practice of non-pharmacological labor pain management was poor in public health facilities in Gamo and Gofa zone. It was observed that having a favorable attitude, having >= 5 years of work experience, being a midwife by professional, and having a satisfactory delivery room were found to be significant predictors of the practice of non -pharmacological labor pain management. Therefore, all health facilities and concerned bodies need efforts to focus on providing training to midwives on non-pharmacological labor pain management practice.	[Wassihun, Biresaw; Alemayehu, Yosef; Gultie, Teklemariam] Arba Minch Univ, Coll Med & Hlth Sci, Dept Midwifery, Arba Minch, Ethiopia; [Tekabe, Beemnet] Arba Minch Univ, Coll Med & Hlth Sci, Dept Hlth Informat, Arba Minch, Ethiopia; [Gebeyehu, Birhaneselasie] Univ Gondar, Coll Med & Hlth Sci, Sch Nursing, Dept Med Nursing, Gondar, Ethiopia	Arba Minch University; Arba Minch University; University of Gondar	Wassihun, B (corresponding author), Arba Minch Univ, Coll Med & Hlth Sci, Dept Midwifery, Arba Minch, Ethiopia.	bireswas@gmail.com	Gultie, Teklemariam/H-5819-2019	Gultie, Teklemariam/0000-0001-7266-8569; Alemayehu Gebrehiwot, Yosef/0000-0002-7233-3029				Arba MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151082; Aziato L, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0398-y; Bishaw KA, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-2844-z; Cyna AM, 2004, BRIT J ANAESTH, V93, P505, DOI 10.1093/bja/aeh225; Geltore TE, 2018, J PAIN RES, V11, P3089, DOI 10.2147/JPR.S165417; FMOH, 2013, FMOH STAND MIDW CAR, P64; Gido R., 2021, OBSTET GYNECOL INT, V2021, P9973001; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; Iliadou M., 2009, HLTH SCI J, V3, P197; Klein MC, 2001, BIRTH-ISS PERINAT C, V28, P243, DOI 10.1046/j.1523-536X.2001.00243.x; Mugambe JM, 2007, S AFR FAM PRACT, V49, P16, DOI 10.1080/20786204.2007.10873535; Mung'ayi V, 2008, East Afr Med J, V85, P438; Nystedt A, 2004, J CLIN NURS, V13, P455, DOI 10.1046/j.1365-2702.2003.00849.x; Ogboli-Nwasor E, 2011, J Pain Res, V4, P227, DOI 10.2147/JPR.S21085; Ohaeri Beatrice, 2019, Eur J Midwifery, V3, P3, DOI 10.18332/ejm/99544; Organization WH, 2019, TRENDS MAT MORT 2000; Roets L, 2005, Curationis, V28, P73; Sahile E, 2017, HLTH SCI J, V11; Sauls DJ, 2002, JOGNN, V31, P733, DOI 10.1177/088421702129005380; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; Tasnim S, 2010, MED TODAY, V22, P20, DOI [10.3329/medtoday, DOI 10.3329/MEDTODAY]; Thomson G, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0735-4; Vehvilainen-Julkunen K, 2014, ANN MED HEALTH SCI R, V4, P511, DOI 10.4103/2141-9248.139290; WHO, 2016, ETH DEM HLTH SURV	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266322	10.1371/journal.pone.0266322	http://dx.doi.org/10.1371/journal.pone.0266322			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1F9GM	35446867	gold, Green Published			2023-01-03	WOS:000795468200041
J	Verdaguer, X				Verdaguer, Xavier			Phosphorus through the looking glass	SCIENCE			English	Editorial Material								A key building block enables a general synthesis of chiral phosphorus drugs	[Verdaguer, Xavier] Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain; [Verdaguer, Xavier] Univ Barcelona, Dept Quim Inorgan & Organ, Seccio Quim Organ, Barcelona 08028, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Verdaguer, X (corresponding author), Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain.; Verdaguer, X (corresponding author), Univ Barcelona, Dept Quim Inorgan & Organ, Seccio Quim Organ, Barcelona 08028, Spain.	xavier.verdaguer@irbbarcelona.org						DiRocco DA, 2017, SCIENCE, V356, P426, DOI 10.1126/science.aam7936; Featherston AL, 2021, SCIENCE, V371, P702, DOI 10.1126/science.abf4359; Forbes KC, 2022, SCIENCE, V376, P1230, DOI 10.1126/science.abp8488; Knouse KW, 2018, SCIENCE, V361, P1234, DOI 10.1126/science.aau3369; KNOWLES WS, 1983, ACCOUNTS CHEM RES, V16, P106, DOI 10.1021/ar00087a006; Lemouzy S, 2020, EUR J ORG CHEM, V2020, P3351, DOI 10.1002/ejoc.202000406; McGuigan C, 2005, J MED CHEM, V48, P3504, DOI 10.1021/jm0491400; Meisenheimer J, 1911, BER DTSCH CHEM GES, V44, P356, DOI 10.1002/cber.19110440154; Zhang H, 2020, J MED CHEM, V63, P3785, DOI 10.1021/acs.jmedchem.9b01039	9	0	0	12	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2022	376	6598					1157	1158		10.1126/science.abq5073	http://dx.doi.org/10.1126/science.abq5073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E6FT	35679417				2023-01-03	WOS:000812323000017
J	Tesfau, YB; Gebrehiwot, TG; Godefay, H; Kahsay, AB				Tesfau, Yemane Berhane; Gebrehiwot, Tesfay Gebregzabher; Godefay, Hagos; Kahsay, Alemayehu Bayray			Effect of health facility linkage with community using postnatal card on postnatal home visit coverage and newborn care practices in rural Ethiopia: A controlled quasi-experimental study design	PLOS ONE			English	Article							NEONATAL-MORTALITY; INTERVENTION; BANGLADESH; DEATHS; PERIOD; TRIAL	Background Postnatal home visit has the potential to improve maternal and newborn health, but it remains as a missed opportunity in many low-and middle-income countries. This study examines the effect of health extension worker administered postnatal card combined with health facility strengthening intervention on postnatal home visit coverage, newborn care practices, and knowledge of newborn danger signs in rural Ethiopia. Methods We employed quasi-experimental design using controlled before-and-after study in intervention and comparison districts of rural Tigray, northern Ethiopia. Training of health extension workers (HEWs) on postnatal home visit (PNHV), training of healthcare providers on maternal and newborn care, and capacity building of healthcare authorities on leadership, management and governance together with health system strengthening were the implemented interventions. Baseline (n = 705) and end line (n = 980) data were collected from mothers who delivered a year before the commencement of the actual data collection in the respective surveys. We used difference-in-differences (DiD) analysis to assess the effect of the intervention on PNHV coverage, essential newborn care practices and maternal knowledge of newborn danger signs. Results A total of 1685 (100%) mothers participated in this study. In all districts, more than 1/3(rd) of the mothers 633(37.57%) were in the age of 30-39 years. The difference-in-differences estimator showed an average of 23.5% increase in coverage of PNHVs within three days (DiD, p<0.001) and the provision of most postnatal contents significantly increased in the intervention district in the end line survey. The knowledge of at least three danger signs increased by 13.6% (p = 0.012).The DiD estimator showed an average of 27.6% increase to check the mothers for heavy bleeding (DiD, p = 0.011). This study also revealed that the checking of maternal blood pressure increased from 5.8% to 11.8% in the comparison districts and from 9.4% to 93.3% in the intervention district. The difference-in-differences estimator result showed a 9% difference in clean cord care practices among the participants (p = 0.025), 12.2% in skin to skin care (p = 0.022), and borderline significant increase in early initiation of breastfeeding (10.5%, p = 0.051). Conclusion We conclude that the intervention package was effective in improving the coverage of PNHV, increase in knowledge of newborn danger sign and essential newborn care practices. Hence, further strengthening the linkages between health facilities and community is imperative to improve the coverage of essential lifesaving maternal and newborn care services by HEWs at home.	[Tesfau, Yemane Berhane] Adigrat Univ, Coll Med & Hlth Sci, Adigrat, Ethiopia; [Tesfau, Yemane Berhane; Gebrehiwot, Tesfay Gebregzabher; Kahsay, Alemayehu Bayray] Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia; [Godefay, Hagos] Tigray Reg Hlth Bur, Mekelle, Ethiopia	Mekelle University	Tesfau, YB (corresponding author), Adigrat Univ, Coll Med & Hlth Sci, Adigrat, Ethiopia.; Tesfau, YB (corresponding author), Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia.	yemaneberhane12@gmail.com			Tigray regional health bureau	Tigray regional health bureau	The authors are grateful to the Tigray regional health bureau and the four district health offices for their facilitation and support of the fieldwork. Lastly, the authors would like to thank the data collectors and the study participants.	Adam MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104027; Aiga H, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2788-4; Akibu M, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/8625437; ALAUDDIN M, 1986, STUD FAMILY PLANN, V17, P13, DOI 10.2307/1966951; Altaye DE, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1978-8; Alvarado R, 1999, STUD FAMILY PLANN, V30, P133, DOI 10.1111/j.1728-4465.1999.00133.x; [Anonymous], 2018, S E ZONE ADMNISTRATI; [Anonymous], 2014, WHO RECOMMENDATIONS; August F, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0916-x; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bang RA, 2004, BJOG-INT J OBSTET GY, V111, P231, DOI 10.1111/j.1471-0528.2004.00063.x; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Barry D, 2014, J MIDWIFERY WOM HEAL, V59, pS44, DOI 10.1111/jmwh.12171; Batistatou E, 2014, STATA J, V14, P159, DOI 10.1177/1536867X1401400111; Beraki GG, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-019-2694-8; Bhutta ZA, 2008, B WORLD HEALTH ORGAN, V86, P452, DOI 10.2471/BLT.07.045849; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bulto GA, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4583-7; Callaghan-Koru JA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-198; Central SA Program TD ICF Rockville M USA, 2019, ETH MIN DEM HLTH SUR; Chan G. J., 2021, Journal of Global Health Reports, V5, DOI 10.29392/001c.22125; Crigler L., 2013, SUPERVISION COMMUNIT; DiBari JN, 2014, J PREGNANCY, V2014, DOI 10.1155/2014/530769; EDHS E., 2016, DHS PROGRAM ICF, V363, P364; Ekirapa E., 2017, RURAL UGANDA GLOBAL; EPHI I, 2019, ETH MIN DEM HLTH SUR; Gogia S, 2016, J PERINATOL, V36, pS54, DOI 10.1038/jp.2016.33; Gogia S, 2010, B WORLD HEALTH ORGAN, V88, P658, DOI 10.2471/BLT.09.069369; Guenther T, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010808; Habib A., 2019, INT J COMMUNITY MED, V6, P4682, DOI DOI 10.18203/2394-6040.IJCMPH20195040; Hanson C, 2017, B WORLD HEALTH ORGAN, V95, P453, DOI 10.2471/BLT.16.175844; Hodgins S., 2017, POSTNATAL CARE FOCUS; Kananura RM, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1362826; Kerie MW., CONTRIBUTION HLTH SE; Kirkwood BR, 2013, LANCET, V381, P2184, DOI 10.1016/S0140-6736(13)60095-1; Koblinsky M, 2010, ETHIOP J HEALTH DEV, V24, P105; Lee BX, 2016, J PUBLIC HEALTH POL, V37, pS13, DOI 10.1057/s41271-016-0002-7; Limenih Miteku Andualem, 2016, Int J Reprod Med, V2016, P7095352, DOI 10.1155/2016/7095352; McPherson R, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010422; Namazzi G, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1345495; Organization WH, 2012, INF M PROV HOM BAS C; Penfold S, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-187; Probandari A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2490-y; Prost A, 2013, LANCET, V381, P1736, DOI 10.1016/S0140-6736(13)60685-6; Shaban IA, 2018, HOME HEALTH CARE SER, V37, P247, DOI 10.1080/01621424.2018.1454865; Sinha LN., 2013, WPSAR, V5, P22; Sitrin D, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.23963; Somefun Oluwaseyi Dolapo, 2016, BMC Res Notes, V9, P21, DOI 10.1186/s13104-015-1823-3; Takai IU., 2015, SAHEL MED J, V18, P109, DOI DOI 10.4103/1118-8561.169282; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; Tesfau YB, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03003-w; Tesfaye S, 2014, J MIDWIFERY WOM HEAL, V59, pS55, DOI 10.1111/jmwh.12168; Teshome M., 2018, HOME BASED NEONATAL; Tewodros Tegene, 2015, Clinics in Mother and Child Health, V12, P1000172; Timilsina S., 2015, SAUDI J MED PHARM PC, V1, P87; Tsawe M, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0162-2; Ugboaja Joseph O, 2013, Niger Med J, V54, P45, DOI 10.4103/0300-1652.108895; Varma DS., 2013, J FAM WELFARE, V56, P31; Victora CG, 2016, LANCET, V387, P2049, DOI 10.1016/S0140-6736(15)00519-X; Waiswa P, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.24584; Workineh YG, 2014, SCI J PUBLIC HLTH, V2, P169, DOI [10.11648/j.sjph.20140203.15, DOI 10.11648/J.SJPH.20140203.15]	61	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2022	17	5							e0267686	10.1371/journal.pone.0267686	http://dx.doi.org/10.1371/journal.pone.0267686			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5I1ZV	35552558	gold, Green Published			2023-01-03	WOS:000868164600028
J	Suran, M				Suran, Melissa			Center for Medicare Director Envisions Holistic Approach to Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13					1214	1215		10.1001/jama.2022.4289	http://dx.doi.org/10.1001/jama.2022.4289		MAR 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35293970				2023-01-03	WOS:000770397800003
J	Alferiev, IS; Guerrero, DT; Guan, P; Nguyen, F; Kolla, V; Soberman, D; Pressly, BB; Fishbein, I; Brodeur, GM; Chorny, M				Alferiev, Ivan S.; Guerrero, David T.; Guan, Peng; Nguyen, Ferro; Kolla, Venkatadri; Soberman, Danielle; Pressly, Benjamin B.; Fishbein, Ilia; Brodeur, Garrett M.; Chorny, Michael			Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance	FASEB JOURNAL			English	Article						ABCG2; drug resistance; neuroblastoma; SN22; topoisomerase I inhibitor	MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CELL-LINES; POLY(ETHYLENE GLYCOL); CAMPTOTHECIN ANALOGS; P53 MUTATIONS; CANCER	High-risk solid tumors continue to pose a tremendous therapeutic challenge due to multidrug resistance. Biological mechanisms driving chemoresistance in high-risk primary and recurrent disease are distinct: in newly diagnosed patients, non-response to therapy is often associated with a higher level of tumor "stemness" paralleled by overexpression of the ABCG2 drug efflux pump, whereas in tumors relapsing after non-curative therapy, poor drug sensitivity is most commonly linked to the dysfunction of the tumor suppressor protein, p53. In this study, we used preclinical models of aggressive neuroblastoma featuring these characteristic mechanisms of primary and acquired drug resistance to experimentally evaluate a macromolecular prodrug of a structurally enhanced camptothecin analog, SN22, resisting ABCG2-mediated export, and glucuronidation. Together with extended tumor exposure to therapeutically effective drug levels via reversible conjugation to Pluronic F-108 (PF108), these features translated into rapid tumor regression and long-term survival in models of both ABCG2-overexpressing and p53-mutant high-risk neuroblastomas, in contrast to a marginal effect of the clinically used camptothecin derivative, irinotecan. Our results demonstrate that pharmacophore enhancement, increased tumor uptake, and optimally stable carrier-drug association integrated into the design of the hydrolytically activatable PF108-[SN22](2) have the potential to effectively combat multiple mechanisms governing chemoresistance in newly diagnosed (chemo-naive) and recurrent forms of aggressive malignancies. As a macromolecular carrier-based delivery system exhibiting remarkable efficacy against two particularly challenging forms of high-risk neuroblastoma, PF108-[SN22](2) can pave the way to a robust and clinically viable therapeutic strategy urgently needed for patients with multidrug-resistant disease presently lacking effective treatment options.	[Alferiev, Ivan S.; Guerrero, David T.; Guan, Peng; Nguyen, Ferro; Kolla, Venkatadri; Soberman, Danielle; Pressly, Benjamin B.; Fishbein, Ilia; Brodeur, Garrett M.; Chorny, Michael] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Abramson Res Bldg,Suite 702,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Chorny, M (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Abramson Res Bldg,Suite 702,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	chorny@chop.edu	Guan, Peng/GWM-9170-2022	Chorny, Michael/0000-0002-8243-9089	HHS \ NIH \ National Cancer Institute (NCI) [R01-CA251883]; Solving Kids' Cancer (SKC); Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF); CURE Childhood Cancer (CURE); Peel Therapeutics; Audrey E. Evans Endowed Chair; U.S. Department of Defense (DOD) [W81XWH2110536]	HHS \ NIH \ National Cancer Institute (NCI); Solving Kids' Cancer (SKC); Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF); CURE Childhood Cancer (CURE); Peel Therapeutics; Audrey E. Evans Endowed Chair; U.S. Department of Defense (DOD)(United States Department of Defense)	HHS vertical bar NIH vertical bar National Cancer Institute (NCI), Grant/Award Number: R01-CA251883; Solving Kids' Cancer (SKC); Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF); CURE Childhood Cancer (CURE); Peel Therapeutics; Audrey E. Evans Endowed Chair; U.S. Department of Defense (DOD), Grant/Award Number: W81XWH2110536	Alakhova DY, 2014, MOL PHARMACEUT, V11, P2566, DOI 10.1021/mp500298q; Alvarez-Lorenzo C, 2011, CURR DRUG TARGETS, V12, P1112, DOI 10.2174/138945011795906615; Bates SE, 2004, J PHARMACOL EXP THER, V310, P836, DOI 10.1124/jpet.103.063149; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; Brangi M, 1999, CANCER RES, V59, P5938; Byrne FL, 2016, METHODS MOL BIOL, V1372, P61, DOI 10.1007/978-1-4939-3148-4_5; Chen L, 2018, INT J ONCOL, V52, P967, DOI 10.3892/ijo.2018.4261; Chesler L, 2011, SEMIN CANCER BIOL, V21, P245, DOI 10.1016/j.semcancer.2011.09.011; Cialfi S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.9524; Davis SS, 2002, DRUG DISCOV TODAY, V7, P1159, DOI 10.1016/S1359-6446(02)02517-5; Ekladious I, 2019, NAT REV DRUG DISCOV, V18, P273, DOI 10.1038/s41573-018-0005-0; Fox ME, 2009, ACCOUNTS CHEM RES, V42, P1141, DOI 10.1021/ar900035f; Gandhi YA, 2009, AAPS J, V11, P541, DOI 10.1208/s12248-009-9132-1; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Ivens IA, 2015, TOXICOL PATHOL, V43, P959, DOI 10.1177/0192623315591171; Keshelava N, 2001, CANCER RES, V61, P6185; Keshelava N, 1998, CANCER RES, V58, P5396; Keshelava N, 2000, CANCER CHEMOTH PHARM, V45, P1, DOI 10.1007/PL00006736; Keshelava N, 2000, MED PEDIATR ONCOL, V35, P563, DOI 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J; KUNIMOTO T, 1987, CANCER RES, V47, P5944; Kuosmanen T, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009418; Laetsch TW, 2021, CANCER DISCOV, V11, P545, DOI 10.1158/2159-8290.CD-20-0779; Lele BS, 1998, J APPL POLYM SCI, V70, P883, DOI 10.1002/(SICI)1097-4628(19981031)70:5<883::AID-APP7>3.0.CO;2-P; London WB, 2017, CANCER-AM CANCER SOC, V123, P4914, DOI 10.1002/cncr.30934; Maskarinec SA, 2003, LANGMUIR, V19, P1809, DOI 10.1021/la026175z; Moloughney Joseph G, 2012, Recent Pat Biotechnol, V6, P200; MOORE JS, 1990, MACROMOLECULES, V23, P65, DOI 10.1021/ma00203a013; Nakagawa H, 2006, CANCER LETT, V234, P81, DOI 10.1016/j.canlet.2005.05.052; Nema Sandeep, 2011, PDA J Pharm Sci Technol, V65, P287, DOI 10.5731/pdajpst.2011.00634; Nguyen F, 2020, CANCER RES, V80, P4258, DOI 10.1158/0008-5472.CAN-20-1344; Pastorino F, 2010, CLIN CANCER RES, V16, P4809, DOI 10.1158/1078-0432.CCR-10-1354; Patterson Danielle M, 2011, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1417s52; Pitto-Barry A, 2014, POLYM CHEM-UK, V5, P3291, DOI 10.1039/c4py00039k; Polunin Y, 2021, ACS PHARMACOL TRANSL, V4, P240, DOI 10.1021/acsptsci.0c00182; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; Sapra P, 2008, CLIN CANCER RES, V14, P1888, DOI 10.1158/1078-0432.CCR-07-4456; Sawada S., 1995, CURR PHARM DESIGN, V1, P113; Schellens JHM, 2000, ANN NY ACAD SCI, V922, P188; Serrano LA, 2018, CHEM COMMUN, V54, P1485, DOI 10.1039/c7cc07668a; Shah N., 2019, CANC DRUG RESIST, V2, P428; Singh-Joy SD, 2008, INT J TOXICOL, V27, P93, DOI 10.1080/10915810802244595; Singla P, 2022, ADV COLLOID INTERFAC, V299, DOI 10.1016/j.cis.2021.102563; Smith V, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5090114; Strickley RG, 2004, PHARM RES-DORDR, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Swift CC, 2018, RADIOGRAPHICS, V38, P566, DOI 10.1148/rg.2018170132; Teitz T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019133; Thomas A, 2019, CLIN CANCER RES, V25, P6581, DOI 10.1158/1078-0432.CCR-19-1089; Toyoda Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00208; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Tweddle DA, 2001, CANCER RES, V61, P8; Westover D, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0275-x; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Wu CP, 2011, MOL PHARMACEUT, V8, P1996, DOI 10.1021/mp200261n; Yamauchi T, 2011, ONCOL REP, V25, P347, DOI 10.3892/or.2010.1100; Yoshikawa M, 2004, INT J CANCER, V110, P921, DOI 10.1002/ijc.20216; Zage PE, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5110148; Zhao H, 2008, BIOCONJUGATE CHEM, V19, P849, DOI 10.1021/bc700333s	59	0	0	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2022	36	3							e22213	10.1096/fj.202101830RR	http://dx.doi.org/10.1096/fj.202101830RR			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZH9LM	35192728	hybrid, Green Published			2023-01-03	WOS:000761250800037
J	Ahmad, T; Khan, FU; Ali, S; Rahman, AU; Khan, SA				Ahmad, Tawseef; Khan, Faiz Ullah; Ali, Sayyad; Rahman, Asad Ur; Khan, Shujaat Ali			Assessment of without prescription antibiotic dispensing at community pharmacies in Hazara Division, Pakistan: A simulated client's study	PLOS ONE			English	Article							SELF-MEDICATION; ANTIMICROBIAL RESISTANCE; ACUTE DIARRHEA; KNOWLEDGE; DETERMINANTS; PERCEPTIONS; EUROPE; SALES; CHINA	Antibiotics dispensing without a prescription is an irrational practice and can increase the risk of antibiotic resistance, which is a significant public health concern around the globe. This study was aimed to determine the extent to which antibiotics are supplied without prescription in the community pharmacies (CPs) at Hazara Division from November 2020 to February 2021. The simulated client method (SCM) was used, and the data were gathered, recorded, and analyzed through different statistical methods with descriptive and inferential techniques. The antibiotic dispensing was observed in CPs (90.5%), the most dispensed antibiotics were azithromycin (29.4%) and ciprofloxacin (46.5%) respectively. Furthermore, visited medical stores/ drug outlets, 9.5% of the visited stores denied dispensing of antibiotics because they preferred a referral to visit physicians (23. 9%) and (12.8%) did not had the antibiotics at the time of visits. Antibiotics were more obtainable in retail medical stores (AOR = 8.6, 95 percent Cl: 3.0-24.7; p = 0.001) than in pharmacies. In rural areas antibiotics dispensing was more (p = 0.004) as compared to urban areas. Staff members also had asked about patient's (17.7%) symptoms and drug allergies (12.3% and 3.9%), and (1.5%) they consoled them about their medications. The findings of this study indicate that nonprescription antibiotic sales are very common, despite national rules prohibiting this activity. When the simulated Client requested for any medication to relieve his or her discomfort, many antibiotics were given out without a prescription. Pharmacies/medical stores in Hazara Division selling antibiotics without a prescription are worrying and need immediate action by regulators.	[Ahmad, Tawseef; Ali, Sayyad; Rahman, Asad Ur; Khan, Shujaat Ali] COMSATS Univ Islamabad, Dept Pharm, Abbottabad Campus, Abbottabad, Pakistan; [Khan, Faiz Ullah] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Peoples R China	COMSATS University Islamabad (CUI); Xi'an Jiaotong University	Khan, SA (corresponding author), COMSATS Univ Islamabad, Dept Pharm, Abbottabad Campus, Abbottabad, Pakistan.	drshujatalikhan@cuiatd.edu.pk	Khan, Faiz Ullah/N-9346-2017	Khan, Faiz Ullah/0000-0002-1022-8688; Rahman, Asad ur/0000-0001-6862-0554				Akinyandenu O, 2014, J SCI INNOV RES, V3, P251; Akkerman AE, 2005, J ANTIMICROB CHEMOTH, V56, P930, DOI 10.1093/jac/dki283; Alhomoud F, 2017, INT J INFECT DIS, V57, P3, DOI 10.1016/j.ijid.2017.01.014; Auta A, 2019, J INFECTION, V78, P8, DOI 10.1016/j.jinf.2018.07.001; Ayukekbong JA, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0208-x; Azkarate I, 2012, MED INTENSIVA, V36, P250, DOI 10.1016/j.medin.2011.10.006; Bahta M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228013; Chang J, 2017, J ANTIMICROB CHEMOTH, V72, P1235, DOI 10.1093/jac/dkw519; Damisie G, 2019, J PHARMACEUTICS, V2019, DOI 10.1155/2019/3510659; de Kraker MEA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002184; Ekambi GAE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212875; Farah R, 2015, J INFECT PUBLIC HEAL, V8, P37, DOI 10.1016/j.jiph.2014.07.003; Gaash B, 2008, INDIAN J PRACTISING, V5, P2008; Gillani AH, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101152; Grigoryan L, 2008, J ANTIMICROB CHEMOTH, V61, P1172, DOI 10.1093/jac/dkn054; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Haddadin RN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216115; Holloway KA, 2017, BMJ-BRIT MED J, V358, P9, DOI 10.1136/bmj.j2291; Horumpende PG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207465; Hoxha I, 2015, INT J RES DEV PHARM, V4, P1545; Hussain A, 2019, EUR J CLIN MICROBIOL, V38, P2145, DOI 10.1007/s10096-019-03658-0; Kalungia A, 2019, LANCET INFECT DIS, V19, P1272, DOI 10.1016/S1473-3099(19)30408-6; Kalungia AC, 2016, EXPERT REV ANTI-INFE, V14, P1215, DOI 10.1080/14787210.2016.1227702; Karras DJ, 2003, ANN EMERG MED, V42, P835, DOI 10.1016/S0196-0644(03)00602-4; Khan FU, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18031320; Khan FU, 2021, EURASIAN BUS REV, V11, P497, DOI 10.1007/s40821-020-00154-w; Khan SA, 2010, MANUAL DRUG LAWS CON; Kot B, 2019, POL J MICROBIOL, V68, P403, DOI 10.33073/pjm-2019-048; Laxminarayan R, 2016, SCIENCE, V353, P874, DOI 10.1126/science.aaf9286; Liu B, 2018, J HETEROCYCLIC CHEM, V55, P1863, DOI 10.1002/jhet.3241; Llor C, 2009, CLIN INFECT DIS, V48, P1345, DOI 10.1086/598183; Malik UR, 2021, INFECT DRUG RESIST, V14, P1129, DOI 10.2147/IDR.S301812; Markovic-Pekovic V, 2017, J RES PHARM PRACT, V6, P120, DOI 10.4103/jrpp.JRPP_17_12; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Nepal G, 2018, CUREUS, V10, DOI 10.7759/cureus.2428; Ocan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2109-3; Prestinaci F, 2015, PATHOG GLOB HEALTH, V109, P309, DOI 10.1179/2047773215Y.0000000030; Rasheed H, 2019, ENCY PHARM PRACTICE, P317; Rezal RSM, 2015, EXPERT REV ANTI-INFE, V13, P665, DOI 10.1586/14787210.2015.1025057; Ronning M, 2003, EUR J CLIN PHARMACOL, V58, P843, DOI 10.1007/s00228-003-0572-8; Sakeena MHF, 2018, INT J ANTIMICROB AG, V52, P771, DOI 10.1016/j.ijantimicag.2018.09.022; Saleem Z, 2020, J PHARM POLICY PRACT, V13, DOI 10.1186/s40545-020-00233-3; Saleem Z, 2018, LANCET INFECT DIS, V18, P1066, DOI 10.1016/S1473-3099(18)30516-4; Saleem Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149929; Sarwar MR, 2018, INFECT DRUG RESIST, V11, P133, DOI 10.2147/IDR.S148102; Servia-Dopazo M, 2018, J ANTIMICROB CHEMOTH, V73, P3244, DOI 10.1093/jac/dky319; Torres NF, 2019, PUBLIC HEALTH, V168, P92, DOI 10.1016/j.puhe.2018.11.018; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Ventola C Lee, 2015, P T, V40, P277; WHO, 2009, MED USE DEV TRANS CO; WHO, 2015, WORLD HLTH ASS ANT R; World Health Organization, 2002, PROMOTING RATIONAL U; Ye D, 2017, INT J CLIN PHARM-NET, V39, P927, DOI 10.1007/s11096-017-0472-0; Zapata-Cachafeiro M, 2019, J ANTIMICROB CHEMOTH, V74, P511, DOI 10.1093/jac/dky440; Zawahir S, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0510-x	55	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0263756	10.1371/journal.pone.0263756	http://dx.doi.org/10.1371/journal.pone.0263756			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176043	Green Published, gold			2023-01-03	WOS:000777505200030
J	Collazos, J; Domingo, P; Fernandez-Araujo, N; Asensi-Diaz, E; Vilchez-Rueda, H; Lalueza, A; Roy-Vallejo, E; Blanes, R; Raya-Cruz, M; Sanz-Canovas, J; Artero, A; Ramos-Rincon, JM; Duenas-Gutierrez, C; Lamas-Ferreiro, JL; Asensi, V				Collazos, Julio; Domingo, Pere; Fernandez-Araujo, Nerio; Asensi-Diaz, Elia; Vilchez-Rueda, Helem; Lalueza, Antonio; Roy-Vallejo, Emilia; Blanes, Rosa; Raya-Cruz, Manuel; Sanz-Canovas, Jaime; Artero, Arturo; Ramos-Rincon, Jose-Manuel; Duenas-Gutierrez, Carlos; Luis Lamas-Ferreiro, Jose; Asensi, Victor		Valproic Acid COVID-19 Study Grp	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19	PLOS ONE			English	Article								Background Valproic acid (VPA) has shown beneficial effects in vitro against SARS-CoV-2 infection, but no study has analyzed its efficacy in the clinical setting. Methods This multicenter, retrospective study included 165 adult patients receiving VPA at the time of admission to hospital, and 330 controls matched for sex, age and date of admission. A number of clinical, outcome and laboratory parameters were recorded to evaluate differences between the two groups. Four major clinical endpoints were considered: development of lung infiltrates, in-hospital respiratory worsening, ICU admissions and death. Results VPA-treated patients had higher lymphocyte (P<0.0001) and monocyte (P = 0.0002) counts, and lower levels of diverse inflammatory parameters, including a composite biochemical severity score (P = 0.016). VPA patients had shorter duration of symptoms (P<0.0001), were more commonly asymptomatic (P = 0.016), and developed less commonly lung infiltrates (65.8%/88.2%, P<0.0001), respiratory worsening (20.6%/30.6%, P = 0.019) and ICU admissions (6.1%/13.0%, P = 0.018). There was no difference in survival (84.8%/88.8%, P = 0.2), although death was more commonly related to non-COVID-19 causes in the VPA group (36.0%/10.8%, P = 0.017). The cumulative hazard for developing adverse clinical endpoints was higher in controls than in the VPA group for infiltrates (P<0.0001), respiratory worsening (P<0.0001), and ICU admissions (P = 0.001), but not for death (0.6). Multivariate analysis revealed that VPA treatment was independently protective for the development of the first three clinical endpoints (P = 0.0002, P = 0.03, and P = 0.025, respectively), but not for death (P = 0.2). Conclusions VPA-treated patients seem to develop less serious COVID-19 than control patients, according to diverse clinical endpoints and laboratory markers.	[Collazos, Julio] Hosp Galdakao Usansolo, Infect Dis Sect, Galdakao, Vizcaya, Spain; [Domingo, Pere] Hosp Santa Creu & Sant Pau, Infect Dis Dept, Barcelona, Spain; [Fernandez-Araujo, Nerio] Hosp Gen Univ Gregorio Maranon, Intens Care Unit, Madrid, Spain; [Asensi-Diaz, Elia] Hosp Univ Fdn Jimenez Diaz, Internal Med Serv, Madrid, Spain; [Vilchez-Rueda, Helem] Hosp Univ Son Espases, Infect Dis Sect, Palma De Mallorca, Spain; [Lalueza, Antonio] Hosp 12 Octubre, Internal Med Serv, Madrid, Spain; [Roy-Vallejo, Emilia] Hosp Univ Princesa, Infect Dis Sect, Madrid, Spain; [Blanes, Rosa] Hosp Univ & Politecn La Fe, Internal Med Serv, Valencia, Spain; [Raya-Cruz, Manuel] Hosp Son Llatzer, Internal Med Serv, Palma De Mallorca, Spain; [Sanz-Canovas, Jaime] Hosp Reg Univ, Internal Med Serv, Malaga, Spain; [Artero, Arturo] Hosp Univ Dr Peset, Internal Med Serv, Valencia, Spain; [Ramos-Rincon, Jose-Manuel] Hosp Gen Univ, Internal Med Serv, Alicante, Spain; [Duenas-Gutierrez, Carlos] Hosp Clin Univ, Infect Dis Unit, Valladolid, Spain; [Luis Lamas-Ferreiro, Jose] Hosp POVISA, Internal Med Serv, Pontevedra, Spain; [Asensi, Victor] Hosp Univ Cent Asturias, Infect Dis Unit, Oviedo, Spain	Galdakao Hospital; Hospital of Santa Creu i Sant Pau; General University Gregorio Maranon Hospital; Hospital Universitari Son Espases; Hospital Universitario 12 de Octubre; Hospital de La Princesa; Hospital Universitari i Politecnic La Fe; Hospital Universitari Son Llatzer; General University Hospital of Alicante; Central University Hospital Asturias	Asensi, V (corresponding author), Hosp Univ Cent Asturias, Infect Dis Unit, Oviedo, Spain.	vasensia@gmail.com	Ramos, Jose M./B-6420-2018	Ramos, Jose M./0000-0002-6501-9867; Raya-Cruz, Manuel/0000-0001-8669-3634; Roy Vallejo, Emilia/0000-0001-5253-5785; Lalueza, Antonio/0000-0003-2711-3817				Agbuduwe C, 2020, EUR J HAEMATOL, V105, P540, DOI 10.1111/ejh.13491; Aldaz A, 2011, Farm Hosp, V35, P326, DOI 10.1016/j.farma.2010.10.005; Andreu S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121356; Anurag A, 2020, DIABETES METAB SYND, V14, P2099, DOI 10.1016/j.dsx.2020.10.029; Asadi-Pooya AA, 2021, ACTA NEUROL SCAND, V143, P624, DOI 10.1111/ane.13404; Bartels M, 2012, J CLIN PSYCHOPHARM, V32, P832, DOI 10.1097/JCP.0b013e318270e5e2; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhargava P., 2020, CANC RES STAT TREAT, V3, P65, DOI [10.4103/CRST.CRST_156_20, DOI 10.4103/CRST.CRST_156_20]; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Fischer William, 2021, medRxiv, DOI 10.1101/2021.06.17.21258639; Fujii K, 2012, HEMATOLOGY, V17, P163, DOI 10.1179/102453312X13376952196494; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Gao HT, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106890; Gil M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091442; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Ornaghi S, 2016, VIROLOGY, V499, P121, DOI 10.1016/j.virol.2016.09.012; Patra A, VIRTUAL SCREENING MO, DOI [10.20944/preprints2020203.0393.v1, DOI 10.20944/PREPRINTS2020203.0393.V1]; Patsalos PN, 2018, THER DRUG MONIT, V40, P526, DOI 10.1097/FTD.0000000000000546; Reis G, 2022, LANCET GLOB HEALTH, V10, pE36, DOI 10.1016/S2214-109X(21)00448-4; Rentsch CT, 2021, LANCET RHEUMATOL, V3, pE19, DOI 10.1016/S2665-9913(20)30378-7; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Saiz ML, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01168-5; Sanchez-Larsen A, 2021, EPILEPSY BEHAV, V125, DOI 10.1016/j.yebeh.2021.108379; Singh S., 2020, INT J RESPIR PULM ME, V7, P138, DOI [10.23937/2378-3516/1410138, DOI 10.23937/2378-3516/1410138]; Snow TAC, 2021, INTENS CARE MED, V47, P641, DOI 10.1007/s00134-021-06416-z; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Sun SY, 2020, CLIN CHIM ACTA, V507, P174, DOI 10.1016/j.cca.2020.04.024; Unal G, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109891; Vazquez-Calvo A, 2011, J VIROL, V85, P1267, DOI 10.1128/JVI.01717-10; Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994	34	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262777	10.1371/journal.pone.0262777	http://dx.doi.org/10.1371/journal.pone.0262777			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085321	Green Published, gold			2023-01-03	WOS:000779379600081
J	Paolillo, G; Petrini, A; Casiraghi, E; De Iorio, MG; Biffani, S; Pagnacco, G; Minozzi, G; Valentini, G				Paolillo, Gianluigi; Petrini, Alessandro; Casiraghi, Elena; De Iorio, Maria Grazia; Biffani, Stefano; Pagnacco, Giulio; Minozzi, Giulietta; Valentini, Giorgio			Automated image analysis to assess hygienic behaviour of honeybees	PLOS ONE			English	Article							BEES; RESISTANCE; LINES	Focus of this study is to design an automated image processing pipeline for handling uncontrolled acquisition conditions of images acquired in the field. The pipeline has been tested on the automated identification and count of uncapped brood cells in honeybee (Apis Mellifera) comb images to reduce the workload of beekeepers during the study of the hygienic behavior of honeybee colonies. The images used to develop and test the model were acquired by beekeepers on different days and hours in summer 2020 and under uncontrolled conditions. This resulted in images differing for background noise, illumination, color, comb tilts, scaling, and comb sizes. All the available 127 images were manually cropped to approximately include the comb area. To obtain an unbiased evaluation, the cropped images were randomly split into a training image set (50 images), which was used to develop and tune the proposed model, and a test image set (77 images), which was solely used to test the model. To reduce the effects of varied illuminations or exposures, three image enhancement algorithms were tested and compared followed by the Hough Transform, which allowed identifying individual cells to be automatically counted. All the algorithm parameters were automatically chosen on the training set by grid search. When applied to the 77 test images the model obtained a correlation of 0.819 between the automated counts and the experts' counts. To provide an assessment of our model with publicly available images acquired by a different equipment and under different acquisition conditions, we randomly extracted 100 images from a comb image dataset made available by a recent literature work. Though it has been acquired under controlled exposure, the images in this new set have varied illuminations; anyhow, our pipeline obtains a correlation between automatic and manual counts equal to 0.997. In conclusion, our tests on the automatic count of uncapped honey bee comb cells acquired in the field and on images extracted from a publicly available dataset suggest that the hereby generated pipeline successfully handles varied noise artifacts, illumination, and exposure conditions, therefore allowing to generalize our method to different acquisition settings. Results further improve when the acquisition conditions are controlled.	[Paolillo, Gianluigi; De Iorio, Maria Grazia; Minozzi, Giulietta] Univ Milan, Dipartimento Med Vet, Lodi, Italy; [Petrini, Alessandro; Casiraghi, Elena; Valentini, Giorgio] Univ Milan, AnacletoLab, Comp Sci Dept Giovanni degli Antoni, Milan, Italy; [Casiraghi, Elena; Valentini, Giorgio] CINI Natl Lab Artificial Intelligence & Intellige, Rome, Italy; [Biffani, Stefano; Pagnacco, Giulio] CNR IBBA Milano, Milan, Italy	University of Milan; University of Milan	Casiraghi, E (corresponding author), Univ Milan, AnacletoLab, Comp Sci Dept Giovanni degli Antoni, Milan, Italy.; Casiraghi, E (corresponding author), CINI Natl Lab Artificial Intelligence & Intellige, Rome, Italy.	elena.casiraghi@unimi.it	Pagnacco, Giulio/K-8202-2017; Minozzi, Giulietta/K-8126-2017; Casiraghi, Elena/M-4867-2017	Pagnacco, Giulio/0000-0002-5013-5179; Biffani, Stefano/0000-0001-5559-3630; Minozzi, Giulietta/0000-0002-0020-8798; Valentini, Giorgio/0000-0002-5694-3919; Casiraghi, Elena/0000-0003-2024-7572; De Iorio, Maria Grazia/0000-0001-9150-2388	BEENOMIX project - Lombardy Region (FEASR program); BEENOMIX 2.0 project - Lombardy Region (FEASR program); PSR 2014-2020 [2016/00361532-G42F16000540002]; PSR [201801057971G44I19001910002]	BEENOMIX project - Lombardy Region (FEASR program); BEENOMIX 2.0 project - Lombardy Region (FEASR program); PSR 2014-2020; PSR	Funded study. G.M. received the funding. This work was supported by the BEENOMIX and BEENOMIX 2.0 projects funded by the Lombardy Region (FEASR program), PSR 2014-2020 (grant number 2016/00361532-G42F16000540002) and PSR (grant number 201801057971G44I19001910002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves TS, 2020, COMPUT ELECTRON AGR, V170, DOI 10.1016/j.compag.2020.105244; Avni D, 2015, JULIUS-KUHN-ARCH, V450, P103; Colin T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205816; Cornelissen B., 2009, P 41 INT AP C MONTP, V48; Cutler GC, 2014, PEERJ, V2, DOI 10.7717/peerj.652; DUDA RO, 1972, COMMUN ACM, V15, P11, DOI 10.1145/361237.361242; Emsen B., 2006, Journal of Animal and Veterinary Advances, V5, P1229; Hoferlin B., 2013, APIDOLOGIE, V44, P19; Jeker L, 2012, J APICULT RES, V51, P63, DOI 10.3896/IBRA.1.51.1.08; Lam HK, 2004, 2004 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH, AND SIGNAL PROCESSING, VOL III, PROCEEDINGS, P493; Liew L.H., 2010, P INT C SCI SOC RES, P191; Macenko M, 2009, I S BIOMED IMAGING, P1107, DOI 10.1109/ISBI.2009.5193250; Momot J. P, 1971, J Apic Res, V10, P11; NEWTON DC, 1986, AM BEE J, V126, P278; Nikitenko D., 2008, J MULTIMEDIA, V3, P921; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Rizzi A, 2003, PATTERN RECOGN LETT, V24, P1663, DOI 10.1016/S0167-8655(02)00323-9; Rodrigues PJ., 2016, EURBEE 2016 7 EUROPE; ROTHENBUHLER WC, 1964, ANIM BEHAV, V12, P578, DOI 10.1016/0003-3472(64)90082-X; Spivak M, 1998, AM BEE J, V138, P283; Vahadane A, 2016, IEEE T MED IMAGING, V35, P1962, DOI 10.1109/TMI.2016.2529665; Wang M., 2013, 8 SETAC EUR SPEC SCI; Wang M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229295; Wilson-Rich N, 2009, ANNU REV ENTOMOL, V54, P405, DOI 10.1146/annurev.ento.53.103106.093301; Yoshiyama M, 2011, J APICULT RES, V50, P170, DOI 10.3896/IBRA.1.50.2.10; Zuiderveld K., 1994, CONTRAST LTD ADAPTIV, VIV, P474, DOI DOI 10.1016/B978-0-12-336156-1.50061-6	26	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0263183	10.1371/journal.pone.0263183	http://dx.doi.org/10.1371/journal.pone.0263183			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085372	gold, Green Published			2023-01-03	WOS:000779379600125
J	Gibbs, K; Wilkie, L; Jarman, J; Barker-Smith, A; Kemp, AH; Fisher, Z				Gibbs, Katie; Wilkie, Lowri; Jarman, Jack; Barker-Smith, Abigail; Kemp, Andrew H.; Fisher, Zoe			Riding the wave into wellbeing: A qualitative evaluation of surf therapy for individuals living with acquired brain injury	PLOS ONE			English	Article							PHYSICAL-ACTIVITY INDOORS; POSITIVE PSYCHOLOGY; PEER SUPPORT; HEALTH; ENVIRONMENTS; MINDFULNESS; HAPPINESS; BENEFITS; INTERVENTIONS; ENGAGEMENT	Nature has long demonstrated the capacity to facilitate wellbeing. Interventions involving the natural environment such as surf therapy, are increasingly being used to facilitate aspects of wellbeing in clinical populations. However, explorations of how nature-based interventions such as surf therapy may be used to promote wellbeing in the context of neurorehabilitation are missing from the peer-reviewed literature. Here we characterize the experience of a five-week surfing intervention involving fifteen adults living with the psycho-social and cognitive sequelae of acquired brain injury. Insights were analysed using reflexive thematic analysis, which highlighted the importance of seven overarching themes, including: 1) Connection to Nature, 2) Facilitating Trust and Safety, 3) Managing and Accepting Difficult Emotions, 4) Facilitating Positive Emotion, Meaning and Purpose, 5) Building Community through Social Connection, and 6) Positive Change. Barriers and opportunities (theme 7) were also identified as components on which clinical services may be improved. We present a theoretical model for the benefits of surf therapy in people living with acquired brain injury (ABI) based on these themes and reflections on findings from the wider literature. Findings emphasise the importance of leveraging community partnerships to augment the holistic model of neurorehabilitation and potential implications for service redesign are discussed, focusing on recent developments in wellbeing science.	[Gibbs, Katie; Wilkie, Lowri; Kemp, Andrew H.] Swansea Univ, Fac Med Hlth & Life Sci, Sch Psychol, Swansea, W Glam, Wales; [Gibbs, Katie; Wilkie, Lowri; Jarman, Jack; Barker-Smith, Abigail; Kemp, Andrew H.; Fisher, Zoe] Morriston Hosp, Reg Neuropsychol & Community Brain Injury Serv, Swansea, W Glam, Wales; [Fisher, Zoe] Swansea Univ, Fac Med Hlth & Life Sci, Hlth & Wellbeing Acad, Swansea, W Glam, Wales	Swansea University; Morriston Hospital; Swansea University	Kemp, AH (corresponding author), Swansea Univ, Fac Med Hlth & Life Sci, Sch Psychol, Swansea, W Glam, Wales.; Kemp, AH (corresponding author), Morriston Hosp, Reg Neuropsychol & Community Brain Injury Serv, Swansea, W Glam, Wales.	a.h.kemp@swansea.ac.uk	Kemp, Andrew Haddon/C-7984-2012	Kemp, Andrew Haddon/0000-0003-1146-3791; Wilkie, Lowri/0000-0001-8446-4926; Fisher, Zoe/0000-0001-8150-2499	Welsh Government -`Integrated Care Fund Wales' [11,758.52]	Welsh Government -`Integrated Care Fund Wales'	11,758.52 pound of funding was awarded to Surfability by the Welsh Government -`Integrated Care Fund Wales' to support four surf therapy intervention groups a year for 2 years. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON RM, 1995, DIABETES CARE, V18, P412, DOI 10.2337/diacare.18.3.412; Andrewes HE, 2014, BRAIN INJURY, V28, P965, DOI 10.3109/02699052.2014.888764; Archer Margaret, 2013, CRITICAL REALISM; Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; Arem H, 2015, JAMA INTERN MED, V175, P959, DOI 10.1001/jamainternmed.2015.0533; Baer RA, 2004, ASSESSMENT, V11, P191, DOI 10.1177/1073191104268029; Bandura A., 1971, SOCIAL LEARNING THEO; Barak Y, 2009, EXPERT REV NEUROTHER, V9, P445, DOI 10.1586/ERN.09.1; Barber S, 2018, DEBATE PACK ACQUIRED; Ben-Yishay Y., 2011, HDB HOLISTIC NEUROPS, DOI [10.1101/gad.2041611 21576265, DOI 10.1101/GAD.204161121576265]; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; Berman MG, 2008, PSYCHOL SCI, V19, P1207, DOI 10.1111/j.1467-9280.2008.02225.x; Berto R, 2005, J ENVIRON PSYCHOL, V25, P249, DOI 10.1016/j.jenvp.2005.07.001; Bowler Diana E, 2010, BMC Public Health, V10, P456, DOI 10.1186/1471-2458-10-456; Braun V., 2013, SUCCESSFUL QUALITATI; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Britton E., 2020, SURFING SENSES USING; Britton E, 2020, HEALTH PROMOT INT, V35, P50, DOI 10.1093/heapro/day103; Buecker S, 2021, HEALTH PSYCHOL REV, V15, P574, DOI 10.1080/17437199.2020.1760728; Caddick N, 2015, QUAL HEALTH RES, V25, P76, DOI 10.1177/1049732314549477; Capaldi C. A., 2015, INT J WELLBEING, V5, DOI DOI 10.1080/08941920.2018.1550229; Capaldi CA, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00976; Cardaciotto L, 2008, ASSESSMENT, V15, P204, DOI 10.1177/1073191107311467; Carr A, 2021, J POSIT PSYCHOL, V16, P749, DOI 10.1080/17439760.2020.1818807; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chekroud S., 2018, LANCET PSYCHIAT, P5; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cohen S., SOCIAL RELATIONSHIPS, DOI [10.1037/0003-066X.59.8.6762004.15554821, DOI 10.1037/0003-066X.59.8.6762004.15554821]; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Coon JT, 2011, ENVIRON SCI TECHNOL, V45, P1761, DOI 10.1021/es102947t; Cullen B, 2018, NEUROPSYCHOL REHABIL, V28, P17, DOI 10.1080/09602011.2015.1131722; de Bell S, 2017, LANDSCAPE URBAN PLAN, V167, P118, DOI 10.1016/j.landurbplan.2017.06.003; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Donker-Cools BHPM, 2016, DISABIL REHABIL, V38, P733, DOI 10.3109/09638288.2015.1061608; Fisher Z, 2020, EMOTION WELLBEING NE; Fleischmann D., 2011, JPO J PROSTHETICS OR, V23, P27; Foley R, 2015, HEALTH PLACE, V35, P157, DOI 10.1016/j.healthplace.2015.07.003; Ford BQ, 2018, J PERS SOC PSYCHOL, V115, P1075, DOI 10.1037/pspp0000157; Forslund MV, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00219; Fredrickson BL, 2013, ADV EXP SOC PSYCHOL, V47, P1, DOI 10.1016/B978-0-12-407236-7.00001-2; Gascon M, 2017, INT J HYG ENVIR HEAL, V220, P1207, DOI 10.1016/j.ijheh.2017.08.004; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Godfrey C., 2015, COMMUNITY PRACTITION, V88; Haig BD, 2005, MULTIVAR BEHAV RES, V40, P303, DOI 10.1207/s15327906mbr4003_2; Halvorsrud K, 2021, J PUBLIC HEALTH-UK, V43, P197, DOI 10.1093/pubmed/fdz126; Hamel RN, 2019, SPORTS MED, V49, P1183, DOI 10.1007/s40279-019-01122-9; Hansmann Ralf, 2007, Urban Forestry & Urban Greening, V6, P213, DOI 10.1016/j.ufug.2007.08.004; Haslam C., 2018, NEW PSYCHOL HLTH UNL; Hignett A, 2018, J ADVENTURE EDUC OUT, V18, P53, DOI 10.1080/14729679.2017.1326829; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hughes R, 2020, BRAIN INJURY, V34, P847, DOI 10.1080/02699052.2020.1762002; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaplan R., 1989, EXPERIENCE NATURE PS; KAPLAN S, 1995, J ENVIRON PSYCHOL, V15, P169, DOI 10.1016/0272-4944(95)90001-2; Kemp A., 2018, SOCIAL TIES HLTH WEL; Kemp Andrew H, 2022, Glob Adv Health Med, V11, p21649561211073077, DOI 10.1177/21649561211073077; Kemp AH, 2013, INT J PSYCHOPHYSIOL, V89, P288, DOI 10.1016/j.ijpsycho.2013.06.018; Kiken LG, 2015, PERS INDIV DIFFER, V81, P41, DOI 10.1016/j.paid.2014.12.044; Kohls N, 2009, PERS INDIV DIFFER, V46, P224, DOI 10.1016/j.paid.2008.10.009; Kwasnicka D, 2016, HEALTH PSYCHOL REV, V10, P277, DOI 10.1080/17437199.2016.1151372; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Leonardi M, 2009, DISABIL REHABIL, V31, pS83, DOI 10.3109/09638280903317948; Levy B, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4110-5; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; Marshall J., 2020, GLOBAL J COMMUNITY P, V11; Martin L, 2020, J ENVIRON PSYCHOL, V68, DOI 10.1016/j.jenvp.2020.101389; Martin R, 2015, DISABIL REHABIL, V37, P1234, DOI 10.3109/09638288.2014.961653; Matos M. G., 2017, J COMMUNITY MED PUBL, DOI [DOI 10.24966/CMPH-1978/100026, 10.24966/CMPH-1978/100026]; Mead J, 2019, RETHINKING WELLBEING; Mead J, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.642093; Meredith GR, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02942; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Ownsworth T., 2014, SELF IDENTITY BRAIN, DOI [10.4324/9781315819549, DOI 10.4324/9781315819549]; Pasanen TP, 2014, APPL PSYCHOL-HLTH WE, V6, P324, DOI 10.1111/aphw.12031; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Porges S. W., 2011, POLYVAGAL THEORY NEU; Porges SW, 2015, CHILD AUST, V40, P114, DOI 10.1017/cha.2015.12; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Pritchard A, 2020, J HAPPINESS STUD, V21, P1145, DOI 10.1007/s10902-019-00118-6; Rabinowitz AR, 2018, APPL NEUROPSYCH-ADUL, V25, P295, DOI 10.1080/23279095.2018.1458514; RYFF CD, 1989, J PERS SOC PSYCHOL, V57, P1069, DOI 10.1037/0022-3514.57.6.1069; Rzezak P, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00839; Salas CE, 2018, NEUROPSYCHOL REHABIL, V28, P1161, DOI 10.1080/09602011.2016.1247730; Schueller SM, 2010, J POSIT PSYCHOL, V5, P253, DOI 10.1080/17439761003794130; Seligman M.E.P., 2011, FLOURISH VISIONARY N; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Tate DG, 2003, AM PSYCHOL, V58, P289, DOI 10.1037/0003-066X.58.4.289; Tsunetsugu Yuko, 2010, Environmental Health and Preventive Medicine, V15, P27, DOI 10.1007/s12199-009-0091-z; Tulip C, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00066; Uchida Y, 2016, JPN PSYCHOL RES, V58, P125, DOI 10.1111/jpr.12103; ULRICH RS, 1981, ENVIRON BEHAV, V13, P523, DOI 10.1177/0013916581135001; ULRICH RS, 1991, J ENVIRON PSYCHOL, V11, P201, DOI 10.1016/S0272-4944(05)80184-7; Van Cappellen P, 2018, PSYCHOL HEALTH, V33, P77, DOI 10.1080/08870446.2017.1320798; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Vibholm AP, 2020, INT J ENVIRON HEAL R, V30, P661, DOI 10.1080/09603123.2019.1620183; Walter K.H, 2020, GLOBAL J COMMUNITY P, V11; Weinstein AA, 2017, J HEAD TRAUMA REHAB, V32, pE49, DOI 10.1097/HTR.0000000000000253; White MP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44097-3; Wilkie L, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.648286; Wong PTP, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.800308; Wong PTP, 2019, COUNS PSYCHOL Q, V32, P275, DOI 10.1080/09515070.2019.1671320	104	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266388	10.1371/journal.pone.0266388	http://dx.doi.org/10.1371/journal.pone.0266388			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390052	gold, Green Published			2023-01-03	WOS:000795077200064
J	Heo, WY; Jung, YH; Lee, HY; Jeung, KW; Lee, BK; Youn, CS; Choi, SP; Park, KN; Min, YI				Heo, Wan Young; Jung, Yong Hun; Lee, Hyoung Youn; Jeung, Kyung Woon; Lee, Byung Kook; Youn, Chun Song; Choi, Seung Pill; Park, Kyu Nam; Min, Yong Il		Korean Hypothermia Network Investi	External validation of cardiac arrest-specific prognostication scores developed for early prognosis estimation after out-of-hospital cardiac arrest in a Korean multicenter cohort	PLOS ONE			English	Article							SPONTANEOUS CIRCULATION; PREDICTING SURVIVAL; MODEL; RESUSCITATION; OUTCOMES; COUNTRIES; REGISTRY; RETURN; CARE; TOOL	We evaluated the performance of cardiac arrest-specific prognostication scores developed for outcome prediction in the early hours after out-of-hospital cardiac arrest (OHCA) in predicting long-term outcomes using independent data. The following scores were calculated for 1,163 OHCA patients who were treated with targeted temperature management (TTM) at 21 hospitals in South Korea: OHCA, cardiac arrest hospital prognosis (CAHP), C-GRApH (named on the basis of its variables), TTM risk, 5-R, NULL-PLEASE (named on the basis of its variables), Serbian quality of life long-term (SR-QOLl), cardiac arrest survival, revised post-cardiac arrest syndrome for therapeutic hypothermia (rCAST), Polish hypothermia registry (PHR) risk, and PROgnostication using LOGistic regression model for Unselected adult cardiac arrest patients in the Early stages (PROLOGUE) scores and prediction score by Aschauer et al. Their accuracies in predicting poor outcome at 6 months after OHCA were determined using the area under the receiver operating characteristic curve (AUC) and calibration belt. In the complete-case analyses, the PROLOGUE score showed the highest AUC (0.923; 95% confidence interval [CI], 0.904-0.941), whereas the SR-QOLl score had the lowest AUC (0.749; 95% CI, 0.711-0.786). The discrimination performances were similar in the analyses after multiple imputation. The PROLOGUE, TTM risk, CAHP, NULL-PLEASE, 5-R, and cardiac arrest survival scores were well calibrated. The rCAST and PHR risk scores showed acceptable overall calibration, although they showed miscalibration under the 80% CI level at extreme prediction values. The OHCA score, C-GRApH score, prediction score by Aschauer et al., and SR-QOLl score showed significant miscalibration in both complete-case (P = 0.026, 0.013, 0.005, and < 0.001, respectively) and multiple-imputation analyses (P = 0.007, 0.018, < 0.001, and < 0.001, respectively). In conclusion, the discrimination performances of the prognostication scores were all acceptable, but some showed significant miscalibration.	[Heo, Wan Young; Jung, Yong Hun; Jeung, Kyung Woon; Lee, Byung Kook; Min, Yong Il] Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea; [Jung, Yong Hun; Jeung, Kyung Woon; Lee, Byung Kook; Min, Yong Il] Chonnam Natl Univ, Dept Emergency Med, Med Sch, Gwangju, South Korea; [Lee, Hyoung Youn] Chonnam Natl Univ Hosp, Trauma Ctr, Gwangju, South Korea; [Youn, Chun Song; Park, Kyu Nam] Catholic Univ Korea, Coll Med, Dept Emergency Med, Seoul St Marys Hosp, Seoul, South Korea; [Choi, Seung Pill] Catholic Univ Korea, Coll Med, Dept Emergency Med, Eunpyeong St Marys Hosp, Seoul, South Korea	Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University; Chonnam National University Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea	Jeung, KW (corresponding author), Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea.; Jeung, KW (corresponding author), Chonnam Natl Univ, Dept Emergency Med, Med Sch, Gwangju, South Korea.	neoneti@hanmail.net			Chonnam National University Hospital Biomedical Research Institute [BCRI21040]	Chonnam National University Hospital Biomedical Research Institute	This study was supported by a grant (BCRI21040) from the Chonnam National University Hospital Biomedical Research Institute (Recipient: KWJ). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrie C, 2006, EUR HEART J, V27, P2840, DOI 10.1093/eurheartj/ehl335; Aschauer S, 2014, RESUSCITATION, V85, P1225, DOI 10.1016/j.resuscitation.2014.06.007; Bae DH, 2021, RESUSCITATION, V159, P60, DOI 10.1016/j.resuscitation.2020.12.022; Balan P, 2019, RESUSCITATION, V144, P46, DOI 10.1016/j.resuscitation.2019.09.009; Collins GS, 2016, STAT MED, V35, P214, DOI 10.1002/sim.6787; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Eertmans W, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0558-2; Finazzi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016110; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Gue YX, 2020, AM J MED, V133, P1328, DOI 10.1016/j.amjmed.2020.03.046; Hayakawa K, 2011, RESUSCITATION, V82, P874, DOI 10.1016/j.resuscitation.2011.02.045; Hunziker S, 2011, CRIT CARE MED, V39, P1670, DOI 10.1097/CCM.0b013e318218a05b; Kiehl EL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.003821; Kim HS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232227; Kim SH, 2020, CLIN EXP EMERG MED, V7, P250, DOI 10.15441/ceem.20.035; Koltowski L, 2021, CARDIOL J, V28, P95, DOI 10.5603/CJ.a2019.0035; Kumagai K, 2015, ACUTE MED SURG, V2, P176, DOI 10.1002/ams2.96; Luescher T, 2019, RESUSCITATION, V142, P50, DOI 10.1016/j.resuscitation.2019.07.003; Martinell L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1677-2; Maupain C, 2016, EUR HEART J, V37, P3222, DOI 10.1093/eurheartj/ehv556; Nattino G, 2016, STAT MED, V35, P709, DOI 10.1002/sim.6744; Nishikimi M, 2019, RESUSCITATION, V140, P135, DOI 10.1016/j.resuscitation.2019.05.028; Nolan JP, 2021, RESUSCITATION, V161, P220, DOI 10.1016/j.resuscitation.2021.02.012; Okada K, 2012, RESUSCITATION, V83, P734, DOI 10.1016/j.resuscitation.2011.12.036; Ong MEH, 2015, RESUSCITATION, V96, P100, DOI 10.1016/j.resuscitation.2015.07.026; Pareek N, 2020, EUR HEART J, V41, P4508, DOI 10.1093/eurheartj/ehaa570; Perkins GD, 2015, RESUSCITATION, V96, P328, DOI 10.1016/j.resuscitation.2014.11.002; Potpara TS, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.05.035; Sladjana A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.06.001; Song H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10091825; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017	32	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0265275	10.1371/journal.pone.0265275	http://dx.doi.org/10.1371/journal.pone.0265275			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T5DI	35363794	gold, Green Published			2023-01-03	WOS:000804748600030
J	Lambert, K; Lightfoot, CJ; Jegatheesan, DK; Gabrys, I; Bennett, PN				Lambert, Kelly; Lightfoot, Courtney J.; Jegatheesan, Dev K.; Gabrys, Iwona; Bennett, Paul N.			Physical activity and exercise recommendations for people receiving dialysis: A scoping review	PLOS ONE			English	Review							CHRONIC KIDNEY-DISEASE; SUDDEN STRENUOUS EXERCISE; POSTEXERCISE HYPOTENSION; POSITION STATEMENT; SPORTS; BARRIERS; CKD; HEMODIALYSIS; MOTIVATIONS; INTENSITY	IntroductionRemaining physically active is important to patients undertaking dialysis, however, clinical recommendations regarding exercise type, timing, intensity, and safety precautions vary. The purpose of this scoping review was to analyse and summarise recommendations for physical activity and exercise for people undertaking dialysis and identify areas that require further research or clarification. Materials and methodsA scoping review of literature from five bibliographic databases (Medline, Scopus, Web of Science, CINAHL, and SPORTDiscus) was conducted. Eligible articles included consensus guidelines, position statements, reviews, or clinical practice guidelines that included specific physical activity and exercise recommendations for people undertaking dialysis. Key search terms included "kidney disease" OR "kidney failure" OR "chronic kidney disease" OR "end stage kidney disease" AND guideline* OR consensus OR "position statement" OR prescription OR statement AND exercise OR "physical activity". Hand searching for relevant articles in all first twenty quartile 1 journals listed on SCImago under 'medicine-nephrology' and 'physical therapy, sports therapy and rehabilitation' using the terms 'exercise and dialysis' was undertaken. Finally, home pages of key societies and professional organisations in the field of sports medicine and nephrology were searched. ResultsThe systematic search strategy identified 19 articles met the inclusion criteria. Two were specific to pediatric dialysis and three to peritoneal dialysis. Whilst many publications provided recommendations on aerobic exercise, progressive resistance training and flexibility, few provided explicit guidance. Recommendations for the intensity, duration and frequency of aerobic and resistance training varied. Discrepancies or gaps in guidance about precautions, contraindications, termination criteria, progression, and access site precautions were also apparent. ConclusionFuture guidelines should include specific guidance regarding physical activity, safety precautions, and timing and intensity of exercise for individuals who undertake dialysis. Collaborative multidisciplinary guideline development and appropriate exercise counselling may lead to increased participation in physical activity and exercise and facilitate better patient outcomes.	[Lambert, Kelly] Univ Wollongong, Fac Sci Med & Hlth, Sch Med, Wollongong, NSW, Australia; [Lambert, Kelly] Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Lightfoot, Courtney J.] Univ Leicester, Dept Hlth Sci, Leicester Kidney Lifestyle Team, Leicester, Leics, England; [Jegatheesan, Dev K.] Princess Alexandra Hosp, Dept Nephrol, Woolloongabba, Qld, Australia; [Gabrys, Iwona] Alberta Hlth Serv, Alberta Kidney Care North, Edmonton, AB, Canada; [Bennett, Paul N.] Univ South Australia, Clin Hlth Sci, Adelaide, SA, Australia; [Bennett, Paul N.] Satellite Healthcare, San Jose, CA USA	University of Wollongong; University of Wollongong; University of Leicester; Alberta Health Services (AHS); University of South Australia	Lambert, K (corresponding author), Univ Wollongong, Fac Sci Med & Hlth, Sch Med, Wollongong, NSW, Australia.; Lambert, K (corresponding author), Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.	klambert@uow.edu.au	Lambert, Kelly/A-3940-2015	Lambert, Kelly/0000-0001-5935-7328; Jegatheesan, Dev Krish/0000-0002-6525-7961; Bennett, Paul/0000-0001-9174-3499	Illawarra Health and Medical Research Institute	Illawarra Health and Medical Research Institute	KL. Funding was received from the Illawarra Health and Medical Research Institute for this work. https://www.ihmri.org.au/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akers A, 2012, ENVIRON SCI TECHNOL, V46, P8661, DOI 10.1021/es301685g; Andrea C., 2018, PRISMA EXTENSION SCO, V169, P467, DOI [10.7326/m18-0850, DOI 10.7326/M18-0850]; Arancibia M. GJ, 2020, GUA NUTRICIONAL PERI; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Ashby D, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1527-3; Aucella F, 2015, J NEPHROL, V28, P143, DOI 10.1007/s40620-014-0169-6; BARNARD RJ, 1973, CIRCULATION, V48, P936, DOI 10.1161/01.CIR.48.5.936; BARNARD RJ, 1973, J APPL PHYSIOL, V34, P833, DOI 10.1152/jappl.1973.34.6.833; Beddhu S, 2009, CLIN J AM SOC NEPHRO, V4, P1901, DOI 10.2215/CJN.01970309; Bennett PN, 2022, PERITON DIALYSIS INT, V42, P8, DOI 10.1177/08968608211055290; Bennett PN, 2010, SEMIN DIALYSIS, V23, P62, DOI 10.1111/j.1525-139X.2009.00652.x; Bishop D, 2003, SPORTS MED, V33, P439, DOI 10.2165/00007256-200333060-00005; Borg G. A., 1998, BORGS PERCEIVED EXER; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brito LC, 2020, CLIN EXP HYPERTENS, V42, P722, DOI 10.1080/10641963.2020.1783546; Carter R, 1999, J APPL PHYSIOL, V87, P1463, DOI 10.1152/jappl.1999.87.4.1463; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Cavalcante PAM, 2015, CLIN INTERV AGING, V10, P1487, DOI 10.2147/CIA.S79625; Chojak-Fijalka K, 2019, DIALIZA TY, V1, P28; Clarke AL, 2015, NEPHROL DIAL TRANSPL, V30, P1885, DOI 10.1093/ndt/gfv208; Cockwell P, 2020, LANCET, V395, P662, DOI 10.1016/S0140-6736(19)32977-0; Donald M, 2019, AM J KIDNEY DIS, V74, P474, DOI 10.1053/j.ajkd.2019.02.006; European Federation of Sports Medicine Associations, 2015, EX PRESCR HLTH TRAIN; Franklin BA., 2020, EXERCISE RELATED ACU, V141, P705, DOI [10.1161/CIR.0000000000000749, DOI 10.1161/CIR.0000000000000749]; Fuhrmann I, 2004, Clin Nephrol, V61 Suppl 1, pS14; Global Renal Exercise Network, GLOB REN EX 2021; Halliwill JR, 2000, J APPL PHYSIOL, V89, P1830, DOI 10.1152/jappl.2000.89.5.1830; Heiwe S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003236.pub2; Huang M, 2019, AM J NEPHROL, V50, P240, DOI 10.1159/000502447; Isnard-Rouchon M, 2019, SEMIN DIALYSIS, V32, P303, DOI 10.1111/sdi.12784; Jhamb M, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0399-z; Kalantar-Zadeh K, 2021, CLIN NEPHROL, V95, P115, DOI 10.5414/CN110436; Kendrick J, 2019, KIDNEY MED, V1, P131, DOI 10.1016/j.xkme.2019.03.004; Kirkman DL., 2021, EXERCISE INTOLERANCE, V320, pF161, DOI [10.1152/ajprenal.00437.2020, DOI 10.1152/AJPRENAL.00437.2020]; Lambert K, 2017, NEPHROLOGY, V22, P899, DOI 10.1111/nep.12892; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Life Options Advisory Council, 1995, EX DIAL PAT PRESCR G; Liguori G., 2021, ACSMS GUIDELINES EXE, V11th ed.; Lu Y, 2019, AM J NEPHROL, V50, P291, DOI 10.1159/000502635; Luttrell MJ, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00204; Malhotra R, 2021, HEMODIAL INT, V25, P240, DOI 10.1111/hdi.12913; Manera KE, 2020, AM J KIDNEY DIS, V75, P404, DOI 10.1053/j.ajkd.2019.09.017; Mendes R., 2016, EXERCISE PRESCRIPTIO, V50, P1379; National Kidney Foundation, 2005, Am J Kidney Dis, V45, pS1; Norton K, 2010, J SCI MED SPORT, V13, P496, DOI 10.1016/j.jsams.2009.09.008; O'Lone E, 2016, AM J KIDNEY DIS, V67, P925, DOI 10.1053/j.ajkd.2015.12.028; Olegario MG, GUIA ORIENTACION PRA; Opazo AM. RE, 2010, GUA NUTRICIONAL HEMO; Patel DR, 2009, PHYSICIAN SPORTSMED, V37, P11, DOI 10.3810/psm.2009.10.1724; Quinn KP, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004205; Raj VMS, 2017, TRANSL PEDIATR, V6, P207, DOI 10.21037/tp.2017.06.03; Robinson-Cohen C, 2009, ARCH INTERN MED, V169, P2116, DOI 10.1001/archinternmed.2009.438; Romero SA, 2017, J APPL PHYSIOL, V122, P925, DOI 10.1152/japplphysiol.00802.2016; Roshanravan B, 2017, AM J KIDNEY DIS, V69, P837, DOI 10.1053/j.ajkd.2017.01.051; Rueckert PA, 1996, MED SCI SPORT EXER, V28, P24, DOI 10.1097/00005768-199601000-00010; Salhab N, 2019, J NEPHROL, V32, P549, DOI 10.1007/s40620-018-00565-z; Servicio Riojano de Salud, 2020, ESTR ENF REN CRNIC A; Sharman JE, 2015, AM J HYPERTENS, V28, P147, DOI 10.1093/ajh/hpu191; SHELLOCK FG, 1985, SPORTS MED, V2, P267, DOI 10.2165/00007256-198502040-00004; Sheng KX, 2014, AM J NEPHROL, V40, P478, DOI 10.1159/000368722; Smart NA, 2013, J SCI MED SPORT, V16, P406, DOI 10.1016/j.jsams.2013.01.005; Stack AG, 2008, ANN EPIDEMIOL, V18, P880, DOI 10.1016/j.annepidem.2008.09.008; Tarca BD, 2020, J PHYS ACT HEALTH, V17, P475, DOI 10.1123/jpah.2019-0338; Tentori F, 2010, NEPHROL DIAL TRANSPL, V25, P3050, DOI 10.1093/ndt/gfq138; Tong A., 2009, PATIENTSEXPERIENCES, V53, P689; United States Renal Data System, 2020, 2020 USRDS ANN DAT R; World Health Organization, 2020, GUIDELINES PHYS ACTI; Zajt-Kwiatkowska J., 2011, DIALIZA TY, V2, P28	68	1	1	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267290	10.1371/journal.pone.0267290	http://dx.doi.org/10.1371/journal.pone.0267290			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482797	Green Published, gold, Green Accepted			2023-01-03	WOS:000794035700049
J	Mammen, JJ; Asirvatham, ES; Lakshmanan, J; Sarman, CJ; Pandey, A; Ranjan, V; Charles, B; Mani, T; Khaparde, SD; Upadhyaya, S; Rajan, S				Mammen, Joy John; Asirvatham, Edwin Sam; Lakshmanan, Jeyaseelan; Sarman, Charishma Jones; Pandey, Arvind; Ranjan, Varsha; Charles, Bimal; Mani, Thenmozhi; Khaparde, Sunil D.; Upadhyaya, Sunita; Rajan, Shobini			The clinical demand and supply of blood in India: A National level estimation study	PLOS ONE			English	Article							ANEMIA; CANCER	BackgroundEstimating the clinical demand for blood and components arising in a health facility is crucial to ensure timely availability of blood. This study aims to estimate disease-specific clinical demand, supply and utilization of whole blood and components in India. MethodsWe conducted a national level cross-sectional study in five randomly selected states from five regions of the country. We included 251 public and private facilities representing primary, secondary and tertiary care facilities. We collected annual disease-specific demand, supply and utilization of blood and components using a structured tool. We estimated the national demand by extrapolating the study data (demand and beds) to the total number of estimated beds in the country. FindingsAccording to the study, the total clinical demand of 251 health facilities with 51,562 beds was 474,627 whole blood units. Based on this, the clinical demand for India was estimated at 14 center dot 6 million whole blood units (95 CI: 14 center dot 59-14 center dot 62), an equivalent of 36 center dot 3 donations per 1,000 eligible populations, which will address whole blood and component requirement. The medicine specialty accounted for 6 center dot 0 million units (41 center dot 2%), followed by surgery 4 center dot 1 million (27 center dot 9%), obstetrics and gynecology 3 center dot 3 million (22 center dot 4%) and pediatrics 1 center dot 2 million (8 center dot 5%) units. The supply was 93% which is equivalent to 33 center dot 8 donations against the demand. ConclusionThe study indicated a demand and supply gap of 2.5 donations per 1,000 eligible persons which is around one million units. The gap emphasises the need for sustained and concerted efforts from all stakeholders and for increasing the awareness about repeat voluntary non-remunerated blood donation (VNRBD); optimizing the availability of blood components through efficient blood component separation units; promoting modern principles of patient blood management and strengthening capacities of human resources in the blood transfusion system in India.	[Mammen, Joy John; Mani, Thenmozhi] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Asirvatham, Edwin Sam; Sarman, Charishma Jones; Ranjan, Varsha; Charles, Bimal] Christian Med Assoc India CMAI, New Delhi, India; [Lakshmanan, Jeyaseelan] Mohammed Bin Rashid Univ Med & Hlth Sci, Biostat, Coll Med, DHCC, Dubai, U Arab Emirates; [Pandey, Arvind] Minist Hlth & Family Welf, Natl Inst Med Stat, New Delhi, India; [Khaparde, Sunil D.] Minist Hlth & Family Welf, Mumbai, Maharashtra, India; [Upadhyaya, Sunita] Ctr Ctr Dis Control & Prevent Cdc, Div Global HIV & TB, New Delhi, India; [Rajan, Shobini] Natl AIDS Control Org NACO, New Delhi, India	Christian Medical College & Hospital (CMCH) Vellore; Indian Council of Medical Research (ICMR); ICMR - National Institute of Medical Statistics (NIMS)	Mammen, JJ (corresponding author), Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.	joymammen@cmcvellore.ac.in		Mammen, Joy/0000-0002-7349-5660	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [5U2G GH001103-02]	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This project has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement number 5U2G GH001103-02.	Arya Rajesh Chand, 2011, J Anaesthesiol Clin Pharmacol, V27, P278, DOI 10.4103/0970-9185.81849; Asirvatham ES, 2021, INDIAN J HEMATOL BLO, V37, P640, DOI 10.1007/s12288-021-01399-9; Bagcchi S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7166; Bailie GR, 2000, AM J KIDNEY DIS, V35, P1, DOI 10.1016/S0272-6386(00)70294-0; Corp I., 2016, IBM SPSS STAT WINDOW; Dhillon PK, 2018, LANCET ONCOL, V19, P1289, DOI 10.1016/S1470-2045(18)30447-9; Drammeh B, 2018, TRANSFUS MED REV, V32, P36, DOI 10.1016/j.tmrv.2017.07.004; Gaspar BL, 2015, HEMATOLOGY, V20, P18, DOI 10.1179/1607845414Y.0000000161; Geldsetzer P, 2018, JAMA INTERN MED, V178, P363, DOI 10.1001/jamainternmed.2017.8094; GOI, DRUG COSM ACT 1940 R; Government of India, 2017, STAT UT WIS PERC CHI; Greinacher A, 2017, BLOOD ADV, V1, P867, DOI 10.1182/bloodadvances.2017005876; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jenny HE, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000167; Kaur Paramjit, 2014, Int J Appl Basic Med Res, V4, pS8, DOI 10.4103/2229-516X.140708; Klein HG, 2018, NEW ENGL J MED, V378, P305, DOI 10.1056/NEJMc1714807; Ludwig H, 2004, EUR J CANCER, V40, P2293, DOI 10.1016/j.ejca.2004.06.019; Mammen JJ, 2020, LANCET HAEMATOL, V7, pE94, DOI 10.1016/S2352-3026(19)30255-8; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Ministry of Health and Family Welfare G of I, 2016, NATL FAMILY HLTH SUR; National AIDS Control Organization, 2017, HIV SENT SURV TECHN; NCDIR-NCRP, 2016, ASS BURD CAR CANC PA; NFHS, 2015, NATL FAMILY HLTH SUR; Organization WH, 2010, 100 VOL BLOOD DON GL; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Singh SK, 2017, TRANSP RES PROC, V25, DOI 10.1016/j.trpro.2017.05.484; Vivek Tiwari, 2014, International Journal of Medicine and Public Health, V4, P62; Volken T, 2018, BLOOD TRANSFUS-ITALY, V16, P73, DOI 10.2450/2016.0079-16; WHO, 2010, WHO EXP CONS EST BLO; WHO, 2017, BLOOD SAF DON; World Health Organization, 2017, GLOB STAT REP BLOOD; Zanin TZ, 2016, AFR J EMERG MED, V6, P70, DOI 10.1016/j.afjem.2016.02.003	33	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0265951	10.1371/journal.pone.0265951	http://dx.doi.org/10.1371/journal.pone.0265951			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6KL	35385543	Green Published, gold			2023-01-03	WOS:000804836900065
J	Gandhi, RT; Malani, PN; del Rio, C				Gandhi, Rajesh T.; Malani, Preeti N.; del Rio, Carlos			COVID-19 Treatments for Nonhospitalized Patients Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Gandhi, Rajesh T.] Harvard Med Sch, Massachusetts Gen Hosp, Cox 548, Boston, MA 02114 USA; [Malani, Preeti N.] Univ Michigan Hlth Syst, Div Infect Dis, Ann Arbor, MI USA; [del Rio, Carlos] Emory Sch Med, Georgia Grady Hlth Syst, Atlanta, GA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Michigan System; University of Michigan; Emory University	Gandhi, RT (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Cox 548, Boston, MA 02114 USA.	rgandhi@mgh.harvard.edu						[Anonymous], ACTIV 6 WEBSITE; Gandhi RT, 2022, JAMA-J AM MED ASSOC, V327, P617, DOI 10.1001/jama.2022.0335; Infectious Disease Society of America, IDSA GUID TREATM MAN; National Institutes of Health, COR DIS 2019 COVID 1; University of Liverpool, COVID 19 DRUG INT; University of Minnesota, COVID OUT	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2022	327	22					2248	2248						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2J5EE	35699707				2023-01-03	WOS:000815679200030
J	Suran, M				Suran, Melissa			Pilot Program for Veterans With PTSD to Train Service Dogs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2022	327	20					1949	1949						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1Y7GZ	35608598				2023-01-03	WOS:000808309800008
J	Moneer, O; Daly, G; Skydel, JJ; Nyhan, K; Lurie, P; Ross, JS; Wallach, JD				Moneer, Osman; Daly, Garrison; Skydel, Joshua J.; Nyhan, Kate; Lurie, Peter; Ross, Joseph S.; Wallach, Joshua D.			Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARTICIPATION; APROTININ; RISK	OBJECTIVE To systematically identify, match, and compare treatment effects and study demographics from individual or meta-analysed observational studies and randomized controlled trials (RCTs) evaluating the same covid-19 treatments, comparators, and outcomes. DESIGN Meta-epidemiological study. DATA SOURCES National Institutes of Health Covid-19 Treatment Guidelines, a living review and network meta-analysis published in The BMJ , a living systematic review with meta-analysis and trial sequential analysis in PLOS Medicine (The LIVING Project), and the Epistemonikos "Living OVerview of Evidence" (L.OVE) evidence database. ELIGIBILITY CRITERIA FOR SELECTION OF STUDIES RCTs in The BMJ's living review that directly compared any of the three most frequently studied therapeutic interventions for covid-19 across all data sources (that is, hydroxychloroquine, lopinavir-ritonavir, or dexamethasone) for any safety and efficacy outcomes. Observational studies that evaluated the same interventions, comparisons, and outcomes that were reported in The BMJ's living review. DATA EXTRACTION AND SYNTHESIS Safety and efficacy outcomes from observational studies were identified and treatment effects for dichotomous (odds ratios) or continuous (mean differences or ratios of means) outcomes were calculated and, when possible, meta-analyzed to match the treatment effects from individual RCTs or meta-analyses of RCTs reported in The BMJ's living review with the same interventions, comparisons, and outcomes (that is, matched pairs). The analysis compared the distribution of study demographics and the agreement between treatment effects from matched pairs. Matched pairs were in agreement if both observational and RCT treatment effects were significantly increasing or decreasing (P<0.05) or if both treatment effects were not significant (P >= 0.05). RESULTS 17 new, independent meta-analyses of observational studies were conducted that compared hydroxychloroquine, lopinavir-ritonavir, or dexamethasone with an active or placebo comparator for any safety or efficacy outcomes in covid-19 treatment. These studies were matched and compared with 17 meta-analyses of RCTs reported in The BMJ's living review. 10 additional matched pairs with only one observational study and/or one RCT were identified. Across all 27 matched pairs, 22 had adequate reporting of demographical and clinical data for all individual studies. All 22 matched pairs had studies with overlapping distributions of sex, age, and disease severity. Overall, 21 (78%) of the 27 matched pairs had treatment effects that were in agreement. Among the 17 matched pairs consisting of meta-analyses of observational studies and meta-analyses of RCTs, 14 (82%) were in agreement; seven (70%) of the 10 matched pairs consisting of at least one observational study or one RCT were in agreement. The 18 matched pairs with treatment effects for dichotomous outcomes had a higher proportion of agreement (n=16, 89%) than did the nine matched pairs with treatment effects for continuous outcomes (n=5, 56%). CONCLUSIONS Meta-analyses of observational studies and RCTs evaluating treatments for covid-19 have summary treatment effects that are generally in agreement. Although our evaluation is limited to three covid-19 treatments, these findings suggest that meta analyzed evidence from observational studies might complement, but should not replace, evidence collected from RCTs.	[Moneer, Osman] Yale Univ, Yale Sch Med, New Haven, CT USA; [Daly, Garrison; Lurie, Peter] Ctr Sci Publ Interest, Washington, DC USA; [Skydel, Joshua J.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Nyhan, Kate] Yale Univ, Harvey Cushing John Hay Whitney Med Lib, New Haven, CT USA; [Nyhan, Kate; Wallach, Joshua D.] Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Sch Med, Dept Internal Med, Sect Gen Med, New Haven, CT USA; [Ross, Joseph S.] Yale Sch Med, Dept Internal Med, Natl Clinician Scholars Program, New Haven, CT USA; [Ross, Joseph S.] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Ross, Joseph S.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	Yale University; Dartmouth College; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Wallach, JD (corresponding author), Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06510 USA.	joshua.wallach@yale.edu		Wallach, Joshua/0000-0002-2816-6905; Moneer, Osman/0000-0003-3191-8028	National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health [K01AA028258]	National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	JDW is supported by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under award K01AA028258. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Akobeng AK, 2005, ARCH DIS CHILD, V90, P840, DOI 10.1136/adc.2004.058222; Anglemyer A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000034.pub2; [Anonymous], 2020, COVID 19 EV HUB; [Anonymous], REAL WORLD EVIDENCE; [Anonymous], 2019, THER, V106, P36, DOI [10.1002/cpt.1426, DOI 10.1002/CPT.1426]; Chaimani A, 2019, COCHRANE HDB SYSTEMA, P285, DOI DOI 10.1002/9781119536604.CH11; Downing NS, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1322-4; Ewald H, 2020, J CLIN EPIDEMIOL, V118, P29, DOI 10.1016/j.jclinepi.2019.10.012; FDA, 2018, FRAM FDAS REAL WORLD; Fergusson DA, 2008, NEW ENGL J MED, V358, P2319, DOI 10.1056/NEJMoa0802395; Flores LE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37640; Franklin JM, 2021, CIRCULATION, V143, P1002, DOI 10.1161/CIRCULATIONAHA.120.051718; Franklin JM, 2019, CLIN PHARMACOL THER, V105, P867, DOI 10.1002/cpt.1351; Gottlieb S, 2019, BREAKING BARRIERS CL; Hemkens LG, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i493; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Janiaud P, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02020-6; Juul S, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003293; Kennedy-Martin T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1023-4; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Lee K, 2009, GLOB INST, P1; Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; MOKKINK LB, 2010, BMC MED RES METHODOL, V10, DOI DOI 10.1186/1471-2288-10-82; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; National Institutes of Health, 2021, COVID 19 TREATM GUID; Naudet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020811; Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925; Patorno E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k119; Pundi K, 2020, JAMA INTERN MED, V180, P1398, DOI 10.1001/jamainternmed.2020.2904; Quinn TJ, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01920-x; Schneeweiss S, 2008, NEW ENGL J MED, V358, P771, DOI 10.1056/NEJMoa0707571; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shepshelovich D, 2021, J ANTIMICROB CHEMOTH, V76, P2415, DOI 10.1093/jac/dkab163; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919	38	3	3	5	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2022	377								e069400	10.1136/bmj-2021-069400	http://dx.doi.org/10.1136/bmj-2021-069400			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1K3DK	35537738	hybrid, Green Published			2023-01-03	WOS:000798485600001
J	Skaritanov, E; Wilkie, G; Kovell, LC				Skaritanov, Ekaterina; Wilkie, Gianna; Kovell, Lara C.			Selection, Effectiveness, and Adverse Effects of Contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERTENSION; WOMEN		[Skaritanov, Ekaterina] Univ Massachusetts, Chan Med Sch, 55 Lake Ave N, Worcester, MA 01605 USA; [Wilkie, Gianna] Univ Massachusetts, Chan Med Sch, Dept Obstet & Gynecol, Worcester, MA 01605 USA; [Kovell, Lara C.] Univ Massachusetts, Chan Med Sch, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kovell, LC (corresponding author), Univ Massachusetts, Chan Med Sch, 55 Lake Ave N, Worcester, MA 01605 USA.	lara.kovell@umassmemorial.org		Wilkie, Gianna/0000-0002-1712-0514				Bramham K, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2301; ChasanTaber L, 1996, CIRCULATION, V94, P483, DOI 10.1161/01.CIR.94.3.483; Curtis KM, 2006, CONTRACEPTION, V73, P179, DOI 10.1016/j.contraception.2005.08.005; Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Teal S, 2021, JAMA-J AM MED ASSOC, V326, P2507, DOI 10.1001/jama.2021.21392	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2022	327	15					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1C3PR	35438734				2023-01-03	WOS:000793035800038
J	Arellano-Saab, A; McErlean, CSP; Lumba, S; Savchenko, A; Stogios, PJ; McCourt, P				Arellano-Saab, Amir; McErlean, Christopher S. P.; Lumba, Shelley; Savchenko, Alexei; Stogios, Peter J.; McCourt, Peter			A novel strigolactone receptor antagonist provides insights into the structural inhibition, conditioning, and germination of the crop parasite Striga	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUICIDAL GERMINATION; SORGHUM; HERMONTHICA; SENSITIVITY; SELECTIVITY; HORMONE; MODEL; DAD2	Crop parasites of the Striga genera are a major biological deterrent to food security in Africa and are one of the largest obstacles to poverty alleviation on the continent. Striga seeds germinate by sensing small-molecule hormones, strigolactones (SLs), that emanate from host roots. Although SL receptors (Striga hermonthica HYPOSENSITIVE TO LIGHT [ShHTL]) have been identified, discerning their function has been diffi- cult because these parasites cannot be easily grown under laboratory conditions. Moreover, many Striga species are obligate outcrossers that are not transformable, hence not amenable to genetic analysis. By combining phenotypic screening with ShHTL structural information and hybrid drug discovery methods, we discovered a potent SL perception inhibitor for Striga, dormirazine (DOZ). Structural analysis of this piperazine-based antagonist reveals a novel binding mechanism, distinct from that of known SLs, blocking access of the hormone to its receptor. Furthermore, DOZ reduces the flexibility of protein-protein interaction domains important for receptor signaling to downstream partners. In planta, we show, via temporal additions of DOZ, that SL receptors are required at a specific time during seed conditioning. This conditioning is essential to prime seed germination at the right time; thus, this SL-sensitive stage appears to be critical for adequate receptor signaling. Aside from uncovering a function for ShHTL during seed conditioning, these results suggest that future Ag-Biotech Solutions to Striga infestations will need to carefully time the application of antagonists to exploit receptor availability and outcompete natural SLs, critical elements for successful parasitic plant invasions. favor turb Striga germination crops also that seeds tions, targets. drolases siveness which season called expression, seeds embryo	[Arellano-Saab, Amir; Lumba, Shelley; McCourt, Peter] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada; [Arellano-Saab, Amir; Savchenko, Alexei; Stogios, Peter J.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada; [McErlean, Christopher S. P.] Univ Sydney, Sch Chem, Camperdown, NSW, Australia; [Savchenko, Alexei] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	University of Toronto; University of Toronto; University of Sydney; University of Calgary	McCourt, P (corresponding author), Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada.; Stogios, PJ (corresponding author), Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada.	p.stogios@utoronto.ca; peter.mccourt@utoronto.ca		McErlean, Chris/0000-0001-8930-7495; McCourt, Peter/0000-0002-5905-7170; Arellano-Saab, Amir/0000-0002-3497-4538	Mexican National Council of Science and Technology (CONACyT); Mitacs Globalink Graduate Scholarship; Natural Sciences and Engineering Research Council of Canada (NSERC) [06752]; NSERC Accelerator Supplement [507992]; NSERC Research Tools and Instruments grant [00356]; New Frontiers in Research Fund [NFRFE-2018-00118]; NSERC [04298]	Mexican National Council of Science and Technology (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Mitacs Globalink Graduate Scholarship; Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC Accelerator Supplement; NSERC Research Tools and Instruments grant; New Frontiers in Research Fund; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	Funding and additional information-A. A.-S. was partially funded by the Mexican National Council of Science and Technology (CONACyT) and by a Mitacs Globalink Graduate Scholarship. This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery grant (grant no.: 06752), an NSERC Accelerator Supplement (grant no.: 507992), an NSERC Research Tools and Instruments grant (grant no.: 00356), a New Frontiers in Research Fund (grant no.: NFRFE-2018-00118) awarded to S. L., as well as an NSERC Discovery grant (grant no.: 04298) awarded to P. M.	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Arellano-Saab A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103175118; Baek M, 2021, SCIENCE, V373, P871, DOI 10.1126/science.abj8754; Bai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37072-x; Baskin JM, 2004, SEED SCI RES, V14, P1, DOI 10.1079/SSR2003150; Bunsick M, 2020, NAT PLANTS, V6, P646, DOI 10.1038/s41477-020-0653-z; Burger M, 2020, PLANT DIRECT, V4, DOI 10.1002/pld3.263; Burger M, 2019, CELL REP, V26, P855, DOI 10.1016/j.celrep.2019.01.003; De Vivo M, 2016, J MED CHEM, V59, P4035, DOI 10.1021/acs.jmedchem.5b01684; Dubach JM, 2017, NAT CHEM BIOL, V13, P168, DOI [10.1038/NCHEMBIO.2248, 10.1038/nchembio.2248]; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fernandez-Aparicio M, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9091184; Flematti GR, 2016, PLANTA, V243, P1361, DOI 10.1007/s00425-016-2523-5; Garcia-Contreras R, 2012, FEBS J, V279, P4145, DOI 10.1111/febs.12007; Gobena D, 2017, P NATL ACAD SCI USA, V114, P4471, DOI 10.1073/pnas.1618965114; Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366; Gurney AL, 1999, NEW PHYTOL, V143, P573, DOI 10.1046/j.1469-8137.1999.00467.x; Hameed US, 2018, EMBO REP, V19, DOI 10.15252/embr.201745619; Hamiaux C, 2018, J BIOL CHEM, V293, P6530, DOI 10.1074/jbc.RA117.001154; Hamiaux C, 2012, CURR BIOL, V22, P2032, DOI 10.1016/j.cub.2012.08.007; Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17; Hearne SJ, 2009, PEST MANAG SCI, V65, P603, DOI 10.1002/ps.1735; Holbrook-Smith D, 2016, NAT CHEM BIOL, V12, P724, DOI 10.1038/nchembio.2129; Hu LY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239013; Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lee HW, 2020, J BIOL CHEM, V295, P4181, DOI 10.1074/jbc.RA119.011509; Lumba S, 2017, TRENDS BIOCHEM SCI, V42, P556, DOI 10.1016/j.tibs.2017.04.006; Mashiguchi K, 2021, PLANT J, V105, P335, DOI 10.1111/tpj.15059; Matusova R, 2004, SEED SCI RES, V14, P335, DOI 10.1079/SSR2004187; McEneny-King A, 2015, BIOORG MED CHEM LETT, V25, P297, DOI 10.1016/j.bmcl.2014.11.046; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Miyakawa T, 2020, CELL MOL LIFE SCI, V77, P1103, DOI 10.1007/s00018-019-03318-8; Moffat JG, 2017, NAT REV DRUG DISCOV, V16, P531, DOI 10.1038/nrd.2017.111; Mohemed N, 2016, PEST MANAG SCI, V72, P2082, DOI 10.1002/ps.4426; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Nakamura H, 2019, MOL PLANT, V12, P44, DOI 10.1016/j.molp.2018.10.006; Parker C, 2009, PEST MANAG SCI, V65, P453, DOI 10.1002/ps.1713; Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331; Samejima H, 2016, PEST MANAG SCI, V72, P2035, DOI 10.1002/ps.4215; Scholes JD, 2008, CURR OPIN PLANT BIOL, V11, P180, DOI 10.1016/j.pbi.2008.02.004; Schrdinger, 2015, PYMOL MOL GRAPHICS S; Skarina T, 2014, METHODS MOL BIOL, V1140, P159, DOI 10.1007/978-1-4939-0354-2_12; Takahashi I, 2018, J EXP BOT, V69, P2241, DOI 10.1093/jxb/ery126; Takeuchi J, 2018, PLANT CELL PHYSIOL, V59, P1545, DOI 10.1093/pcp/pcy087; Tippe DE, 2017, FIELD CROP RES, V214, P14, DOI 10.1016/j.fcr.2017.08.013; Tippe DE, 2017, CROP PROT, V99, P93, DOI 10.1016/j.cropro.2017.05.007; Toh S, 2015, SCIENCE, V350, P203, DOI 10.1126/science.aac9476; Toh S, 2012, PLANT CELL PHYSIOL, V53, P107, DOI 10.1093/pcp/pcr176; Tsuchiya Y, 2015, SCIENCE, V349, P864, DOI 10.1126/science.aab3831; Uraguchi D, 2018, SCIENCE, V362, P1301, DOI 10.1126/science.aau5445; Wang YP, 2021, PLANT PHYSIOL, V185, P1411, DOI 10.1093/plphys/kiaa048; Xie XN, 2010, ANNU REV PHYTOPATHOL, V48, P93, DOI 10.1146/annurev-phyto-073009-114453; Xu YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06452-2; Yao RF, 2016, NATURE, V536, P469, DOI 10.1038/nature19073; Yoneyama K, 2010, PLANT CELL PHYSIOL, V51, P1095, DOI 10.1093/pcp/pcq055; Zhao LH, 2013, CELL RES, V23, P436, DOI 10.1038/cr.2013.19; Zwanenburg B, 2016, PEST MANAG SCI, V72, P2016, DOI 10.1002/ps.4222	61	1	1	5	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR	2022	298	4							101734	10.1016/j.jbc.2022.101734	http://dx.doi.org/10.1016/j.jbc.2022.101734		APR 2022	12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	1D0LO	35181340	gold, Green Published			2023-01-03	WOS:000793502000007
J	[Anonymous]				[Anonymous]			Summary for Patients: Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2022	175	5					I26	I26		10.7326/P22-0003	http://dx.doi.org/10.7326/P22-0003		MAR 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2U5RH	35344375				2023-01-03	WOS:000779639700001
J	Zeng, J; Sun, PS; Ping, QH; Jiang, S; Hu, YJ				Zeng, Jing; Sun, Peisong; Ping, Quanhong; Jiang, Shan; Hu, Yuanjing			Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; IB2; IIB; CARCINOMA; SURVIVAL; CHEMORADIATION; ADENOCARCINOMA; HYSTERECTOMY; REGIMENS; EFFICACY	This study aimed to assess neoadjuvant chemotherapy's clinical outcomes such as efficacy, toxicity, and survival outcomes followed by radical hysterectomy ((NACT-RS) among women with cervical cancer stage IB3 and IIA2, by comparing concurrent chemoradiotherapy (CCRT) and NACT-RS. The study retrospectively reviewed patients with (2018 FIGO) stage IB3 and IIA2 cervical cancer who received preoperative neoadjuvant chemotherapy followed by NACT-RS or concurrent chemoradiotherapy (CCRT). The outcome measures were the 5-year survival and complication rates between the two groups. The median follow-up was 75 months. In total, 218 patients had stage IIA2, 136 patients had stage IB3, 201 patients received CCRT, and 153 patients received preoperative NACT-RS. In the CCRT group, the incidence of early complications (myelosuppression, gastrointestinal and urinary) was higher compared with that in the NACT-RS group (76.1 vs. 26.1%; p < 0.001, respectively). There was no significant difference between the two study groups concerning late complications. Five-year PFS was 79.9% and 85.5% in the NACT-RS and CCRT groups, respectively (p = 0.093). Five-year OS was 86.9% and 85.5% in the NACT-RS and CCRT groups, respectively (p = 0.97). In the multivariate clinicopathologic characteristics analysis for OS, initial tumor size > 4.3 cm (HR 5.11; p < 0.001), AC/ASC (HR 1.89; p = 0.02), histologic grade 2-3 (HR 2.25; p = 0.04), and 2018 FIGO stage IIA2 (HR 8.67; p < 0.001) were independent risk factors. The survival of patients with stage IB3 and IIA2 cervical cancer treated with NACT-RS was similar to that of patients treated with CCRT without increasing side effects.	[Zeng, Jing; Sun, Peisong; Ping, Quanhong; Hu, Yuanjing] Nankai Univ, Tianjin Cent Hosp Gynecol & Obstet, Tianjin Clin Res Ctr Obstet & Gynecol, Dept Gynecol Oncol,Affiliated Hosp, Tianjin, Peoples R China; [Jiang, Shan] Tianjin Univ, Sch Mech Engn, Tianjin, Peoples R China	Nankai University; Tianjin University	Hu, YJ (corresponding author), Nankai Univ, Tianjin Cent Hosp Gynecol & Obstet, Tianjin Clin Res Ctr Obstet & Gynecol, Dept Gynecol Oncol,Affiliated Hosp, Tianjin, Peoples R China.	huyuanjingzxfck@163.com			Health Science and Technology Project of Tianjin [KJ20149, ZC20111]	Health Science and Technology Project of Tianjin	This study was supported by the Health Science and Technology Project of Tianjin (No. KJ20149 and ZC20111). Jing Zeng designed the study and collected and analyzed the data. Quanhong Ping prepared the manuscript, and Peisong Sun decided to publish it.	Bhatla N, 2018, INT J GYNECOL OBSTET, V143, P22, DOI 10.1002/ijgo.12611; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chargui R, 2006, AM J OBSTET GYNECOL, V194, P43, DOI 10.1016/j.ajog.2005.06.029; CHASSAGNE D, 1993, RADIOTHER ONCOL, V26, P195, DOI 10.1016/0167-8140(93)90260-F; Cho YH, 2009, J GYNECOL ONCOL, V20, P22, DOI 10.3802/jgo.2009.20.1.22; Chun M, 2009, J GYNECOL ONCOL, V20, P201, DOI 10.3802/jgo.2009.20.4.201; FREI E, 1982, CANCER, V50, P1979, DOI 10.1002/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D; Gien LT, 2009, J SURG ONCOL, V99, P242, DOI 10.1002/jso.21199; Greggi S, 2019, INT J GYNECOL CANCER, V29, pA12, DOI 10.1136/ijgc-2019-ESGO.13; Gupta S, 2018, J CLIN ONCOL, V36, P1548, DOI 10.1200/JCO.2017.75.9985; Hu K, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1197-5; Hu T, 2012, EUR J CANCER, V48, P2353, DOI 10.1016/j.ejca.2012.03.015; Hwang YY, 2001, GYNECOL ONCOL, V82, P88, DOI 10.1006/gyno.2001.6204; Katsumata N, 2010, J CLIN ONCOL, V28, DOI [10.1200/jco.2010.28.15_suppl.5047, DOI 10.1200/JCO.2010.28.15_SUPPL.5047]; KIM DS, 1988, GYNECOL ONCOL, V29, P321, DOI 10.1016/0090-8258(88)90231-4; Kim HS, 2013, EJSO-EUR J SURG ONC, V39, P115, DOI 10.1016/j.ejso.2012.09.003; Kim HS, 2010, GYNECOL ONCOL, V119, P217, DOI 10.1016/j.ygyno.2010.06.017; Kim Min-Jeong, 2008, J Gynecol Oncol, V19, P181, DOI 10.3802/jgo.2008.19.3.181; Kim SI, 2019, GYNECOL ONCOL, V153, P3, DOI 10.1016/j.ygyno.2019.01.008; Koh WJ, 2019, J NATL COMPR CANC NE, V17, P64, DOI 10.6004/jnccn.2019.0001; Kornovski Y, 2012, Akush Ginekol (Sofiia), V51, P18; Li S, 2016, ONCOTARGET, V7, P21054, DOI 10.18632/oncotarget.8245; Lukas R, 2013, EXPERT REV ANTICANC, V13, P861, DOI 10.1586/14737140.2013.811147; Minig L, 2014, WORLD J CLIN ONCOL, V5, P86, DOI 10.5306/wjco.v5.i2.86; PANICI PB, 1988, OBSTET GYNECOL, V71, P344; Querleu D, 2017, ANN SURG ONCOL, V24, P3406, DOI 10.1245/s10434-017-6031-z; Ryu HS, 2007, INT J GYNECOL CANCER, V17, P132, DOI 10.1111/j.1525-1438.2007.00803.x; Sardi JE, 2005, CURR OPIN OBSTET GYN, V17, P43; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Shoji T, 2013, CANCER CHEMOTH PHARM, V71, P657, DOI 10.1007/s00280-012-2052-2; Sturdza A, 2016, RADIOTHER ONCOL, V120, P428, DOI 10.1016/j.radonc.2016.03.011; Sugalski JM, 2019, J ONCOL PRACT, V15, pE458, DOI 10.1200/JOP.18.00563; Tang J, 2012, GYNECOL ONCOL, V125, P297, DOI 10.1016/j.ygyno.2012.01.033; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Uegaki K, 2014, INT J CLIN ONCOL, V19, P348, DOI 10.1007/s10147-013-0559-0; Wang M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86786-y; Williams NL, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-015-0440-6; Yee GPC, 2013, CURR CANCER DRUG TAR, V13, P205; Zhao YB, 2012, ASIAN PAC J CANCER P, V13, P1487, DOI 10.7314/APJCP.2012.13.4.1487; Zhou J, 2017, INT J SURG, V41, P16, DOI 10.1016/j.ijsu.2017.03.024	41	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2022	17	3							e0266001	10.1371/journal.pone.0266001	http://dx.doi.org/10.1371/journal.pone.0266001			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0K7DW	35324998	Green Published, gold			2023-01-03	WOS:000780951300091
J	Wachterman, MW; Luth, EA; Semco, RS; Weissman, JS				Wachterman, Melissa W.; Luth, Elizabeth A.; Semco, Robert S.; Weissman, Joel S.			Where Americans Die - Is There Really "No Place Like Home"?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							END		[Wachterman, Melissa W.] Vet Affairs Boston Hlth Care Syst, Sect Gen Internal Med, Boston, MA 02130 USA; [Wachterman, Melissa W.; Semco, Robert S.; Weissman, Joel S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Wachterman, Melissa W.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; [Luth, Elizabeth A.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ USA; [Luth, Elizabeth A.] Rutgers State Univ, Dept Family Med & Community Hlth, New Brunswick, NJ USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Wachterman, MW (corresponding author), Vet Affairs Boston Hlth Care Syst, Sect Gen Internal Med, Boston, MA 02130 USA.; Wachterman, MW (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Wachterman, MW (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.							Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Cross SH, 2019, NEW ENGL J MED, V381, P2369, DOI 10.1056/NEJMc1911892; Evans WG, 2006, J PALLIAT MED, V9, P100, DOI 10.1089/jpm.2006.9.100; Gerrard R, 2011, PALLIATIVE MED, V25, P333, DOI 10.1177/0269216310387459; Gray N, 2020, LOS ANGELES TIMES	5	6	5	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2022	386	11					1008	1010		10.1056/NEJMp2112297	http://dx.doi.org/10.1056/NEJMp2112297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2P8CD	35275480	Green Accepted			2023-01-03	WOS:000819960900004
J	Hoepelman, RJ; Ochen, Y; Beeres, FJP; Frima, H; Sommer, C; Michelitsch, C; Babst, R; Buenter, IR; van der Velde, D; Verleisdonk, EJMM; Groenwold, RHH; Houwert, RM; van Heijl, M				Hoepelman, Ruben J.; Ochen, Yassine; Beeres, Frank J. P.; Frima, Herman; Sommer, Christoph; Michelitsch, Christian; Babst, Reto; Buenter, Isabelle R.; van der Velde, Detlef; Verleisdonk, Egerbert-Jan M. M.; Groenwold, Rolf H. H.; Houwert, Roderick M.; van Heijl, Mark			Let's Agree to Disagree on Operative versus Nonoperative (LADON) treatment for proximal humerus fractures: Study protocol for an international multicenter prospective cohort study	PLOS ONE			English	Article							NONSURGICAL TREATMENT; DISPLACED FRACTURES; EPIDEMIOLOGY; TRIALS; ADULTS	Background The proximal humerus fracture is a common injury, but the optimal management is much debated. The decision for operative or nonoperative treatment is strongly influenced by patient specific factors, regional and cultural differences and the preference of the patient and treating surgeon. The aim of this study is to compare operative and nonoperative treatment of proximal humerus fractures for those patients for whom there is disagreement about optimal management. Methods and analysis This protocol describes an international multicenter prospective cohort study, in which all patients of 18 years and older presenting within three weeks after injury with a radiographically diagnosed displaced proximal humerus fracture can be included. Based on patient characteristics and radiographic images several clinical experts advise on the preferred treatment option. In case of disagreement among the experts, the patient can be included in the study. The actual treatment that will be delivered is at the discretion of the treating physician. The primary outcome is the QuickDash score at 12 months. Propensity score matching will be used to control for potential confounding of the relation between treatment modality and QuickDash scores. Discussion The LADON study is an international multicenter prospective cohort study with a relatively new methodological study design. This study is a "natural experiment" meaning patients receive standard local treatment and surgeons perform standard local procedures, therefore high participation rates of patients and surgeons are expected. Patients are only included after expert panel evaluation, when there is proven disagreement between experts, which makes this a unique study design. Through this inclusion process, we create two comparable groups whom received different treatments and where expert disagree about the already initiated treatment. Since we are zooming in on this particular patient group, confounding will be largely mitigated. Internationally the treatment of proximal humerus fractures are still much debated and differs much per country and hospital. This observational study with a natural experiment design will create insight into which treatment modality is to be preferred for patients in whom there is disagreement about the optimal treatment strategy.	[Hoepelman, Ruben J.; Ochen, Yassine; Houwert, Roderick M.; van Heijl, Mark] UMC Utrecht, Dept Trauma Surg, Utrecht, Netherlands; [Hoepelman, Ruben J.; Verleisdonk, Egerbert-Jan M. M.; van Heijl, Mark] Diakonessenhuis Utrecht, Dept Trauma Surg, Utrecht, Netherlands; [Ochen, Yassine; van der Velde, Detlef] St Antonius Hosp Nieuwegein, Dept Trauma Surg, Nieuwegein, Netherlands; [Beeres, Frank J. P.; Babst, Reto; Buenter, Isabelle R.] Cantonal Hosp Lucerne, Dept Trauma Surg, Luzern, Switzerland; [Frima, Herman] Noordwest Ziekenhuisgrp Alkmaar, Dept Trauma Surg, Alkmaar, Netherlands; [Sommer, Christoph; Michelitsch, Christian] Kantonsspital Graubunden, Dept Trauma Surg, Chur, Switzerland; [Babst, Reto] Univ Lucerne, Dept Hlth Sci & Med, Luzern, Switzerland; [Groenwold, Rolf H. H.] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Groenwold, Rolf H. H.] Leiden Univ Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Diakonessenhuis; St. Antonius Hospital Utrecht; Lucerne Cantonal Hospital; Kantonsspital Graubunden; University of Lucerne; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Hoepelman, RJ (corresponding author), UMC Utrecht, Dept Trauma Surg, Utrecht, Netherlands.; Hoepelman, RJ (corresponding author), Diakonessenhuis Utrecht, Dept Trauma Surg, Utrecht, Netherlands.	rjhoepelman@gmail.com		Hoepelman, Ruben/0000-0003-2298-244X	DePuy Synthes;  [DPS-TCMF-2019-033]	DePuy Synthes; 	This study was funded by DePuy Synthes for the completion of the study. No author personally received specific awards. Grant number DPS-TCMF-2019-033). The organization has not been involved in the drafting of this protocol or review of this manuscript. They will not be involved in study design, data collection, analysis or the decision to publish the final manuscript. URL: https://www.jnjmedicaldevices.com/en-EMEA/ companies/depuy-synthes.	Arditi C, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1816-5; Beerekamp MSH, 2017, INJURY, V48, P1355, DOI 10.1016/j.injury.2017.04.047; Beeres FJP, 2017, ARCH ORTHOP TRAUM SU, V137, P1685, DOI 10.1007/s00402-017-2790-z; Beks RB, 2018, J SHOULDER ELB SURG, V27, P1526, DOI 10.1016/j.jse.2018.03.009; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; Fowler RA, 2007, JAMA-J AM MED ASSOC, V298, P39, DOI 10.1001/jama.298.1.39-b; Frieden TR, 2017, NEW ENGL J MED, V377, P465, DOI 10.1056/NEJMra1614394; Frima H, 2019, ARCH ORTHOP TRAUM SU, V139, P203, DOI 10.1007/s00402-018-3063-1; Gilbart MK, 2007, J SHOULDER ELB SURG, V16, P717, DOI 10.1016/j.jse.2007.02.123; Gummesson C, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-44; Handoll HHG, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000434.pub4, 10.1002/14651858.CD003209.pub2]; Krieg JC, 2015, J BONE JOINT SURG AM, V97A, P1890, DOI 10.2106/JBJS.9722.ebo102; McCulloch P, 2002, BRIT MED J, V324, P1448, DOI 10.1136/bmj.324.7351.1448; Metsemakers WJ, 2018, INJURY, V49, P505, DOI 10.1016/j.injury.2017.08.040; Mintken PE, 2009, J SHOULDER ELB SURG, V18, P920, DOI 10.1016/j.jse.2008.12.015; Nowak LL, 2017, INT ORTHOP, V41, P1749, DOI 10.1007/s00264-017-3569-0; Palvanen M, 2006, CLIN ORTHOP RELAT R, P87, DOI 10.1097/01.blo.0000194672.79634.78; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Rangan A, 2015, JAMA-J AM MED ASSOC, V313, P1037, DOI 10.1001/jama.2015.1629; Tepass A, 2013, J SHOULDER ELB SURG, V22, pE8, DOI 10.1016/j.jse.2012.04.002; von Keudell A, 2016, J ORTHOP TRAUMA, V30, pE143, DOI 10.1097/BOT.0000000000000550; Xie L, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1522-5	23	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0264477	10.1371/journal.pone.0264477	http://dx.doi.org/10.1371/journal.pone.0264477			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0U7EE	35213647	gold, Green Published			2023-01-03	WOS:000787811000107
J	Doenyas-Barak, K; Catalogna, M; Kutz, I; Levi, G; Hadanny, A; Tal, S; Daphna-Tekoha, S; Sasson, E; Shechter, Y; Efrati, S				Doenyas-Barak, Keren; Catalogna, Merav; Kutz, Ilan; Levi, Gabriela; Hadanny, Amir; Tal, Sigal; Daphna-Tekoha, Shir; Sasson, Efrat; Shechter, Yarden; Efrati, Shai			Hyperbaric oxygen therapy improves symptoms, brain's microstructure and functionality in veterans with treatment resistant post-traumatic stress disorder: A prospective, randomized, controlled trial	PLOS ONE			English	Article							POST-CONCUSSION SYNDROME; VIETNAM VETERANS; SERVICE MEMBERS; PTSD; CONNECTIVITY; INTEGRITY	Introduction Post-traumatic stress disorder (PTSD) is characterized by changes in both brain activity and microstructural integrity. Cumulative evidence demonstrates that hyperbaric oxygen therapy (HBOT) induces neuroplasticity and case-series studies indicate its potentially positive effects on PTSD. The aim of the study was to evaluate HBOT's effect in veterans with treatment resistant PTSD. Methods Veterans with treatment resistant PTSD were 1:1 randomized to HBOT or control groups. All other brain pathologies served as exclusion criteria. Outcome measures included clinician-administered PTSD scale-V (CAPS-V) questionnaires, brief symptom inventory (BSI), BECK depression inventory (BDI), brain microstructural integrity evaluated by MRI diffuse tensor imaging sequence (DTI), and brain function was evaluated by an n-back task using functional MRI (fMRI). The treatment group underwent sixty daily hyperbaric sessions. No interventions were performed in the control group. Results Thirty-five veterans were randomized to HBOT (N = 18) or control (n = 17) and 29 completed the protocol. Following HBOT, there was a significant improvement in CAPS-V scores and no change in the control (F = 30.57, P<0.0001, Net effect size = 1.64). Significant improvements were also demonstrated in BSI and BDI scores (F = 5.72, P = 0.024 Net effect size = 0.89, and F = 7.65, P = 0.01, Net effect size = 1.03). Improved brain activity was seen in fMRI in the left dorsolateral prefrontal, middle temporal gyri, both thalami, left hippocampus and left insula. The DTI showed significant increases in fractional anisotropy in the frontolimbic white-matter, genu of the corpus callosum and fornix. Conclusions HBOT improved symptoms, brain microstructure and functionality in veterans with treatment resistant PTSD.	[Doenyas-Barak, Keren; Catalogna, Merav; Kutz, Ilan; Levi, Gabriela; Hadanny, Amir; Sasson, Efrat; Shechter, Yarden; Efrati, Shai] Shamir Med Ctr Zerifin, Sagol Ctr Hyperbar Med & Res, Zerifin, Israel; [Doenyas-Barak, Keren; Hadanny, Amir; Tal, Sigal; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Tal, Sigal] Shamir Med Ctr, Radiol Dept, Zerifin, Israel; [Daphna-Tekoha, Shir] Kaplan Med Ctr, Rehovot, Israel; [Daphna-Tekoha, Shir] Ashkelon Acad Coll, Fac Social Work, Ashqelon, Israel; [Daphna-Tekoha, Shir] Emili Sagol Creat Arts Therapies Res Ctr, Haifa, Israel; [Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University	Doenyas-Barak, K (corresponding author), Shamir Med Ctr Zerifin, Sagol Ctr Hyperbar Med & Res, Zerifin, Israel.; Doenyas-Barak, K (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.	Kerendoenyas@gmail.com		Hadanny, Amir/0000-0001-9028-7268; Doenyas-Barak, Keren/0000-0002-9212-5075	Research Fund of Shamir Medical Center, Israel	Research Fund of Shamir Medical Center, Israel	The study was funded by the Research Fund of Shamir Medical Center, Israel.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Doniger GM., 2013, CONSTRUCT VALIDITY M; Efrati S, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00848; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Garcia AJ, 2010, J APPL PHYSIOL, V109, P804, DOI 10.1152/japplphysiol.91429.2008; Gold AL, 2011, PSYCHOL MED, V41, P2563, DOI 10.1017/S0033291711000730; Hadanny A, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02495; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; Harch PG, 2017, MED GAS RES, V7, P156, DOI 10.4103/2045-9912.215745; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Khacho M, 2019, NAT REV NEUROSCI, V20, P34, DOI 10.1038/s41583-018-0091-3; Kida S, 2019, PSYCHOPHARMACOLOGY, V236, P49, DOI 10.1007/s00213-018-5086-2; Koenen KC, 2017, PSYCHOL MED, V47, P2260, DOI 10.1017/S0033291717000708; Marmar CR, 2015, JAMA PSYCHIAT, V72, P875, DOI 10.1001/jamapsychiatry.2015.0803; Miller RS, 2015, JAMA INTERN MED, V175, P43, DOI 10.1001/jamainternmed.2014.5479; Mozayeni BR, 2019, MED GAS RES, V9, P1, DOI 10.4103/2045-9912.254636; Olson EA, 2017, DEPRESS ANXIETY, V34, P437, DOI 10.1002/da.22615; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Sanjuan PM, 2013, PSYCHIAT RES-NEUROIM, V214, P260, DOI 10.1016/j.pscychresns.2013.09.002; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370; Sun YW, 2015, J AFFECT DISORDERS, V188, P80, DOI 10.1016/j.jad.2015.08.021; van Rooij SJH, 2016, NEUROPSYCHOPHARMACOL, V41, P1156, DOI 10.1038/npp.2015.257; Weaver LK, 2018, UNDERSEA HYPERBAR M, V45, P129; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549	33	3	3	5	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2022	17	2							e0264161	10.1371/journal.pone.0264161	http://dx.doi.org/10.1371/journal.pone.0264161			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E9PM	35192645	Green Published, gold			2023-01-03	WOS:000812552500039
J	Ng'ambi, WF; Collins, JH; Colbourn, T; Mangal, T; Phillips, A; Kachale, F; Mfutso-Bengo, J; Revill, P; Hallett, TB				Ng'ambi, Wingston Felix; Collins, Joseph H.; Colbourn, Tim; Mangal, Tara; Phillips, Andrew; Kachale, Fannie; Mfutso-Bengo, Joseph; Revill, Paul; Hallett, Timothy B.			Socio-demographic factors associated with early antenatal care visits among pregnant women in Malawi: 2004-2016	PLOS ONE			English	Article							SYSTEMATIC ANALYSIS; SERVICES	Introduction In 2016, the WHO published recommendations increasing the number of recommended antenatal care (ANC) visits per pregnancy from four to eight. Prior to the implementation of this policy, coverage of four ANC visits has been suboptimal in many low-income settings. In this study we explore socio-demographic factors associated with early initiation of first ANC contact and attending at least four ANC visits ("ANC4+") in Malawi using the Malawi Demographic and Health Survey (MDHS) data collected between 2004 and 2016, prior to the implementation of new recommendations. Methods We combined data from the 2004-5, 2010 and 2015-16 MDHS using Stata version 16. Participants included all women surveyed between the ages of 15-49 who had given birth in the five years preceding the survey. We conducted weighted univariate, bivariate and multivariable logistic regression analysis of the effects of each of the predictor variables on the binary endpoint of the woman attending at least four ANC visits and having the first ANC attendance within or before the four months of pregnancy (ANC4+). To determine whether a factor was included in the model, the likelihood ratio test was used with a statistical significance of P< 0.05 as the threshold. Results We evaluated data collected in surveys in 2004/5, 2010 and 2015/6 from 26386 women who had given birth in the five years before being surveyed. The median gestational age, in months, at the time of presenting for the first ANC visit was 5 (inter quartile range: 4-6). The proportion of women initiating ANC4+ increased from 21.3% in 2004-5 to 38.8% in 2015-16. From multivariate analysis, there was increasing trend in ANC4+ from women aged 20-24 years (adjusted odds ratio (aOR) = 1.27, 95%CI:1.05-1.53, P = 0.01) to women aged 45-49 years (aOR = 1.91, 95%CI:1.18-3.09, P = 0.008) compared to those aged 15-19 years. Women from richest socio-economic position ((aOR = 1.32, 95%CI:1.12-1.58, P<0.001) were more likely to demonstrate ANC4+ than those from low socio-economic position. Additionally, women who had completed secondary (aOR = 1.24, 95%CI:1.02-1.51, P = 0.03) and tertiary (aOR = 2.64, 95%CI:1.65-4.22, P<0.001) education were more likely to report having ANC4+ than those with no formal education. Conversely increasing parity was associated with a reduction in likelihood of ANC4+ with women who had previously delivered 2-3 (aOR = 0.74, 95%CI:0.63-0.86, P<0.001), 4-5 (aOR = 0.65, 95%CI:0.53-0.80, P<0.001) or greater than 6 (aOR = 0.61, 95%CI: 0.47-0.79, <0.001) children being less likely to demonstrate ANC4+. Conclusion The proportion of women reporting ANC4+ and of key ANC interventions in Malawi have increased significantly since 2004. However, we found that most women did not access the recommended number of ANC visits in Malawi, prior to the 2016 WHO policy change which may mean that women are less likely to undertake the 2016 WHO recommendation of 8 contacts per pregnancy. Additionally, our results highlighted significant variation in coverage according to key socio-demographic variables which should be considered when devising national strategies to ensure that all women access the appropriate frequency of ANC visits during their pregnancy.	[Ng'ambi, Wingston Felix; Mfutso-Bengo, Joseph] Kamuzu Univ Hlth Sci, Hlth Econ & Policy Unit, Lilongwe, Malawi; [Collins, Joseph H.; Colbourn, Tim; Phillips, Andrew] UCL, Inst Global Hlth, London, England; [Mangal, Tara; Hallett, Timothy B.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, London, England; [Kachale, Fannie] Minist Hlth, Reprod Hlth Directorate, Lilongwe, Malawi; [Revill, Paul] Univ York, Ctr Hlth Econ, York, N Yorkshire, England	University of London; University College London; Imperial College London; University of York - UK	Ng'ambi, WF (corresponding author), Kamuzu Univ Hlth Sci, Hlth Econ & Policy Unit, Lilongwe, Malawi.	wingston.ngambi@gmail.com		Hallett, Timothy/0000-0002-9681-0424; Revill, Paul/0000-0001-8632-0600; Collins, Joseph/0000-0003-4801-7218	UK Research and Innovation (UKRI) through the GCRF Thanzi la Onse (Health of All) research programme [MR/P028004/1]	UK Research and Innovation (UKRI) through the GCRF Thanzi la Onse (Health of All) research programme	Funding for the project was provided by UK Research and Innovation (UKRI) through the GCRF Thanzi la Onse (Health of All) research programme (MR/P028004/1). During the study period, WN, JC, TC, AP, TM, JMB, PR and TBH worked for on the project. The funder had no role in the study design, data collection and analysis, decision to publish, or the presentation of the manuscript.	Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; [Anonymous], 2002, WHO ANTENATAL CARE R; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Colbourn T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-004150; Creanga AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1331-7; Croft TN, 2018, GUIDE DHS STAT; Dunlop CL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020231; Friedman EM., 2002, P AM STAT ASS JOINT, P1064; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jiwani SS, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010502; Kassebaum NJ, 2016, LANCET, V388, P1775, DOI 10.1016/S0140-6736(16)31470-2; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Kuuire VZ, 2017, GLOB PUBLIC HEALTH, V12, P711, DOI 10.1080/17441692.2017.1316413; Machira K, 2018, INT J WOMENS HEALTH, V10, P25, DOI 10.2147/IJWH.S144426; Mamba KC, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1631-y; Manthalu G, 2019, HEALTH ECON, V28, P461, DOI 10.1002/hec.3856; Mchenga M, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4130-1; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; National Statistical Office (NSO) and ICF Macro, 2011, MAL DEM HLTH SURV 20; National Statistical Office (NSO) [Malawi] and ORC Macro, 2005, MAL DEM HLTH SURV 20; National Statistical Office (NSO) [Malawi] & ICF, 2017, MAL DEM HLTH SURV 20; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Rai Rajesh Kumar, 2013, Home Health Care Serv Q, V32, P106, DOI 10.1080/01621424.2013.779354; Rwabilimbo AG, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00226-7; Sonneveldt E, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S7; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222566; The World Bank, 2019, TRENDS MATERNAL MORT; Tura G, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-60; Vogel JP, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-19; WHO, 2016, WHO TECH REP SER, V997, P1; Yaya S, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000085	31	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0263650	10.1371/journal.pone.0263650	http://dx.doi.org/10.1371/journal.pone.0263650			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134088	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000798968600023
J	Groenewegen, B; van Lingen, E; Ooijevaar, RE; Wessels, E; Feltkamp, MCW; Boeije-Koppenol, E; Verspaget, HW; Kuijper, EJ; van Prehn, J; Keller, JJ; Terveer, EM				Groenewegen, Bas; van Lingen, Emilie; Ooijevaar, Rogier E.; Wessels, Els; Feltkamp, Mariet C. W.; Boeije-Koppenol, Eline; Verspaget, Hein W.; Kuijper, Ed J.; van Prehn, Joffrey; Keller, Josbert J.; Terveer, Elisabeth M.		Study Grp Netherlands Donor Feces	How to prepare stool banks for an appropriate response to the ongoing COVID-19 pandemic: Experiences in the Netherlands and a retrospective comparative cohort study for faecal microbiota transplantation	PLOS ONE			English	Article							DIFFICILE INFECTION; RECURRENT; SARS-COV-2; EFFICACY	Background Faecal microbiota transplantation (FMT) is an efficacious treatment for patients with recurrent Clostridioides difficile infections (rCDI). Stool banks facilitate FMT by providing screened faecal suspensions from highly selected healthy donors. Due to the ongoing coronavirus disease 2019 (COVID-19) pandemic and the potential risk of SARS coronavirus-2 (SARS-CoV-2) transmission via FMT, many stool banks were forced to temporarily halt and adjust donor activities. Goal The evaluation of a strategy to effectively continue stool banking activities during the ongoing COVID-19 pandemic. Study To restart our stool banking activities after an initial halt, we implemented periodic SARS-CoV-2 screening in donor faeces and serum, and frequent donor assessment for COVID-19 related symptoms. FMT donor and recipient data obtained before (2016-2019) and during the COVID-19 pandemic (March 2020-August 2021) were compared to assess stool banking efficacy. Results Two out of ten donors developed COVID-19. No differences during versus before the COVID-19 pandemic were observed in the number of approved faeces donations (14 vs 22/month, p = 0.06), FMT requests for rCDI (3.9 vs 4.3/month, p = 0.6); rCDI patients eligible for FMT (80.6% vs 73.3%, p = 0.2); rCDI cure rate (90.3% vs 89.2%, p = 0.9); CDI-free survival (p = 0.7); the number of non-rCDI patients treated with FMT (0.5/month vs 0.4/month), and the number of possibly FMT related adverse events (9.5% vs 7.8%, p = 0.7). Two FMTs for rCDI were delayed due to COVID-19. Conclusions There is a continued need for FMT treatment of rCDI during the COVID-19 pandemic. Appropriate donor screening and SARS-CoV-2 infection prevention measures can be implemented in existing protocols without increasing the burden for donors, and allow safe, effective and efficient FMT during the ongoing COVID-19 pandemic. Stool banks should evaluate their SARS-CoV-2 donor screening protocols for long-term sustainability and efficacy, and share their experiences to help the utilisation, standardisation and improvement of stool banks worldwide.	[Groenewegen, Bas; Wessels, Els; Feltkamp, Mariet C. W.; Boeije-Koppenol, Eline; Kuijper, Ed J.; van Prehn, Joffrey; Terveer, Elisabeth M.] Leiden Univ, Dept Med Microbiol, Med Ctr LUMC, Leiden, Netherlands; [van Lingen, Emilie; Verspaget, Hein W.; Keller, Josbert J.] LUMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands; [Ooijevaar, Rogier E.] Univ Amsterdam, VU Univ, Dept Gastroenterol & Hepatol, Med Ctr, Amsterdam, Netherlands; [Verspaget, Hein W.] LUMC, Dept Biobanking, Leiden, Netherlands; [Kuijper, Ed J.] Natl Inst Publ Hlth & Environm, Reference Lab C Difficile, LUMC, Bilthoven, Netherlands; [Kuijper, Ed J.] Natl Inst Publ Hlth & Environm, RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [Keller, Josbert J.] Haaglanden Med Ctr, Dept Gastroenterol, The Hague, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); University of Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Haaglanden Medical Center	Terveer, EM (corresponding author), Leiden Univ, Dept Med Microbiol, Med Ctr LUMC, Leiden, Netherlands.	E.M.Terveer@LUMC.nl		Groenewegen, Bas/0000-0001-9116-9175				Administration USFaD, 2020, SAF AL REG US FEC MI; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Coryell MP, 2021, LANCET MICROBE, V2, pE259, DOI 10.1016/S2666-5247(21)00059-8; Dergham J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122696; Foladori P, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140444; Guo M, 2021, NAT REV GASTRO HEPAT, V18, P269, DOI [10.1080/14786419.2021.2011271, 10.1038/s41575-021-00416-6]; Ianiro G, 2020, DIGEST LIVER DIS, V52, P1390, DOI 10.1016/j.dld.2020.09.004; Ianiro G, 2020, GUT, V69, P1555, DOI 10.1136/gutjnl-2020-321829; Ianiro G, 2020, LANCET GASTROENTEROL, V5, P430, DOI 10.1016/S2468-1253(20)30082-0; Jeong HW, 2020, CLIN MICROBIOL INFEC, V26, P1520, DOI 10.1016/j.cmi.2020.07.020; Keller JJ, 2015, ANNU REV MED, V66, P373, DOI 10.1146/annurev-med-070813-114317; Keller JJ, 2021, UNITED EUR GASTROENT, V9, P229, DOI 10.1177/2050640620967898; Khanna S, 2021, MAYO CLIN PROC, V96, P1418, DOI 10.1016/j.mayocp.2021.04.005; Lawley TD, 2013, IMMUNOLOGY, V138, P1, DOI 10.1111/j.1365-2567.2012.03616.x; Li TQ, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02297-w; Manzoor Susan E, 2021, F1000Res, V10, P373, DOI 10.12688/f1000research.52178.1; Natarajan A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25576-6; Ooijevaar RE, 2019, ANNU REV MED, V70, P335, DOI 10.1146/annurev-med-111717-122956; Perchetti G. A., 2020, Journal of Clinical Virology, V128, DOI 10.1016/j.jcv.2020.104438; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Quraishi MN, 2021, LANCET MICROBE, V2, pE133, DOI 10.1016/S2666-5247(21)00036-7; Reusken C, 2020, 8 DNTCCS; Rijksoverheid, 2020, NIEUW MAATR TEG VERS; (RIVM) DNIfPHatE, 2021, COVID 19 AANT GEM PU; Tariq R, 2019, CLIN INFECT DIS, V68, P1351, DOI 10.1093/cid/ciy721; Terveer EM, 2017, CLIN MICROBIOL INFEC, V23, P924, DOI 10.1016/j.cmi.2017.05.015; Terveer EM, 2020, UNITED EUR GASTROENT, V8, P1236, DOI 10.1177/2050640620957765; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; van Prehn J, 2021, CLIN MICROBIOL INFEC, V27, pS1, DOI 10.1016/j.cmi.2021.09.038; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Xiao F, 2020, EMERG INFECT DIS, V26, P1920, DOI 10.3201/eid2608.200681; Zhang Y, 2020, CHINA CDC WEEKLY, V2, P123; Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6	35	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265426	10.1371/journal.pone.0265426	http://dx.doi.org/10.1371/journal.pone.0265426			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P4LU	35298520	Green Published, gold			2023-01-03	WOS:000784193600070
J	Hailu, GA; Weret, ZS; Adasho, ZA; Eshete, BM				Hailu, Genet Atlabachew; Weret, Zewdu Shewngizaw; Adasho, Zerihun Adraro; Eshete, Belete Melesegn			Quality of antenatal care and associated factors in public health centers in Addis Ababa, Ethiopia, a cross-sectional study	PLOS ONE			English	Article								Background Potentially, the risk of morbidity and mortality during pregnancy and child birth can be prevented through comprehensive, quality antenatal care services. The high maternal mortality rate in developing countries, including Ethiopia, is related to poor quality of antenatal care services and is still a major public health problem. The aim of this study is to assess the quality of antenatal care and associated factors in public health centers in Addis Ababa, Ethiopia. Methods An institution-based cross-sectional study was conducted using a quantitative method from December 10 to January 30, 2020. A total of 616 study participants were selected by a systematic random sampling technique. Data was collected using pre-tested structured interview administered questionnaires. The data was entered into Epi-info version 7.2.1 and analyzed by SPSS version 24. Bivariate and multivariable logistic regressions were performed to identify the presence and strength of the association between the outcome and predictor variables. Results Overall, 33% of pregnant women received good-quality antenatal care. Satisfaction with antenatal care service, antenatal care initiation time, maintaining confidentiality, and waiting time become significant predictors of the quality of antenatal care. As a result, a lack of confidential care (AOR = 0.37; 95% CI, (0.40, 0.88)), a long waiting time (AOR = 0.6, 95% CI, (0.48, 0.88)), and no satisfaction with ANC services (AOR = 0.26; 95% CI, (0.109, 0.36)) were identified as factors impeding the quality of antenatal care. While starting ANC later than four months of pregnancy was found to be a positive predictor of the quality of antenatal care (AOR = 1.9, 95% CI: (1.21, 3.12)). Conclusion Only one-third of pregnant mothers received good quality antenatal care. Lack of confidential care, long waiting time and no satisfaction with antenatal care services were factors hindering the quality of antenatal care. While initiation of antenatal care after four months of pregnancy was a positive predictor of the quality of antenatal care.	[Hailu, Genet Atlabachew] Kotebe Metropolitan Univ, Menelik II Med & Hlth Sci Coll, Dept Midwifery, Addis Ababa, Ethiopia; [Weret, Zewdu Shewngizaw; Eshete, Belete Melesegn] Kotebe Metropolitan Univ, Menelik II Med & Hlth Sci Coll, Dept Psychiat, Addis Ababa, Ethiopia; [Adasho, Zerihun Adraro] Kotebe Metropolitan Univ, Menelik II Med & Hlth Sci Coll, Dept Neonatal Nursing, Addis Ababa, Ethiopia		Adasho, ZA (corresponding author), Kotebe Metropolitan Univ, Menelik II Med & Hlth Sci Coll, Dept Neonatal Nursing, Addis Ababa, Ethiopia.	adrarozerihun12@gmail.com		Adraro, Zerihun/0000-0002-9446-5022	Kotebe Metropolitan University Menelik II Medical and Health Science College	Kotebe Metropolitan University Menelik II Medical and Health Science College	The research was funded by Kotebe Metropolitan University Menelik II Medical and Health Science College with grant award number of..5/32/10/4823. The funder provided support in the form of salaries for all the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions section in the main manuscript.	Abate T.M., 2015, OPEN ACCESS LIB J; Akachi Y, 2017, B WORLD HEALTH ORGAN, V95, P465, DOI 10.2471/BLT.16.180190; [Anonymous], 2017, INT J COMMUNITY MED, V4, P4071; [Anonymous], WHO STATEMENT ANTENA; Barreix M, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00554-4; Bastola P., 2018, INT J COMMUNITY MED, V5, P2182; Beeckman K, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-213; Central Statistical Agency Ethiopia and ICF International, 2016, ETH DEM HLTH SURV; Chukwuma A, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1337-1; Dansereau E, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1018-5; Duysburgh E, 2014, BJOG-INT J OBSTET GY, V121, P117, DOI 10.1111/1471-0528.12905; Ejigu T, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-443; Fagbamigbe AF, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0081-0; Fesseha G., 2014, AM J HLTH RES, V2, P146; Gebremariam A, 2019, CAUSES MATERNAL DEAT; Geller SE, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0527-2; Heredia-Pi I, 2016, B WORLD HEALTH ORGAN, V94, P452, DOI 10.2471/BLT.15.168302; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Kare AP, 2021, SAGE OPEN MED, V9, DOI 10.1177/20503121211058055; Legesse T, 2017, INT J WOMENS HEALTH, V9, DOI 10.2147/IJWH.S123455; Lincetto O., CHAPTER 2 ANTENATAL; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Majrooh MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113390; Makonnen N., 2017, J NUTR HLTH FOOD SCI, P1; Muchie KF, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1488-0; Nylenna M., 2015, PROFESSIONS PROFESSI, V5, P1; Saira Mehnaz, 2016, International Journal of Medical Science and Public Health, V5, P1869; T G, 2018, ASSESSMENT QUALITY A, V6; Berehe TT, 2020, ADV PUBLIC HLTH, V2020, DOI 10.1155/2020/5436324; Tafese F, 2017, MED PUB J, V11; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; WHO, 2022, WHO RECOMMENDATIONS; Yabo AN., 2015, AM J NURSING SCI, V4, P57; Yeoh PL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152167	34	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269710	10.1371/journal.pone.0269710	http://dx.doi.org/10.1371/journal.pone.0269710			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2RM	35687552	Green Published, gold			2023-01-03	WOS:000843575700083
J	Nelson, HD; Cantor, A; Jungbauer, RM; Eden, KB; Darney, B; Ahrens, K; Burgess, A; Atchison, C; Goueth, R; Fu, RW				Nelson, Heidi D.; Cantor, Amy; Jungbauer, Rebecca M.; Eden, Karen B.; Darney, Blair; Ahrens, Katherine; Burgess, Amanda; Atchison, Chandler; Goueth, Rose; Fu, Rongwei			Effectiveness and Harms of Contraceptive Counseling and Provision Interventions for Women A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; COMPUTER-ASSISTED PROVISION; EMERGENCY CONTRACEPTION; ORAL-CONTRACEPTIVES; UNINTENDED PREGNANCY; REPRODUCTIVE AUTONOMY; INTRAUTERINE-DEVICE; ADVANCE PROVISION; INCREASED ACCESS; REPEAT ABORTION	Background: The effectiveness and harms of contraceptive counseling and provision interventions are unclear. Purpose: To evaluate evidence of the effectiveness of contraceptive counseling and provision interventions for women to increase use of contraceptives and reduce unintended pregnancy, as well as evidence of their potential harms. Data Sources: English-language searches of Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO, SocINDEX, and MEDLINE (1 January 2000 to 3 February 2022) and reference lists of key studies and systematic reviews. Study Selection: Randomized controlled trials of interventions providing enhanced contraceptive counseling, contraceptives, or both versus usual care or an active control. Data Extraction: Dual extraction and quality assessment of studies; results combined using a profile likelihood random-effects model. Data Synthesis: A total of 38 trials (43 articles [25472 participants]) met inclusion criteria. Contraceptive use was higher with various counseling interventions (risk ratio [RR], 1.39 [95% CI, 1.16 to 1.72]; I-2 = 85.3%; 10 trials), provision of emergency contraception in advance of use (RR, 2.12 [CI, 1.79 to 2.36]; I-2 = 0.0%; 8 trials), and counseling or provision postpartum (RR, 1.15 [CI, 1.01 to 1.52]; I-2 = 6.6%; 5 trials) or at the time of abortion (RR, 1.19 [CI, 1.09 to 1.32]; I-2 = 0.0%; 5 trials) than with usual care or active controls in multiple clinical settings. Pregnancy rates were generally lower with interventions, although most trials were underpowered and did not distinguish pregnancy intention. Interventions did not increase risk for sexually transmitted infections (STIs) (RR, 1.05 [CI, 0.87 to 1.25]; I-2 = 0.0%; 5 trials) or reduce condom use (RR, 1.03 [CI, 0.94 to 1.13]; I-2 = 0.0%; 6 trials). Limitation: Interventions varied; few trials were adequately designed to determine unintended pregnancy outcomes. Conclusion: Contraceptive counseling and provision interventions that provide services beyond usual care increase contraceptive use without increasing STIs or reducing condom use. Contraceptive care in clinical practice could be improved by implementing enhanced contraceptive counseling, provision, and follow-up; providing emergency contraception in advance; and delivering contraceptive services immediately postpartum or at the time of abortion.	[Nelson, Heidi D.] Kaiser Permanente, Bernard J Tyson Sch Med, Pasadena, CA USA; [Cantor, Amy; Jungbauer, Rebecca M.; Eden, Karen B.; Darney, Blair; Atchison, Chandler; Goueth, Rose; Fu, Rongwei] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Darney, Blair] Portland State Univ, Sch Publ Hlth, Portland, OR 97207 USA; [Darney, Blair] Ctr Invest Salud Poblac, Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; [Ahrens, Katherine; Burgess, Amanda] Univ Southern Maine, Muskie Sch Publ Serv, Portland, ME USA	Kaiser Permanente; Oregon Health & Science University; Portland State University; Instituto Nacional de Salud Publica; University of Maine System; University of Southern Maine	Nelson, HD (corresponding author), Kaiser Permanente, Sch Med, Dept Hlth Syst Sci, 100 South Los Robles,Suite 301, Pasadena, CA 91101 USA.	heidi.d.nelson@kp.org		Darney, Blair/0000-0001-8120-028X; Ahrens, Katherine/0000-0001-5139-9208; Goueth, Rose/0000-0003-0827-5159; Cantor, Amy/0000-0002-4467-8484	Resources Legacy Fund [PROSPERO: CRD42020192981]	Resources Legacy Fund	Resources Legacy Fund. (PROSPERO: CRD42020192981)	Agency for Healthcare Research and Quality, 2018, METHODS GUIDE EFFECT; Aiken ARA, 2016, PERSPECT SEX REPRO H, V48, P147, DOI 10.1363/48e10316; American Academy of Family Physicians, COV PAT ED COUNS FAM; American College of Obstetricians and Gynecologists, 2018, WELL WOM CAR ASS REC; American Medical Association, 2016, RED UN PREGN H 75 98; [Anonymous], 2020, LITTLE SISTERS POOR; [Anonymous], 2016, ZUBIK BURWELL; [Anonymous], 2014, BURWELL HOBBY LOBBY; Bednarek PH, 2011, NEW ENGL J MED, V364, P2208, DOI 10.1056/NEJMoa1011600; Belzer Marvin, 2005, J Pediatr Adolesc Gynecol, V18, P347, DOI 10.1016/j.jpag.2005.06.007; Berenson AB, 2012, CONTRACEPTION, V86, P716, DOI 10.1016/j.contraception.2012.06.007; Bryant AG, 2017, J PEDIATR ADOL GYNEC, V30, P389, DOI 10.1016/j.jpag.2016.08.003; Cameron ST, 2020, LANCET, V396, P1585, DOI 10.1016/S0140-6736(20)31785-2; Castano PM, 2012, OBSTET GYNECOL, V119, P14, DOI 10.1097/AOG.0b013e31823d4167; Cavallaro FL, 2020, BMJ SEX REPROD HEAL, V46, P254, DOI 10.1136/bmjsrh-2019-200377; Centers for Disease Control Prevention, 2010, MMWR RECOMM REP, V59, P1, DOI DOI 10.1123/TSP.6.2.111; Chen BA, 2010, OBSTET GYNECOL, V116, P1079, DOI 10.1097/AOG.0b013e3181f73fac; Coalition to Expand Contraceptive Access, 2021, PURP DEV; Comm Gynecologic Practice, 2021, OBSTET GYNECOL, V137, pe75, DOI 10.1097/AOG.0000000000004294; Curtis KM, 2016, MMWR RECOMM REP, V65, P3, DOI 10.15585/mmwr.rr6504a1; Dehlendorf C, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2019.02.015; Edwards SM, 2008, J ADOLESCENT HEALTH, V43, P432, DOI 10.1016/j.jadohealth.2008.06.008; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ekstrand M, 2008, ACTA OBSTET GYN SCAN, V87, P354, DOI 10.1080/00016340801936024; Ekstrand M, 2013, UPSALA J MED SCI, V118, P271, DOI 10.3109/03009734.2013.841308; El Ayadi AM, 2021, J PEDIATR ADOL GYNEC, V34, P355, DOI 10.1016/j.jpag.2020.11.022; El Ayadi AM, 2017, PREV MED, V94, P1, DOI 10.1016/j.ypmed.2016.10.015; Iwarsson KE, 2021, BJOG-INT J OBSTET GY, V128, P1546, DOI 10.1111/1471-0528.16754; Farah D, 2020, EUR J CONTRACEP REPR, V25, P492, DOI 10.1080/13625187.2020.1833187; Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Frarey A, 2019, ARCH GYNECOL OBSTET, V299, P361, DOI 10.1007/s00404-018-4969-0; Frederiksen B, 2021, WOMENS SEXUAL REPROD; Garbers S, 2012, CONTRACEPTION, V86, P536, DOI 10.1016/j.contraception.2012.02.005; Gavin L, 2016, MMWR-MORBID MORTAL W, V65, DOI 10.15585/mmwr.mm6509a3; Gold Melanie A, 2004, J Pediatr Adolesc Gynecol, V17, P87, DOI 10.1016/j.jpag.2003.11.018; Gomez AM, 2014, PERSPECT SEX REPRO H, V46, P171, DOI 10.1363/46e1614; Grubb LK, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-007237; Gubrium AC, 2016, AM J PUBLIC HEALTH, V106, P18, DOI 10.2105/AJPH.2015.302900; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Harper CC, 2005, OBSTET GYNECOL, V106, P483, DOI 10.1097/01.AOG.0000174000.37962.a1; Harper CC, 2015, LANCET, V386, P562, DOI 10.1016/S0140-6736(14)62460-0; Heil SH, 2021, JAMA PSYCHIAT, V78, P1071, DOI 10.1001/jamapsychiatry.2021.1715; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hou MY, 2010, OBSTET GYNECOL, V116, P633, DOI 10.1097/AOG.0b013e3181eb6b0f; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Kirby D, 2010, PERSPECT SEX REPRO H, V42, P251, DOI 10.1363/4225110; Klein JD, 2007, PEDIATRICS, V120, P1135, DOI 10.1542/peds.2007-2535; Kohn JE, 2018, CONTRACEPTION, V97, P198, DOI 10.1016/j.contraception.2017.11.009; Langston AM, 2010, PATIENT EDUC COUNS, V81, P362, DOI 10.1016/j.pec.2010.08.006; Lo SST, 2004, HUM REPROD, V19, P2404, DOI 10.1093/humrep/deh425; Mazza D, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.11.1267; Menon S, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-007252; Michie L, 2014, CONTRACEPTION, V90, P447, DOI 10.1016/j.contraception.2014.05.004; National LGBT Health Education Center, 2016, PROV AFF CAR PAT NON; Pohjoranta E, 2015, HUM REPROD, V30, P2539, DOI 10.1093/humrep/dev233; Policar M., 2011, CONTRACEPTIVE TECHNO; PROSPERO, 2021, INT PROSPECTIVE REGI; Raine TR, 2005, JAMA-J AM MED ASSOC, V293, P54, DOI 10.1001/jama.293.1.54; Raymond EG, 2006, OBSTET GYNECOL, V108, P1098, DOI 10.1097/01.AOG.0000235708.91572.db; Reyes-Lacalle A, 2020, MIDWIFERY, V83, DOI 10.1016/j.midw.2020.102631; Rocca CH, 2007, AM J OBSTET GYNECOL, V196, P29, DOI 10.1016/j.ajog.2006.08.024; Rodriguez MI, 2013, CONTRACEPTION, V87, P590, DOI 10.1016/j.contraception.2012.09.011; Schunmann C, 2006, HUM REPROD, V21, P2296, DOI 10.1093/humrep/del168; Schwarz EB, 2013, CONTRACEPTION, V87, P242, DOI 10.1016/j.contraception.2012.07.003; Schwarz EB, 2008, J GEN INTERN MED, V23, P794, DOI 10.1007/s11606-008-0609-x; Shimoni N, 2011, OBSTET GYNECOL, V118, P623, DOI 10.1097/AOG.0b013e31822ade67; Shlay JC, 2003, AM J OBSTET GYNECOL, V189, P473, DOI 10.1067/S0002-9378(03)00493-9; Sonfield A., 2020, SEEING WHOLE PATTERN; Sothornwit J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011913.pub2; Stevens J, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.06.010; Tebb KP, 2021, CONTRACEPTION, V104, P246, DOI 10.1016/j.contraception.2021.03.004; Torres LN, 2018, WOMEN HEALTH ISS, V28, P393, DOI 10.1016/j.whi.2018.05.003; U.S. Centers for Medicare & Medicaid Services, BIRTH CONTR BEN; U.S. Food and Drug Administration, BIRTH CONTR CHART; U.S. Preventive Services Task Force, METH PROC; Upadhyay UD, 2014, STUD FAMILY PLANN, V45, P19, DOI 10.1111/j.1728-4465.2014.00374.x; Westhoff C, 2007, OBSTET GYNECOL, V109, P1270, DOI 10.1097/01.AOG.0000264550.41242.f2; Whitaker AK, 2016, PATIENT EDUC COUNS, V99, P1663, DOI 10.1016/j.pec.2016.05.011; Wilson A, 2015, EUR J OBSTET GYN R B, V191, P72, DOI 10.1016/j.ejogrb.2015.05.010; Women's Preventive Services Initiative, 2022, CONTRACEPTION; Zapata LB, 2018, AM J PREV MED, V55, P677, DOI 10.1016/j.amepre.2018.07.006	81	3	3	4	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2022	175	7					980	+		10.7326/M21-4380	http://dx.doi.org/10.7326/M21-4380		MAY 2022	17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3F4ZO	35605239				2023-01-03	WOS:000804555100001
J	Elmekaty, EZI; Alibrahim, R; Hassanin, R; Eltaib, S; Elsayed, A; Rustom, F; Ibrahim, MIM; Abu Khattab, M; Al Soub, H; Al Maslamani, M; Al-Khal, A				Elmekaty, Eman Zeyad, I; Alibrahim, Rim; Hassanin, Rania; Eltaib, Sitelbanat; Elsayed, Ahmed; Rustom, Fatima; Ibrahim, Mohamed Izham Mohamed; Abu Khattab, Mohammed; Al Soub, Hussam; Al Maslamani, Muna; Al-Khal, Abdullatif			Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study	PLOS ONE			English	Article							LOPINAVIR/RITONAVIR; DRUG; THERAPY; SARS	Background Coronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in treating patients with COVID-19 pneumonia. Methods and findings This retrospective, multicenter, observational study was conducted on adult patients hospitalized in one of the COVID-19 facilities in Qatar. Patients were included if they received darunavir-cobicistat or lopinavir-ritonavir for at least three days as part of their COVID-19 treatments. Data were collected from patients' electronic medical records. The primary outcome was a composite endpoint of time to clinical improvement and/or virological clearance. Descriptive and inferential statistics were used at alpha level of 0.05. A total of 400 patients was analyzed, of whom 100 received darunavir-cobicistat and 300 received lopinavir-ritonavir. Majority of patients were male (92.5%), with a mean (SD) time from symptoms onset to start of therapy of 7.57 days (4.89). Patients received lopinavir-ritonavir had significantly faster time to clinical improvement and/or virological clearance than patients received darunavir-cobicistat (4 days [IQR 3-7] vs. 6.5 days [IQR 4-12]; HR 1.345 [95%CI: 1.070-1.691], P = 0.011). Patients received lopinavir-ritonavir had significantly faster time to clinical improvement (5 days [IQR 3-8] vs. 8 days [IQR 4-13]; HR 1.520 (95%CI: 1.2-1.925), P = 0.000), and slower time to virological clearance than darunavir-cobicistat (25 days [IQR 15-33] vs. 21 days [IQR 12.8-30]; HR 0.772 (95%CI: 0.607-0.982), P = 0.035). No significant difference in the incidence or severity of adverse events between groups. The study was limited to its retrospective nature and the possibility of covariates, which was accounted for by multivariate analyses. Conclusion In patients with COVID-19 pneumonia, early treatment with lopinavir-ritonavir was associated with faster time to clinical improvement and/or virological clearance than darunavir-cobicistat. Future trials are warranted to confirm these findings.	[Elmekaty, Eman Zeyad, I; Alibrahim, Rim; Hassanin, Rania; Eltaib, Sitelbanat; Elsayed, Ahmed; Rustom, Fatima; Abu Khattab, Mohammed; Al Soub, Hussam; Al Maslamani, Muna; Al-Khal, Abdullatif] Hamad Med Corp, Communicable Dis Ctr, Doha, Qatar; [Ibrahim, Mohamed Izham Mohamed] Qatar Univ, Coll Pharm, Clin Pharm & Practice Dept, QU Hlth, Doha, Qatar	Hamad Medical Corporation; Qatar University	Elmekaty, EZI (corresponding author), Hamad Med Corp, Communicable Dis Ctr, Doha, Qatar.	Eelmekaty@hamad.qa			Medical Research Center at Hamad Medical Corporation, Qatar	Medical Research Center at Hamad Medical Corporation, Qatar	The study is funded by Medical Research Center at Hamad Medical Corporation, Qatar. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.	Almazeedi S, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100448; [Anonymous], MAN PAT CONF 2019 NC; [Anonymous], IDSA GUIDELINES TREA; [Anonymous], COVID 19 TREATMENT G; Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X; Beck BR, 2020, COMPUT STRUCT BIOTEC, V18, P784, DOI 10.1016/j.csbj.2020.03.025; Cancer Therapy Evaluation Program (CTEP), 2017, CANC THER EVAL PROGR, P155; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cevik M, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3862; Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003; Chen J, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa241; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Deeks ED, 2014, DRUGS, V74, P195, DOI 10.1007/s40265-013-0160-x; Destache CJ, 2009, PROG BRAIN RES, V180, P225, DOI 10.1016/S0079-6123(08)80012-X; Elajez R, 2021, OPEN ACCESS J BIOMED, V3, P880; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Khan SA, 2021, J BIOMOL STRUCT DYN, V39, P2607, DOI 10.1080/07391102.2020.1751298; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Lee K, 2009, GLOB INST, P1; Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79; Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744; Magro P, 2021, BIOMED J, V44, P43, DOI 10.1016/j.bj.2020.11.005; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Orkin C, 2013, HIV MED, V14, P49, DOI 10.1111/j.1468-1293.2012.01060.x; R.Shen, 2020, bioRxiv, DOI 10.1101/2020.01.31.929695; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Renjifo B, 2015, AIDS REV, V17, P37; Review R, 2020, SHOULD PROTEASE INHI, V14, P1; Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f; Ngo ST, 2020, J CHEM INF MODEL, V60, P5771, DOI 10.1021/acs.jcim.0c00491; Walsh KA, 2020, J INFECTION, V81, P357, DOI 10.1016/j.jinf.2020.06.067; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; who, COR COVID 19 DASHB W; WHO, 2020, LANDSC AN COVID THER; WHO, 2018, LAB TEST MIDDL E RES; Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101; Xu WX, 2021, CANCER MED-US, V10, P1545, DOI 10.1002/cam4.3708; Yamamoto N., 2020, BIORXIV, DOI [10.1101/2020.04.06.026476v1, DOI 10.1101/2020.04.06.026476]; Yang HN, 2020, CLIN CARDIOL, V43, P450, DOI 10.1002/clc.23341; Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37	44	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2022	17	5							e0267884	10.1371/journal.pone.0267884	http://dx.doi.org/10.1371/journal.pone.0267884			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1HN	35507606	gold, Green Published			2023-01-03	WOS:000818817800051
J	Hurley, R				Hurley, Richard			Severely ill patients are twice as likely to die by suicide, data show	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Campaign for Dignity in Dying, 2021, HIDD TRUTH DYING PEO; Campaign for Dignity in Dying, 2020, ON BRIT TRAV SWITZ A; Hurley R, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2128; Iacobucci G, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1107; ONS, 2022, SUIC PEOPL DIAGN SEV; Royall J, SUICIDE QUESTION CAB	6	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2022	377								o1014	10.1136/bmj.o1014	http://dx.doi.org/10.1136/bmj.o1014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H7OU	35450851				2023-01-03	WOS:000796729200005
J	Mahase, E				Mahase, Elisabeth			Covid-19: Remdesivir has "small effect" against death or progression to ventilation, WHO trial finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Ali K, 2022, CAN MED ASSOC J, V194, pE242, DOI 10.1503/cmaj.211698; [Anonymous], WHO RECOMMENDS USE R; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; WHO Solidarity Trial Consortium, 2022, LANCET	4	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2022	377								o1118	10.1136/bmj.o1118	http://dx.doi.org/10.1136/bmj.o1118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1I9MV	35508315	Bronze			2023-01-03	WOS:000797552400005
J	Gaudry, S; Palevsky, PM; Dreyfuss, D				Gaudry, Stephane; Palevsky, Paul M.; Dreyfuss, Didier			Extracorporeal Kidney-Replacement Therapy for Acute Kidney Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-RENAL-FAILURE; CONTINUOUS VENOVENOUS HEMOFILTRATION; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE PATIENTS; INTERMITTENT HEMODIALYSIS; HIGH-VOLUME; DIALYSIS; INITIATION; MULTICENTER; MANAGEMENT	Extracorporeal Kidney-Replacement Therapy for AKI Acute kidney injury can be accompanied by life-threatening electrolyte and metabolic abnormalities. Kidney-replacement therapy may be urgently needed to prevent death from uremia. This review considers treatment approaches, indications, and intensity in critically ill patients with AKI.	[Gaudry, Stephane; Dreyfuss, Didier] Sorbonne Univ, Common & Rare Kidney Dis, Hop Tenon, INSERM,UMR S1155, Paris, France; [Gaudry, Stephane] Univ Paris 13, Sorbonne Paris Cite, Hop Avicenne, AP HP,Serv Reanimat Med Chirurg, Bobigny, France; [Gaudry, Stephane] Univ Paris 13, Sorbonne Paris Cite, Hlth Care Simulat Ctr, UFR SMBH, Bobigny, France; [Dreyfuss, Didier] Hop Louis Mourier, Serv Med Intens Reanimat, Colombes, France; [Palevsky, Paul M.] Vet Affairs Pittsburgh Health Care Syst, Kidney Med Sect, Med Serv, Pittsburgh, PA USA; [Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Div Renal & Electrolyte, Pittsburgh, PA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dreyfuss, D (corresponding author), Hop Tenon, Unite INSERM, Common & Rare Kidney Dis, 4 Rue Chine, F-75020 Paris, France.	didier.dreyfuss@aphp.fr		Gaudry, Stephane/0000-0002-1105-6785				Alonso A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005283.pub2; [Anonymous], 2012, Kidney Int Suppl (2011), V2, P89; Augustine JJ, 2004, AM J KIDNEY DIS, V44, P1000, DOI 10.1053/j.ajkd.2004.08.022; Bagshaw SM, 2008, CRIT CARE MED, V36, P610, DOI 10.1097/01.CCM.0B013E3181611F552; Bagshaw SM, 2020, NEW ENGL J MED, V383, P240, DOI 10.1056/NEJMoa2000741; Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bellomo R, 1992, ASAIO J, V38, pM654, DOI 10.1097/00002480-199207000-00118; Benichou N, 2020, INTENS CARE MED, V46, P513, DOI 10.1007/s00134-019-05891-9; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Boyer A, 2021, CLIN THER, V43, P1125, DOI 10.1016/j.clinthera.2021.04.015; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Cerda J, 2012, KIDNEY INT, V82, P9, DOI 10.1038/ki.2011.243; Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243; Clark E, 2014, CRIT CARE, V18, DOI 10.1186/cc13184; Dargan PI, 2002, EMERG MED J, V19, P206, DOI 10.1136/emj.19.3.206; Douvris A, 2019, INTENS CARE MED, V45, P1333, DOI 10.1007/s00134-019-05707-w; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Edrees F, 2016, ADV CHRONIC KIDNEY D, V23, P195, DOI 10.1053/j.ackd.2016.03.003; Evans L, 2021, CRIT CARE MED, V49, pE1063, DOI 10.1097/CCM.0000000000005337; Falconi CA, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.686249; Gaudry S, 2021, LANCET, V397, P1293, DOI 10.1016/S0140-6736(21)00350-0; Gaudry S, 2020, LANCET, V395, P1506, DOI 10.1016/S0140-6736(20)30531-6; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Itoh S, 2006, J BIOMED MATER RES A, V77A, P294, DOI 10.1002/jbm.a.30608; Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140-6736(18)31080-8; Joannes-Boyau O, 2013, INTENS CARE MED, V39, P1535, DOI 10.1007/s00134-013-2967-z; Kaplan AA., 1992, CURRENT THERAPY NEPH, V3rd, P264; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Kruczynski K, 1993, ASAIO J, V39, pM778; Lameire N, 2018, AM J RESP CRIT CARE, V198, P4, DOI 10.1164/rccm.201801-0129ED; Legouis D, 2017, ANESTHESIOLOGY, V126, P39, DOI 10.1097/ALN.0000000000001400; Levinsky NG., 1981, KIDNEY, V2nd, P1181; Levraut J, 1997, CRIT CARE MED, V25, P58, DOI 10.1097/00003246-199701000-00013; Liu MC, 2008, J AM SOC NEPHROL, V19, P1360, DOI 10.1681/ASN.2007080901; Megarbane B, 2005, INTENS CARE MED, V31, P189, DOI 10.1007/s00134-004-2521-0; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Murugan R, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5418; Murugan R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2163-1; Nash DM, 2017, J CRIT CARE, V41, P138, DOI 10.1016/j.jcrc.2017.05.002; Paganini EP, 1996, NEPHROL DIAL TRANSPL, V11, P32; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Palevsky PM, 2008, CRIT CARE MED, V36, pS224, DOI 10.1097/CCM.0b013e318168e3fb; Pannu N, 2008, JAMA-J AM MED ASSOC, V299, P793, DOI 10.1001/jama.299.7.793; Parienti JJ, 2008, JAMA-J AM MED ASSOC, V299, P2413, DOI 10.1001/jama.299.20.2413; PARSONS FM, 1961, LANCET, V1, P129; Patel N, 2008, SEMIN DIALYSIS, V21, P493, DOI 10.1111/j.1525-139X.2008.00474.x; Payen D, 2009, CRIT CARE MED, V37, P803, DOI 10.1097/CCM.0b013e3181962316; Quenot JP, 2015, INTENS CARE MED, V41, P2111, DOI 10.1007/s00134-015-4056-y; Rabindranath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003773.pub3; Rimmele T, 2011, CRIT CARE, V15, DOI 10.1186/cc9411; Roberts JA, 2021, CLIN INFECT DIS, V72, P1369, DOI 10.1093/cid/ciaa224; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Saudan P, 2006, KIDNEY INT, V70, P1312, DOI 10.1038/sj.ki.5001705; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schortgen F, 2000, AM J RESP CRIT CARE, V162, P197, DOI 10.1164/ajrccm.162.1.9907098; Seabra VF, 2008, AM J KIDNEY DIS, V52, P272, DOI 10.1053/j.ajkd.2008.02.371; Seidowsky A, 2009, CRIT CARE MED, V37, P2191, DOI 10.1097/CCM.0b013e3181a02490; Sharma S, 2020, CHEST, V158, P1473, DOI 10.1016/j.chest.2020.05.542; Teitelbaum I, 2021, NEW ENGL J MED, V385, P1786, DOI 10.1056/NEJMra2100152; Timmer RT, 1999, J AM SOC NEPHROL, V10, P666; Tolwani A, 2012, NEW ENGL J MED, V367, P2505, DOI 10.1056/NEJMct1206045; Tolwani AJ, 2008, J AM SOC NEPHROL, V19, P1233, DOI 10.1681/ASN.2007111173; Uehlinger DE, 2005, NEPHROL DIAL TRANSPL, V20, P1630, DOI 10.1093/ndt/gfh880; Vaara ST, 2012, CRIT CARE, V16, DOI 10.1186/cc11682; VANBOMMEL EFH, 1995, AM J NEPHROL, V15, P192, DOI 10.1159/000168832; Vijayan A, 2018, KIDNEY INT REP, V3, P456, DOI 10.1016/j.ekir.2017.11.018; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Wald R, 2009, JAMA-J AM MED ASSOC, V302, P1179, DOI 10.1001/jama.2009.1322; Wang X, 2012, RENAL FAILURE, V34, P396, DOI 10.3109/0886022X.2011.647371; Wang Y, 2018, NEPHROL DIAL TRANSPL, V33, P1017, DOI 10.1093/ndt/gfx308; Zarbock A, 2020, JAMA-J AM MED ASSOC, V324, P1629, DOI 10.1001/jama.2020.18618; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	76	6	7	11	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2022	386	10					964	975		10.1056/NEJMra2104090	http://dx.doi.org/10.1056/NEJMra2104090			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP3BU	35263520				2023-01-03	WOS:000766299000013
J	Lu, LM; Zhang, YQ; Tang, XR; Ge, SQ; Wen, H; Zeng, JC; Wang, L; Zeng, Z; Rada, G; Avila, C; Vergara, C; Tang, YY; Zhang, PM; Chen, RH; Dong, Y; Wei, XJ; Luo, W; Wang, L; Guyatt, G; Tang, CZ; Xu, NG				Lu, Liming; Zhang, Yuqing; Tang, Xiaorong; Ge, Shuqi; Wen, Hao; Zeng, Jingchun; Wang, Lai; Zeng, Zhao; Rada, Gabriel; Avila, Camila; Vergara, Camilo; Tang, Yuyuan; Zhang, Peiming; Chen, Rouhao; Dong, Yu; Wei, Xiaojing; Luo, Wen; Wang, Lin; Guyatt, Gordon; Tang, Chunzhi; Xu, Nenggui			Evidence on acupuncture therapies is underused in clinical practice and health policy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POSTSTROKE APHASIA		[Lu, Liming; Tang, Xiaorong; Tang, Yuyuan; Zhang, Peiming; Chen, Rouhao; Dong, Yu; Wei, Xiaojing; Wang, Lin; Tang, Chunzhi; Xu, Nenggui] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China; [Zhang, Yuqing] China Acad Chinese Med Sci, Guanganmen Hosp, Clar Collaborat, CEBIM Ctr Evidence Based Integrat Med, Beijing, Peoples R China; [Zhang, Yuqing; Guyatt, Gordon] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Zhang, Yuqing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Zhang, Yuqing] Univ Nottingham Ningbo, Nottingham Ningbo GRADE Ctr, Nottingham, Peoples R China; [Ge, Shuqi] Zhuhai Hosp Integrated Tradit Chinese & Western M, Dept Rehabil, Zhuhai, Peoples R China; [Wen, Hao] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou, Peoples R China; [Zeng, Jingchun] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Acupuncture, Guangzhou, Peoples R China; [Wang, Lai; Luo, Wen] Guangzhou Univ Chinese Med, Sch Med Informat Engn, Guangzhou, Peoples R China; [Zeng, Zhao] Guangzhou Univ Chinese Med, Lib, Guangzhou, Peoples R China; [Rada, Gabriel] Pontificia Univ Catolica Chile, Ctr Evidencia UC, Santiago, Chile; [Avila, Camila; Vergara, Camilo] Epistemonikos Fdn, Santiago, Chile; McMaster Univ, Dept Med, Fac Hlth Sci, Hamilton, ON, Canada	Guangzhou University of Chinese Medicine; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; McMaster University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; University of Nottingham Ningbo China; Sun Yat Sen University; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Pontificia Universidad Catolica de Chile; McMaster University	Xu, NG (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.	ngxu8018@163.com	Wei, Xiaojing/AFM-6584-2022; Chen, Rouhao/GSE-5762-2022	Zhang, Peiming/0000-0002-6265-2691	Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202004]; Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine; National Natural Science Foundation of China [82174527]; special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program [2020B1111100008]	Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine; Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program	We have read and understood BMJ policy on declaration of interests and declare that the study was supported by: the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202004); the special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program (2020B1111100008); the Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine; and the National Natural Science Foundation of China (82174527). The funders had no influence on study design, data collection, analysis, decision to publish, or manuscript preparation.	Albrecht L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-52; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Berthier ML, 2011, NEUROPSYCHOL REV, V21, P302, DOI 10.1007/s11065-011-9177-7; Bleck R, 2021, ACUPUNCT MED, V39, P461, DOI 10.1177/0964528420964214; Centers for Medicare & Medicaid Services, 2020, DEC MEM AC CHRON LOW; China Institute of Acupuncture and Moxibustion, 2014, EVIDENCE BASED GUIDE; Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9; Ellen ME, 2014, HEALTH RES POLICY SY, V12, DOI 10.1186/1478-4505-12-67; Gang WJ, BMJ OPEN; Higgins JPTTJ, 2020, COCHRANE HDB SYSTEMA; Hou TH, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/7908067; Ji ZC, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03099-9; Khedr EM, 2019, EGYPT J NEUROL PSYCH, V56, DOI 10.1186/s41983-019-0128-1; Lepine Jean-Pierre, 2011, Neuropsychiatr Dis Treat, V7, P3, DOI 10.2147/NDT.S19617; Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4; Longhurst JC, 2010, J ACUPUNCT MERIDIAN, V3, P67, DOI 10.1016/S2005-2901(10)60014-3; Lu LL, BMJ OPEN; Ma QF, 2020, MED ACUPUNCT, V32, P362, DOI 10.1089/acu.2020.1488; Ma Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168123; Moberg J, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0320-2; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; National Aphasia Association, 2016, APH STAT; National Institutes of Health, 2021, REPORTER; NHS, 2019, ACUPUNCTURE; Paley CA, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56010006; Rai SK, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0658-6; Sato A, 1997, Neurosci Behav Physiol, V27, P610, DOI 10.1007/BF02463910; Schunemann Holger J, 2005, COPD, V2, P81; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Su C, 2015, EVALUATION REPORT BI; Tabish Syed Amin, 2008, Int J Health Sci (Qassim), V2, pV; Thomas K, 2004, J PUBLIC HEALTH, V26, P152, DOI 10.1093/pubmed/fdh139; Wang YY., 2014, WORLD CHINESE MED, V9, P1264; Xue CCL, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-105; Yuan QL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30675; Zhang BL, 2019, WIEN KLIN WOCHENSCHR, V131, P221, DOI 10.1007/s00508-019-1478-5	37	15	15	19	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2022	376								e067475	10.1136/bmj-2021-067475	http://dx.doi.org/10.1136/bmj-2021-067475			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK9HK	35217525	Green Published, hybrid			2023-01-03	WOS:000766610900001
J	Downar, J; Vanderspank-Wright, B				Downar, James; Vanderspank-Wright, Brandi			Another piece in the COVID-19 treatment puzzle	LANCET			English	Editorial Material									[Downar, James] Univ Ottawa, Div Palliat Care, Ottawa, ON, Canada; [Vanderspank-Wright, Brandi] Univ Ottawa, Fac Hlth Sci, Sch Nursing, Ottawa, ON, Canada; [Downar, James] Ottawa Hosp, Dept Crit Care, Ottawa, ON K1N SCA, Canada; [Downar, James] Bruyere Res Inst, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Downar, J (corresponding author), Univ Ottawa, Div Palliat Care, Ottawa, ON, Canada.; Downar, J (corresponding author), Ottawa Hosp, Dept Crit Care, Ottawa, ON K1N SCA, Canada.; Downar, J (corresponding author), Bruyere Res Inst, Ottawa, ON, Canada.	jdownar@toh.ca						ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Aitken AE, 2007, DRUG METAB DISPOS, V35, P1687, DOI 10.1124/dmd.107.015511; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Dodd LE, 2020, CLIN TRIALS, V17, P472, DOI 10.1177/1740774520939938; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Ikemura N., 2021, MEDRXIV INTERNET, DOI [10.1101/2021.12.13.21267761, DOI 10.1101/2021.12.13.21267761]; Lodi S, 2019, AM J EPIDEMIOL, V188, P1569, DOI 10.1093/aje/kwz100; O'Brien MP, 2021, NEW ENGL J MED, V385, P1184, DOI 10.1056/NEJMoa2109682; RECOVERY Collaborative Group, 2022, LANCET, V399, P665; Rodriguez-Serrano DA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92497-1; Somersan-Karakaya S., 2021, REGEN COV TREATMENT, DOI [10.1101/2021.11.05.21265656, DOI 10.1101/2021.11.05.21265656]; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163	14	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10325					609	610						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY1RO	35151380	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000754571600004
J	Horby, PW; Mafham, M; Peto, L; Campbell, M; Pessoa-Amorim, G; Spata, E; Staplin, N; Emberson, JR; Prudon, B; Hine, P; Brown, T; Green, CA; Sarkar, R; Desai, P; Yates, B; Bewick, T; Tiberi, S; Felton, T; Baillie, JK; Bitch, MH; Chappell, LC; Faust, SN; Jaki, T; Jeffery, K; Juszczak, E; Lim, WS; Montgomery, A; Mumford, A; Rowan, K; Weinreich, DM; Haynes, R; Landray, MJ				Horby, Peter W.; Mafham, Marion; Peto, Leon; Campbell, Mark; Pessoa-Amorim, Guilherme; Spata, Enti; Staplin, Natalie; Emberson, Jonathan R.; Prudon, Benjamin; Hine, Paul; Brown, Thomas; Green, Christopher A.; Sarkar, Rahuldeb; Desai, Purav; Yates, Bryan; Bewick, Tom; Tiberi, Simon; Felton, Tim; Baillie, J. Kenneth; Bitch, Maya H.; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jeffery, Katie; Juszczak, Edmund; Lim, Wei Shen; Montgomery, Alan; Mumford, Andrew; Rowan, Kathryn; Weinreich, David M.; Haynes, Richard; Landray, Martin J.		RECOVERY Collaborative Grp	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	LANCET			English	Article							NEUTRALIZING ANTIBODIES	Background Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. Methods RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0.79, 95% CI 0.69-0.91; p=0.0009). In an analysis of all randomly assigned patients (regardless of baseline antibody status), 943 (19%) of 4839 patients allocated to casirivimab and imdevimab versus 1029 (21%) of 4946 patients allocated to usual care died within 28 days (RR 0.94, 95% CI 0.86-1.02; p=0.14). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0.002). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab. Interpretation In patients admitted to hospital with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab reduced 28-day mortality in patients who were seronegative (and therefore had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.	[Horby, Peter W.; Landray, Martin J.] RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England		Horby, PW; Landray, MJ (corresponding author), RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England.	recoverytrial@ndph.ox.ac.uk	Baillie, Kenneth/AEK-6650-2022; Evans, D Gareth/AAB-4308-2022; Dosanjh, Davinder/ABD-8895-2021; Mathioudakis, Alexander G./I-2733-2019; Gkrania-Klotsas, Effrossyni/AAT-8424-2021; Chan, Xin Hui S/ABA-5004-2021; MACDONALD, Clint/AAR-6962-2021; Baillie, John Kenneth/F-3124-2011; Caplin, Ben/AAH-1641-2019; Pessoa-Amorim, Guilherme/AAV-4151-2021; Tso, Simon/N-2422-2014; Tageldin, Amr/CAF-8726-2022; Montgomery, Hugh/C-2592-2008; moon, james/F-1031-2014; Gibbison, Ben/J-6611-2014; Faust, Saul/J-9779-2014; Darton, Thomas/J-3611-2013; Eyre, David/P-6887-2016; Payne, Brendan/I-1233-2016; Skene, Imogen/D-6153-2018; Llewelyn, Martin/A-7194-2011	Baillie, Kenneth/0000-0001-5258-793X; Evans, D Gareth/0000-0002-8482-5784; Dosanjh, Davinder/0000-0002-9169-5607; Mathioudakis, Alexander G./0000-0002-4675-9616; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Chan, Xin Hui S/0000-0002-9941-6975; MACDONALD, Clint/0000-0003-0995-0072; Baillie, John Kenneth/0000-0001-5258-793X; Caplin, Ben/0000-0001-9544-164X; Pessoa-Amorim, Guilherme/0000-0002-4050-6191; Tso, Simon/0000-0001-9221-7618; Foley, Paul/0000-0002-4856-832X; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Puxty, Kathryn/0000-0002-5742-6171; Price, David/0000-0002-0562-7326; Kapil, Vikas/0000-0001-5778-6188; Montgomery, Hugh/0000-0001-8797-5019; moon, james/0000-0001-8071-1491; Crocombe, Dominic/0000-0002-1401-6930; Pan, Daniel/0000-0002-1268-2243; Pathan, Nazima/0000-0001-7656-9453; Drysdale, Simon/0000-0002-6350-6557; Rokadiya, Sakib/0000-0003-2955-4907; Naisbitt, Michael/0000-0003-1560-6235; O'Sullivan, Eoin/0000-0002-7709-6595; Peto, Leon/0000-0002-4100-2163; Barker, Joseph/0000-0002-5483-9608; Steward, Matthew/0000-0002-1873-4665; Brankin-Frisby, Thomas/0000-0003-2184-8580; Smith, Christopher/0000-0001-7369-2034; Pfeffer, Paul/0000-0003-0369-2885; Soiza, Roy/0000-0002-1397-4272; Gibbison, Ben/0000-0003-3635-6212; Dixon, Giles/0000-0001-9787-0739; Rowan, Kathryn/0000-0001-8217-5602; Glaysher, Sharon/0000-0002-9584-0621; Dhaliwal, Kevin/0000-0002-3925-3174; Behrouzi, Roya/0000-0002-1978-6539; Faust, Saul/0000-0003-3410-7642; Roehr, Charles Christoph/0000-0001-7965-4637; Gupta-Wright, Ankur/0000-0002-5150-2970; Mentzer, Alexander/0000-0002-4502-2209; Darton, Thomas/0000-0003-2209-9956; Emberson, Jonathan/0000-0001-7792-9422; Gorog, Diana/0000-0002-9286-1451; Denis, Emmanuelle/0000-0001-8463-1341; Peters, Mark/0000-0003-3653-4808; Cathie, Katrina/0000-0001-5074-0769; Harwood, Catherine/0000-0002-1375-0965; de Silva, Thushan/0000-0002-6498-9212; Hodson, Kenneth/0000-0003-3091-6952; McKnight, Gerard/0000-0003-1546-7853; Bancroft, Elizabeth/0000-0002-5482-5660; Pastika, Libor/0000-0001-6892-6553; mumford, andrew/0000-0002-5523-511X; Milligan, Iain D/0000-0002-6501-5524; Gibani, Malick/0000-0003-1781-0053; Bhagani, Sanjay/0000-0003-2557-4337; Ustianowski, Andrew/0000-0002-6134-7855; Colton, Hayley/0000-0002-3287-4103; Hamers, Raph/0000-0002-5007-7896; Nadeem, Iftikhar/0000-0002-8644-925X; Murray, Clare/0000-0002-8961-8055; Hormis, Anil/0000-0001-5510-7639; Underwood, Jonathan/0000-0001-6963-2821; Newman, Tom/0000-0002-7987-9948; Eyre, David/0000-0001-5095-6367; Sahdev, Nikhil/0000-0003-2291-5044; Burden, Christy/0000-0001-6409-5238; , Prof Dr Muhammad Shahid Iqbal/0000-0003-0245-5976; Chaudhuri, Nazia/0000-0003-3325-6996; Brannigan, Jamie/0000-0003-1697-403X; Richards, Alexander James/0000-0003-0817-8631; Noba, Lyrics/0000-0002-5389-7937; Cole, Joby/0000-0002-5258-5835; Hannah, Jennifer/0000-0002-3491-6653; Iliodromiti, Stamatina/0000-0001-6453-6654; Bibby, Anna/0000-0001-7386-7754; Lillie, Patrick/0000-0002-4811-4774; Pant, Suman/0000-0001-6135-7095; Mazzella, Andrea/0000-0003-1560-7465; Ali, Mohammad/0000-0002-4765-615X; Dimitri, Paul/0000-0001-7625-6713; Shelley, Ben/0000-0001-6771-9659; Green, Christopher/0000-0002-1984-4014; Forton, Julian/0000-0002-0580-0432; Abu-Arafeh, Ahmad/0000-0003-2464-3871; Lindsay, Charlotte/0000-0002-7283-857X; vatish, manu/0000-0002-6012-2574; Jethwa, Kishan/0000-0003-1715-9256; Ireland, Aidan Taeke/0000-0001-9513-2302; Linares, Christian Alexander/0000-0002-2473-8873; Vidler, Jennifer/0000-0003-2996-3014; Welch, Hugh/0000-0001-6906-2718; Haynes, Richard/0000-0002-1179-0023; Lim, Wei Shen/0000-0002-7694-3051; Willis, Joanna/0000-0003-3260-4311; Gorick, Hugh/0000-0003-3089-9830; Vallabhaneni, Pramodh/0000-0002-4887-8651; Jhanji, Shaman/0000-0002-1116-628X; Dark, Paul/0000-0003-3309-0164; Taynton, Thomas/0000-0001-7771-9564; Last, Anna/0000-0001-8730-9323; Acquah, Ronald/0000-0002-5375-6106; Payne, Brendan/0000-0002-3101-3512; Skene, Imogen/0000-0001-5215-2899; Razvi, Salman/0000-0002-9047-1556; Burton, Ben/0000-0001-9579-9078; Lowsby, Richard/0000-0001-9940-191X; Whittaker, Elizabeth/0000-0002-7944-8793; Hinshaw, Kim/0000-0003-0468-4326; Collini, Paul/0000-0001-6696-6826; Llewelyn, Martin/0000-0002-6811-1124; Rivera Ortega, Pilar/0000-0002-7960-8822; Kelly, Dominic/0000-0002-6063-8896; Otter, Ashley/0000-0002-8317-9194	UK Research and Innovation (Medical Research Council); National Institute of Health Research	UK Research and Innovation (Medical Research Council); National Institute of Health Research(National Institute for Health Research (NIHR))	UK Research and Innovation (Medical Research Council) and National Institute of Health Research.	ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Adams E. R., 2020, Wellcome Open Research, V5, DOI 10.12688/wellcomeopenres.15927.1; Aitken AE, 2007, DRUG METAB DISPOS, V35, P1687, DOI 10.1124/dmd.107.015511; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266; Hoffmann M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109415; Horby PW, 2021, LANCET, V397, P605, DOI 10.1016/S0140-6736(21)00149-5; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Laustsen AH, 2019, EXPERT OPIN DRUG DIS, V14, P1103, DOI 10.1080/17460441.2019.1646723; Medicines & Healthcare products Regulatory Agency, 2021, INT CLIN COMM POL CA; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Moshe M, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n423; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; O'Brien MP, 2021, NEW ENGL J MED, V385, P1184, DOI 10.1056/NEJMoa2109682; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; RECOVERY Collaborative Group, 2022, Lancet, V399, P143, DOI 10.1016/S0140-6736(21)01825-0; Regeneron, 2020, REGN COV2 IND DAT MO; Self WH, 2022, LANCET INFECT DIS, V22, P622, DOI 10.1016/S1473-3099(21)00751-9; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Starr TN, 2021, SCIENCE, V371, P850, DOI 10.1126/science.abf9302; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Townsend A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22045-y; US Food and Drug Administration, 2021, EUA AUTH SER TEST PE; US Food and Drug Administration, 2021, REV LETT BAML 041620; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; Widera M, 2021, J INFECT DIS, V224, P1109, DOI 10.1093/infdis/jiab355; Wilhelm Alexander, 2021, Viruses, V13, DOI 10.3390/v13091693; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	46	84	84	14	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10325					665	676						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY1RO	35151397	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000754571600024
J	Soeroto, AY; Nurhayati, RD; Purwiga, A; Lestari, BW; Pratiwi, C; Santoso, P; Kulsum, ID; Suryadinata, H; Ferdian, F				Soeroto, Arto Yuwono; Nurhayati, Raden Desy; Purwiga, Aga; Lestari, Bony Wiem; Pratiwi, Chica; Santoso, Prayudi; Kulsum, Iceu Dimas; Suryadinata, Hendarsyah; Ferdian, Ferdy			Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia	PLOS ONE			English	Article							MULTIDRUG-RESISTANT TUBERCULOSIS; CULTURE CONVERSION; PREDICTORS; DISEASE; MALNUTRITION; MANAGEMENT; ANEMIA; IMPACT	Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major burden to TB prevention and eradication globally. Since 2016, WHO guidelines have included options for treating MDR/RR-TB with a standard regimen of 9 to 11 months duration (the 'shorter regimen') rather than an individual regimen of at least 20 months. This regimen has been introduced in Indonesia since September 2017. Therefore, we aimed to determine the success rate and factors associated with the treatment outcome of shorter injectable based regimen in West Java province, Indonesia. Methods This was a retrospective cohort study of MDR/RR-TB patients aged over 18 years old who received the shorter injectable based regimen between September 2017 and December 2020. We defined successful outcomes as the combined proportion of patients who were cured or had complete treatment. While, unsuccessful outcomes were defined as the combined proportion of patients who died from any causes, failure, and loss to follow-up (LTFU). Results A total of 315 patients were included in this study. The success rate was 64.5%. Multivariate analysis showed male gender (aRR = 1.18, 95% CI 1.04 to 1.34) increased the chance of successful outcome, while malnutrition (aRR = 0.78, 95% CI 0.68 to 0.89), history of previous TB treatment (aRR = 0.80%CI 0.68 to 0.94), and time of culture conversion >2 months (aRR = 0.72 (95% CI 0.59 to 0.87) decreased the chance of successful outcome. Conclusion History of previous TB treatment, time of culture conversion >2 months, and malnutrition were independent factors that decrease the chance for success rate, while male gender increase the likelihood for success rate of patients treated by the shorter injectable based regimen.	[Soeroto, Arto Yuwono; Nurhayati, Raden Desy; Santoso, Prayudi; Kulsum, Iceu Dimas; Suryadinata, Hendarsyah; Ferdian, Ferdy] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Div Respirol & Crit Care Med, Dept Internal Med,Fac Med, Bandung, West Java, Indonesia; [Soeroto, Arto Yuwono; Nurhayati, Raden Desy; Purwiga, Aga; Pratiwi, Chica; Santoso, Prayudi; Kulsum, Iceu Dimas; Suryadinata, Hendarsyah; Ferdian, Ferdy] Univ Padjadjaran, Hasan Sadikin Hosp, Dept Internal Med, Fac Med, Bandung, West Java, Indonesia; [Nurhayati, Raden Desy] Rotinsulu Pulm Hosp, Dept Internal Med, Bandung, West Java, Indonesia; [Lestari, Bony Wiem] Rotinsulu Pulm Hosp, Fac Med, Dept Publ Hlth, Bandung, Indonesia; [Lestari, Bony Wiem] Univ Padjadjaran, TB HIV Res Ctr, Fac Med, Bandung, Indonesia; [Pratiwi, Chica] Cimacan Hosp, Dept Internal Med, Cianjur, West Java, Indonesia	Dr Hasan Sadikin General Hospital; Universitas Padjadjaran; Dr Hasan Sadikin General Hospital; Universitas Padjadjaran; Universitas Padjadjaran	Soeroto, AY (corresponding author), Univ Padjadjaran, Hasan Sadikin Gen Hosp, Div Respirol & Crit Care Med, Dept Internal Med,Fac Med, Bandung, West Java, Indonesia.; Soeroto, AY (corresponding author), Univ Padjadjaran, Hasan Sadikin Hosp, Dept Internal Med, Fac Med, Bandung, West Java, Indonesia.	aysoeroto@yahoo.co.id	; Lestari, Bony Wiem/D-5676-2017	, Purwiga/0000-0002-3093-8409; Soeroto, Arto Yuwono/0000-0001-9027-2453; Lestari, Bony Wiem/0000-0002-6476-2034				Abidi S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01467-2019; Agustina R, 2018, JURNAL EPIDEMIOLOGI; Akchurin OM, 2015, BLOOD PURIFICAT, V39, P84, DOI 10.1159/000368940; [Anonymous], 2002, Bull World Health Organ, V80, P983; [Anonymous], 2020, WORLD HLTH ORG, DOI DOI 10.1080/09639284.2021.1971095; Bahi G. A., 2017, International Journal of Biological and Chemical Sciences, V11, P1039, DOI 10.4314/ijbcs.v11i3.9; Basit A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093206; Bennett DA, 2001, AUST NZ J PUBL HEAL, V25, P464, DOI 10.1111/j.1467-842X.2001.tb00294.x; Colijn C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018327; Das PJ, 2022, EDUC PRIM CARE, DOI 10.1080/14739879.2022.2137856; Das PK, 2020, BIOMED BIOTECH RES J, V4, P143, DOI 10.4103/bbrj.bbrj_131_19; Debieu M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061075, 10.1371/journal.pone.0082943]; Dheda K, 2017, LANCET RESP MED, V5, P291, DOI [10.1016/s2213-2600(17)30079-6, 10.1016/S2213-2600(17)30079-6]; Eshetie S, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2323-y; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2006, GEND PERSP DRUG US R; Falzon D, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02308-2016; Gadallah MA, 2016, J FORMOS MED ASSOC, V115, P997, DOI 10.1016/j.jfma.2015.10.002; Girum T, 2017, ANN MED HEALTH SCI R, V7, P331; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Harries AD, 2016, T ROY SOC TROP MED H, V110, P173, DOI 10.1093/trstmh/trv111; Hicks RM, 2014, INT J TUBERC LUNG D, V18, P1074, DOI 10.5588/ijtld.14.0231; Irbah SN, 2019, INT J INFECT DIS, V79, P91, DOI 10.1016/j.ijid.2018.11.228; Janmeja A K, 2018, Indian J Tuberc, V65, P135, DOI 10.1016/j.ijtb.2017.12.015; Javaid A, 2018, CLIN MICROBIOL INFEC, V24, P612, DOI 10.1016/j.cmi.2017.09.012; Karo B, 2015, EUROSURVEILLANCE, V20, P18, DOI 10.2807/1560-7917.ES.2015.20.49.30087; Ketema DB, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7838-2; Khan FA, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00061-2017; Kurbatova EV, 2012, INT J TUBERC LUNG D, V16, P1335, DOI 10.5588/ijtld.11.0811; Kurbatova EV, 2012, TUBERCULOSIS, V92, P397, DOI 10.1016/j.tube.2012.06.003; Lee HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103768; Lee SW, 2006, J KOREAN MED SCI, V21, P1028, DOI 10.3346/jkms.2006.21.6.1028; Leveri Tamary Henry, 2019, Tuberc Res Treat, V2019, P3569018, DOI 10.1155/2019/3569018; Liu Q, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3021-0; Lv LS, 2018, INFECT DRUG RESIST, V11, P147, DOI 10.2147/IDR.S153499; Maharjan S., 2017, J TUBERCULOSIS RES, V5, P106; Melese Addisu, 2018, BMC Res Notes, V11, P25, DOI 10.1186/s13104-018-3129-8; Nagu TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091229; Nair D, 2017, PUBLIC HEALTH ACTION, V7, P32, DOI 10.5588/pha.16.0055; Pefura-Yone EW, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-138; Podewils LJ, 2011, EPIDEMIOL INFECT, V139, P113, DOI 10.1017/S0950268810000907; Ralph AP, 2010, THORAX, V65, P863, DOI 10.1136/thx.2010.136242; Reis-Santos B, 2013, J BRAS PNEUMOL, V39, P585, DOI 10.1590/S1806-37132013000500009; Riza AL, 2014, LANCET DIABETES ENDO, V2, P740, DOI 10.1016/S2213-8587(14)70110-X; Sayem MA., 2020, J TUBERCULOSIS RES, V8, P223; Soeroto AY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246284; Soeroto AY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213017; Tamsil TA., 2014, J RESP INDO, V34, P109; Gler MT, 2013, AM J TROP MED HYG, V89, P943, DOI 10.4269/ajtmh.13-0011; Tiwari Simmi, 2012, Indian J Tuberc, V59, P135; Tola H, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-040862; Trubnikov A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084121; Urbanowski ME, 2020, LANCET INFECT DIS, V20, pE117, DOI 10.1016/S1473-3099(20)30148-1; Wahid A, 2021, AM J TROP MED HYG, V104, P1784, DOI 10.4269/ajtmh.20-1134; Wen YF, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3019-7; World Health Organization, 2013, GUIDELINES MANAGEMEN	55	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2022	17	1							e0263304	10.1371/journal.pone.0263304	http://dx.doi.org/10.1371/journal.pone.0263304			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT4WP	35089981	Green Published, gold			2023-01-03	WOS:000769158400052
J	Chaplow, ZL; Lucas, AR; Grainger, E; Simpson, C; Fairman, CM; DeScenza, VR; Bowman, J; Clinton, SK; Focht, BC				Chaplow, Zachary L.; Lucas, Alexander R.; Grainger, Elizabeth; Simpson, Christina; Fairman, Ciaran M.; DeScenza, Victoria R.; Bowman, Jessica; Clinton, Steven K.; Focht, Brian C.			Social cognitive outcomes are associated with improvements in mobility performance following lifestyle intervention in prostate cancer patients undergoing androgen deprivation therapy	PLOS ONE			English	Article							OLDER-ADULTS; WEIGHT-LOSS; DISABILITY; OBESE	Objective To compare the effects of an exercise and dietary intervention with those of standard-of-care management upon change in lift and carry performance and mobility-related self-efficacy beliefs and explore associations in prostate cancer patients undergoing androgen deprivation therapy. Methods 32 prostate cancer patients (M age = 66.2 years; SD = 7.8) undergoing androgen deprivation therapy were randomly assigned to a 3-month exercise and dietary lifestyle intervention (n = 16) or standard-of-care management (n = 16). Outcome assessments were obtained at baseline, 2- and 3-month follow-up. Results The lifestyle intervention resulted in significantly greater improvements in lift and carry performance (p = 0.01) at 2 Months (d = 1.01; p < 0.01) and 3 Months (d = 0.95; p < 0.01) and superior improvements in mobility-related self-efficacy at 2 Months (d = 0.38) and 3 Months (d = 0.58) relative to standard-of-care. Mobility-related self-efficacy (r = -.66; p = 0.006) and satisfaction with function (r = -.63; p = 0.01) were significantly correlated with lift and carry performance at 3 Months. Conclusions The exercise and dietary lifestyle intervention yielded superior improvements in lift and carry performance and mobility-related self-efficacy relative to standard-of-care and key social cognitive outcomes were associated with more favorable mobility performance.	[Chaplow, Zachary L.; DeScenza, Victoria R.; Bowman, Jessica; Focht, Brian C.] Ohio State Univ, Kinesiol, Dept Human Sci, Columbus, OH 43210 USA; [Lucas, Alexander R.] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA; [Grainger, Elizabeth; Simpson, Christina; Clinton, Steven K.] Ohio State Univ, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA; [Grainger, Elizabeth; Simpson, Christina; Clinton, Steven K.; Focht, Brian C.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Fairman, Ciaran M.] Univ South Carolina, Exercise Sci Dept, Columbia, SC 29208 USA	University System of Ohio; Ohio State University; Virginia Commonwealth University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of South Carolina System; University of South Carolina Columbia	Focht, BC (corresponding author), Ohio State Univ, Kinesiol, Dept Human Sci, Columbus, OH 43210 USA.; Focht, BC (corresponding author), Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.	focht.10@osu.edu	Lucas, Alexander R/AFF-5881-2022	Lucas, Alexander R/0000-0001-7318-3387; DeScenza, Victoria/0000-0002-7649-4137; Chaplow, Zachary/0000-0003-2758-0829	National Cancer Institute [R03 CA16296901]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) was a single-blind, randomized, pilot trial. Support for the present study was provided by National Cancer Institute Grant #R03 CA16296901 Award Received by: BCF https://www.clinicaltrials.gov/ct2/show/NCT02050906 Trial Registration: NCT02050906 Registered; 1/24/14 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the participants and volunteers for their invaluable contributions across the IDEA-P project.	Bandura A, 1997, EFFICACY EXERCISE CO; Beavers KM, 2017, OBESITY, V25, P1823, DOI 10.1002/oby.21977; Brawley L, 2012, ANN BEHAV MED, V44, P353, DOI 10.1007/s12160-012-9390-5; Bylow K, 2007, CANCER-AM CANCER SOC, V110, P2604, DOI 10.1002/cncr.23084; Chaplow Zachary L, 2020, JCSM Clin Rep, V5, P52, DOI 10.1002/crt2.13; Fairman CM, 2018, ENERG BALANCE CANCER, V14, P143, DOI 10.1007/978-3-319-64940-5_8; Focht BC, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419893764; Focht BC, 2018, ANN BEHAV MED, V52, P412, DOI 10.1093/abm/kax002; Reboussin BA, 2000, PSYCHOL HEALTH, V15, P239, DOI 10.1080/08870440008400304; Rejeski WJ, 2011, ARCH INTERN MED, V171, P880, DOI 10.1001/archinternmed.2010.522; Rejeski WJ, 2001, J GERONTOL B-PSYCHOL, V56, pS261, DOI 10.1093/geronb/56.5.S261; REJESKI WJ, 1995, OSTEOARTHR CARTILAGE, V3, P157, DOI 10.1016/S1063-4584(05)80050-0; Rock CL, 2012, CA-CANCER J CLIN, V62, P243, DOI 10.3322/caac.21142; Schwarzer R, 2011, REHABIL PSYCHOL, V56, P161, DOI 10.1037/a0024509; Schwarzer R, 2008, APPL PSYCHOL-INT REV, V57, P1, DOI 10.1111/j.1464-0597.2007.00325.x; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P	16	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0263136	10.1371/journal.pone.0263136	http://dx.doi.org/10.1371/journal.pone.0263136			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085341	gold, Green Published			2023-01-03	WOS:000779379600119
J	Chen, JS; Hoang, HE; Yaskina, MW; Kabbani, D; Doucette, K; Smith, S; Lau, C; Stewart, J; Zurek, K; Schultz, M; Cervera, C				Chen, Justin; Hoang, Holly E.; Yaskina, Maryna W.; Kabbani, Dima; Doucette, Karen; Smith, Stephanie; Lau, Cecilia; Stewart, Jackson; Zurek, Karen; Schultz, Morgan; Cervera, Carlos			Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19: A protocol for a pragmatic clinical trial	PLOS ONE			English	Article							HEALTH-CARE EPIDEMIOLOGY; INFORMED-CONSENT; RESISTANCE	Background The use of broad-spectrum antibiotics is widespread in patients with COVID-19 despite a low prevalence of bacterial co-infection, raising concerns for the accelerated development of antimicrobial resistance. Antimicrobial stewardship (AMS) is vital but there are limited randomized clinical trial data supporting AMS interventions such as prospective audit and feedback (PAF). High quality data to demonstrate safety and efficacy of AMS PAF in hospitalized COVID-19 patients are needed. Methods and design This is a prospective, multi-center, non-inferiority, pragmatic randomized clinical trial evaluating AMS PAF intervention plus standard of care (SOC) versus SOC alone. We include patients with microbiologically confirmed SARS-CoV-2 infection requiring hospital admission for severe COVID-19 pneumonia. Eligible ward beds and critical care unit beds will be randomized prior to study commencement at each participating site by computer-generated allocation sequence stratified by intensive care unit versus conventional ward in a 1:1 fashion. PAF intervention consists of real time review of antibacterial prescriptions and immediate written and verbal feedback to attending teams, performed by site-based AMS teams comprised of an AMS pharmacist and physician. The primary outcome is clinical status at post-admission day 15 measured using a 7-point ordinal scale. Patients will be followed for secondary outcomes out to 30 days. A total of 530 patients are needed to show a statistically significant non-inferiority, with 80% power and 2.5% one-sided alpha assuming standard deviation of 2 and the non-inferiority margin of 0.5. Discussion This study protocol presents a pragmatic clinical trial design with small unit cluster randomization for AMS intervention in hospitalized COVID-19 that will provide high-level evidence and may be adopted in other clinical situations.	[Chen, Justin; Hoang, Holly E.; Kabbani, Dima; Doucette, Karen; Smith, Stephanie; Cervera, Carlos] Univ Alberta, Fac Med & Dent, Dept Med, Div Infect Dis, Edmonton, AB, Canada; [Yaskina, Maryna W.] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB, Canada; [Lau, Cecilia; Stewart, Jackson] Alberta Hlth Serv, Pharm Serv, Edmonton, AB, Canada; [Zurek, Karen; Schultz, Morgan] Covenant Hlth, Pharm Serv, Edmonton, AB, Canada	University of Alberta; University of Alberta; Alberta Health Services (AHS)	Chen, JS (corresponding author), Univ Alberta, Fac Med & Dent, Dept Med, Div Infect Dis, Edmonton, AB, Canada.	jzchen@ualberta.ca						Alsaggaf R, 2018, INFECT CONT HOSP EP, V39, P170, DOI 10.1017/ice.2017.296; Ashiru-Oredope D, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10020110; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Clancy CJ, 2020, CLIN INFECT DIS, V71, P2736, DOI 10.1093/cid/ciaa524; Davey P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub4; Dhamanaskar R, 2020, J INVEST MED, V68, P1341, DOI 10.1136/jim-2020-001481; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Flory JH, 2016, J GEN INTERN MED, V31, P1511, DOI 10.1007/s11606-016-3780-5; Getahun H, 2020, B WORLD HEALTH ORGAN, V98, P442, DOI 10.2471/BLT.20.268573; Giraudeau B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040436; Harris AD, 2004, CLIN INFECT DIS, V38, P1586, DOI 10.1086/420936; Langford BJ, 2021, CLIN MICROBIOL INFEC, V27, P520, DOI 10.1016/j.cmi.2020.12.018; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Le Saux NMA., 2021, PAED CHILD HEALT-CAN, V26, P234, DOI [10.1093/pch/pxaa066, DOI 10.1093/PCH/PXAA066]; Livorsi DJ., 2021, OPEN FORUM INFECT DI, V8, pofab186, DOI [10.1093/ofid/ofab186, DOI 10.1093/OFID/OFAB186]; London Alex John, 2020, Ethics Hum Res, V42, P21, DOI 10.1002/eahr.500071; MacIntyre CR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3548-0; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Manesh A, 2021, LANCET MICROBE, V2, pE419, DOI 10.1016/S2666-5247(21)00173-7; Mazdeyasna H, 2020, CURR INFECT DIS REP, V22, DOI 10.1007/s11908-020-00734-x; McGowan JE, 2012, INFECT CONT HOSP EP, V33, P331, DOI 10.1086/664755; McRae AD, 2011, TRIALS, V12, DOI [10.1186/1745-6215-12-202, 10.1186/1745-6215-12-183]; Morris Andrew M, 2014, Curr Treat Options Infect Dis, V6, P101; Nathwani D, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0471-0; Polgreen PM, 2007, INFECT CONT HOSP EP, V28, P212, DOI 10.1086/512174; Popp M, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD015025; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003; Schuts EC, 2016, LANCET INFECT DIS, V16, P847, DOI 10.1016/S1473-3099(16)00065-7; Schweitzer VA, 2019, CLIN MICROBIOL INFEC, V25, P555, DOI 10.1016/j.cmi.2018.11.002; Schweizer ML, 2016, INFECT CONT HOSP EP, V37, P1135, DOI 10.1017/ice.2016.117; Shah NS, 2016, J CLIN VIROL, V80, P12, DOI 10.1016/j.jcv.2016.04.008; Sim J, 2012, AM J PUBLIC HEALTH, V102, P480, DOI 10.2105/AJPH.2011.300389; Stevens MP, 2020, INFECT CONT HOSP EP, V41, P744, DOI 10.1017/ice.2020.69; The COVID-19 Antimicrobial Management Working Group AHS,, 2020, CURR GUID MAN AD HOS; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Wagner B, 2014, INFECT CONT HOSP EP, V35, P1209, DOI 10.1086/678057	38	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265493	10.1371/journal.pone.0265493	http://dx.doi.org/10.1371/journal.pone.0265493			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P5DL	35320289	gold, Green Published			2023-01-03	WOS:000784240600004
J	Kitenge, MK; Laxmeshwar, C; Aza, EB; Ford-Kamara, E; Van Cutsem, G; Gcwensa, N; Casas, EC; Hlophe, K; Isaakidis, P; Ohler, L				Kitenge, Marcel K.; Laxmeshwar, Chinmay; Aza, Elkin Bermudez; Ford-Kamara, Ellie; Van Cutsem, Gilles; Gcwensa, Ntombi; Casas, Esther C.; Hlophe, Khanyo; Isaakidis, Petros; Ohler, Liesbet			Acceptability of unsupervised peer-based distribution of HIV oral self-testing for the hard-to-reach in rural KwaZulu Natal, South Africa: Results from a demonstration study	PLOS ONE			English	Article							FEMALE SEX WORKERS; POPULATION; SERVICES	BackgroundInnovative models to distribute oral HIV self-tests (HIVST) provide an opportunity to increase access to HIV testing, especially for hard-to-reach populations. This study aimed to describe the acceptability of unsupervised peer-distribution of HIVST as a method to scale-up HIV testing. MethodsIn this study, lay counsellors or community health workers provided HIVST kits to primary recipients (PRs) for distribution to their sexual partners, anyone in their social network (termed secondary recipients) or for self-testing, from September 2018 to March 2020. The study was conducted in Eshowe and Mbongolwane areas in KwaZulu-Natal, South Africa. A structured questionnaire was administered during the recruitment and passive follow-up, when people came for confirmatory HIV testing. Electronic records were retrospectively examined to determine initiation of antiretroviral treatment (ART) for all HIVST users and non-users. ResultsAmong 36,708 people approached to be primary recipients, 9,891 (26.9%) accepted; 31,341 HIVST kits were distributed with a median of three (IQR: 2-4) per peer. PRs were predominately recruited at primary health clinics (PHCs). However, acceptability of HIVST was thrice as high at community-based testing sites compared to PHCs (64.5% vs. 21.0%; p<0.001). During the study period, 34,715 adults were tested for HIV at both PHCs and community-based testing sites; of these, 1,089 individuals reported HIVST use. Among HIVST users, 893 (82.0%) returned to the clinic for confirmatory testing after testing negative on HIVST; 196 (17.9%) were confirmed HIV positive following a positive HIVST. After excluding 36/196 (18.4%) participants for whom clinical records could not be found in electronic register and 25/160 (15.6%) who were already on ART before receiving HIVST, 129/135 (95.5%) initiated ART, whereas 2,362/2685 (88%) of HIV positive HIVST non-users-initiated ART. ConclusionUnsupervised peer-distribution of HIVST was feasible and acceptable, with more than 25% accepting to be peer-distributors. Acceptability of HIVST was thrice as high in community sites compared to clinics.	[Kitenge, Marcel K.; Laxmeshwar, Chinmay; Ford-Kamara, Ellie; Gcwensa, Ntombi; Ohler, Liesbet] Medecins Sans Frontieres MSF, Eshowe, Kwazulu Natal, South Africa; [Kitenge, Marcel K.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Cape Town, South Africa; [Aza, Elkin Bermudez] Int Off, Medecins Sans Frontieres MSF, Amsterdam, Netherlands; [Van Cutsem, Gilles; Casas, Esther C.; Isaakidis, Petros] Medecins Sans Frontieres MSF, Southern Africa Med Unit, Cape Town, South Africa; [Van Cutsem, Gilles] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa; [Hlophe, Khanyo] Dept Hlth, Kwa Zulu, South Africa	Stellenbosch University; University of Cape Town	Kitenge, MK (corresponding author), Medecins Sans Frontieres MSF, Eshowe, Kwazulu Natal, South Africa.; Kitenge, MK (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Cape Town, South Africa.	msfocb-eshowe-epi@brussels.msf.org		Laxmeshwar, Chinmay/0000-0003-1561-3857; Isaakidis, Petros/0000-0002-7881-1554; Kitenge, Marcel/0000-0002-8245-4043				Choko AT, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002719; Choko AT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208191; Choko AT, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001873; Choko AT, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21610; Deville W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215353; Harichund C, 2018, AIDS BEHAV, V22, P560, DOI 10.1007/s10461-017-1848-9; Hatzold K., 2020, ZAMBIA ZIMBABWE, V22, P43; Indravudh PP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4430-4; Jamil MS, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.100991; Jobson G, 2019, JAIDS-J ACQ IMM DEF, V81, pE160, DOI 10.1097/QAI.0000000000002078; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594; Lebina L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4785-7; Makusha T, 2017, PUBLIC HEALTH, V143, P1, DOI 10.1016/j.puhe.2016.10.017; Masters SH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002166; Matovu JKB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236141; Medecins Sans Frontieres, 2019, MBONGOLWANE ESHOWE H, V2; Napierala S, 2019, B WORLD HEALTH ORGAN, V97, P764, DOI 10.2471/BLT.18.223560; Neuman M, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25238; Njau B, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7685-1; Olaru ID, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.7.21751; Organization WH., 2016, GUID HIV SELF TEST P; Perez GM, 2016, TROP MED INT HEALTH, V21, P759, DOI 10.1111/tmi.12703; Pettifor A, 2020, ECLINICALMEDICINE, V21, DOI 10.1016/j.eclinm.2020.100327; SA HIV Clinicians Society, 2017, S AFR HIV SELF TEST; South African National Department of Health, 2018, NAT HIV SELF SCREEN; Statistics South Africa, 2018, MIDYEAR POPULATION E; Thirumurthy H, 2016, LANCET HIV, V3, pE266, DOI 10.1016/S2352-3018(16)00041-2; UN General Assembly, 2016, POL DECL HIV AIDS FA, V17020, P1; UNAIDS, 2018, GLOB HIV STAT 2019, P1; UNAIDS 2020, 2020, TACKL ENTR IN END EP; WHO/UNITAID, 2018, LANDSC HIV RAP DIAGN	31	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264442	10.1371/journal.pone.0264442	http://dx.doi.org/10.1371/journal.pone.0264442			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0T0FS	35353823	Green Published, gold			2023-01-03	WOS:000786647900016
J	Maruyama, Y; Nakayama, M; Abe, M; Yokoo, T; Minakuchi, J; Nitta, K				Maruyama, Yukio; Nakayama, Masaaki; Abe, Masanori; Yokoo, Takashi; Minakuchi, Jun; Nitta, Kosaku			Association between serum beta 2-microglobulin and mortality in Japanese peritoneal dialysis patients: A cohort study	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; BETA-TRACE PROTEIN; CARDIOVASCULAR-DISEASE; KIDNEY-FUNCTION; RISK-FACTORS; CYSTATIN-C; PREDICTORS; BETA(2)-MICROGLOBULIN; CREATININE; MARKERS	Background Higher serum beta 2-microglobulin (B2M) concentrations are associated with higher mortality in the general population, non-dialyzed chronic kidney disease patients and patients receiving hemodialysis (HD). However, this relationship among patients on peritoneal dialysis (PD) has not been validated. Methods We collected baseline data for 3,011 prevalent PD patients from a nationwide dialysis registry in Japan at the end of 2010. Clinical outcomes for 9 years were then evaluated using the registry at the end of 2011 to 2019. All-cause and cardiovascular (CV) mortality was assessed using Cox regression analysis and competing-risks regression analysis, respectively. We used multiple imputation to deal with missing covariate data. Results During a median follow-up of 87 months, 2,054 patients transferred to combined therapy with PD and HD or HD directly. A total of 3,011 patients, 1,235 (41.0%) died, including 437 patients (14.5%) from CV causes. Among them, 612 patients died after transfer to other dialysis modalities. Univariate analyses revealed no significant association between serum B2M and mortality, whereas higher serum B2M was independently associated with both all-cause and CV mortalities in adjusted models. However, the significant association between serum B2M and CV mortality disappeared in analysis treating serum B2M as a categorical variable. The effect of serum B2M on all-cause mortality was significantly higher among patients with higher urinary volume and a significant interaction was evident. Conclusions Using a large-scale registry, we found that serum B2M contributes tenuously but significantly to worse outcome and residual kidney function significantly affects this relationship. On the contrary, serum B2M per se had no predictive value for patient outcome in prevalent PD patients.	[Maruyama, Yukio; Yokoo, Takashi] Jikei Univ, Dept Internal Med, Div Nephrol & Hypertens, Sch Med, Tokyo, Japan; [Maruyama, Yukio; Abe, Masanori; Nitta, Kosaku] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan; [Nakayama, Masaaki] St Lukes Int Hosp, Dept Nephrol, Tokyo, Japan; [Abe, Masanori] Nihon Univ, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Sch Med, Tokyo, Japan; [Minakuchi, Jun] Kawashima Hosp, Dept Kidney Dis, Tokushima, Japan; [Nitta, Kosaku] Tokyo Womens Med Univ, Dept Internal Med 4, Tokyo, Japan	Jikei University; St. Luke's International Hospital; Nihon University; Tokyo Women's Medical University	Maruyama, Y (corresponding author), Jikei Univ, Dept Internal Med, Div Nephrol & Hypertens, Sch Med, Tokyo, Japan.; Maruyama, Y (corresponding author), Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan.	maruyama@td5.so-net.ne.jp		Maruyama, Yukio/0000-0002-5602-8104				ACCHIARDO S, 1989, AM J KIDNEY DIS, V13, P70, DOI 10.1016/S0272-6386(89)80119-2; Aloisio KM, 2014, STATA J, V14, P863, DOI 10.1177/1536867X1401400410; AMICI G, 1993, NEPHRON, V65, P469, DOI 10.1159/000187533; [Anonymous], 2002, NEPHROL DIAL TRANSPL, V17, P16; Astor BC, 2012, AM J KIDNEY DIS, V59, P653, DOI 10.1053/j.ajkd.2011.11.042; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Bianchi C, 2001, RENAL FAILURE, V23, P419, DOI 10.1081/JDI-100104725; Brown EA, 2020, PERITON DIALYSIS INT, V40, P244, DOI 10.1177/0896860819895364; Brown P H, 1988, Nephrol Dial Transplant, V3, P169; Brunati CCM, 2019, BLOOD PURIFICAT, V48, P86, DOI 10.1159/000499830; Chang TI, 2019, NEPHROL DIAL TRANSPL, V34, P138, DOI 10.1093/ndt/gfy193; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; Conway T P, 1976, Adv Exp Med Biol, V73 Pt B, P87; Coviello V, 2004, STATA J, V4, P103, DOI 10.1177/1536867X0400400201; Donadio C, 2001, J PHARMACEUT BIOMED, V24, P835, DOI 10.1016/S0731-7085(00)00550-1; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fink JC, 1999, AM J KIDNEY DIS, V34, P694, DOI 10.1016/S0272-6386(99)70395-1; Foster MC, 2016, AM J KIDNEY DIS, V68, P68, DOI 10.1053/j.ajkd.2016.01.015; Foster MC, 2013, AM J KIDNEY DIS, V62, P42, DOI 10.1053/j.ajkd.2013.01.016; Ignacio de Ulíbarri J., 2005, Nutr. Hosp., V20, P38; Jadoul M, 2016, NEPHROL DIAL TRANSPL, V31, P507, DOI 10.1093/ndt/gfv318; Jaques DA, 2021, J NEPHROL, V34, P473, DOI 10.1007/s40620-020-00906-x; Juraschek SP, 2013, CLIN J AM SOC NEPHRO, V8, P584, DOI 10.2215/CJN.08700812; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; KIN K, 1979, IMMUNOLOGY, V36, P47; Koh ES, 2015, AM J NEPHROL, V42, P91, DOI 10.1159/000439060; Lo WK, 2006, PERITON DIALYSIS INT, V26, P520; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Nakai S, 2012, THER APHER DIAL, V16, P483, DOI 10.1111/j.1744-9987.2012.01143.x; Nakao M, 2017, NEPHROLOGY, V22, P907, DOI 10.1111/nep.12911; Nakayama M, 2010, THER APHER DIAL, V14, P489, DOI 10.1111/j.1744-9987.2010.00901.x; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Shafi T, 2016, KIDNEY INT, V89, P1099, DOI 10.1016/j.kint.2015.10.011; Wu HC, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22056; Xue JL, 2002, KIDNEY INT, V61, P741, DOI 10.1046/j.1523-1755.2002.00176.x; Yokoyama K, 2008, CLIN NEPHROL, V69, P121; Zhang JL, 2022, THER APHER DIAL, V26, P267, DOI 10.1111/1744-9987.13729	37	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266882	10.1371/journal.pone.0266882	http://dx.doi.org/10.1371/journal.pone.0266882			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F9AX	35421178	gold, Green Published			2023-01-03	WOS:000795453600075
J	Wise, J				Wise, Jacqui			Medical cannabis: Allow GPs to prescribe as part of national trial, review urges	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	2022	377								o1567	10.1136/bmj.o1567	http://dx.doi.org/10.1136/bmj.o1567			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2S8LJ	35760442				2023-01-03	WOS:000822038900006
J	Wang, XH; Wu, QW; Li, LL; Wang, P; Wang, Y; Wei, WF; Ma, XJ; Shu, J; Zhang, K; Ma, DM				Wang, Xinhong; Wu, Qingwen; Li, Lulu; Wang, Peng; Wang, Yue; Wei, Weifeng; Ma, Xiaojun; Shu, Jing; Zhang, Kai; Ma, Dongming			Determination of quality markers for quality control of Zanthoxylum nitidum using ultra-performance liquid chromatography coupled with near infrared spectroscopy	PLOS ONE			English	Article							RAPID IDENTIFICATION; ALKALOIDS	With the increasing demand for quality control in the traditional Chinese medicine industry, there is a need for the development of quality markers and a quick, non-destructive technique for the discrimination of related species. In our previous study, ultra-performance liquid chromatography (UPLC) was used for the simultaneous determination of five compounds, including three alkaloids (nitidine chloride, chelerythrine, and magnoflorine), one flavonoid (aurantiamarin), and one lignan (sesamin). In this study, the simultaneous quantification of the above-mentioned compounds could be used to discriminate the powders of roots from those of stems. To further test the reliability of the five compounds, seventy-two batches of wild and seventy-five batches of cultivated Zanthoxylum nitidum samples collected from Guangdong, Guangxi, and Fujian provinces in China were analyzed by UPLC and near-infrared spectroscopy (NIRS). In general, the quantitative results of UPLC were consistent with those of NIRS, and cultivated Z. nitidum has similar major bioactive compounds as the wild one, as supported by principal component analysis. Consequently, these five major bioactive compounds are suggested as potential quality markers. In addition, the NIRS method with discriminant analysis successfully differentiated Z. nitidum from three related species (Z. avicennae, Z. scandens and Toddalia asiatica) of the Rutaceae family. In summary, this study provides a method for the rapid identification of Z. nitidum and discrimination of root and stem powders, and suggests five compounds as quality markers for the evaluation of Z. nitidum.	[Wang, Xinhong; Li, Lulu; Wang, Peng; Ma, Xiaojun; Shu, Jing; Zhang, Kai] Shandong Agr & Engn Univ, Coll Forestry Engn, Jinan, Shandong, Peoples R China; [Wu, Qingwen; Ma, Dongming] Guangzhou Univ Chinese Med, Res Ctr Chinese Herbal Resource Sci & Engn, Guangzhou, Guangdong, Peoples R China; [Wang, Yue] Shandong Acad Agr Sci, Jinan, Shandong, Peoples R China; [Wei, Weifeng] China Resources Sanjiu Med Pharmaceut Co Ltd, Shenzhen, Guangdong, Peoples R China	Shandong Agriculture & Engineering University; Guangzhou University of Chinese Medicine; Shandong Academy of Agricultural Sciences; China Resources Group	Ma, DM (corresponding author), Guangzhou Univ Chinese Med, Res Ctr Chinese Herbal Resource Sci & Engn, Guangzhou, Guangdong, Peoples R China.	madm@gzucm.edu.cn		Qingwen, Wu/0000-0003-2269-0519; Wang, Xinhong/0000-0002-8979-1472; Ma, Dongming/0000-0003-4612-0756	Shandong agriculture and engineering university [31720007]; Guangdong Pearl River Talents Plan [2017GC010368]	Shandong agriculture and engineering university; Guangdong Pearl River Talents Plan	We are grateful for financial support of the doctor fund of Shandong agriculture and engineering university (31720007) and Guangdong Pearl River Talents Plan (2017GC010368).	Bec KB, 2021, J PHARMACEUT BIOMED, V193, DOI 10.1016/j.jpba.2020.113686; Bhattacharya S, 2009, ASIAN J PHARM CLIN R, V2, P30; Bogomolov A, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00388; Chan CO, 2007, ANAL CHIM ACTA, V592, P121, DOI 10.1016/j.aca.2007.04.016; Chen Wei-xuan, 2015, Zhong Yao Cai, V38, P2358; Ciurczak E W, 1986, SPECTROSCOPY-US, V1, P36; Cui Y, 2020, J CANCER, V11, P1250, DOI 10.7150/jca.37890; [冯洁 Feng Jie], 2011, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V27, P60; Han BX, 2014, PHARMACOGN MAG, V10, P353, DOI 10.4103/0973-1296.137378; Huang HB, 2008, J FOOD ENG, V87, P303, DOI 10.1016/j.jfoodeng.2007.12.022; [黄依玲 Huang Yiling], 2013, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V29, P103; Huck CW, 2005, ANAL CHIM ACTA, V538, P195, DOI 10.1016/j.aca.2005.01.064; Kudo M, 2000, J PHARM PHARMACOL, V52, P1271, DOI 10.1211/0022357001777252; Li M, 2017, FOOD CONTROL, V73, P1334, DOI 10.1016/j.foodcont.2016.10.054; Li WL, 2012, VIB SPECTROSC, V62, P159, DOI 10.1016/j.vibspec.2012.07.005; Lu Q, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.112946; Meng Y, 2015, J ANAL METHODS CHEM, V2015, DOI 10.1155/2015/752162; MOODY JO, 1984, PLANTA MED, V50, P101, DOI 10.1055/s-2007-969634; N.P. Commission, 2020, PHARMACOPOEIA PEOPLE, P166; Nguyen QA, 2002, Z NATURFORSCH C, V57, P986; Nicolai BM, 2007, POSTHARVEST BIOL TEC, V46, P99, DOI 10.1016/j.postharvbio.2007.06.024; Peng Z H, 2018, PHARM TODAY, V28, P500; Qiao JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13293-0; Qin FF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00359; Qu HB, 2004, CHINESE J ANAL CHEM, V32, P477; Rinnan A, 2009, TRAC-TREND ANAL CHEM, V28, P1201, DOI 10.1016/j.trac.2009.07.007; Shen T, 2020, MOLECULES, V25, DOI 10.3390/molecules25061442; Wang XH, 2020, IND CROP PROD, V150, DOI 10.1016/j.indcrop.2020.112345; Yan H, 2021, SPECTROCHIM ACTA A, V249, DOI 10.1016/j.saa.2020.119344; Yan SM, 2014, J ANAL METHODS CHEM, V2014, DOI 10.1155/2014/704971; Yang GH, 2008, CHEM BIODIVERS, V5, P1718, DOI 10.1002/cbdv.200890160; Zeng Z, 2021, SAUDI PHARM J, V29, P781, DOI 10.1016/j.jsps.2021.05.003; Zhang S, 2001, Zhong Yao Cai, V24, P649; Ziegel E R, 2004, TECHNOMETRICS, V46, P108, DOI [10.1198/004017004000000167, DOI 10.1198/004017004000000167]; Zou WB, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00184	35	0	0	11	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2022	17	6							e0270315	10.1371/journal.pone.0270315	http://dx.doi.org/10.1371/journal.pone.0270315			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6I0VV	35749476	Green Published, gold			2023-01-03	WOS:000885846600001
J	Taylor, L				Taylor, Luke			Colombia becomes first Latin American country to decriminalise assisted suicide	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		[Anonymous], TIEMPO; Taylor L, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj.o455	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	2022	377								o1219	10.1136/bmj.o1219	http://dx.doi.org/10.1136/bmj.o1219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2C6CS	35577359				2023-01-03	WOS:000810954700001
J	Abbas, F; Becker, S; Jones, BW; Mure, LS; Panda, S; Hanneken, A; Vinberg, F				Abbas, Fatima; Becker, Silke; Jones, Bryan W.; Mure, Ludovic S.; Panda, Satchidananda; Hanneken, Anne; Vinberg, Frans			Revival of light signalling in the postmortem mouse and human retina	NATURE			English	Article							B-WAVE; A-WAVE; ROD; ELECTRORETINOGRAM; RAT; SURVIVAL; RESTORATION; EXPRESSION; RECOVERY; DELAY	Death is defined as the irreversible cessation of circulatory, respiratory or brain activity. Many peripheral human organs can be transplanted from deceased donors using protocols to optimize viability. However, tissues from the central nervous system rapidly lose viability after circulation ceases(1,2), impeding their potential for transplantation. The time course and mechanisms causing neuronal death and the potential for revival remain poorly defined. Here, using the retina as a model of the central nervous system, we systemically examine the kinetics of death and neuronal revival. We demonstrate the swift decline of neuronal signalling and identify conditions for reviving synchronous in vivo-like trans-synaptic transmission in postmortem mouse and human retina. We measure light-evoked responses in human macular photoreceptors in eyes removed up to 5 h after death and identify modifiable factors that drive reversible and irreversible loss of light signalling after death. Finally, we quantify the rate-limiting deactivation reaction of phototransduction, a model G protein signalling cascade, in peripheral and macular human and macaque retina. Our approach will have broad applications and impact by enabling transformative studies in the human central nervous system, raising questions about the irreversibility of neuronal cell death, and providing new avenues for visual rehabilitation.	[Abbas, Fatima; Becker, Silke; Jones, Bryan W.; Vinberg, Frans] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA; [Mure, Ludovic S.; Panda, Satchidananda] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Hanneken, Anne] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA; [Hanneken, Anne] Retina Consultants San Diego, La Jolla, CA 92037 USA; [Mure, Ludovic S.] Univ Bern, Inst Physiol, Bern, Switzerland; [Mure, Ludovic S.] Univ Hosp Bern, Dept Neurol, Zentrum Expt Neurol, Inselspital, Bern, Switzerland	Utah System of Higher Education; University of Utah; Salk Institute; Scripps Research Institute; University of Bern; University of Bern; University Hospital of Bern	Vinberg, F (corresponding author), Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.; Hanneken, A (corresponding author), Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.; Hanneken, A (corresponding author), Retina Consultants San Diego, La Jolla, CA 92037 USA.	ahanneke@scripps.edu; frans.vinberg@utah.edu	Vinberg, Frans/AAK-8615-2021	Vinberg, Frans/0000-0003-3439-4979; Jones, Bryan/0000-0001-5527-6643; Abbas, Fatima/0000-0002-9833-5153	National Institutes of Health [P30 EY014800, R01 EY015128, R01 EY028927, R01: CA236352, R01: DK115214, R01: DK118278]; Research to Prevent Blindness; NIH/NCATS grant [UL1 TR002550]; NIH [EY031706]; Daro Foundation; A. C. Israel Foundation; Warren Family Foundation; Renaissance Charitable Foundation; Rancho Santa Fe Foundation; Money Arenz Foundation; Considine Foundation; Fonseca Foundation; Pfeiffer Foundation; Mericos Eye Institute; Thomas and Audrey Pine Foundation; Research to Prevent Blindness/Dr. H. James and Carole Free Career Development Award; Diabetes Research Connection; International Retinal Research Foundation; ARVO Foundation for Eye Research EyeFind research grant; National Science Foundation [2014862]; Department of Defense [W81XWH1810645]; Wu-Tsai Human Performance Alliance; Joe and Clara Tsai Foundation; Velux Stiftung	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NIH/NCATS grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Daro Foundation; A. C. Israel Foundation; Warren Family Foundation; Renaissance Charitable Foundation; Rancho Santa Fe Foundation; Money Arenz Foundation; Considine Foundation; Fonseca Foundation; Pfeiffer Foundation; Mericos Eye Institute; Thomas and Audrey Pine Foundation; Research to Prevent Blindness/Dr. H. James and Carole Free Career Development Award; Diabetes Research Connection; International Retinal Research Foundation; ARVO Foundation for Eye Research EyeFind research grant; National Science Foundation(National Science Foundation (NSF)); Department of Defense(United States Department of Defense); Wu-Tsai Human Performance Alliance; Joe and Clara Tsai Foundation; Velux Stiftung	This work was supported by National Institutes of Health (P30 EY014800), and an Unrestricted Grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences, University of Utah. A.H. is supported by NIH/NCATS grant UL1 TR002550, NIH EY031706, the Daro Foundation, the A. C. Israel Foundation, the Warren Family Foundation, the Renaissance Charitable Foundation, The Rancho Santa Fe Foundation, the Money Arenz Foundation, the Considine Foundation, the Fonseca Foundation, the Pfeiffer Foundation, the Mericos Eye Institute, the Thomas and Audrey Pine Foundation and additional philanthropic funding. F.V. is supported by NIH grant EY031706, Research to Prevent Blindness/Dr. H. James and Carole Free Career Development Award, Diabetes Research Connection, and International Retinal Research Foundation. S.B. is supported by ARVO Foundation for Eye Research EyeFind research grant. B.W.J. is supported by the National Institutes of Health (R01 EY015128, R01 EY028927) and the National Science Foundation (2014862). S.P. is supported by the National Institutes of Health (R01s: CA236352, DK115214, DK118278), Department of Defense (W81XWH1810645), and Wu-Tsai Human Performance Alliance and the Joe and Clara Tsai Foundation. L.S.M. is supported by Velux Stiftung. Figure schematics were made with resources from Biorender.com. We thank J. Dessert for producing the surgical donation and transportation illustrations in Fig. 3a; J. R. Allen for the fusion 360 model of the ex vivo ERG specimen holder in Extended Data Fig. 3; T. Neikirk, a member of the Hanneken laboratory, for providing technical support and assistance; H. Calligaro, a member of the Panda laboratory, for useful discussions of some of the most recent human retina experiments; C. Faulkner and J. Perlmutter for providing non-human primate eyes; the Utah Lions Eye Bank, Lifesharing and the San Diego Eye bank for providing human donor eyes.	BOLNICK DA, 1979, VISION RES, V19, P1117, DOI 10.1016/0042-6989(79)90006-3; Borjigin Jimo, 2013, Proc Natl Acad Sci U S A, V110, P14432, DOI 10.1073/pnas.1308285110; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; COLE SL, 1956, JAMA-J AM MED ASSOC, V161, P1454, DOI 10.1001/jama.1956.02970150022005; Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Donaldson AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082011; Fortenbach CR, 2015, VISION RES, V110, P57, DOI 10.1016/j.visres.2015.02.011; Granit R, 1933, J PHYSIOL-LONDON, V77, P207, DOI 10.1113/jphysiol.1933.sp002964; Gross OP, 2010, J NEUROSCI, V30, P3450, DOI 10.1523/JNEUROSCI.5391-09.2010; GUREVICH L, 1993, VISION RES, V33, P2431, DOI 10.1016/0042-6989(93)90122-D; HUANG JC, 1993, DOC OPHTHALMOL, V83, P91, DOI 10.1007/BF01206206; HUANG JC, 1990, CURR EYE RES, V9, P151, DOI 10.3109/02713689008995201; HUANG JC, 1990, DOC OPHTHALMOL, V76, P27, DOI 10.1007/BF00140495; Ingram NT, 2020, P NATL ACAD SCI USA, V117, P19599, DOI 10.1073/pnas.2001776117; Iyer A, 2016, TRANSPLANTATION, V100, P2621, DOI 10.1097/TP.0000000000001396; Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018; Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103; Kim H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74935-8; Kling, PREPRINT, DOI 10.1101/2020.08.07.240762(2020; KRAFT TW, 1993, J PHYSIOL-LONDON, V464, P747, DOI 10.1113/jphysiol.1993.sp019661; Kraft TW, 1998, VISION RES, V38, P3663, DOI 10.1016/S0042-6989(97)00371-4; Krispel CM, 2006, NEURON, V51, P409, DOI 10.1016/j.neuron.2006.07.010; Kuchenbecker JA, 2014, J OPT SOC AM A, V31, pA208, DOI 10.1364/JOSAA.31.00A208; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Lu YF, 2020, DEV CELL, V53, P473, DOI 10.1016/j.devcel.2020.04.009; MARC RE, 1995, J NEUROSCI, V15, P5106; MASLAND RH, 1975, J NEUROBIOL, V6, P305, DOI 10.1002/neu.480060306; Mure LS, 2019, SCIENCE, V366, P1251, DOI 10.1126/science.aaz0898; Nymark S, 2006, INVEST OPHTH VIS SCI, V47, P2583, DOI 10.1167/iovs.05-1116; Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267; Parnia S, 2001, RESUSCITATION, V48, P149, DOI 10.1016/S0300-9572(00)00328-2; Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; Raeburn CD, 2001, ARCH SURG-CHICAGO, V136, P1263, DOI 10.1001/archsurg.136.11.1263; Reinhard K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246952; Reinhard K, 2016, INVEST OPHTH VIS SCI, V57, P658, DOI 10.1167/iovs.15-17751; Robson JG, 2003, J PHYSIOL-LONDON, V547, P509, DOI 10.1113/jphysiol.2002.030304; Sakami S, 2011, J BIOL CHEM, V286, P10551, DOI 10.1074/jbc.M110.209759; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; Sinha R, 2017, CELL, V168, P413, DOI 10.1016/j.cell.2017.01.005; Smith NP, 1997, VISION RES, V37, P2943, DOI 10.1016/S0042-6989(97)00094-1; Soto F, 2020, NEURON, V107, P656, DOI 10.1016/j.neuron.2020.05.030; Telias M, 2019, NEURON, V102, P574, DOI 10.1016/j.neuron.2019.02.015; van Hateren JH, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-34; Vinberg F, 2014, VISION RES, V101, P108, DOI 10.1016/j.visres.2014.06.003; Vrselja Z, 2019, NATURE, V568, P336, DOI 10.1038/s41586-019-1099-1; Wang JS, 2009, CURR BIOL, V19, P1665, DOI 10.1016/j.cub.2009.07.054; Wang T, 2019, J NEUROSCI, V39, P6798, DOI 10.1523/JNEUROSCI.2902-18.2019; WEINSTEI.GW, 1967, NATURE, V215, P134, DOI 10.1038/215134a0; WEINSTEIN GW, 1971, SCIENCE, V171, P1021, DOI 10.1126/science.171.3975.1021; WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X; Wu JY, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S1; YAN W, 2020, SCI REP-UK, V10; Yi WY, 2021, NATL SCI REV, V8, DOI 10.1093/nsr/nwaa179; Yu DY, 2006, INVEST OPHTH VIS SCI, V47, P1109, DOI 10.1167/iovs.05-1118; Zhu SY, 2018, EXP EYE RES, V174, P113, DOI 10.1016/j.exer.2018.05.032	58	2	2	4	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 9	2022	606	7913					351	+		10.1038/s41586-022-04709-x	http://dx.doi.org/10.1038/s41586-022-04709-x		MAY 2022	23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2A0PO	35545677				2023-01-03	WOS:000793701500010
J	Hao, D; Low, S; Di Fenza, R; Shenoy, ES; Ananian, L; Prout, LA; La Vita, CJ; Berra, L				Hao, David; Low, Sarah; Di Fenza, Raffaele; Shenoy, Erica S.; Ananian, Lillian; Prout, Laura A.; La Vita, Carolyn J.; Berra, Lorenzo			Prone Positioning of Intubated Patients with an Elevated Body-Mass Index	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ARDS	Prone Positioning of Intubated Patients with a High BMIProne positioning improves oxygenation and decreases mortality in patients with acute respiratory distress syndrome. This video demonstrates how to place an intubated patient in the prone position, with an emphasis on patients who have a body-mass index of more than 30 and for whom the prone position is necessary for a prolonged period.	[Hao, David; Low, Sarah; Di Fenza, Raffaele; Berra, Lorenzo] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA; [Shenoy, Erica S.] Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA; [Prout, Laura A.] Massachusetts Gen Hosp, Nursing & Patient Care Serv, 55 Fruit St, Boston, MA 02114 USA; [La Vita, Carolyn J.] Massachusetts Gen Hosp, Resp Care, Boston, MA 02114 USA; [La Vita, Carolyn J.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Berra, L (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.	lberra@mgh.harvard.edu		Hao, David/0000-0002-0221-9255; Shenoy, Erica/0000-0001-8086-1123				Binda F, 2021, INTENS CRIT CARE NUR, V67, DOI 10.1016/j.iccn.2021.103088; De Jong A, 2013, CHEST, V143, P1554, DOI 10.1378/chest.12-2115; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Jozwiak M, 2013, AM J RESP CRIT CARE, V188, P1428, DOI 10.1164/rccm.201303-0593OC; Scholten EL, 2017, CHEST, V151, P215, DOI 10.1016/j.chest.2016.06.032; Xin Y, 2021, CRIT CARE MED, V49, pE1015, DOI 10.1097/CCM.0000000000005071	6	2	2	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2022	386	14							e34	10.1056/NEJMvcm2108494	http://dx.doi.org/10.1056/NEJMvcm2108494			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1T9JP	35388669				2023-01-03	WOS:000805040200002
J	Hopkins, J; Narasimhan, M				Hopkins, Jon; Narasimhan, Manjulaa			Access to self-care interventions can improve health outcomes for people experiencing homelessness	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hopkins, Jon] U Turn, Cape Town, South Africa; [Narasimhan, Manjulaa] WHO, Dept Sexual & Reprod Hlth & Res, UNDP UNFPA Unicef WHO World Bank Special Programm, Geneva, Switzerland	The World Bank; United Nations Population Fund; World Health Organization	Hopkins, J (corresponding author), U Turn, Cape Town, South Africa.	jon@homeless.org.za		Narasimhan, Manjulaa/0000-0003-0598-6887				Aldridge Robert W, 2019, Wellcome Open Res, V4, P49, DOI 10.12688/wellcomeopenres.15151.1; Allen J, 2008, ADAPTING YOUR PRACTI; Anderson I, 2006, CHANGING ROLE SERVIC; Barker SL, 2017, COMMUNITY MENT HLT J, V53, P598, DOI 10.1007/s10597-017-0102-2; Bring C, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05358-4; BrisDoc Healthcare Services, HOM HLTH SERV PRIM H; Burridge S, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4669; Campbell DJT, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0361-3; Fazel S, 2014, LANCET, V384, P1529, DOI 10.1016/S0140-6736(14)61132-6; Frankish CJ, 2005, CAN J PUBLIC HEALTH, V96, pS23, DOI 10.1007/BF03403700; Gaetz S., 2012, SIERRA MAGAZINE; Goodman L., 2006, NO SAFE PLACE SEXUAL; Hopkins J, 2020, COST HOMELESSNESS CA; Hulton LJ, 2015, GSTF J NURS HLTH CAR, V3, P4; Hwang SW, 2014, LANCET, V384, P1541, DOI 10.1016/S0140-6736(14)61133-8; Keene DE, 2018, CITYSCAPE, V20, P107, DOI 10.2307/26472170; Lewer D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025192; Mathieu E, 2017, TORONTO STAR; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78; Narasimhan M, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l688; Narasimhan M, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1403; National Alliance to End Homelessness, 2020, CHRON HOM; O'Campo P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010581; Omerov P, 2020, HEALTH SOC CARE COMM, V28, P1, DOI 10.1111/hsc.12857; Pathway, 2019, HEALTHC HOM PEOPL WH; Pendyal A, 2021, HEART LUNG, V50, P80, DOI 10.1016/j.hrtlng.2020.08.001; Purkey E, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1004-4; Rice B, CITY VOICES LEARNING; Salhi BA, 2018, ACAD EMERG MED, V25, P577, DOI 10.1111/acem.13358; Schenck R, 2017, SOC WORK-MAATSK WERK, V53, P266, DOI [10.15270/52-2-568, 10.15270/53-2-568]; Seager JR, 2010, DEV SO AFR, V27, P63, DOI 10.1080/03768350903519358; Ungpakorn R, 2020, J ADV NURS, V76, P253, DOI 10.1111/jan.14225; Wenzel SL, 2000, J GEN INTERN MED, V15, P265, DOI 10.1111/j.1525-1497.2000.04269.x; WHO, ADV PUBL COR DIS COV, P2021; WHO, CLASS SELF CAR INT H, P2021; WHO, 2021, SELF CAR INT HLTH; World Health Organization (WHO), 2021, WHO GUID SELF CAR IN	37	2	2	3	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 24	2022	376								e068700	10.1136/bmj-2021-068700	http://dx.doi.org/10.1136/bmj-2021-068700			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	0H0WE	35331989	Green Published, hybrid			2023-01-03	WOS:000778460100011
J	Shitara, K; Ajani, JA; Moehler, M; Garrido, M; Gallardo, C; Shen, L; Yamaguchi, K; Wyrwicz, L; Skoczylas, T; Bragagnoli, AC; Liu, TS; Tehfe, M; Elimova, E; Bruges, R; Zander, T; de Azevedo, S; Kowalyszyn, R; Pazo-Cid, R; Schenker, M; Cleary, JM; Yanez, P; Feeney, K; Karamouzis, MV; Poulart, V; Lei, M; Xiao, H; Kondo, K; Li, MS; Janjigian, YY				Shitara, Kohei; Ajani, Jaffer A.; Moehler, Markus; Garrido, Marcelo; Gallardo, Carlos; Shen, Lin; Yamaguchi, Kensei; Wyrwicz, Lucjan; Skoczylas, Tomasz; Bragagnoli, Arinilda Campos; Liu, Tianshu; Tehfe, Mustapha; Elimova, Elena; Bruges, Ricardo; Zander, Thomas; de Azevedo, Sergio; Kowalyszyn, Ruben; Pazo-Cid, Roberto; Schenker, Michael; Cleary, James M.; Yanez, Patricio; Feeney, Kynan; Karamouzis, Michalis, V; Poulart, Valerie; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun; Janjigian, Yelena Y.			Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer	NATURE			English	Article							OPEN-LABEL; COMBINATION THERAPY; SOLID TUMORS; JUNCTION; CAPECITABINE; CISPLATIN	Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma(1-4). Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial(5) (programmed death ligand-1 (PD-L1) combined positive score >= 5 and all randomized patients). On the basis of these results, nivolumab plus chemotherapy is now approved as a first-line treatment for these patients in many countries(6). Nivolumab and the cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor ipilimumab have distinct but complementary mechanisms of action that contribute to the restoration of anti-tumour T-cell function and induction of de novo anti-tumour T-cell responses, respectively(7-)(11). Treatment combining 1 mg kg(-1) nivolumab with 3 mg kg(-1) ipilimumab demonstrated clinically meaningful anti-tumour activity with a manageable safety profile in heavily pre-treated patients with advanced gastro-oesophageal cancer(12). Here we report both long-term follow-up results comparing nivolumab plus chemotherapyversus chemotherapy alone and the first results comparing nivolumab plus ipilimumab versus chemotherapy alone from CheckMate 649. After the 24.0-month minimum follow-up, nivolumab plus chemotherapy continued to demonstrate improvement in overall survival versus chemotherapy alone in patients with PD-L1 combined positive >= 5 score (hazard ratio 0.70; 95% confidence interval 0.61, 0.81) and all randomized patients (hazard ratio 0.79; 95% confidence interval 0.71, 0.88). Overall survival in patients with PD-L1 combined positive score >= 5 for nivolumab plus ipilimumab versus chemotherapy alone did not meet the prespecified boundary for significance. No new safety signals were identified. Our results support the continued use of nivolumab plus chemotherapy as standard first-line treatment for advanced gastro-oesophageal adenocarcinoma.	[Shitara, Kohei] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Ajani, Jaffer A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Moehler, Markus] Johannes Gutenberg Univ Clin, Mainz, Germany; [Garrido, Marcelo] Pontificia Univ Catolica, Unica San Carlos Apoquindo, Santiago, Chile; [Gallardo, Carlos] Fdn Arturo Lopez Perez, Providencia, Chile; [Shen, Lin] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Beijing, Peoples R China; [Yamaguchi, Kensei] Canc Inst Hosp JFCR, Tokyo, Japan; [Wyrwicz, Lucjan] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland; [Skoczylas, Tomasz] Med Univ Lublin, Klin Chirurgii Ogolnej Gastroenterol & Nowotworow, Lublin, Poland; [Bragagnoli, Arinilda Campos] Fundacao Pio Xii Hosp Canc Barretos, Barretos, Brazil; [Liu, Tianshu] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Tehfe, Mustapha] Ctr Hosp Univ Montreal, Oncol Ctr, Montreal, PQ, Canada; [Elimova, Elena] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Bruges, Ricardo] Inst Nacl Cancerol ESE, Bogota, Colombia; [Zander, Thomas] Univ Cologne, Dept Internal Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany; [Zander, Thomas] Gastrointestinal Canc Grp Cologne GCGC, Cologne, Germany; [de Azevedo, Sergio] Hos Clin Porto Alegre, Porto Alegre, RS, Brazil; [Kowalyszyn, Ruben] Clin Viedma SA, Inst Multidisciplinario Oncol, Viedma, Argentina; [Pazo-Cid, Roberto] Hosp Univ Rio Miguel Servet, Zaragoza, Spain; [Schenker, Michael] SF Nectarie Oncol Ctr, Craiova, Romania; [Cleary, James M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Yanez, Patricio] Univ La Frontera, James Lind Canc Res Ctr, Temuco, Chile; [Feeney, Kynan] St John God Murdoch Hosp, Murdoch, WA, Australia; [Karamouzis, Michalis, V] Laiko Gen Hosp Athens, Athens, Greece; [Poulart, Valerie; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun] Bristol Myers Squibb, Princeton, NJ USA; [Janjigian, Yelena Y.] Mem Hosp Canc & Allied Dis, 1275 York Ave, New York, NY 10021 USA; [Janjigian, Yelena Y.] Weill Cornea Med Coll, New York, NY 10021 USA	National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center; Johannes Gutenberg University of Mainz; Pontificia Universidad Catolica de Chile; Japanese Foundation for Cancer Research; Medical University of Lublin; Hospital de Cancer de Barretos; Fudan University; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Universidad de La Frontera; St John of God Health Care; Laiko General Hospital; Bristol-Myers Squibb; Memorial Sloan Kettering Cancer Center	Janjigian, YY (corresponding author), Mem Hosp Canc & Allied Dis, 1275 York Ave, New York, NY 10021 USA.; Janjigian, YY (corresponding author), Weill Cornea Med Coll, New York, NY 10021 USA.	janjigiy@mskcc.org	Shitara, Kohei/AAA-3877-2021; Schenker, Michael/AAD-6920-2022	Schenker, Michael/0000-0003-2645-6391; Skoczylas, Tomasz/0000-0002-1276-3828; Pazo-Cid, Roberto A./0000-0002-8026-7391	Bristol Myers Squibb; Ono Pharmaceutical Co., Ltd.	Bristol Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical Co., Ltd.(Ono Pharmaceutical Co Ltd)	This study was supported by Bristol Myers Squibb and Ono Pharmaceutical Co., Ltd. We thank the patients and their families who made this study possible, the investigators and the clinical study teams at Bristol Myers Squibb and Ono Pharmaceutical Co., Ltd. for CheckMate 649 study support. Analysis of patient-reported outcomes was supported by S. Blum (Bristol Myers Squibb), and S. Hunter, E. Davenport and J. Wang (RTI Health Solutions). We thank Dako (an Agilent Technologies company) for collaborative development of the PD-L1 IHC 28-8 pharmDx assay. Professional medical writing and editorial assistance were provided by P. Dang (Parexel), funded by Bristol Myers Squibb.	Angell HK, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1544442; Baas P, 2021, LANCET, V397, P375, DOI 10.1016/S0140-6736(20)32714-8; Bang YJ, 2018, ANN ONCOL, V29, P2052, DOI 10.1093/annonc/mdy264; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; Doki Y, 2022, NEW ENGL J MED, V386, P449, DOI 10.1056/NEJMoa2111380; Fassan M, 2020, VIRCHOWS ARCH, V477, P151, DOI 10.1007/s00428-019-02693-8; Fuchs CS, 2019, LANCET ONCOL, V20, P420, DOI 10.1016/S1470-2045(18)30791-5; Garland SN, 2011, CANCER-AM CANCER SOC, V117, P1302, DOI 10.1002/cncr.25556; Hagi T, 2020, BRIT J CANCER, V123, P965, DOI 10.1038/s41416-020-0975-7; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Janjigian YY, 2018, J CLIN ONCOL, V36, P2836, DOI 10.1200/JCO.2017.76.6212; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kulangara K, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4065; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lei M, 2021, CLIN CANCER RES, V27, P3926, DOI 10.1158/1078-0432.CCR-20-2790; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; OPDIVO (Nivolumab) Injection for Intravenous Use, 2021, PRESCRIBING INFORM; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370; Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1; Wang CY, 2014, CANCER IMMUNOL RES, V2, P846, DOI 10.1158/2326-6066.CIR-14-0040; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Xu J., 2021, ANN ONCOL, V32, P1283, DOI [10.1016/j.annonc.2020.10.600, DOI 10.1016/J.ANNONC.2020.10.600]; Xu JM, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT213; Zhou KI, 2020, CLIN CANCER RES, V26, P6453, DOI 10.1158/1078-0432.CCR-20-2085	32	22	22	14	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 31	2022	603	7903					942	+		10.1038/s41586-022-04508-4	http://dx.doi.org/10.1038/s41586-022-04508-4		MAR 2022	21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0E0FI	35322232	Green Published, hybrid			2023-01-03	WOS:000772363100008
J	O'Laughlin, KN; Thompson, M; Hota, B; Gottlieb, M; Plumb, ID; Chang, AM; Wisk, LE; Hall, AJ; Wang, RC; Spatz, ES; Stephens, KA; Huebinger, RM; McDonald, SA; Venkatesh, A; Gentile, N; Slovis, BH; Hill, M; Saydah, S; Idris, AH; Rodriguez, R; Krumholz, HM; Elmore, JG; Weinstein, RA; Nichol, G				O'Laughlin, Kelli N.; Thompson, Matthew; Hota, Bala; Gottlieb, Michael; Plumb, Ian D.; Chang, Anna Marie; Wisk, Lauren E.; Hall, Aron J.; Wang, Ralph C.; Spatz, Erica S.; Stephens, Kari A.; Huebinger, Ryan M.; McDonald, Samuel A.; Venkatesh, Arjun; Gentile, Nikki; Slovis, Benjamin H.; Hill, Mandy; Saydah, Sharon; Idris, Ahamed H.; Rodriguez, Robert; Krumholz, Harlan M.; Elmore, Joann G.; Weinstein, Robert A.; Nichol, Graham		INSPIRE Investigators	Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection	PLOS ONE			English	Article							MULTICENTER TRIALS; HEALTH; CLASSIFICATION; COVID-19; OUTCOMES; SYSTEM	Background Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection. Methods INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2 infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test), regardless of test results. Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants are followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800 participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses. Results Participating sites obtained institutional review board approval. Enrollment and follow-up are ongoing. Conclusions This study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.	[O'Laughlin, Kelli N.; Nichol, Graham] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA; [O'Laughlin, Kelli N.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Thompson, Matthew; Stephens, Kari A.; Gentile, Nikki] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; [Hota, Bala; Weinstein, Robert A.] Rush Univ, Med Ctr, Dept Internal Med, Div Infect Dis, Chicago, IL 60612 USA; [Gottlieb, Michael; Huebinger, Ryan M.] Rush Univ, Dept Emergency Med, Med Ctr, Chicago, IL 60612 USA; [Plumb, Ian D.; Hall, Aron J.; Saydah, Sharon] Ctr Dis Control & Prevent, Div Viral Dis, Resp Viruses Branch, Atlanta, GA USA; [Chang, Anna Marie; Slovis, Benjamin H.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA; [Wisk, Lauren E.; Elmore, Joann G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Wang, Ralph C.; Rodriguez, Robert] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Spatz, Erica S.; Krumholz, Harlan M.] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA; [McDonald, Samuel A.; Idris, Ahamed H.] UT Southwestern, Dept Emergency Med & Clin Informat Ctr, Dallas, TX USA; [Venkatesh, Arjun] Yale Sch Med, Dept Emergency Med, New Haven, CT USA; [Hill, Mandy] UTHlth McGovern Med Sch, Dept Emergency Med, Houston, TX USA; [Weinstein, Robert A.] Cook Cty Hlth, Dept Med, Chicago, IL USA; [Nichol, Graham] Univ Washington, Dept Med, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Rush University; Rush University; Centers for Disease Control & Prevention - USA; Jefferson University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Yale University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yale University; University of Washington; University of Washington Seattle	O'Laughlin, KN (corresponding author), Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA.; O'Laughlin, KN (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.	kolaugh@uw.edu		O'Laughlin, Kelli/0000-0003-3027-1883; Gottlieb, Michael/0000-0003-3276-8375; Wang, Ralph/0000-0001-5382-9486; Huebinger, Ryan/0000-0002-9448-5744	Centers for Disease Control and Prevention (CDC); National Center of Immunization and Respiratory Diseases (NCIRD) [75D30120C08008]	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center of Immunization and Respiratory Diseases (NCIRD)	The Innovative Support for Patients with SARS-COV-2 Infections (INSPIRE) Registry is funded by the Centers for Disease Control and Prevention (CDC, www.cdc.gov), National Center of Immunization and Respiratory Diseases (NCIRD) (contract number: 75D30120C08008; co-PIs Bala Hota, MD, and Robert A. Weinstein, MD). Partners from the CDC (IDP, AJH, SS) assisted with study design, the preparation of this protocol manuscript and the decision to publish this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). No others sponsors or funders (other than the named authors) played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Additionally, I read the journal's policy and the authors of this manuscript have the following financial disclosures: JGE is an Editor for UpToDate on topics related to SARS-CoV-2 (https://www.uptodate.com). GN receives salary support from Leonard A Cobb~ Medic One Foundation (https://www.mediconefoundation.org/ about/who-we-are/) via the University of Washington. He is a consultant to ZOLL Circulation Inc. (https://www.zoll.com/contact/careers-at-zoll/ tms), ZOLL Medical Corporation (https://www.zoll. com/contact/careers-at-zoll/resuscitation), Cellphire Therapeutics Inc. (https://www.cellphire. com/) Kestra Medical Technologies (https:// kestramedical.com/), Abiomed Inc. (https://www. abiomed.com/), CPR Therapeutics Inc. (https:// www.cprtherapeutics.com/). HMK received expenses and/or personal fees from UnitedHealth (https://www.uhc.com/), Element Science (https:// www.elementscience.com/), Aetna (https://www. aetna.com/), Facebook (https://www.facebook. com/), the Siegfried and Jensen Law Firm (https:// www.siegfriedandjensen.com/), Arnold and Porter Law Firm (https://www.theworldlawgroup.com/ member-firms/arnold-porter), Martin/Baughman Law Firm (https://www.martinbaughman.com/ practice-areas/), and F-Prime (https://fprimecapital. com/). He is a co-founder of Refactor Health (https://www.refactorhealth.com/) and had grants and/or contracts from the Centers for Medicare & Medicaid Services (https://www.cms.gov/), the U. S. Food and Drug Administration (https://www.fda. gov/), and Johnson & Johnson (https://www.jnj. com/). MT provided consulting as a paid medical advisor to Visby Medical (https://www. visbymedical.com/) and Roche Molecular Diagnostics (https://diagnostics.roche.com/) which both produce laboratory tests for COVID-19. The authors not otherwise listed here have no financial disclosures.	Adegunsoye A, 2020, ANN AM THORAC SOC, V17, P1336, DOI 10.1513/AnnalsATS.202006-583RL; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Billioux A, 2017, STANDARDIZED SCREENI, P1, DOI 10.31478/201705b; Black N, 2016, QUAL LIFE RES, V25, P1103, DOI 10.1007/s11136-015-1168-3; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Carson G, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01947-0; Carvalho-Schneider C, 2021, CLIN MICROBIOL INFEC, V27, P258, DOI 10.1016/j.cmi.2020.09.052; CDC, RISK COVID 19 INF HO; CDC, 2020, COVID DAT TRACK; CDC, 2021, HEALTHC WORK; CDC, INF HLTH DEP REP CAS; Center for Disease Control, SYMPT COVID 19; Center for Disease Control and Prevention, 2021, HEALTHCARE WORKERS; Coleman KJ, 2012, MED SCI SPORT EXER, V44, P2071, DOI 10.1249/MSS.0b013e3182630ec1; Curci C, 2020, EUR J PHYS REHAB MED, V56, P633, DOI 10.23736/S1973-9087.20.06339-X; Mesquita RD, 2021, WIEN KLIN WOCHENSCHR, V133, P377, DOI 10.1007/s00508-020-01760-4; Datta SD, 2020, JAMA-J AM MED ASSOC, V324, P2251, DOI 10.1001/jama.2020.22717; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Daugherty SE., 2021, SARS COV 2 INFECT RI, DOI [10.1101/2021.03.12.21253448v1.abstract, DOI 10.1101/2021.03.12.21253448V1.ABSTRACT]; Davis HE., 2020, ECLINICALMEDICINE, DOI [10.1101/2020.12.24.20248802v1.full-text, DOI 10.1016/J.ECLINM.2021.101019]; Dechartres A, 2011, ANN INTERN MED, V155, P39, DOI 10.7326/0003-4819-155-1-201107050-00006; Dewitt B, 2018, MED DECIS MAKING, V38, P683, DOI 10.1177/0272989X18776637; Drummond M, 2001, ANN MED, V33, P344, DOI 10.3109/07853890109002088; Feng Yan, 2009, Health Rep, V20, P43; Figliozzi S, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13362; Golightly YM, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.170030; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Hays RD, 2018, QUAL LIFE RES, V27, P1885, DOI 10.1007/s11136-018-1842-3; Hays RD, 2016, PHARMACOECONOMICS, V34, P1015, DOI 10.1007/s40273-016-0408-x; Hernandez-Romieu AC, 2021, MMWR-MORBID MORTAL W, V70, P644, DOI 10.15585/mmwr.mm7017e3; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; HSU JY, 1994, EUR RESPIR J, V7, P1246, DOI 10.1183/09031936.94.07071246; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; IOM, 2019, DIAGNOSTIC CRITERIA; Kerr EA, 2013, JAMA-J AM MED ASSOC, V310, P137, DOI 10.1001/jama.2013.6828; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830; McPadden J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243291; Mikkelsen ME, 2020, CRIT CARE MED, V48, P1670, DOI 10.1097/CCM.0000000000004586; Munari AB, 2018, RESP CARE, V63, P77, DOI 10.4187/respcare.05636; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nichol G, 2016, RESUSCITATION, V107, P115, DOI 10.1016/j.resuscitation.2016.08.004; Perrin A, 2019, HISPANICS BRIDGE SOM; Petersen Maria Skaalum, 2021, Clin Infect Dis, V73, pe4058, DOI 10.1093/cid/ciaa1792; Prins A., 2015, MEAS INSTRUM; PROMIS, SHORT FORM COGN FUNC; Quiles NN, 2019, J PRIM CARE COMMUNIT, V10, DOI 10.1177/2150132719844062; Sepulveda-Loyola W, 2020, J NUTR HEALTH AGING, DOI [10.1007/s12603-020-1500-7, 10.1007/s12603-020-1469-2]; Shah W, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n136; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; TESTA MA, 1994, ANNU REV PUBL HEALTH, V15, P535; Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050; Unverzagt S, 2013, J CLIN EPIDEMIOL, V66, P1271, DOI 10.1016/j.jclinepi.2013.05.016; Vahidy FS, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039849; Valderas JM, 2008, QUAL LIFE RES, V17, P1125, DOI 10.1007/s11136-008-9396-4; Vogels CBF, 2020, NAT MICROBIOL, V5, P1299, DOI 10.1038/s41564-020-0761-6; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Wei XS, 2020, CLIN GASTROENTEROL H, V18, P1753, DOI 10.1016/j.cgh.2020.04.030; Zhan WZ, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1106-1; Zhang JJY, 2020, CLIN INFECT DIS, V71, P2199, DOI 10.1093/cid/ciaa576	63	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264260	10.1371/journal.pone.0264260	http://dx.doi.org/10.1371/journal.pone.0264260			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0D4YH	35239680	Green Published, gold, Green Submitted			2023-01-03	WOS:000776002200023
J	Nguyen, CT; Cifu, AS; Pitrak, D				Nguyen, Cynthia T.; Cifu, Adam S.; Pitrak, David			Prevention and Treatment of Lyme Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								GUIDELINE TITLE Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease DEVELOPERS AND FUNDING SOURCE IDSA, AAN, and ACR RELEASE DATE November 30, 2020 PRIOR VERSION 2010 TARGET POPULATION Adults and children with suspected Lyme disease MAJOR RECOMMENDATIONS " Antibiotic prophylaxis with 1 dose of oral doxycycline (strong recommendation; moderate quality of evidence [QOE]) is recommended within 72 hours of tick removal after a high -risk bite (strong recommendation; high Q0E). " Erythema migrans should be treated with a 10 -day course of doxycycline or a 14 -day course of either amoxicillin or cefuroxime axetil (strong recommendation; moderate QOE). " For acute neurologic manifestations of Lyme disease, a 14- to 21 -day course of intravenous ceftriaxone, cefotaxime, penicillin G, or oral doxycycline is recommended (strong recommendation; moderate QOE). " Oral doxycycline, amoxicillin, or cefuroxime axetil for 28 days are recommended for treatment of Lyme arthritis (strong recommendation; moderate QOE). " Additional antibiotic therapy is not recommended for patients with persistent or recurring nonspecific symptoms (eg, fatigue, pain) who do not have evidence of reinfection or treatment failure (strong recommendation; moderate QOE).	[Nguyen, Cynthia T.; Cifu, Adam S.; Pitrak, David] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	University of Chicago	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu						Kaplan RF, 2003, NEUROLOGY, V60, P1916, DOI 10.1212/01.WNL.0000068030.26992.25; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Kortela E, 2021, CLIN INFECT DIS, V72, P1323, DOI 10.1093/cid/ciaa217; Lantos PM, 2021, ARTHRITIS RHEUMATOL, V73, P12, DOI [10.1093/cid/ciaa1215, 10.1002/art.41562]; Maloney EL, EVIDENCE ASSESSMENTS; Pitrak D, 2022, JAMA-J AM MED ASSOC, V327, P676, DOI 10.1001/jama.2022.0081; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; Stupica D, 2012, CLIN INFECT DIS, V55, P343, DOI 10.1093/cid/cis402; Warshafsky S, 2010, J ANTIMICROB CHEMOTH, V65, P1137, DOI 10.1093/jac/dkq097; Wormser GP, 2003, ANN INTERN MED, V138, P697, DOI 10.7326/0003-4819-138-9-200305060-00005	10	0	0	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2022	327	8					772	773		10.1001/jama.2021.25302	http://dx.doi.org/10.1001/jama.2021.25302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ2NN	35191942				2023-01-03	WOS:000762147200023
J	Spadaro, O; Youm, Y; Shchukina, I; Ryu, S; Sidorov, S; Ravussin, A; Nguyen, K; Aladyeva, E; Predeus, AN; Smith, SR; Ravussin, E; Galban, C; Artyomov, MN; Dixit, VD				Spadaro, O.; Youm, Y.; Shchukina, I; Ryu, S.; Sidorov, S.; Ravussin, A.; Nguyen, K.; Aladyeva, E.; Predeus, A. N.; Smith, S. R.; Ravussin, E.; Galban, C.; Artyomov, M. N.; Dixit, V. D.			Caloric restriction in humans reveals immunometabolic regulators of health span	SCIENCE			English	Article							RANDOMIZED CONTROLLED-TRIAL; INFLAMMATION; MICE; AGE	The extension of life span driven by 40% caloric restriction (CR) in rodents causes trade-offs in growth, reproduction, and immune defense that make it difficult to identify therapeutically relevant CR-mimetic targets. We report that about 14% CR for 2 years in healthy humans improved thymopoiesis and was correlated with mobilization of intrathymic ectopic lipid. CR-induced transcriptional reprogramming in adipose tissue implicated pathways regulating mitochondrial bioenergetics, anti-inflammatory responses, and longevity. Expression of the gene Pia2g7 encoding platelet activating factor acetyl hydrolase (PLA2G7) is inhibited in humans undergoing CR. Deletion of Pla2g7 in mice showed decreased thymic lipoatrophy, protection against age-related inflammation, lowered NLRP3 inflammasome activation, and improved metabolic health. Therefore, the reduction of PLA2G7 may mediate the immunometabolic effects of CR and could potentially be harnessed to lower inflammation and extend the health span.	[Spadaro, O.; Youm, Y.; Ryu, S.; Sidorov, S.; Ravussin, A.; Nguyen, K.; Dixit, V. D.] Yale Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Spadaro, O.; Youm, Y.; Ryu, S.; Sidorov, S.; Ravussin, A.; Nguyen, K.; Dixit, V. D.] Yale Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Spadaro, O.; Youm, Y.; Ryu, S.; Sidorov, S.; Ravussin, A.; Nguyen, K.; Dixit, V. D.] Yale Sch Med, Dept Comparat Med, New Haven, CT 06510 USA; [Shchukina, I; Aladyeva, E.; Predeus, A. N.; Artyomov, M. N.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Smith, S. R.] AdventHealth, Translat Res Inst Metab & Diabet, Orlando, FL USA; [Ravussin, E.] LSU, Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Galban, C.] Univ Michigan, Dept Radiol, Michigan Med, Ann Arbor, MI 48109 USA; [Dixit, V. D.] Yale Sch Med, Yale Ctr Mol & Syst Metab, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Washington University (WUSTL); Adventist Health Services; AdventHealth; (AdventHealth) Central Florida Division; Central Florida Hospital - South; AdventHealth Orlando; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Michigan System; University of Michigan; Yale University	Dixit, VD (corresponding author), Yale Sch Med, Dept Pathol, New Haven, CT 06510 USA.; Dixit, VD (corresponding author), Yale Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Dixit, VD (corresponding author), Yale Sch Med, Dept Comparat Med, New Haven, CT 06510 USA.; Dixit, VD (corresponding author), Yale Sch Med, Yale Ctr Mol & Syst Metab, New Haven, CT 06510 USA.	vishwa.dixit@yale.edu	Smith, Steven/HDM-9496-2022	Aladyeva, Ekaterina/0000-0002-3483-6944; Ravussin, Eric/0000-0003-2129-547X; Smith, Steven/0000-0002-5098-8147; Sidorov, Sviatoslav/0000-0002-1730-265X; Ryu, Seungjin/0000-0001-6353-8789	National Institutes of Health (NIH) [AG031797, AG045712, P01AG051459, AR070811]; Glenn Foundation for Medical Research; Cure Alzheimer's Fund; Aging Biology Foundation; National Institute on Aging [U01AG022132, U01AG020478, U01AG020487, U01AG020480]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Glenn Foundation for Medical Research; Cure Alzheimer's Fund; Aging Biology Foundation; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported in part by the National Institutes of Health (NIH grants AG031797, AG045712, P01AG051459, and AR070811 to V.D.D.); the Glenn Foundation for Medical Research (V.D.D.); Cure Alzheimer's Fund (V.D.D.); and the Aging Biology Foundation (M.N.A.). The CALERIE study was funded by the National Institute on Aging (grants U01AG022132, U01AG020478, U01AG020487, and U01AG020480).	Anderson RM, 2018, J GERONTOL A-BIOL, V73, P1, DOI 10.1093/gerona/glx212; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Cashman JR, 2006, ANNU REV PHARMACOL, V46, P65, DOI 10.1146/annurev.pharmtox.46.120604.141043; Dixit VD, 2010, CURR OPIN IMMUNOL, V22, P521, DOI 10.1016/j.coi.2010.06.010; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gardner EM, 2005, J GERONTOL A-BIOL, V60, P688, DOI 10.1093/gerona/60.6.688; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Kirkwood TBL, 2000, J ANAT, V197, P587, DOI 10.1046/j.1469-7580.2000.19740587.x; Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2; Kristan DM, 2007, AGING CELL, V6, P817, DOI 10.1111/j.1474-9726.2007.00345.x; Lee AH, 2020, IMMUNITY, V53, P510, DOI 10.1016/j.immuni.2020.08.013; Leiser SF, 2015, SCIENCE, V350, P1375, DOI 10.1126/science.aac9257; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Meydani SN, 2016, AGING-US, V8, P1416, DOI 10.18632/aging.100994; Moll L, 2018, ELIFE, V7, DOI 10.7554/eLife.38635; Patel NV, 2002, NEUROBIOL AGING, V23, P707, DOI 10.1016/S0197-4580(02)00017-9; Patel SA, 2016, FASEB J, V30, P1634, DOI 10.1096/fj.15-282475; Poetschke HL, 2000, CARCINOGENESIS, V21, P1959, DOI 10.1093/carcin/21.11.1959; Ravussin E, 2015, J GERONTOL A-BIOL, V70, P1097, DOI 10.1093/gerona/glv057; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rochon J, 2011, J GERONTOL A-BIOL, V66, P97, DOI 10.1093/gerona/glq168; Sergushichev AA, 2016, BIORXIV, DOI [10.1101/060012%0A, 10.1101/060012]; Shinoda K, 2015, NAT MED, V21, P389, DOI 10.1038/nm.3819; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Stafforini DM, 2009, CARDIOVASC DRUG THER, V23, P73, DOI 10.1007/s10557-008-6133-8; Sun DX, 2001, CLIN DIAGN LAB IMMUN, V8, P1003, DOI 10.1128/CDLI.8.5.1003-1011.2001; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Yang HW, 2009, J IMMUNOL, V183, P3040, DOI 10.4049/jimmunol.0900562; Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010; Zaitsev K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09990-5	32	31	31	43	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2022	375	6581					671	+		10.1126/science.abg7292	http://dx.doi.org/10.1126/science.abg7292			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX2ZD	35143297				2023-01-03	WOS:000753975300040
J	Rosenvinge, F; Helweg-Larsen, J; Fosbol, EL; Kober, L; Torp-Pedersen, C; Tonder, N; Moser, C; Iversen, K; Bundgaard, H				Rosenvinge, Flemming; Helweg-Larsen, Jannik; Fosbol, Emil L.; Kober, Lars; Torp-Pedersen, Christian; Tonder, Niels; Moser, Claus; Iversen, Kasper; Bundgaard, Henning			Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Rosenvinge, Flemming] Odense Univ Hosp, Odense, Denmark; [Helweg-Larsen, Jannik; Fosbol, Emil L.; Kober, Lars; Moser, Claus; Bundgaard, Henning] Copenhagen Univ Hosp, Copenhagen, Denmark; [Torp-Pedersen, Christian; Tonder, Niels] Univ Copenhagen, Hillerod, Denmark; [Iversen, Kasper] Copenhagen Univ Hosp, Herlev, Denmark	University of Southern Denmark; Odense University Hospital; University of Copenhagen; University of Copenhagen; University of Copenhagen	Bundgaard, H (corresponding author), Copenhagen Univ Hosp, Copenhagen, Denmark.	henning.bundgaard@regionh.dk	Moser, Claus Ernst/N-5951-2017; Iversen, Kasper/GSD-6427-2022; Bundgaard, Henning/AAA-4381-2020; Moser, Claus Ernst/GPK-5546-2022	Moser, Claus Ernst/0000-0002-7664-8570; Bundgaard, Henning/0000-0002-0563-7049; Moser, Claus Ernst/0000-0002-7664-8570; Christensen, Jens Jorgen/0000-0001-6721-4917; Kober, Lars/0000-0002-6635-1466; Helweg-Larsen, Jannik/0000-0001-7192-0144	Danish Heart Foundation; Svend Andersens Foundation; Capital Regions Research Council; Hartmann's Foundation; Novo Nordisk Foundation	Danish Heart Foundation; Svend Andersens Foundation; Capital Regions Research Council; Hartmann's Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	Supported by grants from the Danish Heart Foundation, the Svend Andersens Foundation, the Capital Regions Research Council, the Hartmann's Foundation, and the Novo Nordisk Foundation.	[Anonymous], 2021, NEW ENGL J MED, V385, P1141, DOI 10.1056/NEJMclde2108866; Bundgaard H, 2019, NEW ENGL J MED, V380, P1373, DOI 10.1056/NEJMc1902096; Iversen K, 2019, NEW ENGL J MED, V380, P415, DOI 10.1056/NEJMoa1808312; Li HK, 2019, NEW ENGL J MED, V380, P425, DOI 10.1056/NEJMoa1710926; Spellberg B, 2020, JAMA INTERN MED, V180, P769, DOI 10.1001/jamainternmed.2020.0555	5	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2022	386	6					601	+		10.1056/NEJMc2114046	http://dx.doi.org/10.1056/NEJMc2114046			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW0GW	35139280				2023-01-03	WOS:000753100900019
J	da Costa, NS; da Silva, ASA; de Melo-Neto, JS				da Costa, Natalia Silva; da Silva, Amanda Suzane Alves; de Melo-Neto, Joao Simao			Effects of dance therapy in women with breast cancer: A systematic review protocol	PLOS ONE			English	Review								Background Cancer is an important public health problem with an increasing global incidence in the recent decades. Breast cancer has become the leading cause of death in women worldwide. Women suffering from breast cancer, as well as survivors, may experience some adverse effects of treatment-including cancer-related fatigue, sleep disorders, and pain-which may manifest alone or in combination with other symptoms. Non-pharmacological interventions, such as physical activity, have been associated with improvements in these adverse effects. This study aims to evaluate the effects of dance therapy in women with breast cancer. Methods We will perform a systematic review according to the Cochrane methodology. An overall search strategy will be developed and adapted for PubMed, Virtual Health Library, PEDro, SciELO, SciVerse Scopus, Cochrane Library, and Web of Science using the descriptors "Dance therapy " or "Dancing " and "Breast neoplasms " or "Breast cancer. " The size of the intervention effect (Z) will be calculated for each outcome included in this review. Outcomes will be pain, cancer-related fatigue, sleep disturbance, body image and depression in women with breast cancer. Quality assessment will be performed using the Cochrane instrument. Metanalysis, if plausible, will be performed using Review Manager 5.3. Discussion Studies have reported positive results of dance therapy as a non-pharmacological intervention in women with breast cancer. Thus, it is expected that robust and conclusive evidence of the effects of dance therapy during or after treatment (radiotherapy, chemotherapy, hormone therapy, and/or surgery) can be obtained.	[da Costa, Natalia Silva; da Silva, Amanda Suzane Alves; de Melo-Neto, Joao Simao] Fed Univ Para UFPA, Belem, PA, Brazil	Universidade Federal do Para	de Melo-Neto, JS (corresponding author), Fed Univ Para UFPA, Belem, PA, Brazil.	jsmeloneto@gmail.com		silva da costa, natalia/0000-0001-7622-4463				American Cancer Society, US; American Dance Therapy Association, US; [Anonymous], PHYS EV DAT; [Anonymous], 2014, REV MANAGER REVMAN C; Boehm K, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/103297; Boeira SF., 2013, CLUSTER SINTOMAS C N, V60, P351, DOI [10.32635/2176-9745.RBC.2014v60n4.462, DOI 10.32635/2176-9745.RBC.2014V60N4.462]; Bradt J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007103.pub3; Dibbell-Hope S, 2000, ART PSYCHOTHER, V27, P51, DOI 10.1016/S0197-4556(99)00032-5; Ellingson L., 2011, J PAIN, V12; Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016; Ferioli Martina, 2018, Oncotarget, V9, P14005, DOI 10.18632/oncotarget.24456; Ho RTH, 2016, CANCER NURS, V39, P32, DOI 10.1097/NCC.0000000000000237; Hohmann L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187363; Instituto Nacional de Cancer, INCA BRAZIL; Koch SC, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01806; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mckee MJ, 2016, ONCOLOGIST, V21, P16, DOI 10.1634/theoncologist.2015-0328; MOHER D., 2015, SYST REV-LONDON, Vv. 4, P2046, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1]; Moseley AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222770; Pan American Health Organization, 2018, PAHO BRAZIL; Pisu M, 2017, J CANCER SURVIV, V11, P350, DOI 10.1007/s11764-016-0593-9; Reis AD, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0882-2; Zimmer P, 2018, INTEGR CANCER THER, V17, P306, DOI 10.1177/1534735417713301	23	0	0	7	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0257948	10.1371/journal.pone.0257948	http://dx.doi.org/10.1371/journal.pone.0257948			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3F0KH	35749369	Green Published, gold			2023-01-03	WOS:000830362700022
J	House, RV; Broge, TA; Suscovich, TJ; Snow, DM; Tomic, MT; Nonet, G; Bajwa, K; Zhu, GY; Martinez, Z; Hackett, K; Earnhart, CG; Dorsey, NM; Hopkins, SA; Natour, DS; Davis, HD; Anderson, MS; Gainey, MR; Cobb, RR				House, Robert, V; Broge, Thomas A.; Suscovich, Todd J.; Snow, Doris M.; Tomic, Milan T.; Nonet, Genevieve; Bajwa, Kamaljit; Zhu, Guangyu; Martinez, Zachary; Hackett, Kyal; Earnhart, Christopher G.; Dorsey, Nicole M.; Hopkins, Svetlana A.; Natour, Dalia S.; Davis, Heather D.; Anderson, Michael S.; Gainey, Melicia R.; Cobb, Ronald R.			Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics	PLOS ONE			English	Article							NEONATAL FC-RECEPTOR; EXTENDED HALF-LIFE; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSE; HUMANIZED OKT3; GAMMA-RI; CORONAVIRUS; CONTRIBUTE; INFECTION; OUTBREAK	The current global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million cases reported globally and more than 4.5 million deaths at the time of writing. In addition to the direct impact of the disease, the economic impact has been significant as public health measures to contain or reduce the spread have led to country wide lockdowns resulting in near closure of many sectors of the economy. Antibodies are a principal determinant of the humoral immune response to COVID-19 infections and may have the potential to reduce disease and spread of the virus. The development of monoclonal antibodies (mAbs) represents a therapeutic option that can be produced at large quantity and high quality. In the present study, a mAb combination mixture therapy was investigated for its capability to specifically neutralize SARS-CoV-2. We demonstrate that each of the antibodies bind the spike protein and neutralize the virus, preventing it from infecting cells in an in vitro cell-based assay, including multiple viral variants that are currently circulating in the human population. In addition, we investigated the effects of two different mutations in the Fc portion (YTE and LALA) of the antibody on Fc effector function and the ability to alleviate potential antibody-dependent enhancement of disease. These data demonstrate the potential of a combination of two mAbs that target two different epitopes on the SARS-CoV2 spike protein to provide protection against SARS-CoV-2 infection in humans while extending serum half-life and preventing antibody-dependent enhancement of disease.	[House, Robert, V; Snow, Doris M.; Hackett, Kyal] Ology Bioserv, Frederick, MD USA; [Broge, Thomas A.; Suscovich, Todd J.] SeromYx Syst, Cambridge, MA USA; [Tomic, Milan T.; Nonet, Genevieve; Bajwa, Kamaljit; Zhu, Guangyu; Martinez, Zachary] Ology Bioserv Inc, Res & Dev, Alameda, CA USA; [Earnhart, Christopher G.; Dorsey, Nicole M.] US Dept Def, Joint Program Execut Off Chem Biol Radiol Nucl De, Washington, DC USA; [Hopkins, Svetlana A.] Logist Management Inst, Tysons, VA USA; [Natour, Dalia S.; Davis, Heather D.; Anderson, Michael S.; Gainey, Melicia R.] Battelle Biomed Res Ctr, Columbus, OH USA; [Cobb, Ronald R.] Ology Bioserv, Proc Dev, Alachua, FL 32615 USA	United States Department of Defense	Cobb, RR (corresponding author), Ology Bioserv, Proc Dev, Alachua, FL 32615 USA.	roncobb76@yahoo.com			Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) [W911QY-20-9003]	Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)	RRC and RVH were leaders on this manuscript which was funded by a contract from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) contract number W911QY-20-9003; 20-05. CGE and NMD are employees of the funding agency and were involved in study design, data analysis and reviewed the manuscript.	Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Bootz A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006601; Borrok MJ, 2017, J PHARM SCI-US, V106, P1008, DOI 10.1016/j.xphs.2016.12.023; Bournazos S, 2019, P NATL ACAD SCI USA, V116, P20054, DOI 10.1073/pnas.1911842116; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Brown EP, 2017, J IMMUNOL METHODS, V443, P33, DOI 10.1016/j.jim.2017.01.010; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; C.Li, 2020, medRxiv, DOI 10.1101/2020.10.08.20209114; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896; Chen A, 2014, BIOPHYS J, V106, P2028, DOI 10.1016/j.bpj.2014.02.038; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00292; Corfield AP, 2015, BBA-GEN SUBJECTS, V1850, P236, DOI 10.1016/j.bbagen.2014.05.003; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014; Earnest JT, 2019, J EXP MED, V216, P2282, DOI 10.1084/jem.20190736; Emu B, 2018, NEW ENGL J MED, V379, P645, DOI 10.1056/NEJMoa1711460; Fox JM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5062; Golden JW, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw9535; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Gutjahr B, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008143; Haick AK, 2014, J GEN VIROL, V95, P578, DOI 10.1099/vir.0.061986-0; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161-12168.2001; HOLMES MJ, 1986, BRIT J EXP PATHOL, V67, P581; Houser KV, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006565; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11; Jiang YT, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010039; Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Khanolkar A, 2009, J VIROL, V83, P9258, DOI 10.1128/JVI.00355-09; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Lee CH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13108-2; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; LUND J, 1991, J IMMUNOL, V147, P2657; Malley R, 1998, J INFECT DIS, V178, P1555, DOI 10.1086/314523; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Migone TS, 2009, NEW ENGL J MED, V361, P135, DOI 10.1056/NEJMoa0810603; Monnet C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00039; Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Remesh SG, 2018, STRUCTURE, V26, P1007, DOI 10.1016/j.str.2018.03.017; Richards J, 1999, CANCER RES, V59, P2096; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Robbie GJ, 2013, ANTIMICROB AGENTS CH, V57, P6147, DOI 10.1128/AAC.01285-13; Rogers T.F.., 2020, BIORXIV, DOI [10.1101/2020.05.11.088674, DOI 10.1101/2020.05.11.088674]; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Saunders KO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01296; Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Thomann M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134949; Tomic MT, 2019, TOXINS, V11, DOI 10.3390/toxins11040208; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Uppal H, 2015, CLIN CANCER RES, V21, P123, DOI 10.1158/1078-0432.CCR-14-2093; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Woodle ES, 1998, TRANSPLANT P, V30, P1369, DOI 10.1016/S0041-1345(98)00278-4; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; X.Gui, 2020, bioRxiv, DOI 10.1101/2020.07.26.222257; Xu DL, 2000, CELL IMMUNOL, V200, P16, DOI 10.1006/cimm.2000.1617; Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005; Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82; Yogo R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48323-w; Yu XQ, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01020-16, 10.1128/aac.01020-16]; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1101/2020.05.12.091462, 10.1038/s41591-020-0998-x]; Zost SJ., 2020, BIORXIV, DOI [10.1101/2020.05.22.111005, DOI 10.1101/2020.05.22.111005]	82	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0267796	10.1371/journal.pone.0267796	http://dx.doi.org/10.1371/journal.pone.0267796			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35657812	Green Published, gold			2023-01-03	WOS:000843619700097
J	Nakajima, D; Mihara, T; Hijikata, T; Tomita, M; Goto, T				Nakajima, Daisuke; Mihara, Takahiro; Hijikata, Toshiyuki; Tomita, Makoto; Goto, Takahisa			Effectiveness of acupuncture therapy for preventing emergence agitation in children: A protocol for systematic review and meta-analysis with trial sequential analysis	PLOS ONE			English	Article							SEVOFLURANE ANESTHESIA; PROPOFOL; EFFICACY; MYRINGOTOMY; STRENGTH; DELIRIUM; FENTANYL; QUALITY; END	Pain, autonomic distress, and emergence agitation occur commonly in children undergoing general anesthesia. While acupuncture therapy has been reported to effectively reduce such pain and autonomic distress in children, its effect in preventing emergence agitation remains unclear. Therefore, we will conduct a systematic review and meta-analysis with trial sequential analysis to evaluate the effect of acupuncture therapy in preventing emergence agitation in children undergoing general anesthesia.& nbsp;Methods and analysis: This protocol was prepared according to the 2015 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for Protocols guidelines. We will conduct a search for randomized controlled trials that evaluated the effect of acupuncture therapy in preventing emergence agitation. The following databases will be searched for relevant articles: MEDLINE, CENTRAL, Embase, and Web of Science; four pre-registration sites will be accessed from inception to April 1, 2021. No language restrictions will be applied. Two authors will independently scan and select eligible studies, extract the data, and assess the risk of bias. The incidence of emergence agitation will be combined as a risk ratio with a 95% confidence interval using a random-effect model. The I-2 statistics will be used to assess heterogeneity. We will evaluate the quality of the clinical trials using the Cochrane methodology and assess the quality of evidence using the Grading of Recommendation Assessment, Development, and Evaluation approach. If appropriate, a trial sequential analysis will be performed. Expected outcomes: This meta-analysis will be the first to evaluate the effect of acupuncture therapy in preventing emergence agitation in children. The findings from this meta-analysis have the potential to reveal pivotal factors that affect the clinical effect of acupuncture therapy, thereby supporting the optimization of acupuncture therapy for emergence agitation.Protocol registration University Hospital Medical Information Network Clinical Trials Registry.	[Nakajima, Daisuke; Mihara, Takahiro; Hijikata, Toshiyuki; Tomita, Makoto] Yokohama City Univ, Grad Sch Data Sci, Dept Hlth Data Sci, Yokohama, Japan; [Goto, Takahisa] Yokohama City Univ, Sch Med, Dept Anesthesiol, Yokohama, Japan	Yokohama City University; Yokohama City University	Mihara, T (corresponding author), Yokohama City Univ, Grad Sch Data Sci, Dept Hlth Data Sci, Yokohama, Japan.	meta.analysis.r@gmail.com						Acar HV, 2012, PEDIATR ANESTH, V22, P1105, DOI 10.1111/j.1460-9592.2012.03876.x; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bodeker G., 2005, GLOBAL ATLAS TRADITI; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024; Costi D, 2015, PEDIATR ANESTH, V25, P517, DOI 10.1111/pan.12617; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hijikata T, 2016, EUR J ANAESTH, V33, P535, DOI 10.1097/EJA.0000000000000379; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kim MR, 2005, NEUROSCI LETT, V387, P17, DOI 10.1016/j.neulet.2005.07.007; Lee IS, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1304152; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nakamura N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204533; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Reinthal M, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-28; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Amorim MAS, 2017, REV BRAS ANESTESIOL, V67, P193, DOI [10.1016/j.bjane.2016.02.007, 10.1016/j.bjan.2016.02.015]; Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179; Usichenko TI, 2016, CLIN J PAIN, V32, P82, DOI 10.1097/AJP.0000000000000222; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Yang MH, 2007, J CLIN NURS, V16, P308, DOI 10.1111/j.1365-2702.2006.01428.x; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004	33	0	1	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264197	10.1371/journal.pone.0264197	http://dx.doi.org/10.1371/journal.pone.0264197			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P0IK	35349573	gold, Green Published			2023-01-03	WOS:000783906500015
J	O'Donoghue, M; Boland, P; Leahy, S; Galvin, R; McManus, J; Lisiecka, D; Hayes, S				O'Donoghue, Mairead; Boland, Pauline; Leahy, Siobhan; Galvin, Rose; McManus, John; Lisiecka, Dominika; Hayes, Sara			Exploring the perspectives of key stakeholders on the design and delivery of a cognitive rehabilitation intervention for people post-stroke	PLOS ONE			English	Article							STROKE SURVIVORS; IMPAIRMENT; CARE; RECOMMENDATIONS; DETERMINANTS; RESTRICTIONS	Purpose Stroke is a leading cause of death and disability worldwide. Despite the prevalence and associated burden of post-stroke cognitive impairment, there is uncertainty regarding optimum interventions to improve cognitive function in people post-stroke. The aim of this study is to explore the perspectives of key stakeholders on the design and development of a multi-disciplinary intervention to rehabilitate cognitive deficits in people post-stroke. Materials and methods Audio-recorded, semi-structured interviews were employed with people post-stroke, care-givers, healthcare professionals and academics. All transcribed interviews were exported to NVivo software and analysed using reflexive thematic analysis. Results Thirty interviews were conducted across stakeholder groups including people post-stroke (n = 10), caregivers (n = 5), healthcare professionals (n = 14) and academics (n = 1). Four themes relevant to the design and development of the intervention were identified (i) engagement in the intervention must be meaningful, (ii) the point of readiness to engage, (iii) a familiar but flexible setting is key (iv) pragmatics of intervention delivery. Conclusions These findings present new perspectives across stakeholder groups on the design and delivery of an intervention to rehabilitate cognitive deficits in people post-stroke. Taken together with existing quantitative evidence, these findings will inform the development of a feasibility trial, examining patient and process outcomes, to rehabilitate cognitive deficits post-stroke.	[O'Donoghue, Mairead; Boland, Pauline; Galvin, Rose; Lisiecka, Dominika; Hayes, Sara] Univ Limerick, Fac Educ & Hlth Sci, Ageing Res Ctr, Sch Allied Hlth,Hlth Res Inst, Limerick, Ireland; [Leahy, Siobhan] Atlantic Technol Univ ATU, Dept Sport Exercise & Nutr, Galway, Ireland; [McManus, John] Univ Hosp Limerick, Geriatr & Stroke Med, Limerick, Ireland; [Lisiecka, Dominika] Munster Technol Univ, Sch Hlth & Social Sci, Dept Nursing & Healthcare Sci, Kerry Campus, Tralee, Kerry, Ireland	University of Limerick; University of Limerick	O'Donoghue, M (corresponding author), Univ Limerick, Fac Educ & Hlth Sci, Ageing Res Ctr, Sch Allied Hlth,Hlth Res Inst, Limerick, Ireland.	mairead.odonoghue@ul.ie	Boland, Pauline/K-2878-2019	Boland, Pauline/0000-0003-0218-327X; o donoghue, Mairead/0000-0002-0546-0933; Lisiecka, Dominika/0000-0002-0763-3076	School of Allied Health, University of Limerick	School of Allied Health, University of Limerick	Maire ' ad O' Donoghue is funded by a scholarship from the School of Allied Health, University of Limerick. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeoye O, 2019, STROKE, V50, pE187, DOI 10.1161/STR.0000000000000173; Akpalu A, 2018, West Afr J Med, V35, P199; Atteih S, 2015, INT J STROKE, V10, P918, DOI 10.1111/ijs.12535; Bo W., EFFECTS COMBINED INT; Bowen A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007039.pub2; Bowen A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub3; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Braun V, 2021, QUAL RES PSYCHOL, V18, P328, DOI 10.1080/14780887.2020.1769238; Braun V, 2019, QUAL RES SPORT EXERC, V11, P589, DOI 10.1080/2159676X.2019.1628806; Byrne D., 2022, QUAL QUANT, V56, P1391, DOI [10.1007/s11135-021-01182-y, DOI 10.1007/S11135-021-01182-Y]; Chen Y, 2020, TOP STROKE REHABIL, V27, P81, DOI 10.1080/10749357.2019.1683792; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Claesson L, 2005, CEREBROVASC DIS, V19, P102, DOI 10.1159/000082787; Clark AM, 2013, SOC SCI MED, V93, P185, DOI 10.1016/j.socscimed.2012.03.035; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Cumming TB, 2014, J PSYCHOSOM RES, V77, P374, DOI 10.1016/j.jpsychores.2014.08.009; Dalemans R, 2009, CLIN REHABIL, V23, P948, DOI 10.1177/0269215509337197; das Nair R, 2017, STROKE, V48, pE28, DOI 10.1161/STROKEAHA.116.015377; Douiri A, 2013, STROKE, V44, P138, DOI 10.1161/STROKEAHA.112.670844; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Fishman KN, 2021, STROKE, V52, P458, DOI 10.1161/STROKEAHA.120.032131; Gillespie DC, 2015, CLIN REHABIL, V29, P120, DOI 10.1177/0269215514538982; Greenwood N, 2008, DISABIL REHABIL, V30, P1329, DOI 10.1080/09638280701602178; Hayes H., 2012, BRIEFING NOTES RES P; Hickey A., 2019, COCHRANE DB SYST REV, V2019; Hill G, 2022, LANCET NEUROL, V21, P312, DOI [10.14256/j.Lancet.15891, 10.1016/S1474-4422(22)00044-8]; Hochstenbach JB, 2003, ARCH PHYS MED REHAB, V84, P1499, DOI 10.1016/S0003-9993(03)00370-8; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Jacova C, 2012, ANN NEUROL, V72, P351, DOI 10.1002/ana.23733; Jokinen H, 2015, EUR J NEUROL, V22, P1288, DOI 10.1111/ene.12743; Kapoor A, 2017, STROKE, V48, P1688, DOI 10.1161/STROKEAHA.117.016728; Kelly BD, 2017, IRISH J MED SCI, V186, P351, DOI 10.1007/s11845-016-1443-5; Kim KT, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.758536; Knutti K, 2022, DISABIL REHABIL, V44, P2581, DOI 10.1080/09638288.2020.1846796; Law LLF, 2014, AGEING RES REV, V15, P61, DOI 10.1016/j.arr.2014.02.008; Lewis J., 2007, RES ETHICS REV, V3, P73; Lezak M., 2012, NEUROPSYCHOLOGICAL A; Loetscher T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002842.pub2; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; McDonald MW, 2019, INT J STROKE, V14, P774, DOI 10.1177/1747493019873600; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Merriman NA, 2020, DISABIL REHABIL, V42, P3359, DOI 10.1080/09638288.2019.1594400; Naderifar M., 2017, STRIDES DEV MED ED, V14, DOI [10.5812/sdme10.5812/sdme.67670, DOI 10.5812/SDME.67670]; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Nys GMS, 2005, ARCH CLIN NEUROPSYCH, V20, P623, DOI 10.1016/j.acn.2005.04.001; O'Donoghue M, 2022, STROKE, V53, P1700, DOI 10.1161/STROKEAHA.121.034218; Obaid M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037982; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Peoples H, 2011, SCAND J OCCUP THER, V18, P163, DOI 10.3109/11038128.2010.509887; Peterson-Burch F, 2017, HOLIST NURS PRACT, V31, P3, DOI 10.1097/HNP.0000000000000187; Pindus DM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192533; Pollock A, 2014, INT J STROKE, V9, P313, DOI 10.1111/j.1747-4949.2012.00942.x; Rasquin SMC, 2004, DEMENT GERIATR COGN, V18, P138, DOI 10.1159/000079193; Rettke H, 2018, NURS RES, V67, P490, DOI 10.1097/NNR.0000000000000307; Rosewilliam S, 2011, CLIN REHABIL, V25, P501, DOI 10.1177/0269215510394467; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Siemonsma P, 2014, DISABIL REHABIL, V36, P2019, DOI 10.3109/09638288.2014.885091; Suri H, 2011, QUAL RES J, V11, P63, DOI 10.3316/QRJ1102063; Tang EYH, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00267; Tang EYH, 2019, FAM PRACT, V36, P506, DOI 10.1093/fampra/cmy109; TATEMICHI TK, 1994, STROKE, V25, P1915, DOI 10.1161/01.STR.25.10.1915; Thirsk LM, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917721068; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van der Kemp J, 2019, NEUROPSYCHOL REHABIL, V29, P638, DOI 10.1080/09602011.2017.1313746; West C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004132.pub2	66	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269961	10.1371/journal.pone.0269961	http://dx.doi.org/10.1371/journal.pone.0269961			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3FU	35709170	gold, Green Published			2023-01-03	WOS:000843613300102
J	Piscoya, A; del Riego, AP; Cerna-Viacava, R; Rocco, J; Roman, YM; Escobedo, AA; Pasupuleti, V; White, CM; Hernandez, AV				Piscoya, Alejandro; Parra del Riego, Angela; Cerna-Viacava, Renato; Rocco, Jonathon; Roman, Yuani M.; Escobedo, Angel A.; Pasupuleti, Vinay; White, C. Michael; Hernandez, Adrian, V			Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis	PLOS ONE			English	Review								Introduction We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. Methods Five electronic databases and two preprint webpages were searched until March 4, 2021. Randomized controlled trials (RCTs) and inverse probability treatment weighting (IPTW) cohorts assessing TCZ effects in hospitalized, COVID-19 adult patients were included. Primary outcomes were all-cause mortality, clinical worsening, clinical improvement, need for mechanical ventilation, and adverse events (AE). Inverse variance random-effects meta-analyses were performed with quality of evidence (QoE) evaluated using GRADE methodology. Results Nine RCTs (n = 7,021) and nine IPTW cohorts (n = 7,796) were included. TCZ significantly reduced all-cause mortality in RCTs (RR 0.89, 95%CI 0.81-0.98, p = 0.03; moderate QoE) and non-significantly in cohorts (RR 0.67, 95%CI 0.44-1.02, p = 0.08; very low QoE) vs. control (standard of care [SOC] or placebo). TCZ significantly reduced the need for mechanical ventilation (RR 0.80, 95%CI 0.71-0.90, p = 0.001; moderate QoE) and length of stay (MD -1.92 days, 95%CI -3.46 to -0.38, p = 0.01; low QoE) vs. control in RCTs. There was no significant difference in clinical improvement or worsening between treatments. AEs, severe AEs, bleeding and thrombotic events were similar between arms in RCTs, but there was higher neutropenia risk with TCZ (very low QoE). Subgroup analyses by disease severity or risk of bias (RoB) were consistent with main analyses. Quality of evidence was moderate to very low in both RCTs and cohorts. Conclusions In comparison to SOC or placebo, TCZ reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in RCTs in hospitalized COVID-19 patients. Other clinical outcomes were not significantly impacted. TCZ did not have effect on AEs, except a significant increased neutropenia risk in RCTs. TCZ has a potential role in the treatment of hospitalized COVID-19 patients.	[Piscoya, Alejandro; Hernandez, Adrian, V] Univ San Ignacio Loyola USIL, Unidad Revis Sistemat & Metaanal URSIGET, Lima, Peru; [Piscoya, Alejandro] Hosp Guillermo Kaelin de La Fuente, Lima, Peru; [Parra del Riego, Angela; Cerna-Viacava, Renato] Univ Peruana Ciencias Aplicadas UPC, Escuela Med, Lima, Peru; [Cerna-Viacava, Renato] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA; [Rocco, Jonathon; Roman, Yuani M.; White, C. Michael; Hernandez, Adrian, V] Univ Connecticut, Sch Pharm, Hlth Outcomes Policy & Evidence Synth Hopes Grp, Storrs, CT 06269 USA; [Escobedo, Angel A.] Natl Inst Gastroenterol, Epidemiol Unit, Havana, Cuba; [Pasupuleti, Vinay] Cello Hlth, Yardley, PA USA	Universidad San Ignacio de Loyola; Universidad Peruana de Ciencias Aplicadas (UPC); Henry Ford Health System; Henry Ford Hospital; University of Connecticut	Hernandez, AV (corresponding author), Univ San Ignacio Loyola USIL, Unidad Revis Sistemat & Metaanal URSIGET, Lima, Peru.; Hernandez, AV (corresponding author), Univ Connecticut, Sch Pharm, Hlth Outcomes Policy & Evidence Synth Hopes Grp, Storrs, CT 06269 USA.	adrianhernandezdiaz@gmail.com		Hernandez, Adrian V./0000-0002-9999-4003; Piscoya, Alejandro/0000-0002-4420-2419				Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380; [Anonymous], 2021, JAMA-J AM MED ASSOC, V325, P880, DOI 10.1001/jama.2020.24415; [Anonymous], 2020, GRADEPRO GDT GRADEPR; [Anonymous], ACTEMRA TOCILIZUMAB; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Australian National COVID-19 Clinical Evidence Taskforce, AUSTR GUIDELINES CLI; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Berardicurti O, 2020, CLIN EXP RHEUMATOL, V38, P1247; Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0; Chilimuri S, 2021, J CLIN PHARM THER, V46, P440, DOI 10.1111/jcpt.13303; Cohen MS, 2021, NEW ENGL J MED, V384, P289, DOI 10.1056/NEJMe2034495; Cortegiani A, 2021, PULMONOLOGY, V27, P52, DOI 10.1016/j.pulmoe.2020.07.003; COVID-19 Treatment Guidelines Panel, CORONAVIRUS DIS 2019; Goldacre B., 2020, MEDRXIV, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hariyanto TI, 2021, DRUG RES, V71, P265, DOI 10.1055/a-1336-2371; Hartung J, 2001, STAT MED, V20, P3875, DOI 10.1002/sim.1009; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Hill JA, 2021, J MED VIROL, V93, P2270, DOI 10.1002/jmv.26674; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Infectious Disease Society of America, COVID 19 GUIDELINE P; Khan FA, 2021, THORAX, V76, P907, DOI 10.1136/thoraxjnl-2020-215266; Lan SH, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106103; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Martinez-Sanz J, 2021, CLIN MICROBIOL INFEC, V27, P238, DOI 10.1016/j.cmi.2020.09.021; McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753; National Institute for Health and Care Excellence (NICE), COVID 19 RAPID GUIDE; National Institutes of Health, COVID 19 TREATMENT G; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Pan American Health Organization, RAPID REV; Piscoya A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243705; Rodriguez-Bano J, 2021, CLIN MICROBIOL INFEC, V27, P244, DOI 10.1016/j.cmi.2020.08.010; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rossi B, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100317; Roumier M, 2021, J CLIN IMMUNOL, V41, P303, DOI 10.1007/s10875-020-00911-6; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Soin AS, 2021, LANCET RESP MED, V9, P511, DOI 10.1016/S2213-2600(21)00081-3; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; UpToDate. Uptodate.com, US; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Veroniki AA, 2016, RES SYNTH METHODS, V7, P55, DOI 10.1002/jrsm.1164; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n433; worldometers, COVID 19 CORONAVIRUS	48	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269368	10.1371/journal.pone.0269368	http://dx.doi.org/10.1371/journal.pone.0269368			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35657993	Green Published, gold			2023-01-03	WOS:000843567600068
J	Cayley, WE				Cayley, William E., Jr.			COVID-19 Treatments for Nonhospitalized Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Cayley, William E., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Eau Claire, WI USA	University of Wisconsin System	Cayley, WE (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Prevea Family Med Residency, 617 W Clairemont Ave, Eau Claire, WI 54701 USA.	bcayley@yahoo.com						Gandhi RT, 2022, JAMA-J AM MED ASSOC, V327, P617, DOI 10.1001/jama.2022.0335; Ramakrishnan S, 2021, LANCET RESP MED, V9, P763, DOI 10.1016/S2213-2600(21)00160-0; Yu LM, 2021, LANCET, V398, P843, DOI 10.1016/S0140-6736(21)01744-X	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2022	327	22					2248	2248						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2J5EE	35699709				2023-01-03	WOS:000815679200029
J	Simonsson, O; Goldberg, SB; Marks, J; Yan, LX; Narayanan, J				Simonsson, Otto; Goldberg, Simon B.; Marks, Joseph; Yan, Liuxin; Narayanan, Jayanth			Bridging the (Brexit) divide: Effects of a brief befriending meditation on affective polarization	PLOS ONE			English	Article							IMAGINED CONTACT; CONSEQUENCES; PARTISANSHIP; IDENTITY	The European Union Brexit referendum has divided the British electorate, with high levels of animosity between those who affiliate with the Remain side (Remainers) and the Leave side (Leavers) of the debate. Previous research has shown that a brief befriending meditation reduces affective polarization among Democrats and Republicans in the United States, but the results have not been replicated in a non-US sample and the psychological mechanisms underlying the effects have yet to be examined. The present study therefore used a post-test only randomized controlled design to investigate the effects of a brief befriending meditation on affective polarization among Remainers and Leavers (n = 922). Results showed that participants in the befriending condition scored modestly lower on affective polarization than participants in the attentional control condition (t(921) = 2.17, p = .030, d = 0.14) and that perceived commonality with the political outgroup mediated the effects. In sum, audio-guided befriending practices may be a highly scalable means to reduce high levels of affective polarization through increasing perceived commonality.	[Simonsson, Otto] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden; [Simonsson, Otto] Univ Oxford, Dept Sociol, Oxford, England; [Simonsson, Otto; Goldberg, Simon B.] Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53706 USA; [Goldberg, Simon B.] Univ Wisconsin, Dept Counseling Psychol, Madison, WI USA; [Marks, Joseph] UCL, Dept Expt Psychol, London, England; [Yan, Liuxin; Narayanan, Jayanth] Natl Univ Singapore, NUS Business Sch, Singapore, Singapore	Karolinska Institutet; University of Oxford; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of London; University College London; National University of Singapore	Simonsson, O (corresponding author), Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden.; Simonsson, O (corresponding author), Univ Oxford, Dept Sociol, Oxford, England.; Simonsson, O (corresponding author), Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53706 USA.	otto.simonsson@ki.se	Goldberg, Simon/AAQ-5173-2021	Goldberg, Simon/0000-0002-6888-0126; Marks, Joseph/0000-0002-9644-2967; Simonsson, Otto/0000-0003-4197-7566	Singapore Ministry of Education Academic Research Fund Tier 1 [T1 17/2019/115]; National University of Singapore Research Fund; Sweden-America Foundation; National Center for Complementary and Integrative Health [K23AT010879]	Singapore Ministry of Education Academic Research Fund Tier 1(Ministry of Education, Singapore); National University of Singapore Research Fund(National University of Singapore); Sweden-America Foundation; National Center for Complementary and Integrative Health	This study was funded by Singapore Ministry of Education Academic Research Fund Tier 1 (T1 17/2019/115) and National University of Singapore Research Fund to JN. OS was supported by the Sweden-America Foundation. SG was supported by a grant (K23AT010879) from the National Center for Complementary and Integrative Health.	Abramowitz AI, 2016, ELECT STUD, V41, P12, DOI 10.1016/j.electstud.2015.11.001; ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037/0022-3514.63.4.596; Bolin JH, 2014, J EDUC MEAS, V51, P335, DOI 10.1111/jedm.12050; Bristow J, 2019, CURR OPIN PSYCHOL, V28, P87, DOI 10.1016/j.copsyc.2018.11.003; Crisp RJ, 2009, SOC PERSONAL PSYCHOL, V3, P1, DOI 10.1111/j.1751-9004.2008.00155.x; Druckman JN, 2021, J EXP POLIT SCI, V8, P223, DOI 10.1017/XPS.2020.28; Druckman JN, 2021, NAT HUM BEHAV, V5, DOI 10.1038/s41562-020-01012-5; Druckman JN, 2019, PUBLIC OPIN QUART, V83, P114, DOI 10.1093/poq/nfz003; Hetherington Marc J., 2015, WHY WASHINGTON WONT; Hobolt SB, 2021, BRIT J POLIT SCI, V51, P1476, DOI 10.1017/S0007123420000125; Iyengar S, 2019, ANNU REV POLIT SCI, V22, P129, DOI 10.1146/annurev-polisci-051117-073034; Kang Y, 2014, J EXP PSYCHOL GEN, V143, P1306, DOI 10.1037/a0034150; Kok BE, 2017, JAMA PSYCHIAT, V74, P126, DOI 10.1001/jamapsychiatry.2016.3360; Levendusky MS, 2018, J POLIT, V80, P59, DOI 10.1086/693987; Macdougall AI, 2020, POLIT PSYCHOL, V41, P979, DOI 10.1111/pops.12660; Martinez-Ebers V, 2021, URBAN AFF REV, V57, P104, DOI 10.1177/1078087419853390; McConnell C, 2018, AM J POLIT SCI, V62, P5, DOI 10.1111/ajps.12330; Meleady R, 2017, J ENVIRON PSYCHOL, V53, P206, DOI 10.1016/j.jenvp.2017.08.005; Miles E, 2014, GROUP PROCESS INTERG, V17, P3, DOI 10.1177/1368430213510573; PRENTICE DA, 1992, PSYCHOL BULL, V112, P160, DOI 10.1037/0033-2909.112.1.160; Simonsson O, 2022, MINDFULNESS, V13, P474, DOI 10.1007/s12671-021-01808-0; Simonsson O, 2022, GROUP PROCESS INTERG, V25, P1577, DOI 10.1177/13684302211020108; Simonsson O, 2021, SOCIOL RES ONLINE, V26, P833, DOI 10.1177/1360780420980761; Simonsson O, 2020, MINDFULNESS, V11, P2725, DOI 10.1007/s12671-020-01486-4; Warner BR, 2017, COMMUN MONOGR, V84, P447, DOI 10.1080/03637751.2017.1336779; Wasil AR, 2020, J CONSULT CLIN PSYCH, V88, P983, DOI 10.1037/ccp0000604; Williams M., 2011, MINDFULNESS PRACTICA, V36869th ed.; Wojcieszak M, 2020, POLIT COMMUN, V37, P789, DOI 10.1080/10584609.2020.1760406; Wojcieszak M, 2018, HUM COMMUN RES, V44, P247, DOI 10.1093/hcr/hqx010	29	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2022	17	5							e0267493	10.1371/journal.pone.0267493	http://dx.doi.org/10.1371/journal.pone.0267493			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1VP	35544456	gold, Green Published			2023-01-03	WOS:000818854500029
J	Campbell, HM; Murata, AE; Conner, TA; Fotieo, G				Campbell, Heather M.; Murata, Allison E.; Conner, Todd A.; Fotieo, Greg			Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; RISK; TRIALS	Non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are among the most-frequently used medications. Although these medications have different mechanisms of action, they have similar indications and treatment duration has been positively correlated with cardiovascular risk although the degree of risk varies by medication. Our objective was to study treatment effects of chronic use of individual NSAID medications and acetaminophen on all-cause mortality among patients who tested positive for COVID-19 while accounting for adherence. We used the VA national datasets in this retrospective cohort study to differentiate between sporadic and chronic medication use: sporadic users filled an NSAID within the last year, but not recently or regularly. Using established and possible risk factors for severe COVID-19, we used propensity scores analysis to adjust for differences in baseline characteristics between treatment groups. Then, we used multivariate logistic regression incorporating inverse propensity score weighting to assess mortality. The cohort consisted of 28,856 patients. Chronic use of aspirin, ibuprofen, naproxen, meloxicam, celecoxib, diclofenac or acetaminophen was not associated with significant differences in mortality at 30 days (OR = 0.98, 95% CI: 0.95-1.00; OR = 0.99, 95% CI: 0.98-1.00; OR = 1.00, 95% CI: 0.98-1.01; OR = 0.99, 95% CI: 0.98-1.00; OR = 1.00, 95% CI: 0.98-1.01; OR = 0.99, 95% CI: 0.97-1.01; and OR = 1.00, 95% CI: 0.99-1.02, respectively) nor at 60 days (OR = 0.97, 95% CI: 0.95-1.00; OR = 1.00, 95% CI: 0.99-1.01; OR = 0.99, 95% CI: 0.98-1.01; OR = 0.99, 95% CI: 0.97-1.00; OR = 0.99, 95% CI: 0.97-1.01; OR = 0.99, 95% CI: 0.97-1.01; and OR = 1.01, 95% CI: 0.99-1.02, respectively). Although the study design cannot determine causality, the study should assure patients as it finds no association between mortality and chronic use of these medications compared with sporadic NSAID use among those infected with COVID-19.	[Campbell, Heather M.; Murata, Allison E.; Conner, Todd A.] US Dept Vet Affairs, Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87108 USA; [Fotieo, Greg] US Dept Vet Affairs, New Mexico VA Healthcare Syst, Albuquerque, NM USA	US Department of Veterans Affairs; US Department of Veterans Affairs	Campbell, HM (corresponding author), US Dept Vet Affairs, Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87108 USA.	heather.campbell@va.gov			Department of Veterans Affairs, Veterans Health Administration	Department of Veterans Affairs, Veterans Health Administration(US Department of Veterans Affairs)	This research was supported by the Department of Veterans Affairs, Veterans Health Administration using resources and facilities at the New Mexico VA Health Care System, Raymond G. Murphy VA Medical Center, as well as the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program using resources and facilities at the VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center. No grant was provided for this work but time, resources, and facilities were used by HMC, AEM, TAC and GF.	Abu Esba LC, 2021, INFECT DIS THER, V10, P253, DOI 10.1007/s40121-020-00363-w; Andersohn F, 2006, CIRCULATION, V113, P1950, DOI 10.1161/CIRCULATIONAHA.105.602425; [Anonymous], 2020, Drug Ther Bull, V58, P69, DOI 10.1136/dtb.2020.000021; Arnold N, 2019, CDW DATE DEATH ANAL, P1; Asadi M, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102319; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berghella V., 2020, INT INF PREV CONTR R; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; Bruce E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082586; Chan AT, 2006, CIRCULATION, V113, P1578, DOI 10.1161/CIRCULATIONAHA.105.595793; Chandan JS, 2021, ARTHRITIS RHEUMATOL, V73, P731, DOI 10.1002/art.41593; Chmiel JF, 2015, J CYST FIBROS, V14, P720, DOI 10.1016/j.jcf.2015.03.007; Chow JH, 2021, ANESTH ANALG, V132, P930, DOI 10.1213/ANE.0000000000005292; Department of Veterans Affairs Veterans Health Administration Office of Policy and Planning, 2018, HEALTHCARE SERVICES; Eeren HV, 2015, MED CARE, V53, P366, DOI 10.1097/MLR.0000000000000325; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Fuster V, 2011, CIRCULATION, V123, P768, DOI 10.1161/CIRCULATIONAHA.110.963843; Gallelli L, 2013, OSTEOARTHR CARTILAGE, V21, P1400, DOI 10.1016/j.joca.2013.06.026; Giollo A, 2021, ANN RHEUM DIS, V80, DOI [10.1136/annrheumdis-2020-218830, 10.1136/annrheumdis-2020-217598]; Helin-Salmivaara A, 2006, EUR HEART J, V27, P1657, DOI 10.1093/eurheartj/ehl053; Hong WX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.561674; Jeong HE, 2021, CLIN INFECT DIS, V73, pE4179, DOI 10.1093/cid/ciaa1056; Kragholm K, 2020, CTS-CLIN TRANSL SCI, V13, P1103, DOI 10.1111/cts.12904; Lund LC, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003308; Meizlish ML, 2021, AM J HEMATOL, V96, P471, DOI [10.1101/2021.01.12.21249577, 10.1002/ajh.26102]; Osborne TF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246825; Petersen ML, 2012, STAT METHODS MED RES, V21, P31, DOI 10.1177/0962280210386207; Rosenbaum PR., 2005, ENCY BIOSTATISTICS, V2nd ed., P4267; Sahai A., 2020, PREPRINT, DOI [10.21203/rs.3.rs-119031/v1, DOI 10.21203/RS.3.RS-119031/V1]; Sahai A, 2021, VASC MED, V26, P626, DOI 10.1177/1358863X211012754; Schmidt M, 2016, EUR HEART J, V37, P1015, DOI 10.1093/eurheartj/ehv505; Schmidt M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3450; Son M, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026670; Nguyen TL, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0338-0; United States Department of Health and Human Services, COVID 19; United States Food and Drug Administration, DRUG SAF AV; Wong AYS, 2021, ANN RHEUM DIS, V80, P943, DOI 10.1136/annrheumdis-2020-219517; Wong ES, 2016, MED CARE RES REV, V73, P493, DOI 10.1177/1077558715617382; Zhao X, 2021, ANESTHESIOLOGY, V135, P1076, DOI 10.1097/ALN.0000000000003999	40	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0267462	10.1371/journal.pone.0267462	http://dx.doi.org/10.1371/journal.pone.0267462			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511939	Green Published, gold			2023-01-03	WOS:000892294900047
J	Sandercock, GRH; Moran, J; Cohen, DD				Sandercock, Gavin R. H.; Moran, Jason; Cohen, Daniel D.			Who is meeting the strengthening physical activity guidelines by definition: A cross-sectional study of 253 423 English adults?	PLOS ONE			English	Article							24-HOUR MOVEMENT GUIDELINES; AGED 18-64 YEARS; SEDENTARY BEHAVIOR; UNITED-STATES; US ADULTS; MUSCLE; HEALTH; PARTICIPATION; INTEGRATION; EXERCISE	The current UK physical activity guidelines recommend that adults aged 19 to 65 years perform activity to strengthen muscle and bone a minimum of twice weekly. The number of adults meeting strengthening activity guidelines is lower than for aerobic activity, but estimates vary between studies partly due to differences in how muscle-strengthening activity is defined. We aimed to provide estimates for strengthening activity prevalence in English adults based on a nationally representative sample of n = 253,423 18-65-year-olds. We attempted to quantify the variation in estimates attributable to differences in the way strengthening activity is defined. Finally, we aim to provide a brief descriptive epidemiology of the factors associated with strengthening activity. Adults met guidelines for aerobic activity if they reported the activity equivalent to > 150 min/week moderate-intensity exercise. Respondents met strengthening guidelines if they reported at least two bouts per week of strengthening activity. We defined strengthening activity, first, according to criteria used in the Health Survey for England (HSE). Second, we counted bouts of strengthening activities for which we could find evidence of health-related benefits (Evidence). Third, we included bouts of strengthening activity as defined in current UK physical activity guidelines (Guideline). Two-thirds (67%) of adults met guidelines for aerobic activity (69% of men, 65% of women). Less than one-third (29% of men and 24% of women) met guidelines for the HSE definition of strengthening activity. Under the Evidence definition, 16% of men and 9% of women met strengthening guidelines. Using the most-stringent definition (Guideline) just 7.3% of men and 4.1% of women achieved the recommendations for strengthening activity. We found females and older adults (50-65 years) were less likely to meet guidelines for aerobic, strengthening, and combined aerobic plus strengthening activity. The prevalence of meeting activity guidelines was lower in adults from more deprived areas (compared with the least deprived); Adults with lower academic qualifications (Level 1) were less likely to meet activity guidelines than those educated to Level 4 (Degree Level) or higher. Having a limiting disability was associated with a lower prevalence of meeting activity guidelines. Associations between socio-demographic measures and the prevalence of adults meeting activity guidelines were stronger for strengthening activity than for aerobic 51(or combined aerobic plus strengthening) activity Compared with aerobic activity, fewer adults engage in strengthening activity regardless of how it is defined. The range in estimates for how many adults meet strengthening activity guidelines can be explained by variations in the definition of 'strengthening' that are used and the specific sports or activities identified as strengthening exercise. When strengthening activity is included, the proportion of English adults meeting current physical activity guidelines could be as high as 1 in 3 but possibly as low as just 1 in 20. A harmonized definition of strengthening activity, that is aligned with physical activity guidelines, is required to provide realistic and comparable prevalence estimates.	[Sandercock, Gavin R. H.; Moran, Jason] Univ Essex, Sch Sport Rehabil & Exercise Sci, Colchester, Essex, England; [Cohen, Daniel D.] Univ Santander UDES, Fac Hlth Sci, Masira Res Inst, Bucaramanga, Colombia	University of Essex; Universidad Industrial de Santander	Sandercock, GRH (corresponding author), Univ Essex, Sch Sport Rehabil & Exercise Sci, Colchester, Essex, England.	gavins@essex.ac.uk		Moran, Jason/0000-0001-7452-6855; Sandercock, Gavin/0000-0002-5443-6518				Ball K, 2006, WOMEN HEALTH, V43, P93, DOI 10.1300/J013v43n01_06; Bennie JA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242220; Bennie JA, 2020, SPORTS MED-OPEN, V6, DOI 10.1186/s40798-020-00271-w; Bennie JA, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0797-2; Bennie JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153225; Bennie JA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2736-3; Bianchim MS, 2020, PREV MED REP, V19, DOI 10.1016/j.pmedr.2020.101142; Brainard J, 2020, INT J PUBLIC HEALTH, V65, P871, DOI 10.1007/s00038-020-01438-8; Brainard J, 2019, PREV MED, V123, P225, DOI 10.1016/j.ypmed.2019.03.043; Celis-Morales CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036345; Craig RJM, 2008, HLTH SURVEY ENGLAND; Dankel SJ, 2016, ARCH CARDIOVASC DIS, V109, P626, DOI 10.1016/j.acvd.2016.04.005; Dankel SJ, 2016, MAYO CLIN PROC, V91, P166, DOI 10.1016/j.mayocp.2015.10.017; Department of Health and Social Care Llwodraeth Cymru Welsh Government Department of Health Northern Ireland and the Scottish Government, 2019, UK CHIEF MED OFF PHY; Du Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7597; England PH, 2018, MUSCL BON STRENGTH B; England S, 2018, ACTIVE LIVES SURVEY; Foster C, 2018, J PHYS ACT HEALTH, V15, pS249; Gibson-Moore H, 2019, NUTR BULL, V44, P320, DOI 10.1111/nbu.12409; Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326; Hillsdon M, 2018, J PHYS ACT HEALTH, V15, pS249; Hirsch SM, 2021, J STRENGTH COND RES, V35, pS89, DOI 10.1519/JSC.0000000000003233; IPSOS.MORI, 2017, ACTIVE LIVES SURVEY; King AC, 2019, MED SCI SPORT EXER, V51, P1340, DOI 10.1249/MSS.0000000000001945; King AC, 2019, MED SCI SPORT EXER, V51, P1203, DOI 10.1249/MSS.0000000000001946; Knuttgen HG, 2007, J STRENGTH COND RES, V21, P973, DOI 10.1519/00124278-200708000-00053; Krzysztofik M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16244897; Lindsay T, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0882-6; Liu Y, 2020, J TEACH PHYS EDUC, V39, P206, DOI 10.1123/jtpe.2018-0352; Loustalot F, 2013, RES Q EXERCISE SPORT, V84, P30, DOI 10.1080/02701367.2013.762289; Lovasi Gina S, 2012, Open Epidemiol J, V5, P13; Manfreda KL, 2008, INT J MARKET RES, V50, P79, DOI 10.1177/147078530805000107; Marques A, 2015, PREV MED, V81, P333, DOI 10.1016/j.ypmed.2015.09.018; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Milton Karen, 2018, J Frailty Sarcopenia Falls, V3, P114, DOI 10.22540/JFSF-03-114; Montalvo-Perez A, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.586113; NHS Digital, 2017, HLTH SURVEY ENGLAND; Oja P, 2015, BRIT J SPORT MED, V49, P434, DOI 10.1136/bjsports-2014-093885; PHE.Gov.UK, 2021, FING PUBL HLTH ENGL; Ross R, 2020, APPL PHYSIOL NUTR ME, V45, pV, DOI 10.1139/apnm-2020-0843; Ross R, 2020, APPL PHYSIOL NUTR ME, V45, pS57, DOI 10.1139/apnm-2020-0467; Scholes S, 2014, AM J EPIDEMIOL, V179, P1493, DOI 10.1093/aje/kwu087; Shakespear-Druery J, 2021, PREV MED, V148, DOI 10.1016/j.ypmed.2021.106566; Sport England, 2017, ACT LIV AD SURV; Sport England, ACTIVE LIVES SURVEY; Sport.England, 2015, ACTIVE LIVES SURVEY; Steele J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4209-8; Steenhuis IHM, 2009, J PHYS ACT HEALTH, V6, P716, DOI 10.1123/jpah.6.6.716; Stocker TF, 2014, CLIMATE CHANGE 2013: THE PHYSICAL SCIENCE BASIS, P1, DOI 10.1017/cbo9781107415324; Strain T, 2020, BRIT J SPORT MED, V54, P1269, DOI 10.1136/bjsports-2018-100355; Strain T, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3774-6; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Tucker JM, 2011, AM J PREV MED, V40, P454, DOI 10.1016/j.amepre.2010.12.016; Whitfield GP, 2019, MMWR-MORBID MORTAL W, V68, P513, DOI 10.15585/mmwr.mm6823a1; Zenko Z, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00135; Zhao GX, 2014, BRIT J SPORT MED, V48, P244, DOI 10.1136/bjsports-2013-092731; Zytnick D, 2021, AM J HEALTH PROMOT, V35, P679, DOI 10.1177/0890117120985834	57	1	1	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2022	17	5							e0267277	10.1371/journal.pone.0267277	http://dx.doi.org/10.1371/journal.pone.0267277			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1HN	35507575	gold, Green Accepted, Green Published			2023-01-03	WOS:000818817800035
J	Bradley, MC; Perez-Vilar, S; Chillarige, Y; Dong, D; Martinez, AI; Weckstein, AR; Dal Pan, GJ				Bradley, Marie C.; Perez-Vilar, Silvia; Chillarige, Yoganand; Dong, Diane; Martinez, Ashley I.; Weckstein, Andrew R.; Dal Pan, Gerald J.			Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter; Early Access								This study uses 2 large US health care claims databases (Medicare fee-for-service and the US Food and Drug Administration's Sentinel System) to examine systemic corticosteroid use among nonhospitalized patients with COVID-19.	[Bradley, Marie C.; Perez-Vilar, Silvia; Dal Pan, Gerald J.] US FDA, Off Surveillance & Epidemiol, Silver Spring, MD USA; [Chillarige, Yoganand] Acumen LLC, Burlingame, CA USA; [Dong, Diane] US Dept Vet Affairs, Ctr Medicat Safety, Hines, IL USA; [Martinez, Ashley I.] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Weckstein, Andrew R.] Aetion Inc, New York, NY USA	US Food & Drug Administration (FDA); US Department of Veterans Affairs; Harvard University; Harvard Medical School	Bradley, MC (corresponding author), US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA.	marie.bradley@fda.hhs.gov		Bradley, Marie/0000-0002-6266-4414	US Food and Drug Administration (FDA) [21-182]; Centers for Medicare & Medicaid Services (CMS) [75FCMC21F0067]; FDA; Centers for Drug Evaluation and Research [75F40119D10037]; US Department of Health and Human Services (DHHS) [75F40119F19001]	US Food and Drug Administration (FDA)(United States Department of Health & Human Services); Centers for Medicare & Medicaid Services (CMS); FDA(United States Department of Health & Human Services); Centers for Drug Evaluation and Research; US Department of Health and Human Services (DHHS)	This study was funded through interagency agreement 21-182 between the US Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) (task order 75FCMC21F0067) for which Acumen LLC is the contractor, with additional funding from the FDA and the Centers for Drug Evaluation and Research (contract 75F40119D10037). The Sentinel System Initiative is funded by the FDA through contract 75F40119F19001 from the US Department of Health and Human Services (DHHS).	Centers for Medicare and Medicaid Services, MED PROGR GEN INF; Cocoros NM, 2021, PHARMACOEPIDEM DR S, V30, P827, DOI 10.1002/pds.5240; Crothers K, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02532-2021; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; National Institutes of Health, THER MAN NONH AD COV; RECOVERY, RAND EV COVID 19 THE	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.4877	http://dx.doi.org/10.1001/jama.2022.4877		APR 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0I5LK	35394487	Bronze, Green Published			2023-01-03	WOS:000779462100001
J	Kamdar, S; Shin, S; Leishangthem, P; Francis, LF; Xu, XL; Cheng, X				Kamdar, Shashank; Shin, Seunghwan; Leishangthem, Premkumar; Francis, Lorraine F.; Xu, Xinliang; Cheng, Xiang			The colloidal nature of complex fluids enhances bacterial motility	NATURE			English	Article							MICROORGANISMS; TRAJECTORIES; LOCOMOTION; VISCOSITY; MOTION	The natural habitats of microorganisms in the human microbiome, ocean and soil ecosystems are full of colloids and macromolecules. Such environments exhibit non-Newtonian flow properties, drastically affecting the locomotion of microorganisms(1-5). Although the low-Reynolds-number hydrodynamics of swimming flagellated bacteria in simple Newtonian fluids has been well developed(6-9), our understanding of bacterial motility in complex non-Newtonian fluids is less mature(10,11). Even after six decades of research, fundamental questions about the nature and origin of bacterial motility enhancement in polymer solutions are still under debate(12-)(23). Here we show that flagellated bacteria in dilute colloidal suspensions display quantitatively similar motile behaviours to those in dilute polymer solutions, in particular a universal particle-size-dependent motility enhancement up to 80% accompanied by a strong suppression of bacterial wobbling(18)(,)(24). By virtue of the hard-sphere nature of colloids, whose size and volume fraction we vary across experiments, our results shed light on the long-standing controversy over bacterial motility enhancement in complex fluids and suggest that polymer dynamics may not be essential for capturing the phenomenon(12-)(23). A physical model that incorporates the colloidal nature of complex fluids quantitatively explains bacterial wobbling dynamics and mobility enhancement in both colloidal and polymeric fluids. Our findings contribute to the understanding of motile behaviours of bacteria in complex fluids, which are relevant for a wide range of microbiological processes' and for engineering bacterial swimming in complex environments(26,27).	[Kamdar, Shashank; Shin, Seunghwan; Francis, Lorraine F.; Cheng, Xiang] Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA; [Leishangthem, Premkumar; Xu, Xinliang] Beijing ComputationalSci Res Ctr, CompLex Syst Div, Beijing, Peoples R China; [Xu, Xinliang] Beijing Normal Univ, Dept Phys, Beijing, Peoples R China	University of Minnesota System; University of Minnesota Twin Cities; Beijing Normal University	Cheng, X (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.; Xu, XL (corresponding author), Beijing ComputationalSci Res Ctr, CompLex Syst Div, Beijing, Peoples R China.; Xu, XL (corresponding author), Beijing Normal Univ, Dept Phys, Beijing, Peoples R China.	xinliang@csrc.ac.cn; xcheng@umn.edu		Kamdar, Shashank/0000-0003-2455-692X; Francis, Lorraine/0000-0003-2516-2957; Shin, Seunghwan/0000-0001-6581-1523; Xu, Xinliang/0000-0003-4940-3612; Cheng, Xiang/0000-0002-2759-764X	IPRIME program of University of Minnesota; US National Science Foundation [CBET-1702352, 2028652]; National Natural Science Foundation of China [11974038, U1930402]; US National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) [ECCS-2025124]	IPRIME program of University of Minnesota; US National Science Foundation(National Science Foundation (NSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); US National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI)	We thank P. Agrawal, S. Ghosh, Y. Kim, Z. Liu, R. Patel and G. Pradipta for help with experiments and data analysis and S. Guo, P. Kolliopoulos, E. Lauga, Y. Man and Z. Qu for fruitful discussions. We would also like to acknowledge the late Professor Howard Berg, who answered our questions on E. coli mutant strains. This research is supported by the IPRIME program of University of Minnesota, and by the US National Science Foundation CBET-1702352 and 2028652. X.X. acknowledges the financial support from National Natural Science Foundation of China no. 11974038 and no. U1930402. Portions of this work were conducted in the Minnesota Nano Center, which is supported by the US National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) under award number ECCS-2025124.	Azam F, 2007, NAT REV MICROBIOL, V5, P782, DOI 10.1038/nrmicro1747; Bechinger C, 2016, REV MOD PHYS, V88, DOI 10.1103/RevModPhys.88.045006; Berg, 2004, COLI MOTION; BERG HC, 1979, NATURE, V278, P349, DOI 10.1038/278349a0; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; Binagia JP, 2020, J FLUID MECH, V900, DOI 10.1017/jfm.2020.456; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; Celli JP, 2009, P NATL ACAD SCI USA, V106, P14321, DOI 10.1073/pnas.0903438106; Childress S., 1981, MECH SWIMMING FLYING; Cortese D, 2021, PHYS REV LETT, V126, DOI 10.1103/PhysRevLett.126.088003; Crenshaw HC, 1996, AM ZOOL, V36, P608; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; Darnton NC, 2007, J BACTERIOL, V189, P1756, DOI 10.1128/JB.01501-06; Elfring GJ, 2015, BIOL MED PHYS BIOMED, P283, DOI 10.1007/978-1-4939-2065-5_8; Hibbing ME, 2010, NAT REV MICROBIOL, V8, P15, DOI 10.1038/nrmicro2259; Hiemenz P.C., 2007, POLYM CHEM-UK; Hyon Y, 2012, J FLUID MECH, V705, P58, DOI 10.1017/jfm.2012.217; JEFFREY DJ, 1984, J FLUID MECH, V139, P261, DOI 10.1017/S0022112084000355; Lauga E, 2006, BIOPHYS J, V90, P400, DOI 10.1529/biophysj.105.069401; Lauga E, 2016, ANNU REV FLUID MECH, V48, P105, DOI 10.1146/annurev-fluid-122414-034606; Lauga E, 2009, REP PROG PHYS, V72, DOI 10.1088/0034-4885/72/9/096601; Li GL, 2008, P NATL ACAD SCI USA, V105, P18355, DOI 10.1073/pnas.0807305105; Liu ZY, 2021, SOFT MATTER, V17, P10806, DOI 10.1039/d1sm01183a; Macosko C.W., 1994, RHEOLOGY PRINCIPLES; Magariyama Y, 2002, BIOPHYS J, V83, P733, DOI 10.1016/S0006-3495(02)75204-1; Man Y, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.023004; Martinez VA, 2014, P NATL ACAD SCI USA, V111, P17771, DOI 10.1073/pnas.1415460111; Nelson BJ, 2010, ANNU REV BIOMED ENG, V12, P55, DOI 10.1146/annurev-bioeng-010510-103409; Patteson AE, 2015, SCI REP-UK, V5, DOI 10.1038/srep15761; Patteson AE, 2016, CURR OPIN COLLOID IN, V21, P86, DOI 10.1016/j.cocis.2016.01.001; Peng Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd1240; Poon WCK, 2012, SOFT MATTER, V8, P21, DOI 10.1039/c1sm06083j; Qu ZJ, 2020, PHYS REV FLUIDS, V5, DOI 10.1103/PhysRevFluids.5.073103; Qu ZJ, 2018, P NATL ACAD SCI USA, V115, P1707, DOI 10.1073/pnas.1714187115; Rossi M, 2017, P NATL ACAD SCI USA, V114, P13085, DOI 10.1073/pnas.1708064114; SCHNEIDER WR, 1974, J BACTERIOL, V117, P696, DOI 10.1128/JB.117.2.696-701.1974; Shimogonya Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep18488; SHOESMITH JG, 1960, J GEN MICROBIOL, V22, P528, DOI 10.1099/00221287-22-2-528; Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047; Verdugo P, 2004, MAR CHEM, V92, P67, DOI 10.1016/j.marchem.2004.06.017; WELLS ML, 1991, NATURE, V353, P342, DOI 10.1038/353342a0; Zhang BK, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100145118; Zhang YC, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.023101; Zottl A, 2019, NAT PHYS, V15, P554, DOI 10.1038/s41567-019-0454-3	44	16	16	14	54	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 31	2022	603	7903					819	+		10.1038/s41586-022-04509-3	http://dx.doi.org/10.1038/s41586-022-04509-3			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0E0FI	35355005	Green Submitted			2023-01-03	WOS:000776361600026
J	Seid, K; Abdo, A				Seid, Kalid; Abdo, Adem			Nurse's spiritual care competence in Ethiopia: A multicenter cross-sectional study	PLOS ONE			English	Article							PERCEPTION	Background Many health care professionals emphasize that spirituality is an important factor in overall health. Although spiritual practices are vital to health, spirituality has received little emphasis in nursing. Hence, the study's purpose has been to evaluate the current state of spiritual care competence and the factors that influence it among nurses in Southwest Ethiopia. Methods From July 1 to 20, 2021, nurses at five hospitals in southwest Ethiopia were enrolled in a facility-based cross-sectional study. The study subjects were chosen using a systematic random sampling. A self-administered questionnaire was undertaken to gather the data. Epi Data 3.1 was used to code the dataset, and SPSS version 25 was used for analysis. To identify factors associated with spiritual care competence, researchers performed bivariate and multivariable linear regression analyses. The significance level was set at p<0.05. Results Three hundred sixty-seven nurses attended in the study, giving a 91.06, percent rate of response. The mean spiritual care competence score among healthcare professionals was 3.140.74. Age (p<0.05), and training in spiritual care (p<0.05) were significantly associated with spiritual care competence. Conclusions Spiritual care competence was moderate among the nurses. Spiritual care competence varies in accordance with a number of factors, including age, and training in spiritual care. Nurses are better suited to focus on the spiritual health of clients, which necessitates the provision of spiritual care competence training for nurses.	[Seid, Kalid; Abdo, Adem] Mizan Tepi Univ, Coll Med & Hlth Sci, Dept Nursing, Mizan, Southwest Peopl, Ethiopia	University of Gondar	Seid, K (corresponding author), Mizan Tepi Univ, Coll Med & Hlth Sci, Dept Nursing, Mizan, Southwest Peopl, Ethiopia.	kalidseid7@gmail.com						Abusafia AH., 2021, NURSE MEDIA J NURSIN, V11, P1; Adib-Hajbaghery M, 2017, NURS ETHICS, V24, P462, DOI 10.1177/0969733015600910; da Rocha ACAL, 2014, REV ESC ENFERM USP, V48, P87, DOI 10.1590/S0080-623420140000800014; Alshehry AS, 2018, RELIGIONS, V9, DOI 10.3390/rel9120384; Baldacchino DR, 2008, NURS EDUC TODAY, V28, P550, DOI 10.1016/j.nedt.2007.09.003; Basinski A, 2013, J RELIG HEALTH, V52, P276, DOI 10.1007/s10943-011-9454-z; Berhanu RD, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254643; Britt KC, 2022, J HOLIST NURS, V40, P46, DOI 10.1177/08980101211026776; Chan MF, 2006, NURS EDUC TODAY, V26, P139, DOI 10.1016/j.nedt.2005.08.006; Chan MF, 2010, J CLIN NURS, V19, P2128, DOI 10.1111/j.1365-2702.2008.02690.x; Ebrahimi H, 2017, INDIAN J PALLIAT CAR, V23, P57, DOI 10.4103/0973-1075.197957; Gallison BS, 2013, J HOLIST NURS, V31, P95, DOI 10.1177/0898010112464121; Harrad Rachel, 2019, Acta Biomed, V90, P44, DOI 10.23750/abm.v90i4-S.8300; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Lewinson LP, 2015, NURS EDUC TODAY, V35, P806, DOI 10.1016/j.nedt.2015.01.011; Littva V., 2015, BMJ SUPPORT PALLIAT, V5, pA81; Livneh H, 2005, J COUNS DEV, V83, P12, DOI 10.1002/j.1556-6678.2005.tb00575.x; McClain-Jacobson C, 2004, GEN HOSP PSYCHIAT, V26, P484, DOI 10.1016/j.genhosppsych.2004.08.002; McSherry W, 2006, MAKING SENSE SPIRITU; Mooney Brona, 2007, Nurse Educ Pract, V7, P275, DOI 10.1016/j.nepr.2006.09.001; Parveen SA, 2021, SAUDI J NURS HLTH CA, V4, P141; Pearce MJ, 2012, SUPPORT CARE CANCER, V20, P2269, DOI 10.1007/s00520-011-1335-1; Puchalski CM, 2012, ANN ONCOL, V23, P49, DOI 10.1093/annonc/mds088; Ramezani M, 2014, INT NURS REV, V61, P211, DOI 10.1111/inr.12099; Sparaco M., 2021, NEUROL SCI, P1; Stranahan S, 2001, WESTERN J NURS RES, V23, P90, DOI 10.1177/01939450122044970; Unantenne N, 2013, J RELIG HEALTH, V52, P1147, DOI 10.1007/s10943-011-9554-9; van Leeuwen R, 2009, J CLIN NURS, V18, P2857, DOI 10.1111/j.1365-2702.2008.02594.x; Weathers E, 2016, NURS FORUM, V51, P79, DOI 10.1111/nuf.12128; Yilmaz M., 2011, J ANATOL NURS HLTH S, V14, P61	30	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2022	17	3							e0265205	10.1371/journal.pone.0265205	http://dx.doi.org/10.1371/journal.pone.0265205			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2R2AR	35271676	gold, Green Published			2023-01-03	WOS:000820912700100
J	White, S; Heath, T; Ibrahim, WK; Ihsan, D; Blanchet, K; Curtis, V; Dreibelbis, R				White, Sian; Heath, Thomas; Ibrahim, Waleed Khalid; Ihsan, Dilveen; Blanchet, Karl; Curtis, Val; Dreibelbis, Robert			How is hygiene behaviour affected by conflict and displacement? A qualitative case study in Northern Iraq	PLOS ONE			English	Article							HAND HYGIENE; HEALTH; HOMEMAKING; DISGUST; HOME	This research aimed to qualitatively explore whether the determinants of handwashing behaviour change according to the duration of displacement or the type of setting that people are displaced to. We conducted an exploratory qualitative study in three different post-conflict settings in Northern Iraq-a long-term displacement camp, a short-term displacement camp, and villages where people were returning to post the conflict. We identified 33 determinants of handwashing in these settings and, of these, 21 appeared to be altered by the conflict and displacement. Determinants of handwashing behaviour in the post-conflict period were predominantly explained by disruptions to the physical, psychological, social and economic circumstances of displaced populations. Future hygiene programmes in post-conflict displacement settings should adopt a holistic way of assessing determinants and design programmes which promote agency, build on adaptive norms, create an enabling environment and which are integrated with other aspects of humanitarian response.	[White, Sian; Curtis, Val; Dreibelbis, Robert] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Heath, Thomas] Act Faim, Operat Dept, Paris, France; [Ibrahim, Waleed Khalid] Cihan Univ, Coll Med Technol, Nutr & Dietet Dept, Erbil, Kurdistan Regio, Iraq; [Blanchet, Karl] Univ Geneva, Geneva Ctr Humanitarian Studies, Geneva, Switzerland	University of London; London School of Hygiene & Tropical Medicine; Cihan University-Erbil; University of Geneva	White, S (corresponding author), London Sch Hyg & Trop Med, Dept Dis Control, London, England.	sina.white@Ishtm.ac.uk			United States Agency for international development's Bureau of Humanitarian Assistance [AID-OFDA-G-16-00270]	United States Agency for international development's Bureau of Humanitarian Assistance	Funding for this research was provided by United States Agency for international development's Bureau of Humanitarian Assistance via grant number AID-OFDA-G-16-00270. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This grant contributed to the salaries of Sian White, Thomas Heath, Waleed Khalid Ibrahum and Dilveen Ihsan, but did not fully fund these.	Abbas AM, 2021, J OBSTET GYNAECOL, V41, P331, DOI 10.1080/01443615.2020.1819214; Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Al-Khatib Issam A., 2011, Eastern Mediterranean Health Journal, V17, P323; Aunger R., 2016, HEALTH PSYCHOL REV; Aunger R., 2017, BEHAV CENTRED DESIGN, DOI [10.1371/journal.pone.0171610, DOI 10.1371/JOURNAL.PONE.0171610]; Biran A, 2012, TROP MED INT HEALTH, V17, P1133, DOI 10.1111/j.1365-3156.2012.03045.x; Blum LS, 2019, CONFL HEALTH, V13, DOI 10.1186/s13031-019-0225-x; Bradt D., 2009, NETWORK PAPER EVIDEN; Braun V, 2021, QUAL RES PSYCHOL, V18, P328, DOI 10.1080/14780887.2020.1769238; Brewis A, 2019, SOC SCI MED, V220, P12, DOI 10.1016/j.socscimed.2018.10.020; Brun C, 2015, SOC ANAL, V59, P19, DOI 10.3167/sa.2015.590102; Brun C, 2015, REFUGE, V31, P5; Cavill S., 2020, WH2O J GENDER WATER, V7; Checchi F, 2007, PUBLIC HLTH CRISIS A; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; Contzen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136445; Contzen N, 2015, AM J INFECT CONTROL, V43, P826, DOI 10.1016/j.ajic.2015.04.186; Coombes Y, 2010, INTRO FOAM FRAMEWORK; Curtis V, 2019, SOC SCI MED, V235, DOI 10.1016/j.socscimed.2019.112398; Curtis V, 2011, PHILOS T R SOC B, V366, P389, DOI 10.1098/rstb.2010.0117; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; D'Mello-Guyett L, 2018, CONFL HEALTH, V12, DOI 10.1186/s13031-018-0159-8; De Buck E., 2017, CAMPBELL COLLABORATI, V7; Dijkzeul D, 2013, DISASTERS, V37, pS1, DOI 10.1111/disa.12009; Dreibelbis R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1015; Flachenberg F., 2017, 40 WEDC INT C; Fontenelle LF, 2012, J ANXIETY DISORD, V26, P377, DOI 10.1016/j.janxdis.2011.12.001; Gaskell GD, 2000, PUBLIC OPIN QUART, V64, P77, DOI 10.1086/316761; Hart J, 2018, HUM ORGAN, V77, P371, DOI 10.17730/0018-7259.77.4.371; HORNSVELD RHJ, 1979, BEHAV RES THER, V17, P223, DOI 10.1016/0005-7967(79)90037-8; Husain F, 2015, CONFL HEALTH, V9, DOI 10.1186/s13031-015-0053-6; Kibreab Gaim, 2000, CAN J AFR STUDIES, V34, P249; Kjellsson G, 2014, J HEALTH ECON, V35, P34, DOI 10.1016/j.jhealeco.2014.01.007; La Valle M.H., 2019, LIFE EVENTS CHANGES, P176; Morgan D.J., 1997, FOCUS GROUPS QUALITA, P8; Mosler HJ, 2012, INT J ENVIRON HEAL R, V22, P431, DOI 10.1080/09603123.2011.650156; Mubarak MY, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1789-3; Nahimana MR, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.54.12265; Neumark D, 2013, HOUS THEORY SOC, V30, P237, DOI 10.1080/14036096.2013.789071; Peterson EA, 1998, INT J EPIDEMIOL, V27, P520, DOI 10.1093/ije/27.3.520; Phillips RM, 2015, CONFL HEALTH, V9, DOI 10.1186/s13031-015-0065-2; Porzig-Drummond R, 2009, SOC SCI MED, V68, P1006, DOI 10.1016/j.socscimed.2009.01.013; Ram P., 2010, GLOB SCAL HANDW PROJ; Ramesh A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124688; Ramos M., 2016, HANDWASHING EMERGENC; Ranasinghe S, 2016, J INFECT PUBLIC HEAL, V9, P429, DOI 10.1016/j.jiph.2015.11.007; Reuven-Magril O, 2008, J ABNORM PSYCHOL, V117, P334, DOI 10.1037/0021-843X.117.2.334; ROGGE JR, 1989, INT MIGR REV, V23, P184, DOI 10.2307/2546257; Sagan S., 2019, Waterlines, V38, P20, DOI 10.3362/1756-3488.17-00; Sanyal R, 2014, INT J URBAN REGIONAL, V38, P558, DOI 10.1111/1468-2427.12020; Slekiene J, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4638-4; Sphere Association, 2018, SPHER HDB HUM CHART, VFourth; Stefanovic D, 2015, J REFUG STUD, V28, P276, DOI 10.1093/jrs/feu029; Strauss A.L., 1973, FIELD RES STRATEGIES; Thorpe SJ, 2011, BEHAV COGN PSYCHOTH, V39, P175, DOI 10.1017/S1352465810000676; Turner S, 2016, J REFUG STUD, V29, P139, DOI 10.1093/jrs/fev024; van de Mortel TF, 2008, AUST J ADV NURS, V25, P40; Vandevoordt R, 2017, J REFUG STUD, V30, P605, DOI 10.1093/jrs/fex017; Verplanken B., 2018, PSYCHOL HABIT THEORY, DOI [10.1007/978-3-319-97529-0_11, DOI 10.1007/978-3-319-97529-0_11]; Watson J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228482; White S, 2020, INT J HYG ENVIR HEAL, V227, DOI 10.1016/j.ijheh.2020.113512; White S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216237; Wolf J, 2019, INT J EPIDEMIOL, V48, P1204, DOI 10.1093/ije/dyy253; Wolf J, 2018, TROP MED INT HEALTH, V23, P508, DOI 10.1111/tmi.13051; Woodruff B., 2009, USE EPIDEMIOLOGICAL; Yates T., 2018, Waterlines, V37, P31, DOI 10.3362/1756-3488.17-00016; Zangana A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231694	67	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264434	10.1371/journal.pone.0264434	http://dx.doi.org/10.1371/journal.pone.0264434			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0D4YH	35239702	gold, Green Published, Green Accepted			2023-01-03	WOS:000776002200033
J	Tiruneh, GT; Demissie, M; Worku, A; Berhane, Y				Tiruneh, Gizachew Tadele; Demissie, Meaza; Worku, Alemayehu; Berhane, Yemane			Predictors of maternal and newborn health service utilization across the continuum of care in Ethiopia: A multilevel analysis	PLOS ONE			English	Article							POSTNATAL CARE; WAITING HOMES; COVERAGE; ACCESS; INTERVENTIONS	Background The continuum of care for maternal and newborn health is a systematic approach for delivery of an integrated effective package of life-saving interventions throughout pregnancy, childbirth, and postpartum as well as across levels of service delivery to women and newborns. Nonetheless, in low-income countries, coverage of these interventions across the life cycle continuum is low. This study examined the predictors of utilization of maternal and newborn health care services along the continuum of care in Ethiopia. Methods This was a cross-sectional population-based study. We measured maternal and newborn health care utilization practices among women who had live births in the last 12 months preceding the survey in Amhara, Oromia, SNNP, and Tigray regions of Ethiopia. We fitted multilevel random-effects logistic regression models to examine the predictors of the continuum of care accounting for the survey design, and individual, and contextual characteristics of the respondents. Results Our analysis revealed that only one-fifth of women utilized maternal and newborn health services across the antepartum, intrapartum, and postpartum continuum; most women discontinued at the postpartum stage. Continued use of services varied significantly across wealth, model family, prenatal stay at maternity waiting homes, antenatal care in the first trimester, complete antenatal care service, and the administrative region at all antepartum, intrapartum, and postpartum stages. Moreover, family conversation during pregnancy [AOR: 2.12; 95% CI: 1.56-2.88], delivery by cesarean [AOR: 2.70; 95% CI: 1.82-4.02] and birth notified to health extension workers [AOR: 1.95; 95% CI: 1.56-2.43] were found to be predictors of the continuum of care at the postpartum stage. Conclusion In Ethiopia, despite good access to antepartum care, compliance with continuity of care across the pathway decreased with significant inequitable distributions, the poorest segment of the population being at most disadvantage. The main modifiable program factors connected to the continued uptake of maternal health services include family conversation, pregnant women conference, complete antenatal care, antenatal care in the first trimester, and birth notification.	[Tiruneh, Gizachew Tadele] JSI Res & Training Inst Inc, Last Ten Kilometers L10K Project, Addis Ababa, Ethiopia; [Demissie, Meaza; Berhane, Yemane] Addis Continental Inst Publ Hlth, Addis Ababa, Ethiopia; [Worku, Alemayehu] Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, Ethiopia	Addis Continental Institute of Public Health; Addis Ababa University	Tiruneh, GT (corresponding author), JSI Res & Training Inst Inc, Last Ten Kilometers L10K Project, Addis Ababa, Ethiopia.	gizt121@gmail.com	Tiruneh, Gizachew Tadele/AAV-6638-2020	Tiruneh, Gizachew Tadele/0000-0002-5842-9518; Berhane, Yemane/0000-0002-2527-1339				Akinyemi JO, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1083-9; Alemayehu M, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03031-6; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Beake S, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-70; Berhe A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221161; Cameron A. C., 2010, MICROECONOMETRICS US; Central Statistical Agency-CSA/Ethiopia ICF, 2017, ETH DEM HLTH SURV 20; Chaka EE, 2019, ETHIOP J HEALTH SCI, V29, P935, DOI 10.4314/ejhs.v29i1.16; Chalise B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215613; Emiru AA, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02953-5; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; FMoH, 2015, NATL STRATEGY NEWBOR; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Iqbal S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2111-9; Jacobs B, 2012, HEALTH POLICY PLANN, V27, P288, DOI 10.1093/heapol/czr038; Karim AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065160; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kerber KJ, 2007, CONTINUUM CARE MATER; Kikuchi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198829; Kikuchi K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164965; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Lori JR, 2013, MIDWIFERY, V29, P1095, DOI 10.1016/j.midw.2013.07.020; Medhanyie A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-352; Mekonnen Y, 2012, IN DEPTH ANAL EDHS 2; MoH, 2018, IMPLEMENTATION GUIDE; MOH, 2013, HSDP 4 ANN PERFORMAN; MOH, 2015, ETHIOPIA HLTH SECTOR; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Muluneh AG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234741; Mwangi W, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1803-4; Oh J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036516; Owili PO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3075-0; Sakuma S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215635; Shibanuma A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000786; Singh K, 2016, MATERN CHILD HLTH J, V20, P281, DOI 10.1007/s10995-015-1827-6; Tesfaye S, 2014, J MIDWIFERY WOM HEAL, V59, pS55, DOI 10.1111/jmwh.12168; Tinker A, 2005, LANCET, V365, P822, DOI 10.1016/S0140-6736(05)71016-3; Tiruneh GT, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03254-7; Tiruneh GT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228137; Tiruneh GT, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2356-x; Tiruneh GT, 2016, ETHIOP J HEALTH DEV, V30, P19; Victora CG, 2005, LANCET, V366, P1460, DOI 10.1016/S0140-6736(05)67599-X; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; WHO, 2016, WHO TECH REP SER, V997, P1; WHO, 2014, WHO REC POSTN CAR MO; WHO, MATERNITY WAITING HO; WHO, 2015, TRENDS MATERNAL MORT; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	50	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0264612	10.1371/journal.pone.0264612	http://dx.doi.org/10.1371/journal.pone.0264612			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0U7EE	35213657	gold, Green Published			2023-01-03	WOS:000787811000129
J	Sheikh, S; Van Cleve, W; Kumar, V; Peerwani, G; Aijaz, S; Pathan, A				Sheikh, Sana; Van Cleve, Wil; Kumar, Vinod; Peerwani, Ghazal; Aijaz, Saba; Pathan, Asad			Cases of acute coronary syndrome and presumed cardiac death prior to arrival at an urban tertiary care hospital in Pakistan during the COVID-19 pandemic	PLOS ONE			English	Article								Background A reduction in overall acute coronary syndrome (ACS) cases, increases in the severity of ACS presentation, and increased rates of out-of-hospital cardiac arrest (OHCA) have been reported from multiple countries during the COVID-19 pandemic. The attributed factors include COVID-19 infection, fear of COVID-19 and resultant avoidance of health care facilities, and restrictions on mobility. Pakistan, a country with a high burden of cardiovascular disease (CVD) and challenges related to health care access, will be expected to demonstrate these same findings. Therefore, we compared ACS hospitalization, ACS severity, and patients who have already died (dead on arrival, or DOA) due to presumed OHCA at a tertiary cardiac hospital during pre-pandemic and intra-pandemic periods in Pakistan. Methods Standardized data elements were extracted from the charts of patients with ACS, and telephonic verbal autopsies (VA) using a validated tool were conducted for patients who were arrived DOA. As a comparison, cases during the same months prior to the COVID-19 were analyzed for respective waves. Events were counted, and proportions and frequencies are reported for each time period. Results A total of 4,480 ACS cases were reviewed; 1,216 cases during March-July 2019, 804 cases in the same months of 2020 (33.8% decrease); 1,304 cases in August 2019-January 2020 and 1,157 in the corresponding months of 2020 and 2021 (11.2% decrease). There was no observed change in the baseline characteristics of patients with ACS or their symptom-to-door time, and in-hospital mortality was unchanged across all time periods. There were 218 DOA cases in pre-pandemic months and 360 cases during the pandemic. The pre- pandemic rate of DOA was 12/1000 emergency patients (95% CI 10-13) compared to 22/1000 (95% CI 22-27) during the pandemic (30/1000in the 1st wave and 17/1000 during 2nd wave). On VA, CVD was found to be the major cause of death during both time periods. Conclusion At a cardiac hospital in Pakistan, the COVID-19 pandemic was associated with a reduction in ACS hospitalization and an increased DOA rate.	[Sheikh, Sana; Peerwani, Ghazal; Aijaz, Saba; Pathan, Asad] Tabba Heart Inst, Dept Clin Res Cardiol, Karachi, Pakistan; [Van Cleve, Wil] Univ Washington, Inst Hlth Metr & Evaluat, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Kumar, Vinod] Tabba Heart Inst, Dept Emergency, Karachi, Pakistan	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle	Sheikh, S (corresponding author), Tabba Heart Inst, Dept Clin Res Cardiol, Karachi, Pakistan.	sanasadiqsheikh@gmail.com						[Anonymous], 2020, VERBAL AUTOPSY TOOLS; [Anonymous], 2020, PAK COR CAS; Baldi Enrico, 2020, Eur Heart J, V41, P3045, DOI 10.1093/eurheartj/ehaa508; Baldi E, 2021, IJC HEART VASC, V35, DOI 10.1016/j.ijcha.2021.100824; Cano-Valderrama O, 2020, BRIT J SURG, V107, pE239, DOI 10.1002/bjs.11667; Chan DZL, 2020, LANCET REG HEALTH-W, V5, DOI 10.1016/j.lanwpc.2020.100056; Coetzee BJ, 2020, GLOB PUBLIC HEALTH, V15, P1093, DOI 10.1080/17441692.2020.1779331; Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011; Guimaraes RB, 2020, ARQ BRAS CARDIOL, V114, P1067, DOI 10.36660/abc.20200358; Hodzic Enisa, 2018, Mater Sociomed, V30, P10, DOI 10.5455/msm.2018.30.10-14; Khan MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0244936; Kocher KE., 2020, JAMA HLTH FORUM; Lai PH, 2020, JAMA CARDIOL, V5, P1154, DOI 10.1001/jamacardio.2020.2488; Lange SJ, 2020, MMWR-MORBID MORTAL W, V69, P795, DOI 10.15585/mmwr.mm6925e2; Marijon E, 2020, LANCET PUBLIC HEALTH, V5, pE437, DOI 10.1016/S2468-2667(20)30117-1; McVaney KE, 2021, ECLINICALMEDICINE, V34, DOI 10.1016/j.eclinm.2021.100815; Moroni Francesco, 2020, JACC Case Rep, V2, P1620, DOI 10.1016/j.jaccas.2020.04.010; Ostergaard L, 2021, AM HEART J, V232, P146, DOI 10.1016/j.ahj.2020.11.004; Papafaklis MI, 2020, CLIN CARDIOL, V43, P1142, DOI 10.1002/clc.23424; Pessoa-Amorim G, 2020, EUR HEART J-QUAL CAR, V6, P210, DOI 10.1093/ehjqcco/qcaa046; Qazi Muhammad Suleman, 2009, J Pak Med Assoc, V59, P10; Singh S, 2021, IJC HEART VASC, V32, DOI 10.1016/j.ijcha.2021.100718; Tan HL, 2020, EUR HEART J, V41, P3055, DOI 10.1093/eurheartj/ehaa599; Verhoeven JI, 2021, NETH HEART J, V29, P188, DOI 10.1007/s12471-021-01560-z	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2022	17	2							e0263607	10.1371/journal.pone.0263607	http://dx.doi.org/10.1371/journal.pone.0263607			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2V2QB	35113963	Green Published, gold			2023-01-03	WOS:000823694700109
J	Gershenson, DM; Miller, A; Brady, WE; Paul, J; Carty, K; Rodgers, W; Millan, D; Coleman, RL; Moore, KN; Banerjee, S; Connolly, K; Secord, AA; O'Malley, DM; Dorigo, O; Gaillard, S; Gabra, H; Slomovitz, B; Hanjani, P; Farley, J; Churchman, M; Ewing, A; Hollis, RL; Herrington, CS; Huang, HQ; Wenzel, L; Gourley, C				Gershenson, David M.; Miller, Austin; Brady, William E.; Paul, James; Carty, Karen; Rodgers, William; Millan, David; Coleman, Robert L.; Moore, Kathleen N.; Banerjee, Susana; Connolly, Kate; Secord, Angeles Alvarez; O'Malley, David M.; Dorigo, Oliver; Gaillard, Stephanie; Gabra, Hani; Slomovitz, Brian; Hanjani, Parviz; Farley, John; Churchman, Michael; Ewing, Ailith; Hollis, Robert L.; Herrington, C. Simon; Huang, Helen Q.; Wenzel, Lari; Gourley, Charlie			Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial	LANCET			English	Article							MEK INHIBITOR; CARCINOMA; WOMEN; THERAPY; RARE; SELUMETINIB; PERITONEUM; IMPACT; TUMORS	Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. Methods This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m(2) by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m(2) by body surface area once every 4 weeks; intravenous topotecan 4 mg/m(2) by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2.5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or =3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting. Findings Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13.0 months (95% CI 9.9-15.0) compared with 7.2 months (5.6-9.9) in the standard-of-care group (hazard ratio 0.48 [95% CI 0.36-0.64]; p<0.0001). The most frequent grade 3 or 4 adverse events in the trametinib group were skin rash (17 [13%] of 128), anaemia (16 [13%]), hypertension (15 [12%]), diarrhoea (13 [10%]), nausea (12 [9%]), and fatigue (ten [8%]). The most frequent grade 3 or 4 adverse events in the standard-ofcare group were abdominal pain (22 [17%]), nausea (14 [11%]), anaemia (12 [10%]), and vomiting (ten [8%]). There were no treatment-related deaths. Interpretation Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous carcinoma. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.	[Gershenson, David M.; Coleman, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Miller, Austin; Brady, William E.; Huang, Helen Q.] Roswell Pk Comprehens Canc Ctr, NRG Oncol Clin Trial Dev Div, Biostat & Bioinformat, Buffalo, NY USA; [Paul, James; Carty, Karen] Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland; [Rodgers, William] Cornell Univ, Weill Med Coll, Dept Pathol, New York Presbyterian Queens, Flushing, NY USA; [Millan, David] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Moore, Kathleen N.] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA; [Banerjee, Susana] Royal Marsden Hosp NHS Fdn Trust, Inst Canc Res, London, England; [Connolly, Kate] Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland; [Secord, Angeles Alvarez] Duke Canc Inst, Durham, NC USA; [O'Malley, David M.] Ohio State Univ, Columbus, OH 43210 USA; [O'Malley, David M.] James Canc Ctr, Columbus, OH 43210 USA; [Dorigo, Oliver] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [Gaillard, Stephanie] Johns Hopkins Sidney Kimmel Canc Ctr, Baltimore, MD USA; [Gabra, Hani] Imperial Coll London, Surg & Canc, London, England; [Slomovitz, Brian] Mt Sinai Med Ctr, Div Gynecol Oncol, Miami Beach, FL 33140 USA; [Hanjani, Parviz] Abington Mem Hosp, Abington, PA 19001 USA; [Farley, John] St Josephs Hosp, Phoenix, AZ USA; [Churchman, Michael; Hollis, Robert L.; Herrington, C. Simon; Gourley, Charlie] Nicola Murray Ctr Ovarian Canc Res, Inst Genet & Canc, Edinburgh, Midlothian, Scotland; [Ewing, Ailith] Univ Edinburgh, Western Gen Hosp, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland; [Ewing, Ailith] Univ Edinburgh, Western Gen Hosp, CRUK Edinburgh Ctr, MRC Inst Genet & Canc, Edinburgh, Midlothian, Scotland; [Wenzel, Lari] Univ Calif Irvine, Med & Publ Hlth, Irvine, CA USA	University of Texas System; UTMD Anderson Cancer Center; University of Glasgow; Cornell University; Queen Elizabeth University Hospital (QEUH); University of Oklahoma System; University of Oklahoma Health Sciences Center; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Edinburgh; Duke University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; Stanford Cancer Institute; Stanford University; Johns Hopkins University; Johns Hopkins Medicine; Imperial College London; Mount Sinai Medical Center; Abington Memorial Hospital; St. Joseph's Hospital and Medical Center; University of Edinburgh; University of Edinburgh; University of California System; University of California Irvine	Gershenson, DM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.	dgershen@mdanderson.org	Hollis, Robert/AAA-1188-2019; Herrington, C Simon/O-4688-2017	Hollis, Robert/0000-0002-1390-3298; Banerjee, Susana/0000-0002-8840-7934; Herrington, C Simon/0000-0001-9177-8165; Gabra, Hani/0000-0002-3322-4399	NRG Oncology; Cancer Research UK; Target Ovarian Cancer; Novartis	NRG Oncology; Cancer Research UK(Cancer Research UK); Target Ovarian Cancer; Novartis(Novartis)	NRG Oncology, Cancer Research UK, Target Ovarian Cancer, and Novartis.	Basen-Engquist K, 2001, J CLIN ONCOL, V19, P1809, DOI 10.1200/JCO.2001.19.6.1809; Bodurka DC, 2012, CANCER-AM CANCER SOC, V118, P3087, DOI 10.1002/cncr.26618; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheasley D, 2021, J PATHOL, V253, P41, DOI 10.1002/path.5545; Dalton HJ, 2017, GYNECOL ONCOL, V145, P37, DOI 10.1016/j.ygyno.2017.01.027; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Emmanuel C, 2014, CLIN CANCER RES, V20, P6618, DOI 10.1158/1078-0432.CCR-14-1292; Fader AN, 2017, GYNECOL ONCOL, V147, P85, DOI 10.1016/j.ygyno.2017.07.127; Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7; Fernandez ML, 2016, AM J CANCER RES, V6, P2235; Gershenson DM, 2006, OBSTET GYNECOL, V108, P361, DOI 10.1097/01.AOG.0000227787.24587.d1; Gershenson DM, 2017, J CLIN ONCOL, V35, P1103, DOI 10.1200/JCO.2016.71.0632; Gershenson DM, 2015, BRIT J CANCER, V113, P1254, DOI 10.1038/bjc.2015.364; Gershenson DM, 2015, J CLIN ONCOL, V33, P2675, DOI 10.1200/JCO.2015.61.0873; Gershenson DM, 2012, GYNECOL ONCOL, V125, P661, DOI 10.1016/j.ygyno.2012.02.037; Gershenson DM, 2009, GYNECOL ONCOL, V114, P48, DOI 10.1016/j.ygyno.2009.03.001; Gore M, 2019, GYNECOL ONCOL, V153, P541, DOI 10.1016/j.ygyno.2019.03.256; Grabowski JP, 2016, GYNECOL ONCOL, V140, P457, DOI 10.1016/j.ygyno.2016.01.022; Hew KE, 2016, CLIN CANCER RES, V22, P935, DOI 10.1158/1078-0432.CCR-15-0534; Hollis RL, 2016, CANCER BIOL MED, V13, P236, DOI 10.20892/j.issn.2095-3941.2016.0024; Hou JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054103; Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; Monk BJ, 2020, J CLIN ONCOL, V38, P3753, DOI 10.1200/JCO.20.01164; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Prat J, 2018, HUM PATHOL, V80, P11, DOI 10.1016/j.humpath.2018.06.018; Tang M, 2019, GYNECOL ONCOL, V154, P531, DOI 10.1016/j.ygyno.2019.06.011; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wong KK, 2010, AM J PATHOL, V177, P1611, DOI 10.2353/ajpath.2010.100212; Young RH, 2014, WHO CLASS TUM SER, V6	31	15	15	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10324					541	553						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E0SF	35123694	Green Accepted, Green Published			2023-01-03	WOS:000811944600001
J	Gonzalez, R; Pena, MA; Torres, NS; Torrado, G				Gonzalez, Rocio; Angeles Pena, Ma; Sofia Torres, Norma; Torrado, Guillermo			Design, development, and characterization of amorphous rosuvastatin calcium tablets	PLOS ONE			English	Article							DRUG-EXCIPIENT COMPATIBILITY; SEDEM DIAGRAM; IN-VITRO	This work proposes a methodology for the design, development, optimisation, and evaluation of amorphous rosuvastatin calcium tablets (BCS class II drug). The main goal was to ensure rapid disintegration and high dissolution rate of the active ingredient, thus enhancing its bioavailability. The design started from a careful selection of excipients, which due to their characteristics and proportions within the formulation allowed the use of their properties such as fluidity or granulometric distribution. The formulation was characterised using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR) and powder X-ray diffraction (PXRD) methods. The galenic SeDeM methodology was used to establish the profile of the active ingredient-excipient mixture and guarantee its suitability for producing tablets by the direct compression method. The results demonstrate that the amorphous rosuvastatin calcium tablets formulation developed made it possible to obtain cost-effective tablets by direct compression with optimal pharmacotechnical characteristics that showed a remarkable disintegration and dissolution rate. The manufactured tablets complied with the pharmacopoeia guidelines regarding content uniformity, tablet hardness, thickness, friability, in vitro disintegration time and dissolution profile.	[Gonzalez, Rocio; Angeles Pena, Ma; Sofia Torres, Norma; Torrado, Guillermo] Univ Alcala, Fac Pharm, Dept Biomed Sci, Madrid, Spain	Universidad de Alcala	Pena, MA (corresponding author), Univ Alcala, Fac Pharm, Dept Biomed Sci, Madrid, Spain.	angeles.pena@uah.es		Gonzalez Crespo, Rocio/0000-0003-3191-5900				Angelo ML, 2019, BRAZ J PHARM SCI, V55, DOI 10.1590/s2175-97902019000117520; [Anonymous], 2011, EUROPEAN PHARMACOPOE, V7; [Anonymous], 2011, EUROPEAN PHARMACOPOE, VSeventh; [Anonymous], 2015, REAL FARMACOPEA ESPA; [Anonymous], 2011, REAL FARMACOPEA ESPA; [Anonymous], 2010, REAL FARMACOPEA ESPA; [Anonymous], 2005, EUROPEAN PHARMACOPOE; [Anonymous], 2008, REAL FARMACOPEA ESPA; Arida AI., 2008, JORDAN J PHARM SCI, V1, P111; Belozerova NM, 2020, RSC ADV, V10, P33585, DOI 10.1039/d0ra06108e; Blatte F, 2011, CRYSTALLINE FORM ROS; BOLHUIS GK, 1995, DRUG DEV IND PHARM, V21, P2057, DOI 10.3109/03639049509065890; Brites FD., 2012, FISIOPATOLOGIA DIAGN; Buhler V., 2005, POLYVINYLPYRROLIDONE; Casar Z, 2008, PROCESS PREPARING AM; Chadha R, 2014, J PHARMACEUT BIOMED, V87, P82, DOI 10.1016/j.jpba.2013.06.016; Chaves LL, 2013, J THERM ANAL CALORIM, V111, P2179, DOI 10.1007/s10973-012-2775-7; Clavijo J., 2013, ELEMENTOS, V3, P133, DOI [10.15765/e.v3i3.420, DOI 10.15765/E.V3I3.420]; Creekmore JR, 2002, European Pa-tent Office. Patent, Patent No. [EP1223918, 1223918]; Aguilar-Diaz JE, 2014, DRUG DEV IND PHARM, V40, P222, DOI 10.3109/03639045.2012.756007; Gibson M, 2009, PHARM PREFORMULATION, V2nd; Hirpara MR, 2018, INT J BIOL MACROMOL, V107, P2190, DOI 10.1016/j.ijbiomac.2017.10.086; Karazniewicz-Lada Marta, 2018, Polim Med, V48, P77, DOI 10.17219/pim/102978; Kishore CRP, 2017, ANAL CHEM RES, V12, P17, DOI [10.1016/j.ancr.2016.11.002, DOI 10.1016/J.ANCR.2016.11.002]; Kiss D, 2006, J THERM ANAL CALORIM, V84, P447, DOI 10.1007/s10943-005-7257-9; Koh PT, 2013, INDIAN J PHARM SCI, V75, P291, DOI 10.4103/0250-474X.117434; Kumar B, 2019, CUREUS, V11, DOI 10.7759/cureus.4898; Lahsen R., 2014, REV M DICA 150 NICA, V25, P47; LANDIN M, 1994, EUR J PHARM SCI, V2, P245, DOI 10.1016/0928-0987(94)90029-9; Lee AY, 2011, ANNU REV CHEM BIOMOL, V2, P259, DOI 10.1146/annurev-chembioeng-061010-114224; Lee BJ., 2008, PHARM MANUFACTURING; Lima G., 2012, REV 101 NCIAS FARMAC, V33, P27; Narang AS, 2017, DEVELOPING SOLID ORAL DOSAGE FORMS: PHARMACEUTICAL THEORY AND PRACTICE, 2ND EDITION, P151, DOI 10.1016/B978-0-12-802447-8.00006-6; Pharma J., 2020, PAGINA WEB JRS PHARM; Potur RG, 2014, STABLE PHARM COMPOSI; Rios M., 2008, PHARM TECHNOL, V2, P36; Rohini P., 2014, INT J PHARM SCI REV, V24, P209; Rowe R., 2010, HDB PHARM EXCIPIENTS; Rowe R., 2006, HDB PHARM EXCIPIENTS; Sachin TV., 2014, INT J PHARM TECHNOLO, V6, P6388; Schwartz JB., 2002, PHARM PROCESS SCALE; Shekhawat PB, 2017, ACTA PHARM SIN B, V7, P260, DOI 10.1016/j.apsb.2016.09.005; Singh J., 2014, J DRUG DELIVERY THER, V4, P173, DOI [10.22270/jddt.v4i5.947, DOI 10.22270/JDDT.V4I5.947]; Sune JM., 2005, CIENCIA TECNOLOGIA P, V3, P125; Negre JMS, 2013, WOODH PUB SER BIOMED, P109, DOI 10.1533/9781908818508.109; Sune-Negre JM, 2008, EUR J PHARM BIOPHARM, V69, P1029, DOI 10.1016/j.ejpb.2008.01.020; Tannebaum EJ., 2005, GOOD DESIGN PRACTICE, V2nd ed; Vindas C, 2013, REV M D COSTA RICA C, V70, P529; Zhou CY, 2013, CARBOHYD POLYM, V96, P156, DOI 10.1016/j.carbpol.2013.03.094	49	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265263	10.1371/journal.pone.0265263	http://dx.doi.org/10.1371/journal.pone.0265263			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1R8XY	35312730	Green Published, gold			2023-01-03	WOS:000803647900041
J	Knight, A; Huang, E; Rai, N; Brown, H				Knight, Andrew; Huang, Eason; Rai, Nicholas; Brown, Hazel			Vegan versus meat-based dog food: Guardian-reported indicators of health	PLOS ONE			English	Article							RAW-MEAT; COMPANION ANIMALS; INSURED DOGS; PET FOODS; DIETS; CATS; SALMONELLA; VEGETARIAN; PROTEIN; GENDER	Alternative pet foods may offer benefits concerning environmental sustainability and the welfare of animals processed into pet foods. However, some worry these may compromise the welfare of pets. We asked 2,639 dog guardians about one dog living with them, for at least one year. Among 2,596 involved in pet diet decision-making, pet health was a key factor when choosing diets. 2,536 provided information relating to a single dog, fed a conventional meat (1,370 = 54%), raw meat (830 = 33%) or vegan (336 = 13%) diet for at least one year. We examined seven general indicators of ill health: unusual numbers of veterinary visits, medication use, progression onto a therapeutic diet after initial maintenance on a vegan or meat-based diet, guardian opinion and predicted veterinary opinion of health status, percentage of unwell dogs and number of health disorders per unwell dog. Dogs fed conventional diets appeared to fare worse than those fed either of the other two diets. Dogs fed raw meat appeared to fare marginally better than those fed vegan diets. However, there were statistically significant differences in average ages. Dogs fed raw meat were younger, which has been demonstrated to be associated with improved health outcomes. Additionally, non-health related factors may have improved apparent outcomes for dogs fed raw meat, for three of seven general health indicators. We also considered the prevalence of 22 specific health disorders, based on predicted veterinary assessments. Percentages of dogs in each dietary group considered to have suffered from health disorders were 49% (conventional meat), 43% (raw meat) and 36% (vegan). Significant evidence indicates that raw meat diets are often associated with dietary hazards, including nutritional deficiencies and imbalances, and pathogens. Accordingly, the pooled evidence to date indicates that the healthiest and least hazardous dietary choices for dogs, are nutritionally sound vegan diets.	[Knight, Andrew; Brown, Hazel] Univ Winchester, Fac Hlth & Wellbeing, Ctr Anim Welf, Winchester, Hants, England; [Knight, Andrew] Griffith Univ, Sch Environm & Sci, Nathan Campus, Nathan, Qld, Australia; [Rai, Nicholas] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia	University of Winchester; Griffith University; Griffith University	Knight, A (corresponding author), Univ Winchester, Fac Hlth & Wellbeing, Ctr Anim Welf, Winchester, Hants, England.; Knight, A (corresponding author), Griffith Univ, Sch Environm & Sci, Nathan Campus, Nathan, Qld, Australia.	andrew.knight@winchester.ac.kr	Knight, Andrew/AAA-3707-2020	Knight, Andrew/0000-0002-9753-6199; Brown, Hazel/0000-0002-3327-3510	food awareness organisation ProVeg International;  [Oct20190000000286]	food awareness organisation ProVeg International; 	This research and its publication open access was funded by food awareness organisation ProVeg International (https://proveg.com).AK received this award ID: Oct20190000000286. However, this funder played no role in study conceptualisation, design, data collection and analysis, preparation of the resultant manuscript nor decisions relating to publication. We are grateful for their financial support.	Alexander P, 2020, GLOBAL ENVIRON CHANG, V65, DOI 10.1016/j.gloenvcha.2020.102153; American Pet Products Association (APPA), 2021, PET IND MARK SIZ TRE; [Anonymous], 2019, ABOUT ONLINE SURVEYS; Brown WY, 2009, BRIT J NUTR, V102, P1318, DOI 10.1017/S0007114509389254; Cohen J., 2013, STAT POWER ANAL BEHA; Davies RH, 2019, J SMALL ANIM PRACT, V60, P329, DOI 10.1111/jsap.13000; Day M J, 2016, J Small Anim Pract, V57, P4, DOI 10.1111/jsap.12431; Deng P, 2015, J ANIM SCI, V93, P823, DOI 10.2527/jas.2014-8520; Dodd SAS, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11082348; Dodd SAS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210806; Egenvall A, 2000, VET REC, V146, P519, DOI 10.1136/vr.146.18.519; Egenvall A, 2000, VET REC, V146, P551, DOI 10.1136/vr.146.19.551; Euromonitor, 2019, WINN PETCARE; Euromonitor International, 2015, MARK SIZ; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Finley R, 2007, CAN VET J, V48, P69; Freeman LM, 2006, JAVMA-J AM VET MED A, V229, P531, DOI 10.2460/javma.229.4.531; Freeman LM, 2013, JAVMA-J AM VET MED A, V243, P1549, DOI 10.2460/javma.243.11.1549; Freeman LM, 2001, J AM VET MED ASSOC, V218, P705, DOI 10.2460/javma.2001.218.705; Giacometti F, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1143-z; Gough A., 2018, BREED PREDISPOSITION; Hedhammar AA, 2011, VET J, V189, P189, DOI 10.1016/j.tvjl.2011.06.018; Hill RC, 2009, JAVMA-J AM VET MED A, V234, P347, DOI 10.2460/javma.234.3.347; Institute for Government analysis, 2021, TIM UK COR LOCKD; Kanakubo K, 2015, JAVMA-J AM VET MED A, V247, P385, DOI 10.2460/javma.247.4.385; Knight A., 2021, REDVET, V22, P1; Knight A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253292; Knight A, 2016, ANIMALS, V6, DOI 10.3390/ani6090057; Leahy E., 2010, 340 ESRI; Lenox Catherine, 2015, JFMS Open Rep, V1, p2055116915579682, DOI 10.1177/2055116915579682; Loeb J, 2020, VET REC, V186, P197, DOI 10.1136/vr.m663; Marks SL, 2011, J VET INTERN MED, V25, P1195, DOI 10.1111/j.1939-1676.2011.00821.x; Martens P, 2019, BIOSCIENCE, V69, P467, DOI 10.1093/biosci/biz044; McKenzie B., 2019, VET PRACTICE NE 0624; Mintel GNPD, 2014, GLOB NEW PROD DAT; Mintel Group, 2019, PET FOOD UK SEPT 201; Morgan SK, 2017, PEERJ, V5, DOI 10.7717/peerj.3031; Morris James G., 1994, Journal of Nutrition, V124, p2520S, DOI 10.1093/jn/124.suppl_12.2520S; O'Neill DG, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02775-3; O'Neill DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090501; Okin GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181301; Reis J. S. dos, 2017, Brazilian Journal of Veterinary Research and Animal Science, V54, P306, DOI 10.11606/issn.1678-4456.bjvras.2017.129264; Robinson NJ, 2016, PREV VET MED, V124, P69, DOI 10.1016/j.prevetmed.2015.12.010; Roshier AL, 2013, VET REC, V172, DOI 10.1136/vr.101125; Sanchez-Vizcaino F, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1138-9; Scallan S., 2019, RKE ETHICS POLICY PR; Schleicher M, 2019, CAN VET J, V60, P644; Schlesinger DP, 2011, CAN VET J, V52, P50; Semp P.-G., 2014, THESIS VET U VIENNA; Stiver SL, 2003, J AM ANIM HOSP ASSOC, V39, P538, DOI 10.5326/0390538; The Insight Partners, 2021, VEG PET FOOD MARK GR; Tilley LP, 2015, BLACKWELLS 5 MINUTE; Tobie C, 2015, ANIMALS, V5, P126, DOI 10.3390/ani5010126; Vacha-Haase T, 2004, J COUNS PSYCHOL, V51, P473, DOI 10.1037/0022-0167.51.4.473; Wang T., 2019, QUANTITATIVE TRANSLA, V1, P829192, DOI [10.1101/829192, DOI 10.1101/829192]; Xu XM, 2021, NAT FOOD, V2, P724, DOI 10.1038/s43016-021-00358-x; YAMADA T, 1987, J NUTR SCI VITAMINOL, V33, P129, DOI 10.3177/jnsv.33.129; Zicker SC, 2008, TOP COMPANION ANIM M, V23, P121, DOI 10.1053/j.tcam.2008.04.003	58	1	1	10	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0265662	10.1371/journal.pone.0265662	http://dx.doi.org/10.1371/journal.pone.0265662			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1A8IV	35417464	Green Published, gold			2023-01-03	WOS:000791994200007
J	Koh, J; Takahashi, M; Ohmae, Y; Taruya, J; Sakata, M; Yasui, M; Terada, M; Ito, H				Koh, Jinsoo; Takahashi, Maiko; Ohmae, Yasuhiko; Taruya, Junko; Sakata, Mayumi; Yasui, Masaaki; Terada, Masaki; Ito, Hidefumi			A single-arm open-label pilot study of brief mindfulness meditation to control impulsivity in Parkinson's disease	PLOS ONE			English	Article							DEFAULT MODE NETWORK; CONTROL DISORDERS; FUNCTIONAL CONNECTIVITY; CONTROL BEHAVIORS; JAPANESE VERSION; DOPAMINE; SCALE; INTERVENTIONS; QUESTIONNAIRE; THERAPY	BackgroundImpulse control disorders are detrimental neuropsychiatric symptoms of Parkinson's disease. Increased impulsivity is a predisposing factor for impulse control disorders and should therefore be controlled. Recently, mindfulness meditation as a non-drug therapy has been reported to be useful in improving neuropsychiatric symptoms, such as impulsivity. MethodsWe performed a prospective single-arm, open-label pilot trial to investigate the effectiveness of mindfulness meditation to control impulsivity in patients with Parkinson's disease (UMIN clinical trials registry: UMIN000037779). ResultsTwenty patients with Parkinson's disease were enrolled in an 8-week mindfulness meditation program. As a primary outcome, we investigated whether the score of the Barratt Impulsiveness Scale (BIS-11) was significantly reduced after the intervention. As an exploratory examination, functional connectivity changes were also assessed by resting-state functional magnetic resonance imaging. After the intervention, the BIS-11 score was decreased from 59.5 [55.6, 63.3] (mean [95% confidence interval]) to 55.2 [50.3, 60.1] (Delta BIS-11: -4.2, [-7.5, -0.9]). Functional connectivity was increased in the default mode network (DMN) at a cluster including the precuneus, posterior cingulate gyrus, and left posterior lobe (false discovery rate-adjusted p [FDR-p] = 0.046) and in the right frontoparietal network (FPN) at the medial frontal lobe (FDR-p = 0.039). ConclusionsThis open-label, single-arm pilot study provided preliminary data for mindfulness meditation to control the impulsivity of patients with PD. A brief mindfulness meditation program may be effective in controlling impulsivity in PD and may change the functional connectivity of the DMN and right FPN.	[Koh, Jinsoo; Takahashi, Maiko; Ohmae, Yasuhiko; Taruya, Junko; Sakata, Mayumi; Yasui, Masaaki; Ito, Hidefumi] Wakayama Med Univ, Dept Neurol, Wakayama, Wakayama, Japan; [Terada, Masaki] Wakayama Minami Radiol Clin, Wakayama, Wakayama, Japan	Wakayama Medical University	Koh, J (corresponding author), Wakayama Med Univ, Dept Neurol, Wakayama, Wakayama, Japan.	jinsoo@wakayama-med.ac.jp		Koh, Jinsoo/0000-0002-9502-1554	Takeda Japan Medical Office Funded Research Grant [2018 [N95]]; Japan Society for the Promotion of Science [18H02743]	Takeda Japan Medical Office Funded Research Grant; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	J.K., Takeda Japan Medical Office Funded Research Grant 2018 [N95]. (https://www.takeda. com/jp/what-we-do/research-and-development/ jmo-frg/) H.I., grant-in-aid for scientific research from the Japan Society for the Promotion of Science [18H02743]. (https://www.jsps.go.jp/ english/e-grants/).	Antonelli F, 2011, J NEUROL SCI, V310, P202, DOI 10.1016/j.jns.2011.06.006; Avila A, 2011, J NEUROL SCI, V310, P197, DOI 10.1016/j.jns.2011.05.044; Bilevicius E, 2018, BRAIN CONNECT, V8, P40, DOI 10.1089/brain.2017.0520; Brewer JA, 2011, P NATL ACAD SCI USA, V108, P20254, DOI 10.1073/pnas.1112029108; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Carriere N, 2015, NEUROLOGY, V84, P2116, DOI 10.1212/WNL.0000000000001619; Cilia R, 2011, MOVEMENT DISORD, V26, P225, DOI 10.1002/mds.23480; Corvol JC, 2018, NEUROLOGY, V91, pE189, DOI 10.1212/WNL.0000000000005816; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Dixon MR, 2019, J CONTEXT BEHAV SCI, V11, P15, DOI 10.1016/j.jcbs.2018.11.003; Dorsey ER, 2018, JAMA NEUROL, V75, P9, DOI 10.1001/jamaneurol.2017.3299; Franco C, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01385; Gilmartin H, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.05.041; Giovannoni G, 2000, J NEUROL NEUROSUR PS, V68, P423, DOI 10.1136/jnnp.68.4.423; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Hlavata P, 2020, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01338; Isaias IU, 2008, MOVEMENT DISORD, V23, P411, DOI 10.1002/mds.21872; Jenkinson C, 2007, PARKINSONISM RELAT D, V13, P22, DOI 10.1016/j.parkreldis.2006.06.006; Jung MH, 2014, NEUROSCI LETT, V583, P120, DOI 10.1016/j.neulet.2014.09.025; Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016; Kashihara K, 2014, MOV DISORD CLIN PRAC, V1, P200, DOI 10.1002/mdc3.12058; Kelly MJ, 2020, J NEUROL NEUROSUR PS, V91, P703, DOI 10.1136/jnnp-2019-322453; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Koh J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68266-x; Kurlan R, 2004, MOVEMENT DISORD, V19, P433, DOI 10.1002/mds.10625; Kwok JYY, 2019, JAMA NEUROL, V76, P755, DOI 10.1001/jamaneurol.2019.0534; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Marek S, 2018, DIALOGUES CLIN NEURO, V20, P133; Marin-Lahoz J, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00465; Matsumoto Naomi, 2006, Brain and Nerve (Tokyo), V58, P785; Newberg AB, 2003, MED HYPOTHESES, V61, P282, DOI 10.1016/S0306-9877(03)00175-0; Nombela C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085747; Okai D, 2013, NEUROLOGY, V80, P792, DOI 10.1212/WNL.0b013e3182840678; Papay K, 2014, NEUROLOGY, V83, P826, DOI 10.1212/WNL.0000000000000729; Payer DE, 2015, MOVEMENT DISORD, V30, P160, DOI 10.1002/mds.26135; Pickut BA, 2013, CLIN NEUROL NEUROSUR, V115, P2419, DOI 10.1016/j.clineuro.2013.10.002; Piet J, 2011, CLIN PSYCHOL REV, V31, P1032, DOI 10.1016/j.cpr.2011.05.002; Prange S, 2019, NEUROLOGY, V92, pE148, DOI 10.1212/WNL.0000000000006737; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Riley M, 2018, PARKINSONS DIS-US, V2018, DOI 10.1155/2018/9472120; Ruitenberg MFL, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00279; Someya T, 2001, PSYCHIAT CLIN NEUROS, V55, P111, DOI 10.1046/j.1440-1819.2001.00796.x; Sperduti M, 2012, CONSCIOUS COGN, V21, P269, DOI 10.1016/j.concog.2011.09.019; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; Tahmasian M, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00317; Takahashi M., 2022, PARKINSONS DIS-US; Taren AA, 2017, PSYCHOSOM MED, V79, P674, DOI 10.1097/PSY.0000000000000466; Tessitore A, 2017, CORTEX, V94, P63, DOI 10.1016/j.cortex.2017.06.008; Thomas A, 2010, ANN NEUROL, V68, P400, DOI 10.1002/ana.22029; Voon V, 2006, NEUROLOGY, V67, P1254, DOI 10.1212/01.wnl.0000238503.20816.13; Weintraub D, 2012, MOVEMENT DISORD, V27, P242, DOI 10.1002/mds.24023; Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65; Weintraub D, 2008, ANN NEUROL, V64, pS93, DOI 10.1002/ana.21454; Wilson AD, 2017, PSYCHOL ADDICT BEHAV, V31, P888, DOI 10.1037/adb0000319; Xue JM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015957; Zhang R, 2019, NEUROIMAGE, V200, P313, DOI 10.1016/j.neuroimage.2019.06.036; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zilverstand A, 2018, NEURON, V98, P886, DOI 10.1016/j.neuron.2018.03.048	59	0	0	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266354	10.1371/journal.pone.0266354	http://dx.doi.org/10.1371/journal.pone.0266354			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6KL	35385563	Green Published, gold			2023-01-03	WOS:000804836900073
J	Strnad, P; Mandorfer, M; Choudhury, G; Griffiths, W; Trautwein, C; Loomba, R; Schluep, T; Chang, T; Yi, M; Given, BD; Hamilton, JC; Martin, JS; Teckman, JH				Strnad, Pavel; Mandorfer, Mattias; Choudhury, Gourab; Griffiths, William; Trautwein, Christian; Loomba, Rohit; Schluep, Thomas; Chang, Ting; Yi, Min; Given, Bruce D.; Hamilton, James C.; Martin, Javier San; Teckman, Jeffery H.			Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; ENDOPLASMIC-RETICULUM; HEPATITIS-B; DEGRADATION; CIRRHOSIS; ADULTS; PROTEIN	BACKGROUND Alpha(1)-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 "Z " mutation (proteinase inhibitor [PI] ZZ). The Z allele produces a mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive liver disease and fibrosis. This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency. METHODS We assigned adults with the PI ZZ genotype and liver fibrosis to receive fazirsiran at a dose of 200 mg (cohorts 1 [4 patients] and 2 [8 patients]) or 100 mg (cohort 1b [4 patients]) subcutaneously on day 1 and week 4 and then every 12 weeks. The primary end point was the change from baseline to week 24 (cohorts 1 and 1b) or week 48 (cohort 2) in liver Z-AAT concentrations, which were measured by means of liquid chromatography-mass spectrometry. RESULTS All the patients had reduced accumulation of Z-AAT in the liver (median reduction, 83% at week 24 or 48). The nadir in serum was a reduction of approximately 90%, and treatment was also associated with a reduction in histologic globule burden (from a mean score of 7.4 [scores range from 0 to 9, with higher scores indicating a greater globule burden] at baseline to 2.3 at week 24 or 48). All cohorts had reductions in liver enzyme concentrations. Fibrosis regression was observed in 7 of 15 patients and fibrosis progression in 2 of 15 patients after 24 or 48 weeks. There were no adverse events leading to trial or drug discontinuation. Four serious adverse events (viral myocarditis, diverticulitis, dyspnea, and vestibular neuronitis) resolved. CONCLUSION In this small trial, fazirsiran was associated with a strong reduction of Z-AAT concentrations in the serum and liver and concurrent improvements in liver enzyme concentrations.	[Strnad, Pavel; Trautwein, Christian] RWTH Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med 3, Hlth Care Provider European Reference Network Rare, Aachen, Germany; [Mandorfer, Mattias] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria; [Choudhury, Gourab] Univ Edinburgh, Royal Infirm Edinburgh Univ Hosp, Dept Resp Med, Edinburgh, Scotland; [Griffiths, William] Cambridge Univ Hosp NHS Fdn Trust, Adden brookes Hosp, Dept Hepatol, Cambridge, England; [Loomba, Rohit] Univ Calif San Diego, Sch Med, Div Gastroenterol, La Jolla, CA USA; [Schluep, Thomas; Chang, Ting; Yi, Min; Given, Bruce D.; Hamilton, James C.; Martin, Javier San] Arrowhead Pharmaceut, Pasadena, CA USA; [Teckman, Jeffery H.] St Louis Univ, Sch Med, Dept Pediat, St Louis, MO USA; [Teckman, Jeffery H.] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO USA; [Strnad, Pavel] RWTH Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med 3, Pauwelsstr 30, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Medical University of Vienna; University of Edinburgh; University of Cambridge; University of California System; University of California San Diego; Saint Louis University; Saint Louis University; RWTH Aachen University; RWTH Aachen University Hospital	Strnad, P (corresponding author), RWTH Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med 3, Pauwelsstr 30, D-52074 Aachen, Germany.	pstrnad@ukaachen.de		Schluep, Thomas/0000-0002-2986-7287	Arrowhead Pharmaceuticals; German Research Foundation (DFG) [STR1095/6-1, CRC/SFB 1382, 403224013]	Arrowhead Pharmaceuticals; German Research Foundation (DFG)(German Research Foundation (DFG))	Supported by Arrowhead Pharmaceuticals. Dr. Strnad is supported by the German Research Foundation (DFG) (grant STR1095/6-1) and by the DFG consortium CRC/SFB 1382 Gutliver axis (ID 403224013).	Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818; Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Clark VC, 2018, J HEPATOL, V69, P1357, DOI 10.1016/j.jhep.2018.08.005; Elzouki AN, 1996, EUR J GASTROEN HEPAT, V8, P989, DOI 10.1097/00042737-199610000-00010; ERIKSSON S, 1987, ACTA MED SCAND, V221, P461; Fromme M, 2022, J HEPATOL, V76, P946, DOI 10.1016/j.jhep.2021.11.022; Gardin A, 2022, J HEPATOL, V76, P1392, DOI 10.1016/j.jhep.2021.12.015; Greene CM, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.51; Hamesch K, 2019, GASTROENTEROLOGY, V157, P705, DOI 10.1053/j.gastro.2019.05.013; Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1; Patel D, 2018, CLIN LIVER DIS, V22, P643, DOI 10.1016/j.cld.2018.06.010; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Powell EE, 2021, LANCET, V397, P2212, DOI 10.1016/S0140-6736(20)32511-3; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Sandhaus RA, 2016, CHRON OBSTR PULM DIS, V3, P668, DOI 10.15326/jcopdf.3.3.2015.0182; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; Strnad P, 2020, NEW ENGL J MED, V382, P1443, DOI 10.1056/NEJMra1910234; Tanash HA, 2019, J GASTROENTEROL, V54, P541, DOI 10.1007/s00535-019-01548-y; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; Townsend SA, 2018, ALIMENT PHARM THER, V47, P877, DOI 10.1111/apt.14537; Vreim CE, 1998, AM J RESP CRIT CARE, V158, P49; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wooddell CI, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135348	24	3	3	2	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2022	387	6					514	524		10.1056/NEJMoa2205416	http://dx.doi.org/10.1056/NEJMoa2205416		JUN 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D7TY	35748699				2023-01-03	WOS:000816444300001
J	[Anonymous]				[Anonymous]			Summary for Patients: Pain, Analgesic Use, and Patient Satisfaction With Spinal Versus General Anesthesia for Hip Fracture Surgery	ANNALS OF INTERNAL MEDICINE			English	Editorial Material; Early Access																			0	0	0	5	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.												10.7326/P22-0012	http://dx.doi.org/10.7326/P22-0012		JUN 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2G1UF	35696692				2023-01-03	WOS:000813382700001
J	Ding, SL; Hsu, C; Wang, ZH; Natesh, NR; Millen, R; Negrete, M; Giroux, N; Rivera, GO; Dohlman, A; Bose, S; Rotstein, T; Spiller, K; Yeung, A; Sun, ZG; Jiang, CM; Xi, R; Wilkin, B; Randon, PM; Williamson, I; Nelson, DA; Delubac, D; Oh, S; Rupprecht, G; Isaacs, J; Jia, JQ; Chen, C; Shen, JP; Kopetz, S; McCall, S; Smith, A; Gjorevski, N; Walz, AC; Antonia, S; Marrer-Berger, E; Clevers, H; Hsu, D; Shen, XL				Ding, Shengli; Hsu, Carolyn; Wang, Zhaohui; Natesh, Naveen R.; Millen, Rosemary; Negrete, Marcos; Giroux, Nicholas; Rivera, Grecia O.; Dohlman, Anders; Bose, Shree; Rotstein, Tomer; Spiller, Kassandra; Yeung, Athena; Sun, Zhiguo; Jiang, Chongming; Xi, Rui; Wilkin, Benjamin; Randon, Peggy M.; Williamson, Ian; Nelson, Daniel A.; Delubac, Daniel; Oh, Sehwa; Rupprecht, Gabrielle; Isaacs, James; Jia, Jingquan; Chen, Chao; Shen, John Paul; Kopetz, Scott; McCall, Shannon; Smith, Amber; Gjorevski, Nikolche; Walz, Antje-Christine; Antonia, Scott; Marrer-Berger, Estelle; Clevers, Hans; Hsu, David; Shen, Xiling			Patient-derived micro-organospheres enable clinical precision oncology	CELL STEM CELL			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; CANCER; ORGANOIDS; BIOBANK; MODELS; PLATFORM; CELLS	Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14 days, a timeline suitable for guiding treatment decisions in the clinic. Furthermore, MOSs capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.	[Ding, Shengli; Wang, Zhaohui; Natesh, Naveen R.; Negrete, Marcos; Giroux, Nicholas; Rivera, Grecia O.; Dohlman, Anders; Bose, Shree; Rotstein, Tomer; Yeung, Athena; Sun, Zhiguo; Xi, Rui; Williamson, Ian; Shen, Xiling] Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Durham, NC 27708 USA; [Hsu, Carolyn] Univ Chapel Hill, Coll Arts & Sci, Chapel Hill, NC 27599 USA; [Clevers, Hans] Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands; [Millen, Rosemary; Clevers, Hans] Univ Med Ctr UMC Utrecht, Royal Netherlands Acad Arts & Sci KNAW, Hubrecht Inst, Oncode, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands; [Wang, Zhaohui; Spiller, Kassandra; Wilkin, Benjamin; Nelson, Daniel A.; Delubac, Daniel; Smith, Amber] Xilis Inc, Durham, NC 27713 USA; [Jiang, Chongming; Chen, Chao] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Randon, Peggy M.] Natl Inst Environm Hlth Sci NIEHS, Durham, NC 27709 USA; [Oh, Sehwa; Rupprecht, Gabrielle; Isaacs, James; Jia, Jingquan; Antonia, Scott; Hsu, David] Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA; [Shen, John Paul; Kopetz, Scott] MD Anderson, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [McCall, Shannon] Duke Univ, Dept Pathol, Durham, NC 27708 USA; [Gjorevski, Nikolche; Walz, Antje-Christine; Marrer-Berger, Estelle; Clevers, Hans] Roche Innovat Ctr, Roche Pharmaceut Res & Early Dev, CH-4058 Basel, Switzerland; [Shen, Xiling] Terasaki Inst Biomed Innovat, Los Angeles, CA 90024 USA	Duke University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Baylor College of Medicine; Duke University; University of Texas System; UTMD Anderson Cancer Center; Duke University; Roche Holding	Shen, XL (corresponding author), Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Durham, NC 27708 USA.; Clevers, H (corresponding author), Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands.; Clevers, H (corresponding author), Univ Med Ctr UMC Utrecht, Royal Netherlands Acad Arts & Sci KNAW, Hubrecht Inst, Oncode, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.; Hsu, D (corresponding author), Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA.; Clevers, H (corresponding author), Roche Innovat Ctr, Roche Pharmaceut Res & Early Dev, CH-4058 Basel, Switzerland.; Shen, XL (corresponding author), Terasaki Inst Biomed Innovat, Los Angeles, CA 90024 USA.	h.clevers@hubrecht.eu; shiaowen.hsu@duke.edu; xiling.shen@terasaki.org		Rivera, Grecia O./0000-0003-3584-0184; Randon, Peggy/0000-0001-8640-7159; Natesh, Naveen R./0000-0003-3736-9402; Walz, Antje-Christine/0000-0002-2177-545X; McCall, Shannon/0000-0003-3957-061X; Negrete, Marcos/0000-0002-1169-2159	National Institutes of Health, United States (NIH) [U01 CA217514, U01 CA214300]; Duke Woo Center for Big Data and Precision Health	National Institutes of Health, United States (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Woo Center for Big Data and Precision Health	The authors acknowledge funding from National Institutes of Health, United States (NIH) U01 CA217514 and U01 CA214300 and the Duke Woo Center for Big Data and Precision Health.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Besser MJ, 2009, J IMMUNOTHER, V32, P415, DOI 10.1097/CJI.0b013e31819c8bda; Blakely CM, 2017, NAT GENET, V49, P1693, DOI 10.1038/ng.3990; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Calandrini C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15155-6; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Dao T, 2015, NAT BIOTECHNOL, V33, P1079, DOI 10.1038/nbt.3349; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Dijkstra KK, 2018, CELL, V174, P1586, DOI 10.1016/j.cell.2018.07.009; Driehuis E, 2019, P NATL ACAD SCI USA, V116, P26580, DOI 10.1073/pnas.1911273116; Driehuis E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111880; Dudley ME, 2010, CLIN CANCER RES, V16, P6122, DOI 10.1158/1078-0432.CCR-10-1297; Ganesh K, 2019, NAT MED, V25, P1607, DOI 10.1038/s41591-019-0584-2; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Han YY, 2020, AM J CANCER RES, V10, P727; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jacob F, 2020, CELL, V180, P188, DOI 10.1016/j.cell.2019.11.036; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kopper O, 2019, NAT MED, V25, P838, DOI 10.1038/s41591-019-0422-6; Lu M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169439; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660; Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Nguyen LT, 2019, CANCER IMMUNOL IMMUN, V68, P773, DOI 10.1007/s00262-019-02307-x; Ooft SN, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aay2574; Pauli C, 2017, CANCER DISCOV, V7, P462, DOI 10.1158/2159-8290.CD-16-1154; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prasad V, 2016, NATURE, V537, pS63, DOI 10.1038/537S63a; Radvanyi LG, 2012, CLIN CANCER RES, V18, P6758, DOI 10.1158/1078-0432.CCR-12-1177; Rius G., 2017, SPRINGER HDB NANOTEC; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwaederle M, 2016, JAMA ONCOL, V2, P1452, DOI 10.1001/jamaoncol.2016.2129; Seidlitz T, 2021, CELL DEATH DIFFER, V28, P68, DOI 10.1038/s41418-020-00662-2; Skardal A, 2015, ANN BIOMED ENG, V43, P2361, DOI 10.1007/s10439-015-1298-3; Stein WD, 2004, CANCER RES, V64, P2805, DOI 10.1158/0008-5472.CAN-03-3383; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; US FDA, 2011, POT TESTS CELL GEN T, V27, P568; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang LQ, 2018, FRONT MED-PRC, V12, P490, DOI 10.1007/s11684-018-0647-7; Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016; Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010; Yuki K, 2020, TRENDS IMMUNOL, V41, P652, DOI 10.1016/j.it.2020.06.010	52	5	5	21	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUN 2	2022	29	6					905	+		10.1016/j.stem.2022.04.006	http://dx.doi.org/10.1016/j.stem.2022.04.006			20	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	2O2ZL	35508177	Bronze			2023-01-03	WOS:000818932800007
J	Choi, HZ; Chang, H; Ko, SH; Kim, MC				Choi, Han Zo; Chang, Hansol; Ko, Seok Hoon; Kim, Myung Chun			Gender effect in survival after out-of-hospital cardiac arrest: A nationwide, population-based, case-control propensity score matched study based Korean national cardiac arrest registry	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; RISK-FACTORS; SEX; AGE; OUTCOMES; MEN; ESTRADIOL; FEMALES; WOMEN; HEART	Objective This study aimed to describe the relationship between sex and survival of patients with out-of-hospital cardiac arrest (OHCA) and further investigate the potential impact of female reproductive hormones on survival outcomes, by stratifying the patients into two age groups. Methods This retrospective, national population-based observational, case-control study, included Korean OHCA data from January 1, 2009, to December 31, 2016. We used multiple logistic regression with propensity score-matched data. The primary outcome was survival-to-discharge. Results Of the 94,160 patients with OHCA included, 34.2% were women. Before propensity score matching (PSM), the survival-to-discharge rate was 5.2% for females and 9.1% for males, in the entire group (OR 0.556, 95% CI [-0.526-0.588], P<0.001). In the reproductive age group (age 18-44 years), the survival-to-discharge rate was 14% for females and 15.6% for males (OR 0.879, 95% CI [0.765-1.012], P= 0,072) and in the post-menopause age group (age >= 55 years), the survival-to-discharge rate was 4.1% for females and 7% for males (OR 0.562, 95% CI [0.524-0.603], P<0.001). After PSM (28,577 patients of each sex), the survival-to-discharge rate was 5.4% for females and 5.4% for males (OR, 1.009 [0.9381.085], P= 0.810). In the reproductive age group, the survival-to-discharge rate was 14.5% for females and 11.5% for males (OR 1.306, 95% CI [1.079-1.580], P = 0.006) and in the post-menopause age group, the survival-to-discharge rate was 4.2% for females and 4.6% for males (OR 0.904, 95% CI [0.828-0.986], P= 0.022). After adjustment for confounders, women of reproductive age were more likely to survive at hospital discharge. However, there was no statistically significant difference in neurological outcome (OR 1.238, 95% CI [0.979-1.566], P= 0.074). Conclusions Females of reproductive age had a better chance of survival when matched for confounding factors. Further studies using sex hormones are needed to improve the survival rate of patients with OHCA.	[Choi, Han Zo; Kim, Myung Chun] Kyung Hee Univ Hosp Gangdong, Dept Emergency Med, Seoul, South Korea; [Chang, Hansol] Sungkyunkwan Univ, Samsung Med Ctr, Dept Emergency Med, Sch Med, Seoul, South Korea; [Chang, Hansol] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Digital Hlth, Seoul, South Korea; [Ko, Seok Hoon] Kyung Hee Univ, Dept Emergency Med, Med Ctr, Seoul, South Korea	Kyung Hee University; Kyung Hee University Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; Samsung; Sungkyunkwan University (SKKU); Kyung Hee University	Kim, MC (corresponding author), Kyung Hee Univ Hosp Gangdong, Dept Emergency Med, Seoul, South Korea.	edkmc@khnmc.or.kr		Choi, Han Zo/0000-0001-9201-5223; Chang, Hansol/0000-0002-2624-0008				Ahn KO, 2012, AM J EMERG MED, V30, P1810, DOI 10.1016/j.ajem.2012.02.018; Ahn KO, 2011, RESUSCITATION, V82, P270, DOI 10.1016/j.resuscitation.2010.10.023; Akahane M, 2011, AM J MED, V124, P325, DOI 10.1016/j.amjmed.2010.10.020; [Anonymous], CARDIAC ARREST STAT; Bougouin W, 2015, RESUSCITATION, V94, P55, DOI 10.1016/j.resuscitation.2015.06.018; Bray JE, 2013, RESUSCITATION, V84, P957, DOI 10.1016/j.resuscitation.2012.12.004; Brouchet L, 2001, CIRCULATION, V103, P423; Centers for Disease Control and Prevention, CHRON DIS IND IND DE; Do Shin S, 2011, RESUSCITATION, V82, P32, DOI 10.1016/j.resuscitation.2010.08.031; dos Santos RL, 2014, HORM MOL BIOL CLIN I, V18, P89, DOI 10.1515/hmbci-2013-0048; Goto Y, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2547-x; Hasan OF, 2014, CURR MED RES OPIN, V30, P2169, DOI 10.1185/03007995.2014.936552; Herlitz J, 2004, RESUSCITATION, V60, P197, DOI 10.1016/j.resuscitation.2003.09.012; Hubert H, 2021, EUR J EMERG MED, V28, P50, DOI 10.1097/MEJ.0000000000000747; Iorga A, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0152-8; Johnson MA, 2013, RESUSCITATION, V84, P639, DOI 10.1016/j.resuscitation.2012.09.011; Jousilahti P, 1999, CIRCULATION, V99, P1165, DOI 10.1161/01.cir.99.9.1165; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kim C, 2001, CIRCULATION, V104, P2699, DOI 10.1161/hc4701.099784; Kitamura T, 2010, EUR HEART J, V31, P1365, DOI 10.1093/eurheartj/ehq059; Korea National Health and Nutrition Examination Survey (KNHANES), AB US; Linde C, 2018, EUROPACE, V20, P1565, DOI 10.1093/europace/euy067; Ng YY, 2016, RESUSCITATION, V102, P116, DOI 10.1016/j.resuscitation.2016.03.002; Niemann JT, 2008, ACAD EMERG MED, V15, P939, DOI 10.1111/j.1553-2712.2008.00237.x; Noppens RR, 2009, J CEREBR BLOOD F MET, V29, P277, DOI 10.1038/jcbfm.2008.116; Perers E, 1999, RESUSCITATION, V40, P133, DOI 10.1016/S0300-9572(99)00022-2; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Siddiqui AN, 2016, CNS NEUROSCI THER, V22, P342, DOI 10.1111/cns.12538; Topjian AA, 2010, CRIT CARE MED, V38, P1254, DOI 10.1097/CCM.0b013e3181d8ca43; Vukmir RB, 2003, J WOMENS HEALTH, V12, P667, DOI 10.1089/154099903322404311; Wibrandt I, 2015, BMC EMERG MED, V15, DOI 10.1186/s12873-015-0028-3; Wise PM, 2005, ENDOCR REV, V26, P308, DOI 10.1210/er.2004-0014; Wissenberg M, 2015, CIRCULATION, V131, P1536, DOI 10.1161/CIRCULATIONAHA.114.013122	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2022	17	5							e0258673	10.1371/journal.pone.0258673	http://dx.doi.org/10.1371/journal.pone.0258673			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1VP	35544548	Green Published, gold			2023-01-03	WOS:000818854500001
J	Anderson, KM; Murphy, D; Groninger, H; Kolm, P; Wang, HJ; Barton-Maxwel, V				Anderson, Kelley M.; Murphy, Dottie; Groninger, Hunter; Kolm, Paul; Wang, Haijun; Barton-Maxwel, Vera			Perceived symptoms as the primary indicators for 30-day heart failure readmission	PLOS ONE			English	Article							2013 ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; SELF-CARE; AMERICAN-COLLEGE; CLINICAL CHARACTERISTICS; SERUM-CHOLESTEROL; PREDICTORS; OUTCOMES; DYSPNEA; MANAGEMENT	Background To identify 30-day rehospitalizations in patients discharged with heart failure (HF) based on clinical indications, physiologic measures and symptoms. Methods Fifty-six patients with heart failure participated. After discharge to home, clinical indicators of dyspnea, fatigue, orthopnea, dyspnea with exertion, daily weight, edema, heart rate, blood pressure, mental condition, medication adherence, and overall well-being were reported by participants daily for up to 30 days. Results Joint modeling of longitudinal and time-to-event approach was applied to assess the association of readmission with longitudinal measurements. There was no association between demographic, physiological, or laboratory variables and re-hospitalization within 30 days post discharge. Perceptions of dyspnea (p = .012) and feeling unwell (p < .001) were associated with rehospitalization. Patients struggling to breath were 10.7 times more likely to be readmitted than those not struggling to breath. Conclusion Perceived measures, particularly dyspnea and feeling unwell were more important factors than demographic, physiological, or laboratory parameters in predicting 30-day rehospitalizations in this racially diverse cohort. The symptomatic experience of heart failure is an important indicator of rehospitalization.	[Anderson, Kelley M.] Georgetown Univ, Dept Profess Nursing Practice, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Murphy, Dottie] Liberty Univ, Dept On Line Nursing, Lynchburg, VA USA; [Groninger, Hunter] Washington Hosp Ctr, Div Palliat Care, Medstar, Washington, DC USA; [Groninger, Hunter] Georgetown Univ, Sch Med, Washington, DC USA; [Kolm, Paul; Wang, Haijun] Hlth Res Inst, Div Bioinformat & Biostat, MedStar, Hyattsville, MD USA; [Barton-Maxwel, Vera] Georgetown Univ, Dept Adv Nursing Practice, Sch Nursing & Hlth Studies, Washington, DC USA	Georgetown University; Liberty University; MedStar Washington Hospital Center; Georgetown University; Georgetown University	Anderson, KM (corresponding author), Georgetown Univ, Dept Profess Nursing Practice, Sch Nursing & Hlth Studies, Washington, DC 20057 USA.	kma25@georgetown.edu		Anderson, Kelley/0000-0002-4405-2991	National Center for Advancing Translational Sciences (NCATS) [UL1TR000101, UL1RR031975]; National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA); DHHS; Roadmap Initiative, Re-Engineering the Clinical Research Enterprise	National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA); DHHS; Roadmap Initiative, Re-Engineering the Clinical Research Enterprise	KMA: This project has been funded in whole or in part with Federal funds (UL1TR000101 previously UL1RR031975) from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, Re-Engineering the Clinical Research Enterprise. The sponsor or funder did not play any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosy AP, 2017, JACC-HEART FAIL, V5, P1, DOI 10.1016/j.jchf.2016.09.012; American Heart Association (AHA), 2021, SELF CHECK PLAN HF M; Ananaba I, 2012, J CARD FAIL, V18, P596, DOI 10.1016/j.cardfail.2012.05.001; Anderson KM, 2014, J CARDIOVASC NURS, V29, P232, DOI 10.1097/JCN.0b013e31828f0d25; [Anonymous], 1994, Image J Nurs Sch, V26, P272; Arestedt K, 2021, ESC HEART FAIL, V8, P2202, DOI 10.1002/ehf2.13312; Arora S, 2017, AM J CARDIOL, V119, P760, DOI 10.1016/j.amjcard.2016.11.022; Bielecka-Dabrowa A, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1135-z; BORG G, 1990, SCAND J WORK ENV HEA, V16, P55, DOI 10.5271/sjweh.1815; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bozkurt B, 2021, J AM COLL CARDIOL, V77, P2053, DOI 10.1016/j.jacc.2020.11.012; Bozkurt B, 2021, EUR J HEART FAIL, V23, P352, DOI 10.1002/ejhf.2115; Bozkurt Biykem, 2017, Methodist Debakey Cardiovasc J, V13, P216, DOI 10.14797/mdcj-13-4-216; Crowther MJ, 2013, STATA J, V13, P165, DOI 10.1177/1536867X1301300112; Curtis BR, 2021, J PAIN SYMPTOM MANAG, V62, P1252, DOI 10.1016/j.jpainsymman.2021.06.001; Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x; Felker GM, 2004, J CARD FAIL, V10, P460, DOI 10.1016/j.cardfail.2004.02.011; Finkelstein J, 2011, WMSCI 2011: 15TH WORLD MULTI-CONFERENCE ON SYSTEMICS, CYBERNETICS AND INFORMATICS, VOL II, P207; Finkelstein J, 2010, SECOND INTERNATIONAL CONFERENCE ON EHEALTH, TELEMEDICINE, AND SOCIAL MEDICINE: ETELEMED 2010, PROCEEDINGS, P90, DOI 10.1109/eTELEMED.2010.32; Fonarow Gregg C, 2003, Rev Cardiovasc Med, V4 Suppl 7, pS21; Fudim M, 2017, J AM COLL CARDIOL, V69, P766, DOI 10.1016/S0735-1097(17)34155-4; Garcia-Hernandez A, 2018, J STAT SOFTW, V84, P1, DOI 10.18637/jss.v084.i12; Gheorghiade M, 2009, J AM COLL CARDIOL, V53, P557, DOI 10.1016/j.jacc.2008.10.041; Harkness K, 2015, J CARDIOVASC NURS, V30, P121, DOI 10.1097/JCN.0000000000000118; Hollenberg SM, 2019, J AM COLL CARDIOL, V74, P1966, DOI 10.1016/j.jacc.2019.08.001; Howie JN, PREDICTORS REHOSPITA; Humphreys J., 2014, MIDDLE RANGE THEORY, V3rd ed., P141; Kapoor JR, 2016, JACC-HEART FAIL, V4, P464, DOI 10.1016/j.jchf.2016.02.017; Khan MS, 2021, CIRC-HEART FAIL, V14, DOI 10.1161/CIRCHEARTFAILURE.121.008335; Koirala B, 2018, HEART LUNG, V47, P539, DOI 10.1016/j.hrtlng.2018.09.004; Kupper N, 2016, J CARD FAIL, V22, P201, DOI 10.1016/j.cardfail.2015.09.016; Lee CS, 2018, HEART LUNG, V47, P40, DOI 10.1016/j.hrtlng.2017.09.004; Lee MMY, 2019, CURR ATHEROSCLER REP, V21, DOI 10.1007/s11883-019-0800-z; Lee S, 2018, J CARDIOVASC NURS, V33, P204, DOI 10.1097/JCN.0000000000000445; Levy WC, 2013, AM J CARDIOL, V111, P1235, DOI 10.1016/j.amjcard.2013.01.286; Lippi G, 2020, AME MED J, V5, DOI [10.21037/amj.2020.03.03, DOI 10.21037/AMJ.2020.03.03]; Logeart D, 2004, J AM COLL CARDIOL, V43, P635, DOI 10.1016/j.jacc.2003.09.044; MADOR MJ, 1995, CHEST, V107, P1590, DOI 10.1378/chest.107.6.1590; Nakagomi A, 2014, INTERNAL MED, V53, P2415, DOI 10.2169/internalmedicine.53.2672; Niazi M, 2020, CURR CLIN PHARMACOL, V15, P30, DOI 10.2174/1574884714666190802125627; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; O'Connor CM, 2005, J CARD FAIL, V11, P200, DOI 10.1016/j.cardfail.2004.08.160; OConnor CM, HIGH HEART FAILURE R; Parshall MB, 2001, HEART LUNG, V30, P47; Pierre-Louis B, 2016, ARCH MED SCI, V12, P538, DOI 10.5114/aoms.2016.59927; Preiss D, 2015, EUR HEART J, V36, P1536, DOI 10.1093/eurheartj/ehv072; Rauchhaus M, 2003, J AM COLL CARDIOL, V42, P1933, DOI 10.1016/j.jacc.2003.07.016; Riegel B, 2012, ADV NURS SCI, V35, P194, DOI 10.1097/ANS.0b013e318261b1ba; Riegel B, 2009, CIRCULATION, V120, P1141, DOI 10.1161/CIRCULATIONAHA.109.192628; Rogers JK, 2014, JACC-HEART FAIL, V2, P289, DOI 10.1016/j.jchf.2013.12.007; Rosa GM, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13044; Sherer AP, 2016, J CARDIOVASC NURS, V31, P114, DOI 10.1097/JCN.0000000000000225; Stiel S, 2011, J PALLIAT MED, V14, P599, DOI 10.1089/jpm.2010.0473; Su A, 2019, MAYO CLIN PROC, V94, P1304, DOI 10.1016/j.mayocp.2019.01.017; Tavazzi L, 2008, LANCET, V372, P1231, DOI 10.1016/S0140-6736(08)61240-4; Vaduganathan M, 2014, HEART FAIL REV, V19, P695, DOI 10.1007/s10741-014-9423-1; van Buuren S., 2012, FLEXIBLE IMPUTATION, DOI 10.1201/b11826; Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Welch Janet L, 2002, Nephrol Nurs J, V29, P337; Westman PC, 2015, J THORAC DIS, V7, P1687, DOI 10.3978/j.issn.2072-1439.2015.10.47; White MF, 2014, CIRCULATION, V129, pE293, DOI 10.1161/CIRCULATIONAHA.113.003991; Wirta SB, 2018, THER CLIN RISK MANAG, V14, P2265, DOI 10.2147/TCRM.S183200; Yancy CW, 2017, J AM COLL CARDIOL, V70, P776, DOI [10.1016/j.jacc.2017.04.025, 10.1161/CIR.0000000000000509]; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yu CM, 2005, CIRCULATION, V112, P841, DOI 10.1161/CIRCULATIONAHA.104.492207; Zafrir B, 2015, CARDIOL J, V22, P375, DOI 10.5603/CJ.a2014.0104; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	68	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0267820	10.1371/journal.pone.0267820	http://dx.doi.org/10.1371/journal.pone.0267820			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511916	Green Published, gold			2023-01-03	WOS:000892294900071
J	Singh, KP; Tong, SYC				Singh, Kasha P.; Tong, Steven Y. C.			In adults hospitalized with COVID-19, adding remdesivir to standard care did not reduce in-hospital mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Singh, Kasha P.] Royal Melbourne Hosp, Melbourne, Vic, Australia; Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	Royal Melbourne Hospital; University of Melbourne	Singh, KP (corresponding author), Royal Melbourne Hosp, Melbourne, Vic, Australia.		Tong, Steven/N-2353-2013	Tong, Steven/0000-0002-1368-8356				Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Lee TC, PREPRINT, DOI [10.1101/2022.01.22.22269545, DOI 10.1101/2022.01.22.22269545]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	4	0	0	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2022	175	5					JC51	JC51		10.7326/J22-0025	http://dx.doi.org/10.7326/J22-0025		MAY 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2U5RH	35500262				2023-01-03	WOS:000796996400001
J	Longo, VD; Anderson, RM				Longo, Valter D.; Anderson, Rozalyn M.			Nutrition, longevity and disease: From molecular mechanisms to interventions	CELL			English	Review							FASTING-MIMICKING DIET; EXTENDS LIFE-SPAN; CALORIC RESTRICTION; LOW-PROTEIN; CARBOHYDRATE DIETS; ALL-CAUSE; HEALTH; GROWTH; MORTALITY; IMPACT	Diet as a whole, encompassing food composition, calorie intake, and the length and frequency of fasting periods, affects the time span in which health and functional capacity are maintained. Here, we analyze aging and nutrition studies in simple organisms, rodents, monkeys, and humans to link longevity to conserved growth and metabolic pathways and outline their role in aging and age-related disease. We focus on feasible nutritional strategies shown to delay aging and/or prevent diseases through epidemiological, model organism, clinical, and centenarian studies and underline the need to avoid malnourishment and frailty. These findings are integrated to define a longevity diet based on a multi-pillar approach adjusted for age and health status to optimize lifespan and healthspan in humans.	[Longo, Valter D.] Univ Southern Calif, Longev Inst, Los Angeles, CA 90089 USA; [Longo, Valter D.] Univ Southern Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA; [Longo, Valter D.] FIRC Inst Mol Oncol, IFOM, Via Adamello 16, I-20139 Milan, Italy; [Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, SMPH, Madison, WI USA; [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA	University of Southern California; University of Southern California; IFOM - FIRC Institute of Molecular Oncology; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Longo, VD (corresponding author), Univ Southern Calif, Longev Inst, Los Angeles, CA 90089 USA.; Longo, VD (corresponding author), Univ Southern Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA.; Longo, VD (corresponding author), FIRC Inst Mol Oncol, IFOM, Via Adamello 16, I-20139 Milan, Italy.	vlongo@usc.edu		Longo, Valter/0000-0002-0946-7534	Associazione Italiana per la Ricerca sul Cancro (AIRC) [17605, 21820]; Breast Cancer Research Program (US Department of Defense) [BC161452]; US National Institute on Aging-National Institutes of Health (NIA-NIH) [P01 AG055369]; NIH-NIA [RF1AG057408, R01AG067330, R01AG074503]; Veterans Adminstration Merit Award [BX003846]; Simons Foundation; William S. Middleton Memorial Veterans Hospial Madison Wisconsin; Impetus Grants	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Breast Cancer Research Program (US Department of Defense)(United States Department of Defense); US National Institute on Aging-National Institutes of Health (NIA-NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Adminstration Merit Award; Simons Foundation; William S. Middleton Memorial Veterans Hospial Madison Wisconsin; Impetus Grants	This work was supported in part by awards to V.D.L. including the Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG#17605 and IG#21820.), the BC161452 grant of the Breast Cancer Research Program (US Department of Defense) and the US National Institute on Aging-National Institutes of Health (NIA-NIH) grants P01 AG055369). R.M.A. is supported by NIH-NIA RF1AG057408, R01AG067330, R01AG074503, Veterans Adminstration Merit Award BX003846, and by Impetus Grants and the Simons Foundation. This work was made possible by support from the William S. Middleton Memorial Veterans Hospial Madison Wisconsin. V.D.L. has equity interest in L-Nutra, a company that commercializes medical food.	Lopez-Espinoza MA, 2021, NUTRIENTS, V13, DOI 10.3390/nu13092946; Aon MA, 2020, CELL METAB, V32, P100, DOI 10.1016/j.cmet.2020.04.018; Balasubramanian P, 2017, AGEING RES REV, V39, P29, DOI 10.1016/j.arr.2017.02.002; Bartke A, 2005, J GERONTOL A-BIOL, V60, P133, DOI 10.1093/gerona/60.1.133; Bartke A, 2013, PHYSIOL REV, V93, P571, DOI 10.1152/physrev.00006.2012; Belsky DW, 2020, ELIFE, V9, DOI 10.7554/eLife.54870; Belsky DW, 2018, J GERONTOL A-BIOL, V73, P4, DOI 10.1093/gerona/glx096; Bendlin BB, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.008; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Burgers AMG, 2011, J CLIN ENDOCR METAB, V96, P2912, DOI 10.1210/jc.2011-1377; Caffa I, 2020, NATURE, V583, P620, DOI 10.1038/s41586-020-2502-7; Campos JC, 2021, EMBO REP, V22, DOI 10.15252/embr.202152964; Campos SE, 2018, AGING CELL, V17, DOI 10.1111/acel.12749; Castillo-Quan JI, 2019, P NATL ACAD SCI USA, V116, P20817, DOI 10.1073/pnas.1913212116; Catterson JH, 2018, CURR BIOL, V28, P1714, DOI 10.1016/j.cub.2018.04.015; Chaix A, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109543; Chaix A, 2019, CELL METAB, V29, P303, DOI 10.1016/j.cmet.2018.08.004; Chaix A, 2014, CELL METAB, V20, P991, DOI 10.1016/j.cmet.2014.11.001; Che TT, 2021, NUTR METAB, V18, DOI 10.1186/s12986-021-00613-9; Cheng CW, 2017, CELL, V168, P775, DOI 10.1016/j.cell.2017.01.040; Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; de Groot S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16138-3; Diaz-Ruiz A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26654-5; Dorling JL, 2021, EUR J NUTR, V60, P1633, DOI 10.1007/s00394-020-02361-7; Duregon E, 2021, GEROSCIENCE, V43, P1083, DOI 10.1007/s11357-021-00335-z; Enns LC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005963; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fadnes L, 2022, PLOS MED, V19, DOI 10.1371/journal.pmed.1003889; Fan SZ, 2021, AGING CELL, V20, DOI 10.1111/acel.13510; Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Forney LA, 2020, OBESITY, V28, P1912, DOI 10.1002/oby.22919; Fung TT, 2010, ANN INTERN MED, V153, P289, DOI 10.7326/0003-4819-153-5-201009070-00003; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gao Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240596; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Heintz C, 2017, NATURE, V541, P102, DOI 10.1038/nature20789; Hernandez AR, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00391; Hill CM, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa019; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; Iranon NN, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008242; Janssen JAMJL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157797; Jin K, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008835; Kaya A, 2021, INNOV AGING, V5, P32; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Koyuncu S, 2021, NATURE, V596, P285, DOI 10.1038/s41586-021-03781-z; Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2; Kumsta C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13540-4; Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006; Longo Valter D, 2021, Nat Aging, V1, P47, DOI 10.1038/s43587-020-00013-3; Ma D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25190-5; Mariotti F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112661; Martens CR, 2020, GEROSCIENCE, V42, P667, DOI 10.1007/s11357-020-00156-6; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; McCracken AW, 2020, J EXP BIOL, V223, DOI 10.1242/jeb.230185; Messaoudi I, 2006, P NATL ACAD SCI USA, V103, P19448, DOI 10.1073/pnas.0606661103; Miller KN, 2017, AGING CELL, V16, P497, DOI 10.1111/acel.12575; Mirisola MG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004113; Mishra A, 2021, NAT METAB, V3, P1342, DOI 10.1038/s42255-021-00469-6; Mitchell SJ, 2019, CELL METAB, V29, P221, DOI 10.1016/j.cmet.2018.08.011; Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027; Most J, 2017, AGEING RES REV, V39, P36, DOI 10.1016/j.arr.2016.08.005; Nashiro K, 2017, J NEUROSCI, V37, P1696, DOI 10.1523/JNEUROSCI.1929-16.2016; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Orozco JM, 2020, NAT METAB, V2, P893, DOI 10.1038/s42255-020-0250-5; Palma C, 2021, CELL METAB, V33, P300, DOI 10.1016/j.cmet.2020.12.016; Pawlosky RJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031044; Pomatto-Watson LCD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26431-4; Ravussin E, 2015, J GERONTOL A-BIOL, V70, P1097, DOI 10.1093/gerona/glv057; Ren B, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101940; Rhoads TW, 2020, CELL SYST, V10, P156, DOI 10.1016/j.cels.2019.12.002; Rhoads TW, 2018, CELL METAB, V27, P677, DOI 10.1016/j.cmet.2018.01.014; Richardson A, 2021, J GERONTOL A-BIOL, V76, P57, DOI 10.1093/gerona/glaa208; Richardson Nicole E, 2021, Nat Aging, V1, P73, DOI 10.1038/s43587-020-00006-2; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Rollins JA, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800281; Romey-Glusing R, 2018, FASEB J, V32, P1993, DOI 10.1096/fj.201700934R; Rong S, 2019, J AM COLL CARDIOL, V73, P2025, DOI 10.1016/j.jacc.2019.01.065; Saito T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08829-3; Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]; Savola E, 2021, EVOLUTION, V75, P450, DOI 10.1111/evo.14146; Schroder JD, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02687-0; Segovia-Siapco G, 2019, EUR J CLIN NUTR, V72, P60, DOI 10.1038/s41430-018-0310-z; Seidelmann SB, 2018, LANCET PUBLIC HEALTH, V3, pE419, DOI 10.1016/S2468-2667(18)30135-X; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Senior AM, 2019, P ROY SOC B-BIOL SCI, V286, DOI 10.1098/rspb.2019.0393; Shahmirzadi AA, 2020, CELL METAB, V32, P447, DOI 10.1016/j.cmet.2020.08.004; Sharma S, 2019, OBESITY, V27, P1305, DOI 10.1002/oby.22534; Shen R, 2016, P NATL ACAD SCI USA, V113, pE3307, DOI 10.1073/pnas.1606106113; Solon-Biet SM, 2019, NAT METAB, V1, P532, DOI 10.1038/s42255-019-0059-2; Solon-Biet SM, 2014, CELL METAB, V19, P418, DOI 10.1016/j.cmet.2014.02.009; Stekovic S, 2020, CELL METAB, V31, P878, DOI 10.1016/j.cmet.2020.02.011; Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010; Tong TYN, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01815-3; Ulgherait M, 2021, NATURE, V598, P353, DOI 10.1038/s41586-021-03934-0; Uno M, 2013, CELL REP, V3, P79, DOI 10.1016/j.celrep.2012.12.018; Velingkaar N, 2020, AGING CELL, V19, DOI 10.1111/acel.13138; Villanueva JE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10563-9; Wahl D, 2018, CELL REP, V25, P2234, DOI 10.1016/j.celrep.2018.10.070; Wali JA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051505; Weber DD, 2020, MOL METAB, V33, P102, DOI 10.1016/j.molmet.2019.06.026; Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700; Weir HJ, 2017, CELL METAB, V26, P884, DOI 10.1016/j.cmet.2017.09.024; Wilder R.M., 1921, MAYO CLIN B, V2, P307, DOI DOI 10.1111/J.1469-8749.1989.TB03973.X; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Willette AA, 2012, DIABETES, V61, P1036, DOI 10.2337/db11-1187; Wilson KA, 2020, CURR BIOL, V30, P2749, DOI 10.1016/j.cub.2020.05.020; Wu YC, 2020, FASEB J, V34, P1412, DOI 10.1096/fj.201901984R; Wu YG, 2021, CELL METAB, V33, P888, DOI 10.1016/j.cmet.2021.01.017; Wu ZY, 2019, CELL METAB, V29, P1192, DOI 10.1016/j.cmet.2019.02.013; Yamada Y, 2013, EXP GERONTOL, V48, P1226, DOI 10.1016/j.exger.2013.08.002; Yan WW, 2015, BRAIN RES, V1603, P22, DOI 10.1016/j.brainres.2015.01.042; Zhang S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041140; Zhou B, 2019, CELL, V177, P299, DOI 10.1016/j.cell.2019.02.013	120	15	15	36	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 28	2022	185	9					1455	1470		10.1016/j.cell.2022.04.002	http://dx.doi.org/10.1016/j.cell.2022.04.002			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	3G0DH	35487190	hybrid			2023-01-03	WOS:000831027800004
J	Kuehn, BM				Kuehn, Bridget M.			Medical Groups Defend Patient-Physician Relationship and Access to Adolescent Gender-Affirming Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2022	327	15					1432	1433						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1C3PR	35353160				2023-01-03	WOS:000793035800009
J	Zhu, I; Liu, R; Garcia, JM; Hyrenius-Wittsten, A; Piraner, DI; Alavi, J; Israni, DV; Liu, B; Khalil, AS; Roybal, KT				Zhu, Iowis; Liu, Raymond; Garcia, Julie M.; Hyrenius-Wittsten, Axel; Piraner, Dan, I; Alavi, Josef; Israni, Divya, V; Liu, Bin; Khalil, Ahmad S.; Roybal, Kole T.			Modular design of synthetic receptors for programmed gene regulation in cell therapies	CELL			English	Article							GAMMA-SECRETASE; T-CELLS; NOTCH; CLEAVAGE; RECOGNITION; ENDOCYTOSIS; ACTIVATION; EXPRESSION; REGION; ROLES	Synthetic biology has established powerful tools to precisely control cell function. Engineering these systems to meet clinical requirements has enormous medical implications. Here, we adopted a clinically driven design process to build receptors for the autonomous control of therapeutic cells. We examined the function of key domains involved in regulated intramembrane proteolysis and showed that systematic modular engineering can generate a class of receptors that we call synthetic intramembrane proteolysis receptors (SNIPRs) that have tunable sensing and transcriptional response abilities. We demonstrate the therapeutic potential of the receptor platform by engineering human primary T cells for multi-antigen recognition and production of dosed, bioactive payloads relevant to the treatment of disease. Our design framework enables the development of fully humanized and customizable transcriptional receptors for the programming of therapeutic cells suitable for clinical translation.	[Zhu, Iowis; Liu, Raymond; Garcia, Julie M.; Hyrenius-Wittsten, Axel; Piraner, Dan, I; Alavi, Josef; Roybal, Kole T.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Zhu, Iowis; Liu, Raymond; Garcia, Julie M.; Hyrenius-Wittsten, Axel; Piraner, Dan, I; Alavi, Josef; Liu, Bin; Roybal, Kole T.] Parker Inst Canc Immunotherapy, San Francisco, CA 94143 USA; [Hyrenius-Wittsten, Axel] Lund Univ, Dept Lab Med, Div Clin Genet, S-22184 Lund, Sweden; [Israni, Divya, V; Khalil, Ahmad S.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; [Israni, Divya, V; Khalil, Ahmad S.] Boston Univ, Biol Design Ctr, Boston, MA 02215 USA; [Khalil, Ahmad S.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA; [Liu, Bin] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94110 USA; [Liu, Bin; Roybal, Kole T.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA; [Roybal, Kole T.] Chan Zuckerberg Biohub, San Francisco, CA 94158 USA; [Roybal, Kole T.] Gladstone UCSF Inst Genet Immunol, San Francisco, CA 94107 USA; [Roybal, Kole T.] UCSF Cell Design Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Lund University; Boston University; Boston University; Harvard University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Roybal, KT (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.; Roybal, KT (corresponding author), Parker Inst Canc Immunotherapy, San Francisco, CA 94143 USA.; Roybal, KT (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.; Roybal, KT (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA 94158 USA.; Roybal, KT (corresponding author), Gladstone UCSF Inst Genet Immunol, San Francisco, CA 94107 USA.; Roybal, KT (corresponding author), UCSF Cell Design Inst, San Francisco, CA 94158 USA.	kole.roybal@ucsf.edu		Piraner, Dan/0000-0003-3857-9487; Israni, Divya/0000-0002-6335-8769; Hyrenius Wittsten, Axel/0000-0002-1239-4954; Alavi, Josef/0000-0002-9877-1510; Zhu, Iowis/0000-0001-7852-0987	National Cancer Institute [5F30CA250247-02]; Parker Institute for Cancer Immunotherapy; NIH Director's New Innovator Award [DP2 CA239143, 1DP2AI131083]; NIH [R01EB029483, P30 DK063720]; DARPA Young Faculty Award [D16AP00142]; DoD Vannevar Bush Faculty Fellowship [N00014-20-1-2825]; NIH S10 Instrumentation grant [S10 1S10OD021822-01];  [5T32AI 07334-29]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Parker Institute for Cancer Immunotherapy; NIH Director's New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DARPA Young Faculty Award; DoD Vannevar Bush Faculty Fellowship; NIH S10 Instrumentation grant; 	I.Z. is funded by an F30 fellowship from the National Cancer Institute (5F30CA250247-02). R.L. was supported by a T32 training grant (5T32AI 07334-29). K.T.R. acknowledges funding from the Parker Institute for Cancer Immunotherapy and an NIH Director's New Innovator Award (DP2 CA239143). This work was also supported by NIH grant R01EB029483 (K.T.R. and A.S.K.). A.S.K. acknowledges funding from a DARPA Young Faculty Award (D16AP00142), NIH Director's New Innovator Award (1DP2AI131083), and DoD Vannevar Bush Faculty Fellowship (N00014-20-1-2825). We acknowledge the PFCC supported in part by grant NIH P30 DK063720 and by the NIH S10 Instrumentation grant S10 1S10OD021822-01.	Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Choe JH, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe7378; Coleman HA, 2010, DEVELOPMENT, V137, P2417, DOI 10.1242/dev.047993; D. V. Israni, 2021, bioRxiv, DOI 10.1101/2021.02.22.432371; Daringer NM, 2014, ACS SYNTH BIOL, V3, P892, DOI 10.1021/sb400128g; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Ellis GI, 2021, NAT REV GENET, V22, P427, DOI 10.1038/s41576-021-00329-9; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fridy PC, 2014, NAT METHODS, V11, P1253, DOI [10.1038/NMETH.3170, 10.1038/nmeth.3170]; Gordon WR, 2009, BLOOD, V113, P4381, DOI 10.1182/blood-2008-08-174748; Guedan S, 2019, MOL THER-METH CLIN D, V12, P145, DOI 10.1016/j.omtm.2018.12.009; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Hayward AN, 2019, ELIFE, V8, DOI 10.7554/eLife.46983; Hernandez-Lopez RA, 2021, SCIENCE, V371, P1166, DOI 10.1126/science.abc1855; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Hyrenius-Wittsten A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd8836; Kandachar V, 2012, CURR OPIN CELL BIOL, V24, P534, DOI 10.1016/j.ceb.2012.06.006; Klebanoff CA, 2016, CELL, V167, P302, DOI 10.1016/j.cell.2016.09.033; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014; Lambrecht BN, 2018, NAT REV IMMUNOL, V18, P745, DOI 10.1038/s41577-018-0068-5; Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975; Li NY, 2007, EMBO J, V26, P494, DOI 10.1038/sj.emboj.7601520; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Moretti J, 2013, INT J MOL SCI, V14, P6359, DOI 10.3390/ijms14036359; Morgan RA, 2012, HUM GENE THER, V23, P1043, DOI 10.1089/hum.2012.041; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Pachella Laura A, 2015, J Adv Pract Oncol, V6, P212; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Roscilli G, 2002, MOL THER, V6, P653, DOI 10.1006/mthe.2002.0717; Roybal KT, 2016, CELL, V167, P419, DOI 10.1016/j.cell.2016.09.011; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Seki M, 2010, FEBS LETT, V584, P2909, DOI 10.1016/j.febslet.2010.05.009; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Toda S, 2018, SCIENCE, V361, P156, DOI 10.1126/science.aat0271; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Wang Y, 2018, HUM GENE THER METHOD, V29, P96, DOI 10.1089/hgtb.2017.198; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Williams JZ, 2020, SCIENCE, V370, P1099, DOI 10.1126/science.abc6270; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; Yamamoto S, 2010, CURR TOP DEV BIOL, V92, P165, DOI 10.1016/S0070-2153(10)92005-X	50	6	6	12	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2022	185	8					1431	+		10.1016/j.cell.2022.03.023	http://dx.doi.org/10.1016/j.cell.2022.03.023		APR 2022	30	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	1M2DH	35427499				2023-01-03	WOS:000799783900001
J	Omerdic, EO; Alagic-Dzambic, L; Krstic, M; Pasic-Kulenovic, M; Medarevic, D; Ivkovic, B; Vasiljevic, D				Omerdic, Ehlimana Osmanovic; Alagic-Dzambic, Larisa; Krstic, Marko; Pasic-Kulenovic, Maja; Medarevic, Dorde; Ivkovic, Branka; Vasiljevic, Dragana			Long-term stability of clopidogrel solid dispersions-Importance of in vitro dissolution test	PLOS ONE			English	Article							SOLUBILITY ENHANCEMENT; FORMULATION; TABLETS; DRUGS	Formulation of solid dispersions (SDs), in which the drug substance is dissolved or dispersed inside a polymer matrix, is one of the modern approaches to increase the solubility and dissolution rate of poorly soluble active pharmaceutical ingredients (APIs), such as clopidogrel. In the form of a free base, clopidogrel is unstable under increased both high moisture and temperature, so it is most often used as its salt form, clopidogrel hydrogen sulfate (CHS).The aim of this study was the formulation, characterization, and long-term stability investigation of CHS solid dispersions, prepared with four different hydrophilic polymers (poloxamer 407, macrogol 6000, povidone, copovidone) in five API/polymer ratios (1:1, 1:2, 1:3, 1:5, 1:9). SDs were prepared by the solvent evaporation method, employing ethanol (96% v/v) as a solvent. Initial results of the in vitro dissolution test showed an increase in the amount of dissolved CHS from all prepared SD samples compared to pure CHS, corresponding physical mixtures (PMs), and commercial tablets. SDs, prepared with poloxamer 407, macrogol 6000, and copovidone, at CHS/polymer ratios 1:5 and 1:9, notably increased the amount of dissolved CHS (> 80%, after 60 min), thus they were selected for further characterization. To assess the SDs long-term stability, in vitro dissolution studies, clopidogrel content determination, differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FT-IR) were performed initially and after 12 months of long-term stability studies under controlled conditions (25 degrees C, 60% RH) meeting the ICH guideline Q1A (R2) requirements. The clopidogrel content in the selected samples was very similar at the beginning (96.13% to 99.93%) and at the end (95.98% to 99.86%) of the conducted test. DSC curves and FT-IR spectra of all SD samples after 12 months of stability study, showed the absence of CHS crystallization, which is an indication of good stability. However, the in vitro dissolution test showed a considerable reduction in CHS released from SDs with macrogol 6000. The amount of dissolved CHS from SDs with macrogol 6000 was initially 94.02% and 92.01%, and after 12 months of stability study, only 65.13% and 49.62%. In contrast, the amount of dissolved CHS from SDs prepared with poloxamer 407 and copovidone was very similar after 12 months of the stability study compared to the initial values. Results obtained indicated the great importance of the in vitro dissolution test in determining the long-term stability and quality of SDs.	[Omerdic, Ehlimana Osmanovic; Pasic-Kulenovic, Maja] Bosnalijek Dd, Dev & Registrat Dept, Sarajevo, Bosnia & Herceg; [Alagic-Dzambic, Larisa] Bosnalijek Dd, Qual Assurance & Qual Control Dept, Sarajevo, Bosnia & Herceg; [Krstic, Marko] Univ Belgrade, Fac Pharm, Dept Anal Chem, Belgrade, Serbia; [Medarevic, Dorde; Vasiljevic, Dragana] Univ Belgrade, Fac Pharm, Dept Pharm Technol & Cosmetol, Belgrade, Serbia; [Ivkovic, Branka] Univ Belgrade, Fac Pharm, Dept Pharmaceut Chem, Belgrade, Serbia	University of Belgrade; University of Belgrade; University of Belgrade	Omerdic, EO (corresponding author), Bosnalijek Dd, Dev & Registrat Dept, Sarajevo, Bosnia & Herceg.	ehlimana.osmanovic.omerdic@bosnalijek.ba			Ministry of Education, Science and Technological Development, Republic of Serbia; University of Belgrade -Faculty of Pharmacy [451-03-9/2021-14/200161]	Ministry of Education, Science and Technological Development, Republic of Serbia; University of Belgrade -Faculty of Pharmacy	This research was funded by the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade -Faculty of Pharmacy No: 451-03-9/2021-14/200161. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alladi S., 2010, J PHARM SCI TECHNOL, V20, P308; [Anonymous], 2012, Drug Discov Today Technol, V9, pe71, DOI 10.1016/j.ddtec.2011.10.002; Bolourchian N, 2013, IRAN J PHARM RES, V12, P9; Center for drug evaluation and research FDA, 2018, FULL PRESCR INF PLAV; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Damian F, 2002, INT J PHARM, V244, P87, DOI 10.1016/S0378-5173(02)00316-2; European Medicines Agency, 1992, GUID 3AQ11A SPEC CON; European Medicines Agency, 2003, ICH TOP Q1A R2 STAB; FORD JL, 1980, PHARM ACTA HELV, V55, P1; FORD JL, 1979, PHARM ACTA HELV, V54, P353; Fouad SA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245482; HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210; Homayouni A, 2014, IRAN J BASIC MED SCI, V17, P322; Jang SW, 2014, INT J PHARMACEUT, V473, P187, DOI 10.1016/j.ijpharm.2014.06.006; Jassim ZE., 2014, INT J PHARM PHARM SC, V6, P838; Jermain SV, 2018, INT J PHARMACEUT, V535, P379, DOI 10.1016/j.ijpharm.2017.10.051; Karthikeyan M, 2021, J PHARM INNOV, V16, P551, DOI 10.1007/s12247-020-09459-9; Kolasinac N, 2012, INT J PHARMACEUT, V436, P161, DOI 10.1016/j.ijpharm.2012.06.060; Koradia Vishal, 2004, Acta Pharmaceutica (Zagreb), V54, P193; Lestari MLAD, 2010, PROF DRUG SUB EXCIP, V35, P71, DOI 10.1016/S1871-5125(10)35002-3; Li B, 2013, CARBOHYD POLYM, V92, P1443, DOI 10.1016/j.carbpol.2012.10.051; Liron LR., 2006, US patent, Patent No. [7074928B2, 7074928]; Liu Xu, 2018, Journal of Pharmaceutical Investigation, V48, P19, DOI 10.1007/s40005-017-0361-5; Mehatha KA., 2014, TURK J PHARM SCI, V11, P113; Meng F, 2015, DRUG DEV IND PHARM, V41, P1401, DOI 10.3109/03639045.2015.1018274; Omerdic EO, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10144792; Patel BB, 2015, SAUDI PHARM J, V23, P352, DOI 10.1016/j.jsps.2013.12.013; Paudel A, 2013, INT J PHARMACEUT, V453, P253, DOI 10.1016/j.ijpharm.2012.07.015; Paudwal G, 2019, CURR PHARM DESIGN, V25, P1524, DOI 10.2174/1381612825666190618121553; Raijada DK, 2010, AAPS PHARMSCITECH, V11, P197, DOI 10.1208/s12249-010-9376-1; Sapkal S., 2013, INT J PHARM TECH RES, V5, P31; Savu SN, 2016, FARMACIA, V64, P302; Song YJ, 2013, J PHARM SCI-US, V102, P1915, DOI 10.1002/jps.23538; Srivastava A, 2010, J MOL STRUCT, V964, P88, DOI 10.1016/j.molstruc.2009.11.016; Duong TV, 2016, EXPERT OPIN DRUG DEL, V13, P1681, DOI 10.1080/17425247.2016.1198769; Vasconcelos T, 2016, ADV DRUG DELIVER REV, V100, P85, DOI 10.1016/j.addr.2016.01.012; Zupancic V, 2010, ACTA CHIM SLOV, V57, P376	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2022	17	4							e0266237	10.1371/journal.pone.0266237	http://dx.doi.org/10.1371/journal.pone.0266237			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4W9BZ	35377908	gold, Green Published			2023-01-03	WOS:000860451200027
J	Gardiner, LJ; Carrieri, AP; Bingham, K; Macluskie, G; Bunton, D; McNeil, M; Pyzer-Knapp, EO				Gardiner, Laura-Jayne; Carrieri, Anna Paola; Bingham, Karen; Macluskie, Graeme; Bunton, David; McNeil, Marian; Pyzer-Knapp, Edward O.			Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; PERSONALIZED MEDICINE; EXPRESSION ANALYSIS; CODON OPTIMALITY; P38 MAPK; PATHOGENESIS	Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, affect several million individuals worldwide. These diseases are heterogeneous at the clinical, immunological and genetic levels and result from complex host and environmental interactions. Investigating drug efficacy for IBD can improve our understanding of why treatment response can vary between patients. We propose an explainable machine learning (ML) approach that combines bioinformatics and domain insight, to integrate multi-modal data and predict inter-patient variation in drug response. Using explanation of our models, we interpret the ML models' predictions to infer unique combinations of important features associated with pharmacological responses obtained during preclinical testing of drug candidates in ex vivo patient-derived fresh tissues. Our inferred multi-modal features that are predictive of drug efficacy include multi-omic data (genomic and transcriptomic), demographic, medicinal and pharmacological data. Our aim is to understand variation in patient responses before a drug candidate moves forward to clinical trials. As a pharmacological measure of drug efficacy, we measured the reduction in the release of the inflammatory cytokine TNFa from the fresh IBD tissues in the presence/absence of test drugs. We initially explored the effects of a mitogen-activated protein kinase (MAPK) inhibitor; however, we later showed our approach can be applied to other targets, test drugs or mechanisms of interest. Our best model predicted TNF alpha levels from demographic, medicinal and genomic features with an error of only 4.98% on unseen patients. We incorporated transcriptomic data to validate insights from genomic features. Our results showed variations in drug effectiveness (measured by ex vivo assays) between patients that differed in gender, age or condition and linked new genetic polymorphisms to patient response variation to the anti-inflammatory treatment BIRB796 (Doramapimod). Our approach models IBD drug response while also identifying its most predictive features as part of a transparent ML precision medicine strategy.	[Gardiner, Laura-Jayne; Carrieri, Anna Paola; Pyzer-Knapp, Edward O.] Hartree Ctr, IBM Res Europe Daresbury, Warrington, Cheshire, England; [Bingham, Karen; Macluskie, Graeme; Bunton, David] REPROCELL Europe Ltd, Glasgow, Lanark, Scotland; [McNeil, Marian] Queen Elizabeth Univ Hosp, Precis Med Scotland Innovat Ctr, Teaching & Learning Bldg, Glasgow, Lanark, Scotland	Queen Elizabeth University Hospital (QEUH)	Gardiner, LJ; Carrieri, AP (corresponding author), Hartree Ctr, IBM Res Europe Daresbury, Warrington, Cheshire, England.	Laura-Jayne.Gardiner@ibm.com; acarrieri@uk.ibm.com	Gardiner, Laura-Jayne/ABD-3850-2020	Gardiner, Laura-Jayne/0000-0002-9177-4452; Bunton, David/0000-0001-9262-1696	Science and Technologies facilities Council (STFC) - UK Research and Innovation (UKRI); IBM - UK Research and Innovation (UKRI); Precision Medicine Scotland Innovation Centre (PMS-IC); Scottish Funding Council; Scottish Enterprise	Science and Technologies facilities Council (STFC) - UK Research and Innovation (UKRI)(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); IBM - UK Research and Innovation (UKRI); Precision Medicine Scotland Innovation Centre (PMS-IC); Scottish Funding Council; Scottish Enterprise	This work was supported by the Hartree National Centre for Digital Innovation, a collaboration between the Science and Technologies facilities Council (STFC) and IBM (LJG, APC, EPK) that is funded by the UK Research and Innovation (UKRI) funding agency. The functional pharmacology experiments and whole exome sequencing for this study were part-funded via a project grant from Precision Medicine Scotland Innovation Centre (PMS-IC), provided to REPROCELL Europe Ltd (KB, GM, DB). PMS-IC is funded by the Scottish Funding Council and Scottish Enterprise.	Agyeman AA, 2015, J PHARM BIOALLIED SC, V7, P239, DOI 10.4103/0975-7406.160040; Alatab S, 2020, LANCET GASTROENTEROL, V5, P17, DOI 10.1016/S2468-1253(19)30333-4; ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209; [Anonymous], 2019, PIC TOOLK; [Anonymous], NG130 NICE; [Anonymous], NICE GUIDELINE NG129; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Brunet S, 2014, TRAFFIC, V15, P803, DOI 10.1111/tra.12183; Carlton S.M, 2013, ENCY PAIN, DOI [10.1007/978-3-642-28753-4_1945, DOI 10.1007/978-3-642-28753-4_1945]; Carrieri AP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83922-6; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; Chang HC, 2018, J DERMATOL SCI, V92, P151, DOI 10.1016/j.jdermsci.2018.08.011; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Chen YX, 2016, J PERS MED, V6, DOI 10.3390/jpm6040020; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Cowan K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226564; Denson LA, 2019, INFLAMM BOWEL DIS, V25, pS31, DOI 10.1093/ibd/izz078; Dubuquoy L, 2002, LANCET, V360, P1410, DOI 10.1016/S0140-6736(02)11395-X; Galeotti N, 2012, NEUROPHARMACOLOGY, V62, P289, DOI 10.1016/j.neuropharm.2011.07.020; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Kim JA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122680; Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200; Kumar M, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02174-1; Gardiner LJ, 2021, bioRxiv, DOI 10.1101/2021.02.04.429826; Lea S, 2020, J MOL MED, V98, P361, DOI 10.1007/s00109-020-01873-3; Lee SH, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154872; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lucafo M, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040277; Lundberg SM, 2017, ADV NEUR IN, V30; Mandrekar SJ, 2011, J THORAC ONCOL, V6, P658, DOI 10.1097/JTO.0b013e31820e17cb; Moden O, 2014, ADV CANCER RES, V122, P199, DOI 10.1016/B978-0-12-420117-0.00006-2; Morampudi V, 2015, AM J PHYSIOL-GASTR L, V308, pG389, DOI 10.1152/ajpgi.00195.2014; Morgan P, 2012, DRUG DISCOV TODAY, V17, P419, DOI 10.1016/j.drudis.2011.12.020; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Nelson G, 2003, J CELL SCI, V116, P2495, DOI 10.1242/jcs.00461; Nicora G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01030; Olsen T, 2007, SCAND J GASTROENTERO, V42, P1312, DOI 10.1080/00365520701409035; Pagani F, 2005, P NATL ACAD SCI USA, V102, P6368, DOI 10.1073/pnas.0502288102; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Pechmann S, 2013, NAT STRUCT MOL BIOL, V20, P237, DOI 10.1038/nsmb.2466; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Plevy SE, 1997, J IMMUNOL, V159, P6276; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roden DM, 2013, CLIN PHARMACOL THER, V94, P168, DOI 10.1038/clpt.2013.101; Rousseaux C, 2005, J EXP MED, V201, P1205, DOI 10.1084/jem.20041948; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Schapire R.E., 2013, EMPIRICAL INFERENCE, P37, DOI [DOI 10.1007/978-3-642-41136-6_5, 10.1007/978-3-642-41136-6_5]; Stergachis AB, 2013, SCIENCE, V342, P1367, DOI 10.1126/science.1243490; Stocco G, 2007, INFLAMM BOWEL DIS, V13, P57, DOI 10.1002/ibd.20004; Tin Kam Ho, 1995, Proceedings of the Third International Conference on Document Analysis and Recognition, P278, DOI 10.1109/ICDAR.1995.598994; Trusheim MR, 2011, NAT REV DRUG DISCOV, V10, P817, DOI 10.1038/nrd3557	56	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2022	17	2							e0263248	10.1371/journal.pone.0263248	http://dx.doi.org/10.1371/journal.pone.0263248			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0QE	35196350	Green Published, gold			2023-01-03	WOS:000835161600011
J	Wu, SN; Tsai, MS; Huang, CH; Chen, WJ				Wu, Shih-Ni; Tsai, Min-Shan; Huang, Chien-Hua; Chen, Wen-Jone			Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; REVERSIBLE MYOCARDIAL DYSFUNCTION; ARREST; RESUSCITATION; CARDIOPULMONARY; ASSOCIATION; SURVIVAL; CARE; PROGNOSTICATION; INCREASE	Background Myocardial dysfunction is a major cause of poor outcomes in the post-cardiac arrest period. Omecamtiv mecarbil (OM) is a selective small molecule activator of cardiac myosin that prolongs myocardial systole and increases stroke volume without apparent effects on myocardial oxygen demand. OM administration is safe and improves cardiac function in patients with acute heart failure. Whether OM improves post-resuscitation myocardial dysfunction remains unclear. This study investigated the effect of OM treatment on post-resuscitation myocardial dysfunction and outcomes. Methods and results Adult male rats were resuscitated after 9.5 min of asphyxia-induced cardiac arrest. OM and normal saline was continuously intravenously infused after return of spontaneous circulation (ROSC) at 0.25 mg/kg/h for 4 h in the experimental group and control group, respectively (n = 20 in each group). Hemodynamic parameters were measured hourly and monitored for 4 h after cardiac arrest. Recovery of neurological function was evaluated by neurological functioning scores (0-12; favorable: 11-12) for rats 72 h after cardiac arrest. OM treatment prolonged left ventricular ejection time and improved post-resuscitation cardiac output. Post-resuscitation heart rate and left ventricular systolic function (dp/dt40) were not different between groups. Kaplan-Meier analysis showed non-statistically higher 72-h survival in the OM group (72.2% [13/18] and 58.8% [10/17], p = 0.386). The OM group had a higher chance of having favorable neurological outcomes in surviving rats 72 h after cardiac arrest (84.6% [11/13] vs. 40% [4/10], p = 0.026). The percentage of damaged neurons was lower in the OM group in a histology study at 72 h after cardiac arrest (55.5 +/- 2.3% vs. 76.2 +/- 10.2%, p = 0.004). Conclusions OM treatment improved post-resuscitation myocardial dysfunction and neurological outcome in an animal model. These findings support further pre-clinical studies to improve outcomes in post-cardiac arrest care.	[Wu, Shih-Ni; Tsai, Min-Shan; Huang, Chien-Hua; Chen, Wen-Jone] Natl Taiwan Univ, Dept Emergency Med, Med Coll & Hosp, Taipei, Taiwan; [Chen, Wen-Jone] Natl Taiwan Univ, Dept Internal Med, Div Cardiol, Med Coll & Hosp, Taipei, Taiwan	National Taiwan University; National Taiwan University	Huang, CH (corresponding author), Natl Taiwan Univ, Dept Emergency Med, Med Coll & Hosp, Taipei, Taiwan.	chhuang5940@ntu.edu.tw	TSAI, MIN-SHAN/AHE-3825-2022	TSAI, MIN-SHAN/0000-0002-2862-7572; CHEN, WEN-JONE/0000-0002-2098-5922; HUANG, CHIEN-HUA/0000-0003-2981-4537	Ministry of Science and Technology [105-2314-B-002-125-MY3, 104-2314-B-002-204]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	The study was supported by research grant (105-2314-B-002-125-MY3 & 104-2314-B-002-204) from the Ministry of Science and Technology.	Aronson D, 2012, PHARMACOL THERAPEUT, V135, P1, DOI 10.1016/j.pharmthera.2012.03.002; Becker L B, 1997, New Horiz, V5, P145; Bigham BL, 2011, RESUSCITATION, V82, P979, DOI 10.1016/j.resuscitation.2011.03.024; Chalkias A, 2012, HEART FAIL REV, V17, P117, DOI 10.1007/s10741-011-9255-1; Chang WT, 2007, INTENS CARE MED, V33, P88, DOI 10.1007/s00134-006-0442-9; Dragancea I, 2013, RESUSCITATION, V84, P337, DOI 10.1016/j.resuscitation.2012.09.015; Garman RH, 2011, TOXICOL PATHOL, V39, P22, DOI 10.1177/0192623310389621; Howard Robin S, 2011, Pract Neurol, V11, P4, DOI 10.1136/jnnp.2010.235218; Huang CH, 2007, SHOCK, V28, P53, DOI 10.1097/shk.0b013e31802f0218; Huang CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166324; Huang CH, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0516-3; Huang L, 2005, J LAB CLIN MED, V146, P256, DOI 10.1016/j.lab.2005.07.005; Jentzer JC, 2018, RESUSCITATION, V123, P15, DOI 10.1016/j.resuscitation.2017.12.004; Jentzer JC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/314796; Kaplinsky Edgardo, 2018, Drugs Context, V7, P212518, DOI 10.7573/dic.212518; Kern KB, 1997, CIRCULATION, V95, P2610, DOI 10.1161/01.CIR.95.12.2610; Kern KB, 1996, J AM COLL CARDIOL, V28, P232, DOI 10.1016/0735-1097(96)00130-1; Kim MJ, 2015, RESUSCITATION, V97, P115, DOI 10.1016/j.resuscitation.2015.08.019; Laurent I, 2002, J AM COLL CARDIOL, V40, P2110, DOI 10.1016/S0735-1097(02)02594-9; Lemiale V, 2008, RESUSCITATION, V76, P17, DOI 10.1016/j.resuscitation.2007.06.028; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Malik FI, 2011, SCIENCE, V331, P1439, DOI 10.1126/science.1200113; Menasche P, 2001, SHOCK, V16, P20, DOI 10.1097/00024382-200116001-00005; Mongardon N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-45; Niemann JT, 2003, CIRCULATION, V108, P3031, DOI 10.1161/01.CIR.0000101925.37174.85; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Ruiz-Bailen M, 2005, RESUSCITATION, V66, P175, DOI 10.1016/j.resuscitation.2005.01.012; Tariq S, 2015, INT J MOL SCI, V16, P29060, DOI 10.3390/ijms161226147; Teerlink JR, 2016, J AM COLL CARDIOL, V67, P1444, DOI 10.1016/j.jacc.2016.01.031; Teerlink JR, 2009, HEART FAIL REV, V14, P243, DOI 10.1007/s10741-009-9153-y; Tsai MS, 2019, RESUSCITATION, V137, P52, DOI 10.1016/j.resuscitation.2019.01.040; Uray T, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018657; Uray T, 2018, CRIT CARE MED, V46, pE508, DOI 10.1097/CCM.0000000000003070; Vaagenes P, 1997, RESUSCITATION, V35, P41, DOI 10.1016/S0300-9572(97)01108-8; Vasquez A, 2004, RESUSCITATION, V61, P199, DOI 10.1016/j.resuscitation.2004.01.002; Wang CH, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016139; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; Xanthos T, 2009, AM J EMERG MED, V27, P651, DOI 10.1016/j.ajem.2008.05.004; Yeo D, 2020, GEROSCIENCE, V42, P963, DOI 10.1007/s11357-020-00171-7	41	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0264165	10.1371/journal.pone.0264165	http://dx.doi.org/10.1371/journal.pone.0264165			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176110	gold, Green Published			2023-01-03	WOS:000777505200089
J	Karki, B; Thapa, S; Khadka, D; Karki, S; Shrestha, R; Khanal, A; Shrestha, R; Paudel, BN				Karki, Binod; Thapa, Suresh; Khadka, Dibas; Karki, Sanjit; Shrestha, Roshan; Khanal, Ajit; Shrestha, Ramila; Paudel, Bidhan Nidhi			Intravenous Ringers lactate versus normal saline for predominantly mild acute pancreatitis in a Nepalese Tertiary Hospital	PLOS ONE			English	Article							FLUID RESUSCITATION; ATLANTA CLASSIFICATION; VALIDATION; REVISION; ACIDOSIS; BLIND	Background Acute pancreatitis (AP) is a common presentation in patients admitted with acute abdomen. Whether Ringers lactate (RL) or Normal Saline (NS) as a resuscitation fluid is better still remains unclear. The aim of this study is to compare the efficacy of RL and NS in terms of control of systemic inflammation by measuring indirect markers specifically Systemic Inflammation Response Syndrome (SIRS) scores and C- Reactive Protein (CRP) level. Methods This was an open label randomized trial conducted in a tertiary level hospital of Nepal. Ethical approval was obtained prior to the study. Patients with acute pancreatitis were randomized to either RL or NS group for the fluid resuscitation. The fluid was given as per the study protocol for three days for hydration. Baseline SIRS and CRP were recorded on admission and subsequently as defined. All the data were analyzed using SPSS ver 20.0 software. Results Total 51 patients were enrolled, 26 in RL and 25 in NS group. The commonest etiology of AP was alcohol (84.31%). SIRS was present in 46.2% and 64.0% of patients in RL and NS group respectively (p = 0.20) on admission. At least one SIRS criteria was still present in 44.0% of patients in the NS group compared to only 15.4% in the RL group after 24 hours (p = 0.025). The baseline CRP were comparable in both the groups. However after 72 hours, the increment of CRP was more in the NS group compared to the RL group; median value of 14.2 mg/dl (12.15, 16.45) and 22.2 mg/dl (18.20, 30.60) in RL and NS group respectively (p<0.001). Conclusions Ringers lactate was associated with a reduction in systemic inflammation compared to normal saline in patients with acute pancreatitis. Incidence of SIRS at 72 hours and occurrence of local complications were however similar in both the groups.	[Karki, Binod] Nepalese Army Inst Hlth Sci, Dept Med, Kathmandu, Nepal; [Thapa, Suresh] Pokhara Acad Hlth Sci, Dept Med, Pokhara, Nepal; [Khadka, Dibas; Khanal, Ajit; Shrestha, Ramila; Paudel, Bidhan Nidhi] Natl Acad Med Sci, Dept Med, Gastroenterol Unit, Kathmandu, Nepal; [Karki, Sanjit; Shrestha, Roshan] Patan Acad Hlth Sci, Dept Med, Lalitpur, Nepal		Karki, B (corresponding author), Nepalese Army Inst Hlth Sci, Dept Med, Kathmandu, Nepal.	binodkarki@yahoo.com						Aboelsoud Mohammed M, 2016, R I Med J (2013), V99, P39; Acevedo-Piedra NG, 2014, CLIN GASTROENTEROL H, V12, P311, DOI 10.1016/j.cgh.2013.07.042; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Choosakul S, 2017, GASTROENTEROLOGY, V152, pS72, DOI 10.1016/S0016-5085(17)30594-2; de-Madaria E, 2018, UNITED EUR GASTROENT, V6, P63, DOI 10.1177/2050640617707864; Hadimioglu N, 2008, ANESTH ANALG, V107, P264, DOI 10.1213/ane.0b013e3181732d64; Johnson CD, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4859; Kellum JA, 2004, AM J PHYSIOL-REG I, V286, pR686, DOI 10.1152/ajpregu.00564.2003; Khajavi MR, 2008, RENAL FAILURE, V30, P535, DOI 10.1080/08860220802064770; Lakhey PJ, 2013, J NEPAL MED ASSOC, V52, P580; Lee A, 2021, GASTROENTEROLOGY, V160, P955, DOI 10.1053/j.gastro.2020.10.044; Lipinski M, 2015, WORLD J GASTROENTERO, V21, P9367, DOI 10.3748/wjg.v21.i31.9367; Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254; Reid F, 2003, CLIN SCI, V104, P17, DOI 10.1042/cs1040017; Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007; Singh VK, 2009, CLIN GASTROENTEROL H, V7, P1247, DOI 10.1016/j.cgh.2009.08.012; Tenner S., 2016, SLEISENGER FORDTRANS, V10th ed, P969; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; Vinish DB, 2017, INDIAN J GASTROENTER, V36, P43, DOI 10.1007/s12664-017-0728-6; Wall I, 2011, PANCREAS, V40, P547, DOI 10.1097/MPA.0b013e318215368d; Wu BU, 2011, CLIN GASTROENTEROL H, V9, P710, DOI 10.1016/j.cgh.2011.04.026	22	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2022	17	1							e0263221	10.1371/journal.pone.0263221	http://dx.doi.org/10.1371/journal.pone.0263221			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT4WP	35089964	gold, Green Published			2023-01-03	WOS:000769158400044
J	Gomes, ID; Santana, CA; Marcolino, LS; de Lima, LHF; de Melo-Minardi, RC; Dias, RS; de Paula, SO; Silveira, SD				Gomes, Isabela de Souza; Santana, Charles Abreu; Marcolino, Leandro Soriano; Franca de Lima, Leonardo Henrique; de Melo-Minardi, Raquel Cardoso; Dias, Roberto Sousa; de Paula, Sergio Oliveira; Silveira, Sabrina de Azevedo			Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics	PLOS ONE			English	Article							MOLECULAR-DYNAMICS; DRUG DISCOVERY; FORCE-FIELD; GROMACS; SOFTWARE; DESIGN; TOOL	The development of new drugs is a very complex and time-consuming process, and for this reason, researchers have been resorting heavily to drug repurposing techniques as an alternative for the treatment of various diseases. This approach is especially interesting when it comes to emerging diseases with high rates of infection, because the lack of a quickly cure brings many human losses until the mitigation of the epidemic, as is the case of COVID-19. In this work, we combine an in-house developed machine learning strategy with docking, MM-PBSA calculations, and metadynamics to detect potential inhibitors for SARS-COV-2 main protease among FDA approved compounds. To assess the ability of our machine learning strategy to retrieve potential compounds we calculated the Enrichment Factor of compound datasets for three well known protein targets: HIV-1 reverse transcriptase (PDB 4B3P), 5-HT2A serotonin receptor (PDB 6A94), and H1 histamine receptor (PDB 3RZE). The Enrichment Factor for each target was, respectively, 102.5, 12.4, 10.6, which are considered significant values. Regarding the identification of molecules that can potentially inhibit the main protease of SARS-COV-2, compounds output by the machine learning step went through a docking experiment against SARS-COV-2 M-pro. The best scored poses were the input for MM-PBSA calculations and metadynamics using CHARMM and AMBER force fields to predict the binding energy for each complex. Our work points out six molecules, highlighting the strong interaction obtained for M-pro-mirabegron complex. Among these six, to the best of our knowledge, ambenonium has not yet been described in the literature as a candidate inhibitor for the SARS-COV-2 main protease in its active pocket.	[Gomes, Isabela de Souza; Silveira, Sabrina de Azevedo] Univ Fed Vicosa, Dept Comp Sci, Vicosa, MG, Brazil; [Santana, Charles Abreu; de Melo-Minardi, Raquel Cardoso] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil; [Santana, Charles Abreu; de Melo-Minardi, Raquel Cardoso] Univ Fed Minas Gerais, Dept Comp Sci, Belo Horizonte, MG, Brazil; [Marcolino, Leandro Soriano] Univ Lancaster, Sch Comp & Commun, Lancaster, England; [Franca de Lima, Leonardo Henrique] Univ Fed Sao Joao Rei, Dept Exact & Biol Sci, Sete Lagoas Campus, Sete Lagoas, MG, Brazil; [Dias, Roberto Sousa] Univ Fed Vicosa, Dept Gen Biol, Vicosa, MG, Brazil; [de Paula, Sergio Oliveira] Univ Fed Vicosa, Dept Microbiol, Vicosa, MG, Brazil	Universidade Federal de Vicosa; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Lancaster University; Universidade Federal de Sao Joao del-Rei; Universidade Federal de Vicosa; Universidade Federal de Vicosa	Silveira, SD (corresponding author), Univ Fed Vicosa, Dept Comp Sci, Vicosa, MG, Brazil.	sabrina@ufv.br	Silveira, Sabrina/AID-6483-2022	Silveira, Sabrina/0000-0002-4723-2349; de Souza Gomes, Isabela/0000-0001-9311-707X; Lima, Leonardo/0000-0003-4346-9880	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [23038.004007/2014-82, 051/2013]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 23038.004007/2014-82 -Grant 051/2013; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG). The funding agencies had no role in study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.	Acharya C, 2011, CURR COMPUT-AID DRUG, V7, P10, DOI 10.2174/157340911793743547; Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254; Anderson AC, 2003, CHEM BIOL, V10, P787, DOI 10.1016/j.chembiol.2003.09.002; [Anonymous], RDKIT OPEN SOURCE CH; Banegas-Luna AJ, 2018, FUTURE MED CHEM, V10, P2641, DOI 10.4155/fmc-2018-0076; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biovia D.S., 2017, DISCOVERY STUDIO MOD; Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r; Brandt AML, 2016, PROTEINS, V84, P473, DOI 10.1002/prot.24994; Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005; Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273; Davies M, 2015, NUCLEIC ACIDS RES, V43, pW612, DOI 10.1093/nar/gkv352; Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z; Galindez G, 2021, NAT COMPUT SCI, V1, P33, DOI 10.1038/s43588-020-00007-6; Garcia-Hernandez C, 2019, J CHEM INF MODEL, V59, P1410, DOI 10.1021/acs.jcim.8b00820; Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072; Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375; Gonczarek A, 2018, COMPUT BIOL MED, V100, P253, DOI 10.1016/j.compbiomed.2017.09.007; Guo HX, 2017, EXPERT SYST APPL, V73, P220, DOI 10.1016/j.eswa.2016.12.035; HESTENES MR, 1952, J RES NAT BUR STAND, V49, P409, DOI 10.6028/jres.049.044; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Kuhne R, 2009, J CHEM INF MODEL, V49, P2660, DOI 10.1021/ci900313u; Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m; Le TT, 2020, BIOINFORMATICS, V36, P250, DOI 10.1093/bioinformatics/btz470; Legnik S, 2015, J CHEM INF MODEL, V55, P1521, DOI 10.1021/acs.jcim.5b00136; Li HJ, 2021, WIRES COMPUT MOL SCI, V11, DOI 10.1002/wcms.1478; Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010; Luo HM, 2021, BRIEF BIOINFORM, V22, P1604, DOI 10.1093/bib/bbz176; Martins PM, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-020-03881-z; Mendolia I, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03645-9; Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Morse PM, 1953, METHODS THEORETICAL, V1; Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Pedregosa F, 2011, JMLR, V12, P2825; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Rifaioglu AS, 2019, BRIEF BIOINFORM, V20, P1878, DOI 10.1093/bib/bby061; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Santana CA, 2020, BIOINFORMATICS, V36, pI726, DOI 10.1093/bioinformatics/btaa805; Shang JL, 2017, BIOINFORMATICS, V33, P3480, DOI 10.1093/bioinformatics/btx418; Sledz P, 2018, CURR OPIN STRUC BIOL, V48, P93, DOI 10.1016/j.sbi.2017.10.010; Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; U.S. Food & Drug Administration, US; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; VEKLURY, US; Wall M.E., 2003, PRACTICAL APPROACH M, P91, DOI DOI 10.1007/0-306-47815-3_5; Wallach I., 2015, ARXIV; Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Yasuo N, 2019, J CHEM INF MODEL, V59, P1050, DOI 10.1021/acs.jcim.8b00673; Zaki Mohammed J., 2014, DATA MINING ANAL; Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405; Zheng MH, 2014, MOL DIVERS, V18, P829, DOI 10.1007/s11030-014-9545-3; Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816	65	2	2	7	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267471	10.1371/journal.pone.0267471	http://dx.doi.org/10.1371/journal.pone.0267471			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1C1KV	35452494	gold, Green Published			2023-01-03	WOS:000792887700006
J	Isono, M; Okubo, K; Asano, T; Sato, A				Isono, Makoto; Okubo, Kazuki; Asano, Takako; Sato, Akinori			Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells	PLOS ONE			English	Article							DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; 2,2-DIFLUORODEOXYCYTIDINE; MECHANISMS; CHK1	The ataxia telangiectasia and rad3-related-checkpoint kinase 1 (ATR-CHK1) pathway is involved in DNA damage responses in many cancer cells. ATR inhibitors have been used in clinical trials in combination with radiation or chemotherapeutics; however, their effects against bladder cancer remain unclear. Here, the efficacy of combining gemcitabine with the novel ATR inhibitor AZD6738 was investigated in vitro in three bladder cancer cell lines (J82, T24, and UM-UC-3 cells). The effects of gemcitabine and AZD6738 on cell viability, clonogenicity, cell cycle, and apoptosis were examined. The combined use of gemcitabine and AZD6738 inhibited the viability and colony formation of bladder cancer cells compared to either treatment alone. Gemcitabine (5 nM) and AZD6738 (1 mu M) inhibited cell cycle progression, causing cell accumulation in the S phase. Moreover, combined treatment enhanced cleaved poly[ADP-ribose]-polymerase expression alongside the number of annexin V-positive cells, indicating apoptosis induction. Mechanistic investigations showed that AZD6738 treatment inhibited the repair of gemcitabine-induced double-strand breaks by interfering with CHK1. Combining AZD6738 with gemcitabine could therefore be useful for bladder cancer therapy.	[Isono, Makoto; Okubo, Kazuki; Asano, Takako; Sato, Akinori] Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama, Japan	National Defense Medical College - Japan	Isono, M (corresponding author), Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama, Japan.	mktisn@hotmail.com		Isono, Makoto/0000-0002-1307-0281				Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Carballido EM, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-014-0404-2; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dash A, 2006, CANCER, V107, P506, DOI 10.1002/cncr.22031; Dillon MT, 2018, CLIN TRANSL RAD ONCO, V12, P16, DOI 10.1016/j.ctro.2018.06.001; Dunlop CR, 2020, BRIT J CANCER, V123, P1424, DOI 10.1038/s41416-020-1016-2; Earl J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1450-3; Gralewska P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249715; HEINEMANN V, 1992, CANCER RES, V52, P533; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUANG P, 1991, CANCER RES, V51, P6110; Hur J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031223; Isono M, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0473-1; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kim ST, 2021, CLIN CANCER RES, V27, P4700, DOI 10.1158/1078-0432.CCR-21-0251; Li CC, 2016, ONCOTARGET, V7, P1947, DOI 10.18632/oncotarget.6482; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Mao ZY, 2008, DNA REPAIR, V7, P1765, DOI 10.1016/j.dnarep.2008.06.018; Milowsky MI, 2016, J CLIN ONCOL, V34, P1945, DOI 10.1200/JCO.2015.65.9797; Montano R, 2017, ONCOTARGET, V8, P67754, DOI 10.18632/oncotarget.18834; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sheng HL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000340; Shibata A, 2014, CLIN ONCOL-UK, V26, P243, DOI 10.1016/j.clon.2014.02.004; Wallez Y, 2018, MOL CANCER THER, V17, P1670, DOI 10.1158/1535-7163.MCT-18-0010; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642	30	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266476	10.1371/journal.pone.0266476	http://dx.doi.org/10.1371/journal.pone.0266476			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Y6SQ	35413091	Green Published, gold			2023-01-03	WOS:000790519000020
J	Kim, JH; Baek, AR; Lee, SI; Kim, WY; Na, YS; Lee, BY; Seong, GM; Baek, MS				Kim, Jin Hyoung; Baek, Ae-Rin; Lee, Song-, I; Kim, Won-Young; Na, Yong Sub; Lee, Bo Young; Seong, Gil Myeong; Baek, Moon Seong			ROX index and SpO(2)/FiO(2) ratio for predicting high-flow nasal cannula failure in hypoxemic COVID-19 patients: A multicenter retrospective study	PLOS ONE			English	Article							RESPIRATORY-FAILURE; LUNG INJURY; INTUBATION; VENTILATION; CHILDREN; THERAPY	BackgroundThe ratio of oxygen saturation (ROX) index, defined as the ratio of oxygen saturation (SpO(2))/fraction of inspired oxygen (FiO(2)) to respiratory rate, can help identify patients with hypoxemic respiratory failure at high risk for intubation following high-flow nasal cannula (HFNC) initiation; however, whether it is effective for predicting intubation in coronavirus disease 2019 (COVID-19) patients receiving HFNC remains unknown. Moreover, the SpO(2)/FiO(2) ratio has been assessed as a prognostic marker for acute hypoxemic respiratory failure. This study aimed to determine the utility of the ROX index and the SpO(2)/FiO(2) ratio as predictors of failure in COVID-19 patients who received HFNC. MethodsThis multicenter study was conducted in seven university-affiliated hospitals in Korea. Data of consecutive hospitalized patients diagnosed with COVID-19 between February 10, 2020 and February 28, 2021 were retrospectively reviewed. We calculated the ROX index and the SpO(2)/FiO(2) ratio at 1 h, 4 h, and 12 h after HFNC initiation. The primary outcome was HFNC failure defined as the need for subsequent intubation despite HFNC application. The receiver operating characteristic curve analysis was used to evaluate discrimination of prediction models for HFNC failure. ResultsOf 1,565 hospitalized COVID-19 patients, 133 who received HFNC were analyzed. Among them, 63 patients (47.4%) were successfully weaned from HFNC, and 70 (52.6%) were intubated. Among patients with HFNC failure, 32 (45.7%) died. The SpO(2)/FiO(2) ratio at 1 h after HFNC initiation was an important predictor of HFNC failure (AUC 0.762 [0.679-0.846]). The AUCs of SpO(2)/FiO(2) ratio at 4 h and ROX indices at 1 h and 4 h were 0.733 (0.640-0.826), 0.697 (0.597-0.798), and 0.682 (0.583-0.781), respectively. Multivariable analysis showed that the patients aged >= 70 years are 3.4 times more likely to experience HFNC failure than those aged <70 years (HR 3.367 [1.358-8.349], p = 0.009). The SpO(2)/FiO(2) ratio (HR 0.983 [0.972-0.994], p = 0.003) at 1 h was significantly associated with HFNC failure. ConclusionsThe SpO(2)/FiO(2) ratio following HFNC initiation was an acceptable predictor of HFNC failure. The SpO(2)/FiO(2) ratio may be a good prognostic marker for predicting intubation in COVID-9 patients receiving HFNC.	[Kim, Jin Hyoung] Univ Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Resp & Crit Care Med,Coll Med, Ulsan, South Korea; [Baek, Ae-Rin] Soonchunhyang Univ, Dept Internal Med, Div Allergy & Pulmonol, Bucheon Hosp, Bucheon, South Korea; [Lee, Song-, I] Chungnam Natl Univ Hosp, Dept Pulm & Crit Care Med, Daejeon, South Korea; [Kim, Won-Young; Baek, Moon Seong] Chung Ang Univ, Chung Ang Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; [Na, Yong Sub] Chosun Univ Hosp, Dept Pulmonol & Crit Care Med, Gwangju, South Korea; [Lee, Bo Young] Soonchunhyang Univ Hosp, Div Allergy & Resp Dis, Seoul, South Korea; [Seong, Gil Myeong] Jeju Natl Univ, Dept Internal Med, Coll Med, Jeju, South Korea	University of Ulsan; Ulsan University Hospital; Soonchunhyang University; Chungnam National University; Chungnam National University Hospital; Chung Ang University; Chung Ang University Hospital; Chosun University; Soonchunhyang University; Soonchunhyang University Hospital; Jeju National University	Baek, MS (corresponding author), Chung Ang Univ, Chung Ang Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea.	wido21@cau.ac.kr	Kim, Won-Young/AHE-5670-2022	Kim, Won-Young/0000-0002-6038-9818; Baek, Moon Seong/0000-0001-6455-0376; Kim, Jin Hyoung/0000-0002-2229-2388				Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Calligaro GL, 2020, ECLINICALMEDICINE, V28, DOI 10.1016/j.eclinm.2020.100570; Catoire P, 2021, AM J EMERG MED, V44, P116, DOI 10.1016/j.ajem.2021.01.092; Chandel A, 2021, RESP CARE, V66, P909, DOI 10.4187/respcare.08631; Duan J, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.639100; Flenady T, 2017, AUSTRALAS EMERG NURS, V20, P45, DOI 10.1016/j.aenj.2016.12.003; Fukuda Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245927; Grieco DL, 2019, MINERVA ANESTESIOL, V85, P1014, DOI 10.23736/S0375-9393.19.13418-9; Hernandez-Romieu AC, 2020, CRIT CARE MED, V48, pE1045, DOI 10.1097/CCM.0000000000004600; Hu M, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01354-w; Hyman Jaime B, 2020, Crit Care Explor, V2, pe0254, DOI 10.1097/CCE.0000000000000254; Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5; Karim HMR, 2019, AM J RESP CRIT CARE, V200, P116, DOI 10.1164/rccm.201902-0419LE; Kim GE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92893-7; KSCCM, ICU PROT HOSP DED IN; Mayordomo-Colunga J, 2013, INTENS CARE MED, V39, P1095, DOI 10.1007/s00134-013-2880-5; Ni YN, 2017, CHEST, V151, P764, DOI 10.1016/j.chest.2017.01.004; Panadero C, 2020, MULTIDISCIP RESP MED, V15, DOI 10.4081/mrm.2020.693; Patel M, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000650; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617; Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC; Roca O, 2016, J CRIT CARE, V35, P200, DOI 10.1016/j.jcrc.2016.05.022; Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5; Suliman LA, 2021, ADV RESPIR MED, V89, P1, DOI 10.5603/ARM.a2020.0176; Tobin MJ, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01520-y; Yao WL, 2020, BRIT J ANAESTH, V125, pE28, DOI 10.1016/j.bja.2020.03.026; Zaboli A, 2021, J ADV NURS, V77, P3361, DOI 10.1111/jan.14848; Zhao HY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1760-8	28	1	1	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5							e0268431	10.1371/journal.pone.0268431	http://dx.doi.org/10.1371/journal.pone.0268431			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L2YO	35551328	gold, Green Published			2023-01-03	WOS:000834632000005
J	Tesfau, YB; Gebrehiwot, TG; Debeb, HG; Kahsay, AB				Tesfau, Yemane Berhane; Gebrehiwot, Tesfay Gebregzabher; Debeb, Hagos Godefay; Kahsay, Alemayehu Bayray			"Mothers will be lucky if utmost receive a single scheduled postnatal home visit": An exploratory qualitative study, Northern Ethiopia	PLOS ONE			English	Article							COMMUNITY-HEALTH WORKERS; CARE; COUNTRIES; PROGRAM	BackgroundPostnatal home visits (PNHVs) have been endorsed as strategy for delivery of postnatal care (PNC) to reduce newborn mortality and improve maternal outcomes. Despite the important role of the Health Extension Workers (HEWs) in improving the overall healthcare coverage, PNHV remains as a missed opportunity in rural Ethiopia. Thus, this study aimed to explore the barriers and facilitators of scheduled postnatal home visits in Northern Ethiopia. MethodsWe conducted an exploratory qualitative study on a total of 16 in-depth interviews with HEWs and mothers who gave birth one year prior to the study. In addition, focus group discussions were conducted with HEWs and key informant interviews were conducted with women development group leaders, supervisors, and healthcare authorities from April to June 2019 in two rural districts of Northern Ethiopia. Discussions and interviews were audio recorded and transcribed verbatim in the local language (Tigrigna) and translated into English. The translated scripts were thematically coded using Atlas ti scientific software. Field notes were also taken during the discussion and while conducting the interviews. ResultsHealth system factors, community context, and individual level factors were considered as the barriers and facilitators of scheduled PNHVs. Leadership, governance, management, support and supervision, referral linkages, overwhelming workload, capacity building, logistics and supplies are the major sub-themes identified as health system factors. Physical characteristics like geographical location and topography, distance, and coverage of the catchment; and community support and participation like support from women's development groups (WDGs), awareness of the community on the presence of the service and cultural and traditional beliefs were community contexts that affect PNHVs. Self-motivation to support and intrinsic job satisfaction were individual level factors that were considered as barriers and facilitators. ConclusionThe finding of this study suggested that the major barriers of postnatal home visits were poor attention of healthcare authorities of the government bodies, lack of effective supervision, poor functional linkages, inadequate logistics and supplies, unrealistic catchment area coverage, poor community participation and support, and lack of motivation of HEWs. Henceforth, to achieve the scheduled PNHV in rural Ethiopia, there should be strong political commitment and healthcare authorities should provide attention to postnatal care both at facility and home with a strong controlling system.	[Tesfau, Yemane Berhane] Adigrat Univ, Coll Med & Hlth Sci, Adigrat, Ethiopia; [Tesfau, Yemane Berhane; Gebrehiwot, Tesfay Gebregzabher; Kahsay, Alemayehu Bayray] Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia; [Debeb, Hagos Godefay] Tigray Reg Hlth Bur, Mekelle, Ethiopia	Mekelle University	Tesfau, YB (corresponding author), Adigrat Univ, Coll Med & Hlth Sci, Adigrat, Ethiopia.; Tesfau, YB (corresponding author), Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia.	yemaneberhane12@gmail.com			Bill and Melinda Gates foundation; World Health Organization [201526690]	Bill and Melinda Gates foundation(Bill & Melinda Gates Foundation); World Health Organization(World Health Organization)	This study was carried out by Adigrat University and the "Tigray KMC Project" which is funded by Bill and Melinda Gates foundation and World Health Organization [Grant Number: 201526690]. The funding body had no role in the design of the study, collection, analysis, interpretation of data, and in writing the manuscript.	Abbott L, 2011, HEALTH CARE WOMEN IN, V32, P225, DOI 10.1080/07399332.2010.529217; Akibu M, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/8625437; ALAUDDIN M, 1986, STUD FAMILY PLANN, V17, P13, DOI 10.2307/1966951; Alvarado R, 1999, STUD FAMILY PLANN, V30, P133, DOI 10.1111/j.1728-4465.1999.00133.x; Amare Y, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5922-7; Bang RA, 2004, BJOG-INT J OBSTET GY, V111, P231, DOI 10.1111/j.1471-0528.2004.00063.x; Berhanu D, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05151-3; Bilal NK., YES AFRICA CAN SUCCE, P433; Callaghan-Koru JA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-55; Callaghan-Koru JA, 2012, AM J TROP MED HYG, V87, P61, DOI 10.4269/ajtmh.2012.11-0665; Central SA., 2019, ETH MIN HLTH SURV; Colvin D., WHAT MOTIVATES COMMU; DiBari JN, 2014, J PREGNANCY, V2014, DOI 10.1155/2014/530769; Furth R., 2012, IMPROVING CHW PROGRA; Gebretsadik A, 2018, PEDIATR HEALTH MED T, V9, P147, DOI 10.2147/PHMT.S179339; Gogia S, 2010, B WORLD HEALTH ORGAN, V88, P658, DOI 10.2471/BLT.09.069369; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; Hill Z, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.24085; Hodgins S., POSTNATAL CARE FOCUS; Jaskiewicz W, 2012, HUM RESOUR HEALTH, V10, DOI 10.1186/1478-4491-10-38; Kalyango JN, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-282; Kerie MW., CONTRIBUTION HLTH SE; Kok MC, 2015, HEALTH POLICY PLANN, V30, P1207, DOI 10.1093/heapol/czu126; Kok MC, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0001-3; Limenih MA., 2016, INT J REPROD MED; McPherson R, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010422; Namazzi G, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1345495; Ndima SD, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0063-x; Ochieng BM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-S1-S4; Probandari A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2490-y; Razee H, 2012, SOC SCI MED, V75, P828, DOI 10.1016/j.socscimed.2012.04.013; Roberton T, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0010-x; Sacks E, 2017, MATERN CHILD HLTH J, V21, P599, DOI 10.1007/s10995-016-2144-4; Schneider H, 2008, HEALTH POLICY PLANN, V23, P179, DOI 10.1093/heapol/czn006; Scott K, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0304-x; Seutloali T, 2018, AFR J PRIM HEALTH CA, V10, DOI 10.4102/phcfm.v10i1.1558; SEZAO. (South-eastern Zone Administrative Office) of Tigray region, 2018, ANNU REP PROG CHEM; Shaban IA, 2018, HOME HEALTH CARE SER, V37, P247, DOI 10.1080/01621424.2018.1454865; Shega SA, 2014, EXPLORING FACTORS AF; Sinha LN, 2014, WEST PAC SURVEILL RE, V5, P22, DOI [10.5365/WPSAR.2014.5.1.006, 10.5365/wpsar.2014.5.1.006]; Sitrin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068930; Smith S, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-24; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; Teklehaimanot A., 2007, ETHIOP J HEALTH DEV, V21; Tesfau YB, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03003-w; Teshome M., 2018, HOME BASED NEONATAL; Ugboaja Joseph O, 2013, Niger Med J, V54, P45, DOI 10.4103/0300-1652.108895; Varma DS., 2013, J FAM WELFARE, V56, P31; Victora CG, 2016, LANCET, V387, P2049, DOI 10.1016/S0140-6736(15)00519-X; Willis-Shattuck M, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-247; Workineh YG, 2014, SCI J PUBLIC HLTH, V2, P169, DOI [10.11648/j.sjph.20140203.15, DOI 10.11648/J.SJPH.20140203.15]; World Health Organization (WHO), 2007, COMMUNITY HLTH WORKE; World Hlth Org, 1999, BIRTH-ISS PERINAT C, V26, P255; Yared A., NONFINANCIAL INCENTI; Ye-Ebiyo Y., 2007, ETHIOP J HEALTH DEV, V21	55	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265301	10.1371/journal.pone.0265301	http://dx.doi.org/10.1371/journal.pone.0265301			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0T0FS	35353832	Green Published, gold			2023-01-03	WOS:000786647900051
J	Ide, M; Tabata, N; Yonemura, Y; Shirasaki, T; Murai, K; Wang, Y; Ishida, A; Okada, H; Honda, M; Kaneko, S; Doi, N; Ito, S; Yanagawa, H				Ide, Mayuko; Tabata, Noriko; Yonemura, Yuko; Shirasaki, Takayoshi; Murai, Kazuhisa; Wang, Ying; Ishida, Atsuya; Okada, Hikari; Honda, Masao; Kaneko, Shuichi; Doi, Nobuhide; Ito, Satoru; Yanagawa, Hiroshi			Guanine nucleotide exchange factor DOCK11-binding peptide fused with a single chain antibody inhibits hepatitis B virus infection and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EGF RECEPTOR; RHO GTPASES; IN-VITRO; ACTIVATION; PROTEINS; IDENTIFICATION; PHOSPHORYLATION; METABOLISM; SELECTION	Hepatitis B virus (HBV) infection is a major global health problem with no established cure. Dedicator of cytokinesis 11 (DOCK11), known as a guanine nucleotide exchange factor (GEF) for Cdc42, is reported to be essential for the maintenance of HBV. However, potential therapeutic strategies targeting DOCK11 have not yet been explored. We have previously developed an in vitro virus method as a more efficient tool for the analysis of proteomics and evolutionary protein engineering. In this study, using the in vitro virus method, we screened and identified a novel antiasialoglycoprotein receptor (ASGR) antibody, ASGR3-10M, and a DOCK11-binding peptide, DCS8-42A, for potential use in HBV infection. We further constructed a fusion protein (10M-D42AN) consisting of ASGR3-10M, DCS8-42A, a fusogenic peptide, and a nuclear localization signal to deliver the peptide inside hepatocytes. We show using immunofluorescence staining that 10M-D42AN was endocytosed into early endosomes and released into the cytoplasm and nucleus. Since DCS8-42A shares homology with activated cdc42-associated kinase 1 (Ack1), which promotes EGFR endocytosis required for HBV infection, we also found that 10M-D42AN inhibited endocytosis of EGFR and Ack1. Furthermore, we show 10MD42AN suppressed the function of DOCK11 in the host DNA repair system required for covalently closed circular DNA synthesis and suppressed HBV proliferation in mice. In conclusion, this study realizes a novel hepatocyte-specific drug delivery system using an anti-ASGR antibody, a fusogenic peptide, and DOCK11-binding peptide to provide a novel treatment for HBV.	[Ide, Mayuko; Tabata, Noriko; Yonemura, Yuko; Ito, Satoru; Yanagawa, Hiroshi] Purotech Bio Inc, Res Dept, Yokohama, Kanagawa, Japan; [Shirasaki, Takayoshi; Murai, Kazuhisa; Wang, Ying; Ishida, Atsuya; Honda, Masao] Kanazawa Univ, Dept Clin Lab Med, Grad Sch Hlth Med, Kanazawa, Ishikawa, Japan; [Okada, Hikari; Honda, Masao; Kaneko, Shuichi] Kanazawa Univ, Dept Gastroenterol, Grad Sch Med, Kanazawa, Ishikawa, Japan; [Doi, Nobuhide] Keio Univ, Dept Biosci & Informat, Yokohama, Kanagawa, Japan	Kanazawa University; Kanazawa University; Keio University	Yanagawa, H (corresponding author), Purotech Bio Inc, Res Dept, Yokohama, Kanagawa, Japan.	hyana@purotech-bio.com			Program on the Innovative Development and the Application of New Drugs for Hepatitis B from the Japan Agency for Medical Research and Development (AMED) [21fk0310110T0005]; Japan Agency for Medical Research and Development, Japan	Program on the Innovative Development and the Application of New Drugs for Hepatitis B from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Agency for Medical Research and Development, Japan(Japan Agency for Medical Research and Development (AMED))	We thank Prof. M. Harada (Tohoku Univ.) for the gift of a plasmid containing EYFP-actin, and Dr N. Nagao, J. Shimizu, T. Saito, and Y. Hanai for their help throughout the experiments. This work was supported by the Program on the Innovative Development and the Application of New Drugs for Hepatitis B from the Japan Agency for Medical Research and Development (AMED) [21fk0310110T0005]. Funding for open access charge: Japan Agency for Medical Research and Development, Japan.	Akiyama T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095992; [Anonymous], 2017, GLOB HEP REP 2017; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Doi N, 2007, J BIOTECHNOL, V131, P231, DOI 10.1016/j.jbiotec.2007.07.947; Fukuda I, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl618; Gao M, 2021, NUCLEIC ACIDS RES, V49, P3322, DOI 10.1093/nar/gkab134; Guo JT, 2015, ANTIVIR RES, V122, P91, DOI 10.1016/j.antiviral.2015.08.005; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris Rebecca Louise, 2012, Mol Biol Int, V2012, P283974, DOI 10.1155/2012/283974; Hashimoto S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246313; Horisawa K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh167; Iwamoto M, 2019, P NATL ACAD SCI USA, V116, P8487, DOI 10.1073/pnas.1811064116; Jefferies M, 2018, WORLD J CLIN CASES, V6, P589, DOI 10.12998/wjcc.v6.i13.589; Jiang BF, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092023; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kontermann R, 2001, ANTIBODY ENG; Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106; Kosugi S, 2009, J BIOL CHEM, V284, P478, DOI 10.1074/jbc.M807017200; Liang TJ, 2009, HEPATOLOGY, V49, pS13, DOI 10.1002/hep.22881; Lin Q, 2006, J BIOL CHEM, V281, P35253, DOI 10.1074/jbc.M606248200; Lin Q, 2012, BIOCHEM J, V445, P255, DOI 10.1042/BJ20111575; Lin Q, 2010, MOL CELL BIOL, V30, P1541, DOI 10.1128/MCB.00013-10; Liu QH, 2000, GENE DEV, V14, P1448; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Luo J, 2020, MBIO, V11, DOI 10.1128/mBio.03423-19; Macovei A, 2013, J VIROL, V87, P6415, DOI 10.1128/JVI.00393-13; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Matsumura N, 2010, FASEB J, V24, P2201, DOI 10.1096/fj.09-143008; Miyamoto-Sato E, 2005, GENOME RES, V15, P710, DOI 10.1101/gr.3510505; Miyamoto-Sato E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng078; Nagata T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109163; Nemoto N, 1997, FEBS LETT, V414, P405, DOI 10.1016/S0014-5793(97)01026-0; Nishikimi A, 2013, EXP CELL RES, V319, P2343, DOI 10.1016/j.yexcr.2013.07.024; Prieto-Echague Victoria, 2011, J Signal Transduct, V2011, P742372, DOI 10.1155/2011/742372; Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031; Shen F, 2007, MOL BIOL CELL, V18, P732, DOI 10.1091/mbc.E06-02-0142; Shiheido H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017898; Shinzawa M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10758; Sudo K, 2017, J CONTROL RELEASE, V255, P1, DOI 10.1016/j.jconrel.2017.03.398; Suzuki M, 2022, BIOCHEM BIOPH RES CO, V586, P63, DOI 10.1016/j.bbrc.2021.11.065; Swaine T, 2015, VIRUSES-BASEL, V7, P6526, DOI 10.3390/v7122955; Tabata N, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp184; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Wang YH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01805-9; Wei L, 2020, NAT MICROBIOL, V5, P715, DOI 10.1038/s41564-020-0678-0; Witzigmann D, 2016, HEPATOL RES, V46, P686, DOI 10.1111/hepr.12599; Wu M, 2019, HAEMATOLOGICA, V104, P2418, DOI 10.3324/haematol.2018.208843; Yanagawa H, 2013, BIOCHEMISTRY-US, V52, P3841, DOI 10.1021/bi301704x; Yang HC, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.64; Yang J, 2009, SCIENCE, V325, P1398, DOI 10.1126/science.1174468; Yokoyama N, 2005, J BIOL CHEM, V280, P42219, DOI 10.1074/jbc.M506996200; Zhang X, 2011, ARCH VIROL, V156, P637, DOI 10.1007/s00705-010-0903-x; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	54	0	0	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL	2022	298	7							102097	10.1016/j.jbc.2022.102097	http://dx.doi.org/10.1016/j.jbc.2022.102097			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	4Y3JY	35660020	gold, Green Published			2023-01-03	WOS:000861425800011
J	Vellano, CP; White, MG; Andrews, MC; Chelvanambi, M; Witt, RG; Daniele, JR; Titus, M; McQuade, JL; Conforti, F; Burton, EM; Lastrapes, MJ; Ologun, G; Cogdill, AP; Morad, G; Prieto, P; Lazar, AJ; Chu, YS; Han, GC; Khan, MAW; Helmink, B; Davies, MA; Amaria, RN; Kovacs, JJ; Woodman, SE; Patel, S; Hwu, P; Peoples, M; Lee, JE; Cooper, ZA; Zhu, HF; Gao, G; Banerjee, H; Lau, M; Gershenwald, JE; Lucci, A; Keung, EZ; Ross, MI; Pala, L; Pagan, E; Segura, RL; Liu, Q; Borthwick, MS; Lau, E; Yates, MS; Westin, SN; Wani, K; Tetzlaff, MT; Haydu, LE; Mahendra, M; Ma, XY; Logothetis, C; Kulstad, Z; Johnson, S; Hudgens, CW; Feng, NP; Federico, L; Long, GV; Futreal, PA; Arur, S; Tawbi, HA; Moran, AE; Wang, LH; Heffernan, TP; Marszalek, JR; Wargo, JA				Vellano, Christopher P.; White, Michael G.; Andrews, Miles C.; Chelvanambi, Manoj; Witt, Russell G.; Daniele, Joseph R.; Titus, Mark; McQuade, Jennifer L.; Conforti, Fabio; Burton, Elizabeth M.; Lastrapes, Matthew J.; Ologun, Gabriel; Cogdill, Alexandria P.; Morad, Golnaz; Prieto, Peter; Lazar, Alexander J.; Chu, Yanshuo; Han, Guangchun; Khan, M. A. Wadud; Helmink, Beth; Davies, Michael A.; Amaria, Rodabe N.; Kovacs, Jeffrey J.; Woodman, Scott E.; Patel, Sapna; Hwu, Patrick; Peoples, Michael; Lee, Jeffrey E.; Cooper, Zachary A.; Zhu, Haifeng; Gao, Guang; Banerjee, Hiya; Lau, Mike; Gershenwald, Jeffrey E.; Lucci, Anthony; Keung, Emily Z.; Ross, Merrick, I; Pala, Laura; Pagan, Eleonora; Segura, Rossana Lazcano; Liu, Qian; Borthwick, Mikayla S.; Lau, Eric; Yates, Melinda S.; Westin, Shannon N.; Wani, Khalida; Tetzlaff, Michael T.; Haydu, Lauren E.; Mahendra, Mikhila; Ma, XiaoYan; Logothetis, Christopher; Kulstad, Zachary; Johnson, Sarah; Hudgens, Courtney W.; Feng, Ningping; Federico, Lorenzo; Long, Georgina, V; Futreal, P. Andrew; Arur, Swathi; Tawbi, Hussein A.; Moran, Amy E.; Wang, Linghua; Heffernan, Timothy P.; Marszalek, Joseph R.; Wargo, Jennifer A.			Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy	NATURE			English	Article							TUMOR-GROWTH; MELANOMA; ENZALUTAMIDE; COMBINATION; RESISTANCE; ESTROGEN; PROGRESSION; DABRAFENIB; TRAMETINIB; SURVIVAL	Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized care in melanoma and other cancers; however, therapeutic resistance is common and innovative treatment strategies are needed(1,2). Here we studied a group of patients with melanoma who were treated with neoadjuvant BRAF/MEK-targeted therapy (NCT02231775, n = 51) and observed significantly higher rates of major pathological response (MPR; <= 10% viable tumour at resection) and improved recurrence-free survival (RFS) in female versus male patients (MPR, 66% versus 14%, P = 0.001; RFS, 64% versus 32% at 2 years, P = 0.021). The findings were validated in several additional cohorts(2-4) of patients with unresectable metastatic melanoma who were treated with BRAF- and/or MEK-targeted therapy (n = 664 patients in total), demonstrating improved progression-free survival and overall survival in female versus male patients in several of these studies. Studies in preclinical models demonstrated significantly impaired anti-tumour activity in male versus female mice after BRAF/MEK-targeted therapy (P = 0.006), with significantly higher expression of the androgen receptor in tumours of male and female BRAF/MEK-treated mice versus the control (P = 0.0006 and P = 0.0025). Pharmacological inhibition of androgen receptor signalling improved responses to BRAF/MEK-targeted therapy in male and female mice (P = 0.018 and P = 0.003), whereas induction of androgen receptor signalling (through testosterone administration) was associated with a significantly impaired response to BRAF/MEK-targeted therapy in male and female patients (P = 0.021 and P < 0.0001). Together, these results have important implications for therapy.	[Vellano, Christopher P.; Daniele, Joseph R.; Kovacs, Jeffrey J.; Peoples, Michael; Gao, Guang; Mahendra, Mikhila; Ma, XiaoYan; Feng, Ningping; Federico, Lorenzo; Heffernan, Timothy P.; Marszalek, Joseph R.] Univ Texas MD Anderson Canc Ctr, Therapeut Discovery Div, TRACTION Platform, Houston, TX 77030 USA; [White, Michael G.; Andrews, Miles C.; Chelvanambi, Manoj; Witt, Russell G.; Burton, Elizabeth M.; Lastrapes, Matthew J.; Ologun, Gabriel; Cogdill, Alexandria P.; Morad, Golnaz; Prieto, Peter; Khan, M. A. Wadud; Helmink, Beth; Lee, Jeffrey E.; Cooper, Zachary A.; Gershenwald, Jeffrey E.; Lucci, Anthony; Keung, Emily Z.; Ross, Merrick, I; Haydu, Lauren E.; Kulstad, Zachary; Johnson, Sarah; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Titus, Mark; Logothetis, Christopher] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA; [McQuade, Jennifer L.; Davies, Michael A.; Amaria, Rodabe N.; Patel, Sapna; Hwu, Patrick; Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA; [Conforti, Fabio; Pala, Laura] European Inst Oncol, Div Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy; [Lazar, Alexander J.; Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; [Lazar, Alexander J.; Chu, Yanshuo; Han, Guangchun; Woodman, Scott E.; Zhu, Haifeng; Futreal, P. Andrew; Wang, Linghua; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Lazar, Alexander J.; Segura, Rossana Lazcano; Wani, Khalida; Hudgens, Courtney W.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA; [Banerjee, Hiya] Novartis Pharmaceut, Clin Dev & Analyt, E Hanover, NJ USA; [Lau, Mike] Novartis Pharmaceut, Basel, Switzerland; [Pagan, Eleonora] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Milan, Italy; [Liu, Qian; Lau, Eric] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL USA; [Borthwick, Mikayla S.; Yates, Melinda S.; Westin, Shannon N.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA; [Long, Georgina, V] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, Georgina, V] Royal North Shore & Mater Hosp, Sydney, NSW, Australia; [Arur, Swathi] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX USA; [Moran, Amy E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Cell Dev & Canc Biol, Portland, OR USA; [Andrews, Miles C.] Monash Univ, Cent Clin Sch, Dept Med, Melbourne, Vic, Australia; [Ologun, Gabriel] Guthrie Courtland Med Ctr, Dept Surg, Courtland, NY USA; [Cogdill, Alexandria P.] Immunai, New York, NY USA; [Prieto, Peter] Univ Rochester, Dept Surg, Rochester, NY USA; [Helmink, Beth] Washington Univ, Dept Surg, St Louis, MO USA; [Hwu, Patrick] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Cooper, Zachary A.] AstraZeneca, Gaithersburg, MD USA; [Tetzlaff, Michael T.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; IRCCS European Institute of Oncology (IEO); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Novartis; Novartis; University of Milano-Bicocca; H Lee Moffitt Cancer Center & Research Institute; University of Texas System; UTMD Anderson Cancer Center; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University; Monash University; University of Rochester; Washington University (WUSTL); H Lee Moffitt Cancer Center & Research Institute; AstraZeneca; University of California System; University of California San Francisco	Heffernan, TP; Marszalek, JR (corresponding author), Univ Texas MD Anderson Canc Ctr, Therapeut Discovery Div, TRACTION Platform, Houston, TX 77030 USA.; Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.	TPHeffernan@mdanderson.org; jrmarszalek@mdanderson.org; jwargo@mdanderson.org	Mahendra, Mikhila/AEC-6580-2022; Davies, Michael/GWV-2527-2022; Burton, Elizabeth/AAB-9393-2021; Long, Georgina/C-1771-2013	Mahendra, Mikhila/0000-0001-6670-6792; Burton, Elizabeth/0000-0002-3424-4922; Waters, Mikayla/0000-0003-2620-2076; White, Michael/0000-0001-5022-5505; Chelvanambi, Manoj/0000-0003-2130-3118; Wang, Linghua/0000-0001-9380-0266; Andrews, Miles/0000-0003-1231-8641; Long, Georgina/0000-0001-8894-3545	NIH [1 R01 CA219896-01A1]; Melanoma Research Alliance [4022024]; American Association for Cancer Research Stand Up To Cancer [SU2C-AACR-IRG-19-17]; MD Anderson Cancer Center's Melanoma Moon Shots Program; American Society of Clinical Oncology and Conquer Cancer Foundation Career Development Award; Elkins Foundation; Seerave Foundation; Rising Tide Foundation; Mark Foundation; MD Anderson Cancer Center (MDACC) Melanoma SPORE Developmental Research Program Award; MD Anderson Physician Scientist Program; Melanoma Research Alliance; Transdisciplinary Research in Energetics and Cancer Research Training Workshop [R25CA203650]; CPRIT Research Training Program at the MD Anderson Cancer Center [RP170067]; US Department of State, Bureau of Educational and Cultural Affairs; Fulbright Franco-Americaine Commission; National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship [1148680]; National Institutes of Health [T32 CA 009599, 1F32CA260769-01]; MD Anderson Cancer Center support grant [P30 CA016672]; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; NIH/NCI [1 P50 CA221703-02]; Cancer Fighters of Houston; Anne and John Mendelsohn Chair for Cancer Research; CPRIT Core Facility Support Awards [CPRIT RP170002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; American Association for Cancer Research Stand Up To Cancer; MD Anderson Cancer Center's Melanoma Moon Shots Program; American Society of Clinical Oncology and Conquer Cancer Foundation Career Development Award; Elkins Foundation; Seerave Foundation; Rising Tide Foundation; Mark Foundation; MD Anderson Cancer Center (MDACC) Melanoma SPORE Developmental Research Program Award; MD Anderson Physician Scientist Program; Melanoma Research Alliance; Transdisciplinary Research in Energetics and Cancer Research Training Workshop; CPRIT Research Training Program at the MD Anderson Cancer Center; US Department of State, Bureau of Educational and Cultural Affairs; Fulbright Franco-Americaine Commission; National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Cancer Center support grant; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Fighters of Houston; Anne and John Mendelsohn Chair for Cancer Research; CPRIT Core Facility Support Awards	J.A.W. is supported by the NIH (1 R01 CA219896-01A1), the Melanoma Research Alliance (4022024), the American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17) and the MD Anderson Cancer Center's Melanoma Moon Shots Program. J.L.M. is supported by the Melanoma Research Alliance, an American Society of Clinical Oncology and Conquer Cancer Foundation Career Development Award, the Elkins Foundation, the Seerave Foundation, the Rising Tide Foundation, the Mark Foundation, an MD Anderson Cancer Center (MDACC) Melanoma SPORE Developmental Research Program Award and the MD Anderson Physician Scientist Program, and acknowledges the Transdisciplinary Research in Energetics and Cancer Research Training Workshop R25CA203650 and the MDACC Center for Energy Balance in Cancer Prevention and Survivorship. A.P.C. is supported by the CPRIT Research Training Program at the MD Anderson Cancer Center (RP170067), The US Department of State, Bureau of Educational and Cultural Affairs, and the Fulbright Franco-Americaine Commission. M.C.A. is supported by a National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship (1148680). B.H. was supported by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center support grant (P30 CA016672). M.G.W. is supported by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center support grant (P30 CA016672). R.G.W. is supported by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center support grant (P30 CA016672). G.M. is supported by the National Institute of Health (1F32CA260769-01). M.A.D. is supported by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (1 P50 CA221703-02), Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. G.O. is supported by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center support grant (P30 CA016672). The University of Texas MD Anderson Cancer Center Science Park Next-Generation Sequencing (NGS) Facility is supported by CPRIT Core Facility Support Awards (CPRIT RP170002).	Aguirre-Portoles C, 2021, CANCER RES, V81, P5991, DOI 10.1158/0008-5472.CAN-21-0982; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews S., 2010, FASTQC QUALITY CONTR; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; BALZANO S, 1987, CLIN ENDOCRINOL, V27, P491, DOI 10.1111/j.1365-2265.1987.tb01178.x; Boese AC, 2017, AM J PHYSIOL-HEART C, V313, pH524, DOI 10.1152/ajpheart.00217.2016; Capone I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00552; Clocchiatti A, 2018, J CLIN INVEST, V128, P5531, DOI 10.1172/JCI99159; Cross TWL, 2018, MOL METAB, V15, P70, DOI 10.1016/j.molmet.2018.05.016; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Efstathiou E, 2020, EUR UROL ONCOL, V3, P119, DOI 10.1016/j.euo.2019.01.008; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gaballa R, 2020, CANCERS, V12, DOI 10.3390/cancers12082300; Guan XN, 2022, NATURE, V606, P791, DOI 10.1038/s41586-022-04522-6; Jin HJ, 2013, TRANSL ANDROL UROL, V2, P158, DOI 10.3978/j.issn.2223-4683.2013.09.01; KERRIGAN JR, 1994, PEDIATR RES, V35, P102, DOI 10.1203/00006450-199401000-00021; Korotkevich G., BIORXIV, DOI [10.1101/060012(2021, DOI 10.1101/060012(2021]; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Leung JK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00002; Li SZ, 2019, CANCER RES, V79, P2580, DOI 10.1158/0008-5472.CAN-18-2812; Liang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0197-y; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Long GV, 2019, LANCET ONCOL, V20, P961, DOI 10.1016/S1470-2045(19)30331-6; Long GV, 2016, LANCET ONCOL, V17, P1743, DOI 10.1016/S1470-2045(16)30578-2; Ma M, 2021, J EXP MED, V218, DOI 10.1084/jem.20201137; Maity SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep35354; Martin AM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00428; Marzagalli M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00140; Maughan BL, 2014, ASIAN J ANDROL, V16, P807, DOI 10.4103/1008-682X.137680; McQuade JL, 2018, LANCET ONCOL, V19, P310, DOI 10.1016/S1470-2045(18)30078-0; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; MORVILLO V, 1995, PIGM CELL RES, V8, P135, DOI 10.1111/j.1600-0749.1995.tb00654.x; Natale CA, 2018, ELIFE, V7, DOI 10.7554/eLife.31770; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Pinto JA, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000344; Qi JF, 2012, PIGM CELL MELANOMA R, V25, P293, DOI 10.1111/j.1755-148X.2012.01000.x; Ribeiro MPC, 2017, CHEM-BIOL INTERACT, V277, P176, DOI 10.1016/j.cbi.2017.09.017; Ricke EA, 2012, CARCINOGENESIS, V33, P1391, DOI 10.1093/carcin/bgs153; Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059; Robert C, 2019, EUR J CANCER, V109, P61, DOI 10.1016/j.ejca.2018.12.015; Rothenberger NJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020611; Rubin JB, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00291-x; Scatena C, 2020, BREAST CANCER RES TR, V182, P55, DOI 10.1007/s10549-020-05682-7; Schmidt K, 2019, CELL REP, V27, P2493, DOI 10.1016/j.celrep.2019.04.101; Smalley KSM, 2018, ELIFE, V7, DOI 10.7554/eLife.33511; Stacchiotti S, 2009, RADIOLOGY, V251, P447, DOI 10.1148/radiol.2512081403; Sudo N, 2014, ADV EXP MED BIOL, V817, P177, DOI 10.1007/978-1-4939-0897-4_8; Wang DP, 2011, METHODS MOL BIOL, V776, P25, DOI 10.1007/978-1-61779-243-4_2; Wang Y, 2017, ONCOGENE, V36, P1644, DOI 10.1038/onc.2016.330; Wu HX, 2017, CANCER LETT, V385, P108, DOI 10.1016/j.canlet.2016.10.036; Xia N, 2019, J PATHOL, V248, P304, DOI 10.1002/path.5257; Zhang M, 2019, CANCER LETT, V442, P483, DOI 10.1016/j.canlet.2018.11.008; Zhao LJ, 2018, P NATL ACAD SCI USA, V115, pE3673, DOI 10.1073/pnas.1803291115; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	58	8	8	10	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 23	2022	606	7915					797	+		10.1038/s41586-022-04833-8	http://dx.doi.org/10.1038/s41586-022-04833-8		JUN 2022	31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2J7WG	35705814	Green Submitted			2023-01-03	WOS:000811501700006
J	McDonagh, MS; Morasco, BJ; Wagner, J				McDonagh, M. S.; Morasco, B. J.; Wagner, J.			Summary for Patients: Cannabis-Based Products for Chronic Pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2022	175	8					I28	I28		10.7326/P22-0009	http://dx.doi.org/10.7326/P22-0009		JUN 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4M3OG	35667062				2023-01-03	WOS:000809493800001
J	Statsyuk, AV				Statsyuk, Alexander V.			Inhibiting protein synthesis to treat malaria	SCIENCE			English	Editorial Material							ARTEMISININ; HEME; UBIQUITIN		[Statsyuk, Alexander V.] Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77030 USA	University of Houston System; University of Houston	Statsyuk, AV (corresponding author), Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77030 USA.	avstatsyuk@uh.edu			 [R01GM115632];  [1R01CA256543-01A1]	; 	I thankV. E. Mgbemena for helpful comments.A.V.S. is funded by R01GM115632 and 1R01CA256543-01A1 (co-investigator).	An H, 2013, J AM CHEM SOC, V135, P16948, DOI 10.1021/ja4099643; Chen XC, 2006, P NATL ACAD SCI USA, V103, P14548, DOI 10.1073/pnas.0604101103; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Lannine BR, 2014, NAT CHEM BIOL, V10, P760, DOI [10.1038/NCHEMBIO.1582, 10.1038/nchembio.1582]; Matthews ML, 2017, NAT CHEM, V9, P234, DOI [10.1038/NCHEM.2645, 10.1038/nchem.2645]; Meunier B, 2010, ACCOUNTS CHEM RES, V43, P1444, DOI 10.1021/ar100070k; Misra M., 2017, STRUCTURE, V25, P1120, DOI DOI 10.1016/J.STR.2017.05.001; Mok S, 2015, SCIENCE, V347, P431, DOI 10.1126/science.1260403; Ngivprom U, 2021, RSC ADV, V11, P3510, DOI 10.1039/d0ra10878b; Robert A, 2005, P NATL ACAD SCI USA, V102, P13676, DOI 10.1073/pnas.0500972102; Shi YL, 2020, ACCOUNTS CHEM RES, V53, P20, DOI 10.1021/acs.accounts.9b00562; Stoye A, 2019, J MED CHEM, V62, P5562, DOI 10.1021/acs.jmedchem.9b00504; Wang J., 2015, NAT COMMUN, V6, P10111, DOI [10.1038/ncomms8170, DOI 10.1038/NCOMMS8170]; Xie SC, 2022, SCIENCE, V376, P1074, DOI 10.1126/science.abn0611	14	0	0	7	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2022	376	6597					1049	1050		10.1126/science.abq4457	http://dx.doi.org/10.1126/science.abq4457			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1V4HS	35653471				2023-01-03	WOS:000806053500026
J	Tang, FY; Xu, D; Wang, SQ; Wong, CK; Martinez-Fundichely, A; Lee, CJ; Cohen, S; Park, J; Hill, CE; Eng, K; Bareja, R; Han, T; Liu, EM; Palladino, A; Di, W; Gao, D; Abida, W; Beg, S; Puca, L; Meneses, M; de Stanchina, E; Berger, MF; Gopalan, A; Dow, LE; Mosquera, JM; Beltran, H; Sternberg, CN; Chi, P; Scher, HI; Sboner, A; Chen, Y; Khurana, E				Tang, Fanying; Xu, Duo; Wang, Shangqian; Wong, Chen Khuan; Martinez-Fundichely, Alexander; Lee, Cindy J.; Cohen, Sandra; Park, Jane; Hill, Corinne E.; Eng, Kenneth; Bareja, Rohan; Han, Teng; Liu, Eric Minwei; Palladino, Ann; Di, Wei; Gao, Dong; Abida, Wassim; Beg, Shaham; Puca, Loredana; Meneses, Maximiliano; de Stanchina, Elisa; Berger, Michael F.; Gopalan, Anuradha; Dow, Lukas E.; Mosquera, Juan Miguel; Beltran, Himisha; Sternberg, Cora N.; Chi, Ping; Scher, Howard, I; Sboner, Andrea; Chen, Yu; Khurana, Ekta			Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets	SCIENCE			English	Article							LINEAGE PLASTICITY; INHIBITORS; PATHWAY; YAP/TAZ; METASTASIS; GROWTH; AP-1	In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR) dependence leads to clinically aggressive tumors with few therapeutic options. We used ATAC-seq (assay for transposase-accessible chromatin sequencing), RNA-seq, and DNA sequencing to investigate 22 organoids, six patient-derived xenografts, and 12 cell lines. We identified the well-characterized AR-dependent and neuroendocrine subtypes, as well as two AR-negative/low groups: a Wnt-dependent subtype, and a stem cell-like (SCL) subtype driven by activator protein-1 (AP-1) transcription factors. We used transcriptomic signatures to classify 366 patients, which showed that SCL is the second most common subtype of CRPC after AR-dependent. Our data suggest that AP-1 interacts with the YAP/TAZ and TEAD proteins to maintain subtype-specific chromatin accessibility and transcriptomic landscapes in this group. Together, this molecular classification reveals drug targets and can potentially guide therapeutic decisions.	[Tang, Fanying; Xu, Duo; Martinez-Fundichely, Alexander; Cohen, Sandra; Liu, Eric Minwei; Palladino, Ann; Puca, Loredana; Dow, Lukas E.; Mosquera, Juan Miguel; Sternberg, Cora N.; Khurana, Ekta] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY 10021 USA; [Tang, Fanying; Xu, Duo; Martinez-Fundichely, Alexander; Liu, Eric Minwei; Palladino, Ann; Sboner, Andrea; Khurana, Ekta] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY 10021 USA; [Xu, Duo; Martinez-Fundichely, Alexander; Khurana, Ekta] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; [Xu, Duo; Martinez-Fundichely, Alexander; Eng, Kenneth; Bareja, Rohan; Beg, Shaham; Puca, Loredana; Mosquera, Juan Miguel; Beltran, Himisha; Sternberg, Cora N.; Sboner, Andrea; Khurana, Ekta] Weill Cornell Med, Englander Inst Precis Med, New York, NY 10021 USA; [Wang, Shangqian; Wong, Chen Khuan; Lee, Cindy J.; Han, Teng; Di, Wei; Gao, Dong; Chi, Ping; Chen, Yu] Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Wang, Shangqian] Nanjing Med Univ, Urol Dept, State Key Lab Reprod Med, Affiliated Hosp 1, Nanjing 211116, Peoples R China; [Park, Jane; Hill, Corinne E.] Mem Sloan Kettering Canc Ctr, Ctr Epigenet Res, New York, NY 10065 USA; [Liu, Eric Minwei] Mem Sloan Kettering Canc Ctr, Computat Oncol Serv, New York, NY 10065 USA; [Gao, Dong] Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol,Shanghai Key Lab Mol Andr, Shanghai 200031, Peoples R China; [Abida, Wassim; Chi, Ping; Scher, Howard, I; Chen, Yu] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Meneses, Maximiliano; de Stanchina, Elisa] Mem Sloan Kettering Canc Ctr, Antitumor Assessment Core Facil, New York, NY 10065 USA; [Berger, Michael F.; Gopalan, Anuradha] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Dow, Lukas E.; Chi, Ping; Chen, Yu] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Dow, Lukas E.; Chi, Ping; Chen, Yu] New York Presbyterian Hosp, New York, NY 10065 USA; [Mosquera, Juan Miguel; Sboner, Andrea] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA; [Beltran, Himisha] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Scher, Howard, I] Mem Sloan Kettering Canc Ctr, Biomarker Dev Program, New York, NY 10065 USA	Cornell University; Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Nanjing Medical University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Cornell University; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Khurana, E (corresponding author), Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY 10021 USA.; Khurana, E (corresponding author), Weill Cornell Med Coll, Inst Computat Biomed, New York, NY 10021 USA.; Khurana, E (corresponding author), Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.; Khurana, E (corresponding author), Weill Cornell Med, Englander Inst Precis Med, New York, NY 10021 USA.; Chen, Y (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Chen, Y (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.; Chen, Y (corresponding author), Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.	cheny1@mskcc.org; ekk2003@med.cornell.edu		Meneses, Maximiliano/0000-0002-4093-3070; Martinez-Fundichely, Alexander/0000-0002-7660-5511; Wong, Chen Khuan/0000-0001-9811-3334	NIH [P30CA008748, P50CA221745, P50CA211024, R37CA241486, R37CA241486-02, U54CA224079, U01CA224044, R01CA193837, R01CA208100, U01CA252048, R01CA228216, DP2CA174499, R01CA218668]; Department of Defense [W81XWH-17-1-0653]; Prostate Cancer Foundation; STARR Cancer Consortium; Geoffrey Beene Cancer Center; Irma T. Hirschl Trust; WorldQuant Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Prostate Cancer Foundation; STARR Cancer Consortium; Geoffrey Beene Cancer Center; Irma T. Hirschl Trust; WorldQuant Foundation	Supported by NIH grants P30CA008748 (Y.C., H.I.S., P.C., A.G., W.A., E.D.S., and M.F.B.), P50CA221745 (Y.C., H.I.S., A.G., W.A., and E.D.S.), P50CA211024 (A.S., E.K., and J.M.M.), R37CA241486 and R37CA241486-02 (H.B.), U54CA224079, U01CA224044, R01CA193837, and R01CA208100 (Y.C.), U01CA252048, R01CA228216, and DP2CA174499 (P.C.), R01CA218668 (E.K.); Department of Defense W81XWH-17-1-0653 (H.B.), Prostate Cancer Foundation (Y.C., H.I.S., and W.A.); STARR Cancer Consortium (Y.C., P.C., and H.B.); Geoffrey Beene Cancer Center (Y.C. and P.C.); Irma T. Hirschl Trust (E.K.); and WorldQuant Foundation (K.).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Adams EJ, 2019, NATURE, V571, P408, DOI 10.1038/s41586-019-1318-9; Aikawa Y, 2008, NAT BIOTECHNOL, V26, P817, DOI 10.1038/nbt1412; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Chen WS, 2019, EUR UROL, V76, P562, DOI 10.1016/j.eururo.2019.03.020; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; Dasari VR, 2017, ONCOTARGET, V8, P28628, DOI 10.18632/oncotarget.15614; Dhingra P, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1266-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Galli GG, 2015, MOL CELL, V60, P328, DOI 10.1016/j.molcel.2015.09.001; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hoshida Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015543; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Leibold J, 2020, CANCER DISCOV, V10, P1038, DOI 10.1158/2159-8290.CD-19-1242; Li ZJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1642-2; Liu CY, 2017, J BIOL CHEM, V292, P9420, DOI 10.1074/jbc.M117.783787; Ma S, 2020, CELL, V183, P1103, DOI 10.1016/j.cell.2020.09.056; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Nyquist MD, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107669; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Parolia A, 2019, NATURE, V571, P413, DOI 10.1038/s41586-019-1347-4; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rudin CM, 2019, NAT REV CANCER, V19, P289, DOI 10.1038/s41568-019-0133-9; Shukla S, 2017, CANCER CELL, V32, P792, DOI 10.1016/j.ccell.2017.10.008; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Velho PI, 2020, EUR UROL, V77, P14, DOI 10.1016/j.eururo.2019.05.032; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Ye N, 2014, J MED CHEM, V57, P6930, DOI 10.1021/jm5004733; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15	50	7	7	18	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2022	376	6596			SI		960	+		10.1126/science.abe1505	http://dx.doi.org/10.1126/science.abe1505			77	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1V1HP	35617398	Green Accepted			2023-01-03	WOS:000805850000028
J	Beavers, DP; Hsieh, KL; Kitzman, DW; Kritchevsky, SB; Messier, SP; Neiberg, RH; Nicklas, BJ; Rejeski, WJ; Beavers, KM				Beavers, Daniel P.; Hsieh, Katherine L.; Kitzman, Dalane W.; Kritchevsky, Stephen B.; Messier, Stephen P.; Neiberg, Rebecca H.; Nicklas, Barbara J.; Rejeski, W. Jack; Beavers, Kristen M.			Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity	PLOS ONE			English	Article							DIETARY WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; KNEE OSTEOARTHRITIS; CLINICAL-TRIALS; ADIPOSE-TISSUE; GAIT SPEED; OVERWEIGHT; MOBILITY; INFLAMMATION; EXERCISE	Clinical trials conventionally test aggregate mean differences and assume homogeneous variances across treatment groups. However, significant response heterogeneity may exist. The purpose of this study was to model treatment response variability using gait speed change among older adults participating in caloric restriction (CR) trials. Eight randomized controlled trials (RCTs) with five- or six-month assessments were pooled, including 749 participants randomized to CR and 594 participants randomized to non-CR (NoCR). Statistical models compared means and variances by CR assignment and exercise assignment or select subgroups, testing for treatment differences and interactions for mean changes and standard deviations. Continuous equivalents of dichotomized variables were also fit. Models used a Bayesian framework, and posterior estimates were presented as means and 95% Bayesian credible intervals (BCI). At baseline, participants were 67.7 (SD = 5.4) years, 69.8% female, and 79.2% white, with a BMI of 33.9 (4.4) kg/m(2). CR participants reduced body mass [CR: -7.7 (5.8) kg vs. NoCR: -0.9 (3.5) kg] and increased gait speed [CR: +0.10 (0.16) m/s vs. NoCR: +0.07 (0.15) m/s] more than NoCR participants. There were no treatment differences in gait speed change standard deviations [CR-NoCR: -0.002 m/s (95% BCI: -0.013, 0.009)]. Significant mean interactions between CR and exercise assignment [0.037 m/s (95% BCI: 0.004, 0.070)], BMI [0.034 m/s (95% BCI: 0.003, 0.066)], and IL-6 [0.041 m/s (95% BCI: 0.009, 0.073)] were observed, while variance interactions were observed between CR and exercise assignment [-0.458 m/s (95% BCI: -0.783, -0.138)], age [-0.557 m/s (95% BCI: -0.900, -0.221)], and gait speed [-0.530 m/s (95% BCI: -1.018, -0.062)] subgroups. Caloric restriction plus exercise yielded the greatest gait speed benefit among older adults with obesity. High BMI and IL-6 subgroups also improved gait speed in response to CR. Results provide a novel statistical framework for identifying treatment heterogeneity in RCTs.	[Beavers, Daniel P.; Neiberg, Rebecca H.] Wake Forest Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27101 USA; [Hsieh, Katherine L.; Kritchevsky, Stephen B.; Nicklas, Barbara J.] Wake Forest Sch Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27101 USA; [Kitzman, Dalane W.] Wake Forest Sch Med, Sect Cardiovasc Med, Winston Salem, NC 27101 USA; [Messier, Stephen P.; Rejeski, W. Jack; Beavers, Kristen M.] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27101 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Beavers, DP (corresponding author), Wake Forest Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27101 USA.	dbeavers@wakehealth.edu		Beavers, Daniel/0000-0002-4286-9463	National Institutes of Health [P60 AG10484, R01 HL076441, R01 AG020583, R01 AR052528, R01 HL093713, R01 AG018915, P30 AG21332, T32 AG033534, R21 AG061344]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the several grants from the National Institutes of Health: https://reporter.nih.gov/[reporter.nih.gov] (P60 AG10484 (SBK), R01 HL076441 (WJR), R01 AG020583 (BJN), R01 AR052528 (SPM), R01 HL093713 (BJN), R01 AG018915 (DWK), P30 AG21332 (SBK), T32 AG033534 (SBK), and R21 AG061344 (DPB)).	Atkinson G, 2018, DIABETOLOGIA, V61, P496, DOI 10.1007/s00125-017-4501-2; Atkinson G, 2015, EXP PHYSIOL, V100, P577, DOI 10.1113/EP085070; Beavers DP., 2017, INNOV AGING, V1, P694; Beavers KM, 2015, OSTEOARTHR CARTILAGE, V23, P249, DOI 10.1016/j.joca.2014.11.005; Beavers KM, 2019, J GERONTOL A-BIOL, V74, P929, DOI 10.1093/gerona/gly146; Bonafiglia JT, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14163; Chaston TB, 2007, INT J OBESITY, V31, P743, DOI 10.1038/sj.ijo.0803483; Chen LM, 2019, ACTA PHARM SIN B, V9, P659, DOI 10.1016/j.apsb.2019.01.007; Clayton JA, 2018, CLIN CARDIOL, V41, P179, DOI 10.1002/clc.22907; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dankel SJ, 2020, SPORTS MED, V50, P231, DOI 10.1007/s40279-019-01147-0; DiMilia PR, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1249-8; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Hortobagyi T, 2015, SPORTS MED, V45, P1627, DOI 10.1007/s40279-015-0371-2; Houston DK, 2009, J AM DIET ASSOC, V109, P1886, DOI 10.1016/j.jada.2009.08.014; Khoury MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/j.amepre.2015.08.031; Kim S, 2017, INNOV AGING, V1, DOI 10.1093/geroni/igx008; Kitzman DW, 2016, JAMA-J AM MED ASSOC, V315, P36, DOI 10.1001/jama.2015.17346; Locher JL, 2016, EXP GERONTOL, V86, P4, DOI 10.1016/j.exger.2016.03.009; Martini D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081805; Menezes R, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020117; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Middleton A, 2015, J AGING PHYS ACTIV, V23, P314, DOI 10.1123/japa.2013-0236; Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018; Nicklas BJ, 2019, J GERONTOL A-BIOL, V74, P1084, DOI 10.1093/gerona/gly159; Nicklas BJ, 2015, AM J CLIN NUTR, V101, P991, DOI 10.3945/ajcn.114.105270; Normandin E, 2018, J FRALITY AGING, V7, P198, DOI 10.14283/jfa.2018.17; Pahor M, 1998, J Nutr Health Aging, V2, P97; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; Pai MP, 2014, ADV DRUG DELIVER REV, V77, P50, DOI 10.1016/j.addr.2014.05.016; Peel NM, 2013, J GERONTOL A-BIOL, V68, P39, DOI 10.1093/gerona/gls174; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Rejeski WJ, 2011, ARCH INTERN MED, V171, P880, DOI 10.1001/archinternmed.2010.522; Ridker PM, 2005, TEX HEART I J, V32, P384; Ross R, 2019, BRIT J SPORT MED, V53, P1141, DOI 10.1136/bjsports-2018-100328; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Shephard RJ, 2004, EUR J APPL PHYSIOL, V91, P199, DOI 10.1007/s00421-003-0990-4; Simonsick EM, 2001, J AM GERIATR SOC, V49, P1544, DOI 10.1046/j.1532-5415.2001.4911247.x; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Taylor AL, 2005, CIRCULATION, V112, P3654, DOI 10.1161/CIRCULATIONAHA.105.540443; Whipple MO, 2018, J AGING PHYS ACTIV, V26, P655, DOI 10.1123/japa.2017-0054; You TJ, 2006, CURR DIABETES REV, V2, P29, DOI 10.2174/157339906775473626	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0267779	10.1371/journal.pone.0267779	http://dx.doi.org/10.1371/journal.pone.0267779			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511858	gold, Green Published			2023-01-03	WOS:000892294900068
J	Hager, KJ; Marc, GP; Gobeil, P; Diaz, RS; Heizer, G; Llapur, C; Makarkov, AI; Vasconcellos, E; Pillet, S; Riera, F; Saxena, P; Wolff, PG; Bhutada, K; Wallace, G; Aazami, H; Jones, CE; Polack, FP; Ferrara, L; Atkins, J; Boulay, I; Dhaliwall, J; Charland, N; Couture, MMJ; Jiang-Wright, J; Landry, N; Lapointe, S; Lorin, A; Mahmood, A; Moulton, LH; Pahmer, E; Parent, J; Seguin, A; Tran, L; Breuer, T; Ceregido, MA; Koutsoukos, M; Roman, F; Namba, J; D'Aoust, MA; Trepanier, S; Kimura, Y; Ward, BJ				Hager, Karen J.; Perez Marc, Gonzalo; Gobeil, Philipe; Diaz, Ricardo S.; Heizer, Gretchen; Llapur, Conrado; Makarkov, Alexander I.; Vasconcellos, Eduardo; Pillet, Stephane; Riera, Fernando; Saxena, Pooja; Geller Wolff, Priscila; Bhutada, Kapil; Wallace, Garry; Aazami, Hessam; Jones, Christine E.; Polack, Fernando P.; Ferrara, Luciana; Atkins, Judith; Boulay, Iohann; Dhaliwall, Jiwanjeet; Charland, Nathalie; Couture, Manon M. J.; Jiang-Wright, Julia; Landry, Nathalie; Lapointe, Sophie; Lorin, Aurelien; Mahmood, Asif; Moulton, Lawrence H.; Pahmer, Emily; Parent, Julie; Seguin, Annie; Tran, Luan; Breuer, Thomas; Ceregido, Maria-Angeles; Koutsoukos, Marguerite; Roman, Francois; Namba, Junya; D'Aoust, Marc-Andre; Trepanier, Sonia; Kimura, Yosuke; Ward, Brian J.			Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access							IMMUNOGENICITY; MULTICENTER	BACKGROUND Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine. METHODS In this phase 3, multinational, randomized, placebo-controlled trial conducted at 85 centers, we assigned adults (>= 18 years of age) in a 1:1 ratio to receive two intramuscular injections of the CoVLP+AS03 vaccine or placebo 21 days apart. The primary objective of the trial was to determine the efficacy of the CoVLP+AS03 vaccine in preventing symptomatic coronavirus disease 2019 (Covid-19) beginning at least 7 days after the second injection, with the analysis performed after the detection of at least 160 cases. RESULTS A total of 24,141 volunteers participated in the trial; the median age of the participants was 29 years. Covid-19 was confirmed by polymerase-chain-reaction assay in 165 participants in the intention-to-treat population; all viral samples that could be sequenced contained variants of the original strain. Vaccine efficacy was 69.5% (95% confidence interval [CI], 56.7 to 78.8) against any symptomatic Covid-19 caused by five variants that were identified by sequencing. In a post hoc analysis, vaccine efficacy was 78.8% (95% CI, 55.8 to 90.8) against moderate-to-severe disease and 74.0% (95% CI, 62.1 to 82.5) among the participants who were seronegative at baseline. No severe cases of Covid-19 occurred in the vaccine group, in which the median viral load for breakthrough cases was lower than that in the placebo group by a factor of more than 100. Solicited adverse events were mostly mild or moderate and transient and were more frequent in the vaccine group than in the placebo group; local adverse events occurred in 92.3% and 45.5% of participants, respectively, and systemic adverse events in 87.3% and 65.0%. The incidence of unsolicited adverse events was similar in the two groups up to 21 days after each dose (22.7% and 20.4%) and from day 43 through day 201 (4.2% and 4.0%). CONCLUSIONS The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.	[Hager, Karen J.; Perez Marc, Gonzalo; Heizer, Gretchen; Makarkov, Alexander I.; Pillet, Stephane; Saxena, Pooja; Bhutada, Kapil; Atkins, Judith; Boulay, Iohann; Dhaliwall, Jiwanjeet; Charland, Nathalie; Couture, Manon M. J.; Jiang-Wright, Julia; Landry, Nathalie; Lapointe, Sophie; Lorin, Aurelien; Mahmood, Asif; Pahmer, Emily; Parent, Julie; Seguin, Annie; Tran, Luan; Namba, Junya; D'Aoust, Marc-Andre; Trepanier, Sonia; Kimura, Yosuke; Ward, Brian J.] Medicago, Quebec City, PQ, Canada; [Wallace, Garry] Dawson Clin Res, Guelph, ON, Canada; [Ward, Brian J.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; [Perez Marc, Gonzalo] Hosp Mil, Buenos Aires, DF, Argentina; [Polack, Fernando P.] Fdn INFANT, Buenos Aires, DF, Argentina; [Llapur, Conrado] Clin Mayo Urgencias Med Cruz Blanca, San Miguel De Tucuman, Argentina; [Riera, Fernando] Sanatorio Allende, Cordoba, Argentina; [Diaz, Ricardo S.; Ferrara, Luciana] Univ Fed Sao Paulo, Paulista Sch Med, Div Infect Dis, Sao Paulo, Brazil; [Diaz, Ricardo S.; Ferrara, Luciana] Azidus Brasil Pesquisa & Desenvolvimento, Sao Paulo, Brazil; [Vasconcellos, Eduardo] Inst Pesquisas Clin L2IP, Brasilia, DF, Brazil; [Geller Wolff, Priscila] Inst Brasil Pequisa Clin, Rio De Janeiro, Brazil; [Aazami, Hessam] Hope Clin, Canoga Pk, CA USA; [Jones, Christine E.] Univ Southampton, Clin & Expt Sci, Southampton, Hants, England; [Jones, Christine E.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil, Southampton, Hants, England; [Jones, Christine E.] Univ Hosp Southampton NHS Fdn Trust, Biomed Res Ctr, Southampton, Hants, England; [Moulton, Lawrence H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Breuer, Thomas; Ceregido, Maria-Angeles; Koutsoukos, Marguerite; Roman, Francois] GlaxoSmithKline Vaccines, Wavre, Belgium	McGill University; Universidade Federal de Sao Paulo (UNIFESP); University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; GlaxoSmithKline	Hager, KJ (corresponding author), Medicago, Quebec City, PQ, Canada.		Jones, Chrissie/GXG-4400-2022; Del Carpio-Orantes, Luis/H-6745-2017	Del Carpio-Orantes, Luis/0000-0003-2436-5744; Moore, Patrick/0000-0001-8279-6724; Soiza, Roy/0000-0002-1397-4272; Jones, Christine/0000-0003-1523-2368; Makarkov, Alexander/0000-0003-4255-7627	Medicago; Canadian Innovation, Science and Economic Development Strategic Innovation Fund	Medicago; Canadian Innovation, Science and Economic Development Strategic Innovation Fund	Supported by Medicago with financial assistance from the Canadian Innovation, Science and Economic Development Strategic Innovation Fund.	AboulFotouh K, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249-021-01974-3; Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Budroni S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00337-0; Cai CJ, 2021, MOL THER, V29, P2890, DOI 10.1016/j.ymthe.2021.09.024; Castiello T, 2022, HEART FAIL REV, V27, P251, DOI 10.1007/s10741-021-10087-9; Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048; covid19, 2021, WHO CORONAVIRUS DIS; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; El Zein S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255981; Fiolet T, 2022, CLIN MICROBIOL INFEC, V28, P202, DOI 10.1016/j.cmi.2021.10.005; Funk CD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030418; Gobeil P., 2021, INTERIM REPORT PHASE, DOI [10.1101/2021.05.14.21257248, DOI 10.1101/2021.05.14.21257248]; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Hotez PJ., 2021, ANNU REV MED, V73, P55; Khare S, 2021, CHINA CDC WEEKLY, V3, P1049, DOI 10.46234/ccdcw2021.255; Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011; Munro APS, 2021, LANCET, V398, P2258, DOI 10.1016/S0140-6736(21)02717-3; Pillet S, 2022, CELL MOL IMMUNOL, V19, P222, DOI 10.1038/s41423-021-00809-2; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Rotshild V, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02321-z; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; U.S. Food and Drug Administration, 2021, COVID 19 DEV DRUGS B; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	32	27	27	12	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2201300	http://dx.doi.org/10.1056/NEJMoa2201300		MAY 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D4VV	35507508	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000793800700001
J	Grenier, L; Onguti, B; Whiting-Collins, LJ; Omanga, E; Suhowatsky, S; Winch, PJ				Grenier, Lindsay; Onguti, Brenda; Whiting-Collins, Lillian J.; Omanga, Eunice; Suhowatsky, Stephanie; Winch, Peter J.			Transforming women's and providers' experience of care for improved outcomes: A theory of change for group antenatal care in Kenya and Nigeria	PLOS ONE			English	Article							PRENATAL-CARE; MODEL; SATISFACTION; PERSPECTIVES	Background Group antenatal care (G-ANC) is a promising model for improving quality of maternal care and outcomes in low- and middle-income countries (LMICs) but little has been published examining the mechanisms by which it may contribute to those improvements. Substantial interplay can be expected between pregnant women and providers' respective experiences of care, but most studies report findings separately. This study explores the experience and effects of G-ANC on both women and providers to inform an integrated theory of change for G-ANC in LMICs. Methods This paper reports on multiple secondary outcomes from a pragmatic cluster randomized controlled trial of group antenatal care in Kenya and Nigeria conducted from October 2016 -November 2018 including 20 clusters per country. We collected qualitative data from providers and women providing or receiving group antenatal care via focus group discussions (19 with women; 4 with providers) and semi-structured interviews (42 with women; 4 with providers). Quantitative data were collected via surveys administered to 1) providers in the intervention arm at enrollment and after facilitating 4 cohorts and 2) women in both study arms at enrollment; 3-6 weeks postpartum; and 1 year postpartum. Through an iterative approach with framework analysis, we explored the interactions of voiced experience and perceived effects of care and placed them relationally within a theory of change. Selected variables from baseline and final surveys were analyzed to examine applicability of the theory to all study participants. Results Findings support seven inter-related themes. Three themes relate to the shared experience of care of women and providers: forming supportive relationships and open communication; becoming empowered partners in learning and care; and providing and receiving meaningful clinical services and information. Four themes relate to effects of that experience, which are not universally shared: self-reinforcing cycles of more and better care; linked improvements in health knowledge, confidence, and healthy behaviors; improved communication, support, and care beyond G-ANC meetings; and motivation to continue providing G-ANC. Together these themes map to a theory of change which centers the shared experience of care for women and providers among multiple pathways to improved outcomes. Discussion The reported experience and effects of G-ANC on women and providers are consistent with other studies in LMICs. This study is novel because it uses the themes to present a theory of change for G-ANC in low-resource settings. It is useful for G-ANC implementation to inform model development, test adaptations, and continue exploring mechanisms of action in future research.	[Grenier, Lindsay; Suhowatsky, Stephanie] Jhpiego, Maternal & Newborn Hlth Unit, Baltimore, MD 21231 USA; [Onguti, Brenda] Jhpiego, Global Programs, Nairobi, Kenya; [Whiting-Collins, Lillian J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Omanga, Eunice] Jhpiego, Dept Monitoring Evaluat & Res, Nairobi, Kenya; [Winch, Peter J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Onguti, Brenda] Harvard Univ, Publ Hlth Program, Boston, MA 02115 USA; [Omanga, Eunice] Urban Res & Dev Ctr Africa, MERL, Nairobi, Kenya	Jhpiego; Jhpiego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jhpiego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University	Grenier, L (corresponding author), Jhpiego, Maternal & Newborn Hlth Unit, Baltimore, MD 21231 USA.	lindsay.grenier@jhpiego.org		GRENIER, LINDSAY/0000-0002-9679-6570; , Eunice/0000-0003-2579-4014	Bill and Melinda Gates Foundation [OPP1134962]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was funded via Grant #OPP1134962, awarded to the Jhpiego Corporation from the Bill and Melinda Gates Foundation, www.gatesfoundation.org.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adaji SE, 2019, INT J GYNECOL OBSTET, V145, P164, DOI 10.1002/ijgo.12788; Adegoke AA, 2015, MIDWIFERY, V31, P946, DOI 10.1016/j.midw.2015.06.010; Afulani PA, 2020, HEALTH POLICY PLANN, V35, P577, DOI 10.1093/heapol/czaa009; Buffington ST., 2010, HOME BASED LIFE SAVI, V2nd; Chirwa E, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8276-x; Downe S, 2016, BJOG-INT J OBSTET GY, V123, P529, DOI 10.1111/1471-0528.13819; Eluwa GI, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1805-2; European Commission, HOR 2020 GROUP CAR 1; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Grenier L, 2020, J MIDWIFERY WOM HEAL, V65, P694, DOI 10.1111/jmwh.13143; Grenier L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222177; Group Care Global, OVERVIEW; Heberlein EC, 2016, J MIDWIFERY WOM HEAL, V61, P224, DOI 10.1111/jmwh.12379; Jafari F, 2010, IRAN J PUBLIC HEALTH, V39, P52; Jafari F, 2010, HEALTH CARE WOMEN IN, V31, P571, DOI 10.1080/07399331003646323; Kabue Mark M, 2018, Gates Open Res, V2, P56, DOI 10.12688/gatesopenres.12867.2; Lazar J, 2021, REPROD HEALTH, V18, DOI 10.1186/s12978-021-01200-0; Liese KL, 2021, INT J GYNECOL OBSTET, V153, P154, DOI 10.1002/ijgo.13432; Lori JR, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0644-y; Lori JR, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1414-5; Lori JR, 2016, INT J NURS STUD, V54, P84, DOI 10.1016/j.ijnurstu.2015.03.018; Lundeen T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219471; Manant A, 2011, J MIDWIFERY WOM HEAL, V56, P94, DOI 10.1111/j.1542-2011.2010.00021.x; McDonald SD, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-334; McKinnon B, 2020, HEALTH POLICY PLANN, V35, P587, DOI 10.1093/heapol/czz178; McNeil DA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S6; McNeil DA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-17; Musabyimana A, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0750-5; Musange Sabine Furere, 2019, Gates Open Res, V3, P1548, DOI 10.12688/gatesopenres.13053.1; Noguchi L, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-3099-x; Novick G, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.03.026; Okedo-Alex IN, 2020, INT J WOMENS HEALTH, V12, P1145, DOI 10.2147/IJWH.S277827; Patil CL, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1493-3; Patil CL, 2017, INT J GYNECOL OBSTET, V139, P290, DOI 10.1002/ijgo.12324; Rising SS, 1998, J NURSE-MIDWIFERY, V43, P46, DOI 10.1016/S0091-2182(97)00117-1; Sayinzoga F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246442; Sharma J, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0476-9; Sheeder J, 2012, MATERN CHILD HLTH J, V16, P177, DOI 10.1007/s10995-010-0709-1; Sultana M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218169; Thapa P, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0820-8; The Global Group Antenatal Care Collaborative, COLL COLL; The World Bank, HLTH STATS SERV DEL; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; WHO, 2016, WHO TECH REP SER, V997, P1	44	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2022	17	5							e0265174	10.1371/journal.pone.0265174	http://dx.doi.org/10.1371/journal.pone.0265174			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6I1LZ	35503773	Green Published, gold			2023-01-03	WOS:000885891700005
J	Wilson-Menzfeld, G; Naisby, J; Baker, K; Morris, R; Robinson, J; Barry, G				Wilson-Menzfeld, Gemma; Naisby, Jenni; Baker, Katherine; Morris, Rosie; Robinson, Jonathan; Barry, Gill			Yoga provision for individuals living with Multiple Sclerosis: Is the future online?	PLOS ONE			English	Article							DIGITAL DIVIDE; INTERNET USE; SYMPTOM MANAGEMENT; PEOPLE	BackgroundYoga has multiple benefits for individuals living with Multiple Sclerosis (MS), including reduced pain, depression, fatigue, strength, and improved quality of life. During the COVID-19 pandemic, home-based delivery of yoga increased. However, no studies to date have explored online home-based yoga for individuals living with MS, more specifically the motivations, experiences, or the sustainability of home-based yoga practice for individuals living with MS. AimThis study aimed to explore the facilitators and barriers of online yoga provision for individuals living with MS. MethodsOne focus group and three semi-structured interviews were carried out online via Zoom with one yoga instructor and seven yoga participants living with MS. Thematic Analysis was used to analyse this data. FindingsTwo themes were generated from the interviews, the environment and future provision, each with their own sub-themes. The themes reflect various facilitators and barriers of home-based yoga provision which differed depending upon the individuals home environment, social connections, physical ability, and confidence practising yoga. Furthermore, preferences of home provision fluctuated over time depending upon symptoms of MS. ConclusionsHome-based yoga practice is a viable and enjoyable option for individuals living with MS. It is recommended that yoga studios offering home-based yoga provision consider individual differences in preference, as well as fluctuations in symptoms that may create inequitable access to services and may prevent participation for some.	[Wilson-Menzfeld, Gemma] Northumbria Univ, Dept Nursing Midwifery & Hlth, Newcastle Upon Tyne, Tyne & Wear, England; [Naisby, Jenni; Baker, Katherine; Morris, Rosie; Barry, Gill] Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne, Tyne & Wear, England; [Robinson, Jonathan] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough, Cleveland, England	Northumbria University; Northumbria University; University of Teesside	Wilson-Menzfeld, G (corresponding author), Northumbria Univ, Dept Nursing Midwifery & Hlth, Newcastle Upon Tyne, Tyne & Wear, England.	gemma.wilson-menzfeld@northumbria.ac.uk		Morris, Rosie/0000-0002-0290-6688; Robinson, Jonathan/0000-0001-8631-5465; Barry, Gill/0000-0003-4886-920X; Baker, Katherine/0000-0003-4216-6298; Menzfeld, Gemma/0000-0001-7362-7048; Naisby, Jenni/0000-0001-8050-7669				Abbadessa G, 2022, J NEUROL, V269, P1209, DOI 10.1007/s00415-021-10608-4; Age UK., 2015, LATER LIFE DIGITAL W; Bergstrom A, 2017, NORD REV, V38, P79, DOI 10.1515/nor-2017-0398; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Braun V, 2019, QUAL RES SPORT EXERC, V11, P589, DOI 10.1080/2159676X.2019.1628806; Browne P, 2014, NEUROLOGY, V83, P1022, DOI 10.1212/WNL.0000000000000768; Choi NG, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2645; Cramer H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112414; Cresci MK, 2010, GERIATR NURS, V31, P455, DOI 10.1016/j.gerinurse.2010.10.006; Ensari I, 2014, J PSYCHOSOM RES, V76, P465, DOI 10.1016/j.jpsychores.2014.03.014; Feuerstein G., 1998, YOGA TRADITION ITS H, V100, P103; Frank R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00133; Friemel TN, 2016, NEW MEDIA SOC, V18, P313, DOI 10.1177/1461444814538648; Ghahfarrokhi MM, 2021, MULT SCLER RELAT DIS, V55, DOI 10.1016/j.msard.2021.103177; Ghram A, 2021, POSTGRAD MED, V133, P469, DOI 10.1080/00325481.2020.1860394; Gilleard C, 2008, EUR J AGEING, V5, P233, DOI 10.1007/s10433-008-0083-7; Gordon NP, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2986-0; Halabchi F, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0960-9; Hale L., 2003, NEW ZEAL J PHYS, V31, P130; Hargittai E, 2017, CAN J COMMUN, V42, P195, DOI 10.22230/cjc2017v42n2a3176; Hasanpour-Dehkordi A, 2016, J CLIN DIAGN RES, V10, pVC1, DOI 10.7860/JCDR/2016/18204.7916; Hosseini SS., 2018, ASIAN J SPORTS MED, V9, pe68807; Koopmans A., 2022, DISABILITIES, V2, P41; Lavorgna L, 2017, INTERACT J MED RES, V6, DOI 10.2196/ijmr.7402; Matthews K, 2019, AGEING SOC, V39, P1914, DOI 10.1017/S0144686X18000326; Momsen AMH, 2022, ANN PHYS REHABIL MED, V65, DOI 10.1016/j.rehab.2021.101529; Neves BB, 2013, SOCIOL RES ONLINE, V18, DOI 10.5153/sro.2998; Regan EW, 2022, PHYSIOTHER THEOR PR, V38, P401, DOI 10.1080/09593985.2020.1765438; Rogers KA, 2015, J ALTERN COMPLEM MED, V21, P655, DOI 10.1089/acm.2015.0015; Senders A, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/567324; Tollar J, 2020, MED SCI SPORT EXER, V52, P1007, DOI 10.1249/MSS.0000000000002228; UK government, 2018, AG GROUPS; Yeroushalmi S, 2020, J TELEMED TELECARE, V26, P400, DOI 10.1177/1357633X19840097; Yoon H, 2020, J APPL GERONTOL, V39, P105, DOI 10.1177/0733464818770772	34	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2022	17	4							e0266786	10.1371/journal.pone.0266786	http://dx.doi.org/10.1371/journal.pone.0266786			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1C7NT	35486611	Green Accepted, gold, Green Published			2023-01-03	WOS:000793302300008
J	Tonorezos, ES; Cohn, RJ; Glaser, AW; Lewin, J; Poon, E; Wakefield, CE; Oeffinger, KC				Tonorezos, Emily S.; Cohn, Richard J.; Glaser, Adam W.; Lewin, Jeremy; Poon, Eileen; Wakefield, Claire E.; Oeffinger, Kevin C.			Long-term care for people treated for cancer during childhood and adolescence	LANCET			English	Article							YOUNG-ADULT CANCER; QUALITY-OF-LIFE; FOLLOW-UP; SURVIVORS; TRANSITION; INTERVENTION; SYMPTOMS; FAMILIES; OUTCOMES; FEASIBILITY	Worldwide advances in treatment and supportive care for children and adolescents with cancer have resulted in a increasing population of survivors growing into adulthood. Yet, this population is at very high risk of late occurring health problems, including significant morbidity and early mortality. Unique barriers to high-quality care for this group include knowledge gaps among both providers and survivors as well as fragmented health-care delivery during the transition from paediatric to adult care settings. Survivors of childhood and adolescent cancer are at risk for a range of late-occuring side-effects from treatment, including cardiac, endocrine, pulmonary, fertility, renal, psychological, cognitive, and socio-developmental impairments. Care coordination and transition to adult care are substantial challenges, but can be empowering for survivors and improve outcomes, and could be facilitated by clear, effective communication and support for self-management. Resources for adult clinical care teams and primary care providers include late-effects surveillance guidelines and web-based support services.	[Tonorezos, Emily S.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Rockville, MD 29050 USA; [Cohn, Richard J.; Wakefield, Claire E.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Cohn, Richard J.; Wakefield, Claire E.] UNSW Sydney, Sch Womens & Childrens Hlth, UNSW Med, Kensington, NSW, Australia; [Glaser, Adam W.] Univ Leeds, Leeds Inst Med Res, Leeds, W Yorkshire, England; [Lewin, Jeremy] Univ Melbourne, ONTrac Peter Mac Victorian Adolscent & Young Adul, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Poon, Eileen] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore; [Oeffinger, Kevin C.] Duke Univ, Dept Med, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of New South Wales Sydney; University of Leeds; Peter Maccallum Cancer Center; University of Melbourne; National Cancer Centre Singapore (NCCS); Duke University	Tonorezos, ES (corresponding author), NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Rockville, MD 29050 USA.	emily.tonorezos@nih.gov						Anazodo AC, 2021, J ADOLESC YOUNG ADUL, V10, P131, DOI 10.1089/jayao.2020.0157; Armenian SH, 2015, LANCET ONCOL, V16, pE123, DOI 10.1016/S1470-2045(14)70409-7; Barr RD, 2016, JAMA PEDIATR, V170, P495, DOI 10.1001/jamapediatrics.2015.4689; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; Brinkman TM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.5552; Brinkman TM, 2013, J NEURO-ONCOL, V113, P425, DOI 10.1007/s11060-013-1130-6; Children's Oncology Group, 2018, LONG TERM FOLL UP GU; Dieluweit U, 2011, KLIN PADIATR, V223, P152, DOI 10.1055/s-0031-1271779; Ehrhardt MJ, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29030; Emery J, 2022, LANCET, V399, P1537, DOI 10.1016/S0140-6736(22)00242-2; Escherich G, 2017, J ADOLESC YOUNG ADUL, V6, P194, DOI 10.1089/jayao.2016.0075; Ford JS, 2020, CANCER-AM CANCER SOC, V126, P619, DOI 10.1002/cncr.32568; Freyer DR, 2008, PEDIATR BLOOD CANCER, V50, P1116, DOI 10.1002/pbc.21455; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Gibson TM, 2018, LANCET ONCOL, V19, P1590, DOI 10.1016/S1470-2045(18)30537-0; Hardy KK, 2017, J PEDIATR PSYCHOL, V42, P815, DOI 10.1093/jpepsy/jsx060; Hewitt M., 2005, CANC PATIENT CANC SU; Huang IC, 2013, J CLIN ONCOL, V31, P4242, DOI 10.1200/JCO.2012.47.8867; Hudson MM, 2015, J CLIN ONCOL, V33, P479, DOI 10.1200/JCO.2014.57.4863; IJsbrandy C, 2021, J CANCER SURVIV, V15, P163, DOI 10.1007/s11764-020-00921-8; International Agency for Research on Cancer, 2020, EST NUMB NEW CAS 202; Jacobsen PB, 2018, J CLIN ONCOL, V36, P2088, DOI 10.1200/JCO.2018.77.7482; Jefford M, 2022, LANCET, V399, P1551, DOI 10.1016/S0140-6736(22)00306-3; Kadan-Lottick NS, 2002, JAMA-J AM MED ASSOC, V287, P1832, DOI 10.1001/jama.287.14.1832; Kazak AE, 2019, PEDIATR BLOOD CANCER, V66, pS50; Kazak AE, 2004, J FAM PSYCHOL, V18, P493, DOI 10.1037/0893-3200.18.3.493; Kremer LCM, 2013, PEDIATR BLOOD CANCER, V60, P543, DOI 10.1002/pbc.24445; Landier W, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.77.0180; Lewis DR, 2021, CANCER-AM CANCER SOC, V127, P4277, DOI 10.1002/cncr.33793; Licht SD, 2014, LANCET, V383, P1981, DOI 10.1016/S0140-6736(13)62564-7; Lown EA, 2015, PEDIATR BLOOD CANCER, V62, pS531, DOI 10.1002/pbc.25783; McDonnell GA, 2017, J ADOLESCENT HEALTH, V61, P409, DOI 10.1016/j.jadohealth.2017.04.004; Michel G, 2020, PEDIATR CLIN N AM, V67, P1103, DOI 10.1016/j.pcl.2020.07.005; Moskowitz CS, 2014, J CLIN ONCOL, V32, P2217, DOI 10.1200/JCO.2013.54.4601; Mulder RL, 2020, J CLIN ONCOL, V38, P4194, DOI 10.1200/JCO.20.00562; Murphy D, 2015, CANCER-AM CANCER SOC, V121, P2529, DOI 10.1002/cncr.29466; Nathan PC, 2011, CANCER-AM CANCER SOC, V117, P2335, DOI 10.1002/cncr.26042; National Academies of Sciences EaM, 2020, CHILDH CANC FUNCT IM; Oeffinger KC, 2006, J CLIN ONCOL, V24, P5117, DOI 10.1200/JCO.2006.07.0474; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Patel SK, 2011, PSYCHO-ONCOLOGY, V20, P1324, DOI 10.1002/pon.1859; Peikert ML, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196151; Prasad PK, 2015, J CLIN ONCOL, V33, P2545, DOI 10.1200/JCO.2014.57.7528; Reulen RC, 2010, JAMA-J AM MED ASSOC, V304, P172, DOI 10.1001/jama.2010.923; Robertson EG, 2016, J ADOLESC YOUNG ADUL, V5, P286, DOI 10.1089/jayao.2015.0061; Rosen DS, 2003, J ADOLESCENT HEALTH, V33, P309, DOI 10.1016/S1054-139X(03)00208-8; Rosenberg-Yunger ZRS, 2013, J ADOLESC YOUNG ADUL, V2, P104, DOI 10.1089/jayao.2013.0003; Ryan D, 2018, PEDIAT HEMATOLOGY ON, V3, P90; Sadak KT, 2021, CANCER MED-US, V10, P6239, DOI 10.1002/cam4.4164; Salem H, 2017, ACTA ONCOL, V56, P367, DOI 10.1080/0284186X.2016.1269194; Sansom-Daly UM, 2019, PSYCHO-ONCOLOGY, V28, P284, DOI 10.1002/pon.4938; Sawyer SM, 2019, SUPPORT CARE CANCER, V27, P1783, DOI 10.1007/s00520-018-4420-x; Signorelli C, 2022, BMJ SUPPORT PALLIAT, V12, pE687, DOI 10.1136/bmjspcare-2019-002001; Signorelli C, 2019, ONCOLOGIST, V24, P710, DOI 10.1634/theoncologist.2018-0103; Suh E, 2020, LANCET ONCOL, V21, P421, DOI 10.1016/S1470-2045(19)30800-9; Suh E, 2014, ANN INTERN MED, V160, P11, DOI 10.7326/M13-1941; Sutradhar R, 2015, CANCER-AM CANCER SOC, V121, P4389, DOI 10.1002/cncr.29679; Tonorezos ES, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.5180; Turcotte LM, 2017, JAMA-J AM MED ASSOC, V317, P814, DOI 10.1001/jama.2017.0693; van der Hout A, 2020, LANCET ONCOL, V21, P80, DOI 10.1016/S1470-2045(19)30675-8; van der Meer DJ, 2020, CANCERS, V12, DOI 10.3390/cancers12113421; van der Pal HJ, 2012, J CLIN ONCOL, V30, P1429, DOI 10.1200/JCO.2010.33.4730; van Kalsbeek RJ, 2021, EUR J CANCER, V154, P316, DOI 10.1016/j.ejca.2021.06.004; Wakefield CE, 2016, SUPPORT CARE CANCER, V24, P2685, DOI 10.1007/s00520-016-3077-6; Wallace WHB, 2001, BRIT MED J, V323, P271, DOI 10.1136/bmj.323.7307.271; Yan AP, 2020, J CLIN ONCOL, V38, P1711, DOI 10.1200/JCO.19.01825; Yeh JM, 2020, JAMA ONCOL, V6, P350, DOI 10.1001/jamaoncol.2019.5582; Zebrack BJ, 2011, CANCER-AM CANCER SOC, V117, P2289, DOI 10.1002/cncr.26056; Zebrack BJ, 2010, PSYCHO-ONCOLOGY, V19, P814, DOI 10.1002/pon.1641; Zhang AA, 2021, J PSYCHOSOC ONCOL, DOI 10.1080/07347332.2021.2011530	70	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2022	399	10334					1561	1572						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	1G1JN	35430023				2023-01-03	WOS:000795611300027
J	Zhang, MM; Hu, P; Xu, XW; Ai, JW; Li, Y; Bao, Y; Tangamornsuksan, W; Chan, AL; Xie, S; Hu, H; Liang, ST; Zhang, WH; Xie, F				Zhang, Mengmeng; Hu, Peng; Xu, Xiaowei; Ai, Jingwen; Li, Yang; Bao, Yun; Tangamornsuksan, Wimonchat; Chan, Alain; Xie, Shelley; Hu, Hao; Liang, Shuting; Zhang, Wenhong; Xie, Feng			A look back at the first wave of COVID-19 in China: A systematic review and meta-analysis of mortality and health care resource use among severe or critical patients	PLOS ONE			English	Review							CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; DISEASE SEVERITY; ILL PATIENTS; WUHAN; PNEUMONIA; OUTCOMES	Background To investigate the mortality and health care resource use among patients with severe or critical coronavirus disease of 2019 (COVID-19) in the first wave of pandemic in China. Methods We performed a systematic review and meta-analysis to investigate the mortality, discharge rate, length of hospital stay, and use of invasive ventilation in severe or critical COVID-19 cases in China. We searched electronic databases for studies from China with no restrictions on language or interventions patients received. We screened records, extracted data and assessed the quality of included studies in duplicate. We performed the meta-analysis using random-effect models through a Bayesian framework. Subgroup analyses were conducted to examine studies by disease severity, study location and patient enrolment start date. We also performed sensitivity analysis using various priors, and assessed between-study heterogeneity and publication bias for the primary outcomes. Results Out of 6,205 titles and abstracts screened, 500 were reviewed in full text. A total of 42 studies were included in the review, of which 95% were observational studies (n = 40). The pooled 28-day and 14-day mortalities among severe or critical patients were 20.48% (7,136 patients, 95% credible interval (CrI), 13.11 to 30.70) and 10.83% (95% CrI, 6.78 to 16.75), respectively. The mortality declined over time and was higher in patients with critical disease than severe cases (1,235 patients, 45.73%, 95% CrI, 22.79 to 73.52 vs. 3,969 patients, 14.90%, 95% CrI, 4.70 to 39.57) and patients in Hubei compared to those outside Hubei (6,719 patients, 26.62%, 95% CrI, 13.11 to 30.70 vs. 244 patients, 5.88%, 95% CrI 2.03 to 14.11). The length of hospital stay was estimated at 18.48 days (6,847 patients, 95% CrI, 17.59 to 21.21), the 28-day discharge rate was 50.48% (3,645 patients, 95% CrI, 26.47 to 79.53), and the use of invasive ventilation rate was 13.46% (4,108 patients, 95% CrI, 7.61 to 22.31). Conclusions Our systematic review and meta-analysis found high mortality among severe and critical COVID-19 cases. Severe or critical COVID-19 cases consumed a large amount of hospital resources during the outbreak.	[Zhang, Mengmeng; Tangamornsuksan, Wimonchat; Xie, Feng] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Hu, Peng] Chongqing Med Univ, Dept Infect Dis, Hosp 2, Chongqing, Peoples R China; [Xu, Xiaowei] Zhejiang Univ, Dept Infect Dis, Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Ai, Jingwen; Li, Yang; Zhang, Wenhong] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China; [Bao, Yun] Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Gansu, Peoples R China; [Tangamornsuksan, Wimonchat] Chulabhorn Royal Acad, Princess Srisavangavadhana Coll Med, Bangkok, Thailand; [Chan, Alain; Xie, Shelley] Gilead Sci, China Med Affairs, Foster City, CA USA; [Hu, Hao] Gilead Sci, Global Value & Access, Foster City, CA USA; [Liang, Shuting] Gilead Sci, Global Med Affairs Res, Foster City, CA USA; [Xie, Feng] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada	McMaster University; Chongqing Medical University; Zhejiang University; Fudan University; Chulabhorn Royal Academy; Gilead Sciences; Gilead Sciences; Gilead Sciences; McMaster University	Xie, F (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; Zhang, WH (corresponding author), Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China.; Xie, F (corresponding author), McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada.	zhangwenhong@fudan.edu.cn; fengxie@mcmaster.ca	Tangamornsuksan, Wimonchat/X-4150-2018	Tangamornsuksan, Wimonchat/0000-0003-3473-6000	Gilead Sciences	Gilead Sciences(Gilead Sciences)	This study was supported by an unrestricted grant from Gilead Sciences. The funder has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bartsch SM, 2020, HEALTH AFFAIR, V39, P927, DOI 10.1377/hlthaff.2020.00426; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Busse JW., TOOL ASSESS RISK BIA; Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309; Centers for Disease Control and Prevention (CDC), 2021, COVID 19 MORT OVERVI; Chen FF, 2020, J CRIT CARE, V60, P32, DOI 10.1016/j.jcrc.2020.07.003; Chen YH, 2020, ANN PALLIAT MED, V9, P2118, DOI 10.21037/apm-20-1273; Cheng K., SHANGHAI MED J, V43, P224; Dennis JM, 2021, CRIT CARE MED, V49, P209, DOI 10.1097/CCM.0000000000004747; Dias S, 2011, TECHNICAL SUPPORT DO; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86853-4; Guyatt GH, MODIFICATION COCHRAN; Hu SL., 2020, PRACT J CARDIAC CERE, V28, P10; Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371; Huang M, 2020, AM J MED SCI, V360, P120, DOI 10.1016/j.amjms.2020.05.038; International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), COVID 19 EV REP; Johns Hopkins Coronavirus Resource Center, COVID 19 MAP; Kuhn A, S KOREAN CITY IS CHA; Ledford H, 2020, NATURE, V587, P190, DOI 10.1038/d41586-020-03132-4; Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757; Liu D, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100471; Liu JM, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n415; Liu J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00706-3; Liu XF, 2020, J INFECTION, V81, pE95, DOI 10.1016/j.jinf.2020.04.008; Liu XT, 2020, AGING-US, V12, P12432, DOI 10.18632/aging.103417; Liu ZM, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00478; Ma Q, 2020, EUR REV MED PHARMACO, V24, P8194, DOI 10.26355/eurrev_202008_22508; Ma YM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01198; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Madhav N, 2017, DIS CONTROL PRIORITI, Vthird, DOI [DOI 10.1596/978-1-4648-0527-1_CH17, 10.1596/978-1-4648-0527-1_ch17, DOI 10.1596/978-1-4648-0527-1]; Mi YN, 2020, INT J INFECT DIS, V97, P1, DOI 10.1016/j.ijid.2020.04.055; Nasiri MJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00459; National Health Commission of People's Republic of China, 2020, DIAGN TREATM GUID CO, V8th; National Institute for Health and Care Excellence Decision Support Unit, TSDS COMPL CURR PROG; Pan F, 2020, INT J MED SCI, V17, P1281, DOI 10.7150/ijms.46614; Rees EM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01726-3; Riccioni Luigi, 2020, Recenti Prog Med, V111, P207, DOI 10.1701/3347.33183; Shao F, 2020, RESUSCITATION, V151, P18, DOI 10.1016/j.resuscitation.2020.04.005; Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735; Tang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032; Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; Wang W, 2020, CHEST, V158, P939, DOI 10.1016/j.chest.2020.05.515; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO, 2021, ENDING NEGLECT ATTAI; WHO, 2020, PREP PREV CONTR COR; Wu JF, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa627; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079; Xie JF, 2020, INTENS CARE MED, V46, P1863, DOI 10.1007/s00134-020-06211-2; Xiong P., J PRACTICAL MED, V36, P1710; XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012; Xu JB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72164-7; Xu JQ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03098-9; Xu KD, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001533; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yu CZ, 2020, J INFECT PUBLIC HEAL, V13, P1202, DOI 10.1016/j.jiph.2020.07.002; Yu H., 2020, JIANGSU MED J, V46, P904; Yu Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02939-x; Zhang P, 2021, CLIN NUTR, V40, P534, DOI 10.1016/j.clnu.2020.05.051; Zhang SY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00710-6; Zhang S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03123-x; Zhang S, 2020, SLEEP MED, V75, P354, DOI 10.1016/j.sleep.2020.08.010; [张永喜 Zhang Yongxi], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P472; Zhong J., J PRACTICAL MED, V36, P2325; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou SL, 2020, SHOCK, V54, P644, DOI 10.1097/SHK.0000000000001629; Zhu YJ, 2020, MED CLIN-BARCELONA, V155, P191, DOI [10.1016/j.medcli.2020.05.012, 10.1016/j.medcle.2020.05.015]	79	1	1	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2022	17	3							e0265117	10.1371/journal.pone.0265117	http://dx.doi.org/10.1371/journal.pone.0265117			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4H6NN	35275943	Green Published, gold			2023-01-03	WOS:000849994500048
J	Pfafflin, F; Stegemann, MS; Heim, KM; Achterberg, S; Pfitzner, U; Gotze, L; Oesterhelweg, L; Suttorp, N; Herzog, C; Stadtmann, B; Uhrig, A				Pfaefflin, Frieder; Stegemann, Miriam Songa; Heim, Katrin Moira; Achterberg, Stephan; Pfitzner, Ursula; Goetze, Louise; Oesterhelweg, Lars; Suttorp, Norbert; Herzog, Christian; Stadtmann, Benjamin; Uhrig, Alexander			Preparing for patients with high-consequence infectious diseases: Example of a high-level isolation unit	PLOS ONE			English	Article							EBOLA-VIRUS DISEASE; MANAGEMENT; CARE	Introduction Patients with high-consequence infectious diseases (HCID) are rare in Western Europe. However, high-level isolation units (HLIU) must always be prepared for patient admission. Case fatality rates of HCID can be reduced by providing optimal intensive care management. We here describe a single centre's preparation, its embedding in the national context and the challenges we faced during the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Methods Ten team leaders organize monthly whole day trainings for a team of doctors and nurses from the HLIU focusing on intensive care medicine. Impact and relevance of training are assessed by a questionnaire and a perception survey, respectively. Furthermore, yearly exercises with several partner institutions are performed to cover different real-life scenarios. Exercises are evaluated by internal and external observers. Both training sessions and exercises are accompanied by intense feedback. Results From May 2017 monthly training sessions were held with a two-month and a seven-month break due to the first and second wave of the SARS-CoV-2 pandemic, respectively. Agreement with the statements of the questionnaire was higher after training compared to before training indicating a positive effect of training sessions on competence. Participants rated joint trainings for nurses and doctors at regular intervals as important. Numerous issues with potential for improvement were identified during post processing of exercises. Action plans for their improvement were drafted and as of now mostly implemented. The network of the permanent working group of competence and treatment centres for HCID (Standiger Arbeitskreis der Kompetenz- und Behandlungszentren fur Krankheiten durch hochpathogene Erreger (STAKOB)) at the Robert Koch-Institute (RKI) was strengthened throughout the SARS-CoV-2 pandemic. Discussion Adequate preparation for the admission of patients with HCID is challenging. We show that joint regular trainings of doctors and nurses are appreciated and that training sessions may improve perceived skills. We also show that real-life scenario exercises may reveal additional deficits, which cannot be easily disclosed in training sessions. Although the SARS-CoV-2 pandemic interfered with our activities the enhanced cooperation among German HLIU during the pandemic ensured constant readiness for the admission of HCID patients to our or to collaborating HLIU. This is a single centre's experience, which may not be generalized to other centres. However, we believe that our work may address aspects that should be considered when preparing a unit for the admission of patients with HCID. These may then be adapted to the local situations.	[Pfaefflin, Frieder; Stegemann, Miriam Songa; Heim, Katrin Moira; Achterberg, Stephan; Pfitzner, Ursula; Goetze, Louise; Suttorp, Norbert; Stadtmann, Benjamin; Uhrig, Alexander] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany; [Pfaefflin, Frieder; Stegemann, Miriam Songa; Heim, Katrin Moira; Achterberg, Stephan; Pfitzner, Ursula; Goetze, Louise; Oesterhelweg, Lars; Suttorp, Norbert; Stadtmann, Benjamin; Uhrig, Alexander] Free Univ Berlin, Berlin, Germany; [Pfaefflin, Frieder; Stegemann, Miriam Songa; Heim, Katrin Moira; Achterberg, Stephan; Pfitzner, Ursula; Goetze, Louise; Oesterhelweg, Lars; Suttorp, Norbert; Stadtmann, Benjamin; Uhrig, Alexander] Humboldt Univ, Berlin, Germany; [Pfaefflin, Frieder; Stegemann, Miriam Songa; Heim, Katrin Moira; Achterberg, Stephan; Pfitzner, Ursula; Goetze, Louise; Oesterhelweg, Lars; Suttorp, Norbert; Stadtmann, Benjamin; Uhrig, Alexander] Berlin Inst Hlth, Berlin, Germany; [Oesterhelweg, Lars] Charite Univ Med Berlin, Inst Legal Med & Forens Sci, Berlin, Germany; [Herzog, Christian] Robert Koch Inst, Ctr Biol Threats Strategy & Incident Response, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute	Pfafflin, F (corresponding author), Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany.; Pfafflin, F (corresponding author), Free Univ Berlin, Berlin, Germany.; Pfafflin, F (corresponding author), Humboldt Univ, Berlin, Germany.; Pfafflin, F (corresponding author), Berlin Inst Hlth, Berlin, Germany.	frieder.pfaefflin@charite.de		Stegemann, Miriam Songa/0000-0002-7968-0429				Andonian J, 2019, HEALTH SECUR, V17, P69, DOI 10.1089/hs.2018.0104; Baka A, 2007, Euro Surveill, V12, pE5; Bannister B, 2009, LANCET INFECT DIS, V9, P45, DOI 10.1016/S1473-3099(08)70304-9; Bauer MP, 2019, CLIN MICROBIOL INFEC, V21, pE28, DOI 10.1111/1469-0691.12673; Ehlkes L, 2017, EUROSURVEILLANCE, V22, P24, DOI 10.2807/1560-7917.ES.2017.22.39.16-00728; Garibaldi BT, 2016, ANN AM THORAC SOC, V13, P600, DOI 10.1513/AnnalsATS.201509-587PS; Gottschalk R, 2009, BUNDESGESUNDHEITSBLA, V52, P214, DOI 10.1007/s00103-009-0766-z; Herstein JJ, 2018, J NURS ADMIN, V48, P553, DOI 10.1097/NNA.0000000000000679; Herzog C., 2019, ROBERT KOCH INSTITUT; Kreuels B, 2014, NEW ENGL J MED, V371, P2394, DOI 10.1056/NEJMoa1411677; Lamontagne F, 2018, LANCET, V391, P700, DOI 10.1016/S0140-6736(17)31795-6; Lehmann C, 2017, EUROSURVEILLANCE, V22, P15, DOI 10.2807/1560-7917.ES.2017.22.39.17-00088; Schilling S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100401; Uyeki TM, 2016, NEW ENGL J MED, V374, P636, DOI 10.1056/NEJMoa1504874; Vaughan A, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.38.1800509; Wolf T, 2015, LANCET, V385, P1428, DOI 10.1016/S0140-6736(14)62384-9	16	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264644	10.1371/journal.pone.0264644	http://dx.doi.org/10.1371/journal.pone.0264644			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0D4YH	35239726	Green Published, gold			2023-01-03	WOS:000776002200057
J	Belohlavek, J; Smalcova, J; Rob, D; Franek, O; Smid, O; Pokorna, M; Horak, J; Mrazek, V; Kovarnik, T; Zemanek, D; Kral, A; Havranek, S; Kavalkova, P; Kompelentova, L; Tomkova, H; Mejstrik, A; Valasek, J; Peran, D; Pekara, J; Rulisek, J; Balik, M; Huptych, M; Jarkovsky, J; Malik, J; Valerianova, A; Mlejnsky, F; Kolouch, P; Havrankova, P; Romportl, D; Komarek, A; Linhart, A				Belohlavek, Jan; Smalcova, Jana; Rob, Daniel; Franek, Ondrej; Smid, Ondrej; Pokorna, Milana; Horak, Jan; Mrazek, Vratislav; Kovarnik, Tomas; Zemanek, David; Kral, Ales; Havranek, Stepan; Kavalkova, Petra; Kompelentova, Lucie; Tomkova, Helena; Mejstrik, Alan; Valasek, Jaroslav; Peran, David; Pekara, Jaroslav; Rulisek, Jan; Balik, Martin; Huptych, Michal; Jarkovsky, Jiri; Malik, Jan; Valerianova, Anna; Mlejnsky, Frantisek; Kolouch, Petr; Havrankova, Petra; Romportl, Dan; Komarek, Arnost; Linhart, Ales		Prague OHCA Study Grp	Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COUNCIL GUIDELINES; LIFE-SUPPORT; SURVIVAL; HYPOTHERMIA; CANDIDATES; TIME	IMPORTANCE Out-of-hospital cardiac arrest (OHCA) has poor outcome. Whether intra-arrest transport, extracorporeal cardiopulmonary resuscitation (ECPR), and immediate invasive assessment and treatment (invasive strategy) is beneficial in this setting remains uncertain. OBJECTIVE To determine whether an early invasive approach in adults with refractory OHCA improves neurologically favorable survival. DESIGN, SETTING, AND PARTICIPANTS Single-center, randomized clinical trial in Prague, Czech Republic, of adults with a witnessed OHCA of presumed cardiac origin without return of spontaneous circulation. A total of 256 participants, of a planned sample size of 285, were enrolled between March 2013 and October 2020. Patients were observed until death or day 180 (last patient follow-up ended on March 30, 2021). INTERVENTIONS In the invasive strategy group (n = 124), mechanical compression was initiated, followed by intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment. Regular advanced cardiac life support was continued on-site in the standard strategy group (n = 132). MAIN OUTCOMES AND MEASURES The primary outcome was survival with a good neurologic outcome (defined as Cerebral Performance Category [CPC] 1-2) at 180 days after randomization. Secondary outcomes included neurologic recovery at 30 days (defined as CPC 1-2 at any time within the first 30 days) and cardiac recovery at 30 days (defined as no need for pharmacological or mechanical cardiac support for at least 24 hours). RESULTS The trial was stopped at the recommendation of the data and safety monitoring board when prespecified criteria for futility were met. Among 256 patients (median age, 58 years; 44 [17%] women), 256 (100%) completed the trial. In the main analysis, 39 patients (31.5%) in the invasive strategy group and 29 (22.0%) in the standard strategy group survived to 180 days with good neurologic outcome (odds ratio [OR], 1.63 [95% CI, 0.93 to 2.85]; difference, 9.5% [95% CI, -1.3% to 20.1%]; P = .09). At 30 days, neurologic recovery had occurred in 38 patients (30.6%) in the invasive strategy group and in 24 (18.2%) in the standard strategy group (OR, 1.99 [95% CI, 1.11 to 3.57]; difference, 12.4% [95% CI, 1.9% to 22.7%]; P = .02), and cardiac recovery had occurred in 54 (43.5%) and 45 (34.1%) patients, respectively (OR, 1.49 [95% CI, 0.91 to 2.47]; difference, 9.4% [95% CI, -2.5% to 21%]; P = .12). Bleeding occurred more frequently in the invasive strategy vs standard strategy group (31% vs 15%, respectively). CONCLUSIONS AND RELEVANCE Among patients with refractory out-of-hospital cardiac arrest, the bundle of early intra-arrest transport, ECPR, and invasive assessment and treatment did not significantly improve survival with neurologically favorable outcome at 180 days compared with standard resuscitation. However, the trial was possibly underpowered to detect a clinically relevant difference.	[Belohlavek, Jan; Smalcova, Jana; Rob, Daniel; Smid, Ondrej; Horak, Jan; Mrazek, Vratislav; Kovarnik, Tomas; Zemanek, David; Kral, Ales; Havranek, Stepan; Kavalkova, Petra; Linhart, Ales] Charles Univ Prague, Fac Med 1, Dept Med 2, Dept Cardiovasc Med, U Nemocnice 2, Prague 12800 2, Czech Republic; [Belohlavek, Jan; Smalcova, Jana; Rob, Daniel; Smid, Ondrej; Horak, Jan; Mrazek, Vratislav; Kovarnik, Tomas; Zemanek, David; Kral, Ales; Havranek, Stepan; Kavalkova, Petra; Rulisek, Jan; Balik, Martin; Malik, Jan; Valerianova, Anna; Mlejnsky, Frantisek; Havrankova, Petra; Linhart, Ales] Gen Univ Hosp, U Nemocnice 2, Prague 12800 2, Czech Republic; [Smalcova, Jana; Franek, Ondrej; Pokorna, Milana; Kompelentova, Lucie; Tomkova, Helena; Mejstrik, Alan; Valasek, Jaroslav; Peran, David; Pekara, Jaroslav; Kolouch, Petr] Emergency Med Serv, Prague, Czech Republic; [Rulisek, Jan; Balik, Martin] Charles Univ Prague, Fac Med 1, Dept Anesthesiol Resuscitat & Intens Med, Prague, Czech Republic; [Huptych, Michal] Czech Tech Univ, Czech Inst Informat Robot & Cybernet CIIRC, Prague, Czech Republic; [Jarkovsky, Jiri] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Malik, Jan; Valerianova, Anna] Charles Univ Prague, Fac Med 1, Dept Med 3, Prague, Czech Republic; [Mlejnsky, Frantisek] Charles Univ Prague, Fac Med 1, Dept Surg 2, Cardiovasc Surg, Prague, Czech Republic; [Havrankova, Petra] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Romportl, Dan] Etoile, Long Term Intens Care Unit, Prague, Czech Republic; [Komarek, Arnost] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague, Czech Republic	Charles University Prague; General University Hospital Prague; Charles University Prague; Czech Technical University Prague; Institute of Biostatistics & Analyses; Masaryk University Brno; Charles University Prague; Charles University Prague; Charles University Prague; Charles University Prague	Belohlavek, J (corresponding author), Charles Univ Prague, Fac Med 1, Dept Med 2, Dept Cardiovasc Med, U Nemocnice 2, Prague 12800 2, Czech Republic.; Belohlavek, J (corresponding author), Gen Univ Hosp, U Nemocnice 2, Prague 12800 2, Czech Republic.	jan.belohlavek@vfn.cz	Havranek, Stepan/G-6768-2017; Havrankova, Petra/HDM-9598-2022; Peran, David/W-4438-2019; Jech, Robert/HHY-7342-2022; Šmalcová, Jana/AFX-7343-2022; Smalcova, Jana/N-1773-2017; Komarek, Arnost/A-5534-2012; Malik, Jan/K-8681-2019; Rob, Daniel/K-8374-2017	Havranek, Stepan/0000-0001-9694-0344; Peran, David/0000-0001-5135-4974; Jech, Robert/0000-0002-9732-8947; Smalcova, Jana/0000-0002-4418-7984; Komarek, Arnost/0000-0001-8778-3762; Malik, Jan/0000-0002-2386-3293; Rob, Daniel/0000-0002-3927-2674	Internal Grant Agency Ministry of Health, Czech Republic [NT 13225-4/2012]; Cooperatio/INCA institutional [Q38/LF1]	Internal Grant Agency Ministry of Health, Czech Republic; Cooperatio/INCA institutional	This study was supported by a research grant from the Internal Grant Agency Ministry of Health, Czech Republic (NT 13225-4/2012), by Progres Q38/LF1 and Cooperatio/INCA institutional support. BeneChill Inc provided 8 Rhinochill devices and, for the purpose of this study, provided the application sets and evaporative liquid at a reduced cost. Physio-Control, a division of Medtronic, provided 8 LUCAS devices for the purpose of this study. Maquet provided the MAQUET PLS device for ECLS.	Alm-Kruse K, 2021, RESUSCITATION, V162, P35, DOI 10.1016/j.resuscitation.2021.01.038; Bartos JA, 2020, CIRCULATION, V141, P877, DOI 10.1161/CIRCULATIONAHA.119.042173; Bartos JA, 2018, RESUSCITATION, V132, P47, DOI 10.1016/j.resuscitation.2018.08.030; Belohlavek J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-163; Bougouin W, 2020, EUR HEART J, V41, P1961, DOI 10.1093/eurheartj/ehz753; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385; Dankiewicz J, 2021, NEW ENGL J MED, V384, P2283, DOI 10.1056/NEJMoa2100591; de Graaf C, 2019, RESUSCITATION, V138, P235, DOI 10.1016/j.resuscitation.2019.03.030; Dennis M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016521; Drennan IR, 2014, RESUSCITATION, V85, P1488, DOI 10.1016/j.resuscitation.2014.07.011; Franek O, 2010, RESUSCITATION, V81, P831, DOI 10.1016/j.resuscitation.2010.03.005; Gaieski DF, 2009, RESUSCITATION, V80, P418, DOI 10.1016/j.resuscitation.2008.12.015; Grasner JT, 2020, RESUSCITATION, V148, P218, DOI 10.1016/j.resuscitation.2019.12.042; Grunau B, 2020, JAMA-J AM MED ASSOC, V324, P1058, DOI 10.1001/jama.2020.14185; Grunau B, 2016, PREHOSP EMERG CARE, V20, P615, DOI 10.3109/10903127.2016.1149652; Haas NL, 2017, RESUSCITATION, V119, P56, DOI 10.1016/j.resuscitation.2017.08.003; Holmberg MJ, 2018, RESUSCITATION, V131, P91, DOI 10.1016/j.resuscitation.2018.07.029; JENNETT B, 1975, LANCET, V1, P480; Leick J, 2013, CLIN RES CARDIOL, V102, P661, DOI 10.1007/s00392-013-0580-3; Lott C, 2021, RESUSCITATION, V161, P152, DOI 10.1016/j.resuscitation.2021.02.011; Maekawa K, 2013, CRIT CARE MED, V41, P1186, DOI 10.1097/CCM.0b013e31827ca4c8; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Ortega-Deballon I, 2014, Heart Lung Vessel, V6, P149; Ortega-Deballon I, 2016, RESUSCITATION, V101, P12, DOI 10.1016/j.resuscitation.2016.01.018; Ortega-Deballon I, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0985-7; Poppe M, 2015, RESUSCITATION, V91, P131, DOI 10.1016/j.resuscitation.2015.03.003; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Schooer A, 2017, EMERG MED J, V34, P277, DOI 10.1136/emermed-2015-205232; Sinning C, 2020, EUR HEART J-ACUTE CA, V9, pS193, DOI 10.1177/2048872620963492; Thiele H, 2017, NEW ENGL J MED, V377, P2419, DOI 10.1056/NEJMoa1710261; Thomas J, 2018, SEMIN THROMB HEMOST, V44, P20, DOI 10.1055/s-0037-1606179; Wengenmayer T, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1744-8; Yannopoulos D, 2020, LANCET, V396, P1807, DOI 10.1016/S0140-6736(20)32338-2	36	32	32	4	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2022	327	8					737	747		10.1001/jama.2022.1025	http://dx.doi.org/10.1001/jama.2022.1025			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ2NN	35191923	Green Published			2023-01-03	WOS:000762147200020
J	de Almeida, JM; Matheus, HR; Alves, BES; Gusman, DJR; Nagata, MJH; Furquim, EMD; Ervolino, E				de Almeida, Juliano Milanezi; Matheus, Henrique Rinaldi; Sendao Alves, Breno Edson; Rodrigues Gusman, David Jonathan; Hitomi Nagata, Maria Jose; de Abreu Furquim, Elisa Mara; Ervolino, Edilson			Evaluation of antimicrobial photodynamic therapy with acidic methylene blue for the treatment of experimental periodontitis	PLOS ONE			English	Article							CITRIC-ACID; LISTERIA-MONOCYTOGENES; PERI-IMPLANTITIS; EXPRESSION; ADHESION; DENTIN; DEMINERALIZATION; INFLAMMATION; PRINCIPLES; BIOFILMS	Objective To investigate the security and effectiveness of antimicrobial photodynamic therapy (aPDT) with a citric acid-based methylene blue (MB) on the periodontal repair following the treatment of ligature-induced experimental periodontitis (EP) in rats. Material and methods Were used 120 male rats, randomly divided into 4 experimental groups (n = 30): no treatment (NT), SRP alone (SRP), SRP plus aPDT using conventional MB pH 7.0 (aPDT-pH7), SRP plus aPDT using acidic MB pH 1.0 (aPDT-pH1). EP was induced at day 0 by the placement of a ligature around the mandibular left first molars. Ten animals per group/period were euthanized at 14, 22 and 37 days. Histopathological, histometric (percentage of bone in the furcation [PBF]) and immunohistochemical (for tartrate-resistant acid phosphatase [TRAP] and osteocalcin [OCN]) analyses were performed. Data were statistically analyzed. Results aPDT-pH1 showed the highest PBF as compared with the other treatments. Collectively, tissues' reaction to both dyes were controlled and healthy for the periodontium. Both aPDT protocols reduced the extent and intensity of the local inflammatory response, reduced the alveolar bone resorption, and promoted a better structural arrangement of the connective tissue as compared with SRP. TRAP expression was downregulated while OCN expression was upregulated by aPDT as compared with SRP alone. Conclusion Our data implicate that the novel MB pH 1.0 is as safe as the conventional MB for use in aPDT and raises its additional benefit of increasing the amount of alveolar bone in the furcation.	[de Almeida, Juliano Milanezi; Matheus, Henrique Rinaldi; Sendao Alves, Breno Edson; Rodrigues Gusman, David Jonathan; Hitomi Nagata, Maria Jose; de Abreu Furquim, Elisa Mara] Sao Paulo State Univ Unesp, Sch Dent, Dept Diag & Surg, Periodont Div, Aracatuba, Brazil; [de Almeida, Juliano Milanezi; Matheus, Henrique Rinaldi; Sendao Alves, Breno Edson; Rodrigues Gusman, David Jonathan; Hitomi Nagata, Maria Jose; de Abreu Furquim, Elisa Mara; Ervolino, Edilson] Sao Paulo State Univ Unesp, Nucleus Study & Res Periodont & Implantol NEPPI, Sch Dent, Aracatuba, SP, Brazil; [Ervolino, Edilson] Sao Paulo State Univ Unesp, Sch Dent, Dept Basic Sci, Aracatuba, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista	de Almeida, JM (corresponding author), Sao Paulo State Univ Unesp, Sch Dent, Dept Diag & Surg, Periodont Div, Aracatuba, Brazil.; de Almeida, JM (corresponding author), Sao Paulo State Univ Unesp, Nucleus Study & Res Periodont & Implantol NEPPI, Sch Dent, Aracatuba, SP, Brazil.	jumilanezi@hotmail.com	de Abreu Furquim, Elisa Mara/AAI-2683-2020; /F-7995-2012	de Abreu Furquim, Elisa Mara/0000-0002-0618-2787; Rinaldi Matheus, Henrique/0000-0003-3318-5980; /0000-0002-5995-5747				Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449; Allaker RP, 2009, INT J ANTIMICROB AG, V33, P8, DOI 10.1016/j.ijantimicag.2008.07.014; Arany PR, 2016, J DENT RES, V95, P977, DOI 10.1177/0022034516648939; Araujo NC, 2014, LASER MED SCI, V29, P629, DOI 10.1007/s10103-013-1369-3; Bartold PM, 2013, PERIODONTOL 2000, V62, P203, DOI 10.1111/j.1600-0757.2012.00450.x; Bertero E, 2018, CIRC RES, V122, P1460, DOI 10.1161/CIRCRESAHA.118.310082; BEUCHAT LR, 1989, FOOD TECHNOL-CHICAGO, V43, P134; Braham P, 2009, J PERIODONTOL, V80, P1790, DOI 10.1902/jop.2009.090214; BUCHANAN RL, 1994, J FOOD PROTECT, V57, P567, DOI 10.4315/0362-028X-57.7.567; Burel C, 2021, LETT APPL MICROBIOL, V72, P332, DOI 10.1111/lam.13420; Cadore UB, 2019, J PERIODONTOL, V90, P339, DOI 10.1002/JPER.18-0373; Carrera ET, 2016, LASER PHYS, V26, DOI 10.1088/1054-660X/26/12/123001; Chambrone L, 2018, J PERIODONTOL, V89, P783, DOI 10.1902/jop.2017.170172; Darveau RP, 2012, J DENT RES, V91, P816, DOI 10.1177/0022034512453589; Dascalu LM, 2020, MATERIALS, V13, DOI 10.3390/ma13133012; De Almeida J, 2015, J PERIODONTOL, V86, P1166, DOI 10.1902/jop.2015.150166; de Almeida JM, 2008, J PERIODONTOL, V79, P2156, DOI [10.1902/jop.2008.080103, 10.1902/jop.2008.080103 ]; de Freitas LM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050769; de Molon RS, 2014, J PERIODONTOL, V85, P465, DOI 10.1902/jop.2013.130225; de Oliveira RR, 2007, J PERIODONTOL, V78, P965, DOI 10.1902/jop.2007.060494; de Rezende MLR, 2015, J PERIODONTOL, V86, P146, DOI 10.1902/jop.2014.130657; du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000410; Eke PI, 2018, J AM DENT ASSOC, V149, P576, DOI 10.1016/j.adaj.2018.04.023; Ghorbani Jaber, 2018, Laser Ther, V27, P293, DOI 10.5978/islsm.27_18-RA-01; Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665-199001000-00011; Horowitz M., 2006, BONE RESORPTION, P91; Htet M, 2016, J PERIODONTOL, V87, P953, DOI 10.1902/jop.2016.150615; Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200; JOHNSON IH, 1975, J PERIODONTAL RES, V10, P332, DOI 10.1111/j.1600-0765.1975.tb00042.x; Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361; Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491; Klepac-Ceraj V, 2011, LASER SURG MED, V43, P600, DOI 10.1002/lsm.21069; Matheus HR, 2018, J CLIN PERIODONTOL, V45, P241, DOI 10.1111/jcpe.12824; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; Misra DN, 1996, J DENT RES, V75, P1418, DOI 10.1177/00220345960750061401; Mizutani K, 2016, PERIODONTOL 2000, V71, P185, DOI 10.1111/prd.12123; MOUGHAL NA, 1992, J PERIODONTAL RES, V27, P623, DOI 10.1111/j.1600-0765.1992.tb01746.x; Nikinmaa S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232775; Pfitzner A, 2004, J PERIODONTOL, V75, P1343, DOI 10.1902/jop.2004.75.10.1343; Polimeni G, 2006, PERIODONTOL 2000, V41, P30, DOI 10.1111/j.1600-0757.2006.00157.x; Qi ML, 2019, INT J NANOMED, V14, P6937, DOI 10.2147/IJN.S212807; Qin YL, 2008, J PERIODONTAL RES, V43, P162, DOI 10.1111/j.1600-0765.2007.01007.x; Ren L, 2005, J PERIODONTOL, V76, P1950, DOI 10.1902/jop.2005.76.11.1950; Renvert S, 2002, J CLIN PERIODONTOL, V29, P82, DOI 10.1034/j.1600-051X.29.s-3.2.x; Gusman DJR, 2019, J CLIN PERIODONTOL, V46, P457, DOI 10.1111/jcpe.13101; Gusman DJR, 2018, CLIN ORAL INVEST, V22, P361, DOI 10.1007/s00784-017-2120-4; Romanova NA, 2003, APPL ENVIRON MICROB, V69, P6393, DOI 10.1128/AEM.69.11.6393-6398.2003; ROVIN SHELDON, 1966, J PERIODONTAL RES, V1, P193, DOI 10.1111/j.1600-0765.1966.tb01860.x; Ruggeri A, 2007, ARCH ORAL BIOL, V52, P1, DOI 10.1016/j.archoralbio.2006.07.001; Sharma M, 2008, ANTIMICROB AGENTS CH, V52, P299, DOI 10.1128/AAC.00988-07; Shih MH, 2013, PHOTODIAGN PHOTODYN, V10, P664, DOI 10.1016/j.pdpdt.2013.07.003; Souza JGS, 2019, J PERIODONTOL, V90, P149, DOI 10.1002/JPER.18-0178; STERRETT JD, 1993, J CLIN PERIODONTOL, V20, P366, DOI 10.1111/j.1600-051X.1993.tb00374.x; Subramanian S, 2017, J CLIN DIAGN RES, V11, pZC82, DOI 10.7860/JCDR/2017/27768.10443; Tonetti MS, 1997, J PERIODONTAL RES, V32, P104, DOI 10.1111/j.1600-0765.1997.tb01389.x; Zhang XM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4170	56	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2022	17	2							e0263103	10.1371/journal.pone.026310	http://dx.doi.org/10.1371/journal.pone.026310			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1J1AU	35143492				2023-01-03	WOS:000797657800023
J	Jung, E; Ro, YS; Ryu, HH; Shin, SD				Jung, Eujene; Ro, Young Sun; Ryu, Hyun Ho; Shin, Sang Do			Association of prehospital airway management technique with survival outcomes of out-of-hospital cardiac arrest patients	PLOS ONE			English	Article							ENDOTRACHEAL INTUBATION; CARDIOPULMONARY-RESUSCITATION; DEVICE; VENTILATION; STRATEGY; TIME; CARE	Introduction Despite numerous studies on airway management in out-of-hospital cardiac arrest (OHCA) patients, the choice of prehospital airway management technique remains controversial. Our study aimed to investigate the association between prehospital advanced airway management and survival outcomes according to a transport time interval (TTI) using nationwide OHCA registry database in Korea. Methods The inclusion criteria were patients with OHCA aged over 18 years old with a presumed cardiac etiology between January 2015 and December 2018. The primary outcome was survival to hospital discharge. The main exposure was the prehospital airway management technique performed by the emergency medical technicians (EMTs), classified as bagvalve mask (BVM), supraglottic airway (SGA), or endotracheal intubation (ETI).We performed multivariable logistic regression analysis and interaction analysis between the type of airway management and TTI for adjusted odds ratios (aORs) and 95% confidence intervals (CIs). Results Of a total of 70,530 eligible OHCA patients, 26,547 (37.6%), 38,391 (54.4%), and 5,592 (7.9%) were managed with BVM, SGA, ETI, respectively. Patients in the SGA and ETI groups had a higher odds of survival to discharge than BVM groups (aOR, 1.11 (1.05-1.16) and 1.13 (1.05-1.23)). And the rates of survival to discharge with SGA and ETI were significantly higher in groups with TTI more than 8 minutes (1.17 (1.08-1.27) and 1.38 (1.20-1.59)). Conclusion The survival to discharge was significantly higher among patients who received ETI and SGA than in those who received BVM. The transport time interval influenced the effect of prehospital airway management on the clinical outcomes after OHCA.	[Jung, Eujene; Ryu, Hyun Ho] Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea; [Ro, Young Sun; Shin, Sang Do] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Ryu, Hyun Ho] Chonnam Natl Univ, Coll Med, Gwangju, South Korea	Chonnam National University; Chonnam National University Hospital; Seoul National University (SNU); Chonnam National University	Ryu, HH (corresponding author), Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea.; Ryu, HH (corresponding author), Chonnam Natl Univ, Coll Med, Gwangju, South Korea.	81823ej@hanmail.net			Korea Centers for Disease Control and Prevention (CDC) [BCRI-20064]; Chonnam National University Hospital Biomedical Research Institute	Korea Centers for Disease Control and Prevention (CDC); Chonnam National University Hospital Biomedical Research Institute	This study was supported by the Korea Centers for Disease Control and Prevention (CDC) and a grand (BCRI-20064) of Chonnam National University Hospital Biomedical Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen LW, 2018, RESUSCITATION, V125, P79, DOI 10.1016/j.resuscitation.2018.02.006; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Benger JR, 2018, JAMA-J AM MED ASSOC, V320, P779, DOI 10.1001/jama.2018.11597; Benoit JL, 2015, RESUSCITATION, V93, P124, DOI 10.1016/j.resuscitation.2015.06.005; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Cha WC, 2012, RESUSCITATION, V83, P1338, DOI 10.1016/j.resuscitation.2012.03.024; Hasegawa K, 2013, JAMA-J AM MED ASSOC, V309, P257, DOI 10.1001/jama.2012.187612; Jabre P, 2018, JAMA-J AM MED ASSOC, V319, P779, DOI 10.1001/jama.2018.0156; Jentzer JC, 2016, ANN EMERG MED, V68, P678, DOI 10.1016/j.annemergmed.2016.05.022; Jung E, 2020, J EMERG MED, V58, P424, DOI 10.1016/j.jemermed.2019.11.022; Jung E, 2020, THER HYPOTHERMIA TEM, V10, P141, DOI 10.1089/ther.2019.0015; Kim TH, 2019, RESUSCITATION, V139, P269, DOI 10.1016/j.resuscitation.2019.04.020; Lyon RM, 2010, EMERG MED J, V27, P321, DOI 10.1136/emj.2009.076737; McMullan J, 2014, RESUSCITATION, V85, P617, DOI 10.1016/j.resuscitation.2014.02.007; Myat A, 2018, LANCET, V391, P970, DOI 10.1016/S0140-6736(18)30472-0; Odegaard S, 2008, RESUSCITATION, V77, P57, DOI 10.1016/j.resuscitation.2007.11.005; Park JH, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e73; Penketh JA, 2020, RESUSCITATION, V153, P143, DOI 10.1016/j.resuscitation.2020.05.028; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Wang HE, 2020, JACEP OPEN, V1, P24, DOI 10.1002/emp2.12003; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044; Wang HE, 2009, ANN EMERG MED, V54, P645, DOI 10.1016/j.annemergmed.2009.05.024	22	0	0	5	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269599	10.1371/journal.pone.0269599	http://dx.doi.org/10.1371/journal.pone.0269599			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2RM	35666760	Green Published, gold			2023-01-03	WOS:000843575700025
J	Steyaert, A; Lenoir, C; Lavand'homme, P; van den Broeke, EN; Mouraux, A				Steyaert, Arnaud; Lenoir, Cedric; Lavand'homme, Patricia; van den Broeke, Emanuel N.; Mouraux, Andre			Multichannel transcranial direct current stimulation over the left dorsolateral prefrontal cortex may modulate the induction of secondary hyperalgesia, a double-blinded cross-over study in healthy volunteers	PLOS ONE			English	Article							LONG-TERM POTENTIATION; MAGNETIC STIMULATION; CENTRAL SENSITIZATION; PAIN THRESHOLDS; TDCS; PERCEPTION; ALLODYNIA; ANALGESIA; KETAMINE	Background Central sensitization is thought to play a critical role in the development of chronic pain, and secondary mechanical hyperalgesia is considered one of its hall-mark features. Consequently, interventions capable of modulating its development could have important therapeutic value. Non-invasive neuromodulation of the left dorsolateral prefrontal cortex (DLPFC) has shown potential to reduce pain, both in healthy volunteers and in patients. Whether it can modulate the induction of central sensitization, however, is less well known. Objective To determine whether multifocal transcranial direct current stimulation (tDCS) targeting the left DLPFC affects the development of secondary mechanical hyperalgesia. Methods In this within-subjects, cross-over, double-blinded study, eighteen healthy volunteers participated in three experimental sessions. After 20 minutes of either anodal, cathodal, or sham multichannel tDCS over the left DLPFC, secondary mechanical hyperalgesia was induced using high-frequency electrical stimulation (HFS) of the volar forearm. We assessed intensity of perception to 128 mN mechanical pinprick stimuli at baseline and up to 240 minutes after HFS. We also mapped the area of mechanical hyperalgesia. Results HFS resulted in a robust and unilateral increase in the intensity of perception to mechanical pinprick stimuli at the HFS arm, which was not different between tDCS stimulation conditions. However, the area of hyperalgesia was reduced after anodal tDCS compared to sham. Conclusion Anodal tDCS over the left DLPFC modestly modulates the size of the HFS-induced area of secondary mechanical hyperalgesia, suggesting that non-invasive neuromodulation targeting the left DLPFC may be a potential intervention to limit the development of central sensitization.	[Steyaert, Arnaud; Lenoir, Cedric; Lavand'homme, Patricia; van den Broeke, Emanuel N.; Mouraux, Andre] Univ Catholique Louvain UCLouvain, Inst Neurosci IONS, Brussels, Belgium; [Steyaert, Arnaud; Lavand'homme, Patricia] Clin Univ St Luc, Dept Anaesthesiol, Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Steyaert, A (corresponding author), Univ Catholique Louvain UCLouvain, Inst Neurosci IONS, Brussels, Belgium.; Steyaert, A (corresponding author), Clin Univ St Luc, Dept Anaesthesiol, Brussels, Belgium.	arnaud.steyaert@uclouvain.be			Fonds de Recherche Clinique (Cliniques Universitaires Saint-Luc, Belgium); BESARPP (Belgian Society for Anaesthesiology and Reanimation)	Fonds de Recherche Clinique (Cliniques Universitaires Saint-Luc, Belgium); BESARPP (Belgian Society for Anaesthesiology and Reanimation)	AS is supported for this research by a grant from the Fonds de Recherche Clinique (Cliniques Universitaires Saint-Luc, Belgium) and from the BESARPP (Belgian Society for Anaesthesiology and Reanimation). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonzo A, 2012, BRAIN STIMUL, V5, P208, DOI 10.1016/j.brs.2011.04.006; Arendt-Nielsen L, 2018, EUR J PAIN, V22, P216, DOI 10.1002/ejp.1140; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Borckardt JJ, 2007, PAIN RES MANAG, V12, P287, DOI 10.1155/2007/741897; Borckardt JJ, 2006, ANESTHESIOLOGY, V105, P557, DOI 10.1097/00000542-200609000-00020; Borckardt JJ, 2017, BRAIN STIMUL, V10, P1096, DOI 10.1016/j.brs.2017.09.006; Borckardt JJ, 2014, BRAIN STIMUL, V7, P42, DOI 10.1016/j.brs.2013.07.007; Borckardt JJ, 2012, J PAIN, V13, P112, DOI 10.1016/j.jpain.2011.07.001; Borckardt JJ, 2008, BRAIN STIMUL, V1, P122, DOI 10.1016/j.brs.2008.04.002; Brighina F, 2011, J HEADACHE PAIN, V12, P185, DOI 10.1007/s10194-011-0322-8; De Martino E, 2019, J PAIN, V20, P1459, DOI 10.1016/j.jpain.2019.05.010; De Martino E, 2019, NEUROIMAGE, V186, P93, DOI 10.1016/j.neuroimage.2018.10.076; Deumens R, 2013, PROG NEUROBIOL, V104, P1, DOI 10.1016/j.pneurobio.2013.01.002; Dinn W., 2017, BRAIN STIMUL, V10, P401, DOI [10.1016/j.brs.2017.01.188, DOI 10.1016/J.BRS.2017.01.188]; Fischer DB, 2017, NEUROIMAGE, V157, P34, DOI 10.1016/j.neuroimage.2017.05.060; Gallucci A, 2019, PAIN MANAG, V9, P93, DOI 10.2217/pmt-2018-0053; Giannoni-Luza S, 2020, PAIN, V161, P1955, DOI 10.1097/j.pain.0000000000001893; Hughes SW, 2020, EUR J PAIN, V24, P1130, DOI 10.1002/ejp.1557; Iadarola MJ, 1998, BRAIN, V121, P931, DOI 10.1093/brain/121.5.931; Klein T, 2004, J NEUROSCI, V24, P964, DOI 10.1523/JNEUROSCI.1222-03.2004; Klein T, 2007, NEUROPHARMACOLOGY, V52, P655, DOI 10.1016/j.neuropharm.2006.09.008; Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7; Lavand'homme P, 2005, ANESTHESIOLOGY, V103, P813, DOI 10.1097/00000542-200510000-00020; Lee MC, 2008, J NEUROSCI, V28, P11642, DOI 10.1523/JNEUROSCI.2638-08.2008; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Mariano TY, 2016, PAIN MED, V17, P737, DOI 10.1093/pm/pnv042; Martinez V, 2012, PAIN, V153, P1478, DOI 10.1016/j.pain.2012.04.004; Meeker TJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00467; Momeni M, 2010, Acta Anaesthesiol Belg, V61, P55; Mylius V, 2012, EUR J PAIN, V16, P974, DOI 10.1002/j.1532-2149.2011.00105.x; O'Connell NE, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008208.pub4, 10.1002/14651858.CD008208.pub5]; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Reckow J, 2018, BRAIN STIMUL, V11, P991, DOI 10.1016/j.brs.2018.04.022; Ruffini G, 2014, NEUROIMAGE, V89, P216, DOI 10.1016/j.neuroimage.2013.12.002; Sacco P, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0166-3; Sandkuhler J, 2009, PHYSIOL REV, V89, P707, DOI 10.1152/physrev.00025.2008; Seminowicz DA, 2018, PAIN, V159, P2486, DOI 10.1097/j.pain.0000000000001350; Seminowicz DA, 2017, J PAIN, V18, P1027, DOI 10.1016/j.jpain.2017.03.008; Splittgerber M, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.00349; Stagg CJ, 2013, J NEUROSCI, V33, P11425, DOI 10.1523/JNEUROSCI.3887-12.2013; Steyaert A, 2019, ACTA ANAESTH BELG, V70, P173; Tan LL, 2017, NAT NEUROSCI, V20, P1591, DOI 10.1038/nn.4645; Turner C, 2021, EUR J NEUROSCI, V53, P1592, DOI 10.1111/ejn.15018; Van Amerongen G, 2016, BRIT J CLIN PHARMACO, V82, P903, DOI 10.1111/bcp.13018; van den Broeke EN, 2018, CLIN PSYCHOL SCI, V6, P761, DOI 10.1177/2167702618781804; van den Broeke EN, 2014, J NEUROPHYSIOL, V112, P2059, DOI 10.1152/jn.00342.2014; van den Broeke EN, 2010, J NEUROPHYSIOL, V103, P2107, DOI 10.1152/jn.00979.2009; Vaseghi B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118340; Vo L, 2022, J PAIN, V23, P305, DOI 10.1016/j.jpain.2021.08.004; Watson PF, 2010, THERIOGENOLOGY, V73, P1167, DOI 10.1016/j.theriogenology.2010.01.003; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030	52	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0270047	10.1371/journal.pone.0270047	http://dx.doi.org/10.1371/journal.pone.0270047			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3FU	35709234	gold, Green Published			2023-01-03	WOS:000843613300121
J	Toporek, A; Lechtzin, N				Toporek, Alexandra; Lechtzin, Noah			Viruses to the rescue-Use of bacteriophage to treat resistant pulmonary infections	CELL			English	Editorial Material								People with cystic fibrosis (CF) are commonly infected with difficult to treat organisms, including non-tuberculous mycobacteria. Bacteriophage are viruses that lyse specific bacteria. Nick and colleagues describe the first successful treatment of a Mycobacterium abscessus lung infection with bacteriophage in an immune competent individual. This report provides important information regarding the efficacy of phage therapy and timeline of treatment response.	[Toporek, Alexandra; Lechtzin, Noah] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, Baltimore, MD 21205 USA	Johns Hopkins University	Lechtzin, N (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, Baltimore, MD 21205 USA.	nlechtz@jhmi.edu						Dedrick RM, 2021, NAT MED, V27, P1357, DOI 10.1038/s41591-021-01403-9; Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Hatfull GF, 2022, ANNU REV MED, V73, P197, DOI 10.1146/annurev-med-080219-122208; Johansen MD, 2020, NAT REV MICROBIOL, V18, P392, DOI 10.1038/s41579-020-0331-1; Martiniano SL, 2016, CLIN CHEST MED, V37, P83, DOI 10.1016/j.ccm.2015.11.001; Nick JA, 2022, CELL, V185, P1860, DOI 10.1016/j.cell.2022.04.024; Qvist T, 2016, J CYST FIBROS, V15, P380, DOI 10.1016/j.jcf.2015.09.007; Salmond GPC, 2015, NAT REV MICROBIOL, V13, P777, DOI 10.1038/nrmicro3564; Shteinberg M, 2021, LANCET, V397, P2195, DOI 10.1016/S0140-6736(20)32542-3; Skolnik Kate, 2016, Curr Treat Options Infect Dis, V8, P259, DOI 10.1007/s40506-016-0092-6	10	2	2	7	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 26	2022	185	11					1807	1808		10.1016/j.cell.2022.04.037	http://dx.doi.org/10.1016/j.cell.2022.04.037			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	3J6WR	35623325				2023-01-03	WOS:000833535400001
J	Wise, J				Wise, Jacqui			Why are there shortages of HRT and other drugs in the UK?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jacquiyoung1@gmail.com						[Anonymous], Press release: PGEU medicine shortages survey 2021 results; [Anonymous], 2022, JOINT BMS FSRH RCGP; [Anonymous], 2022, 3 NEW SSPS INTRODUCE; British Generic Manufacturers Association, BGMA SUPPL ISS DASHB; British Menopause Society, 2022, BRIT MEN SOC UPD HRT; Cox T., 2020, CHEM DRUG; Cox T, 2019, PHARM STAFF SUFFER S; Department of Health and Social Care, 2022, VACC TASKF DIR GEN W; Department of Health and Social Care Medicines and Healthcare Products Regulatory Agency, 2019, MED CANN BE PAR EXP; Ferner RE, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5841; Freemantle A, 2022, ONLINE MED SUPPLY TO; Iacobucci G, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj.o1100; NHS England, 2021, BECT DICK BLOOD SPEC; NHS Open Data Portal, PRESCRIPTION COST AN; Pharmaceutical Services Negotiating Committee, SUPPL CHAIN SHORT; Roberts M., 2022, BBC NEWS 0509; Specialist Pharmacy Service, 2022, PRESCR AV HRT PROD; Wise J, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5838	18	0	0	4	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	2022	377								o1183	10.1136/bmj.o1183	http://dx.doi.org/10.1136/bmj.o1183			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1Y8ZL	35584843				2023-01-03	WOS:000808426800001
J	Mandadi, S; Pulluru, H; Annie, F				Mandadi, Subhadra; Pulluru, Harish; Annie, Frank			Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients	PLOS ONE			English	Article								Remdesivir (RDV) reduces time to clinical improvement in hospitalized COVID-19 patients requiring supplemental oxygen. Dexamethasone improves survival in those requiring oxygen support. Data is lacking on the efficacy of combination therapy in patients on mechanical ventilation. We analyzed for comparative outcomes between Corticosteroid (CS) therapy with combined Corticosteroid and Remdesivir (CS-RDV) therapy. We conducted an observational cohort study of patients aged 18 to 90 with COVID-19 requiring ventilatory support using TriNetX (COVID-19 Research Network) between January 20, 2020, and February 9, 2021. We compared patients who received at least 48 hours of CS-RDV combination therapy to CS monotherapy. The primary outcome was 28-day all-cause mortality rates in propensity-matched (PSM) cohorts. Secondary outcomes were Length of Stay (LOS), Secondary Bacterial Infections (SBI), and MRSA (Methicillin-Resistant Staphylococcus aureus), and Pseudomonas infections. We used univariate and multivariate Cox proportional hazards models and stratified log-rank tests. Of 388 patients included, 91 (23.5%) received CS-RDV therapy, and 297 (76.5%) received CS monotherapy. After propensity score matching, with 74 patients in each cohort, all-cause mortality was 36.4% and 29.7% in the CS-RDV and CS therapy, respectively (P = 0.38). We used a Kaplan-Meier with a log-rank test on follow up period (P = 0.23), and a Hazards Ratio model (P = 0.26). SBI incidence was higher in the CS group (13.5% vs. 35.1%, P = 0.02) with a similar LOS (13.4 days vs. 13.4 days, P = 1.00) and similar incidence of MRSA/Pseudomonas infections (13.5% vs. 13.5%, P = 1.00) in both the groups. Therefore, CS-RDV therapy is non-inferior to CS therapy in reducing 28-day all-cause in-hospital mortality but associated with a significant decrease in the incidence of SBI in critically ill COVID-19 patients.	[Mandadi, Subhadra] Charleston Area Med Ctr, Dept Infect Dis, Charleston, WV 25301 USA; [Pulluru, Harish] Charleston Area Med Ctr, Dept Hosp Med, Charleston, WV USA; [Annie, Frank] Charleston Area Med Ctr, Hlth Educ & Res Inst, Charleston, WV USA		Mandadi, S (corresponding author), Charleston Area Med Ctr, Dept Infect Dis, Charleston, WV 25301 USA.	Subhadra.mandadi@gmail.com	Annie, Frank/AAQ-1779-2021	Annie, Frank/0000-0001-8423-4119				Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Elezkurtaj S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82862-5; FDA, FDA WEBSITE; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Janiaud P, 2021, JAMA-J AM MED ASSOC, V325, P1185, DOI 10.1001/jama.2021.2747; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; Lam C, 2021, CLIN THER, V43, P871, DOI 10.1016/j.clinthera.2021.03.016; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9; McCullers JA, 2003, J INFECT DIS, V187, P1000, DOI 10.1086/368163; Piscoya A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243705; Punjabi CD, 2021, INFECT CONT HOSP EP, V42, P1156, DOI 10.1017/ice.2020.440; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Russell AM, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0171-y; Salazar E, 2020, AM J PATHOL, V190, P2290, DOI 10.1016/j.ajpath.2020.08.001; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Vazzana N, 2022, ACTA CLIN BELG, V77, P268, DOI 10.1080/17843286.2020.1824749; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	21	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2022	17	2							e0264301	10.1371/journal.pone.0264301	http://dx.doi.org/10.1371/journal.pone.0264301			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0QE	35196344	gold, Green Published			2023-01-03	WOS:000835161600035
J	Lago, AF; Basile, A; de Oliveira, AS; de Souza, HCD; dos Santos, DO; Gastaldi, AC				Lago, Alessandra Fabiane; Basile-Filho, Anibal; de Oliveira, Anamaria Siriani; Dutra de Souza, Hugo Celso; dos Santos, Daniele Oliveira; Gastaldi, Ada Clarice			Effects of physical therapy with neuromuscular electrical stimulation in acute and late septic shock patients: A randomised crossover clinical trial	PLOS ONE			English	Article							INTERNATIONAL CONSENSUS DEFINITIONS; SEPSIS; ICU; CRITERIA; WEAKNESS	Background Patients with sepsis and immobility in the intensive care unit are associated with muscle weakness, and early mobilisation can counteract it. However, during septic shock, mobilisation is often delayed due to the severity of the illness. Neuromuscular electrical stimulation (NMES) may be an alternative to mobilise these patients early. This study aims to identify whether NMES performed within the first 72 hours of septic shock diagnosis or later is safe from a metabolic perspective. Methods This is the analysis of two randomised controlled crossover studies. Patients with acute septic shock (within the first 72 hours of diagnosis) and sepsis and septic shock in the late phase (after 72 hours of diagnosis) were eligible. Patients were submitted in a random order to the intervention protocol (dorsal decubitus position with the lower limbs raised and NMES) and control (dorsal decubitus position with the lower limbs raised without NMES). The patients were allocated in group 1 (intervention and control) or group 2 (control and intervention) with a wash-out period of 4 to 6 hours. Metabolic variables were evaluated by indirect calorimetry. Results Sixteen patients were analysed in the acute septic shock study and 21 in the late sepsis/septic shock study. There were no significant differences between Oxygen Consumption (VO2) values in the acute phase of septic shock when the baseline period, intervention, and control protocols were compared (186.59 +/- 46.10; 183.64 +/- 41.39; 188.97 +/- 44.88, p > 0.05-expressed in mL/Kg/min). The same was observed when the VO2 values in the late phase were compared (224.22 +/- 53.09; 226.20 +/- 49.64; 226.79 +/- 58.25, p>0.05). The other metabolic variables followed the same pattern, with no significant differences between the protocols. When metabolic variables were compared between acute to late phase, significant differences were observed (p<0.05). Conclusions As metabolic rates in septic shock patients had no increase during NMES, either in the first 72 hours of diagnosis or later, NMES can be considered safe from a metabolic viewpoint, even despite the higher metabolic demand in the acute phase of shock.	[Lago, Alessandra Fabiane; de Oliveira, Anamaria Siriani; Dutra de Souza, Hugo Celso; dos Santos, Daniele Oliveira; Gastaldi, Ada Clarice] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Ribeirao Preto, SP, Brazil; [Basile-Filho, Anibal] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Div Intens Care Med, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Gastaldi, AC (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Ribeirao Preto, SP, Brazil.	ada@fmrp.usp.br	Gastaldi, Ada C/I-4329-2013; Souza, Hugo/C-5818-2012	Gastaldi, Ada C/0000-0001-9845-3611; Souza, Hugo/0000-0002-0009-0005	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) [001]; Fundacao de Amparo ao Ensino, Pesquisa e Assistencia (FAEPA)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo ao Ensino, Pesquisa e Assistencia (FAEPA)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) and Fundacao de Amparo ao Ensino, Pesquisa e Assistencia (FAEPA). AFL received a sponsorship given by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) Finance Code 001 https://www.gov.br/capes ACG received a financial contribution by Fundacao de Amparo ao Ensino, Pesquisa e Assistencia (FAEPA) https://www.faepa.br/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Abu-Khaber HA, 2013, ALEX J MED, V49, P309, DOI 10.1016/j.ajme.2013.03.011; Angelopoulos E, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-39; Clapis Franciele C Meireles, 2010, J Crit Care, V25, DOI 10.1016/j.jcrc.2009.11.010; Collings N, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-1; Cuthbertson DP, 1942, LANCET, V1, P433; Daugherty EL, 2009, CRIT CARE MED, V37, P1210, DOI [10.1097/CCM.0b013e3181b6fa29, 10.1097/CCM.0b013e31819d67b5]; Dirks ML, 2015, CLIN SCI, V128, P357, DOI 10.1042/CS20140447; Dwan K, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4378; Ferreira M, 2016, AM J CRIT CARE, V25, pE21, DOI 10.4037/ajcc2016758; Fossat G, 2018, JAMA-J AM MED ASSOC, V320, P368, DOI 10.1001/jama.2018.9592; Gerovasili V, 2009, CRIT CARE, V13, DOI 10.1186/cc8123; Gruther W, 2010, J REHABIL MED, V42, P593, DOI 10.2340/16501977-0564; Hickmann CE, 2018, CRIT CARE MED, V46, P1436, DOI 10.1097/CCM.0000000000003263; KREYMANN G, 1993, CRIT CARE MED, V21, P1012, DOI 10.1097/00003246-199307000-00015; Lago AF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009736; Lago Alessandra Fabiane, 2015, J Clin Med Res, V7, P700, DOI 10.14740/jocmr2250w; Liu M, 2020, INT J NURS SCI, V7, P228, DOI 10.1016/j.ijnss.2020.03.002; Morete Márcia Carla, 2014, Rev. bras. ter. intensiva, V26, P373, DOI 10.5935/0103-507X.20140057; Poulsen JB, 2011, CRIT CARE MED, V39, P456, DOI 10.1097/CCM.0b013e318205c7bc; Rattanachaiwong S, 2019, CLIN NUTR, V38, P2531, DOI 10.1016/j.clnu.2018.12.035; Reeves MM, 2004, J APPL PHYSIOL, V97, P130, DOI 10.1152/japplphysiol.01212.2003; Rodriguez PO, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.04.010; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stefanou C, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0123-y; Tipping CJ, 2017, INTENS CARE MED, V43, P171, DOI 10.1007/s00134-016-4612-0; Zayed Y, 2020, AUST CRIT CARE, V33, P203, DOI 10.1016/j.aucc.2019.04.003	29	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0264068	10.1371/journal.pone.0264068	http://dx.doi.org/10.1371/journal.pone.0264068			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176099	gold, Green Published			2023-01-03	WOS:000777505200075
J	Mitsakos, AT; Irish, W; Parikh, AA; Snyder, RA				Mitsakos, Anastasios T.; Irish, William; Parikh, Alexander A.; Snyder, Rebecca A.			The association of health insurance and race with treatment and survival in patients with metastatic colorectal cancer	PLOS ONE			English	Article							RACIAL DISPARITIES; ETHNIC DISPARITIES; OUTCOMES; STAGE; IMPROVEMENT; MORTALITY	Background Black patients and underinsured patients with colorectal cancer (CRC) present with more advanced disease and experience worse outcomes. The study aim was to evaluate the interaction of health insurance status and race with treatment and survival in metastatic CRC. Materials and methods Patients diagnosed with metastatic CRC within NCDB from 2006-2016 were included. Primary outcomes included receipt of chemotherapy and 3-year all-cause mortality. Multivariable logistic regression and Cox-regression (MVR) including a two-way interaction term of race and insurance were performed to evaluate the differential association of race and insurance with receipt of chemotherapy and mortality, respectively. Results 128,031 patients were identified; 70.6% White, 14.4% Black, 5.7% Hispanic, and 9.3% Other race. Chemotherapy use was higher among White compared to Black patients. 3year mortality rate was higher for Blacks and lower for Hispanics, in comparison with White patients. By MVR, Black patients were less likely to receive chemotherapy. When stratified by insurance status, Black patients with private and Medicare insurance were less likely to receive chemotherapy than White patients. All-cause mortality was higher in Black patients and lower in Hispanic patients, and these differences persisted after controlling for insurance and receipt of chemotherapy. Conclusion Black patients and uninsured or under-insured patients with metastatic CRC are less likely to receive chemotherapy and have increased mortality. The effect of health insurance among Blacks and Whites differs, however, and improving insurance alone does not appear to fully mitigate racial disparities in treatment and outcomes.	[Mitsakos, Anastasios T.; Parikh, Alexander A.; Snyder, Rebecca A.] East Carolina Univ, Dept Surg, Div Surg Oncol, Brody Sch Med, Greenville, NC 27858 USA; [Irish, William] East Carolina Univ, Dept Surg, Div Surg Res, Brody Sch Med, Greenville, NC 27858 USA; [Irish, William; Snyder, Rebecca A.] East Carolina Univ, Dept Publ Hlth, Brody Sch Med, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Snyder, RA (corresponding author), East Carolina Univ, Dept Surg, Div Surg Oncol, Brody Sch Med, Greenville, NC 27858 USA.; Snyder, RA (corresponding author), East Carolina Univ, Dept Publ Hlth, Brody Sch Med, Greenville, NC 27858 USA.	snyderre19@ecu.edu						Aizer AA, 2014, CANCER-AM CANCER SOC, V120, P1532, DOI 10.1002/cncr.28617; Boffa DJ, 2017, JAMA ONCOL, V3, P1722, DOI 10.1001/jamaoncol.2016.6905; Castleberry AW, 2014, J GASTROINTEST SURG, V18, P1194, DOI 10.1007/s11605-014-2515-3; Coughlin SS, 2020, INT J COLORECTAL DIS, V35, P985, DOI 10.1007/s00384-020-03585-z; Coughlin SS, 2016, J RACIAL ETHN HEALTH, V3, P555, DOI 10.1007/s40615-015-0174-z; Daniel CL, 2017, FRONT BIOSCI-LANDMRK, V22, P465, DOI 10.2741/4495; Ellis L, 2018, J CLIN ONCOL, V36, P25, DOI 10.1200/JCO.2017.74.2049; Emmons KM, 2009, HEALTH AFFAIR, V28, P169, DOI 10.1377/hlthaff.28.1.169; Fitzgerald TL, 2014, RURAL REMOTE HEALTH, V14; Green PM, 2004, CANCER NURS, V27, P206, DOI 10.1097/00002820-200405000-00004; Jackson CS, 2016, J GASTROINTEST ONCOL, V7, pS32, DOI 10.3978/j.issn.2078-6891.2015.039; Jayakrishnan Thejus T, 2020, Cancer Treat Res Commun, V24, P100204, DOI 10.1016/j.ctarc.2020.100204; Lai YZ, 2016, GASTROENTEROLOGY, V150, P1135, DOI 10.1053/j.gastro.2016.01.030; Lau-Min K, 2020, CLIN COLORECTAL CANC, V19, pE49, DOI 10.1016/j.clcc.2019.09.002; Martini G, 2017, WORLD J GASTROENTERO, V23, P4675, DOI 10.3748/wjg.v23.i26.4675; Modest DP, 2019, EUR J CANCER, V109, P70, DOI 10.1016/j.ejca.2018.12.019; Mohan G, 2020, JAMA ONCOL, V6, P1434, DOI 10.1001/jamaoncol.2020.1460; National Cancer Institute, 2019, CANC DISP; Polite BN, 2005, MED CLIN N AM, V89, P771, DOI 10.1016/j.mcna.2005.03.001; Rhoads KF, 2015, J CLIN ONCOL, V33, P854, DOI 10.1200/JCO.2014.56.8642; Robbins AS, 2012, J CLIN ONCOL, V30, P401, DOI 10.1200/JCO.2011.37.5527; Sanoff HK, 2009, J CLIN ONCOL, V27, P4109, DOI 10.1200/JCO.2009.21.9527; Scally BJ, 2018, CANCER CAUSE CONTROL, V29, P527, DOI 10.1007/s10552-018-1027-y; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Simpson DR, 2013, JNCI-J NATL CANCER I, V105, P1814, DOI 10.1093/jnci/djt318; Sineshaw HM, 2018, GASTROENTEROLOGY, V154, P906, DOI 10.1053/j.gastro.2017.11.005; Sineshaw HM, 2014, CANCER CAUSE CONTROL, V25, P419, DOI 10.1007/s10552-014-0344-z; Tammana VS, 2014, WORLD J GASTROENTERO, V20, P869, DOI 10.3748/wjg.v20.i4.869; Tapan U, 2017, CANCER EPIDEMIOL, V49, P30, DOI 10.1016/j.canep.2017.05.003; Tawk R, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010048; Thornblade LW, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16019; United States Census Bureau, QUICK FACTS; Vassos N, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0563-8; Wallace K, 2017, CLIN COLORECTAL CANC, V16, P178, DOI 10.1016/j.clcc.2016.11.006	34	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0263818	10.1371/journal.pone.0263818	http://dx.doi.org/10.1371/journal.pone.0263818			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176030	Green Published, gold			2023-01-03	WOS:000777505200033
J	Uwimana, P; Mukamana, D; Babenko-Mould, Y; Adejumo, O				Uwimana, Philomene; Mukamana, Donatilla; Babenko-Mould, Yolanda; Adejumo, Oluyinka			Exploring factors affecting the facilitation of nursing students to learn paediatric pain management in Rwanda: A descriptive qualitative study	PLOS ONE			English	Article							PERCEIVED CHALLENGES; EDUCATION; CHILDREN	Nurse educators and nurse preceptors play a fundamental role in facilitating nursing students' acquisition and utilization of professional competencies. Previous studies about key elements for teaching and learning about pain in nursing education programs include students' personal characteristics and previous experiences; educators' knowledge, skills, and beliefs; learners' exposure to leaders in pain education; and curricular pain content and delivery approaches. These studies were mainly carried out in developed countries, with a context of educational and health care systems different from those of developing countries. The current study explores academics', clinical nurse preceptors', and nursing students' perceptions about factors influencing the facilitation of nursing students' competency for paediatric pain management in Rwanda. A qualitative descriptive exploratory design was used in this study that utilized in-depth interviews with six nurse educators and eight nurse preceptors, and focus group discussions with nineteen senior year nursing students. The study setting included five sites: two academic institutions and three clinical settings. Narratives from participants were transcribed verbatim and analysed using thematic analysis. The analysis yielded six themes describing factors that affected the facilitation of students' learning about paediatric pain management. The themes included student motivation, facilitators' attributes, collaboration between academics and clinicians, nurses' limited autonomy for decision-making regarding PPM practices, shortage of human and material resources, and educational qualification. Knowing these factors is essential as it provides an opportunity to design targeted interventions aimed to enhance the capacity of nurse educators and clinical nurse preceptors involved in teaching nursing students about paediatric pain management.	[Uwimana, Philomene; Mukamana, Donatilla; Adejumo, Oluyinka] Univ Rwanda, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Kigali, Rwanda; [Babenko-Mould, Yolanda] Western Univ, Fac Hlth Sci, Arthur Labatt Family Sch Nursing, London, ON, Canada	University of Rwanda; Western University (University of Western Ontario)	Uwimana, P (corresponding author), Univ Rwanda, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Kigali, Rwanda.	philouwim@gmail.com			Global Affairs Canada	Global Affairs Canada(CGIAR)	The Training Support Access Model (TSAM/MNCH) for Rwanda (https://tsam.uwo.ca/), a Western University project funded by Global Affairs Canada, financially supported the study data collection related expenses. There was no involvement of funders in designing the study protocol, data collection and analysis, or in writing the manuscript.	Alreshidi N., 2016, IMPACT INTERACTIVE E; Amponsah AK., 2020, PAIN RES MANAG, V2020, P1; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Bawa Monika, 2015, J Pain Palliat Care Pharmacother, V29, P353, DOI 10.3109/15360288.2015.1082010; Bengtsson M, 2010, NURS EDUC TODAY, V30, P150, DOI 10.1016/j.nedt.2009.07.005; Birnie KA, 2014, PAIN RES MANAG, V19, P198, DOI 10.1155/2014/614784; Bradshaw C, 2017, EMPLOYING QUALITATIV; Brant JM, 2017, PAIN MANAG NURS, V18, P214, DOI 10.1016/j.pmn.2017.04.003; Cederbaum J, 2009, J NURS EDUC, V48, P422, DOI 10.3928/01484834-20090518-01; Clarke V, 2013, PSYCHOLOGIST, V26, P120; Cousins MJ, 2011, PAIN, V152, P2673, DOI 10.1016/j.pain.2011.09.012; DeJonckheere M, 2019, FAM MED COMMUNITY HE, V7, DOI 10.1136/fmch-2018-000057; Dev MDB, 2020, NURS HEALTH SCI, V22, P1131, DOI 10.1111/nhs.12782; Doyle L, 2020, J RES NURS, V25, P443, DOI 10.1177/1744987119880234; Drasiku A, 2021, BMC NURS, V20, DOI 10.1186/s12912-020-00528-5; Elo S, 2014, SAGE OPEN, V4, DOI 10.1177/2158244014522633; Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5; Friedrichsdorf SJ, 2016, CHILDREN-BASEL, V3, DOI 10.3390/children3040042; Friedrichsdorf Stefan J, 2015, Hosp Pediatr, V5, P18, DOI 10.1542/hpeds.2014-0084; Fusch PI, 2015, QUAL REP, V20, P1408; Gadallah MA, 2017, J NURS ED PRACT, V7, P100, DOI [10.5430/jnep.v7n6p100, DOI 10.5430/JNEP.V7N6P100]; Gordon DB, 2018, PAIN REP, V3, DOI 10.1097/PR9.0000000000000663; Guba E.G., 1989, 4 GENERATION EVALUAT; Guest G, 2017, FIELD METHOD, V29, P3, DOI 10.1177/1525822X16639015; Harerimana A., 2015, BR J MED HEAL RSEARC, V2, P1; International Association for the Study of Pain, 2018, CURR OUTL PAIN NURS; Jones MP, 2015, J NURS ED PRACT, V5, P19; Kahsay H., 2017, CURR PEDIAT RES, V21, P148; Kholowa ET., 2017, J BIOSCI MED, V5, P46; Kim H, 2017, RES NURS HEALTH, V40, P23, DOI 10.1002/nur.21768; Liossi C, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0331; Mediani HS, 2017, J CHILD HEALTH CARE, V21, P273, DOI 10.1177/1367493517715146; Mukamana D., 2015, RWANDA J SER F MED H, V2, P9; Mwale OG, 2016, BMC NURS, V15, DOI 10.1186/s12912-016-0153-7; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; NOWELL L, 2017, INT J QUAL METH, V16, P1, DOI [DOI 10.1177/1609406917733847, 10.1177%2F1609406917733847]; Nyumba TO, 2018, METHODS ECOL EVOL, V9, P20, DOI 10.1111/2041-210X.12860; Phuma-Ngaiyaye E, 2017, Int J Nurs Sci, V4, P164, DOI 10.1016/j.ijnss.2017.03.001; Polit D.F., 2017, NURSING RES GENERATI, V10th, DOI DOI 10.1016/J.ICCN.2015.01.005; Rhodes M., 2011, ONLINE J ISSUES NURS, V16; Roberts K, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0707-y; Rwanda Law Reform Commision, 2012, OFFICIAL GAZETT 0409, P1; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Scanlan CL., 2020, PREPARING UNANTICIPA; Thompson K, 2018, PAIN, V159, P2146, DOI 10.1097/j.pain.0000000000001352; Uwimana P., 2020, J NURS ED PRACT, V10, P21; Watt-Watson J, 2013, PAIN MANAG, V3, P351, DOI [10.2217/pmt.13.39, 10.2217/PMT.13.39]; Yang CI, 2018, JPN J NURS SCI, V15, P50, DOI 10.1111/jjns.12167; Younas A, 2019, NURS EDUC TODAY, V81, P39, DOI 10.1016/j.nedt.2019.07.002; Zamawe FC, 2015, MALAWI MED J, V27, P13, DOI 10.4314/mmj.v27i1.4	50	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2022	17	2							e0263609	10.1371/journal.pone.0263609	http://dx.doi.org/10.1371/journal.pone.0263609			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1G5LQ	35171933	gold, Green Published			2023-01-03	WOS:000795889700030
J	Rhoads, TW; Anderson, RM				Rhoads, Timothy W.; Anderson, Rozalyn M.			Caloric restriction has a new player	SCIENCE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ADIPOSE-TISSUE; HEALTH		[Rhoads, Timothy W.; Anderson, Rozalyn M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Anderson, RM (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.; Anderson, RM (corresponding author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.	rozalyn.anderson@wisc.edu			National Institutes of Health [AG067330, AG057408, AG070686]; Department for VeteransAffairs [BX003846]; Simons Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department for VeteransAffairs; Simons Foundation	The authors are supported by National Institutes of Health grants AG067330, AG057408, AG070686; the Department for VeteransAffairs BX003846; the Simons Foundation; and Impetus Grants.	Balasubramanian P, 2017, EBIOMEDICINE, V21, P37, DOI 10.1016/j.ebiom.2017.06.015; Boyd JT, 2021, NAT METAB, V3, P762, DOI 10.1038/s42255-021-00410-x; Das SK, 2017, AM J CLIN NUTR, V105, P913, DOI 10.3945/ajcn.116.137232; Furmanet al D., 2019, NAT MED, V25, P1822; Jackisch L, 2018, DIABETOLOGIA, V61, P1155, DOI 10.1007/s00125-018-4558-6; Kahn CR, 2019, J CLIN INVEST, V129, P3990, DOI 10.1172/JCI129187; Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2; Lee AH, 2020, IMMUNITY, V53, P510, DOI 10.1016/j.immuni.2020.08.013; Miller KN, 2017, AGING CELL, V16, P497, DOI 10.1111/acel.12575; Most J, 2018, AM J PHYSIOL-ENDOC M, V314, pE396, DOI 10.1152/ajpendo.00261.2017; Ravussin E, 2015, J GERONTOL A-BIOL, V70, P1097, DOI 10.1093/gerona/glv057; Richardson A, 2021, J GERONTOL A-BIOL, V76, P57, DOI 10.1093/gerona/glaa208; Spadaro O, 2022, SCIENCE, V375, P671, DOI 10.1126/science.abg7292; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	15	2	2	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2022	375	6581					620	621		10.1126/science.abn6576	http://dx.doi.org/10.1126/science.abn6576			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX2ZD	35143311				2023-01-03	WOS:000753975300024
J	Alanazi, AS; Awwad, S; Khan, TM; Asdaq, SMB; Mohzari, Y; Alanazi, F; Alrashed, A; Alamri, AS; Alsanie, WF; Alhomrani, M; AlMotairi, M				Alanazi, Ahmed S.; Awwad, Sameh; Khan, Tahir M.; Asdaq, Syed Mohammed Basheeruddin; Mohzari, Yahya; Alanazi, Foz; Alrashed, Ahmed; Alamri, Abdulhakeem S.; Alsanie, Walaa F.; Alhomrani, Majid; AlMotairi, Mohammed			Medication reconciliation on discharge in a tertiary care Riyadh Hospital: An observational study	PLOS ONE			English	Article							PROGRAM	The purpose of this study was to assess the frequency and characteristics of discharge medication discrepancies as identified by pharmacists during discharge medication reconciliation. We also attempted to identify the factors that influence the occurrence of drug discrepancies during medication reconciliation. From June to December 2019, a prospective study was performed at the cardiac center of King Fahad Medical City (KFMC), a tertiary care hospital in Riyadh. The information from discharge prescriptions as compared to the medication administration record (MAR), medication history in the cortex system, and the patient home medication list collected from the medication reconciliation form on admission. The study included all adult patients discharged from KFMC's cardiac center. These participants comprised 776 patients, 64.6 percent of whom were men and 35.4 percent of whom were women. Medication discrepancies were encountered in 180 patients (23.2%) out of 776 patients. In regards to the number of discharged medications, 651(83.9%) patients had >= 5 medications. Around, 174 (73.4%) discrepancies were intentional, and 63 (26.6%) were unintentional discrepancies. The risk of unintentional medication discrepancy was increased with an increasing number of medications (P-value = 0.008). One out of every four cardiac patients discharged from our hospital had at least one medication discrepancy. The number of drugs taken and the number of discrepancies was found to be related. Necessary steps should be taken to reduce these discrepancies and improve the standard of care.	[Alanazi, Ahmed S.; Alrashed, Ahmed] King Fahad Med City, Pharmaceut Serv Dept, Main Hosp, Riyadh, Saudi Arabia; [Awwad, Sameh; Khan, Tahir M.] Univ Vet & Anim Sci, Inst Pharmaceut Sci IPS, Lahore, Pakistan; [Asdaq, Syed Mohammed Basheeruddin] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh, Saudi Arabia; [Mohzari, Yahya] King Saudi Med City, Clin Pharm Sect, Pharm Dept, Riyadh, Saudi Arabia; [Alanazi, Foz] Minist Natl Guard Hlth Affairs, Cardiac Ctr, Riyadh, Saudi Arabia; [Alamri, Abdulhakeem S.; Alsanie, Walaa F.; Alhomrani, Majid] Taif Univ, Fac Appl Med Sci, Dept Clin Lab Sci, Taif, Saudi Arabia; [Alamri, Abdulhakeem S.; Alsanie, Walaa F.; Alhomrani, Majid] Taif Univ, Ctr Biomed Sci Res CBSR, Deanship Sci Res, Taif, Saudi Arabia; [AlMotairi, Mohammed] King Fahad Med City, Dept Clin Pharm, Riyadh, Saudi Arabia	King Fahad Medical City; University of Veterinary & Animal Science - Pakistan; Almaarefa University; King Saud Bin Abdulaziz University for Health Sciences; Ministry of National Guard - Health Affairs; Taif University; Taif University; King Fahad Medical City	Asdaq, SMB (corresponding author), AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh, Saudi Arabia.	sasdag@mcst.edu.sa	asdaq, Syed Mohammed Basheeruddin/AAH-8283-2019; alhomrani, majid/HJB-1187-2022	asdaq, Syed Mohammed Basheeruddin/0000-0003-1533-9667; Alamri, Abdulhakeem/0000-0003-3174-0434	AlMaarefa University, Riyadh, Saudi Arabia [TURSP 2020/288]	AlMaarefa University, Riyadh, Saudi Arabia	Authors would like to extend their appreciation to the discharge pharmacy team for their effort in this project. The authors are also thankful to AlMaarefa University, Riyadh, Saudi Arabia for extending support (TUMA-2021-1) to do this research.	AbuRuz SM, 2011, INT J CLIN PHARM-NET, V33, P501, DOI 10.1007/s11096-011-9497-y; AbuYassin BH, 2011, SAUDI PHARM J, V19, P263, DOI 10.1016/j.jsps.2011.04.006; Al-Hashar A, 2018, INT J CLIN PHARM-NET, V40, P1154, DOI 10.1007/s11096-018-0650-8; Al-Rashoud I, 2017, SAUDI PHARM J, V25, P1082, DOI 10.1016/j.jsps.2017.05.004; [Anonymous], 2020, READMISSIONS ADVERSE; [Anonymous], 2020, MEDICATION RECONCILI; Elamin MaramMohamed, 2021, SAUDI J HEAL SCI, V10, P73; Grimes TC, 2011, BRIT J CLIN PHARMACO, V71, P449, DOI 10.1111/j.1365-2125.2010.03834.x; Horne R., 2020, ADHERENCE TREATMENT, P285; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; Jaam M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253588; Joint Commission, 2012, NAT PAT SAF GOALS; Lehr CA, 2009, REM SPEC EDUC, V30, P19, DOI 10.1177/0741932508315645; Mazhar F, 2017, PHARM PRACT-GRANADA, V15, DOI [10.18549/PharmPract.2017.01.864, 10.18549/pharmpract.2017.01.864]; Mekonnen AB, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0353-9; Murphy EM, 2009, AM J HEALTH-SYST PH, V66, P2126, DOI 10.2146/ajhp080552; Straka RJ, 1997, PHARMACOTHERAPY, V17, P126; Tariq RA., 2022, STATPEARLS; Uhlenhopp DJ, 2020, INTEGR PHARM RES PRA, V9, P195, DOI 10.2147/IPRP.S269857; Wagner MM, 1996, J AM MED INFORM ASSN, V3, P234, DOI 10.1136/jamia.1996.96310637; Walker PC, 2009, ARCH INTERN MED, V169, P2003, DOI 10.1001/archinternmed.2009.398; Wong JD, 2008, ANN PHARMACOTHER, V42, P1373, DOI 10.1345/aph.1L190	22	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265042	10.1371/journal.pone.0265042	http://dx.doi.org/10.1371/journal.pone.0265042			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3VR	35290378	Green Published, gold			2023-01-03	WOS:000799901400014
J	Burgess-Hull, AJ; Smith, KE; Panlilio, LV; Schriefer, D; Preston, KL; Alter, A; Yeager, C; Chizmar, T; Delbridge, T; Zamore, K; Beeson, J; Epstein, DH				Burgess-Hull, Albert J.; Smith, Kirsten E.; Panlilio, Leigh, V; Schriefer, Destiny; Preston, Kenzie L.; Alter, Aliese; Yeager, Christopher; Chizmar, Timothy; Delbridge, Ted; Zamore, Kenan; Beeson, Jeff; Epstein, David H.			Nonfatal opioid overdoses before and after Covid-19: Regional variation in rates of change	PLOS ONE			English	Article							UNITED-STATES; MORTALITY; SPREAD	BackgroundThe Covid-19 pandemic and its accompanying public-health orders (PHOs) have led to (potentially countervailing) changes in various risk factors for overdose. To assess whether the net effects of these factors varied geographically, we examined regional variation in the impact of the PHOs on counts of nonfatal overdoses, which have received less attention than fatal overdoses, despite their public health significance. MethodsData were collected from the Overdose Detection Mapping Application Program (ODMAP), which recorded suspected overdoses between July 1, 2018 and October 25, 2020. We used segmented regression models to assess the impact of PHOs on nonfatal-overdose trends in Washington DC and the five geographical regions of Maryland, using a historical control time series to adjust for normative changes in overdoses that occurred around mid-March (when the PHOs were issued). ResultsThe mean level change in nonfatal opioid overdoses immediately after mid-March was not reliably different in the Covid-19 year versus the preceding control time series for any region. However, the rate of increase in nonfatal overdose was steeper after mid-March in the Covid-19 year versus the preceding year for Maryland as a whole (B = 2.36; 95% CI, 0.65 to 4.06; p = .007) and for certain subregions. No differences were observed for Washington DC. ConclusionsThe pandemic and its accompanying PHOs were associated with steeper increases in nonfatal opioid overdoses in most but not all of the regions we assessed, with a net effect that was deleterious for the Maryland region as a whole.	[Burgess-Hull, Albert J.; Smith, Kirsten E.; Panlilio, Leigh, V; Schriefer, Destiny; Preston, Kenzie L.; Epstein, David H.] NIDA, Intramural Res Program, Baltimore, MD 21224 USA; [Alter, Aliese; Yeager, Christopher; Beeson, Jeff] Off Natl Drug Control Policy, High Intens Drug Trafficking Area, Washington, DC USA; [Chizmar, Timothy; Delbridge, Ted] Maryland Inst Emergency Med Serv Syst MIEMSS, Baltimore, MD USA; [Zamore, Kenan] Dist Columbia Dept Hlth, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Burgess-Hull, AJ (corresponding author), NIDA, Intramural Res Program, Baltimore, MD 21224 USA.	albert.burgess-hull@nih.gov		Chizmar, Timothy/0000-0003-0067-880X; Schriefer, Destiny/0000-0003-3583-1659; Burgess-Hull, Albert/0000-0003-2494-5538; Smith, Kirsten/0000-0002-9278-1830	Intramural Research Program of the National Institutes of Health NIDA	Intramural Research Program of the National Institutes of Health NIDA	ABH, DHE, KES, LVP, DS, and KLP were supported in part by the Intramural Research Program of the National Institutes of Health NIDA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was supported in part by the Intramural Research Program of the NIH NIDA.	AMA, ISS BRIEF REP INCR O; Bareket-Bojmel L, 2021, INT J COGN THER, V14, P566, DOI 10.1007/s41811-020-00078-3; Bergmann BG, 2021, ADDICT BEHAV, V113, DOI 10.1016/j.addbeh.2020.106661; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Centers for Disease Control, INCR FAT DRUG OV US; Centers for Disease Control and Prevention, 2020, 1 TRAV REL CAS 2019; Dave D, 2021, ECON INQ, V59, P29, DOI 10.1111/ecin.12944; Del Boca D, 2020, REV ECON HOUSEHOLD, V18, P1001, DOI 10.1007/s11150-020-09502-1; del Pozo B, 2020, J SUBST ABUSE TREAT, V119, DOI 10.1016/j.jsat.2020.108139; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021; Forati AM, 2021, J URBAN HEALTH, V98, P551, DOI 10.1007/s11524-021-00554-x; Glober N, 2020, J URBAN HEALTH, V97, P802, DOI 10.1007/s11524-020-00484-0; Haffajee RL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6373; Hategeka C, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003567; Holland KM, 2021, JAMA PSYCHIAT, V78, P372, DOI 10.1001/jamapsychiatry.2020.4402; Hoots B, 2020, ADDICTION, V115, P946, DOI 10.1111/add.14878; Knell G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176268; Kontopantelis E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2750; Lin L, 2020, JAMA PSYCHIAT, V77, P1209, DOI 10.1001/jamapsychiatry.2020.1698; Linas BP, 2021, J SUBST ABUSE TREAT, V120, DOI 10.1016/j.jsat.2020.108158; McGinty EE, 2020, JAMA-J AM MED ASSOC, V324, P93, DOI 10.1001/jama.2020.9740; Melamed OC, 2020, SUBST ABUS, V41, P286, DOI 10.1080/08897077.2020.1784363; Mellis AM, 2021, J SUBST ABUSE TREAT, V121, DOI 10.1016/j.jsat.2020.108180; Mervosh S., 2020, SEE WHICH STATES CIT; Monnat SM, 2019, J RURAL STUD, V68, P319, DOI 10.1016/j.jrurstud.2018.12.004; NEWEY WK, 1994, REV ECON STUD, V61, P631, DOI 10.2307/2297912; Ochalek TA, 2020, JAMA-J AM MED ASSOC, V324, P1673, DOI 10.1001/jama.2020.17477; Olfson M, 2018, DRUG ALCOHOL DEPEN, V190, P112, DOI 10.1016/j.drugalcdep.2018.06.004; Ornell F, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113096; Rigg KK, 2018, INT J DRUG POLICY, V57, P119, DOI 10.1016/j.drugpo.2018.04.011; Rodda LN, 2020, J URBAN HEALTH, V97, P808, DOI 10.1007/s11524-020-00486-y; Schuchat A, 2020, MMWR-MORBID MORTAL W, V69, P551, DOI 10.15585/mmwr.mm6918e2; Shadish C., 2002, EXPT QUASIEXPERIMENT; Slavova S, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108176; Soares WE, 2022, ANN EMERG MED, V79, P158, DOI 10.1016/j.annemergmed.2021.03.013; Spagnolo PA, 2020, AM J PSYCHIAT, V177, P805, DOI 10.1176/appi.ajp.2020.20040417; Stoove MA, 2009, DRUG ALCOHOL REV, V28, P347, DOI 10.1111/j.1465-3362.2009.00057.x; Substance Abuse and Mental Health Services Administration, OP TREATM PROGR GUID; Swift H., 2020, NEW YORK TIMES; Team R. C, 2018, R LANG ENV STAT COMP; Thylstrup B, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107714; Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048; Vivolo-Kantor AM, 2020, MMWR-MORBID MORTAL W, V69, P371, DOI 10.15585/mmwr.mm6913a3; World Health Organization, 2015, ICD10CM WHO; Zibbell J., 2019, NONFATAL OPIOID OVER	46	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0263893	10.1371/journal.pone.0263893	http://dx.doi.org/10.1371/journal.pone.0263893			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T3NB	35263326	gold, Green Published			2023-01-03	WOS:000804638700034
J	De Pascale, G; Cutuli, SL; Carelli, S; Xhemalaj, R; Rosa, T; Bello, G; Vargas, J; Cesarano, M; Montini, L; Tanzarella, ES; Pintaudi, G; Di Muro, M; Grieco, DL; Antonelli, M				De Pascale, Gennaro; Cutuli, Salvatore Lucio; Carelli, Simone; Xhemalaj, Rikardo; Rosa, Tommaso; Bello, Giuseppe; Vargas, Joel; Cesarano, Melania; Montini, Luca; Tanzarella, Eloisa Sofia; Pintaudi, Gabriele; Di Muro, Mariangela; Grieco, Domenico Luca; Antonelli, Massimo			Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation	PLOS ONE			English	Article							SEPSIS; SCORE	IntroductionRemdesivir and Dexamethasone represent the cornerstone of therapy for critically ill patients with acute hypoxemic respiratory failure caused by Coronavirus Disease 2019 (COVID-19). However, clinical efficacy and safety of concomitant administration of Remdesivir and Dexamethasone (Rem-Dexa) in severe COVID-19 patients on high flow oxygen therapy (HFOT) or non-invasive ventilation (NIV) remains unknown. Materials and methodsProspective cohort study that was performed in two medical Intensive Care Units (ICUs) of a tertiary university hospital. The clinical impact of Rem-Dexa administration in hypoxemic patients with COVID-19, who required NIV or HFOT and selected on the simplified acute physiology score II, the sequential organ failure assessment score and the Charlson Comorbidity Index score, was investigated. The primary outcome was 28-day intubation rate; secondary outcomes were end-of-treatment clinical improvement and PaO2/FiO2 ratio, laboratory abnormalities and clinical complications, ICU and hospital length of stay, 28-day and 90-day mortality. ResultsWe included 132 patients and found that 28-day intubation rate was significantly lower among Rem-Dexa group (19.7% vs 48.5%, p<0.01). Although the end-of-treatment clinical improvement was larger among Rem-Dexa group (69.7% vs 51.5%, p = 0.05), the 28-day and 90-day mortalities were similar (4.5% and 10.6% vs. 15.2% and 16.7%; p = 0.08 and p = 0.45, respectively). The logistic regression and Cox-regression models showed that concomitant Rem-Dexa therapy was associated with a reduction of 28-day intubation rate (OR 0.22, CI95% 0.05-0.94, p = 0.04), in absence of laboratory abnormalities and clinical complications (p = ns). ConclusionsIn COVID-19 critically ill patients receiving HFO or NIV, 28-day intubation rate was lower in patients who received Rem-Dexa and this finding corresponded to lower end-of-treatment clinical improvement. The individual contribution of either Remdesevir or Dexamethasone to the observed clinical effect should be further investigated.	[De Pascale, Gennaro; Cutuli, Salvatore Lucio; Carelli, Simone; Xhemalaj, Rikardo; Rosa, Tommaso; Bello, Giuseppe; Vargas, Joel; Cesarano, Melania; Montini, Luca; Tanzarella, Eloisa Sofia; Pintaudi, Gabriele; Di Muro, Mariangela; Grieco, Domenico Luca; Antonelli, Massimo] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Emergenza Anestesiol & Rianimaz, Rome, Italy; [De Pascale, Gennaro; Cutuli, Salvatore Lucio; Carelli, Simone; Xhemalaj, Rikardo; Rosa, Tommaso; Bello, Giuseppe; Vargas, Joel; Cesarano, Melania; Montini, Luca; Tanzarella, Eloisa Sofia; Pintaudi, Gabriele; Di Muro, Mariangela; Grieco, Domenico Luca; Antonelli, Massimo] Univ Cattolica Sacro Cuore, Ist Anestesiol & Rianimaz, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	De Pascale, G (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Emergenza Anestesiol & Rianimaz, Rome, Italy.; De Pascale, G (corresponding author), Univ Cattolica Sacro Cuore, Ist Anestesiol & Rianimaz, Rome, Italy.	gennaro.depascalemd@gmail.com	Grieco, Domenico Luca/D-9706-2018	Grieco, Domenico Luca/0000-0002-4557-6308; Di Muro, Mariangela/0000-0002-1070-4955; Cutuli, Salvatore Lucio/0000-0001-8135-6284; Vargas, Joel/0000-0002-9765-4945				Arabi YM, 2020, INTENS CARE MED, V46, P2067, DOI 10.1007/s00134-020-06223-y; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Beigel JH, 2021, CURR OPIN CRIT CARE, V27, P487, DOI 10.1097/MCC.0000000000000866; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benfield T, 2021, CLIN INFECT DIS, V73, P2031, DOI 10.1093/cid/ciab536; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Borbone N, 2021, MOLECULES, V26, DOI 10.3390/molecules26040986; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1; Cutuli SL, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57060552; De la Calle C, 2016, EUR J CLIN MICROBIOL, V35, P497, DOI 10.1007/s10096-015-2566-8; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Grieco DL, 2021, INTENS CARE MED, V47, P851, DOI 10.1007/s00134-021-06459-2; Grieco DL, 2021, JAMA-J AM MED ASSOC, V325, P1731, DOI 10.1001/jama.2021.4682; Hanson K., CLIN INFECT DIS, V2021; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Lapadula G, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa481; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Nili A, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2133; Olender Susan A, 2021, Clin Infect Dis, V73, pe4166, DOI 10.1093/cid/ciaa1041; Pasquini Z, 2020, J ANTIMICROB CHEMOTH, V75, P3359, DOI 10.1093/jac/dkaa321; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rochwerg B, 2020, INTENS CARE MED, V46, P2226, DOI 10.1007/s00134-020-06312-y; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5	35	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267038	10.1371/journal.pone.0267038	http://dx.doi.org/10.1371/journal.pone.0267038			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482703	Green Published, gold			2023-01-03	WOS:000794035700074
J	Feng, SX; Yuan, J; Zhao, D; Li, RR; Liu, XF; Tian, YG; Li, JS				Feng, Suxiang; Yuan, Jie; Zhao, Di; Li, Rongrong; Liu, Xuefang; Tian, Yange; Li, Jiansheng			Systematic characterization of the effective constituents and molecular mechanisms of Ardisiae Japonicae Herba using UPLC-Orbitrap Fusion MS and network pharmacology	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; TRITERPENOID SAPONINS; INFLAMMATION; ACTIVATION	Objective Ardisiae Japonicae Herba (AJH), the dried whole herb of Ardisia japonica (Thunb.) Blume [Primulaceae], has been used in treating chronic obstructive pulmonary disease (COPD) in China. However, the material basis and molecular mechanisms of AJH against COPD remain unclear. Therefore, in this study, we attempt to establish a systematic approach to elucidate the material basis and molecular mechanisms through compound identification, network analysis, molecular docking, and experimental validation. Methods Ultra-high performance liquid chromatography-Orbitrap Fusion mass spectrometry (UPLC-Orbitrap Fusion MS) was used to characterize the chemical compounds of AJH. The SwissTargetPrediction, String and Metascape databases were selected for network pharmacology analysis, including target prediction, protein-protein interaction (PPI) network analysis, GO and KEGG pathway enrichment analysis. Cytoscape 3.7.2 software was used to construct a component-target-pathway network to screen out the main active compounds. Autodock Vina software was used to verify the affinity between the key compounds and targets. TNF-alpha-stimulated A549 cell inflammation model was built to further verify the anti-inflammatory effects of active compounds. Results Altogether, 236 compounds were identified in AJH, including 33 flavonoids, 21 Phenylpropanoids, 46 terpenes, 7 quinones, 27 steroids, 71 carboxylic acids and 31 other compounds. Among them, 41 compounds were selected as the key active constituents, which might exhibit therapeutic effects against COPD by modulating 65 corresponding targets primarily involved in inflammation/metabolism/immune-related pathways. The results of molecular docking showed that the key compounds could spontaneously bind to the receptor proteins with a strong binding ability. Finally, the anti-inflammatory effects of the three active compounds were validated with the decreased levels of Interleukin-6 (IL-6) and Matrix Metalloproteinase 9 (MMP9) in TNF-alpha-induced A549 cells model. Conclusion This study clarified that AJH may exert therapeutic actions for COPD via regulating inflammation/immune/metabolism-related pathways using UPLC-Orbitrap Fusion MS technology combined with network pharmacology for the first time. This study had a deeper exploration of the chemical components and pharmacological activities in AJH, which provided a reference for the further study and clinical application of AJH in the treatment of COPD.	[Feng, Suxiang; Zhao, Di; Liu, Xuefang; Tian, Yange] Henan Univ Chinese Med, Acad Chinese Med Sci, Zhengzhou, Henan, Peoples R China; [Feng, Suxiang; Yuan, Jie; Zhao, Di; Li, Rongrong; Liu, Xuefang; Tian, Yange; Li, Jiansheng] Collaborat Innovat Ctr Chinese Med & Resp Dis Coc, Zhengzhou, Henan, Peoples R China; [Yuan, Jie; Li, Rongrong] Henan Univ Chinese Med, Coll Pharm, Zhengzhou, Henan, Peoples R China; [Li, Jiansheng] Henan Univ Chinese Med, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China	Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine	Feng, SX (corresponding author), Henan Univ Chinese Med, Acad Chinese Med Sci, Zhengzhou, Henan, Peoples R China.; Feng, SX; Li, JS (corresponding author), Collaborat Innovat Ctr Chinese Med & Resp Dis Coc, Zhengzhou, Henan, Peoples R China.; Li, JS (corresponding author), Henan Univ Chinese Med, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.	fengsx221@163.com; li_js8@163.com						Amin MN., 2015, INT J PHARMACOGNOSY, V7; Annalicia VG., 2014, J THORAC DIS, V6; Beran D, 2015, LANCET RESP MED, V3, P159, DOI 10.1016/S2213-2600(15)00004-1; Calzetta L, 2020, EXPERT OPIN INV DRUG, V29, P723, DOI 10.1080/13543784.2020.1769064; Chang WA, 2016, ONCOTARGET, V7, P85220, DOI 10.18632/oncotarget.13240; Chang XL, 2007, J NAT PROD, V70, P179, DOI 10.1021/np0604681; Chanput W, 2016, INT IMMUNOPHARMACOL, V40, P170, DOI 10.1016/j.intimp.2016.08.038; Chao J, 2017, BIOCHEM PHARMACOL, V139, P94, DOI 10.1016/j.bcp.2017.06.123; Chen CY, 2007, LIFE SCI, V81, P1602, DOI 10.1016/j.lfs.2007.09.028; [陈四清 Chen Siqing], 2017, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V23, P147; Chen Y, 2018, INT J ANAL CHEM, V2018, DOI 10.1155/2018/1707853; Chung MJ, 2015, INT IMMUNOPHARMACOL, V25, P302, DOI 10.1016/j.intimp.2015.01.031; Cong W., 2018, J SHANXI MED U, V49, P305, DOI [10.13753/j.issn.1007-6611.2018.03.021, DOI 10.13753/J.ISSN.1007-6611.2018.03.021]; Dat NT, 2007, J NAT PROD, V70, P839, DOI 10.1021/np060359m; Fang K., 2015, ESTABLISHMENT MODEL; Feng F, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/6471815; Gan WQ, 2013, AM J RESP CRIT CARE, V187, P721, DOI 10.1164/rccm.201211-2004OC; Ge Z., 2006, J BASIC CHINESE MED, V012, P289; Ge Z., 2006, J BASIC CHINESE MED, P289; Ge Z., 2016, LISHIZHEN MED MAT ME, V27, P3; Hou H., 2020, J GUANGXI MED U, V37, P1772, DOI 10.16190/j.cnki.45-1211/r.2020.10.003; Hu NH, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112361; [胡文杰 Hu Wenjie], 2013, [广东农业科学, Guangdong Agricultural Sciences], V40, P66; Huang B., 1981, ACTA PHARM SIN, P29; Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008; Kobayashi H, 2005, J ETHNOPHARMACOL, V96, P347, DOI 10.1016/j.jep.2004.09.037; Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC; Leu YL, 2020, MOLECULES, V25, DOI 10.3390/molecules25040941; Li Q, 2012, BIOORG MED CHEM LETT, V22, P6120, DOI 10.1016/j.bmcl.2012.08.027; Li Y, 2016, J MODERN MED HLTH, V32, P1216; Li Z., 2019, J TRADITIONAL CHINES, V38, P17, DOI [10.13823/j.cnki.jtcvm.2019.02.004, DOI 10.13823/J.CNKI.JTCVM.2019.02.004]; Liu M., 2019, J MED PHARM CHINESE, V25, P26, DOI [10.16041/j.cnki.cn15-1175.2019.11.018, DOI 10.16041/J.CNKI.CN15-1175.2019.11.018]; [刘伟林 LIU Wei-lin], 2009, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V20, P3002; Logan SM, 2018, PEERJ, V6, DOI 10.7717/peerj.4911; Luo X., 2014, STUDY MECH RHSG REGU; Ma L, 2015, J PHARMACEUT BIOMED, V102, P400, DOI 10.1016/j.jpba.2014.10.013; Pan H., 2019, J TRADITIONAL CHINES, V38, P6; Peng L., 2016, ACAD J SHANGHAI U TR, V30, P5; Peng L., 2016, ACAD J SHANGHAI U TR, V30, P90; Piacente S, 1996, J NAT PROD, V59, P565, DOI 10.1021/np960074h; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Su Y, 2020, FOOD SCI NUTR, V8, P6603, DOI 10.1002/fsn3.1952; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Tang QH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.651664; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; van Rijn AL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223952; Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1016/j.arbres.2017.02.001, 10.1164/rccm.201701-0218PP]; Wu H., 2017, WORLD CLIN DRUGS, V38, P248; Xiang FS., 2020, J LIQUID CHROMATOGRA, V43, P7; Xiao Z., 2016, CHINA MED HERALD, V13, P130; [谢凯 Xie Kai], 2021, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V36, P2294; Xu Chang-yan, 2014, Zhong Yao Cai, V37, P1570; Xu F, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1281420; Yu KY, 2017, J SEP SCI, V40, P4347, DOI 10.1002/jssc.201700667; Yuan CH, 2017, INT J CHRONIC OBSTR, V12, P1385, DOI 10.2147/COPD.S134161; Yuan X., 2014, GUIZHOU U TRADITIONA; Zeng L., 2019, GUANGXI SCI, V26, P6; Zhan Y., 2003, 2003 NATL S MIAO MED; Zhang L., 2020, CHINA J TRADITIONAL, V35, P6; Zhao P, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01212; Zhong Y., LIAONING J TRADITION, P1; Zhou SQ, 2021, J FUNCT FOODS, V80, DOI 10.1016/j.jff.2021.104456; Zhou X., 2012, CHINESE J EXPT TRADI, V18, P305	64	0	0	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269087	10.1371/journal.pone.0269087	http://dx.doi.org/10.1371/journal.pone.0269087			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35704651	Green Published, gold			2023-01-03	WOS:000832307900017
J	Gurung, AB; Ali, MA; Lee, J; El-Zaidy, M; Aljowaie, RM; Almutairi, SM				Gurung, Arun Bahadur; Ali, Mohammad Ajmal; Lee, Joongku; El-Zaidy, Mohamed; Aljowaie, Reem M.; Almutairi, Saeedah M.			Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19	PLOS ONE			English	Article							SARS-COV ENTRY; REPLICATION; INFECTION; ORIGIN; CD4	The appearance of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of effective antiviral therapeutics for coronavirus disease 2019 (COVID-19), a highly infectious disease caused by the virus, demands the search for alternative therapies. Most antiviral drugs known are passive defenders which must enter the cell to execute their function and suffer from concerns such as permeability and effectiveness, therefore in this current study, we aim to identify peptide inactivators that can act without entering the cells. SARS-CoV-2 spike protein is an essential protein that plays a major role in binding to the host receptor angiotensin-converting enzyme 2 and mediates the viral cell membrane fusion process. SARS vaccines and treatments have also been developed with the spike protein as a target. The virtual screening experiment revealed antiviral peptides which were found to be non-allergen, non-toxic and possess good water solubility. U-1, GST-removed-HR2 and HR2-18 exhibit binding energies of -47.8 kcal/mol, -43.01 kcal/mol, and -40.46 kcal/mol, respectively. The complexes between these peptides and spike protein were stabilized through hydrogen bonds as well as hydrophobic interactions. The stability of the top-ranked peptide with the drug-receptor is evidenced by 50-ns molecular dynamics (MD) simulations. The binding of U-1 induces conformational changes in the spike protein with alterations in its geometric properties such as increased flexibility, decreased compactness, the increased surface area exposed to solvent molecules, and an increase in the number of total hydrogen bonds leading to its probable inactivation. Thus, the identified antiviral peptides can be used as anti-SARS-CoV-2 candidates, inactivating the virus's spike proteins and preventing it from infecting host cells.	[Gurung, Arun Bahadur] North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong, Meghalaya, India; [Ali, Mohammad Ajmal; El-Zaidy, Mohamed; Aljowaie, Reem M.; Almutairi, Saeedah M.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh, Saudi Arabia; [Lee, Joongku] Chungnam Natl Univ, Dept Environm & Forest Resources, Daejeon, South Korea	North Eastern Hill University; King Saud University; Chungnam National University	Gurung, AB (corresponding author), North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong, Meghalaya, India.; Lee, J (corresponding author), Chungnam Natl Univ, Dept Environm & Forest Resources, Daejeon, South Korea.	arunbgurung@gmail.com; joongku@cnu.ac.kr						Araf Y, 2022, J MED VIROL, V94, P1825, DOI 10.1002/jmv.27588; Cetina-Corona A, 2016, INTERVIROLOGY, V59, P235, DOI 10.1159/000464134; Chen WZ, 2014, J VIROL, V88, P1125, DOI 10.1128/JVI.02566-13; Chu LHM, 2008, J CELL BIOCHEM, V104, P2335, DOI 10.1002/jcb.21790; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Li MC, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00767-1; Lu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-104; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Pal M, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.7423; Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147; Phillips DM, 2000, CONTRACEPTION, V62, P149, DOI 10.1016/S0010-7824(00)00156-6; Qi QQ, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.46; Schutz D, 2020, ADV DRUG DELIVER REV, V167, P47, DOI 10.1016/j.addr.2020.11.007; Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05; Su XJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01063; Weng GQ, 2019, NUCLEIC ACIDS RES, V47, pW322, DOI 10.1093/nar/gkz397; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu HY, 2010, P NATL ACAD SCI USA, V107, P12257, DOI 10.1073/pnas.1000378107; Yu YF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15672; Yuan KH, 2004, BIOCHEM BIOPH RES CO, V319, P746, DOI 10.1016/j.bbrc.2004.05.046; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhou P., 2020, NATURE, P1; Zhou P, 2018, NUCLEIC ACIDS RES, V46, pW443, DOI 10.1093/nar/gky357	31	1	1	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268919	10.1371/journal.pone.0268919	http://dx.doi.org/10.1371/journal.pone.0268919			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35657783	Green Published, gold			2023-01-03	WOS:000832307900091
J	Slomski, A				Slomski, Anita			Adding Time-Restricted Eating to Caloric Restriction for Weight Loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	4	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2022	327	20					1950	1950						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1Y7GZ	35608585				2023-01-03	WOS:000808309800011
J	Nobuhara, C; Devinney, M; Berger, M				Nobuhara, Chloe; Devinney, Michael, Jr.; Berger, Miles			Regional vs General Anesthesia and Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK-FACTORS		[Nobuhara, Chloe] Duke Univ, Sch Med, Durham, NC USA; [Devinney, Michael, Jr.; Berger, Miles] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC USA	Duke University; Duke University	Berger, M (corresponding author), Duke Univ, Med Ctr, Duke South Orange Zone, Room 4317,Box 3094, Durham, NC 27710 USA.	miles.berger@duke.edu		Devinney, Michael/0000-0003-3906-6421				Green JR, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1129-8; Hamadnalla H, 2021, J CLIN ANESTH, V71, DOI 10.1016/j.jclinane.2021.110233; Li T, 2022, JAMA-J AM MED ASSOC, V327, P50, DOI 10.1001/jama.2021.22647; Slor CJ, 2013, J PSYCHOSOM RES, V74, P444, DOI 10.1016/j.jpsychores.2012.12.007; Yang YJ, 2017, AGING CLIN EXP RES, V29, P115, DOI 10.1007/s40520-016-0541-6	5	0	0	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2022	327	17					1707	1708						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D3AC	35503352				2023-01-03	WOS:000793675300025
J	Liu, DY; Huang, Y; Huang, CSH; Yang, SY; Wei, XY; Zhang, PZ; Guo, D; Lin, JY; Xu, BY; Li, CW; He, H; He, J; Liu, SQ; Shi, LN; Xue, YM; Zhang, HJ				Liu, Deying; Huang, Yan; Huang, Chensihan; Yang, Shunyu; Wei, Xueyun; Zhang, Peizhen; Guo, Dan; Lin, Jiayang; Xu, Bingyan; Li, Changwei; He, Hua; He, Jiang; Liu, Shiqun; Shi, Linna; Xue, Yaoming; Zhang, Huijie			Calorie Restriction with or without Time-Restricted Eating in Weight Loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED-TRIAL; MEAL FREQUENCY; ADULTS; HEALTH; OVERWEIGHT; REVEALS; DIET; MEN	Background The long-term efficacy and safety of time-restricted eating for weight loss are not clear. Methods We randomly assigned 139 patients with obesity to time-restricted eating (eating only between 8:00 a.m. and 4:00 p.m.) with calorie restriction or daily calorie restriction alone. For 12 months, all the participants were instructed to follow a calorie-restricted diet that consisted of 1500 to 1800 kcal per day for men and 1200 to 1500 kcal per day for women. The primary outcome was the difference between the two groups in the change from baseline in body weight; secondary outcomes included changes in waist circumference, body-mass index (BMI), amount of body fat, and measures of metabolic risk factors. Results Of the total 139 participants who underwent randomization, 118 (84.9%) completed the 12-month follow-up visit. The mean weight loss from baseline at 12 months was -8.0 kg (95% confidence interval [CI], -9.6 to -6.4) in the time-restriction group and -6.3 kg (95% CI, -7.8 to -4.7) in the daily-calorie-restriction group. Changes in weight were not significantly different in the two groups at the 12-month assessment (net difference, -1.8 kg; 95% CI, -4.0 to 0.4; P=0.11). Results of analyses of waist circumferences, BMI, body fat, body lean mass, blood pressure, and metabolic risk factors were consistent with the results of the primary outcome. In addition, there were no substantial differences between the groups in the numbers of adverse events. Conclusions Among patients with obesity, a regimen of time-restricted eating was not more beneficial with regard to reduction in body weight, body fat, or metabolic risk factors than daily calorie restriction.	[Liu, Deying; Huang, Yan; Huang, Chensihan; Wei, Xueyun; Zhang, Peizhen; Guo, Dan; Lin, Jiayang; Xu, Bingyan; Liu, Shiqun; Xue, Yaoming; Zhang, Huijie] Southern Med Univ, Nanfang Hosp, Dept Endocrinol & Metab, Guangzhou, Peoples R China; [Yang, Shunyu; Shi, Linna] Southern Med Univ, Nanfang Hosp, Dept Nutr, Guangzhou, Peoples R China; [Li, Changwei; He, Hua; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; [Zhang, Huijie] Southern Med Univ, Nanfang Hosp, Dept Endocrinol & Metab, Guangdong Prov Key Lab Shock & Microcirculat,State, 1838 North Guangzhou Ave, Guangzhou 510515, Peoples R China	Southern Medical University - China; Southern Medical University - China; Tulane University; Southern Medical University - China	Zhang, HJ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Endocrinol & Metab, Guangdong Prov Key Lab Shock & Microcirculat,State, 1838 North Guangzhou Ave, Guangzhou 510515, Peoples R China.	huijiezhang2005@126.com	zhang, hui/GXH-6098-2022; Zhang, Hui/HHN-8494-2022; He, Jiang/AAF-5303-2020	He, Jiang/0000-0002-8286-9652	National Key Research and Development Project [2018YFA0800404]	National Key Research and Development Project	Funded by the National Key Research and Development Project [No. 2018YFA0800404] and others; ClinicalTrials.gov num-ber, NCT03745612.	Antoni R, 2018, J NUTR SCI, V7, DOI 10.1017/jns.2018.13; Bray GA, 2016, LANCET, V387, P1947, DOI 10.1016/S0140-6736(16)00271-3; Cai H, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1132-8; Chinese Nutrition Society, 2016, DIET GUIDL CHIN RES; Chow LS, 2020, OBESITY, V28, P860, DOI [10.1002/oby.22756, 10.1002/oby.22785]; Cienfuegos S, 2020, CELL METAB, V32, P366, DOI 10.1016/j.cmet.2020.06.018; Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X; Eckel R. H., 2014, Circulation, V129, pS76, DOI [10.1016/j.jacc.2013.11.003, 10.1161/01.cir.0000437740.48606.d1]; Gabel Kelsey, 2018, Nutr Healthy Aging, V4, P345, DOI 10.3233/NHA-170036; Gill S, 2015, CELL METAB, V22, P789, DOI 10.1016/j.cmet.2015.09.005; Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; Kahleova H, 2017, J NUTR, V147, P1722, DOI 10.3945/jn.116.244749; Kahleova H, 2014, DIABETOLOGIA, V57, P1552, DOI 10.1007/s00125-014-3253-5; Kesztyus D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122854; Lopez-Minguez J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112624; Lowe DA, 2020, JAMA INTERN MED, V180, P1491, DOI 10.1001/jamainternmed.2020.4153; Moro T, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1044-0; Pureza IRDM, 2021, CLIN NUTR, V40, P759, DOI 10.1016/j.clnu.2020.06.036; Romero-Gomez M, 2017, J HEPATOL, V67, P829, DOI 10.1016/j.jhep.2017.05.016; Ruge T, 2009, J CLIN ENDOCR METAB, V94, P1781, DOI 10.1210/jc.2008-2090; Stote KS, 2007, AM J CLIN NUTR, V85, P981, DOI 10.1093/ajcn/85.4.981; Stratton MT, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041126; Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010; Tinsley GM, 2017, EUR J SPORT SCI, V17, P200, DOI 10.1080/17461391.2016.1223173; Tong YB, 2014, MED PHYS, V41, DOI 10.1118/1.4876275; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004; Williams RL, 2015, OBES REV, V16, P171, DOI 10.1111/obr.12241; Yang Y, 2018, CHINESE FOOD COMPOSI, Vstandard	29	48	48	65	160	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	2022	386	16					1495	1504		10.1056/NEJMoa2114833	http://dx.doi.org/10.1056/NEJMoa2114833			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1F4SD	35443107				2023-01-03	WOS:000795157900007
J	Kiragu, ZW; Rockers, PC; Onyango, MA; Mungai, J; Mboya, J; Laing, R; Wirtz, VJ				Kiragu, Zana Wangari; Rockers, Peter C.; Onyango, Monica A.; Mungai, John; Mboya, John; Laing, Richard; Wirtz, Veronika J.			Household access to non-communicable disease medicines during universal health care roll-out in Kenya: A time series analysis	PLOS ONE			English	Article								Objectives This study aims to describe trends and estimate impact of county-level universal health coverage expansion in Kenya on household availability of non-communicable disease medicines, medicine obtainment at public hospitals and proportion of medicines obtained free of charge. Methods Data from phone surveillance of households in eight Kenyan counties between December 2016 and September 2019 were used. Three primary outcomes related to access were assessed based on patient report: availability of non-communicable disease medicines at the household; non-communicable disease medicine obtainment at a public hospital versus a different outlet; and non-communicable disease medicine obtainment free of cost versus at a non-zero price. Mixed models adjusting for fixed and random effects were used to estimate associations between outcomes of interest and UHC exposure. Results The 197 respondents with universal health coverage were similar on all demographic factors to the 415 respondents with no universal health coverage. Private chemists were the most popular place of purchase throughout the study. Adjusting for demographic factors, county and time fixed effects, there was a significant increase in free medicines (aOR 2.55, 95% CI 1.73, 3.76), significant decrease in medicine obtainment at public hospitals (aOR 0.68, 95% CI 0.47, 0.97), and no impact on the availability of non-communicable disease medicines in households (a beta -0.004, 95% CI -0.058, 0.050) with universal health coverage. Conclusions Access to universal health coverage caused a significant increase in free non-communicable disease medicines, indicating financial risk protection. Interestingly, this is not accompanied with increases in public hospitals purchases or household availability of non-communicable disease medicines, with public health centers playing a greater role in supply of free medicines. This raises the question as to the status of supply-side investments at the public hospitals, to facilitate availability of quality-assured medicines.	[Kiragu, Zana Wangari; Rockers, Peter C.; Onyango, Monica A.; Laing, Richard; Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA; [Mungai, John; Mboya, John] Innovat Poverty Act, Nairobi, Kenya; [Laing, Richard] Univ Western Cape, Sch Publ Hlth, Bellville, South Africa	Boston University; Innovations for Poverty Action (IPA); University of the Western Cape	Kiragu, ZW (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA.	zkiragu@bu.edu		Kiragu, Zana/0000-0003-1289-5983; Wirtz, Veronika J./0000-0002-0863-8768	Sandoz International GmBH	Sandoz International GmBH	The authors have read the journal's policy and have the following competing interests: This work was supported by commercial funder Sandoz International GmBH, a subsidiary of Novartis International AG. Peter C. Rockers received grants from Access Accelerated, Gilead Sciences, F. Hoffmann-La Roche, and Amgen outside the submitted work. Richard O. Laing received nonfinancial support from Novartis International AG, Gilead Sciences, and F. Hoffmann-La Roche outside the submitted work. Veronika J. Wirtz received grants from Access Accelerated, Gilead Sciences, F. Hoffmann-La Roche, and Amgen outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Ashigbie PG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035132; Barasa E, 2018, HEALTH SYST REFORM, V4, P346, DOI 10.1080/23288604.2018.1513267; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Centre for Sport and Human Rights, 2019, MAPP ACC REM MECH SP; Dutta A., 2018, KENYA HLTH FINANCING; Gathara P, 2018, MAKUENI HEALTHCARE R; Government of Makueni County, 2018, MAK UNV 200 BED ULTR; Indonesia T., 2021, TELKOM CSS 2021 2025; Kenya National Bureau of Statistics (KNBS), 2019, KENYA NATL BUREAU ST; Laing R., 2016, EVALUATION NOVARTIS; Makeuni County Government, 2020, MAK UN HLTH CAR REC; Ministry of Health, 2015, KEN NAT STRAT PREV C; Ministry of Health, 2015, KEN STEPWISE SURV NO; Mulaki A., 2019, KENYA HLTH SYSTEM AS; Nzwili F, 2018, KENYAN PRESIDENT LAU; Onyango MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201917; Pariyo GW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214450; Pariyo GW, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7302; PRB, 2019, FAM PLANN DAT 2019; Rockers PC, 2019, LANCET GLOB HEALTH, V7, pE492, DOI 10.1016/S2214-109X(18)30563-1; Rockers PC, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000828; Rockers PC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013386; Subramanian S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190113; ThinkWell Gobal, 2019, KEN KNOWL LEARN BRIE; Turpin K., 2018, E AFR MED J, V95, P1286; United Nations, 2015, UN; Vialle-Valentin CE, 2015, HEALTH POLICY PLANN, V30, P1044, DOI 10.1093/heapol/czu107; Wamai RG, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6051-z; Wangia E, 2018, POLICY BRIEF REFOCUS; Wirtz VJ, 2018, TROP MED INT HEALTH, V23, P879, DOI 10.1111/tmi.13081; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2012, WORLD HLTH DAY 2012	32	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2022	17	4							e0266715	10.1371/journal.pone.0266715	http://dx.doi.org/10.1371/journal.pone.0266715			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2T6VD	35443014	Green Published, gold			2023-01-03	WOS:000822608900032
J	Szewczak, L; Cook, DJ				Szewczak, Lara; Cook, Deborah J.			Bringing research to the intensive care setting	CELL			English	Editorial Material								Dr. Deborah J. Cook's contributions in the field of critical care have not only impacted the intensive care unit (ICU) patients she treats and countless others worldwide but have also helped establish research programs and clinical trials as integral components of improving care and outcomes for the most seriously ill. Lara Szewczak spoke with Dr. Cook, recipient of the 2022 Canada Gairdner Wightman award, about critical care research, her reflections on the COVID-19 pandemic, and her views on mentorship. An edited version of this conversation is presented below.	[Cook, Deborah J.] McMaster Univ, Med Clin Epidemiol & Biostat, Acad Chair St Josephs Healthcare Hamilton, Hamilton, ON L8S 4L8, Canada; [Cook, Deborah J.] McMaster Univ, Hamilton, ON, Canada	McMaster University; McMaster University									0	0	0	2	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2022	185	8					1275	1278						4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	1V8JR	35385690	Bronze, Green Published			2023-01-03	WOS:000806331300004
J	Rubin, R; Suran, M				Rubin, Rita; Suran, Melissa			Supervised Consumption Sites-A Tool for Reducing Risk of Overdose Deaths and Infectious Diseases in People Who Use Illicit Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item; Early Access								This Medical News feature discusses supervised consumption sites for people who use illicit drugs.											0	1	1	4	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.4017	http://dx.doi.org/10.1001/jama.2022.4017		APR 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0I5LL	35385054				2023-01-03	WOS:000779462200001
J	Abdelhafiz, AS; Ali, A; Maaly, AM; Mahgoub, MA; Ziady, HH; Sultan, EA				Abdelhafiz, Ahmed Samir; Ali, Asmaa; Maaly, Ayman Mohamed; Mahgoub, Mohamed Anwar; Ziady, Hany Hassan; Sultan, Eman Anwar			Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated	PLOS ONE			English	Article							SURVIVORS	Objectives COVID-19 is a multisystem disease, and some patients suffer from physical or psychological symptoms for weeks or even months after infection, which is described as post-COVID syndrome. The goal of this study is evaluating the prevalence of post-COVID-19 symptoms among Egyptian patients and detecting the factors associated with the presence of these symptoms. Methods An on-line cross-sectional survey using Google Forms was used to conduct the present study, which took place between June and August 2021. Results Three hundred and ninety-six participants filled in the survey. The mean age of participants was 41.4 years. Most participants had mild to moderate COVID-19 (81.31%). The prevalence of post-COVID-19 symptoms was 87.63%, where the most frequent symptom was fatigue (60.86%). Female sex, the presence of comorbidities, lower degree of education, longer disease duration, as well as severe and critical forms of the disease were significantly associated with the presence of post-COVID symptoms. Using regression analysis, the predictors of post-COVID symptoms were severe and critical forms of the disease and intake of antibiotics and corticosteroids for treatment of COVID-19. Conclusions COVID-19 is followed by high prevalence of post-COVID symptoms. To the best of our knowledge, this is the first study to report the relationship between the use of antibiotics and the development of post-COVID symptoms. We recommend further studies to understand this relationship. We also recommend restricting the use of these drugs to indicated cases according to the international guidelines. More studies are needed to gain better understanding of post-COVID symptoms especially in females.	[Abdelhafiz, Ahmed Samir] Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Cairo, Egypt; [Ali, Asmaa] MOH, Dept Pulm Med, Abbassia Chest Hosp, Cairo, Egypt; [Ali, Asmaa] Alexandria Univ, Fac Med, Dept Anaesthesia & Surg Intens Care, Alexandria, Egypt; [Maaly, Ayman Mohamed] Alexandria Univ, High Inst Publ Hlth, Dept Microbiol, Alexandria, Egypt; [Mahgoub, Mohamed Anwar] Alexandria Univ, Fac Med, Dept Community Med, Alexandria, Egypt; [Ziady, Hany Hassan; Sultan, Eman Anwar] Jiangsu Univ, Sch Med, Dept Lab Med, Zhenjiang, Jiangsu, Peoples R China	Egyptian Knowledge Bank (EKB); Cairo University; National Cancer Institute - Egypt; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Abbassia Chest Hospital; Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Alexandria University; Jiangsu University	Abdelhafiz, AS (corresponding author), Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Cairo, Egypt.	ahmed.samir@nci.cu.edu.eg		Sultan, Eman/0000-0002-9801-0607				Abdelhafiz AS, 2021, VIROLOGY, V563, P74, DOI 10.1016/j.virol.2021.08.012; Abdelhafiz AS, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.590190; Ahmed H, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2694; Amenta EM, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa509; Belot A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.22.2001010; Biehl Michelle, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc055; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; CDC, POST COVID COND; Colafrancesco S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102573; D'Cruz RF, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00655-2020; Dani M, 2021, CLIN MED, V21, pE63, DOI 10.7861/clinmed.2020-0896; Fathi N, 2020, CELL BIOL INT, V44, P1792, DOI 10.1002/cbin.11403; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Inoue S, 2019, ACUTE MED SURG, V6, P233, DOI 10.1002/ams2.415; Iqbal A, 2021, CUREUS, V13, DOI 10.7759/cureus.13080; Kamal M, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13746; Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384; Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783; Leow MKS, 2005, CLIN ENDOCRINOL, V63, P197, DOI 10.1111/j.1365-2265.2005.02325.x; Lu YP, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100484; Miyazato Y, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa507; Moldofsky H, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-37; Morris SB, 2020, MMWR-MORBID MORTAL W, V69, P1450, DOI 10.15585/mmwr.mm6940e1; Nabavi N, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3489; Pavli A, 2021, ARCH MED RES, V52, P575, DOI 10.1016/j.arcmed.2021.03.010; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Perrin R, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110055; Poyraz BC, 2021, PSYCHIAT RES, V295, DOI 10.1016/j.psychres.2020.113604; Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016; Sarkar S, 2021, J MED VIROL, V93, P1538, DOI 10.1002/jmv.26483; Taboada M, 2021, J INFECTION, V82, pE31, DOI 10.1016/j.jinf.2020.12.022; Tavakolpour S, 2020, IMMUNOL LETT, V225, P31, DOI 10.1016/j.imlet.2020.06.013; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI 10.15585/mmwr.mm6930e1externalicon; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Townsend L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240784; Truffaut L, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01625-y; Valent A, 2020, ANAESTH CRIT CARE PA, V39, P740, DOI 10.1016/j.accpm.2020.10.001; van den Borst B, 2021, CLIN INFECT DIS, V73, pE1089, DOI 10.1093/cid/ciaa1750; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Wijeratne T, 2020, J NEUROL SCI, V419, DOI 10.1016/j.jns.2020.117179; Wu F., 2020, MEDRXIV, DOI 10.1101/2020.03.30.20047365; Yuan ML, 2020, SHOCK, V54, P638, DOI 10.1097/SHK.0000000000001574; Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577	47	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2022	17	3							e0266175	10.1371/journal.pone.0266175	http://dx.doi.org/10.1371/journal.pone.0266175			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M2UI	35358268	Green Published, gold			2023-01-03	WOS:000799828800076
J	Mas-Ubillus, G; Ortiz, PJ; Huaringa-Marcelo, J; Sarzo-Miranda, P; Munoz-Aguirre, P; Diaz-Ramos, A; Arribasplata-Purizaca, K; Mendoza, D; Rojas-Poma, J; Marcelo-Ruiz, C; Ayala-Diaz, P; Hidalgo-Arroyo, E; Tupia-Cespedes, L				Mas-Ubillus, Guiliana; Ortiz, Pedro J.; Huaringa-Marcelo, Jorge; Sarzo-Miranda, Paola; Munoz-Aguirre, Patricia; Diaz-Ramos, Alejandra; Arribasplata-Purizaca, Kattia; Mendoza, Doris; Rojas-Poma, Juan; Marcelo-Ruiz, Cristian; Ayala-Diaz, Pedro; Hidalgo-Arroyo, Edwin; Tupia-Cespedes, Lourdes			High mortality among hospitalized adult patients with COVID-19 pneumonia in Peru: A single centre retrospective cohort study	PLOS ONE			English	Article								Background Peru is the country with the world's highest COVID-19 death rate per capita. Characteristics associated with increased mortality among adult patients with COVID-19 pneumonia in this setting are not well described. Methods Retrospective, single-center cohort study including 1537 adult patients hospitalized with a diagnosis of SARS-CoV-2 pneumonia between May 2020 and August 2020 at a national hospital in Lima, Peru. The primary outcome measure was in-hospital mortality. Results In-hospital mortality was 49.71%. The mean age was 60 +/- 14.25 years, and 68.38% were males. We found an association between mortality and inflammatory markers, mainly leukocytes, D-dimer, lactate dehydrogenase, C-reactive protein and ferritin. A multivariate model adjusted for age, hypertension, diabetes mellitus, and corticosteroid use demonstrated that in-hospital mortality was associated with greater age (RR: 2.01, 95%CI: 1.59-2.52) and a higher level of oxygen requirement (RR: 2.77, 95%CI: 2.13-3.62). Conclusions: In-hospital mortality among COVID-19 patients in Peru is high and is associated with greater age and higher oxygen requirements.	[Mas-Ubillus, Guiliana; Ortiz, Pedro J.; Huaringa-Marcelo, Jorge; Sarzo-Miranda, Paola; Munoz-Aguirre, Patricia; Diaz-Ramos, Alejandra; Arribasplata-Purizaca, Kattia; Mendoza, Doris; Rojas-Poma, Juan; Marcelo-Ruiz, Cristian; Ayala-Diaz, Pedro; Hidalgo-Arroyo, Edwin; Tupia-Cespedes, Lourdes] Hosp Nacl Arzobispo Loayza, Dept Emergency, Lima, Peru; [Mas-Ubillus, Guiliana; Ortiz, Pedro J.; Munoz-Aguirre, Patricia; Diaz-Ramos, Alejandra; Ayala-Diaz, Pedro; Hidalgo-Arroyo, Edwin; Tupia-Cespedes, Lourdes] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru; [Huaringa-Marcelo, Jorge] Univ Cient Sur Carr, Fac Med, Lima, Peru	Universidad Peruana Cayetano Heredia	Ortiz, PJ (corresponding author), Hosp Nacl Arzobispo Loayza, Dept Emergency, Lima, Peru.; Ortiz, PJ (corresponding author), Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru.	pedro.ortiz@upch.pe	Mendoza, Doris/HHT-0772-2022	Ayala Diaz, Pedro/0000-0002-9108-0901; Ortiz, Pedro J/0000-0001-8071-8650				Abate SM, 2021, ANN MED SURG, V64, DOI 10.1016/j.amsu.2021.102204; Agencia Peruana de Noticias, 2021, HLTH MIN PER IS PREP; [Anonymous], 2021, COVID 19 DASHBOARD C; [Anonymous], 2021, MINISTERIO SALUD; [Anonymous], 2021, HOSP NACL ARZOBISPO; Baskaran V, 2021, J MED MICROBIOL, V70, DOI 10.1099/jmm.0.001350; Bellan M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77698-4; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Brown SM, 2016, CHEST, V150, P307, DOI 10.1016/j.chest.2016.01.003; Chatterjee NA, 2021, INFLUENZA OTHER RESP, V15, P569, DOI 10.1111/irv.12869; Chaudhary AH, 2021, INT J CONSUM STUD, V45, P478, DOI 10.1111/ijcs.12638; Chedid M, 2021, J INFECT PUBLIC HEAL, V14, P570, DOI 10.1016/j.jiph.2021.02.001; Chemical and Engineering News (CEN), 2020, DEV COUNTR FAC DIAGN; Chong WH, 2021, INFECTION, V49, P591, DOI 10.1007/s15010-021-01602-z; Chua F, 2021, THORAX, V76, P696, DOI 10.1136/thoraxjnl-2020-216425; Fabre V, 2022, INFECT CONT HOSP EP, V43, P570, DOI 10.1017/ice.2021.175; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; FOPH, 2020, SCARC MED OX WORLDW, P2020; Quispe-Canari JF, 2021, SAUDI PHARM J, V29, P1, DOI 10.1016/j.jsps.2020.12.001; Garcia PJ, 2019, LANCET, V394, P2119, DOI 10.1016/S0140-6736(19)32527-9; Gras M, 2021, ANN PHARM FR, V79, P522, DOI 10.1016/j.pharma.2021.02.003; Gue YX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78505-w; HelpPeru, 2021, OX CRIS PER; Herrera-Anazco P, 2021, INT J HEALTH PLAN M, V36, P995, DOI 10.1002/hpm.3135; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Instituto de Evaluacion de Tecnologias en Salud e Investigacion, 2021, GUIA PRACT CLIN MAN; Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414; Kamran SM, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.11368; Khan MMA, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020503; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Lopez-Pais J, 2021, PREV MED REP, V21, DOI 10.1016/j.pmedr.2020.101298; Martinez-Valle A, 2021, J PUBLIC HEALTH POL, V42, P27, DOI 10.1057/s41271-020-00269-4; Mejia F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244171; Miller MJ, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008265; Ministerio de Salud, 2021, US; Ministerio de Salud. Lima-Peru. MINSA, 2020, DOC TECN MAN AMB PER; Montenegro-Idrogo Juan José, 2020, Rev. perú. med. exp. salud publica, V37, P781, DOI 10.17843/rpmesp.2020.374.5786; National Health Commission of the People's Republic of China, 2021, UPD NOV COR PNEUM OU; Noor FM, 2020, J COMMUN HEALTH, V45, P1270, DOI 10.1007/s10900-020-00920-x; opencovid, 2021, OPEN COVID PERU; Melo JRR, 2021, CAD SAUDE PUBLICA, V37, DOI [10.1590/0102-311X00053221, 10.1590/0102-311x00053221]; Rees GH, 2021, INT J HEALTH PLAN M, V36, P190, DOI 10.1002/hpm.3127; Rocha R, 2021, LANCET GLOB HEALTH, V9, pE782, DOI 10.1016/S2214-109X(21)00081-4; Ryu S, 2021, J INFECT DIS, V224, P949, DOI [10.1093/infdis/jiab708, 10.1093/infdis/jiab208]; Sanz F, 2015, RESPIROLOGY, V20, P813, DOI 10.1111/resp.12560; Schwalb A, 2021, AM J TROP MED HYG, V104, P1176, DOI 10.4269/ajtmh.20-1323; Staub MB, 2021, INFECT CONT HOSP EP, V42, P810, DOI 10.1017/ice.2020.1291; Tandon T, 2021, J EDUC HEALTH PROMOT, V10, DOI 10.4103/jehp.jehp_481_20; Taylor L, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n611; Vidal-Anzardo Margot, 2020, Rev. perú. med. exp. salud publica, V37, P203, DOI 10.17843/rpmesp.2020.372.5534; Videnza Consultores, 2021, PER HLTH SYST, DOI [10.6084/m9.figshare.14977839.v1, DOI 10.6084/M9.FIGSHARE.14977839.V1]; World Health Organization, 2021, PUBL HLTH EM INT CON; Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016; Zhang AR, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10030232	54	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2022	17	3							e0265089	10.1371/journal.pone.0265089	http://dx.doi.org/10.1371/journal.pone.0265089			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0II	35259196	gold, Green Published			2023-01-03	WOS:000835141200044
J	Jacka, MJ				Jacka, Michael J.			In COVID-19 with hypoxemia, 12 vs. 6 mg/d of dexamethasone did not increase days alive without life support	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Jacka, Michael J.] Univ Alberta, Edmonton, AB, Canada	University of Alberta	Jacka, MJ (corresponding author), Univ Alberta, Edmonton, AB, Canada.							Granholm A, 2022, INTENS CARE MED, V48, P45, DOI 10.1007/s00134-021-06573-1; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2022	175	3					JC33	JC33		10.7326/J22-0001	http://dx.doi.org/10.7326/J22-0001		MAR 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0O5UF	35226531				2023-01-03	WOS:000767339200001
J	Hammond, J; Leister-Tebbe, H; Gardner, A; Abreu, P; Bao, WH; Wisemandle, W; Baniecki, M; Hendrick, VM; Damle, B; Simon-Campos, A; Pypstra, R; Rusnak, JM				Hammond, Jennifer; Leister-Tebbe, Heidi; Gardner, Annie; Abreu, Paula; Bao, Weihang; Wisemandle, Wayne; Baniecki, MaryLynn; Hendrick, Victoria M.; Damle, Bharat; Simon-Campos, Abraham; Pypstra, Rienk; Rusnak, James M.		EPIC-HR Investigators	Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DESIGN; SARS	BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M-pro) inhibitor with potent pan-human-coronavirus activity in vitro. METHODS We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTS A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmaltrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log(10) copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONS Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.)	[Hammond, Jennifer; Leister-Tebbe, Heidi] Pfizer, 500 Arcola Rd, Collegeville, PA 19426 USA; [Gardner, Annie] Pfizer, Global Prod Dev, Cambridge, MA USA; [Baniecki, MaryLynn] Pfizer, Early Clin Dev, Cambridge, MA USA; [Abreu, Paula; Bao, Weihang; Damle, Bharat; Pypstra, Rienk] Pfizer, Global Prod Dev, New York, NY USA; [Wisemandle, Wayne] Pfizer, Global Prod Dev, Lake Forest, IL USA; [Hendrick, Victoria M.] Pfizer, Med & Safety, Sandwich, Kent, England; [Simon-Campos, Abraham] Kohler & Milstein Res, Merida, Yucatan, Mexico; [Rusnak, James M.] Pfizer, Global Prod Dev, Tampa, FL USA	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Hammond, J (corresponding author), Pfizer, 500 Arcola Rd, Collegeville, PA 19426 USA.	jennifer.hammond@pfizer.com	Del Carpio-Orantes, Luis/H-6745-2017; yavuz, serap şimşek/AAE-2131-2020	Del Carpio-Orantes, Luis/0000-0003-2436-5744; yavuz, serap şimşek/0000-0002-4675-169X; SIMON CAMPOS, JESUS ABRAHAM/0000-0001-9630-7792	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.; We thank all the patients who volunteered for this trial, the study site personnel for their contributions, and the members of the C4671005 external data monitoring committee for their dedication and their diligent review of the data. We also thank the following colleagues at Pfizer: Charlotte Allerton, Mohanish Anand, Annaliesa Anderson, Jeremias Antinew, Daniel Arenson, Edmund Arthur, Ayman Ayoub, Karen Baker, Elizabeth Bateman, Arthur Bergman, Mary Boylon-Bost, Kevin Brown, Carol Buck, Marjorie Buonanno, Paul Butler, Victoria Butler, Regina Calderon, Anna Maria Calella, Rhonda Cardin, Kristopher Chrisman, Ellen Chung Yi, Carol Connell, Tamara Costopoulos, Darren Cowan, Donna Cox, Amit Dagar, Bernita Davies, Gabriela Davila, Caridad Del Castillo-Castaneda, Gretchen Dean, Mikael Dolsten, Elizabeth Dushin, Martin Eck, Susannah Fitzgerald, Michael T. Gaffney, Ramakanth GSH, Eileen Mary Girten, Marie-Pierre Hellio Le Graverand-Gastineau, Jim Huang, Ileana Ionita, Farhad Kazazi, David Keller, Kelly Kincaid, Charles Knirsch, Stephen Langman, Catherine Lee, Joep Lelieveld, Cathy Q. Li, Katherine Liau, Carlos Linn, Marianne Lorenzen, Rod MacKenzie, Kannan Natarajan, Demetris Neophytou Zambas, Seleen Ong, Russ Orrico, Dafydd Owen, Seema Pai, Shyam Parvatini, Claire Penick, Jay Purdy, Amanda Radola, Kathleen Reilly Thompson, Amy Robey, Liz Rodgers, Glenda Rojas, Eve Rowe, Jean Satish, Cara Sclafani, Namita Singh, Ravi Shankar Singh, Phylinda Chan, Kawleen Singh Oberoi, Karen Singletary, Lisa Skeens, Patricia Smith, Holly Soares, Karan Somasundar, Anna Spolnik, Craig Stevenson, Kathleen Szymczak, Margaret Tawadrous, Manjit Toor, Arianna Trevisiol, Sarah Tweedy, Sophie Van De Leest, Jia Yi Liang, and all the colleagues not named here who contributed to the success of this trial. We thank Judith Kandel, Ph.D., Sheena Hunt, Ph.D., and Tricia Newell, Ph.D. of ICON, who wrote the first draft of the manuscript under direction from the authors, with funding from	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Center for Systems Science and Engineering at Johns Hopkins University, COVID 19 DASHB; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Guthold R, 2020, LANCET CHILD ADOLESC, V4, P23, DOI 10.1016/S2352-4642(19)30323-2; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936; Kim L, 2021, CLIN INFECT DIS, V72, pE206, DOI 10.1093/cid/ciaa1012; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n158; Merck, 2021, MERCK RIDG BIOTH ANN; Merck, 2021, PFIZ PROV US GOV 10; National Institutes of Health, COR DIS 2019 COVID 1; Ning L, 2020, AM J TRANSPLANT, V20, P1864, DOI 10.1111/ajt.15897; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OShaughnessy, 2021, REEMERGENCY USE AUTH; Owen DR, 2021, SCIENCE, V374, P1586, DOI 10.1126/science.abl4784; Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010; Sevrioukova IF, 2010, P NATL ACAD SCI USA, V107, P18422, DOI 10.1073/pnas.1010693107; Thakur B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88130-w; United Nations, 2017, WORLD POP AG; US Food and Drug Administration, 2021, FDA HOLD ADV COMM M; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; WHO, 2021, MALNUTRITION 0609; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	28	274	277	65	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	2022	386	15					1397	1408		10.1056/NEJMoa2118542	http://dx.doi.org/10.1056/NEJMoa2118542		FEB 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1K8EP	35172054	Bronze, Green Published			2023-01-03	WOS:000755954300001
J	Hamzeh, H; Spencer, S; Kelly, C				Hamzeh, Hayat; Spencer, Sally; Kelly, Carol			Development of a core outcome set and outcome measurement set for physiotherapy trials in adults with Bronchiectasis (COS-PHyBE study): A protocol	PLOS ONE			English	Article							CYSTIC FIBROSIS BRONCHIECTASIS; MORTALITY; UK	Background Bronchiectasis is a chronic respiratory disease characterised by airways widening and recurrent infections, resulting in episodes of chronic cough, sputum expectoration, and dyspnoea. This leads to deterioration in daily function, repeated hospital admissions and poor quality of life. The prevalence and mortality related to bronchiectasis is increasing worldwide with growing economic burden on healthcare systems. Physiotherapy for bronchiectasis aims to decrease accumulation of sputum, dyspnoea, and improve exercise capacity and daily function. A robust evidence base to support physiotherapy in bronchiectasis is currently lacking. This is partly because of inconsistency and poor reporting of outcomes in available studies. A core outcome set is the minimum acceptable group of outcomes that should be used in clinical trials for a specific condition. This decreases research waste by improving consistency and reporting of key outcomes and facilitates the synthesis of study outcomes in systematic reviews and guidelines. The aim of the study is therefore to develop a core outcome set and outcome measurement set for physiotherapy research in adults with bronchiectasis. This will ensure outcomes important to key stakeholders are consistently used and reported in future research. Methods and analysis This project will use the COMET Initiative and COSMIN guidelines of core outcome set development and will include three phases. In the first phase, a comprehensive list of outcomes will be developed using systematic review of reported outcomes and qualitative interviews with patients and physiotherapists. Then consensus on key outcomes will be established in phase two using a Delphi survey and a consensus meeting. Finally, in phase three, we will identify appropriate instruments to measure the core outcomes by evaluating the psychometric properties of available instruments and a stakeholders' meeting to establish consensus.	[Hamzeh, Hayat; Spencer, Sally; Kelly, Carol] Edge Hill Univ, Fac Hlth Social Care & Med, Ormskirk, England; [Spencer, Sally; Kelly, Carol] Edge Hill Univ, Resp Res Ctr, Ormskirk, Lancs, England; [Spencer, Sally] Edge Hill Univ, Hlth Res Inst, Ormskirk, Lancs, England	Edge Hill University; Edge Hill University; Edge Hill University	Hamzeh, H (corresponding author), Edge Hill Univ, Fac Hlth Social Care & Med, Ormskirk, England.	hamzehh@edgehill.ac.uk	Hamzeh, Hayat/U-3249-2019	Hamzeh, Hayat/0000-0002-1074-2599; Kelly, Carol/0000-0002-9927-1382	Edge Hill University	Edge Hill University	HH has a Graduate Teaching Assistant studentship from Edge Hill University for this doctoral research. https://www.edgehill.ac.uk/The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliberti S, 2016, EUR RESPIR J, V48, P632, DOI 10.1183/13993003.01888-2015; Aliberti S, 2016, EUR RESPIR J, V47, P1113, DOI 10.1183/13993003.01899-2015; Blanchette Christopher M, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040020; Bott J, 2009, THORAX, V64, P1, DOI 10.1136/thx.2008.110726; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chandrasekaran R, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0638-0; Diel R, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02033-2018; Dodd S, 2018, J CLIN EPIDEMIOL, V96, P84, DOI 10.1016/j.jclinepi.2017.12.020; Dudgeon EK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0631-7; Gargon E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0209869, 10.1371/journal.pone.0225980]; Goeminne PC, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0818-6; Hill AT, 2019, THORAX, V74, P1, DOI 10.1136/thoraxjnl-2018-212463; Hill AT., 2018, BRIT THORACIC SOC RE, V9; Hsu C, 2007, RES EVALUAT, V12, P10, DOI [10.7275/pdz9-th90, DOI 10.7275/PDZ9-TH90]; Kelly C, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012528.pub2; Kirkham JJ, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3230-x; Kirkham JJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002447; Lee AL, 2017, ARCH PHYS MED REHAB, V98, P774, DOI 10.1016/j.apmr.2016.05.017; Lee AL, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008351.pub3; Lee AL, 2015, CHRON RESP DIS, V12, P36, DOI 10.1177/1479972314562407; McDonnell MJ, 2016, LANCET RESP MED, V4, P969, DOI 10.1016/S2213-2600(16)30320-4; O'Neill B, 2002, INT J CLIN PRACT, V56, P34; Pasteur MC, 2010, THORAX, V65, pI1, DOI 10.1136/thx.2010.136119; Phillips Jennifer, 2021, Arch Physiother, V11, P3, DOI 10.1186/s40945-020-00097-5; Phillips J, 2020, PHYSIOTHER THEOR PR, V36, P1300, DOI 10.1080/09593985.2019.1579286; Prinsen CAC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1555-2; QSR International Pty L, 2020, NVIVO RELEASED MARCH; Quint JK, 2016, EUR RESPIR J, V47, P186, DOI 10.1183/13993003.01033-2015; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Sinha IP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000393; Spargo M, 2018, CHRON RESP DIS, V16, DOI 10.1177/1479972318804167; Spinou A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01610-2019; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; VANDEVEN AH, 1972, AM J PUBLIC HEALTH N, V62, P337, DOI 10.2105/AJPH.62.3.337; Welsh EJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010337.pub2; Williamson PR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1978-4; Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0263695	10.1371/journal.pone.0263695	http://dx.doi.org/10.1371/journal.pone.0263695			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134099	gold, Green Published			2023-01-03	WOS:000798968600026
J	Wartelle, A; Mourad-Chehade, F; Yalaoui, F; Questiaux, H; Monneret, T; Soliveau, G; Chrusciel, J; Duclos, A; Laplanche, D; Sanchez, S				Wartelle, Adrien; Mourad-Chehade, Farah; Yalaoui, Farouk; Questiaux, Helene; Monneret, Thomas; Soliveau, Ghislain; Chrusciel, Jan; Duclos, Antoine; Laplanche, David; Sanchez, Stephane			Multimorbidity clustering of the emergency department patient flow: Impact analysis of new unscheduled care clinics	PLOS ONE			English	Article							MEDICAID ENROLLEES; CONVENIENT CARE; ACCESS; CLASSIFICATION; VISITS; USERS	Background In France, the number of emergency department (ED) admissions doubled between 1996 and 2016. To cope with the resulting crowding situation, redirecting patients to new healthcare services was considered a viable solution which would spread demand more evenly across available healthcare delivery points and render care more efficient. The objective of this study was to analyze the impact of opening new on-demand care services based on variations in patient flow at a large hospital emergency department. Methods We performed a before-and-after study investigating the use of unscheduled care services in the Aube region in eastern France, that focused on ED attendance at Troyes Hospital. A hierarchical clustering based on co-occurrence of diagnoses was applied which divided the population into different multimorbidity profiles. Temporal trends of the resultant clusters were also studied empirically and using regression models. A multivariate logistic regression model was constructed to adjust the periodic effect for appropriate confounders and therefore confirm its presence. Results In total, 120,722 visits to the ED were recorded over a 24-month period (2018-2019) and 16 clusters were identified, accounting for 94.76% of all visits. There was a decrease of 56.77 visits per week in seven specific clusters and an increase of use of unscheduled health care services by 328.12 visits per week. Conclusions Using an innovative and reliable methodology to evaluate changes in patient flow through the ED, these findings may help inform public health policy experts on the implementation of unscheduled care services to ease pressure on hospital EDs.	[Wartelle, Adrien; Mourad-Chehade, Farah; Yalaoui, Farouk] Univ Technol Troyes, Comp Sci & Digital Soc Lab LIST3N, Troyes, France; [Wartelle, Adrien; Chrusciel, Jan; Laplanche, David; Sanchez, Stephane] Ctr Hosp Troyes, Publ Hlth & Performance Dept, Troyes, France; [Questiaux, Helene] Ctr Hosp Troyes, Emergency Dept, Troyes, France; [Monneret, Thomas; Soliveau, Ghislain] Etab Aubois Soins Immediats, Troyes, France; [Duclos, Antoine] Univ Claude Bernard Lyon 1, Res Healthcare Performance Lab, INSERM U1290 RESHAPE, Villeurbanne, France; [Duclos, Antoine] Hosp Civils Lyon, Hlth Data Dept, Lyon, France; [Sanchez, Stephane] Univ Reims, Res Hlth Univ Dept, Reims, France	Universite de Technologie de Troyes; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Universite de Reims Champagne-Ardenne	Wartelle, A (corresponding author), Univ Technol Troyes, Comp Sci & Digital Soc Lab LIST3N, Troyes, France.; Wartelle, A; Sanchez, S (corresponding author), Ctr Hosp Troyes, Publ Hlth & Performance Dept, Troyes, France.; Sanchez, S (corresponding author), Univ Reims, Res Hlth Univ Dept, Reims, France.	adrien.wartelle@ch-troyes.fr; stephane.sanchez@hcs-sante.fr	Sanchez, Stephane/ABD-3014-2020	Sanchez, Stephane/0000-0002-0925-6948; Wartelle, Adrien/0000-0003-1471-0866	French Regional Health Agency	French Regional Health Agency	Our institution received an exceptional funding of 3000 euros for this study from the French Regional Health Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No authors received salaries from the French Regional Health Agency.	Ablard S, 2017, EMERG MED J, V34, P672, DOI 10.1136/emermed-2016-206539; Afilal M, 2016, IFAC PAPERSONLINE, V49, P721, DOI 10.1016/j.ifacol.2016.07.859; Afilal M, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0527-0; Ahmadi-Javid A, 2020, OPER RES HEALTH CARE, V24, DOI 10.1016/j.orhc.2019.100226; [Anonymous], 2015, CHIFFR CLS; Baum Z, 2016, PEERJ, V4, DOI 10.7717/peerj.1544; Bertrand M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; Bozdogan H, 2000, J MATH PSYCHOL, V44, P62, DOI 10.1006/jmps.1999.1277; Capp R, 2016, ACAD EMERG MED, V23, P476, DOI 10.1111/acem.12952; Capp R, 2015, MED CARE, V53, P530, DOI 10.1097/MLR.0000000000000364; Chauvin A., 2016, MEDITERRANEAN J EMER, P5; Chrusciel J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026200; de la Fuente DO, 2007, EUR J PUBLIC HEALTH, V17, P186, DOI 10.1093/eurpub/ckl085; DeVries A, 2013, MED CARE, V51, P224, DOI 10.1097/MLR.0b013e3182726b83; DREES. France. Ministre du travail de lemploi et de la sant., 2017, DIR RECH TUD LVAL ST, V2017; Durand Anne-Claire, 2012, BMC Res Notes, V5, P525, DOI 10.1186/1756-0500-5-525; EVERITT B, 1980, QUAL QUANT, V14, P75, DOI 10.1007/BF00154794; Gandhi SO, 2014, AM J MANAG CARE, V20, P315; Gay B., 2019, M DECINE, V15, P34, DOI [10.1684/med.2019.401, DOI 10.1684/MED.2019.401]; Granger B., 2019, DEBAT, DOI [10.3917/deba.203.0098, DOI 10.3917/DEBA.203.0098]; Han JH, 2007, ACAD EMERG MED, V14, P338, DOI 10.1197/j.aem.2006.12.005; Hansen-Turton T, 2007, DIS MANAGE, V10, P61, DOI 10.1089/dis.2006.636; Hefner JL, 2015, AM J MED QUAL, V30, P135, DOI 10.1177/1062860614521278; Hsia RY, 2017, INT J QUAL HEALTH C, V29, P642, DOI 10.1093/intqhc/mzx081; Imbens GW, 2008, J ECONOMETRICS, V142, P615, DOI 10.1016/j.jeconom.2007.05.001; Jarvis PRE, 2016, CLIN EXP EMERG MED, V3, P63, DOI 10.15441/ceem.16.127; Jones D, 2011, J PRIM CARE COMMUNIT, V2, P250, DOI 10.1177/2150131911408431; Khanolkar AR, 2019, EUR J PUBLIC HEALTH, V29; LaCalle E, 2010, ANN EMERG MED, V56, P42, DOI 10.1016/j.annemergmed.2010.01.032; Leporatti L, 2016, HEALTH POLICY, V120, P462, DOI 10.1016/j.healthpol.2016.03.005; Moe Jessica, 2019, Healthc Q, V22, P42, DOI 10.12927/hcq.2019.25837; Morley C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203316; Naouri D, 2020, BMJ QUAL SAF, V29, P449, DOI 10.1136/bmjqs-2019-009396; Naouri D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198474; Parchman ML., 2007, APPL MULTIVAR RES, V12, P163, DOI [10.22329/amr.v12i3.658, DOI 10.22329/AMR.V12I3.658]; Patel PB., 2018, AM J MANAG CARE; Patwardhan A, 2012, J PRIM CARE COMMUNIT, V3, P243, DOI 10.1177/2150131911436251; Petrou P, 2019, PUBLIC HEALTH, V169, P50, DOI 10.1016/j.puhe.2018.12.014; Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021; Raven MC, 2016, ANN EMERG MED, V68, P467, DOI 10.1016/j.annemergmed.2016.04.015; Salway R.J., 2017, REV MED CLIN CONDES, V28, P213, DOI [10.1016/J.RMCLC.2017.04.008, DOI 10.1016/J.RMCLC.2017.04.008, 10.1016/j.rmclc.2017.04.008]; Scailteux LM, 2019, THERAPIE, V74, P215, DOI 10.1016/j.therap.2018.09.072; Schafer I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015941; Soler G, 2018, IEEE INT CON AUTO SC, P365, DOI 10.1109/COASE.2018.8560585; Tangianu F, 2018, ITAL J MED, V12, P137, DOI 10.4081/itjm.2018.940; Thakkar AB, 2019, FAM MED, V51, P420, DOI 10.22454/FamMed.2019.477798; Travers DA, 2003, ACAD EMERG MED, V10, P1337, DOI 10.1197/S1069-6563(03)00536-0; Vetrano DL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16780-x; Violan C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029594; Violan C, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0790-x; Wartelle A, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11052373; Whitt W, 2017, OPER RES HEALTH CARE, V12, P1, DOI 10.1016/j.orhc.2016.11.001	53	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2022	17	1							e0262914	10.1371/journal.pone.0262914	http://dx.doi.org/10.1371/journal.pone.0262914			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P3UI	35100301	Green Published, Green Submitted, gold			2023-01-03	WOS:000801937600025
J	Rodriguez-Hernandez, AJ; Sevcik, C				Javier Rodriguez-Hernandez, Antonio; Sevcik, Carlos			Hidden chaos factors inducing random walks which reduce hospital operative efficiency	PLOS ONE			English	Article							VENOM COMPLEXITY; SCORPION-VENOM; DIMENSION; ALGORITHM; ENTROPY; STORM	Operative parameters of La Fuenfria Hospital such as: hospitalized patients; daily admissions and discharges were studies for the hospital as a whole, and for each hospital's service unit (henceforth called 'services'). Conventional statistical analyzes and fractal dimension analyzes were performed on daily In-Patient series. The sequence of daily admissions and patients staying on each service were found to be a kind of random series known as random walks (Rw), sequences where what happens next, depends on what happens now plus a random variable. Rw analyzed with parametric or nonparametric statistics may simulate cycles and drifts which resemble seasonal variations or fake trends which reduce the Hospital's efficiency. Globally, inpatients Rw s in LFH, were found to be determined by the time elapsed between daily discharges and admissions. The factors determining LFH R were found to be the difference between daily admissions and discharges. The discharges are replaced by admissions with some random delay and the random difference determines LFH Rw s. These findings show that if the daily difference between admissions and discharges is minimized, the number of inpatients would fluctuate less and the number of unoccupied beds would be reduced, thus optimizing the Hospital service.	[Javier Rodriguez-Hernandez, Antonio] Hosp Fuenfria, Madrid, Spain; [Sevcik, Carlos] Inst Venezolano Invest Cient, Ctr Biofis & Bioquim, Caracas, Venezuela; [Sevcik, Carlos] SciMeDAn, Barcelona, Spain	Venezuelan Institute Science Research	Sevcik, C (corresponding author), Inst Venezolano Invest Cient, Ctr Biofis & Bioquim, Caracas, Venezuela.; Sevcik, C (corresponding author), SciMeDAn, Barcelona, Spain.	carlos.sevcik.s@gmail.com		Sevcik, Carlos/0000-0003-3783-6541	Hospital La Fuenfria, Servicio Madrileno de Salud (SERMAS), Comunidad Autonoma de Madrid, Madrid, Spain	Hospital La Fuenfria, Servicio Madrileno de Salud (SERMAS), Comunidad Autonoma de Madrid, Madrid, Spain	All funds were provided by Hospital La Fuenfria, Servicio Madrileno de Salud (SERMAS), Comunidad Autonoma de Madrid, Madrid, Spain.	Adams S, 2019, ANN ONCOL, V30, P397, DOI 10.1093/annonc/mdy517; [Anonymous], HDB EUR DAT PROT LAW, V20108th, P218; Bak P, 1995, FRACTAL DYNAMICS EAR; BARNETT VD, 1966, J AM STAT ASSOC, V61, P1205, DOI 10.2307/2283210; Barnsley MF., 1993, FRACTALS EVERYWHERE; Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z; Bera AK, 1981, EFFICIENT LARGE SAMP; Besicovitch AS, 1929, MATH ANN, V101, P161, DOI 10.1007/BF01454831; Bharucha-Reid A. T, 1960, ELEMENTS THEORY MARK; Bhattacharya P, 2009, FRACTAL MODELS EARTH; BLACKMAN RB, 1958, AT&T TECH J, V37, P185, DOI 10.1002/j.1538-7305.1958.tb03874.x; BOX GEP, 1958, ANN MATH STAT, V29, P610, DOI 10.1214/aoms/1177706645; Brown R., 1829, PHILOS MAG, V6, P161, DOI [DOI 10.1080/14786442908675115, 10.1080/14786442908675115]; Brown R, 1828, PHILOS MAG, V4, P161, DOI [10.1080/14786442808674769, DOI 10.1080/14786442808674769]; BURT Stephen D., 1988, WEATHER, V43, P90, DOI [10.1002/j.1477-8696.1988.tb03885.x, DOI 10.1002/J.1477-8696.1988.TB03885.X]; Chebyshev P.L., 1867, J MATH PURE APPL, V12, P177; COOLEY JW, 1965, MATH COMPUT, V19, P297, DOI 10.2307/2003354; Cramer H., 1991, MATH METHODS STAT, V18th; D'Suze G, 2015, TOXICON, V108, P62, DOI 10.1016/j.toxicon.2015.09.034; D'Suze G, 2010, J THEOR BIOL, V267, P405, DOI 10.1016/j.jtbi.2010.09.009; Dahlquist G., 1974, NUMERICAL METHODS; Deming WE., 2018, OUT CRISIS; Diao XY, 2017, ALGORITHMS, V10, DOI 10.3390/a10030096; Dunne J, 2013, STORM HITS HOME 1987; FAMA EF, 1968, J AM STAT ASSOC, V63, P817, DOI 10.2307/2283875; Fisher RA., 1954, STAT METHODS RES WOR, V12th ed; Gel YR, 2008, ECON LETT, V99, P30, DOI 10.1016/j.econlet.2007.05.022; GRASSBERGER P, 1983, PHYS REV A, V28, P2591, DOI 10.1103/PhysRevA.28.2591; Guttman I., 1971, INTRO ENG STAT; HARRIS FJ, 1978, P IEEE, V66, P51, DOI 10.1109/PROC.1978.10837; Hasselman F, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00075; Hastings HH., 1993, USERS GUIDE NATURAL; Hausdorff F, 1919, MATH ANN, V79, P157; Hojat M, 2004, ADV HEALTH SCI EDUC, V9, P241, DOI 10.1023/B:AHSE.0000038173.00909.f6; Hollander M., 1973, NONPARAMETRIC STAT M, V1st; International Diabetes Federation, 2019, IDF DIABETES ATLAS, V9th ed; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536; JARRAUD M, 1989, WEATHER FORECAST, V4, P517, DOI 10.1175/1520-0434(1989)004<0517:POAESO>2.0.CO;2; Kolmogorov A., 1933, G I ITAL ATTUARI, V4, P83; Kolodziej M, 2020, 21 INT C COMP PROBL, P1; Lohninger H, 2012, FUNDAMENTALS STAT; LORENC AC, 1988, METEOROL MAG, V117, P118; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; Macrotrends, 2019, CRUD OIL PRIC 70 YEA; MANDELBROT B, 1967, SCIENCE, V156, P636, DOI 10.1126/science.156.3775.636; MANDELBROT B, 1963, J BUS, V36, P394, DOI 10.1086/294632; Mandelbrot B.B., 1983, AM J PHYS, DOI 10.1119/1.13295; Mathers CD, 2015, LANCET, V385, P540, DOI 10.1016/S0140-6736(14)60569-9; Matsumoto M., 1998, ACM Transactions on Modeling and Computer Simulation, V8, P3, DOI 10.1145/272991.272995; Matsumoto M, 2000, MONTE CARLO AND QUASI-MONTE CARLO METHODS 1998, P56; MELTZER MI, 1991, PREV VET MED, V11, P255, DOI 10.1016/S0167-5877(05)80011-X; Metropolis N, 1987, LOS ALARNOS SCI SPEC, P125; Mitchel C., 2020, INVESTORPEDIA; Mood AM, 1940, ANN MATH STAT, V11, P367, DOI 10.1214/aoms/1177731825; Nepiklonov VB., 2020, GEODES PHOTO SYS, V64, P380, DOI [10.30533/0536-101X-2020-64-4-380-390, DOI 10.30533/0536-101X-2020-64-4-380-390]; Norman GR., 1989, PDQ STAT, V1; Petunin DFVYI, 1980, THEOR PROBAB MATH ST, V21, P25; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Pincus SM, 2001, ANN NY ACAD SCI, V954, P245; Pitman J., 1993, SPRINGER TEXTS STAT, V1st; Rodriguez-Hernandez J, 2017, THESIS U POMPEU FABR; Rosenblatt M, 1974, GRADUATE TEXT MATH; Ross SM., 1996, STOCHASTIC PROCESSES; ROTHENBERG TJ, 1964, J AM STAT ASSOC, V59, P460, DOI 10.2307/2282999; Sevcik C., 1998, COMPLEX INT, V5, P1; Sevcik C, 2018, EXP MATH, V27, P331, DOI 10.1080/10586458.2017.1279092; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Sharma N., 2013, INT J COMP SCI TECH, V4, P52; Shi CT, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8081327; Smirnoff N., 1939, B MOSCOW U, P3; SMIRNOV N, 1948, ANN MATH STAT, V19, P279, DOI 10.1214/aoms/1177730256; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Streiner DL, 2012, CHEST, V141, P595, DOI 10.1378/chest.11-2473; Telesca L, 2005, PHYSICA A, V354, P629, DOI 10.1016/j.physa.2005.02.053; Theil H., 1950, PROC K NED AKAD WEIN, V53, P1397; Theil H., 1992, HENRI THEILS CONTRIB, P345, DOI [DOI 10.1007/978-94-011-2546-8_20, DOI 10.1007/978-94-011-2546-820]; Theil H, 1950, P KON NED AKDA WETEN, V53, P1897; Vysochansky DF., 1979, THEOR PROBAB MATH ST, V21, P23; Vysochansky DF, 1983, THEOR PROBAB MATH ST, V27, P27; Walck C., 1996, SUFPFY9601 U STOCKH; Wald A, 1940, ANN MATH STAT, V11, P147, DOI 10.1214/aoms/1177731909; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wilks SS., 1962, MATH STAT; Wolfram S., 2003, MATH BOOK, V5th ed; World population review, 2019, HAW POP 2019 DEM MAP; Xue R, 2020, INFORMATION, V11, DOI 10.3390/info11110520	89	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262815	10.1371/journal.pone.0262815	http://dx.doi.org/10.1371/journal.pone.0262815			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085317	gold, Green Submitted, Green Published			2023-01-03	WOS:000779379600085
J	Verweij, L; Petri, ACM; MacNeil-Vroomen, JL; Jepma, P; Latour, CHM; Peters, RJG; Reimer, WJMSO; Buurman, BM; Bosmans, JE				Verweij, Lotte; Petri, Adrianne C. M.; MacNeil-Vroomen, Janet L.; Jepma, Patricia; Latour, Corine H. M.; Peters, Ron J. G.; Reimer, Wilma J. M. Scholte Op; Buurman, Bianca M.; Bosmans, Judith E.			The Cardiac Care Bridge transitional care program for the management of older high-risk cardiac patients: An economic evaluation alongside a randomized controlled trial	PLOS ONE			English	Article							HEART-FAILURE; COST-EFFECTIVENESS; INTERVENTIONS; READMISSIONS; OUTCOMES	Objective To evaluate the cost-effectiveness of the Cardiac Care Bridge (CCB) nurse-led transitional care program in older (>= 70 years) cardiac patients compared to usual care. Methods The intervention group (n = 153) received the CCB program consisting of case management, disease management and home-based cardiac rehabilitation in the transition from hospital to home on top of usual care and was compared with the usual care group (n = 153). Outcomes included a composite measure of first all-cause unplanned hospital readmission or mortality, Quality Adjusted Life Years (QALYs) and societal costs within six months follow-up. Missing data were imputed using multiple imputation. Statistical uncertainty surrounding Incremental Cost-Effectiveness Ratios (ICERs) was estimated by using bootstrapped seemingly unrelated regression. Results No significant between group differences in the composite outcome of readmission or mortality nor in societal costs were observed. QALYs were statistically significantly lower in the intervention group, mean difference -0.03 (95% CI: -0.07; -0.02). Cost-effectiveness acceptability curves showed that the maximum probability of the intervention being cost-effective was 0.31 at a Willingness To Pay (WTP) of Euro0,00 and 0.14 at a WTP of Euro50,000 per composite outcome prevented and 0.32 and 0.21, respectively per QALY gained. Conclusion The CCB program was on average more expensive and less effective compared to usual care, indicating that the CCB program is dominated by usual care. Therefore, the CCB program cannot be considered cost-effective compared to usual care.	[Verweij, Lotte; Petri, Adrianne C. M.; Jepma, Patricia; Latour, Corine H. M.; Buurman, Bianca M.] Amsterdam Univ Appl Sci, Fac Hlth, Ctr Expertise Urban Vital, Amsterdam, Netherlands; [Verweij, Lotte; Jepma, Patricia; Peters, Ron J. G.; Reimer, Wilma J. M. Scholte Op] Univ Amsterdam, Dept Cardiol, Amsterdam UMC, Amsterdam, Netherlands; [MacNeil-Vroomen, Janet L.; Buurman, Bianca M.] Univ Amsterdam, Dept Internal Med, Sect Geriatr Med, Amsterdam UMC, Amsterdam, Netherlands; [Reimer, Wilma J. M. Scholte Op] HU Univ Appl Sci Utrecht, Res Grp Chron Dis, Utrecht, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, Fac Sci, Amsterdam Publ Hlth Res Inst, Dept Hlth Sci, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	Verweij, L (corresponding author), Amsterdam Univ Appl Sci, Fac Hlth, Ctr Expertise Urban Vital, Amsterdam, Netherlands.; Verweij, L (corresponding author), Univ Amsterdam, Dept Cardiol, Amsterdam UMC, Amsterdam, Netherlands.	l.verweij@amsterdamumc.nl		Bosmans, Judith/0000-0002-1443-1026; Verweij, Lotte/0000-0002-4727-0126; Verweij, Lotte/0000-0002-0672-6668	Netherlands Organization for Health Research and Development (ZonMw) [520002002]; Dutch Research Council (NWO) [023.008.024]	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Dutch Research Council (NWO)(Netherlands Organization for Scientific Research (NWO))	This study is funded by a grant from the [1] Netherlands Organization for Health Research and Development (ZonMw) as part of the 'From Knowledge to Action II program', grant number 520002002 and is partly financed by the [2] Dutch Research Council (NWO) grant number 023.008.024. The funders had no role in study design, data collection and analysis, and neither in the preparation or publication of the manuscript. [1] https://www.zonmw.nl/nl/over-zonmw/onderwijs/programmas/programma-detail/tussenweten-en-doen-ii/[2] https://www.nwo.nl/onderzoeksprogrammas/promotiebeurs-voorleraren.; We are grateful to the participants in the CCB program and the participating organisations, hospitals, homecare organisations and physical therapy practices. In addition, we thank the supporting research staff for their effort to complete the study.	Bell SP, 2016, J GERIATR CARDIOL, V13, P1, DOI 10.11909/j.issn.1671-5411.2016.01.019; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Boter H, 2005, Ned Tijdschr Geneeskd, V149, P29; Bryant-Lukosius D, 2015, J EVAL CLIN PRACT, V21, P763, DOI 10.1111/jep.12401; Cardiology DSf, 2011, MULTIDISCIPLINARY GU; Centraal bureau voor de statistiek, 2019, INT OND JONG; Drummond MF, 2015, METHODS EC EVALUATIO; Faria R, 2014, PHARMACOECONOMICS, V32, P1157, DOI 10.1007/s40273-014-0193-3; Feltner C, 2014, ANN INTERN MED, V160, P774, DOI 10.7326/M14-0083; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Jepma P, 2019, NETH HEART J, V27, P134, DOI 10.1007/s12471-019-1227-4; Jepma P, 2021, AGE AGEING, V50, P2105, DOI 10.1093/ageing/afab146; Koster L., 2014, GENERIEKE KOSTEN MED; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Meisinger C, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-115; Naylor MD, 2017, J AM GERIATR SOC, V65, P1119, DOI 10.1111/jgs.14782; Ribbink ME, 2019, J AM MED DIR ASSOC, V20, P1300, DOI 10.1016/j.jamda.2019.03.013; RIVM, NAT EN ATL; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Seidl H, 2016, J EVAL CLIN PRACT, V22, P446, DOI 10.1111/jep.12506; Stamp KD, 2014, J CARDIOVASC NURS, V29, P140, DOI 10.1097/JCN.0b013e31827db560; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Stewart S, 2005, EUR J HEART FAIL, V7, P423, DOI 10.1016/j.ejheart.2005.01.001; van den Brink M, 2004, MED CARE, V42, P740, DOI 10.1097/01.mlr.0000132351.78009.a1; Van Spall HGC, 2017, EUR J HEART FAIL, V19, P1427, DOI 10.1002/ejhf.765; Van Spall HGC, 2019, JAMA-J AM MED ASSOC, V321, P753, DOI 10.1001/jama.2019.0710; Verhaegh KJ, 2014, HEALTH AFFAIR, V33, P1531, DOI 10.1377/hlthaff.2014.0160; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003; Verweij L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3301-9; Verweij L, 2021, J ADV NURS, V77, P2498, DOI 10.1111/jan.14786; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Willan AR, 2004, HEALTH ECON, V13, P461, DOI 10.1002/hec.843; Zorginstituut Nederland, 2015, KOSTENHANDLEIDING ME	36	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0263130	10.1371/journal.pone.0263130	http://dx.doi.org/10.1371/journal.pone.0263130			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0I4GM	35085361	gold, Green Published			2023-01-03	WOS:000779379600116
J	Li, Z; Wang, DD; Zhang, Y; Wang, S; Wang, XQ; Li, YX; Gui, YR; Dong, J; Hou, W				Li, Zheng; Wang, Dandan; Zhang, Ying; Wang, Shuo; Wang, Xueqian; Li, Yuxiao; Gui, Yuerong; Dong, Jun; Hou, Wei			Efficacy and safety of Xuebijing injection for radiation pneumonitis: A meta-analysis	PLOS ONE			English	Article							LUNG-CANCER; RADIOTHERAPY; PREVENTION	Background Currently, the treatment of radiation pneumonitis (RP) remains a clinical challenge. Although glucocorticoids are used for RP treatment, they have associated side effects. Xuebijing injection (XBJ) has been widely used for RP treatment in China, but so far no meta-analysis has evaluated its efficacy and safety. Methods PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure, WANFANG database, SinoMED, and China Science and Technology J Database were searched for randomized controlled trials related to XBJ in RP treatment. Two researchers independently conducted literature screening, data extraction, and risk of bias assessment. The outcomes were synthesized and analyzed using the Cochrane Review Manager (RevMan 5.3) software, and a forest plot generated. Result Eight articles met the eligibility criteria for further data extraction and meta-analysis. A total of 578 patients with RP participated in these studies, including 296 in the experimental group (XBJ+BT), and 282 in the control group (BT). The results of the meta-analysis revealed that compared to the BT group, XBJ+BT significantly increased the total effective rate (n = 578; RR = 1.45, 95% CI: 1.30 to 1.61, p<0.0001), and IL-10 expression (n = 296; MD = 17.62, 95% CI:13.95 to 21.29, p<0.00001), decreased interleukin-6 (IL-6) expression (n = 296; MD = -21.56, 95% CI:-27.37 to -15.76, p<0.00001), that of tumor necrosis factor alpha (n = 246; MD = -25.63, 95% CI:-30.77 to -20.50, p<0.00001), and that of C-reactive protein (n = 296; MD = -48.61, 95% CI:-56.49-40.73, p< 0.00001). Conclusion Based on our results, we do not recommend XBJ as an adjuvant treatment for RP. Further randomized controlled trials with rigorous design, strict implementation, and standard reporting are needed to further evaluate the efficacy and safety of XBJ for RP treatment.	[Li, Zheng; Zhang, Ying; Wang, Xueqian; Hou, Wei] China Acad Chinese Med Sci, Guangan Men Hosp, Dept Oncol, Beijing, Peoples R China; [Wang, Dandan; Li, Yuxiao; Gui, Yuerong; Dong, Jun] China Acad Chinese Med Sci, Grad Sch Chinese Med, Beijing, Peoples R China; [Wang, Shuo] Beijing Univ Chinese Med, Grad Sch Chinese Med, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Beijing University of Chinese Medicine	Hou, W (corresponding author), China Acad Chinese Med Sci, Guangan Men Hosp, Dept Oncol, Beijing, Peoples R China.	houwei1964@163.com						Arpin D, 2005, J CLIN ONCOL, V23, P8748, DOI 10.1200/JCO.2005.01.7145; Cai HJ., 2014, J TRADIT CHIN MED SC, V1, P49; Chen YY, 2001, INT J RADIAT ONCOL, V49, P641, DOI 10.1016/S0360-3016(00)01445-0; Gu X, 2016, CHINESE COMMUNITY DO, V32, P114; Gui YG., 2009, CHIN J TCM WM CRIT C, V16, P326; Han SY, 2015, J CANCER, V6, P1172, DOI 10.7150/jca.12314; Henkenberens C, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0580-3; Higgins J., 2011, COCHRAN HDB SYSTEMAT, V5; Inoue A, 2001, INT J RADIAT ONCOL, V49, P649, DOI 10.1016/S0360-3016(00)00783-5; Kang Z., 2017, J FRONTIERS MED, V7, P109; Li Z, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024344; Lu WJ., 2019, MODERN J INTEGRATED, V28, P3567; Moghadam-Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365-4632.2009.04322.x; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Ozturk B, 2004, INT J RADIAT ONCOL, V58, P213, DOI 10.1016/S0360-3016(03)01444-5; Park HR, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017321; Qi F, 2011, J TRADIT CHIN MED, V31, P46, DOI 10.1016/S0254-6272(11)60011-3; Qifei L., 2015, J EMERGENCY TRADITIO, V24, P1149; Shi W, 2017, CHINA CONTINUING MED, V9, P200; Sun M, 2018, J TIANJIN U TRADIT C, V37, P13; Tan B., 2014, CHIN J CANC PREV TRE, V24, P1986; Tyldesley S, 2001, INT J RADIAT ONCOL, V49, P973, DOI 10.1016/S0360-3016(00)01401-2; Ullah T, 2020, CURR OPIN PULM MED, V26, P321, DOI 10.1097/MCP.0000000000000682; Wang P, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1282-8; Xu D., 2016, CHINAS RURAL HLTH, P31; Yang Chengliang, 2012, CHIN J EXP PHARM, V24, P320; Yang Z., 2015, CHINESE COMMUNITY DO, V31; Zhai Z., 2016, GUIDE CHINA MED, V14, P196; Zhao J, 2016, CLIN RES PRACT, V1; Zhao ZJ, 2020, CLIM DYNAM, V55, P681, DOI 10.1007/s00382-020-05283-6; Zheng R, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2018.09.26; Zhou TC., 2019, J INNER MONGOLIA MED, V4, P446; Zuo LH, 2017, J PHARMACEUT BIOMED, V137, P220, DOI 10.1016/j.jpba.2017.01.024; 王绿化, 2015, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V24, P4; 杨龙峰, 2013, [广东医学, Guangdong Medical Journal], V34, P3497	35	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268819	10.1371/journal.pone.0268819	http://dx.doi.org/10.1371/journal.pone.0268819			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3H8VI	35648739	Green Published, gold			2023-01-03	WOS:000832307900042
J	Norman, JE; Stock, SJ; Harmer, C				Norman, Jane E.; Stock, Sarah J.; Harmer, Clea			After the Ockenden review: a chance to reset maternal and perinatal care in the UK?	LANCET			English	Editorial Material									[Norman, Jane E.] Univ Bristol, Fac Hlth Sci, Bristol BS8 1UD, Avon, England; [Stock, Sarah J.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Harmer, Clea] Sands Stillbirth & Neonatal Death Char, London, England	University of Bristol; University of Edinburgh	Norman, JE (corresponding author), Univ Bristol, Fac Hlth Sci, Bristol BS8 1UD, Avon, England.	dean-fohs@bristol.ac.uk		Norman, Jane/0000-0001-6031-6953				Accelerating Innovation for Mothers (AIM), 2020, AIM PUBL SERV ANN; [Anonymous], 2022, LANCET, V399, P1359, DOI 10.1016/S0140-6736(22)00654-7; Bohren MA, 2019, LANCET, V394, P1750, DOI 10.1016/S0140-6736(19)31992-0; Chappell LC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002161; Fisk NM, 2008, PLOS MED, V5, P22, DOI 10.1371/journal.pmed.0050022; Independent Investigation into East Kent Maternity Services, INVESTIGATION; Kirkup B., 2015, REPORT MORECAMBE BAY; National Institute for Health and Care Excellence, NICE GUIDELINE NG192, P2021; National Institute for Health and Care Excellence Royal College of Obstetricians and Gynaecologists, 2021, NICE GUIDELINE NG201; NHS Nottingham and Nottinghamshire Clinical Commissioning Group NHS England NHS Improvement, 2021, IND THEM REV INT NOT; Ockenden DC, 2022, FINAL FINDINGS CONCL; Stock Sarah Je, 2019, F1000Res, V8, DOI 10.12688/f1000research.17535.1	12	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	2022	399	10344					2331	2333		10.1016/S0140-6736(22)00823-6	http://dx.doi.org/10.1016/S0140-6736(22)00823-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2Q2HY	35551763	Green Submitted			2023-01-03	WOS:000820250200005
J	Dor-Haim, H; Horowitz, M; Yaakobi, E; Katzburg, S; Barak, S				Dor-Haim, Horesh; Horowitz, Michal; Yaakobi, Eldad; Katzburg, Sara; Barak, Sharon			Intermittent aerobic-resistance interval training versus continues aerobic training: Improvement in cardiac electrophysiologic and anthropometric measures in male patients post myocadiac infarction, a randomized control trial	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; ATRIAL-FIBRILLATION; PHYSICAL-ACTIVITY; RISK-FACTORS; MUSCLE MASS; EXERCISE; FAILURE; DISEASE; RECOMMENDATIONS; REHABILITATION	Purpose Exercise is a valuable intervention modality for patients post-myocardial infarction (MI). Aerobic and resistance training are both commonly used separately in cardiac rehabilitation. However, the effect of aerobic interval exercise combined with alternating sets of resistance training (super-circuit training, SCT) on cardiac electrophysiologic and anthropometric measures had not been thoroughly investigated. Aim The primary objective of this study was to compare the effectiveness of moderate-intensity continuous-aerobic training (CAT) vs. SCT on cardiac electrical measures (resting electrocardiographic, ECG; a nd heart rate variability, HRV) in patients' post-MI presenting reduced left ventricular function. Second, to examine its effect on anthropometric measures. Material and methods Twenty-nine men post-MI with reduced left ventricular function were assigned randomly to either 12 weeks of CAT (n = 15) or SCT (n = 14). CAT group performed moderate-intensity activity. SCT group performed high-intensity exercise, alternating between resistance and aerobic training. Differences between CAT and SCT groups were done using independent t-tests, paired t-tests and effect size (ES). Results Participants in both groups improved their HRV measures (increase in HFnu; p < 0.05; ES > 0.51) and ECG (reduction in QT-dispersion; p < 0.05; ES > 0.51). Only the SCT group had significant improvements in waist circumference (p < 0.05). Conclusion Exercise improves cardiac electrical measures post-MI. However, in comparison to CAT, SCT may yield greater anthropometric changes. In order to have improvements in cardiac electrical stability, clinicians working with post-MI patients may use both CAT and SCT. However, SCT might result in greater improvements.	[Dor-Haim, Horesh; Katzburg, Sara] O2 Hlth Promot & Sports Med Dept, Jerusalem, Israel; [Horowitz, Michal] Hebrew Univ Jerusalem, Fac Dent, Lab Environm Physiol Dept Physiol, Hadassah Kerem Campus Jerusalem, Jerusalem, Israel; [Yaakobi, Eldad] Yitzhak Shamir Med Ctr, Sagol Ctr Hyperbar Med & Res, Beer Yaagov, Israel; [Katzburg, Sara] Hebrew Univ Jerusalem, Fac Med, Israel Canada Med Res Inst, Dept Dev Biol & Canc Res, Jerusalem, Israel; [Barak, Sharon] Chaim Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Dept Pediat Rehabil, Ramat Gan, Israel; [Barak, Sharon] Kaye Acad Coll Educ, Beer Sheva, Israel	Hebrew University of Jerusalem; Shamir Medical Center (Assaf Harofeh); Hebrew University of Jerusalem; Chaim Sheba Medical Center	Barak, S (corresponding author), Chaim Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Dept Pediat Rehabil, Ramat Gan, Israel.; Barak, S (corresponding author), Kaye Acad Coll Educ, Beer Sheva, Israel.	shroni.braki@gmail.com						Adachi H, 1996, EUR HEART J, V17, P1511; ADAMOPOULOS S, 1993, J AM COLL CARDIOL, V21, P1101, DOI 10.1016/0735-1097(93)90231-O; Barnard K L, 1999, J Cardiopulm Rehabil, V19, P52, DOI 10.1097/00008483-199901000-00007; Benito B, 2011, CIRCULATION, V123, P13, DOI 10.1161/CIRCULATIONAHA.110.938282; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Billman GE, 2009, AM J PHYSIOL-HEART C, V297, pH1171, DOI 10.1152/ajpheart.00534.2009; Bjarnason-Wehrens B, 2004, EUR J CARDIOV PREV R, V11, P352, DOI 10.1097/01.hjr.0000137692.36013.27; Camm AJ, 1996, CIRCULATION, V93, P1043; Caraballo C, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.014240; Carlsson L, 2010, TRENDS PHARMACOL SCI, V31, P364, DOI 10.1016/j.tips.2010.05.001; Chintala KK, 2015, J CLIN DIAGN RES, V9, pCC6, DOI 10.7860/JCDR/2015/12145.5434; Cutler MJ, 2011, TRENDS PHARMACOL SCI, V32, P174, DOI 10.1016/j.tips.2010.12.001; Davies EJ, 2010, EUR J HEART FAIL, V12, P706, DOI 10.1093/eurjhf/hfq056; Dor-Haim H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188551; Dor-Haim H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005989; Frankel JE, 2006, CLIN GERIATR MED, V22, P239, DOI 10.1016/j.cger.2005.12.002; Frost L, 2005, AM J MED, V118, P489, DOI 10.1016/j.amjmed.2005.01.031; Fujimoto S, 1999, JPN CIRC J, V63, P577, DOI 10.1253/jcj.63.577; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Grundy SM, 2013, J OBES, V2013, DOI 10.1155/2013/454285; Guerra RS, 2012, NUTR HOSP, V27, P1554, DOI 10.3305/nh.2012.27.5.5922; Guzzetti S, 2005, EUR HEART J, V26, P357, DOI 10.1093/eurheartj/ehi067; Kessler HS, 2012, SPORTS MED, V42, P489, DOI 10.2165/11630910-000000000-00000; Kiani A, 2011, IRAN J PEDIATR, V21, P220; La Gerche A, 2012, EUR HEART J, V33, P998, DOI 10.1093/eurheartj/ehr397; Leon AS, 2005, CIRCULATION, V111, P369, DOI 10.1161/01.CIR.0000151788.08740.5C; Li C, 2013, STATA J, V13, P795, DOI 10.1177/1536867X1301300407; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; MALLIANI A, 1994, J CARDIOVASC ELECTR, V5, P274, DOI 10.1111/j.1540-8167.1994.tb01164.x; MCKELVIE RS, 1995, J AM COLL CARDIOL, V25, P789, DOI 10.1016/0735-1097(94)00428-S; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Ouwerkerk W, 2014, JACC-HEART FAIL, V2, P429, DOI 10.1016/j.jchf.2014.04.006; Paoli A, 2010, J SPORT MED PHYS FIT, V50, P43; Park Sang-Kab, 2003, Journal of Physiological Anthropology and Applied Human Science, V22, P129, DOI 10.2114/jpa.22.129; Schnabel RB, 2010, ARCH INTERN MED, V170, P1909, DOI 10.1001/archinternmed.2010.434; Sessa F, 2018, AGING-US, V10, P166, DOI 10.18632/aging.101386; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Shekha Karthik, 2005, Indian Pacing Electrophysiol J, V5, P122; Smart Neil A, 2012, Congest Heart Fail, V18, P205, DOI 10.1111/j.1751-7133.2011.00274.x; SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760; Srikanthan P, 2016, AM J CARDIOL, V117, P1355, DOI 10.1016/j.amjcard.2016.01.033; Srikanthan P, 2014, AM J MED, V127, P547, DOI 10.1016/j.amjmed.2014.02.007; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Tavora F, 2012, PATHOLOGY, V44, P187, DOI 10.1097/PAT.0b013e3283513f54; TREMBLAY A, 1994, METABOLISM, V43, P814, DOI 10.1016/0026-0495(94)90259-3; Triggiani AI, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223058; Tucker WJ, 2019, PROG CARDIOVASC DIS, V62, P163, DOI 10.1016/j.pcad.2018.08.006; Vanhees L, 2012, EUR J PREV CARDIOL, V19, P1005, DOI 10.1177/1741826711430926; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115	50	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2022	17	5							e0267888	10.1371/journal.pone.0267888	http://dx.doi.org/10.1371/journal.pone.0267888			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6I1LZ	35503787	gold, Green Published			2023-01-03	WOS:000885891700027
J	Kaso, AW; Agero, G; Hurissa, Z; Kaso, T; Ewune, HA; Hareru, HE; Hailu, A				Kaso, Abdene Weya; Agero, Gebi; Hurissa, Zewdu; Kaso, Taha; Ewune, Helen Ali; Hareru, Habtamu Endashaw; Hailu, Alemayehu			Survival analysis of COVID-19 patients in Ethiopia: A hospital-based study	PLOS PATHOGENS			English	Article							PROGNOSTIC-FACTORS	BackgroundCOVID-19 is a global public health problem causing high mortality worldwide. This study aimed to assess time to death and predictors of mortality among patients hospitalized for COVID-19 in the Arsi zone treatment center. MethodWe performed a retrospective observational cohort study using medical records of laboratory-confirmed COVID-19 cases hospitalized at Bokoji Hospital COVID-19 treatment center from 1(st) July 2020 to 5(th) March 2021. We extracted data on the patients' sociodemographic and clinical characteristics from medical records of hospitalized patients retrospectively. We carried out Kaplan Meier and Cox regression analysis to estimate survival probability and investigate predictors of COVID-19 death 5% level of significance. The Adjusted Hazard Ratio (aHR) with 95% Confidence Interval (CI) was estimated and interpreted for predictors of time to death in the final cox model. ResultA total of 422 COVID-19 patients treated were analyzed, of these more than one tenth (11.14%) deaths, with a mortality rate of 6.35 cases per 1000 person-days. The majority (87.2%) of deaths occurred within the first 14 days of admission, with a median time-to-death of nine (IQR: 8-12) days. We found patients that age between 31 and 45 years (aHR = 2.55; 95% CI: (1.03, 6.34), older than 46 years (aHR = 2.59 (1.27, 5.30), chronic obstructive pulmonary disease (aHR = 4.60, 95%CI: (2.37, 8.91), Chronic kidney disease (aHR = 5.58, 95%CI: (1.70, 18.37), HIV/AIDS (aHR = 3.66, 95%CI: (1.20, 11.10), admission to the Intensive care unit(aHR = 7.44, 95%CI: (1.82, 30.42), and being on intranasal oxygen care (aHR = 6.27, 95%CI: (2.75, 4.30) were independent risk factors increasing risk of death from COVID-19 disease than their counterparts. ConclusionThe risk of dying due to COVID-19 disease was higher among patients with HIV/AIDS, chronic obstructive pulmonary disease, and chronic kidney diseases. We also found that older people, those admitted to ICU, and patients who received intranasal oxygen care had a higher risk of dying due to COVID-19 disease. Therefore, close monitoring hospitalized patients that are old aged and those with comorbidities after hospitalization is crucial within the first ten days of admission.	[Kaso, Abdene Weya; Ewune, Helen Ali; Hareru, Habtamu Endashaw] Dilla Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dilla, Ethiopia; [Agero, Gebi] Arsi Univ, Coll Hlth Sci, Dept Publ Hlth, Assela, Ethiopia; [Hurissa, Zewdu] Arsi Univ, Coll Hlth Sci, Dept Internal Med, Assela, Ethiopia; [Kaso, Taha] Arsi Univ, Coll Hlth Sci, Dept Surg, Assela, Ethiopia; [Hailu, Alemayehu] Univ Bergen, Bergen Ctr Ethics & Prior Setting, Dept Global Publ Hlth & Primary Care, Bergen, Norway	Dilla University; University of Bergen	Agero, G (corresponding author), Arsi Univ, Coll Hlth Sci, Dept Publ Hlth, Assela, Ethiopia.	gebi.agero@yahoo.com		Endashaw Hareru, Habtamu/0000-0002-0591-0893; Hailu, Alemayehu/0000-0003-4872-8036				Abate SM., 2020, B WORLD HEALTH ORGAN; Altonen BL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243343; Alwafi H, 2021, J MULTIDISCIP HEALTH, V14, P839, DOI 10.2147/JMDH.S304788; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], 2006, SAMPLE SIZE DETERMIN; [Anonymous], 2020, RISK FACT COVID 19 M; Bhandari S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.585850; Boari GEM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20203455; Byeon KH, 2021, INT J INFECT DIS, V105, P588, DOI 10.1016/j.ijid.2021.02.101; CDC A., 2022, AFR UN MEMB STAT REP; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; De Meester J, 2021, J AM SOC NEPHROL, V32, P385, DOI 10.1681/ASN.2020060875; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; ECDC, 2020, RAPID RISK ASSESSMEN; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Federal Democratic Republic of Ethiopia Ministry of Health, 2020, NAT COMPR COVID 19 M; FMOH, 2022, COVID 19 DAIL SIT RE; FMOH, 2021, NAT GUID INT COVID 1; Gupta M, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00159-y; Hospital B., 2021, ANN WOR BAS OP PLANN; Hu L, 2020, CLIN INFECT DIS, V71, P2089, DOI 10.1093/cid/ciaa539; Martins PR, 2020, EUR J INTERN MED, V76, P97, DOI 10.1016/j.ejim.2020.04.043; Mi J, 2020, AM J TRANSL RES, V12, P6537; Public Health England, 2020, DISP RISK OUTC COVID; Salinas-Escudero G, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09721-2; Sousa GJB, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001405; Ssentongo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238215; Unhale S.S., 2020, WJPLS, V2020, P109; van Gerwen M, 2021, J MED VIROL, V93, P907, DOI 10.1002/jmv.26337; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; WHO, 2022, WHO COR COVID 19 DAS; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	34	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7366	1553-7374		PLOS PATHOG	PLoS Pathog.	MAY	2022	18	5							e0268280	10.1371/journal.pone.0268280	http://dx.doi.org/10.1371/journal.pone.0268280			11	Microbiology; Parasitology; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Microbiology; Parasitology; Virology	6J0DV	35533178	Green Published, gold			2023-01-03	WOS:000886499700010
J	Dyer, O				Dyer, Owen			Ohio doctor is acquitted of murdering 14 intensive care patients with fentanyl overdoses	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Dyer O, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l4170	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	2022	377								o1051	10.1136/bmj.o1051	http://dx.doi.org/10.1136/bmj.o1051			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1E3RT	35470157				2023-01-03	WOS:000794410900001
J	Tanne, JH				Tanne, Janice Hopkins			Covid-19: US sees increase in sexually transmitted diseases and teen drug overdose deaths	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Centers for Disease Control and Prevention, 2022, NEW DAT SUGG STDS CO; Centers for Disease Control and Prevention, 2022, PREL DAT 2021 SYPH; Centers for Disease Control and Prevention, 2021, DRUG OVERDOSE DEATHS; Centers for Disease Control and Prevention, SEXUALLY TRANSMITTED; Friedman J, 2022, JAMA-J AM MED ASSOC, V327, P1398, DOI 10.1001/jama.2022.2847	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2022	377								o991	10.1136/bmj.o991	http://dx.doi.org/10.1136/bmj.o991			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1H2DR	35440470	Bronze			2023-01-03	WOS:000796356300008
J	Zheng, MD				Zheng, Mingde			Listen to your body	SCIENCE			English	Editorial Material									[Zheng, Mingde] Nokia Bell Labs, Murray Hill, NJ 07974 USA	Nokia Corporation; Nokia Bell Labs	Zheng, MD (corresponding author), Nokia Bell Labs, Murray Hill, NJ 07974 USA.								0	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2022	376	6590					318	318						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0O1VO	35420965				2023-01-03	WOS:000783317900053
J	Zhang, YQ; Jiao, RM; Witt, CM; Lao, LX; Liu, JP; Thabane, L; Sherman, KJ; Cummings, M; Richards, DP; Kim, EKA; Kim, TH; Lee, MS; Wechsler, ME; Brinkhaus, B; Mao, JJ; Smith, CA; Gang, WJ; Liu, BY; Liu, ZS; Liu, Y; Zheng, H; Wu, JN; Carrasco-Labra, A; Bhandari, M; Devereaux, PJ; Jing, XH; Guyatt, G				Zhang, Yu-Qing; Jiao, Rui-Min; Witt, Claudia M.; Lao, Lixing; Liu, Jian-Ping; Thabane, Lehana; Sherman, Karen J.; Cummings, Mike; Richards, Dawn P.; Kim, Eun-Kyung Anna; Kim, Tae-Hun; Lee, Myeong Soo; Wechsler, Michael E.; Brinkhaus, Benno; Mao, Jun J.; Smith, Caroline A.; Gang, Wei-Juan; Liu, Bao-Yan; Liu, Zhi-Shun; Liu, Yan; Zheng, Hui; Wu, Jia-Ni; Carrasco-Labra, Alonso; Bhandari, Mohit; Devereaux, Philip J.; Jing, Xiang-Hong; Guyatt, Gordon			How to design high quality acupuncture trials-a consensus informed by evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; LOW-BACK-PAIN; RECOVERY EXPECTATIONS; PATIENT EXPECTATIONS; PUBLIC INVOLVEMENT; SHAM ACUPUNCTURE; CLINICAL-TRIALS; KNEE; OSTEOARTHRITIS; VALIDATION	An international panel including patients, clinicians, researchers, acupuncture and surgery trialists, statisticians, and experts in clinical epidemiology and methodology have developed new guidance for randomised controlled trials in acupuncture. It addresses the most prevalent and critical concerns of current acupuncture trials and will help funding agencies, trial registers, and journal editors to evaluate the relevance, importance, and quality of submitted trial proposals and completed trials	[Zhang, Yu-Qing; Jiao, Rui-Min; Gang, Wei-Juan; Jing, Xiang-Hong] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Zhang, Yu-Qing] China Acad Chinese Med Sci, Guanganmen Hosp, CEBIM Ctr Evidence Based Integrat Med Clar Collab, Beijing, Peoples R China; [Zhang, Yu-Qing; Guyatt, Gordon] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Zhang, Yu-Qing] Univ Nottingham Ningbo, Nottingham Ningbo GRADE Ctr, Ningbo, Peoples R China; [Jiao, Rui-Min; Gang, Wei-Juan; Jing, Xiang-Hong] China Acad Chinese Med Sci, China Ctr Evidence Based Tradit Chinese Med, Beijing, Peoples R China; [Witt, Claudia M.] Univ Hosp Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland; [Witt, Claudia M.] Univ Zurich, Zurich, Switzerland; [Lao, Lixing] Virginia Univ Integrat Med, Fairfax, VA USA; [Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Liu, Jian-Ping] Beijing Univ Chinese Med, Inst Excellence Evidence Based Chinese Med, Beijing, Peoples R China; [Thabane, Lehana; Bhandari, Mohit; Devereaux, Philip J.; Guyatt, Gordon] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON, Canada; [Sherman, Karen J.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA; [Sherman, Karen J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Cummings, Mike] British Med Acupuncture Soc, London, England; [Richards, Dawn P.] Clin Trials Ontario, Patient & Publ Engagement, Toronto, ON, Canada; [Kim, Eun-Kyung Anna] Virginia Univ Integrat Med, Dept Western Med, Fairfax, VA USA; [Kim, Tae-Hun] Korean Med Clin Trial Ctr, Seoul, South Korea; [Kim, Tae-Hun] Korean Med Hosp, Seoul, South Korea; [Kim, Tae-Hun] Kyung Hee Univ, Seoul, South Korea; [Lee, Myeong Soo] Korea Inst Oriental Med, Clin Med Div, Daejeon, South Korea; [Lee, Myeong Soo] Univ Sci & Technol, Korean Convergence Med, Daejeon, South Korea; [Wechsler, Michael E.] Natl Jewish Hlth, Denver, CO USA; [Brinkhaus, Benno] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Brinkhaus, Benno] Free Univ Berlin, Berlin, Germany; [Brinkhaus, Benno] Humboldt Univ, Berlin, Germany; [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA; [Smith, Caroline A.] Western Sydney Univ, Translat Hlth Res Inst, Penrith, NSW, Australia; [Liu, Bao-Yan] China Acad Chinese Med Sci, Beijing, Peoples R China; [Liu, Zhi-Shun; Wu, Jia-Ni] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China; [Liu, Yan] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ, Beijing, Peoples R China; [Zheng, Hui] Chengdu Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Affiliated Hosp 3, Chengdu, Sichuan, Peoples R China; [Carrasco-Labra, Alonso] Univ Penn, Ctr Integrat Global Oral Hlth, Sch Dent Med, Philadelphia, PA 19104 USA	China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; McMaster University; University of Nottingham Ningbo China; China Academy of Chinese Medical Sciences; University of Zurich; University Zurich Hospital; University of Zurich; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; McMaster University; Kaiser Permanente; University of Washington; University of Washington Seattle; Kyung Hee University; Kyung Hee University Hospital; Kyung Hee University; Korea Institute of Oriental Medicine (KIOM); University of Science & Technology (UST); National Jewish Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Memorial Sloan Kettering Cancer Center; Western Sydney University; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Beijing University of Chinese Medicine; Chengdu University of Traditional Chinese Medicine; University of Pennsylvania	Jing, XH (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China.; Jing, XH (corresponding author), China Acad Chinese Med Sci, China Ctr Evidence Based Tradit Chinese Med, Beijing, Peoples R China.	xhjingt66@163.com	Witt, Claudia M./AAX-2370-2021; Jing, Xianghong/HHS-4003-2022	Witt, Claudia M./0000-0002-5440-7805; 	China Academy of Chinese Medical Sciences (CACMS) Innovation Fund [CI 2021A03503, CI2021B011]; "Belt and Road" Traditional Chinese Medicine Cooperation Project of China Academy of Chinese Medical Sciences [GH201901]	China Academy of Chinese Medical Sciences (CACMS) Innovation Fund; "Belt and Road" Traditional Chinese Medicine Cooperation Project of China Academy of Chinese Medical Sciences	Funding: The China Academy of Chinese Medical Sciences (CACMS) Innovation Fund (CI 2021A03503 and CI2021B011) and " The Belt and Road" Traditional Chinese Medicine Cooperation Project of China Academy of Chinese Medical Sciences (GH201901) supported this work. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Avis NE, 2016, MENOPAUSE, V23, P626, DOI 10.1097/GME.0000000000000597; Barth J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026712; Bednarska E, 2008, CLIN ORTHOP RELAT R, V466, P1734, DOI 10.1007/s11999-008-0273-9; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Bialosky JE, 2010, PHYS THER, V90, P1345, DOI 10.2522/ptj.20090306; Brett J, 2014, HEALTH EXPECT, V17, P637, DOI 10.1111/j.1369-7625.2012.00795.x; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Clarke M, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-39; Constantino MJ, 2012, PSYCHOTHERAPY, V49, P557, DOI 10.1037/a0029440; Crocker JC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4738; Devereaux PJ, 2005, BMJ-BRIT MED J, V330, P88, DOI 10.1136/bmj.330.7482.88; DeVore AD, 2020, AM HEART J, V220, P41, DOI 10.1016/j.ahj.2019.09.012; Deyo RA, 2014, PAIN MED, V15, P1249, DOI 10.1111/pme.12538; Domecq JP, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-89; Du Y., 2000, ZHONGGUO ZHENJIU, V20, P312; Evaniew N, 2016, JAMA SURG, V151, P657, DOI 10.1001/jamasurg.2016.0072; Foster NE, 2007, BMJ-BRIT MED J, V335, P436, DOI 10.1136/bmj.39280.509803.BE; FUNG KP, 1986, LANCET, V2, P1419; Gang WJ, BMJ OPEN; Glasziou P, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4645; Goldfarb D. S, 2004, ACP J CLUB; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Haynes RB, 2006, J CLIN EPIDEMIOL, V59, P873, DOI 10.1016/j.jclinepi.2006.06.005; Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907; Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660; Iles RA, 2009, J OCCUP REHABIL, V19, P25, DOI 10.1007/s10926-008-9161-0; Johnston BC, 2008, SPINE, V33, P914, DOI 10.1097/BRS.0b013e31816b4be4; Jones SMW, 2016, J ALTERN COMPLEM MED, V22, P936, DOI 10.1089/acm.2016.0242; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Kim TH, 2020, ACUPUNCT MED, V38, P37, DOI 10.1136/acupmed-2018-011671; Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/180805; Li J, 2015, KEY POINT IMPLEMENTA; Li Z.Q., 2014, ACAD FORUM, V37, P99; Loudon K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2147; Luo S.P, 2016, CLIN APPL GUIDE CHIN; Ma Peifeng, 2016, Zhongguo Zhen Jiu, V36, P1027, DOI 10.13703/j.0255-2930.2016.10.006; MacPherson Hugh, 2002, Acupunct Med, V20, P22; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; Madsen MV, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3115; Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22; Mondloch MV, 2001, CAN MED ASSOC J, V165, P174; Moura CD, 2019, REV ESC ENFERM USP, V53, DOI [10.1590/S1980-220X2018009003418, 10.1590/s1980-220x2018009003418]; Moustgaard H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6802; Nielsen Arya, 2021, Glob Adv Health Med, V10, p21649561211007091, DOI 10.1177/21649561211007091; Oxman AD, 2009, J CLIN EPIDEMIOL, V62, P485, DOI 10.1016/j.jclinepi.2008.08.015; Pach D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/125937; Paterson C, 2004, J ALTERN COMPLEM MED, V10, P791; Price A, 2018, J EVAL CLIN PRACT, V24, P240, DOI 10.1111/jep.12805; Riddle DL, 2010, J CLIN EPIDEMIOL, V63, P1271, DOI 10.1016/j.jclinepi.2010.03.006; Santosa KB, 2018, JAMA SURG, V153, P891, DOI 10.1001/jamasurg.2018.1677; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Schlaeger Judith M, 2018, Pilot Feasibility Stud, V4, P72, DOI 10.1186/s40814-018-0265-9; Scholtes Vanessa A, 2012, J Bone Joint Surg Am, V94 Suppl 1, P24, DOI 10.2106/JBJS.K.01626; Shuai P, 2012, STAT MED, V31, P606, DOI 10.1002/sim.4034; Skovlund Pernille Christiansen, 2020, Res Involv Engagem, V6, P43, DOI 10.1186/s40900-020-00214-5; Smith CA, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1986-4; Smith TO, 2019, J RHEUMATOL, V46, P981, DOI 10.3899/jrheum.181194; Su CX, 2015, EVALUATION BIAS ACUP; Takakura N, 2008, ACUPUNCT MED, V26, P224, DOI 10.1136/aim.26.4.224; Takakura Nobuari, 2007, BMC Complement Altern Med, V7, P31, DOI 10.1186/1472-6882-7-31; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; Vas J, 2019, ACTA OBSTET GYN SCAN, V98, P1307, DOI 10.1111/aogs.13635; Vickers AJ, 2021, ACUPUNCT MED, V39, P309, DOI 10.1177/0964528420959089; Wasan AD, 2010, J PAIN, V11, P555, DOI 10.1016/j.jpain.2009.09.013; Wayne PM, 2005, ARCH PHYS MED REHAB, V86, P2248, DOI 10.1016/j.apmr.2005.07.287; Wenden AJ, 2018, MED J AUSTRALIA, V208, DOI 10.5694/mja17.00623; White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489; Witt CM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-169; Witt CM, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-148; Witt CM, 2010, J PAIN, V11, P431, DOI 10.1016/j.jpain.2009.08.010; Xu Ze-Gong, 2020, Zhongguo Zhen Jiu, V40, P538, DOI 10.13703/j.0255-2930.20190514-0001; Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8; Zucker NA, 2017, PAIN MED, V18, P1582, DOI 10.1093/pm/pnx001	77	7	7	6	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 30	2022	376								e067476	10.1136/bmj-2021-067476	http://dx.doi.org/10.1136/bmj-2021-067476			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0I6XR	35354583	Green Published, hybrid			2023-01-03	WOS:000779561800010
J	Zulkifly, MFM; Lehr, A; van de Velden, D; Khan, A; Focke, NK; Wolters, CH; Paulus, W				Zulkifly, Mohd Faizal Mohd; Lehr, Albert; van de Velden, Daniel; Khan, Asad; Focke, Niels K.; Wolters, Carsten H.; Paulus, Walter			Directionality of the injected current targeting the P20/N20 source determines the efficacy of 140 Hz transcranial alternating current stimulation (tACS)-induced aftereffects in the somatosensory cortex	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; WORKING-MEMORY; MOTOR CORTEX; FUNCTIONAL-ORGANIZATION; EEG; EXCITABILITY; PLASTICITY; TDCS; LOCALIZATION; OSCILLATIONS	Interindividual anatomical differences in the human cortex can lead to suboptimal current directions and may result in response variability of transcranial electrical stimulation methods. These differences in brain anatomy require individualized electrode stimulation montages to induce an optimal current density in the targeted area of each individual subject. We aimed to explore the possible modulatory effects of 140 Hz transcranial alternating current stimulation (tACS) on the somatosensory cortex using personalized multi-electrode stimulation montages. In two randomized experiments using either tactile finger or median nerve stimulation, we measured by evoked potentials the plasticity aftereffects and oscillatory power changes after 140 Hz tACS at 1.0 mA as compared to sham stimulation (n = 17, male = 9). We found a decrease in the power of oscillatory mu-rhythms during and immediately after tactile discrimination tasks, indicating an engagement of the somatosensory system during stimulus encoding. On a group level both the oscillatory power and the evoked potential amplitudes were not modulated by tACS neither after tactile finger stimulation nor after median nerve stimulation as compared to sham stimulation. On an individual level we could however demonstrate that lower angular difference (i.e., differences between the injected current vector in the target region and the source orientation vector) is associated with significantly higher changes in both P20/N20 and N30/P30 source activities. Our findings suggest that the higher the directionality of the injected current correlates to the dipole orientation the greater the tACS-induced aftereffects are.	[Zulkifly, Mohd Faizal Mohd; Lehr, Albert; van de Velden, Daniel; Focke, Niels K.; Paulus, Walter] Georg August Univ, Univ Med Ctr, Dept Clin Neurophysiol, Gottingen, Germany; [Zulkifly, Mohd Faizal Mohd] Univ Sains Malaysia, Dept Neurosci, Sch Med Sci, Hlth Campus, Kota Baharu, Kelantan, Malaysia; [Zulkifly, Mohd Faizal Mohd] Univ Sains Malaysia, Sch Med Sci, Brain & Behav Cluster, Hlth Campus, Kota Baharu, Kelantan, Malaysia; [Khan, Asad; Wolters, Carsten H.] Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Wolters, Carsten H.] Univ Munster, Otto Creutzfeldt Ctr Cognit Neurosci, Munster, Germany; [Paulus, Walter] Ludwig Maximilians Univ Munchen, Dept Neurol, Marchioninistr, Munich, Germany	University of Gottingen; Universiti Sains Malaysia; Universiti Sains Malaysia; University of Munster; University of Munster; University of Munich	Zulkifly, MFM (corresponding author), Georg August Univ, Univ Med Ctr, Dept Clin Neurophysiol, Gottingen, Germany.; Zulkifly, MFM (corresponding author), Univ Sains Malaysia, Dept Neurosci, Sch Med Sci, Hlth Campus, Kota Baharu, Kelantan, Malaysia.; Zulkifly, MFM (corresponding author), Univ Sains Malaysia, Sch Med Sci, Brain & Behav Cluster, Hlth Campus, Kota Baharu, Kelantan, Malaysia.	faizal.zulkifly@usm.my	Paulus, Walter/A-3544-2009; Zulkifly, Faizal/GPX-6987-2022	Paulus, Walter/0000-0001-5549-8377; Mohd Zulkifly, Mohd Faizal/0000-0003-4925-9972; van de Velden, Daniel/0000-0003-2834-4457	Ministry of Education (MOE), Malaysia; Gottingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB) of the Georg-August-Universitat Gottingen; German Research Foundation (DFG) [WO1425/5-2, SPP1665, WO1425/10-1]	Ministry of Education (MOE), Malaysia; Gottingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB) of the Georg-August-Universitat Gottingen; German Research Foundation (DFG)(German Research Foundation (DFG))	MFMZ was supported by the Ministry of Education (MOE), Malaysia. This work was partly supported by the Gottingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB) of the Georg-August-Universitat Gottingen. AK and CHW were supported by the priority program SPP1665 of the German Research Foundation (DFG), project WO1425/5-2, and by DFG project WO1425/10-1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aberra AS, 2020, BRAIN STIMUL, V13, P175, DOI 10.1016/j.brs.2019.10.002; Agboada D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54621-0; ALLISON T, 1991, BRAIN, V114, P2465, DOI 10.1093/brain/114.6.2465; Antal A, 2008, BRAIN STIMUL, V1, P97, DOI 10.1016/j.brs.2007.10.001; Antonakakis M, 2020, NEUROIMAGE, V223, DOI 10.1016/j.neuroimage.2020.117353; Antonakakis M, 2019, HUM BRAIN MAPP, V40, P5011, DOI 10.1002/hbm.24754; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bland NS, 2019, EXP BRAIN RES, V237, P3071, DOI 10.1007/s00221-019-05666-0; Cancelli A, 2015, BRAIN STIMUL, V8, P555, DOI 10.1016/j.brs.2015.01.398; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; Del Felic A, 2019, NEUROIMAGE-CLIN, V22, DOI 10.1016/j.nicl.2019.101768; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Fernandez-Corazza M, 2020, NEUROIMAGE, V209, DOI 10.1016/j.neuroimage.2019.116403; Ferree TC, 2000, IEEE T BIO-MED ENG, V47, P1584, DOI 10.1109/10.887939; Feurra M, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00013; Filmer HL, 2019, NEUROIMAGE, V196, P41, DOI 10.1016/j.neuroimage.2019.04.026; Fuchs M, 1998, ELECTROEN CLIN NEURO, V107, P93, DOI 10.1016/S0013-4694(98)00046-7; Ghasemian-Shirvan E, 2020, BRAIN STIMUL, V13, P1588, DOI 10.1016/j.brs.2020.09.004; Gotz T, 2014, J CLIN NEUROPHYSIOL, V31, P253, DOI 10.1097/WNP.0000000000000048; Gundlach C, 2020, NEUROIMAGE, V221, DOI 10.1016/j.neuroimage.2020.117175; Hannah R, 2022, NEUROIMAGE, V251, DOI 10.1016/j.neuroimage.2022.118975; Hannah R, 2019, BRAIN STIMUL, V12, P684, DOI 10.1016/j.brs.2019.01.016; HARI R, 1993, EUR J NEUROSCI, V5, P724, DOI 10.1111/j.1460-9568.1993.tb00536.x; Helfrich RF, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002031; Herrmann CS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00279; Hill AT, 2019, CORTEX, V113, P37, DOI 10.1016/j.cortex.2018.11.022; Jamil A, 2017, J PHYSIOL-LONDON, V595, P1273, DOI 10.1113/JP272738; Kaarre O, 2018, ADDICT BIOL, V23, P268, DOI 10.1111/adb.12486; Kasten FH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13417-6; Khan A, 2022, CLIN NEUROPHYSIOL, V134, P9, DOI 10.1016/j.clinph.2021.10.016; Kim JH, 2014, NEUROSCI LETT, V564, P6, DOI 10.1016/j.neulet.2014.01.054; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Klink K, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10120932; Komssi S, 2004, CLIN NEUROPHYSIOL, V115, P534, DOI 10.1016/j.clinph.2003.10.034; Krieg TD, 2013, BRAIN STIMUL, V6, P898, DOI 10.1016/j.brs.2013.05.007; Laakso I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37226-x; Laakso I, 2015, BRAIN STIMUL, V8, P906, DOI 10.1016/j.brs.2015.05.002; Lee S, 2018, EUR J NEUROSCI, V48, P2001, DOI 10.1111/ejn.14085; Li K, 2016, COMPUT INTEL NEUROSC, V2016, DOI 10.1155/2016/1349851; Li LM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00181; Lisman JE, 2001, J PHYSIOL-LONDON, V532, P285, DOI 10.1111/j.1469-7793.2001.0285f.x; Lucka F, 2012, NEUROIMAGE, V61, P1364, DOI 10.1016/j.neuroimage.2012.04.017; Luu P, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00377; Manzo N, 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Matsunaga K, 2004, CLIN NEUROPHYSIOL, V115, P456, DOI 10.1016/S1388-2457(03)00362-6; Mehta AR, 2015, BRAIN STIMUL, V8, P260, DOI 10.1016/j.brs.2014.11.003; Moliadze V, 2012, BRAIN STIMUL, V5, P505, DOI 10.1016/j.brs.2011.11.004; Moliadze V, 2010, J PHYSIOL-LONDON, V588, P4891, DOI 10.1113/jphysiol.2010.196998; Murphy OW, 2020, BRAIN STIMUL, V13, P1370, DOI 10.1016/j.brs.2020.07.001; Nikolin S, 2018, BRAIN STIMUL, V11, P518, DOI 10.1016/j.brs.2018.01.003; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2012, J PHYSIOL-LONDON, V590, P4641, DOI 10.1113/jphysiol.2012.232975; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Parazzini M, 2017, IEEE T BIO-MED ENG, V64, P184, DOI 10.1109/TBME.2016.2553177; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Peirce JW, 2009, FRONT NEUROINFORM, V2, DOI 10.3389/neuro.11.010.2008; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Piastra MC, 2021, HUM BRAIN MAPP, V42, P978, DOI 10.1002/hbm.25272; Pleger B, 2006, J NEUROSCI, V26, P1945, DOI 10.1523/JNEUROSCI.4097-05.2006; Premoli I, 2017, NEUROIMAGE, V163, P1, DOI 10.1016/j.neuroimage.2017.09.023; Radecke JO, 2020, IEEE ACCESS, V8, P182610, DOI 10.1109/ACCESS.2020.3028618; Rahman A, 2013, J PHYSIOL-LONDON, V591, P2563, DOI 10.1113/jphysiol.2012.247171; Rawji V, 2018, BRAIN STIMUL, V11, P289, DOI 10.1016/j.brs.2017.11.001; Reato D, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00687; Rezaei A, 2021, NEUROIMAGE, V245, DOI 10.1016/j.neuroimage.2021.118726; Rezaei A, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10120934; Ridding MC, 2010, J PHYSIOL-LONDON, V588, P2291, DOI 10.1113/jphysiol.2010.190314; Romo R, 1999, NATURE, V399, P470, DOI 10.1038/20939; Russell GS, 2005, CLIN NEUROPHYSIOL, V116, P1130, DOI 10.1016/j.clinph.2004.12.022; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Saito K, 2019, BEHAV BRAIN RES, V375, DOI 10.1016/j.bbr.2019.112168; Salman A, 2016, CONCURR COMP-PRACT E, V28, P2213, DOI 10.1002/cpe.3510; Saturnino GB, 2019, NEUROIMAGE, V188, P821, DOI 10.1016/j.neuroimage.2018.12.053; Schmidt C, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/4/046028; Smith MJ, 1999, NEUROLOGY, V53, P2069, DOI 10.1212/WNL.53.9.2069; Stropahl M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00309; Sun FQ, 2021, CLIN NEUROPHYSIOL, V132, P487, DOI 10.1016/j.clinph.2020.11.032; Tame L, 2012, J COGNITIVE NEUROSCI, V24, P2306, DOI 10.1162/jocn_a_00272; Tremblay S, 2017, BRAIN STIMUL, V10, P744, DOI 10.1016/j.brs.2017.03.009; Vieira PG, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000834; Viola FC, 2009, CLIN NEUROPHYSIOL, V120, P868, DOI 10.1016/j.clinph.2009.01.015; Vorwerk J, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00531; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004; Wagner S, 2016, NEUROIMAGE, V140, P163, DOI 10.1016/j.neuroimage.2016.04.005; Wischnewski M, 2019, BRAIN STIMUL, V12, P1381, DOI 10.1016/j.brs.2019.07.023; Wittenberg MA., 2019, FRONT NEUROSCI, V13, P1, DOI [10.3389/fnins.2019.00001, DOI 10.3389/FNINS.2019.00001]; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Zulkifly MFM, 2021, CLIN NEUROPHYSIOL, V132, P1367, DOI 10.1016/j.clinph.2021.01.024; Zulkifly MFM, 2021, PSYCHONEUROENDOCRINO, V127, DOI 10.1016/j.psyneuen.2021.105201; Zulkifly MFM, 2020, CLIN NEUROPHYSIOL, V131, P778, DOI 10.1016/j.clinph.2019.11.062	93	0	0	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2022	17	3							e0266107	10.1371/journal.pone.0266107	http://dx.doi.org/10.1371/journal.pone.0266107			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0K7DW	35324989	Green Published, gold			2023-01-03	WOS:000780951300101
J	Davies, DJ; Hadis, M; Di Pietro, V; Lazzarino, G; Forcione, M; Harris, G; Stevens, AR; Soon, WC; Oppenheimer, PG; Milward, M; Belli, A; Palin, WM				Davies, David J.; Hadis, Mohammed; Di Pietro, Valentina; Lazzarino, Giuseppe; Forcione, Mario; Harris, Georgia; Stevens, Andrew R.; Soon, Wai Cheong; Oppenheimer, Pola Goldberg; Milward, Michael; Belli, Antonio; Palin, William M.			Photobiomodulation reduces hippocampal apoptotic cell death and produces a Raman spectroscopic "signature"	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; LEVEL LASER THERAPY; SPINAL-CORD; IN-VITRO; LIGHT; TISSUE; MODEL; MECHANISMS; INDUCTION; PRESSURE	Apoptotic cell death within the brain represents a significant contributing factor to impaired post-traumatic tissue function and poor clinical outcome after traumatic brain injury. After irradiation with light in the wavelength range of 600-1200 nm (photobiomodulation), previous investigations have reported a reduction in apoptosis in various tissues. This study investigates the effect of 660 nm photobiomodulation on organotypic slice cultured hippocampal tissue of rats, examining the effect on apoptotic cell loss. Tissue optical Raman spectroscopic changes were evaluated. A significantly higher proportion of apoptotic cells 62.8 +/- 12.2% vs 48.6 +/- 13.7% (P<0.0001) per region were observed in the control group compared with the photobiomodulation group. After photobiomodulation, Raman spectroscopic observations demonstrated 1440/1660 cm(-1) spectral shift. Photobiomodulation has the potential for therapeutic utility, reducing cell loss to apoptosis in injured neurological tissue, as demonstrated in this in vitro model. A clear Raman spectroscopic signal was observed after apparent optimal irradiation, potentially integrable into therapeutic light delivery apparatus for real-time dose metering.	[Davies, David J.; Di Pietro, Valentina; Forcione, Mario; Stevens, Andrew R.; Soon, Wai Cheong; Belli, Antonio] Univ Birmingham, Inst Inflammat & Ageing, Dept Neurosci & Ophthalmol, Birmingham, W Midlands, England; [Davies, David J.; Forcione, Mario; Stevens, Andrew R.; Belli, Antonio] Univ Hosp Birmingham Edgbaston, Natl Inst Hlth Res Surg Reconstruct, Birmingham, W Midlands, England; [Davies, David J.; Forcione, Mario; Stevens, Andrew R.; Belli, Antonio] Univ Hosp Birmingham Edgbaston, Microbiol Res Ctr, Birmingham, W Midlands, England; [Hadis, Mohammed; Milward, Michael; Palin, William M.] Univ Birmingham, Coll Med & Dent Sci, Sch Dent, Inst Clin Sci,Photobiol Res Grp, Birmingham, W Midlands, England; [Lazzarino, Giuseppe] Univ Catania, Dept Chem Sci, Lab Biochem, Catania, Italy; [Harris, Georgia; Oppenheimer, Pola Goldberg] Univ Birmingham, Fac Chem & Biol Engn, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Catania; University of Birmingham	Davies, DJ (corresponding author), Univ Birmingham, Inst Inflammat & Ageing, Dept Neurosci & Ophthalmol, Birmingham, W Midlands, England.; Davies, DJ (corresponding author), Univ Hosp Birmingham Edgbaston, Natl Inst Hlth Res Surg Reconstruct, Birmingham, W Midlands, England.; Davies, DJ (corresponding author), Univ Hosp Birmingham Edgbaston, Microbiol Res Ctr, Birmingham, W Midlands, England.	daviesdj@doctors.org.uk	Stevens, Andrew/GXH-1543-2022	Stevens, Andrew/0000-0002-3222-133X; Harris, Georgia/0000-0001-8826-7057; Goldberg Oppenheimer, Pola/0000-0002-1014-4724	Midland Neuroscience Teaching and Research Fund (University of Birmingham) [1001177]	Midland Neuroscience Teaching and Research Fund (University of Birmingham)	DD received a grant from the Midland Neuroscience Teaching and Research Fund (University of Birmingham Grant Number 1001177) (https://mntrf.org.uk/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asnaashari M, 2013, J LASERS MED SCI, V4, P57; BANBURY C, 2019, SCI REP-UK, V9, P1, DOI DOI 10.1038/S41598-018-37186-230626917; Banbury C, 2020, BIOMED OPT EXPRESS, V11, P6249, DOI 10.1364/BOE.399473; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Chu YH, 2018, LASER MED SCI, V33, P279, DOI 10.1007/s10103-017-2364-x; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Darlot F, 2016, ANN NEUROL, V79, P59, DOI 10.1002/ana.24542; de Medeiros ML, 2017, LASER MED SCI, V32, P35, DOI 10.1007/s10103-016-2080-y; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; El Gammal ZH, 2017, LASER MED SCI, V32, P1637, DOI 10.1007/s10103-017-2271-1; Ferland RJ, 2002, NEUROSCIENCE, V115, P669, DOI 10.1016/S0306-4522(02)00514-6; Fukuoka CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169443; Galli R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01165; Giuliani A, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-8; Hadis MA, 2017, J BIOPHOTONICS, V10, P1514, DOI 10.1002/jbio.201600273; Hadis MA, 2016, LASER MED SCI, V31, P789, DOI 10.1007/s10103-016-1914-y; Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864; Hanlon EB, 2000, PHYS MED BIOL, V45, pR1, DOI 10.1088/0031-9155/45/2/201; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Humpel C, 2015, NEUROSCIENCE, V305, P86, DOI 10.1016/j.neuroscience.2015.07.086; Jagdeo JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047460; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kohler M, 2009, ANAL BIOANAL CHEM, V393, P1513, DOI 10.1007/s00216-008-2592-9; Kumar V, 2010, INDIAN J PURE AP PHY, V48, P85; Lalonde JW., 2019, MECH PHOTOBIOMODULAT, P18, DOI [10.1117/12.2508684.full, DOI 10.1117/12.2508684.FULL]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lanzafame RJ, 2007, LASER SURG MED, V39, P534, DOI 10.1002/lsm.20519; Liang JG, 2012, FREE RADICAL BIO MED, V53, P1459, DOI 10.1016/j.freeradbiomed.2012.08.003; Lim W, 2009, FREE RADICAL BIO MED, V47, P850, DOI 10.1016/j.freeradbiomed.2009.06.023; Lima PLV, 2019, J PHOTOCH PHOTOBIO B, V194, P71, DOI 10.1016/j.jphotobiol.2019.03.015; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Moro C, 2014, J NEUROSURG, V120, P670, DOI 10.3171/2013.9.JNS13423; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Mowbray M, 2021, ACS BIOMATER SCI ENG, V7, P1252, DOI 10.1021/acsbiomaterials.0c01156; Muthuselvi C., 2018, ASIAN J APPL SCI, V11, P83, DOI [DOI 10.3923/AJAPS.2018.83.91, 10.3923/ajaps.2018.83.91]; Pansani TN, 2014, INT J ORAL MAX SURG, V43, P1030, DOI 10.1016/j.ijom.2014.02.011; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reinhart F, 2016, J NEUROSURG, V124, P1829, DOI 10.3171/2015.5.JNS15735; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Sacharz J, 2018, SPECTROCHIM ACTA A, V188, P581, DOI 10.1016/j.saa.2017.07.046; Salehpour F, 2018, MOL NEUROBIOL, V55, P6601, DOI 10.1007/s12035-017-0852-4; Shipp DW., 2017, SPECTROSCOPY RAMAN 1, DOI [10.1364/aop.XX.XXXXXX, DOI 10.1364/AOP.XX.XXXXXX]; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Sommer AP, 2012, PHOTOMED LASER SURG, V30, P54, DOI 10.1089/pho.2011.3073; Staniszewska-Slezak E, 2015, SPECTROCHIM ACTA A, V147, P245, DOI 10.1016/j.saa.2015.03.086; Sun Grace, 2004, Dent Clin North Am, V48, P1061, DOI 10.1016/j.cden.2004.05.004; Sussai DA, 2010, LASER MED SCI, V25, P115, DOI 10.1007/s10103-009-0697-9; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yoon SR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071664	56	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264533	10.1371/journal.pone.0264533	http://dx.doi.org/10.1371/journal.pone.0264533			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0D4YH	35239693	gold, Green Published			2023-01-03	WOS:000776002200042
J	Martianez-Ramirez, NL; Pineda-Galan, C; Rodriguez-Bailon, M; Romero-Galisteo, RP				Lola Martianez-Ramirez, Noa; Pineda-Galan, Consolacion; Rodriguez-Bailon, Maria; Romero-Galisteo, Rita-Pilar			Competence assessment rubric in the Physiotherapy Practicum	PLOS ONE			English	Article							HIGHER-EDUCATION; PROFESSIONAL COMPETENCE; PRACTICE APP; STUDENTS	Introduction Competence-based learning must be integrated into the practical development of Physiotherapy. Teamwork, interpersonal relations, analytical skills or critical/clinical thinking are some examples of internationally recommended competences in this kind of university studies. Therefore, there is a need to evaluate this learning in Physiotherapy through valid tools that facilitate this task. Objective To analyze the psychometric properties according to competences in Clinical Practices (RECOPC-FIS II) in order to assess 14 transversal or universal competences of under-graduate students in the Physiotherapy degree. Methods A validation study was conducted with 197 students in the 3rd and 4th year of the Physiotherapy degree and 202 clinical tutors who assessed these students using the RECOPC-FIS II. Different psychometric properties were analyzed: factor structure, internal consistency and sensitivity to change. Results The RECOPC-FIS II has a high internal consistency. Its 14 items saturate in a single factor. Regarding the sensitivity to change, the rubric showed higher scores in the Practicum of the 4th year with respect to that of the 3rd year, reaching significant differences in all of them. Conclusion The RECOPC-FIS II is a valid and reliable instrument to assess the transversal competencies of undergraduate students of Physiotherapy during their clinical practice. Therefore, it is intended to facilitate the acquisition of essential skills for the development of their professional career. The flexibility of this tool would allow its adaptation to other health science courses.	[Lola Martianez-Ramirez, Noa] Autonomous Univ Madrid, La Salle Higher Educ Ctr, Dept Physiotherapy, Madrid, Spain; [Pineda-Galan, Consolacion; Rodriguez-Bailon, Maria; Romero-Galisteo, Rita-Pilar] Univ Malaga, Fac Hlth Sci, Dept Physiotherapy, Malaga, Spain	Autonomous University of Madrid; Universidad de Malaga	Rodriguez-Bailon, M (corresponding author), Univ Malaga, Fac Hlth Sci, Dept Physiotherapy, Malaga, Spain.	mariabailon@uma.es	Pineda Galan, Consolacion C/GNW-6464-2022; Romero Galisteo, Rita Pilar/Z-1976-2018	Pineda Gaan, Consolacion/0000-0003-2997-0396; Rodriguez-Bailon, Maria/0000-0001-6658-7658; Romero Galisteo, Rita Pilar/0000-0003-4669-0679	University of Malaga from an Educational Innovation Project with title: Evaluation rubric for competency-based interventions and training program for clinical tutors in the Physiotherapy and Occupational Therapy Practicum [PIE17-008]; University of Malaga	University of Malaga from an Educational Innovation Project with title: Evaluation rubric for competency-based interventions and training program for clinical tutors in the Physiotherapy and Occupational Therapy Practicum; University of Malaga	CPG,RPRG,MRB,NMR. This work was supported by the University of Malaga from an Educational Innovation Project with title: Evaluation rubric for competency-based interventions and training program for clinical tutors in the Physiotherapy and Occupational Therapy Practicum. Code: PIE17-008. This work also received financial support from University of Malaga.	Allison H., 2004, AUSTR OCCUPATIONAL T, V51, P125, DOI [10.1111/j.1440-1630.2004.00414.x, DOI 10.1111/J.1440-1630.2004.00414.X]; [Anonymous], 2004, LIBRO BLANCO T TULO; Bergsmann E, 2018, ASSESS EVAL HIGH EDU, V43, P537, DOI 10.1080/02602938.2017.1378617; Bergsmann E, 2015, EVAL PROGRAM PLANN, V52, P1, DOI 10.1016/j.evalprogplan.2015.03.001; Blomeke S, 2015, Z PSYCHOL, V223, P3, DOI 10.1027/2151-2604/a000194; Cebrian-de-la-Serna M, 2014, COMUNICAR, V22, P153, DOI 10.3916/C43-2014-15; Chan A, 2016, MED EDUC, V50, P898, DOI 10.1111/medu.13117; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; Copley J, 2012, BRIT J OCCUP THER, V75, P456, DOI 10.4276/030802212X13496921049662; Dalton M, 2012, J PHYSIOTHER, V58, P49, DOI 10.1016/S1836-9553(12)70072-3; Dalton M, 2011, J PHYSIOTHER, V57, P239, DOI 10.1016/S1836-9553(11)70054-6; Diaz-Mohedo E., DELPHI APPROACH, V4, P1, DOI [10.1186/s12909-021-02904-4, DOI 10.1186/S12909-021-02904-4]; Dogan CD., 2015, TURKIYE KLIN J SPORT, V7, P9; Durante E., 2012, REV DOCENCIA U, V10, P149, DOI 10.4995/redu.2012.6101; European Association for Quality Assurance in Higher Education, 2015, QUAL PROC EUR HIGH E; Fahy A, 2011, Nurs Stand, V25, P42; Gantt LT, 2010, NURS EDUC PERSPECT, V31, P101; Gonzalez J., 2006, CONTRIBUCION U PROCE; Hartig J., 2008, ASSESSMENT COMPETENC; Jimenez Galan YI., 2011, CPU E REV INVESTIG E, V13, P1; Marin-Garcia JA, 2015, INTANG CAP, V11, P118, DOI 10.3926/ic.538; Martianez N.L., 2016, HERNANDO COMPETENCIA; Martianez NL., 2015, FISIOTERAPIA, V37, P83; Martianez Ramirez NL., 2016, RUBRICA COMO INSTRUM; Miller L., 2001, OCCUPATIONAL THERAPY, V8, P244, DOI DOI 10.1002/OTI.149; MostafaKhan HSE., 2013, IRAN REHABIL J, V11, P46; Noble C, 2020, ADV HEALTH SCI EDUC, V25, P55, DOI 10.1007/s10459-019-09905-5; Nunez-Cortes JM., 2014, GUIA EVALUACION PRAC; O'Connor A, 2018, PHYSIOTHERAPY, V104, P46, DOI 10.1016/j.physio.2017.01.005; Osana H.P., 2004, EDUC RES EVAL, V10, P473, DOI [10.1080/13803610512331383529, DOI 10.1080/13803610512331383529]; Ossenberg C, 2016, NURS EDUC TODAY, V36, P23, DOI 10.1016/j.nedt.2015.07.012; Panadero E, 2013, EDUC RES REV-NETH, V9, P129, DOI 10.1016/j.edurev.2013.01.002; Pozo Florez JA del, 2015, COMPETENCIAS PROFESI, V3a; Rodriguez de Castro F, 2015, ED MED S1, V16, P50; Iglesias-Parra MR, 2015, J NURS SCHOLARSHIP, V47, P371, DOI 10.1111/jnu.12140; Shavelson R.J., 2010, EMPIRICAL RES VOCATI, V2, P41, DOI 10.1007/BF03546488; Shipman D, 2012, NURS EDUC TODAY, V32, P246, DOI 10.1016/j.nedt.2011.04.007; T Campos Garcia CRB y ARR, 2011, GUIA TUT FORM PRACT; Tabachnick B. G., 2007, USING MULTIVARIATE S, Vfifth; Tamayo-Caballero RL., 2018, ATLANTE CUAD ED DESA; Tejada Fernandez J, 2005, REDIE REV ELECT INVE, V7, P10; Fernandez JT, 2016, EDUC XX1, V19, P17, DOI 10.5944/educXX1.12175; Terron-Lopez MJ., 2012, VERTICE; The Chartered Society of Physiotherapy, 2013, PHYS FRAM PUTT PHYS; Tilson JK, 2011, BMC MED EDUC, V11, DOI 10.1186/1472-6920-11-78; Torres-Narvaez MR, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1377-x; Tractenberg RE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225256; Turpin M, 2011, AUST OCCUP THER J, V58, P67, DOI 10.1111/j.1440-1630.2010.00890.x; World Confederation for Physical Therapy (WCPT), 2018, ADV PRACT PHYS EUR R; World Confederation for Physical Therapy (WCPT), 2017, WCPT GUID CLIN ED CO; Beraza MAZ, 2011, REV EDUC-MADRID, P21	51	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0264120	10.1371/journal.pone.0264120	http://dx.doi.org/10.1371/journal.pone.0264120			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0U7EE	35213586	Green Published, gold			2023-01-03	WOS:000787811000049
J	Veziari, Y; Kumar, S; Leach, MJ				Veziari, Yasamin; Kumar, Saravana; Leach, Matthew J.			An exploration of barriers and enablers to the conduct and application of research among complementary and alternative medicine stakeholders in Australia and New Zealand: A qualitative descriptive study	PLOS ONE			English	Article							ACUTE STROKE CARE; FEE-FOR-SERVICE; CLINICAL-PRACTICE; HEALTH-PROFESSIONALS; FACULTY-DEVELOPMENT; RESEARCH CAPACITY; SAMPLE-SIZE; IMPLEMENTATION; KNOWLEDGE; ATTITUDES	Background Most studies examining complementary and alternative medicine (CAM) stakeholder engagement with evidence-based practice have relied on quantitative research methods, which often fail to capture the nuances of this phenomena. Using qualitative methods, this study aimed to explore the experiences of CAM stakeholders regarding the barriers and enablers to the conduct and application of research. Methods This research was guided by a qualitative descriptive framework. CAM practitioners and researchers of multiple CAM disciplines from across Australia and New Zealand were invited to share their personal perspectives of the study phenomena. Semi-structured interviews were conducted via Zoom, which were audio-recorded and transcribed verbatim. Rigour strategies were applied to ensure the credibility of results. The transcript was analysed using thematic analysis. Results CAM stakeholders identified an array of barriers and enablers to the conduct and application of research within their disciplines. The barriers and enablers that emerged were found to be inter-connected with two similar constructs: capacity and culture. Captured within the construct of capacity were five themes-lack of resources, inadequate governance/leadership, lack of competency, bias directed from outside and within CAM, and lack of time for research. Within the construct of culture were two themes-intrinsic perceptions in CAM, and lack of communication within and outside CAM. Conclusions Promoting evidence-based practice and engaging with research in CAM continues to face challenges. This study, for the first time, has highlighted the multitude of interlinked barriers that confront CAM stakeholders when engaging with research. These findings highlight the need for a concerted and targeted approach to tackle these challenges.	[Veziari, Yasamin; Kumar, Saravana] Univ South Australia, UniSA Allied Hlth & Human Performance, North Terrace, Adelaide, SA, Australia; [Leach, Matthew J.] Southern Cross Univ, Natl Ctr Naturopath Med, East Lismore, NSW, Australia	University of South Australia; Southern Cross University	Kumar, S (corresponding author), Univ South Australia, UniSA Allied Hlth & Human Performance, North Terrace, Adelaide, SA, Australia.	saravana.kumar@unisa.edu.au	Kumar, Saravana/B-8876-2009	Kumar, Saravana/0000-0002-4003-4411	Australian Government Research Training Program Scholarship; Commonwealth Scholarships Program of South Australia	Australian Government Research Training Program Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Commonwealth Scholarships Program of South Australia	We acknowledge the participation of all the participants who participated in this study for giving up their time to share their perspectives on the issue of barriers and enablers to the conduct and application of research in complementary and alternative medicine. We would like to also thank the CAM organisations, Professional CAM associations, university alumni, CAM schools from Australia and New Zealand, the Tertiary and Further Education institutions from Australia, practice-based research networks, research organisations and CAM social media groups on Twitter, Facebook and LinkedIn who helped with the overall broader body of this research. Ms. Veziari acknowledges the Australian Government Research Training Program Scholarship and the Commonwealth Scholarships Program of South Australia that fund her PhD.	Abbott R., 2014, DOCUMENTING TRADITIO; Allen ES, 2011, EXPLORE-NY, V7, P88, DOI 10.1016/j.explore.2010.12.001; [Anonymous], 1999, NUD 1 VIVO N VIVO, V10; Ataee M, 2015, J Med Life, V8, P12; Australian Bureau of Statistics, 2011, 85700 AUSTR BUR STAT; Avila C, 2020, COMPLEMENT THER MED, V49, DOI 10.1016/j.ctim.2020.102317; Baatiema L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0599-3; Bach-Mortensen AM, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0789-7; Bakken S, 2009, J AM BOARD FAM MED, V22, P436, DOI 10.3122/jabfm.2009.04.090017; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barrett B, 2004, ANN FAM MED, V2, P253, DOI 10.1370/afm.81; Barriers and Bridges to Evidence-Based Clinical Practice, 2002, GETTING RES FINDINGS, P11522; Birt L, 2016, QUAL HEALTH RES, V26, P1802, DOI 10.1177/1049732316654870; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Bridges Diane R, 2011, Med Educ Online, V16, DOI 10.3402/meo.v16i0.6035; Brownson RC, 2006, PUBLIC HEALTH REP, V121, P97, DOI 10.1177/003335490612100118; Bussieres Andre E, 2015, J Can Chiropr Assoc, V59, P332; Cant S., 2020, SOC CULTURE S ASIA, V6, P31, DOI DOI 10.1177/2393861719883064; Castillo-Montoya M., 2016, PREPARING INTERVIEW, V21, P811, DOI [10.1016/j.circir.2016.05.008, DOI 10.1016/J.CIRCIR.2016.05.008]; Chhotray S, 2018, J INT ENTREP, V16, P38, DOI 10.1007/s10843-017-0201-8; Chrystal Kathryn, 2003, N Z Med J, V116, pU296; Coulter ID, 2004, MED J AUSTRALIA, V180, P587, DOI 10.5694/j.1326-5377.2004.tb06099.x; Cramer GD., 2015, MED SCI EDUC, V25, P27; Creswell JW., 1994, RES DESIGN QUALITATI, P228; Crowe S, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0643-3; Curtis K, 2017, J CLIN NURS, V26, P862, DOI 10.1111/jocn.13586; Dale S, 2015, WORLDV EVID-BASED NU, V12, P41, DOI 10.1111/wvn.12078; Dean KS, 2010, STRATEGIES BENEFITS; Dizon JM, 2017, HEALTH RES POLICY SY, V15, DOI 10.1186/s12961-017-0243-3; Donnellan C, 2013, HEALTH POLICY, V111, P245, DOI 10.1016/j.healthpol.2013.05.002; Ekor M., 2014, Y, V4, P177; Evans R, 2011, EXPLORE-NY, V7, P265, DOI 10.1016/j.explore.2011.04.014; Eysenbach G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e13; Fischer FH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-46; Forero R, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2915-2; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Friesen EL, 2017, AUST J PRIM HEALTH, V23, P123, DOI 10.1071/PY15131; Gaboury I, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-131; Glasziou P, 2017, LANCET, V390, P169, DOI 10.1016/S0140-6736(16)30946-1; Goodman MS, 2017, TRANSL BEHAV MED, V7, P486, DOI 10.1007/s13142-017-0495-z; Greenhalgh T., 2004, BMJ-BRIT MED J, V328, P529, DOI [10.1136/bmj.328.7438.529, DOI 10.1136/BMJ.328.7438.529]; Greenhalgh T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0437-x; Haas M, 2012, J MANIP PHYSIOL THER, V35, P701, DOI 10.1016/j.jmpt.2012.10.014; Hao PP, 2017, J AM COLL CARDIOL, V69, P2952, DOI 10.1016/j.jacc.2017.04.041; Hawk C, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/528487; Herman PM, 2015, COMPLEMENTARY ALTERN; Hofseth LJ, 2018, CARCINOGENESIS, V39, P21, DOI 10.1093/carcin/bgx085; Hunt K, 2009, J HEALTH SERV RES PO, V14, P219, DOI 10.1258/jhsrp.2009.009009; Ikegami N, 2015, INT J HEALTH POLICY, V4, P57, DOI 10.15171/ijhpm.2015.26; Jabbour M, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0832-8; Jagtenberg T, 2006, J ALTERN COMPLEM MED, V12, P323, DOI 10.1089/acm.2006.12.323; Jang A, 2017, J ALTERN COMPLEM MED, V23, P362, DOI 10.1089/acm.2016.0289; Kaiser RB, 2008, AM PSYCHOL, V63, P96, DOI 10.1037/0003-066X.63.2.96; Karimian Z., 2012, Eastern Mediterranean Health Journal, V18, P1143; Khazaal Y, 2014, J MED INTERNET RES, V16, P44, DOI 10.2196/jmir.2759; Kinsel JE, 2003, ANNU REV PHARMACOL, V43, P463, DOI 10.1146/annurev.pharmtox.43.100901.135757; Koch T, 2006, J ADV NURS, V53, P91, DOI 10.1111/j.1365-2648.2006.03681.x; Laird S, 2010, J AM OSTEOPATH ASSOC, V110, P593; Leach MJ, 2008, J EVAL CLIN PRACT, V14, P792, DOI 10.1111/j.1365-2753.2008.01046.x; Leach MJ, 2018, COMPLEMENT THER CLIN, V31, P38, DOI 10.1016/j.ctcp.2018.01.011; Leach MJ, 2017, EXPLORE-NY, V13, P53, DOI 10.1016/j.explore.2016.10.005; Leach MJ, 2013, COMPLEMENT THER MED, V21, P364, DOI 10.1016/j.ctim.2013.04.004; Leach MJ, 2011, COMPLEMENT THER MED, V19, P128, DOI 10.1016/j.ctim.2011.04.002; Lemonnier N., 2017, PROGR PREVENTIVE MED, V2, DOI [10.1097/pp9.0000000000000010, DOI 10.1097/PP9.0000000000000010]; Leung K, 2016, NURS EDUC TODAY, V39, P189, DOI 10.1016/j.nedt.2016.01.026; Long CR, 2014, J ALTERN COMPLEM MED, V20, P563, DOI 10.1089/acm.2013.0385; Luckson M, 2018, J CLIN NURS, V27, pE1462, DOI 10.1111/jocn.14264; MacArtney JI, 2014, QUAL HEALTH RES, V24, P114, DOI 10.1177/1049732313518977; Magill MK, 2016, ANN FAM MED, V14, P400, DOI 10.1370/afm.1977; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; Marian F, 2006, FORSCH KOMP KLAS NAT, V13, P70, DOI 10.1159/000090735; Mason M., 2010, FORUM QUAL SOC RES, V11, P1, DOI DOI 10.17169/FQS-11.3.1428; Mathieson A, 2018, PRIM HEALTH CARE RES, V20, DOI 10.1017/S1463423618000488; Matus J, 2019, J MULTIDISCIP HEALTH, V12, P83, DOI 10.2147/JMDH.S178696; Mazzotta C, 2016, J NURSING ED PRACTIC, V6; Mc Goldrick EL, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1858-8; McCarty RL, 2011, EXPLORE-NY, V7, P249, DOI 10.1016/j.explore.2011.04.003; McGrath C, 2019, MED TEACH, V41, P1002, DOI 10.1080/0142159X.2018.1497149; Miles A, 2008, J EVAL CLIN PRACT, V14, P621, DOI 10.1111/j.1365-2753.2008.01094.x; Mills SY, 2001, BRIT MED J, V322, P158, DOI 10.1136/bmj.322.7279.158; Milstein M, 2000, CAN VET J, V41, P769; Morse JM, 2000, QUAL HEALTH RES, V10, P3, DOI 10.1177/104973200129118183; Nancarrow SA, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-19; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; O'Leary D, 2021, SYNTHESE, V199, P1977, DOI 10.1007/s11229-020-02869-9; Okoduwa SIR., 2018, ATTITUDES PERCEPTION, V3; Olaussen A, 2017, EMERG MED AUSTRALAS, V29, P204, DOI 10.1111/1742-6723.12734; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Patwardhan B, 2009, DRUG DISCOV TODAY, V14, P804, DOI 10.1016/j.drudis.2009.05.009; Polit D., 2012, NURSING RESEARCHGENE; Power M, 2011, J ROY SOC MED, V104, P155, DOI 10.1258/jrsm.2011.100271; Raheim M, 2016, INT J QUAL STUD HEAL, V11, DOI 10.3402/qhw.v11.30996; Ray CE, 2013, SEMIN INTERVENT RAD, V30, P331, DOI 10.1055/s-0033-1359725; Richards H, 2000, FAM PRACT, V17, P71, DOI 10.1093/fampra/17.1.71; Robson C., 2017, REAL WORLD RES, V4th ed.; Roecker CB, 2013, CHIROPR MAN THER, V21, DOI 10.1186/2045-709X-21-43; Ross JS, 2009, AM J MED, V122, P955, DOI 10.1016/j.amjmed.2009.04.013; Ryan JC, 2019, J INNOV KNOWL, V4, P47, DOI 10.1016/j.jik.2017.10.004; Sandelowski M., 2000, WHATEVER HAPPENED QU, V23, P334; Schneider MJ, 2015, CHIROPR MAN THER, V23, DOI 10.1186/s12998-015-0060-0; Shahvisi A, 2016, BIOETHICS, V30, P69, DOI 10.1111/bioe.12228; Sharplin G, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7040142; Shayan SJ., 2019, BARRIERS ASS EVIDENC, V16, P12; Shifaza F., 2014, ADV IN NURSING, V2014; Shim JM, 2016, ASIA-PAC J PUBLIC HE, V28, P51, DOI 10.1177/1010539515613411; Steel A, 2014, AUSTR J HERBAL MED, V26, P136; Stokke K, 2014, BMC NURS, V13, DOI 10.1186/1472-6955-13-8; Stoneman P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053174; Straus SE, 2011, J CLIN EPIDEMIOL, V64, P6, DOI 10.1016/j.jclinepi.2009.08.016; STRUTZEL E, 1968, NURS RES, V17, P364; Stub T, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1770-8; Sullivan B., 2013, EXPLORE-NY, V9, P323; Sullivan T., 1998, COLLABORATION HEATHC; Sundberg T., 2019, ADV INTEGR MED, V6, pS44; Tabish Syed Amin, 2008, Int J Health Sci (Qassim), V2, pV; Tilburt JC, 2009, ARCH INTERN MED, V169, P670, DOI 10.1001/archinternmed.2009.49; Tonelli MR, 2001, ACAD MED, V76, P1213, DOI 10.1097/00001888-200112000-00011; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Verhoef Marja J, 2006, BMC Complement Altern Med, V6, P6; Veziari Y, 2021, COMPLEMENT THER MED, V60, DOI 10.1016/j.ctim.2021.102752; Veziari Y, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1660-0; von Conrady DM, 2017, AUST FAM PHYSICIAN, V46, P315; Wade C, 2008, J WOMENS HEALTH, V17, P829, DOI 10.1089/jwh.2007.0579; Walker BF, 2013, CHIROPR MAN THER, V21, DOI 10.1186/2045-709X-21-44; Wardle J., 2015, AUSTR J HERBAL MED, V27, P47; Wayne PM, 2008, ALTERN THER HEALTH M, V14, P52; Wieland LS, 2011, ALTERN THER HEALTH M, V17, P50; Wiese M., 2016, FOCUS ALTERNATIVE CO, V21, P143; World Health Organzation, 2013, WHO TRADITIONAL MED; Zank S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174731; Zwickey H, 2014, J ALTERN COMPLEM MED, V20, P925, DOI 10.1089/acm.2014.0087; Zwolsman S, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X652382	132	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2022	17	2							e0264221	10.1371/journal.pone.0264221	http://dx.doi.org/10.1371/journal.pone.0264221			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H3HL	35180276	Green Accepted, gold, Green Published			2023-01-03	WOS:000796435800054
J	Gressens, SB; Esnault, V; De Castro, N; Sellier, P; Sene, D; Chantelot, L; Hervier, B; Delaugerre, C; Chevret, S; Molina, JM				Gressens, Simon B.; Esnault, Violaine; De Castro, Nathalie; Sellier, Pierre; Sene, Damien; Chantelot, Louise; Hervier, Baptiste; Delaugerre, Constance; Chevret, Sylvie; Molina, Jean-Michel		Saint-Louis Core Grp	Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study	PLOS ONE			English	Article								Background Dexamethasone is standard of care for the treatment of patients with COVID-19 requiring oxygen. The objective is to assess the clinical benefit of adding remdesivir to dexamethasone. Patients and methods A retrospective cohort study of hospitalized patients with COVID-19 pneumonia requesting low-flow oxygen who received dexamethasone. Patients admitted to infectious diseases wards also received remdesivir. Primary outcome was duration of hospitalization after oxygen initiation. Secondary outcomes were in-hospital death, and death and/or transfer to the intensive care unit. To handle potential confounding by indication bias, outcome comparison was performed on propensity score-matched populations. Propensity score was estimated by a multivariable logistic model including prognostic covariates; then 1:1 matching was performed without replacement, using the nearest neighbor algorithm with a caliper of 0.10 fold the standard deviation of the propensity score as the maximal distance. Balance after matching was checked on standardized mean differences. Results From August 15th 2020, to February 28th, 2021, 325 patients were included, 101 of whom received remdesivir. At admission median time from symptoms onset was 7 days, median age: 68 years, male sex; 61%, > 1 comorbidity: 58.5%. Overall 180 patients matched on propensity score were analyzed, 90 each received remdesivir plus dexamethasone or dexamethasone alone. Median duration of hospitalization was 9 (IQR: 7-13) and 9 (IQR: 5-18) days with and without remdesivir, respectively (p = 0.37). In-hospital death rates and rates of transfer to the intensive care unit or death were 8.9 and 17.8% (HR: 0.46, 95% CI: 0.21-1.02, p = 0.06) and 20.0 and 35.6% with and without remdesivir, respectively (HR: 0.45, 95% CI: 0.23-0.89, p = 0.015). Conclusion In hospitalized patients with COVID-19 pneumonia receiving low-flow oxygen and dexamethasone, the addition of remdesivir was not associated with shorter hospitalization or lower in-hospital mortality but may have reduced the combined outcome of death and transfer to the intensive care unit.	[Gressens, Simon B.; Esnault, Violaine; De Castro, Nathalie; Sellier, Pierre; Molina, Jean-Michel] Univ Paris, Hop St Louis Lariboisiere, AP HP, Dept Malad Infect, Paris, France; [Sene, Damien] Hop Lariboisiere, AP HP, Dept Med Interne, Paris, France; [Chantelot, Louise] Hop St Louis, AP HP, Serv Pneumol, Paris, France; [Hervier, Baptiste] Hop St Louis, AP HP, UF Med Interne, Paris, France; [Delaugerre, Constance] Hop St Louis, AP HP, Lab Virol, Paris, France; [Chevret, Sylvie] Hop St Louis, AP HP, Serv Biostat & Informat Med, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Gressens, SB (corresponding author), Univ Paris, Hop St Louis Lariboisiere, AP HP, Dept Malad Infect, Paris, France.	simon.gressens@aphp.fr	sene, damien/R-3970-2017	sene, damien/0000-0001-8640-4580				Austin PC, 2014, STAT MED, V33, P1057, DOI 10.1002/sim.6004; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benfield T, 2021, CLIN INFECT DIS, V73, P2031, DOI 10.1093/cid/ciab536; Franklin JM, 2014, STAT MED, V33, P1685, DOI 10.1002/sim.6058; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Garibaldi BT, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.3071; HCSP, 2021, COV 19 REC THER ACT; Hill JA, 2021, IDWEEK VIRT C SEPT 2; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; INSERM, 2021, DISC STOPS TEST REMD; Jorgensen SCJ, 2020, PHARMACOTHERAPY, V40, P659, DOI 10.1002/phar.2429; Khachfe HH, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.7313; Lane HC, 2021, NEW ENGL J MED, V384, P755, DOI 10.1056/NEJMe2024638; Li F, 2019, AM J EPIDEMIOL, V188, P250, DOI 10.1093/aje/kwy201; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Ohl ME, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14741; Olender Susan A, 2021, Clin Infect Dis, V73, pe4166, DOI 10.1093/cid/ciaa1041; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wilt TJ, 2021, ANN INTERN MED, V174, P209, DOI 10.7326/M20-5752	23	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0262564	10.1371/journal.pone.0262564	http://dx.doi.org/10.1371/journal.pone.0262564			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176057	gold, Green Published			2023-01-03	WOS:000777505200009
J	Tiyoula, FN; Aryapour, H				Tiyoula, Fereshteh Noroozi; Aryapour, Hassan			Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations	PLOS ONE			English	Article							CORONAVIRUS; DISCOVERY; PROTEASE; SUMD	The main protease (3CLpro) is one of the essential components of the SARS-CoVs viral life cycle, which makes it an interesting target for overpowering these viruses. Although many covalent and noncovalent inhibitors have been designed to inhibit this molecular target, none have gained FDA approval as a drug. Because of the high rate of COVID-19 pandemic development, in addition to laboratory research, we require in silico methods to accelerate rational drug design. The unbinding pathways of two SARS-CoV and SARS-CoV-2 3CLpro noncovalent inhibitors with the PDB IDs: 3V3M, 4MDS, 6W63, 5RF7 were explored from a comparative perspective using unbiased molecular dynamics (UMD) simulations. We uncovered common weak points for selected inhibitors that could not interact significantly with a binding pocket at specific residues by all their fragments. So water molecules entered the free binding S regions and weakened protein-inhibitor fundamental interactions gradually. N142, G143, and H163 are the essential residues, which cause key protein-ligand interactions in the binding pocket. We believe that these results will help design new potent inhibitors against SARS-CoV-2.	[Tiyoula, Fereshteh Noroozi; Aryapour, Hassan] Golestan Univ, Dept Biol, Fac Sci, Gorgan, Golestan, Iran		Aryapour, H (corresponding author), Golestan Univ, Dept Biol, Fac Sci, Gorgan, Golestan, Iran.	hassan.aryapour@gmail.com	Noroozi, Fereshteh/N-3791-2017		Golestan University, Gorgan, Iran [99-213-1]	Golestan University, Gorgan, Iran	This investigation was supported by grant number 99-213-1 from Golestan University, Gorgan, Iran. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Barducci A, 2011, WIRES COMPUT MOL SCI, V1, P826, DOI 10.1002/wcms.31; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Crawshaw A.D., 2020, PANDDA ANAL GROUP DE; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n; Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kumar R, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111602; Li QX, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081250; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Maier HJ, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7; Mesecar A.D., 2020, FRACT CALC APPL ANAL, V23, P635; Mollica L, 2015, SCI REP-UK, V5, DOI 10.1038/srep11539; Niu YZ, 2016, PHYS CHEM CHEM PHYS, V18, P5622, DOI 10.1039/c5cp06257h; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Pathak N, 2021, ACS NANO, V15, P857, DOI 10.1021/acsnano.0c07383; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rydzewski J, 2019, J CHEM PHYS, V150, DOI 10.1063/1.5108638; Sabbadin D, 2018, METHODS MOL BIOL, V1824, P287, DOI 10.1007/978-1-4939-8630-9_17; Sabbadin D, 2014, J CHEM INF MODEL, V54, P372, DOI [10.1021/ci400766b, 10.1021/ci4007t6b]; Sohraby F, 2021, SEMIN CANCER BIOL, V68, P249, DOI 10.1016/j.semcancer.2020.04.007; Sohraby F, 2020, BIOINFORMATICS, V36, P4714, DOI 10.1093/bioinformatics/btaa565; Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI 10.1186/1756-0500-5-367; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Tiwary P, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700014; Tiwary P, 2015, P NATL ACAD SCI USA, V112, pE386, DOI 10.1073/pnas.1424461112; Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112; ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009; W. H. Organization, WHO; Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Zangrillo A, 2020, CRIT CARE RESUSC, V22, P91; Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053; Zhu HB, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00135-6	39	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263251	10.1371/journal.pone.0263251	http://dx.doi.org/10.1371/journal.pone.0263251			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139108	gold, Green Published			2023-01-03	WOS:000821499100024
J	Doki, Y; Ajani, JA; Kato, K; Xu, J; Wyrwicz, L; Motoyama, S; Ogata, T; Kawakami, H; Hsu, CH; Adenis, A; El Hajbi, F; Di Bartolomeo, M; Braghiroli, MI; Holtved, E; Ostoich, SA; Kim, HR; Ueno, M; Mansoor, W; Yang, WC; Liu, T; Bridgewater, J; Makino, T; Xynos, I; Liu, X; Lei, M; Kondo, K; Patel, A; Gricar, J; Chau, I; Kitagawa, Y				Doki, Y.; Ajani, J. A.; Kato, K.; Xu, J.; Wyrwicz, L.; Motoyama, S.; Ogata, T.; Kawakami, H.; Hsu, C. -H.; Adenis, A.; El Hajbi, F.; Di Bartolomeo, M.; Braghiroli, M. I.; Holtved, E.; Ostoich, S. A.; Kim, H. R.; Ueno, M.; Mansoor, W.; Yang, W. -C.; Liu, T.; Bridgewater, J.; Makino, T.; Xynos, I.; Liu, X.; Lei, M.; Kondo, K.; Patel, A.; Gricar, J.; Chau, I.; Kitagawa, Y.		CheckMate 648 Trial Investigators	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; PLUS CHEMOTHERAPY; PHASE-II; MULTICENTER; IPILIMUMAB; 5-FLUOROURACIL; CISPLATIN; JUNCTION	BACKGROUND First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma. METHODS In this open-label, phase 3 trial, we randomly assigned adults with previously untreated, unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma in a 1:1:1 ratio to receive nivolumab plus chemotherapy, nivolumab plus the monoclonal antibody ipilimumab, or chemotherapy. The primary end points were overall survival and progression-free survival, as determined by blinded independent central review. Hierarchical testing was performed first in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater and then in the overall population (all randomly assigned patients). RESULTS A total of 970 patients underwent randomization. At a 13-month minimum follow-up, overall survival was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone, both among patients with tumor-cell PD-L1 expression of 1% or greater (median, 15.4 vs. 9.1 months; hazard ratio, 0.54; 99.5% confidence interval [CI], 0.37 to 0.80; P<0.001) and in the overall population (median, 13.2 vs. 10.7 months; hazard ratio, 0.74; 99.1% CI, 0.58 to 0.96; P=0.002). Overall survival was also significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with tumor-cell PD-L1 expression of 1% or greater (median, 13.7 vs. 9.1 months; hazard ratio, 0.64; 98.6% CI, 0.46 to 0.90; P=0.001) and in the overall population (median, 12.7 vs. 10.7 months; hazard ratio, 0.78; 98.2% CI, 0.62 to 0.98; P=0.01). Among patients with tumor-cell PD-L1 expression of 1% or greater, a significant progression-free survival benefit was also seen with nivolumab plus chemotherapy over chemotherapy alone (hazard ratio for disease progression or death, 0.65; 98.5% CI, 0.46 to 0.92; P=0.002) but not with nivolumab plus ipilimumab as compared with chemotherapy. The incidence of treatment-related adverse events of grade 3 or 4 was 47% with nivolumab plus chemotherapy, 32% with nivolumab plus ipilimumab, and 36% with chemotherapy alone. CONCLUSIONS Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma, with no new safety signals identified.	[Doki, Y.; Makino, T.] Osaka Univ, Grad Sch Med, Osaka, Japan; [Kato, K.] Natl Canc Ctr, Tokyo, Japan; [Ueno, M.] Toranomon Gen Hosp, Tokyo, Japan; [Kitagawa, Y.] Keio Univ, Sch Med, Tokyo, Japan; [Motoyama, S.] Akita Univ Hosp, Akita, Japan; [Ogata, T.] Kanagawa Canc Ctr, Kanagawa, Japan; [Kawakami, H.] Kindai Univ, Fac Med, Osakasayama, Japan; [Ajani, J. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA; [Xu, J.] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China; [Liu, T.] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Wyrwicz, L.] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland; [Hsu, C. -H.] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Yang, W. -C.] E Da Hosp, Kaohsiung, Taiwan; [Yang, W. -C.] I Shou Univ, Kaohsiung, Taiwan; [Adenis, A.] Univ Montpellier, Inst Canc Montpellier, Inst Rech Cancerol Montpellier, INSERM, Montpellier, France; [El Hajbi, F.] Ctr Oscar Lambret, Lille, France; [Di Bartolomeo, M.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Braghiroli, M. I.] Univ Sao Paulo, Inst Canc Sao Paulo, Sao Paulo, Brazil; [Holtved, E.] Odense Univ Hosp, Odense, Denmark; [Ostoich, S. A.] Hosp Prov Centenario, Rosario, Argentina; Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; [Mansoor, W.] Christie NHS Fdn Trust, Manchester, Lancs, England; [Bridgewater, J.] UCL, UCL Canc Inst, London, England; [Chau, I.] Royal Marsden Hosp, Surrey, England; [Xynos, I.; Liu, X.; Lei, M.; Kondo, K.; Patel, A.; Gricar, J.] Bristol Myers Squibb, Princeton, NJ USA	Osaka University; National Cancer Center - Japan; Toranomon Hospital; Keio University; Akita University; Kanagawa Prefectural Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese People's Liberation Army General Hospital; Fifth Medical Center of Chinese PLA General Hospital; Fudan University; National Taiwan University; National Taiwan University Hospital; E-Da Hospital; I Shou University; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Centre Oscar Lambret; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universidade de Sao Paulo; University of Southern Denmark; Odense University Hospital; Yonsei University; Yonsei University Health System; Christie NHS Foundation Trust; University of London; University College London; Royal Marsden NHS Foundation Trust; Bristol-Myers Squibb	Kato, K (corresponding author), Natl Canc Ctr Hosp, Dept Head & Neck, Esophageal Med Oncol, Chuo, Tokyo 1040045, Japan.	kenkato@ncc.go.jp	ADENIS, ANTOINE/AFL-9835-2022; ADENIS, ANTOINE/AAH-2034-2022; Chau, Ian/ABC-2023-2020	Chau, Ian/0000-0003-0286-8703; Gu, Kangsheng/0000-0002-5800-5256	Bristol Myers Squibb; Ono Pharmaceutical	Bristol Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical	Supported by Bristol Myers Squibb and Ono Pharmaceutical. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	[Anonymous], 2019, CHINESE J CANCER RES, V31, P223, DOI 10.21147/j.issn.1000-9604.2019.02.01; [Anonymous], PLYMOUTH M, P2022; [Anonymous], OESOPHAGEAL CANC INC; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Baas P, 2021, LANCET, V397, P375, DOI 10.1016/S0140-6736(20)32714-8; Bleiberg H, 1997, EUR J CANCER, V33, P1216, DOI 10.1016/S0959-8049(97)00088-9; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; COX DR, 1972, J R STAT SOC B, V34, P187; Darling G, 2006, CANCER, V107, P854, DOI 10.1002/cncr.22055; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8; IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kato K, 2020, CANCER SCI, V111, P1676, DOI 10.1111/cas.14380; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kitagawa Y, 2019, ESOPHAGUS-TOKYO, V16, P1, DOI 10.1007/s10388-018-0641-9; Koch GG., 1989, STAT METHODOLOGY PHA, P389; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Kudo T, 2017, LANCET ONCOL, V18, P631, DOI 10.1016/S1470-2045(17)30181-X; Kulangara K, 2019, ARCH PATHOL LAB MED, V143, P330, DOI 10.5858/arpa.2018-0043-OA; Lee SJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1716-9; Lei M, 2021, CLIN CANCER RES, V27, P3926, DOI 10.1158/1078-0432.CCR-20-2790; Lordick F, 2016, ANN ONCOL, V27, pv50, DOI 10.1093/annonc/mdw329; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Moehler M, 2020, ANN ONCOL, V31, P228, DOI 10.1016/j.annonc.2019.10.018; Patel N, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3709; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Ringash J, 2007, CANCER-AM CANCER SOC, V110, P196, DOI 10.1002/cncr.22799; Salem ME, 2018, ONCOLOGIST, V23, P1319, DOI 10.1634/theoncologist.2018-0143; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Sun JM, 2021, LANCET, V398, P759, DOI 10.1016/S0140-6736(21)01234-4; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tachimori Y, 2019, ESOPHAGUS-TOKYO, V16, P221, DOI 10.1007/s10388-019-00674-z; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Xu RH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4000	38	97	97	24	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2022	386	5					449	462		10.1056/NEJMoa2111380	http://dx.doi.org/10.1056/NEJMoa2111380			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR1JU	35108470	Green Published			2023-01-03	WOS:000749755800010
J	Du, JX; Tao, QY; Liu, Y; Huang, ZM; Jin, H; Lin, WJ; Huang, XY; Zeng, JY; Zhao, YC; Liu, LY; Xu, Q; Han, X; Chen, LX; Chen, XL; Wen, Y				Du, Jiaxin; Tao, Quyuan; Liu, Ying; Huang, Zhanming; Jin, He; Lin, Wenjia; Huang, Xinying; Zeng, Jingyan; Zhao, Yongchang; Liu, Lingyu; Xu, Qian; Han, Xue; Chen, Lixia; Chen, Xin-lin; Wen, Yi			Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; MESENCHYMAL TRANSITION; EXPRESSION; CELLS; PROTEINS	ObjectiveSijunzi decoction (SJZD) was used to treat patients with colorectal cancer (CRC) as an adjuvant method. The aim of the study was to investigate the therapeutic targets and pathways of SJZD towards the tumor microenvironment of CRC via network pharmacology and the ESTIMATE algorithm. MethodsThe ESTIMATE algorithm was used to calculate immune and stromal scores to predict the level of infiltrating immune and stromal cells. The active targets of SJZD were searched in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and UniProt database. The core targets were obtained by matching the differentially expressed genes in CRC tissues and the targets of SJZD. Then, GO, KEGG and validation in TCGA were carried out. ResultsAccording to the ESTIMATE algorithm and survival analysis, the median survival time of the low stromal score group was significantly higher than that of the high stromal score group (P = 0.018), while the patients showed no significant difference of OS between different immune groups (P = 0.19). A total of 929 genes were upregulated and 115 genes were downregulated between the stromal score groups (|logFC| > 2, adjusted P < 0.05); 357 genes were upregulated and 472 genes were downregulated between the immune score groups. The component-target network included 139 active components and 52 related targets. The core targets were HSPB1, SPP1, IGFBP3, and TGFB1, which were significantly associated with poor prognosis in TCGA validation. GO terms included the response to hypoxia, the extracellular space, protein binding and the TNF signaling pathway. Immunoreaction was the main enriched pathway identified by KEGG analysis. ConclusionThe core genes (HSPB1, SPP1, IGFBP3 and TGFB1) affected CRC development and prognosis by regulating hypoxia, protein binding and epithelial-mesenchymal transition in the extracellular matrix.	[Du, Jiaxin; Tao, Quyuan; Liu, Ying; Jin, He; Lin, Wenjia; Huang, Xinying; Liu, Lingyu; Xu, Qian; Han, Xue; Chen, Lixia; Chen, Xin-lin] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China; [Huang, Zhanming; Zhao, Yongchang; Wen, Yi] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China; [Zeng, Jingyan] Guangzhou Univ Chinese Med, Shenzhen Clin Coll, Guangzhou, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Chen, XL (corresponding author), Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China.; Wen, Y (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.	chenxlsums@126.com; 20172101031@stu.gzucm.edu.cn			National Natural Science Foundation of China [81774451]; Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine [XH20190102]; National Innovation and Entrepreneurship Program for Chinese College Students [202010572017]; Guangzhou University of Chinese Medicine College Student Innovation and Entrepreneurship Project [202010572201]; Guangzhou Science and technology project [201707010319]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine; National Innovation and Entrepreneurship Program for Chinese College Students; Guangzhou University of Chinese Medicine College Student Innovation and Entrepreneurship Project; Guangzhou Science and technology project	This study was funded by the National Natural Science Foundation of China (81774451), the Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine (XH20190102), 2020 National Innovation and Entrepreneurship Program for Chinese College Students (202010572017), Guangzhou University of Chinese Medicine College Student Innovation and Entrepreneurship Project (202010572201), and Guangzhou Science and technology project (201707010319). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, LANCET ONCOL, V18, P413, DOI 10.1016/S1470-2045(17)30202-4; Augustin RC, 2020, CANCERS, V12, DOI 10.3390/cancers12123802; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Chatterji P, 2018, TRENDS MOL MED, V24, P490, DOI 10.1016/j.molmed.2018.03.008; Chen MS, 2019, MOL CANCER RES, V17, P697, DOI 10.1158/1541-7786.MCR-18-0666; Chen ML, 2001, PHARMACEUT RES, V18, P1645, DOI 10.1023/A:1013319408893; Chen XR, 2020, NUTR CANCER, V72, P723, DOI 10.1080/01635581.2019.1653470; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Craig SG, 2020, BRIT J CANCER, V123, P1280, DOI 10.1038/s41416-020-0985-5; Deng B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063777; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Freilich R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07012-4; Gibert B, 2012, BRIT J CANCER, V107, P63, DOI 10.1038/bjc.2012.188; Gu MJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3968-z; Guo Jian-hong, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P674; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hussain M, 2019, LIFE SCI, V227, P175, DOI 10.1016/j.lfs.2019.04.053; Jia D, 2018, AGING-US, V10, P592, DOI 10.18632/aging.101415; Jiao LJ, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575-017-0066-1; Jie Y, 2017, CANCER GENE THER, V24, P361, DOI 10.1038/cgt.2017.25; Klement JD, 2018, J CLIN INVEST, V128, P5549, DOI 10.1172/JCI123360; Koelzer VH, 2015, TRANSL RES, V166, P207, DOI 10.1016/j.trsl.2015.02.008; Kuo YT, 2018, INTEGR CANCER THER, V17, P531, DOI 10.1177/1534735417716302; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee SI, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1281-z; Lenos KJ, 2018, NAT CELL BIOL, V20, P1193, DOI 10.1038/s41556-018-0179-z; Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017; Li Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34160-w; Lin XC, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-105; Liu L, 2005, BRIT J NUTR, V93, P21, DOI 10.1079/BJN20041295; Liu SS, 2017, WORLD J GASTROENTERO, V23, P7618, DOI 10.3748/wjg.v23.i42.7618; Liu Y, 2006, J PHARMACEUT BIOMED, V41, P1642, DOI 10.1016/j.jpba.2006.02.033; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Masuda H, 2005, J GASTROENTEROL, V40, P409, DOI 10.1007/s00535-005-1567-2; Melenotte C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680146; Ning K, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7573904; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Patel Swati G, 2018, Curr Gastroenterol Rep, V20, P15, DOI 10.1007/s11894-018-0618-9; Pittet MJ, 2009, CURR OPIN ONCOL, V21, P53, DOI 10.1097/CCO.0b013e32831bc38a; Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019; Ransom D, 2014, ANN ONCOL, V25, P117, DOI 10.1093/annonc/mdt479; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Sautes-Fridman C, 2011, CANCER METAST REV, V30, P13, DOI 10.1007/s10555-011-9279-y; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Smith FM, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4472; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Su XY, 2007, MINI-REV MED CHEM, V7, P87, DOI 10.2174/138955707779317830; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164; Thorsteinsson M, 2012, INT J COLORECTAL DIS, V27, P1579, DOI 10.1007/s00384-012-1517-4; Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447; Wang CY, 2018, CANCER BIOMARK, V21, P701, DOI 10.3233/CBM-170805; Wang XY, 2020, J ETHNOPHARMACOL, V252, DOI 10.1016/j.jep.2020.112600; Wang YL, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/7023420; Wu B, 2007, CHIN J INTEGR MED, V13, P156, DOI 10.1007/s11655-007-0156-z; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang M, 2020, COMPUT BIOL CHEM, V86, DOI 10.1016/j.compbiolchem.2020.107248; Zhang SF, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6180810; Zhang YL, 2017, CHIN MED-UK, V12, DOI 10.1186/s13020-017-0140-2; Zielinska HA, 2020, CANCERS, V12, DOI 10.3390/cancers12123821	64	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264720	10.1371/journal.pone.0264720	http://dx.doi.org/10.1371/journal.pone.0264720			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P4VV	35303006	Green Published, gold			2023-01-03	WOS:000784220200009
J	Mu, TY; Xu, RX; Xu, JY; Dong, D; Zhou, ZN; Dai, JN; Shen, CZ				Mu, Ting-Yu; Xu, Ri-Xiang; Xu, Jia-Yi; Dong, Die; Zhou, Zhi-Nan; Dai, Jia-Ning; Shen, Cui-Zhen			Association between self-care disability and depressive symptoms among middle-aged and elderly Chinese people	PLOS ONE			English	Article							OLDER-ADULTS; SHORT-FORM; POPULATION; PREVALENCE; HEALTH; RISK	ObjectiveIn the context of an increased focus on geriatric depression in recent years, this study examined the associations between different types of self-care disability, the number of self-care disabilities, and depressive symptoms among middle-aged and elderly Chinese people. MethodThe data for this study were extracted from the follow-up survey (conducted in 2018) of the China Health and Retirement Longitudinal Study (CHARLS). The sample comprised 10808 participants aged 45 years and older. The Activities of Daily Living (ADL) scale and the Center for Epidemiological Studies Depression (CESD-10) Scale were used to assess self-care disability and depressive symptoms, respectively. ResultThe prevalence of depressive symptoms and self-care disability among the surveyed residents was 45.1% and 23.4%, respectively. Overall, there was a significant positive association between self-care disability and depressive symptoms. Participants who reported having a self-care disability in relation dressing, bathing, transferring in and out of bed, using the toilet, and controlling urination and defecation were found to have a significantly higher risk of depressive symptoms. In addition, participants with a greater cumulative quantity of self-care disabilities had a higher risk of depressive symptoms, and higher CESD-10 scores. ConclusionSelf-care disability is a risk factor for depressive symptoms among middle-aged and elderly Chinese people. A positive correlation between the number of self-care disabilities and the risk of depressive symptoms was found.	[Mu, Ting-Yu; Xu, Jia-Yi; Dong, Die; Zhou, Zhi-Nan; Dai, Jia-Ning; Shen, Cui-Zhen] Zhejiang Chinese Med Univ, Sch Nursing, Hangzhou, Zhejiang, Peoples R China; [Mu, Ting-Yu] Anhui Univ Chinese Med, Nursing Coll, Hefei, Anhui, Peoples R China; [Xu, Ri-Xiang] Zhejiang Chinese Med Univ, Sch Humanities & Management, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Anhui University of Chinese Medicine; Zhejiang Chinese Medical University	Shen, CZ (corresponding author), Zhejiang Chinese Med Univ, Sch Nursing, Hangzhou, Zhejiang, Peoples R China.; Xu, RX (corresponding author), Zhejiang Chinese Med Univ, Sch Humanities & Management, Hangzhou, Zhejiang, Peoples R China.	ahmusop@126.com; shencuizhen@163.com	Xu, Rixiang/AAX-9585-2021	Xu, Rixiang/0000-0003-1885-6061				Alexapoulos GS, 2005, LANCET, V365, P1961, DOI 10.1016/S0140-6736(05)66665-2; Barberger-Gateau P, 2000, DISABIL REHABIL, V22, P308, DOI 10.1080/096382800296665; Boey KW, 1999, INT J GERIATR PSYCH, V14, P608, DOI 10.1002/(SICI)1099-1166(199908)14:8<608::AID-GPS991>3.0.CO;2-Z; Bowen ME, 2015, J AGING HEALTH, V27, P1286, DOI 10.1177/0898264315580121; Bromet E, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-90; Bruce ML, 2001, AM J GERIAT PSYCHIAT, V9, P102, DOI 10.1176/appi.ajgp.9.2.102; Chen CM, 2012, J GERONTOL A-BIOL, V67, P1059, DOI 10.1093/gerona/gls074; Chen HJ, 2014, INT PSYCHOGERIATR, V26, P49, DOI 10.1017/S1041610213001701; Chisholm D, 2016, LANCET PSYCHIAT, V3, P415, DOI 10.1016/S2215-0366(16)30024-4; Chung SS, 2017, ARCH PSYCHIAT NURS, V31, P164, DOI 10.1016/j.apnu.2016.09.009; Covinsky K, 2006, ARTHRIT RHEUM-ARTHR, V55, P175, DOI 10.1002/art.21861; Fan XW, 2021, J AFFECT DISORDERS, V293, P222, DOI 10.1016/j.jad.2021.06.044; Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547; Gillibrand Warren, 2012, Br J Community Nurs, V17, P364; Hajek A, 2017, INT PSYCHOGERIATR, V29, P885, DOI 10.1017/S1041610216002507; He MF, 2019, J AFFECT DISORDERS, V242, P135, DOI 10.1016/j.jad.2018.08.060; Hua Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117998; Huan X., 2020, CHINESE NURSING RES, V34, P3858; Huan Z., 2021, CHINESE GEN PRACTICE, V19, P305; Santini ZI, 2015, J AFFECT DISORDERS, V175, P53, DOI 10.1016/j.jad.2014.12.049; Jerez-Roig J, 2016, EXP AGING RES, V42, P479, DOI 10.1080/0361073X.2016.1224673; Jiang CH, 2020, CURR MED SCI, V40, P858, DOI 10.1007/s11596-020-2270-5; Joo J, 2017, INT PSYCHOGERIATR, V29, P883, DOI 10.1017/S1041610217000497; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Lei XY, 2014, SOC SCI MED, V120, P224, DOI 10.1016/j.socscimed.2014.09.028; Li A, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.755220; Li D, 2014, ARCH GERONTOL GERIAT, V58, P1, DOI 10.1016/j.archger.2013.07.016; Li Z., 2021, MED SOC, V34, P79; Lim GY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21243-x; Ling C., 2021, MODERN PREVENTIVE ME, V48, P2401; [刘昊 Liu Hao], 2019, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V23, P966; Luo HQ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5834-6; Luo MS, 2020, AGING MENT HEALTH, V24, P1990, DOI 10.1080/13607863.2019.1655706; Malhi GS, 2018, LANCET, V392, P2299, DOI 10.1016/S0140-6736(18)31948-2; Malhi GS, 2018, MED J AUSTRALIA, V208, P175, DOI 10.5694/mja17.00659; Manandhar K, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2258-5; Marques A, 2020, EUR J SPORT SCI, V20, P1268, DOI 10.1080/17461391.2019.1701716; Marti CN, 2021, INT J GERIATR PSYCH, V36, P802, DOI 10.1002/gps.5480; Martin LG, 2014, DISABIL HEALTH J, V7, pS4, DOI 10.1016/j.dhjo.2013.06.007; Martinez M, 2017, PALLIATIVE MED, V31, P492, DOI 10.1177/0269216316665562; Na T., CHINESE J SOCIAL MED, V34, P22; Noh JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166238; Rahman MS, 2020, J AFFECT DISORDERS, V264, P157, DOI 10.1016/j.jad.2019.12.025; Singh Ranbir, 2015, Psychiatr Danub, V27 Suppl 1, pS231; World Health Organization, 2017, DEPRESSION OTHER COM; World Health Organization, 2018, MENTAL HLTH ATLAS 20; Xiang XL, 2020, AGING MENT HEALTH, V24, P27, DOI 10.1080/13607863.2018.1509298; Xie H, 2018, ARCH PSYCHIAT NURS, V32, P256, DOI 10.1016/j.apnu.2017.11.012; Yaka E, 2014, ARCH GERONTOL GERIAT, V59, P150, DOI 10.1016/j.archger.2014.03.014; Yu J, 2012, INT J GERIATR PSYCH, V27, P305, DOI 10.1002/gps.2721; Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040793	51	2	2	10	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266950	10.1371/journal.pone.0266950	http://dx.doi.org/10.1371/journal.pone.0266950			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F4SK	35404987	Green Published, gold			2023-01-03	WOS:000795158700032
J	Porta, L; Huang, SS; Wei, C; Su, CH; Hsu, WT; Sheng, WH; Lee, CC				Porta, Lorenzo; Huang, Sih-Shiang; Wei, Chen; Su, Chin-Hua; Hsu, Wan-Ting; Sheng, Wang-Huei; Lee, Chien-Chang			Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME	Objectives While corticosteroids have been hypothesized to exert protective benefits in patients infected with SARS-CoV-2, data remain mixed. This study sought to investigate the outcomes of methylprednisone administration in an Italian cohort of hospitalized patients with confirmed SARS-CoV-2 infection. Methods Patients with confirmatory testing for SARS-CoV-2 were retrospectively enrolled from a tertiary university hospital in Milan, Italy from March 1st to April 30th, 2020 and divided into two groups by administration of corticosteroids. Methylprednisolone was administered to patients not responding to pharmacological therapy and ventilatory support at 0.5-1 mg/kg/day for 4 to 7 days. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences between the steroid and non-steroid cohorts via inverse probability of treatment weight. Primary outcomes included acute respiratory failure (ARF), shock, and 30-day mortality among surviving patients. Results Among 311 patients enrolled, 71 patients received steroids and 240 did not receive steroids. The mean age was 63.1 years, 35.4% were female, and hypertension, diabetes, heart disease, and chronic pulmonary disease were present in 3.5%, 1.3%, 14.8% and 12.2% respectively. Crude analysis revealed no statistically significant reduction in the incidence of 30-day mortality (36,6% vs 21,7%; OR, 2.09; 95% CI, 1.18-3.70; p = 0.011), shock (2.8% vs 4.6%; OR, 0.60; 95% CI = 0.13-2.79; p = 0.514) or ARF (12.7% vs 15%; OR, 0.82; 95% CI = 0.38-1.80; p = 0.625) between the steroid and non-steroid groups. After IPTW analysis, the steroid-group had lower incidence of shock (0.9% vs 4.1%; OR, 0.21; 95% CI,0.06-0.77; p = 0.010), ARF (6.6% vs 16.0%; OR, 0.37; 95% CI, 0.22-0.64; p<0.001) and 30-day mortality (20.3% vs 22.8%; OR 0.86; 95% CI, 0.59-1.26 p = 0.436); even though, for the latter no statistical significance was reached. Steroid use was also associated with increased length of hospital stay both in crude and IPTW analyses. Subgroup analysis revealed that patients with cardiovascular comorbidities or chronic lung diseases were more likely to be steroid responsive. No significant survival benefit was seen after steroid treatment. Conclusions Physicians should avoid routine methylprednisolone use in SARS-CoV-2 patients, since it does not reduce 30-day mortality. However, they must consider its use for severe patients with cardiovascular or respiratory comorbidities in order to reduce the incidence of either shock or acute respiratory failure.	[Porta, Lorenzo] Univ Milano Bicocca, Sch Med & Surg, Dept Emergency Med, Milan, Italy; [Huang, Sih-Shiang; Su, Chin-Hua; Lee, Chien-Chang] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Wei, Chen] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Wei, Chen] Stanford Hlth Care, Dept Internal Med, Stanford, CA USA; [Hsu, Wan-Ting] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Sheng, Wang-Huei] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Lee, Chien-Chang] Natl Taiwan Univ Hosp, Ctr Intelligent Healthcare, Taipei, Taiwan; [Lee, Chien-Chang] Stanford Univ, Byers Ctr Biodesign, Stanford, CA 94305 USA	University of Milano-Bicocca; National Taiwan University; National Taiwan University Hospital; Harvard University; Harvard Medical School; Stanford University; Harvard University; Harvard T.H. Chan School of Public Health; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Stanford University	Lee, CC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.; Lee, CC (corresponding author), Natl Taiwan Univ Hosp, Ctr Intelligent Healthcare, Taipei, Taiwan.; Lee, CC (corresponding author), Stanford Univ, Byers Ctr Biodesign, Stanford, CA 94305 USA.	cclee100@gmail.com	Lee, Chien-Chang/HHM-5986-2022	LEE, CHIEN-CHANG/0000-0002-1243-2463; Huang, Sih-Shiang/0000-0002-9388-4786; Hsu, Wan-Ting/0000-0002-6677-0951	Taiwan Ministry of Science and Technology Grant [MOST 110-2314-B-002-053-MY3]; National Taiwan University Hospital [NTUH 110-MM022-4, NTUH 111-S0248]	Taiwan Ministry of Science and Technology Grant; National Taiwan University Hospital(National Taiwan University)	This study was funded by the Taiwan Ministry of Science and Technology Grant (MOST 110-2314-B-002-053-MY3) and National Taiwan University Hospital Grants (NTUH 110-MM022-4, and NTUH 111-S0248). No funding bodies had any role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; [Anonymous], 2019, CORONAVIRUS COVID 19; [Anonymous], SYSTEMIC CORTICOSTER; [Anonymous], PULMONARY VASCULAR E, DOI [10.1056/NEJMoa2015432?query=recirc_curatedRelated_article, DOI 10.1056/NEJMOA2015432?QUERY=RECIRC_CURATEDRELATED_ARTICLE]; Bansal P, 2021, ANN MED, V53, P117, DOI 10.1080/07853890.2020.1839959; Bauer TT, 2006, CLIN INFECT DIS, V43, P748, DOI 10.1086/506430; Corral L, 2020, INFECT DIS EXCEPT HI, DOI [DOI 10.1101/2020.06.17.20133579, 10.1101/2020.06.17.20133579v1]; Dagens A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1936; Edalatifard M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02808-2020; Fiolet T, 2021, CLIN MICROBIOL INFEC, V27, P19, DOI 10.1016/j.cmi.2020.08.022; Frontiers | Use of Corticosteroids in Coronavirus Disease, 2019, PNEUM SYST REV LIT M, DOI [10.3389/fmed.2020.00170/full, DOI 10.3389/FMED.2020.00170/FULL]; George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jeronimo CMP., 2020, CLIN INFECT DIS PUBL; Lamontagne F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3284; Li H, 2020, LEUKEMIA, V34, P1503, DOI [10.1038/s41375-020-0848-3, 10.1007/s11263-020-01364-5]; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; WHO, NOV COR CHIN; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu Renyi, 2020, Curr Pharmacol Rep, V6, P56, DOI 10.1007/s40495-020-00216-7; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005; Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0266901	10.1371/journal.pone.0266901	http://dx.doi.org/10.1371/journal.pone.0266901			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3FU	35714141	gold, Green Published			2023-01-03	WOS:000843613300016
J	Rubin, R				Rubin, Rita			Websites Selling Controlled Drugs Without a Prescription	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	2022	327	19					1860	1860						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3V2BU	35579653				2023-01-03	WOS:000841466900019
J	Uzoigwe, CE; Campbell-Jones, F				Uzoigwe, Chika Edward; Campbell-Jones, Frederick			Regional vs General Anesthesia and Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Uzoigwe, Chika Edward] Harcourt House, Orthopaed, Sheffield, S Yorkshire, England; [Campbell-Jones, Frederick] Hereford Cty Hosp, Hereford, England		Uzoigwe, CE (corresponding author), Harcourt House, Orthopaed Harcourt, Sheffield S10 1DG29, S Yorkshire, England.	chika@doctors.org.uk		Devinney, Michael/0000-0003-3906-6421				Baker HP, 2022, J AM ACAD ORTHOP SUR, V30, pE384, DOI 10.5435/JAAOS-D-21-00561; Guay J, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001159.pub3; Kim CH, 2022, ORTHOP TRAUMATOL-SUR, V108, DOI 10.1016/j.otsr.2021.103151; Li T, 2022, JAMA-J AM MED ASSOC, V327, P50, DOI 10.1001/jama.2021.22647; Punjasawadwong Y, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011283.pub2; Wainwright TW, 2020, ACTA ORTHOP, V91, P3, DOI 10.1080/17453674.2019.1683790	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2022	327	17					1707	1707						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D3AC	35503353				2023-01-03	WOS:000793675300024
J	Davis, ID				Davis, Ian D.			Triplet therapy for prostate cancer Comment	LANCET			English	Editorial Material									[Davis, Ian D.] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia; [Davis, Ian D.] Eastern Hlth, Dept Canc Serv, Melbourne, Vic 3128, Australia	Monash University	Davis, ID (corresponding author), Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia.; Davis, ID (corresponding author), Eastern Hlth, Dept Canc Serv, Melbourne, Vic 3128, Australia.	ian.davis@monash.edu						Armstrong AJ, ANN ONCOL, V32, pS1283; Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; Fizazi K, 2022, LANCET, V399, P1695, DOI 10.1016/S0140-6736(22)00367-1; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Smith MR, 2022, NEW ENGL J MED, DOI 10.1056/NEJMoa2119115; Sweeney CJ, 2021, EUR UROL, V80, P275, DOI 10.1016/j.eururo.2021.05.016; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747	10	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2022	399	10336					1670	1671		10.1016/S0140-6736(22)00380-4	http://dx.doi.org/10.1016/S0140-6736(22)00380-4		APR 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	1K4GY	35405082				2023-01-03	WOS:000798562500004
J	Friedman, J; Godvin, M; Shover, CL; Gone, JP; Hansen, H; Schriger, DL				Friedman, Joseph; Godvin, Morgan; Shover, Chelsea L.; Gone, Joseph P.; Hansen, Helena; Schriger, David L.			Trends in Drug Overdose Deaths Among US Adolescents, January 2010 to June 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Friedman, Joseph; Hansen, Helena] Univ Calif Los Angeles, Ctr Social Med & Humanities, Los Angeles, CA USA; [Godvin, Morgan] Local Publ Safety Coordinating Council, Portland, OR USA; [Shover, Chelsea L.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA; [Gone, Joseph P.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Schriger, David L.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	Friedman, J (corresponding author), UCLA Semel Inst, 760 Westwood Plaza,B7-435, Los Angeles, CA 90024 USA.	joseph.robert.friedman@gmail.com		Shover, Chelsea/0000-0002-0728-4101; Gone, Joseph/0000-0002-0572-1179	UCLA Medical Scientist Training Program (National Institute of General Medical Sciences) [GM008042]; National Institute on Drug Abuse [K01-DA050771]; Korein Foundation	UCLA Medical Scientist Training Program (National Institute of General Medical Sciences); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Korein Foundation	Mr Friedman received support from the UCLA Medical Scientist Training Program (National Institute of General Medical Sciences training grant GM008042). Dr Shover was supported by a grant from the National Institute on Drug Abuse (K01-DA050771). Dr Schriger's time on this project was supported in part by an unrestricted educational grant from the Korein Foundation.	[Anonymous], 2021, PROTECTING YOUTH MEN; Centers for Disease Control and Prevention, CDCWONDER DAT; Ciccarone D, 2021, CURR OPIN PSYCHIATR, V34, P344, DOI 10.1097/YCO.0000000000000717; Friedman JR, 2022, JAMA PSYCHIAT, V79, P379, DOI 10.1001/jamapsychiatry.2022.0004; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Monitoring the Future, DAT IN SCH SURV 8 10	6	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2022	327	14					1398	1400						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1FH	35412573	Green Published			2023-01-03	WOS:000783967600019
J	Sutton, RM; Wolfe, HA; Reeder, RW; Ahmed, T; Bishop, R; Bochkoris, M; Burns, C; Diddle, JW; Federman, M; Fernandez, R; Franzon, D; Frazier, AH; Friess, SH; Graham, K; Hehir, D; Horvat, CM; Huard, LL; Landis, WP; Maa, T; Manga, A; Morgan, RW; Nadkarni, VM; Naim, MY; Palmer, CA; Schneiter, C; Sharron, MP; Siems, A; Srivastava, N; Tabbutt, S; Tilford, B; Viteri, S; Berg, RA; Bell, MJ; Carcillo, JA; Carpenter, TC; Dean, JM; Fink, EL; Hall, M; McQuillen, PS; Meert, KL; Mourani, PM; Notterman, D; Pollack, MM; Sapru, A; Wessel, D; Yates, AR; Zuppa, AF				Sutton, Robert M.; Wolfe, Heather A.; Reeder, Ron W.; Ahmed, Tageldin; Bishop, Robert; Bochkoris, Matthew; Burns, Candice; Diddle, J. Wesley; Federman, Myke; Fernandez, Richard; Franzon, Deborah; Frazier, Aisha H.; Friess, Stuart H.; Graham, Kathryn; Hehir, David; Horvat, Christopher M.; Huard, Leanna L.; Landis, William P.; Maa, Tensing; Manga, Arushi; Morgan, Ryan W.; Nadkarni, Vinay M.; Naim, Maryam Y.; Palmer, Chella A.; Schneiter, Carleen; Sharron, Matthew P.; Siems, Ashley; Srivastava, Neeraj; Tabbutt, Sarah; Tilford, Bradley; Viteri, Shirley; Berg, Robert A.; Bell, Michael J.; Carcillo, Joseph A.; Carpenter, Todd C.; Dean, J. Michael; Fink, Ericka L.; Hall, Mark; McQuillen, Patrick S.; Meert, Kathleen L.; Mourani, Peter M.; Notterman, Daniel; Pollack, Murray M.; Sapru, Anil; Wessel, David; Yates, Andrew R.; Zuppa, Athena F.		ICU-RESUS & Eunice Kennedy Shriver; Human Dev Collaborative Pediatric	Effect of Physiologic Point-of-Care Cardiopulmonary Resuscitation Training on Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY POSTRESUSCITATION HYPOTENSION; AMERICAN-HEART-ASSOCIATION; IMPROVES SURVIVAL; PERFORMANCE CATEGORY; QUALITY; STATEMENT; DISCHARGE; CHILDREN; SUPPORT; UPDATE	IMPORTANCE Approximately 40% of children who experience an in-hospital cardiac arrest survive to hospital discharge. Achieving threshold intra-arrest diastolic blood pressure (BP) targets during cardiopulmonary resuscitation (CPR) and systolic BP targets after the return of circulation may be associated with improved outcomes. OBJECTIVE To evaluate the effectiveness of a bundled intervention comprising physiologically focused CPR training at the point of care and structured clinical event debriefings. DESIGN, SETTING, AND PARTICIPANTS A parallel, hybrid stepped-wedge, cluster randomized trial (Improving Outcomes from Pediatric Cardiac Arrest-the ICU-Resuscitation Project [ICU-RESUS]) involving 18 pediatric intensive care units (ICUs) from 10 clinical sites in the US. In this hybrid trial, 2 clinical sites were randomized to remain in the intervention group and 2 in the control group for the duration of the study, and 6 were randomized to transition from the control condition to the intervention in a stepped-wedge fashion. The index (first) CPR events of 1129 pediatric ICU patients were included between October 1, 2016, and March 31, 2021, and were followed up to hospital discharge (final follow-up was April 30, 2021). INTERVENTION During the intervention period (n = 526 patients), a 2-part ICU resuscitation quality improvement bundle was implemented, consisting of CPR training at the point of care on a manikin (48 trainings/unit per month) and structured physiologically focused debriefings of cardiac arrest events (1 debriefing/unit per month). The control period (n = 548 patients) consisted of usual pediatric ICU management of cardiac arrest. MAIN OUTCOMES AND MEASURES The primary outcome was survival to hospital discharge with a favorable neurologic outcome defined as a Pediatric Cerebral Performance Category score of 1 to 3 or no change from baseline (score range, 1 [normal] to 6 [brain death or death]). The secondary outcome was survival to hospital discharge. RESULTS Among 1389 cardiac arrests experienced by 1276 patients, 1129 index CPR events (median patient age, 0.6 [IQR, 0.2-3.8] years; 499 girls [44%]) were included and 1074 were analyzed in the primary analysis. There was no significant difference in the primary outcome of survival to hospital discharge with favorable neurologic outcomes in the intervention group (53.8%) vs control (52.4%); risk difference (RD), 3.2% (95% CI, -4.6% to 11.4%); adjusted OR, 1.08 (95% CI, 0.76 to 1.53). There was also no significant difference in survival to hospital discharge in the intervention group (58.0%) vs control group (56.8%); RD, 1.6% (95% CI, -6.2% to 9.7%); adjusted OR, 1.03 (95% CI, 0.73 to 1.47). CONCLUSIONS AND RELEVANCE In this randomized clinical trial conducted in 18 pediatric intensive care units, a bundled intervention of cardiopulmonary resuscitation training at the point of care and physiologically focused structured debriefing, compared with usual care, did not significantly improve patient survival to hospital discharge with favorable neurologic outcome among pediatric patients who experienced cardiac arrest in the ICU.	[Sutton, Robert M.; Wolfe, Heather A.; Graham, Kathryn; Hehir, David; Landis, William P.; Morgan, Ryan W.; Nadkarni, Vinay M.; Naim, Maryam Y.; Berg, Robert A.; Zuppa, Athena F.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Reeder, Ron W.; Palmer, Chella A.; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Ahmed, Tageldin; Tilford, Bradley; Meert, Kathleen L.] Cent Michigan Univ, Childrens Hosp Michigan, Dept Pediat, Detroit, MI USA; [Bishop, Robert; Schneiter, Carleen; Carpenter, Todd C.; Mourani, Peter M.] Univ Colorado, Childrens Hosp Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Bochkoris, Matthew; Horvat, Christopher M.; Bell, Michael J.; Carcillo, Joseph A.; Fink, Ericka L.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Burns, Candice; Friess, Stuart H.; Manga, Arushi] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Diddle, J. Wesley; Sharron, Matthew P.; Bell, Michael J.; Pollack, Murray M.; Wessel, David] George Washington Univ, Sch Med, Dept Pediat, Natl Childrens Hosp, Washington, DC 20052 USA; [Federman, Myke; Huard, Leanna L.; Srivastava, Neeraj; Sapru, Anil] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Los Angeles, CA 90024 USA; [Fernandez, Richard; Maa, Tensing; Hall, Mark; Yates, Andrew R.] Ohio State Univ, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Franzon, Deborah; Tabbutt, Sarah; McQuillen, Patrick S.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA USA; [Frazier, Aisha H.; Hehir, David; Viteri, Shirley] Nemours Alfred I duPont Hosp Children, Dept Pediat, Wilmington, DE USA; [Frazier, Aisha H.; Hehir, David; Viteri, Shirley] Thomas Jefferson Univ, Wilmington, DE USA; [Notterman, Daniel] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Utah System of Higher Education; University of Utah; Central Michigan University; Children's Hospital of Michigan; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Children's National Health System; George Washington University; University of California System; University of California Los Angeles; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of California System; University of California San Francisco; Nemours Alfred I. duPont Hospital for Children; Jefferson University; Princeton University	Sutton, RM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 3401 Civ Ctr Blvd,Wood Bldg,Sixth Floor, Philadelphia, PA 19104 USA.	suttonr@chop.edu	Carpenter, Todd/A-7503-2011	Carpenter, Todd/0000-0002-9855-0021; Morgan, Ryan/0000-0003-1664-5316; sapru, anil/0000-0003-1528-8249	National Heart, Lung, and Blood Institute [R01HL131544]; National Institute of Child Health and Human Development [U01HD049934, UG1HD049981, UG1HD049983, UG1HD050096, UG1HD063108, UG1HD083166, UG1HD083170, UG1HD083171]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was funded by grants R01HL131544 from the National Heart, Lung, and Blood Institute and U01HD049934, UG1HD049981, UG1HD049983, UG1HD050096, UG1HD063108, UG1HD083166, UG1HD083170, and UG1HD083171 from the National Institute of Child Health and Human Development.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Bembea MM, 2010, PEDIATR CRIT CARE ME, V11, P723, DOI 10.1097/PCC.0b013e3181dde659; Bennett KS, 2013, CRIT CARE MED, V41, P1534, DOI 10.1097/CCM.0b013e318287f54c; Berg RA, 2018, RESUSCITATION, V133, P173, DOI 10.1016/j.resuscitation.2018.08.013; Berg RA, 2018, CIRCULATION, V137, P1784, DOI 10.1161/CIRCULATIONAHA.117.032270; Berg RA, 2016, CRIT CARE MED, V44, P798, DOI 10.1097/CCM.0000000000001484; Berg RA, 2013, CRIT CARE MED, V41, P2292, DOI 10.1097/CCM.0b013e31828cf0c0; Bhanji F, 2017, JAMA PEDIATR, V171, P39, DOI 10.1001/jamapediatrics.2016.2535; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Conlon TW, 2015, PEDIATR CRIT CARE ME, V16, P146, DOI 10.1097/PCC.0000000000000305; de Caen AR, 2015, CIRCULATION, V132, pS526, DOI 10.1161/CIR.0000000000000266; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Gaies M, 2015, CARDIOL YOUNG, V25, P951, DOI 10.1017/S1047951114001450; Girotra S, 2013, CIRC-CARDIOVASC QUAL, V6, P42, DOI 10.1161/CIRCOUTCOMES.112.967968; Hamrick JT, 2017, PEDIATR CRIT CARE ME, V18, pE575, DOI 10.1097/PCC.0000000000001299; Holmberg MJ, 2019, CIRCULATION, V140, P1398, DOI 10.1161/CIRCULATIONAHA.119.041667; Holmberg MJ, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005580; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Matos RI, 2013, CIRCULATION, V127, P442, DOI 10.1161/CIRCULATIONAHA.112.125625; Meaney PA, 2006, PEDIATRICS, V118, P2424, DOI 10.1542/peds.2006-1724; Moler FW, 2017, NEW ENGL J MED, V376, P318, DOI 10.1056/NEJMoa1610493; Morgan RW, 2018, AM J RESP CRIT CARE, V197, P905, DOI 10.1164/rccm.201709-1818OC; Morgan RW, 2017, RESUSCITATION, V111, P41, DOI 10.1016/j.resuscitation.2016.11.018; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Naim MY, 2016, CRIT CARE MED, V44, pE1111, DOI 10.1097/CCM.0000000000001859; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Reeder RW, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2590-y; Sutton RM, 2019, CRIT CARE MED, V47, P1627, DOI 10.1097/CCM.0000000000003898; Sutton RM, 2018, RESUSCITATION, V130, P159, DOI 10.1016/j.resuscitation.2018.07.015; Sutton RM, 2016, RESUSCITATION, V106, P76, DOI 10.1016/j.resuscitation.2016.06.018; Sutton RM, 2014, AM J RESP CRIT CARE, V190, P1255, DOI 10.1164/rccm.201407-1343OC; Topjian AA, 2020, CIRCULATION, V142, pE246, DOI 10.1161/CIR.0000000000000911; Topjian AA, 2018, JAMA PEDIATR, V172, P143, DOI 10.1001/jamapediatrics.2017.4043; Topjian AA, 2016, PEDIATR CRIT CARE ME, V17, P547, DOI 10.1097/PCC.0000000000000740; Topjian AA, 2014, CRIT CARE MED, V42, P1518, DOI 10.1097/CCM.0000000000000216; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Willson DF, 2006, PEDIATR CRIT CARE ME, V7, P301, DOI 10.1097/01.PCC.0000227106.66902.4F; Wolfe H, 2014, CRIT CARE MED, V42, P1688, DOI 10.1097/CCM.0000000000000327	40	5	5	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2022	327	10					934	945		10.1001/jama.2022.1738	http://dx.doi.org/10.1001/jama.2022.1738			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT9ON	35258533	Green Published			2023-01-03	WOS:000769478000016
J	Chen, Y; Yang, WH; Chen, HF; Huang, LM; Gao, JY; Lin, CW; Wang, YC; Yang, CS; Liu, YL; Hou, MH; Tsai, CL; Chou, YZ; Huang, BY; Hung, CF; Hung, YL; Wang, WJ; Su, WC; Kumar, V; Wu, YC; Chao, SW; Chang, CS; Chen, JS; Chiang, YP; Cho, DY; Jeng, LB; Tsai, CH; Hung, MC				Chen, Yeh; Yang, Wen-Hao; Chen, Hsiao-Fan; Huang, Li-Min; Gao, Jing-Yan; Lin, Cheng-Wen; Wang, Yu-Chuan; Yang, Chia-Shin; Liu, Yi-Liang; Hou, Mei-Hui; Tsai, Chia-Ling; Chou, Yi-Zhen; Huang, Bao-Yue; Hung, Chian-Fang; Hung, Yu-Lin; Wang, Wei-Jan; Su, Wen-Chi; Kumar, Vathan; Wu, Yu-Chieh; Chao, Shih-Wei; Chang, Chih-Shiang; Chen, Jin-Shing; Chiang, Yu-Ping; Cho, Der-Yang; Jeng, Long-Bin; Tsai, Chang-Hai; Hung, Mien-Chie			Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-VIVAX MALARIA; THERMAL SHIFT ASSAYS; MAIN PROTEINASE; PREVENTION; RELAPSE; COVID-19; ENTRY	The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has severely affected human lives around the world as well as the global economy. Therefore, effective treatments against COVID-19 are urgently needed. Here, we screened a library containing Food and Drug Administration (FDA)-approved compounds to identify drugs that could target the SARS-CoV-2 main protease (M-pro), which is indispensable for viral protein maturation and regard as an important therapeutic target. We identified antimalarial drug tafenoquine (TFQ), which is approved for radical cure of Plasmodium vivax and malaria prophylaxis, as a top candidate to inhibit Mpro protease activity. The crystal structure of SARS-CoV-2 M-pro in complex with TFQ revealed that TFQ non-covalently bound to and reshaped the substrate-binding pocket of Mpro by altering the loop region (residues 139-144) near the catalytic Cys145, which could block the catalysis of its peptide substrates. We also found that TFQ inhibited human trans-membrane protease serine 2 (TMPRSS2). Furthermore, one TFQ derivative, compound 7, showed a better therapeutic in-dex than TFQ on TMPRSS2 and may therefore inhibit the infectibility of SARS-CoV-2, including that of several mutant variants. These results suggest new potential strategies to block infection of SARS-CoV-2 and rising variants.	[Chen, Yeh; Wang, Yu-Chuan; Yang, Chia-Shin; Hou, Mei-Hui; Tsai, Chia-Ling; Chou, Yi-Zhen] China Med Univ, Inst New Drug Dev, Taichung, Taiwan; [Chen, Yeh; Yang, Wen-Hao; Gao, Jing-Yan; Kumar, Vathan; Chao, Shih-Wei; Chang, Chih-Shiang; Hung, Mien-Chie] China Med Univ, Drug Dev Ctr, Taichung, Taiwan; [Chen, Yeh; Yang, Wen-Hao; Wang, Wei-Jan; Hung, Mien-Chie] China Med Univ, Res Ctr Canc Biol, Taichung, Taiwan; [Yang, Wen-Hao; Chen, Hsiao-Fan; Huang, Bao-Yue; Hung, Chian-Fang; Su, Wen-Chi; Cho, Der-Yang; Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Yang, Wen-Hao; Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Huang, Li-Min; Chiang, Yu-Ping] Natl Taiwan Univ, Coll Med, Dept Pediat, Taipei, Taiwan; [Gao, Jing-Yan; Wu, Yu-Chieh; Chang, Chih-Shiang] China Med Univ, Coll Pharm, Sch Pharm, Taichung, Taiwan; [Lin, Cheng-Wen] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Lin, Cheng-Wen] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Liu, Yi-Liang] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Hung, Yu-Lin] China Med Univ, Program Digital Hlth Innovat, Taichung, Taiwan; [Wang, Wei-Jan] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Chen, Jin-Shing] Natl Taiwan Univ Hosp, Coll Med, Dept Surg, Taipei, Taiwan; [Chen, Jin-Shing] Natl Taiwan Univ, Taipei, Taiwan; [Cho, Der-Yang] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Jeng, Long-Bin; Tsai, Chang-Hai] China Med Univ, China Med Univ Hosp, Sch Med, Taichung, Taiwan; [Jeng, Long-Bin] China Med Univ, China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Tsai, Chang-Hai] China Med Univ, China Med Univ Childrens Hosp, Taichung, Taiwan; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; National Taiwan University; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; National Chung Hsing University; China Medical University Taiwan; China Medical University Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Chen, Y (corresponding author), China Med Univ, Inst New Drug Dev, Taichung, Taiwan.; Chen, Y; Hung, MC (corresponding author), China Med Univ, Drug Dev Ctr, Taichung, Taiwan.; Chen, Y; Hung, MC (corresponding author), China Med Univ, Res Ctr Canc Biol, Taichung, Taiwan.; Hung, MC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Hung, MC (corresponding author), China Med Univ, Ctr Mol Med, Taichung, Taiwan.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung, Taiwan.	bluecrystalprotein@gmail.com; mhung@cmu.edu.tw	Yang, wenhao/GXG-5965-2022	Hung, Mien-Chie/0000-0003-4317-4740; Yang, Wen-Hao/0000-0002-6292-9048; Wang, Wei-Jan/0000-0002-0811-8199; Hung, Yu-Lin/0000-0002-6394-9753; Jeng, Long-Bin/0000-0002-2928-4698; CHEN, JIN-SHING/0000-0001-5077-4483	Ministry of Science and Technology, Taiwan [MOST108-2311-B-241-001, MOST109-2327-B039-003, MOST110-2923-B-039-001-MY3]; Yingtsai Young Scholar Award [CMU108-YTY-04]; "Drug Development Center, China Medical University" from the Featured Areas Research Center Program by the Ministry of Education (MOE), Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Yingtsai Young Scholar Award; "Drug Development Center, China Medical University" from the Featured Areas Research Center Program by the Ministry of Education (MOE), Taiwan	This research was supported in part by the following: The Ministry of Science and Technology, Taiwan (MOST108-2311-B-241-001; to Y. C., MOST109-2327-B039-003; to M.-C. H. and MOST110-2923-B-039-001-MY3; to C.-W. L.); Yingtsai Young Scholar Award (CMU108-YTY-04; to W.-H. Y.); the "Drug Development Center, China Medical University" from the Featured Areas Research Center Program within the Framework of the Higher Education Sprout Project by the Ministry of Education (MOE), Taiwan.	Aljoundi A, 2020, PROTEIN J, V39, P97, DOI 10.1007/s10930-020-09884-2; Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Ayerbe L, 2021, LANCET RHEUMATOL, V3, pE172, DOI [10.1016/S2665-9913(21)00031-X, 10.1016/S2665-9913(21)00030-8]; Bansal P., 2021, ANN MED, DOI DOI 10.1056/NEJMoa2021801; Bottger R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178943; Campo B, 2015, PATHOG GLOB HEALTH, V109, P107, DOI 10.1179/2047773215Y.0000000013; Cherian S., 2021, BIORXIV, DOI [10.1101/2021. 04.22.440932, DOI 10.1101/2021.04.22.440932, 10.1101/2021.05.14.444076, DOI 10.1101/2021.05.14.444076]; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ebstie YA, 2016, DRUG DES DEV THER, V10, P2387, DOI 10.2147/DDDT.S61443; Fornasier E., 2021, BIORXIV, DOI [DOI 10.3390/v13020174, 10.1101/2021.03.04.433882, DOI 10.1101/2021.03.04.433882]; Frampton JE, 2018, DRUGS, V78, P1517, DOI 10.1007/s40265-018-0979-2; Gordon D. E., 2020, SARS, DOI DOI 10.1016/j.cell.2020.02.052; Gunther S, 2021, SCIENCE, V372, P642, DOI 10.1126/science.abf7945; Haston JC, 2019, MMWR-MORBID MORTAL W, V68, P1062, DOI 10.15585/mmwr.mm6846a4; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hoffmann M., 2021, SARS COV 2, DOI DOI 10.3346/jkms.2020.35.e84; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hossain MK, 2021, EXPERT REV VACCINES, V20, P635, DOI 10.1080/14760584.2021.1915140; Hounkpatin AB, 2019, INFECT DRUG RESIST, V12, P553, DOI 10.2147/IDR.S151031; Zahradník J, 2021, bioRxiv, DOI 10.1101/2021.01.06.425392; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Jirjees F, 2021, INFECT DIS REP, V13, P259, DOI 10.3390/idr13020029; Katz IT, 2021, NEW ENGL J MED, V384, P1281, DOI 10.1056/NEJMp2103614; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kumar V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179131; Lee TC, 2021, INT J INFECT DIS, V104, P671, DOI 10.1016/j.ijid.2021.01.065; Levine-Tiefenbrun M., 2021, INITIAL REPORT DECRE, DOI DOI 10.1038/s41562-021-01122-8; Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031; Lockbaum GJ, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020174; Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073; Mahmoud IS, 2020, BIOCHIMIE, V175, P93, DOI 10.1016/j.biochi.2020.05.012; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Mitja O, 2021, NEW ENGL J MED, V384, P417, DOI 10.1056/NEJMoa2021801; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Naqvi A. A. T., 2020, BIOCH BIOPHYS ACTA M, DOI DOI 10.1021/acs.jmedchem.5b01461; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Park WB, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e84; Pawlowski C, 2021, MED-CAMBRIDGE, V2, P979, DOI 10.1016/j.medj.2021.06.007; Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461; Ragia G, 2020, EUR J CLIN PHARMACOL, V76, P1623, DOI 10.1007/s00228-020-02963-4; Reynolds C. J., UK COVIDSOR TIUM IMM, P2021, DOI [10.1101/ 2021.01.06.425392, DOI 10.1101/2021.01.06.425392]; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Seetoh WG, 2016, J AM CHEM SOC, V138, P14303, DOI 10.1021/jacs.6b07440; Singh J, 2021, NAT MED, V27, P1131, DOI 10.1038/s41591-021-01397-4; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Su H., 2020, BIORXIV, DOI [DOI 10.1007/s10930-020-09884-2, 10. 1101/2020.04.13.038687, DOI 10.1101/2020.04.13.038687]; Tada T., 2021, BIORXIV2021051444407, DOI [DOI 10.1126/science.abc6952, 10.1101/2021.05.14.444076, DOI 10.1101/2021.05.14.444076]; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Vaidyanathan G, 2021, NATURE, V593, P321, DOI 10.1038/d41586-021-01274-7; Verschueren KHG, 2008, CHEM BIOL, V15, P597, DOI 10.1016/j.chembiol.2008.04.011; Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wang YC, 2020, AM J CANCER RES, V10, P2535; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Woolger N, 2017, J BIOL CHEM, V292, P18577, DOI 10.1074/jbc.M117.790014; World Health Organization (Who), 2020, SITUATION REPORT; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xiu SY, 2020, J MED CHEM, V63, P12256, DOI 10.1021/acs.jmedchem.0c00502; Yan HM, 2004, J MED VIROL, V73, P323, DOI 10.1002/jmv.20094; Yang H., 2003, P NATL ACAD SCI USA, DOI DOI 10.1016/j.chembiol.2008.04.011; Zhang J., 2020, EMERG INFECT DIS, DOI DOI 10.1007/s00228-020-02963-4; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	70	3	3	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR	2022	298	3							101658	10.1016/j.jbc.2022.101658	http://dx.doi.org/10.1016/j.jbc.2022.101658		FEB 2022	15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	1F0KH	35101449	gold, Green Published			2023-01-03	WOS:000794865600003
J	Nieto-Garcia, L; Carpio-Perez, A; Moreiro-Barroso, MT; Ruiz-Antunez, E; Nieto-Garcia, A; Alonso-Sardon, M				Nieto-Garcia, Leticia; Carpio-Perez, Adela; Teresa Moreiro-Barroso, Maria; Ruiz-Antunez, Emilia; Nieto-Garcia, Ainhoa; Alonso-Sardon, Montserrat			Are there differences between COVID-19 and non-COVID-19 inpatient pressure injuries? Experiences in Internal Medicine Units	PLOS ONE			English	Article							ULCERS; MORTALITY	Background Pressure Injuries (PIs) are major worldwide public health threats within the different healthcare settings. Objective To describe and compare epidemiological and clinical features of PIs in COVID-19 patients and patients admitted for other causes in Internal Medicine Units during the first wave of COVID-19 pandemic. Design A descriptive longitudinal retrospective study. Setting This study was conducted in Internal Medicine Units in Salamanca University Hospital Complex, a tertiary hospital in the Salamanca province, Spain. Participants All inpatients.18-year-old admitted from March 1, 2020 to June 1, 2020 for more than 24 hours in the Internal Medicine Units with one or more episodes of PIs. Results A total of 101 inpatients and 171 episodes were studied. The prevalence of PI episodes was 6% and the cumulative incidence was 2.9% during the first-wave of COVID-19. Risk of acute wounds was four times higher in the COVID-19 patient group (p< 0.001). Most common locations were sacrum and heels. Among hospital acquired pressure injuries a significant association was observed between arterial hypertension and diabetes mellitus in patients with COVID-19 diagnosis. Conclusion During the first wave of COVID-19, COVID-19 patients tend to present a higher number of acute wounds, mainly of hospital origin, compared to the profile of the non-COVID group. Diabetes mellitus and arterial hypertension were identified as main associated comorbidities in patients with COVID-19 diagnosis.	[Nieto-Garcia, Leticia; Nieto-Garcia, Ainhoa] Univ Salamanca, Sch Nursing & Physiotherapy, Salamanca, Spain; [Carpio-Perez, Adela] Univ Salamanca CIETUS, Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, Internal Med Serv,Trop Dis Res Ctr, Salamanca, Spain; [Teresa Moreiro-Barroso, Maria] Univ Hosp Salamanca, Internal Med Serv, Salamanca, Spain; [Ruiz-Antunez, Emilia] Univ Hosp Salamanca, Training Dev & Innovat Area, Salamanca, Spain; [Alonso-Sardon, Montserrat] Univ Salamanca CIETUS, Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Prevent Med & Publ Hlth Area,Trop Dis Res Ctr, Salamanca, Spain	University of Salamanca; University of Salamanca; University of Salamanca	Alonso-Sardon, M (corresponding author), Univ Salamanca CIETUS, Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Prevent Med & Publ Hlth Area,Trop Dis Res Ctr, Salamanca, Spain.	sardonm@usal.es		Alonso-Sardon, Montserrat/0000-0003-1829-5858; Nieto Garcia, Leticia/0000-0002-5227-4076; Nieto Garcia, Ainhoa/0000-0002-5514-3696; Rubio Gil, Francisco Javier/0000-0002-4813-2761				Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2; Bellosta R, 2020, J VASC SURG, V72, P1864, DOI 10.1016/j.jvs.2020.04.483; Black J, 2020, UNAVOIDABLE PRESSURE; Bloomfield R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008095.pub2; Boyko TV, 2018, ADV WOUND CARE, V7, P57, DOI 10.1089/wound.2016.0697; Chen JK, 2022, POSTGRAD MED J, V98, P515, DOI 10.1136/postgradmedj-2021-140674; Colling ME, 2020, VASC MED, V25, P471, DOI 10.1177/1358863X20932640; Cuker A., 2020, CORONAVIRUS DIS 2019; Edsberg LE, 2016, J WOUND OSTOMY CONT, V43, P585, DOI 10.1097/WON.0000000000000281; Gefen A, 2020, J WOUND CARE, V29, P540, DOI 10.12968/jowc.2020.29.10.540; Guerin C, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.63; Haesler Emily, 2019, EUR PRESS ULC ADV PA; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; Jaul E, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0997-7; Junta de Castilla y Leon, SIT EP COR COVID 19; Labeau SO, 2021, INTENS CARE MED, V47, P160, DOI 10.1007/s00134-020-06234-9; Lima-Martinez MM, 2021, CLIN INVEST ARTERIOS, V33, P151, DOI 10.1016/j.arteri.2020.10.001; Livesley NJ, 2002, CLIN INFECT DIS, V35, P1390, DOI 10.1086/344059; Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149; Moore Z, 2019, J WOUND CARE, V28, P710, DOI 10.12968/jowc.2019.28.11.710; Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT; Pancorbo-Hidalgo Pedro L., 2019, Gerokomos, V30, P76; World Health Organization, 133 WHO; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017	24	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0263900	10.1371/journal.pone.0263900	http://dx.doi.org/10.1371/journal.pone.0263900			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176083	gold, Green Published			2023-01-03	WOS:000777505200042
J	Gonzalez, CJ; Hogan, CJ; Rajan, M; Wells, MT; Safford, MM; Pinheiro, LC; Ghosh, AK; Choi, JJ; Burchenal, CA; Shah, PD; Shapiro, MF				Gonzalez, Christopher J.; Hogan, Cameron J.; Rajan, Mangala; Wells, Martin T.; Safford, Monika M.; Pinheiro, Laura C.; Ghosh, Arnab K.; Choi, Justin J.; Burchenal, Clare A.; Shah, Pooja D.; Shapiro, Martin F.			Predictors of life-threatening complications in relatively lower-risk patients hospitalized with COVID-19	PLOS ONE			English	Article							COMORBIDITY; DISEASE; STATES	Older individuals with chronic health conditions are at highest risk of adverse clinical outcomes from COVID-19, but there is widespread belief that risk to younger, relatively lower-risk individuals is negligible. We assessed the rate and predictors of life-threatening complications among relatively lower-risk adults hospitalized with COVID-19. Of 3766 adults hospitalized with COVID-19 to three hospitals in New York City from March to May 2020, 963 were relatively lower-risk based on absence of preexisting health conditions. Multivariable logistic regression models examined in-hospital development of life-threatening complications (major medical events, intubation, or death). Covariates included age, sex, race/ethnicity, hypertension, weight, insurance type, and area-level sociodemographic factors (poverty, crowdedness, and limited English proficiency). In individuals >= 55 years old (n = 522), 33.3% experienced a life-threatening complication, 17.4% were intubated, and 22.6% died. Among those <55 years (n = 441), 15.0% experienced a life-threatening complication, 11.1% were intubated, and 5.9% died. In multivariable analyses among those >= 55 years, age (OR 1.03 [95%CI 1.01-1.06]), male sex (OR 1.72 [95%CI 1.14-2.64]), being publicly insured (versus commercial insurance: Medicare, OR 2.02 [95%CI 1.22-3.38], Medicaid, OR 1.87 [95%CI 1.10-3.20]) and living in areas with relatively high limited English proficiency (highest versus lowest quartile: OR 3.50 [95%CI 1.74-7.13]) predicted life-threatening complications. In those <55 years, no sociodemographic factors significantly predicted life-threatening complications. A substantial proportion of relatively lower-risk patients hospitalized with COVID-19 experienced life-threatening complications and more than 1 in 20 died. Public messaging needs to effectively convey that relatively lower-risk individuals are still at risk of serious complications.	[Gonzalez, Christopher J.; Rajan, Mangala; Safford, Monika M.; Pinheiro, Laura C.; Ghosh, Arnab K.; Choi, Justin J.; Burchenal, Clare A.; Shah, Pooja D.; Shapiro, Martin F.] Cornell Univ, Dept Med, Weill Med Coll, New York, NY 14850 USA; [Hogan, Cameron J.; Wells, Martin T.] Cornell Univ, Dept Stat & Data Sci, Ithaca, NY USA	Cornell University; Cornell University	Gonzalez, CJ (corresponding author), Cornell Univ, Dept Med, Weill Med Coll, New York, NY 14850 USA.	cjg7003@med.cornell.edu		Gonzalez, Christopher/0000-0003-2916-4175	Diversity Center of Excellence (from the Health Resources and Services Administration) [D34HP31879]; Clinical and Translational Science Center (from the National Institutes of Health) [UL1 TR000457]; New York-Presbyterian Hospital; Weill Cornell Medicine	Diversity Center of Excellence (from the Health Resources and Services Administration); Clinical and Translational Science Center (from the National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York-Presbyterian Hospital; Weill Cornell Medicine	CJG was supported by the Diversity Center of Excellence (grant D34HP31879 from the Health Resources and Services Administration), the Clinical and Translational Science Center (grant UL1 TR000457 from the National Institutes of Health), New York-Presbyterian Hospital, and Weill Cornell Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16938; Anderson MR, 2020, ANN INTERN MED, V173, P782, DOI 10.7326/M20-3214; [Anonymous], NEW YORK TIMES; Berkowitz SA, 2015, HEALTH SERV RES, V50, P398, DOI 10.1111/1475-6773.12229; Bonito AJ., 2008, AHRQ PUBLICATION; Bosman J., NEW YORK TIMES; Burr JA, 2010, J GERONTOL B-PSYCHOL, V65, P772, DOI 10.1093/geronb/gbq069; CDC, AM I HIGH RISK SEV I; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cunningham JW, 2021, JAMA INTERN MED, V181, P379, DOI 10.1001/jamainternmed.2020.5313; DeBiasi RL, 2020, J PEDIATR-US, V223, P199, DOI 10.1016/j.jpeds.2020.05.007; Furuse Y, 2020, EMERG INFECT DIS, V26, P2176, DOI 10.3201/eid2609.202272; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Glasheen WP, 2019, AM HEALTH DRUG BENEF, V12, P188; Goyal P, 2020, ANN INTERN MED, V173, P855, DOI 10.7326/M20-2730; Gross CP, 2020, J GEN INTERN MED, V35, P3097, DOI 10.1007/s11606-020-06081-w; Gutierrez-Gonzalez E, 2019, J INFECT PUBLIC HEAL, V12, P486, DOI 10.1016/j.jiph.2018.11.011; Hutchins HJ, 2020, MMWR-MORBID MORTAL W, V69, P1584, DOI 10.15585/mmwr.mm6943e4; Kass DA, 2020, ANN INTERN MED, V173, P840, DOI 10.7326/M20-5677; Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2; Klang E, 2020, OBESITY, V28, P1595, DOI 10.1002/oby.22913; Liao JQ, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.04.001; Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415; Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005; NYC Department of City Planning, LANG ACC; Pew Research Center, REC 64 MILL AM LIV M; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Schaeffer K., 2020, LOOK AM WHO BELIEVE; Skiest DJ, 1996, AM J MED, V101, P605, DOI 10.1016/S0002-9343(96)00329-4; Sorci G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75848-2; Tartof SY, 2020, ANN INTERN MED, V173, P773, DOI 10.7326/M20-3742; Thrush G, NEW YORK TIMES, V22, P2020; Torres E., ABC NEWS; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197; World Health Organization, 2010, CONC FRAM ACT SOC DE; Zaiets K., USA TODAY	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2022	17	2							e0263995	10.1371/journal.pone.0263995	http://dx.doi.org/10.1371/journal.pone.0263995			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P8AU	35167610	Green Published, gold			2023-01-03	WOS:000802227200030
J	Omenai, SA; Ajani, MA; Okolo, CA				Omenai, Sebastian A.; Ajani, Mustapha A.; Okolo, Clement A.			Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients	PLOS ONE			English	Article							PD-L1 EXPRESSION; CANCER; IMMUNITY; CELLS; TUMOR	Background The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body's own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated the immunohistochemical expression of PD-L1 in uterine cervical carcinomas. Women with cervical cancer would benefit from its use as a marker in therapy and prognosis. Methods Hospital-based cross-sectional retrospective study was conducted. The study materials included 183 archived formalin fixed and paraffin embedded (FFPE) tissue blocks with histological diagnosis of cervical carcinoma diagnosed in our facility within a five-year period (January 2012 and December 2016) that met the study criteria. Data were extracted from records in the Department and immunohistochemistry was done using polyclonal antibodies to PD-L1 (GTX104763, Genetex). Obtained data were analysed using SPSS version 23. P < 0.05 was considered significant. Results A hundred and eighty-three cases of cervical cancer were studied. PD-L1 was positive in 57.4% of all cases. The diffuse pattern of staining was the major pattern accounting for 88.5% of positive cases. Poorly differentiated cervical carcinomas are less likely to express PD-L1. Within the histologic types, the squamous cell carcinomas expressed PD-L1 in 58.7%, and 50% of adenocarcinomas were positive. PD-L1 was not expressed in all cases of adenoid cystic carcinomas and basaloid squamous cell carcinomas. Conclusion A significant population of cervical carcinoma expresses PD-L1 by immunohistochemistry. PD-L1 prevalence is lower amongst the poorly differentiated cancers compared to other grades.	[Omenai, Sebastian A.; Ajani, Mustapha A.; Okolo, Clement A.] Univ Coll Hosp, Dept Pathol, Ibadan, Oyo State, Nigeria; [Omenai, Sebastian A.] Edo State Univ, Dept Anat Pathol, Uzairue, Edo State, Nigeria	University of Ibadan; University College Hospital, Ibadan	Omenai, SA (corresponding author), Univ Coll Hosp, Dept Pathol, Ibadan, Oyo State, Nigeria.; Omenai, SA (corresponding author), Edo State Univ, Dept Anat Pathol, Uzairue, Edo State, Nigeria.	sebeanom@gmail.com	Omenai, Sebastian Anebuokhae/AAP-1636-2021	Omenai, Sebastian Anebuokhae/0000-0002-1841-1487				Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen H, 2020, INT J BIOL MARKER, V35, P65, DOI 10.1177/1724600819888771; Chen JJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8164365; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; de Ruiter EJ, 2021, MODERN PATHOL, V34, P1125, DOI 10.1038/s41379-020-0644-7; Denny L, 2014, INT J CANCER, V134, P1389, DOI 10.1002/ijc.28425; Enwere EK, 2017, MODERN PATHOL, V30, P577, DOI 10.1038/modpathol.2016.221; Eskander RN, 2015, CLIN THER, V37, P20, DOI 10.1016/j.clinthera.2014.11.010; Feng M, 2018, INT J CLIN EXP PATHO, V11, P5370; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gu XB, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0861-7; Heeren AM, 2016, MODERN PATHOL, V29, P753, DOI 10.1038/modpathol.2016.64; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Jedy-Agba E, 2012, CANCER EPIDEMIOL, V36, pE271, DOI 10.1016/j.canep.2012.04.007; Karpathiou G, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2019.152782; Kumar S, 2009, ARCH GYNECOL OBSTET, V280, P25, DOI 10.1007/s00404-008-0851-9; Kurman RJ, 2014, WORLD HLTH ORG CLASS; Lin PL, 2017, CANCER MED-US, V6, P2052, DOI 10.1002/cam4.1143; Lin YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142656; Loharamtaweethong K., 2019, ASIAN PAC J ALLERGY, V10, P1; Ndiaye C, 2012, TROP MED INT HEALTH, V17, P1432, DOI 10.1111/tmi.12004; Noguchi T, 2017, CANCER IMMUNOL RES, V5, P106, DOI 10.1158/2326-6066.CIR-16-0391; Otter SJ, 2019, CLIN ONCOL-UK, V31, P834, DOI 10.1016/j.clon.2019.07.003; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Reddy OL, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0631-6; Rotman J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.596825; Saglam Ozlen, 2018, Integr Cancer Sci Ther, V5, DOI 10.15761/ICST.1000272; Vinh-Hung V, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-164; WENTZ WB, 1959, CANCER, V12, P384, DOI 10.1002/1097-0142(195903/04)12:2<384::AID-CNCR2820120222>3.0.CO;2-C; Witkiewicz AK., 2011, BLAUSTEINS PATHOLOGY, V6th, P156; Wu SF, 2017, ONCOTARGET, V8, P16421, DOI 10.18632/oncotarget.14851; Yang W, 2013, IMMUNOLOGY, V139, P513, DOI 10.1111/imm.12101; Zhang QQ, 2021, ONCOTARGETS THER, V14, P4275, DOI 10.2147/OTT.S318082; Zhang YX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000515	35	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263615	10.1371/journal.pone.0263615	http://dx.doi.org/10.1371/journal.pone.0263615			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139126	gold, Green Published			2023-01-03	WOS:000821499100036
J	Sarzynski, SH; Mancera, A; Mann, C; Dai, MT; Sun, JF; Warner, S; Kadri, SS				Sarzynski, Sadia H.; Mancera, Alex; Mann, Clay; Dai, Mengtao; Sun, Junfeng; Warner, Sarah; Kadri, Sameer S.			Frequency and Risk of Emergency Medical Service Interhospital Transportation of Patients With Acute Lower Respiratory Tract Illness During the COVID-19 Pandemic in the US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sarzynski, Sadia H.; Mancera, Alex; Sun, Junfeng; Warner, Sarah; Kadri, Sameer S.] NIH, Crit Care Med Dept, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Mann, Clay; Dai, Mengtao] Univ Utah, Sch Med, Natl Emergency Med Serv Informat Syst, Tech Assistance Ctr, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Utah System of Higher Education; University of Utah	Kadri, SS (corresponding author), NIH, Clin Epidemiol Sect, Crit Care Med Dept, 10 Ctr Dr,Bldg 10-2C145, Bethesda, MD 20892 USA.	Sameer.Kadri@nih.gov			Intramural Research Program of the National Institutes of Health (NIH) Clinical Center	Intramural Research Program of the National Institutes of Health (NIH) Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the Intramural Research Program of the National Institutes of Health (NIH) Clinical Center.	Allen Rebecca, 2020, Air Med J, V39, P498, DOI 10.1016/j.amj.2020.07.007; Kadri SS, 2021, ANN INTERN MED, V174, P1240, DOI 10.7326/M21-1213; Kadri SS, 2020, JAMA-J AM MED ASSOC, V324, P2553, DOI 10.1001/jama.2020.20323; Painvin B, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00841-5; Payet C, 2022, CRIT CARE MED, V50, P138, DOI 10.1097/CCM.0000000000005215; Troncoso Ruben D Jr, 2021, Air Med J, V40, P220, DOI 10.1016/j.amj.2021.04.001	6	1	1	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2022	327	9					874	877		10.1001/jama.2022.0812	http://dx.doi.org/10.1001/jama.2022.0812		JAN 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZO9OI	35089309	Green Published, Bronze			2023-01-03	WOS:000747991100002
J	Wang, L; Xian, J; Sun, M; Wang, X; Zang, XM; Zhang, X; Yu, HJ; Tan, QW				Wang, Ling; Xian, Jin; Sun, Mi; Wang, Xue; Zang, Xiaoming; Zhang, Xin; Yu, Huijuan; Tan, Qi-Wen			Acupuncture for emotional symptoms in patients with functional gastrointestinal disorders: A systematic review and meta-analysis	PLOS ONE			English	Review							ANXIETY	Background Patients with functional gastrointestinal disorders (FGIDs) also often have emotional symptoms, such as anxiety and depression. The main drugs used for the treatment of FGIDs mainly target single gastrointestinal symptoms and are not effective in regulating emotional symptoms. Evidence has shown that acupuncture can relieve gastrointestinal symptoms in FGIDs patients, but there is no high-quality evidence to show that acupuncture can relieve psychological symptoms in these patients. Objectives To systematically evaluate the clinical efficacy and safety of acupuncture for emotional symptoms in patients with FGIDs. Methods Randomized controlled trials (RCTs) published from database inception through July 31, 2021, were retrieved from three English-language databases (PubMed, the Cochrane Central Register of Controlled Trials, and Embase) and five Chinese-language databases (the China National Knowledge Infrastructure, Wanfang, VIP, Chinese Biomedical, and TCM Literature Analysis and Retrieval databases). RCTs that compared acupuncture with sham acupuncture and pharmacotherapy were included in this study. The score on the depression or anxiety scale after treatment were considered as primary outcomes. The 'meta' package (version 4.19-0) in RStudio 1.1.463 was used to analyse the data. Results A total of 2151 patients from 24 RCTs were included in this study. Compared with sham acupuncture, acupuncture was not significantly better at relieving anxiety (standardized mean difference [SMD] -0.35, 95% CI -1.05 to 0.33) and depression (SMD -0.32, 95% CI -0.71 to 0.07) symptoms. Compared with pharmacotherapy, acupuncture was significantly better at relieving anxiety (SMD -0.64, 95% CI -0.93 to -0.35) and depression (SMD -0.46, 95% CI -0.69 to -0.22) symptoms. Conclusions This meta-analysis found that acupuncture can alleviate emotional symptoms in FGID patients better than pharmacotherapy. However, it is not clear whether this effect is based on the placebo effect, specific effect or nonspecific effect of acupuncture. The evidence should be proven by rigorously designed RCTs in the future.	[Wang, Ling; Sun, Mi; Wang, Xue; Zang, Xiaoming; Zhang, Xin; Yu, Huijuan; Tan, Qi-Wen] Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China; [Xian, Jin] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Shandong, Peoples R China	Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine	Yu, HJ; Tan, QW (corresponding author), Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China.	huijuanyu@163.com; qiwentan@sdutcm.edu.cn		xian, jin/0000-0002-0968-7182	TCM "Zhi Wei Bing" Scientific Research Innovation Team of Shandong University of Traditional Chinese Medicine [220318]; Traditional Chinese Medicine Science and Technology Project of Shandong Province [2021Q110]; National Key R&D Program of China [2018YFC1707504, 2020YFC0845000]	TCM "Zhi Wei Bing" Scientific Research Innovation Team of Shandong University of Traditional Chinese Medicine; Traditional Chinese Medicine Science and Technology Project of Shandong Province; National Key R&D Program of China	This study is supported by funding from TCM "Zhi Wei Bing" Scientific Research Innovation Team of Shandong University of Traditional Chinese Medicine (NO.220318), Traditional Chinese Medicine Science and Technology Project of Shandong Province (2021Q110), National Key R&D Program of China (2018YFC1707504 & 2020YFC0845000). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen Huiyi., 2019, CLIN STUDY ACUPUNCTU; Chen Yue-Hua, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P594; Da Nili., 2014, CLIN RES RELEVANCE F; Deutsch JK, 2020, AM J GASTROENTEROL, V115, P350, DOI 10.14309/ajg.0000000000000539; Ding Pei, 2016, CLIN TRIAL ELECTROAC; Drossman DA, 2016, GASTROENTEROLOGY, V150, P1262, DOI 10.1053/j.gastro.2016.02.032; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; Du Ruo., 2016, MODERN J INTEGRATED, V25, P1375; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Foster JA, 2013, TRENDS NEUROSCI, V36, P305, DOI 10.1016/j.tins.2013.01.005; Gong Yi, 2019, Zhen Ci Yan Jiu, V44, P693, DOI 10.13702/j.1000-0607.180909; Huang F, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.649103; Jiayao Yang., 2011, CHIN J GASTROENTEROL, V20, P268; Krishna Vybhava, 2019, Journal of Basic and Clinical Physiology and Pharmacology, V30, P20180089, DOI 10.1515/jbcpp-2018-0089; Li Hao, 2011, CLIN OBSERVATION EFF; Li Jing., 2017, CLIN EFFICACY EVALUA; Li MX, 2019, COMPLEMENT THER MED, V43, P247, DOI 10.1016/j.ctim.2019.02.013; Lian Songyong., 2016, J GUANGZHOU U TRADIT, V33, P650; Mak ADP, 2019, J GASTROEN HEPATOL, V34, P1736, DOI 10.1111/jgh.14667; Man Tian, 2014, THESIS HUAZHONG U SC; Meng GJ, 2019, J ACUPUNCT TUINA SCI, V17, P422, DOI 10.1007/s11726-019-1138-3; min Yang., 2020, HUBEI J TRADITIONAL, P51; Nie Jingtao., 2017, MODERN J INTEGRATED, V26, P192; Peng Suifeng., 2013, CHINESE J INTEGRATED, V21, P426; Rucker G, 2021, RES SYNTH METHODS, V12, P13, DOI 10.1002/jrsm.1410; Schunemann HJ, 2019, COCHRANE HDB SYSTEMA, P375, DOI DOI 10.1002/9781119536604.CH14; Schwarzer G, meta: General Package for Meta-Analysis, P2021; Shen Xuli., 2018, CLIN EFFECT OBSERVAT; Smith CA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009514.pub2; Sperber AD, 2021, GASTROENTEROLOGY, V160, P99, DOI 10.1053/j.gastro.2020.04.014; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Sun Hui, 2021, Zhen Ci Yan Jiu, V46, P592, DOI 10.13702/j.1000-0607.200647; Talley NJ, 2015, GASTROENTEROLOGY, V149, P340, DOI 10.1053/j.gastro.2015.04.020; Wang Liu-Jing, 2020, Zhongguo Zhen Jiu, V40, P526, DOI 10.13703/j.0255-2930.20191121-0002; Wang XY, 2021, J GASTROEN HEPATOL, V36, P3015, DOI 10.1111/jgh.15645; Wang XM, 2012, WORLD J GASTROENTERO, V18, P6819, DOI 10.3748/wjg.v18.i46.6819; Wei DN, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/9730176; Wu Qiong., 2013, SHANXI J TRADITIONAL, V29, P29, DOI [10.3969/j.issn.1000-7156.2013.03.019, DOI 10.3969/J.ISSN.1000-7156.2013.03.019]; Xie C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127815; Xiong Fan., 2014, RES INTEGRATED TRADI, V6, P126; Yuan Xingxing., 2015, J CLIN ACUPUNCTURE M, V31, P52; Zheng Huabin, 2014, MULTICENTER CLIN RAN; Zhong, 2018, J HUNAN U CHIN MED, V38, P435; Zhong F., 2013, MULTICENTER CLIN RAN; Zhong Feng., 2018, J ANHUI U CHINESE ME, V37, P68	47	2	2	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0263166	10.1371/journal.pone.0263166	http://dx.doi.org/10.1371/journal.pone.0263166			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085351	gold, Green Published			2023-01-03	WOS:000779379600122
J	Abdu-Aguye, SN; Labaran, KS; Danjuma, NM; Mohammed, S				Abdu-Aguye, Samirah N.; Labaran, Kamilu S.; Danjuma, Nuhu M.; Mohammed, Shafiu			An exploratory study of outpatient medication knowledge and satisfaction with medication counselling at selected hospital pharmacies in Northwestern Nigeria	PLOS ONE			English	Article							PATIENT SATISFACTION; COMMUNITY PHARMACIES; HEALTH LITERACY; EXIT-KNOWLEDGE; ADHERENCE; SERVICES; MEDICINES; ETHIOPIA; LEVEL; CARE	BackgroundMedication counselling is an important activity that improves patient therapeutic outcomes. After this activity has been carried out, patients should be satisfied with counselling, and possess adequate knowledge about their medications. ObjectivesTo describe outpatient/caregiver medication knowledge and satisfaction with medication counselling at the main outpatient pharmacies of eight public secondary and tertiary hospitals located in two states in Northwestern Nigeria. MethodsExit interviews were conducted from December 2019 to March 2020 with randomly sampled patients/caregivers who had just been dispensed one or more prescription medications from the main pharmacies of the hospitals. The questionnaire used contained 31 questions in three sections. The first section collected demographic information. The second section assessed respondents' experiences and overall satisfaction with the counselling they had received. The last section evaluated respondents' knowledge of one randomly selected prescription medication that had been dispensed to them. Data collected were coded and analyzed to generate descriptive statistics. To explore associations between respondent characteristics and overall satisfaction, non-parametric tests were used, and statistical significance set at pResultsA total of 684 patients/caregivers were interviewed. Majority of respondents agreed that the time spent (97.1%) and quantity of information (99.1%) provided during counselling was adequate. However, over 60% of them also agreed that dispensers did not assess their understanding of information provided or invite them to ask questions. Despite this, their average overall satisfaction with counselling on a 10-point scale was 8.6 +/- 1.6. Over 90% of them also correctly identified the routes and frequency of administration of the prescribed medication selected for the knowledge assessment. Although, more than 60% of respondents did not know the duration of therapy or names of these medications. ConclusionRespondents' satisfaction with medication counselling was fairly high even though they did not seem to know much about their medication.	[Abdu-Aguye, Samirah N.; Labaran, Kamilu S.; Mohammed, Shafiu] Ahmadu Bello Univ Zaria, Dept Clin Pharm & Pharm Practice, Zaria, Kaduna State, Nigeria; [Danjuma, Nuhu M.] Ahmadu Bello Univ Zaria, Dept Pharmacol & Therapeut, Zaria, Kaduna State, Nigeria; [Mohammed, Shafiu] Ahmadu Bello Univ Zaria, Hlth Syst & Policy Res Unit, Zaria, Kaduna State, Nigeria	Ahmadu Bello University; Ahmadu Bello University; Ahmadu Bello University	Abdu-Aguye, SN (corresponding author), Ahmadu Bello Univ Zaria, Dept Clin Pharm & Pharm Practice, Zaria, Kaduna State, Nigeria.	sn.abduaguye@gmail.com	Mohammed, Shafiu/P-2016-2014; Abdu-Aguye, Samirah/R-5815-2019; Abdu-Aguye, Samirah/HIA-0420-2022	Mohammed, Shafiu/0000-0001-5715-966X; Abdu-Aguye, Samirah/0000-0001-7534-632X; Abdu-Aguye, Samirah/0000-0001-7534-632X				Adeloye D, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0205-4; Adeola AM., 2020, NIGERIAN J PHARM, V54, P22; Afolabi M. O., 2003, Tropical Journal of Pharmaceutical Research, V2, P207; Ali S, 2019, ETHIOP J HEALTH SCI, V29, P727, DOI 10.4314/ejhs.v29i6.9; Alkatheri AM, 2013, ANN THORAC MED, V8, P105, DOI 10.4103/1817-1737.109823; Almanasreh E, 2019, RES SOC ADMIN PHARM, V15, P214, DOI 10.1016/j.sapharm.2018.03.066; AlShayban DM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00138; Amponsah Alexandria O, 2015, Malar Res Treat, V2015, P452539, DOI 10.1155/2015/452539; Aregbeshola BS, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00048; Aziz MM, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122914; Babelghaith SD, 2019, SAUDI J ANAESTH, V13, P106, DOI 10.4103/sja.SJA_557_18; Munoz EB, 2015, ATEN PRIM, V47, P228, DOI 10.1016/j.aprim.2014.04.014; Burge S, 2005, FAM MED, V37, P712; Collins S, 2014, PHARMACY, V2, P114, DOI 10.3390/pharmacy2010114; Gariani A., 2009, Eastern Mediterranean Health Journal, V15, P934; Gu HY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005738; Hirko N, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00254; Hirko N, 2017, PATIENT PREFER ADHER, V11, P205, DOI 10.2147/PPA.S128658; Horvat N, 2010, EVAL HEALTH PROF, V33, P197, DOI 10.1177/0163278710361924; Hussain S, 2013, EUR J HOSP PHARM-S P, V20, P241, DOI 10.1136/ejhpharm-2012-000263; Khudair IF, 2013, INT J HEALTH CARE Q, V26, P398, DOI 10.1108/IJHCQA-03-2011-0025; Koce F, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4046-9; Kooy MJ, 2015, PATIENT EDUC COUNS, V98, P797, DOI 10.1016/j.pec.2015.02.020; Leguelinel-Blache G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001805; Marks JR, 2010, PATIENT EDUC COUNS, V78, P372, DOI 10.1016/j.pec.2009.06.017; Martinez-Lopez-de-Castro N, 2018, EUR J HOSP PHARM, V25, P183, DOI 10.1136/ejhpharm-2016-001192; Masino C, 2014, TELEMED E-HEALTH, V20, P1150, DOI 10.1089/tmj.2013.0350; Mekonnen GB, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4392058; Naqvi AA, 2019, J PHARM HEALTH SERV, V10, P243, DOI 10.1111/jphs.12294; Ni Dhubhlaing C, 2017, SCHIZOPHR RES TREAT, V2017, DOI 10.1155/2017/6120970; Nigussie S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01132; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Okuyan B, 2013, PHARMACOEPIDEM DR S, V22, P209, DOI 10.1002/pds.3275; Ramia E, 2017, INT J CLIN PHARM-NET, V39, P1084, DOI 10.1007/s11096-017-0517-4; Romero-Sanchez J, 2016, J EVAL CLIN PRACT, V22, P808, DOI 10.1111/jep.12547; Rubio JS., 2015, 101 N SA DE COLET, V20, P219, DOI [10.1590/1413-81232014201.20952013, DOI 10.1590/1413-81232014201.20952013]; Salama AA, 2017, MENOUFIA MED J, V30, P63, DOI [DOI 10.4103/1110-2098.211476, 10.4103/1110-2098.211476]; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Semegn S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224400; Surur AS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0900-6; World Health Organization, ANAT THER CHEM CLASS; Yusuf H., 2019, NIG J PHARM RES, V15, P143, DOI [10.4314/njpr.v15i2.2, DOI 10.4314/NJPR.V15I2.2]; Zhao SJ, 2015, ACTA CARDIOL, V70, P197, DOI 10.1080/AC.70.2.3073511	43	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266723	10.1371/journal.pone.0266723	http://dx.doi.org/10.1371/journal.pone.0266723			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0X7AZ	35395046	Green Published, gold			2023-01-03	WOS:000789855700027
J	Appiah, F				Appiah, Francis			Individual and community-level factors associated with early initiation of antenatal care: Multilevel modelling of 2018 Cameroon Demographic and Health Survey	PLOS ONE			English	Article							DEVELOPING-COUNTRIES; SERVICES; DETERMINANTS	BackgroundEarly initiation of antenatal care (ANC) provided by skilled personnel is essential as it enables pregnant women to receive comprehensive reproductive health services. Early ANC utilisation could prevent complications related to pregnancy and improve maternal and neonatal health outcomes. Regardless of this, only forty-one in every hundred women in Cameroon seek early ANC services. Studies on the uptake of antenatal care in Cameroon have not focused on individual and community-level factors that influence early initiation of ANC. This study aimed at investigating the association between individual and community-level factors and early ANC uptake in Cameroon. MethodsThis study was a cross-sectional survey design. Data was extracted from the women's file of the 2018 Cameroon Demographic and Health Survey (CDHS). A sample of 4,183 women aged 15-49 who had complete information on variables of interest to the study was used. The outcome variable was early ANC (i.e. women whose first ANC occurred between 0-3 months of pregnancy). Eighteen explanatory variables consisting of fifteen individual-level variables and three community-level variables were selected for the study. At 95% confidence interval (95% CI), two-level multilevel models were built. The results for the fixed effects were presented in adjusted odds ratio (aOR) and the random effects were expressed in terms of Intra-Class Correlation (ICC) and Primary Sampling Units (PSUs) variance. ResultsDescriptively, 46% [CI = 45.0-48.0] of the women aged 15-49 attended ANC earlier. The median age at which women started utilising early ANC was 28 (15 to 48) years. For the fixed effects results, it was found that the odds of seeking early ANC increased among those aged 35-39 [aOR = 1.78, CI = 1.24-2.57], the richest [aOR = 2.43, CI = 1.63-3.64] and those with secondary/higher education [aOR = 1.38, CI = 1.05-1.82]. Muslims [aOR = 0.73, CI = 0.60-0.88] and women at parity four or more had lesser odds to seek early ANC [aOR = 0.63, CI = 0.49-0.82]. The study found that primary sampling unit (community/cluster) [sigma(2) = 0.53, CI = 0.40-0.72] and individual [sigma(2) = 0.16, CI = 0.09-0.29] level variations exist in early initiation of ANC. About 14% (intra-class correlation (ICC) = 0.14) and 5% (ICC = 0.05) variability in early initiation of ANC were attributable to variations in the primary sampling unit (community/cluster) and individual-level factors, respectively. ConclusionIndividual-level factors (maternal age, wealth status, educational attainment and religious affiliation) were associated with early initiation of ANC whereas variations in cluster/community characteristics contributed to the variations in early initiation of ANC seeking. The Departments of Health Promotion, Health Information Center and eHealth under the Ministry of Public Health, Cameroon, have to strengthen mass sensitisation programs on early ANC uptake and such programs should consider individual differences such as age, wealth status, education, and religious affiliation in its program design.	[Appiah, Francis] Berekum Coll Educ, Berekum, Ghana; [Appiah, Francis] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana; [Appiah, Francis] Univ Cape Coast, Dept Populat & Hlth, Cape Coast, Ghana	Kwame Nkrumah University Science & Technology; University of Cape Coast	Appiah, F (corresponding author), Berekum Coll Educ, Berekum, Ghana.; Appiah, F (corresponding author), Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana.; Appiah, F (corresponding author), Univ Cape Coast, Dept Populat & Hlth, Cape Coast, Ghana.	Engman477@yahoo.com						Abor PA, 2011, INT J SOC ECON, V38, P628, DOI 10.1108/03068291111139258; Acharya Dilaram, 2015, BMC Res Notes, V8, P345, DOI 10.1186/s13104-015-1312-8; Adewuyi EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197324; Ahinkorah BO, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241050; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Andersen RM, 2008, MED CARE, V46, P647, DOI 10.1097/MLR.0b013e31817f4d48; Andrew EVW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093025; Azfredrick EC, 2016, INT J ADOLESC YOUTH, V21, P523, DOI 10.1080/02673843.2015.1124790; Babitsch Birgit, 2012, Psychosoc Med, V9, pDoc11, DOI 10.3205/psm000089; Banke-Thomas A, 2017, SEX REPROD HEALTHC, V12, P37, DOI 10.1016/j.srhc.2017.02.004; Bbaale E, 2011, AUSTRALAS MED J, V4, P516, DOI 10.4066/AMJ.2011.849; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Gebresilassie B, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2490-5; Geta M. B., 2017, Advances in Public Health, V2017, P1624245, DOI 10.1155/2017/1624245; Graham W, 2016, LANCET, V388, P2164, DOI 10.1016/S0140-6736(16)31533-1; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Grown C, 2005, LANCET, V365, P541, DOI 10.1016/S0140-6736(05)70278-6; Halle-Ekane GE, 2014, OPEN J OBSTET GYNECO, V4, P846, DOI DOI 10.4236/OJOG.2014.414119; Halle-Ekane GE., 2015, WOMEN HLTH OPEN J, V1, P31, DOI [10.17140/WHOJ-1-105, DOI 10.17140/WHOJ-1-105]; Janevic T, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-69; Kuuire VZ, 2017, GLOB PUBLIC HEALTH, V12, P711, DOI 10.1080/17441692.2017.1316413; Lindelow M, 2005, J AFR ECON, V14, P435, DOI 10.1093/jae/eji015; Makate M, 2017, J EPIDEMIOL GLOB HEA, V7, P255, DOI 10.1016/j.jegh.2017.08.005; Manyeh AK, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-2738-0; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; National Institute of Statistics and Informatics, 2000, DEM FAM HLTH SURV EN; Ochako R, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-1; Oladokun A, 2010, ANN AFR MED, V9, P222, DOI 10.4103/1596-3519.70959; Ononokpono DN., 2015, AFRICAN POPULATION S, V29, P1554; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Say L, 2007, B WORLD HEALTH ORGAN, V85, P812, DOI 10.2471/BLT.06.035659; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Solanke BL, 2019, CONTRACEP REPROD MED, V4, DOI 10.1186/s40834-019-0093-1; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Teshale AB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235538; Tolefac Paul Nkemtendong, 2017, Matern Health Neonatol Perinatol, V3, P29, DOI 10.1186/s40748-017-0067-8; United Nations, 2015, UN; Venyuy MA, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.2020.35.112.18712; Verney A, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12565; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; WHO, 2016, WHO TECH REP SER, V997, P1; World Health Organization, 2002, WHO ANT CAR RAND TRI, DOI DOI 10.3109/09638288.2013.777803; World Health Organization, 2015, STRATEGIES ENDING PR; Yaya S, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1846-6; Zegeye Amtatachew M, 2013, Afr J Reprod Health, V17, P130; Zegeye B, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5529375; Zolotor AL, 2014, AM FAM PHYSICIAN, V89, P199	49	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266594	10.1371/journal.pone.0266594	http://dx.doi.org/10.1371/journal.pone.0266594			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6KL	35385559	gold, Green Published			2023-01-03	WOS:000804836900069
J	Baru, A; Sultan, M; Beza, L				Baru, Ararso; Sultan, Menbeu; Beza, Lemlem			The status of prehospital care delivery for COVID-19 patients in Addis Ababa, Ethiopia: The study emphasizing adverse events occurring in prehospital transport and associated factors	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; INTRAHOSPITAL TRANSPORT; GROUND TRANSPORT; SCIENCE; HEALTH	BackgroundCOVID-19 patients may require emergency medical services for emergent treatment and/or transport to a hospital for further treatment. However, it is common for the patients to experience adverse events during transport, even the shortest transport may cause life-threatening conditions. Most of the studies that have been done on prehospital care of COVID-19 patients were conducted in developed countries. Differences in population demographics and economy may limit the generalizability of available studies. So, this study was aimed at investigating the status of prehospital care delivery for COVID-19 patients in Addis Ababa focusing on adverse events that occurred during transport and associated factors. MethodsA total of 233 patients consecutively transported to Saint Paul's Hospital Millennium Medical College from November 6 to December 31, 2020, were included in the study. A team of physicians and nurses collected the data using a structured questionnaire. Descriptive statistics were used to summarize data, and ordinal logistic regression was carried out to assess the association between explanatory variables and the outcome variable. Results are presented using frequency, percentage, chi-square, crude and adjusted odds ratios (OR) with 95% confidence intervals. ResultsThe overall level of adverse events in prehospital setting was 44.2%. Having history of at least one chronic medical illness, [AOR3.2 (95%; CI; 1.11-9.53)]; distance traveled to reach destination facility, [AOR 0.11(95%; CI; 0.02-0.54)]; failure to recognize and administer oxygen to the patient in need of oxygen, [AOR 15.0(95%; CI; 4.0-55.7)]; absent or malfunctioned suctioning device, [AOR 4.0(95%; CI; 1.2-13.0)]; patients handling mishaps, [AOR 12.7(95%; CI; 2.9-56.8)] were the factors associated with adverse events in prehospital transport of COVID-19 patients. ConclusionsThere were a significant proportion of adverse events in prehospital care among COVID-19 patients. Most of the adverse events were preventable. There is an urgent need to strengthen prehospital emergency care in Ethiopia by equipping the ambulances with essential and properly functioning equipment and trained manpower. Awareness creation and training of transport staff in identifying potential hazards, at-risk patients, adequate documentation, and patient handling during transport could help to prevent or minimize adverse events in prehospital care.	[Baru, Ararso] Arbaminch Univ, Coll Med & Hlth Sci, Arbaminch, Ethiopia; [Baru, Ararso] Slum & Rural Hlth Initiat Ethiopia, Addis Ababa, Ethiopia; [Sultan, Menbeu] St Pauls Hosp, Millennium Med Coll, Dept Emergency Med & Crit Care, Addis Ababa, Ethiopia; [Beza, Lemlem] Addis Ababa Univ, Dept Emergency Med & Crit Care, Addis Ababa, Ethiopia	Arba Minch University; Addis Ababa University	Baru, A (corresponding author), Arbaminch Univ, Coll Med & Hlth Sci, Arbaminch, Ethiopia.; Baru, A (corresponding author), Slum & Rural Hlth Initiat Ethiopia, Addis Ababa, Ethiopia.	ararsob@gmail.com		Baru, Ararso/0000-0003-1646-3571				Allen Rebecca, 2020, Air Med J, V39, P498, DOI 10.1016/j.amj.2020.07.007; Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; Beckmann U, 2004, INTENS CARE MED, V30, P1579, DOI 10.1007/s00134-004-2177-9; Bergman LM, 2017, CRIT CARE MED, V45, pE1043, DOI 10.1097/CCM.0000000000002653; Bitely C, 2019, CURR EMERG HOSP ME R, V7, P135, DOI 10.1007/s40138-019-00200-6; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; Brown Abigail S, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc045; de Vries J, 2020, SAMJ S AFR MED J, V110, P635, DOI 10.7196/SAMJ.2020.v110i7.14863; Edelson DP, 2020, CIRCULATION, V141, pE933, DOI 10.1161/CIRCULATIONAHA.120.047463; EPHI, 2020, PUBL HLTH EMERG OPER; European Commission  European Medicines Agency  National Head of Medicines Agencies, 2020, COM EUR, V19, P1; Fernandez AR, 2020, PREHOSP EMERG CARE, V25, P16, DOI 10.1080/10903127.2020.1792016; Hagiwara MA, 2019, BMC EMERG MED, V19, DOI 10.1186/s12873-019-0228-3; Hayward RA, 2005, J GEN INTERN MED, V20, P686, DOI 10.1111/j.1525-1497.2005.0152.x; Jia L, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1183-y; Kang J, 2018, AM J INFECT CONTROL, V46, P235, DOI 10.1016/j.ajic.2017.08.041; Laeke T, 2019, WORLD NEUROSURG, V127, pE186, DOI 10.1016/j.wneu.2019.03.044; Lancet EA, 2021, JACEP OPEN, V2, DOI 10.1002/emp2.12407; Laudermilch DJ, 2010, J AM COLL SURGEONS, V210, P220, DOI 10.1016/j.jamcollsurg.2009.10.008; Liew MF, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2828-4; Ligtenberg JJM, 2005, CRIT CARE, V9, pR446, DOI 10.1186/cc3749; Mazzoli C. A., 2020, AIR MED J, V39, P423; McPherson ML, 2021, PEDIATR EMERG CARE, V37, P175, DOI 10.1097/PEC.0000000000002330; Meisel ZF, 2008, PREHOSP EMERG CARE, V12, P411, DOI 10.1080/10903120802290851; Mosadeghrad Ali Mohammad, 2019, Human Antibodies, V27, pS33, DOI 10.3233/HAB-190368; Nogueira LC, 2016, HEALTH CARE MANAG SC, V19, P31, DOI 10.1007/s10729-014-9280-4; Papson JPN, 2007, ACAD EMERG MED, V14, P574, DOI 10.1197/j.aem.2007.02.034; Patterson PD, 2014, PREHOSP EMERG CARE, V18, P35, DOI 10.3109/10903127.2013.818179; Patterson PD, 2012, AM J MED QUAL, V27, P139, DOI 10.1177/1062860611415515; Price R, 2013, EMERG MED J, V30, P583, DOI 10.1136/emermed-2011-200971; Qureshi K, 2005, J URBAN HEALTH, V82, P378, DOI 10.1093/jurban/jti086; Shigute Z, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010369; Siman-Tov M, 2021, AM J EMERG MED, V44, P45, DOI 10.1016/j.ajem.2021.01.051; Sultan M, 2018, ETHIOPIAN MED J, V56, P119; Sultan M, 2019, BMC EMERG MED, V19, DOI 10.1186/s12873-019-0242-5; Sultan M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3820-4; Wang HE, 2009, QUAL SAF HEALTH CARE, V18, P213, DOI 10.1136/qshc.2007.024562; Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x; Yirga AA, 2019, AFR HEALTH SCI, V19, P1897, DOI 10.4314/ahs.v19i2.13; Yousuf B, 2020, INTENS CARE MED, V46, P1663, DOI 10.1007/s00134-020-06115-1; Zikargae MH, 2020, RISK MANAG HEALTHC P, V13, P2803, DOI 10.2147/RMHP.S278234	41	0	0	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	2							e0263278	10.1371/journal.pone.0263278	http://dx.doi.org/10.1371/journal.pone.0263278			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR1WR	35104287	Green Published, gold			2023-01-03	WOS:000749789300011
J	Munir, M; Sadia, S; Khan, A; Rahim, BZ; Nayyar, BG; Ahmad, KS; Khan, AM; Fatima, I; Qureshi, R				Munir, Mubashrah; Sadia, Sehrish; Khan, Adnan; Rahim, Bakht Zareen; Nayyar, Brian Gagosh; Ahmad, Khawaja Shafique; Khan, Arshad Mahmood; Fatima, Ishrat; Qureshi, Rahmatullah			Ethnobotanical study of Mandi Ahmad Abad, District Okara, Pakistan	PLOS ONE			English	Article							MEDICINAL-PLANTS; INDIGENOUS KNOWLEDGE; KOTLI	This study hypothesized that native people have unique traditional knowledge of plant resources in the rural areas and basic objective was the documentation of this valuable inheritance. Ethnobotanical data was collected from a remote rural area of Mandi Ahmad Abad, Union council number NA-144 Tehsil Depalpur District Okara, Pakistan. A total of 94 informants were randomly interviewed to collect data about local names of plant species, mode of administration, recipes and ailments, and ethnobotanical uses through semi-structured questionnaire, interviews and group discussion methods. The collected data was statistically analyzed by calculating use value (UV), frequency of citation (FC), relative frequency of citation (RFC), factor of informant consensus (FIC), family importance value, and relative importance (RI). This study is also compared with ethnobotanical literature by using Jaccard's index (JI) for similarity analysis. A total of 126 species belonging to 52 families were documented. The Poaceae (13spp.), Leguminosae (12spp.), Solanaceae (10spp.) and Cucurbitaceae (10spp.) were dominant families. Highest used value (UV = 0.22) was obtained for Azadirachta indica. The minimum used value (UV) was showed by Alhagi maurorum, Eclipta prostrata, Hibiscus rosa-sinensis, Solanum virginianum and Trianthema potulacastrum (UV = 0.01). Hepatitis, stomach ulcer, bowel disorders, urinary problems, psoriasis, cancer, and leucoderma were the most treated ailments with ICF value of 1, followed by leucorrhea (ICF: 0.89), and vomiting (ICF: 0.86). The highest Jaccard's similarity index value (JI = 0.329) showed that plant species reported in our study was more similar with Arid regions of Northern Punjab, Pakistan. This novel ethnobotanical report concluded that traditional knowledge about use of medicinal plants is decreasing due to allopathic medicines. Immediate steps should be taken for conservation and documentation of traditional knowledge of plants especially those having medicinal properties.	[Munir, Mubashrah; Sadia, Sehrish; Khan, Adnan; Fatima, Ishrat] Univ Vet & Anim Sci, Dept Biol Sci, Lahore, Pakistan; [Rahim, Bakht Zareen] Univ Balochistan, Dept Bot, Quetta, Pakistan; [Nayyar, Brian Gagosh] Univ Sialkot, Dept Bot, Sialkot, Pakistan; [Ahmad, Khawaja Shafique] Univ Poonch, Dept Bot, Rawalakot, Azad Jammu & Ka, Pakistan; [Khan, Arshad Mahmood] Govt Hashmat Ali Islamia Associate Coll Rawalpind, Punjab, Pakistan; [Qureshi, Rahmatullah] Pir Mehr Ali Shah Arid Agr Univ Rawalpindi, Dept Bot, Punjab, Pakistan	University of Veterinary & Animal Science - Pakistan; University of Balochistan	Sadia, S; Ahmad, KS (corresponding author), Univ Vet & Anim Sci, Dept Biol Sci, Lahore, Pakistan.; Ahmad, KS (corresponding author), Univ Poonch, Dept Bot, Rawalakot, Azad Jammu & Ka, Pakistan.	sehrish.sadia@uvas.edu.pk; shafiquebot@gmail.com	Khan, Arshad Mahmood/V-7426-2019	Khan, Arshad Mahmood/0000-0003-0683-1553; sadia, sehrish/0000-0002-7805-8611				Abbas Z, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0114-y; Agrawal T., 2017, BR J RES, V4, P18; Ahmad M, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-36; Ali S., 2018, PAKISTAN J WEED SCI, V24; Altaf R., 2019, Pakistan Journal of Science, V71, P260; Arshad F., 2020, ETHNOBOT RES APPLI, V20, P1, DOI DOI 10.32859/ERA.20.33.1-13; Ashfaq S., 2019, MED PLANT BIODIVERSI; Aziz MA, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0212-0; Dapar MLG, 2020, J ETHNOBIOL ETHNOMED, V16, DOI 10.1186/s13002-020-00363-7; Dapar Mlg., 2020, BIODIVERSITAS J BIOL, V21; Din BU., 2020, ACAD J PLANT SCI, V13, P15; Eddouks M, 2017, J ETHNOPHARMACOL, V198, P516, DOI 10.1016/j.jep.2016.12.017; Farooq A, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0323-2; Irfan M, 2018, SPECIAL J BIOL SCI, V4, P7; Ishtiaq M, 2015, J ETHNOPHARMACOL, V168, P201, DOI 10.1016/j.jep.2015.01.054; Kuete V, 2017, MEDICINAL SPICES AND VEGETABLES FROM AFRICA: THERAPEUTIC POTENTIAL AGAINST METABOLIC, INFLAMMATORY, INFECTIOUS AND SYSTEMIC DISEASES, P363, DOI 10.1016/B978-0-12-809286-6.00015-7; Malik S, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0018-2; Murad H., 2020, EUR J BIOL, V5, P41, DOI 10.47672/ejb.564; Murad W, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-77; Qaseem MF, 2019, APPL ECOL ENV RES, V17, P2799, DOI 10.15666/aeer/1702_27992829; Rakib-Uz-Zaman SM, 2020, J GENET ENG BIOTECHN, V18, DOI 10.1186/s43141-020-00030-0; Rana D, 2021, ENVIRON DEV SUSTAIN, V23, P1162, DOI 10.1007/s10668-020-00617-0; Ranjbar Mohammadmehdi, 2013, Pak J Biol Sci, V16, P2066, DOI 10.3923/pjbs.2013.2066.2069; Roozbeh Nasibeh, 2016, J Menopausal Med, V22, P129, DOI 10.6118/jmm.2016.22.3.129; Sabeen M, 2009, ETHNOBOT LEAFLETS, V13, P810; Safeera Sajid, 2017, Journal of Coastal Life Medicine, V5, P109, DOI 10.12980/jclm.5.2017J6-246; Saqib Z, 2014, J ETHNOPHARMACOL, V151, P820, DOI 10.1016/j.jep.2013.11.034; Shinwari S, 2011, PAK J BOT, V43, P135; Suwardi A.B., 2020, BIODIVERS J BIOL DIV, V21, P1850, DOI [10.13057/biodiv/d210511, DOI 10.13057/BIODIV/D210511]; Tufail M., 2020, ETHNOBOT RES APPL, V20, P1, DOI [10.32859/era.20.23.1-14, DOI 10.32859/ERA.20.23.1-14]; Tugume P, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-015-0077-4; Ulian T, 2020, PLANTS PEOPLE PLANET, V2, P421, DOI 10.1002/ppp3.10145; Ullah S, 2020, PLANT SCI TODAY, V7, P17, DOI 10.14719/pst.2020.7.1.625; Umair M, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0285-4; Zare H., 2010, BIOMED PHARMACOL J, V3; Zeb A., 2020, ASIAN PLANT RES J, P34; Zereen A, 2013, BANGL J PLANT TAXON, V20, P67, DOI 10.3329/bjpt.v20i1.15466; Zubair M., 2019, INT J MULTIDISCIPLIN, V2, P40	38	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0265125	10.1371/journal.pone.0265125	http://dx.doi.org/10.1371/journal.pone.0265125			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35389994	gold, Green Published			2023-01-03	WOS:000795077200016
J	Salas-Gama, K; Onakpoya, IJ; Daza, JC; Perera, R; Heneghan, CJ				Salas-Gama, Karla; Onakpoya, Igho J.; Coronado Daza, Jorge; Perera, Rafael; Heneghan, Carl J.			Recommendations of high-quality clinical practice guidelines related to the process of starting dialysis: A systematic review	PLOS ONE			English	Review							CHRONIC KIDNEY-DISEASE; PERITONEAL-DIALYSIS; DECISION-MAKING; PREVENTION; MANAGEMENT; APPRAISAL; SOCIETY	Background The optimal time for initiation of dialysis and which modality to choose as the starting therapy is currently unclear. This systematic review aimed to assess the recommendations across high-quality clinical practice guidelines (CPGs) related to the start of dialysis. Methods We systematically searched MEDLINE, EMBASE, Web of Science, LILACS, and databases of organisations that develop CPGs between September 2008 to August 2021 for CPGs that addressed recommendations on the timing of initiation of dialysis, selection of dialysis modality, and interventions to support the decision-making process to select a dialysis modality. We used the Appraisal of Guidelines for Research and Evaluation instrument to assess the methodological quality of the CPGs and included only high-quality CPGs. This study is registered in PROSPERO, number CRD42018110325. Results We included 12 high-quality CPGs. Six CPGs addressed recommendations related to the timing of initiating dialysis, and all agreed on starting dialysis in the presence of symptoms or signs. Six CPGs addressed recommendations related to the selection of modality but varied greatly in their content. Nine CPGs addressed recommendations related to interventions to support the decision-making process. Eight CPGs agreed on recommended educational programs that include information about dialysis options. One CPG considered using patient decision aids a strong recommendation. Limitations We could have missed potentially relevant guidelines since we limited our search to CPGs published from 2008, and we set up a cut-off point of 60% in domains of the rigour of development and editorial independence. Conclusion High-quality CPGs related to the process of starting dialysis were consistent in initiating dialysis in the presence of symptoms or signs and offering patients education at the point of decision-making. There was variability in how CPGs addressed the issue of dialysis modality selection. CPGs should improve strategies on putting recommendations into practice and the quality of evidence to aid decision-making for patients.	[Salas-Gama, Karla] Hosp Univ Vall dHebron, Qual Proc & Innovat Direct, Barcelona, Spain; [Salas-Gama, Karla] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Hlth Serv Res Grp, Barcelona, Spain; [Salas-Gama, Karla] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Barcelona, Spain; [Onakpoya, Igho J.; Perera, Rafael; Heneghan, Carl J.] Univ Oxford, Ctr Evidence Based Med, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Coronado Daza, Jorge] Univ Cartagena, Med Dept, Cartagena, Bolivar, Colombia	Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Oxford; Universidad de Cartagena	Salas-Gama, K (corresponding author), Hosp Univ Vall dHebron, Qual Proc & Innovat Direct, Barcelona, Spain.; Salas-Gama, K (corresponding author), Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Hlth Serv Res Grp, Barcelona, Spain.; Salas-Gama, K (corresponding author), Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Barcelona, Spain.	ksalas@vhebron.net	Salas-Gama, Karla/AAN-2667-2021; Salas, Karla/GSN-7005-2022; Salas, Karla/GRX-5251-2022	Salas, Karla/0000-0003-4845-4899; Coronado Daza, Jorge Antonio/0000-0002-0531-870X; Onakpoya, Igho/0000-0002-2420-0811				Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2089; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Arevalo-Rodriguez I, 2013, AM J ALZHEIMERS DIS, V28, P111, DOI 10.1177/1533317512470209; Bilo H, 2015, NEPHROL DIAL TRANSPL, V30, P1, DOI 10.1093/ndt/gfv100; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Brown EA, 2020, PERITON DIALYSIS INT, V40, P244, DOI 10.1177/0896860819895364; Chan CT, 2019, KIDNEY INT, V96, P37, DOI 10.1016/j.kint.2019.01.017; Choosing Wisely [Internet, 2012, AM SOC NEPHR 5 THING; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Daza JC, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1387-x; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; Engels N, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034142; Farrington K, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfw356; Farrington K, 2011, NEPHRON CLIN PRACT, V118, pC189, DOI 10.1159/000328069; Fresenius Medical Care, 2018, FRES MED CAR 2018 AN, P2; Grupo de trabajo de la Guia de Practica Clinica sobre la Deteccion y el Manejo de la Enfermedad Renal Cronica, 2016, GUIAS PRACTICA CLINI; Harwood L, 2013, INT J NURS STUD, V50, P109, DOI 10.1016/j.ijnurstu.2012.04.003; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Hoffmann-Esser W, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2954-8; Hoffmann-Esser W, 2018, J CLIN EPIDEMIOL, V95, P120, DOI [10.1016/j.jclinepi.2017.12.009, 10.1016/j.clinepi.2017.12.009]; Incze M, 2019, JAMA INTERN MED, V179, P561, DOI 10.1001/jamainternmed.2018.7471; Institute of Medicine, 2011, CLIN PRACTICE GUIDEL; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT SUPPL, V3, P1, DOI [DOI 10.1038/KISUP.2012.73, 10.1038/kisup.2012.73]; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Koo TK., 2010, MINISTERIO SALUD GUI; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Lee VW, 2015, SEMIN NEPHROL, V35, P595, DOI 10.1016/j.semnephrol.2015.10.011; Legare F, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006732.pub4; Lopez-Vargas PA, 2013, NEPHROLOGY, V18, P592, DOI 10.1111/nep.12119; Mustafa RA, 2017, J CLIN EPIDEMIOL, V92, P38, DOI 10.1016/j.jclinepi.2017.09.004; National Institute for Health and Care Excellence, 2018, REN REPL THER CONS M; Nesrallah GE, 2014, CAN MED ASSOC J, V186, P112, DOI 10.1503/cmaj.130363; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n160; Pandian Z, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003357.pub2; Molino CDRC, 2019, JAMA INTERN MED, V179, P553, DOI 10.1001/jamainternmed.2018.7529; Salas-Gama K, 2021, JBI EVID SYNTH, V19, P3347, DOI 10.11124/JBIES-20-00437; Schunemann H, HDB GRADING QUALITY; Sekercioglu N, 2017, INT UROL NEPHROL, V49, P273, DOI 10.1007/s11255-016-1436-3; Vanommeslaeghe F, 2015, NEPHROL DIAL TRANSPL, V30, P1300, DOI 10.1093/ndt/gfv220; Woodrow G, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0687-2	40	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0266202	10.1371/journal.pone.0266202	http://dx.doi.org/10.1371/journal.pone.0266202			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35696388	Green Published, gold			2023-01-03	WOS:000843619700052
J	Nakano, Y; Watari, T; Adachi, K; Watanabe, K; Otsuki, K; Amano, Y; Takaki, Y; Onigata, K				Nakano, Yasuhisa; Watari, Takashi; Adachi, Kazuya; Watanabe, Kenji; Otsuki, Kazuya; Amano, Yu; Takaki, Yuji; Onigata, Kazumichi			Survey of potentially inappropriate prescriptions for common cold symptoms in Japan: A cross-sectional study	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTION; PATIENT-SATISFACTION; PREVENTION; COUGH; COST	Background Common cold is among the main reasons patients visit a medical facility. However, few studies have investigated whether prescriptions for common cold in Japan comply with domestic and international evidence. Objective To determine whether prescriptions for common cold complied with domestic and international evidence. Methods This cross-sectional study was conducted between October 22, 2020, and January 16, 2021. Patients with cold symptoms who visited the two dispensing pharmacies and met the eligibility criteria were interviewed. Main outcome measure The pharmacists at each store and a physician classified the patients into two groups: the potentially inappropriate prescribing group and the appropriate prescribing group. Results Of the 150 selected patients, 14 were excluded and 136 were included in the analysis. Males accounted for 44.9% of the total study population, and the median patient age was 34 years (interquartile range [IQR], 27-42). The prevalence rates of potentially inappropriate prescriptions and appropriate prescriptions were 89.0% and 11.0%, respectively and the median drug costs were 602.0 yen (IQR, 479.7-839.2) [$5.2 (IQR, 4.2-7.3)] and 406.7 yen (IQR, 194.5-537.2) [$3.5 (IQR, 1.7-4.7)], respectively. The most common potentially inappropriate prescriptions were the prescription of oral cephem antibacterial agents to patients who did not have symptoms of bacterial infections (50.4%) and beta 2 stimulants to those who did not have respiratory symptoms due to underlying disease or history (33.9%). Conclusions Approximately 90% of prescriptions for common cold symptoms in the area were potentially inappropriate. Our findings could contribute to the monitoring of the use of medicines for the treatment of common cold symptoms.	[Nakano, Yasuhisa; Otsuki, Kazuya; Amano, Yu; Onigata, Kazumichi] Shimane Univ, Fac Med, Matsue, Shimane, Japan; [Watari, Takashi] Shimane Univ, Gen Med Ctr, Matsue, Shimane, Japan; [Watari, Takashi] Univ Michigan Hlth Syst, Div Hosp Med, Ann Arbor, MI 48109 USA; [Adachi, Kazuya; Watanabe, Kenji; Takaki, Yuji] Midori Pharm Co Ltd, Matsue, Shimane, Japan; [Onigata, Kazumichi] Shimane Univ Hosp, Postgrad Clin Training Ctr, Matsue, Shimane, Japan	Shimane University; Shimane University; University of Michigan System; University of Michigan; Shimane University	Watari, T (corresponding author), Shimane Univ, Gen Med Ctr, Matsue, Shimane, Japan.; Watari, T (corresponding author), Univ Michigan Hlth Syst, Div Hosp Med, Ann Arbor, MI 48109 USA.	wataritari@gmail.com			National Academic Research Grant Funds (JSPS KAKENHI) [20H03913]	National Academic Research Grant Funds (JSPS KAKENHI)	YES T.W. is supported by grants from the National Academic Research Grant Funds (JSPS KAKENHI: 20H03913). The sponsor of the study had no role in the study design, data collection, analysis, or preparation of the manuscript.	Allan GM, 2014, CAN MED ASSOC J, V186, P190, DOI 10.1503/cmaj.121442; Arroll B, 2005, RESP MED, V99, P1477, DOI 10.1016/j.rmed.2005.09.039; Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; Becker LA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001726.pub4; Blaiss MS, 2015, CURR MED RES OPIN, V31, P1527, DOI 10.1185/03007995.2014.1002558; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Cannon Katrina T, 2006, Am J Geriatr Pharmacother, V4, P134, DOI 10.1016/j.amjopharm.2006.06.010; Cazzola M, 2020, RESP MED, V164, DOI 10.1016/j.rmed.2020.105904; Deckx L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009612.pub2; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; Douma Joeri A J, 2015, Ned Tijdschr Geneeskd, V159, pA9132; Ebihara S, 2008, RESP MED, V102, P1497, DOI 10.1016/j.rmed.2008.03.005; Fashner J, 2012, AM FAM PHYSICIAN, V86, P153; Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487; Fenton JJ, 2012, ARCH INTERN MED, V172, P405, DOI 10.1001/archinternmed.2011.1662; Fernandez-Liz E, 2008, BRIT J CLIN PHARMACO, V65, P407, DOI 10.1111/j.1365-2125.2007.03029.x; FIXEN DR, 2019, PHARM TODAY, V25, P42; Higashi T, 2009, INTERNAL MED, V48, P1369, DOI 10.2169/internalmedicine.48.1893; Horiguchi Takahiko, 2007, Allergol Int, V56, P263, DOI 10.2332/allergolint.O-06-473; Huntington Mark K, 2013, S D Med, V66, P136; Ida H, 1997, CLIN THER, V19, P215, DOI 10.1016/S0149-2918(97)80111-7; ISHIBASHI Y, 1987, J FAM PRACTICE, V25, P83; Issa I, 2014, WORLD J GASTROENTERO, V20, P17788, DOI 10.3748/wjg.v20.i47.17788; Jungersen Mikkel, 2014, Microorganisms, V2, P92, DOI 10.3390/microorganisms2020092; Katona G, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0084-5; Kenealy T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000247.pub3; Kirkpatrick GL, 1996, PRIMARY CARE, V23, P657, DOI 10.1016/S0095-4543(05)70355-9; Komagamine Junpei, 2017, BMC Res Notes, V10, P728, DOI 10.1186/s13104-017-3070-2; Lee CC, 2018, J AM COLL CARDIOL, V72, P1369, DOI 10.1016/j.jacc.2018.06.067; Lemiengre MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006089.pub4; Murai Mitsuya, 2005, BMC Med Educ, V5, P33, DOI 10.1186/1472-6920-5-33; Muscat DM, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033126; Nino-Serna LF, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3260; O'Mahony D, 2008, AGE AGEING, V37, P138, DOI 10.1093/ageing/Afm189; Onda M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007581; Sato D, 2021, INFECT CONT HOSP EP, V42, P280, DOI 10.1017/ice.2020.427; Satomura K, 2005, AM J PREV MED, V29, P302, DOI 10.1016/j.amepre.2005.06.013; Scaglione Francesco, 2019, Clin Med Insights Ear Nose Throat, V12, p1179550618821930, DOI 10.1177/1179550618821930; Shikamura Y, 2016, YAKUGAKU ZASSHI, V136, P1263, DOI 10.1248/yakushi.16-00024; Shulman ST, 2012, CLIN INFECT DIS, V55, pE86, DOI 10.1093/cid/cis629; Sterrantino C, 2016, ACTA MEDICA PORT, V29, P164, DOI 10.20344/amp.7526; Tamura G, 2007, RESP MED, V101, P1895, DOI 10.1016/j.rmed.2007.05.001; Tsutsumi M, 2017, J GEN FAM MED, V18, P336, DOI 10.1002/jgf2.81; Zgierska A, 2012, JAMA-J AM MED ASSOC, V307, P1377, DOI 10.1001/jama.2012.419; Ziegler TR, 1996, NUTRITION, V12, pS68, DOI 10.1016/S0899-9007(96)00019-6	46	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2022	17	5							e0265874	10.1371/journal.pone.0265874	http://dx.doi.org/10.1371/journal.pone.0265874			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5I1ZV	35552542	Green Published, gold			2023-01-03	WOS:000868164600009
J	Harrison, NE; Meram, S; Li, XR; White, MB; Henry, S; Gupta, S; Zhu, DX; Pang, P; Levy, P				Harrison, Nicholas Eric; Meram, Sarah; Li, Xiangrui; White, Morgan B.; Henry, Sarah; Gupta, Sushane; Zhu, Dongxiao; Pang, Peter; Levy, Phillip			Hemodynamic profiles by non-invasive monitoring of cardiac index and vascular tone in acute heart failure patients in the emergency department: External validation and clinical outcomes	PLOS ONE			English	Article							ARTERIAL-BLOOD PRESSURE; RISK-STRATIFICATION; FINGER CUFF; PATHOPHYSIOLOGY; IDENTIFICATION; ASSOCIATION; DYSFUNCTION; GUIDELINES; MANAGEMENT; MORTALITY	Background Non-invasive finger-cuff monitors measuring cardiac index and vascular tone (SVRI) classify emergency department (ED) patients with acute heart failure (AHF) into three otherwise-indistinguishable subgroups. Our goals were to validate these "hemodynamic profiles" in an external cohort and assess their association with clinical outcomes. Methods AHF patients (n = 257) from five EDs were prospectively enrolled in the validation cohort (VC). Cardiac index and SVRI were measured with a ClearSight finger-cuff monitor (formerly NexFin, Edwards Lifesciences) as in a previous study (derivation cohort, DC, n = 127). A control cohort (CC, n = 127) of ED patients with sepsis was drawn from the same study as the DC. K-means cluster analysis previously derived two-dimensional (cardiac index and SVRI) hemodynamic profiles in the DC and CC (k = 3 profiles each). The VC was subgrouped de novo into three analogous profiles by unsupervised K-means consensus clustering. PERMANOVA tested whether VC profiles 1-3 differed from profiles 1-3 in the DC and CC, by multivariate group composition of cardiac index and vascular tone. Profiles in the VC were compared by a primary outcome of 90-day mortality and a 30-day ranked composite secondary outcome (death, mechanical cardiac support, intubation, new/emergent dialysis, coronary intervention/surgery) as time-to-event (survival analysis) and binary events (odds ratio, OR). Descriptive statistics were used to compare profiles by two validated risk scores for the primary outcome, and one validated score for the secondary outcome. Results The VC had median age 60 years (interquartile range {49-67}), and was 45% (n = 116) female. Multivariate profile composition by cardiac index and vascular tone differed significantly between VC profiles 1-3 and CC profiles 1-3 (p = 0.001, R-2 = 0.159). A difference was not detected between profiles in the VC vs. the DC (p = 0.59, R-2 = 0.016). VC profile 3 had worse 90-day survival than profiles 1 or 2 (HR = 4.8, 95%CI 1.4-17.1). The ranked secondary outcome was more likely in profile 1 (OR = 10.0, 1.2-81.2) and profile 3 (12.8, 1.7-97.9) compared to profile 2. Diabetes prevalence and blood urea nitrogen were lower in the high-risk profile 3 (p<0.05). No significant differences between profiles were observed for other clinical variables or the 3 clinical risk scores. Conclusions Hemodynamic profiles in ED patients with AHF, by non-invasive finger-cuff monitoring of cardiac index and vascular tone, were replicated de novo in an external cohort. Profiles showed significantly different risks of clinically-important adverse patient outcomes.	[Harrison, Nicholas Eric; Meram, Sarah; Henry, Sarah; Gupta, Sushane; Levy, Phillip] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI 48202 USA; [Harrison, Nicholas Eric; White, Morgan B.; Pang, Peter] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Li, Xiangrui] Washington Univ, Sch Med, Div Biostat, St Louis, MO USA; [Zhu, Dongxiao] Wayne State Univ, Dept Comp Sci, Coll Engn, Detroit, MI USA	Wayne State University; Indiana University System; Indiana University Bloomington; Washington University (WUSTL); Wayne State University	Harrison, NE (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI 48202 USA.; Harrison, NE (corresponding author), Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA.	Harrisne@iu.edu		Pang, Peter/0000-0003-3444-2811; Harrison, Nicholas/0000-0002-8331-7833	ClearSight monitor's manufacturer, Edwards Lifesciences Corporation	ClearSight monitor's manufacturer, Edwards Lifesciences Corporation	The ClearSight monitor's manufacturer, Edwards Lifesciences Corporation, provided funding for this study in the form of the Edwards Lifesciences Investigator-Initiated Grant. The funding was used for research assistant time and the monitors used in the study. Edwards Lifesciences Corporation also provided salary support for PL. The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145881; Ameloot K, 2015, CURR OPIN CRIT CARE, V21, P232, DOI 10.1097/MCC.0000000000000198; Beeson MS, 2020, J EMERG MED, V59, P96, DOI 10.1016/j.jemermed.2020.03.018; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Bilchick KC, 2018, J CARD FAIL, V24, P43, DOI 10.1016/j.cardfail.2017.07.001; Butler J, 1998, AM J CARDIOL, V81, P41, DOI 10.1016/S0002-9149(97)00851-5; Chang PP, 2018, CIRCULATION, V138, P12, DOI 10.1161/CIRCULATIONAHA.117.027551; Chaudhry A, 2008, AM J EMERG MED, V26, P196, DOI 10.1016/j.ajem.2007.04.029; Collins SP, 2019, CIRCULATION, V139, P1157, DOI 10.1161/CIRCULATIONAHA.118.038472; Collins SP, 2018, ACAD EMERG MED, V25, P85, DOI 10.1111/acem.13331; Collins SP, 2015, JACC-HEART FAIL, V3, P737, DOI 10.1016/j.jchf.2015.05.007; Collins SP, 2015, ACAD EMERG MED, V22, P94, DOI 10.1111/acem.12538; Collins Sean P, 2009, Crit Pathw Cardiol, V8, P99, DOI 10.1097/HPC.0b013e3181b5a534; Favot M, 2019, ULTRASOUND J, V11, DOI 10.1186/s13089-019-0125-8; FORRESTER JS, 1976, NEW ENGL J MED, V295, P1404, DOI 10.1056/NEJM197612162952505; Fudim M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006817; Garg N, 2021, WEST J EMERG MED, V22, P672, DOI 10.5811/westjem.2021.1.48978; de Almeida GLG, 2018, ARQ BRAS CARDIOL, V110, P270, DOI 10.5935/abc.20180046; Harjola VP, 2017, EUR J HEART FAIL, V19, P821, DOI 10.1002/ejhf.872; Harrison N, 2021, CURR HYPERTENS REP, V23, DOI 10.1007/s11906-021-01127-8; Harrison Nicholas, 2019, Curr Heart Fail Rep, V16, P21, DOI 10.1007/s11897-019-0420-5; Hernandez GA, 2019, J CARD FAIL, V25, P364, DOI 10.1016/j.cardfail.2019.03.004; Hollenberg SM, 2019, J AM COLL CARDIOL, V74, P1966, DOI 10.1016/j.jacc.2019.08.001; Lee DS, 2019, CIRCULATION, V139, P1146, DOI 10.1161/CIRCULATIONAHA.118.035509; Lee DS, 2010, CIRC-HEART FAIL, V3, P228, DOI 10.1161/CIRCHEARTFAILURE.109.885285; Martina JR, 2012, ANESTHESIOLOGY, V116, P1092, DOI 10.1097/ALN.0b013e31824f94ed; McCausland JB, 2010, ACAD EMERG MED, V17, P108, DOI 10.1111/j.1553-2712.2009.00623.x; Nohria A, 2003, J AM COLL CARDIOL, V41, P1797, DOI 10.1016/S0735-1097(03)00309-7; Nowak RM, 2017, AM J EMERG MED, V35, P536, DOI 10.1016/j.ajem.2016.12.003; Obokata M, 2017, J CARD FAIL, V23, P216, DOI 10.1016/j.cardfail.2016.10.001; Pandey A, 2018, JAMA CARDIOL, V3, P489, DOI 10.1001/jamacardio.2018.0579; Peterson PN, 2010, CIRC-CARDIOVASC QUAL, V3, P25, DOI 10.1161/CIRCOUTCOMES.109.854877; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Reddy YNV, 2017, J AM COLL CARDIOL, V70, P136, DOI 10.1016/j.jacc.2017.05.029; Saugel B, 2020, BRIT J ANAESTH, V125, P25, DOI 10.1016/j.bja.2020.03.013; Sax DR, 2021, ANN EMERG MED, V77, P237, DOI 10.1016/j.annemergmed.2020.09.436; Shiraishi Y, 2016, AM HEART J, V171, P33, DOI 10.1016/j.ahj.2015.10.008; Suzuki S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008316; Viau DM, 2015, HEART, V101, P1861, DOI 10.1136/heartjnl-2015-307461; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Weil BR, 2019, JACC-BASIC TRANSL SC, V4, P527, DOI 10.1016/j.jacbts.2019.04.002; Weil BR, 2018, J AM COLL CARDIOL, V71, P2906, DOI 10.1016/j.jacc.2018.04.029; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170	43	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2022	17	3							e0265895	10.1371/journal.pone.0265895	http://dx.doi.org/10.1371/journal.pone.0265895			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M2UI	35358231	Green Submitted, gold, Green Published			2023-01-03	WOS:000799828800051
J	Gee, JE; Bower, WA; Kunkel, A; Petras, J; Gettings, J; Bye, M; Firestone, M; Elrod, MG; Liu, L; Blaney, DD; Zaldivar, A; Raybern, C; Ahmed, FS; Honza, H; Stonecipher, S; O'Sullivan, BJ; Lynfield, R; Hunter, M; Brennan, S; Pavlick, J; Gabel, J; Drenzek, C; Geller, R; Lee, C; Ritter, JM; Zaki, SR; Gulvik, CA; Wilson, WW; Beshearse, E; Currie, BJ; Webb, JR; Weiner, ZP; Negron, ME; Hoffmaster, AR				Gee, Jay E.; Bower, William A.; Kunkel, Amber; Petras, Julia; Gettings, Jenna; Bye, Maria; Firestone, Melanie; Elrod, Mindy G.; Liu, Lindy; Blaney, David D.; Zaldivar, Allison; Raybern, Chelsea; Ahmed, Farah S.; Honza, Heidi; Stonecipher, Shelley; O'Sullivan, Briana J.; Lynfield, Ruth; Hunter, Melissa; Brennan, Skyler; Pavlick, Jessica; Gabel, Julie; Drenzek, Cherie; Geller, Rachel; Lee, Crystal; Ritter, Jana M.; Zaki, Sherif R.; Gulvik, Christopher A.; Wilson, W. Wyatt; Beshearse, Elizabeth; Currie, Bart J.; Webb, Jessica R.; Weiner, Zachary P.; Negron, Maria E.; Hoffmaster, Alex R.			Multistate Outbreak of Melioidosis Associated with Imported Aromatherapy Spray	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BURKHOLDERIA-PSEUDOMALLEI; INFECTION	Melioidosis and Aromatherapy Four cases of non-travel-associated melioidosis (caused by Burkholderia pseudomallei) that were identified across the United States were associated with the use of a contaminated aromatherapy room spray. Melioidosis, caused by the bacterium Burkholderia pseudomallei, is an uncommon infection that is typically associated with exposure to soil and water in tropical and subtropical environments. It is rarely diagnosed in the continental United States. Patients with melioidosis in the United States commonly report travel to regions where melioidosis is endemic. We report a cluster of four non-travel-associated cases of melioidosis in Georgia, Kansas, Minnesota, and Texas. These cases were caused by the same strain of B. pseudomallei that was linked to an aromatherapy spray product imported from a melioidosis-endemic area.	[Gee, Jay E.; Bower, William A.; Petras, Julia; Elrod, Mindy G.; Liu, Lindy; Blaney, David D.; Gulvik, Christopher A.; Weiner, Zachary P.; Negron, Maria E.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30329 USA; [Kunkel, Amber] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA; [Ritter, Jana M.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30329 USA; [Kunkel, Amber; Petras, Julia; Gettings, Jenna; Firestone, Melanie; Wilson, W. Wyatt; Beshearse, Elizabeth] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Epidem Intelligence Serv, Atlanta, GA 30329 USA; [Wilson, W. Wyatt; Beshearse, Elizabeth] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA 30329 USA; [Gettings, Jenna; Brennan, Skyler; Pavlick, Jessica; Gabel, Julie; Drenzek, Cherie] Georgia Dept Publ Hlth, Atlanta, GA USA; [Geller, Rachel] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Hunter, Melissa] Georgia Dept Publ Hlth, Publ Hlth Dist 1 1, Rome, GA USA; [Geller, Rachel; Lee, Crystal] Dekalb Cty Med Examiners Off, Decatur, GA USA; [Bye, Maria; Firestone, Melanie; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA; [Zaldivar, Allison; Raybern, Chelsea; Ahmed, Farah S.] Kansas Dept Hlth & Environm, Topeka, KS USA; [Honza, Heidi; Stonecipher, Shelley] Texas Dept Scam Hlth Serv, Publ Hlth Reg 2 & 3 Texas, Arlington, TX USA; [O'Sullivan, Briana J.] Texas Dept State Hlth Serv, Austin, TX USA; [Currie, Bart J.; Webb, Jessica R.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia; [Currie, Bart J.; Webb, Jessica R.] Royal Darwin Hosp, Darwin, NT, Australia; [Webb, Jessica R.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Minnesota Department of Health (MHD); Texas Department of State Health Services; Charles Darwin University; Menzies School of Health Research; University of Melbourne	Gee, JE (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop H17-2, Atlanta, GA 30329 USA.	xzg4@cdc.gov		O'Sullivan, Briana/0000-0003-2330-7876; Gulvik, Christopher/0000-0001-8754-9829; Firestone, Melanie/0000-0003-2244-3729; Gee, Jay/0000-0003-4308-1659				Benoit TJ, 2015, MMWR SURVEILL SUMM, V64, P1; Benoit TJ, 2015, AM J TROP MED HYG, V93, P1134, DOI 10.4269/ajtmh.15-0405; Centers for Disease Control and Prevention, 2020 ANN REP FED SEL; Clark B, 2018, INTERN MED J, V48, P461, DOI 10.1111/imj.13752; Cossaboom CM, 2020, EMERG INFECT DIS, V26, P1295, DOI 10.3201/eid2606.190975; Dawson P, 2021, EMERG INFECT DIS, V27, P3030, DOI 10.3201/eid2712.211756; Doker TJ, 2014, AM J TROP MED HYG, V91, P743, DOI 10.4269/ajtmh.14-0172; Engelthaler DM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001347; Gal D, 2004, AM J TROP MED HYG, V71, P360, DOI 10.4269/ajtmh.2004.71.360; Gee JE, 2017, EMERG INFECT DIS, V23, P1133, DOI 10.3201/eid2307.161978; Greer RC, 2019, T ROY SOC TROP MED H, V113, P48, DOI 10.1093/trstmh/try108; Gulati U., AM J TROP MED HYG; Hoffmaster Alex R, 2015, Emerg Infect Dis, V21, DOI 10.3201/eid2102.141045; Johnson CH, 2013, COMPARATIVE MED, V63, P528; Limmathurotsakul D, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.8, 10.1038/nmicrobiol.2015.8]; Ritter JM, 2013, VET PATHOL, V50, P1139, DOI 10.1177/0300985813485249; Ryan CW, 2018, ZOONOSES PUBLIC HLTH, V65, P420, DOI 10.1111/zph.12450; Schweizer HP, 2008, EMERG INFECT DIS, V14, P1689, DOI [10.3201/eid1411.080431, 10.3201/eid1407.071501]; Stewart T, 2011, EMERG INFECT DIS, V17, P1286, DOI 10.3201/eid1707.100661; Wiersinga WJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.107; Wu B, 2021, EMERG INFECT DIS, V27, P964, DOI 10.3201/eid2703.191769; Zehnder AM, 2014, EMERG INFECT DIS, V20, P304, DOI 10.3201/eid2002.131314	22	7	7	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	2022	386	9					861	868		10.1056/NEJMoa2116130	http://dx.doi.org/10.1056/NEJMoa2116130			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK5CH	35235727				2023-01-03	WOS:000763005000011
J	Geng, DY; Liu, XY; Wang, Y; Wang, JX				Geng, Duyan; Liu, Xuanyu; Wang, Yan; Wang, Jiaxing			The effect of transcutaneous auricular vagus nerve stimulation on HRV in healthy young people	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; EPILEPSY; TVNS; EAR	Transcutaneous auricular vagus nerve stimulation (taVNS) has shown positive effects on a variety of diseases. Considering that decreased heart rate variability (HRV) is closely associated with morbidity and mortality for a variety of diseases, it is important to investigate the effect of taVNS on HRV. In Study 1, we conducted a two-stage cross-over trial to compare the effects of taVNS and sham taVNS (staVNS) on HRV. In Study 2, we systematically tested the effects of different taVNS parameters on high frequency (HF) component of HRV. The results showed that taVNS significantly increased measurements of root mean square of the difference between successive RR intervals (RMSSD), percentage of number of pairs of adjacent RR intervals differing greater than 50ms (pRR50), standard deviation of all RR intervals (SDRR), HF. Significantly, enhancement of HF and pRR50 persisted into recovery period. In addition, higher baseline LF/HF ratio was associated with greater LF/HF ratio decrease. Findings also showed that there was no significant difference in measurements of HF between different taVNS parameters. These studies suggest that taVNS could increase HRV, it may help taVNS in the treatment of low HRV related diseases. However, taVNS may not have parameter-specific effects on HRV.	[Geng, Duyan; Liu, Xuanyu; Wang, Yan; Wang, Jiaxing] Hebei Univ Technol, State Key Lab Reliabil & Intelligence Elect Equip, Tianjin, Peoples R China; [Liu, Xuanyu; Wang, Yan; Wang, Jiaxing] Hebei Univ Technol, Key Lab Electromagnet Field & Elect Apparat Relia, Tianjin, Peoples R China	Hebei University of Technology; Hebei University of Technology	Geng, DY (corresponding author), Hebei Univ Technol, State Key Lab Reliabil & Intelligence Elect Equip, Tianjin, Peoples R China.	dygeng@hebut.edu.cn						Acharya UR, 2006, MED BIOL ENG COMPUT, V44, P1031, DOI 10.1007/s11517-006-0119-0; Aysin B, 2006, 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-15, P1726; Badran BW, 2018, BRAIN STIMUL, V11, P699, DOI 10.1016/j.brs.2018.04.004; Berthoud HR, 2000, AUTON NEUROSCI-BASIC, V85, P1, DOI 10.1016/S1566-0702(00)00215-0; Borges U, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223848; Camm AJ, 1996, CIRCULATION, V93, P1043; Clancy JA, 2014, BRAIN STIMUL, V7, P871, DOI 10.1016/j.brs.2014.07.031; Colzato LS, 2018, NEUROPSYCHOLOGIA, V111, P72, DOI 10.1016/j.neuropsychologia.2018.01.003; De Couck M, 2017, AUTON NEUROSCI-BASIC, V203, P88, DOI 10.1016/j.autneu.2016.11.003; De Couck M, 2012, CLIN SCI, V122, P323, DOI 10.1042/CS20110299; De Ferrari GM, 2011, EUR HEART J, V32, P847, DOI 10.1093/eurheartj/ehq391; de Lartigue G, 2016, J PHYSIOL-LONDON, V594, P5791, DOI 10.1113/JP271538; Elliott RE, 2011, EPILEPSY BEHAV, V20, P57, DOI 10.1016/j.yebeh.2010.10.017; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; Fang JL, 2016, BIOL PSYCHIAT, V79, P266, DOI 10.1016/j.biopsych.2015.03.025; Frangos E, 2015, BRAIN STIMUL, V8, P624, DOI 10.1016/j.brs.2014.11.018; George MS, 2000, BIOL PSYCHIAT, V47, P287, DOI 10.1016/S0006-3223(99)00308-X; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Haensel A, 2008, PSYCHONEUROENDOCRINO, V33, P1305, DOI 10.1016/j.psyneuen.2008.08.007; Haker E, 2000, J AUTONOM NERV SYST, V79, P52, DOI 10.1016/S0165-1838(99)00090-9; Joshi S, 2016, NEURON, V89, P221, DOI 10.1016/j.neuron.2015.11.028; Kaniusas E, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00890; Kaniusas E, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00854; Koenig J, 2014, EUR J PAIN, V18, P301, DOI 10.1002/j.1532-2149.2013.00379.x; Laborde S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00213; Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003; Milby AH, 2008, NEUROTHERAPEUTICS, V5, P75, DOI 10.1016/j.nurt.2007.10.071; Murray AR, 2016, AUTON NEUROSCI-BASIC, V199, P48, DOI 10.1016/j.autneu.2016.06.004; Ness TJ, 2001, NEUROLOGY, V56, P985, DOI 10.1212/WNL.56.7.985; Peuker ET, 2002, CLIN ANAT, V15, P35, DOI 10.1002/ca.1089; Polak T, 2009, J NEURAL TRANSM, V116, P1237, DOI 10.1007/s00702-009-0282-1; Probe Q., 2014, POWER SPECTRUM ANAL, V213, P13; Rong Peijing, 2014, Clin Sci (Lond); Shahwan A, 2009, EPILEPSIA, V50, P1220, DOI 10.1111/j.1528-1167.2008.01940.x; Thayer JF, 2010, INT J CARDIOL, V141, P122, DOI 10.1016/j.ijcard.2009.09.543; Tsutsumi T, 2008, CARDIOVASC RES, V77, P713, DOI 10.1093/cvr/cvm092; Val-Laillet D, 2010, APPETITE, V55, P245, DOI 10.1016/j.appet.2010.06.008; Ventura-Bort C, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00202; Vlcek M, 2008, AUTON NEUROSCI-BASIC, V143, P53, DOI 10.1016/j.autneu.2008.08.001; Weise D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120786; Widjaja D, 2010, COMPUT CARDIOL CONF, V37, P533; Wulsin LR, 2015, J CLIN ENDOCR METAB, V100, P2443, DOI 10.1210/jc.2015-1748; Yoshino K, 2012, METHOD INFORM MED, V51, P39, DOI 10.3414/ME11-01-0027; Zulfiqar U, 2010, AM J CARDIOL, V105, P1181, DOI 10.1016/j.amjcard.2009.12.022	44	3	3	8	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2022	17	2							e0263833	10.1371/journal.pone.0263833	http://dx.doi.org/10.1371/journal.pone.0263833			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1J1AU	35143576	gold, Green Published			2023-01-03	WOS:000797657800084
J	Hakim, FE; Farooq, AV				Hakim, Farida E.; Farooq, Asim, V			Dry Eye Disease An Update in 2022	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hakim, Farida E.; Farooq, Asim, V] Univ Chicago, Dept Ophthalmol & Visual Sci, Med Ctr, 5841S Maryland Ave, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center	Farooq, AV (corresponding author), Univ Chicago, Dept Ophthalmol & Visual Sci, Med Ctr, 5841S Maryland Ave, Chicago, IL 60637 USA.	afarooq@bsd.uchicago.edu						Craig JP, 2017, OCUL SURF, V15, P802, DOI 10.1016/j.jtos.2017.08.003; Dana R, 2019, AM J OPHTHALMOL, V202, P47, DOI 10.1016/j.ajo.2019.01.026; Kawashima M, 2018, J OCCUP HEALTH, V60, P281, DOI 10.1539/joh.2017-0191-OA; Kojima T, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100842; Park JY, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.31; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615; Shtein RM, 2020, OPHTHALMOLOGY, V127, P128, DOI 10.1016/j.ophtha.2019.08.018; Thode AR, 2015, DRUGS, V75, P1177, DOI 10.1007/s40265-015-0432-8; Wolffsohn JS, 2017, OCUL SURF, V15, P539, DOI 10.1016/j.jtos.2017.05.001; Xiao JX, 2020, AM J OPHTHALMOL, V209, P160, DOI 10.1016/j.ajo.2019.09.005	10	7	7	6	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2022	327	5					478	479						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9QB	35103781				2023-01-03	WOS:000753056200020
J	Birke, H; Foxvig, I; Burns, K; Toft, U; Hansen, ABG; Hauge, PI; Foghmar, S; Mindegaard, RB; Jakobsen, LM				Birke, Hanne; Foxvig, Ida; Burns, Karin; Toft, Ulla; Hansen, Anders Blaedel Gottlieb; Hauge, Pernille Ibsen; Foghmar, Sussie; Mindegaard, Rikke Bulow; Jakobsen, Louise Meinertz			Heart Rehabilitation for All (HeRTA): Protocol for a feasibility study and pilot randomized trial	PLOS ONE			English	Article							CARDIAC REHABILITATION; HEALTH; ENROLLMENT; DESIGN	IntroductionToday, 50% of people with cardiac disease do not participate in rehabilitation. The HeRTA-study aims to develop and test a sustainable rehabilitation model supporting vulnerable patients in participating in rehabilitation and long-term physical activity. MethodsA feasibility study with a non-blinded pilot randomized trial was developed in collaboration with partners and cardiac patients to test a multi-component rehabilitation intervention across hospital, municipality, and civil society. The study runs from January 2020 to December 2024. Eligibility criteria for participants: a) diagnosed with either ischemic heart disease, persistent atrial fibrillation, heart failure, or have had cardiac valve surgery, b) residents in Hvidovre Hospitals uptake area, c) cognitively functional, d) physically able to participate in rehabilitation. Patient recruitment will be located at Hvidovre Hospital, Capital Region of Denmark, data collection at Hvidovre Hospital, Rehabilitation Center Albertslund, the Danish Heart Association, and in two municipalities (Hvidovre and Brondby). Patients in the control group have access to usual care at the hospital: rehabilitation-needs-assessment, patient education, and physical training. After or instead of hospital rehabilitation, the patient can be referred to municipal rehabilitation with patient education, and a total of 12 weeks of physical training across sectors. Patients in the intervention group will in addition to usual care, have access to an information book about cardiac disease, patient supporters from the Danish Heart Association, Information materials to inform employers about the employees' rehabilitation participation, a rehabilitation goal setting plan, a support cafe for relatives, and follow-up phone calls from physiotherapists 1 and 3 months after rehabilitation to support physical activities. Patients with vulnerabilities will additionally receive patient education conducted in small groups, pro-active counselling by a cardiac nurse, psychologist, or social worker, paid transportation to rehabilitation, and paid membership in a sports association. Patients are computer block-randomized so patients with vulnerability are distributed evenly in the two study arms by stratifying on a) a cut-off score of >= 5 in the Tilburg Frailty Indicator questionnaire and/or b) need of language translator support. A power calculation, based on an estimated 20% difference in participation proportion between groups, 80% power, a type 1 error of 5% (two-tailed), results in 91 participants in each study arm. The primary outcome: rehabilitation participation (attending >= two activities: patient education, smoking cessation, dietary counseling, and physical training) and reaching at least 50% attendance. Secondary outcomes: health-related quality of life, coping strategies, level of physical activities, and sustainability regarding participation in active communities after rehabilitation. The study is registered at ClinicalTrials.gov (NCT05104658). ResultsDifferences between changes in outcomes between groups will be analyzed according to the intention-to-treat principle. Sensitivity analysis and analysis of the effect of the combined activities will be made. A process evaluation will clarify the implementation of the model, the partnership, and patients' experiences. ConclusionCross-sectoral collaborations between hospitals, municipalities, and organizations in civil society may lead to sustainable and affordable long-term physical activities for persons with chronic illness. The results can lead to improve cross-sectoral collaborations in other locations and patient groups.	[Birke, Hanne; Foxvig, Ida; Burns, Karin; Toft, Ulla; Hansen, Anders Blaedel Gottlieb; Jakobsen, Louise Meinertz] Frederiksberg Univ Hosp, Ctr Clin Res & Prevent, Frederiksberg, Denmark; [Toft, Ulla] Univ Copenhagen, Dept Publ Hlth, Sect Social Med, Copenhagen, Denmark; [Hauge, Pernille Ibsen] Danish Heart Assoc, Copenhagen, Denmark; [Foghmar, Sussie] Univ Hosp Hvidovre, Cardiol Dept, Hvidovre, Denmark; [Mindegaard, Rikke Bulow] Rehabil Ctr, 6 Capital Reg, Hillerod, Denmark; [Jakobsen, Louise Meinertz] Capital Reg, Hillerod, Denmark	University of Copenhagen; University of Copenhagen	Birke, H (corresponding author), Frederiksberg Univ Hosp, Ctr Clin Res & Prevent, Frederiksberg, Denmark.	Hanne.birke.01@regionh.dk		Birke, Hanne/0000-0001-5923-2170	Danish Heart Association [19-R136-A9125-22129, A36031]; Helsefonden [21-B-0016]	Danish Heart Association; Helsefonden	We appreciate Rikke Kart Jacobsen, statistician in the StatPharm Section, CCRP, Frederiksberg Hospital, for helping with the power calculation and the statistical plan for analyses.	Al-Sharifi F, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4041-1; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; Bellmann B, 2020, CARDIOL THER, V9, P35, DOI 10.1007/s40119-020-00164-9; Boaz A, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0337-6; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; ClinicalTrials.gov, US; Corbin JH, 2018, HEALTH PROMOT INT, V33, P4, DOI 10.1093/heapro/daw061; Cornish F., 2014, SAGE HDB QUALITATIVE, P79, DOI 10.4135/9781446282243.N6; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Danquah IH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5538-y; Det sektorfri Forebyggelseslaboratorium, 2020, RESS ET UDV VEDL PAR; Egan M., 2019, GUIDANCE SYSTEMS A 1; Fridrich A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/414832; Gobbens RJJ, 2010, J AM MED DIR ASSOC, V11, P344, DOI 10.1016/j.jamda.2009.11.003; Graversen CB, 2017, SCAND CARDIOVASC J, V51, P316, DOI 10.1080/14017431.2017.1385838; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hawkins J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4695-8; Hickey G., 2018, NIHR INVOLV; Jones J, 2011, HEALTH PROMOT INT, V26, P408, DOI 10.1093/heapro/dar002; Kirolos I, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.64; Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x; Lawler PR, 2011, AM HEART J, V162, P571, DOI 10.1016/j.ahj.2011.07.017; Leask CF., 2019, RES INVOLV ENGAGEM, V5, P1, DOI [10.1186/s40900-018-0136-9, DOI 10.1186/S40900-018-0136-9]; Malterud K., 2011, KVALITATIVE METODER, V3; Maruish ME, 2011, USERS MANUAL SF 36V2, V3rd; Meillier LK, 2012, SCAND J PUBLIC HEALT, V40, P286, DOI 10.1177/1403494812443600; Meroni A., 2018, MASSIVE CODESIGN PRO; Nielsen KM, 2008, EUR J PUBLIC HEALTH, V18, P479, DOI 10.1093/eurpub/ckn060; O'Cathain A., 2015, PILOT FEASIBILITY ST, V1, P1; O'Cathain A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029954; Osborne RH, 2007, PATIENT EDUC COUNS, V66, P192, DOI 10.1016/j.pec.2006.12.002; Rouleau CR, 2018, DISABIL REHABIL, V40, P469, DOI 10.1080/09638288.2016.1261417; Schiotz ML, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4314-8; Skivington K, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2061; Sommer CG., 2021, EUR J CARDIOVASC NUR, P1; Statistics Denmark, US; Sutton JL, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0225-2; Taylor RS, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23250; Taylor RS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub4; The Capital Region of Copenhagen, 2019, CARD REH; The Capital Region of Denmark, US; The Danish Data Protection Agency, US; The Danish Heart Association, FACTS CARD DIS DENM; The Danish National Committee on Health Research Ethics, 2019, US; The World Health Organization, CARDIOVASCULAR DIS E; Touray MML, 2018, J PHARM HEALTH SERV, V9, P109, DOI 10.1111/jphs.12218; Valentine L, 2017, DES J, V20, P755, DOI 10.1080/14606925.2017.1372926; Vichealth, 2016, PARTN AN TOOL, P8; Wagner E H, 1998, Eff Clin Pract, V1, P2; Ware JE., 2002, SF 12 SCORE SF 12 PH, V4th ed; Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955; WORLD HEALTH ORGANIZATION, 1978, INT C PRIM HLTH CAR, DOI DOI 10.1016/S0140-6736(79)90622-6; World Health Organization, CARDIOVASCULAR DIS	54	1	1	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0270159	10.1371/journal.pone.0270159	http://dx.doi.org/10.1371/journal.pone.0270159			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D4TG	35714121	gold, Green Published			2023-01-03	WOS:000829295700035
J	Kassa, AM; Engvall, G; Blom, MD; Lilja, HE				Kassa, Ann-Marie; Engvall, Gunn; Blom, Michaela Dellenmark; Lilja, Helene Engstrand			Understanding of the transition to adult healthcare services among individuals with VACTERL association in Sweden: A qualitative study	PLOS ONE			English	Article							ANORECTAL-MALFORMATIONS; YOUNG-ADULTS; EXPERIENCES; ADOLESCENTS; RECOMMENDATIONS; CONSENSUS	Current knowledge of transitional care from the perspective of individuals with congenital malformations is scarce. Their viewpoints are required for the development of follow-up programs and transitional care corresponding to patients' needs. The study aimed to describe expectations, concerns, and experiences in conjunction with transfer to adult health care among adolescents, young adults, and adults with VACTERL association, (i.e. vertebral defects, anorectal malformations (ARM), cardiac defects (CHD), esophageal atresia (EA), renal, and limb abnormalities). Semi-structured telephone interviews were performed and analyzed with qualitative content analysis. Of 47 invited individuals, 22 participated (12 males and 10 females). An overarching theme emerged: Leaving the safe nest of pediatric health care for an unfamiliar and uncertain follow up yet growing in responsibility and appreciating the adult health care. The participants described expectations of qualified adult health care but also concerns about the process and transfer to an unfamiliar setting. Individuals who were transferred described implemented or absence of preparations. Positive and negative experiences of adult health care were recounted including being treated as adults. The informants described increasing involvement in health care but were still supported by their parents. Ongoing follow up of health conditions was recounted but also uncertainty around the continuation, missing follow up and limited knowledge of how to contact health care. The participants recommended information ahead of transfer and expressed wishes for continued health care with regular follow up and accessibility to a contact person. Based on the participants' perspective, a transitional plan is required including early information about transfer and follow up to prepare the adolescents and reduce uncertainty concerning future health care. Meetings with the pediatric and adult team together with the patient and the parents are essential before transfer. Follow up should be centralized to centers with multi-professional teams well-experienced with the condition. Further studies are warranted to evaluate the transition process for adolescents and young adults with complex congenital health conditions.	[Kassa, Ann-Marie; Engvall, Gunn; Lilja, Helene Engstrand] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Kassa, Ann-Marie; Lilja, Helene Engstrand] Univ Childrens Hosp, Dept Paediat Surg, Uppsala, Sweden; [Blom, Michaela Dellenmark] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; [Blom, Michaela Dellenmark] Queen Silv Childrens Hosp SU Ostra, Dept Paediat Surg, Gothenburg, Sweden	Uppsala University; University of Gothenburg	Kassa, AM (corresponding author), Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.; Kassa, AM (corresponding author), Univ Childrens Hosp, Dept Paediat Surg, Uppsala, Sweden.	ann-marie.kassa@kbh.uu.se		Kassa, Ann-Marie/0000-0001-9788-6159	Gillbergska foundation; HRH Crownprincess Lovisas Association for Child Medical Care Grant [2016-00250, 2018-00438, 2019-00494, 2020-00550]	Gillbergska foundation; HRH Crownprincess Lovisas Association for Child Medical Care Grant	Funding provided from Gillbergska foundation for 2017, 2018, 2019, 2020 (no Grant number provided)(A-MK) URL: http://www. gillbergska.se/ HRH Crownprincess Lovisas Association for Child Medical Care Grant number: 2016-00250, 2018-00438, 2019-00494, 2020-00550 (A-MK) URL: http://www.	Amer Acad Pediat, 2011, PEDIATRICS, V128, P182, DOI 10.1542/peds.2011-0969; BLUM RW, 1993, J ADOLESCENT HEALTH, V14, P570, DOI 10.1016/1054-139X(93)90143-D; Burstrom A, 2017, EUR J PEDIATR, V176, P881, DOI 10.1007/s00431-017-2917-9; Busse FP, 2007, HORM RES, V67, P132, DOI 10.1159/000096583; Campbell F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009794.pub2; Coyne I, 2019, J CLIN NURS, V28, P4062, DOI 10.1111/jocn.15006; Danielson J, 2019, INT J COLORECTAL DIS, V34, P551, DOI 10.1007/s00384-018-3220-6; Danielson J, 2017, J PEDIATR SURG, V52, P463, DOI 10.1016/j.jpedsurg.2016.10.051; Dingemann C, 2020, EUR J PEDIATR SURG, V30, P475, DOI 10.1055/s-0039-3400284; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Fegran L, 2014, INT J NURS STUD, V51, P123, DOI 10.1016/j.ijnurstu.2013.02.001; Giuliani S, 2017, J PEDIATR SURG, V52, P1866, DOI 10.1016/j.jpedsurg.2017.06.008; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Graneheim UH, 2017, NURS EDUC TODAY, V56, P29, DOI 10.1016/j.nedt.2017.06.002; Hartman EE, 2005, J PEDIATR GASTR NUTR, V41, P210, DOI 10.1097/01.mpg.0000168993.21557.5d; Heon-Klin V, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0676-3; Hoel AT, 2021, J PEDIATR SURG, V56, P257, DOI 10.1016/j.jpedsurg.2020.05.015; Iversen E, 2019, SCAND J CARING SCI, V33, P723, DOI 10.1111/scs.12668; Kennedy A, 2008, CURR OPIN PEDIATR, V20, P403, DOI 10.1097/MOP.0b013e328305e128; Knauth Meadows Alison, 2009, Curr Cardiol Rep, V11, P291; Krishnan U, 2016, J PEDIATR GASTR NUTR, V63, P550, DOI 10.1097/MPG.0000000000001401; Mantoo S, 2013, COLORECTAL DIS, V15, pE330, DOI 10.1111/codi.12186; Mazur A, 2017, ACTA PAEDIATR, V106, P1354, DOI 10.1111/apa.13901; McCann ME, 2014, SEMIN PEDIATR SURG, V23, P244, DOI 10.1053/j.sempedsurg.2014.09.003; Moons P, 2009, J ADOLESCENT HEALTH, V44, P316, DOI 10.1016/j.jadohealth.2008.11.007; Mora MA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014593; Orphanet, 2022, PREVALENCE INCIDENCE, V1; Polit D.F., 2018, ESSENTIALS NURSING R; Raam MS, 2011, EUR J MED GENET, V54, P34, DOI 10.1016/j.ejmg.2010.09.007; Rothstein DH, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1303; Sawyer SM, 2012, LANCET, V379, P1630, DOI 10.1016/S0140-6736(12)60072-5; Sobota Amy E, 2015, J Hematol Res, V2, P17; Solomon BD, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-56; Tuchman LK, 2008, CHILD CARE HLTH DEV, V34, P557, DOI 10.1111/j.1365-2214.2008.00844.x; van Staa AL, 2011, CHILD CARE HLTH DEV, V37, P821, DOI 10.1111/j.1365-2214.2011.01261.x; Wheeler PG, 2005, AM J MED GENET A, V138A, P212, DOI 10.1002/ajmg.a.30938; White Abby, 2017, Curr Treat Options Gastroenterol, V15, P46, DOI 10.1007/s11938-017-0127-1; World Health Organization, 2020, AD HLTH	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5							e0269163	10.1371/journal.pone.0269163	http://dx.doi.org/10.1371/journal.pone.0269163			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L8PY	35622841	Green Published, gold			2023-01-03	WOS:000835025800009
J	Belohlavek, J; Rob, D; Smalcova, J				Belohlavek, Jan; Rob, Daniel; Smalcova, Jana			Effect of Intra-arrest Transport and Extracorporeal Cardiopulmonary Resuscitation on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Belohlavek, Jan; Rob, Daniel; Smalcova, Jana] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Prague, Czech Republic	Charles University Prague; General University Hospital Prague	Belohlavek, J (corresponding author), Charles Univ Prague, Fac Med 1, Dept Cardiovasc Med, Dept Med 2, U Nemocnice 2, Prague 12800, Czech Republic.; Belohlavek, J (corresponding author), Gen Univ Hosp, U Nemocnice 2, Prague 12800, Czech Republic.	jan.belohlavek@vfn.cz						Belohlavek J, 2022, JAMA-J AM MED ASSOC, V327, P737, DOI 10.1001/jama.2022.1025; Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385; Nordberg P, 2019, JAMA-J AM MED ASSOC, V321, P1677, DOI 10.1001/jama.2019.4149; Thiele H, 2017, NEW ENGL J MED, V377, P2419, DOI 10.1056/NEJMoa1710261	4	0	0	4	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2022	327	23					2357	2357		10.1001/jama.2022.6548	http://dx.doi.org/10.1001/jama.2022.6548			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L3ZC	35727279				2023-01-03	WOS:000816956000026
J	McDermott, MM				McDermott, Mary M.			Home-Based Walking Exercise for Peripheral Artery Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOWER-EXTREMITY; DISTANCE		[McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	McDermott, MM (corresponding author), Northwestern Univ, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	mdm608@northwestern.edu			National Institute on Aging [R01-AG057693]	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding was provided in part by a grant from the National Institute on Aging (R01-AG057693).	Bearne L, 2022, JAMA-J AM MED ASSOC, V327, P1344, DOI 10.1001/jama.2022.3391; Divakaran S, 2021, CIRC-CARDIOVASC QUAL, V14, DOI 10.1161/CIRCOUTCOMES.121.007953; Dua A, 2020, J VASC SURG, V71, P1702, DOI 10.1016/j.jvs.2019.08.238; Fakhry F, 2012, J VASC SURG, V56, P1132, DOI 10.1016/j.jvs.2012.04.046; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; McDermott MM, 2021, JAMA-J AM MED ASSOC, V325, P1266, DOI 10.1001/jama.2021.2536; McDermott MM, 2020, J VASC SURG, V71, P988, DOI 10.1016/j.jvs.2019.05.058; Polonsky TS, 2021, JAMA-J AM MED ASSOC, V325, P2188, DOI 10.1001/jama.2021.2126; Pymer S, 2021, J VASC SURG, V74, P2076, DOI 10.1016/j.jvs.2021.03.063	9	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2022	327	14					1339	1340						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1FH	35412576				2023-01-03	WOS:000783967600012
J	Havranek, MM; Ondrej, J; Bollmann, S; Widmer, PK; Spika, S; Boes, S				Havranek, Michael M.; Ondrej, Josef; Bollmann, Stella; Widmer, Philippe K.; Spika, Simon; Boes, Stefan			Identification and assessment of a comprehensive set of structural factors associated with hospital costs in Switzerland	PLOS ONE			English	Article							STAY	Structural factors can influence hospital costs beyond case-mix differences. However, accepted measures on how to distinguish hospitals with regard to cost-related organizational and regional differences are lacking in Switzerland. Therefore, the objective of this study was to identify and assess a comprehensive set of hospital attributes in relation to average case-mix adjusted costs of hospitals. Using detailed hospital and patient-level data enriched with regional information, we derived a list of 23 cost predictors, examined how they are associated with costs, each other, and with different hospital types, and identified principal components within them. Our results showed that attributes describing size, complexity, and teaching-intensity of hospitals (number of beds, discharges, departments, and rate of residents) were positively related to costs and showed the largest values in university (i.e., academic teaching) and central general hospitals. Attributes related to rarity and financial risk of patient mix (ratio of rare DRGs, ratio of children, and expected loss potential based on DRG mix) were positively associated with costs and showed the largest values in children's and university hospitals. Attributes characterizing the provision of essential healthcare functions in the service area (ratio of emergency/ambulance admissions, admissions during weekends/ nights, and admissions from nursing homes) were positively related to costs and showed the largest values in central and regional general hospitals. Regional attributes describing the location of hospitals in large agglomerations (in contrast to smaller agglomerations and rural areas) were positively associated with costs and showed the largest values in university hospitals. Furthermore, the four principal components identified within the hospital attributes fully explained the observed cost variations across different hospital types. These uncovered relationships may serve as a foundation for objectifying discussions about cost-related heterogeneity in Swiss hospitals and support policymakers to include structural characteristics into cost benchmarking and hospital reimbursement.	[Havranek, Michael M.; Ondrej, Josef; Bollmann, Stella; Boes, Stefan] Univ Lucerne, Dept Hlth Sci & Med, Luzern, Switzerland; [Widmer, Philippe K.] Spital Limmattal Zurich, Zurich, Switzerland; [Spika, Simon] Univ Hosp Zurich, Zurich, Switzerland	University of Lucerne; University of Zurich; University Zurich Hospital	Havranek, MM (corresponding author), Univ Lucerne, Dept Hlth Sci & Med, Luzern, Switzerland.	michael.havranek@unilu.ch			Swiss Innovation Agency (Innosuisse) [38988.1 IP-SBM]	Swiss Innovation Agency (Innosuisse)	This study (MMH) was funded by the Research Grant 38988.1 IP-SBM of the Swiss Innovation Agency (Innosuisse, https://www.innosuisse.ch/inno/de/home.html), which promotes science-based innovations commissioned by the Swiss Confederation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Busse R, 2011, DIAGNOSIS RELATED GR; Einkaufsgemeinschaft HSK, 2020, BENCHM SWISSDRG TAR, DOI [10.4414/smw.2020.20180, DOI 10.4414/SMW.2020.20180]; Garvey Melissa, 2013, Midwifery Today Int Midwife, P68; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Longo F, 2019, EUR J HEALTH ECON, V20, P7, DOI 10.1007/s10198-017-0935-1; Meacock R, 2015, HEALTH ECON, V24, P907, DOI 10.1002/hec.3207; Merenstein D, 2005, PEDIATRICS, V115, P839, DOI 10.1542/peds.2004-1622; Raol N, 2016, OTOLARYNG HEAD NECK, V154, P486, DOI 10.1177/0194599815621739; Robinson BRH, 2014, SURGERY, V156, P814, DOI 10.1016/j.surg.2014.06.071; Scarf V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149463; Short Heather L, 2018, Hosp Pediatr, V8, P753, DOI 10.1542/hpeds.2017-0152; Silber JH, 2020, ANN SURG, V271, P412, DOI 10.1097/SLA.0000000000003602; Skolasky RL, 2015, SPINE, V40, pE936, DOI 10.1097/BRS.0000000000000910; Solberg BCJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6903; Thompson RT, 2013, PEDIATRICS, V131, pE805, DOI 10.1542/peds.2012-2015; Verein SpitalBenchmark, 2020, BENCHM SCHWEIZ SPIT; Wang L, 2011, SURGERY, V150, P727, DOI 10.1016/j.surg.2011.08.019; Watanabe Y, 2018, INT J HEALTH CARE Q, V31, P265, DOI 10.1108/IJHCQA-03-2017-0043; Widmer P., 2015, POLYNOMICS; Widmer P., 2017, POLYNOMICS; Widmer P., 2010, 52 U ZUR DEP EC	22	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2022	17	2							e0264212	10.1371/journal.pone.0264212	http://dx.doi.org/10.1371/journal.pone.0264212			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0F6ZJ	35176112	gold, Green Published			2023-01-03	WOS:000777505200091
J	Pizzo, E; Wenborn, J; Burgess, J; Mundy, J; Orrell, M; King, M; Omar, R; Morris, S				Pizzo, Elena; Wenborn, Jennifer; Burgess, Jane; Mundy, Jacqueline; Orrell, Martin; King, Michael; Omar, Rumana; Morris, Stephen			Cost-utility analysis of community occupational therapy in dementia (COTiD-UK) versus usual care: Results from VALID, a multi-site randomised controlled trial in the UK	PLOS ONE			English	Article							QUALITY-OF-LIFE; UNCERTAINTY; FRAMEWORK; EUROQOL; PEOPLE; GIVERS; DEMQOL	Background A community-based occupational therapy intervention for people with mild to moderate dementia and their family carers: the Community Occupational Therapy in Dementia-UK version (COTiD-UK); and Treatment as usual (TAU) were randomly assigned to 468 pairs (each comprising a person with dementia and a family carer) in the Valuing Active Life in Dementia (VALID) randomised controlled trial (RCT). Objectives To compare the cost-utility of the COTiD-UK intervention compared to TAU, using data from the VALID RCT. Methods We performed a cost-utility analysis estimating mean costs and quality adjusted life years (QALYs) per person with dementia and carer for both treatments over a 26 weeks' time horizon based on resource use data and utility values collected in the trial. Results Taking the National Health Service and Personal Social Services perspective, including costs and benefits to the person with dementia only, measuring Health Related Quality of Life based on Dementia Quality of Life scale (DEMQOL), accounting for missing data and adjusting for baseline values, there was a significant difference in costs between COTiD-UK and TAU (mean incremental cost for COTiD-UK 784 (95% CI 233 pound to 1334)) pound, but no significant difference in outcomes (mean QALYs gained 0.00664 (95% CI -0.00404, 0.01732)). The Incremental Net Monetary Benefit (INMB) for COTiD-UK versus TAU was negative at a maximum willingness to pay for a QALY of 20000 pound (mean -651 pound, 95% CI -878 pound to -424) pound or 30000 pound (mean -585 pound, 95% CI -824 pound to -345) pound. Extensive sensitivity analyses confirmed the results. Conclusions This community-based occupational therapy intervention has a very low probability of being cost-effective.	[Pizzo, Elena] UCL, Dept Appl Hlth Res, London, England; [Wenborn, Jennifer; King, Michael] UCL, Div Psychiat, London, England; [Wenborn, Jennifer; Burgess, Jane] North East London NHS Fdn Trust NELFT, Res & Dev Dept, London, England; [Mundy, Jacqueline] North East London NHS Fdn Trust NELFT, Essex Stroke Hub Team, London, England; [Orrell, Martin] Univ Nottingham, Inst Mental Hlth, Nottingham, England; [King, Michael; Omar, Rumana] UCL, Fac Brain Sci, Priment Clin Trials Unit, London, England; [Omar, Rumana] UCL, Dept Stat Sci, London, England; [Morris, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England	University of London; University College London; University of London; University College London; University of Nottingham; University of London; University College London; University of London; University College London; University of Cambridge	Pizzo, E (corresponding author), UCL, Dept Appl Hlth Res, London, England.	e.pizzo@ucl.ac.uk		Omar, Rumana/0000-0003-1483-1932; Orrell, Martin/0000-0002-1169-3530; Burgess, Jane/0000-0002-4626-6424; Pizzo, Elena/0000-0003-0790-7505	National Institute for Health Research (NIHR) under Programme Grants for Applied Research Programme [RP-PG0610-10108]; National Institute for Health Research (NIHR) ARC North Thames	National Institute for Health Research (NIHR) under Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR)); National Institute for Health Research (NIHR) ARC North Thames	This study is funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference number RP-PG0610-10108), awarded to MO and co-applicants MK, RO, SM, and JW. EP was supported by the National Institute for Health Research (NIHR) ARC North Thames. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	AgeUK, US; Ahmadi-Abhari S, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2856; Alzheimer's Society, 2014, DEM 2014 OPP CHANG; Alzheimers Society, 2018, DEM FRIENDL UT GUID; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, VFourth; BMA  RPSGB, 2017, BRIT NATL FORMULARY; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Briggs AH, 1999, BRIT MED J, V319, P635, DOI 10.1136/bmj.319.7210.635; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Bucks RS, 1996, AGE AGEING, V25, P113, DOI 10.1093/ageing/25.2.113; Curtis L, 2017, UNIT COSTS HLTH SOCI, DOI DOI 10.22024/UNIKENT/01.02.79286; Devlin NJ, 2018, HEALTH ECON, V27, P7, DOI 10.1002/hec.3564; Graff MJL, 2007, J GERONTOL A-BIOL, V62, P1002, DOI 10.1093/gerona/62.9.1002; Graff MJL, 2008, BMJ-BRIT MED J, V336, P134, DOI 10.1136/bmj.39408.481898.BE; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Gronlie S., 2006, ISLENDINGABOK KRISTN; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Morris S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007382; National Institute for Health and Care Excellence, 2018, DEM ASS MAN SUPP PEO; NHS, NHS EMPL; NHS England, 2017, NAT PRIC NAT TAR WOR; NICE, 2021, GUIDE METHODS TECHNO; ONS, ONS SER GDP DEFL MAR; ONS Office for National, 2017, UK LAB MARK; Rowen D, 2012, VALUE HEALTH, V15, P346, DOI 10.1016/j.jval.2011.10.016; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Smith SC, 2005, INT J GERIATR PSYCH, V20, P889, DOI 10.1002/gps.1374; Smith SC, 2005, HEALTH TECHNOL ASSES, V9, P1; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Thokala P, 2020, J MANAG CARE SPEC PH, V26, P1162, DOI 10.18553/jmcp.2020.26.9.1162; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Voigt-Radloff S, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000096; Wenborn J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003433; Wenborn J, 2016, TRIALS, V17, DOI 10.1186/s13063-015-1150-y; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	35	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2022	17	2							e0262828	10.1371/journal.pone.0262828	http://dx.doi.org/10.1371/journal.pone.0262828			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M6VZ	35148329	Green Published, gold			2023-01-03	WOS:000800108800013
J	Jiang, CL; Zheng, Q				Jiang, Chunling; Zheng, Qiang			Outcomes of peritoneal dialysis in elderly vs non-elderly patients: A systemic review and meta-analysis	PLOS ONE			English	Review							QUALITY-OF-LIFE; CLINICAL-OUTCOMES; TECHNIQUE FAILURE; KIDNEY-DISEASE; RISK-FACTORS; SURVIVAL; MODALITY; HEMODIALYSIS; EXPERIENCES; PREDICTORS	Objectives Several studies have compared outcomes of peritoneal dialysis (PD) between elderly and non-elderly patients but with variable results. We hereby designed this review to compare mortality, peritonitis, and technique survival between elderly and non-elderly patients on PD. Methods PubMed, Embase, and Google Scholar were searched for studies comparing outcomes of PD between elderly and non-elderly patients. The last search date was 14th July 2021. Results Fourteen studies were included. 12 studies defined the elderly as >= 65 years of age and these were included in the meta-analysis. Pooled analysis of crude (RR: 2.45 95% CI: 1.36, 4.40 I-2 = 97% p = 0.003) and adjusted data (HR: 2.80 95% CI: 2.45, 3.09 I-2 = 0% p<0.00001) indicated a statistically significant increased risk of mortality amongst elderly patients as compared to non-elderly patients. Meta-analysis of four studies demonstrated a statistically significant increased risk of peritonitis in the elderly (RR: 1.56 95% CI: 1.18, 2.07 I-2 = 76% p = 0.002). Pooled analysis demonstrated no statistically significant difference in technique survival between the two groups (RR: 0.95 95% CI: 0.86, 1.05 I-2 = 86% p = 0.32). Conclusion Elderly patients on PD have a significantly increased risk of mortality as compared to non-elderly patients. The risk of peritonitis is also significantly increased in older adults but the increased age has no impact on technique survival. Further studies are needed to strengthen our conclusions.	[Jiang, Chunling; Zheng, Qiang] Jiangsu Univ, Dept Nephrol, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China	Jiangsu University	Jiang, CL (corresponding author), Jiangsu Univ, Dept Nephrol, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China.	jcl98@163.com						Auguste BL, 2019, CAN J KIDNEY HEALTH, V6, DOI 10.1177/2054358119871031; Basile C, 2019, J NEPHROL, V32, P741, DOI 10.1007/s40620-019-00611-4; Berger JR, 2016, ADV CHRONIC KIDNEY D, V23, P36, DOI 10.1053/j.ackd.2015.08.005; Brown EA, 2017, KIDNEY INT, V91, P294, DOI 10.1016/j.kint.2016.08.026; Castrale C, 2010, NEPHROL DIAL TRANSPL, V25, P255, DOI 10.1093/ndt/gfp375; Cheng CH, 2013, NEPHROLOGY, V18, P468, DOI 10.1111/nep.12090; De Vecchi AF, 1998, AM J KIDNEY DIS, V31, P479, DOI 10.1053/ajkd.1998.v31.pm9506685; Duquennoy S, 2016, PERITON DIALYSIS INT, V36, P291, DOI 10.3747/pdi.2014.00154; Fernandez Maria A, 2004, Adv Perit Dial, V20, P128; Han SS, 2015, CLIN J AM SOC NEPHRO, V10, P983, DOI 10.2215/CJN.05160514; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Hiramatsu M, 2012, CONTRIB NEPHROL, V177, P48, DOI 10.1159/000336935; Htay H, 2019, PERITON DIALYSIS INT, V39, P163, DOI 10.3747/pdi.2018.00056; Hung CC, 2009, INT J CLIN PRACT, V63, P254, DOI 10.1111/j.1742-1241.2006.01216.x; Jeloka T, 2016, Indian J Nephrol, V26, P23, DOI 10.4103/0971-4065.157801; Joshi U, 2014, PERITON DIALYSIS INT, V34, P299, DOI 10.3747/pdi.2012.00209; Kim H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131393; Lai S, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011953; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Li PKT, 2007, PERITON DIALYSIS INT, V27, pS196; Lim WH, 2011, PERITON DIALYSIS INT, V31, P663, DOI 10.3747/pdi.2010.00209; Lyasere OU, 2016, CLIN J AM SOC NEPHRO, V11, P423, DOI 10.2215/CJN.01050115; Amaral TLM, 2019, REV SAUDE PUBL, V53, DOI [10.11606/S1518-8787.2019053000727, 10.11606/s1518-8787.2019053000727]; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nessim SJ, 2009, CLIN J AM SOC NEPHRO, V4, P135, DOI 10.2215/CJN.02060508; Perez-Contreras J, 2000, Adv Perit Dial, V16, P267; Portoles J, 2021, NEFROLOGIA, V41, P529, DOI 10.1016/j.nefro.2020.10.010; Sakai K, 2018, CONTRIB NEPHROL, V196, P141, DOI 10.1159/000485714; Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014; See EJ, 2018, AM J KIDNEY DIS, V72, P188, DOI 10.1053/j.ajkd.2017.10.019; Smyth A, 2012, INT UROL NEPHROL, V44, P283, DOI 10.1007/s11255-011-9973-2; Song QH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94032-8; Song YH, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02026-x; Taveras Ana E, 2012, Adv Perit Dial, V28, P84; Vesga JI, 2021, KIDNEY MED, V3, P335, DOI 10.1016/j.xkme.2020.12.010; Wang Z, 2015, KIDNEY BLOOD PRESS R, V40, P298, DOI 10.1159/000368505; Wells GA, NEWCASTLE OTTAWA SCA; Wu HS, 2020, PERITON DIALYSIS INT, V40, P26, DOI 10.1177/0896860819879868; Wu HS, 2016, PERITON DIALYSIS INT, V36, P640, DOI 10.3747/pdi.2015.00203; Xu R, 2012, PERITON DIALYSIS INT, V32, P94, DOI 10.3747/pdi.2010.00213; Yang X, 2007, INT UROL NEPHROL, V39, P1295, DOI 10.1007/s11255-007-9279-6; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6	42	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0263534	10.1371/journal.pone.0263534	http://dx.doi.org/10.1371/journal.pone.0263534			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134073	Green Published, gold			2023-01-03	WOS:000798968600018
J	Faulkner, SM; Drake, RJ; Ogden, M; Gardani, M; Bee, PE				Faulkner, Sophie M.; Drake, Richard J.; Ogden, Margaret; Gardani, Maria; Bee, Penny E.			A mixed methods expert opinion study on the optimal content and format for an occupational therapy intervention to improve sleep in schizophrenia spectrum disorders	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; CIRCADIAN-RHYTHM DISRUPTION; QUALITATIVE RESEARCH; PATIENT EXPERIENCE; DELPHI TECHNIQUE; ASSESSOR-BLIND; MENTAL-HEALTH; LIGHT THERAPY; SAMPLE-SIZE; INSOMNIA	Introduction People with schizophrenia spectrum disorder diagnoses commonly have poor sleep, which predicts various negative outcomes. The problems are diverse, including substantial circadian dysregulation, sleep-wake timing issues, hypersomnia (excessive sleep), and more classic insomnia. Methods This paper reports on a mixed methods expert opinion study based on the principles of Delphi methodology. The study examines and explores opinion on the optimal contents and format for an occupational therapy intervention to improve poor sleep in this population. Views of clinical and academic topic experts (n = 56), were elicited, examined and explored in three rounds, views from previous rounds being presented back to participants in subsequent rounds. Participants with relevant personal experience (n = 26) then rated and commented on suggestions, with a focus on acceptability. Descriptive statistics and graphs of ratings were triangulated with qualitative content analysis of free-text. Results Participants emphasised the central importance of intervention personalisation, although the manner and extent of personalisation suggested varied. Many components and domains were acknowledged as important, with the challenge being how to keep such an intervention simple, brief, and feasible for end-users, for sustainable implementation. The strongest consensus was to address evening routine, daytime activity, and environmental interventions. Relaxation, mindfulness, thermoregulation, sensory factors, and cognitive or psychological approaches were rated as less important. There was disagreement on whether to include time in bed restriction, and how to address napping, as well as how far to address medication timing. Clinicians and researchers advocated some version of stimulus control, but participants with personal experience reported low levels of acceptability for this, describing entirely negative experiences using 'the 15-minute rule' (part of stimulus control). Conclusion These results are informative for clinicians treating sleep problems in people with schizophrenia and related conditions, as well as for decision makers considering the potential contribution of the profession of occupational therapy toward sleep treatment.	[Faulkner, Sophie M.; Drake, Richard J.; Bee, Penny E.] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Faulkner, Sophie M.; Drake, Richard J.; Ogden, Margaret] Greater Manchester Mental Hlth NHS Fdn Trust, Manchester, Lancs, England; [Gardani, Maria] Univ Edinburgh, Sch Hlth Social Sci, Edinburgh, Midlothian, Scotland	University of Manchester; University of Edinburgh	Faulkner, SM (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.; Faulkner, SM (corresponding author), Greater Manchester Mental Hlth NHS Fdn Trust, Manchester, Lancs, England.	sophine.faulkner@manchester.ac.uk			National Institute for Health Research [ICA-CDRF-2016-02-007]; Health Education England [ICA-CDRF-2016-02-007]	National Institute for Health Research(National Institute for Health Research (NIHR)); Health Education England	This report is independent research arising from a Clinical Doctoral Research Fellowship, awarded to SF (NIHR award identifier: ICA-CDRF-2016-02-007) supported by the National Institute for Health Research and Health Education England (www.nihr.ac.uk).The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, Health Education England or the Department of Health. The funder commented on study design at the stage of funding application. The funder had no role in data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JR, 2006, COMMUNITY MENT HLT J, V42, P87, DOI 10.1007/s10597-005-9005-8; Barrett EA, 2020, COMPR PSYCHIAT, V103, DOI 10.1016/j.comppsych.2020.152207; Bennett-Levy J, 2006, BEHAV COGN PSYCHOTH, V34, P57, DOI 10.1017/S1352465805002420; Berry N, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-018-1979-1; Bird V, 2010, BRIT J PSYCHIAT, V197, P350, DOI 10.1192/bjp.bp.109.074526; Birken Mary, 2018, Pilot Feasibility Stud, V4, P81, DOI 10.1186/s40814-018-0267-7; Boddy CR, 2016, QUAL MARK RES, V19, P426, DOI 10.1108/QMR-06-2016-0053; Bradley J, 2018, BEHAV COGN PSYCHOTH, V46, P276, DOI 10.1017/S1352465817000601; Brandt J, 2017, DRUGS R&D, V17, P493, DOI 10.1007/s40268-017-0207-7; Chan MS, 2017, SLEEP MED REV, V32, P69, DOI 10.1016/j.smrv.2016.03.001; Chern JS, 1996, AM J OCCUP THER, V50, P516, DOI 10.5014/ajot.50.7.516; Chiu VW, 2018, PSYCHIAT RES, V268, P279, DOI 10.1016/j.psychres.2018.07.027; Chiu VW, 2015, J NERV MENT DIS, V203, P798, DOI 10.1097/NMD.0000000000000370; Creek J, 2005, BRIT J OCCUPATIONAL, V68, P281; Dahlgren GH, 2015, J VACAT MARK, V21, P318, DOI 10.1177/1356766715577503; Danielsson K, 2016, BEHAV SLEEP MED, V14, P212, DOI 10.1080/15402002.2014.981817; Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002; Elo S, 2014, SAGE OPEN, V4, DOI 10.1177/2158244014522633; Farrell NR, 2013, J ANXIETY DISORD, V27, P781, DOI 10.1016/j.janxdis.2013.09.003; Faulkner S, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1329-8; Faulkner S, 2015, BRIT J OCCUP THER, V78, P516, DOI 10.1177/0308022614564771; Faulkner SM, 2020, SLEEP HEALTH, V6, P690, DOI 10.1016/j.sleh.2020.01.014; Faulkner SM, 2019, SLEEP MED REV, V46, P108, DOI 10.1016/j.smrv.2019.04.012; Fiddick L, 2020, MENT HEALTH REV J, V25, P185, DOI 10.1108/MHRJ-04-2019-0013; Freeman D, 2015, LANCET PSYCHIAT, V2, P975, DOI 10.1016/S2215-0366(15)00314-4; Fung C, 2013, BRIT J OCCUP THER, V76, P384, DOI 10.4276/030802213X13757040168432; Geiger-Brown JM, 2015, SLEEP MED REV, V23, P54, DOI 10.1016/j.smrv.2014.11.007; Gooley JJ, 2008, ANN ACAD MED SINGAP, V37, P669; Gradisar M, 2011, SLEEP, V34, P1671, DOI 10.5665/sleep.1432; Green A., 2015, OCCUPATIONAL THERAPI; Hardaker L, 2007, ADV MENT HEALTH, V6, P194, DOI 10.5172/jamh.6.3.194; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hawton K, 2016, LANCET PSYCHIAT, V3, P740, DOI 10.1016/S2215-0366(16)30070-0; Hsu C., 2007, THE DELPHI TECHNIQUE, P12; Hutchison KJ, 2012, J EVAL CLIN PRACT, V18, P984, DOI 10.1111/j.1365-2753.2012.01905.x; Hwang DK, 2019, PSYCHIAT RES, V274, P182, DOI 10.1016/j.psychres.2019.02.002; Jacobson S, 2011, HARLEY THERAPY COUNS; Jagannath A, 2013, CURR OPIN NEUROBIOL, V23, P888, DOI 10.1016/j.conb.2013.03.008; Jolley S, 2015, BEHAV RES THER, V64, P24, DOI 10.1016/j.brat.2014.11.006; Keeney S, 2006, J ADV NURS, V53, P205, DOI 10.1111/j.1365-2648.2006.03716.x; Keeney S, 2001, INT J NURS STUD, V38, P195, DOI 10.1016/S0020-7489(00)00044-4; Kielhofner G., 2008, MODEL HUMAN OCCUPATI, V4; Kinn LG, 2009, AUST OCCUP THER J, V56, P112, DOI 10.1111/j.1440-1630.2007.00714.x; Kripke DF, 2016, DRUG SAFETY, V39, P93, DOI 10.1007/s40264-015-0362-0; Krumpal I, 2013, QUAL QUANT, V47, P2025, DOI 10.1007/s11135-011-9640-9; Kumar PNS, 2007, J CLIN PSYCHIAT, V68, P237, DOI 10.4088/JCP.v68n0208; Kyle SD, 2011, SLEEP MED, V12, P735, DOI 10.1016/j.sleep.2011.03.016; Lemyre A, 2020, SLEEP MED REV, V50, DOI 10.1016/j.smrv.2019.101253; Louis R, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0088-2017; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Maurer LF, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa096; Meyer N., BMJ OPEN RESP RES PP, V6, DOI [10.1136/bmjresp-2019-bssconf.29, DOI 10.1136/BMJRESP-2019-BSSCONF.29]; Meyer N, 2020, SCHIZOPHRENIA BULL, V46, P1126, DOI 10.1093/schbul/sbaa024; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Migiro SO, 2011, AFR J BUS MANAGE, V5, P3757; Mishima K, 2017, SLEEP BIOL RHYTHMS, V15, P11, DOI 10.1007/s41105-016-0076-4; Mishra A, 2020, EUR NEUROPSYCHOPHARM, V31, P109, DOI 10.1016/j.euroneuro.2019.11.008; Monti JM, 2017, SLEEP MED REV, V33, P51, DOI 10.1016/j.smrv.2016.05.002; Morgan D L, 1993, Qual Health Res, V3, P112, DOI 10.1177/104973239300300107; Morin CM, 2003, PSYCHOSOM MED, V65, P259, DOI 10.1097/01.PSY.0000030391.09558.A3; Munch Mirjam, 2012, Dialogues Clin Neurosci, V14, P448; Murphy MK., 1998, HLTH TECHNOLOGY ASSE, V2, pi, DOI [10.3310/hta2030, DOI 10.3310/HTA2030]; Nakamura M, 2003, PSYCHIAT CLIN NEUROS, V57, P472, DOI 10.1046/j.1440-1819.2003.01150.x; National Centre for Mental Health, 2019, SLEEP PROBLEMS MANAG; Ochoa S, 2012, SCHIZOPHR RES TREAT, V2012, DOI 10.1155/2012/916198; Oliveira P, 2019, PHARMACOPSYCHIATRY, V52, P165, DOI 10.1055/a-0658-1645; Ozawa S, 2014, HEALTH POLICY PLANN, V29, P323, DOI 10.1093/heapol/czt019; Paterson M., 2005, BRIT J OCCUP THER, V68, P409, DOI [10.1177/030802260506800905, DOI 10.1177/030802260506800905]; Pentland D., 2018, OCCUPATIONAL THERAPY; Phillips AJK, 2019, P NATL ACAD SCI USA, V116, P12019, DOI 10.1073/pnas.1901824116; Poulin J, 2010, PSYCHIAT RES, V179, P274, DOI 10.1016/j.psychres.2009.08.009; Pritchett D, 2012, J NEURAL TRANSM, V119, P1061, DOI 10.1007/s00702-012-0817-8; Prytys M, 2011, CLIN PSYCHOL PSYCHOT, V18, P48, DOI 10.1002/cpp.691; Ramos J, SLEEP BETTER, DOI [10.31988/scitrends.8002, DOI 10.31988/SCITRENDS.8002]; Rehman A, 2017, PSYCHOSIS, V9, P129, DOI 10.1080/17522439.2016.1206955; Robillard Rebecca, 2012, Clin Psychopharmacol Neurosci, V10, P1, DOI 10.9758/cpn.2012.10.1.1; Robinson OC, 2014, QUAL RES PSYCHOL, V11, P25, DOI 10.1080/14780887.2013.801543; Roley Susanne Smith, 2008, Am J Occup Ther, V62, P625; Shamir E, 2000, J CLIN PSYCHIAT, V61, P373, DOI 10.4088/JCP.v61n0509; Sheaves B, HAVING TROUBLE YOUR; Sheaves B, 2018, PSYCHOL MED, V48, P1694, DOI 10.1017/S0033291717003191; Sim J, 2018, INT J SOC RES METHOD, V21, P619, DOI 10.1080/13645579.2018.1454643; SMITH NR, 1986, AM J OCCUP THER, V40, P278, DOI 10.5014/ajot.40.4.278; Solet JM, 2014, WILLARD SPACKMANS OC, V12th, P714; Sweetman A, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa002; Taylor RR., 2017, KIELHOFNERS RES OCCU, V2nd, P1; Teddlie C, 2007, J MIX METHOD RES, V1, P77, DOI 10.1177/2345678906292430; Tickle-Degnen L, 2002, AM J OCCUP THER, V56, P470, DOI 10.5014/ajot.56.4.470; Trevelyan EG, 2015, EUR J INTEGR MED, V7, P423, DOI 10.1016/j.eujim.2015.07.002; van Straten A, 2018, SLEEP MED REV, V38, P3, DOI 10.1016/j.smrv.2017.02.001; Vandelanotte C, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-27; Varma S., 2016, MEDICINE, V44, P764; Waite F, 2020, SCHIZOPHR RES, V221, P44, DOI 10.1016/j.schres.2019.11.014; Waite F, 2016, BEHAV COGN PSYCHOTH, V44, P273, DOI 10.1017/S1352465815000430; Waite F, 2016, PSYCHOL PSYCHOTHER-T, V89, P181, DOI 10.1111/papt.12073; Waller G, 2016, BEHAV RES THER, V77, P129, DOI 10.1016/j.brat.2015.12.005; Waters F, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00990; WEINSTEIN BD, 1993, THEOR MED, V14, P57, DOI 10.1007/BF00993988; Williams I, 2016, AUST J PUBL ADMIN, V75, P149, DOI 10.1111/1467-8500.12155; Wood L, 2018, PSYCHIAT RES, V262, P303, DOI 10.1016/j.psychres.2017.12.030; Wu JQ, 2015, JAMA INTERN MED, V175, P1461, DOI 10.1001/jamainternmed.2015.3006; Wulff K, 2006, CHRONOBIOL INT, V23, P485, DOI 10.1080/07420520500545987; Wulff K, 2012, BRIT J PSYCHIAT, V200, P308, DOI 10.1192/bjp.bp.111.096321; Wulff K, 2011, BRIT J PSYCHIAT, V198, P250, DOI 10.1192/bjp.bp.110.085068; Wulff K, 2009, CURR OPIN GENET DEV, V19, P237, DOI 10.1016/j.gde.2009.03.007; Zilcha-Mano S, 2018, COGNITIVE THER RES, V42, P146, DOI 10.1007/s10608-017-9866-5	106	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269453	10.1371/journal.pone.0269453	http://dx.doi.org/10.1371/journal.pone.0269453			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35666738	gold, Green Published			2023-01-03	WOS:000843567600107
J	Masugi, Y; Kawai, H; Ejiri, M; Hirano, H; Fujiwara, Y; Tanaka, T; Iijima, K; Inomata, T; Obuchi, SP				Masugi, Yohei; Kawai, Hisashi; Ejiri, Manami; Hirano, Hirohiko; Fujiwara, Yoshinori; Tanaka, Tomoki; Iijima, Katsuya; Inomata, Takashi; Obuchi, Shuichi P.			Early strong predictors of decline in instrumental activities of daily living in community-dwelling older Japanese people	PLOS ONE			English	Article							MINI-MENTAL-STATE; FUNCTIONAL DEPENDENCE; WALKING SPEED; DISABILITY; VALIDITY; RELIABILITY; POPULATION; IMPAIRMENT; SARCOPENIA; UTILITY	ObjectiveOur aim is to determine the strong predictors of the onset of instrumental activities of daily living (IADL) decline in community-dwelling older people. DesignA prospective cohort study with a two-year follow-up. SettingKashiwa City, Chiba Prefecture, Japan and Toshima Ward, Tokyo Metropolitan, Japan. ParticipantsThe data were acquired from two cohorts. The final sample comprised 1,523 community-dwelling older people aged 65-94 years (681 men, 842 women). They were individuals who were independent in IADL at baseline and participated in follow-up IADL assessments two years later. MeasurementsAt baseline, comprehensive assessments were performed including: health interview, gait function, hand-grip strength, skeletal muscle mass, balance function, oral function, dietary lifestyle, cognitive function, quality of life, mental status, and social network. When the two-year follow-up was performed, IADL declines were observed in 53 out of 1,523 people. The association of each Z-transformed parameter with the occurrence of IADL decline was examined by employing a binominal logistic regression model adjusting for age, gender, body weight, body height, and medical history. An odds ratio (OR) and a 95% confidence interval were calculated and compared between different parameters. ResultsA decrease in walking speed and one-legged stance time, whereas an increased timed up & go test time was associated with significant ORs for the occurrence of IADL decline. ConclusionGait-related parameters appear to be the strong predictors of the onset of IADL decline in community-dwelling older people.	[Masugi, Yohei; Kawai, Hisashi; Ejiri, Manami; Hirano, Hirohiko; Fujiwara, Yoshinori; Inomata, Takashi; Obuchi, Shuichi P.] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan; [Tanaka, Tomoki; Iijima, Katsuya] Univ Tokyo, Inst Gerontol, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tokyo	Obuchi, SP (corresponding author), Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.	obuchipc@tmig.or.jp		Ejiri, Manami/0000-0003-3544-4587; Kawai, Hisashi/0000-0003-3015-6041	Ministry of Health, Labour and Welfare of Japan [H24-Choju-Ippan-002, H25-Choju-Ippan-005, H26-Choju-Itaku]; Japan Agency for Medical Research and Development [15dk0107013h0002, 16dk0110013h0003]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	The project via which data were collected was supported by Health and Labor Sciences Research Grants (H24-Choju-Ippan-002, H25-Choju-Ippan-005) from the Ministry of Health, Labour and Welfare of Japan, 2014 Health and Labour Sciences Research Grants (H26-Choju-Itaku) from the Ministry of Health, Labour and Welfare of Japan, 2015-2016the Research and Development Grants for Longevity Science from the Japan Agency for Medical Research and Development (15dk0107013h0002, 16dk0110013h0003).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awata S, 2007, INT PSYCHOGERIATR, V19, P77, DOI 10.1017/S1041610206004212; Balzi D, 2010, AGE AGEING, V39, P92, DOI 10.1093/ageing/afp209; den Ouden MEM, 2013, J AM MED DIR ASSOC, V14, P18, DOI 10.1016/j.jamda.2012.08.014; Dewolf AH, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.749366; Drusini AG, 2002, AGING CLIN EXP RES, V14, P42; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ford GR, 1996, J GERONTOL A-BIOL, V51, pM185, DOI 10.1093/gerona/51A.4.M185; Franz JR, 2016, EXERC SPORT SCI REV, V44, P129, DOI 10.1249/JES.0000000000000086; Fujiwara Y, 2003, ARCH GERONTOL GERIAT, V36, P141, DOI 10.1016/S0167-4943(02)00081-X; Gobbens Robbert J J, 2014, Curr Gerontol Geriatr Res, V2014, P358137, DOI 10.1155/2014/358137; Gueugnon M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00173; Ishii S, 2014, GERIATR GERONTOL INT, V14, P93, DOI 10.1111/ggi.12197; Ishizaki T, 2000, J AM GERIATR SOC, V48, P1424, DOI 10.1111/j.1532-5415.2000.tb02632.x; Ishizaki T, 2006, ARCH GERONTOL GERIAT, V42, P47, DOI 10.1016/j.archger.2005.06.001; Judge JO, 1996, J AM GERIATR SOC, V44, P1332, DOI 10.1111/j.1532-5415.1996.tb01404.x; Kera T, 2017, GERIATR GERONTOL INT, V17, P2602, DOI 10.1111/ggi.13119; Kera T, 2016, RESP CARE, V61, P1644, DOI 10.4187/respcare.04609; Kong DX, 2019, J AM GERIATR SOC, V67, pS538, DOI 10.1111/jgs.15801; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Kumagai Shu, 2003, Nihon Koshu Eisei Zasshi, V50, P1117; Kurimoto Ayumi, 2011, Nihon Ronen Igakkai Zasshi, V48, P149; LAWTON MP, 1970, GERONTOLOGIST, V10, P38, DOI 10.1093/geront/10.1_Part_1.38; Li G, 2017, J AM GERIATR SOC, V65, P2627, DOI 10.1111/jgs.15077; Middleton A, 2015, J AGING PHYS ACTIV, V23, P314, DOI 10.1123/japa.2013-0236; Millan-Calenti JC, 2010, ARCH GERONTOL GERIAT, V50, P306, DOI 10.1016/j.archger.2009.04.017; Millan-Calenti JC, 2012, ARCH GERONTOL GERIAT, V54, P197, DOI 10.1016/j.archger.2011.02.010; Reas ET, 2017, AM J GERIAT PSYCHIAT, V25, P889, DOI 10.1016/j.jagp.2017.03.008; Shinkai S, 2000, AGE AGEING, V29, P441, DOI 10.1093/ageing/29.5.441; Shinkai S., 2003, GERIATR GERONTOL INT, V3, pS31, DOI [DOI 10.1111/J.1444-0594.2003.00094.X, 10.1111/j.1444-0594.2003.00094.x]; Sugishita K, 2017, CLIN GERONTOLOGIST, V40, P233, DOI 10.1080/07317115.2016.1199452; Suzuki T, 2021, REJUV RES, V24, P37, DOI 10.1089/rej.2019.2291; Tanaka T, 2018, J GERONTOL A-BIOL, V73, P1661, DOI 10.1093/gerona/glx225; Vermeulen J, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-33	33	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266614	10.1371/journal.pone.0266614	http://dx.doi.org/10.1371/journal.pone.0266614			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6EQ	35381051	gold, Green Published			2023-01-03	WOS:000804820900033
J	Tetteh, J; Adomako, I; Udofia, EA; Yarney, E; Quansah, H; Yawson, AO; Essuman, A; Yawson, AE				Tetteh, John; Adomako, Isaac; Udofia, Emilia Asuquo; Yarney, Elom; Quansah, Henry; Yawson, Anita Ohenewa; Essuman, Akye; Yawson, Alfred Edwin			Hygienic disposal of stools and risk of diarrheal episodes among children aged under two years: Evidence from the Ghana Demographic Health Survey, 2003-2014	PLOS ONE			English	Article								Background Most childhood diarrheal illnesses are a result of the faeco-oral transmission of infected food, water, and unclean fingers. The present paper was conducted to estimate the prevalence of hygienic disposal of stools (HDS) and its associated factors, and further quantify the impact of HDS on diarrheal diseases among children under two years. Methods A cross-sectional design was used to evaluate three rounds of the Ghana Demographic Health Survey (GDHS) from 2003-2014 involving 4869 women with children aged under two years. The outcomes were prevalence of HDS and diarrheal diseases. Poisson regression model was employed to assess risk factors associated with HDS and dominance analysis was used to rank the important risk factors. Inverse Probability Weighting Poisson Regression Adjustment (IPWPRA) with Propensity Score 1:1 density kernel-based matching was employed to assess impact. Results The pooled prevalence rate of HDS was 26.5%(95%CI = 24.6-28.4) and it ranged from 18.7% (95%CI = 16.4-21.2) in 2014 to 38.8%(95%CI = 35.3-42.4) in 2003. Diarrhea diseases pooled prevalence was 17.9%(95%CI = 16.4-19.5) and ranged from 13.3%(95%CI = 11.1-15.9) in 2014 to 25.4%(95%CI = 22.2-28.9) in 2003. The overall growth rate for HDS and prevalence of diarrhea diseases, decreased by 21.6% and 11.4% respectively. The most important risk factors of HDS from dominance analysis included; age of the child, wealth index, and differences in region. From pooled data wealth index, increasing age of the child, and regional disparity constituted approximately 72% of the overall impact (Weighted Standardized Dominance Statistics (WSDS) = 0.30, 0.24, and 0.19 respectively). In 2014, they constituted approximately 79% (WSDS = 0.139, 0.177 and 0.471 respectively). The average prevalence of diarrheal diseases among children of women who practiced HDS reduced over the period of the GDHS compared to those whose mothers did not practice HDS [2008 ATE(95%CI) = -0.09(-0.16-0.02), 2014 ATE(95%CI) = -0.05(-0.09-0.01) and Pooled data ATE(95%CI) = -0.05(-0.09-0.02)]. Conclusion This analysis has provided empirical evidence of the impact of practicing HDS in Ghana from a national household survey. Implementation of the WASH agenda in this low-income setting requires a synergy of interventions and collaborations of actors (government, private and development partners) to improve water and sanitation facilities and to increase hygiene education to prevent the spread of diseases including diarrhea by 2025.	[Tetteh, John; Adomako, Isaac; Udofia, Emilia Asuquo; Yarney, Elom; Quansah, Henry; Essuman, Akye; Yawson, Alfred Edwin] Univ Ghana, Sch Med, Coll Hlth Sci, Dept Community Hlth, Accra, Ghana; [Yawson, Anita Ohenewa] Korle Bu Teaching Hosp, Dept Anaesthesia, Ground Floor Surg Intens Care Unit, Accra, Ghana; [Yawson, Anita Ohenewa] Univ Ghana, Sch Nursing & Midwifery, Coll Hlth Sci, Accra, Ghana	University of Ghana; University of Ghana	Tetteh, J (corresponding author), Univ Ghana, Sch Med, Coll Hlth Sci, Dept Community Hlth, Accra, Ghana.	jhtetteh@ug.edu.gh	Udofia, Emilia Asuquo/AAQ-6729-2020	Udofia, Emilia Asuquo/0000-0002-7279-1839; Tetteh, John/0000-0002-1986-4103				Asamoah A, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.1.6261; Azage M, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0090-z; Bawankule R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3948-2; Bezatu Mengistie, 2013, Open Journal of Preventive Medicine, V3, P446, DOI 10.4236/ojpm.2013.37060; Brown J, 2013, ARCH DIS CHILD, V98, P629, DOI 10.1136/archdischild-2011-301528; Martinez BAF, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00193; Ghana Statistical Service, 2014, GHANA DEMOGRAPHIC HL; Islam M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236163; Lamichhane P, 2018, INT HEALTH, V10, P277, DOI [10.1093/inthealth/ihy0, 10.1093/inthealth/ihy030]; Larbi RT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245466; Majorin F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089551; Mihrete TS, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-102; MLGRD, 1999, ENV SAN POL; MLGRD, 2001, ENV SAN POL; Morita T, 2016, TROP MED INT HEALTH, V21, P1403, DOI 10.1111/tmi.12773; Sahiledengle B, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7325-9; Seidu AA, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10155-7; Tetteh J, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100311; Tetteh J, 2018, J TROP MED-US, V2018, DOI 10.1155/2018/4863607; Tighe EL, 2014, READ WRIT, V27, P101, DOI 10.1007/s11145-013-9435-6; Tulchinsky T. H., 2014, TECH REP, P149, DOI DOI 10.1016/B978-0-12-415766-8.00004-5; UNICEF, 2014, CHILD FEC DISP NEP; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; WaterAid, TOTAL SANITATION SOC; WHO, 2021, DIARRH DIS; WHO, GUID SAN HLTH; WHO/UNICEF, 2017, JOINT MON PROGR JMP; World Health Organization, 2014, PREV DIARRH BETT WAT; World Health Organization, 2019, SAN; World Vision, 2021, SCAL UP SAN COV GHAN; WSP/UNICEF, 2015, WATER SUPPLY SANITAT	31	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266681	10.1371/journal.pone.0266681	http://dx.doi.org/10.1371/journal.pone.0266681			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390094	gold, Green Published			2023-01-03	WOS:000795077200109
J	Reynaud, A; Magdeleine, M; Patel, A; Gay, AS; Debayle, D; Abelanet, S; Antonny, B				Reynaud, Antoine; Magdeleine, Maud; Patel, Amanda; Gay, Anne-Sophie; Debayle, Delphine; Abelanet, Sophie; Antonny, Bruno			Tumor protein D54 binds intracellular nanovesicles via an extended amphipathic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CURVATURE; LIPID-MEMBRANES; ALPHA-SYNUCLEIN; WEB SERVER; MOTIF; TRANSPORT; VESICLES; ARFGAP1; FLAT; MECHANISMS	Tumor protein D54 (TPD54) is an abundant cytosolic pro-tein that belongs to the TPD52 family, a family of four proteins (TPD52, 53, 54, and 55) that are overexpressed in several cancer cells. Even though the functions of these proteins remain elusive, recent investigations indicate that TPD54 binds to very small cytosolic vesicles with a diameter of ca. 30 nm, half the size of classical (e.g., COPI and COPII) transport vesicles. Here, we investigated the mechanism of intracellular nanovesicle capture by TPD54. Bioinformatical analysis sug-gests that TPD54 contains a small coiled-coil followed by four amphipathic helices (AH1-4), which could fold upon binding to lipid membranes. Limited proteolysis, CD spectroscopy, tryp-tophan fluorescence, and cysteine mutagenesis coupled to co-valent binding of a membrane-sensitive probe showed that binding of TPD54 to small liposomes is accompanied by large structural changes in the amphipathic helix region. Further-more, site-directed mutagenesis indicated that AH2 and AH3 have a predominant role in TPD54 binding to membranes both in cells and using model liposomes. We found that AH3 has the physicochemical features of an amphipathic lipid packing sensor (ALPS) motif, which, in other proteins, enables mem-brane binding in a curvature-dependent manner. Accordingly, we observed that binding of TPD54 to liposomes is very sen-sitive to membrane curvature and lipid unsaturation. We conclude that TPD54 recognizes nanovesicles through a com-bination of ALPS-dependent and ALPS-independent mechanisms.	[Reynaud, Antoine; Magdeleine, Maud; Patel, Amanda; Gay, Anne-Sophie; Debayle, Delphine; Abelanet, Sophie; Antonny, Bruno] Univ Cote Azur, Inst Pharmacol Mol & Cellulaire, Nice, Valbonne, France; [Reynaud, Antoine; Magdeleine, Maud; Patel, Amanda; Gay, Anne-Sophie; Debayle, Delphine; Abelanet, Sophie; Antonny, Bruno] Inst Pharmacol Mol & Cellulaire, CNRS, Nice, Valbonne, France	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)	Antonny, B (corresponding author), Univ Cote Azur, Inst Pharmacol Mol & Cellulaire, Nice, Valbonne, France.; Antonny, B (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, Nice, Valbonne, France.	antonny@ipmc.cnrs.fr			Agence Nationale de la Recherche (ANR Grant) [195624]	Agence Nationale de la Recherche (ANR Grant)(French National Research Agency (ANR))	We thank S Miserey (institute Curie) , G Lenoir (Universite Paris Saclay) , and all lab members for support and helpful discussions. This work was supported by the Agence Nationale de la Recherche (ANR Grant #195624, Vesicle Filtering) .	Ambroggio E, 2010, EMBO J, V29, P292, DOI 10.1038/emboj.2009.341; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Antonny B, 2011, ANNU REV BIOCHEM, V80, P101, DOI 10.1146/annurev-biochem-052809-155121; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Boutros R, 2004, BIOCHEM BIOPH RES CO, V325, P1115, DOI 10.1016/j.bbrc.2004.10.112; Brier LW, 2019, MOL BIOL CELL, V30, P1098, DOI 10.1091/mbc.E18-11-0743; Cabrera M, 2010, J CELL BIOL, V191, P845, DOI 10.1083/jcb.201004092; Dell'Angelica EC, 2019, ANNU REV CELL DEV BI, V35, P131, DOI 10.1146/annurev-cellbio-100818-125234; Drin G, 2008, SCIENCE, V320, P670, DOI 10.1126/science.1155821; Drin G, 2007, NAT STRUCT MOL BIOL, V14, P138, DOI 10.1038/nsmb1194; Drin G, 2010, FEBS LETT, V584, P1840, DOI 10.1016/j.febslet.2009.10.022; Erdos G, 2021, NUCLEIC ACIDS RES, V49, pW297, DOI 10.1093/nar/gkab408; Fan W, 2011, P NATL ACAD SCI USA, V108, P7769, DOI 10.1073/pnas.1016472108; Garten M, 2015, PHYS CHEM CHEM PHYS, V17, P15589, DOI 10.1039/c5cp00244c; Gautier R, 2008, BIOINFORMATICS, V24, P2101, DOI 10.1093/bioinformatics/btn392; Gimenez-Andres M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030045; Goedhart J, 2021, MOL BIOL CELL, V32, P470, DOI 10.1091/mbc.E20-09-0583; Hatzakis NS, 2009, NAT CHEM BIOL, V5, P835, DOI 10.1038/nchembio.213; Ho RY, 2016, TRAFFIC, V17, P1078, DOI 10.1111/tra.12421; Horchani H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113484; Hu G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24773-7; Hurley JH, 2010, CELL, V143, P875, DOI 10.1016/j.cell.2010.11.030; Hutchings J, 2019, CURR OPIN CELL BIOL, V59, P104, DOI 10.1016/j.ceb.2019.04.002; Ishida T, 2007, NUCLEIC ACIDS RES, V35, pW460, DOI 10.1093/nar/gkm363; Jamecna D, 2019, DEV CELL, V49, P220, DOI 10.1016/j.devcel.2019.02.021; Jao CC, 2008, P NATL ACAD SCI USA, V105, P19666, DOI 10.1073/pnas.0807826105; Jensen MB, 2011, J BIOL CHEM, V286, P42603, DOI 10.1074/jbc.M111.271130; Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034; Knowles DG, 2019, J BIOL CHEM, V294, P15531, DOI 10.1074/jbc.RA119.009850; Krabben L, 2011, J NEUROSCI, V31, P18149, DOI 10.1523/JNEUROSCI.4345-11.2011; Larocque G, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009028; Larocque G, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201812044; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Magdeleine M, 2016, ELIFE, V5, DOI 10.7554/eLife.16988; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McCaughey J, 2019, TRENDS CELL BIOL, V29, P940, DOI 10.1016/j.tcb.2019.08.007; Mesmin B, 2007, BIOCHEMISTRY-US, V46, P1779, DOI 10.1021/bi062288w; Mesmin B, 2017, EMBO J, V36, P3156, DOI 10.15252/embj.201796687; Monje-Galvan V, 2018, J PHYS CHEM B, V122, P9713, DOI 10.1021/acs.jpcb.8b07067; Nordeen SA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19885-5; Ohashi Y, 2020, ELIFE, V9, DOI 10.7554/eLife.58281; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pranke IM, 2011, J CELL BIOL, V194, P88, DOI 10.1083/jcb.201011118; Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106; Sathasivam P, 2001, BIOCHEM BIOPH RES CO, V288, P56, DOI 10.1006/bbrc.2001.5721; Sato K, 2015, MOL BIOL CELL, V26, P537, DOI 10.1091/mbc.E14-10-1450; Tian A, 2009, BIOPHYS J, V96, P2676, DOI 10.1016/j.bpj.2008.11.067; Tunyasuvunakool K, 2021, NATURE, V596, P590, DOI 10.1038/s41586-021-03828-1; Vamparys L, 2013, BIOPHYS J, V104, P585, DOI 10.1016/j.bpj.2012.11.3836; van Hilten N, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00250; Vanni S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5916; Vanni S, 2013, BIOPHYS J, V104, P575, DOI 10.1016/j.bpj.2012.11.3837; von Filseck JM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7671; Wiedemann C, 2013, BIOINFORMATICS, V29, P1750, DOI 10.1093/bioinformatics/btt278; Wong M, 2017, BMC BIOL, V15, DOI 10.1186/s12915-016-0345-3; Wong M, 2014, SCIENCE, V346, P601, DOI 10.1126/science.1256898; Xu P, 2013, J CELL BIOL, V202, P875, DOI 10.1083/jcb.201305094; Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011; Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061; Zendeh-boodi Z, 2013, J BIOCHEM, V153, P573, DOI 10.1093/jb/mvt025; Zhang L, 2022, DEV CELL, V57, P750, DOI 10.1016/j.devcel.2022.02.021	65	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL	2022	298	7							102136	10.1016/j.jbc.2022.102136	http://dx.doi.org/10.1016/j.jbc.2022.102136			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	3E7NR	35714773	Green Published, gold			2023-01-03	WOS:000830168100008
J	Meyhoff, TS; Hjortrup, PB; Wetterslev, J; Sivapalan, P; Laake, JH; Cronhjort, M; Jakob, SM; Cecconi, M; Nalos, M; Ostermann, M; Malbrain, M; Pettila, V; Moller, MH; Kjaer, MBN; Lange, T; Overgaard-Steensen, C; Brand, BA; Winther-Olesen, M; White, JO; Quist, L; Westergaard, B; Jonsson, AB; Hjortso, CJS; Meier, N; Jensen, TS; Engstrom, J; Nebrich, L; Andersen-Ranberg, NC; Jensen, JV; Joseph, NA; Poulsen, LM; Herlov, LS; Solling, CG; Pedersen, SK; Knudsen, KK; Straarup, TS; Vang, ML; Bundgaard, H; Rasmussen, BS; Aagaard, SR; Hildebrandt, T; Russell, L; Bestle, MH; Schonemann-Lund, M; Brochner, AC; Elvander, CF; Hoffmann, SKL; Rasmussen, ML; Martin, YK; Friberg, FF; Seter, H; Aslam, TN; Adnoy, S; Seidel, P; Strand, K; Johnstad, B; Joelsson-Alm, E; Christensen, J; Ahlstedt, C; Pfortmueller, CA; Siegemund, M; Greco, M; Radej, J; Kriz, M; Gould, DW; Rowan, KM; Mouncey, PR; Perner, A				Meyhoff, T. S.; Hjortrup, P. B.; Wetterslev, J.; Sivapalan, P.; Laake, J. H.; Cronhjort, M.; Jakob, S. M.; Cecconi, M.; Nalos, M.; Ostermann, M.; Malbrain, M.; Pettila, V; Moller, M. H.; Kjaer, M-B N.; Lange, T.; Overgaard-Steensen, C.; Brand, B. A.; Winther-Olesen, M.; White, J. O.; Quist, L.; Westergaard, B.; Jonsson, A. B.; Hjortso, C. J. S.; Meier, N.; Jensen, T. S.; Engstrom, J.; Nebrich, L.; Andersen-Ranberg, N. C.; Jensen, J., V; Joseph, N. A.; Poulsen, L. M.; Herlov, L. S.; Solling, C. G.; Pedersen, S. K.; Knudsen, K. K.; Straarup, T. S.; Vang, M. L.; Bundgaard, H.; Rasmussen, B. S.; Aagaard, S. R.; Hildebrandt, T.; Russell, L.; Bestle, M. H.; Schonemann-Lund, M.; Brochner, A. C.; Elvander, C. F.; Hoffmann, S. K. L.; Rasmussen, M. L.; Martin, Y. K.; Friberg, F. F.; Seter, H.; Aslam, T. N.; Adnoy, S.; Seidel, P.; Strand, K.; Johnstad, B.; Joelsson-Alm, E.; Christensen, J.; Ahlstedt, C.; Pfortmueller, C. A.; Siegemund, M.; Greco, M.; Radej, J.; Kriz, M.; Gould, D. W.; Rowan, K. M.; Mouncey, P. R.; Perner, A.		CLASSIC Trial Grp	Restriction of Intravenous Fluid in ICU Patients with Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEPSIS; RESUSCITATION; MANAGEMENT; MORTALITY; PROTOCOL; TRIALS; ADULTS	BACKGROUND Intravenous fluids are recommended for the treatment of patients who are in septic shock, but higher fluid volumes have been associated with harm in patients who are in the intensive care unit (ICU). METHODS In this international, randomized trial, we assigned patients with septic shock in the ICU who had received at least 1 liter of intravenous fluid to receive restricted intravenous fluid or standard intravenous fluid therapy; patients were included if the onset of shock had been within 12 hours before screening. The primary outcome was death from any cause within 90 days after randomization. RESULTS We enrolled 1554 patients; 770 were assigned to the restrictive-fluid group and 784 to the standard-fluid group. Primary outcome data were available for 1545 patients (99.4%). In the ICU, the restrictive-fluid group received a median of 1798 ml of intravenous fluid (interquartile range, 500 to 4366); the standard-fluid group received a median of 3811 ml (interquartile range, 1861 to 6762). At 90 days, death had occurred in 323 of 764 patients (42.3%) in the restrictive-fluid group, as compared with 329 of 781 patients (42.1%) in the standard-fluid group (adjusted absolute difference, 0.1 percentage points; 95% confidence interval [CI], -4.7 to 4.9; P=0.96). In the ICU, serious adverse events occurred at least once in 221 of 751 patients (29.4%) in the restrictive-fluid group and in 238 of 772 patients (30.8%) in the standard-fluid group (adjusted absolute difference, -1.7 percentage points; 99% CI, -7.7 to 4.3). At 90 days after randomization, the numbers of days alive without life support and days alive and out of the hospital were similar in the two groups. CONCLUSIONS Among adult patients with septic shock in the ICU, intravenous fluid restriction did not result in fewer deaths at 90 days than standard intravenous fluid therapy.	[Meyhoff, T. S.; Hjortrup, P. B.; Sivapalan, P.; Moller, M. H.; Kjaer, M-B N.; Overgaard-Steensen, C.; Brand, B. A.; Winther-Olesen, M.; White, J. O.; Quist, L.; Westergaard, B.; Jonsson, A. B.; Hjortso, C. J. S.; Meier, N.; Jensen, T. S.; Perner, A.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark; [Wetterslev, J.; Engstrom, J.] Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark; [Lange, T.] Univ Copenhagen, Sect Biostat, Copenhagen, Denmark; [Hoffmann, S. K. L.] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Copenhagen, Denmark; [Nebrich, L.; Andersen-Ranberg, N. C.; Jensen, J., V; Joseph, N. A.; Poulsen, L. M.; Herlov, L. S.] Zealand Univ Hosp, Koge, Denmark; [Solling, C. G.; Pedersen, S. K.; Knudsen, K. K.; Straarup, T. S.] Viborg Hosp, Viborg, Denmark; [Vang, M. L.; Bundgaard, H.] Randers Cent Hosp, Randers, Denmark; [Rasmussen, B. S.; Aagaard, S. R.] Aalborg Univ, Aalborg Univ Hosp, Aalborg, Denmark; [Hildebrandt, T.; Russell, L.] Zealand Univ Hosp, Roskilde, Denmark; [Bestle, M. H.; Schonemann-Lund, M.] Copenhagen Univ Hosp North Zealand, Hillerod, Denmark; [Brochner, A. C.; Elvander, C. F.] Univ Southern Denmark, Kolding Hosp, Kolding, Denmark; [Rasmussen, M. L.] Herning Hosp, Herning, Denmark; [Laake, J. H.; Aslam, T. N.; Adnoy, S.] Oslo Univ Hosp, Oslo, Norway; [Martin, Y. K.; Friberg, F. F.; Seter, H.] Hosp Ostfold Kalnes, Gralum, Norway; [Seidel, P.; Strand, K.] Stavanger Univ Hosp, Stavanger, Norway; [Johnstad, B.] Hosp Innland Hamar, Hamar, Norway; [Cronhjort, M.; Joelsson-Alm, E.; Christensen, J.] Karolinska Inst, Dept Clin Sci & Educ, Sadersjukhuset, Sweden; [Ahlstedt, C.] Karolinska Univ Hosp, Huddinge, Sweden; [Jakob, S. M.; Pfortmueller, C. A.] Univ Bern, Inselspiral Bern Univ Hosp, Bern, Switzerland; [Siegemund, M.] Basel Univ Hosp, Basel, Switzerland; [Cecconi, M.; Greco, M.] Humanitas Univ, IRCCS Humanitas Res Hosp, Milan, Italy; [Nalos, M.; Radej, J.; Kriz, M.] Univ Hosp Plzen, Plzen, Czech Republic; [Ostermann, M.] Guys & St Thomas Hosp, London, England; [Gould, D. W.; Rowan, K. M.; Mouncey, P. R.] Intens Care Natl Audit & Res Ctr, Clin Trials Unit, London, England; [Malbrain, M.] Univ Hosp Brussels, Brussels, Belgium; [Pettila, V] Univ Helsinki, Helsinki, Finland; [Pettila, V] Helsinki Univ Hosp, Helsinki, Finland	Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; Aarhus University; Aarhus University; Aalborg University; Aalborg University Hospital; Kolding Hospital; University of Southern Denmark; Aarhus University; University of Oslo; Stavanger University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Bern; University of Basel; Humanitas University; University Hospital Plzen; Guy's & St Thomas' NHS Foundation Trust; Intensive Care National Audit & Research Centre; University Hospital Brussels; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Perner, A (corresponding author), Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	anders.perner@regionh.dk	Sivapalan, Praleene/GQZ-1594-2022; greco, massimiliano/GNM-8140-2022; Cecconi, Maurizio/A-6241-2012; Joelsson-Alm, Eva/L-6617-2019; Cecconi, Maurizio/HDN-8785-2022; Camporota, Luigi/G-2390-2017	Sivapalan, Praleene/0000-0002-0442-0032; greco, massimiliano/0000-0003-1003-4637; Cecconi, Maurizio/0000-0002-4376-6538; Joelsson-Alm, Eva/0000-0002-9041-2468; Cecconi, Maurizio/0000-0002-4376-6538; Camporota, Luigi/0000-0001-5600-1676; Herlov, Louise Stenbryggen/0000-0001-6638-1529; Friberg, Fredrik Femtehjell/0000-0003-2992-2327; Rasmussen, Bodil Steen/0000-0003-2190-145X; Lange, Theis/0000-0001-6807-8347; Gould, Doug/0000-0003-4148-3312; Hildebrandt, Thomas/0000-0001-7845-9899; Laake, Jon/0000-0001-6157-5359; Solling, Christoffer/0000-0003-0721-926X; Bestle, Morten/0000-0001-6585-2659; Rowan, Kathryn/0000-0001-8217-5602; Schefold, Joerg C./0000-0001-9162-5724; Mouncey, Paul/0000-0002-8510-8517; Cronhjort, Maria/0000-0002-0444-8553				Acheampong A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0970-1; Ait-Oufella H, 2011, INTENS CARE MED, V37, P801, DOI 10.1007/s00134-011-2163-y; Andersen PK, 2010, STAT BIOL HEALTH, P43; Andrews B, 2017, JAMA-J AM MED ASSOC, V318, P1233, DOI 10.1001/jama.2017.10913; Andrews B, 2014, CRIT CARE MED, V42, P2315, DOI 10.1097/CCM.0000000000000541; Bagshaw SM, 2020, NEW ENGL J MED, V383, P240, DOI 10.1056/NEJMoa2000741; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Evans L, 2021, INTENS CARE MED, V47, P1181, DOI 10.1007/s00134-021-06506-y; Finfer S, 2022, NEW ENGL J MED, V386, P815, DOI 10.1056/NEJMoa2114464; Granholm A, 2018, ACTA ANAESTH SCAND, V62, P336, DOI 10.1111/aas.13048; Hernandez G, 2019, JAMA-J AM MED ASSOC, V321, P654, DOI 10.1001/jama.2019.0071; Hjortrup PB, 2016, INTENS CARE MED, V42, P1695, DOI 10.1007/s00134-016-4500-7; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jakobsen JC, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-34; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P361, DOI 10.5603/AIT.2014.0060; Meyhoff TS, 2020, CHEST, V157, P1478, DOI 10.1016/j.chest.2019.11.050; Meyhoff TS, 2019, ACTA ANAESTH SCAND, V63, P1262, DOI 10.1111/aas.13434; Neuberg LG, 2003, ECONOMET THEOR, V19, P675, DOI 10.1017/S026646603004109; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Pettila V, 2016, INTENS CARE MED, V42, P1912, DOI 10.1007/s00134-016-4444-y; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Ridgeon EE, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1726-x; Rygard SL, 2018, INTENS CARE MED, V44, P1003, DOI 10.1007/s00134-018-5197-6; SepNet Critical Care Trials Grp, 2016, INTENS CARE MED, V42, P1980, DOI 10.1007/s00134-016-4504-3; Seventieth World Health Assembly, 2017, IMPROVING PREVENTION; Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Vaara ST, 2012, CRIT CARE, V16, DOI 10.1186/cc11682; Zampieri FG, 2021, JAMA-J AM MED ASSOC, V326, P818, DOI 10.1001/jama.2021.11684	33	19	19	15	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2022	386	26					2459	2470		10.1056/NEJMoa2202707	http://dx.doi.org/10.1056/NEJMoa2202707		JUN 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D8GD	35709019				2023-01-03	WOS:000813051200001
J	Dorabawila, V; Hoefer, D; Bauer, UE; Bassett, MT; Lutterloh, E; Rosenberg, ES				Dorabawila, Vajeera; Hoefer, Dina; Bauer, Ursula E.; Bassett, Mary T.; Lutterloh, Emily; Rosenberg, Eli S.			Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Dorabawila, Vajeera; Hoefer, Dina; Bauer, Ursula E.; Bassett, Mary T.; Lutterloh, Emily; Rosenberg, Eli S.] New York State Dept Hlth, Albany, NY 12237 USA	State University of New York (SUNY) System	Dorabawila, V (corresponding author), Bur Surveillance & Data Syst BSDS, Div Epidemiol, Corning Tower,Room 754,Empire State Plaza, Albany, NY 12237 USA.	vajeera.dorabawila@health.ny.gov	Dorabawila, Vajeera/GNP-4756-2022					covid.cdc, DEMOGRAPHIC TRENDS C; Fowlkes AL, 2022, MMWR-MORBID MORTAL W, V71, P422, DOI [10.15585/mmwr.mm7111e1, 10.1101/2021.12.10.21267408v3]; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Reis B, 2021, NEW ENGL J MED, V385, P2101, DOI 10.1056/NEJMc2114290; Rosenberg ES, 2022, NEW ENGL J MED, V386, P116, DOI 10.1056/NEJMoa2116063; Walter EB, 2022, NEW ENGL J MED, V386, P35, DOI 10.1056/NEJMoa2116298	6	16	16	2	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2022	327	22					2242	2244						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2J5EE	35559959	Green Published, Bronze			2023-01-03	WOS:000815679200023
J	Khater, I; Nassar, A				Khater, Ibrahim; Nassar, Aaya			Seeking antiviral drugs to inhibit SARS-CoV-2 RNA dependent RNA polymerase: A molecular docking analysis	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; PROTEIN; DYNAMICS; SIMULATIONS; AFFINITY; WUHAN	COVID-19 outbreak associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) raised health concerns across the globe and has been considered highly transmissible between people. In attempts for finding therapeutic treatment for the new disease, this work has focused on examining the polymerase inhibitors against the SARS-CoV-2 nsp12 and co-factors nsp8 and nsp7. Several polymerase inhibitors were examined against PDB ID: 6M71 using computational analysis evaluating the ligand's binding affinity to replicating groove to the active site. The findings of this analysis showed Cytarabine of -5.65 Kcal/mol with the highest binding probability (70%) to replicating groove of 6M71. The complex stability was then examined over 19 ns molecular dynamics simulation suggesting that Cytarabine might be possible potent inhibitor for the SARS-CoV-2 RNA Dependent RNA Polymerase.	[Khater, Ibrahim; Nassar, Aaya] Cairo Univ, Dept Biophys, Fac Sci, Giza, Egypt; [Nassar, Aaya] George Washington Univ, Sch Med & Hlth Sci, Dept Clin Res & Leadership, Washington, DC 20052 USA	Egyptian Knowledge Bank (EKB); Cairo University; George Washington University	Nassar, A (corresponding author), Cairo Univ, Dept Biophys, Fac Sci, Giza, Egypt.; Nassar, A (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Clin Res & Leadership, Washington, DC 20052 USA.	aaya_nassar@cu.edu.eg		Nassar, Aaya/0000-0002-5542-9387				Adhami M, 2021, BMC BIOTECHNOL, V21, DOI 10.1186/s12896-021-00680-z; Aftab SO, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02439-0; Al-Dorzi HM, 2016, ERS MONOGR, V2016, P21, DOI [10.1183/2312508X.10010015, DOI 10.1183/2312508X.10010015]; Al-Muharrmi Zakariya, 2010, Sultan Qaboos Univ Med J, V10, P187; Appleby TC, 2015, STRUCTURAL BASIS RNA, P347; Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186; Barh D, 2020, COMPUT BIOL MED, V126, DOI 10.1016/j.compbiomed.2020.104051; Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011; Braz HLB, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106119; Bhowmick S, 2021, MOL DIVERS, V25, P1979, DOI 10.1007/s11030-021-10214-6; Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008; Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7; Cascella M., 2020, FEATURES EVALUATION; Cavasotto CN, 2021, MOL INFORM, V40, DOI 10.1002/minf.202000115; Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489; Das Shaoli, 2020, Res Sq, DOI 10.21203/rs.3.rs-39128/v1; Deshpande RR, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173430; Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Elfiky AA, 2021, J BIOMOL STRUCT DYN, V39, P3204, DOI 10.1080/07391102.2020.1761882; Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592; Fu ZY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20718-8; Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498; Gapsys V, 2020, ELIFE, V9, DOI 10.7554/eLife.57589; GBD 2017 Saudi Arabia, 2020, LANCET PLANET HEALTH, V4, pE195, DOI 10.1016/S2542-5196(20)30075-9; Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17; Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8; Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Jang WD, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024302118; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945; Jo SW, 2014, ADV PROTEIN CHEM STR, V96, P235, DOI 10.1016/bs.apcsb.2014.06.002; Khater I, INT J INTELL COMPUT, V21, P149, DOI [10.21608/ijicis.2021.66637.1068, DOI 10.21608/IJICIS.2021.66637.1068]; Khater I, 2021, BIOCHEM BIOPHYS REP, V27, DOI 10.1016/j.bbrep.2021.101032; Kim S, 2017, J COMPUT CHEM, V38, P1879, DOI 10.1002/jcc.24829; Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3; Knapp B, 2011, J COMPUT BIOL, V18, P997, DOI 10.1089/cmb.2010.0237; Kumar V, 2021, COMPUT BIOL MED, V135, DOI 10.1016/j.compbiomed.2021.104634; Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997; Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu XH, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111035; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Maffucci I, 2020, J PROTEOME RES, V19, P4637, DOI 10.1021/acs.jproteome.0c00383; Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w; Martellucci Cecilia Acuti, 2020, Advances in Biological Regulation, V77, P100730, DOI [10.1016/j.jbior.2020.100736, 10.1016/j.jbior.2020.100730]; Molavi Z, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111544; Morens DM, 2010, CRIT CARE MED, V38, pE10, DOI 10.1097/CCM.0b013e3181ceb25b; Muhammed Yusuf, 2021, Biosaf Health, V3, P249, DOI 10.1016/j.bsheal.2021.07.003; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; Ode H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00258; PICHE SW, 1994, IEEE T NEURAL NETWOR, V5, P198, DOI 10.1109/72.279185; Pilnick AR, 2021, SCI REP-UK, V11, DOI [10.1155/2014/139030, 10.1038/s41598-021-90564-1, 10.18280/isi.270101]; Pirzada RH, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051052; Prajapat M, 2020, J MOL GRAPH MODEL, V101, DOI 10.1016/j.jmgm.2020.107716; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Qiao JX, 2021, SCIENCE, V371, P1374, DOI 10.1126/science.abf1611; Ren L-L, 2020, CHINESE MED J-PEKING, V1, DOI [10.1097/CM90000000000000722, DOI 10.1097/CM90000000000000722]; Reva BA, 1998, FOLD DES, V3, P141, DOI 10.1016/S1359-0278(98)00019-4; Reynolds CH, 2008, J MED CHEM, V51, P2432, DOI 10.1021/jm701255b; Reynolds CH, 2007, BIOORG MED CHEM LETT, V17, P4258, DOI 10.1016/j.bmcl.2007.05.038; Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1; Rudolph U, 2011, NAT REV DRUG DISCOV, V10, P685, DOI 10.1038/nrd3502; Saha S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.634047; Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315; Shin D, 2020, NATURE, V587, P657, DOI 10.1038/s41586-020-2601-5; Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wishart DS, 2020, NUCLEIC ACIDS RES, V395, P441, DOI [10.1056/nejmoa2001316, DOI 10.1056/NEJMOA2001316]; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916; Yi DR, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01440; Zhang W, 2018, BIOCHEM BIOPH RES CO, V497, P705, DOI 10.1016/j.bbrc.2018.02.136; Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3	81	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2022	17	5							e0268909	10.1371/journal.pone.0268909	http://dx.doi.org/10.1371/journal.pone.0268909			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3V2EB	35639751	gold, Green Published			2023-01-03	WOS:000841472800020
J	O'Dowd, A				O'Dowd, Adrian			Advanced diagnosis and personalised treatment: the clinical geneticist	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2022	377								o1160	10.1136/bmj.o1160	http://dx.doi.org/10.1136/bmj.o1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1S5AC	35609898	Bronze			2023-01-03	WOS:000804061800011
J	Pan, RQ; Ryan, J; Pan, D; Wucherpfennig, KW; Letai, A				Pan, Rongqing; Ryan, Jeremy; Pan, Deng; Wucherpfennig, Kai W.; Letai, Anthony			Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis	CELL			English	Article							NATURAL-KILLER-CELLS; GRANZYME-B; T-CELLS; IN-VIVO; CASPASE ACTIVATION; ADOPTIVE TRANSFER; BCL-2 INHIBITION; CANCER; DEATH; CYTOTOXICITY	Interest in harnessing natural killer (NK) cells for cancer immunotherapy is rapidly growing. However, efficacy of NK cell-based immunotherapy remains limited in most trials. Strategies to augment the killing efficacy of NK cells are thus much needed. In the current study, we found that mitochondrial apoptosis (mtApoptosis) pathway is essential for efficient NK killing, especially at physiologically relevant effector-to-target ratios. Furthermore, NK cells can prime cancer cells for mtApoptosis and mitochondrial priming status affects cancer-cell susceptibility to NK-mediated killing. Interestingly, pre-activating NK cells confers on them resistance to BH3 mimetics. Combining BH3 mimetics with NK cells synergistically kills cancer cells in vitro and suppresses tumor growth in vivo. The ideal BH3 mimetic to use in such an approach can be predicted by BH3 profiling. We herein report a rational and precision strategy to augment NK-based immunotherapy, which may be adaptable to T cell-based immunotherapies as well.	[Pan, Rongqing; Ryan, Jeremy; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA; [Pan, Rongqing; Ryan, Jeremy; Pan, Deng; Wucherpfennig, Kai W.; Letai, Anthony] Harvard Med Sch, Boston, MA 02215 USA; [Pan, Deng; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, 450 Brookline Ave, Boston, MA 02215 USA; [Pan, Deng] Tsinghua Univ, Dept Basic Med Sci, Beijing 100084, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Tsinghua University	Pan, RQ; Letai, A (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.; Pan, RQ; Letai, A (corresponding author), Harvard Med Sch, Boston, MA 02215 USA.	rongqing_pan@dfci.harvard.edu; anthony_letai@dfci.harvard.edu		Pan, Rongqing/0000-0002-9494-412X; Ryan, Jeremy/0000-0002-3327-1283	NIH through an NCI [R35 CA242427, R01 CA249062]; NIH [R01 CA238039, R01 CA251599, P01 CA163222, P01 CA236749, P01 CA066996]; Cancer Research Institute (CRI)	NIH through an NCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute (CRI)	Work by R.P., J.R., and A.L. was supported by the NIH through an NCI Outstanding Investigator award R35 CA242427, R01 CA249062, and through P01 CA066996. K.W.W. was supported by NIH grants R01 CA238039, R01 CA251599, P01 CA163222, and P01 CA236749. D.P. was supported by a postdoctoral fellowship from the Cancer Research Institute (CRI). K.W.W. is a member of the Parker Institute for Cancer Immunotherapy (PICI) and the Ludwig Center at Harvard. Graphical abstract was created with BioRender.com.	Aglietti RA, 2017, TRENDS IMMUNOL, V38, P261, DOI 10.1016/j.it.2017.01.003; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; Baysal H, 2020, BRIT J CANCER, V123, P752, DOI 10.1038/s41416-020-0934-3; Beck RJ, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007972; Callen E, 2013, CELL, V153, P1266, DOI 10.1016/j.cell.2013.05.023; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Childs RW, 2015, NAT REV DRUG DISCOV, V14, P487, DOI 10.1038/nrd4506; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Crinier A, 2020, CELL, V180, P1280, DOI 10.1016/j.cell.2020.02.029; Dall'Ozzo S, 2004, CANCER RES, V64, P4664, DOI 10.1158/0008-5472.CAN-03-2862; Denais CM, 2016, SCIENCE, V352, P353, DOI 10.1126/science.aad7297; Freeman AJ, 2019, CELL REP, V28, P2784, DOI 10.1016/j.celrep.2019.08.017; Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008-5472.CAN-08-3712; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Halle S, 2016, IMMUNITY, V44, P233, DOI 10.1016/j.immuni.2016.01.010; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Humphries F, 2020, SCIENCE, V369, P1633, DOI 10.1126/science.abb9818; Huntington ND, 2020, NAT REV CANCER, V20, P437, DOI 10.1038/s41568-020-0272-z; James AM, 2013, BLOOD, V121, P2627, DOI 10.1182/blood-2012-06-437012; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kimura H, 2007, CANCER SCI, V98, P1275, DOI 10.1111/j.1349-7006.2007.00510.x; Kundu S, 2021, CYTOTHERAPY, V23, P559, DOI 10.1016/j.jcyt.2020.12.002; Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Letai A, 2017, NAT MED, V23, P1028, DOI 10.1038/nm.4389; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; Lutz CT, 2011, J IMMUNOL, V186, P4590, DOI 10.4049/jimmunol.1002732; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Montero J, 2015, CELL, V160, P977, DOI 10.1016/j.cell.2015.01.042; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nayyar G, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00051; Pan RQ, 2017, CANCER CELL, V32, P748, DOI 10.1016/j.ccell.2017.11.003; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Riegman M, 2020, NAT CELL BIOL, V22, P1042, DOI 10.1038/s41556-020-0565-1; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Ryan J, 2016, BIOL CHEM, V397, P671, DOI 10.1515/hsz-2016-0107; Ryan JA, 2010, P NATL ACAD SCI USA, V107, P12895, DOI 10.1073/pnas.0914878107; Sharma P, 2020, NAT REV IMMUNOL, V20, P75, DOI 10.1038/s41577-020-0275-8; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580-018-0089-8; Spencer SL, 2011, CELL, V144, P926, DOI 10.1016/j.cell.2011.03.002; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Vo TT, 2012, CELL, V151, P344, DOI 10.1016/j.cell.2012.08.038; Villalobos-Ortiz M, 2020, CELL DEATH DIFFER, V27, P999, DOI 10.1038/s41418-019-0391-9; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weigelin B., 2020, BIORXIV, DOI [10.1101/2020.04.22.054718, DOI 10.1101/2020.04.22.054718]; Weigelin B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25282-3; Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149	68	8	8	37	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 28	2022	185	9					1521	+		10.1016/j.cell.2022.03.030	http://dx.doi.org/10.1016/j.cell.2022.03.030			36	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	3G0DH	35447071				2023-01-03	WOS:000831027800008
J	Maddox, KEJ; Shashikumar, SA; Ryan, AM				Maddox, Karen E. Joynt; Shashikumar, Sukruth A.; Ryan, Andrew M.			Medicare's Bundled Payment Models-Progress and Pitfalls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PARTICIPATION; QUALITY		[Maddox, Karen E. Joynt; Shashikumar, Sukruth A.] Washington Univ, Sch Med, Dept Med, Cardiovasc Div, 660 S Euclid Ave, St Louis, MO 63110 USA; [Maddox, Karen E. Joynt] Washington Univ, Inst Publ Hlth, Ctr Hlth Econ & Policy, St Louis, MO 63110 USA; [Ryan, Andrew M.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Ryan, Andrew M.] Univ Michigan, Ctr Evaluating Hlth Reform, Ann Arbor, MI 48109 USA	Washington University (WUSTL); Washington University (WUSTL); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Maddox, KEJ (corresponding author), Washington Univ, Sch Med, Dept Med, Cardiovasc Div, 660 S Euclid Ave, St Louis, MO 63110 USA.	kjoyntmaddox@wustl.edu						Ades PA, 2001, NEW ENGL J MED, V345, P892, DOI 10.1056/NEJMra001529; Agarwal R, 2020, HEALTH AFFAIR, V39, P50, DOI 10.1377/hlthaff.2019.00784; Berlin NL, 2020, HEALTH AFFAIR, V39, P1479, DOI 10.1377/hlthaff.2020.00104; Dieleman JL, 2021, JAMA-J AM MED ASSOC, V326, P649, DOI 10.1001/jama.2021.9937; Keating NL, 2021, JAMA-J AM MED ASSOC, V326, P1829, DOI 10.1001/jama.2021.17642; Kim H, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14696; Smith B, 2021, NEW ENGL J MED, V384, P759, DOI 10.1056/NEJMsb2031138; Wolfe JD, 2022, J GEN INTERN MED, V37, P513, DOI 10.1007/s11606-021-06820-7	8	3	3	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2022	327	18					1761	1762		10.1001/jama.2022.6402	http://dx.doi.org/10.1001/jama.2022.6402		APR 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1P8WO	35452088				2023-01-03	WOS:000784924600003
J	Bartholomew, T; Naci, H; Robertson, E; Schmidt, H				Bartholomew, Theodore; Naci, Huseyin; Robertson, Emma; Schmidt, Harald			Use of adherence monitoring in drug contracts tied to outcomes: put patients first	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH OUTCOMES; UNITED-STATES; INTERVENTIONS; PAYMENT		[Bartholomew, Theodore] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England; [Naci, Huseyin] London Sch Econ, Dept Hlth Policy, London, England; [Schmidt, Harald] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	Royal Surrey County Hospital; University of London; London School Economics & Political Science; University of Pennsylvania	Bartholomew, T (corresponding author), Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England.	tb.public@mailbox.org						Armendariz Y, 2019, VALUE HEALTH, V22, pS720; Association of the British Pharmaceutical Industry (ABPI) National Institute for Health and Clinical Excellence (NICE), 2011, AGR ABPI NICE GUID R; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Burkitt R, 2018, PUBLIC NHS WHATS DEA; Campbell JI, 2016, J GEN INTERN MED, V31, P338, DOI 10.1007/s11606-015-3502-4; Carlson JJ, 2010, HEALTH POLICY, V96, P179, DOI 10.1016/j.healthpol.2010.02.005; Chai PR, 2021, AIDS BEHAV, V25, P1661, DOI 10.1007/s10461-020-03082-y; Chapman S, 2003, BRIT MED J, V326, P707, DOI 10.1136/bmj.326.7391.707; Cole A, 2019, MAKING OUTCOME BASED; Department of Health and Social Care, 2015, NHS CONST ENGL; DeSilva MB, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/957862; Dinh CT, 2021, PREV MED, V148, DOI 10.1016/j.ypmed.2021.106534; Finitsis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088166; Garrison LP, 2015, AM J MANAG CARE, V21, P632; Haskell H, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3099; Kim J, 2020, J MED ETHICS, V46, P386, DOI 10.1136/medethics-2019-105667; Klugman CM, 2018, AM J BIOETHICS, V18, P38, DOI 10.1080/15265161.2018.1498933; Lam WY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/217047; Leo S, 2019, IMPACT SMARTPHONEBAS; Lothian NHS, 2017, PHARM CAR PAT REQ SU; McCormick JB, 2018, MAYO CLIN PROC, V93, P1346, DOI 10.1016/j.mayocp.2018.05.029; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Moon Z, 2019, HEALTH PSYCHOL, V38, P888, DOI 10.1037/hea0000785; Nazareth T, 2017, J MANAG CARE SPEC PH, V23, P1018, DOI 10.18553/jmcp.2017.23.10.1018; Neiheisel MB, 2014, J AM ASSOC NURSE PRA, V26, P49, DOI 10.1002/2327-6924.12099; Neumann PJ, 2011, HEALTH AFFAIR, V30, P2329, DOI 10.1377/hlthaff.2010.1147; NHS England, 2018, NHS ENGLAND BLO 0129; NHS England, 2017, NHS ENGL STRIK NEW D; Osipenko L, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-051812; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; PhocusWire, 2021, NHS LEARNING SUPPORT; Pickin M, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-1; Radley A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-343; Relton C, 2011, J PUBLIC HEALTH-UK, V33, P536, DOI 10.1093/pubmed/fdr030; Seeley E, 2018, J LAW MED ETHICS, V46, P952, DOI 10.1177/1073110518821995; Seeley Elizabeth, 2017, Issue Brief (Commonw Fund), V2017, P1; Sekalala S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003359; Stirratt MJ, 2018, J GEN INTERN MED, V33, P216, DOI 10.1007/s11606-017-4198-4; Story A, 2019, LANCET, V393, P1216, DOI 10.1016/S0140-6736(18)32993-3; Thomas BE, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/16634; Trueman P., 2010, EVALUATION SCALE CAU; Viswanathan M, 2012, ANN INTERN MED, V157, P785, DOI 10.7326/0003-4819-157-11-201212040-00538; Volpp KG, 2017, JAMA INTERN MED, V177, P1093, DOI 10.1001/jamainternmed.2017.2449	43	1	1	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2022	376								e062188	10.1136/bmj-2020-062188	http://dx.doi.org/10.1136/bmj-2020-062188			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP8GL	35256379	hybrid, Green Accepted			2023-01-03	WOS:000766656400001
J	Dizman, N; Meza, L; Bergerot, P; Alcantara, M; Dorff, T; Lyou, Y; Frankel, P; Cui, YJ; Mira, V; Llamas, M; Hsu, J; Zengin, Z; Salgia, N; Salgia, S; Malhotra, J; Chawla, N; Chehrazi-Raffle, A; Muddasani, R; Gillece, J; Reining, L; Trent, J; Takahashi, M; Oka, K; Higashi, S; Kortylewski, M; Highlander, SK; Pal, SK				Dizman, Nazli; Meza, Luis; Bergerot, Paulo; Alcantara, Marice; Dorff, Tanya; Lyou, Yung; Frankel, Paul; Cui, Yujie; Mira, Valerie; Llamas, Marian; Hsu, Joann; Zengin, Zeynep; Salgia, Nicholas; Salgia, Sabrina; Malhotra, Jasnoor; Chawla, Neal; Chehrazi-Raffle, Alex; Muddasani, Ramya; Gillece, John; Reining, Lauren; Trent, Jeff; Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya; Kortylewski, Marcin; Highlander, Sarah K.; Pal, Sumanta K.			Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	NATURE MEDICINE			English	Article							CLOSTRIDIUM-BUTYRICUM; TRANSPLANTATION; MICROBIOME; BUTYRATE; EFFICACY; COLITIS	Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut microbiome. In this open-label, single-center study (NCT03829111), 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk disease were randomized 2:1 to receive nivolumab and ipilimumab with or without daily oral CBM588, respectively. Stool metagenomic sequencing was performed at multiple timepoints. The primary endpoint to compare the relative abundance of Bifidobacterium spp. at baseline and at 12 weeks was not met, and no significant differences in Bifidobacterium spp. or Shannon index associated with the addition of CBM588 to nivolumab-ipilimumab were detected. Secondary endpoints included response rate, progression-free survival (PFS) and toxicity. PFS was significantly longer in patients receiving nivolumab-ipilimumab with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15, 95% confidence interval 0.05-0.47, P = 0.001). Although not statistically significant, the response rate was also higher in patients receiving CBM588 (58% versus 20%, P = 0.06). No significant difference in toxicity was observed between the study arms. The data suggest that CBM588 appears to enhance the clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab-ipilimumab. Larger studies are warranted to confirm this clinical observation and elucidate the mechanism of action and the effects on microbiome and immune compartments. A randomized trial in treatment-naive patients with metastatic renal cell carcinoma shows that the addition of a live bacterial product to an immunotherapy combination elicits promising clinical benefit in association with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders.	[Dizman, Nazli; Meza, Luis; Dorff, Tanya; Lyou, Yung; Mira, Valerie; Llamas, Marian; Hsu, Joann; Zengin, Zeynep; Salgia, Nicholas; Salgia, Sabrina; Malhotra, Jasnoor; Chawla, Neal; Chehrazi-Raffle, Alex; Muddasani, Ramya; Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA; [Dizman, Nazli] Yale Univ, Sch Med, New Haven, CT USA; [Bergerot, Paulo] Cettro Oncol, Brasilia, DF, Brazil; [Alcantara, Marice; Kortylewski, Marcin] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Immunol, Duarte, CA USA; [Frankel, Paul; Cui, Yujie] City Hope Comprehens Canc Ctr, Div Biostat, Duarte, CA USA; [Gillece, John; Reining, Lauren; Trent, Jeff; Highlander, Sarah K.] Translat Genom Res Inst TGen, Phoenix, AZ 85004 USA; [Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya] Miyarisan Pharmaceut Co Ltd, Tokyo, Japan	City of Hope; Yale University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Translational Genomics Research Institute	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA.; Highlander, SK (corresponding author), Translat Genom Res Inst TGen, Phoenix, AZ 85004 USA.	sarah@skhighlander.us; spal@coh.org	Zengin, Zeynep Busra/AAW-5912-2021	Zengin, Zeynep Busra/0000-0002-2751-5915; Takahashi, Motomichi/0000-0003-4773-5904; Meza, Luis/0000-0002-0235-297X	Gateway for Cancer Research [G-20-100]	Gateway for Cancer Research	We thank the patients and families for their participation in this study. Funding for the study was provided by a grant from the Gateway for Cancer Research (S.K.P; Grant ID: G-20-100). CBM588 was supplied by Miyarisan Pharmaceuticals Co., Ltd. and OSEL, Inc.	Adams S, 2019, ANN ONCOL, V30, P397, DOI 10.1093/annonc/mdy517; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Ariyoshi T, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.587725; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Busi S. B., 2018, CANCER RES, V78; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Choueiri TK, 2020, ANN ONCOL, V31, pS1159, DOI 10.1016/j.annonc.2020.08.2257; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Cremonesi E, 2018, GUT, V67, P1984, DOI 10.1136/gutjnl-2016-313498; DeFilipp Z, 2019, NEW ENGL J MED, V381, P2043, DOI 10.1056/NEJMoa1910437; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Derosa L, 2021, CANCER DISCOV, V11, P2396, DOI 10.1158/2159-8290.CD-21-0236; Dizman N, 2021, CANCER MED-US, V10, P79, DOI 10.1002/cam4.3569; Dudani S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.21869; Escudier B, 2019, ANN ONCOL, V30, P706, DOI 10.1093/annonc/mdz056; Francisco-Anderson L, 2021, CANCER RES, V81; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grasso CS, 2020, CANCER CELL, V38, P500, DOI 10.1016/j.ccell.2020.08.005; Hagihara M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100772; Isa K, 2016, HUM EXP TOXICOL, V35, P818, DOI 10.1177/0960327115607372; Liu CM, 2012, BMC MICROBIOL, V12, DOI [10.1186/1471-2180-12-56, 10.1186/1471-2180-12-255]; Louis P, 2017, ENVIRON MICROBIOL, V19, P29, DOI 10.1111/1462-2920.13589; Lu J, 2017, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.104; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer R, 2019, LANCET ONCOL, V20, P1370, DOI 10.1016/S1470-2045(19)30413-9; Motzer RJ, 2019, J NATL COMPR CANC NE, V17, P1279, DOI 10.6004/jnccn.2019.0054; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Okamoto T, 2000, J GASTROENTEROL, V35, P341, DOI 10.1007/s005350050358; Reichardt N, 2018, ISME J, V12, P610, DOI 10.1038/ismej.2017.196; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Salgia NJ, 2020, EUR UROL, V78, P498, DOI 10.1016/j.eururo.2020.07.011; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Takahashi M, 2004, FEMS IMMUNOL MED MIC, V41, P219, DOI 10.1016/j.femsim.2004.03.010; Tomita Y, 2020, CANCER IMMUNOL RES, V8, P1236, DOI 10.1158/2326-6066.CIR-20-0051; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; Zhang X, 2021, GUT, V70, P761, DOI 10.1136/gutjnl-2019-319664	43	41	41	19	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					704	+		10.1038/s41591-022-01694-6	http://dx.doi.org/10.1038/s41591-022-01694-6		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35228755	hybrid, Green Published			2023-01-03	WOS:000762162700003
J	Zhang, YQ; Lu, LM; Xu, NG; Tang, XR; Shi, XS; Carrasco-Labra, A; Schunemann, H; Chen, YL; Xia, J; Chen, G; Liu, JP; Liu, BY; Wang, JY; Qaseem, A; Jing, XH; Guyatt, G; Zhao, H				Zhang, Yu-Qing; Lu, Liming; Xu, Nenggui; Tang, Xiaorong; Shi, Xiaoshuang; Carrasco-Labra, Alonso; Schunemann, Holger; Chen, Yaolong; Xia, Jun; Chen, Guang; Liu, Jianping; Liu, Baoyan; Wang, Jiyao; Qaseem, Amir; Jing, Xianghong; Guyatt, Gordon; Zhao, Hong			Increasing the usefulness of acupuncture guideline recommendations	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL-PRACTICE GUIDELINES		[Zhang, Yu-Qing] China Acad Chinese Med Sci, Guanganmen Hosp, CEBIM Ctr Evidence Based Integrat Med Clar Collab, Beijing, Peoples R China; [Zhang, Yu-Qing; Schunemann, Holger; Guyatt, Gordon] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Zhang, Yu-Qing; Shi, Xiaoshuang; Jing, Xianghong; Zhao, Hong] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Zhang, Yu-Qing; Xia, Jun] Univ Nottingham Ningbo, Nottingham Ningbo GRADE Ctr, Nottingham, Peoples R China; [Lu, Liming; Xu, Nenggui; Tang, Xiaorong] Guangzhou Univ Chinese Med, South China Res Ctr Acupuncture & Moxibust, Med Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China; [Carrasco-Labra, Alonso] Univ Penn, Sch Dent Med, Ctr Integrat Global Oral Hlth, Philadelphia, PA 19104 USA; [Chen, Yaolong] Lanzhou Univ, Inst Hlth Data Sci, Lanzhou, Peoples R China; [Chen, Yaolong] WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou, Peoples R China; [Xia, Jun] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England; [Chen, Guang] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA; [Liu, Jianping] Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Liu, Baoyan] China Acad Chinese Med Sci, Beijing, Peoples R China; [Wang, Jiyao] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA USA; [Guyatt, Gordon] McMaster Univ, Dept Med, Fac Hlth Sci, Hamilton, ON, Canada; [Lu, Liming; Zhao, Hong] Shenzhen Luohu Dist Hosp TCM, Shenzhen, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; McMaster University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; University of Nottingham Ningbo China; Guangzhou University of Chinese Medicine; University of Pennsylvania; Lanzhou University; University of Nottingham; Harvard University; Harvard Medical School; China Academy of Chinese Medical Sciences; Fudan University; American College of Physicians; McMaster University	Zhao, H (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China.; Zhao, H (corresponding author), Shenzhen Luohu Dist Hosp TCM, Shenzhen, Peoples R China.	hongzhao2005@aliyun.com	Jing, Xianghong/HHS-4003-2022	Schunemann, Holger/0000-0003-3211-8479	special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program [2020B1111100008]; Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202004]; National Natural Science Foundation of China [82174527]	special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program; Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We have read and understood BMJ policy on declaration of interests and declare that the study was supported by the special project of "Lingnan Modernization of Traditional Chinese Medicine" within the 2019 Guangdong Provincial Research and Development Program (2020B1111100008); the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202004); and the National Natural Science Foundation of China (82174527). The funders had no influence on study design, data collection, analysis, decision to publish, or manuscript preparation.	Birch S, 2018, J ALTERN COMPLEM MED, V24, P752, DOI 10.1089/acm.2018.0092; Brignardello-Petersen R, 2021, JAMA-J AM MED ASSOC, V326, P1516, DOI 10.1001/jama.2021.15319; Chen YL, 2017, ANN INTERN MED, V166, P128, DOI 10.7326/M16-1565; Cho HW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088027; Czarnawska-Iliev I, 2016, EUR J INTEGR MED, V8, P342, DOI 10.1016/j.eujim.2016.07.004; Deng GE, 2013, CHEST, V143, pE420, DOI 10.1378/chest.12-2364; Dobos GJ, 2012, CHIN J INTEGR MED, V18, P643, DOI 10.1007/s11655-012-1200-1; Eccles MP, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-60; Epp A, 2017, J OBSTET GYNAECOL CA, V39, pE422, DOI 10.1016/j.jogc.2017.08.017; Ghildayal Neha, 2016, Glob Adv Health Med, V5, P69, DOI 10.7453/gahmj.2015.104; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Howick J, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003294; Ijaz N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226601; Jun JH, 2017, EUR J INTEGR MED, V9, P18, DOI 10.1016/j.eujim.2017.01.003; Langford BJ, CLIN INFECT DIS, V73, P782; Lu LL, BMJ OPEN; Lunny C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250356; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; National Institute for Health and Care Excellence, 2012, HEAD 12S DIAGN MAN; Neumann I, 2020, CAN MED ASSOC J, V192, pE23, DOI 10.1503/cmaj.190144; Neumann I, 2018, J CLIN EPIDEMIOL, V99, P33, DOI 10.1016/j.jclinepi.2018.02.026; Neumann I, 2016, J CLIN EPIDEMIOL, V72, P45, DOI 10.1016/j.jclinepi.2015.11.017; Qaseem A, 2020, ANN INTERN MED, V173, P739, DOI 10.7326/M19-3602; Qaseem Amir, 2017, Ann Intern Med, V166, P514, DOI 10.7326/M16-2367; Tang C, J CLIN EPIDEMIOL, V139, P330; Tang X, BMJ OPEN; Veterans Affairs Department of Defence., CLIN PRACT GUID PRIM; WHO (World Health Organization), 2019, WHO GLOB REP TRAD CO; Wiercioch W, 2020, BLOOD ADV, V4, P2351, DOI 10.1182/bloodadvances.2020001768; [中华中医药学会骨伤科分会膝痹病(膝骨关节炎)临床诊疗指南制定工作组 Working Group on Setting Up Guidelines for Diagnosis And Treatment of Knee Osteoarthritis (Xibibing) in Orthopedics Section of China Association of Chinese Medicine], 2019, [康复学报, Rehabilitation Medicine], V29, P1; Zhang Y, 2019, J CLIN EPIDEMIOL, V111, P83, DOI 10.1016/j.jclinepi.2018.05.011; Zhou L, 2014, EUR J INTEGR MED, V6, P147, DOI 10.1016/j.eujim.2014.03.006	33	2	2	6	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2022	376								e070533	10.1136/bmj-2022-070533	http://dx.doi.org/10.1136/bmj-2022-070533			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1B5HI	35217506	hybrid, Green Published			2023-01-03	WOS:000792467400014
J	Samarasekera, U				Samarasekera, Udani			Ros Taylor: seeing palliative care as relational	LANCET			English	Editorial Material																			0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB-MAR	2022	399	10327					783	783		10.1016/S0140-6736(22)00146-5	http://dx.doi.org/10.1016/S0140-6736(22)00146-5		FEB 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZJ4WT	35114147	Green Published			2023-01-03	WOS:000762307100011
J	Pires, JA; Bragato, EF; Momolli, M; Guerra, MB; Neves, LM; Bruscagnin, MAD; Horliana, ACRT; Fernandes, KPS; Bussadori, SK; Ferrari, RAM				Pires, Jefferson Andre; Bragato, Erick Frank; Momolli, Marcos; Guerra, Marina Bertoni; Neves, Leonel Manea; de Oliveira Bruscagnin, Meire Augusto; Ratto Tempestini Horliana, Anna Carolina; Santos Fernandes, Kristianne Porta; Bussadori, Sandra Kalil; Mesquita Ferrari, Raquel Agnelli			Effect of the combination of photobiomodulation therapy and the intralesional administration of corticoid in the preoperative and postoperative periods of keloid surgery: A randomized, controlled, double-blind trial protocol study	PLOS ONE			English	Article							LEVEL LASER THERAPY; LIGHT-EMITTING DIODE; HYPERTROPHIC SCARS; EARLOBE KELOIDS; CELLULAR-RESPONSES; RADIATION-THERAPY; SURGICAL EXCISION; TRIAMCINOLONE; PREVENTION; EFFICACY	Keloid scars are characterized by the excessive proliferation of fibroblasts and an imbalance between the production and degradation of collagen, leading to its buildup in the dermis. There is no "gold standard" treatment for this condition, and the recurrence is frequent after surgical procedures removal. In vitro studies have demonstrated that photobiomodulation (PBM) using the blue wavelength reduces the proliferation speed and the number of fibroblasts as well as the expression of TGF-beta. There are no protocols studied and established for the treatment of keloids with blue LED. Therefore, the purpose of this study is to determine the effects of the combination of PBM with blue light and the intralesional administration of the corticoid triamcinolone hexacetonide on the quality of the remaining scar by Vancouver Scar Scale in the postoperative period of keloid surgery. A randomized, controlled, double-blind, clinical trial will be conducted involving two groups: 1) Sham (n = 29): intralesional administration of corticoid (IAC) and sham PBM in the preoperative and postoperative periods of keloid removal surgery; and 2) active PBM combined with IAC (n = 29) in the preoperative and postoperative periods of keloid removal surgery. Transcutaneous PBM will be performed on the keloid region in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 400 mW, 4J per point on 10 linear points). The patients will answer two questionnaires: one for the assessment of quality of life (Qualifibro-UNIFESP) and one for the assessment of satisfaction with the scar (PSAQ). team of five plastic surgeons will answer the Vancouver Scar Scale (VSS). All questionnaires will be administered one, three, six, and twelve months postoperatively. The keloids will be molded in silicone prior to the onset of treatment and prior to excision to assess pretreatment and post-treatment size. The same will be performed for the remaining scar at one, three, six, and twelve months postoperatively. The removed keloid will be submitted to histopathological analysis for the determination of the quantity of fibroblasts, the organization and distribution of collagen (picrosirius staining), and the genic expression of TGF-beta (qPCR). All data will be submitted to statistical analysis.	[Pires, Jefferson Andre; Bragato, Erick Frank; Momolli, Marcos; Guerra, Marina Bertoni; Ratto Tempestini Horliana, Anna Carolina; Santos Fernandes, Kristianne Porta; Bussadori, Sandra Kalil; Mesquita Ferrari, Raquel Agnelli] Univ Nove Julho UNINOVE, Dept Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil; [Pires, Jefferson Andre; Neves, Leonel Manea; de Oliveira Bruscagnin, Meire Augusto] Mandaqui Hosp Complex, Dept Plast Surg, Sao Paulo, SP, Brazil; [Mesquita Ferrari, Raquel Agnelli] Univ Nove Julho UNINOVE, Dept Rehabil Sci Appl Hlth Sci, Sao Paulo, SP, Brazil; [Mesquita Ferrari, Raquel Agnelli] Univ Nove Julho UNINOVE, Postgrad Program, Rehabil Sci & Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil	Universidade Nove de Julho; Universidade Nove de Julho; Universidade Nove de Julho	Ferrari, RAM (corresponding author), Univ Nove Julho UNINOVE, Dept Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil.; Ferrari, RAM (corresponding author), Univ Nove Julho UNINOVE, Dept Rehabil Sci Appl Hlth Sci, Sao Paulo, SP, Brazil.; Ferrari, RAM (corresponding author), Univ Nove Julho UNINOVE, Postgrad Program, Rehabil Sci & Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil.	raquel.mesquita@gmail.com	Horliana, Anna/ABH-9640-2020; Ferrari, Raquel/I-4419-2016; Horliana, Anna Carolina Ratto Tempestini/J-3257-2015; Fernandes, Kristianne Porta Santos/I-4417-2016	Ferrari, Raquel/0000-0001-5142-9526; Horliana, Anna Carolina Ratto Tempestini/0000-0003-3476-9064; Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; PIRES, JEFFERSON ANDRE/0000-0001-7437-7108				Alsharnoubi J, 2018, LASER MED SCI, V33, P1991, DOI 10.1007/s10103-018-2572-z; Arno AI, 2014, BURNS, V40, P1255, DOI 10.1016/j.burns.2014.02.011; Barolet D, 2010, LASER SURG MED, V42, P597, DOI 10.1002/lsm.20952; Berman B, 1997, J AM ACAD DERMATOL, V37, P755, DOI 10.1016/S0190-9622(97)70113-0; Bock O, 2006, ARCH DERMATOL RES, V297, P433, DOI 10.1007/s00403-006-0651-7; Bonatti S, 2011, ACTA CIR BRAS, V26, P25, DOI 10.1590/S0102-86502011000100006; Motoki THC, 2019, BURNS, V45, P610, DOI 10.1016/j.burns.2018.10.009; Chen AD, 2019, ANN PLAS SURG, V83, pS50, DOI 10.1097/SAP.0000000000002090; Chen B, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13553; Colwell AS, 2005, PLAST RECONSTR SURG, V116, P1387, DOI 10.1097/01.prs.0000182343.99694.28; Davison SP, 2009, AESTHET SURG J, V29, P40, DOI 10.1016/j.asj.2008.11.006; de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201; Carvalho RLD, 2010, PHOTOMED LASER SURG, V28, P417, DOI 10.1089/pho.2009.2548; Durani P, 2009, PLAST RECONSTR SURG, V123, P1481, DOI 10.1097/PRS.0b013e3181a205de; Epstein JB, 2018, PHOTOMED LASER SURG, V36, P92, DOI 10.1089/pho.2017.4297; Erol O, 2008, AESTHET PLAST SURG, V32, P902, DOI 10.1007/s00266-008-9161-7; Fernandes KPS., 2017, BIOFOTONICA CONCEITO, V1; Ferreira LM., 2007, GUIAS MEDIC AMBULATO, V1; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Freitas CP, 2013, J COSMET LASER THER, V15, P171, DOI 10.3109/14764172.2013.769272; Frigo L, 2010, PHOTOMED LASER SURG, V28, pS151, DOI 10.1089/pho.2008.2475; Fujii S., 2008, LASER THER, V17, P35; Fujiwara M, 2005, BRIT J DERMATOL, V153, P295, DOI 10.1111/j.1365-2133.2005.06698.x; Furtado FMP., 2008, THESIS U FEDERAL SAO; Gold MH, 2014, DERMATOL SURG, V40, P825, DOI 10.1111/dsu.0000000000000050; Gupta S, 2002, DERMATOLOGY, V204, P130, DOI 10.1159/000051830; Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864; Hamrick M, 2009, J PEDIATR SURG, V44, P286, DOI 10.1016/j.jpedsurg.2008.10.058; Han B, 2019, LASER MED SCI, V34, P1, DOI 10.1007/s10103-018-2567-9; Har-Shai Y, 2007, J EUR ACAD DERMATOL, V21, P191, DOI 10.1111/j.1468-3083.2006.01890.x; Hawkins D, 2006, PHOTOMED LASER SURG, V24, P705, DOI 10.1089/pho.2006.24.705; Heiskanen V, 2018, PHOTOCH PHOTOBIO SCI, V17, P1003, DOI [10.1039/c8pp90049c, 10.1039/c8pp00176f]; Herascu N, 2005, PHOTOMED LASER SURG, V23, P70, DOI 10.1089/pho.2005.23.70; Hewedy ES, 2022, J DERMATOL TREAT, V33, P150, DOI 10.1080/09546634.2020.1730742; Hochman B., 2004, REVISO ESTIMA, V2; Huu Nghi Dinh, 2019, Open Access Maced J Med Sci, V7, P275, DOI 10.3889/oamjms.2019.093; Jagadeesan Jagajeevan, 2007, Int J Surg, V5, P278, DOI 10.1016/j.ijsu.2006.04.007; Jin R, 2013, PLAST RECONSTR SURG, V132, P1747, DOI 10.1097/PRS.0b013e3182a97e43; Jung JY, 2009, ANN DERMATOL, V21, P221, DOI 10.5021/ad.2009.21.3.221; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; KIIL J, 1977, SCAND J PLAST RECONS, V11, P169, DOI 10.3109/02844317709025514; Ledon JA, 2013, DERMATOL SURG, V39, P1745, DOI 10.1111/dsu.12346; Lee HS, 2017, ANN DERMATOL, V29, P149, DOI 10.5021/ad.2017.29.2.149; Lev-Tov H, 2013, DERMATOL SURG, V39, P422, DOI 10.1111/dsu.12087; Limandjaja GC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00360; Mamalis A, 2016, J BIOPHOTONICS, V9, P1167, DOI 10.1002/jbio.201600059; Marneros Alexander G, 2004, J Dtsch Dermatol Ges, V2, P905, DOI 10.1046/j.1439-0353.2004.04077.x; Ramos RM, 2019, AESTHET PLAST SURG, V43, P147, DOI 10.1007/s00266-018-1271-2; Mignon C, 2018, LASER SURG MED, V50, P859, DOI 10.1002/lsm.22823; Nangole Ferdinand W, 2019, JPRAS Open, V22, P44, DOI 10.1016/j.jpra.2019.09.004; Neligam PC., 2015, CIRURGIA PLASTICA PR, V1; Ojea AR, 2016, PHOTOMED LASER SURG, V34, P580, DOI 10.1089/pho.2016.4149; Oplander C, 2011, J PHOTOCH PHOTOBIO B, V103, P118, DOI 10.1016/j.jphotobiol.2011.02.018; Ota AS., 2016, THESIS U FEDERAL SAO; Park YJ, 2016, DERMATOL SURG, V42, P526, DOI 10.1097/DSS.0000000000000680; Qu L, 2012, LASER SURG MED, V44, P517, DOI 10.1002/lsm.22055; Santos MC., 2014, REV BRAS QUEIMADURAS, V13, P26; Sarrazy V, 2011, WOUND REPAIR REGEN, V19, pS10, DOI 10.1111/j.1524-475X.2011.00708.x; Sclafani AP, 1996, DERMATOL SURG, V22, P569, DOI 10.1111/j.1524-4725.1996.tb00376.x; Shin JY, 2016, PLAST RECONSTR SURG, V137, P1718, DOI 10.1097/PRS.0000000000002165; SHONS AR, 1983, ANN PLAS SURG, V10, P480, DOI 10.1097/00000637-198306000-00008; SULLIVAN T, 1990, Journal of Burn Care and Rehabilitation, V11, P256, DOI 10.1097/00004630-199005000-00014; van Drooge AM, 2015, DERMATOL SURG, V41, P371, DOI 10.1097/DSS.0000000000000306; van Leeuwen MCE, 2015, PLAST RECONSTR SURG, V135, P580, DOI 10.1097/PRS.0000000000000911; van Leeuwen MCE, 2014, J PLAST RECONSTR AES, V67, P1703, DOI 10.1016/j.bjps.2014.08.046; Vrijman C, 2011, BRIT J DERMATOL, V165, P934, DOI 10.1111/j.1365-2133.2011.10492.x; Wang ZC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603187; Wolfram D, 2009, DERMATOL SURG, V35, P171, DOI 10.1111/j.1524-4725.2008.34406.x	68	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2022	17	2							e0263453	10.1371/journal.pone.0263453	http://dx.doi.org/10.1371/journal.pone.0263453			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1P8AU	35167583	Green Published, gold			2023-01-03	WOS:000802227200007
J	Cha, YH; Gleghorn, D; Doudican, BC				Cha, Yoon-Hee; Gleghorn, Diamond; Doudican, Benjamin Chipper			Double-blind randomized N-of-1 trial of transcranial alternating current stimulation for mal de debarquement syndrome	PLOS ONE			English	Article							MAGNETIC STIMULATION; FREQUENCY; DIZZINESS; CONNECTIVITY; DEPRESSION; VERTIGO	Background Mal de Debarquement Syndrome (MdDS) is a medically refractory neurotological disorder characterized by persistent oscillating vertigo that follows a period of entrainment to oscillating motion such as experienced during sea or air travel. Fronto-occipital hypersynchrony may correlate with MdDS symptom severity. Materials and methods Individuals with treatment refractory MdDS lasting at least 6 months received single administrations of three fronto-occipital transcranial alternating current stimulation (tACS) protocols in an "n-of-1" double-blind randomized design: alpha frequency anti-phase, alpha-frequency in-phase, and gamma frequency control. Baseline assessments were made on Day 1. The treatment protocol that led to the most acute reduction in symptoms during a test session on Day 2 was administered for 10-12 stacked sessions given on Days 3 through 5 (20-minutes at 2-4mA). Pre to post symptom changes were assessed on Day 1 and Day 5. Participants who could clearly choose a preferred protocol on Day 2 did better on Day 5 than those who could not make a short-term determination on Day 2 and either chose a protocol based on minimized side effects or were randomized to one of the three protocols. In addition, weekly symptom assessments were made for four baseline and seven post stimulation points for the Dizziness Handicap Inventory (DHI), MdDS Balance Rating Scale (MBRS), and Hospital Anxiety and Depression Scale (HADS). Results Of 24 participants, 13 chose anti-phase, 7 chose in-phase, and 4 chose control stimulation. Compared to baseline, 10/24 completers noted >= 25% reduction, 5/24 >= 50% reduction, and 2/24 >= 75% reduction in oscillating vertigo intensity from Day 1 to Day 5. Stimulating at a frequency slightly higher than the individual alpha frequency (IAF) was better than stimulating at exactly the IAF, and slightly better than stimulating with a strategy of standardized stimulation at 10Hz. A one-way repeated measures ANOVA of weekly DHI, MBRS, and HADS measurements showed significant reductions immediately after treatment with improvement increasing through post-treatment week 6. Conclusion Fronto-occipital tACS may be effective in reducing the oscillating vertigo of MdDS and serve as a portable neuromodulation alternative for longer-term treatment. Stimulation frequency relative to the IAF may be important in determining the optimum treatment protocol [ClinicalTrials.gov study NCT02540616. https://clinicaltrials.gov/ct2/show/NCT02540616].	[Cha, Yoon-Hee; Doudican, Benjamin Chipper] Univ Minnesota, Minneapolis, MN 55455 USA; [Cha, Yoon-Hee] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Gleghorn, Diamond] Missouri State Univ, Springfield, MO USA	University of Minnesota System; University of Minnesota Twin Cities; Laureate Institute for Brain Research, Inc.; Missouri State University	Cha, YH (corresponding author), Univ Minnesota, Minneapolis, MN 55455 USA.; Cha, YH (corresponding author), Laureate Inst Brain Res, Tulsa, OK 74136 USA.	ycha@umn.edu		Cha, Yoon-Hee/0000-0003-3804-0879	Laureate Institute for Brain Research; William K. Warren Foundation; MdDS Balance Disorders Foundation; Springbank Foundation; NSF EPSCoR RII Track-2 [1539068]; NSF (NIH/NIGMS) [P20 GM121312]	Laureate Institute for Brain Research; William K. Warren Foundation; MdDS Balance Disorders Foundation; Springbank Foundation; NSF EPSCoR RII Track-2; NSF (NIH/NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)National Science Foundation (NSF))	This work was supported by the Laureate Institute for Brain Research, the William K. Warren Foundation, the MdDS Balance Disorders Foundation, the Springbank Foundation (YHC), NSF EPSCoR RII Track-2 #1539068 (YHC, and NIH/NIGMS grant P20 GM121312 (YHC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn S, 2021, NEUROMODULATION, V24, P960, DOI 10.1111/ner.13389; Antal A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00317; Arroll MA, 2016, J HEALTH PSYCHOL, V21, P1339, DOI 10.1177/1359105314553046; Bland NS, 2019, EXP BRAIN RES, V237, P3071, DOI 10.1007/s00221-019-05666-0; BROWN JJ, 1987, AM J OTOLARYNG, V8, P219, DOI 10.1016/S0196-0709(87)80007-8; Cha YH, 2008, J NEUROL, V255, P1038, DOI 10.1007/s00415-008-0837-3; Cha YH, 2019, OTOL NEUROTOL, V40, pE928, DOI 10.1097/MAO.0000000000002341; Cha YH, 2018, BRAIN TOPOGR, V31, P1047, DOI 10.1007/s10548-018-0671-6; Cha YH, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00261; Cha YH, 2016, BRAIN STIMUL, V9, P539, DOI 10.1016/j.brs.2016.03.016; Cha YH, 2016, OTOL NEUROTOL, V37, P805, DOI 10.1097/MAO.0000000000001045; Cha YH, 2013, CEPHALALGIA, V33, P1160, DOI 10.1177/0333102413487999; Cha YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049560; Cha Yoon-Hee, 2012, Continuum (Minneap Minn), V18, P1142, DOI 10.1212/01.CON.0000421623.56525.11; Cha YH, 2009, SEMIN NEUROL, V29, P520, DOI 10.1055/s-0029-1241038; Chen YF, 2019, BRAIN CONNECT, V9, P311, DOI 10.1089/brain.2018.0647; Ding L, 2014, IEEE T BIO-MED ENG, V61, P2070, DOI 10.1109/TBME.2014.2313575; Golding JF, 2016, HAND CLINIC, V137, P371, DOI 10.1016/B978-0-444-63437-5.00027-3; Grandy TH, 2013, NEUROIMAGE, V79, P10, DOI 10.1016/j.neuroimage.2013.04.059; Grandy TH, 2013, PSYCHOPHYSIOLOGY, V50, P570, DOI 10.1111/psyp.12043; Haegens S, 2014, NEUROIMAGE, V92, P46, DOI 10.1016/j.neuroimage.2014.01.049; Hain TC, 1999, ARCH OTOLARYNGOL, V125, P615, DOI 10.1001/archotol.125.6.615; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Macke A, 2012, J NEUROL, V259, P1326, DOI 10.1007/s00415-011-6349-6; Neuhauser HK, 2006, NEUROLOGY, V67, P1028, DOI 10.1212/01.wnl.0000237539.09942.06; Neuhauser HK, 2005, NEUROLOGY, V65, P898, DOI 10.1212/01.wnl.0000175987.59991.3d; Patterson JA, 2014, INT J SPORTS PHYS TH, V9, P135; Smit CM, 2006, INT J PSYCHOPHYSIOL, V61, P235, DOI 10.1016/j.ijpsycho.2005.10.004; Staab JP, 2017, J VESTIBUL RES-EQUIL, V27, P191, DOI 10.3233/VES-170622; Tavakoli AV, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00214; Vieira R, 2017, HEALTH PSYCHOL REV, V11, P222, DOI 10.1080/17437199.2017.1343680; Yuan H, 2017, BRAIN CONNECT, V7, P617, DOI 10.1089/brain.2017.0514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2022	17	2							e0263558	10.1371/journal.pone.0263558	http://dx.doi.org/10.1371/journal.pone.0263558			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0W8MA	35120184	Green Published, gold			2023-01-03	WOS:000789273600053
J	Alle, S; Kanakan, A; Siddiqui, S; Garg, A; Karthikeyan, A; Mehta, P; Mishra, N; Chattopadhyay, P; Devi, P; Waghdhare, S; Tyagi, A; Tarai, B; Hazarik, PP; Das, P; Budhiraja, S; Nangia, V; Dewan, A; Sethuraman, R; Subramanian, C; Srivastava, M; Chakravarthi, A; Jacob, J; Namagiri, M; Konala, V; Dash, D; Sethi, T; Jha, S; Agrawal, A; Pandey, R; Vinod, PK; Priyakumar, UD				Alle, Shanmukh; Kanakan, Akshay; Siddiqui, Samreen; Garg, Akshit; Karthikeyan, Akshaya; Mehta, Priyanka; Mishra, Neha; Chattopadhyay, Partha; Devi, Priti; Waghdhare, Swati; Tyagi, Akansha; Tarai, Bansidhar; Hazarik, Pranjal Pratim; Das, Poonam; Budhiraja, Sandeep; Nangia, Vivek; Dewan, Arun; Sethuraman, Ramanathan; Subramanian, C.; Srivastava, Mashrin; Chakravarthi, Avinash; Jacob, Johnny; Namagiri, Madhuri; Konala, Varma; Dash, Debasish; Sethi, Tavpritesh; Jha, Sujeet; Agrawal, Anurag; Pandey, Rajesh; Vinod, P. K.; Priyakumar, U. Deva			COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits	PLOS ONE			English	Article								The variability of clinical course and prognosis of COVID-19 highlights the necessity of patient sub-group risk stratification based on clinical data. In this study, clinical data from a cohort of Indian COVID-19 hospitalized patients is used to develop risk stratification and mortality prediction models. We analyzed a set of 70 clinical parameters including physiological and hematological for developing machine learning models to identify biomarkers. We also compared the Indian and Wuhan cohort, and analyzed the role of steroids. A bootstrap averaged ensemble of Bayesian networks was also learned to construct an explainable model for discovering actionable influences on mortality and days to outcome. We discovered blood parameters, diabetes, co-morbidity and SpO2 levels as important risk stratification features, whereas mortality prediction is dependent only on blood parameters. XGboost and logistic regression model yielded the best performance on risk stratification and mortality prediction, respectively (AUC score 0.83, AUC score 0.92). Blood coagulation parameters (ferritin, D-Dimer and INR), immune and inflammation parameters IL6, LDH and Neutrophil (%) are common features for both risk and mortality prediction. Compared with Wuhan patients, Indian patients with extreme blood parameters indicated higher survival rate. Analyses of medications suggest that a higher proportion of survivors and mild patients who were administered steroids had extreme neutrophil and lymphocyte percentages. The ensemble averaged Bayesian network structure revealed serum ferritin to be the most important predictor for mortality and Vitamin D to influence severity independent of days to outcome. The findings are important for effective triage during strains on healthcare infrastructure.	[Alle, Shanmukh; Garg, Akshit; Karthikeyan, Akshaya; Vinod, P. K.; Priyakumar, U. Deva] Int Inst Informat Technol, Ctr Computat Nat Sci & Bioinformat, Hyderabad, Telangana, India; [Kanakan, Akshay; Mehta, Priyanka; Mishra, Neha; Chattopadhyay, Partha; Devi, Priti; Dash, Debasish; Agrawal, Anurag; Pandey, Rajesh] CSIR Inst Genom & Integrat Biol CSIR IGIB, INtegrat Genom HOst PathogEn INGEN HOPE Lab, Delhi, India; [Siddiqui, Samreen; Waghdhare, Swati; Tyagi, Akansha; Tarai, Bansidhar; Hazarik, Pranjal Pratim; Das, Poonam; Budhiraja, Sandeep; Nangia, Vivek; Dewan, Arun; Jha, Sujeet] Max Healthcare, Max Super Special Hosp, Delhi, India; [Chattopadhyay, Partha; Devi, Priti] Intel Technol India Private Ltd, Bangalore, Karnataka, India; [Sethuraman, Ramanathan; Subramanian, C.; Srivastava, Mashrin; Chakravarthi, Avinash; Jacob, Johnny; Namagiri, Madhuri; Konala, Varma] Indraprastha Inst Informat Technol Delhi, New Delhi, India; [Sethi, Tavpritesh] Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India	International Institute of Information Technology Hyderabad; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Intel Corporation; Indraprastha Institute of Information Technology Delhi; Academy of Scientific & Innovative Research (AcSIR)	Vinod, PK; Priyakumar, UD (corresponding author), Int Inst Informat Technol, Ctr Computat Nat Sci & Bioinformat, Hyderabad, Telangana, India.; Agrawal, A; Pandey, R (corresponding author), CSIR Inst Genom & Integrat Biol CSIR IGIB, INtegrat Genom HOst PathogEn INGEN HOPE Lab, Delhi, India.; Jha, S (corresponding author), Max Healthcare, Max Super Special Hosp, Delhi, India.	sujeet.jha@maxhealthcare.com; a.agrawal@igib.res.in; rajeshp@igib.in; vinod.pk@iit.ac.in; deva@iiit.ac.in	Chattopadhyay, Partha/GYU-3580-2022; Agrawal, Anurag/GZL-5821-2022					Ahmed S, 2021, ANN MED SURG, V63, DOI 10.1016/j.amsu.2021.02.009; Awasthi R., 2020, LEARNING EXPLAINABLE; Bajgain KT, 2021, AM J INFECT CONTROL, V49, P238, DOI 10.1016/j.ajic.2020.06.213; Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhargava A, 2020, CLIN INFECT DIS, V71, P1962, DOI 10.1093/cid/ciaa674; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005; Chowdhury MEH, 2021, COGN COMPUT, DOI 10.1007/s12559-020-09812-7; Djakpo DK, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200817; Duan J, 2020, J MED VIROL, V92, P2616, DOI 10.1002/jmv.26082; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Hao BR, 2020, ELIFE, V9, DOI 10.7554/eLife.60519; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jha IP, 2021, JMIR MENT HEALTH, V8, DOI 10.2196/25097; Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414; Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1; Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926; Kar S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92146-7; Karthikeyan A, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.626697; Koller D., 2009, PROBABILISTIC GRAPHI; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Linssen J., 2020, ELIFE, P9; Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775; Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020; Magunia H, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03720-4; Mahdavi M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252384; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Mitra A, 2020, AM J HEMATOL, V95, P999, DOI 10.1002/ajh.25793; Olalla J, 2020, NEW ENGL J MED, V383, P993, DOI 10.1056/NEJMc2022236; Ponsford MJ, 2020, CIRCULATION, V142, P1791, DOI 10.1161/CIRCULATIONAHA.120.050753; RANA R., 2015, J PRACT CARDIOVASC S, V1, P69, DOI [10.4103/2395-5414.157577, DOI 10.4103/2395-5414.157577]; Rizo-Tellez SA, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101560; Roberts M, 2021, NAT MACH INTELL, V3, P199, DOI 10.1038/s42256-021-00307-0; Saha P, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201312; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Sethi T, 2019, AAAI CONF ARTIF INTE, P710; Subudhi S, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00456-x; Vetter P, 2020, LANCET MICROBE, V1, pE309, DOI 10.1016/S2666-5247(20)30173-7; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wang R, 2020, GENOMICS, V112, P5204, DOI 10.1016/j.ygeno.2020.09.028; Xie J, 2020, DEV EXTERNAL VALIDAT, DOI [10.2139/ssrn.3562456, 10.1101/2020.03.28.20045997]; Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006; Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7; Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504; Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889; Zhao Y, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00723-1; Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490	51	3	3	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264785	10.1371/journal.pone.0264785	http://dx.doi.org/10.1371/journal.pone.0264785			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P4LU	35298502	gold, Green Published			2023-01-03	WOS:000784193600024
J	Brignone, L; Gomez, AM				Brignone, Laura; Gomez, Anu Manchikanti			Access to domestic violence advocacy by race, ethnicity and gender: The impact of a digital warm handoff from the emergency department	PLOS ONE			English	Article							INTIMATE PARTNER VIOLENCE; SOCIAL-SERVICES; NATIONAL-SURVEY; HEALTH; PAIN; BARRIERS; IDENTIFICATION; VICTIMS; ABUSE	BackgroundRacial/ethnic minority survivors of domestic violence (DV) referred from emergency departments (EDs) face barriers connecting with advocacy services due to systemic inequities. This study assesses the impact of Domestic Violence Report and Referral (DVRR), a digital mandatory reporting compliance system with integrated direct-to-advocacy referrals sent with patient consent, on survivors' likelihood of receiving advocacy by race/ethnicity and gender. MethodsWe assessed ED charts between 2014-2018 in an urban, Level 1 trauma center for DV-related positive screening, chief concern, or documentation in medical/social work notes. We matched these visits by name to local DV advocacy agency records. Using logistic regression, we assessed survivor odds of reaching advocacy by DVRR receipt, race/ethnicity and gender. We used predicted probabilities to identify between-group differences in advocacy services received. ResultsOf the 1366 visits, 740 received the DVRR intervention; 323 received advocacy services Without DVRR, compared to white, female survivors (n = 87), male survivors (n = 132) had 0.20 (95% CI: 0.07-0.56) times the odds of reaching advocacy compared to female survivors; Latinx survivors (n = 136) had 2.53 (95% CI: 1.58-4.07) times the odds of reaching advocacy compared to white survivors. With DVRR, the odds and predicted probabilities of reaching advocacy increased significantly for all survivors. White, female survivors (n = 74) who received DVRR experienced 2.60 (95% CI: 1.66-4.07) times the odds of connecting with advocacy. Compared to this reference group, Black survivors (n = 480) who received DVRR experienced 4.66 additional times the odds of reaching advocacy services (95% CI: 3.09-7.04) and male survivors (n = 84) experienced 8.96 additional times the odds (95% CI: 2.81-28.56). Overall, we predict 43% (95% CI: 38-53%) of Latinx survivors (n = 177), 36% (95% CI: 31-40%) of Black survivors (n = 480) and 23% (95% CI: 14-32%) of white survivors (n = 83); 37% (95% CI: 33-40%) of women (n = 656) and 29% (95% CI: 18-42%) of men (n = 84) received advocacy services with DVRR. ConclusionDirect-to-advocacy ED referrals facilitated by eHealth technology improve access to advocacy care for all survivors in this sample; marginalized racial and ethnic groups most often victimized by DV appear to have the highest rates of connection to advocacy.	[Brignone, Laura; Gomez, Anu Manchikanti] Univ Calif Berkeley, Sexual Hlth & Reprod Equity Program SHARE, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Brignone, L (corresponding author), Univ Calif Berkeley, Sexual Hlth & Reprod Equity Program SHARE, Berkeley, CA 94720 USA.	laura.b@berkeley.edu			Gilead Inc. [00495]	Gilead Inc.(Gilead Sciences)	Funding: LB received funding for this research from Gilead Inc. Grant #00495. The funders played no role in the study design, data collection or analysis, decision to publish or preparation of the manuscript. Their website can be accessed here: https://www.gilead.com/purpose/giving/funding-requests.	Al'Uqdah SN, 2016, J FAM VIOLENCE, V31, P877, DOI 10.1007/s10896-016-9819-x; Anderson EJ, 2021, TRAUMA VIOLENCE ABUS, V22, P870, DOI 10.1177/1524838019888889; Black M.C., 2010, NATL INTIMATE PARTNE; Brignone L, 2020, POSTER; Btoush R, 2008, J EMERG NURS, V34, P419, DOI 10.1016/j.jen.2007.10.015; Btoush R, 2009, WOMEN HEALTH ISS, V19, P253, DOI 10.1016/j.whi.2009.03.004; Campbell JC, 2009, J INTERPERS VIOLENCE, V24, P653, DOI 10.1177/0886260508317180; Cerulli C, 2012, J FAM VIOLENCE, V27, P773, DOI 10.1007/s10896-012-9469-6; Cho H, 2021, J FAM VIOLENCE, V36, P143, DOI 10.1007/s10896-019-00107-6; Choo EK, 2015, ANN EMERG MED, V65, P447, DOI 10.1016/j.annemergmed.2014.11.004; Chou CH, 2013, J HEALTH CARE POOR U, V24, P1353, DOI 10.1353/hpu.2013.0131; Cook JM, 2013, AM J GERIAT PSYCHIAT, V21, P877, DOI 10.1016/j.jagp.2013.01.016; D'Inverno A., 2019, IMPACT INTIMATE PART, P20; Davidov DM, 2015, J EMERG MED, V48, P94, DOI 10.1016/j.jemermed.2014.07.053; Davies J, 2009, ADVOCATES GUIDE 1 PD; Dheensa S, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-4924-1; Dillon Gina, 2013, Int J Family Med, V2013, P313909, DOI 10.1155/2013/313909; Donovan C, 2020, J SOCIOL, V56, P554, DOI 10.1177/1440783319882088; Feder G, 2011, LANCET, V378, P1788, DOI 10.1016/S0140-6736(11)61179-3; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Gillum TL, 2021, J AGGRESS MALTREAT T, V30, P731, DOI 10.1080/10926771.2019.1607962; Halliwell G, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4621-0; Hamberger LK, 2015, J FAM VIOLENCE, V30, P699, DOI 10.1007/s10896-015-9732-8; Hanson GC, 2021, J INTERPERS VIOLENCE, V36, P8768, DOI 10.1177/0886260519853401; Harland KK, 2021, J INTERPERS VIOLENCE, V36, pNP6125, DOI 10.1177/0886260518812070; Hine B, 2022, J INTERPERS VIOLENCE, V37, pNP5594, DOI 10.1177/0886260520944551; Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Huntley AL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-021960; Kempner J., 2018, DEV NEUROETHICS BIOE, V1, P105; Kirst M, 2012, TRAUMA VIOLENCE ABUS, V13, P198, DOI 10.1177/1524838012454942; Langenderfer-Magruder L, 2016, J INTERPERS VIOLENCE, V31, P855, DOI 10.1177/0886260514556767; Lizdas KC., 2019, COMPENDIUM STATE US, VFourth Edition, P126; Mariscal ES, 2020, CHILD YOUTH SERV REV, V113, DOI 10.1016/j.childyouth.2020.104975; Minsky-Kelly D, 2005, J INTERPERS VIOLENCE, V20, P1288, DOI 10.1177/0886260505278861; Monterrosa AE, 2021, J INTERPERS VIOLENCE, V36, pNP9153, DOI 10.1177/0886260519853403; NCADV, NAT COAL DOM VIOL; O'Neal EN, 2017, VIOLENCE AGAINST WOM, V23, P643, DOI 10.1177/1077801216646223; Overstreet NM, 2013, BASIC APPL SOC PSYCH, V35, P109, DOI 10.1080/01973533.2012.746599; Perryman SM, 2016, J RES NURS, V21, P386, DOI 10.1177/1744987116653785; Rahmqvist J, 2019, INT EMERG NURS, V42, P2, DOI 10.1016/j.ienj.2018.10.007; Rhodes KV, 2007, ANN INTERN MED, V147, P620, DOI 10.7326/0003-4819-147-9-200711060-00006; Saberi E, 2017, AUSTRALAS EMERG NURS, V20, P82, DOI 10.1016/j.aenj.2017.02.001; Satyen L, 2019, J IMMIGR MINOR HEALT, V21, P879, DOI 10.1007/s10903-018-0803-9; Serrata J, 2020, TRAUMA INFORM PRINCI, P12; Silva-Martinez E, 2017, AFFILIA J WOM SOC WO, V32, P446, DOI 10.1177/0886109917721140; Smith SG., 2017, ATLANTA GA NATL CENT, P272; Stark E., 2009, COERCIVE CONTROL ENT; Stockman JK, 2015, J WOMENS HEALTH, V24, P62, DOI 10.1089/jwh.2014.4879; Sundborg EM, 2012, BMC NURS, V11, DOI 10.1186/1472-6955-11-1; Voith LA, 2019, TRAUMA VIOLENCE ABUS, V20, P385, DOI 10.1177/1524838017717744; Vonkeman J, 2019, CUREUS, V11, DOI 10.7759/cureus.6493; Wandner LD, 2012, J PAIN, V13, P220, DOI 10.1016/j.jpain.2011.10.014; Wolff J, 2017, J EMERG MED, V53, P771, DOI 10.1016/j.jemermed.2017.06.044; Zijlstra E, 2017, J INTERPERS VIOLENCE, V32, P1044, DOI 10.1177/0886260515587663	54	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264814	10.1371/journal.pone.0264814	http://dx.doi.org/10.1371/journal.pone.0264814			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0P4VV	35302999	gold, Green Published			2023-01-03	WOS:000784220200044
J	Habte, A; Lukas, K; Melis, T; Tamene, A; Sahle, T; Hailu, M; Gizachew, A				Habte, Aklilu; Lukas, Kaleegziabher; Melis, Tamirat; Tamene, Aiggan; Sahle, Tadesse; Hailu, Mulugeta; Gizachew, Addisalem			Determinants of neonatal near miss among neonates admitted to public hospitals in Southern Ethiopia, 2021: A case-control study	PLOS ONE			English	Article							HEALTH-CARE; MORTALITY; SURVIVAL; CRITERIA	BackgroundNeonatal near-miss (NNM) cases refer to situations in which babies are on the verge of dying between the ages of 0 and 28 days due to severe morbidity that occurs during pregnancy, delivery, or extra-uterine life, but survive either by luck or due to high-quality health care. Identifying NNM cases and addressing their determinants is crucial for devising comprehensive and relevant interventions to tackle neonatal morbidity and mortality. Hence, this study aimed at finding out the determinants of NNM in neonates admitted to public hospitals in Hadiya zone, southern Ethiopia. MethodsA hospital-based unmatched case-control study was conducted in three selected hospitals in southern Ethiopia from May 1 to June 30, 2021. A total of 484 participants took part in the study (121 cases and 363 controls). Controls were chosen using systematic sampling approaches, whereas cases were recruited consecutively at the time of discharge. Cases were selected based on the Latin American Centre for Perinatology (CLAP) criteria of an NNM. A structured interviewer-administered questionnaire and a data extraction checklist were used for data collection. The Data were entered into Epi-Data version 3.1 and exported to SPSS version 23 for analysis. A multivariable logistic regression analysis with a p-value of ResultsNinety-seven (80.1%) and 56 (46.2%) near-miss cases encountered at least one pragmatic and management criteria, respectively. The most common pragmatic and management criteria were gestational age less than 33 weeks (44.6%) and intravenous antibiotic usage up to 7 days and before 28 days of life (27.3%), respectively. A short birth interval [AOR = 2.15, 95% CI: 1.29, 3.57], lack of ANC [AOR = 3.37; 95%CI: 1.35, 6.39], Caesarean mode of delivery [AOR = 2.24; 95%CI: 1.20, 4.16], the occurrence of a third maternal delay [AOR = 3.47; 95% CI: 2.11, 5.75], and poor birth preparedness and complication readiness (BPCR) plan[AOR = 2.50; 95% CI: 1.49,4.13] were identified as a significant determinants of NNM. Conclusion and recommendationThe provision of adequate ANC should be a priority for health care providers at service delivery points. To avoid serious neonatal problems, mothers who deliver by Cesarean section should receive more attention from their families and health care providers. Health care providers in the ANC unit should encourage pregnant women to implement the WHO-recommended elements of the BPCR plan. To achieve optimal birth spacing, healthcare providers should focus on the contraceptive provision. Unnecessary delays in health facilities during childbirth should be avoided at all costs.	[Habte, Aklilu; Lukas, Kaleegziabher; Tamene, Aiggan; Hailu, Mulugeta; Gizachew, Addisalem] Wachemo Univ, Coll Med & Hlth Sci, Sch publ Hlth, Hosanna, Ethiopia; [Melis, Tamirat] Wolk Univ, Coll Med & Hlth Sci, Dept publ Hlth, Wolkite, Ethiopia; [Sahle, Tadesse] Wolk Univ, Coll Med & Hlth Sci, Dept Nursing, Wolkite, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Habte, A (corresponding author), Wachemo Univ, Coll Med & Hlth Sci, Sch publ Hlth, Hosanna, Ethiopia.	akliluhabte57@gmail.com	hailegebireal, aklilu habte/ABD-1527-2020; Habte, Aklilu/ABB-7649-2020	hailegebireal, aklilu habte/0000-0002-5719-4294; 				Abebo TA, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-018-0256-6; Afolabi bm., 2017, BMC J NEONATAL BIOL, V6, P1; American Academy of Pediatrics, 2012, GUID PER CAR, V7th; [Anonymous], 2019, ETH MIN DEM HLTH SUR; [Anonymous], SUST DEV GOAL 3 ENS; Avenant T, 2009, BEST PRACT RES CL OB, V23, P369, DOI 10.1016/j.bpobgyn.2008.12.005; de Lima THB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2020-x; Conde-Agudelo A, 2006, JAMA-J AM MED ASSOC, V295, P1809, DOI 10.1001/jama.295.15.1809; Carvalho OMC, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03128-y; CSA ICF, 2016, ETH DEM HLTH SURV; Essendi H, 2011, J URBAN HEALTH, V88, P356, DOI 10.1007/s11524-010-9481-1; Gonçalves Annelise C., 2015, Rev. Bras. Saude Mater. Infant., V15, P337, DOI 10.1590/S1519-38292015000300009; Habte A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251826; Habte A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246243; Haftu A., 2018, BMC RES NOTES, V11, P1, DOI [10.1186/s13104-017-3088-5, DOI 10.1186/S13104-017-3088-5]; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Kale PL, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051006587, 10.11606/s1518-8787.2017051006587]; Kale PL, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00179115, 10.1590/0102-311x00179115]; Karim AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065160; Kassar SB, 2013, J PEDIAT-BRAZIL, V89, P269, DOI 10.1016/j.jped.2012.11.005; Lansky S, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00133213; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Mamta G., 2018, J CLIN DIAGN RES, V12; Mersha A, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2684-x; Moss William, 2002, J Perinatol, V22, P484; Moster D, 2008, NEW ENGL J MED, V359, P262, DOI 10.1056/NEJMoa0706475; da Silva AAM, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00129613; Mukwevho MT, 2007, 27 C PRIOR PER CAR S; Nakimuli A, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0362-3; Nisha MK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024392; Organization W.H, 2014, EV NEWB ACT PLAN END; Organization W.H, 2015, WHO REC HLTH PROM IN; Orsido TT, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2227-5; Pileggi-Castro C, 2014, BJOG-INT J OBSTET GY, V121, P110, DOI 10.1111/1471-0528.12637; Prado DS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000742, 10.11606/s1518-8787.2018052000742]; Roga E.Y., 2020, DETERMINANTS NEONATA; Rutstein SO, 2005, INT J GYNECOL OBSTET, V89, pS7, DOI 10.1016/j.ijgo.2004.11.012; Sankar MJ, 2016, J PERINATOL, V36, pS1, DOI 10.1038/jp.2016.27; Santos JP, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0758-y; Santos JP, 2015, CLINICS, V70, P820, DOI 10.6061/clinics/2015(12)10; Say L, 2010, J PEDIAT-BRAZIL, V86, P1, DOI [10.2223/JPED.1978, 10.1590/S0021-75572010000100001]; Shroff BD, 2019, J OBSTET GYN INDIA, V69, P50, DOI 10.1007/s13224-018-1093-9; Silva Guilherme Alberto, 2017, Rev. Bras. Saude Mater. Infant., V17, P159, DOI 10.1590/1806-93042017000100009; Singh PK, 2014, HEALTH POLICY PLANN, V29, P542, DOI 10.1093/heapol/czt039; Surve S., 2017, CURR PEDIAT RES, V21, P264; Tassew HA, 2020, INT J PEDIAT, V2020, DOI 10.1155/2020/1092479; Tekola AF, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03601-2; Uleanya ND, 2019, AFR HEALTH SCI, V19, P1554, DOI 10.4314/ahs.v19i1.29; UNICEF, 2013, SAV CHILDR APPL 3 DE; UNICEF United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2019, MONIT SITUATION CHIL, V386, P2276; United Nations Children's Fund (UNICEF) World Health Organization (WHO), 2019, WHONMHNHD1921; USAID, 2017, MAT NEON CHILD HLTH; USAID, 2016, USAID COMB MAT NEON; Victora C G, 2001, Sao Paulo Med J, V119, P33; WHO, 2009, MON EM OBST CAR; WHO UNICEF, 2009, HOM VIS NEWB CHILD S; Wondemagegn AT, 2018, PUBLIC HEALTH REV, V39, DOI 10.1186/s40985-018-0110-y; World Health Organization, 2015, PREGN CHILDB POSTP N; World Health Organization, 2014, EV NEWB ACT PLAN END; World Health Organization, 2018, GLOB HLTH OBS GHO DA	61	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5								10.1371/journal.pone.0268041	http://dx.doi.org/10.1371/journal.pone.0268041			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M1MQ	35522663	gold, Green Published			2023-01-03	WOS:000835222600013
J	Hepkema, BW; Koster, L; Geleijn, E; Van den Ende, E; Tahir, L; Oste, J; Prins, B; Van der Velde, N; Van Hout, H; Nanayakkara, PWB				Hepkema, Bouke W.; Koster, Lydia; Geleijn, Edwin; Van den Ende, Eva; Tahir, Lara; Oste, Johan; Prins, Bernard; Van der Velde, Nathalie; Van Hout, Hein; Nanayakkara, Prabath W. B.			Feasibility of a new multifactorial fall prevention assessment and personalized intervention among older people recently discharged from the emergency department	PLOS ONE			English	Article							COMMUNITY; RISK	Background and importance Falls among older people occur frequently and are a leading cause of Emergency department (ED) admissions, disability, death and rising health care costs. Multifactorial fall prevention programs that are aimed to target the population at risk have shown to effectively reduce the rate of falling and fall-related injuries in community-dwelling older people. However, the participation of and adherence to these programs in real life situation is generally low. Objective To test the feasibility of a transitionally organized fall prevention assessment with accompanying personalized intervention initiated at the ED. Design, settings and participants A process evaluation, of a non-randomized controlled pilot trial for implementing a transitionally organized multifactorial fall prevention intervention, was performed using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to gain insight into the barriers and facilitators of implementation. Older fallers (>70yrs) presenting at the ED were selected based on ZIP-code and after obtaining informed consent, data for the evaluation was collected through questionnaires and interviews. Furthermore, feedback was collected from the healthcare providers. Main results The consent was obtained by 24 (70%) of the patients approached directly at the ED and 17 (26%) of the patients approached later by phone. Adherence to the protocol by the participants, clinical assessors and family practice were all more than 90%. After three months, nine (26%) of the participants had at least one recurrent fall: three (20%) patients in the intervention group and six (32%) in the control group. Conclusion ED presentation due to a fall in older persons provides a window of opportunity for optimizing adherence to a multifactorial fall prevention program as willingness to participate was higher when the patients were approached at the ED during their stay. Implementing a transitionally organized multidisciplinary fall prevention program was successful with a high protocol adherence.	[Hepkema, Bouke W.; Koster, Lydia; Geleijn, Edwin] Amsterdam UMC Locat VUmc, Dept Rehabil VUmc, Amsterdam, Netherlands; [Van den Ende, Eva; Tahir, Lara; Nanayakkara, Prabath W. B.] Amsterdam UMC Locat VUmc, Sect Gen Internal Med, Dept Internal Med, Unit Acute Med, Amsterdam, Netherlands; [Oste, Johan] Senior Policy Advisor Hlth Care, Amsterdam, Netherlands; [Prins, Bernard] Gen Practitioner Med Ctr Gelderlandpl, Amsterdam, Netherlands; [Van der Velde, Nathalie] Amsterdam UMC Locat AMC, Dept Internal Med, Sect Geriatr Med, Acad Med Ctr, Amsterdam, Netherlands; [Van Hout, Hein] Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Gen Practice & Elderly Care Med, Amsterdam UMC, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	Hepkema, BW (corresponding author), Amsterdam UMC Locat VUmc, Dept Rehabil VUmc, Amsterdam, Netherlands.	b.hepkema@amsterdamumc.nl						Berg RL., 1992, 2 50 YEARS PROMOTING; Brouwers C, 2017, NETH J MED, V75, P335; cbs, CBS STATL; Church S, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01801-7; Driessen MLS, 2020, INJURY, V51, P2553, DOI 10.1016/j.injury.2020.08.013; Fisher S, 2009, AGING CLIN EXP RES, V21, P445, DOI 10.1007/BF03327444; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Graf C, 2008, AM J NURS, V108, P52, DOI 10.1097/01.NAJ.0000314810.46029.74; Hastings SN, 2005, ACAD EMERG MED, V12, P978, DOI 10.1197/j.aem.2005.05.032; Kempen GIJM, 2008, AGE AGEING, V37, P45, DOI 10.1093/ageing/afm157; Kloet S, 2017, NETHERLANDS HAALBAAR; Lette M, 2022, HEALTH SOC CARE COMM, V30, pE469, DOI 10.1111/hsc.13230; Matchar DB, 2017, ARCH PHYS MED REHAB, V98, P1086, DOI 10.1016/j.apmr.2017.01.014; Mello JD, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2014.11.007; Milisen K, 2009, GERONTOLOGY, V55, P169, DOI 10.1159/000165172; richtlijnendatabase, RN NETHERLANDS PREVE; Schrijver EJM, 2013, NETH J MED, V71, P324; Thomas S, 2010, AGE AGEING, V39, P681, DOI 10.1093/ageing/afq102; van Lier LI, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1702-1; veiligheid, 2019, VEILIGHEIDNL PRIV BI	20	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268682	10.1371/journal.pone.0268682	http://dx.doi.org/10.1371/journal.pone.0268682			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2XL	35679254	Green Published, gold			2023-01-03	WOS:000843591400005
J	Hsu, CH; Chiu, CL; Lin, YT; Yu, AY; Kang, YT; Cherng, M; Chen, YH; Chuang, TH; Huang, HY; Pao, JL; Chen, KH; Chang, CH				Hsu, Chih-Ho; Chiu, Chen-Lun; Lin, Yi-Ting; Yu, Ann-Yu; Kang, Yen-Te; Cherng, Michael; Chen, Yi-Hui; Chuang, Ting-Hui; Huang, Hsin-Yi; Pao, Jwo-Luen; Chen, Kuo-Hsin; Chang, Chih-Hung			Triage admission protocol with a centralized quarantine unit for patients after acute care surgery during the COVID-19 pandemic: A tertiary center experience in Taiwan	PLOS ONE			English	Article								Background During the COVID-19 surge in Taiwan, the Far East Memorial Hospital established a system including a centralized quarantine unit and triage admission protocol to facilitate acute care surgical inpatient services, prevent nosocomial COVID-19 infection and maintain the efficiency and quality of health care service during the pandemics. Materials and methods This retrospective cohort study included patients undergoing acute care surgery. The triage admission protocol was based on rapid antigen tests, Liat (R) PCR and RT-PCT tests. Type of surgical procedure, patient characteristics, and efficacy indices of the centralized quarantine unit and emergency department (ED) were collected and analyzed before (Phase I: May 11 to July 2, 2021) and after (Phase II: July 3 to July 31, 2021) the system started. Results A total of 287 patients (105 in Phase I and 182 in Phase II) were enrolled. Nosocomial COVID-19 infection occur in 27 patients in phase I but zero in phase II. More patients received traumatological, orthopedic, and neurologic surgeries in phase II than in phase I. The patients' surgical risk classification, median total hospital stay, intensive care unit (ICU) stay, intraoperative blood loss, operation time, and the number of patients requiring postoperative ICU care were similar in both groups. The duration of ED stay and waiting time for acute care surgery were longer in Phase II (397 vs. 532 minutes, p < 0.0001). The duration of ED stay was positively correlated with the number of surgical patients visiting the ED (median = 66 patients, Spearman's rho = 0.207) and the occupancy ratio in the centralized quarantine unit on that day (median = 90.63%, Spearman's rho = 0.191). Conclusions The triage admission protocol provided resilient quarantine needs and sustainable acute care surgical services during the COVID-19 pandemic. The efficiency was related to the number of medical staff dedicated to the centralized quarantine unit and number of surgical patients visited in ED.	[Hsu, Chih-Ho; Chiu, Chen-Lun; Lin, Yi-Ting; Yu, Ann-Yu; Chen, Yi-Hui] Far Eastern Mem Hosp, Dept Surg, Div Gen Surg, New Taipei, Taiwan; [Hsu, Chih-Ho] Natl Yang Ming Chiao Tung Univ, Inst Hosp & Hlth Care Adm, Taipei, Taiwan; [Kang, Yen-Te; Cherng, Michael; Chen, Kuo-Hsin] Far Eastern Mem Hosp, Dept Surg, New Taipei, Taiwan; [Chuang, Ting-Hui; Huang, Hsin-Yi; Pao, Jwo-Luen; Chang, Chih-Hung] Far Eastern Mem Hosp, Dept Orthoped, New Taipei, Taiwan; [Chen, Kuo-Hsin] Yuan Ze Univ, Div Elect Engn, Taoyuan, Taiwan; [Chang, Chih-Hung] Yuan Ze Univ, Grad Sch Biotechnol & Bioengn, Taoyuan, Taiwan	Far Eastern Memorial Hospital; National Yang Ming Chiao Tung University; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; Yuan Ze University; Yuan Ze University	Chen, KH (corresponding author), Far Eastern Mem Hosp, Dept Surg, New Taipei, Taiwan.; Chang, CH (corresponding author), Far Eastern Mem Hosp, Dept Orthoped, New Taipei, Taiwan.; Chen, KH (corresponding author), Yuan Ze Univ, Div Elect Engn, Taoyuan, Taiwan.; Chang, CH (corresponding author), Yuan Ze Univ, Grad Sch Biotechnol & Bioengn, Taoyuan, Taiwan.	chen.kuohsin@gmail.com; orthocch@mail.femh.org.tw		Hsu, Chih-Ho/0000-0003-3359-5429				[Anonymous], WHO COVID 19 DASHBOA; Burke SA, 2021, CDC 2019 NOVEL CORON; Cano-Valderrama O, 2020, INT J SURG, V80, P157, DOI 10.1016/j.ijsu.2020.07.002; Chen SC, 2021, NAT IMMUNOL, V22, P393, DOI 10.1038/s41590-021-00908-2; Cheng HY, 2021, BIOCHEM BIOPH RES CO, V538, P238, DOI 10.1016/j.bbrc.2020.10.100; Corp. TT, 2021, US MAN VTRUST COVID; Deora H, 2021, WORLD NEUROSURG, V148, pE197, DOI 10.1016/j.wneu.2020.12.111; Don D, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.594831; Dreifuss NH, 2020, BRIT J SURG, V107, pE368, DOI 10.1002/bjs.11806; Erie County Medical Examiner's Office, 2021, CLOS CAS REP THROUGH; Finkelstein P, 2021, J LAPAROENDOSC ADV S, V31, P243, DOI 10.1089/lap.2020.0749; Hansen G, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02811-20; Horvath B, 2021, ANESTHESIOLOGY, V135, P904, DOI 10.1097/ALN.0000000000003947; Jewkes SV, 2020, CLIN MED, V20, pE173, DOI 10.7861/clinmed.2020-0422; Kim J, 2022, NAT PROD RES, V36, P1084, DOI 10.1080/14786419.2020.1849200; Kim PS, 2020, JAMA-J AM MED ASSOC, V324, P2149, DOI 10.1001/jama.2020.22813; Krutsri C, 2021, INT J SURG OPEN, V28, P50, DOI 10.1016/j.ijso.2020.11.021; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Li Q., 2020, NEW ENGL J MED, V382, P1199, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316]; Liu YC, 2020, BIOMED J, V43, P328, DOI 10.1016/j.bj.2020.04.007; Passarelli VC, 2021, INT J INFECT DIS, V102, P412, DOI 10.1016/j.ijid.2020.10.057; Ritchie H, OUR WORLD DATA; Wake RM, 2020, CLIN MED, V20, pE141, DOI 10.7861/clinmed.2020-0411; Zhang M, 2021, J CLIN NURS, V30, P1584, DOI 10.1111/jocn.15707	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0263688	10.1371/journal.pone.0263688	http://dx.doi.org/10.1371/journal.pone.0263688			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T3NB	35263347	gold, Green Published			2023-01-03	WOS:000804638700046
J	Sandhu, T; Szyld, EG; Anderson, MP; Shah, BA				Sandhu, Tavleen; Szyld, Edgardo G.; Anderson, Michael P.; Shah, Birju A.			Effect of rotating providers on chest compression performance during simulated neonatal cardiopulmonary resuscitation	PLOS ONE			English	Article							CARDIOVASCULAR CARE SCIENCE; BASIC LIFE-SUPPORT; INTERNATIONAL CONSENSUS; RESCUER FATIGUE; DELIVERY ROOM; QUALITY; INFANTS	ObjectiveSimulation studies in adults and pediatrics demonstrate improvement in chest compression (CCs) quality as providers rotate every two minutes. There is paucity of studies in neonates on this matter. This study hypothesized that frequent rotation while performing CCs improves provider performance and decreases fatigue. Study designProspective randomized, observational crossover study where 51 providers performed 3:1 compression-ventilation CPR as a pair on a term manikin. Participants performed CCs as part of 3 simulation models, rotating every 3, 5 and 10 minutes. Data on various CC metrics were collected. Participant vitals were recorded at multiple points during the simulation and participants reported their level of fatigue at completion of simulation. ResultsNo statistically significant difference was seen in any of the compression metrics. However, differences in the providers' fatigue scores were statistically significant. ConclusionCC performance metrics did not differ significantly, however, providers' vital signs and self-reported fatigue scores significantly increased with longer CC durations.	[Sandhu, Tavleen; Szyld, Edgardo G.; Shah, Birju A.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Sect Neonatal Perinatal Med, Oklahoma City, OK 73190 USA; [Anderson, Michael P.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Sandhu, T (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Sect Neonatal Perinatal Med, Oklahoma City, OK 73190 USA.	tavleen-sandhu@ouhsc.edu	Shah, Birju A./C-4811-2014	Shah, Birju A./0000-0002-9051-1183; sandhu, tavleen/0000-0002-7143-5859				Atkins DL, 2015, CIRCULATION, V132, pS519, DOI 10.1161/CIR.0000000000000265; Badaki-Makun O, 2013, PEDIATRICS, V131, pE797, DOI 10.1542/peds.2012-1892; Bjorshol CA, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-46; Enriquez D, 2018, AM J PERINAT, V35, P796, DOI 10.1055/s-0037-1620231; Gianotto-Oliveira R, 2015, CLINICS, V70, P190, DOI 10.6061/clinics/2015(03)07; Guideline ANZCOR, 2016, 13 6 CHEST COMPRESSI; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; Kwak SJ, 2016, CLIN EXP EMERG MED, V3, P148, DOI 10.15441/ceem.15.105; Li ES, 2015, J PERINATOL, V35, P142, DOI 10.1038/jp.2014.165; Madar J, 2021, RESUSCITATION, V161, P291, DOI 10.1016/j.resuscitation.2021.02.014; Manders S, 2009, RESUSCITATION, V80, P1015, DOI 10.1016/j.resuscitation.2009.05.014; PERLMAN JM, 1995, ARCH PEDIAT ADOL MED, V149, P20, DOI 10.1001/archpedi.1995.02170130022005; Schmolzer GM, 2016, ACTA PAEDIATR, V105, P866, DOI 10.1111/apa.13449; Soraisham AS, 2014, RESUSCITATION, V85, P238, DOI 10.1016/j.resuscitation.2013.10.016; Srikantan Shoba Krishnan, 2005, Pediatr Crit Care Med, V6, P293, DOI 10.1097/01.PCC.0000161621.74554.15; Travers AH, 2015, CIRCULATION, V132, pS51, DOI 10.1161/CIR.0000000000000272; Wyckoff MH, 2020, CIRCULATION, V142, pS185, DOI 10.1161/CIR.0000000000000895	18	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265072	10.1371/journal.pone.0265072	http://dx.doi.org/10.1371/journal.pone.0265072			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3NO	35286358	gold, Green Published			2023-01-03	WOS:000799880200033
J	Zaman, N; Parvaiz, N; Farid, R; Navid, A; Abbas, G; Azam, SS				Zaman, Naila; Parvaiz, Nousheen; Farid, Rabia; Navid, Afifa; Abbas, Ghulam; Azam, Syed Sikander			Senna makki and other active phytochemicals: Myths and realities behind covid19 therapeutic interventions	PLOS ONE			English	Article							DRUG-INTERACTIONS; CORONAVIRUS; PROTEASES; BINDING	This study aims to investigate the binding potential of chemical compounds of Senna in comparison with the experimentally tested active phytochemicals against SARS-CoV-2 protein targets to assist in prevention of infection by exploring multiple treatment options. The entire set of phytochemicals from both the groups were subjected to advanced computational analysis that explored functional molecular descriptors from a set of known medicinal-based active therapeutics followed by MD simulations on multiple SARS-CoV-2 target proteins. Our findings manifest the importance of hydrophobic substituents in chemical structures of potential inhibitors through cross-validation with the FDA-approved anti-3CL(pro) drugs. Noteworthy improvement in end-point binding free energies and pharmacokinetic profiles of the proposed compounds was perceived in comparison to the control drug, vizimpro. Moreover, the identification of common drug targets namely; AKT1, PTGS1, TNF, and DPP4 between proposed active phytochemicals and Covid19 using network pharmacological analysis further substantiate the importance of medicinal scaffolds. The structural dynamics and binding affinities of phytochemical compounds xanthoangelol_E, hesperetin, and beta-sitosterol reported as highly potential against 3CL(pro). in cell-based and cell-free assays are consistent with the computational analysis. Whereas, the secondary metabolites such as sennosides A, B, C, D present in higher amount in Senna exhibited weak binding affinity and instability against the spike protein, helicase nsp13, RdRp nsp12, and 3CL Pm . In conclusion, the results contravene fallacious efficacy claims of Senna tea interventions circulating on electronic/social media as Covid19 cure; thus emphasizing the importance of well-examined standardized data of the natural products in hand; thereby preventing unnecessary deaths under pandemic hit situations worldwide.	[Zaman, Naila; Parvaiz, Nousheen; Farid, Rabia; Navid, Afifa; Abbas, Ghulam; Azam, Syed Sikander] Quaid I Azam Univ, Natl Ctr Bioinformat, Computat Biol Lab, Islamabad, Pakistan	Quaid I Azam University	Azam, SS (corresponding author), Quaid I Azam Univ, Natl Ctr Bioinformat, Computat Biol Lab, Islamabad, Pakistan.	syedazam2008@gmail.com		Zaman, Naila/0000-0002-0664-6545	Pakistan-United States Science and Technology Cooperation Program and Higher Education Commission (HEC), Pakistan	Pakistan-United States Science and Technology Cooperation Program and Higher Education Commission (HEC), Pakistan	We are generally thankful to Pakistan-United States Science and Technology Cooperation Program and Higher Education Commission (HEC), Pakistan for financial assistance of Computational Biology Lab.	3ds, BIOVIA DISC STUD; Ahmad S, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105387; ambermd, AMB MOL DYN PACK; Andrade RJ, 2019, J HEPATOL, V70, P1222, DOI 10.1016/j.jhep.2019.02.014; Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019; Bashir A., 2022, STATPEARLS, DOI [10.1016/B978-0-444-53717-1.00960-4, DOI 10.1016/B978-0-444-53717-1.00960]; Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052; Begum J, 2021, TRANSBOUND EMERG DIS, V68, P1111, DOI 10.1111/tbed.13804; Benarba B, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01189; BEUERS U, 1991, LANCET, V337, P372, DOI 10.1016/0140-6736(91)91012-J; CDC, DIFF COVID 19 VACC; Davies M, 2015, NUCLEIC ACIDS RES, V43, pW612, DOI 10.1093/nar/gkv352; dawn, SINDH GOV CLAIMS HER; Douangamath A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18709-w; Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.1016/S1875-5364(20)30022-4, 10.3724/SP.J.1009.2019.000000]; dw, COR PAND IS FAR SCI; Elansary HO, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1463579; Ferreira JC, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.692168; fiercebiotech, PFIZ VIZ IS 3 FDA AP; G.Asantewaa, 2020, bioRxiv, DOI 10.1101/2020.11.25.398859; Gao D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00746; Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936; Ghasemiyeh P, 2021, IRAN J PHARM RES, V20, P66, DOI 10.22037/ijpr.2021.114717.15007; Goc A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253489; Grottesi A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155346; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480; Kc GB, 2021, NAT MACH INTELL, V3, P527, DOI 10.1038/s42256-021-00335-w; Khan Z., 2021, Le Pharmacien Hospitalier & Clinicien, V56, P3, DOI 10.1016/j.phclin.2020.06.003; Khezri MR, 2021, HUM CELL, V34, P700, DOI 10.1007/s13577-021-00484-5; Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12; Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P170, DOI 10.3760/cma.j.issn.1001-0939.2020.03.004; Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002; Mody V, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01577-x; Mohammadi S, 2020, PHYTOTHER RES, V34, P1556, DOI 10.1002/ptr.6628; Mohebbi N, 2020, BASIC CLIN NEUROSCI, V11, P185, DOI 10.32598/bcn.11.covid19.2500.1; Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215; Park JY, 2013, BIOORGAN MED CHEM, V21, P3730, DOI 10.1016/j.bmc.2013.04.026; Parks JM, 2020, NEW ENGL J MED, V382, P2261, DOI 10.1056/NEJMcibr2007042; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Raju S, 2020, INT J COMMUNITY MED, V7, P5088, DOI [10.18203/2394-6040.ijcmph20205189, DOI 10.18203/2394-6040.IJCMPH20205189]; Ramos-Guzman CA, 2020, ACS CATAL, V10, P12544, DOI 10.1021/acscatal.0c03420; Raza S, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3601-3; Ribas J, 2002, J ORG CHEM, V67, P7057, DOI 10.1021/jo0201225; Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035; Senna, HLTH BEN SID EFF US; Smit C, 2020, CLIN PHARMACOKINET, V59, P659, DOI 10.1007/s40262-020-00891-1; Solerte SB, 2020, ACTA DIABETOL, V57, P779, DOI 10.1007/s00592-020-01539-z; Spina E, 2016, PHARMACOL RES, V106, P72, DOI 10.1016/j.phrs.2016.02.014; statnews, HES NOB LAUR CRIT SA; Su HX, 2021, FUND RES-CHINA, V1, P151, DOI 10.1016/j.fmre.2021.01.013; thenews, GROW DEM DRIV HERB P; Vandebroek I, 2020, NAT PLANTS, V6, P723, DOI 10.1038/s41477-020-0691-6; Viana J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23938-8; Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117; WHO Coronavirus (COVID-19) Dashboard, WHO COR COVID 19 DAS; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Yang JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18319-6; Zhao Y, 2016, CURR PHARM BIOTECHNO, V17, P1134, DOI 10.2174/1389201017666160819151153; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	63	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0268454	10.1371/journal.pone.0268454	http://dx.doi.org/10.1371/journal.pone.0268454			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35700199	gold, Green Published			2023-01-03	WOS:000843619700137
J	Schietinger, A				Schietinger, Andrea			Turbocharging the T Cell to Fight Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SCREEN	Potentiating the T CellModified autologous T cells have been successfully used to treat tumors in a small proportion of patients. How can this general approach be used to treat more patients? A recent study of lymphoma, modeled in vitro, points to a potential approach.	[Schietinger, Andrea] Mem Sloan Kettering Canc Ctr, Immunol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Schietinger, A (corresponding author), Mem Sloan Kettering Canc Ctr, Immunol Program, New York, NY 10065 USA.							Legut M, 2022, NATURE, V603, P728, DOI 10.1038/s41586-022-04494-7; Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577-021-00574-3; Schmidt R, 2022, SCIENCE, V375, P513, DOI 10.1126/science.abj4008; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Ye LP, 2022, CELL METAB, V34, P595, DOI 10.1016/j.cmet.2022.02.009	5	0	0	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2022	386	24					2334	2336		10.1056/NEJMcibr2203616	http://dx.doi.org/10.1056/NEJMcibr2203616		JUN 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E6OS	35648702				2023-01-03	WOS:000806167700001
J	Plata, GG				Plata, G. Gabriel			The black market for covid-19 antiviral drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												gabrielgarciaplata@gmail.com						[Anonymous], 2021, REUTERS 1126; [Anonymous], 2022, LAUNCH SCALE SPEEDOM; [Anonymous], 2021, REUTERS 1230; [Anonymous], 2022, GOOGLE TRENDS MOLNUP; [Anonymous], 2021, FACEBOOK; Arribas JR, 2021, NEJM EVIDENCE, DOI [10.1056/EVI-Doa2100044, DOI 10.1056/EVI-DOA2100044]; Brophy J, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj.o443; Burkhalter EC, 2021, NEW YORK TIMES, P2021; Caraco Y., 2021, NEJM EVIDENCE, DOI 10.1056/EVIDoa2100043; Cofepris, 2022, COF AUTH TREATM COV; Cofepris, 2022, HLTH AL ILL MARK MOL; Huang P, 2022, NPR 0222; IDDO, MED QUAL MON GLOB IN; Mahase E, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2602; Manahan J, 2022, ABS CBN NEWS 0119; Medicines and Healthcare Products Regulatory Agency, 2021, 1 OR ANT COV 19 LAG; Medicines Patent Pool, 2021, MPP MSD ANN NEW LIC; Merck, 2021, HUM CRIS IND MERCK A; Merck, 2021, MERCK RIDG INV OR AN; Merck, 2021, MERCK RIDG MOLN OR C; Merck, 2021, MERCK RIDG ANN UK GO; National Institute for Health and Care Excellence, MOLN; Pfizer, 2021, PFIZ NOV COV 19 OR A; Phuong L, 2022, VN EXPRESS 0307	24	1	1	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2022	376								o1282	10.1136/bmj.o1282	http://dx.doi.org/10.1136/bmj.o1282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2B9AW	35640944	Bronze			2023-01-03	WOS:000810474000002
J	Hong, W; Park, YK; Kim, BO; Park, SK; Shin, J; Jang, SP; Park, HW; Yang, W; Jang, J; Jang, SW; Hwang, TH				Hong, Wooyoung; Park, Yu-Kyung; Kim, Bong-Ok; Park, Sung Kyu; Shin, Jiin; Jang, Soon-Pyo; Park, Hea-Woon; Yang, Wonjong; Jang, Joonyoung; Jang, Soon-Woo; Hwang, Tae-Ho			Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study	PLOS ONE			English	Article							CORONAVIRUS DISEASE 2019; HYDROXYCHLOROQUINE; LOPINAVIR/RITONAVIR; GUIDELINES; DIAGNOSIS; COVID-19; QUALITY; RISK	Objectives To assess efficacy and safety of the combined treatment of antibiotics (3rd-generation cephalosporin and azithromycin) and antiviral agents (lopinavir/ritonavir or hydroxychloroquine) on moderate COVID-19 patients in South Korea. Methods A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients was conducted. 299 patients met inclusion criteria for analysis. Propensity score matching (PSM) and Cox regression method were used to control and adjust for confounding factors. Mild to moderate COVID-19 patients were managed with either CA/LoP (cephalosporin, azithromycin, and lopinavir/ritonavir) (n = 57), CA/HQ (cephalosporin, azithromycin, and hydroxychloroquine) (n = 25) or standard supportive care (n = 217). We analyzed the association between treatment group and standard supportive group in terms of three endpoints: time to symptom resolution, time to viral clearance, and hospital stay duration. Using propensity-score matching analysis, three rounds of propensity-matching analysis were performed to balance baseline characteristics among three cohorts. Results Kaplan-Meier curves fitted using propensity score-matched data revealed no significant differences on time to symptom resolution, time to viral clearance, hospital stay duration among the three treatment arms (CA/LoP vs Standard, log-rank p-value = 0.2, 0.58, and 0.74 respectively for the three endpoints) (CA/HQ vs Standard, log-rank p-value = 0.46, 0.99, and 0.75 respectively). Similarly, Cox regression analysis on matched cohorts of CA/LoP and standard supportive group showed that hazard ratios of time to symptom resolution (HR: 1.447 [95%-CI: 0.813-2.577]), time to viral clearance(HR: 0.861, [95%-CI: 0.485-1.527]), and hospital stay duration (HR: 0.902, [95%-CI: 0.510-1.595]) were not significant. For CA/HQ and standard supportive group, hazard ratios of the three endpoints all showed no statistical significance (HR: 1.331 [95%-CI:0.631-2.809], 1.005 [95%-CI:0.480-2.105], and 0.887, [95%-CI:0.422-1.862] respectively). No severe adverse event or death was observed in all groups. Conclusions Combined treatment of 3rd cephalosporin, azithromycin and either low-dose lopinavir/ritonavir or hydroxychloroquine was not associated with better clinical outcomes in terms of time to symptom resolution, time to viral clearance, and hospital stay duration compared to standard supportive treatment alone. Microbiological evidence should be closely monitored when treating SARS-CoV-2 patients with antibiotics to prevent indiscreet administration of empirical antimicrobial treatments.	[Hong, Wooyoung] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA USA; [Park, Yu-Kyung; Kim, Bong-Ok; Park, Sung Kyu; Park, Hea-Woon; Yang, Wonjong; Jang, Joonyoung] Korea Workers Compensat & Welf Serv Daegu Hosp, Daegu, South Korea; [Shin, Jiin] Seoul Natl Univ, Sch Med, Seoul, South Korea; [Jang, Soon-Pyo] Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Div Oral Pathobiol Sci, Sapporo, Hokkaido, Japan; [Jang, Soon-Woo] Bukha Publ Hlth Ctr, Jangseong, South Korea; [Jang, Soon-Woo] Pusan Univ, Sch Med, Yangsan, South Korea; [Hwang, Tae-Ho] Pusan Natl Univ, Sch Med, Dept Pharmacol, Yangsan, South Korea; [Hwang, Tae-Ho] Pusan Natl Univ, Gene & Cell Therapy Res Ctr Vessel Associated Dis, Sch Med, Yangsan, South Korea	Harvard University; Seoul National University (SNU); Hokkaido University; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital	Jang, SW (corresponding author), Bukha Publ Hlth Ctr, Jangseong, South Korea.; Hwang, TH (corresponding author), Pusan Natl Univ, Sch Med, Dept Pharmacol, Yangsan, South Korea.; Hwang, TH (corresponding author), Pusan Natl Univ, Gene & Cell Therapy Res Ctr Vessel Associated Dis, Sch Med, Yangsan, South Korea.	kmedicsoon@pusan.ac.kr; thhwang@pusan.ac.kr	Jang, Soonwoo/AAC-3896-2021	Jang, Soonwoo/0000-0003-2303-7124	Pusan National University [201914420004]	Pusan National University(Pusan National University)	This study was supported by a 2-Year Research Grant of Pusan National University (No. 201914420004).	Adler H, 2020, LANCET MICROBE, V1, pE62, DOI 10.1016/S2666-5247(20)30036-7; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]; Campbell SG, 2003, CHEST, V123, P1142, DOI 10.1378/chest.123.4.1142; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Choi MJ, 2021, INT J INFECT DIS, V102, P275, DOI 10.1016/j.ijid.2020.10.062; Choi WS, 2020, EMERG INFECT DIS, V26, P2338, DOI 10.3201/eid2610.201539; Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786; ClinicalTrials.gov, COV 19 CLIN TRIALS S; Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932; Corman V, 2020, DIAGNOSTIC DETECTION, P13; COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1; Danish N., 2020, CLIN INFECT DIS, V70, P1186, DOI [10.1093/cid/ciz320, DOI 10.1093/CID/CIZ320, DOI 10.1093/CID/CIAA1470]; Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x; Fernandes FM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199028; Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Govind R, 2021, BRIT J PSYCHIAT, V219, P368, DOI [10.1192/bjp.2020.151, 10.1192/bjp.2021.35]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Han Y C, 1996, Respirology, V1, P115, DOI 10.1111/j.1440-1843.1996.tb00019.x; Hannah Ritchie EO-O, 2020, DAILY CONFIRMED DEAT; Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351; Huang JT, 2020, CLIN INFECT DIS, V71, P2158, DOI 10.1093/cid/ciaa631; Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268; JEFFERSON H, 1975, AM J CLIN PATHOL, V64, P689; Ji W, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e237; Karolyi M, 2021, WIEN KLIN WOCHENSCHR, V133, P284, DOI 10.1007/s00508-020-01720-y; Kim J, 2022, NAT PROD RES, V36, P1084, DOI 10.1080/14786419.2020.1849200; Kim Sollip, 2006, Korean J Lab Med, V26, P93, DOI 10.3343/kjlm.2006.26.2.93; Kim SB, 2020, INFECT CHEMOTHER, V52, P281, DOI 10.3947/ic.2020.52.2.281; Kim TS, 2021, OBESITY, V29, P279, DOI 10.1002/oby.23076; Kumar R, 2021, COMPUT BIOL MED, V130, DOI 10.1016/j.compbiomed.2020.104186; Lee JY, 2020, INT J INFECT DIS, V98, P462, DOI 10.1016/j.ijid.2020.07.017; Li YP, 2020, MED-CAMBRIDGE, V1, P105, DOI 10.1016/j.medj.2020.04.001; Lin SH, 2020, GENES DIS, V7, P520, DOI 10.1016/j.gendis.2020.06.009; Lofgren Sarah M, 2020, medRxiv, DOI 10.1101/2020.07.16.20155531; Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1844, 10.1136/bmj.m2328]; Manohar P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00420; Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570; Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Prevention KCfDCa, 2020, MANAGEMENT GUIDELINE; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Rismanbaf A, 2020, ARCH ACAD EMERG MED, V8; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Roson B, 2004, CLIN INFECT DIS, V38, P222, DOI 10.1086/380639; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x; Sharma S, 2022, ENG COMPUT-GERMANY, V38, P2897, DOI 10.1007/s00366-021-01294-x; Tang C, 2012, INTERN MED J, V42, P968, DOI 10.1111/j.1445-5994.2012.02886.x; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Townsend L, 2020, JAC-ANTIMICROB RESIS, V2, DOI 10.1093/jacamr/dlaa071; van der Eerden MM, 2005, EUR J CLIN MICROBIOL, V24, P241, DOI 10.1007/s10096-005-1316-8; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; World Health Organization, 2020, COR DIS COVID 19 SIT; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706; You X, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244128; Yu X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02893-8; Zhao W, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.558539; Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443	69	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2022	17	5							e0267645	10.1371/journal.pone.0267645	http://dx.doi.org/10.1371/journal.pone.0267645			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1HN	35507600	Green Published, gold			2023-01-03	WOS:000818817800044
J	Teal, S; Edelman, A				Teal, Stephanie; Edelman, Alison			Selection, Effectiveness, and Adverse Effects of Contraception Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Teal, Stephanie] Case Western Reserve Univ, Univ Hosp Med Ctr, Cleveland, OH 44106 USA; [Edelman, Alison] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	Case Western Reserve University; University Hospitals of Cleveland; Oregon Health & Science University	Teal, S (corresponding author), Univ Hosp Med Ctr, Dept Obstet & Gynecol, 11100 Euclid Ave,MAC 5034, Cleveland, OH 44106 USA.	stephanie.teal@uhhospitals.org						American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women Contraceptive Equity Expert Work Group and Committee on Ethics, 2022, Obstet Gynecol, V139, P350, DOI 10.1097/AOG.0000000000004659; Brabaharan S, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.43730; Centers for Disease Control and Prevention, PREGN MORT SURV SYST; Centers for Disease Control and Prevention, 2016, US MED EL CRIT US ME; Teal S, 2021, JAMA-J AM MED ASSOC, V326, P2507, DOI 10.1001/jama.2021.21392	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2022	327	15					1505	1505						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1C3PR	35438730				2023-01-03	WOS:000793035800039
J	Tsay, SV; Bartoces, M; Gouin, K; Kabbani, S; Hicks, LA				Tsay, Sharon V.; Bartoces, Monina; Gouin, Katryna; Kabbani, Sarah; Hicks, Lauri A.			Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter; Early Access								This study of Medicare claims data examines the prescribing of antibiotics to older US patients who had outpatient visits for COVID-19 in an effort to address unnecessary antibiotic use for viral infections.	[Tsay, Sharon V.; Bartoces, Monina; Gouin, Katryna; Kabbani, Sarah; Hicks, Lauri A.] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Tsay, SV (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.	lxq1@cdc.gov			CDC	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was funded by the CDC.	Bosworth ARJ., 2020, MEDICARE BENEFICIARY; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Gerber JS, 2013, PEDIATRICS, V131, P677, DOI 10.1542/peds.2012-2500; King Laura M, 2021, Antimicrob Steward Healthc Epidemiol, V1, P1, DOI 10.1017/ash.2021.230; Kow CS, 2020, CLIN DRUG INVEST, V40, P989, DOI 10.1007/s40261-020-00961-z; Oldenburg CE, 2021, JAMA-J AM MED ASSOC, V326, P490, DOI 10.1001/jama.2021.11517	6	3	3	2	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.5471	http://dx.doi.org/10.1001/jama.2022.5471		APR 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0I5LK	35394497	Bronze, Green Published			2023-01-03	WOS:000779462100002
J	Panagiotoglou, D				Panagiotoglou, Dimitra			Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series	PLOS ONE			English	Article							FACILITIES; REDUCTION	Background On 14 April 2016, British Columbia's Provincial Medical Health Officer declared the overdose crisis a public health emergency, sanctioning the implementation of new overdose prevention sites (OPS) and supervised consumption sites (SCS) across the province. Methods We used the BC Centre for Disease Control's Provincial Overdose Cohort of all overdose events between 1 January 2015 and 31 December 2017 to evaluate the population-level effects of OPSs and SCSs on acute health service use and mortality. We matched local health areas (LHA) that implemented any site with propensity score matched controls and conducted controlled interrupted time series analysis. Results During the study period, twenty-five OPSs and SCSs opened across fourteen of British Columbia's 89 LHAs. Results from analysis of LHAs with matched controls (i.e. excluding Vancouver DTES) were mixed. Significant declines in reported overdose events, paramedic attendance, and emergency department visits were observed. However, there were no changes to trends in monthly hospitalization or mortality rates. Extensive sensitivity analyses found these results persisted. Conclusions We found OPSs and SCSs reduce opioid-related paramedic attendance and emergency department visit rates but no evidence that they reduce local hospitalization or mortality rates.	[Panagiotoglou, Dimitra] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada	McGill University	Panagiotoglou, D (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.	dimitra.panagiotoglou@mcgill.ca						Abadie A, 2010, J AM STAT ASSOC, V105, P493, DOI 10.1198/jasa.2009.ap08746; [Anonymous], 2018, **DATA OBJECT**; [Anonymous], 2017, BC PROVINCIAL OVERDO; [Anonymous], 2015, TRANSLATION MASTER F; [Anonymous], 2019, OVERDOSE PREVENTION; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; B.C. Ministry of Public Safety and Solicitor General, 2020, FENTANYL DETECTED IL; BC Centre for Disease Control, 2017, PUBL HLTH EM BC; BC Centre for Disease Control, 2019, OV RESP IND; BC Centre on Substance Use BMoH, 2017, SUP CONS SERV OP GUI; BC Coroners Service, 2018, ILL DRUG OV DEATHS B; BC government, 2007, COR ACT; BC Ministry of Health, 2017, NAT AMB CAR REP SYST; BC Ministry of Health, 2017, VIT STAT DEATHS; BC Ministry of Health, 2017, OV PREV; Bernal JL, 2019, INT J EPIDEMIOL, V48, P2062, DOI 10.1093/ije/dyz050; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; British Colombia Coroners Service, 2021, ILL DRUG TOX DEATHS; British Columbia Coroners Service, 2020, ILL DRUG TOX DEATHS; British Columbia Ministry of Health [creator], 2017, MED SERV PLAN MSP PA; Canadian Institute for Health Information [creator], 2018, DISCH ABSTR DAT HOSP; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Collins AB, 2019, INT J DRUG POLICY, V73, P199, DOI 10.1016/j.drugpo.2019.08.002; Dietze P, 2012, INT J DRUG POLICY, V23, P257, DOI 10.1016/j.drugpo.2012.02.006; DURBIN J, 1971, BIOMETRIKA, V58, P1; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.2307/2332391; Elzey MJ, 2016, PAIN PHYSICIAN, V19, P215; European Centre for Disease Prevention and Control, 2018, CONS ANT SYST US COM; Cruz MF, 2007, INT J DRUG POLICY, V18, P54, DOI 10.1016/j.drugpo.2006.12.001; Fox J., 2011, R COMPANION APPL REG, V2nd; Fraser Health, 2017, FRAS HLTH WILL OP 1; Fraser Health Vancouver Coastal Health, 2017, OV PREV RESP POL PRO; Government of Canada, SUP CONS SIT STAT AP; Harnett CE, 2016, TIMES COLONIST 1216; Hawkins NG, 2007, AM J PREV MED, V33, P162, DOI 10.1016/j.amepre.2007.03.020; Hooper T, 2016, VICTORIA BUZZ 1209; Irvine MA, 2019, ADDICTION, V114, P1602, DOI 10.1111/add.14664; Irvine MA, 2018, LANCET PUBLIC HEALTH, V3, pE218, DOI 10.1016/S2468-2667(18)30044-6; Island Health, 2017, NAN CAN MENT HLTH AS; Karamouzian M, 2020, INT J DRUG POLICY, V77, DOI 10.1016/j.drugpo.2020.102665; Kennedy MC, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002964; Kurjata A, 2017, CBC NEWS; Little S, 2019, GLOBAL NEWS 0606; Lupick T., 2016, THE GEORGIA STRAIGHT; Lupick T, 2016, THE GEORGIA STRAIGHT; Lupick T, 2018, THE GEORGIA STRAIGHT; MacNeil J, 2010, HARM REDUCT J, V7, DOI 10.1186/1477-7517-7-11; Maple Ridge Opioid Overdose Response Task Group, 2018, MAPL RIDG OP OV COMM; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Mema SC, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0273-3; Middlemass M., 2016, DUNCANS OVERDOSE PRE; Ministry of Health Uganda, 2020, CONSOLIDATED GUIDELI; Morrow Richard L, 2019, CMAJ Open, V7, pE484, DOI 10.9778/cmajo.20190003; NCHECR, 2007, SYDN MED SUP INJ CTR; Panagiotoglou D, 2018, AIDS BEHAV, V22, P3071, DOI 10.1007/s10461-018-2166-6; Papamihali K, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00436-6; Pauly B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229208; Pinheiro J, 2020, PACKAGENLME; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; R Core Team, 2021, R LANG ENV STAT COMP; Rhodes T, 2006, ADDICTION, V101, P1384, DOI 10.1111/j.1360-0443.2006.01556.x; SAS Institute Inc, 2013, SAS 9 4 STAT REF; Schuchat A, 2017, JAMA-J AM MED ASSOC, V318, P425, DOI 10.1001/jama.2017.8913; Shaw T., 2017, AB; van der Schier Rutger, 2014, F1000Prime Rep, V6, P79, DOI 10.12703/P6-79; Vancouver Coastal Health, 2018, RESP OP OV CRIS VANC; Vancouver Coastal Health, 2017, OV PREV SIT MAN; Wagar Lori, 2018, EVALUATION OVERDOSE; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wallace B, 2019, INT J DRUG POLICY, V66, P64, DOI 10.1016/j.drugpo.2019.01.017; Walters A, 2019, VERNON MORNING STAR; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Woo A. B.C, 2017, GLOBE MAIL; Wood E, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-13; Wood E, 2006, CAN MED ASSOC J, V175, P1399, DOI 10.1503/cmaj.060863; Zhang F, 2011, J CLIN EPIDEMIOL, V64, P1252, DOI 10.1016/j.jclinepi.2011.02.007	78	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2022	17	3							e0265665	10.1371/journal.pone.0265665	http://dx.doi.org/10.1371/journal.pone.0265665			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3K7EP	35316284	Green Published, gold			2023-01-03	WOS:000834238000032
J	Gupta, A; Gonzalez-Rojas, Y; Juarez, E; Casal, MC; Moya, J; Falci, DR; Sarkis, E; Solis, J; Zheng, HZ; Scott, N; Cathcart, AL; Parra, S; Sager, JE; Austin, D; Peppercorn, A; Alexander, E; Yeh, WW; Brinson, C; Aldinger, M; Shapiro, AE				Gupta, Anil; Gonzalez-Rojas, Yaneicy; Juarez, Erick; Casal, Manuel Crespo; Moya, Jaynier; Falci, Diego Rodrigues; Sarkis, Elias; Solis, Joel; Zheng, Hanzhe; Scott, Nicola; Cathcart, Andrea L.; Parra, Sergio; Sager, Jennifer E.; Austin, Daren; Peppercorn, Amanda; Alexander, Elizabeth; Yeh, Wendy W.; Brinson, Cynthia; Aldinger, Melissa; Shapiro, Adrienne E.		COMET-ICE Investigators	Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression. OBJECTIVE To evaluate the efficacy and adverse events of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial including 1057 nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for progression conducted at 57 sites in Brazil, Canada, Peru, Spain, and the US from August 27, 2020, through March 11, 2021; follow-up data were collected through April 8, 2021. INTERVENTIONS Patients were randomized (1:1) to an intravenous infusion with 500mg of sotrovimab (n = 528) or placebo (n = 529). MAIN OUTCOMES AND MEASURES The primary outcomewas the proportion of patients with COVID-19 progression through day 29 (all-cause hospitalization lasting >24 hours for acute illness management or death); 5 secondary outcomes were tested in hierarchal order, including a composite of all-cause emergency department (ED) visit, hospitalization of any duration for acute illness management, or death through day 29 and progression to severe or critical respiratory COVID-19 requiring supplemental oxygen or mechanical ventilation. RESULTS Enrollment was stopped early for efficacy at the prespecified interim analysis. Among 1057 patients randomized (median age, 53 years [IQR, 42-62], 20% were >= 65 years of age, and 65% Latinx), the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo. All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) (adjusted relative risk [RR], 0.21 [95% CI, 0.09 to 0.50]; absolute difference, -4.53%[95% CI, -6.70% to -2.37%]; P<.001). Four of the 5 secondary outcomes were statistically significant in favor of sotrovimab, including reduced ED visit, hospitalization, or death (13/528 [2%] for sotrovimab vs 39/529 [7%] for placebo; adjusted RR, 0.34 [95% CI, 0.19 to 0.63]; absolute difference, -4.91%[95% CI, -7.50% to -2.32%]; P<.001) and progression to severe or critical respiratory COVID-19 (7/528 [1%] for sotrovimab vs 28/529 [5%] for placebo; adjusted RR, 0.26 [95% CI, 0.12 to 0.59]; absolute difference, -3.97%[95% CI, -6.11% to -1.82%]; P=.002). Adverse events were infrequent and similar between treatment groups (22% for sotrovimab vs 23% for placebo); the most common events were diarrhea with sotrovimab (n = 8; 2%) and COVID-19 pneumonia with placebo (n = 22; 4%). CONCLUSIONS AND RELEVANCE Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the studywas completed is unknown.	[Gupta, Anil] William Osler Hlth Ctr, Albion Finch Med, Toronto, ON, Canada; [Gonzalez-Rojas, Yaneicy] Optimus U Corp, Miami, FL USA; [Juarez, Erick] Florida Int Med Res, Miami, FL USA; [Casal, Manuel Crespo] Alvaro Cunqueiro Hosp, IIS Galicia Sur, Vigo, Pontevedra, Spain; [Moya, Jaynier] Pines Care Res Ctr, Pembroke Pines, FL USA; [Falci, Diego Rodrigues] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Sarkis, Elias] Sarkis Clin Trials, Gainesville, FL USA; [Solis, Joel] Centex Studies, Mcallen, TX USA; [Zheng, Hanzhe; Cathcart, Andrea L.; Parra, Sergio; Sager, Jennifer E.; Alexander, Elizabeth; Yeh, Wendy W.; Aldinger, Melissa] Vir Biotechnol Inc, San Francisco, CA USA; [Scott, Nicola; Austin, Daren] GlaxoSmithKline, Brentford, England; [Peppercorn, Amanda] GlaxoSmithKline, Cambridge, MA USA; [Brinson, Cynthia] Cent Texas Clin Res, Austin, TX USA; [Shapiro, Adrienne E.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Shapiro, Adrienne E.] Univ Washington, Dept Med, Seattle, WA USA; [Shapiro, Adrienne E.] Fred Hutchinson Canc Res Ctr, E5-110,1100 Fairview Ave N, Seattle, WA 98109 USA	GlaxoSmithKline; GlaxoSmithKline; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Shapiro, AE (corresponding author), Fred Hutchinson Canc Res Ctr, E5-110,1100 Fairview Ave N, Seattle, WA 98109 USA.	aeshapir@uw.edu	Shapiro, Adrienne E/GQZ-4527-2022	Shapiro, Adrienne E/0000-0002-3106-1258	Vir Biotechnology Inc; GlaxoSmithKline	Vir Biotechnology Inc; GlaxoSmithKline(GlaxoSmithKline)	This study was sponsored by Vir Biotechnology Inc in collaboration with GlaxoSmithKline.	Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cervantes L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0684; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Craft JF, 2021, AM J TROP MED HYG, V104, P32, DOI 10.4269/ajtmh.20-1294; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Flores LE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37640; Focosi D, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2231; Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Han A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3220-8; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lee K, 2009, GLOB INST, P1; Lempp FA, 2021, NATURE, V598, P342, DOI 10.1038/s41586-021-03925-1; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Liu Haolin, 2021, bioRxiv, DOI 10.1101/2021.02.16.431305; National Institutes of Health, OPENDATA PORT SARS C; National Institutes of Health, COR DIS 2019 COVID 1; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Riley AR, 2021, SSM-POPUL HLTH, V15, DOI 10.1016/j.ssmph.2021.100860; SeyedAlinaghi S, 2021, ARCH ACAD EMERG MED, V9, DOI 10.22037/aaem.v9i1.1058; Starr Tyler N, 2021, Cell Rep Med, V2, P100255, DOI [10.1101/2021.02.17.431683, 10.1016/j.xcrm.2021.100255]; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; US Centers for Disease Control and Prevention, SARS COV 2 VAR CLASS; US Food and Drug Administration, 2021, COVID 19 DEV DRUGS B; US Food and Drug Administration, FACT SHE HEAL PROV E; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443	32	46	46	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13					1236	1246		10.1001/jama.2022.2832	http://dx.doi.org/10.1001/jama.2022.2832		MAR 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35285853	Green Published, Bronze			2023-01-03	WOS:000770397700002
J	Hortobagyi, GN; Stemmer, SM; Burris, HA; Yap, YS; Sonke, GS; Hart, L; Campone, M; Petrakova, K; Winer, EP; Janni, W; Conte, P; Cameron, DA; Andre, F; Arteaga, CL; Zarate, JP; Chakravartty, A; Taran, T; Le Gac, F; Serra, P; O'Shaughnessy, J				Hortobagyi, Gabriel N.; Stemmer, Salomon M.; Burris, Howard A.; Yap, Yoon-Sim; Sonke, Gabe S.; Hart, Lowell; Campone, Mario; Petrakova, Katarina; Winer, Eric P.; Janni, Wolfgang; Conte, Pierfranco; Cameron, David A.; Andre, Fabrice; Arteaga, Carlos L.; Zarate, Juan P.; Chakravartty, Arunava; Taran, Tetiana; Le Gac, Fabienne; Serra, Paolo; O'Shaughnessy, Joyce			Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULVESTRANT; ANASTROZOLE; THERAPY; MULTICENTER; EXEMESTANE; TARGETS; PLACEBO; CDK4/6	BACKGROUND In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether overall survival would also be longer with ribociclib was not known. METHODS Here we report the results of the protocol-specified final analysis of overall survival, a key secondary end point. Patients were randomly assigned in a 1:1 ratio to receive either ribociclib or placebo in combination with letrozole. Overall survival was assessed with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods after 400 deaths had occurred. A hierarchical testing strategy was used for the analysis of progression-free survival and overall survival to ensure the validity of the findings. RESULTS After a median follow-up of 6.6 years, 181 deaths had occurred among 334 patients (54.2%) in the ribociclib group and 219 among 334 (65.6%) in the placebo group. Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% confidence interval [CI], 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (hazard ratio for death, 0.76; 95% CI, 0.63 to 0.93; two-sided P = 0.008). No new safety signals were observed. CONCLUSIONS First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.	[Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd,Unit 1354, Houston, TX 77030 USA; [Arteaga, Carlos L.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [O'Shaughnessy, Joyce] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA; [Stemmer, Salomon M.] Tel Aviv Univ, Rabin Med Ctr, Davidoff Ctr, Inst Oncol, Tel Aviv, Israel; [Burris, Howard A.] Sarah Cannon Res Inst, Nashville, TN USA; [Yap, Yoon-Sim] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore; [Sonke, Gabe S.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Sonke, Gabe S.] Borstkanker Onderzoek Grp Study Ctr, Amsterdam, Netherlands; [Hart, Lowell] Sarah Cannon Res Inst, Florida Canc Specialists, Ft Myers, FL USA; [Campone, Mario] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France; [Andre, Fabrice] Univ Paris Saclay, Med Sch, Inst Gustave Roussy, Dept Med Oncol, Villejuif, France; [Petrakova, Katarina] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic; [Winer, Eric P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Janni, Wolfgang] Univ Ulm, Dept Gynecol, Ulm, Germany; [Conte, Pierfranco] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Conte, Pierfranco] IRCCS, Ist Oncol Veneto, Div Med Oncol 2, Padua, Italy; [Cameron, David A.] Univ Edinburgh, Inst Genom & Canc, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland; [Zarate, Juan P.; Chakravartty, Arunava] Novartis Pharmaceut, E Hanover, NJ USA; [Taran, Tetiana; Le Gac, Fabienne; Serra, Paolo] Novartis Pharmaceut, Basel, Switzerland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Baylor University; Baylor University Medical Center; Texas Oncology; US Oncology Network; Rabin Medical Center; Tel Aviv University; Sarah Cannon Research Institute; National Cancer Centre Singapore (NCCS); Netherlands Cancer Institute; Florida Cancer Specialists; Sarah Cannon Research Institute; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Masaryk Memorial Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Ulm University; University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University of Edinburgh; Novartis; Novartis	Hortobagyi, GN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd,Unit 1354, Houston, TX 77030 USA.	ghortoba@mdanderson.org	ANDRE, Fabrice/AAL-2683-2020	ANDRE, Fabrice/0000-0001-5795-8357; Yap, Yoon-Sim/0000-0002-0347-5066	Novartis	Novartis(Novartis)	Supported by Novartis.	Andre F, 2021, ANN ONCOL, V32, P208, DOI 10.1016/j.annonc.2020.11.011; Basaran GA, 2018, CANCER TREAT REV, V63, P144, DOI 10.1016/j.ctrv.2017.12.002; Bergh J, 2012, J CLIN ONCOL, V30, P1919, DOI 10.1200/JCO.2011.38.1095; Cardoso F, 2020, ANN ONCOL, V31, P1623, DOI 10.1016/j.annonc.2020.09.010; Chen P, 2016, MOL CANCER THER, V15, P2273, DOI 10.1158/1535-7163.MCT-16-0300; Cristofanilli M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.1000; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Ellis MJ, 2015, J CLIN ONCOL, V33, P3781, DOI 10.1200/JCO.2015.61.5831; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Hortobagyi GN, 2018, ANN ONCOL, V29, P1541, DOI 10.1093/annonc/mdy155; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Hosford SR, 2014, PHARMACOGEN PERS MED, V7, P203, DOI 10.2147/PGPM.S52762; Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765; Johnston S, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-018-0097-z; Johnston SRD, 2013, LANCET ONCOL, V14, P989, DOI 10.1016/S1470-2045(13)70322-X; Lobbezoo DJA, 2013, BREAST CANCER RES TR, V141, P507, DOI 10.1007/s10549-013-2711-y; Mehta RS, 2019, NEW ENGL J MED, V380, P1226, DOI 10.1056/NEJMoa1811714; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; National Comprehensive Cancer Network, 2020, MET BREAST CANC; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456; ROBINS JM, 1991, COMMUN STAT THEORY, V20, P2609, DOI 10.1080/03610929108830654; Rugo HS, 2019, BREAST CANCER RES TR, V174, P719, DOI 10.1007/s10549-018-05125-4; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Slamon DJ, 2021, ANN ONCOL, V32, P1015, DOI 10.1016/j.annonc.2021.05.353; Slamon DJ, 2020, NEW ENGL J MED, V382, P514, DOI 10.1056/NEJMoa1911149; Sledge GW, 2020, JAMA ONCOL, V6, P116, DOI 10.1001/jamaoncol.2019.4782; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Tripathy D, 2021, CANCER RES, V81, DOI 10.1158/1538-7445.SABCS20-PD2-04; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527	30	21	21	2	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2022	386	10					942	950		10.1056/NEJMoa2114663	http://dx.doi.org/10.1056/NEJMoa2114663			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP3BU	35263519	Green Published			2023-01-03	WOS:000766299000011
J	Harding, C; Mossop, H; Homer, T; Chadwick, T; King, W; Carnell, S; Lecouturier, J; Abouhajar, A; Vale, L; Watson, G; Forbes, R; Currer, S; Pickard, R; Eardley, I; Pearce, I; Thiruchelvam, N; Guerrero, K; Walton, K; Hussain, Z; Lazarowicz, H; Ali, A				Harding, Chris; Mossop, Helen; Homer, Tara; Chadwick, Thomas; King, William; Carnell, Sonya; Lecouturier, Jan; Abouhajar, Alaa; Vale, Luke; Watson, Gillian; Forbes, Rebecca; Currer, Stephanie; Pickard, Robert; Eardley, Ian; Pearce, Ian; Thiruchelvam, Nikesh; Guerrero, Karen; Walton, Katherine; Hussain, Zahid; Lazarowicz, Henry; Ali, Ased			Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections with the current standard prophylaxis of daily low dose antibiotics. DESIGN Multicentre, open label, randomised, non-inferiority trial. SETTING Eight centres in the UK, recruiting from June 2016 to June 2018. PARTICIPANTS Women aged >= 18 years with recurrent urinary tract infections, requiring prophylactic treatment. INTERVENTIONS Random assignment (1:1, using permuted blocks of variable length via a web based system) to receive antibiotic prophylaxis or methenamine hippurate for 12 months. Treatment allocation was not masked and crossover between arms was allowed. MAIN OUTCOME MEASURE Absolute difference in incidence of symptomatic, antibiotic treated, urinary tract infections during treatment. A patient and public involvement group predefined the non-inferiority margin as one episode of urinary tract infection per person year. Analyses performed in a modified intention-to-treat population comprised all participants observed for at least six months. RESULTS Participants were randomly assigned to antibiotic prophylaxis (n=120) or methenamine hippurate (n=120). The modified intention-to-treat analysis comprised 205 (85%) participants (antibiotics, n=102 (85%); methenamine hippurate, n=103 (86%)). Incidence of antibiotic treated urinary tract infections during the 12 month treatment period was 0.89 episodes per person year (95% confidence interval 0.65 to 1.12) in the antibiotics group and 1.38 (1.05 to 1.72) in the methenamine hippurate group, with an absolute difference of 0.49 (90% confidence interval 0.15 to 0.84) confirming non-inferiority. Adverse reactions were reported by 34/142 (24%) in the antibiotic group and 35/127 (28%) in the methenamine group and most reactions were mild. CONCLUSION Non-antibiotic prophylactic treatment with methenamine hippurate might be appropriate for women with a history of recurrent episodes of urinary tract infections, informed by patient preferences and antibiotic stewardship initiatives, given the demonstration of non-inferiority to daily antibiotic prophylaxis seen in this trial.	[Harding, Chris] Freeman Rd Hosp, Dept Urol, Newcastle Upon Tyne, Tyne & Wear, England; [Mossop, Helen; Homer, Tara; Chadwick, Thomas; King, William; Lecouturier, Jan; Vale, Luke] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Carnell, Sonya; Abouhajar, Alaa; Watson, Gillian; Forbes, Rebecca; Currer, Stephanie] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Harding, Chris; Pickard, Robert] Translat & Clin Res Inst, Med Sch, William Leech Bldg, Newcastle Upon Tyne, Tyne & Wear, England; [Eardley, Ian] Leeds Teaching Hosp rust, Leeds, W Yorkshire, England; [Pearce, Ian] Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England; [Thiruchelvam, Nikesh] Addenbrookes Hosp, Cambridge, England; [Guerrero, Karen] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Walton, Katherine] Freeman Rd Hosp, Dept Microbiol, Newcastle Upon Tyne, Tyne & Wear, England; [Hussain, Zahid] Royal Oldham Hosp, Oldham, England; [Lazarowicz, Henry] Liverpool Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Ali, Ased] Pinderfields Gen Hosp, Wakefield, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Wythenshawe Hospital NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Queen Elizabeth University Hospital (QEUH); Newcastle Freeman Hospital; Newcastle University - UK; Pinderfields Hospital	Harding, C (corresponding author), Freeman Rd Hosp, Dept Urol, Newcastle Upon Tyne, Tyne & Wear, England.; Harding, C (corresponding author), Translat & Clin Res Inst, Med Sch, William Leech Bldg, Newcastle Upon Tyne, Tyne & Wear, England.	C.Harding@nhs.net	Hussain, Zahid/HGU-8912-2022	Hussain, Zahid/0000-0003-4989-6496; Harding, Chris/0000-0002-9407-382X; Vale, Luke/0000-0001-8574-8429; guerrero, karen lesley/0000-0001-9591-059X; Ali, Ased/0000-0001-9576-9047; King, Will/0000-0001-7040-9133	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme [13/88/21]	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme(National Institute for Health Research (NIHR))	This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (reference 13/88/21) and will be published in full in the NIHR Journals Library. Further information is available at https://research.ncl.ac.uk/altar/.CH, HM, TH, TC, WK, JL, AAb, LV, RF, KW, and AAl report grants from the NIHR HTA programme pertaining to the reported study. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views and opinions expressed are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS, or UK Department of Health.	Albert X, 2004, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD001209.pub2, DOI 10.1002/14651858.CD001209.PUB2]; Anger J, 2019, J UROLOGY, V202, P282, DOI [10.1097/JU.0000000000000296, 10.1097/JU.0000000000000503]; Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; British Infection Association, 2020, DIAGN UTI QUICK REF; Forbes R, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2998-4; Gupta K, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3140; Langford BJ, 2021, CLIN INFECT DIS, V73, pE782, DOI 10.1093/cid/ciab116; Lee BSB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003265.pub3; Litwin MS, 2005, J UROLOGY, V173, P933, DOI 10.1097/01.ju.0000152365.43125.3b; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; National Institute for Health and Care Excellence, GUID NG112 UR TRACT; Pickard R, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22240; Scottish Intercollegiate Guidelines Network. Scottish Intercollegiate Guidelines Network (SIGN), 2012, SIGN PUBL, V88; Stapleton A, 1999, LANCET, V353, P7, DOI 10.1016/S0140-6736(05)74875-3; UK Government, TACKLING ANTIMICROBI; UK Health Protection Agency Standards Unit Department for Evaluations Standards and Training Centre for Infections, 2012, NAT STAND METH INV U	17	11	11	2	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2022	376								e068229	10.1136/bmj-2021-068229	http://dx.doi.org/10.1136/bmj-2021-068229			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR9PU	35264408				2023-01-03	WOS:000768108200003
J	Shemtob, L; Asanati, K; Majeed, A				Shemtob, Lara; Asanati, Kaveh; Majeed, Azeem			Covid-19: Ending the legal requirement to self isolate puts vulnerable people at risk	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Shemtob, Lara; Asanati, Kaveh; Majeed, Azeem] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England	Imperial College London	Shemtob, L (corresponding author), Imperial Coll London, Dept Primary Care & Publ Hlth, London, England.			Majeed, Azeem/0000-0002-2357-9858	National Institute for Health Research (NIHR) Academic Clinical Fellowship; NIHR Applied Research Collaboration North west London	National Institute for Health Research (NIHR) Academic Clinical Fellowship(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration North west London	LS is supported by a National Institute for Health Research (NIHR) Academic Clinical Fellowship. KA and AM are supported by the NIHR Applied Research Collaboration North west London. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	[Anonymous], Statutory Sick Pay (SSP); [Anonymous], NHS Staff Survey 2020 national dashboards	2	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	2022	376								o461	10.1136/bmj.o461	http://dx.doi.org/10.1136/bmj.o461			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH2YW	35193884	Bronze			2023-01-03	WOS:000760810800004
J	Meyer, S; Cignacco, E; Monteverde, S; Trachsel, M; Raio, L; Oelhafen, S				Meyer, Stephanie; Cignacco, Eva; Monteverde, Settimio; Trachsel, Manuel; Raio, Luigi; Oelhafen, Stephan			'We felt like part of a production system': A qualitative study on women's experiences of mistreatment during childbirth in Switzerland	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SHARED DECISION-MAKING; RESPECTFUL CARE; PREVALENCE; PERCEPTIONS; PRESSURES; SERVICES; LEVERAGE; BIRTH	Introduction Mistreatment during childbirth is an issue of global magnitude that not only violates fundamental human rights but also seriously impacts women's well-being. The purpose of this study was to gain a better understanding of the phenomenon by exploring the individual experiences of women who reported mistreatment during childbirth in Switzerland. Materials and methods This project used a mixed methods approach to investigate women's experiences of mistreatment during childbirth in general and informal coercion specifically: The present qualitative study expands on the findings from a nationwide online survey on childbirth experience. It combines inductive with theoretical thematic analysis to study the 7,753 comments women wrote in the survey and the subsequent interviews with 11 women who reported being mistreated during childbirth. Results The women described a wide range of experiences of mistreatment during childbirth in both the survey comments and the interviews. Out of all survey participants who wrote at least one comment (n = 3,547), 28% described one or more experiences of mistreatment. Six of the seven types of mistreatment listed in Bohren and colleagues' typology of mistreatment during childbirth were found, the most frequent of which were ineffective communication and lack of informed consent. Five additional themes were identified in the interviews: Informal coercion, risk factors for mistreatment, consequences of mistreatment, examples of good care, and what's needed to improve maternity care. Conclusion The findings from this study show that experiences of mistreatment are a reality in Swiss maternity care and give insight into women's individual experiences as well as how these affect them during and after childbirth. This study emphasises the need to respect women's autonomy in order to prevent mistreatment and empower women to actively participate in decisions. Both individual and systemic efforts are required to prevent mistreatment and guarantee respectful, dignified, and high-quality maternity care for all.	[Meyer, Stephanie; Cignacco, Eva; Oelhafen, Stephan] Bern Univ Appl Sci, Dept Hlth Profess, Appl Res Dev Midwifery, Bern, Switzerland; [Monteverde, Settimio; Trachsel, Manuel] Univ Zurich, Inst Biomed Ethics & Hist Med, Zurich, Switzerland; [Monteverde, Settimio] Bern Univ Appl Sci, Sch Nursing, Dept Hlth Profess, Bern, Switzerland; [Trachsel, Manuel] Univ Hosp Basel & Psychiat Univ Clin Basel, Clin Ethics Unit, Basel, Switzerland; [Raio, Luigi] Univ Hosp Bern, Dept Obstet & Gynaecol, Bern, Switzerland	University of Zurich; University of Bern; University Hospital of Bern	Oelhafen, S (corresponding author), Bern Univ Appl Sci, Dept Hlth Profess, Appl Res Dev Midwifery, Bern, Switzerland.	stephan.oelhafen@bfh.ch	Monteverde, Settimio/AAA-8661-2021	Monteverde, Settimio/0000-0002-7041-2663; Oelhafen, Stephan/0000-0002-4238-6728	Kathe-Zingg-Schwichtenberg-Fund of the Swiss Academy of Medical Sciences (SAMS) [KZS 13/18]; Lindenhof Foundation Bern Research Teaching Fund [19-05-F]	Kathe-Zingg-Schwichtenberg-Fund of the Swiss Academy of Medical Sciences (SAMS); Lindenhof Foundation Bern Research Teaching Fund	SO received funding from the Kathe-Zingg-Schwichtenberg-Fund of the Swiss Academy of Medical Sciences (SAMS, https://www.samw.ch/en/Funding/Kaethe-Zingg-SchwichtenbergFund.html) (grant number KZS 13/18) and from the Lindenhof Foundation Bern Research & Teaching Fund (https://www.stiftunglindenhof.ch/de/foerderung/fonds-lehre-und-forschung/) (grant number 19-05-F). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abuya T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123606; Alcorn KL, 2010, PSYCHOL MED, V40, P1849, DOI 10.1017/S0033291709992224; ATLAS.ti Scientific Software Development GmbH, 2002, US; Ayers Susan, 2006, Psychol Health Med, V11, P389, DOI 10.1080/13548500600708409; Ayers S, 2007, BIRTH-ISS PERINAT C, V34, P253, DOI 10.1111/j.1523-536X.2007.00178.x; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Bastos MH, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007194.pub2; Baxter JD, 2014, MIDWIFERY, V30, P194, DOI 10.1016/j.midw.2013.12.013; Beatty JR, 2014, DRUG ALCOHOL DEPEN, V134, P280, DOI 10.1016/j.drugalcdep.2013.10.016; Beck CT, 2018, JOGNN-J OBST GYN NEO, V47, P94, DOI 10.1016/j.jogn.2016.08.015; Begley K, 2019, J EVAL CLIN PRACT, V25, P1113, DOI 10.1111/jep.13243; Blue Jeans Network Inc, 2009, US; Bohren MA, 2020, BEST PRACT RES CL OB, V67, P113, DOI 10.1016/j.bpobgyn.2020.02.005; Bohren MA, 2019, LANCET, V394, P1750, DOI 10.1016/S0140-6736(19)31992-0; Bohren MA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001847; Bowser D., 2010, EXPLORING EVIDENCE D; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Byrne V, 2017, MIDWIFERY, V51, P1, DOI 10.1016/j.midw.2017.04.017; Canvin K, 2013, INT J LAW PSYCHIAT, V36, P100, DOI 10.1016/j.ijlp.2013.01.002; Cook N, 2018, J AFFECT DISORDERS, V225, P18, DOI 10.1016/j.jad.2017.07.045; Czarnocka J, 2000, BRIT J CLIN PSYCHOL, V39, P35, DOI 10.1348/014466500163095; Davis Dana-Ain, 2020, Reprod Biomed Soc Online, V11, P56, DOI 10.1016/j.rbms.2020.10.001; de Graaff LF, 2018, ACTA OBSTET GYN SCAN, V97, P648, DOI 10.1111/aogs.13291; Dekel S, 2020, ARCH WOMEN MENT HLTH, V23, P557, DOI 10.1007/s00737-019-01006-x; Dekel S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00560; Dey A, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0409-z; Downe Soo, 2018, Reprod Health, V15, P23, DOI 10.1186/s12978-018-0466-y; dr. dresing & pehl GmbH, US; Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6; Grekin R, 2014, CLIN PSYCHOL REV, V34, P389, DOI 10.1016/j.cpr.2014.05.003; Harris R, 2012, PSYCHOL HEALTH, V27, P1166, DOI 10.1080/08870446.2011.649755; Helfferich C., 2011, QUALIT T QUALITATIVE, V4th; Hollander MH, 2017, ARCH WOMEN MENT HLTH, V20, P515, DOI 10.1007/s00737-017-0729-6; Khosla R, 2016, HEALTH HUM RIGHTS, V18, P131; Kruk ME, 2018, HEALTH POLICY PLANN, V33, pE26, DOI 10.1093/heapol/czu079; Megregian M, 2018, J MIDWIFERY WOM HEAL, V63, P340, DOI 10.1111/jmwh.12747; Mena-Tudela D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217726; Oelhafen S, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03826-1; Qualtrics, 2005, US; Ravaldi C, 2018, EUR J OBSTET GYN R B, V224, P208, DOI 10.1016/j.ejogrb.2018.03.055; Reed R, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-016-1197-0; Shakibazadeh E, 2018, BJOG-INT J OBSTET GY, V125, P932, DOI 10.1111/1471-0528.15015; Simonovic D, 2019, HUMAN RIGHTS BASED A; Swiss Academy of Medical Sciences (SAMS), 2017, MED ETH GUID COERC M; Szmukler G, 2008, J MENT HEALTH, V17, P233, DOI 10.1080/09638230802052203; United Nations General Assembly, 1993, DECL EL VIOL WOM; United Nations General Assembly, 1976, INT COVENANT EC SOCI; van der Pijl MSG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233114; Vedam S, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0729-2; Vogel JP, 2016, BJOG-INT J OBSTET GY, V123, P671, DOI 10.1111/1471-0528.13750; What Women Want Campaign, 2019, WHAT WOM WANT DEM QU; White Ribbon Alliance, 2011, RESP MAT CAR UN RIGH; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8; Williams CR, 2018, BJOG-INT J OBSTET GY, V125, P1208, DOI 10.1111/1471-0528.15270; World Health Organization, WHO REC INTR CAR POS; World Health Organization, 2015, WHO STAT PREV EL DIS; Zapf A, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0200-9	57	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2022	17	2							e0264119	10.1371/journal.pone.0264119	http://dx.doi.org/10.1371/journal.pone.0264119			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H3HL	35180269	gold, Green Published			2023-01-03	WOS:000796435800046
J	Zemp, M; Friedrich, AS; Holzmeier, L; Seebacher, S; Rossler, M; Nater, UM				Zemp, Martina; Friedrich, Amos-Silvio; Holzmeier, Lorena; Seebacher, Simone; Rossler, Maggie; Nater, Urs M.			Effects of clown visits on stress and mood in children and adolescents in psychiatric care-Protocol for a pilot study	PLOS ONE			English	Article							DIFFICULTIES QUESTIONNAIRE SDQ; PREOPERATIVE ANXIETY; PSYCHOMETRIC PROPERTIES; INTERVENTION; HUMOR; STRENGTHS; PEDIATRICS; PARENTS; MODEL; KINDL	Scientific evidence has shown that healthcare clowning can decrease the level of stress and anxiety in pediatric patients. However, little attention has been devoted to the potentially beneficial impact of clown visits in the child and adolescent psychiatry setting. Therefore, this pilot study aims at investigating short-term effects of clown visits by RED NOSES Clowndoctors Austria on stress and mood levels of children and adolescents in psychiatric care. The sample will consist of approximately 50 children and adolescents in inpatient psychiatric wards who receive clown visits on a weekly basis over four consecutive weeks. The examined intervention, i.e., the clown visits, is an integral part within the selected psychiatric institutions. Using a non-controlled pre-/post-test design, the level of salivary cortisol and self-reported stress and mood will be measured as primary outcomes before and immediately after each clown visit. Additionally, self-reported effects on care staff at the health care facilities will be assessed based on a questionnaire after each clown visit within the same time period of four weeks. Secondary outcome measures (i.e., health-related quality of life, emotional and conduct problems, perceived chronic stress) will be assessed at baseline and at close-out assessment after the four intervention weeks. Further control variables and potential moderators are included at baseline. Due to the nested data structure, multilevel modeling will be used to analyze the data. To our knowledge, this is the first study to examine the stress-reducing and mood-improving effects of clown visits on inpatients in child and adolescent psychiatry. Results will be relevant for the design of future large-scale RCTs and might provide valuable implications for the use of healthcare clowning to reduce stress and improve mood in children and adolescents in psychiatric care. The study is registered at ClinicalTrials.gov (Identifier: NCT04844398).	[Zemp, Martina; Friedrich, Amos-Silvio; Holzmeier, Lorena; Nater, Urs M.] Univ Vienna, Dept Clin & Hlth Psychol, Vienna, Austria; [Zemp, Martina; Nater, Urs M.] Univ Vienna, Res Platform Stress Life Processes & Mech Underly, Vienna, Austria; [Seebacher, Simone] RED NOSES Clowndoctors, Dept Res & Learning, Vienna, Austria; [Rossler, Maggie] RED NOSES Int, Dept Res & Learning, Vienna, Austria	University of Vienna; University of Vienna	Zemp, M (corresponding author), Univ Vienna, Dept Clin & Hlth Psychol, Vienna, Austria.	martina.zemp@univie.ac.at		Nater, Urs/0000-0002-2430-5090; Friedrich, Amos-Silvio/0000-0003-1970-4668	RED NOSES Clowndoctors Austria; IBL International GmbH, a Tecan Group Company	RED NOSES Clowndoctors Austria; IBL International GmbH, a Tecan Group Company	RED NOSES Clowndoctors Austria provided financial support including travel expenses for the examiners and research materials (i.e., Salicaps collection devices). The IBL International GmbH, a Tecan Group Company, sponsored the test kits for the saliva analyses. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed Mohammad I., 2011, Middle East Journal of Anesthesiology, V21, P153; Auerbach S., 2016, TRANSL ISSUES PSYCHO, V2, P14, DOI [10.1037/tps0000055, DOI 10.1037/TPS0000055]; Barkmann C, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-166; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Becker A, 2004, EUR CHILD ADOLES PSY, V13, P17, DOI 10.1007/s00787-004-2004-4; Ben-Pazi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175028; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blain S., 2012, ARTS HEALTH, V4, P26, DOI [10.1080/17533015.2011.561359, DOI 10.1080/17533015.2011.561359]; Bullinger M, 2008, EUR CHILD ADOLES PSY, V17, P125, DOI 10.1007/s00787-008-1014-z; Chammas F, 2021, ANN MED-PSYCHOL, V179, P487, DOI 10.1016/j.amp.2020.11.003; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Delvecchio E, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00250; Dionigi A, 2014, J HEALTH PSYCHOL, V19, P369, DOI 10.1177/1359105312471567; Eschenbeck H, 2006, DIAGNOSTICA, V52, P131, DOI 10.1026/0012-1924.52.3.131; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fernandes SC, 2010, J HEALTH PSYCHOL, V15, P405, DOI 10.1177/1359105309350231; GELKOPF M, 1994, J SOC PSYCHOL, V134, P175, DOI 10.1080/00224545.1994.9711380; Ghaffari Fatemeh, 2015, Med J Islam Repub Iran, V29, P182; Goldberg A, 2014, ALLERGY, V69, P1372, DOI 10.1111/all.12463; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Gruber A, 2015, ISR J PSYCHIATR REL, V52, P20; Higueras A, 2006, INT J CLIN HLTH PSYC, V6, P53; Johnson DR, 2011, J MARRIAGE FAM, V73, P926, DOI 10.1111/j.1741-3737.2011.00861.x; Kain ZN, 1996, ARCH PEDIAT ADOL MED, V150, P1238, DOI 10.1001/archpedi.1996.02170370016002; Kim K-H., 1999, KOREAN J REHABIL NUR, V2, P95; Klein EM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0875-9; Koller D, 2008, EVID-BASED COMPL ALT, V5, P17, DOI 10.1093/ecam/nem033; Lohaus A., 2006, FRAGEBOGEN ERHEBUNG; Lohbeck A, 2015, DIAGNOSTICA, V61, P222, DOI 10.1026/0012-1924/a000153; Lopes LC, 2020, CANCER NURS, V43, P290, DOI 10.1097/NCC.0000000000000690; Markova G, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.653884; Masetti M, 2019, J HEALTH PSYCHOL, V24, P166, DOI 10.1177/1359105316650274; McCann ME, 2001, ANESTH ANALG, V93, P98; Price J, 2016, J PEDIATR PSYCHOL, V41, P86, DOI 10.1093/jpepsy/jsv074; Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715; RED NOSES CLOWNDOCTORS International, RED NOSES; Rei ALDP, 2012, J NERV MENT DIS, V200, P88, DOI 10.1097/NMD.0b013e31823fafb9; Rennick JE, 2009, J CHILD HEALTH CARE, V13, P128, DOI 10.1177/1367493509102472; Rimon A., 2016, MEDICAL CLOWNS CORTI, V18, P680; Leguizamon CR, 2017, BRIT J ANAESTH, V119, P847, DOI 10.1093/bja/aex278; Ruckgaber C., 2016, HUMOR PSYCHIAT PSYCH, P290; Saliba FG, 2016, PEDIATRIC REP, V8, P12, DOI 10.4081/pr.2016.6188; Sanchez Julio C, 2017, Hosp Pediatr, V7, P46, DOI 10.1542/hpeds.2016-0128; Smerling AJ., 1999, ANESTH ANALG, V88, p306S, DOI [10.1097/00000539-199902001-00303, DOI 10.1097/00000539-199902001-00303]; Sridharan K, 2016, EUR J PEDIATR, V175, P1353, DOI 10.1007/s00431-016-2764-0; Steyer R., 1997, MEHRDIMENSIONALE BEF; Steyer R., 1994, DIAGNOSTICA, V40, P320; Thoma MV, 2015, INT J BEHAV MED, V22, P498, DOI 10.1007/s12529-014-9439-x; Tiedeman M E, 1990, J Pediatr Nurs, V5, P334; Vagnoli L, 2005, PEDIATRICS, V116, pE563, DOI 10.1542/peds.2005-0466; Viggiano MP, 2015, PEDIATRIC REP, V7, DOI 10.4081/pr.2015.5682; Vilaythong AP, 2003, HUMOR, V16, P79, DOI 10.1515/humr.2003.006; Wild B, 2007, NERVENARZT, V78, P571, DOI 10.1007/s00115-006-2076-0; Wilson ME, 2010, J PEDIATR HEALTH CAR, V24, P95, DOI 10.1016/j.pedhc.2009.02.008; Woerner W, 2002, Z KINDER JUG-PSYCH, V30, P105, DOI 10.1024//1422-4917.30.2.105; Wolyniez I, 2013, CLIN PEDIATR, V52, P1168, DOI 10.1177/0009922813502257; Zhang QH, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00415; Zhang YF, 2017, J PAEDIATR CHILD H, V53, P237, DOI 10.1111/jpc.13369	59	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2022	17	2							e0264012	10.1371/journal.pone.0264012	http://dx.doi.org/10.1371/journal.pone.0264012			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H3HL	35180260	gold, Green Published			2023-01-03	WOS:000796435800042
J	Meacham, MC; Nobles, AL; Tompkins, DA; Thrul, J				Meacham, Meredith C.; Nobles, Alicia L.; Tompkins, D. Andrew; Thrul, Johannes			"I got a bunch of weed to help me through the withdrawals": Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums	PLOS ONE			English	Article							SOCIAL NETWORKING; USE DISORDER; DRONABINOL; MANAGEMENT; DEPENDENCE; SYMPTOMS; DEATHS; LAWS	A growing body of research has reported on the potential opioid-sparing effects of cannabis and cannabinoids, but less is known about specific mechanisms. The present research examines cannabis-related posts in two large online communities on the Reddit platform ("subreddits") to compare mentions of naturalistic cannabis use by persons self-identifying as actively using opioids versus persons in recovery. We extracted all posts mentioning cannabis-related keywords (e.g., "weed", "cannabis", "marijuana") from December 2015 through August 2019 from an opioid use subreddit and an opioid recovery subreddit. To investigate how cannabis is discussed at-scale, we identified and compared the most frequent phrases in cannabis-related posts in each subreddit using term-frequency-inverse document frequency (TF-IDF) weighting. To contextualize these findings, we also conducted a qualitative content analysis of 200 random posts (100 from each subreddit). Cannabis-related posts were about twice as prevalent in the recovery subreddit (n = 908; 5.4% of 16,791 posts) than in the active opioid use subreddit (n = 4,224; 2.6% of 159,994 posts, p < .001). The most frequent phrases from the recovery subreddit referred to time without using opioids and the possibility of using cannabis as a "treatment." The most frequent phrases from the opioid subreddit referred to concurrent use of cannabis and opioids. The most common motivations for using cannabis were to manage opioid withdrawal symptoms in the recovery subreddit, often in conjunction with anti-anxiety and GI-distress "comfort meds," and to enhance the "high" when used in combination with opioids in the opioid subreddit. Despite limitations in generalizability from pseudonymous online posts, this examination of reports of naturalistic cannabis use in relation to opioid use identified withdrawal symptom management as a common motivation. Future research is warranted with more structured assessments that examines the role of cannabis and cannabinoids in addressing both somatic and affective symptoms of opioid withdrawal.	[Meacham, Meredith C.; Tompkins, D. Andrew] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94143 USA; [Nobles, Alicia L.] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, San Diego, CA 92103 USA; [Thrul, Johannes] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Thrul, Johannes] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Thrul, Johannes] La Trobe Univ, Ctr Alcohol Policy Res, Melbourne, Vic, Australia	University of California System; University of California San Francisco; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; La Trobe University	Meacham, MC (corresponding author), Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94143 USA.	Meredith.meacham@ucsf.edu		Meacham, Meredith/0000-0001-5752-767X	U.S. National Institute of Drug Abuse [K01DA046697, K25DA049944, R21DA047520, R21 DA048175]	U.S. National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	This research was supported by U.S. National Institute of Drug Abuse grants K01DA046697 (MCM), K25DA049944 (ALN), R21DA047520 (DAT), and R21 DA048175 (JT). URL: https://www.drugabuse.gov/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams DI, 2018, EUR J INTERN MED, V49, P7, DOI 10.1016/j.ejim.2018.01.003; Alexa, 2020, TRAFF STAT; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; Bagra I, 2018, J ADDICT MED, V12, P315, DOI 10.1097/ADM.0000000000000406; Baumgartner Jason, 2020, ARXIV200108435; Benoit K., 2018, J OPEN SOURCE SOFTW, V3, P774, DOI [10.21105/joss.00774, DOI 10.21105/JOSS.00774, 10.21105/joss10.21105/joss.00774]; Bergeria CL, 2020, J SUBST ABUSE TREAT, V113, DOI 10.1016/j.jsat.2020.108005; Bisaga A, 2015, DRUG ALCOHOL DEPEN, V154, P38, DOI 10.1016/j.drugalcdep.2015.05.013; Boehnke KF, 2016, J PAIN, V17, P739, DOI 10.1016/j.jpain.2016.03.002; Bruneau A, 2021, DRUG ALCOHOL DEPEN, V225, DOI 10.1016/j.drugalcdep.2021.108787; Budney AJ, 1998, ADDICTION, V93, P493, DOI 10.1046/j.1360-0443.1998.9344935.x; Bunting AM, 2021, DRUG ALCOHOL DEPEN, V222, DOI 10.1016/j.drugalcdep.2021.108672; Butehorn L, 2017, ALTERN COMPLEMENT TH, V23, P228, DOI DOI 10.1089/act.2017.29139.lbu; Campbell G, 2018, INT REV PSYCHIATR, V30, P91, DOI 10.1080/09540261.2018.1509842; Carter J, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0149-1; Ceasar RC, 2021, DRUG ALCOHOL DEPEN, V219, DOI 10.1016/j.drugalcdep.2020.108421; Chancellor S, 2019, CHI 2019: PROCEEDINGS OF THE 2019 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, DOI 10.1145/3290605.3300354; Chancellor S, 2018, PROCEEDINGS OF THE 2018 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI 2018), DOI 10.1145/3173574.3174240; Cinnamon Bidwell L, 2018, Addict Behav Rep, V8, P102, DOI 10.1016/j.abrep.2018.08.004; Cooke AC, 2019, INT J DRUG POLICY, V63, P23, DOI 10.1016/j.drugpo.2018.09.002; Costello KL, 2017, J ASSOC INF SCI TECH, V68, P2439, DOI 10.1002/asi.23880; Croff R, 2019, J BEHAV HEALTH SER R, V46, P330, DOI 10.1007/s11414-018-9616-9; Csete J, 2019, AM J PUBLIC HEALTH, V109, P419, DOI 10.2105/AJPH.2018.304852; D'Agostino AR, 2017, DRUG ALCOHOL DEPEN, V181, P5, DOI 10.1016/j.drugalcdep.2017.09.010; Deering DEA, 2011, ADDICT BEHAV, V36, P636, DOI 10.1016/j.addbeh.2011.01.004; Dunning T., 1993, Computational Linguistics, V19, P61; Enghoff O, 2019, INT J DRUG POLICY, V73, P210, DOI 10.1016/j.drugpo.2019.01.023; Epstein DH, 2015, AM J ADDICTION, V24, P323, DOI 10.1111/ajad.12183; Franklyn AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187633; Hall NY, 2021, DRUG ALCOHOL DEPEN, V221, DOI 10.1016/j.drugalcdep.2021.108651; Hurd YL, 2019, AM J PSYCHIAT, V176, P911, DOI 10.1176/appi.ajp.2019.18101191; Ilgen MA, 2013, DRUG ALCOHOL DEPEN, V132, P654, DOI 10.1016/j.drugalcdep.2013.04.019; Knopf A, 2019, FILTER; Kosten TR, 2019, AM J ADDICTION, V28, P55, DOI 10.1111/ajad.12862; Kral AH, 2015, DRUG ALCOHOL DEPEN, V153, P236, DOI 10.1016/j.drugalcdep.2015.05.014; Krawczyk N, 2018, SUBST ABUS, V39, P404, DOI 10.1080/08897077.2018.1439798; Lake S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233463; Lake S, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002967; Leas EC, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.13853; Lister JJ, 2020, AM J DRUG ALCOHOL AB, V46, P273, DOI 10.1080/00952990.2019.1694536; Livingston MD, 2017, AM J PUBLIC HEALTH, V107, P1827, DOI [10.2105/AJPH.2017.304059, 10.2105/ajph.2017.304059]; Lofwall MR, 2016, DRUG ALCOHOL DEPEN, V164, P143, DOI 10.1016/j.drugalcdep.2016.05.002; McBrien Heather, 2019, CMAJ Open, V7, pE665, DOI 10.9778/cmajo.20190026; Meacham MC, 2018, DRUG ALCOHOL DEPEN, V188, P364, DOI 10.1016/j.drugalcdep.2018.03.041; Meier MH, 2017, DRUG ALCOHOL DEPEN, V179, P25, DOI 10.1016/j.drugalcdep.2017.06.015; Pew Research Center, 2019, SOC MED FACT SHEET; Powell D, 2018, J HEALTH ECON, V58, P29, DOI 10.1016/j.jhealeco.2017.12.007; Rayson P., 2000, WORKSH COMP CORP, DOI DOI 10.3115/1117729.1117730; Reboussin BA, 2020, DRUG ALCOHOL DEPEN, V215, DOI 10.1016/j.drugalcdep.2020.108182; Reiman A, 2017, CANNABIS CANNABINOID, V2, P160, DOI 10.1089/can.2017.0012; Rosic T, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00468-6; Scavone JL, 2013, NEUROSCIENCE, V248, P637, DOI 10.1016/j.neuroscience.2013.04.034; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Shover CL, 2019, P NATL ACAD SCI USA, V116, P12624, DOI 10.1073/pnas.1903434116; Shulman M., 2018, AM OPIOID EPIDEMIC P, P249; Socias ME, 2018, ADDICTION, V113, P2250, DOI 10.1111/add.14398; Sowles SJ, 2017, SUBST ABUS, V38, P477, DOI 10.1080/08897077.2017.1354956; Tofighi B, 2019, SUBST USE MISUSE, V54, P2409, DOI 10.1080/10826084.2019.1653324; Tucker JS, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108188; Wasserman DA, 1998, DRUG ALCOHOL DEPEN, V52, P183, DOI 10.1016/S0376-8716(98)00092-1; Wiese B, 2018, CANNABIS CANNABINOID, V3, P179, DOI 10.1089/can.2018.0022; Wu LT, 2016, DRUG ALCOHOL DEPEN, V169, P117, DOI 10.1016/j.drugalcdep.2016.10.015; Zarrabi AJ, 2020, NEW ENGL J MED, V382, P1876, DOI 10.1056/NEJMp2003095	63	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0263583	10.1371/journal.pone.0263583	http://dx.doi.org/10.1371/journal.pone.0263583			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134074	gold, Green Published			2023-01-03	WOS:000798968600020
J	Sun, P; Tang, LP; Yan, DM; Li, B; Xu, LX; Wang, F				Sun, Peng; Tang, Liping; Yan, Dongmei; Li, Bin; Xu, Lingxia; Wang, Fei			Efficacy and safety of Yunkang oral liquid combined with conventional therapy for threatened miscarriage of first-trimester pregnancy a protocol for systematic review and meta-analysis	PLOS ONE			English	Review								Introduction Threatened miscarriages is a common complication of first-trimester pregnancy. Due to the beneficial effects, there are increasing clinical studies on Yunkang oral liquid(YKOL). However, the efficacy and safety of YKOL are still unknown. The aim of this systematic review was to assess the efficacy and safety of YKOL in the treatment of threatened miscarriage during the first-trimester pregnancy (TMFP). Methods This protocol will be prepared according to the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) statement. The systematic review will include all randomized controlled trials (RCTs) studies published until April 2021. Electronic sources including CNKI, WF, VIP, CBM, MEDLINE(PubMed), Embase, Cochrane Library, and Web of Science will be searched for potentially eligible studies. The international clinical trial registration platform and the Chinese clinical trial registration platform of controlled trials will be searched from their inception until April 1st, 2021. According to the inclusion and exclusion criteria, screening literature, extraction data will be conducted by two researchers independently. Statistical analysis will use RevMan 5.3.5 software. The strength of evidence from the studies will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods. Results This study will provide evidence for YKOL combined with conventional therapy for TMFP. Conclusion The efficacy and safety of YKOL combined with conventional therapy for TMFP will be assessed.	[Sun, Peng] Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China; [Tang, Liping; Yan, Dongmei; Li, Bin; Xu, Lingxia; Wang, Fei] Jiangxi Univ Chinese Med, Academician Workstn, Nanchang, Jiangxi, Peoples R China	Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine	Xu, LX; Wang, F (corresponding author), Jiangxi Univ Chinese Med, Academician Workstn, Nanchang, Jiangxi, Peoples R China.	xulingxia94@163.com; skywf@163.com		Xu, Lingxia/0000-0002-1184-7528	National Natural Science Foundation of China [81202911, 81360509]; Evidence based ability improvement project of traditional Chinese Medicine in The State Administration of Traditional Chinese Medicine of China; Academician Workstation of Jiangxi University of Traditional Chinese Medicine Project [ysgzz201806]; First-class Discipline Construction Funding of Jiangxi Province [JXSYLXK-ZHYAO148]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Evidence based ability improvement project of traditional Chinese Medicine in The State Administration of Traditional Chinese Medicine of China; Academician Workstation of Jiangxi University of Traditional Chinese Medicine Project; First-class Discipline Construction Funding of Jiangxi Province	This work is supported by National Natural Science Foundation of China (No. 81202911 and 81360509), Evidence based ability improvement project of traditional Chinese Medicine in The State Administration of Traditional Chinese Medicine of China (No.2019XZZX-LG005), Academician Workstation of Jiangxi University of Traditional Chinese Medicine Project (No. ysgzz201806) and First-class Discipline Construction Funding of Jiangxi Province (No. JXSYLXK-ZHYAO148). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chan DMK, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1509-8; Chen Bo, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1894, DOI 10.19540/j.cnki.cjcmm.2018.0064; Giakoumelou S, 2016, HUM REPROD UPDATE, V22, P116, DOI 10.1093/humupd/dmv041; Huang XM, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153154; Ke RW, 2014, OBSTET GYN CLIN N AM, V41, P103, DOI 10.1016/j.ogc.2013.10.003; Ku CW, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2002-z; Liu M, 2013, BMC COMPLEM ALTERN M, V13, DOI [10.1186/1472-6882-13-141, 10.1186/1472-6882-13-11]; Mei J., 2019, MEDICINE, V98, pe17841; NAKAJIMA ST, 1991, FERTIL STERIL, V55, P516; National Pharmacopoeia Commission, 2020, PHARMACOPOEIA PEOPLE, V1; Pasquier E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025649; Sapra KJ, 2017, REPROD SCI, V24, P502, DOI 10.1177/1933719116654994; Saraswat L, 2010, BJOG-INT J OBSTET GY, V117, P245, DOI 10.1111/j.1471-0528.2009.02427.x; Shi Qiu-Qiu, 2019, Zhongguo Zhong Yao Za Zhi, V44, P1227, DOI 10.19540/j.cnki.cjcmm.20181218.002; Shobeiri SS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/692198; Sun L, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/8312020; Wu HZ, 2016, J ETHNOPHARMACOL, V182, P129, DOI 10.1016/j.jep.2016.02.019; Yang M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4748264; Yuan SF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016026; Zeng PF, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000023288; Zhen Li., 2017, MODERN MED CLIN, V32, P1310	21	2	2	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0263581	10.1371/journal.pone.0263581	http://dx.doi.org/10.1371/journal.pone.0263581			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134068	Green Published, gold			2023-01-03	WOS:000798968600019
J	Wu, Y; Zhu, YH; Xie, NN; Wang, H; Wang, FF; Zhou, J; Qu, F				Wu, Yan; Zhu, Yuhang; Xie, Ningning; Wang, Hui; Wang, Fangfang; Zhou, Jue; Qu, Fan			A network pharmacology approach to explore active compounds and pharmacological mechanisms of a patented Chinese herbal medicine in the treatment of endometriosis	PLOS ONE			English	Article							EXPRESSION	Objective Endometriosis is a common benign disease in women of reproductive age. Qu's formula (QUF) is a patented Chinese herbal medicine for treating endometriosis that has been proven to be effective in treating and preventing the recurrence of endometriosis. This study is aimed to discover its molecular mechanism and to explore the potential drug Methods A QUF target and endometriosis-related gene set was identified by the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) databases and five disease-gene databases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed, and a protein-protein interaction (PPI) network was established to discover the potential mechanism. MalaCards was searched for targets and signaling pathways related to endometriosis, and the search results were also used to identify the key factors in QUF. Molecular docking was performed to visualize the interactions between the effective molecules and proteins encoded by critical genes. Cell experiments and molecular dynamics (MD) simulations were used to further validate the therapeutic effects of the active compounds in QUF on endometriosis. Results A compound-target network with 117 nodes (94 genes and 23 active compounds) and 224 edges was generated. The results of GO and KEGG analyses indicated that QUF could act by regulating the immune response, apoptosis and proliferation, oxidative stress, and angiogenesis. VEGFA, CXCL8, CCL2, IL1B and PTGS2 were selected for molecular docking analysis from two critical subnetworks with high correlation scores in MalaCards, and the active compounds of QUF had binding potential and high affinity for them. The mRNA expression levels of CCL2, IL1B and PTGS2-significantly decreased after treatment with quercetin. MD simulations showed that the combinations of quercetin and these proteins were relatively stable. Conclusion The network pharmacological strategy integrates molecular docking to unravel the molecular mechanism by which QUF protects against endometriosis. Our findings not only confirm the clinical effectiveness of QUF but also provide a foundation for further experimental study.	[Wu, Yan; Zhu, Yuhang; Xie, Ningning; Wang, Fangfang; Qu, Fan] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wang, Hui] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Rehabil & Sports Med Res Inst Zhejiang Prov, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China; [Zhou, Jue] Zhejiang Gongshang Univ, Coll Food Sci & Biotechnol, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Zhejiang Gongshang University	Qu, F (corresponding author), Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Zhou, J (corresponding author), Zhejiang Gongshang Univ, Coll Food Sci & Biotechnol, Hangzhou, Zhejiang, Peoples R China.	juezhou@zjgsu.edu.cn; syqufan@zju.edu.cn	wang, fang/GYD-4295-2022; Qu, Fan/S-6928-2016	Qu, Fan/0000-0003-1851-1514	National Natural Science Foundation of China (NSFC) [81973900, 81874480, 82074476]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (NSFC) (81973900 by JZ, 81874480 by FQ, 82074476 by FQ). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bafort C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011031.pub3; Becker CM, 2017, FERTIL STERIL, V108, P125, DOI 10.1016/j.fertnstert.2017.05.004; Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465; Bergqvist A, 2001, FERTIL STERIL, V75, P489, DOI 10.1016/S0015-0282(00)01752-0; Bulun SE, 2012, SEMIN REPROD MED, V30, P39, DOI 10.1055/s-0031-1299596; Fu J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009881.pub2; Gazvani R, 2002, REPRODUCTION, V123, P217, DOI 10.1530/rep.0.1230217; Hu C, 2014, CLIMACTERIC, V17, P410, DOI 10.3109/13697137.2013.876618; Ji XY, 2011, J ETHNOPHARMACOL, V134, P624, DOI 10.1016/j.jep.2011.01.003; Kumar R, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111602; Lai ZZ, 2019, INT J BIOL SCI, V15, P2783, DOI 10.7150/ijbs.35128; Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.1016/S1875-5364(13)60037-0, 10.3724/SP.J.1009.2013.00110]; Mari-Alexandre J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215322; Rappaport N, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat018; Rocha ALL, 2013, OBSTET GYNECOL INT, V2013, DOI 10.1155/2013/859619; Saunders PTK, 2021, CELL, V184, P2807, DOI 10.1016/j.cell.2021.04.041; Seguella L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133240; Tesone M, 2008, GYNECOL OBSTET INVES, V66, P10, DOI 10.1159/000148026; Ulukus M, 2009, FERTIL STERIL, V91, P687, DOI 10.1016/j.fertnstert.2007.12.067; Wang HX, 2021, PEERJ, V9, DOI 10.7717/peerj.11087; Wang X, 2021, INT J MED SCI, V18, P2401, DOI 10.7150/ijms.55789; Weng Q, 2015, INT J CLIN EXP MED, V8, P11307; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang F, 2018, CURR MED SCI, V38, P499, DOI 10.1007/s11596-018-1906-1; Zheng WL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00147; Zondervan KT, 2020, NEW ENGL J MED, V382, P1244, DOI 10.1056/NEJMra1810764; Zondervan KT, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0008-5	27	2	2	4	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2022	17	2							e0263614	10.1371/journal.pone.0263614	http://dx.doi.org/10.1371/journal.pone.0263614			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1U6OX	35130311	gold, Green Published			2023-01-03	WOS:000805530700041
J	Behr, CL; Maddox, KJE; Meara, E; Epstein, AM; Orav, EJ; Barnett, ML				Behr, Caroline L.; Joynt Maddox, Karen E.; Meara, Ellen; Epstein, Arnold M.; Orav, E. John; Barnett, Michael L.			Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.	[Behr, Caroline L.] Harvard Med Sch, Boston, MA 02115 USA; [Joynt Maddox, Karen E.] Washington Univ, Sch Med St Louis, Dept Internal Med, St Louis, MO 63110 USA; [Meara, Ellen] Dartmouth Coll, Geisel Sch Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA; [Epstein, Arnold M.; Orav, E. John; Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Saint Louis University; Washington University (WUSTL); Dartmouth College; Harvard University; Harvard T.H. Chan School of Public Health	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA.	mbarnett@hsph.harvard.edu		Meara, Ellen/0000-0003-0211-1970	NIA [K23 AG058806]; Agency for Healthcare Research and Quality [U19 HS024075]	NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by grant K23 AG058806 from the NIA to Dr Barnett and award U19 HS024075 from the Agency for Healthcare Research and Quality to Drs Meara and Barnett.	Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; National Institutes of Health, UPD COVID 19 TREATM; National Institutes of Health, COR DIS 2019 COVID 1; Office of the Assistant Secretary for Preparedness and Response, UPD DISTR ADM COVID; US Department of Health and Human Services, HHS ANN STAT TERR CO	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2022	327	10					980	983		10.1001/jama.2022.1243	http://dx.doi.org/10.1001/jama.2022.1243		FEB 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT9ON	35119452	Green Published, Bronze			2023-01-03	WOS:000750998100001
J	Adams, R				Adams, Rachel			Urgent care: disability, pandemic, and the value of a life	LANCET			English	Editorial Material									[Adams, Rachel] Columbia Univ, Dept English & Comparat Literature, New York, NY 10027 USA	Columbia University	Adams, R (corresponding author), Columbia Univ, Dept English & Comparat Literature, New York, NY 10027 USA.	rea15@columbia.edu							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2022	399	10323					430	431						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY9YU	35093220	Green Published, Bronze			2023-01-03	WOS:000755141600014
J	Chen, HA; Hsu, ST; Hsieh, MJ; Sim, SS; Chu, SE; Yang, WS; Chien, YC; Wang, YC; Lee, BC; Huang, EPC; Lin, HY; Ma, MHM; Chiang, WC; Sun, JT				Chen, Hsuan-An; Hsu, Shuo-Ting; Hsieh, Ming-Ju; Sim, Shyh-Shyong; Chu, Sheng-En; Yang, Wen-Shuo; Chien, Yu-Chun; Wang, Yao-Cheng; Lee, Bin-Chou; Huang, Edward Pei-Chuan; Lin, Hao-Yang; Ma, Matthew Huei-Ming; Chiang, Wen-Chu; Sun, Jen-Tang			Influence of advanced life support response time on out-of-hospital cardiac arrest patient outcomes in Taipei	PLOS ONE			English	Article							ADVANCED AIRWAY MANAGEMENT; SURVIVAL; RESUSCITATION; INTERVENTIONS; ASSOCIATION; INTUBATION; IMPROVE; RHYTHM	Background The association between out-of-hospital cardiac arrest patient survival and advanced life support response time remained controversial. We aimed to test the hypothesis that for adult, non-traumatic, out-of-hospital cardiac arrest patients, a shorter advanced life support response time is associated with a better chance of survival. We analyzed Utstein-based registry data on adult, non-traumatic, out-of-hospital cardiac arrest patients in Taipei from 2011 to 2015. Methods Patients without complete data, witnessed by emergency medical technicians, or with response times of >= 15 minutes, were excluded. We used logistic regression with an exposure of advanced life support response time. Primary and secondary outcomes were survival to hospital discharge and favorable neurological outcomes (cerebral performance category <= 2), respectively. Subgroup analyses were based on presenting rhythms of out-of-hospital cardiac arrest, bystander cardiopulmonary resuscitation, and witness status. Results A total of 4,278 cases were included in the final analysis. The median advanced life support response time was 9 minutes. For every minute delayed in advanced life support response time, the chance of survival to hospital discharge would reduce by 7% and chance of favorable neurological outcome by 9%. Subgroup analysis showed that a longer advanced life support response time was negatively associated with the chance of survival to hospital discharge among out-of-hospital cardiac arrest patients with shockable rhythm and pulse electrical activity groups. Conclusions In non-traumatic, adult, out-of-hospital cardiac arrest patients in Taipei, a longer advanced life support response time was associated with declining odds of survival to hospital discharge and favorable neurologic outcomes, especially in patients presenting with shockable rhythm and pulse electrical activity.	[Chen, Hsuan-An; Hsu, Shuo-Ting; Sim, Shyh-Shyong; Chu, Sheng-En; Sun, Jen-Tang] Far Eastern Mem Hosp, Dept Emergency Med, New Taipei, Taiwan; [Hsieh, Ming-Ju; Lin, Hao-Yang; Ma, Matthew Huei-Ming; Chiang, Wen-Chu] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Emergency Med, Taipei, Taiwan; [Yang, Wen-Shuo; Wang, Yao-Cheng] Taipei City Fire Dept, Emergency Med Serv Div, Taipei, Taiwan; [Chien, Yu-Chun] Minist Interior, Emergency Med Serv Div, Natl Fire Agcy, New Taipei, Taiwan; [Lee, Bin-Chou] Natl Taiwan Univ Hosp, Taipei City Hosp, Dept Emergency Med, Zhongxiao Branch, Taipei, Taiwan; [Huang, Edward Pei-Chuan] Natl Taiwan Univ Hosp, Dept Emergency Med, Hsin Chu Branch, Hsinchu, Taiwan; [Ma, Matthew Huei-Ming; Chiang, Wen-Chu] Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Touliu, Taiwan; [Sun, Jen-Tang] Tzu Chi Univ, Sch Med, Hualien, Taiwan	Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Taipei City Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Tzu Chi University	Sun, JT (corresponding author), Far Eastern Mem Hosp, Dept Emergency Med, New Taipei, Taiwan.; Chiang, WC (corresponding author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Emergency Med, Taipei, Taiwan.; Chiang, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Touliu, Taiwan.; Sun, JT (corresponding author), Tzu Chi Univ, Sch Med, Hualien, Taiwan.	drchiang.tw@gmail.com; tangtang05231980@gmail.com		Hsu, Shuoting/0000-0003-2753-0346; HSIEH, MING-JU/0000-0003-3636-6250; CHEN, HSUAN-AN/0000-0003-0701-1944; MA, MATTHEW HUEI-MING/0000-0002-4388-9984; Chu, Sheng-En/0000-0002-0453-9973; CHIANG, WEN-CHU/0000-0001-8620-7982; Pei-Chuan Huang, Edward/0000-0002-4800-2561; yang, wen shuo/0000-0002-6905-9049	Taiwan Ministry of Science and Technology [MOST 1082314-B-002-130-MY3, MOST 105-2314-B-002200-MY3, MOST 109-2314-B-002 -154 -MY2]	Taiwan Ministry of Science and Technology	This study was funded by the Taiwan Ministry of Science and Technology (MOST 1082314-B-002-130-MY3, MOST 105-2314-B-002200-MY3, MOST 109-2314-B-002 -154 -MY2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Andrew E, 2014, RESUSCITATION, V85, P1633, DOI 10.1016/j.resuscitation.2014.07.015; Benoit JL, 2019, PREHOSP EMERG CARE, V23, P838, DOI 10.1080/10903127.2019.1595236; Bergstrom M, 2018, RESUSCITATION, V133, P147, DOI 10.1016/j.resuscitation.2018.10.018; Chiang WC, 2018, ANN EMERG MED, V71, P387, DOI 10.1016/j.annemergmed.2017.08.008; Chiang WC, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0181-4; Chiang WC, 2009, RESUSCITATION, V80, P9, DOI 10.1016/j.resuscitation.2008.10.010; Coppler PJ, 2016, RESUSCITATION, V98, P9, DOI 10.1016/j.resuscitation.2015.09.399; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; Earnest A, 2012, PREHOSP EMERG CARE, V16, P256, DOI 10.3109/10903127.2011.615974; Fukuda T, 2014, INT J CARDIOL, V176, P910, DOI 10.1016/j.ijcard.2014.08.057; Gaspari R, 2016, RESUSCITATION, V109, P33, DOI 10.1016/j.resuscitation.2016.09.018; Gold LS, 2010, RESUSCITATION, V81, P622, DOI 10.1016/j.resuscitation.2010.02.004; Gold LS, 2009, PREHOSP EMERG CARE, V13, P341, DOI 10.1080/10903120902935389; Goto Y, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007568; Grunau B, 2019, RESUSCITATION, V135, P137, DOI 10.1016/j.resuscitation.2018.12.003; Hanif MA, 2010, ACAD EMERG MED, V17, P926, DOI 10.1111/j.1553-2712.2010.00829.x; Hansen M, 2018, CIRCULATION, V137, P2032, DOI 10.1161/CIRCULATIONAHA.117.033067; Hasegawa K, 2013, JAMA-J AM MED ASSOC, V309, P257, DOI 10.1001/jama.2012.187612; Hawkes C, 2017, RESUSCITATION, V110, P133, DOI 10.1016/j.resuscitation.2016.10.030; Herlitz J, 2008, RESUSCITATION, V76, P31, DOI 10.1016/j.resuscitation.2007.06.027; Holzer M, 2002, NEW ENGL J MED, V346, P549; Homma Y, 2019, AM J EMERG MED, V37, P241, DOI 10.1016/j.ajem.2018.05.037; Izawa J, 2018, RESUSCITATION, V128, P16, DOI 10.1016/j.resuscitation.2018.04.024; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Ko DT, 2016, AM HEART J, V177, P129, DOI 10.1016/j.ahj.2016.04.018; Ko Y-C., 2019, RESUSCITATION, V142, pe101; Kurz MC, 2018, RESUSCITATION, V128, P132, DOI 10.1016/j.resuscitation.2018.04.031; Larsen JM, 2012, RESUSCITATION, V83, P1427, DOI 10.1016/j.resuscitation.2012.08.337; Lee AF, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.48871; Lee DW, 2019, AM J EMERG MED, V37, P1999, DOI 10.1016/j.ajem.2019.02.021; Ma MHM, 2007, RESUSCITATION, V74, P461, DOI 10.1016/j.resuscitation.2007.02.006; McNally B., 2011, MMWR SURVEILL SUMM, V60; Michelland L, 2020, J EVAL CLIN PRACT, V26, P1013, DOI 10.1111/jep.13268; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; O'Keeffe C, 2011, EMERG MED J, V28, P703, DOI 10.1136/emj.2009.086363; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Ono Y, 2016, RESUSCITATION, V107, P65, DOI 10.1016/j.resuscitation.2016.08.005; Pell JP, 2001, BRIT MED J, V322, P1385, DOI 10.1136/bmj.322.7299.1385; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Perkins GD, 2020, INTENS CARE MED, V46, P426, DOI 10.1007/s00134-019-05836-2; Perkins GD, 2015, RESUSCITATION, V96, P328, DOI 10.1016/j.resuscitation.2014.11.002; Flato UAP, 2015, RESUSCITATION, V92, P1, DOI 10.1016/j.resuscitation.2015.03.024; Ran LY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014330; Sanghavi P, 2015, JAMA INTERN MED, V175, P196, DOI 10.1001/jamainternmed.2014.5420; Sigal AP, 2019, RESUSCITATION, V139, P182, DOI 10.1016/j.resuscitation.2019.04.018; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Sun JT, 2018, RESUSCITATION, V122, P48, DOI 10.1016/j.resuscitation.2017.11.048; Tsai BM, 2020, PLOS ONE, V15, DOI [10.1371/journal.pone.0235315, 10.1371/journal.pone.0235315.r001, 10.1371/journal.pone.0235315.r002, 10.1371/journal.pone.0235315.r003, 10.1371/journal.pone.0235315.r004]; Tuttle JE, 2018, WEST J EMERG MED, V19, P654, DOI 10.5811/westjem.2018.3.37051; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Wang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122675; Wang CH, 2020, ANN EMERG MED, V75, P627, DOI 10.1016/j.annemergmed.2019.12.003; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044; Wang HE, 2010, ANN EMERG MED, V55, P527, DOI 10.1016/j.annemergmed.2009.12.020; Wu CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191636	57	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266969	10.1371/journal.pone.0266969	http://dx.doi.org/10.1371/journal.pone.0266969			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F9AX	35421162	Green Published, gold			2023-01-03	WOS:000795453600089
J	de Brito, SAF; Scianni, AA; Peniche, PD; Faria, CDCD				Ferreira de Brito, Sherindan Ayessa; Scianni, Aline Alvim; Peniche, Paula da Cruz; Coelho de Morais Faria, Christina Danielli			Measurement properties of outcome measures used in neurological telerehabilitation: A systematic review protocol	PLOS ONE			English	Review							QUALITY-OF-LIFE; PATIENT; INDIVIDUALS; EXERCISE; MOBILITY; BARRIERS; INJURY; PEOPLE; STROKE	Several measurement tools commonly used in face-to-face neurological rehabilitation have been used in telerehabilitation. However, it is not known whether these tools have adequate measurement properties and clinical utility. This systematic review aims to investigate the measurement properties and the clinical utility of measurement tools used in telerehabilitation in individuals with neurological diseases. A systematic review to investigate the measurement properties and clinical utility of measurement tools used in telerehabilitation in individuals with neurological conditions will be conducted. This systematic review will follow the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement. this systematic review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) on 28 May 2021 (registration number: CRD42021257662). Electronic searches will be performed in following databases: Medical Literature Analysis and Retrieval System Online (MEDLINE Ovid), Excerpta Medica Database (Embase Classic + Embase Ovid), Physiotherapy Evidence Database (PEDro), Scientific Electronic Library Online (Scielo), and Literatura Latino-Americana e do Caribe em Ciencias da Saude (LILACS). Two trained independent reviewers will select the studies according to the inclusion criteria, and will also extract the data, evaluate the clinical utility and methodological quality. The relevant data such as design, participants, settings, and mode of administration, measurement properties, and clinical utility will be summarized. Disagreements between reviewers will be resolved by consensus or by the decision of a third independent reviewer. Hand searches of other relevant studies will be employed. The COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist and the clinical utility scale will be used to assess the methodological quality and clinical utility of these tools, respectively. This systematic review will provide information regarding the measurement properties and the clinical utility of the measurement tools used in neurological telerehabilitation. This information will be useful to assist health professionals in choosing adequate measurement tools and planning new research studies.	[Ferreira de Brito, Sherindan Ayessa; Scianni, Aline Alvim; Peniche, Paula da Cruz; Coelho de Morais Faria, Christina Danielli] Univ Fed Minas Gerais, Dept Phys Therapy, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais	Faria, CDCD (corresponding author), Univ Fed Minas Gerais, Dept Phys Therapy, Belo Horizonte, MG, Brazil.	cdcmf@ufmg.br	Faria, Christina DCM/D-2464-2017; Scianni, Aline Alvim/A-9336-2013	Faria, Christina DCM/0000-0001-9784-9729; Scianni, Aline Alvim/0000-0002-5968-2195				Annaswamy TM, 2020, DISABIL HEALTH J, V13, DOI 10.1016/j.dhjo.2020.100973; Appleby E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225150; Boakye M, 2012, J NEUROSURG-SPINE, V17, P29, DOI 10.3171/2012.6.AOSPINE1252; Brennan DM, 2009, STUD HEALTH TECHNOL, V145, P231, DOI 10.3233/978-1-60750-018-6-231; Chirra M, 2019, TELEMED E-HEALTH, V25, P541, DOI 10.1089/tmj.2018.0101; Cieza A, 2020, LANCET, V396, P2006, DOI 10.1016/S0140-6736(20)32340-0; De Wit L, 2017, DISABIL REHABIL, V39, P1435, DOI 10.1080/09638288.2016.1200676; Di Tella S, 2020, J TELEMED TELECARE, V26, P385, DOI 10.1177/1357633X19850381; Domingos J, 2019, J PARKINSON DIS, V9, P615, DOI 10.3233/JPD-191616; Hjelm NM, 2005, J TELEMED TELECARE, V11, P60, DOI 10.1258/1357633053499886; Hwang R, 2019, HEART LUNG CIRC, V28, P1795, DOI 10.1016/j.hlc.2018.11.010; Johnson C.O., 2019, LANCET NEUROL, V18, P439, DOI [10.1016/s1474-4422(19)30034-1, 10.1016/S1474-4422(19)30034-1]; Kuopio AM, 2000, MOVEMENT DISORD, V15, P216, DOI 10.1002/1531-8257(200003)15:2<216::AID-MDS1003>3.0.CO;2-#; Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3; Marinho-Buzelli AR, 2015, CLIN REHABIL, V29, P741, DOI 10.1177/0269215514556297; McCabe MP, 2002, J CLIN PSYCHOL MED S, V9, P287, DOI 10.1023/A:1020734901150; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223; Mokkink L., 2018, COSMIN RISK BIAS CHE, DOI 10.1007/s11136-017-1765-4; Mokkink LB, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01179-5; Mokkink LB, 2018, QUAL LIFE RES, V27, P1171, DOI 10.1007/s11136-017-1765-4; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Ownsworth T, 2018, J HEAD TRAUMA REHAB, V33, pE33, DOI 10.1097/HTR.0000000000000350; Page M.J., 2020, METAARXIV; Palmieri L, 2021, AGING CLIN EXP RES, V33, P193, DOI 10.1007/s40520-020-01764-0; Peretti Alessandro, 2017, JMIR Rehabil Assist Technol, V4, pe7, DOI 10.2196/rehab.7511; Portney LG., 2000, FDN CLIN RES APPL PR, V2, DOI DOI 10.1016/S0039-6257(02)00362-4; Prinsen CAC, 2018, QUAL LIFE RES, V27, P1147, DOI 10.1007/s11136-018-1798-3; Rimmer JH, 2008, J REHABIL RES DEV, V45, P315, DOI 10.1682/JRRD.2007.02.0042; Scelza WM, 2005, AM J PHYS MED REHAB, V84, P576, DOI 10.1097/01.phm.0000171172.96290.67; Silva PFS, 2014, BRAZ J PHYS THER, V18, P99, DOI 10.1590/S1413-35552012005000155; Tchero H, 2018, J MED INTERNET RES, V20, DOI 10.2196/10867; Terwee CB, 2012, QUAL LIFE RES, V21, P651, DOI 10.1007/s11136-011-9960-1; Tousignant M, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3844; Tyson S, 2009, CLIN REHABIL, V23, P1018, DOI 10.1177/0269215509339004; Valier A, 2015, ATHL TRAIN ED J, V10, P91, DOI [10.4085/100191, DOI 10.4085/100191]; WHO, 2006, NEUR DIS PUBL HLTH C; World-Health-Organization, 2020, SCI BRIEF ADV US POI	39	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265841	10.1371/journal.pone.0265841	http://dx.doi.org/10.1371/journal.pone.0265841			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1R8XY	35312708	gold, Green Published			2023-01-03	WOS:000803647900025
J	Gebeyehu, NA; Gelaw, KA; Azeze, GA; Admass, BA; Lake, EA; Adela, GA				Gebeyehu, Natnael Atnafu; Gelaw, Kelemu Abebe; Azeze, Gedion Asnake; Admass, Biruk Adie; Lake, Eyasu Alem; Adela, Getachew Asmare			Knowledge, attitude and practice towards kangaroo mother care among postnatal women in Ethiopia: Systematic review and meta-analysis	PLOS ONE			English	Review							BIRTH; PRETERM; INTERVENTIONS; RISK	BackgroundKangaroo mother care is a key procedure in reducing neonatal mortality and morbidity associated with preterm birth. In Ethiopia, neonatal death remains a serious problem, and this study aims to determine the prevalence of the knowledge, attitudes and practice of kangaroo mother care among Ethiopia women. MethodsPubMed, Web of Science, Google Scholar, EMBASE and the Ethiopian University online library were searched. Data were extracted using Microsoft Excel and analysed using STATA statistical software (v. 11). Publication bias was checked by forest plot, Begg's rank test and Egger's regression test. To look for heterogeneity, I-2 were computed and an overall estimated analysis carried out. Subgroup analysis was done by region, study setting, publication, gestational age, birth weight and component of kangaroo care. The Joanna Briggs Institute risk of bias assessment tool was used. We carried out a leave one out sensitivity analysis. ResultsOut of 273 articles retrieved, 16 studies met the eligibility criteria and are thus included in this study. Those 16 studies had a total of 12,345 respondents who reported kangaroo mother practice, with five (comprising 1,232 participants combined) reporting that both knowledge and attitude were used to determine the overall estimation. The pooled estimates of good knowledge, positive attitude and poor practice of kangaroo mother care were found to be 64.62% (95% CI: 47.15%-82.09%; I-2 = 97.8%), 61.55% (49.73%-73.38%; I-2 = 94.8%) and 45.7% (95% CI: 37.23%-54.09%; I-2 = 98.5%), respectively. This study is limited to postnatal women and does not take account their domestic partners or health providers. ConclusionThe findings revealed significant gaps in the knowledge, attitudes and practice of kangaroo mother care in Ethiopia when compared with other developing countries. Therefore, kangaroo mother care training to women, along with further studies on domestic partners and health providers.	[Gebeyehu, Natnael Atnafu; Gelaw, Kelemu Abebe; Azeze, Gedion Asnake] Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Midwifery, Wolaita Sodo, Ethiopia; [Admass, Biruk Adie] Univ Gondar, Coll Hlth Sci & Med, Dept Anesthesia, Gondar, Ethiopia; [Lake, Eyasu Alem] Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Nursing, Wolaita Sodo, Ethiopia; [Adela, Getachew Asmare] Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Publ Hlth, Wolaita Sodo, Ethiopia	University of Gondar	Gebeyehu, NA (corresponding author), Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Midwifery, Wolaita Sodo, Ethiopia.	jossyatnafu2020@gmail.com		Asmare, Getachew/0000-0001-8469-7754				A-M B., 2011, KANGAROO MOTHER CARE; Abdulghani N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205696; Abrham Roba A., 2017, J NEONATAL BIOL, V6, P100264, DOI 10.4172/2167-0897.1000257; Acharya N., 2014, Journal of Nepal Paediatric Society, V34, P18; Akbari E, 2018, EARLY HUM DEV, V122, P22, DOI 10.1016/j.earlhumdev.2018.05.004; Alelign Zewditu., ADDIS ABABA U INSTIT; Ayele M.W., 2021, J NEONATAL NURSING, V27, P118; Baley J, 2015, PEDIATRICS, V136, P596, DOI 10.1542/peds.2015-2335; Beck S, 2010, B WORLD HEALTH ORGAN, V88, P31, DOI 10.2471/BLT.08.062554; Bedaso A, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4176-5; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bigelow A, 2012, JOGNN-J OBST GYN NEO, V41, P369, DOI 10.1111/j.1552-6909.2012.01350.x; Boundy EO, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2238; Broughton EI, 2013, REV PANAM SALUD PUBL, V34, P176; Conde-Agudelo A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub3; Cong SN, 2021, MATERN CHILD NUTR, V17, DOI 10.1111/mcn.13245; Dawit Aster., 2015, THESIS ADDIS ABABA U; Demissie BW, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1238-0; Emishaw, J IMMUNOLOGY; Endalamaw A, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0586-6; Engler Arthur J, 2002, MCN Am J Matern Child Nurs, V27, P146, DOI 10.1097/00005721-200205000-00004; Ethiopian Public Health Institute (EPHI) and ICF [Ethiopia], 2019, ETH MIN HLTH SURV 20; Feldman-Winter L, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1889; FMOH, 2015, HLTH SECT TRANSF PLA, P184; Gebre B, 2018, J TROP PEDIATRICS, V64, P90, DOI 10.1093/tropej/fmx031; Gebremedhin Haftay., PREPRINTS, DOI [10.21203/rs.3.rs-57242/v1, DOI 10.21203/RS.3.RS-57242/V1]; Getinet, J HLTH MED NURSING; Ghojazadeh M, 2019, REV RECENT CLIN TRIA, V14, P31, DOI 10.2174/1574887113666180924165844; Gomez HM., 1992, INT CHILD HLTH, V3, P55; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Jafari M, 2019, J EDUC HEALTH PROMOT, V8, DOI 10.4103/jehp.jehp_310_18; Jamie A.H., 2020, PUBLIC HLTH INDONESI, V6, P116; Kalmakoff S, 2018, WOMEN BIRTH, V31, P202, DOI 10.1016/j.wombi.2017.08.131; Karimi FZ, 2020, J TURK-GER GYNECOL A, V21, P46, DOI 10.4274/jtgga.galenos.2019.2018.0138; Karimi FZ, 2019, TAIWAN J OBSTET GYNE, V58, P1, DOI 10.1016/j.tjog.2018.11.002; Kumbhojkar S., 2016, INTJHEALTH SCIRES, V6, P36; Lakew W., 2014, OPEN J PEDIAT, V4, P143; Lassi ZS, 2015, EBIOMEDICINE, V2, P985, DOI 10.1016/j.ebiom.2015.05.023; Lau Y, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12492; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lee ACC, 2019, LANCET GLOB HEALTH, V7, pE2, DOI 10.1016/S2214-109X(18)30484-4; Lumbanraja S N, 2016, J Neonatal Perinatal Med, V9, P385, DOI 10.3233/NPM-161628; Macaraya JRG., 2016, PHILIPINS J PEDIAT V, V64; Maternal and Child Health Directorate Federal Ministry of Health, 2015, NAT STRAT NEWB CHILD; Mekonnen AG, 2019, INT BREASTFEED J, V14, DOI 10.1186/s13006-019-0206-0; Ministry of Health, 2015, ETH NAT HLTH CAR QUA; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mose A, 2021, PEDIATR HEALTH MED T, V12, P289, DOI 10.2147/PHMT.S306411; Muchie KF, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03271-6; Mwendwa A C, 2012, East Afr Med J, V89, P53; Nigatu D, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8841349; Oza S, 2014, LANCET GLOB HEALTH, V2, pE635, DOI 10.1016/S2214-109X(14)70309-2; Penfold S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015593; Sharma D, 2019, J MATERN-FETAL NEO M, V32, P129, DOI 10.1080/14767058.2017.1304535; Sharma D, 2018, J MATERN-FETAL NEO M, V31, P2986, DOI 10.1080/14767058.2017.1359832; Shrivastava SR, 2013, S AFR FAM PRACT, V55, P340, DOI 10.1080/20786204.2013.10874373; UN Inter-agency Group for Child Mortality Estimation, 2019, LEVELS TRENDS CHILD; Vaivada T, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-4308; Vesel L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S5; Vohra AS, 2017, INT J CONT MED RES, V4, P1029; Weldearegay HG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225258; WHO UNICEF, 2009, HOM VIS NEWB CHILD S; World Health Organization, 2017, GUID PROT PROM SUPP, V8; World Health Organization, 2015, REC INT IMPR PRET BI; World Health Organization (WHO), 2003, KANGAROO MOTHER CARE; Yusuf E., 2018, DIVERS EQUAL HLTH CA, V15, P87	67	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5								10.1371/journal.pone.0265411	http://dx.doi.org/10.1371/journal.pone.0265411			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M1MQ	35522657	gold, Green Published, Green Submitted			2023-01-03	WOS:000835222600010
J	Opoku-Addai, K; Korsah, KA; Mensah, GP				Opoku-Addai, Kwabena; Korsah, Kwadwo Ameyaw; Mensah, Gwendolyn Patience			Nutritional self-care practices and skills of patients with diabetes mellitus: A study at a tertiary hospital in Ghana	PLOS ONE			English	Article							CARDIOMETABOLIC RISK PROFILES; ADULTS; CONSUMPTION; RECOMMENDATIONS; MANAGEMENT; KNOWLEDGE; EDUCATION; ALCOHOL; MEALS; FRUIT	IntroductionNutritional management decreases and/or prevents the complications and deaths associated with diabetes mellitus. However, the majority of patients living with diabetes do not engage in optimal nutritional management of diabetes because they see it as the most difficult aspect of managing the condition. This study aimed to explore and describe the practices and skills on nutritional management of diabetes mellitus among patients living with diabetes attending a Ghanaian hospital. Materials and methodsThis study employed an exploratory, descriptive qualitative research design. Fifteen participants were recruited using purposive sampling, and interviewed with a semi-structured interview guide. Content analysis was performed on the data gathered, following which three main themes emerged. ResultsMore than two-thirds of the participants of this study had adequate meal planning skills, ate the right quantity of foods, engaged in healthy eating habits, and consumed healthy sources of carbohydrates, fats and protein when eating. However, more than half of the participants had insufficient knowledge and skills in the reading and usage of food labels. ConclusionsThe participants of this study largely engaged in optimal nutritional management of diabetes due to their healthy dietary practices and preferences. It is recommended that health care professionals in Ghana find practical and robust ways to factor the reading and usage of food labels into the care and management of patients with diabetes.	[Opoku-Addai, Kwabena; Korsah, Kwadwo Ameyaw; Mensah, Gwendolyn Patience] Univ Ghana, Coll Hlth Sci, Sch Nursing & Midwifery, Legon, Accra, Ghana; [Opoku-Addai, Kwabena] Presbyterian Univ Coll, Fac Hlth & Med Sci, Dept Nursing & Midwifery, Asante Akyem, Agogo, Ghana	University of Ghana	Mensah, GP (corresponding author), Univ Ghana, Coll Hlth Sci, Sch Nursing & Midwifery, Legon, Accra, Ghana.	gpmensah@ug.edu.gh		Mensah, Gwendolyn Patience/0000-0002-9943-1622				Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS38, DOI 10.2337/dc18-S004; Andaya AA, 2011, J NUTR EDUC BEHAV, V43, P308, DOI 10.1016/j.jneb.2009.11.005; [Anonymous], 2017, 2016 ANN REP; Baliunas DO, 2009, DIABETES CARE, V32, P2123, DOI 10.2337/dc09-0227; Beck J, 2017, DIABETES EDUCATOR, V43, P449, DOI 10.1177/0145721717722968; Beck JK, 2015, FAM SYST HEALTH, V33, P28, DOI 10.1037/fsh0000101; Boucher Jackie L, 2017, Diabetes Spectr, V30, P72, DOI 10.2337/ds16-0074; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Burke SD, 2014, DIABET METAB SYND OB, V7, P45, DOI 10.2147/DMSO.S40036; Chen Wei, 2011, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V33, P253, DOI 10.3881/j.issn.1000-503X.2011.03.009; Cotton B, 2018, CALLS HALTELECTRONIC; Doherty ML, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1069; Ducrot P, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-017-0461-7; Dyson PA, 2011, DIABETIC MED, V28, P1282, DOI [10.1111/j.1464-5491.2011.03371.x, 10.1111/dme.13603]; Ekong G, 2016, PATIENT EDUC COUNS, V99, P944, DOI 10.1016/j.pec.2015.11.022; Evert AB, 2014, DIABETES CARE, V37, pS120, DOI 10.2337/dc14-S120; Ewers B, 2019, NUTRITION, V61, P49, DOI 10.1016/j.nut.2018.10.021; Gibney MJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050559; Gray A., 2015, ENDOTEXT; Griffith DM, 2013, HEALTH PROMOT PRACT, V14, P181, DOI 10.1177/1524839912437789; International Diabetes Federation, 2021, IDF DIAB ATL; International Diabetes Federation, 2017, DIABETES ATLAS, Veighth; Iqbal K, 2017, EUR J CLIN NUTR, V71, P1312, DOI 10.1038/ejcn.2017.116; Jaffar S, 2017, LANCET DIABETES ENDO, V5, P574, DOI 10.1016/S2213-8587(17)30219-X; Jakobsen ML, 2016, SCAND J PUBLIC HEALT, V44, P517, DOI 10.1177/1403494816645223; Kahleova H, 2014, DIABETOLOGIA, V57, P1552, DOI 10.1007/s00125-014-3253-5; Kamuhabwa AR, 2014, DRUG HEALTHC PATIENT, V6, P155, DOI 10.2147/DHPS.S68786; Levesque C, 2017, NURS CLIN N AM, V52, P679, DOI 10.1016/j.cnur.2017.07.012; Li YC, 2017, BIOMED ENVIRON SCI, V30, P863, DOI 10.3967/bes2017.117; Li ZJ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/8948452; Manne-Goehler J, 2016, LANCET DIABETES ENDO, V4, P903, DOI 10.1016/S2213-8587(16)30181-4; Mason M., 2010, FORUM QUAL SOC RES, V11, P1, DOI DOI 10.17169/FQS-11.3.1428; Miller ST, 2014, J OBES, V2014, DOI 10.1155/2014/345941; Peek ME, 2014, HEALTH PROMOT PRACT, V15, p40S, DOI 10.1177/1524839914532292; Raimi TH, 2014, AFR J DIABETES MED, V22, P9; Ruhee D, 2015, J DIABETES METAB DIS, V14, DOI 10.1186/s40200-015-0187-5; Sakai R, 2018, ENDOCR J, V65, P395, DOI 10.1507/endocrj.EJ17-0414; Sandhu SK, 2017, DIABETIC MED, V34, P539, DOI 10.1111/dme.13081; Sato-Mito N, 2011, SLEEP MED, V12, P289, DOI 10.1016/j.sleep.2010.09.012; Sorato MM, 2016, J DIABETES METAB, V7, DOI 10.4172/2155-6156.1000684; Spronk I, 2014, BRIT J NUTR, V111, P1713, DOI 10.1017/S0007114514000087; Uchenna O., 2010, INT J PSYCHOL BEHAV, V4, P2004; Ulrich PA, 2010, AM J NURS, V110, P62, DOI 10.1097/01.NAJ.0000383938.76085.00; Washi S, 2012, INT J MARKETING STUD, V4, P38, DOI DOI 10.5539/IJMS.V4N1P38; Yoshimura Y, 2012, GERIATR GERONTOL INT, V12, P29, DOI 10.1111/j.1447-0594.2011.00810.x; Zanchim MC, 2018, CIENC SAUDE COLETIVA, V23, P4199, DOI 10.1590/1413-812320182312.01412017	46	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265608	10.1371/journal.pone.0265608	http://dx.doi.org/10.1371/journal.pone.0265608			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P5DL	35320308	gold, Green Published			2023-01-03	WOS:000784240600018
J	Peng, J; Ye, LF; Wu, MM; Wu, MH; Ma, ZG; Cao, H; Zhang, Y				Peng, Jie; Ye, Lifang; Wu, Mengmei; Wu, Menghua; Ma, Zhiguo; Cao, Hui; Zhang, Ying			Evaluation of processing mechanism in Astragali Radix by low-field nuclear magnetic resonance and magnetic resonance imaging	PLOS ONE			English	Article							ACTIVE COMPONENT; LF-NMR; KINETICS; OPTIMIZATION; ULTRASOUND; WATER; MRI	Astragali Radix (Huangqi) is an important herb medicine that is always processed into pieces for clinical use. Many operations need to be performed before use, among which drying of Astragali Radix (AR) pieces is a key step. Unfortunately, research on its drying mechanism is still limited. Low-field nuclear magnetic resonance (LF-NMR) and magnetic resonance imaging (MRI) techniques were applied to study the moisture state and distribution during drying. The content of bioactive components and texture changes were measured by HPLC and texture analyzer, respectively. The moisture content of the AR pieces decreased significantly during drying, and the time to reach the drying equilibrium were different at different temperatures. The time when at 70 degrees C, 80 degrees C, and 90 degrees C reach complete drying are 180 min, 150 min and 120 min, respectively. 80 degrees C was determined as the optimum drying temperature, and it was observed that the four flavonoids and astragaloside IV have some thermal stability in AR pieces. When dried at 80 degrees C, although the total water content decreased, the free water content decreased from 99.38% to 15.49%, in contrast to the increase in bound water content from 0.62% to 84.51%. The texture parameters such as hardness changed to some extent, with the hardness rising most significantly from 686.23 g to 2656.67 g. Correlation analysis revealed some connection between moisture content and LF-NMR and texture analyzer parameters, but the springiness did not show a clear correlation with most parameters. This study shows that HPLC, LF-NMR, MRI, and texture analyzers provide a scientific basis for elucidating the drying principles of AR pieces. The method is useful and shows potential for extension and application; therefore, it can be easily extended to other natural herb medicines.	[Peng, Jie; Ye, Lifang; Wu, Mengmei; Wu, Menghua; Ma, Zhiguo; Cao, Hui; Zhang, Ying] Jinan Univ, Res Ctr TCM Lingnan Southern China, Guangzhou, Peoples R China; [Peng, Jie; Wu, Menghua; Zhang, Ying] Natl Engn Res Ctr Modernizat Tradit Chinese Med L, Guangzhou, Peoples R China; [Ma, Zhiguo; Cao, Hui] Guangdong Key Lab Tradit Chinese Med Informat Tec, Guangzhou, Peoples R China	Jinan University	Cao, H; Zhang, Y (corresponding author), Jinan Univ, Res Ctr TCM Lingnan Southern China, Guangzhou, Peoples R China.; Zhang, Y (corresponding author), Natl Engn Res Ctr Modernizat Tradit Chinese Med L, Guangzhou, Peoples R China.; Cao, H (corresponding author), Guangdong Key Lab Tradit Chinese Med Informat Tec, Guangzhou, Peoples R China.	kovhuicao@aliyun.com; zhangying@jnu.edu.cn			National Key Research and Development Project of China [2019YFC17115000]; National Natural Science Foundation of China [82074015]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010577]; Guangdong Key Lab of Traditional Chinese Medicine Information Technology [2021B1212040007]	National Key Research and Development Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Guangdong Key Lab of Traditional Chinese Medicine Information Technology	This work was supported by the National Key Research and Development Project of China under Grant (No.2019YFC17115000), the National Natural Science Foundation of China (No.82074015), the Guangdong Basic and Applied Basic Research Foundation (No.2020A1515010577) and Guangdong Key Lab of Traditional Chinese Medicine Information Technology (No.2021B1212040007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali M, 2018, PHYTOTHER RES, V32, P199, DOI 10.1002/ptr.5957; An KJ, 2020, FOOD BIOPROCESS TECH, V13, P1661, DOI 10.1007/s11947-020-02504-y; Azzouz S, 2002, J FOOD ENG, V55, P323, DOI 10.1016/S0260-8774(02)00109-7; Bi YQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.562376; Chen YN, 2020, FOOD CHEM, V306, DOI 10.1016/j.foodchem.2019.125625; Cheng SS, 2019, MEAT SCI, V147, P44, DOI 10.1016/j.meatsci.2018.08.020; Cheng XF, 2014, FOOD BIOPROCESS TECH, V7, P2782, DOI 10.1007/s11947-014-1355-1; China Pharmacopoeia Committee, 2020, CHINESE PHARMACOPOEI, VI; Cui L, 2020, DRY TECHNOL, V38, P304, DOI 10.1080/07373937.2019.1565577; Dai YT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.554777; Dinani ST, 2015, J CLEAN PROD, V95, P203, DOI 10.1016/j.jclepro.2015.02.033; Ding Fei-fei, 2015, Zhong Yao Cai, V38, P156; Ezeanaka MC, 2019, FOOD BIOPROCESS TECH, V12, P1435, DOI 10.1007/s11947-019-02296-w; Gong P, 2021, PHYTOMEDICINE, V84, DOI 10.1016/j.phymed.2021.153509; Heikkinen S, 2006, J APPL POLYM SCI, V100, P937, DOI 10.1002/app.23051; Huang S, 1982, SHEN NONG BEN CAO JI; Ismagilov ZR, 2005, CATAL TODAY, V105, P484, DOI 10.1016/j.cattod.2005.06.054; Kirtil E, 2016, FOOD ENG REV, V8, P1, DOI 10.1007/s12393-015-9118-y; Li K, 2019, MOLECULES, V24, DOI 10.3390/molecules24203644; Li M, 2019, LWT-FOOD SCI TECHNOL, V116, DOI 10.1016/j.lwt.2019.108563; [李瑶瑶 Li Yaoyao], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P226; Liu MH, 2015, INT J MOL SCI, V16, P5047, DOI 10.3390/ijms16035047; Liu YH, 2019, J MED BIOL ENG, V39, P54, DOI 10.1007/s40846-018-0379-9; Mina B., 2012, INT J CURRENT PHARM, V3, P54; Murthy TPK, 2014, J FOOD SCI TECH MYS, V51, P3712, DOI 10.1007/s13197-013-0941-y; Nemeth K, 2003, EUR J NUTR, V42, P29, DOI 10.1007/s00394-003-0397-3; Oliveira WP, 2006, DRY TECHNOL, V24, P523, DOI 10.1080/07373930600612073; Phu HT, 2020, CURR VASC PHARMACOL, V18, P369, DOI 10.2174/1570161117666190715121939; Sekiyama Y, 2012, FOOD RES INT, V48, P374, DOI 10.1016/j.foodres.2012.05.019; Sheridan H, 2015, SCIENCE, V350, pS64; Siwicka D, 2011, CENT EUR J IMMUNOL, V36, P104; Song YK, 2018, DRY TECHNOL, V36, P72, DOI 10.1080/07373937.2017.1300807; Sun YA, 2021, J FOOD ENG, V292, DOI 10.1016/j.jfoodeng.2020.110354; Tang Yi-jin, 2014, Chinese Journal of Nonferrous Metals, V24, P8; Tunde-Akintunde TY, 2011, RENEW ENERG, V36, P2139, DOI 10.1016/j.renene.2011.01.017; Wang G, 2016, FOOD CONTROL, V59, P743, DOI 10.1016/j.foodcont.2015.06.047; Wang L, 2018, ULTRASON SONOCHEM, V40, P619, DOI 10.1016/j.ultsonch.2017.08.005; Wu XL, 2006, ACTA PHARMACOL SIN, V27, P1007, DOI 10.1111/j.1745-7254.2006.00349.x; Xiao QL, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20174940; Yang JH, 2010, PROCEEDINGS OF THE ASME INTERNATIONAL HEAT TRANSFER CONFERENCE - 2010, VOL 1, P91; Zhao ZZ, 2010, PLANTA MED, V76, P1975, DOI 10.1055/s-0030-1250522; 孙乐, 2020, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V31, P1616	42	0	0	8	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265383	10.1371/journal.pone.0265383	http://dx.doi.org/10.1371/journal.pone.0265383			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3NO	35286357	gold, Green Published			2023-01-03	WOS:000799880200049
J	Prado, IA; Rocha, NCD; Rocha, TAH; Thomaz, EBAF				Prado, Isabelle Aguiar; da Silva Rocha, Nubia Cristina; Hernandes Rocha, Thiago Augusto; Abreu Fonseca Thomaz, Erika Barbara			Spatiotemporal analysis of hospital admissions for primary care-sensitive conditions in women and children in the first 1000 days of life	PLOS ONE			English	Article							FAMILY HEALTH STRATEGY; ACCESS; SYSTEM; STATE	Objective To analyze the spatiotemporal distribution of hospital admission rates for primary care-sensitive conditions (PCSC) in women and children in the first 1000 days of life in Brazil. Methods Ecological study, with spatiotemporal analyses, using secondary data from Brazilian municipalities. PCSC in women, related to prenatal care and childbirth, and in children under two years old, from 2008 to 2019 were used to characterize trends and formations of spatiotemporal clusters/outliers. Crude PCSC rates were calculated and adjusted by the local empirical Bayesian method, presented in choropleth maps. We also used Anselin Local Moran I type analyses to identify spatial clusters, and space-time cube with clustering by emerging hotspot, followed by time series clustering, for analysis of spatiotemporal trends (alpha = 5 %). Results A total of 1,850,776 PCSC were registered in pregnant women, puerperae, and children under two years of age in Brazil, representing 1.7% of the total number of hospital admissions in the period. PCSC rates showed different behaviors when the groups of women and children were evaluated, with a predominant growing trend of 109% in admissions in the first group and a reduction of 34.4% in the second. The North, Northeast, and Midwest regions had larger high-risk clusters and more significant increasing trends in PCSC in the two sub-populations studied. Conclusions Health actions and services in primary care may be reducing hospital admissions for children, but they are not being effective in reducing hospital admissions for women for causes related to prenatal care and childbirth, especially in the North, Northeast, and Midwest of Brazil. Investments in the qualification of care over the thousand days are urgent in the country.	[Prado, Isabelle Aguiar; Abreu Fonseca Thomaz, Erika Barbara] Univ Fed Maranhao, Dept Saude Publ, Programa Posgrad Saude Colet, Sao Luis, Maranhao, Brazil; [da Silva Rocha, Nubia Cristina] MATH CONSORTIUM Methods Analyt & Technol Hlth, Belo Horizonte, MG, Brazil; [Hernandes Rocha, Thiago Augusto] Duke Univ, Duke Global Hlth Inst, Durham, NC USA	Universidade Federal do Maranhao; Duke University	Prado, IA; Thomaz, EBAF (corresponding author), Univ Fed Maranhao, Dept Saude Publ, Programa Posgrad Saude Colet, Sao Luis, Maranhao, Brazil.	isabelleaguiarpp@gmail.com; erika.barbara@ufma.br		Prado, Isabelle/0000-0001-9970-7783	Bill & Melinda Gates Foundation [OPP1202186]; National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq acronym in Portuguese) [443834/2018-0, 306592/2018-5]; Maranhao Foundation for Research and Scientific and Technological Development (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao -FAPEMA acronym in Portuguese) [RCUK-01538/19]; Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES acronym in Portuguese) [001, 88887.468042/2019-00]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq acronym in Portuguese)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Maranhao Foundation for Research and Scientific and Technological Development (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao -FAPEMA acronym in Portuguese); Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES acronym in Portuguese)	This work was supported, in whole or in part, by: i) The Bill & Melinda Gates Foundation [OPP1202186]: ii) The National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnolo ' gico -CNPq acronym in Portuguese) [Grants 443834/2018-0 and 306592/2018-5]; iii) The Maranhao Foundation for Research and Scientific and Technological Development (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cienti ' fico e Tecnolo ' gico do Maranhao -FAPEMA acronym in Portuguese) [RCUK-01538/19]; and iv) The Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior -CAPES acronym in Portuguese) [finance code 001 and process n degrees 88887.468042/2019-00]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfradique ME, 2009, CAD SAUDE PUBLICA, V25, P1337, DOI 10.1590/S0102-311X2009000600016; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Carvalho SC, 2015, CAD SAUDE PUBLICA, V31, P744, DOI 10.1590/0102-311X00069014; Ceccon Roger Flores, 2014, Rev. bras. epidemiol., V17, P968, DOI 10.1590/1809-4503201400040014; Costa LD, 2017, EPIDEMIOL SERV SAUDE, V26, P51, DOI [10.5123/s1679-49742017000100006, 10.5123/S1679-49742017000100006]; Cusick SE, 2016, J PEDIATR-US, V175, P16, DOI 10.1016/j.jpeds.2016.05.013; de S Mendonca S., 2014, EPIDEMIOL SERVI OS S, V23, P277; Druck S, 2004, ANALISE ESPACIAL DAD; Ebener S, 2015, INT J HEALTH GEOGR, V14, DOI 10.1186/s12942-015-0012-x; Esri, 2016, EM HOT SPOT AN WORKS; Farias YN, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311X00001019, 10.1590/0102-311x00001019]; Franca GVA, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0445-2; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; IBGE, 2020, ESTATISTICAS; Leal MD, 2018, CIENC SAUDE COLETIVA, V23, P1915, DOI [10.1590/1413-81232018236.03942018, 10.1590/1413-81232018236.039420181]; Maciel Antônio Gonçalves, 2014, Saúde debate, V38, P319, DOI 10.5935/0103-1104.2014S024; Macinko J, 2017, J AMBUL CARE MANAG, V40, pS4, DOI 10.1097/JAC.0000000000000189; Barreto JOM, 2012, CAD SAUDE PUBLICA, V28, P515, DOI 10.1590/S0102-311X2012000300012; Rocha MCN, 2014, EPIDEMIOL SERV SAUDE, V23, P277, DOI 10.5123/S1679-49742014000200009; Neves RG, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000100008, 10.5123/S1679-49742020000100008]; Pazo RG., 2017, REV BRAS MED FAM LIA, V12, P1, DOI [10.5712/rbmfc12(39)1546, DOI 10.5712/RBMFC12(39)1546]; Pinto LF, 2018, CIENC SAUDE COLETIVA, V23, P1903, DOI 10.1590/1413-81232018236.05592018; Rosano A, 2013, EUR J PUBLIC HEALTH, V23, P356, DOI 10.1093/eurpub/cks053; Russo LX, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005429; Tomasi Elaine, 2017, Cad. Saúde Pública, V33, pe00195815, DOI 10.1590/0102-311x00195815; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7	26	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269548	10.1371/journal.pone.0269548	http://dx.doi.org/10.1371/journal.pone.0269548			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35679226	gold, Green Published			2023-01-03	WOS:000843567600157
J	Weiner, SG; Hendricks, MA; El Ibrahimi, S; Ritter, GA; Hallvik, SE; Hildebran, C; Weiss, RD; Boyer, EW; Flores, DP; Nelson, LS; Kreiner, PW; Fischer, MA				Weiner, Scott G.; Hendricks, Michelle A.; El Ibrahimi, Sanae; Ritter, Grant A.; Hallvik, Sara E.; Hildebran, Christi; Weiss, Roger D.; Boyer, Edward W.; Flores, Diana P.; Nelson, Lewis S.; Kreiner, Peter W.; Fischer, Michael A.			Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone	PLOS ONE			English	Article							UNITED-STATES; CHRONIC PAIN; ASSOCIATION; THERAPY	BackgroundHydrocodone and oxycodone are prescribed commonly to treat pain. However, differences in risk of opioid-related adverse outcomes after an initial prescription are unknown.This study aims to determine the risk of opioid-related adverse events, defined as either chronic use or opioid overdose, following a first prescription of hydrocodone or oxycodone to opioid naive patients. MethodsA retrospective analysis of multiple linked public health datasets in the state of Oregon. Adult patients ages 18 and older who a) received an initial prescription for oxycodone or hydrocodone between 2015-2017 and b) had no opioid prescriptions or opioid-related hospitalizations or emergency department visits in the year preceding the prescription were followed through the end of 2018. First-year chronic opioid use was defined as >= 6 opioid prescriptions (including index) and average <= 30 days uncovered between prescriptions. Fatal or non-fatal opioid overdose was indicated from insurance claims, hospital discharge data or vital records. ResultsAfter index prescription, 2.8% (n = 14,458) of individuals developed chronic use and 0.3% (n = 1,480) experienced overdose. After adjustment for patient and index prescription characteristics, patients receiving oxycodone had lower odds of developing chronic use relative to patients receiving hydrocodone (adjusted odds ratio = 0.95, 95% confidence interval (CI) 0.91-1.00) but a higher risk of overdose (adjusted hazard ratio (aHR) = 1.65, 95% CI 1.45-1.87). Oxycodone monotherapy appears to greatly increase the hazard of opioid overdose (aHR 2.18, 95% CI 1.86-2.57) compared with hydrocodone with acetaminophen. Oxycodone combined with acetaminophen also shows a significant increase (aHR 1.26, 95% CI 1.06-1.50), but not to the same extent. ConclusionsAmong previously opioid-naive patients, the risk of developing chronic use was slightly higher with hydrocodone, whereas the risk of overdose was higher after oxycodone, in combination with acetaminophen or monotherapy. With a goal of reducing overdose-related deaths, hydrocodone may be the favorable agent.	[Weiner, Scott G.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Weiner, Scott G.; Weiss, Roger D.] Harvard Med Sch, Boston, MA 02115 USA; [Hendricks, Michelle A.; El Ibrahimi, Sanae; Hallvik, Sara E.; Hildebran, Christi; Flores, Diana P.] Comagine Hlth, Div Res & Evaluat, Portland, OR USA; [El Ibrahimi, Sanae] Univ Nevada, Dept Epidemiol & Biostat, Sch Publ Hlth, Las Vegas, NV 89154 USA; [Ritter, Grant A.; Kreiner, Peter W.] Brandeis Univ, Waltham, MA USA; [Weiss, Roger D.] McLean Hosp, Dept Psychiat, 115 Mill St, Belmont, MA 02178 USA; [Boyer, Edward W.] Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ USA; [Fischer, Michael A.] Boston Univ, Boston Med Ctr, Sect Gen Internal Med, Sch Med, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Brandeis University; Harvard University; McLean Hospital; University System of Ohio; Ohio State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Boston Medical Center; Boston University	Weiner, SG (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.; Weiner, SG (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	sweiner@bwh.harvard.edu		Weiner, Scott/0000-0002-4672-5184	National Institute on Drug Abuse [5-R01DA044167]; Agency for Healthcare Research and Quality [5-R01-HS026753]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	National Institute on Drug Abuse 5-R01DA044167 (SGW, MAH, SEI, GAR, SEH, CH, RDW, EWB, DPF, PWK) and Agency for Healthcare Research and Quality 5-R01-HS026753 (SGW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agnoli A, 2021, JAMA-J AM MED ASSOC, V326, P411, DOI 10.1001/jama.2021.11013; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Centers for Disease Control and Prevention, 2022, DRAFT CLIN PRACT GUI; Centers for Disease Control and Prevention, AN OP PRESCR DAT OR; Chang AK, 2015, ACAD EMERG MED, V22, P1254, DOI 10.1111/acem.12813; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Council of State and Territorial Epidemiologists, 2014, EPI TOOL AN OV DEATH; Department of Environmental Affairs (DEA), 2019, S AFR 3 BIENN UPD RE; Deyo RA, 2017, J GEN INTERN MED, V32, P21, DOI 10.1007/s11606-016-3810-3; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drug Enforcement Administration Department of Justice, 2014, Fed Regist, V79, P49661; Drug Enforcement Agency Drug and Chemical Evaluation Section, 2020, OX; El Ibrahimi S, 2022, PREPRINT; Enamorado T, 2018, **DATA OBJECT**; Food and Drug Administration, NAT DRUG COD DIR; Fremont Allen, 2016, Rand Health Q, V6, P16; Gatti A, 2010, CLIN DRUG INVEST, V30, P3, DOI 10.2165/1158414-S0-000000000-00000; Hallvik SE, 2021, PHARMACOEPIDEM DR S, V30, P927, DOI 10.1002/pds.5259; Hoppe JA, 2015, ANN EMERG MED, V66, P253, DOI 10.1016/j.annemergmed.2015.03.026; Ingram Deborah D, 2014, Vital Health Stat 2, P1; IQVIA Institute, 2018, MED US SPEND US REV; Jenkin DE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.34988; Khanna K, 2021, **DATA OBJECT**; Liu YN, 2020, PAIN MED, V21, P1863, DOI 10.1093/pm/pnz210; Marco CA, 2005, ACAD EMERG MED, V12, P282, DOI 10.1197/j.aem.2004.12.005; McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007; Moreland B, 2021, MMWR-MORBID MORTAL W, V70, P661, DOI 10.15585/mmwr.mm7018a1; National Center for Health Statistics, PROVISIONAL DRUG OVE; National Institute on Drug Abuse, OR OP INV DEATHS REL; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Raffa RB, 2010, DRUG TODAY, V46, P379, DOI 10.1358/dot.2010.46.6.1470106; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Substance Abuse and Mental Health Services Administration, US INT CLASS DIS ICD; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Walsh SL, 2008, DRUG ALCOHOL DEPEN, V98, P191, DOI 10.1016/j.drugalcdep.2008.05.007; Weiner SG, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.45691; Weiner SG, 2020, PAIN MED, V21, P3669, DOI 10.1093/pm/pnaa293; Wightman R, 2012, J MED TOXICOL, V8, P335, DOI 10.1007/s13181-012-0263-x; Zacny JR, 2009, DRUG ALCOHOL DEPEN, V101, P107, DOI 10.1016/j.drugalcdep.2008.11.013; Zikovich Shannon, 2022, Ann Surg, V276, pe1070, DOI 10.1097/SLA.0000000000004793	40	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266561	10.1371/journal.pone.0266561	http://dx.doi.org/10.1371/journal.pone.0266561			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6EQ	35381052	Green Published, gold			2023-01-03	WOS:000804820900002
J	Wu, JK; Yu, MC; Chen, SH; Liao, SH; Wang, YJ				Wu, Jian-Kuen; Yu, Min-Chin; Chen, Shih-Han; Liao, Shu-Hsien; Wang, Yu-Jen			Low cost multifunctional 3D printed image quality and dose verification phantom for an image-guided radiotherapy system	PLOS ONE			English	Article							ASSURANCE; CT; DOSIMETRY; MRI	PurposeImage-guided radiation therapy (IGRT) is used to precisely deliver radiation to a tumour to reduce the possible damage to the surrounding normal tissues. Clinics use various quality assurance (QA) equipment to ensure that the performance of the IGRT system meets the international standards set for the system. The objective of this study was to develop a low-cost and multipurpose module for evaluating image quality and dose. MethodsA multipurpose phantom was designed to meet the clinical requirements of high accuracy, easy setup, and calibration. The outer shell of the phantom was fabricated using acrylic. Three dimensional (3D) printing technology was used to fabricate inner slabs with the characteristics of high spatial resolution, low-contrast detectability, a 3D grid, and liquid-filled uniformity. All materials were compatible with magnetic resonance (MR). Computed tomography (CT) simulator and linear accelerator (LINAC) modules were developed and validated. ResultsThe uniformity slab filled with water is ideal for the assessment of Hounsfield units, whereas that filled with wax is suitable for consistency checks. The high-spatial-resolution slab enables measurements with a resolution up to 5 lp/cm. The low-contrast detectability slab contains rods of 5 different sizes that can be clearly visualised. These components meet the American College of Radiology (ACR) standards for QA of CT simulators and LINACs. ConclusionsThe multifunctional phantom module meets the ACR recommended QA guidelines and is suitable for both LINACs and CT-sim. Further measurements in an MR simulator and an MR linear accelerator (MR-LINAC) will be arranged in the future.	[Wu, Jian-Kuen] Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, Taipei, Taiwan; [Yu, Min-Chin] Taipei Med Univ Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Chen, Shih-Han] Natl Taiwan Univ, Dept Med Imaging, Canc Ctr, Taipei, Taiwan; [Liao, Shu-Hsien] Natl Taiwan Normal Univ, Inst Electroopt Sci & Technol, Taipei, Taiwan; [Wang, Yu-Jen] Fu Jen Catholic Univ Hosp, Dept Radiat Oncol, New Taipei, Taiwan; [Wang, Yu-Jen] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; Taipei Medical University; Taipei Medical University Hospital; National Taiwan University; National Taiwan Normal University; Fu Jen Catholic University; Fu Jen Catholic University Hospital; Fu Jen Catholic University	Wang, YJ (corresponding author), Fu Jen Catholic Univ Hosp, Dept Radiat Oncol, New Taipei, Taiwan.; Wang, YJ (corresponding author), Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.	138697@mail.fju.edu.tw		Wang, Yu Jen/0000-0001-5642-0352	Fu Jen Catholic University Hospital	Fu Jen Catholic University Hospital	This research was partially supported by Fu Jen Catholic University Hospital but it had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], US; Baumann Michael, 2005, Rays, V30, P99; Bissonnette JP, 2012, MED PHYS, V39, P1946, DOI 10.1118/1.3690466; Chang Z, 2012, J APPL CLIN MED PHYS, V13, P113, DOI 10.1120/jacmp.v13i4.3754; Firbank MJ, 2000, BRIT J RADIOL, V73, P376, DOI 10.1259/bjr.73.868.10844863; Gach HM, 2019, MED PHYS, V46, P1785, DOI 10.1002/mp.13429; Goldman LW, 2007, J NUCL MED TECHNOL, V35, DOI 10.2967/jnmt.106.037846; Goyal S, 2014, RADIOL RES PRACT, V2014, DOI 10.1155/2014/705604; Hobson MA, 2014, J APPL CLIN MED PHYS, V15, P226, DOI [10.1120/jacmp.v15i4.4835, 10.1120/jacmp.v15i6.5228]; Kim MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176227; McCollough CH, 2004, MED PHYS, V31, P2423, DOI 10.1118/1.1769632; McDonald DG, 2017, J APPL CLIN MED PHYS, V18, P170, DOI 10.1002/acm2.12025; Renstrom J, 2006, EVALUATION ELEKTA SY; Slotman B, 2019, CLIN TRANSL RAD ONCO, V18, P102, DOI 10.1016/j.ctro.2019.04.011; Smit K, 2014, PHYS MED BIOL, V59, P4099, DOI 10.1088/0031-9155/59/15/4099; Wang D, 2004, MAGN RESON IMAGING, V22, P1211, DOI 10.1016/j.mri.2004.08.012	16	1	1	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266604	10.1371/journal.pone.0266604	http://dx.doi.org/10.1371/journal.pone.0266604			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1T6KL	35385553	gold, Green Published			2023-01-03	WOS:000804836900059
J	Yu, H; Yu, H; Si, LG; Meng, HSL; Chen, WS; Wang, ZL; Gula, A				Yu, Hong; Yu, Hui; Si, Lengge; Meng, Husileng; Chen, Wensheng; Wang, Zhanli; Gula, A.			Influence of warm acupuncture on gut microbiota and metabolites in rats with insomnia induced by PCPA	PLOS ONE			English	Article							EXPRESSION PROFILE; SLEEP; BRAIN; NEUROTRANSMITTERS; DISORDER; PATHWAY	BackgroundInsomnia is the most common of the sleep disorders. Current pharmacotherapy treatment options are usually associated with adverse effects and withdrawal phenomena. Therapeutic alternatives with a more favorable safety profile for patients are needed. Mongolian medical warm acupuncture (MMWA) is an emerging therapeutic option for treating insomnia. However, the underlying mechanisms responsible for the anti-insomnia efficacy of the MMWA remain unclear. This study aims to investigate the effect of the MMWA on the alterations of the gut microbiota and serum metabolome in rats with insomnia. ResultsWe found that the relative abundances of gut bacteria and the concentrations of several serum metabolites were obviously altered in PCPA-induced insomnia rats. The MMWA treatment exerted an anti-insomnia effect. In addition, the dysbiosis of the gut microbiota and the serum metabolites were ameliorated by the MMWA. Correlation analysis between the gut microbiota and metabolites suggested that the levels of Amide c18, Benzoyl chloride, Cytosine, and N, n-dimethylarginine were positively correlated with the relative abundance of Clostridium XlVa and Blautia, which characterized the insomnia rats. KEGG enrichment analysis identified the cAMP signaling pathway involving anti-insomnia effect of the MMWA. Moreover, the MMWA intervention significantly increased contents of butyrate in feces, while effectively inhibited the expression level of GAT-1 in brain tissues. ConclusionThis study reveals that the MMWA intervention might have a major impact on the modulation of host gut microbiota and metabolites, which in turn have a crucial role in the regulation of the host's signaling pathways associated with insomnia. The present study could provide useful ideas for the study of the intervention mechanisms of the MMWA in insomnia rat models.	[Yu, Hong; Gula, A.] Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing, Peoples R China; [Yu, Hong] Baotou Med Coll, Sch Nursing, Baotou, Peoples R China; [Yu, Hui; Wang, Zhanli; Gula, A.] Baotou Med Coll, Inner Mongolia Key Lab Dis Related Biomarkers, Baotou, Peoples R China; [Si, Lengge; Meng, Husileng; Chen, Wensheng] Inner Mongolia Med Univ, Mongolian Med Sch, Hohhot, Inner Mongolia, Peoples R China	Beijing University of Chinese Medicine; Baotou Medical College; Baotou Medical College; Inner Mongolia Medical University	Gula, A (corresponding author), Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing, Peoples R China.; Wang, ZL; Gula, A (corresponding author), Baotou Med Coll, Inner Mongolia Key Lab Dis Related Biomarkers, Baotou, Peoples R China.	wang.zhanli@hotmail.com; agula372000@126.com			National Natural Science Foundation of China [82074577]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (no. 82074577). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMICI R, 1990, EXPERIENTIA, V46, P58, DOI 10.1007/BF01955415; Appert O, 2020, ENVIRON MICROBIOL, V22, P3909, DOI 10.1111/1462-2920.15167; Bier A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091154; Bo A, 2017, EXP THER MED, V14, P289, DOI 10.3892/etm.2017.4452; Bo A, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/6190285; Bollu Pradeep C, 2019, Mo Med, V116, P68; Clark A, 2014, SLEEP, V37, P851, DOI 10.5665/sleep.3646; Di Guida R, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1030-9; Dogra SK, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.572921; Downing AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046135; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Fisher CK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102451; Ghirardini E, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0346-y; Gula A, 2019, ACUPUNCT MED, V37, P301, DOI 10.1136/acupmed-2016-011243; He WQ, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02619-6; Hong JJ, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3626120; Jang JH, 2020, BRAIN BEHAV IMMUN, V89, P641, DOI 10.1016/j.bbi.2020.08.015; Kamphuis J, 2013, SLEEP MED, V14, P1164, DOI 10.1016/j.sleep.2013.03.008; Lee SM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43112-x; Li YY, 2020, NAT SCI SLEEP, V12, P895, DOI 10.2147/NSS.S271927; Li YY, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00669; Lin A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102409; Liu BD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01770; Lu NS, 2017, J STEROID BIOCHEM, V172, P89, DOI 10.1016/j.jsbmb.2017.06.004; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Maki KA, 2020, PHYSIOL GENOMICS, V52, P280, DOI 10.1152/physiolgenomics.00039.2020; OGASAHARA S, 1981, BRAIN RES, V213, P163, DOI 10.1016/0006-8993(81)91256-7; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Parkar SG, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7020041; Borges-Martins VPP, 2019, NEUROCHEM INT, V131, DOI 10.1016/j.neuint.2019.104550; Si LG, 2015, EUR J INTEGR MED, V7, P492, DOI 10.1016/j.eujim.2015.05.008; Si YP, 2022, PHARM BIOL, V60, P131, DOI 10.1080/13880209.2021.2019283; Si YP, 2022, NEUROCHEM RES, V47, P574, DOI 10.1007/s11064-021-03466-z; Smith RP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222394; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; Tilg H, 2016, GUT, V65, P2035, DOI 10.1136/gutjnl-2016-312729; Wang QS, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.698967; Wei DN, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/9730176; Wen B, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1579-y; Wilkinson TJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01095; Xu HR, 2018, MOLECULES, V23, DOI 10.3390/molecules23092375; Xu YA, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20191517; Zhou J, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.722662; Zou R, 2020, AUTISM RES, V13, P1614, DOI 10.1002/aur.2358	45	1	1	6	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267843	10.1371/journal.pone.0267843	http://dx.doi.org/10.1371/journal.pone.0267843			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1D8GY	35482778	gold, Green Published			2023-01-03	WOS:000794035700056
J	Farmakiotis, D				Farmakiotis, Dimitrios			COVID-19 Treatments for Nonhospitalized Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Farmakiotis, Dimitrios] Brown Univ, Warren Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA	Brown University	Farmakiotis, D (corresponding author), Rhode Isl Hosp, 593 Eddy St,Gerry House 111, Providence, RI 02903 USA.	dimitrios.farmakiotis@lifespan.org						Ao GY, 2021, TRANSPLANT REV-ORLAN, V35, DOI 10.1016/j.trre.2021.100628; Azzi JR, 2013, J IMMUNOL, V191, P5785, DOI 10.4049/jimmunol.1390055; Gandhi RT, 2022, JAMA-J AM MED ASSOC, V327, P617, DOI 10.1001/jama.2022.0335; Lange NW, 2022, AM J TRANSPLANT, V22, P1925, DOI 10.1111/ajt.16955; McMinn J, 2021, KIDNEY INT REP, V6, P2694, DOI 10.1016/j.ekir.2021.07.012	5	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2022	327	22					2247	2247						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2J5EE	35699710				2023-01-03	WOS:000815679200028
J	Acosta-Rodriguez, V; Rijo-Ferreira, F; Izumo, M; Xu, P; Wight-Carter, M; Green, CB; Takahashi, JS				Acosta-Rodriguez, Victoria; Rijo-Ferreira, Filipa; Izumo, Mariko; Xu, Pin; Wight-Carter, Mary; Green, Carla B.; Takahashi, Joseph S.			Circadian alignment of early onset caloric restriction promotes longevity in male C57BL/6J mice	SCIENCE			English	Article							WHEEL-RUNNING ACTIVITY; LIFE-SPAN; DIETARY RESTRICTION; FOOD-INTAKE; CLOCK; TIME; HEALTH; METABOLISM; RHYTHMS; DEFICIENCY	Caloric restriction (CR) prolongs life span, yet the mechanisms by which it does so remain poorly understood. Under CR, mice self-impose chronic cycles of 2-hour feeding and 22-hour fasting, raising the question of if it is calories, fasting, or time of day that is the cause of this increased life span. We show here that 30% CR was sufficient to extend the life span by 10%; however, a daily fasting interval and circadian alignment of feeding acted together to extend life span by 35% in male C57BL/6J mice. These effects were independent of body weight. Aging induced widespread increases in gene expression associated with inflammation and decreases in the expression of genes encoding components of metabolic pathways in liver from ad libitum-fed mice. CR at night ameliorated these aging-related changes. Our results show that circadian interventions promote longevity and provide a perspective to further explore mechanisms of aging.	[Acosta-Rodriguez, Victoria; Rijo-Ferreira, Filipa; Izumo, Mariko; Xu, Pin; Green, Carla B.; Takahashi, Joseph S.] Univ Texas Southwestern Med Ctr Dallas, Peter ODonnell Jr Brain Inst, Dept Neurosci, Dallas, TX 75390 USA; [Rijo-Ferreira, Filipa; Takahashi, Joseph S.] Univ Texas Southwestern Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Wight-Carter, Mary] Univ Texas Southwestern Med Ctr Dallas, Anim Resources Ctr, Dallas, TX 75390 USA; [Rijo-Ferreira, Filipa] Univ Calif Berkeley, Infect Dis & Vaccinol, Sch Publ Hlth, Berkeley, CA 94720 USA; [Rijo-Ferreira, Filipa] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Green, CB; Takahashi, JS (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Peter ODonnell Jr Brain Inst, Dept Neurosci, Dallas, TX 75390 USA.	carla.green@utsouthwestern.edu; joseph.takahashi@utsouthwestern.edu	; Takahashi, Joseph/E-8482-2012	Wight- Carter, Mary/0000-0002-0988-8582; Takahashi, Joseph/0000-0003-0384-8878; Acosta-Rodriguez, Victoria/0000-0002-4818-0667; Xu, Pin/0000-0003-1281-563X	Howard Hughes Medical Institute; National Institutes of Health (NIH) National Institute on Aging [R01 AG045795, R56 AG072736]; NIH National Institute of General Medical Sciences (NIGMS) [R35 GM127122, K99 GM132557]; Milky Way Research Foundation [MWRF210823]	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health (NIH) National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)General Electric); Milky Way Research Foundation	This work was supported by the Howard Hughes Medical Institute (J.S.T.); the National Institutes of Health (NIH) National Institute on Aging (grant R01 AG045795 and R56 AG072736 to J.S.T. and C.B.G.); the NIH National Institute of General Medical Sciences (NIGMS) (grant R35 GM127122 to C.B.G. and grant K99 GM132557 to F.R.-F.); and the Milky Way Research Foundation (grant MWRF210823 to J.S.T. and C.B.G.). J.S.T. is an investigator and F.R.-F. was an associate at the Howard Hughes Medical Institute.	Acosta-Rodriguez VA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22922-6; Acosta-Rodriguez VA, 2017, CELL METAB, V26, P267, DOI 10.1016/j.cmet.2017.06.007; Allada R, 2021, NEW ENGL J MED, V384, P550, DOI 10.1056/NEJMra1802337; AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; Andersen A, 2018, NAT REV ENDOCRINOL, V14, P390, DOI 10.1038/s41574-018-0016-2; Aon MA, 2020, CELL METAB, V32, P100, DOI 10.1016/j.cmet.2020.04.018; Arble DM, 2009, OBESITY, V17, P2100, DOI 10.1038/oby.2009.264; Argmann C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000752; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Asher G, 2015, CELL, V161, P84, DOI 10.1016/j.cell.2015.03.015; Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006; Bass J, 2016, SCIENCE, V354, P994, DOI 10.1126/science.aah4965; Bass J, 2010, SCIENCE, V330, P1349, DOI 10.1126/science.1195027; Bellet MM, 2011, COLD SH Q B, V76, P31, DOI 10.1101/sqb.2011.76.010520; Chaix A, 2019, ANNU REV NUTR, V39, P291, DOI 10.1146/annurev-nutr-082018-124320; Chaix A, 2014, CELL METAB, V20, P991, DOI 10.1016/j.cmet.2014.11.001; Chaudhari Amol, 2017, Nutr Healthy Aging, V4, P101, DOI 10.3233/NHA-160006; Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557; Costa SSF, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00043; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Di Francesco A, 2018, SCIENCE, V362, P770, DOI 10.1126/science.aau2095; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dubrovsky YV, 2010, AGING-US, V2, P936, DOI 10.18632/aging.100241; Eckel-Mahan KL, 2013, CELL, V155, P1464, DOI 10.1016/j.cell.2013.11.034; Ernszt D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01515; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Froy O, 2018, P NUTR SOC, V77, P216, DOI 10.1017/S0029665117003962; Froy O, 2013, AGEING RES REV, V12, P931, DOI 10.1016/j.arr.2013.09.002; Froy O, 2010, AGING-US, V2, P7, DOI 10.18632/aging.100116; Garcia-Valles Rebeca, 2013, Longev Healthspan, V2, P14, DOI 10.1186/2046-2395-2-14; Gibson EM, 2009, EXP GERONTOL, V44, P51, DOI 10.1016/j.exger.2008.05.007; Gill S, 2015, SCIENCE, V347, P1265, DOI 10.1126/science.1256682; Gonzalez-Freire M, 2020, AGEING RES REV, V59, DOI 10.1016/j.arr.2020.101037; Greenwell BJ, 2019, CELL REP, V27, P649, DOI 10.1016/j.celrep.2019.03.064; Habib WA, 2018, GENET MED, V20, P250, DOI 10.1038/gim.2017.105; Harada Y, 2005, J BIOL CHEM, V280, P31714, DOI 10.1074/jbc.M506225200; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; He BK, 2016, CELL METAB, V23, P610, DOI 10.1016/j.cmet.2016.03.007; Hirota T, 2008, P NATL ACAD SCI USA, V105, P20746, DOI 10.1073/pnas.0811410106; Hofman MA, 2006, AGEING RES REV, V5, P33, DOI 10.1016/j.arr.2005.07.001; Hughes ME, 2010, J BIOL RHYTHM, V25, P372, DOI 10.1177/0748730410379711; Izumo M, 2014, ELIFE, V3, DOI 10.7554/eLife.04617; Katewa SD, 2016, CELL METAB, V23, P143, DOI 10.1016/j.cmet.2015.10.014; Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339; Kolberg Liis, 2020, F1000Res, V9, DOI 10.12688/f1000research.24956.1; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Kondratova AA, 2012, NAT REV NEUROSCI, V13, P325, DOI 10.1038/nrn3208; Korstanje R, 2021, GEROSCIENCE, V43, P2129, DOI 10.1007/s11357-021-00421-2; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Lamia KA, 2009, SCIENCE, V326, P437, DOI 10.1126/science.1172156; Lee MB, 2021, SCIENCE, V374, P953, DOI 10.1126/science.abe7365; Levine DC, 2020, MOL CELL, V78, P835, DOI 10.1016/j.molcel.2020.04.010; Liao YJ, 2010, PROTEOM CLIN APPL, V4, P394, DOI 10.1002/prca.200900074; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; Liu SP, 2007, HEPATOLOGY, V46, P1413, DOI 10.1002/hep.21863; Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manella G, 2021, NAT METAB, V3, P829, DOI 10.1038/s42255-021-00395-7; Manoogian ENC, 2019, J BIOL RHYTHM, V34, P579, DOI 10.1177/0748730419892105; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Martinez-Chantar ML, 2008, HEPATOLOGY, V47, P1191, DOI 10.1002/hep.22159; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Mattson MP, 2014, P NATL ACAD SCI USA, V111, P16647, DOI 10.1073/pnas.1413965111; Mitchell SJ, 2019, CELL METAB, V29, P221, DOI 10.1016/j.cmet.2018.08.011; Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Northeast RC, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz157; Pak HH, 2021, NAT METAB, V3, P1327, DOI 10.1038/s42255-021-00466-9; Palmisano BT, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00044; Panda S, 2016, SCIENCE, V354, P1008, DOI 10.1126/science.aah4967; Patel SA, 2016, FASEB J, V30, P1634, DOI 10.1096/fj.15-282475; Pellizzon MA, 2020, CURR DEV NUTR, V4, DOI 10.1093/cdn/nzaa031; Pellizzon Michael A, 2018, Curr Protoc Toxicol, V77, pe55, DOI 10.1002/cptx.55; Pellizzon MA, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0243-5; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Reinke H, 2019, NAT REV MOL CELL BIO, V20, P227, DOI 10.1038/s41580-018-0096-9; Rijo-Ferreira F, 2020, SCIENCE, V368, P746, DOI 10.1126/science.aba2658; Rijo-Ferreira F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0704-0; Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042; Scarbrough Kathryn, 1997, American Journal of Physiology, V272, pR1219; Selman C, 2018, EMBO J, V37, DOI 10.15252/embj.2018100862; Siepka SM, 2005, METHOD ENZYMOL, V393, P230, DOI 10.1016/S0076-6879(05)93008-5; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Solanas G, 2017, CELL, V170, P678, DOI 10.1016/j.cell.2017.07.035; Sun YF, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02138-5; Takahashi JS, 2015, METHOD ENZYMOL, V551, P285, DOI 10.1016/bs.mie.2014.10.059; Thaben PF, 2014, J BIOL RHYTHM, V29, P391, DOI 10.1177/0748730414553029; Tumasian R. A, 2014, NAT COMMUN, V12, P2021; Tumasian RA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22168-2; Turturro A, 2002, J GERONTOL A-BIOL, V57, pB379, DOI 10.1093/gerona/57.11.B379; Ulgherait M, 2021, NATURE, V598, P353, DOI 10.1038/s41586-021-03934-0; Ulgherait M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15617-x; Valentinuzzi VS, 1997, AM J PHYSIOL-REG I, V273, pR1957, DOI 10.1152/ajpregu.1997.273.6.R1957; Vollmers C, 2009, P NATL ACAD SCI USA, V106, P21453, DOI 10.1073/pnas.0909591106; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004; Wu G, 2016, BIOINFORMATICS, V32, P3351, DOI 10.1093/bioinformatics/btw405; Xiang Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1318-5; Xu M, 2016, ONCOTARGETS THER, V9, P4023, DOI 10.2147/OTT.S107050; Yamazaki S, 2002, P NATL ACAD SCI USA, V99, P10801, DOI 10.1073/pnas.152318499; Yang R, 2010, BIOINFORMATICS, V26, pi168, DOI 10.1093/bioinformatics/btq189; Yuan R, 2009, AGING CELL, V8, P277, DOI 10.1111/j.1474-9726.2009.00478.x; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031; [张旗 Zhang Qi], 2014, [岩石矿物学杂志, Acta Petrologica et Mineralogica], V33, P199	108	27	27	42	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2022	376	6598					1192	+	eabk0297	10.1126/science.abk0297	http://dx.doi.org/10.1126/science.abk0297			39	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E6FT	35511946	Green Accepted			2023-01-03	WOS:000812323000035
J	Deota, S; Panda, S				Deota, Shaunak; Panda, Satchidananda			Aligning mealtimes to live longer	SCIENCE			English	Editorial Material							CALORIE RESTRICTION; LIFE-SPAN	Calorie restriction, fasting, and circadian rhythms sync together for a long, healthy life in mice	[Deota, Shaunak; Panda, Satchidananda] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA	Salk Institute	Panda, S (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	satchin@salk.edu	Deota, Shaunak/AGN-0999-2022	Deota, Shaunak/0000-0002-4862-7414				Acosta-Rodriguez V, 2022, SCIENCE, V376, P1192, DOI 10.1126/science.abk0297; Acosta-Rodriguez VA, 2017, CELL METAB, V26, P267, DOI 10.1016/j.cmet.2017.06.007; Chavan R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10580; Hatori M, 2010, TRENDS MOL MED, V16, P435, DOI 10.1016/j.molmed.2010.07.005; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Katewa SD, 2016, CELL METAB, V23, P143, DOI 10.1016/j.cmet.2015.10.014; Liu DY, 2022, NEW ENGL J MED, V386, P1495, DOI 10.1056/NEJMoa2114833; Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001; Manoogian ENC, 2022, ENDOCR REV, V43, P405, DOI 10.1210/endrev/bnab027; Mure LS, 2018, SCIENCE, V359, P1232, DOI 10.1126/science.aao0318; Patel SA, 2016, FASEB J, V30, P1634, DOI 10.1096/fj.15-282475; Sanford JA, 2020, CELL, V181, P1464, DOI 10.1016/j.cell.2020.06.004; Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010; Ulgherait M, 2021, NATURE, V598, P353, DOI 10.1038/s41586-021-03934-0	14	0	0	5	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2022	376	6598					1159	1160		10.1126/science.adc8824	http://dx.doi.org/10.1126/science.adc8824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E6FT	35679410				2023-01-03	WOS:000812323000019
J	Kitayama, M; Unoki, T; Matsuda, Y; Matsuishi, Y; Kawai, Y; Iida, Y; Teramoto, M; Tatsuno, J; Hamamoto, M				Kitayama, Mio; Unoki, Takeshi; Matsuda, Yui; Matsuishi, Yujiro; Kawai, Yusuke; Iida, Yasuo; Teramoto, Mio; Tatsuno, Junko; Hamamoto, Miya			Development and initial validation of the Japanese healthy work environment assessment tool for critical care settings	PLOS ONE			English	Article							INTRACLASS CORRELATION-COEFFICIENTS; COMMUNICATION; NURSES	Aim This study aims to translate the Healthy Work Environment Assessment Tool (HWE-AT) into Japanese and evaluate its validity and reliability. Design and methods The authors followed the guidelines for scale translation, adaptation, and validation in cross-cultural healthcare research. After translation and back-translation, a series of pilot studies were conducted to assess comprehensibility. Subsequently, an expert panel established the content validity. Content validity was calculated using the content validity index (CVI). Finally, we verified the construct validity and calculated the test-retest reliability. Results The updated HWE-AT achieved sufficient comprehensibility after conducting the two pilot tests. Content validity was calculated using the scale-level CVI/average and all the items were 1.00. The content validity indices CFI and RMSEA were 0.918 and 0.082, respectively. Intraclass correlation coefficients for all dimensions ranged from 0.618 to 0.903, indicating acceptable test-retest reliability. Our findings suggest that the Japanese version of the HWE-AT has good validity and reliability.	[Kitayama, Mio] Kanazawa Med Univ Hosp, Nursing Dept, Uchinada, Ishikawa, Japan; [Unoki, Takeshi] Sapporo City Univ, Sch Nursing, Sapporo, Hokkaido, Japan; [Matsuda, Yui] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL USA; [Matsuishi, Yujiro] Sei Roka Kango Daigaku, Neurosci Nursing, Tokyo, Japan; [Kawai, Yusuke] Fujita Hlth Univ Hosp, Dept Nursing, Toyoake, Aichi, Japan; [Iida, Yasuo] Kanazawa Med Univ, Div Gen Educ Nat Sci Math, Uchinada, Ishikawa, Japan; [Teramoto, Mio] Columbia Univ, Teachers Coll, New York, NY 10027 USA; [Tatsuno, Junko] Kokura Mem Hosp, Nursing Dept, Kokura, Japan; [Hamamoto, Miya] Tosei Gen Hosp, Nursing Dept, Seto, Japan	Kanazawa Medical University; University of Miami; Fujita Health University; Kanazawa Medical University; Columbia University; Columbia University Teachers College; Kokura Memorial Hospital; Tosei General Hospital	Kitayama, M (corresponding author), Kanazawa Med Univ Hosp, Nursing Dept, Uchinada, Ishikawa, Japan.	mimio-f@kanazawa-med.ac.jp		Matsuda, Yui/0000-0003-4936-1504				American Association of Critical are Nurses, AACN HLTH WORK ENV A; American Association of Critical Care Nurses, 2009, AACN HLTH WORK ENV A; American Association of Critical-Care Nurses, 2005, AM J CRIT CARE, DOI 10.4037/ajcc2005.14.3.187; Beth U, 2019, FINDINGS IMPLICATION, V39, P67, DOI [10.4037/ccn2019605, DOI 10.4037/CCN2019605]; Chatzittofis A, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.707293; Cohen J, 2020, PREV MED, V141, DOI 10.1016/j.ypmed.2020.106263; Connor JA, 2018, AM J CRIT CARE, V27, P363, DOI 10.4037/ajcc2018179; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Hoe SL, 2008, J APPL QUANT METHODS, V3, P76; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Huddleston P, 2016, J NURS ADMIN, V46, P373, DOI 10.1097/NNA.0000000000000361; KAISER HF, 1974, EDUC PSYCHOL MEAS, V34, P111, DOI 10.1177/001316447403400115; Kelly L, 2017, AACN ADV CRIT CARE, V28, P351, DOI 10.4037/aacnacc2017283; Kenny DA, 2015, SOCIOL METHOD RES, V44, P486, DOI 10.1177/0049124114543236; Kitchin Rob, 2016, P I MECH ENG C-J MEC, V3, p205395171663113, DOI [10.1177/001316447403400115, DOI https://doi.org/10.1177/0025802420918487, 10.1177/2053951716631130, DOI 10.1177/0954406219850598]; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Kyriazos T., 2018, PSYCHOLOGY, V9, DOI 10.4236/psych.2018.98126; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Manojlovich M, 2007, AM J CRIT CARE, V16, P536; Manojlovich M, 2009, AM J CRIT CARE, V18, P21, DOI 10.4037/ajcc2009353; Maskey R, 2018, ASIAN J SHIPPING LOG, V34, P91, DOI 10.1016/j.ajsl.2018.06.006; Massoudi A.H., 2017, J BUSINESS MANAGEMEN, V19, P35, DOI [10.9790/487X-1901033542, DOI 10.9790/487X-1901033542]; McDonald RP, 2002, PSYCHOL METHODS, V7, P64, DOI 10.1037//1082-989X.7.1.64; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; McHugh MD, 2016, MED CARE, V54, P74, DOI 10.1097/MLR.0000000000000456; Munro CL, 2020, AM J CRIT CARE, V29, P4, DOI 10.4037/ajcc2020940; Olds DM, 2017, INT J NURS STUD, V74, P155, DOI 10.1016/j.ijnurstu.2017.06.004; Sezgin D, 2021, INT NURS REV, DOI 10.1111/inr.12740; Shah M, 2021, CLIN J ONCOL NURS, V25, P69, DOI 10.1188/21.CJON.69-75; Sousa VD, 2011, J EVAL CLIN PRACT, V17, P268, DOI 10.1111/j.1365-2753.2010.01434.x; Thing R, 2010, WHO HLTH WORKPLACE F; Yusoff M.S.B., 2019, RESOURCE, V11, P49, DOI [10.21315/eimj2019.11.2.6, DOI 10.21315/EIMJ2019.11.2.6, 10.21315/eimj2019.11.2]; Zou GY, 2012, STAT MED, V31, P3972, DOI 10.1002/sim.5466	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2022	17	5							e0268124	10.1371/journal.pone.0268124	http://dx.doi.org/10.1371/journal.pone.0268124			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5I2GE	35552559	Green Published, gold			2023-01-03	WOS:000868181100001
J	Slomski, A				Slomski, Anita			Mindfulness-Based Therapy Reduces Chronic Pain and Opioid Misuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2022	327	17					1641	1641						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D3AC	35503359				2023-01-03	WOS:000793675300003
J	Vagnozzi, RJ; McKinsey, TA				Vagnozzi, Ronald J.; McKinsey, Timothy A.			T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR	CELL STEM CELL			English	Editorial Material								Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts in mouse hearts, offering a promising and tractable immunotherapy approach for tackling fibrosis.	[Vagnozzi, Ronald J.; McKinsey, Timothy A.] Univ Colorado Anschutz Med Campus, Dept Med, Div Cardiol, Aurora, CO 80045 USA; [Vagnozzi, Ronald J.; McKinsey, Timothy A.] Univ Colorado Anschutz Med Campus, Consortium Fibrosis Res & Translat, Aurora, CO 80045 USA; [Vagnozzi, Ronald J.] Univ Colorado Anschutz Med Campus, Gates Ctr Regenerat Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Vagnozzi, RJ; McKinsey, TA (corresponding author), Univ Colorado Anschutz Med Campus, Dept Med, Div Cardiol, Aurora, CO 80045 USA.; Vagnozzi, RJ; McKinsey, TA (corresponding author), Univ Colorado Anschutz Med Campus, Consortium Fibrosis Res & Translat, Aurora, CO 80045 USA.; Vagnozzi, RJ (corresponding author), Univ Colorado Anschutz Med Campus, Gates Ctr Regenerat Med, Aurora, CO 80045 USA.	ronald.vagnozzi@cuanschutz.edu; timothy.mckinsey@cuanschutz.edu						Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039; Han MY, 2022, CURR CARDIOL REP, V24, P295, DOI 10.1007/s11886-022-01647-y; Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586-020-2938-9; Ivey MJ, 2018, J MOL CELL CARDIOL, V114, P161, DOI 10.1016/j.yjmcc.2017.11.012; Kanisicak O, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12260; Kaur H, 2016, CIRC RES, V118, P1906, DOI 10.1161/CIRCRESAHA.116.308643; Landmesser U, 2020, EUR HEART J, V41, P3884, DOI 10.1093/eurheartj/ehaa229; Lopez B, 2021, NAT REV CARDIOL, V18, P479, DOI 10.1038/s41569-020-00504-1; Rurik JG, 2022, SCIENCE, V375, P91, DOI 10.1126/science.abm0594	10	0	0	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	MAR 3	2022	29	3					352	354		10.1016/j.stem.2022.02.002	http://dx.doi.org/10.1016/j.stem.2022.02.002		MAR 2022	3	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	ZO2XT	35245466				2023-01-03	WOS:000765594000005
J	Hayes, H				Hayes, Hannah			Cracking delayed discharges will need local innovation and bold national action	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hayes, Hannah] NHS Providers, London, England		Hayes, H (corresponding author), NHS Providers, London, England.							ADASS Press Release, SNAP SURV REV RAP DE; [Anonymous], GUARDIAN; Community Network, DISCH ASS CAS PERM F; HSJ, HOSP TRUST LAUNCH SO; Independent, CAR STAFF SHORT MEAN; NHS Digital, NHS VAC STAT ENGL AP; Providers NHS, NHS WINT WATCH 2021	7	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	2022	376								o547	10.1136/bmj.o547	http://dx.doi.org/10.1136/bmj.o547			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX8XR	35236712	Bronze			2023-01-03	WOS:000772178100009
J	Glober, N; Supples, M; Persaud, S; Kim, D; Liao, M; Glidden, M; O'Donnell, D; Tainter, C; Boustani, M; Alexander, A				Glober, Nancy; Supples, Michael; Persaud, Sarah; Kim, David; Liao, Mark; Glidden, Michele; O'Donnell, Dan; Tainter, Christopher; Boustani, Malaz; Alexander, Andreia			A novel emergency medical services protocol to improve treatment time for large vessel occlusion strokes	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; ENDOVASCULAR THROMBECTOMY; CARE	In many systems, patients with large vessel occlusion (LVO) strokes experience delays in transport to thrombectomy-capable centers. This pilot study examined use of a novel emergency medical services (EMS) protocol to expedite transfer of patients with LVOs to a comprehensive stroke center (CSC). From October 1, 2020 to February 22, 2021, Indianapolis EMS piloted a protocol, in which paramedics, after transporting a patient with a possible stroke remained at the patient's bedside until released by the emergency department or neurology physician. In patients with possible LVO, EMS providers remained at the bedside until the clinical assessment and CT angiography (CTA) were complete. If indicated, the paramedics at bedside transferred the patient, via the same ambulance, to a nearby thrombectomycapable CSC with which an automatic transfer agreement had been arranged. This fivemonth mixed methods study included case-control assessment of use of the protocol, number of transfers, safety during transport, and time saved in transfer compared to emergent transfers via conventional interfacility transfer agencies. In qualitative analysis EMS providers, and ED physicians and neurologists at both sending and receiving institutions, completed e-mail surveys on the process, and offered suggestions for process improvement. Responses were coded with an inductive content analysis approach. The protocol was used 42 times during the study period; four patients were found to have LVOs and were transferred to the CSC. There were no adverse events. Median time from decision-to-transfer to arrival at the CSC was 27.5 minutes (IQR 24.5-29.0), compared to 314.5 minutes (IQR 204.0-459.3) for acute non-stroke transfers during the same period. Major themes of provider impressions included: incomplete awareness of the protocol, smooth process, challenges when a stroke alert was activated after EMS left the hospital, greater involvement of EMS in patient care, and comments on communication and efficiency. This pilot study demonstrated the feasibility, safety, and efficiency of a novel approach to expedite endovascular therapy for patients with LVOs.	[Glober, Nancy; Supples, Michael; Persaud, Sarah; Liao, Mark; Glidden, Michele; O'Donnell, Dan; Boustani, Malaz; Alexander, Andreia] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Kim, David] Stanford Univ, Dept Emergency Med, Santa Clara Cty, CA USA; [Tainter, Christopher] Univ Calif San Diego, Dept Anesthesiol Crit Care, San Diego, CA 92103 USA	Indiana University System; Indiana University Bloomington; University of California System; University of California San Diego	Glober, N (corresponding author), Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA.	nglober@iu.edu		Glober, Nancy/0000-0001-5769-3651; Kim, David/0000-0003-0151-5121	Agency for Healthcare Research and Quality [K12 HS026390]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	NG - K12 HS026390 Agency for Healthcare Research and Quality https://www.ahrq. gov/funding/index.html sponsors did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeoye O, 2019, STROKE, V50, pE187, DOI 10.1161/STR.0000000000000173; Adeoye O, 2014, STROKE, V45, P3019, DOI 10.1161/STROKEAHA.114.006293; Bureau TUSC, AM FACTFINDER 2020; Campbell BCV, 2017, CIRCULATION, V136, P2322, DOI 10.1161/CIRCULATIONAHA.117.031444; Corbin J., 2014, BASICS QUALITATIVE R; Dozois A, 2017, STROKE, V48, P3397, DOI 10.1161/STROKEAHA.117.018925; Dunbar SB, 2018, CIRCULATION, V137, pE558, DOI 10.1161/CIR.0000000000000570; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Froehler MT, 2017, CIRCULATION, V136, P2311, DOI 10.1161/CIRCULATIONAHA.117.028920; Gaynor E, 2022, J NEUROINTERV SURG, V14, P573, DOI 10.1136/neurintsurg-2021-017653; Glaser B., 1967, MILL VALLEY; Goyal M, 2016, RADIOLOGY, V279, P888, DOI 10.1148/radiol.2016160204; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Jayaraman MV, 2020, J NEUROINTERV SURG, V12, P233, DOI 10.1136/neurintsurg-2019-015033; Keenan KJ, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0734-x; Malhotra K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00651; Menon BK, 2016, CIRCULATION, V133, P2279, DOI 10.1161/CIRCULATIONAHA.115.019983; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Rennert RC, 2019, NEUROSURGERY, V85, pS4, DOI 10.1093/neuros/nyz042; RODGERS BL, 1993, RES NURS HEALTH, V16, P219, DOI 10.1002/nur.4770160309; Ryan GW., 2009, ANAL QUALITATIVE DAT; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Vidale S, 2018, ACTA NEUROL SCAND, V138, P24, DOI 10.1111/ane.12908; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757	25	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0264539	10.1371/journal.pone.0264539	http://dx.doi.org/10.1371/journal.pone.0264539			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0U7EE	35213646	Green Published, gold			2023-01-03	WOS:000787811000118
J	Beyene, MM; Shimbre, MS; Ukke, GG; Gebremichael, MA; Gurara, MK				Beyene, Maechel Maile; Shimbre, Mulugeta Shegaze; Ukke, Gebresilasea Gendisha; Gebremichael, Mathewos Alemu; Gurara, Mekdes Kondale			Factors associated with antenatal exercise in Arba Minch town, Southern Ethiopia: A community-based cross-sectional study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; GUIDELINES; PREGNANCY; DISEASES; WOMEN	Background Many health risks in pregnant women and their foetuses can be reduced by practicing antenatal exercise. However, the adequate practice of antenatal exercise among pregnant women is low in Ethiopia. Therefore, this study aimed to assess the practice of antenatal exercise and its associated factors among pregnant women in Arba Minch town. Methods A community-based cross-sectional study design was conducted. Data were collected by using a structured questionnaire from 422 pregnant women selected by a simple random sampling technique. Descriptive statistics were computed and a binary logistic regression model was fitted. In multivariable logistic-regression adjusted odds ratio (AOR) with 95% confidence intervals were used to determine the strength of associations. The significance level was declared at a p-value < 0.05. Results Among 410 participants, 32.9% (95% CI 28%-37%) adequately practiced antenatal exercise. Factors negatively associated with an adequate antenatal exercise were husband's primary school level [Adjusted odds ratio (AOR) = 0.3, (95% CI: 0.1, 0.7)], history of miscarriage [AOR = 0.3, (95% CI: 0.1, 0.7)], inadequate knowledge [AOR = 0.2, (95% CI: 0.1, 0.3)], and unfavorable attitude [AOR = 0.3, (95% CI 0.2, 0.5)]. Whereas, factors positively associated with an adequate antenatal exercise were employment status of women [AOR = 4.8, (95% CI: 1.8, 13.1)], and a practice of regular exercise before current pregnancy [AOR = 1.9, (95% CI: 1.1, 3.2)]. Conclusions The findings of this study indicated that adequate practice of antenatal exercise was found to be low. Appropriate measures should be taken to improve the husband's educational level, mother's occupation, knowledge, and attitudes towards antenatal exercise. Special consideration should be given to those with a history of miscarriage and women should be encouraged to practice regular exercise before pregnancy.	[Beyene, Maechel Maile; Ukke, Gebresilasea Gendisha] Arba Minch Univ, Coll Med & Hlth Sci, Dept Midwifery, Arba Minch, Ethiopia; [Shimbre, Mulugeta Shegaze; Gebremichael, Mathewos Alemu; Gurara, Mekdes Kondale] Arba Minch Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Arba Minch, Ethiopia	Arba Minch University; Arba Minch University	Beyene, MM (corresponding author), Arba Minch Univ, Coll Med & Hlth Sci, Dept Midwifery, Arba Minch, Ethiopia.	maechelmaile11@gmail.com		Kondale, Mekdes/0000-0001-8977-8772; Alemu, Mathewos/0000-0003-3652-9013; Maile, Maechel/0000-0003-3656-9357; Shimbre, Mulugeta Shegaze/0000-0001-5633-1309	Arba Minch University, college of Medicine and Health sciences	Arba Minch University, college of Medicine and Health sciences	Funding was obtained from Arba Minch University, college of Medicine and Health sciences.https://www.amu.edu.et/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Bongaarts J, 2016, POPUL DEV REV, V42, P726, DOI 10.1111/padr.12033; Evenson KR, 2019, OBSTET GYNECOL SURV, V74, P481, DOI 10.1097/OGX.0000000000000693; Evenson KR, 2014, AM J LIFESTYLE MED, V8, P102, DOI 10.1177/1559827613498204; Janakiraman B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247533; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; May LE, 2010, EARLY HUM DEV, V86, P213, DOI 10.1016/j.earlhumdev.2010.03.002; Mbada CE, 2015, INT J WOMEN HEAL REP, V3, P93, DOI 10.15296/ijwhr.2015.18; My A., 2015, PHYS ACTIVITY EXERCI; Nascimento SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128953; Nkhata LA., 2014, J SCI RES REPORTS, P1986; Nkhata LA., 2015, SCI J PUBL HLTH, V3, P361; Okafor UB, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03439-0; Pasanen T, 2017, BRIT J SPORT MED, V51, P1459, DOI 10.1136/bjsports-2016-097132; Puchalski S, 2017, J PREGNANCY REPROD, V1, DOI [10.15761/JPR.1000107, DOI 10.15761/JPR.1000107]; Ribeiro CP, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-31; Sarfraz M., 2013, PAKISTAN J MED DENT, V1, P34; Sujindra E., 2015, INT J ED PSYCHOL RES, V1, P234, DOI [10.4103/2395-2296.158347, DOI 10.4103/2395-2296.158347]; Timar R, 2016, PATIENT PREFER ADHER, V10, P2471, DOI 10.2147/PPA.S124858; Todorovic J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041366; Walsh JM, 2011, INT J GYNECOL OBSTET, V114, P154, DOI 10.1016/j.ijgo.2011.02.016; Wijesiriwardana W., 2016, SRI LANKA J OBSTET G, V37; Zavorsky GS, 2011, SPORTS MED, V41, P345, DOI 10.2165/11583930-000000000-00000	23	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2022	17	2							e0260840	10.1371/journal.pone.0260840	http://dx.doi.org/10.1371/journal.pone.0260840			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2E9PM	35192634	gold, Green Published			2023-01-03	WOS:000812552500005
J	Colunga-Lozano, LE; Nampo, FK; Agarwal, A; Desai, P; Litzow, M; Sekeres, MA; Guyatt, GH; Brignardello-Petersen, R				Colunga-Lozano, Luis Enrique; Nampo, Fernando Kenji; Agarwal, Arnav; Desai, Pinkal; Litzow, Mark; Sekeres, Mikkael A.; Guyatt, Gordon H.; Brignardello-Petersen, Romina			Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis	PLOS ONE			English	Review							LOW-DOSE CYTARABINE; CONVENTIONAL CARE REGIMENS; AMERICAN SOCIETY; ELDERLY-PATIENTS; RETINOIC ACID; OPEN-LABEL; ARA-C; AZACITIDINE; GUIDELINES; GRADE	Introduction Elderly patients with acute myeloid leukemia not eligible for intensive antileukemic therapy are treated with less intensive therapies, uncertainty remains regarding their relative merits. Objectives To compare the effectiveness and safety of less intensive antileukemic therapies for older adults with newly diagnosed AML not candidates for intensive therapies. Methods We included randomized controlled trials (RCTs) and non-randomized studies (NRS) comparing less intensive therapies in adults over 55 years with newly diagnosed AML. We searched MEDLINE and EMBASE from inception to August 2021. We assessed risk of bias of RCTs with a modified Cochrane Risk of Bias tool, and NRS with the Non-Randomized Studies of Interventions tool (ROBINS-I). We calculated pooled hazard ratios (HRs), risk ratios (RRs), mean differences (MD) and their 95% confidence intervals (CIs) using a random-effects pairwise meta-analyses and assessed the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results We included 27 studies (17 RCTs, 10 NRS; n = 5,698), which reported 9 comparisons. Patients were treated with azacitidine, decitabine, and low-dose cytarabine (LDAC), as monotherapies or in combination with other agents. Moderate certainty of evidence suggests no convincing difference in overall survival of patients who receive azacitidine monotherapy compared to LDAC monotherapy (HR 0.69; 95% CI, 0.31-1.53), fewer febrile neutropenia events occurred between azacitidine monotherapy to azacitidine combination (RR 0.45; 95% CI, 0.31-0.65), and, fewer neutropenia events occurred between LDAC monotherapy to decitabine monotherapy (RR 0.62; 95% CI 0.44-0.86). All other comparisons and outcomes had low or very low certainty of evidence. Conclusion There is no convincing superiority in OS when comparing less intensive therapies. Azacitidine monotherapy is likely to have fewer adverse events than azacitidine combination (febrile neutropenia), and LDAC monotherapy is likely to have fewer adverse events than decitabine monotherapy (neutropenia).	[Colunga-Lozano, Luis Enrique; Guyatt, Gordon H.; Brignardello-Petersen, Romina] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Nampo, Fernando Kenji] Univ Latin Amer Integrat, Dept Latin Amer Inst Life & Nat Sci, Foz Do Iguacu, Parana, Brazil; [Agarwal, Arnav] Univ Toronto, Dept Med, Toronto, ON, Canada; [Desai, Pinkal] Weill Cornell Med Ctr, Div Hematol & Med Oncol, New York, NY USA; [Litzow, Mark] Mayo Clin, Div Hematol, Rochester, MN USA; [Sekeres, Mikkael A.] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol, Miami, FL USA; [Colunga-Lozano, Luis Enrique] Univ Guadalajara, Dept Clin Med, Guadalajara, Jalisco, Mexico	McMaster University; University of Toronto; Cornell University; Mayo Clinic; University of Miami; Universidad de Guadalajara	Colunga-Lozano, LE (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; Colunga-Lozano, LE (corresponding author), Univ Guadalajara, Dept Clin Med, Guadalajara, Jalisco, Mexico.	dr.colunga.lozano@gmail.com	Agarwal, Arnav/J-1553-2014	Agarwal, Arnav/0000-0002-0931-7851; Colunga-Lozano, Luis Enrique/0000-0001-7737-4914	American Society of Hematology	American Society of Hematology	The American Society of Hematology provided funding for the development of the clinical practice guideline related to this topic (American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults), however, no funding was used during the development of this study. Information added as "Related Manuscript".	Almeida Antonio M, 2016, Leuk Res Rep, V6, P1, DOI 10.1016/j.lrr.2016.06.001; [Anonymous], 2020, GRADEPRO GDT GRADEPR; [Anonymous], 2020, REV MANAGER REVMAN C; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Boddu PC, 2017, CANCER-AM CANCER SOC, V123, P3050, DOI 10.1002/cncr.30704; Burnett AK, 2013, LEUKEMIA, V27, P75, DOI 10.1038/leu.2012.229; Burnett AK, 2011, LEUKEMIA, V25, P1122, DOI 10.1038/leu.2011.59; Cortes JE, 2019, LEUKEMIA, V33, P379, DOI 10.1038/s41375-018-0312-9; Craddock CF, 2017, CLIN CANCER RES, V23, P6430, DOI 10.1158/1078-0432.CCR-17-1423; Creutzig U, 2008, CANCER-AM CANCER SOC, V112, P562, DOI 10.1002/cncr.23220; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dennis M, 2015, BLOOD, V125, P2923, DOI 10.1182/blood-2014-10-608117; Di Febo Annalaura, 2007, Am J Ther, V14, P351, DOI 10.1097/01.mjt.0000208277.65249.52; DiNardo CD, 2020, NEW ENGL J MED, V383, P617, DOI 10.1056/NEJMoa2012971; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; DiNardo CL, 2018, LANCET ONCOL, V19, P216, DOI 10.1016/S1470-2045(18)30010-X; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9; Finn L, 2017, OCHSNER J, V17, P398; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011; Guyatt JB, 2015, MODIFICATION COCHRAN; Jacob Linu A, 2015, Adv Hematol, V2015, P167029, DOI 10.1155/2015/167029; Yepes-Nunez JJ, 2019, J CLIN EPIDEMIOL, V115, P1, DOI 10.1016/j.jclinepi.2019.04.018; Kanakasetty GB, 2019, ANN HEMATOL, V98, P881, DOI 10.1007/s00277-019-03600-6; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Lubbert M, 2020, J CLIN ONCOL, V38, P257, DOI 10.1200/JCO.19.01053; Milligan DW, 2006, BRIT J HAEMATOL, V135, P450, DOI 10.1111/j.1365-2141.2006.06314.x; Montalban-Bravo G, 2017, LEUKEMIA, V31, P1659, DOI 10.1038/leu.2017.85; Montesinos P, 2021, LEUKEMIA, V35, P62, DOI 10.1038/s41375-020-0773-5; Nanah R, 2017, AM J HEMATOL, V92, P866, DOI 10.1002/ajh.24780; Network. NCC, 2021, ACUTE MYELOID LEUKEM, V3; Onec B, 2018, J CANCER RES THER, V14, P1105, DOI 10.4103/0973-1482.187369; Page MJ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003583; Palmieri R, 2020, CANCERS, V12, DOI 10.3390/cancers12010120; Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102; Quintas-Cardama A, 2012, BLOOD, V120, P4840, DOI 10.1182/blood-2012-06-436055; Roboz GJ, 2018, BLOOD ADV, V2, P3608, DOI 10.1182/bloodadvances.2018023689; Schunemann HJ, 2019, J CLIN EPIDEMIOL, V111, P105, DOI 10.1016/j.jclinepi.2018.01.012; Sekeres MA, 2020, BLOOD ADV, V4, P3528, DOI 10.1182/bloodadvances.2020001920; Sekeres MA, 2013, HAEMATOLOGICA, V98, P119, DOI 10.3324/haematol.2012.066613; Smith BD, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162-3619-3-10; Talati C, 2020, HAEMATOLOGICA, V105, P398, DOI 10.3324/haematol.2018.208637; Thein MS, 2013, CANCER-AM CANCER SOC, V119, P2720, DOI 10.1002/cncr.28129; Wei AH, 2020, BLOOD, V135, P2137, DOI 10.1182/blood.2020004856; Wiercioch W, 2020, BLOOD ADV, V4, P2351, DOI 10.1182/bloodadvances.2020001768; Zeng LN, 2021, J CLIN EPIDEMIOL, V137, P163, DOI 10.1016/j.jclinepi.2021.03.026	52	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2022	17	2							e0263240	10.1371/journal.pone.0263240	http://dx.doi.org/10.1371/journal.pone.0263240			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0D3HO	35108310	gold, Green Published			2023-01-03	WOS:000775890100053
J	Chen, J; Yang, YY; Yu, NN; Sun, WX; Yang, YY; Zhao, M				Chen, Jing; Yang, Yuying; Yu, Ningning; Sun, Wanxiao; Yang, Yuanyuan; Zhao, Mei			Relationship between gut microbiome characteristics and the effect of nutritional therapy on glycemic control in pregnant women with gestational diabetes mellitus	PLOS ONE			English	Article							PROBIOTIC SUPPLEMENTATION; GLUCOSE; METABOLISM; INSULIN; INTERVENTION; METAANALYSIS; SYNBIOTICS; BUTYRATE; DISEASE; IMPACT	The purpose of this study was to explore the relationship between the characteristics of gut microbiome and the effect of medical nutrition therapy (MNT) on glycemic control in pregnant women with gestational diabetes mellitus (GDM). Seventy-four pregnant women newly diagnosed with GDM received MNT for one-week. The effect of glycemic control was evaluated by fasting and 2-hour postprandial blood glucose; and stool samples of pregnant women were collected to detect the gut microbiome before and after MNT. We used a nested case-control study design, with pregnant women with GDM who did not meet glycemic standards after MNT as the ineffective group and those with an age difference of <= 5 years, matched for pre-pregnancy body mass index (BMI) 1:1, and meeting glycemic control criteria as the effective group. Comparison of the gut microbiome characteristics before MNT showed that the ineffective group was enriched in Desulfovibrio, Aeromonadales, Leuconostocaceae, Weissella, Prevotella, Bacillales_Incertae Sedis XI, Gemella and Bacillales, while the effective group was enriched in Roseburia, Clostridium, Bifidobacterium, Bifidobacteriales, Bifidobacteriaceae, Holdemania and Proteus. After treatment, the effective group was enriched in Bifidobacterium and Actinomycete, while the ineffective group was enriched in Holdemania, Proteus, Carnobacteriaceae and Granulicatella. In conclusion, the decrease in the abundance of characteristic gut microbiome positively correlated with blood glucose may be a factor influencing the poor hypoglycemic effect of MNT in pregnant women with GDM. Abundance of more characteristic gut microbiome negatively correlated with blood glucose could help control blood glucose in pregnant women with GDM.	[Chen, Jing; Yu, Ningning; Sun, Wanxiao; Zhao, Mei] Anhui Med Univ, Sch Nursing, Hefei, Anhui, Peoples R China; [Yang, Yuying] Univ Sci & Technol China, Affiliated Hosp USTC 1, Hefei Ion Med Ctr, Dept Nursing,Div Life Sci & Med, Hefei, Anhui, Peoples R China; [Yang, Yuanyuan] Anhui Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Hefei, Anhui, Peoples R China	Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Zhao, M (corresponding author), Anhui Med Univ, Sch Nursing, Hefei, Anhui, Peoples R China.	zhapmei@ahmu.edu.cn		Zhao, Mei/0000-0003-3530-0233; Chen, Jing/0000-0003-0764-969X	National Natural Science Foundation of China [81671471]; Major projects of Humanities and social sciences research projects in Colleges and universities in Anhui Province [SK2021ZD0030]; Scientific research cultivation project of Nursing College of Anhui Medical University [hlzd2020003]; Young seedling cultivation project of Nursing College of Anhui Medical University [hlqm20201903, hlqm2021037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major projects of Humanities and social sciences research projects in Colleges and universities in Anhui Province; Scientific research cultivation project of Nursing College of Anhui Medical University; Young seedling cultivation project of Nursing College of Anhui Medical University	This study was supported by National Natural Science Foundation of China (81671471), Major projects of Humanities and social sciences research projects in Colleges and universities in Anhui Province (SK2021ZD0030), Scientific research cultivation project of Nursing College of Anhui Medical University(hlzd2020003), and Young seedling cultivation project of Nursing College of Anhui Medical University (hlqm20201903, hlqm2021037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akagawa S, 2021, METABOLITES, V11, DOI 10.3390/metabo11120887; Amaretti A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02614; Aranaz P, 2021, INT J OBESITY, V45, P2261, DOI 10.1038/s41366-021-00904-4; Asgharian H, 2020, EUR J NUTR, V59, P205, DOI 10.1007/s00394-019-01900-1; Bajaj JS, 2012, AM J PHYSIOL-GASTR L, V303, pG675, DOI 10.1152/ajpgi.00152.2012; Balsells M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h102; Barandouzi ZA, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00541; Barka EA, 2016, MICROBIOL MOL BIOL R, V80, P1, DOI 10.1128/MMBR.00019-15; Blumer I, 2013, J CLIN ENDOCR METAB, V98, P4227, DOI 10.1210/jc.2013-2465; Callaway LK, 2019, DIABETES CARE, V42, P364, DOI 10.2337/dc18-2248; Casarin RCV, 2013, J PERIODONTAL RES, V48, P30, DOI 10.1111/j.1600-0765.2012.01498.x; Caughey AB, 2017, OBSTET GYNECOL, V130, pE17, DOI 10.1097/AOG.0000000000002159; Chen MY, 2020, INT J BIOL MACROMOL, V155, P890, DOI 10.1016/j.ijbiomac.2019.11.047; Chesdachai S, 2022, J INFECTION, V84, P511, DOI 10.1016/j.jinf.2022.01.039; Cuevas-Sierra A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082710; D'Anna R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88329-x; Dodd JM, 2019, LANCET DIABETES ENDO, V7, P15, DOI [10.1016/S2213-8587(18)30310-3, 10.1016/s2213-8587(18)30310-3]; Ericson U, 2020, J NUTR, V150, P861, DOI 10.1093/jn/nxz293; Gao CH, 2019, J DIABETES INVEST, V10, P154, DOI 10.1111/jdi.12854; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Hamilton AL, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00085-17; Han SS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009275.pub3; Hasain Z, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.680622; Heym N, 2019, PSYCHOPHARMACOLOGY, V236, P1459, DOI 10.1007/s00213-019-05230-2; Hughes RCE, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018493; Jiang HY, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23650; Jose PA, 2021, MICROBIOL RES, V246, DOI 10.1016/j.micres.2021.126708; Kapur K., 2021, NUTR MANAGEMENT GEST, V1, P1, DOI [10.1159/000509900, DOI 10.1159/000509900]; Karamali M, 2016, DIABETES METAB, V42, P234, DOI 10.1016/j.diabet.2016.04.009; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; Kimber-Trojnar Z, 2014, CURR PHARM BIOTECHNO, V15, P100, DOI 10.2174/1389201015666140330200254; Koren O, 2012, CELL, V150, P470, DOI 10.1016/j.cell.2012.07.008; Kuang YS, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix058; Lee Kyoung-Hee, 2020, Obstet Gynecol Sci, V63, P19, DOI 10.5468/ogs.2020.63.1.19; Li MX, 2020, INT J BIOL MACROMOL, V149, P717, DOI 10.1016/j.ijbiomac.2020.01.305; Lippert K, 2017, BENEF MICROBES, V8, P545, DOI 10.3920/BM2016.0184; Lu RY, 2021, INQUIRY-J HEALTH CAR, V58, DOI 10.1177/00469580211012491; Martin-Pelaez S, 2022, NUTRIENTS, V14, DOI 10.3390/nu14020341; McNabney SM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121348; Mistry SK, 2021, ENDOCRIN DIAB METAB, V4, DOI 10.1002/edm2.285; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Nie K, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.757718; Nikbakht E, 2018, EUR J NUTR, V57, P95, DOI 10.1007/s00394-016-1300-3; Olsson LM, 2020, GUT, V69, P1229, DOI 10.1136/gutjnl-2019-319322; Pan YS, 2022, J GASTROEN HEPATOL, V37, P7, DOI 10.1111/jgh.15713; Pellonpera O, 2019, DIABETES CARE, V42, P1009, DOI 10.2337/dc18-2591; Ponzo V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020330; Qi WW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016352; Qian YW, 2018, BRAIN BEHAV IMMUN, V70, P194, DOI 10.1016/j.bbi.2018.02.016; Reigadas E, 2020, ANAEROBE, V61, DOI 10.1016/j.anaerobe.2019.102079; Rus M, 2022, MEDICINA-LITHUANIA, V58, DOI 10.3390/medicina58020271; Saleh S, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800435; Sanmiguel C, 2015, CURR OBES REP, V4, P250, DOI 10.1007/s13679-015-0152-0; Sayavedra L, 2021, ENVIRON MICROBIOL, V23, P3164, DOI 10.1111/1462-2920.15538; Shaik A, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00792; Sung JJY, 2020, GUT, V69, P1572, DOI 10.1136/gutjnl-2019-319826; Tarry-Adkins JL, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002848; Teixeira CG, 2021, PROBIOTICS ANTIMICRO, V13, P915, DOI 10.1007/s12602-021-09751-1; Tett A, 2021, NAT REV MICROBIOL, V19, P585, DOI 10.1038/s41579-021-00559-y; The Chinese medical association branch of obstetrics and gynaecology obstetric group, 2014, CHIN J OBSTET GYNECO, V49, P561; Tims S, 2013, ISME J, V7, P707, DOI 10.1038/ismej.2012.146; Tremblay A, 2021, J DIET SUPPL, V18, P227, DOI 10.1080/19390211.2020.1749751; Wang JK, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.110965; Wang JF, 2018, GUT, V67, P1614, DOI 10.1136/gutjnl-2018-315988; Wang T, 2020, EUR J NUTR, V59, P2709, DOI 10.1007/s00394-019-02117-y; Wang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104784; Wickens KL, 2017, BRIT J NUTR, V117, P804, DOI [10.1017/S0007114517000289, 10.1017/s0007114517000289]; Yamamoto JM, 2018, DIABETES CARE, V41, P1346, DOI 10.2337/dc18-0102; Yang YH, 2019, FOOD FUNCT, V10, P5952, DOI [10.1039/c9fo00766k, 10.1039/C9FO00766K]; Zhang CJ, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-04039-2; Zhang L, 2022, BIOENGINEERED, V13, P5625, DOI 10.1080/21655979.2021.2023789; Zhang MX, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2343-2; Zhang W, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109131; Zheng J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197771; Zheng JP, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112225; Zhou LY, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00985	76	2	2	5	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0267045	10.1371/journal.pone.0267045	http://dx.doi.org/10.1371/journal.pone.0267045			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1E2NP	35427393	Green Published, gold			2023-01-03	WOS:000794332400035
J	Ghazel, N; Souissi, A; Salhi, I; Dergaa, I; Martins-Costa, HC; Musa, S; Ben Saad, H; Ben Abderrahman, A				Ghazel, Nourhen; Souissi, Amine; Salhi, Iyed; Dergaa, Ismail; Martins-Costa, Hugo Cesar; Musa, Sarah; Ben Saad, Helmi; Ben Abderrahman, Abderraouf			Effects of eight weeks of mat pilates training on selected hematological parameters and plasma volume variations in healthy active women	PLOS ONE			English	Article							BLOOD-VOLUME; EXERCISE	Aim To evaluate the effects of eight weeks of mat Pilates training on selected hematological parameters, i.e. white blood cell, neutrophils, monocyte, lymphocyte, hematocrit, hemoglobin as well as plasma volume variations in healthy, active women. Methods Twenty-eight women physical education students volunteered to participate in the present investigation. They were assigned to two groups: a Pilates training group (n = 14) that followed an 8-week Pilates training program, and a control group (n = 14). Blood samples were collected at rest at two separate occasions before and after Pilates training. Results The Pilates training group had higher values of plasma volume variations and lower values of white blood cell (19.4%), neutrophils (32%), hematocrit (4.3%) and hemoglobin (4.6%) compared to control group (p<0.05). Conclusion The results of the present study suggested that Pilates training could be an effective strategy for increasing plasma volume variations and boosting immune system in healthy active women.	[Ghazel, Nourhen; Souissi, Amine; Salhi, Iyed; Ben Abderrahman, Abderraouf] Higher Inst Sport & Phys Educ Ksar Said, Manouba, Tunisia; [Souissi, Amine; Ben Saad, Helmi] Univ Sousse, Hop Farhat HACHED, Fac Med Sousse, Lab Rech Insuffisance Cardiaque LR12SP09, Sousse, Tunisia; [Dergaa, Ismail; Musa, Sarah] Primary Hlth Care Corp, Preventat Hlth Dept Wellness, PHCC, Doha, Qatar; [Martins-Costa, Hugo Cesar] Pontificia Univ Catolica Minas Gerais, Dept Phys Educ, Belo Horizonte, MG, Brazil	Universite de la Manouba; Universite de Sousse; Hopital Farhat Hached; Hamad Medical Corporation; Primary Health Care Corporation (PHCC); Pontificia Universidade Catolica de Minas Gerais	Dergaa, I (corresponding author), Primary Hlth Care Corp, Preventat Hlth Dept Wellness, PHCC, Doha, Qatar.	Idergaa@phcc.gov.ga	Ben Saad, Helmi/C-8263-2018	Ben Saad, Helmi/0000-0002-7477-2965; Souissi, Amine/0000-0003-2072-2425; , Sarah/0000-0002-4457-9953; Dergaa, Ismail/0000-0001-8091-1856	Qatar National Library	Qatar National Library(Qatar National Research Fund (QNRF))	The publication of this article was funded by the Qatar National Library.	Bahram ME, 2020, J HLTH PROMOT MANAG, V9, P56; Bekris E, 2015, SPORT SCI REV, V24, P103, DOI [10.1515/ssr-2015-0011, DOI 10.1515/SSR-2015-0011]; Ben Abderrahman A, 2013, INT J SPORT PHYSIOL, V8, P358, DOI 10.1123/ijspp.8.4.358; Byrnes K, 2018, J BODYW MOV THER, V22, P192, DOI 10.1016/j.jbmt.2017.04.008; CARROLL JF, 1995, MED SCI SPORT EXER, V27, P79; Cazotti LD, 2018, ARCH PHYS MED REHAB, V99, P1740, DOI 10.1016/j.apmr.2018.04.018; Chmielewska D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225647; DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; dos Santos JM, 2020, J BODYW MOV THER, V24, P496, DOI 10.1016/j.jbmt.2020.06.020; Fernandez-Rodriguez R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251391; Finatto P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194057; Fleming KM, 2020, MENT HEALTH PHYS ACT, V19, DOI 10.1016/j.mhpa.2020.100341; Ghazel N, 2022, RES SPORTS MED, V30, P50, DOI 10.1080/15438627.2020.1860045; Gronesova P, 2018, GEN PHYSIOL BIOPHYS, V37, P443, DOI 10.4149/gpb_2018007; HARRISON MH, 1985, PHYSIOL REV, V65, P149, DOI 10.1152/physrev.1985.65.1.149; Hopkins W., 2002, STAT VS CLIN PRACTIC, V6; Johannsen NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031319; Kakanis MW, 2010, EXERC IMMUNOL REV, V16, P119; Kargotich S, 1998, SPORTS MED, V26, P101, DOI 10.2165/00007256-199826020-00004; Kayaoglu B., 2019, J ED TRAINING STUDIE, V7, P71; KHajehlandi M, 2019, J ARDABIL U MED SCI, V19, P311; Khajehlandi Mozhdeh, 2020, MEDICAL J TABRIZ U M, V42, P2020; Latey P., 2001, J BODYW MOV THER, V5, P275, DOI [10.1054/jbmt.2001.0237, DOI 10.1054/JBMT.2001.0237]; LUETKEMEIER MJ, 1994, MED SCI SPORT EXER, V26, P503; Michishita R, 2010, AM J MED SCI, V339, P152, DOI 10.1097/MAJ.0b013e3181c6a980; Mollinedo-Cardalda I, 2018, REJUV RES, V21, P423, DOI 10.1089/rej.2017.2007; Rhibi F, 2019, PHYSIOL BEHAV, V199, P137, DOI 10.1016/j.physbeh.2018.11.020; Romano-Spica V, 2015, ANN IG MED PREV COMU, V27, P406, DOI 10.7416/ai.2015.2028; Rayes ABR, 2019, PEERJ, V7, DOI 10.7717/peerj.6022; Segal NA, 2004, ARCH PHYS MED REHAB, V85, P1977, DOI 10.1016/j.apmr.2004.01.036; Sellami M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02187; Serhier Zineb, 2020, Tunis Med, V98, P1; Shahrokhian S, 2017, JUNDISHAPUR SCI MED, V16, P243; Souissi A, 2022, MOVEMENT SPORT SCI S, V115, P25, DOI DOI 10.1051/SM/2021020; Souissi A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244191; Souissi A, 2020, BIOL RHYTHM RES, V51, P980, DOI 10.1080/09291016.2019.1573462; Souissi A, 2020, BIOL RHYTHM RES, V51, P560, DOI 10.1080/09291016.2018.1543638; Suna G., 2020, ASIAN J ED TRAIN, V6, P226, DOI [10.20448/journal.522.2020.62.226.230, DOI 10.20448/JOURNAL.522.2020.62.226.230]; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Weiner J.S., 1981, PRACTICAL HUMAN BIOL	40	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0267437	10.1371/journal.pone.0267437	http://dx.doi.org/10.1371/journal.pone.0267437			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y3IG	35657955	Green Published, gold			2023-01-03	WOS:000843619700072
J	Lee, JJB; Lee, E; Choi, WH; Kim, J; Chang, KH; Kim, DW; Shin, HB; Kim, TH; Byun, HK; Cho, J				Lee, Jason Joon Bock; Lee, Eungman; Choi, Won Hoon; Kim, Jihun; Chang, Kyung Hwan; Kim, Dong Wook; Shin, Han Back; Kim, Tae Hyung; Byun, Hwa Kyung; Cho, Jaeho			Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy	PLOS ONE			English	Article							QUALITY-OF-LIFE; EXTERNAL-BEAM RADIATION; INTERSTITIAL BRACHYTHERAPY; PERMANENT BRACHYTHERAPY; I-125 SEEDS; PSA BOUNCE; CANCER; IMPLANT; DISPLACEMENT; SELECTION	This study aimed to evaluate the quality of low-dose-rate (LDR) prostate brachytherapy (BT) based on treatment-related dosimetric outcomes. Data of 100 patients treated using LDR BT with stranded seeds from November 2012 to November 2017 were collected. The prescription dose for the prostate was 145 Gy. The dose constraints for the preoperative plan were: V100% >= 95%, V150% <= 60%, V200% <= 20% for the prostate; V100% for rectum, <= 1 cc; and V200 Gy for urethra, 0.0 cc. Intraoperative real-time dose calculation and postoperative dose distribution analysis on days 0 and 30 were performed. Median dosimetric outcomes on days 0 and 30 respective were: V100% 92.28% and 92.23%, V200% 18.63% and 25.02%, and D90% 150.88 Gy and 151.46 Gy for the prostate; V100% for the rectum, 0.11 cc and 0.22 cc; and V200 Gy for the urethra, 0.00 cc and 0.00 cc, respectively. Twenty patients underwent additional seed implantation to compensate for insufficient dose coverage of the prostate. No loss or substantial migration of seeds or severe toxicity was reported. With stranded seed implantation and intraoperative optimization, appropriate dose delivery to the prostate without excessive dose to the organs at risk could be achieved.	[Lee, Jason Joon Bock; Lee, Eungman; Kim, Jihun; Kim, Dong Wook; Shin, Han Back; Kim, Tae Hyung; Byun, Hwa Kyung; Cho, Jaeho] Yonsei Univ, Yonsei Canc Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Lee, Jason Joon Bock] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Radiat Oncol, Sch Med, Seoul, South Korea; [Lee, Eungman] Ewha Womans Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Choi, Won Hoon] INFINITT Healthcare, Seoul, South Korea; [Chang, Kyung Hwan] Douzone Bizon, Dept Digital Hlth Solut, Seoul, South Korea; [Kim, Tae Hyung] Nowon Eulji Med Ctr, Dept Radiat Oncol, Seoul, South Korea	Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Samsung Medical Center; Ewha Womans University	Cho, J (corresponding author), Yonsei Univ, Yonsei Canc Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea.	jjhmd@yuhs.ac	; Kim, Dong Wook/I-8636-2014	Lee, Jason Joon Bock/0000-0003-3170-1427; Cho, Jaeho/0000-0001-9966-5157; Kim, Jihun/0000-0003-4856-6305; Kim, Tae Hyung/0000-0002-5205-3775; Kim, Dong Wook/0000-0002-5819-9783; Byun, Hwa Kyung/0000-0002-8964-6275				Acher P, 2008, INT J RADIAT ONCOL, V71, P1518, DOI 10.1016/j.ijrobp.2008.03.065; Agarwal M, 2018, BRACHYTHERAPY, V17, P882, DOI 10.1016/j.brachy.2018.07.001; Al-Qaisieh B, 2004, INT J RADIAT ONCOL, V59, P397, DOI 10.1016/j.ijrobp.2003.10.034; Albert JM, 2013, BRACHYTHERAPY, V12, P30, DOI 10.1016/j.brachy.2012.03.009; Birekhead BJ, 2016, BRACHYTHERAPY, V15, P714, DOI 10.1016/j.brachy.2016.07.004; Blanchard P, 2018, BJU INT, V121, P540, DOI 10.1111/bju.14021; Bloemen-van Gurp EJ, 2009, INT J RADIAT ONCOL, V73, P314, DOI 10.1016/j.ijrobp.2008.08.040; Bowes D, 2013, BRACHYTHERAPY, V12, P38, DOI 10.1016/j.brachy.2012.03.007; Brown D, 2000, INT J RADIAT ONCOL, V47, P353, DOI 10.1016/S0360-3016(00)00433-8; Butler WM, 2000, MED PHYS, V27, P381, DOI 10.1118/1.598842; Caloglu M, 2011, INT J RADIAT ONCOL, V80, P735, DOI 10.1016/j.ijrobp.2010.02.021; Cha CM, 1999, INT J RADIAT ONCOL, V45, P391, DOI 10.1016/S0360-3016(99)00187-X; Cherpak AJ, 2014, BRACHYTHERAPY, V13, P169, DOI 10.1016/j.brachy.2013.11.004; Crook J, 2007, INT J RADIAT ONCOL, V69, P426, DOI 10.1016/j.ijrobp.2007.03.031; Fuller Donald B, 2004, Brachytherapy, V3, P10, DOI 10.1016/j.brachy.2004.02.003; Henderson A, 2004, EUR UROL, V45, P134, DOI 10.1016/j.eururo.2003.09.015; Jani Ashesh B, 2004, Med Dosim, V29, P42, DOI 10.1016/j.meddos.2003.09.005; Kollmeier MA, 2003, INT J RADIAT ONCOL, V57, P645, DOI 10.1016/S0360-3016(03)00627-8; Kollmeier MA, 2012, BRACHYTHERAPY, V11, P271, DOI 10.1016/j.brachy.2011.11.002; Kono Y, 2010, JPN J CLIN ONCOL, V40, P1159, DOI 10.1093/jjco/hyq118; Kudchadker RJ, 2008, INT J RADIAT ONCOL, V72, P623, DOI 10.1016/j.ijrobp.2008.03.001; Kudchadker RJ, 2012, MED DOSIM, V37, P387, DOI 10.1016/j.meddos.2012.03.001; Kunogi H, 2016, J CONTEMP BRACHYTHER, V8, P167, DOI 10.5114/jcb.2016.60452; Lardas M, 2017, EUR UROL, V72, P869, DOI 10.1016/j.eururo.2017.06.035; LING CC, 1994, INT J RADIAT ONCOL, V28, P971, DOI 10.1016/0360-3016(94)90117-1; Matzkin H, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-288; Melchert C, 2018, J CONTEMP BRACHYTHER, V10, P232, DOI 10.5114/jcb.2018.76748; Merrell KW, 2019, BRACHYTHERAPY, V18, P306, DOI 10.1016/j.brachy.2019.01.007; Morris WJ, 2014, BRACHYTHERAPY, V13, P32, DOI 10.1016/j.brachy.2013.08.006; Peschel RE, 2004, CANCER J, V10, P170, DOI 10.1097/00130404-200405000-00006; Reed DR, 2007, BRACHYTHERAPY, V6, P129, DOI 10.1016/j.brachy.2007.01.003; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Sasaki H, 2014, INT J UROL, V21, P572, DOI 10.1111/iju.12373; Shukla G, 2017, BRACHYTHERAPY, V16, P490, DOI 10.1016/j.brachy.2016.12.014; Steggerda MJ, 2017, RADIOTHER ONCOL, V124, P68, DOI 10.1016/j.radonc.2017.05.017; Stish BJ, 2018, TRANSL ANDROL UROL, V7, P341, DOI 10.21037/tau.2017.12.15; Stone NN, 2002, EUR UROL, V41, P427, DOI 10.1016/S0302-2838(02)00019-2; Sugawara A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-130; Sylvester JE, 2003, INT J RADIAT ONCOL, V57, P944, DOI 10.1016/S0360-3016(03)00739-9; Taussky D, 2017, J CONTEMP BRACHYTHER, V9, P304, DOI 10.5114/jcb.2017.68467; Thaker NG, 2016, BRACHYTHERAPY, V15, P274, DOI 10.1016/j.brachy.2016.01.003; Tisseverasinghe S, 2021, BRACHYTHERAPY, V20, P849, DOI 10.1016/j.brachy.2021.03.005; van Tol-Geerdink JJ, 2013, BRIT J CANCER, V108, P1784, DOI 10.1038/bjc.2013.181	43	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265143	10.1371/journal.pone.0265143	http://dx.doi.org/10.1371/journal.pone.0265143			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0T0FS	35353847	Green Published, gold			2023-01-03	WOS:000786647900043
J	Li, DS; Li, YY; Zeng, HX; Wu, YG				Li, Dashan; Li, Yuanyuan; Zeng, Hanxu; Wu, Yonggui			Risk factors for Encapsulating Peritoneal Sclerosis in patients undergoing peritoneal dialysis: A meta-analysis	PLOS ONE			English	Article							SINGLE-CENTER EXPERIENCE; COMPLICATION; DIAGNOSIS	PurposeEncapsulating Peritoneal Sclerosis (EPS) is the most serious complication of long-term peritoneal dialysis (PD), which considerably reduces the patient's quality of life, leading to patients discontinuing PD. Considering these negative effects, it is necessary to systematically review and determine the risk factors of EPS. MethodsThe PubMed, Embase, Web of Science, Cochrane Library, and China Biology Medicine (CBM) were searched from their inception to January 1(st), 2022, and the bibliographies from the citations of relevant articles were manually searched. The ROBINS-I (Risk of Bias in Non-randomized studies of Interventions) tool was used to evaluate the risk of bias of included studies. ResultsTen studies involving 12595 participants were included in this meta-analysis. The results revealed that a younger age at PD onset (MD = -7.70, 95% CI, -11.53~-3.86), a higher transporter (MD = 0.13, 95% CI, 0.09~0.18), a longer PD duration (SMD = 1.15, 95% CI, 0.68~1.61), a longer peritonitis duration (MD = 12.66, 95% CI, 3.85~21.47), and history of glomerulonephritis (OR = 1.42, 95% CI, 1.02~1.97) were significant risk factors for EPS. However, sex, use of icodextrin, the number of peritonitis episodes, and history of multicystic kidney disease did not affect the risk of EPS. ConclusionsThis review provides a scientific basis for further understanding the etiology of PD-related EPS and improving prevention strategies. More high-quality studies are necessary to validate this paper's findings.	[Li, Dashan; Li, Yuanyuan; Zeng, Hanxu; Wu, Yonggui] Anhui Med Univ, Affiliated Hosp 1, Dept Nephropathy, Hefei, Anhui, Peoples R China	Anhui Medical University	Wu, YG (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Nephropathy, Hefei, Anhui, Peoples R China.	wuyonggui@medmail.com.cn	li, yuanyuan/GZA-4435-2022					Abouchacra S, 2013, CASE REP NEPHROL DIA, V3, P22, DOI 10.1159/000349999; Abrahams AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112050; Alatab S, 2017, RENAL FAILURE, V39, P32, DOI 10.1080/0886022X.2016.1244075; Bansal Saurabh, 2010, Adv Perit Dial, V26, P75; Betjes MGH, 2017, PERITON DIALYSIS INT, V37, P230, DOI 10.3747/pdi.2016.00109; BRADLEY JA, 1983, LANCET, V2, P113; Brown EA, 2017, PERITON DIALYSIS INT, V37, P362, DOI 10.3747/pdi.2017.00018; Brown MC, 2009, CLIN J AM SOC NEPHRO, V4, P1222, DOI 10.2215/CJN.01260209; Chew CG, 1997, NEPHROL DIAL TRANSPL, V12, P821, DOI 10.1093/ndt/12.4.821; Chin AI, 2006, AM J KIDNEY DIS, V47, P697, DOI 10.1053/j.ajkd.2005.12.049; FLANIGAN M, 1984, AM J MED, V76, pA113, DOI 10.1016/0002-9343(84)91017-9; Gayomali C, 2011, PERITON DIALYSIS INT, V31, P279, DOI 10.3747/pdi.2010.00196; GOLDMAN M, 1990, NEPHRON, V56, P277, DOI 10.1159/000186154; Habib AM, 2010, NEPHROL DIAL TRANSPL, V25, P1633, DOI 10.1093/ndt/gfp677; Honda K, 2005, PERITON DIALYSIS INT, V25, pS19; Hsu HJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8250589; Jagirdar RM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225765; Johnson DW, 2010, KIDNEY INT, V77, P904, DOI 10.1038/ki.2010.16; Kawaguchi Y, 2000, PERITON DIALYSIS INT, V20, pS43; Kawanishi H, 2004, AM J KIDNEY DIS, V44, P729, DOI 10.1053/j.ajkd.2004.06.020; Kern G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096377; Koc Y, 2018, MINERVA UROL NEFROL, V70, P429, DOI 10.23736/S0393-2249.18.03057-6; Korte MR, 2011, NAT REV NEPHROL, V7, P528, DOI 10.1038/nrneph.2011.93; Korte MR, 2011, PERITON DIALYSIS INT, V31, P269, DOI 10.3747/pdi.2010.00167; Lambie ML, 2010, KIDNEY INT, V78, P611, DOI 10.1038/ki.2010.186; Lambie MR, 2016, NEPHROL DIAL TRANSPL, V31, P480, DOI 10.1093/ndt/gfv440; Lee HY, 2003, NEPHROLOGY, V8, pS33, DOI 10.1046/j.1440-1797.8.s.11.x; Lim BJ, 2009, PEDIATR NEPHROL, V24, P513, DOI 10.1007/s00467-008-1055-z; Lopez-Anton M, 2017, AM J PATHOL, V187, P1537, DOI 10.1016/j.ajpath.2017.03.007; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nagavally RR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910252; Nakao M, 2017, NEPHROLOGY, V22, P907, DOI 10.1111/nep.12911; Nakao M, 2014, THER APHER DIAL, V18, P68, DOI 10.1111/1744-9987.12048; Nakayama M, 2001, PERITON DIALYSIS INT, V21, pS72; Nakayama Masaaki, 2002, Nihon Jinzo Gakkai Shi, V44, P396; Nakayama Masaaki, 2002, Adv Perit Dial, V18, P144; Nomoto Y, 1996, AM J KIDNEY DIS, V28, P420, DOI 10.1016/S0272-6386(96)90501-6; Page MJ, 2021, INT J SURG, V88, DOI 10.1016/j.ijsu.2021.105906; Phelan PJ, 2010, RENAL FAILURE, V32, P459, DOI 10.3109/08860221003658274; Pollock CA, 2001, PERITON DIALYSIS INT, V21, pS61; Rigby RJ, 1998, NEPHROL DIAL TRANSPL, V13, P154, DOI 10.1093/ndt/13.1.154; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Strippoli R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3543678; Summers AM, 2005, KIDNEY INT, V68, P2381, DOI 10.1111/j.1523-1755.2005.00701.x; Topley N, 1996, BLOOD PURIFICAT, V14, P188, DOI 10.1159/000170262; Trigka K, 2011, INT UROL NEPHROL, V43, P519, DOI 10.1007/s11255-010-9848-y; Tseng CC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190079; Vizzardi V, 2016, J NEPHROL, V29, P259, DOI 10.1007/s40620-015-0241-x; Yamahatsu A, 2015, CLIN EXP NEPHROL, V19, P961, DOI 10.1007/s10157-015-1081-7; Yamamoto Ryo, 2005, Clin Exp Nephrol, V9, P148, DOI 10.1007/s10157-005-0349-8; Yamamoto Ryo, 2002, Adv Perit Dial, V18, P131; Zemel D, 1996, BLOOD PURIFICAT, V14, P198, DOI 10.1159/000170263	52	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265584	10.1371/journal.pone.0265584	http://dx.doi.org/10.1371/journal.pone.0265584			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1R8XY	35312717	gold, Green Published			2023-01-03	WOS:000803647900043
J	Lin, SY; Sung, CW; Huang, EPC; Chen, CH; Fan, CY; Lee, HY; Huang, CT; Huang, YS; Zhuang, BY; Liu, CH; Chang, JH				Lin, Shao-Yung; Sung, Chih-Wei; Huang, Edward Pei-Chuan; Chen, Chi-Hsin; Fan, Cheng-Yi; Lee, Hsin-Yu; Huang, Chien-Tai; Huang, Yu-Sheng; Zhuang, Bo-Yu; Liu, Cheng-Heng; Chang, Jia-How			Intravenous antibiotics at the index emergency department visit as an independent risk factor for hospital admission at the return visit within 72 hours	PLOS ONE			English	Article							PREDICTORS; OUTCOMES; SAFETY; COSTS	IntroductionAlthough infection was the most common symptom in patients returning to the ED, whether intravenous antibiotic administration at the index visit could serve as an indicator of patients with infectious diseases at high risk for hospital admission after returning to the ED within a short period of time remains unclear. The study aimed to investigate the potential risk factors for hospital admission in patients returning to the ED within 72 hours with a final diagnosis of infectious diseases. Material and methodsThis retrospective cohort study analyzed return visits to the ED from January to December 2019. Adult patients aged >20 years who had a return visit to the ED within 72 hours with an infectious disease were included herein. In total, 715 eligible patients were classified into the intravenous antibiotics and non-intravenous antibiotics group (reference group). The outcome studied was hospital admission to general ward and intensive care unit (ICU) at the return visits. ResultsPatients receiving intravenous antibiotics at index visits had significantly higher risk-approximately two times-for hospital admission at the return visits than those did not (adjusted odds ratio = 2.47, 95% CI = 1.34-4.57, p = 0.004). For every 10 years increase in age, the likelihood for hospital admission increased by 38%. Other factors included abnormal respiratory rate and high C-reactive protein levels. ConclusionsIntravenous antibiotic administration at the index visit was an independent risk factor for hospital admission at return visits in patients with an infection disease. Physicians should consider carefully before discharging patients receiving intravenous antibiotics.	[Lin, Shao-Yung; Huang, Edward Pei-Chuan; Lee, Hsin-Yu; Huang, Chien-Tai] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei City, Taiwan; [Sung, Chih-Wei; Huang, Edward Pei-Chuan; Chen, Chi-Hsin; Fan, Cheng-Yi; Huang, Yu-Sheng; Chang, Jia-How] Natl Taiwan Univ Hosp, Dept Emergency Med, Hsin Chu Branch, Hsinchu, Taiwan; [Zhuang, Bo-Yu] New Taipei City Hosp, Dept Family Med, New Taipei City, Taiwan; [Liu, Cheng-Heng] Natl Taiwan Univ Hosp, Dept Med Educ, Taipei City, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chang, JH (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Hsin Chu Branch, Hsinchu, Taiwan.	jiahowchang@gmail.com		Pei-Chuan Huang, Edward/0000-0002-4800-2561	National Taiwan University Hospital Hsin-Chu Branch [109-HCH013]	National Taiwan University Hospital Hsin-Chu Branch	We thanked the study nurses (Wan-Chun Liu, Wen-Ling Chiu, Hsiu-Mei Tuan) and research assistants (Yurou Deng, Yu-An Chen, Yi-Wei Lee, Wei-Yu Chen) in data collection from medical charts.	Aaronson E, 2018, AM J EMERG MED, V36, P359, DOI 10.1016/j.ajem.2017.08.019; DAVID FN, 1951, BIOMETRIKA, V38, P43, DOI 10.2307/2332316; Duseja R, 2015, ANN INTERN MED, V162, P750, DOI 10.7326/M14-1616; Fan JS, 2007, AM J EMERG MED, V25, P1009, DOI 10.1016/j.ajem.2007.03.005; Fayyaz J, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-83; Gordon JA, 1998, ANN EMERG MED, V32, P569, DOI 10.1016/S0196-0644(98)70034-4; Hayward J, 2018, WEST J EMERG MED, V19, P912, DOI [10.5811/westjem.2018.38225, 10.5811/westjem.2018.8.38225]; Hou S-W., 2014, ISRN EMERGENCY MED, V2014, P461258; Jorgensen S, 2018, AM J EMERG MED, V36, P12, DOI 10.1016/j.ajem.2017.06.041; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kim DU, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051406; Ng CJ, 2019, EMERG MED J, V36, P472, DOI 10.1136/emermed-2018-207509; Nunez S, 2006, QUAL SAF HEALTH CARE, V15, P102, DOI 10.1136/qshc.2005.016618; Pham JC, 2011, ACAD EMERG MED, V18, P390, DOI 10.1111/j.1553-2712.2011.01042.x; Rising KL, 2014, ACAD EMERG MED, V21, P864, DOI 10.1111/acem.12442; Sabbatini AK, 2016, JAMA-J AM MED ASSOC, V315, P663, DOI 10.1001/jama.2016.0649; Schenkel S, 2000, ACAD EMERG MED, V7, P1204, DOI 10.1111/j.1553-2712.2000.tb00466.x; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Tsai IT, 2016, TZU CHI MED J, V28, P151, DOI 10.1016/j.tcmj.2016.07.002; Wu CL, 2010, J EMERG MED, V38, P512, DOI 10.1016/j.jemermed.2008.03.039	20	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0264946	10.1371/journal.pone.0264946	http://dx.doi.org/10.1371/journal.pone.0264946			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P4VV	35303001	Green Published, gold			2023-01-03	WOS:000784220200029
J	Methi, F; Hernaes, KH; Skyrud, KD; Magnusson, K				Methi, Fredrik; Hernaes, Kjersti Helene; Skyrud, Katrine Damgaard; Magnusson, Karin			Pandemic trends in health care use: From the hospital bed to self-care with COVID-19	PLOS ONE			English	Article								AimTo explore whether the acute 30-day burden of COVID-19 on health care use has changed from February 2020 to February 2022. MethodsIn all Norwegians (N = 493 520) who tested positive for SARS-CoV-2 in four pandemic waves (February 26(th), 2020 -February 16(th), 2021 (1(st) wave dominated by the Wuhan strain), February 17(th)-July 10(th), 2021 (2(nd) wave dominated by the Alpha variant), July 11(th)-December 27(th), 2021 (3(rd) wave dominated by the Delta variant), and December 28(th), 2021 -January 14(th), 2022 (4(th) wave dominated by the Omicron variant)), we studied the age- and sex-specific share of patients (by age groups 1-19, 20-67, and 68 or more) who had: 1) Relied on self-care, 2) used outpatient care (visiting general practitioners or emergency ward for COVID-19), and 3) used inpatient care (hospitalized >= 24 hours with COVID-19). ResultsWe find a remarkable decline in the use of health care services among COVID-19 patients for all age/sex groups throughout the pandemic. From 83% [95%CI = 83%-84%] visiting outpatient care in the first wave, to 80% [81%-81%], 69% [69%-69%], and 59% [59%-59%] in the second, third, and fourth wave. Similarly, from 4.9% [95%CI = 4.7%-5.0%] visiting inpatient care in the first wave, to 3.6% [3.4%-3.7%], 1.4% [1.3%-1.4%], and 0.5% [0.4%-0.5%]. Of persons testing positive for SARS-CoV-2, 41% [41%-41%] relied on self-care in the 30 days after testing positive in the fourth wave, compared to 16% [15%-16%] in the first wave. ConclusionFrom 2020 to 2022, the use of COVID-19 related outpatient care services decreased with 29%, whereas the use of COVID-19 related inpatient care services decreased with 80%.	[Methi, Fredrik; Hernaes, Kjersti Helene; Skyrud, Katrine Damgaard; Magnusson, Karin] Norwegian Inst Publ Hlth, Cluster Hlth Serv Res, Oslo, Norway; [Magnusson, Karin] Lund Univ, Fac Med, Dept Clin Sci Lund, Clin Epidemiol Unit, Lund, Sweden	Norwegian Institute of Public Health (NIPH); Lund University	Methi, F (corresponding author), Norwegian Inst Publ Hlth, Cluster Hlth Serv Res, Oslo, Norway.	fredrik.methi@fhi.no		Magnusson, Karin/0000-0003-4851-5794; Methi, Fredrik/0000-0002-7091-0806				Ahrenfeldt LJ, 2021, WIEN KLIN WOCHENSCHR, V133, P393, DOI [10.1007/s00508-020-01793-9, 10.21203/rs.3.rs-61444/v1]; Alexander GC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.21476; Bagi HM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258697; Bakken IJ, 2020, SCAND J PUBLIC HEALT, V48, P49, DOI 10.1177/1403494819859737; Bergman J, 2021, EUR J EPIDEMIOL, V36, P287, DOI 10.1007/s10654-021-00732-w; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Faktisk.no, 2020, ARE CORONA RELATED D; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Gutierrez-Gutierrez B, 2021, LANCET INFECT DIS, V21, P783, DOI 10.1016/S1473-3099(21)00019-0; Menachemi N, 2021, J PUBLIC HEALTH MAN, V27, P246, DOI 10.1097/PHH.0000000000001331; Nagy A, 2021, INT J ANTIMICROB AG, V57, DOI 10.1016/j.ijantimicag.2020.106272; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Norwegian Institute of Public Health, 2021, VACC SCEN; Norwegian Institute of Public Health, 2020, NORW EM PREP REG BE; Norwegian Institute of Public Health, 2020, UPD COR GUID; Norwegian Institute of Public Health, 2020, TEST CRIT SARS COV 2; Norwegian Institute of Public Health, 2021, NEW VAR SARS COV2 KN; Park S, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3691; Pulliam JRC, 2021, INCREASED RISK SARSC, V2021, DOI [10.1101/2021.11.11.21266068, DOI 10.1101/2021.11.11.21266068, 10.1002/jmv.27516, DOI 10.1002/jmv.27516]; Reilev M, 2020, INT J EPIDEMIOL, V49, P1468, DOI 10.1093/ije/dyaa140; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Skyrud KD., 2021, MEDRXIV, DOI [10.1101/2021.02.16.21251807, DOI 10.1101/2021.02.16.21251807]; Sporaland Geir Lindquist, 2019, Tidsskr Nor Laegeforen, V139, DOI 10.4045/tidsskr.18.0440; Varmdal T, 2016, SCAND J PUBLIC HEALT, V44, P143, DOI 10.1177/1403494815621641; Veneti L, 2022, EUROSURVEILLANCE, V27, DOI 10.2807/1560-7917.ES.2022.27.4.2200077; Veneti L, 2022, INT J INFECT DIS, V115, P178, DOI 10.1016/j.ijid.2021.12.321; Whittaker R, 2021, J INFECTION, V83, pE14, DOI 10.1016/j.jinf.2021.07.025	27	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265812	10.1371/journal.pone.0265812	http://dx.doi.org/10.1371/journal.pone.0265812			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P5DL	35320323	Green Published, gold			2023-01-03	WOS:000784240600010
J	Wise, J				Wise, Jacqui			Medical leaders call for pilot scheme of overdose prevention centres	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Faculty of Public Health, 2022, CALL AM MIS DRUGS RE; Torjesen I, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n3068	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	2022	377								o1514	10.1136/bmj.o1514	http://dx.doi.org/10.1136/bmj.o1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L6HQ	35724986				2023-01-03	WOS:000817119300003
J	Bai, W; Jackson, T; Xiang, YT				Bai, Wei; Jackson, Todd; Xiang, Yu-Tao			Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Bai, Wei; Xiang, Yu-Tao] Univ Macau, Fac Hlth Sci, Ave,Univ,1-F,Bldg E12, Macau, Peoples R China; [Jackson, Todd] Univ Macau, Dept Psychol, Macau, Peoples R China	University of Macau; University of Macau	Xiang, YT (corresponding author), Univ Macau, Fac Hlth Sci, Ave,Univ,1-F,Bldg E12, Macau, Peoples R China.	xyutly@gmail.com						Botchway S, 2021, LANCET PSYCHIAT, V8, P552, DOI 10.1016/S2215-0366(21)00117-6; Fu LW, 2022, SLEEP MED, V91, P273, DOI 10.1016/j.sleep.2021.10.020; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Heesakkers H, 2022, JAMA-J AM MED ASSOC, V327, P559, DOI 10.1001/jama.2022.0040; Singer S, 2009, BRIT J CANCER, V100, P908, DOI 10.1038/sj.bjc.6604952	5	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2022	327	21								10.1001/jama.2022.5889	http://dx.doi.org/10.1001/jama.2022.5889			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2E5JY	35670792				2023-01-03	WOS:000812264900028
J	Xie, SC; Metcalfe, RD; Dunn, E; Morton, CJ; Huang, SC; Puhalovich, T; Du, YW; Wittlin, S; Nie, S; Luth, MR; Ma, LT; Kim, MS; Pasaje, CFA; Kumpornsin, K; Giannangelo, C; Houghton, FJ; Churchyard, A; Famodimu, MT; Barry, DC; Gillett, DL; Dey, S; Kosasih, CC; Newman, W; Niles, JC; Lee, MCS; Baum, J; Ottilie, S; Winzeler, EA; Creek, DJ; Williamson, N; Parker, MW; Brand, S; Langston, SP; Dick, LR; Griffin, MDW; Gould, AE; Tilley, L				Xie, Stanley C.; Metcalfe, Riley D.; Dunn, Elyse; Morton, Craig J.; Huang, Shih-Chung; Puhalovich, Tanya; Du, Yawei; Wittlin, Sergio; Nie, Shuai; Luth, Madeline R.; Ma, Liting; Kim, Mi-Sook; Pasaje, Charisse Flerida A.; Kumpornsin, Krittikorn; Giannangelo, Carlo; Houghton, Fiona J.; Churchyard, Alisje; Famodimu, Mufuliat T.; Barry, Daniel C.; Gillett, David L.; Dey, Sumanta; Kosasih, Clara C.; Newman, William; Niles, Jacquin C.; Lee, Marcus C. S.; Baum, Jake; Ottilie, Sabine; Winzeler, Elizabeth A.; Creek, Darren J.; Williamson, Nicholas; Parker, Michael W.; Brand, Stephen; Langston, Steven P.; Dick, Lawrence R.; Griffin, Michael D. W.; Gould, Alexandra E.; Tilley, Leann			Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy	SCIENCE			English	Article							SUBSTRATE-ASSISTED INHIBITION; PLASMODIUM-FALCIPARUM; PROTEIN-SYNTHESIS; IN-VITRO; NEDD8-ACTIVATING ENZYME; MALARIA; SCATTERING; RESISTANCE; MUTATIONS; ASCAMYCIN	Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we present class I and II aaRSs as previously unrecognized targets for adenosine 5'-monophosphate-mimicking nucleoside sulfamates. The target enzyme catalyzes the formation of an inhibitory amino acid-sulfamate conjugate through a reaction-hijacking mechanism. We identified adenosine 5'-sulfamate as a broad-specificity compound that hijacks a range of aaRSs and ML901 as a specific reagent a specific reagent that hijacks a single aaRS in the malaria parasite Plasmodium falciparum, namely tyrosine RS (PfYRS). ML901 exerts whole-life-cycle-killing activity with low nanomolar potency and single-dose efficacy in a mouse model of malaria. X-ray crystallographic studies of plasmodium and human YRSs reveal differential flexibility of a loop over the catalytic site that underpins differential susceptibility to reaction hijacking by ML901.	[Xie, Stanley C.; Metcalfe, Riley D.; Dunn, Elyse; Morton, Craig J.; Puhalovich, Tanya; Du, Yawei; Houghton, Fiona J.; Barry, Daniel C.; Gillett, David L.; Kosasih, Clara C.; Newman, William; Parker, Michael W.; Dick, Lawrence R.; Griffin, Michael D. W.; Tilley, Leann] Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Dept Biochem & Pharmacol, Melbourne, Vic 3010, Australia; [Huang, Shih-Chung; Ma, Liting; Kim, Mi-Sook; Langston, Steven P.; Gould, Alexandra E.] Takeda Dev Ctr Amer Inc, Cambridge, MA 02139 USA; [Wittlin, Sergio] Swiss Trop & Publ Hlth Inst, CH-4051 Basel, Switzerland; [Wittlin, Sergio] Univ Basel, CH-4003 Basel, Switzerland; [Nie, Shuai; Williamson, Nicholas] Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Melbourne Mass Spectrometry & Prote Facil, Melbourne, Vic 3010, Australia; [Luth, Madeline R.; Ottilie, Sabine; Winzeler, Elizabeth A.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; [Pasaje, Charisse Flerida A.; Dey, Sumanta; Niles, Jacquin C.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Kumpornsin, Krittikorn; Lee, Marcus C. S.] Wellcome Sanger Inst, Parasites & Microbes Programme, Hinxton CB10 1SA, England; [Giannangelo, Carlo; Creek, Darren J.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, Parkville, Vic 3052, Australia; [Churchyard, Alisje; Famodimu, Mufuliat T.; Baum, Jake] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England; [Parker, Michael W.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Brand, Stephen] Med Malaria Venture, POB 1826,20 Route Prebois, CH-1215 Geneva 15, Switzerland; [Dick, Lawrence R.] Seofon Consulting, Natick, MA 01760 USA	University of Melbourne; Takeda Pharmaceutical Company Ltd; Takeda Development Center Americas, Inc.; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Melbourne; University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT); Wellcome Trust Sanger Institute; Monash University; Imperial College London; St. Vincent's Institute of Medical Research	Tilley, L (corresponding author), Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Dept Biochem & Pharmacol, Melbourne, Vic 3010, Australia.; Gould, AE (corresponding author), Takeda Dev Ctr Amer Inc, Cambridge, MA 02139 USA.	sandy.gould11@gmail.com; ltilley@unimelb.edu.au	Nie, Shuai/AAE-7778-2019; Winzeler, Elizabeth/AAP-6752-2020; Pasaje, Charisse Flerida A./J-7990-2014; Morton, Craig/GON-8638-2022; Yawei, Du/GPF-7398-2022; Parker, Michael/F-9069-2013	Nie, Shuai/0000-0002-6425-972X; Winzeler, Elizabeth/0000-0002-4049-2113; Pasaje, Charisse Flerida A./0000-0002-9780-3680; Morton, Craig/0000-0001-5452-5193; Yawei, Du/0000-0002-0829-1901; Dunn, Elyse/0000-0002-5941-2187; Barry, Daniel/0000-0001-5288-8863; Brand, Stephen/0000-0002-7010-5348; Parker, Michael/0000-0002-3101-1138; Dick, Larry/0000-0002-6880-0405; Xie, Stanley/0000-0001-7003-4677; Metcalfe, Riley/0000-0002-7154-780X; Luth, Madeline/0000-0001-9059-1200; Creek, Darren/0000-0001-7497-7082; Puhalovich, Tanya/0000-0001-5199-7267; Lee, Marcus/0000-0002-4973-0915	Global Health Innovative Technology Fund, Japan [H2019-104]; National Health and Medical Research Council (NHMRC) [1139884]; Medicines for Malaria Venture [MMV RD/15/0007, RD-08-2800]; Millennium Pharmaceuticals; Wellcome [100993/B/13/Z]; NHMRC [APP1117183, APP1194263]; Malaria Drug Accelerator (MalDA, BMGF) [OPP1054480]; Australian Research Council Laureate Fellowship [FL150100106]; Ruth L. Kirschstein Institutional National Research Award from the National Institute for General Medical Sciences [T32 GM008666]; NHMRC Synergy Grant [APP1185354]	Global Health Innovative Technology Fund, Japan; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Medicines for Malaria Venture; Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Wellcome; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Malaria Drug Accelerator (MalDA, BMGF); Australian Research Council Laureate Fellowship(Australian Research Council); Ruth L. Kirschstein Institutional National Research Award from the National Institute for General Medical Sciences; NHMRC Synergy Grant(National Health and Medical Research Council (NHMRC) of Australia)	This work was funded by the following: the Global Health Innovative Technology Fund, Japan (H2019-104 to L.T., A.E.G., and S.B.); National Health and Medical Research Council (NHMRC, 1139884 to L.T.); Medicines for Malaria Venture (MMV RD/15/0007 to S.B., RD-08-2800 to J.B.); and Millennium Pharmaceuticals (to A.E.G. and S.P.L.), a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited. J.B. is supported by an Investigator Award from Wellcome (100993/B/13/Z); M.W.P. is an NHMRC Research Fellow (APP1117183) and Investigator (APP1194263). The project was also supported by the Malaria Drug Accelerator (MalDA, BMGF OPP1054480 to M.R.L., S.O., K.K., M.C.S.L., J.C.N., and E.A.W.); L.T. was supported by an Australian Research Council Laureate Fellowship (FL150100106); M.R.L. was supported by a Ruth L. Kirschstein Institutional National Research Award from the National Institute for General Medical Sciences (T32 GM008666); D.J.C. was supported by a NHMRC Synergy Grant (APP1185354)	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; ANDERSON JD, 1986, J HETEROCYCLIC CHEM, V23, P1869, DOI 10.1002/jhet.5570230651; Angulo-Barturen I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002252; Aragao D, 2018, J SYNCHROTRON RADIAT, V25, P885, DOI 10.1107/S1600577518003120; Balikagala B, 2021, NEW ENGL J MED, V385, P1163, DOI 10.1056/NEJMoa2101746; Baragana B, 2015, NATURE, V522, P315, DOI 10.1038/nature14451; Jimenez-Diaz MB, 2009, ANTIMICROB AGENTS CH, V53, P4533, DOI 10.1128/AAC.00519-09; Bhatt TK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1522; BLOCH A, 1971, BIOCHEMISTRY-US, V10, P4394, DOI 10.1021/bi00800a007; Bridgford JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06221-1; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Cabrita LD, 2007, PROTEIN SCI, V16, P2360, DOI 10.1110/ps.072822507; Castilho BA, 2014, BBA-MOL CELL RES, V1843, P1948, DOI 10.1016/j.bbamcr.2014.04.006; Chen JJ, 2011, J BIOL CHEM, V286, P40867, DOI 10.1074/jbc.M111.279984; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Dai R, 2015, J MED CHEM, V58, P5208, DOI 10.1021/acs.jmedchem.5b00092; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Delves MJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05777-2; Dogovski C, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002132; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061; Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X; Florini J., 1967, ANTIBIOTICS I MECH A, P427; Florini J, 1967, ANTIBIOTICS MECH ACT, P427; FLORINI JR, 1966, J BIOL CHEM, V241, P1091; Franke D, 2017, J APPL CRYSTALLOGR, V50, P1212, DOI 10.1107/S1600576717007786; Torres AG, 2019, P NATL ACAD SCI USA, V116, P8451, DOI 10.1073/pnas.1821120116; Ganesan SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10727; Hall J, 2019, PROTEIN SCI, V28, P1880, DOI 10.1002/pro.3701; Huang SC, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115681; ISONO K, 1984, J ANTIBIOT, V37, P670, DOI 10.7164/antibiotics.37.670; Jimenez-Diaz MB, 2009, CYTOM PART A, V75A, P225, DOI 10.1002/cyto.a.20647; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Karpiyevich M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008086; Kirby N, 2016, ACTA CRYSTALLOGR D, V72, P1254, DOI 10.1107/S2059798316017174; Kirby NM, 2013, J APPL CRYSTALLOGR, V46, P1670, DOI 10.1107/S002188981302774X; Lawrence G, 2000, VACCINE, V18, P1925, DOI 10.1016/S0264-410X(99)00444-2; Lim MYX, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.166, 10.1038/nmicrobiol.2016.166]; Liu J, 2012, P NATL ACAD SCI USA, V109, P413, DOI 10.1073/pnas.1111561108; Luft JR, 1999, ACTA CRYSTALLOGR D, V55, P988, DOI 10.1107/S0907444999002085; Lux MC, 2019, J ANTIBIOT, V72, P325, DOI 10.1038/s41429-019-0171-2; Manary MJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-63; Mandelbaum J., 2015, AUTOPHAGY, V19, DOI [10.1080/15548627.2015.1056966, DOI 10.1080/15548627.2015.1056966]; McCarthy JS, 2017, LANCET INFECT DIS, V17, P626, DOI [10.1016/S1473-3099(17)30171-8, 10.1016/s1473-3099(17)30171-8]; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Milhollen MA, 2012, CANCER CELL, V21, P388, DOI 10.1016/j.ccr.2012.02.009; Moriarty NW, 2009, ACTA CRYSTALLOGR D, V65, P1074, DOI 10.1107/S0907444909029436; Mujumdar P, 2018, BIOORG MED CHEM LETT, V28, P3009, DOI 10.1016/j.bmcl.2018.04.038; Nasamu AS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-77644-4; OSADA H, 1985, ANTIMICROB AGENTS CH, V27, P230, DOI 10.1128/AAC.27.2.230; Paquet T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aad9735; PETTY RD, 1995, J BIOLUM CHEMILUM, V10, P29, DOI 10.1002/bio.1170100105; Rambo RP, 2013, NATURE, V496, P477, DOI 10.1038/nature12070; Ryan TM, 2018, J APPL CRYSTALLOGR, V51, P97, DOI 10.1107/S1600576717017101; Sajish M, 2015, NATURE, V519, P370, DOI 10.1038/nature14028; Schalkwijk J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aas9917; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Smilkstein MJ, 2008, MOL BIOCHEM PARASIT, V159, P64, DOI 10.1016/j.molbiopara.2008.01.002; Snyder C, 2007, EXP PARASITOL, V115, P296, DOI 10.1016/j.exppara.2006.09.016; Solyakov L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1558; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stickles AM, 2015, ANTIMICROB AGENTS CH, V59, P1977, DOI 10.1128/AAC.04149-14; Straimer J, 2015, SCIENCE, V347, P428, DOI 10.1126/science.1260867; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; van der Pluijm RW, 2019, LANCET INFECT DIS, V19, P952, DOI 10.1016/S1473-3099(19)30391-3; Walker DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067047; WHO, 2011, WORLD MALARIA REPORT 2011, P1; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Xie SC, 2014, INT J PARASITOL, V44, P893, DOI 10.1016/j.ijpara.2014.07.008; Yang XL, 2002, P NATL ACAD SCI USA, V99, P15369, DOI 10.1073/pnas.242611799	72	7	7	11	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2022	376	6597					1074	+	abn0611	10.1126/science.abn0611	http://dx.doi.org/10.1126/science.abn0611			64	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1V4HS	35653481	Green Accepted			2023-01-03	WOS:000806053500040
J	Brown, KM; Nair, JK; Janas, MM; Anglero-Rodriguez, YI; Dang, LTH; Peng, HY; Theile, CS; Castellanos-Rizaldos, E; Brown, C; Foster, D; Kurz, J; Allen, J; Maganti, R; Li, J; Matsuda, S; Stricos, M; Chickering, T; Jung, MC; Wassarman, K; Rollins, J; Woods, L; Kelin, A; Guenther, DC; Mobley, MW; Petrulis, J; McDougall, R; Racie, T; Bombardier, J; Cha, DA; Agarwal, S; Johnson, L; Jiang, YF; Lentini, S; Gilbert, J; Nguyen, T; Chigas, S; LeBlanc, S; Poreci, U; Kasper, A; Rogers, AB; Chong, SH; Davis, W; Sutherland, JE; Castoreno, A; Milstein, S; Schlegel, MK; Zlatev, I; Charisse, K; Keating, M; Manoharan, M; Fitzgerald, K; Wu, JT; Maier, MA; Jadhav, V				Brown, Kirk M.; Nair, Jayaprakash K.; Janas, Maja M.; Anglero-Rodriguez, Yesseinia I.; Dang, Lan T. H.; Peng, Haiyan; Theile, Christopher S.; Castellanos-Rizaldos, Elena; Brown, Christopher; Foster, Donald; Kurz, Jeffrey; Allen, Jeffrey; Maganti, Rajanikanth; Li, Jing; Matsuda, Shigeo; Stricos, Matthew; Chickering, Tyler; Jung, Michelle; Wassarman, Kelly; Rollins, Jeff; Woods, Lauren; Kelin, Alex; Guenther, Dale C.; Mobley, Melissa W.; Petrulis, John; McDougall, Robin; Racie, Timothy; Bombardier, Jessica; Cha, Diana; Agarwal, Saket; Johnson, Lei; Jiang, Yongfeng; Lentini, Scott; Gilbert, Jason; Nguyen, Tuyen; Chigas, Samantha; LeBlanc, Sarah; Poreci, Urjana; Kasper, Anne; Rogers, Arlin B.; Chong, Saeho; Davis, Wendell; Sutherland, Jessica E.; Castoreno, Adam; Milstein, Stuart; Schlegel, Mark K.; Zlatev, Ivan; Charisse, Klaus; Keating, Mark; Manoharan, Muthiah; Fitzgerald, Kevin; Wu, Jing-Tao; Maier, Martin A.; Jadhav, Vasant			Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates	NATURE BIOTECHNOLOGY			English	Article							IN-VIVO; MOUSE MODEL; SIRNA; DELIVERY; METABOLITE; IMPROVE; PROTEIN; IMPACT	Lipophilic siRNA conjugates exert therapeutic activity in the mouse CNS. Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new delivery solutions are needed to target additional organs. Here we show that conjugation of 2 '-O-hexadecyl (C16) to siRNAs enables safe, potent and durable silencing in the central nervous system (CNS), eye and lung in rodents and non-human primates with broad cell type specificity. We show that intrathecally or intracerebroventricularly delivered C16-siRNAs were active across CNS regions and cell types, with sustained RNA interference (RNAi) activity for at least 3 months. Similarly, intravitreal administration to the eye or intranasal administration to the lung resulted in a potent and durable knockdown. The preclinical efficacy of an siRNA targeting the amyloid precursor protein was evaluated through intracerebroventricular dosing in a mouse model of Alzheimer's disease, resulting in amelioration of physiological and behavioral deficits. Altogether, C16 conjugation of siRNAs has the potential for safe therapeutic silencing of target genes outside the liver with infrequent dosing.	[Brown, Kirk M.; Nair, Jayaprakash K.; Janas, Maja M.; Anglero-Rodriguez, Yesseinia I.; Dang, Lan T. H.; Peng, Haiyan; Theile, Christopher S.; Castellanos-Rizaldos, Elena; Brown, Christopher; Foster, Donald; Kurz, Jeffrey; Allen, Jeffrey; Maganti, Rajanikanth; Li, Jing; Matsuda, Shigeo; Stricos, Matthew; Chickering, Tyler; Jung, Michelle; Wassarman, Kelly; Rollins, Jeff; Woods, Lauren; Kelin, Alex; Guenther, Dale C.; Mobley, Melissa W.; Petrulis, John; McDougall, Robin; Racie, Timothy; Bombardier, Jessica; Cha, Diana; Agarwal, Saket; Johnson, Lei; Jiang, Yongfeng; Lentini, Scott; Gilbert, Jason; Nguyen, Tuyen; Chigas, Samantha; LeBlanc, Sarah; Poreci, Urjana; Kasper, Anne; Rogers, Arlin B.; Chong, Saeho; Davis, Wendell; Sutherland, Jessica E.; Castoreno, Adam; Milstein, Stuart; Schlegel, Mark K.; Zlatev, Ivan; Charisse, Klaus; Keating, Mark; Manoharan, Muthiah; Fitzgerald, Kevin; Wu, Jing-Tao; Maier, Martin A.; Jadhav, Vasant] Alnylam Pharmaceut, Cambridge, MA 02138 USA		Maier, MA; Jadhav, V (corresponding author), Alnylam Pharmaceut, Cambridge, MA 02138 USA.	mmaier@alnylam.com; vjadhav@alnylam.com	Wu, Jing/GZK-5063-2022	Agarwal, Saket/0000-0002-1681-2842				Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153; Alterman JF, 2019, NAT BIOTECHNOL, V37, P884, DOI 10.1038/s41587-019-0205-0; Alterman JF, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.38; Balwani M, 2020, NEW ENGL J MED, V382, P2289, DOI 10.1056/NEJMoa1913147; Beaucage SL, 2008, CURR OPIN DRUG DISC, V11, P203; Biscans A, 2019, NUCLEIC ACIDS RES, V47, P1082, DOI 10.1093/nar/gky1239; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; Byrne M, 2013, J OCUL PHARMACOL TH, V29, P855, DOI 10.1089/jop.2013.0148; Chappell AE, 2020, NUCLEIC ACIDS RES, V48, P4382, DOI 10.1093/nar/gkaa164; Chen QM, 2010, J CONTROL RELEASE, V144, P227, DOI 10.1016/j.jconrel.2010.02.011; Colton CA, 2014, J NEUROPATH EXP NEUR, V73, P752, DOI 10.1097/NEN.0000000000000094; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107; DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104; Eyford BA, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.611367; Foster DJ, 2018, MOL THER, V26, P708, DOI 10.1016/j.ymthe.2017.12.021; Garrelfs SF, 2021, NEW ENGL J MED, V384, P1216, DOI 10.1056/NEJMoa2021712; Gregory JV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19225-7; Gupta A, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108482; Hall Helene, 2012, Curr Top Behav Neurosci, V11, P169, DOI 10.1007/7854_2011_166; Janas MM, 2019, NUCLEIC ACIDS RES, V47, P3306, DOI 10.1093/nar/gkz140; Janas MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02989-4; Kan MJ, 2015, J NEUROSCI, V35, P5969, DOI 10.1523/JNEUROSCI.4668-14.2015; Kohonen P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15932; Kristen AV, 2019, NEURODEGENER DIS MAN, V9, P5, DOI 10.2217/nmt-2018-0033; Kubo T, 2011, MOL PHARMACEUT, V8, P2193, DOI 10.1021/mp200250f; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; Li J, 2019, BIOANALYSIS, V11, P1955, DOI 10.4155/bio-2019-0118; Liu J, 2019, BIOANALYSIS, V11, P1967, DOI 10.4155/bio-2019-0137; Manoharan M, 2002, ANTISENSE NUCLEIC A, V12, P103, DOI 10.1089/108729002760070849; Nagata T, 2021, NAT BIOTECHNOL, V39, P1529, DOI 10.1038/s41587-021-00972-x; Nair JK, 2017, NUCLEIC ACIDS RES, V45, P10969, DOI 10.1093/nar/gkx818; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Nikan M, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.50; O'Shea J, 2018, TETRAHEDRON, V74, P6182, DOI 10.1016/j.tet.2018.09.008; Osborn MF, 2018, NUCLEIC ACID THER, V28, P128, DOI 10.1089/nat.2018.0725; Parmar R, 2016, CHEMBIOCHEM, V17, P985, DOI 10.1002/cbic.201600130; Raal FJ, 2020, NEW ENGL J MED, V382, P1520, DOI 10.1056/NEJMoa1913805; Raouane M, 2012, BIOCONJUGATE CHEM, V23, P1091, DOI 10.1021/bc200422w; Ray KK, 2020, NEW ENGL J MED, V382, P1507, DOI 10.1056/NEJMoa1912387; Ray KK, 2017, NEW ENGL J MED, V376, P1430, DOI 10.1056/NEJMoa1615758; Schlegel MK, 2017, J AM CHEM SOC, V139, P8537, DOI 10.1021/jacs.7b02694; Schlegel MK, 2009, J ORG CHEM, V74, P4615, DOI 10.1021/jo900365a; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Su L, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.140; Sullivan JM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02461-2; Wang H, 2015, J ALZHEIMERS DIS, V46, P1049, DOI 10.3233/JAD-143225; Wilcock DM, 2008, J NEUROSCI, V28, P1537, DOI 10.1523/JNEUROSCI.5066-07.2008; Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339; Zhang LL, 2006, SYNTHESIS-STUTTGART, P645, DOI 10.1055/s-2006-926313; Zhang LL, 2005, J AM CHEM SOC, V127, P4174, DOI 10.1021/ja042564z; Zhou YT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc7031	52	8	8	16	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2022	40	10					1500	+		10.1038/s41587-022-01334-x	http://dx.doi.org/10.1038/s41587-022-01334-x		JUN 2022	18	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	5D7CS	35654979	Green Submitted, Bronze			2023-01-03	WOS:000805096000002
J	Oliver, D				Oliver, David			David Oliver: A new legal duty to provide specialist palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Association for Palliative Medicine of Great Britain and Ireland, 2019, REP OV PALL MED WORK; Care Quality Commission, 2021, IMPR OV REF NEED PRE; Cicely Saunders International, 2022, NEW UK LEG RIGHT PAL; Colvin H.R., 2016, NATL SURVEY BEREAVED; Dixon J, 2019, BMJ SUPPORT PALLIAT, V9, P316, DOI 10.1136/bmjspcare-2015-000971; Lee YC, 2021, THESIS; National Center for Health Statistics, 2022, ROMANIA REACHES HIST, DOI [10.1101/2020.09.15.20195081, DOI 10.1101/2020.09.15.20195081]; NHS Benchmarking Network, NAT AUD CAR END LIF; Office for National Statistics, 2022, COR COVID 19 LAT INS; Office for National Statistics, 2021, DEATHS HOM INCR 3 20; Siddique H., 2015, GUARDIAN 1006; Sleeman KE, 2021, BMC PALLIAT CARE, V20, DOI 10.1186/s12904-021-00802-6; Together for Short Lives, 2022, NHS HAV LEG DUT COMM; UK Hansard, 2022, HLTH CAR BILL; University of Sheffield, 2021, END OF LIF CAR COV 1	15	2	2	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	2022	377								o1146	10.1136/bmj.o1146	http://dx.doi.org/10.1136/bmj.o1146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1U3UK	35545252	Bronze			2023-01-03	WOS:000805341900013
J	Mitter, B; Csapo, R; Bauer, P; Tschan, H				Mitter, Benedikt; Csapo, Robert; Bauer, Pascal; Tschan, Harald			Reproducibility of strength performance and strength-endurance profiles: A test-retest study	PLOS ONE			English	Article							ONE REPETITION MAXIMUM; BENCH PRESS; PREDICTION EQUATIONS; MUSCULAR ENDURANCE; WORK CAPACITY; FIBER-TYPE; NUMBER; RELIABILITY; ACCURACY; SQUAT	The present study was designed to evaluate the test-retest consistency of repetition maximum tests at standardized relative loads and determine the robustness of strength-endurance profiles across test-retest trials. Twenty-four resistance-trained males and females (age, 27.4 +/- 4.0 y; body mass, 77.2 +/- 12.6 kg; relative bench press one-repetition maximum [1-RM], 1.19 +/- 0.23 kg.kg(-1)) were assessed for their 1-RM in the free-weight bench press. After 48 to 72 hours, they were tested for the maximum number of achievable repetitions at 90%, 80% and 70% of their 1-RM. A retest was completed for all assessments one week later. Gathered data were used to model the relationship between relative load and repetitions to failure with respect to individual trends using Bayesian multilevel modeling and applying four recently proposed model types. The maximum number of repetitions showed slightly better reliability at lower relative loads (ICC at 70% 1-RM = 0.86, 90% highest density interval: [0.71, 0.93]) compared to higher relative loads (ICC at 90% 1-RM = 0.65 [0.39, 0.83]), whereas the absolute agreement was slightly better at higher loads (SEM at 90% 1-RM = 0.7 repetitions [0.5, 0.9]; SEM at 70% 1-RM = 1.1 repetitions [0.8, 1.4]). The linear regression model and the 2-parameters exponential regression model revealed the most robust parameter estimates across test-retest trials. Results testify to good reproducibility of repetition maximum tests at standardized relative loads obtained over short periods of time. A complementary free-to-use web application was developed to help practitioners calculate strength-endurance profiles and build individual repetition maximum tables based on robust statistical models.	[Mitter, Benedikt; Csapo, Robert; Bauer, Pascal; Tschan, Harald] Univ Vienna, Ctr Sport Sci & Univ Sport, Vienna, Austria	University of Vienna	Mitter, B (corresponding author), Univ Vienna, Ctr Sport Sci & Univ Sport, Vienna, Austria.	benedikt.mitter@univie.ac.at		Mitter, Benedikt/0000-0001-6056-5853; Csapo, Robert/0000-0003-3571-2799	University of Vienna	University of Vienna	Open access funding provided by University of Vienna.	Anders John Paul V, 2020, J Funct Morphol Kinesiol, V5, DOI 10.3390/jfmk5010004; Baumgartner R, 2018, EJNMMI RES, V8, DOI 10.1186/s13550-018-0366-8; Bergstrom HC, 2021, SPORTS, V9, DOI 10.3390/sports9020015; Brechue WF, 2009, J STRENGTH COND RES, V23, P2477, DOI 10.1519/JSC.0b013e3181b1ae5f; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; Dankel SJ, 2017, MUSCLE NERVE, V56, P307, DOI 10.1002/mus.25488; de Vet HCW, 2006, J CLIN EPIDEMIOL, V59, P1033, DOI 10.1016/j.jclinepi.2005.10.015; Desgorces FD, 2010, J STRENGTH COND RES, V24, P394, DOI 10.1519/JSC.0b013e3181c7c72d; DeWeese BH, 2015, J SPORT HEALTH SCI, V4, P318, DOI 10.1016/j.jshs.2015.07.002; Dinyer TK, 2019, INT J SPORT PHYSIOL, V14, P1364, DOI 10.1123/ijspp.2018-0981; Douris PC, 2006, J STRENGTH COND RES, V20, P699; Fountain WA, 2021, J SPORT MED PHYS FIT, V61, P1587, DOI 10.23736/S0022-4707.21.12010-9; Garcia-Ramos A, 2018, INT J SPORT PHYSIOL, V13, P353, DOI 10.1123/ijspp.2017-0302; Grgic J, 2020, SPORTS MED-OPEN, V6, DOI 10.1186/s40798-020-00260-z; Hackett DA, 2017, J STRENGTH COND RES, V31, P2162, DOI 10.1519/JSC.0000000000001683; Hoeger WW., 1990, J STRENGTH COND RES, V4, P47, DOI 10.1519/00124278-199005000-00004; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; LaChance PF., 1994, J STRENGTH COND RES, V8, P76, DOI DOI 10.1519/00124278-199405000-00003; Lawton TW, 2011, SPORTS MED, V41, P413, DOI 10.2165/11588540-000000000-00000; LeSuer DA, 1997, J STRENGTH COND RES, V11, P211; Makowski D., 2019, J OPEN SOURCE SOFTW, V4, DOI 10.21105/joss.01541; Mann JB, 2014, J STRENGTH COND RES, V28, P1427, DOI 10.1519/JSC.0000000000000411; Mattocks KT, 2017, MED SCI SPORT EXER, V49, P1945, DOI 10.1249/MSS.0000000000001300; Mayhew JL, 2008, J STRENGTH COND RES, V22, P1570, DOI 10.1519/JSC.0b013e31817b02ad; MONOD H, 1965, ERGONOMICS, V8, P329, DOI 10.1080/00140136508930810; Morton RH., 2014, INT J EXERC SCIE, V7, P152; Moss AC, 2021, J STRENGTH COND RES, V35, pS31, DOI 10.1519/JSC.0000000000003795; Pereira MIR., 2003, REV BRAS MED ESPORTE, V9, P336, DOI [10.1590/S1517-86922003000500007, DOI 10.1590/S1517-86922003000500007]; Pick J, 2000, J STRENGTH COND RES, V14, P175; Reynolds JM, 2006, J STRENGTH COND RES, V20, P584, DOI 10.1519/00124278-200608000-00020; Ribeiro AS, 2014, ISOKINET EXERC SCI, V22, P137, DOI 10.3233/IES-130530; Richens B, 2014, BIOL SPORT, V31, P157, DOI 10.5604/20831862.1099047; Rose K., 1992, J STRENGTH COND RES, V6, P103; Sakamoto A, 2006, J STRENGTH COND RES, V20, P523; Sanchez-Medina L, 2011, MED SCI SPORT EXER, V43, P1725, DOI 10.1249/MSS.0b013e318213f880; Shimano T, 2006, J STRENGTH COND RES, V20, P819; Steele J, 2017, MUSCLE NERVE, V56, P368, DOI 10.1002/mus.25557; Suchomel TJ, 2021, SPORTS MED, V51, P2051, DOI 10.1007/s40279-021-01488-9; Terzis G, 2008, J STRENGTH COND RES, V22, P845, DOI 10.1519/JSC.0b013e31816a5ee4; Ware JS., 1995, J STRENGTH COND RES, V9, P99; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Wood T. M., 2002, Measurement in Physical Education and Exercise Science, V6, P67, DOI 10.1207/S15327841MPEE0602_1	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0268074	10.1371/journal.pone.0268074	http://dx.doi.org/10.1371/journal.pone.0268074			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511896	gold, Green Published			2023-01-03	WOS:000892294900104
J	Yamamoto, E; Kato, T; Yaku, H; Morimoto, T; Inuzuka, Y; Tamaki, Y; Ozasa, N; Yoshikawa, Y; Kitai, T; Taniguchi, R; Iguchi, M; Kato, M; Takahashi, M; Jinnai, T; Ikeda, T; Nagao, K; Kawai, T; Komasa, A; Nishikawa, R; Kawase, Y; Morinaga, T; Kawato, M; Seko, Y; Shiba, M; Toyofuku, M; Furukawa, Y; Nakagawa, Y; Ando, K; Kadota, K; Shizuta, S; Ono, K; Sato, Y; Kuwahara, K; Kimura, T				Yamamoto, Erika; Kato, Takao; Yaku, Hidenori; Morimoto, Takeshi; Inuzuka, Yasutaka; Tamaki, Yodo; Ozasa, Neiko; Yoshikawa, Yusuke; Kitai, Takeshi; Taniguchi, Ryoji; Iguchi, Moritake; Kato, Masashi; Takahashi, Mamoru; Jinnai, Toshikazu; Ikeda, Tomoyuki; Nagao, Kazuya; Kawai, Takafumi; Komasa, Akihiro; Nishikawa, Ryusuke; Kawase, Yuichi; Morinaga, Takashi; Kawato, Mitsunori; Seko, Yuta; Shiba, Masayuki; Toyofuku, Mamoru; Furukawa, Yutaka; Nakagawa, Yoshihisa; Ando, Kenji; Kadota, Kazushige; Shizuta, Satoshi; Ono, Koh; Sato, Yukihito; Kuwahara, Koichiro; Kimura, Takeshi			Appetite loss at discharge from acute decompensated heart failure: Observation from KCHF registry	PLOS ONE			English	Article							BODY-WEIGHT; CONGESTION; CACHEXIA; MORTALITY	Objective The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BM I < 22 kg/m(2) (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11-2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04-2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99-6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39-0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50-0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29-2.07, P<0.001). Conclusions Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.	[Yamamoto, Erika; Kato, Takao; Ozasa, Neiko; Yoshikawa, Yusuke; Komasa, Akihiro; Seko, Yuta; Shiba, Masayuki; Shizuta, Satoshi; Ono, Koh; Kimura, Takeshi] Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan; [Yaku, Hidenori; Kato, Masashi] Mitsubishi Kyoto Hosp, Dept Cardiol, Kyoto, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan; [Inuzuka, Yasutaka] Shiga Gen Hosp, Dept Cardiovasc Med, Otsu, Shiga, Japan; [Tamaki, Yodo] Tenri Hosp, Div Cardiol, Nara, Japan; [Kitai, Takeshi] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan; [Taniguchi, Ryoji; Sato, Yukihito] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Cardiol, Amagasaki, Hyogo, Japan; [Iguchi, Moritake] Natl Hosp Org, Dept Cardiol, Kyoto Med Ctr, Kyoto, Japan; [Takahashi, Mamoru] Shimabara Hosp, Dept Cardiol, Kyoto, Japan; [Jinnai, Toshikazu] Japanese Red Cross Otsu Hosp, Dept Cardiol, Otsu, Shiga, Japan; [Ikeda, Tomoyuki] Hikone Municipal Hosp, Dept Cardiol, Otsu, Shiga, Japan; [Nagao, Kazuya] Osaka Red Cross Hosp, Dept Cardiol, Osaka, Japan; [Kawai, Takafumi] Kishiwada City Hosp, Dept Cardiol, Osaka, Japan; [Nishikawa, Ryusuke] Shizuoka Prefectural Gen Hosp, Dept Cardiol, Shizuoka, Japan; [Kawase, Yuichi; Kadota, Kazushige] Kurashiki Cent Hosp, Dept Cardiol, Okayama, Japan; [Morinaga, Takashi; Ando, Kenji] Kokura Mem Hosp, Dept Cardiol, Fukuoka, Japan; [Kawato, Mitsunori] Kobe City Nishi Kobe Med Ctr, Dept Cardiol, Kobe, Hyogo, Japan; [Toyofuku, Mamoru] Japanese Red Cross Wakayama Med Ctr, Dept Cardiol, Wakayama, Japan; [Furukawa, Yutaka] Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Med, Kobe, Hyogo, Japan; [Nakagawa, Yoshihisa] Shiga Univ Med Sci, Dept Cardiovasc Med, Shizuoka, Japan; [Kuwahara, Koichiro] Shinshu Univ, Dept Cardiovasc Med, Grad Sch Med, Matsumoto, Nagano, Japan	Kyoto University; Hyogo College of Medicine; Tenri Hospital; National Cerebral & Cardiovascular Center - Japan; Osaka Red Cross Hospital; Shizuoka General Hospital; Kurashiki Central Hospital; Kokura Memorial Hospital; Kobe City Medical Center General Hospital; Kobe City Medical Center General Hospital; Shinshu University	Kato, T (corresponding author), Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan.	tkato75@kuhp.kyoto-u.ac.jp		KITAI, TAKESHI/0000-0003-2416-5865; Kato, Takao/0000-0001-8213-7999	Japan Agency for Medical Research and Development [18059186]	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work was supported by the Japan Agency for Medical Research and Development [18059186] (Drs T. Kato, T. Kuwahara, and N. Ozasa). The founder had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.	Ambrosy AP, 2013, EUR HEART J, V34, P835, DOI 10.1093/eurheartj/ehs444; Anker SD, 2003, LANCET, V361, P1077, DOI 10.1016/S0140-6736(03)12892-9; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Bielecka-Dabrowa A, 2020, EUR J HEART FAIL, V22, P2314, DOI 10.1002/ejhf.2011; Cheng YL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004876; Dewan P, 2020, EUR J HEART FAIL, V22, P2123, DOI 10.1002/ejhf.1832; Dunlay SM, 2015, CIRC-HEART FAIL, V8, P261, DOI 10.1161/CIRCHEARTFAILURE.114.001542; Ferreira JP, 2022, CLIN RES CARDIOL, V111, P451, DOI 10.1007/s00392-021-01962-4; Garcia JM, 2007, ONCOLOGIST, V12, P594, DOI 10.1634/theoncologist.12-5-594; Invernizzi M, 2014, AGING CLIN EXP RES, V26, P341, DOI 10.1007/s40520-013-0186-7; Kamisaka K, 2022, ESC HEART FAIL, V8, P5293, DOI 10.1002/ehf2.13619; Kappetein AP, 2012, J AM COLL CARDIOL, V60, P1438, DOI [10.1093/ejcts/ezs533, 10.1016/j.jacc.2012.09.001]; Katano S, 2021, CLIN RES CARDIOL, V110, P1202, DOI 10.1007/s00392-020-01774-y; Kato T., 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]; Kato T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243818; Kobayashi M, 2019, INT J CARDIOL, V289, P91, DOI 10.1016/j.ijcard.2019.01.091; Konishi M, 2021, J CACHEXIA SARCOPENI, V12, P568, DOI 10.1002/jcsm.12702; McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368; Melenovsky V, 2015, EUR J HEART FAIL, V17, P1161, DOI 10.1002/ejhf.417; Ministry of Health L and W, 2021, ETH GUID MED HLTH RE; Nishimoto Y, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041068; Nochioka K, 2013, CIRC J, V77, P2318, DOI 10.1253/circj.CJ-13-0127; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Rossignol P, 2015, EUR J HEART FAIL, V17, P424, DOI 10.1002/ejhf.240; Temel JS, 2016, LANCET ONCOL, V17, P519, DOI 10.1016/S1470-2045(15)00558-6; Valentova M, 2016, EUR HEART J, V37, P1684, DOI 10.1093/eurheartj/ehw008; von Haehling S, 2009, PHARMACOL THERAPEUT, V121, P227, DOI 10.1016/j.pharmthera.2008.09.009; Wakabayashi H, 2021, J CACHEXIA SARCOPENI, V12, P14, DOI 10.1002/jcsm.12675; Yaku H, 2021, EUR J INTERN MED, V85, P133, DOI 10.1016/j.ejim.2020.11.023; Yaku H, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5892; Yaku H, 2018, CIRC J, V82, P2811, DOI 10.1253/circj.CJ-17-1386; Yamamoto E, 2020, ESC HEART FAIL, V7, P2485, DOI 10.1002/ehf2.12815; Yamamoto E, 2017, ESC HEART FAIL, V4, P216, DOI 10.1002/ehf2.12138; Yasumura K, 2020, ESC HEART FAIL, V7, P1801, DOI 10.1002/ehf2.12743; Yoshikawa Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239100	35	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2022	17	5							e0267327	10.1371/journal.pone.0267327	http://dx.doi.org/10.1371/journal.pone.0267327			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4SM	35511913	Green Published, gold			2023-01-03	WOS:000892294900037
J	Liu, ST; Lin, CC; Wei, JCC				Liu, Shu-Tsen; Lin, Chieh-Chung; Wei, James Cheng-Chung			Mediterranean Diet or Mindfulness-Based Stress Reduction and Prevention of Small-for-Gestational-Age BirthWeights in Newborns Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Liu, Shu-Tsen] China Med Univ Childrens Hosp, Dept Child & Adolescent Psychiat, Taichung, Taiwan; [Lin, Chieh-Chung] Taichung Vet Gen Hosp, Childrens Med Ctr, Taichung, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ, Chung Shan Med Univ Hosp, Taichung, Taiwan	Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Dept Med, 110 Jianguo N Rd,Sect 1, Taichung 40201, Taiwan.	jccwei@gmail.com						[Anonymous], 2018, PREGNANCY MONITORING, V3rd; Crovetto F, 2021, JAMA-J AM MED ASSOC, V326, P2150, DOI 10.1001/jama.2021.20178; Sevild CH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09111-8	3	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2022	327	13					1293	+						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0P1EM	35380584				2023-01-03	WOS:000783965500038
J	Somekh, J; Lotan, N; Sussman, E; Yehuda, GA				Somekh, Judith; Lotan, Nir; Sussman, Ehud; Yehuda, Gur Arye			Predicting mechanical ventilation effects on six human tissue transcriptomes	PLOS ONE			English	Article							GENE-EXPRESSION; INDUCED LUNG; DIFFERENTIATION; PNEUMONIA	Background Mechanical ventilation (MV) is a lifesaving therapy used for patients with respiratory failure. Nevertheless, MV is associated with numerous complications and increased mortality. The aim of this study is to define the effects of MV on gene expression of direct and peripheral human tissues. Methods Classification models were applied to Genotype-Tissue Expression Project (GTEx) gene expression data of six representative tissues-liver, adipose, skin, nerve-tibial, muscle and lung, for performance comparison and feature analysis. We utilized 18 prediction models using the Random Forest (RF), XGBoost (eXtreme Gradient Boosting) decision tree and ANN (Artificial Neural Network) methods to classify ventilation and non-ventilation samples and to compare their prediction performance for the six tissues. In the model comparison, the AUC (area under receiver operating curve), accuracy, precision, recall, and F1 score were used to evaluate the predictive performance of each model. We then conducted feature analysis per each tissue to detect MV marker genes followed by pathway enrichment analysis for these genes. Results XGBoost outperformed the other methods and predicted samples had undergone MV with an average accuracy for the six tissues of 0.951 and average AUC of 0.945. The feature analysis detected a combination of MV marker genes per each tested tissue, some common across several tissues. MV marker genes were mainly related to inflammation and fibrosis as well as cell development and movement regulation. The MV marker genes were significantly enriched in inflammatory and viral pathways. Conclusion The XGBoost method demonstrated clear enhanced performance and feature analysis compared to the other models. XGBoost was helpful in detecting the tissue-specific marker genes for identifying transcriptomic changes related to MV. Our results show that MV is associated with reduced development and movement in the tissues and higher inflammation and injury not only in direct tissues such as the lungs but also in peripheral tissues and thus should be carefully considered before being implemented.	[Somekh, Judith; Lotan, Nir; Sussman, Ehud; Yehuda, Gur Arye] Univ Haifa, Dept Informat Syst, Haifa, Israel	University of Haifa	Somekh, J (corresponding author), Univ Haifa, Dept Informat Syst, Haifa, Israel.	judith_somekh@is.haifa.ac.il		Sussman, Ehud/0000-0002-6008-9567	Data Science Research Center (DSRC) at the University of Haifa; University of Haifa	Data Science Research Center (DSRC) at the University of Haifa; University of Haifa	The research was funded by a grant from the Data Science Research Center (DSRC) at the University of Haifa and by an internal funding from the University of Haifa. There was no additional external funding received for this study.	Abadi M, 2016, PROCEEDINGS OF OSDI'16: 12TH USENIX SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P265; Abiodun OI, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00938; Acun T, 2017, OMICS, V21, P257, DOI 10.1089/omi.2017.0016; Agarap A.F, 2018, DEEP LEARNING USING; [Anonymous], TOR1A GENE MEDLINEPL; [Anonymous], 2020, XGBOOST PYTHON LIB; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Basha O, 2020, BIOINFORMATICS, V36, P2821, DOI 10.1093/bioinformatics/btaa034; Biau G, 2012, J MACH LEARN RES, V13, P1063; Bilotta F, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2546-y; Brander L, 2006, INTENSIVE CARE MEDICINE: ANNUAL UPDATE 2006, P424, DOI 10.1007/0-387-35096-9_39; Brower RG, 2004, NEW ENGL J MED, V351, P327; Burnham JP, 2017, CLIN INFECT DIS, V64, P1089, DOI 10.1093/cid/cix060; Cai YF, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919035; Cakouros D, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-018-0247-4; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Chin SCN, 2020, AM J PHYSIOL-GASTR L, V319, pG175, DOI 10.1152/ajpgi.00019.2020; Chollet F., 2015, KERAS; Dimitrakopoulos GN, 2018, 10TH HELLENIC CONFERENCE ON ARTIFICIAL INTELLIGENCE (SETN 2018), DOI 10.1145/3200947.3201029; Dokhaee Fatemeh, 2018, Gastroenterol Hepatol Bed Bench, V11, pS140; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Ferreira PG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02772-x; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Gharib SA, 2006, AM J RESP CRIT CARE, V173, P653, DOI 10.1164/rccm.200509-1473OC; Gharib SA, 2009, PHYSIOL GENOMICS, V37, P239, DOI 10.1152/physiolgenomics.00027.2009; Ghorbel MT, 2010, PHYSIOL GENOMICS, V42, P67, DOI 10.1152/physiolgenomics.00174.2009; Glau CL, 2018, PEDIATR CRIT CARE ME, V19, P406, DOI 10.1097/PCC.0000000000001485; Grunwell Jocelyn R, 2021, Crit Care Explor, V3, pe0431, DOI 10.1097/CCE.0000000000000431; Hepokoski ML, 2018, NEPHRON, V140, P90, DOI 10.1159/000491557; Huang S., 2020, ARXIV; Kingma D. P, 2015, 3 INT C LEARN REPR; Koenig SM, 2006, CLIN MICROBIOL REV, V19, P637, DOI 10.1128/CMR.00051-05; Konigshoff M, 2007, AM J RESP CELL MOL, V37, P640, DOI 10.1165/rcmb.2006-0379TR; La Scola B, 2003, EMERG INFECT DIS, V9, P815, DOI 10.3201/eid0907.030065; Liu FT, 2008, IEEE DATA MINING, P413, DOI 10.1109/ICDM.2008.17; Liu JL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246306; Liu J, 2018, ONCOL REP, V40, P2023, DOI 10.3892/or.2018.6590; Loo N., 2018, IFAC PAPERSONLINE, V51, P378, DOI [DOI 10.1016/j.ifacol.2018.11.610, 10.1016/j.ifacol.2018.11.610]; Lundberg SM, 2017, ADV NEUR IN, V30; McCall MN, 2016, AM J HUM GENET, V99, P624, DOI 10.1016/j.ajhg.2016.07.007; Ogunleye A, 2020, IEEE ACM T COMPUT BI, V17, P2131, DOI 10.1109/TCBB.2019.2911071; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Plani N, 2013, PHYSIOTHER THEOR PR, V29, P211, DOI 10.3109/09593985.2012.718410; Rawat VPS, 2010, P NATL ACAD SCI USA, V107, P16946, DOI 10.1073/pnas.1001878107; Reddy GT, 2020, IEEE ACCESS, V8, P54776, DOI 10.1109/ACCESS.2020.2980942; Schapire RE, 1999, IJCAI-99: PROCEEDINGS OF THE SIXTEENTH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 & 2, P1401; Somekh J, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2855-9; Tang HB, 2018, AM J RESP CELL MOL, V59, P417, DOI 10.1165/rcmb.2018-0022TR; van den Kieboom CH, 2015, EUR RESPIR J, V45, P718, DOI 10.1183/09031936.00085614; Wewer UM, 1998, DEV BIOL, V200, P247, DOI 10.1006/dbio.1998.8962; Winiarska A, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/8170759; Yen SH, 2020, AM J PHYSIOL-LUNG C, V318, pL494, DOI 10.1152/ajplung.00492.2019; Yu LM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249285	58	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2022	17	3							e0264919	10.1371/journal.pone.0264919	http://dx.doi.org/10.1371/journal.pone.0264919			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2R2AR	35271646	gold, Green Published, Green Submitted			2023-01-03	WOS:000820912700059
J	Howe, J; Chua, W; Sumner, E; Drozdowska, B; Laverick, R; Bevins, RL; Jean-Baptiste, E; Russell, M; Rotshtein, P; Wing, AM				Howe, Jo; Chua, Winnie; Sumner, Emily; Drozdowska, Bogna; Laverick, Rosanna; Bevins, Rachel L.; Jean-Baptiste, Emilie; Russell, Martin; Rotshtein, Pia; Wing, Alan M.			The efficacy of a task model approach to ADL rehabilitation in stroke apraxia and action disorganisation syndrome: A randomised controlled trial	PLOS ONE			English	Article							RHYTHMIC AUDITORY-STIMULATION; COGNITIVE REHABILITATION; OCCUPATIONAL-THERAPY; LIMB APRAXIA; LATERALIZATION; POSTSTROKE; MEMORY; BLIND	Background Apraxia and action disorganization syndrome (AADS) after stroke can disrupt activities of daily living (ADL). Occupational therapy has been effective in improving ADL performance, however, inclusion of multiple tasks means it is unclear which therapy elements contribute to improvement. We evaluated the efficacy of a task model approach to ADL rehabilitation, comparing training in making a cup of tea with a stepping training control condition. Methods Of the 29 stroke survivors with AADS who participated in this cross-over randomized controlled feasibility trial, 25 were included in analysis [44% females; mean(SD) age = 71.1(7.8) years; years post-stroke = 4.6(3.3)]. Participants attended five 1-hour weekly tea making training sessions in which progress was monitored and feedback given using a computer-based system which implemented a Markov Decision Process (MDP) task model. In a control condition, participants received five 1-hour weekly stepping sessions. Results Compared to stepping training, tea making training reduced errors across 4 different tea types. The time taken to make a cup of tea was reduced so the improvement in accuracy was not due to a speed-accuracy trade-off. No improvement linked to tea making training was evident in a complex tea preparation task (making two different cups of tea simultaneously), indicating a lack of generalisation in the training. Conclusions The clearly specified but flexible training protocol, together with information on the distribution of errors, provide pointers for further refinement of task model approaches to ADL rehabilitation. It is recommended that the approach be tested under errorless learning conditions with more impaired patients in future research. Trial registration Retrospectively registered at ClinicalTrials.gov on 5(th) August 2019 [NCT04044911] https://clinicaltrials.gov/ct2/show/NCT04044911?term=Cogwatch&rank=1	[Howe, Jo; Chua, Winnie; Sumner, Emily; Drozdowska, Bogna; Laverick, Rosanna; Bevins, Rachel L.; Rotshtein, Pia; Wing, Alan M.] Univ Birmingham, Coll Life & Environm Sci, Sch Psychol, Birmingham, W Midlands, England; [Howe, Jo] Aston Univ, Sch Pharm, Birmingham, W Midlands, England; [Chua, Winnie] Univ Birmingham, Coll Med & Dent Sci, Inst Cardiovasc Sci, Birmingham, W Midlands, England; [Bevins, Rachel L.] Coventry Univ, Fac Hlth & Life Sci, Sch Life Sci, Coventry, W Midlands, England; [Jean-Baptiste, Emilie; Russell, Martin] Univ Birmingham, Coll Engn & Phys Sci, Sch Elect Elect & Syst Engn, Birmingham, W Midlands, England	University of Birmingham; Aston University; University of Birmingham; Coventry University; University of Birmingham	Chua, W (corresponding author), Univ Birmingham, Coll Life & Environm Sci, Sch Psychol, Birmingham, W Midlands, England.; Chua, W (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Cardiovasc Sci, Birmingham, W Midlands, England.	w.chua.1@bham.ac.uk		Wing, Alan/0000-0002-2623-3801; Bevins, Rachel/0000-0001-7673-3196; Rotshtein, Pia/0000-0002-0301-9511; Howe, Jo/0000-0002-7567-075X; Chua, Winnie/0000-0002-6747-8813	European Commission [FP7-ICT-2011-288912]; BBSRC [BB/R003971/1]	European Commission(European CommissionEuropean Commission Joint Research Centre); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The work presented in this manuscript was supported by the European Commission under grant FP7-ICT-2011-288912 (CogWatch) and BBSRC BB/R003971/1 to AW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alashram AR, 2022, APPL NEUROPSYCH-ADUL, V29, P1658, DOI 10.1080/23279095.2021.1900188; Ballinger C, 1999, CLIN REHABIL, V13, P301, DOI 10.1191/026921599673198490; Berger VW, 2005, STAT PRACT, P1, DOI 10.1002/0470863641; Bickerton WL, 2012, J NEUROL NEUROSUR PS, V83, P513, DOI 10.1136/jnnp-2011-300968; Bienkiewicz MMN, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00353; Buxbaum Laurel J, 2018, Handb Clin Neurol, V151, P349, DOI 10.1016/B978-0-444-63622-5.00017-6; Cappa SF, 2005, EUR J NEUROL, V12, P665; CREIGHTON C, 1992, AM J OCCUP THER, V46, P45, DOI 10.5014/ajot.46.1.45; De Wit L, 2006, STROKE, V37, P1483, DOI 10.1161/01.STR.0000221709.23293.c2; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Dworzynski K, 2015, CLIN MED, V15, P461, DOI 10.7861/clinmedicine.15-5-461; Aguilar-Ferrandiz ME, 2021, ARCH PHYS MED REHAB, V102, P940, DOI 10.1016/j.apmr.2020.12.015; Fergusson D, 2004, BRIT MED J, V328, P432, DOI 10.1136/bmj.37952.631667.EE; Flores-Medina Y, 2014, BRAIN COGNITION, V84, P164, DOI 10.1016/j.bandc.2013.11.010; Foley N, 2012, DISABIL REHABIL, V34, P2132, DOI 10.3109/09638288.2012.676145; Geusgens C, 2006, NEUROPSYCHOL REHABIL, V16, P213, DOI 10.1080/09602010500172350; Goldenberg G, 2001, NEUROPSYCHOL REHABIL, V11, P147, DOI 10.1080/09602010042000204; Goldenberg G., 2013, APRAXIA COGNITIVE SI; Hanna-Pladdy B, 2001, CORTEX, V37, P219, DOI 10.1016/S0010-9452(08)70569-0; Hazell A, 2013, REPORT HEALTHCARE PR; Heitz RP, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00150; Hsieh YW, 2007, STROKE, V38, P3052, DOI 10.1161/STROKEAHA.107.490730; Hughes CML, 2015, ERGONOMICS, V58, P75, DOI 10.1080/00140139.2014.957735; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; Humphreys GW., 2012, BCOS BRAIN BEHAV ANA; Intercollegiate Stroke Working Party, 2016, NAT CLIN GUID STROK; Jean-Baptiste EMD, 2017, J AMB INTEL SMART EN, V9, P707, DOI 10.3233/AIS-170461; Jean-Baptiste EMD, 2014, 2014 IEEE INTERNATIONAL CONFERENCE ON HEALTHCARE INFORMATICS (ICHI), P39, DOI 10.1109/ICHI.2014.13; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Lambercy O, 2021, FRONT ROBOT AI, V8, DOI 10.3389/frobt.2021.612415; Legg L, 2007, BMJ-BRIT MED J, V335, P922, DOI 10.1136/bmj.39343.466863.55; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Rusted J, 2002, NEUROCASE, V8, P111, DOI 10.1093/neucas/8.1.111; Sackley CM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h468; Schulz KF, 2010, LANCET, V375, P1144, DOI 10.1016/S0140-6736(10)60413-8; Sentinel Stroke National Audit Programme, 2020, NAT RES CLIN; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Thaut MH, 2010, MUSIC PERCEPT, V27, P263, DOI 10.1525/MP.2010.27.4.263; Walker MF, 2012, CLIN REHABIL, V26, P675, DOI 10.1177/0269215511431089; Watson CE, 2015, CORTEX, V65, P65, DOI 10.1016/j.cortex.2015.01.007; West C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004132.pub2; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Worthington A, 2016, NEUROREHABILITATION, V39, P163, DOI 10.3233/NRE-161348; Wright RL, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00412; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	45	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2022	17	3							e0264678	10.1371/journal.pone.0264678	http://dx.doi.org/10.1371/journal.pone.0264678			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0D4YH	35239707	Green Published, gold, Green Accepted			2023-01-03	WOS:000776002200061
J	Gayatri, M; Utomo, B; Budiharsana, M; Dasvarma, G				Gayatri, Maria; Utomo, Budi; Budiharsana, Meiwita; Dasvarma, Gouranga			Pregnancy resumption following contraceptive discontinuation: Hazard survival analysis of the Indonesia Demographic and Health Survey Data 2007, 2012 and 2017	PLOS ONE			English	Article							FERTILITY; WOMEN; REMOVAL; RETURN; BENEFITS; IMPLANTS; MYTHS; OLDER	Objective The objective of this research is to estimate the probability of pregnancy resumption after discontinuing reversible contraceptives-pills, injectables, implants and IUDs, and to examine the factors associated with the resumption of fertility. Method The study uses pregnancy calendar data from Indonesia Demographic and Health Surveys (IDHS) of 2007, 2012 and 2017. A hazard model survival method is used for estimating the time needed to resume pregnancy since discontinuing reversible contraceptives. Retrospective data on 4,573; 5,183 and 5,989 episodes of reversible contraceptive discontinuation at the three surveys respectively have been analysed. Results This study shows that women regained fecundity within one year of discontinuing IUD, pill, injectables or implants. Women using IUD could resume their pregnancy faster than those using implants, pills and injectables. Over the three IDHS 2007, 2012 and 2017 the age-specific percentages of women becoming pregnant after one year of contraceptive discontinuation vary between 72 and 85 for IUD, 75 and 81 for pills, 72 and 76 for implants and 64 and 67 for injectables, with the percentages being higher among younger women. The analysis further shows that length of contraceptive use, parity, prior sexually transmitted infections, knowledge of fertile period, household wealth status and place of residence have no impact on occurrence of pregnancy after contraceptive discontinuation. Conclusion The analysis disproves a myth that reversible contraceptives make women infertile. Depending on the type of reversible contraceptive used, 65% to 85% of the women were able to conceive after one year of discontinuation.	[Gayatri, Maria] Badan Kependudukan & Keluarga Berencana Nasl, Ctr Res & Dev Family Planning & Family Welf, East Jakarta, Indonesia; [Utomo, Budi; Budiharsana, Meiwita] Univ Indonesia, Fac Publ Hlth, Depok, Indonesia; [Dasvarma, Gouranga] Flinders Univ S Australia, Coll Humanities Arts & Social Sci, Adelaide, SA, Australia	University of Indonesia; Flinders University South Australia	Gayatri, M (corresponding author), Badan Kependudukan & Keluarga Berencana Nasl, Ctr Res & Dev Family Planning & Family Welf, East Jakarta, Indonesia.	maria.gayatri.bkkbn@gmail.com		Dasvarma, Gouranga/0000-0002-1784-7967; Gayatri, Maria/0000-0002-2792-5586				[Anonymous], 2014, Obstet Gynecol, V123, P719, DOI [10.1016/j.fertnstert.2013.12.032, 10.1097/01.AOG.0000444440.96486.61]; Amnesty International, 2010, TAK AD PIL RINT AT K; Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023; Barnhart K, 2009, FERTIL STERIL, V91, P1654, DOI 10.1016/j.fertnstert.2008.02.122; Barzilai-Pesach V, 2006, J OCCUP ENVIRON MED, V48, P56, DOI 10.1097/01.jom.0000183099.47127.e9; *BPS, 2008, IND DEM HLTH SURV 20; BUCKSHEE K, 1995, CONTRACEPTION, V51, P237, DOI 10.1016/0010-7824(95)00039-D; Cleves M., 2008, INTRO SURVIVAL ANAL, V2; Cornelius ME, 2015, TOB CONTROL, V24, P4, DOI 10.1136/tobaccocontrol-2013-051376; Cronin M, 2009, OBSTET GYNECOL, V114, P616, DOI 10.1097/AOG.0b013e3181b46f54; Daniluk JC, 2012, FERTIL STERIL, V97, P420, DOI 10.1016/j.fertnstert.2011.11.046; Dechanet C, 2011, HUM REPROD UPDATE, V17, P76, DOI 10.1093/humupd/dmq033; Delbarge W, 2002, EUR J CONTRACEP REPR, V7, P24, DOI 10.1080/713604288; Farley TMM, 2001, CONTRACEPTION, V63, P167; Farrow A, 2002, HUM REPROD, V17, P2754, DOI 10.1093/humrep/17.10.2754; Girum T, 2018, CONTRACEP REPROD MED, V3, DOI 10.1186/s40834-018-0064-y; Gray R H, 1979, J Biosoc Sci Suppl, P97; Gueye A, 2015, INT PERSPECT SEX R H, V41, P191, DOI 10.1363/4119115; Hyttel M, 2012, REPROD HEALTH MATTER, V20, P148, DOI 10.1016/S0968-8080(12)40654-1; Issa AA, 1998, CURR THER RES CLIN E, V59, P257, DOI 10.1016/S0011-393X(98)85080-7; Klein J, 2001, AM J OBSTET GYNECOL, V185, P758, DOI 10.1067/mob.2001.114689; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; Laufer N, 2004, FERTIL STERIL, V81, P1328, DOI 10.1016/j.fertnstert.2003.09.056; Mansour D, 2011, CONTRACEPTION, V84, P465, DOI 10.1016/j.contraception.2011.04.002; Najafi-Sharjabad Fatemeh, 2013, Glob J Health Sci, V5, P181, DOI 10.5539/gjhs.v5n5p181; Population National. and Family Planning Board Statistics Indonesia.  Ministry of Health ICF, 2018, IND DEM HLTH SURV 20; Russo JA, 2013, J ADOLESCENT HEALTH, V52, pS14, DOI 10.1016/j.jadohealth.2013.02.003; Rutstein S., 2006, GUIDE DHS STAT DEMOG; Schindler AE, 2013, INT J ENDOCRINOL MET, V11, P41, DOI 10.5812/ijem.4158; Sedgh G, 2014, STUD FAMILY PLANN, V45, P151, DOI 10.1111/j.1728-4465.2014.00382.x; SPIRA A, 1986, HUM REPROD, V1, P111, DOI 10.1093/oxfordjournals.humrep.a136353; Statistics Indonesia National Population and Family Planning Board Ministry of Health of the Republic of Indonesia and ICF International, 2013, IND DEM HLTH SURV 20; Stoddard AM, 2015, EUR J CONTRACEP REPR, V20, P223, DOI 10.3109/13625187.2015.1010639; Tabong PTN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054429; USAID, 2018, DHS CONTR CAL TUR DE; Utomo B, 2021, POPUL HEALTH METR, V19, DOI 10.1186/s12963-020-00245-w; Vathiny O, 2011, RECLAIMING REDEFININ, P45; Wiegratz I., 2006, FERTILITY DISCONTINU, P85; World Health Organization, 2016, SEL PRACT REC CONTR; World Health Organization Department of Reproductive Health and Research, 2018, FAMILY PLANNING GLOB; Zhu HL, 2013, CONTRACEPTION, V87, P416, DOI 10.1016/j.contraception.2012.11.002; Zinaman M, 2012, CURR MED RES OPIN, V28, P749, DOI 10.1185/03007995.2012.681638	42	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2022	17	2							e0264318	10.1371/journal.pone.0264318	http://dx.doi.org/10.1371/journal.pone.0264318			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M0QE	35196329	gold, Green Published			2023-01-03	WOS:000835161600037
J	de Graaf, JF; van Nieuwkoop, S; Bestebroer, T; Groeneveld, D; van Eijck, CHJ; Fouchier, RAM; van den Hoogen, BG				de Graaf, J. Frederique; van Nieuwkoop, Stefan; Bestebroer, Theo; Groeneveld, Daphne; van Eijck, Casper H. J.; Fouchier, Ron A. M.; van den Hoogen, Bernadette G.			Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes	PLOS ONE			English	Article							FUSION PROTEIN; CLEAVAGE SITE; INTERFERON; PATHOGENICITY; REPLICATION; DETERMINANT; EXPRESSION; INDUCTION; VIRULENCE; ALPHA	Newcastle Disease Virus (NDV) is an avian RNA virus, which was shown to be effective and safe for use in oncolytic viral therapy for several tumour malignancies. The presence of a multi basic cleavage site (MBCS) in the fusion protein improved its oncolytic efficacy in vitro and in vivo. However, NDV with a MBCS can be virulent in poultry. We aimed to develop an NDV with a MBCS but with reduced virulence for poultry while remaining effective in killing human tumour cells. To this end, the open reading frame of the V protein, an avian specific type I interferon antagonist, was disrupted by introducing multiple mutations. NDV with a mutated V gene was attenuated in avian cells and chicken and duck eggs. Although this virus still killed tumour cells, the efficacy was reduced compared to the virulent NDV. Introduction of various mutations in the fusion (F) and hemagglutinin-neuraminidase (HN) genes slightly improved this efficacy. Taken together, these data demonstrated that NDV with a MBCS but with abrogation of the V protein ORF and mutations in the F and HN genes can be safe for evaluation in oncolytic viral therapy.	[de Graaf, J. Frederique; van Nieuwkoop, Stefan; Bestebroer, Theo; Groeneveld, Daphne; Fouchier, Ron A. M.; van den Hoogen, Bernadette G.] Erasmus MC, Virosci Dept, Rotterdam, Netherlands; [van Eijck, Casper H. J.] Erasmus MC, Dept Surg, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van den Hoogen, BG (corresponding author), Erasmus MC, Virosci Dept, Rotterdam, Netherlands.	b.vandenhoogen@erasmusmc.nl		van den Hoogen, Bernadette/0000-0003-1996-8559; Groeneveld, Daphne/0000-0001-6614-9586	Dutch Foundation "Overleven with alvleesklierkanker"; NWO-TTW grant (NWO-domein Toegepaste en Technische Wetenschappen) [15414]	Dutch Foundation "Overleven with alvleesklierkanker"; NWO-TTW grant (NWO-domein Toegepaste en Technische Wetenschappen)	JFG and DG obtained funding from the Dutch Foundation "Overleven with alvleesklierkanker"; https://www.supportcasper.nl/nl/over-support-casper/stichting/RF and SN obtained funding from NWO-TTW grant #15414 (NWO-domein Toegepaste en Technische Wetenschappen; https://www.nwo.nl/toegepasteen-technische-wetenschappen-ttw).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], US; Buijs PRA, 2014, CANCER GENE THER, V21, P463, DOI 10.1038/cgt.2014.51; Buijs PRA, 2014, CANCER GENE THER, V21, P24, DOI 10.1038/cgt.2013.78; Buijs P, 2015, VIRUSES-BASEL, V7, P2980, DOI 10.3390/v7062756; Burke S, 2020, CANCER IMMUNOL IMMUN, V69, P1015, DOI 10.1007/s00262-020-02495-x; Cheng X, 2016, J VIROL, V90, P5343, DOI 10.1128/JVI.00136-16; de Graaf JF, 2018, CYTOKINE GROWTH F R, V41, P28, DOI 10.1016/j.cytogfr.2018.03.006; de Leeuw OS, 2005, J GEN VIROL, V86, P1759, DOI 10.1099/vir.0.80822-0; Elankumaran S, 2006, J VIROL, V80, P7522, DOI 10.1128/JVI.00241-06; Engel-Herbert I, 2003, J VIROL METHODS, V108, P19, DOI 10.1016/S0166-0934(02)00247-1; Fournier P, 2012, INT J ONCOL, V40, P840, DOI 10.3892/ijo.2011.1265; Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016; GELB J, 1979, AVIAN DIS, V23, P534, DOI 10.2307/1589585; Hotte SJ, 2007, CLIN CANCER RES, V13, P977, DOI 10.1158/1078-0432.CCR-06-1817; Huang ZH, 2003, J VIROL, V77, P8676, DOI 10.1128/JVI.77.16.8676-8685.2003; Karsunke J, 2019, VIRUS RES, V263, P207, DOI 10.1016/j.virusres.2019.02.003; King DJ, 1998, AVIAN DIS, V42, P507, DOI 10.2307/1592677; Koks CA, 2015, INT J CANCER, V136, pE313, DOI 10.1002/ijc.29202; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Laurie SA, 2006, CLIN CANCER RES, V12, P2555, DOI 10.1158/1078-0432.CCR-05-2038; Linster M, 2014, CELL, V157, DOI 10.1016/j.cell.2014.02.040; Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; Mariappan Asok Kumar, 2018, VirusDisease, V29, P180, DOI 10.1007/s13337-018-0445-5; Mebatsion T, 2003, J VIROL, V77, P9259, DOI 10.1128/JVI.77.17.9259-9265.2003; Mebatsion T, 2001, J VIROL, V75, P420, DOI 10.1128/JVI.75.1.420-428.2001; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Panda A, 2004, MICROB PATHOGENESIS, V36, P1, DOI 10.1016/j.micpath.2003.07.003; Park MS, 2003, J VIROL, V77, P9522, DOI 10.1128/JVI.77.17.9522-9532.2003; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Peeters BPH, 1999, J VIROL, V73, P5001, DOI 10.1128/JVI.73.6.5001-5009.1999; Qiu XS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148560; Rangaswamy US, 2017, J VIROL, V91, DOI [10.1128/JVI.00770-17, 10.1128/jvi.00770-17]; REED L. J., 1938, AMER JOUR HYG, V27, P493; Samal S, 2013, J VIROL, V87, P10083, DOI 10.1128/JVI.01446-13	36	0	0	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263707	10.1371/journal.pone.0263707	http://dx.doi.org/10.1371/journal.pone.0263707			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139115	Green Published, gold			2023-01-03	WOS:000821499100045
J	Efendi, D; Hasan, F; Natalia, R; Utami, AR; Sonko, I; Asmarini, TA; Yuningsih, R; Wanda, D; Sari, D				Efendi, Defi; Hasan, Faizul; Natalia, Regina; Utami, Ayuni Rizka; Sonko, Ismaila; Asmarini, Titik Ambar; Yuningsih, Risna; Wanda, Dessie; Sari, Dian			Nursing care recommendation for pediatric COVID-19 patients in the hospital setting: A brief scoping review	PLOS ONE			English	Article							DISEASE 2019 COVID-19; CORONAVIRUS DISEASE; CUFF PRESSURE; MENTAL-HEALTH; NEONATAL MANAGEMENT; UNITED-STATES; NEW-YORK; CHILDREN; SARS-COV-2; INFECTION	Background The hospitalization of children during the COVID-19 pandemic has affected their physical and mental health. Pediatric nurses have faced challenges in providing high-quality nursing care for children and their families. However, the pediatric nursing care recommendations for COVID-19 patients in the hospital setting remain unclear. The current scoping review provides recommendations for nursing interventions for pediatric COVID-19 patients in the hospital setting. Methods and findings The selected articles containing management and nursing recommendations for COVID-19 that have occurred in pediatric patients ages 0-19 years old. A search strategy was developed and implemented in seven databases. We included peer-reviewed articles that reported observational or interventional studies, as well as policy papers, guides or guidelines, letters and editorials, and web articles. A total of 134 articles and other documents relevant to this review were included. We categorized the results based on The Nursing Intervention Classification (NIC) taxonomy which consists of six domains (e.g., Physiological: Basic); eleven classes (e.g., Nutrition Support); and eighteen intervention themes (e.g., Positioning, Family Presence Facilitation, Family Support, and Discharge Planning). Conclusion Apart from the intervention of physical problems, there is a need to promote patient- and family-centered care, play therapy, and discharge planning to help children and families cope with their new situation.	[Efendi, Defi; Utami, Ayuni Rizka; Asmarini, Titik Ambar; Wanda, Dessie] Univ Indonesia, Fac Nursing, Dept Pediat Nursing, Depok, Indonesia; [Efendi, Defi] Univ Indonesia Hosp, Neonatal Intens Care Unit, Depok, Indonesia; [Hasan, Faizul; Sonko, Ismaila] Taipei Med Univ, Sch Nursing, Taipei, Taiwan; [Natalia, Regina] Mitra Bunda Hlth Inst, Sch Nursing, Batam, Indonesia; [Sonko, Ismaila] Minist Hlth & Social Welf, Banjul, Gambia; [Asmarini, Titik Ambar] Gatot Soebroto Indonesian Cent Army Hosp, Neonatal & Pediat Intens Care Unit, Jakarta, Indonesia; [Yuningsih, Risna] Dr Dradjat Prawiranegara Gen Hosp, Neonatal Intens Care Unit, Banten, Indonesia; [Sari, Dian] Prima Nusantara Hlth Inst, Sch Nursing, Bukittinggi, Indonesia	University of Indonesia; Taipei Medical University	Efendi, D (corresponding author), Univ Indonesia, Fac Nursing, Dept Pediat Nursing, Depok, Indonesia.; Efendi, D (corresponding author), Univ Indonesia Hosp, Neonatal Intens Care Unit, Depok, Indonesia.	defiefendi@ui.ac.id		HASAN, FAIZUL/0000-0001-7802-1328; Yuningsih, Risna/0000-0002-6418-9290; Natalia, Regina/0000-0002-1648-2329; Efendi, Defi/0000-0001-7838-169X	KEMENRISTEK/BRIN under Hibah PDUPT Tahun Anggaran 2021 [NKB-072/UN2.RST/HKP.05.00/2021]	KEMENRISTEK/BRIN under Hibah PDUPT Tahun Anggaran 2021	DW was funded by KEMENRISTEK/BRIN under Hibah PDUPT Tahun Anggaran 2021 (Contract No: NKB-072/UN2.RST/HKP.05.00/2021)	Abdollahpour S, 2022, J MATERN-FETAL NEO M, V35, P1601, DOI 10.1080/14767058.2020.1759540; Abuali M, 2021, AM J INFECT CONTROL, V49, P226, DOI 10.1016/j.ajic.2020.07.003; Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Ahmad MDF, 2021, SAUDI PHARM J, V29, P121, DOI 10.1016/j.jsps.2020.12.014; Al Juhani T, 2020, SAUDI J ANAESTH, V14, P370, DOI 10.4103/sja.SJA_358_20; Aleebrahim-Dehkordi E, 2021, J PEDIATR NURS, V56, P70, DOI 10.1016/j.pedn.2020.10.020; AlQahtani A, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.congress-2020.2026; Mascarenhas VHA, 2020, REV LAT-AM ENFERM, V28, DOI 10.1590/1518-8345.4596.3359; American Academy of Pediatrics, 2020, FAQS MAN INF BORN MO; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, https://doi.org/10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Aromaratis E., 2020, JOANNA BRIGGS I, DOI [10.46658/JBIMES-20-01, DOI 10.46658/JBIMES-20-01]; Ashokka B, 2020, AM J OBSTET GYNECOL, V223, P66, DOI 10.1016/j.ajog.2020.04.005; Atout M, 2021, J PEDIATR NURS, V58, DOI 10.1016/j.pedn.2021.01.009; Aubey J, 2020, SEMIN PERINATOL, V44, DOI 10.1016/j.semperi.2020.151280; Badal S, 2021, J CLIN VIROL, V135, DOI 10.1016/j.jcv.2020.104715; Barney A, 2020, J ADOLESCENT HEALTH, V67, P164, DOI 10.1016/j.jadohealth.2020.05.006; Barrero-Castillero A, 2021, J PERINATOL, V41, P940, DOI 10.1038/s41372-020-00874-x; Barton M., 2020, MEDRXIV, P1, DOI DOI 10.1101/2020.05.05.20091751; Beccaria LM, 2017, REV BRAS ENFERM, V70, P1145, DOI 10.1590/0034-7167-2016-0486; Goes FGB, 2020, REV LAT-AM ENFERM, V28, DOI 10.1590/1518-8345.4550.3367; Bhuiyan MU, 2021, VACCINE, V39, P667, DOI 10.1016/j.vaccine.2020.11.078; Boelig RC, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100110; Bogiatzopoulou Aliki, 2020, Paediatr Child Health (Oxford), V30, P438, DOI 10.1016/j.paed.2020.09.005; Bolt SR, 2021, INT J NURS STUD, V113, DOI 10.1016/j.ijnurstu.2020.103781; de Freitas BHBM, 2020, REV BRAS ENFERM, V73, DOI 10.1590/0034-7167-2020-0467; Bouffet E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28327; Breneol S, 2018, J PEDIATR NURS, V41, P60, DOI 10.1016/j.pedn.2018.01.014; Bressan S, 2020, ANN EMERG MED, V76, P788, DOI 10.1016/j.annemergmed.2020.05.018; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]; Bsiri-Moghaddam K, 2011, IRAN J PEDIATR, V21, P201; Bulamba F, 2017, ANESTHESIOL RES PRAC, V2017, DOI 10.1155/2017/2032748; Butcher H. K., 2018, NURSING INTERVENTION, V7th; Cai XF, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00258; Campagnaro R, 2020, CHILD YOUTH SERV REV, V118, DOI 10.1016/j.childyouth.2020.105469; Cavicchiolo ME, 2021, PEDIATR RES, V89, P399, DOI 10.1038/s41390-020-0937-z; Center for Disease Control Prevention, 2021, STRAT OPT SUPPL N95; Centers for Disease Control and Prevention, 2020, INT GUID HEALTHC FAC; Centers for Disease Control and Prevention (CDC), 2010, BREASTF REP CARD US; Chang TH, 2020, J FORMOS MED ASSOC, V119, P982, DOI 10.1016/j.jfma.2020.04.007; Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006; Chawla D, 2020, INDIAN PEDIATR, V57, P536, DOI 10.1007/s13312-020-1852-4; Chen H, 2021, JNP-J NURSE PRACT, V17, P26, DOI 10.1016/j.nurpra.2020.09.014; Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5; Choi KR, 2020, JOGNN-J OBST GYN NEO, V49, P409, DOI 10.1016/j.jogn.2020.07.004; Choi Soo-Han, 2020, Clin Exp Pediatr, V63, P125, DOI 10.3345/cep.2020.00535; Choron RL, 2021, J INTENSIVE CARE MED, V36, P484, DOI 10.1177/0885066620979622; Conlon C, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06284-9; Carlotti APDP, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1894; de Souza TH, 2020, PEDIATR PULM, V55, P1892, DOI 10.1002/ppul.24885; DeFazio JR, 2020, J PEDIATR SURG, V55, P1427, DOI 10.1016/j.jpedsurg.2020.05.043; Deitrick K, 2020, J EMERG NURS, V46, P748, DOI 10.1016/j.jen.2020.07.010; Deprest J, 2020, FETAL DIAGN THER, V47, P689, DOI 10.1159/000508254; Devrim I, 2020, AM J INFECT CONTROL, V48, P933, DOI 10.1016/j.ajic.2020.05.022; Ding H, 2021, DISASTER MED PUBLIC, V15, pE39, DOI 10.1017/dmp.2020.289; Dokken D., 2020, PEDIATR NURS, V46, P304; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Drewry AM, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03186-w; Dumpa V, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8165; Enyama D, 2020, ARCH PEDIATRIE, V27, DOI 10.1016/j.arcped.2020.09.004; European Society Paediatric and Neonatal Intensive Care, 2020, NURS GUID CAR CHILD; Evans YN, 2020, J ADOLESCENT HEALTH, V67, P469, DOI 10.1016/j.jadohealth.2020.07.015; Extracorporeal Life Support Organization, 2020, EXTRACORPOREAL LIFE; Ezenwa BN, 2022, J MATERN-FETAL NEO M, V35, P1789, DOI 10.1080/14767058.2020.1763948; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Farshi MR., 2020, HORMOZGAN MED J, V24, DOI [10.5812/hmj.108040, DOI 10.5812/HMJ.108040]; Fernandes SC, 2010, J HEALTH PSYCHOL, V15, P405, DOI 10.1177/1359105309350231; Frampton Susan, 2020, JAMA Health Forum, V1, pe200807, DOI 10.1001/jamahealthforum.2020.0807; Frauenfelder C, 2020, INT J PEDIATR OTORHI, V134, DOI 10.1016/j.ijporl.2020.110030; Gale C, 2021, LANCET CHILD ADOLESC, V5, P113, DOI 10.1016/S2352-4642(20)30342-4; Gerall CD, 2021, J PEDIATR SURG, V56, P905, DOI 10.1016/j.jpedsurg.2020.10.008; Gilissen J, 2020, J PAIN SYMPTOM MANAG, V60, pE56, DOI 10.1016/j.jpainsymman.2020.04.151; Girona-Alarcon M, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05786-5; Giuliani C, 2020, DIABETES RES CLIN PR, V165, DOI 10.1016/j.diabres.2020.108239; Gleissman H, 2021, ACTA ANAESTH SCAND, V65, P360, DOI 10.1111/aas.13741; Goldschmidt K, 2021, J PEDIATR NURS, V58, DOI 10.1016/j.pedn.2021.03.001; Gozen D, 2019, J SPEC PEDIATR NURS, V24, DOI 10.1111/jspn.12239; Graber KM, 2021, CHILD CARE HLTH DEV, V47, P143, DOI 10.1111/cch.12832; Gralton KS, 2020, J PEDIATR NURS, V55, P264, DOI 10.1016/j.pedn.2020.08.009; Green Janet, 2021, J Neonatal Nurs, V27, P172, DOI 10.1016/j.jnn.2020.11.004; Green Janet, 2021, J Neonatal Nurs, V27, P21, DOI 10.1016/j.jnn.2020.10.005; Green Janet, 2020, J Neonatal Nurs, V26, P239, DOI 10.1016/j.jnn.2020.06.005; Hafeez A, 2020, EURASIAN J MED ONCOL, V4, P116, DOI 10.14744/ejmo.2020.90853; Hart JL, 2020, J PAIN SYMPTOM MANAG, V60, pE93, DOI 10.1016/j.jpainsymman.2020.04.017; Hester M, 2020, AAP ISSUES GUIDANCE; Hoang A, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100433; Hong H, 2020, PEDIATR NEONATOL, V61, P131, DOI 10.1016/j.pedneo.2020.03.001; Houtrow A, 2020, J PEDIATR REHAB MED, V13, P415, DOI 10.3233/PRM-200769; Hu YL, 2020, J EMERG NURS, V46, P898, DOI 10.1016/j.jen.2020.08.001; Human Milk Banking Association of North America, 2020, MILK HANDLING COVID, DOI [10.6061/clinics/2020/e1932, DOI 10.6061/CLINICS/2020/E1932]; Imran N, 2020, PAK J MED SCI, V36, P1106, DOI 10.12669/pjms.36.5.3088; Ingram MCE, 2020, J PEDIATR SURG, V55, P1431, DOI 10.1016/j.jpedsurg.2020.06.001; Jain PN, 2020, PAEDIATR RESPIR REV, V35, P15, DOI 10.1016/j.prrv.2020.06.002; Jiang L, 2020, LANCET INFECT DIS, V20, pE276, DOI 10.1016/S1473-3099(20)30651-4; Jiao WY, 2020, J PEDIATR-US, V221, P264, DOI 10.1016/j.jpeds.2020.03.013; Johnson SJ., 2021, 2021 PROVIDENCE RN C; Joosten KFM, 2019, CURR OPIN CLIN NUTR, V22, P152, DOI 10.1097/MCO.0000000000000549; Kache S, 2020, PEDIATR RES, V88, P705, DOI 10.1038/s41390-020-1053-9; Kallem VR, 2022, J MATERN-FETAL NEO M, V35, P1610, DOI 10.1080/14767058.2020.1759542; Kari JA, 2021, J INFECT PUBLIC HEAL, V14, P543, DOI 10.1016/j.jiph.2021.01.011; Kassab M., 2020, INT J PHARM RES, V12, P2178, DOI [10.31838/ijpr/2020.12.01.341, DOI 10.31838/IJPR/2020.12.01.341]; Kaushik A, 2020, INDIAN J PEDIATR, V87, P970, DOI 10.1007/s12098-020-03374-0; Kazzaz YM, 2020, ANN THORAC MED, V15, P107, DOI 10.4103/atm.ATM_212_20; Klaiman T, 2021, ANN AM THORAC SOC, V18, P300, DOI 10.1513/AnnalsATS.202005-571OC; Kneyber M, 2020, PRACTICE RECOMMENDAT; Krishnamurthy G, 2020, SEMIN PERINATOL, V44, DOI 10.1016/j.semperi.2020.151282; Kumar CM, 2021, J CLIN MONIT COMPUT, V35, P3, DOI 10.1007/s10877-020-00501-2; Lakhani A, 2020, J ORTHOP, V21, P326, DOI 10.1016/j.jor.2020.06.002; Lee K, 2009, GLOB INST, P1; Leff RA, 2021, CLIN CHILD PSYCHOL P, V26, P33, DOI 10.1177/1359104520972453; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Li HCW, 2007, RES NURS HEALTH, V30, P320, DOI 10.1002/nur.20191; Li WHC, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0570-5; Liu JJ, 2020, LANCET CHILD ADOLESC, V4, P347, DOI 10.1016/S2352-4642(20)30096-1; Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Loomba RS, 2020, INT J PEDIAT, V2020, DOI 10.1155/2020/9680905; Lopez AS, 2020, MMWR-MORBID MORTAL W, V69, P1319, DOI 10.15585/mmwr.mm6937e3; Lopez-Bueno R, 2021, PREV MED, V143, DOI 10.1016/j.ypmed.2020.106349; Lotfi M, 2020, CLIN CHIM ACTA, V508, P254, DOI 10.1016/j.cca.2020.05.044; MaGowan N., 2020, PEDIATR NURS, V46, P273; Marino LV, 2021, CLIN NUTR, V40, P895, DOI 10.1016/j.clnu.2020.10.007; Marraro Giuseppe A, 2020, Zhongguo Dang Dai Er Ke Za Zhi, V22, P183; Matava CT, 2020, ANESTH ANALG, V131, P61, DOI 10.1213/ANE.0000000000004872; McMeekin N, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01061-4; Mihatsch W, 2018, CLIN NUTR, V37, P2306, DOI 10.1016/j.clnu.2018.06.943; Mirlashari J, 2021, J PEDIATR NURS, V57, P25, DOI 10.1016/j.pedn.2020.10.024; Montes Maria Teresa, 2020, J Neonatal Nurs, V26, P247, DOI 10.1016/j.jnn.2020.07.005; Monzani A, 2020, DISASTER MED PUBLIC, V14, P648, DOI 10.1017/dmp.2020.198; Moore SA, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-00987-8; Moro GE, 2020, J HUM LACT, V36, P604, DOI 10.1177/0890334420934391; Mulay KV, 2021, PEDIATR NEONATOL, V62, P70, DOI 10.1016/j.pedneo.2020.09.003; Naranje KM., 2020, J NEONATOL, V34, P88, DOI [10.1177/0973217920928638, DOI 10.1177/0973217920928638]; National Institutes of Health, 2020, SPECIAL POPULATION; Nicholas David B, 2020, Glob Pediatr Health, V7, p2333794X20957652, DOI 10.1177/2333794X20957652; Nolan JP, 2020, RESUSCITATION, V153, P45, DOI 10.1016/j.resuscitation.2020.06.001; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Orsborn J, 2016, PEDIATR EMERG CARE, V32, P20, DOI 10.1097/PEC.0000000000000365; Panda PK, 2020, SEIZURE-EUR J EPILEP, V81, P29, DOI 10.1016/j.seizure.2020.07.013; Passanisi S, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00491; Paterson C, 2020, SEMIN ONCOL NURS, V36, DOI 10.1016/j.soncn.2020.151028; Peck JL, 2020, J PEDIATR HEALTH CAR, V34, P619, DOI 10.1016/j.pedhc.2020.07.004; Peng SC, 2020, LANCET REG HEALTH-W, V4, DOI 10.1016/j.lanwpc.2020.100045; Pereira A, 2020, INT BREASTFEED J, V15, DOI 10.1186/s13006-020-00314-8; Petrone P, 2021, EUR J TRAUMA EMERG S, V47, P1017, DOI 10.1007/s00068-020-01542-7; Phiri PGMC, 2020, J PEDIATR NURS, V55, P10, DOI 10.1016/j.pedn.2020.05.018; Rajapakse N, 2021, PAEDIATR INT CHILD H, V41, P36, DOI 10.1080/20469047.2020.1781356; Rathore P, 2020, INDIAN J PALLIAT CAR, V26, pS170, DOI 10.4103/IJPC.IJPC_167_20; Reardon S, 2015, NATURE, V519, P13, DOI 10.1038/519013a; Remppis J, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05791-8; Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722; Robinson C, 2020, CAN J KIDNEY HEALTH, V7, DOI 10.1177/2054358120970713; Yago MAR, 2020, MED INTENSIVA, V44, P566, DOI [10.1016/j.medin.7020.05.004, 10.1016/j.medin.2020.05.004]; Royal College of Paediatrics and Child Health, 2020, BAPM COVID 19 FREQ A; Salmela Marja, 2009, Pediatr Nurs, V35, P269; Salvatore CM, 2020, LANCET CHILD ADOLESC, V4, P721, DOI 10.1016/S2352-4642(20)30235-2; Sankar J, 2020, INDIAN J PEDIATR, V87, P433, DOI 10.1007/s12098-020-03292-1; Sarman A., 2021, ACTA MEDICA ALANYA, V5, P98, DOI [10.30565/medalanya.843403, DOI 10.30565/MEDALANYA.843403]; Sarman A, 2021, PERSPECT PSYCHIATR C, V57, P957, DOI 10.1111/ppc.12643; Sattar S, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107282; Schlaudecker JD, 2020, J AM MED DIR ASSOC, V21, P983, DOI 10.1016/j.jamda.2020.05.027; Schmitt BD., 2020, CONT PEDIAT, V37, P8; Shang Y, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00689-1; Sharafi SM, 2021, REV ENVIRON HEALTH, V36, P193, DOI 10.1515/reveh-2020-0075; Sharma SK, 2020, J PAK MED ASSOC, V70, pS118, DOI 10.5455/JPMA.29; Shelhamer MC, 2021, J INTENSIVE CARE MED, V36, P241, DOI 10.1177/0885066620980399; Shen KL, 2020, WORLD J PEDIATR, V16, P232, DOI 10.1007/s12519-020-00362-4; Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7; Shi Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.22; Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6; Skarsgard ED, 2020, CAN MED ASSOC J, V192, pE1212, DOI 10.1503/cmaj.201577; Slone JS, 2020, PEDIATR HEMAT ONCOL, V37, P549, DOI 10.1080/08880018.2020.1772913; Soltani J, 2020, NORTH CLIN ISTANB, V7, P284, DOI 10.14744/nci.2020.90277; Soma M, 2020, INT J PEDIATR OTORHI, V134, DOI 10.1016/j.ijporl.2020.110075; Sullivan M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28409; Tagarro A, 2021, JAMA PEDIATR, V175, P316, DOI 10.1001/jamapediatrics.2020.1346; Talekar CR, 2014, ANAESTH INTENS CARE, V42, P761, DOI 10.1177/0310057X1404200612; Tan WH, 2020, J OCCUP ENVIRON MED, V62, P420, DOI 10.1097/JOM.0000000000001877; Taylor JB, 2021, PEDIATR PULM, V56, P539, DOI 10.1002/ppul.25218; Teoh CW, 2020, CAN J KIDNEY HEALTH, V7, DOI 10.1177/2054358120967845; Thampi S, 2020, PEDIATR ANESTH, V30, P642, DOI 10.1111/pan.13863; Trevisanuto D, 2022, J MATERN-FETAL NEO M, V35, P2395, DOI 10.1080/14767058.2020.1784873; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tscherning C, 2020, ACTA PAEDIATR, V109, P1937, DOI 10.1111/apa.15455; Udrea DS, 2022, J PEDIATR GENET, V11, P309, DOI 10.1055/s-0040-1718874; United Nations International Children's Emergency Fund India Country Office ChildLine India Foundation, 2020, PSYCH SUPP CHILDR CO; Venturini E, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00900-w; Verma S, 2020, CURR PROB PEDIATR AD, V50, DOI 10.1016/j.cppeds.2020.100795; Vogt TM, 2020, MMWR-MORBID MORTAL W, V69, P859, DOI 10.15585/mmwr.mm6927a2; Voo TC, 2020, J BIOETHIC INQ, V17, P767, DOI 10.1007/s11673-020-10009-8; Wang H, 2020, INT J NURS SCI, V7, P128, DOI 10.1016/j.ijnss.2020.03.010; Wang LS, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.20; Wei L, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00839-x; WHO, 2020, CORT COVID 19; WHO, 2020, NAM COR DIS COVID 19; WIDEX, 2020, YOU CAN HELP COMM WH; Willer BL, 2020, INT J PEDIATR OTORHI, V136, DOI 10.1016/j.ijporl.2020.110174; World Health Organization, 2014, WHO REC POSTN CAR MO; Worldometers, 2020, COVID 19 COR PAND, DOI DOI 10.2307/J.CTV16T6N4G; Yale Health, 2020, COVID 19 KIDS MANAGI; Ye JC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/19867; Yonker LM, 2020, J PEDIATR-US, V227, P45, DOI 10.1016/j.jpeds.2020.08.037; Zhang FJ, 2020, CURR MED SCI, V40, P602, DOI 10.1007/s11596-020-2222-0; Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660	203	2	2	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2022	17	2							e0263267	10.1371/journal.pone.0263267	http://dx.doi.org/10.1371/journal.pone.0263267			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2V2QB	35113925	Green Published, gold			2023-01-03	WOS:000823694700071
J	Fukunaga, A; Inoue, Y; Yamamoto, S; Miki, T; Hoang, DV; Shrestha, RM; Ishiwari, H; Ishii, M; Miyo, K; Konishi, M; Ohmagari, N; Mizoue, T				Fukunaga, Ami; Inoue, Yosuke; Yamamoto, Shohei; Miki, Takako; Dong Van Hoang; Shrestha, Rachana Manandhar; Ishiwari, Hironori; Ishii, Masamichi; Miyo, Kengo; Konishi, Maki; Ohmagari, Norio; Mizoue, Tetsuya			Association between chronic physical conditions and depressive symptoms among hospital workers in a national medical institution designated for COVID-19 in Japan	PLOS ONE			English	Article							HEALTH; SEVERITY; DISEASES	Objective This study aimed to investigate the cross-sectional association between the presence of chronic physical conditions and depressive symptoms among hospital workers at a national medical institution designated for COVID-19 treatment in Tokyo, Japan. We also accounted for the combined association of chronic physical conditions and SARS-CoV-2 infection risk at work in relation to depressive symptoms, given that occupational infection risk might put additional psychological burden among those with chronic physical conditions with risk of severe COVID-19 outcome. Methods The study sample consisted of 2,440 staff members who participated in a health survey conducted at the national medical institution during period between October 2020 and December 2020. Participants who reported at least one chronic physical condition that were deemed risk factors of severe COVID-19 outcome were regarded as having chronic physical conditions. Depressive symptoms were assessed using the patient health questionnaire-9 (PHQ-9). We performed logistic regression analysis to assess the association between chronic physical conditions and depressive symptoms. Results Our results showed that the presence of chronic physical conditions was significantly associated with depressive symptoms (odds ratio (OR) = 1.49, 95% confidence interval (CI) = 1.10-2.02). In addition, the prevalence of depressive symptoms was significantly higher among healthcare workers with chronic physical conditions who were at a higher occupational infection risk (OR = 1.81, 95% CI = 1.04-3.16). Conclusion Our findings suggest the importance of providing more assistance to those with chronic physical conditions regarding the prevention and control of mental health issues, particularly among frontline healthcare workers engaging in COVID-19-related work.	[Fukunaga, Ami; Inoue, Yosuke; Yamamoto, Shohei; Miki, Takako; Dong Van Hoang; Shrestha, Rachana Manandhar; Konishi, Maki; Mizoue, Tetsuya] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan; [Ishiwari, Hironori; Ishii, Masamichi; Miyo, Kengo] Natl Ctr Global Hlth & Med, Ctr Med Informat Intelligence, Tokyo, Japan; [Ohmagari, Norio] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan	Fukunaga, A (corresponding author), Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan.	afukunaga@hosp.ncgm.go.jp	Ohmagari, Norio/GLN-5290-2022	Ohmagari, Norio/0000-0002-4622-8970; Hoang, DT/0000-0002-4463-4270; Ishii, Masamichi/0000-0002-4228-1723; Yamamoto, Shohei/0000-0001-6503-8577; Fukunaga, Ami/0000-0002-8705-0056	NCGM COVID-19 Gift Fund; Japan Health Research Promotion Bureau Research Fund [2020-B-09]	NCGM COVID-19 Gift Fund; Japan Health Research Promotion Bureau Research Fund	The study was supported by NCGM COVID-19 Gift Fund and the Japan Health Research Promotion Bureau Research Fund (2020-B-09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atmosudigdo IS, 2021, CLIN MED INSIGHTS-EN, V14, DOI [10.1177/1179551421990675, 10.1016/j.jceh.2021.01.007]; Bloom DE, 2020, J ECON AGEING, V17, DOI 10.1016/j.jeoa.2018.09.002; Centers for Disease Control and Prevention, 2021, PEOPL CERT MED COND; Damara FA, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102312; De Brier N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244052; Hariyanto TI, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102926; Ho SMY, 2005, J CONSULT CLIN PSYCH, V73, P344, DOI 10.1037/0022-006X.73.2.344; Huang CQ, 2010, AGEING RES REV, V9, P131, DOI 10.1016/j.arr.2009.05.005; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Javanmardi F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241265; Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976; Liu L, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101111; Liu M, 2020, J INFECTION, V81, pE93, DOI 10.1016/j.jinf.2020.05.065; Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936; Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Muramatsu K, 2018, GEN HOSP PSYCHIAT, V52, P64, DOI 10.1016/j.genhosppsych.2018.03.007; Ozamiz-Etxebarria N, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00054020, 10.1590/0102-311x00054020]; Ozdin S, 2020, INT J SOC PSYCHIATR, V66, P504, DOI 10.1177/0020764020927051; Preti E, 2020, CURR PSYCHIAT REP, V22, DOI 10.1007/s11920-020-01166-z; Read JR, 2017, J AFFECT DISORDERS, V221, P36, DOI 10.1016/j.jad.2017.06.009; Schubert M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18126183; Stanton R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114065; Tanaka A, 2021, J INFECTION, V82, pE1, DOI 10.1016/j.jinf.2021.01.010; Xiong JQ, 2020, J AFFECT DISORDERS, V277, P55, DOI 10.1016/j.jad.2020.08.001; Yamamoto S., 2021, J INFECT	28	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266260	10.1371/journal.pone.0266260	http://dx.doi.org/10.1371/journal.pone.0266260			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1F3NG	35390049	gold, Green Published			2023-01-03	WOS:000795077200050
J	Schaffer, AL; Henry, D; Zoega, H; Elliott, JH; Pearson, SA				Schaffer, Andrea L.; Henry, David; Zoega, Helga; Elliott, Julian H.; Pearson, Sallie-Anne			Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia	PLOS ONE			English	Article							OUTCOMES	Background Since COVID-19 was first recognised, there has been ever-changing evidence and misinformation around effective use of medicines. Understanding how pandemics impact on medicine use can help policymakers act quickly to prevent harm. We quantified changes in dispensing of common medicines proposed for "re-purposing" due to their perceived benefits as therapeutic or preventive for COVID-19 in Australia. Methods We performed an interrupted time series analysis and cross-sectional study using nationwide dispensing claims data (January 2017-November 2020). We focused on six subsidized medicines proposed for re-purposing: hydroxychloroquine, azithromycin, ivermectin, colchicine, corticosteroids, and calcitriol (Vitamin D analog). We quantified changes in monthly dispensing and initiation trends during COVID-19 (March-November 2020) using autoregressive integrated moving average models and compared characteristics of initiators in 2020 and 2019. Results In March 2020, we observed a 99% (95%CI: 96%-103%) increase in hydroxychloroquine dispensing (approximately 22% attributable to new users), and a 199% increase (95%CI: 184%-213%) in initiation, with an increase in prescribing by general practitioners (42% in 2020 vs 25% in 2019) rather than specialists. These increases subsided following regulatory restrictions on prescribing. There was a small but sustained increase in ivermectin dispensing over multiple months, with an 80% (95%CI 42%-118%) increase in initiation in May 2020 following its first identification as potentially disease-modifying in April. Other than increases in March related to stockpiling, we observed no change in the initiation of calcitriol or colchicine during COVID-19. Dispensing of corticosteroids and azithromycin was lower than expected from April through November 2020. Conclusions While most increases in dispensing observed early on during COVID-19 were temporary and appear to be related to stockpiling among existing users, we observed increases in the initiation of hydroxychloroquine and ivermectin and a shift in prescribing patterns which may be related to the media hype around these medicines. A quick response by regulators can help limit inappropriate repurposing to lessen the impact on medicine supply and patient harm.	[Schaffer, Andrea L.; Zoega, Helga; Pearson, Sallie-Anne] UNSW Sydney, Ctr Big Data Res Hlth, Sydney, NSW, Australia; [Henry, David] Bond Univ, Inst Evidence Based Healthcare, Gold Coast, Australia; [Zoega, Helga] Univ Iceland, Fac Med, Ctr Publ Hlth Serv, Reykjavik, Iceland; [Elliott, Julian H.] Monash Univ, Sch Publ Hlth & Prevent Med, Cochrane Australia, Monash, Australia; [Pearson, Sallie-Anne] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW, Australia	University of New South Wales Sydney; Bond University; University of Iceland; Monash University; University of Sydney	Schaffer, AL (corresponding author), UNSW Sydney, Ctr Big Data Res Hlth, Sydney, NSW, Australia.	andrea.schaffer@unsw.edu.au	Henry, David/L-3895-2017; Schaffer, Andrea/Q-9121-2016	Henry, David/0000-0003-2934-2242; Schaffer, Andrea/0000-0002-3701-4997	National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence [1196900]; NHMRC Early Career Fellowship [1158763]; University of New South Wales Scientia Program Award	National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of New South Wales Scientia Program Award	AS, SAP, DH and HZ are supported by the National Health and Medical Research Council (NHMRC, https://www.nhmrc.gov.au/) Centre of Research Excellence in Medicines Intelligence (#1196900). AS is supported by a NHMRC Early Career Fellowship (#1158763). HZ is supported by a University of New South Wales Scientia Program Award(https://www.scientia.unsw.edu.au/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Abella BS, 2021, JAMA INTERN MED, V181, P195, DOI 10.1001/jamainternmed.2020.6319; Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; Arriagada NB, 2020, MED J AUSTRALIA, V213, P282, DOI [10.5694.mja2.50545, 10.5694/mja2.50545]; Australian Government Department of Health, 2019, COVID 19; Australian Government Department of Health, PBS RPBS SECTION 85; Australian Government Department of Health, REVISED HYDROXYCHLOR; Australian Government Therapeutic Goods Administration, 2020, THERAPEUTIC GOODS AD; Australian Institute of Health and Welfare, 2020, IMPACTS COVID 19 MED; Badreldin HA, 2021, RES SOC ADMIN PHARM, V17, P1946, DOI 10.1016/j.sapharm.2020.05.017; Bartoszko JJ, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n949; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Bull-Otterson L, 2020, MMWR-MORBID MORTAL W, V69, P1210, DOI 10.15585/mmwr.mm6935a4; Burry LD, 2020, CHEST, V158, P2414, DOI 10.1016/j.chest.2020.08.015; Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787; COVID-19 National Incident Room Surveillance Team, 2020, COMMUN DIS INTELL, V44, DOI [10.33321/cdi.2020.44.92, DOI 10.33321/CDI.2020.44.92]; Davey M., 2020, GUARDIAN; Enners S, 2021, PHARMACOEPIDEM DR S, V30, P1493, DOI 10.1002/pds.5324; Gabler Ellen, 2020, NEW YORK TIMES; Geller AI, 2021, JAMA INTERN MED, V181, P869, DOI 10.1001/jamainternmed.2021.0299; Gillies MB, 2022, BRIT J CLIN PHARMACO, V88, P1143, DOI 10.1111/bcp.15000; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Karlsson P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253944; Kekatos M, 2020, DAILY MAIL ONLINE; Kuo SC, 2021, J AM PHARM ASSOC, V61, pE12, DOI 10.1016/j.japh.2020.08.029; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Mian M, 2021, MED J AUSTRALIA, V214, P428, DOI 10.5694/mja2.51029; Monash Biomedicine Discovery Institute, 2020, LAB EXPT SHOW ANTIPA; nps, HYDROXYCHLOROQUINE D; Qato DM, 2018, JAMA-J AM MED ASSOC, V319, P2289, DOI 10.1001/jama.2018.6741; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Schaffer AL, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-021-01235-8; Schraer R, 2021, BBC NEWS; Shin YH, 2021, LANCET RHEUMATOL, V3, pE698, DOI 10.1016/S2665-9913(21)00151-X; Socal MP, 2021, AM J PUBLIC HEALTH, V111, P635, DOI 10.2105/AJPH.2020.306138; Sullivan SG, 2020, EUROSURVEILLANCE, V25, DOI 10.2807/1560-7917.ES.2020.25.47.2001847; Tang M, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100226; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; vidence, 2021, NATL COVID 19 CLIN E; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; World Health Organization (WHO), 2021, THERAPEUTICS COVID 1	41	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269482	10.1371/journal.pone.0269482	http://dx.doi.org/10.1371/journal.pone.0269482			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	35704621	Green Published, gold, Green Submitted			2023-01-03	WOS:000843567600126
J	Tie, J; Cohen, JD; Lahouel, K; Lo, SN; Wang, YX; Kosmider, S; Wong, R; Shapiro, J; Lee, M; Harris, S; Khattak, A; Burge, M; Harris, M; Lynam, J; Nott, L; Day, F; Hayes, T; McLachlan, SA; Lee, B; Ptak, J; Silliman, N; Dobbyn, L; Popoli, M; Hruban, R; Lennon, AM; Papadopoulos, N; Kinzler, KW; Vogelstein, B; Tomasetti, C; Gibbs, P				Tie, Jeanne; Cohen, Joshua D.; Lahouel, Kamel; Lo, Serigne N.; Wang, Yuxuan; Kosmider, Suzanne; Wong, Rachel; Shapiro, Jeremy; Lee, Margaret; Harris, Sam; Khattak, Adnan; Burge, Matthew; Harris, Marion; Lynam, James; Nott, Louise; Day, Fiona; Hayes, Theresa; McLachlan, Sue-Anne; Lee, Belinda; Ptak, Janine; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Hruban, Ralph; Lennon, Anne Marie; Papadopoulos, Nicholas; Kinzler, Kenneth W.; Vogelstein, Bert; Tomasetti, Cristian; Gibbs, Peter		DYNAMIC Investigators	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							12-GENE RECURRENCE SCORE; CHEMOTHERAPY; RISK; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; SURVIVAL	Background The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood. Methods We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based or fluoropyrimidine chemotherapy. Patients who were ctDNA-negative were not treated. The primary efficacy end point was recurrence-free survival at 2 years. A key secondary end point was adjuvant chemotherapy use. Results Of the 455 patients who underwent randomization, 302 were assigned to ctDNA-guided management and 153 to standard management. The median follow-up was 37 months. A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65). In the evaluation of 2-year recurrence-free survival, ctDNA-guided management was noninferior to standard management (93.5% and 92.4%, respectively; absolute difference, 1.1 percentage points; 95% CI, -4.1 to 6.2 [noninferiority margin, -8.5 percentage points]). Three-year recurrence-free survival was 86.4% among ctDNA-positive patients who received adjuvant chemotherapy and 92.5% among ctDNA-negative patients who did not. Conclusions A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.)	[Tie, Jeanne; Wong, Rachel; Lee, Margaret; Lee, Belinda; Gibbs, Peter] Walter & Eliza Hall Inst Med Res, Div Personalised Oncol, Melbourne, Vic, Australia; [Tie, Jeanne; Lee, Belinda] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia; [Tie, Jeanne; Kosmider, Suzanne; Lee, Margaret; Gibbs, Peter] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [Tie, Jeanne; Gibbs, Peter] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Wong, Rachel; Lee, Margaret] Eastern Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [Wong, Rachel; Lee, Margaret] Monash Univ, Eastern Hlth Clin Sch, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia; [Shapiro, Jeremy] Cabrini Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [Harris, Marion] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [McLachlan, Sue-Anne] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia; [Lee, Belinda] Northern Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [Lo, Serigne N.] Univ Sydney, Res & Biostat Grp, Melanoma Inst Australia, Sydney, NSW, Australia; [Lo, Serigne N.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Harris, Sam] Bendigo Hlth, Dept Med Oncol, Bendigo, Vic, Australia; [Khattak, Adnan] Fiona Stanley Hosp, Dept Med Oncol, Perth, WA, Australia; [Khattak, Adnan] Edith Cowan Univ, Perth, WA, Australia; [Burge, Matthew] Royal Brisbane & Womens Hosp, Dept Med Oncol, Brisbane, Qld, Australia; [Burge, Matthew] Univ Queensland, Brisbane, Qld, Australia; [Lynam, James] Newcastle Private Hosp, Newcastle, NSW, Australia; [Day, Fiona] Calvary Mater Newcastle Hosp, Dept Med Oncol, Newcastle, NSW, Australia; [Nott, Louise] Royal Hobart Hosp, Dept Med Oncol, Hobart, Tas, Australia; [Hayes, Theresa] South West Healthcare, Warrnambool, Vic, Australia; [Cohen, Joshua D.; Wang, Yuxuan; Ptak, Janine; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Papadopoulos, Nicholas; Kinzler, Kenneth W.; Vogelstein, Bert] Johns Hopkins Univ, Sch Med, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD USA; [Lahouel, Kamel; Tomasetti, Cristian] Johns Hopkins Univ, Sch Med, Div Biostat & Bioinformat, Baltimore, MD USA; [Cohen, Joshua D.; Wang, Yuxuan; Ptak, Janine; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Hruban, Ralph; Lennon, Anne Marie; Papadopoulos, Nicholas; Kinzler, Kenneth W.; Vogelstein, Bert] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Cohen, Joshua D.; Wang, Yuxuan; Ptak, Janine; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Hruban, Ralph; Lennon, Anne Marie; Papadopoulos, Nicholas; Kinzler, Kenneth W.; Vogelstein, Bert] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA; [Hruban, Ralph] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Lennon, Anne Marie] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Ptak, Janine; Silliman, Natalie; Vogelstein, Bert] Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD USA; [Cohen, Joshua D.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Tomasetti, Cristian] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Lo, Serigne N.] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dammam, Saudi Arabia	Peter Maccallum Cancer Center; University of Melbourne; Monash University; Cabrini Health; St Vincent's Hospital Melbourne; Melanoma Institute Australia; University of Sydney; University of Sydney; Edith Cowan University; Royal Brisbane & Women's Hospital; University of Queensland; Calvary Mater Newcastle Hospital; Royal Hobart Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Imam Abdulrahman Bin Faisal University	Tie, J (corresponding author), Walter & Eliza Hall Inst Med Res, Div Personalised Oncol, 1G Royal Parade, Parkville, Vic 3050, Australia.	tie.j@wehi.edu.au		Wong, Rachel/0000-0002-4926-5689	Australian National Health and Medical Research Council [APP1085531]; Medical Research Future Fund [APP1194970]; Marcus Foundation; Virginia and D.K. Ludwig Fund for Cancer Research; Lustgarten Foundation; Conrad R. Hilton Foundation; Sol Goldman Charitable Trust; John Templeton Foundation from the National Institutes of Health [CA62924, CA009071, GM136577, CA06973]; Linda Williams Memorial Grant from the Eastern Health Research Foundation	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Future Fund(Medical Research Future Fund (MRFF)); Marcus Foundation; Virginia and D.K. Ludwig Fund for Cancer Research; Lustgarten Foundation; Conrad R. Hilton Foundation; Sol Goldman Charitable Trust; John Templeton Foundation from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Linda Williams Memorial Grant from the Eastern Health Research Foundation	Supported by a grant (APP1085531) from the Australian National Health and Medical Research Council, a grant (APP1194970) from the Medical Research Future Fund, the Marcus Foundation, the Virginia and D.K. Ludwig Fund for Cancer Research, the Lustgarten Foundation, the Conrad R. Hilton Foundation, the Sol Goldman Charitable Trust, John Templeton Foundation, grants (CA62924, CA009071, GM136577, and CA06973) from the National Institutes of Health, and a Linda Williams Memorial Grant from the Eastern Health Research Foundation.	Anandappa G, 2020, J CLIN ONCOL, V38; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; Argiles G, 2020, ANN ONCOL, V31, P1291, DOI 10.1016/j.annonc.2020.06.022; Bockelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Christensen E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.18.02052; Costas-chavarri A, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.18.00214; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Figueredo A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005390.pub2; FOLPRECHT G, 2020, J CLIN ONCOL, V38; Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Kopetz S, 2015, ONCOLOGIST, V20, P127, DOI 10.1634/theoncologist.2014-0325; Loupakis F, 2021, JCO PRECIS ONCOL, V5, P1166, DOI 10.1200/PO.21.00101; Moding EJ, 2020, NAT CANCER, V1, P176, DOI 10.1038/s43018-019-0011-0; Morris VK, 2020, J CLIN ONCOL, V38; National Comprehensive Cancer Network, COL CANC NCCN GUID E; Nors J, 2020, ACTA ONCOL, V59, P336, DOI 10.1080/0284186X.2019.1711170; O'Connor Erin S, 2011, J Clin Oncol, V29, P3381, DOI 10.1200/JCO.2010.34.3426; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Parikh AR, 2021, CLIN CANCER RES, V27, P5586, DOI 10.1158/1078-0432.CCR-21-0410; Rebuzzi SE, 2020, CANCERS, V12, DOI 10.3390/cancers12092584; Schraa SJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07252-y; Taieb J, 2020, DIGEST LIVER DIS, V52, P730, DOI 10.1016/j.dld.2020.04.010; Taniguchi H, 2021, CANCER SCI, V112, P2915, DOI 10.1111/cas.14926; Tie J., 2021, CIRCULATING TUMOUR D, DOI [10.1101/2021.09.02.21262816v1, DOI 10.1101/2021.09.02.21262816V1]; Tie J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003620; Tie J, 2019, GUT, V68, P663, DOI 10.1136/gutjnl-2017-315852; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645; Venook AP, 2013, J CLIN ONCOL, V31, P1775, DOI 10.1200/JCO.2012.45.1096; Verhoeff SR, 2016, INT J CANCER, V139, P187, DOI 10.1002/ijc.30053; Yamanaka T, 2016, J CLIN ONCOL, V34, P2906, DOI 10.1200/JCO.2016.67.0414	35	47	47	14	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2022	386	24					2261	2272		10.1056/NEJMoa2200075	http://dx.doi.org/10.1056/NEJMoa2200075		JUN 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2D3FY	35657320	Green Accepted			2023-01-03	WOS:000806811000001
J	Wang, LH; Ding, YN; Zhang, CY; Chen, R				Wang, Luhong; Ding, Yinan; Zhang, Chuanyong; Chen, Rong			Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients	PLOS ONE			English	Article							SET ENRICHMENT ANALYSIS; GENE-EXPRESSION; COVID-19; DATABASE; CANCER; CELLS	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19), which poses a major threat to humans worldwide. With the continuous progress of the pandemic, a growing number of people are infected with SARSCoV-2, including hepatocellular carcinoma (HCC) patients. However, the relationship between COVID-19 and HCC has not been fully elucidated. In order to provide better treatment for HCC patients infected with SARS-CoV-2, it's urgently needed to identify common targets and find effective drugs for both. In our study, transcriptomic analysis was performed on both selected lung epithelial cell datasets of COVID-19 patients and the datasets of HCC patients to identify the synergistic effect of COVID-19 in HCC patients. What's more, common differentially expressed genes were identified, and a protein-protein interactions network was designed. Then, hub genes and basic modules were detected based on the protein-protein interactions network. Next, functional analysis was performed using gene ontology terminology and the Kyoto Encyclopedia of Genes and Genomes pathway. Finally, protein-protein interactions revealed COVID-19 interaction with key proteins associated with HCC and further identified transcription factor (TF) genes and microRNAs (miRNA) with differentially expressed gene interactions and transcription factor activity. This study reveals that COVID-19 and HCC are closely linked at the molecular level and proposes drugs that may play an important role in HCC patients with COVID-19. More importantly, according to the results of our research, two critical drugs, Ilomastat and Palmatine, may be effective for HCC patients with COVID-19, which provides clinicians with a novel therapeutic idea when facing possible complications in HCC patients with COVID-19.	[Wang, Luhong; Ding, Yinan] Southeast Univ, Med Coll, Nanjing, Jiangsu, Peoples R China; [Wang, Luhong; Chen, Rong] Southeast Univ, Zhongda Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Zhang, Chuanyong] Nanjing Med Univ, Dept Liver Transplantat, Key Lab Living Donor Liver Transplantat, Affiliated Hosp 1,Minist Publ Hlth, Nanjing, Jiangsu, Peoples R China	Southeast University - China; Southeast University - China; Nanjing Medical University	Chen, R (corresponding author), Southeast Univ, Zhongda Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.	rr1977@163.com			Jiangsu Provincial Medical Youth Talent [QNRC2016816]; Project of Jiangsu Provincial Health and Family Planning Commission [H2018090]	Jiangsu Provincial Medical Youth Talent; Project of Jiangsu Provincial Health and Family Planning Commission	This study was co-funded by Jiangsu Provincial Medical Youth Talent (QNRC2016816) and Project of Jiangsu Provincial Health and Family Planning Commission (H2018090) to Rong Chen. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Baristaite G, 2022, DRUG DEVELOP RES, V83, P622, DOI 10.1002/ddr.21891; Benedicto A, 2021, WORLD J GASTROENTERO, V27, P3516, DOI 10.3748/wjg.v27.i24.3516; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Cambier S, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.155055; Chan SL, 2020, LIVER CANCER, V9, P491, DOI 10.1159/000510765; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen TY, 2011, ANN SURG ONCOL, V18, P2348, DOI 10.1245/s10434-011-1574-x; Chu JS, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-16; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Doms A, 2005, NUCLEIC ACIDS RES, V33, pW783, DOI 10.1093/nar/gki470; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ekpanyapong S, 2022, J VIRAL HEPATITIS, V29, P4, DOI 10.1111/jvh.13590; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Fu DZ, 2014, INT J ONCOL, V44, P153, DOI 10.3892/ijo.2013.2147; Guan CJ, 2019, BIOCHEM BIOPH RES CO, V515, P112, DOI 10.1016/j.bbrc.2019.05.025; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang WJ, 2021, BIOENGINEERED, V12, P4054, DOI 10.1080/21655979.2021.1952791; JENKINS DJA, 1995, DIABETES CARE, V18, P1491, DOI 10.2337/diacare.18.11.1491; Jin Y, 2020, PATHOLOGY, V52, P359, DOI 10.1016/j.pathol.2020.01.436; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378; Katneni UK, 2020, THROMB HAEMOSTASIS, V120, P1668, DOI 10.1055/s-0040-1715841; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3; Lim S, 2021, NAT REV ENDOCRINOL, V17, P11, DOI 10.1038/s41574-020-00435-4; Liu Y, 2017, MOL MED REP, V16, P6674, DOI 10.3892/mmr.2017.7457; Liu ZP, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav095; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Malehmir M, 2019, NAT MED, V25, P641, DOI 10.1038/s41591-019-0379-5; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929; Petito E, 2021, J INFECT DIS, V223, P933, DOI 10.1093/infdis/jiaa756; Qu K, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.352; Schwarz C, 2020, GUT LIVER, V14, P218, DOI 10.5009/gnl17115; Shirvaliloo M, 2021, TISSUE BARRIERS, V9, DOI 10.1080/21688370.2021.1937013; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Takaya H, 2018, UNITED EUR GASTROENT, V6, P1401, DOI 10.1177/2050640618779660; Vaira LA, 2021, RHINOLOGY, V59, DOI 10.4193/Rhin20.515; Wang BF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00570-5; Xia JG, 2015, NAT PROTOC, V10, P823, DOI 10.1038/nprot.2015.052; Yang CW, 2020, BIOMED J, V43, P368, DOI 10.1016/j.bj.2020.05.003; Ye ZM, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1605-9; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980; Zhang HM, 2015, BRIEF BIOINFORM, V16, P45, DOI 10.1093/bib/bbt085; Zhang XR, 2018, LIVER INT, V38, P2006, DOI 10.1111/liv.13757; Zhang YM, 2021, EUR J PHARM SCI, V160, DOI 10.1016/j.ejps.2021.105771; Zheng SS, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.648156; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240; Zong ZY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01643	57	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2022	17	5							e0269249	10.1371/journal.pone.026924	http://dx.doi.org/10.1371/journal.pone.026924			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3V2EB	35639708				2023-01-03	WOS:000841472800032
J	Fizazi, K; Foulon, S; Carles, J; Roubaud, G; McDermott, R; Flechon, A; Tombal, B; Supiot, S; Berthold, D; Ronchin, P; Kacso, G; Gravis, G; Calabro, F; Berdah, JF; Hasbini, A; Silva, M; Thiery-Vuillemin, A; Latorzeff, I; Mourey, L; Laguerre, B; Abadie-Lacourtoisie, S; Martin, E; El Kouri, C; Escande, A; Rosello, A; Magne, N; Schlurmann, F; Priou, F; Chand-Fouche, ME; Freixa, SV; Jamaluddin, M; Rieger, I; Bossi, A				Fizazi, Karim; Foulon, Stephanie; Carles, Joan; Roubaud, Guilhem; McDermott, Ray; Flechon, Aude; Tombal, Bertrand; Supiot, Stephane; Berthold, Dominik; Ronchin, Philippe; Kacso, Gabriel; Gravis, Gwenaelle; Calabro, Fabio; Berdah, Jean-Francois; Hasbini, Ali; Silva, Marlon; Thiery-Vuillemin, Antoine; Latorzeff, Igor; Mourey, Loic; Laguerre, Brigitte; Abadie-Lacourtoisie, Sophie; Martin, Etienne; El Kouri, Claude; Escande, Anne; Rosello, Alvar; Magne, Nicolas; Schlurmann, Friederike; Priou, Frank; Chand-Fouche, Marie-Eve; Freixa, Salvador Villa; Jamaluddin, Muhammad; Rieger, Isabelle; Bossi, Alberto		PEACE-1 Investigators	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design	LANCET			English	Article							DISEASE PROGRESSION; ACETATE; MEN; TRIALS	Background Current standard of care for metastatic castration-sensitive prostate cancer supplements androgen deprivation therapy with either docetaxel, second-generation hormonal therapy, or radiotherapy. We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care. Methods We conducted an open-label, randomised, phase 3 study with a 2 x 2 factorial design (PEACE-1) at 77 hospitals across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland. Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 due to bone pain). Participants were randomly assigned (1: 1:1:1) to standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m(2) once every 3 weeks), standard of care plus radiotherapy, standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily), or standard of care plus radiotherapy plus abiraterone. Neither the investigators nor the patients were masked to treatment allocation. The coprimary endpoints were radiographic progression-free survival and overall survival. Abiraterone efficacy was first assessed in the overall population and then in the population who received androgen deprivation therapy with docetaxel as standard of care (population of interest). This study is ongoing and is registered with ClinicalTrials.gov, NCT01957436. Findings Between Nov 27, 2013, and Dec 20, 2018, 1173 patients were enrolled (one patient subsequently withdrew consent for analysis of his data) and assigned to receive standard of care (n=296), standard of care plus radiotherapy (n=293), standard of care plus abiraterone (n=292), or standard of care plus radiotherapy plus abiraterone (n=291). Median follow-up was 3.5 years (IQR 2.8-4.6) for radiographic progression-free survival and 4.4 years (3.5-5.4) for overall survival. Adjusted Cox regression modelling revealed no interaction between abiraterone and radiotherapy, enabling the pooled analysis of abiraterone efficacy. In the overall population, patients assigned to receive abiraterone (n=583) had longer radiographic progression-free survival (hazard ratio [HR] 0.54, 99.9% CI 0.41-0.71; p<0.0001) and overall survival (0.82, 95.1% CI 0.69-0.98; p=0.030) than patients who did not receive abiraterone (n=589). In the androgen deprivation therapy with docetaxel population (n=355 in both with abiraterone and without abiraterone groups), the HRs were consistent (radiographic progression-free survival 0.50, 99.9% CI 0.34-0.71; p<0.0001; overall survival 0.75, 95.1% CI 0.59-0.95; p=0.017). In the androgen deprivation therapy with docetaxel population, grade 3 or worse adverse events occurred in 217 (63%) of 347 patients who received abiraterone and 181 (52%) of 350 who did not; hypertension had the largest difference in occurrence (76 [22%] patients and 45 [13%], respectively). Addition of abiraterone to androgen deprivation therapy plus docetaxel did not increase the rates of neutropenia, febrile neutropenia, fatigue, or neuropathy compared with androgen deprivation therapy plus docetaxel alone. Interpretation Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients. Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Fizazi, Karim] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, F-94805 Villejuif, France; [Foulon, Stephanie] Univ Paris Saclay, Dept Biostat & Epidemiol, Inst Gustave Roussy, Villejuif, France; [Foulon, Stephanie] Univ Paris Saclay, Inst Gustave Roussy, Ligue Canc, Oncostat U1018,Inserm, Villejuif, France; [Bossi, Alberto] Univ Paris Saclay, Inst Gustave Roussy, Dept Radiotherapy, Villejuif, France; [Carles, Joan] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Roubaud, Guilhem] Inst Bergonie 229 Cours Argonne, Bordeaux, France; [McDermott, Ray] St Vincents Univ Hosp, Canc Trials Ireland, Dublin, Ireland; [Flechon, Aude] Ctr Leon Berard, Lyon, France; [Tombal, Bertrand] Clin Univ St Luc, Brussels, Belgium; [Supiot, Stephane] Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France; [Berthold, Dominik] CHU Vaudois, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland; [Ronchin, Philippe] Ctr Azureen Cancerol, Mougins, France; [Kacso, Gabriel] Iuliu Hatieganu Univ Med & Pharm, Amethyst Radiotherapy Ctr, Cluj Napoca, Romania; [Gravis, Gwenaelle] Aix Marseille Univ, Inst Paoli Calmettes, CRCM, Marseille, France; [Calabro, Fabio] San Camillo Forlanini Hosp, Rome, Italy; [Berdah, Jean-Francois] Clin St Marguerite, Hyeres, France; [Hasbini, Ali] Clin Pasteur, Brest, France; [Silva, Marlon] Ctr Francois Baclesse, Caen, France; [Thiery-Vuillemin, Antoine] CHU Jean Minjoz, Besancon, France; [Latorzeff, Igor] Clin Pasteur, Toulouse, France; [Mourey, Loic] IUCT Oncopole, Toulouse, France; [Laguerre, Brigitte] Ctr Eugene Marquis, Rennes, France; [Abadie-Lacourtoisie, Sophie] Inst Cancerol Ouest, Angers, France; [Martin, Etienne] Ctr Georges Francois Leclerc, Dijon, France; [El Kouri, Claude] Ctr Catherine Sienne, Nantes, France; [Escande, Anne] Strasbourg Oncol Liberale, Strasbourg, France; [Rosello, Alvar] Hosp Univ Josep Trueta, Inst Catala Oncol, Girona, Spain; [Magne, Nicolas] Inst Cancerol Lucien Neuwirth, St Priest En Jarez, France; [Schlurmann, Friederike] CHIC Quimper, Quimper, France; [Priou, Frank] CHD Vendee, La Roche Sur Yon, France; [Chand-Fouche, Marie-Eve] Ctr Antoine Lacassagne, Nice, France; [Freixa, Salvador Villa] Hosp Univ Germans Trias, Inst Catala Oncol, Cap Serv Oncol Radioterap, Badalona, Catalunya, Spain; [Jamaluddin, Muhammad] Cork Univ Hosp, Cork, Ireland; [Rieger, Isabelle] Unicancer, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); University College Dublin; Saint Vincent's University Hospital; UNICANCER; Centre Leon Berard; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Iuliu Hatieganu University of Medicine & Pharmacy; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Azienda Ospedaliera San Camillo-Forlanini; UNICANCER; Centre Francois Baclesse; Universite de Franche-Comte; CHU Besancon; UNICANCER; Centre Eugene Marquis; UNICANCER; Centre Georges-Francois Leclerc; Catalan Institute of Oncology; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut de Cancerologie de la Loire; CHD Vendee; UNICANCER; Centre Antoine Lacassagne; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; University College Cork; UNICANCER	Fizazi, K (corresponding author), Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, F-94805 Villejuif, France.	karim.fizazi@gustaveroussy.fr	Gravis, Gwenaelle/CAG-3019-2022	Gravis, Gwenaelle/0000-0002-3127-1554; Calabro', Fabio/0000-0002-7863-3540; McDermott, Ray/0000-0002-8952-4315	Janssen-Cilag; Ipsen; Sanofi; French Government	Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Ipsen(Ipsen); Sanofi; French Government	Janssen-Cilag, Ipsen, Sanofi, and the French Government.	Armstrong AJ, 2021, ESMO C SEPT 18; Chi KN, 2021, J CLIN ONCOL, V39, P2294, DOI 10.1200/JCO.20.03488; Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI 10.1093/annonc/mdz396; Duran MAC, 2020, J CLIN ONCOL, V38; Colomba E, 2020, EUR J CANCER, V129, P117, DOI 10.1016/j.ejca.2020.01.017; Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; de Bono JS, 2017, EUR UROL, V71, P656, DOI 10.1016/j.eururo.2016.06.033; Deb S, 2014, J STEROID BIOCHEM, V144, P50, DOI 10.1016/j.jsbmb.2013.10.027; Feyerabend S, 2018, EUR J CANCER, V103, P78, DOI 10.1016/j.ejca.2018.08.010; Fizazi K, 2019, LANCET ONCOL, V20, P686, DOI 10.1016/S1470-2045(19)30082-8; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Fizazi K, 2015, EUR UROL, V67, P904, DOI 10.1016/j.eururo.2014.08.076; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Francini E, 2018, PROSTATE, V78, P889, DOI 10.1002/pros.23645; Gravis G, 2018, EUR UROL, V73, P847, DOI 10.1016/j.eururo.2018.02.001; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657; Massard C., PHASE 1 3 TRIAL CABA; Parker C, 2020, ANN ONCOL, V31, P1119, DOI 10.1016/j.annonc.2020.06.011; Parker CC, 2018, LANCET, V392, P2353, DOI 10.1016/S0140-6736(18)32486-3; Rydzewska LHM, 2017, EUR J CANCER, V84, P88, DOI 10.1016/j.ejca.2017.07.003; Schaeffer E, 2021, J NATL COMPR CANC NE, V19, P135, DOI 10.6004/jnccn.2021.0008; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tagawa ST, 2016, EUR UROL, V70, P718, DOI 10.1016/j.eururo.2016.01.028; Vale CL, 2018, ANN ONCOL, V29, P1249, DOI 10.1093/annonc/mdy071; van Waterschoot RAB, 2009, CANCER RES, V69, P8996, DOI 10.1158/0008-5472.CAN-09-2915; Vogl UM, 2022, EUR J CANCER, V160, P24, DOI 10.1016/j.ejca.2021.09.036	31	40	41	11	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2022	399	10336					1695	1707		10.1016/S0140-6736(22)00367-1	http://dx.doi.org/10.1016/S0140-6736(22)00367-1		APR 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1K4GY	35405085				2023-01-03	WOS:000798562500019
J	Li, Y; Wang, DM; Ping, XD; Zhang, YK; Zhang, T; Wang, L; Jin, L; Zhao, WJ; Guo, MW; Shen, F; Meng, MY; Chen, X; Zheng, Y; Wang, JQ; Li, DL; Zhang, Q; Hu, C; Xu, LY; Ma, XR				Li, Yu; Wang, Dongmei; Ping, Xiaodan; Zhang, Yankang; Zhang, Ting; Wang, Li; Jin, Li; Zhao, Wenjun; Guo, Mingwei; Shen, Fei; Meng, Meiyao; Chen, Xin; Zheng, Ying; Wang, Jiqiu; Li, Dali; Zhang, Qiang; Hu, Cheng; Xu, Lingyan; Ma, Xinran			Local hyperthermia therapy induces of white fat and treats	CELL			English	Article							BROWN ADIPOSE-TISSUE; HEAT-SHOCK RESPONSE; ENERGY-EXPENDITURE; TRANSCRIPTIONAL ACTIVITY; METABOLIC DYSFUNCTION; CARDIOVASCULAR-RESPONSES; SUPRACLAVICULAR REGION; HSF1; HEALTHY; OBESITY	Beige fat plays key roles in the regulation of systemic energy homeostasis; however, detailed mechanisms and safe strategy for its activation remain elusive. In this study, we discovered that local hyperthermia therapy (LHT) targeting beige fat promoted its activation in humans and mice. LHT achieved using a hydrogel-based photothermal therapy activated beige fat, preventing and treating obesity in mice without adverse effects. HSF1 is required for the effects since HSF1 deficiency blunted the metabolic benefits of LHT. HSF1 regulates Hnrnpa2b1 (A2b1) transcription, leading to increased mRNA stability of key metabolic genes. Importantly, analysis of human association studies followed by functional analysis revealed that the HSF1 gain-of-function variant p.P365T is associated with improved metabolic performance in humans and increased A2b1 transcription in mice and cells. Overall, we demonstrate that LHT offers a promising strategy against obesity by inducing beige fat activation via HSF1-A2B1 transcriptional axis.	[Li, Yu; Wang, Dongmei; Ping, Xiaodan; Zhang, Yankang; Zhang, Ting; Wang, Li; Zhao, Wenjun; Guo, Mingwei; Shen, Fei; Meng, Meiyao; Chen, Xin; Zheng, Ying; Li, Dali; Zhang, Qiang; Xu, Lingyan; Ma, Xinran] East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Jin, Li; Hu, Cheng] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Shanghai Clin Ctr Diabet, Shanghai Key Lab Diabet Mellitus, Shanghai Diabet Inst, Shanghai 200233, Peoples R China; [Hu, Cheng; Ma, Xinran] Southern Med Univ, Fengxian Cent Hosp, Dept Endocrinol & Metab, Shanghai 201499, Peoples R China; [Wang, Jiqiu] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Endocrinol & Metab, Sch Med, Shanghai 200025, Peoples R China; [Li, Dali; Xu, Lingyan; Ma, Xinran] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Li, Dali; Xu, Lingyan; Ma, Xinran] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China	East China Normal University; Shanghai Jiao Tong University; Southern Medical University - China; Shanghai Jiao Tong University; East China Normal University; East China Normal University	Zhang, Q; Xu, LY; Ma, XR (corresponding author), East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.; Hu, C (corresponding author), Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Shanghai Clin Ctr Diabet, Shanghai Key Lab Diabet Mellitus, Shanghai Diabet Inst, Shanghai 200233, Peoples R China.; Hu, C; Ma, XR (corresponding author), Southern Med Univ, Fengxian Cent Hosp, Dept Endocrinol & Metab, Shanghai 201499, Peoples R China.; Xu, LY; Ma, XR (corresponding author), East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.; Xu, LY; Ma, XR (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.	qzhang@bio.ecnu.edu.cn; alfredhc@sjtu.edu.cn; lyxu@bio.ecnu.edu.cn; xrma@bio.ecnu.edu.cn	Hu, Cheng/C-3346-2008; Wang, Jiqiu/AGM-1346-2022	Hu, Cheng/0000-0003-4314-2386; Li, Yu/0000-0003-2914-158X; Wang, Jiqiu/0000-0002-9383-7656	National Natural Science Foundation of China [32022034, 31770840, 32071148, 31800989, 81902980]; National Key Research and Development Program of China [2019YFA0904500, 2018YFC1313800]; Shanghai Outstanding Academic Leaders [20XD1433300]; Shuguang Project [21SG11]; ECNU Public Platform for Innovation [011]; Instruments Sharing Platform of School of Life Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Shanghai Outstanding Academic Leaders; Shuguang Project(Chinese Academy of Sciences); ECNU Public Platform for Innovation; Instruments Sharing Platform of School of Life Sciences	We are grateful to Shanghai Fat Distribution and Disease (FADE) for assistance with human study and clinical data resources. We acknowledge Dr. Richard L. Prioa and Dr. Elisabetta Mueller from NIDDK, NIH for generously sharing HSF1 loxp mice and Dr. Yiyun Cheng (ECNU) for technique advice on photothermal therapy. This work was supported by funds from the National Natural Science Foundation of China (32022034, 31770840, 32071148, 31800989, and 81902980), the National Key Research and Development Program of China (2019YFA0904500 and 2018YFC1313800), the Shanghai Outstanding Academic Leaders (20XD1433300), the Shuguang Project (21SG11), the ECNU Public Platform for Innovation (011), and the Instruments Sharing Platform of School of Life Sciences.	Abdullahi A, 2019, ANN SURG, V269, P554, DOI 10.1097/SLA.0000000000002465; Abreu-Vieira G, 2015, AM J PHYSIOL-ENDOC M, V308, pE822, DOI 10.1152/ajpendo.00494.2014; Alarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011; Andrews S, 2010, FASTQC QUALITY CONTR; Archer AE, 2018, AM J PHYSIOL-REG I, V315, pR696, DOI 10.1152/ajpregu.00073.2018; Asano Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19174; Baird NA, 2014, SCIENCE, V346, P360, DOI 10.1126/science.1253168; Bakker LEH, 2014, LANCET DIABETES ENDO, V2, P210, DOI 10.1016/S2213-8587(13)70156-6; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bao YQ, 2013, J CLIN ENDOCR METAB, V98, P345, DOI 10.1210/jc.2012-2906; Barbatelli G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1244, DOI 10.1152/ajpendo.00600.2009; Baskaran P, 2016, BRIT J PHARMACOL, V173, P2369, DOI 10.1111/bph.13514; Bhadada SV, 2011, THER ADV ENDOCRINOL, V2, P65, DOI 10.1177/2042018810390259; BOREHAM DR, 1995, INT J HYPERTHER, V11, P745, DOI 10.3109/02656739509052332; Bouitbir J, 2012, EUR HEART J, V33, P1397, DOI 10.1093/eurheartj/ehr224; Brunt VE, 2016, J APPL PHYSIOL, V121, P716, DOI 10.1152/japplphysiol.00424.2016; Butler AA, 2010, DIABETES, V59, P323, DOI 10.2337/db09-1471; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chan SL, 2010, AGEING RES REV, V9, P20, DOI 10.1016/j.arr.2009.09.006; Chen LM, 2021, CELL DEATH DIFFER, V28, P1880, DOI 10.1038/s41418-020-00714-7; Chen PZ, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0734-8; Cheng W, 2019, ACS NANO, V13, P8537, DOI 10.1021/acsnano.9b04436; Choa R, 2021, SCIENCE, V373, P532, DOI 10.1126/science.abd2893; Chouchani ET, 2016, NATURE, V532, P112, DOI 10.1038/nature17399; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105; Cohen P, 2014, CELL, V156, P304, DOI 10.1016/j.cell.2013.12.021; Dai C, 2016, TRENDS CELL BIOL, V26, P17, DOI 10.1016/j.tcb.2015.10.011; Dong BS, 2019, TRENDS PHARMACOL SCI, V40, P986, DOI 10.1016/j.tips.2019.10.008; Fu YS, 2010, AUTON NEUROSCI-BASIC, V155, P49, DOI 10.1016/j.autneu.2010.01.006; Geissler R, 2016, GENE DEV, V30, P1070, DOI 10.1101/gad.277392.116; Gomez-Pastor R, 2018, NAT REV MOL CELL BIO, V19, P4, DOI 10.1038/nrm.2017.73; Gomez-Pastor R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14405; Harms M, 2013, NAT MED, V19, P1252, DOI 10.1038/nm.3361; Henriques F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107998; Hoerter J, 2004, CIRCULATION, V110, P528, DOI 10.1161/01.CIR.0000137824.30476.0E; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hooper PL, 1999, NEW ENGL J MED, V341, P924, DOI 10.1056/NEJM199909163411216; Ikeda K, 2017, NAT MED, V23, P1454, DOI 10.1038/nm.4429; Jespersen NZ, 2013, CELL METAB, V17, P798, DOI 10.1016/j.cmet.2013.04.011; Ji CB, 2019, NAT REV ENDOCRINOL, V15, P731, DOI 10.1038/s41574-019-0260-0; Jimenez V, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708791; Johansen OS, 2021, CELL, V184, P3502, DOI 10.1016/j.cell.2021.04.037; Jung AE, 2008, MOL THER, V16, P1048, DOI 10.1038/mt.2008.68; Kazak L, 2015, CELL, V163, P643, DOI 10.1016/j.cell.2015.09.035; Kihara T, 2002, J AM COLL CARDIOL, V39, P754, DOI 10.1016/S0735-1097(01)01824-1; Kleiner S, 2012, P NATL ACAD SCI USA, V109, P9635, DOI 10.1073/pnas.1207287109; Kriszt R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00291-9; Labbadia J, 2017, CELL REP, V21, P1481, DOI 10.1016/j.celrep.2017.10.038; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larsen TM, 2002, AM J CLIN NUTR, V76, P780, DOI 10.1093/ajcn/76.4.780; Laukkanen T, 2015, JAMA INTERN MED, V175, P542, DOI 10.1001/jamainternmed.2014.8187; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lin CD, 2019, IMMUNITY, V50, P137, DOI 10.1016/j.immuni.2018.11.013; Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a; Lo KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019778; Long JZ, 2014, CELL METAB, V19, P810, DOI 10.1016/j.cmet.2014.03.025; Lute B, 2014, CELL METAB, V20, P333, DOI 10.1016/j.cmet.2014.05.021; Ma XR, 2015, CELL METAB, V22, P695, DOI 10.1016/j.cmet.2015.08.005; Martinez FJ, 2016, NEURON, V92, P780, DOI 10.1016/j.neuron.2016.09.050; Masuda Y, 2019, J THERM BIOL, V82, P83, DOI 10.1016/j.jtherbio.2019.03.014; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Mina AI, 2018, CELL METAB, V28, P656, DOI 10.1016/j.cmet.2018.06.019; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Neudegger T, 2016, NAT STRUCT MOL BIOL, V23, P140, DOI 10.1038/nsmb.3149; Nguyen HP, 2020, MOL CELL, V77, P600, DOI 10.1016/j.molcel.2019.12.002; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Patsouris D, 2015, CELL REP, V13, P1538, DOI 10.1016/j.celrep.2015.10.028; Pellegrinelli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07453-x; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qiao AJ, 2017, J CELL BIOL, V216, P723, DOI 10.1083/jcb.201607091; Redman LM, 2007, J CLIN ENDOCR METAB, V92, P527, DOI 10.1210/jc.2006-1740; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rosen ED, 2014, CELL, V156, P20, DOI 10.1016/j.cell.2013.12.012; Scheja L, 2019, NAT REV ENDOCRINOL, V15, P507, DOI 10.1038/s41574-019-0230-6; Seki T, 2018, J EXP MED, V215, P611, DOI 10.1084/jem.20171012; Shiuchi T, 2009, CELL METAB, V10, P466, DOI 10.1016/j.cmet.2009.09.013; Soncin F, 2003, BIOCHEM BIOPH RES CO, V303, P700, DOI 10.1016/S0006-291X(03)00398-X; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Symonds ME, 2012, J PEDIATR-US, V161, P892, DOI 10.1016/j.jpeds.2012.04.056; Tharp KM, 2021, CELL METAB, V33, P1322, DOI 10.1016/j.cmet.2021.04.017; Thomas KN, 2017, AM J PHYSIOL-REG I, V312, pR281, DOI 10.1152/ajpregu.00404.2016; Tschop MH, 2012, NAT METHODS, V9, P57, DOI [10.1038/NMETH.1806, 10.1038/nmeth.1806]; Uchiyama T, 2007, ATHEROSCLEROSIS, V190, P321, DOI 10.1016/j.atherosclerosis.2006.03.037; Vasconcelos J, 2013, ENVIRON POLLUT, V183, P14, DOI 10.1016/j.envpol.2013.01.037; Vinaik R, 2019, AM J PHYSIOL-ENDOC M, V317, pE751, DOI 10.1152/ajpendo.00180.2019; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Vitali A, 2012, J LIPID RES, V53, P619, DOI 10.1194/jlr.M018846; Wang L, 2019, SCIENCE, V365, P656, DOI 10.1126/science.aav0758; Wang T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20691; Wang XH, 2020, IMMUNITY, V52, P328, DOI 10.1016/j.immuni.2020.01.006; Wang X, 2017, CHEM MATER, V29, P1370, DOI 10.1021/acs.chemmater.6b05192; Wang XY, 2016, BIOMATERIALS, V81, P114, DOI 10.1016/j.biomaterials.2015.11.037; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Xu L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.22; Xu YT, 2019, CLIN NUTR, V38, P2704, DOI 10.1016/j.clnu.2018.11.025; Ye L, 2013, P NATL ACAD SCI USA, V110, P12480, DOI 10.1073/pnas.1310261110; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu TZ, 2019, J CELL PHYSIOL, V234, P13292, DOI 10.1002/jcp.28006; Yun J, 2014, CELL METAB, V19, P757, DOI 10.1016/j.cmet.2014.01.011; Zeng X, 2019, NATURE, V569, P229, DOI 10.1038/s41586-019-1156-9; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang ZZ, 2021, CELL METAB, V33, P1624, DOI 10.1016/j.cmet.2021.06.001; Zhou ZJ, 2017, BIOMATERIALS, V141, P116, DOI 10.1016/j.biomaterials.2017.06.030	105	28	29	78	192	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2022	185	6					949	+		10.1016/j.cell.2022.02.004	http://dx.doi.org/10.1016/j.cell.2022.02.004		MAR 2022	38	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZZ6CW	35247329				2023-01-03	WOS:000773355400005
J	Robertson, C; Houtz, M				Robertson, Christopher; Houtz, Margaret			When Desperate Patients Go to Court for Unproven Treatments - The Battle for Hospital Independence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Robertson, Christopher; Houtz, Margaret] Boston Univ, Sch Law, Boston, MA 02215 USA	Boston University	Robertson, C (corresponding author), Boston Univ, Sch Law, Boston, MA 02215 USA.			Robertson, Christopher/0000-0001-6188-8005				Coleman DL, 2020, J LAW BIOSCI, V7, DOI 10.1093/jlb/lsaa031; Huynh TN, 2014, CRIT CARE MED, V42, P1977, DOI 10.1097/CCM.0000000000000402; Kherbache A, 2022, J HEALTH PSYCHOL, V27, P1971, DOI 10.1177/13591053211014586; Popp M, 2021, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD015017.pub2, 10.1002/14651858.CD015017]	4	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2022	386	13					1200	1202		10.1056/NEJMp2200209	http://dx.doi.org/10.1056/NEJMp2200209		MAR 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2Q8KI	35263516	Green Published			2023-01-03	WOS:000766309900001
J	Shibata, T; Oishi, S; Mizuno, A; Ohmori, T; Okamura, T; Kashiwagi, H; Sakashita, A; Kishi, T; Obara, H; Kakuma, T; Fukumoto, Y				Shibata, Tatsuhiro; Oishi, Shogo; Mizuno, Atsushi; Ohmori, Takashi; Okamura, Tomonao; Kashiwagi, Hideyuki; Sakashita, Akihiro; Kishi, Takuya; Obara, Hitoshi; Kakuma, Tatsuyuki; Fukumoto, Yoshihiro			Evaluation of the effectiveness of the physician education program on primary palliative care in heart failure	PLOS ONE			English	Article							TASK-FORCE; DIFFICULTIES; ASSOCIATION; MANAGEMENT	Major cardiology societies' guidelines support integrating palliative care into heart failure (HF) care. This study aimed to identify the effectiveness of the HEart failure Palliative care Training program for comprehensive care providers (HEPT), a physician education program on primary palliative care in HF. We performed a pre- and post-test survey to evaluate HEPT outcomes. Physician-reported practices, difficulties and knowledge were evaluated using the Palliative Care Self-Reported Practices Scale in HF (PCPS-HF), Palliative Care Difficulties Scale in HF (PCDS-HF), and Palliative care knowledge Test in HF (PT-HF), respectively. Structural equation models (SEM) were used to estimate path coefficients for PCPS-HF, PCDS-HF, and PT-HF. A total of 207 physicians participated in the HEPT between February 2018 and July 2019, and 148 questionnaires were ultimately analyzed. The total PCPS-HF, PCDS-HF, and PT-HF scores were significantly improved 6 months after HEPT completion (61.1 vs 67.7, p<0.001, 54.9 vs 45.1, p<0.001, and 20.8 vs 25.7, p<0.001, respectively). SEM analysis showed that for pre-post difference (Dif) PCPS-HF, "clinical experience of more than 14 years" and pre-test score had significant negative effects (-2.31, p = 0.048, 0.52, p<0.001, respectively). For Dif PCDS-HF, >= "28 years old or older" had a significant positive direct effect (13.63, p<0.001), although the pre-test score had a negative direct effect (-0.56, p<0.001). For PT-HF, "involvement in more than 50 HF patients' treatment in the past year" showed a positive direct effect (0.72, p = 0.046), although the pre-test score showed a negative effect (-0.78, p<0.001). Physicians who completed the HEPT showed significant improvements in practice, difficulty, and knowledge scales in HF palliative care.	[Shibata, Tatsuhiro; Fukumoto, Yoshihiro] Kurume Univ, Sch Med, Dept Internal Med, Div Cardiovasc Med, Fukuoka, Japan; [Oishi, Shogo; Sakashita, Akihiro] Himeji Cardiovasc Ctr, Dept Cardiol, Himeji, Hyogo, Japan; [Mizuno, Atsushi] St Lukes Int Hosp, Dept Cardiovasc Med, Tokyo, Japan; [Mizuno, Atsushi] Juntendo Univ, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; [Mizuno, Atsushi] Univ Penn, Penn Med Nudge Unit, Philadelphia, PA 19104 USA; [Mizuno, Atsushi] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Ohmori, Takashi; Okamura, Tomonao; Kashiwagi, Hideyuki] Iizuka Hosp, Dept Transit & Palliat Care, Fukuoka, Japan; [Sakashita, Akihiro] Kobe Univ, Sch Med, Dept Palliat Med, Kobe, Hyogo, Japan; [Kishi, Takuya] Int Univ Hlth & Welf, Fac Hlth & Welf Sci Fukuoka, Fukuoka, Japan; [Obara, Hitoshi; Kakuma, Tatsuyuki] Kurume Univ, Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan	Kurume University; St. Luke's International Hospital; Juntendo University; University of Pennsylvania; University of Pennsylvania; Kobe University; International University of Health & Welfare; Kurume University	Fukumoto, Y (corresponding author), Kurume Univ, Sch Med, Dept Internal Med, Div Cardiovasc Med, Fukuoka, Japan.	fukumoto_yoshihiro@med.kurume-u.ac.jp		Ohmori, Takashi/0000-0002-9446-6498	Sasakawa Health Foundation; Cardiovascular Research Fund; AMED, Japan [JP18ek0210072]	Sasakawa Health Foundation; Cardiovascular Research Fund; AMED, Japan	This research was supported by grants from the Sasakawa Health Foundation (T.S.), the Cardiovascular Research Fund (T.S.), and AMED under Grant Number JP18ek0210072 (A.M.), Japan. The funders had no role in study design, data collection, and analysis, decision to publish, and preparation of the manuscript.	Allen LA, 2012, CIRCULATION, V125, P1928, DOI 10.1161/CIR.0b013e31824f2173; Brannstrom M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151; Braun LT, 2016, CIRCULATION, V134, pE198, DOI 10.1161/CIR.0000000000000438; Crousillat DR, 2018, J AM COLL CARDIOL, V71, P1391, DOI 10.1016/j.jacc.2018.02.019; Goodlin SJ, 2009, J AM COLL CARDIOL, V54, P386, DOI 10.1016/j.jacc.2009.02.078; Hamatani Y, 2020, CIRC J, V84, P584, DOI 10.1253/circj.CJ-19-0225; Ioroi T, 2015, SAGE OPEN MED, V3, DOI 10.1177/2050312115621313; Jessup M, 2015, J AM COLL CARDIOL, V65, P1866, DOI 10.1016/j.jacc.2015.03.031; Kavalieratos D, 2017, J AM COLL CARDIOL, V70, P1919, DOI 10.1016/j.jacc.2017.08.036; Kuragaichi T, 2018, CIRC J, V82, P1336, DOI 10.1253/circj.CJ-17-1305; Mizuno A, 2020, J CARDIOL, V76, P177, DOI 10.1016/j.jjcc.2020.02.010; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Munoz-Mendoza J, 2015, J AM COLL CARDIOL, V65, P750, DOI 10.1016/j.jacc.2014.12.030; Nakazawa Y, 2018, CANCER-AM CANCER SOC, V124, P626, DOI 10.1002/cncr.31071; Nakazawa Y, 2010, J PALLIAT MED, V13, P427, DOI 10.1089/jpm.2009.0289; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Rogers JG, 2017, J AM COLL CARDIOL, V70, P332, DOI 10.1016/j.jacc.2017.05.030; Schenker Y, 2015, JAMA-J AM MED ASSOC, V314, P1565, DOI 10.1001/jama.2015.11217; Sidebottom AC, 2015, J PALLIAT MED, V18, P134, DOI 10.1089/jpm.2014.0192; Tsutsui H, 2019, CIRC J, V83, P2084, DOI 10.1253/circj.CJ-19-0342; Wong FKY, 2016, HEART, V102, P1100, DOI 10.1136/heartjnl-2015-308638; Yamamoto R, 2015, J PALLIAT MED, V18, P45, DOI 10.1089/jpm.2014.0122; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2022	17	2							e0263523	10.1371/journal.pone.0263523	http://dx.doi.org/10.1371/journal.pone.0263523			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0W8MA	35120191	Green Published, gold			2023-01-03	WOS:000789273600050
J	Begum, MY; Osmani, RAM; Alqahtani, A; Ghazwani, M; Hani, U; Ather, H; Atiya, A; Rahamathulla, M; Siddiqua, A				Begum, M. Yasmin; M. Osmani, Riyaz Ali; Alqahtani, Ali; Ghazwani, Mohammed; Hani, Umme; Ather, Hissana; Atiya, Akhtar; Rahamathulla, Mohamed; Siddiqua, Ayesha			Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation	PLOS ONE			English	Article							RHEUMATOID-ARTHRITIS; SKIN PERMEATION; PLASMA; PHARMACOKINETICS; OSTEOARTHRITIS; MICROEMULSION; STABILITY; COMPLEX	Celecoxib (CLB) is a highly hydrophobic selective cyclo-oxygenase inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism. CLB is highly effective in the treatment of osteo and rheumatoid arthritis as first line therapy but produces severe gastro-intestinal toxicities and cardiovascular side effects. In this research, stealth liposomes of CLB were developed with the intention to reduce the side effects and increase the accumulation of drug in the sites of inflammation. Stealth liposomes were prepared by thin film hydration technique using distearoylphosphatidylcholine and PE-PEG 2000 with variable amounts of cholesterol and characterized. The effects of various lipids such as hydrogenated soy phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoylphosphatidylcholine and cholesterol content on % drug encapsulation was investigated. The optimized stealth liposomes were characterized by FT-IR and DSC for possible drug excipients interaction. Pharmacokinetics, pharmacodynamics and biodistribution studies were carried out for the stealth liposomes. The results revealed that the stealth liposomes reduced the inflammation to the larger magnitude and have also sustained the magnitude when compared to free drug along with maximum analgesic response. Higher elimination half-life, AUC, MRT and lowered clearance rate denotes the extended bioavailability of the drug in blood. Biodistribution studies revealed that stealth liposomes extend the circulation time of liposomes in blood by decreasing opsonisation and be less concentrated in kidney, thereby reducing the toxicities to RES and renal organs and facilitate the drug accumulation in the area of inflammation. Our results indicated that CLB, without the requirement of modifications to enhance solubilisation, can be encapsulated and released from liposomal formulations. This new-fangled drug delivery approach may be used to circumvent the low bioavailability and toxic side effects of oral CLB formulations.	[Begum, M. Yasmin; Hani, Umme; Rahamathulla, Mohamed] King Khalid Univ, Coll Pharm, Dept Pharmaceut, Abha, Saudi Arabia; [M. Osmani, Riyaz Ali] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru, Karnataka, India; [Alqahtani, Ali] King Khalid Univ, Coll Pharm, Dept Pharmacol, Abha, Saudi Arabia; [Ghazwani, Mohammed; Ather, Hissana] King Khalid Univ, Coll Pharm, Dept Pharmaceut Chem, Abha, Saudi Arabia; [Atiya, Akhtar] King Khalid Univ, Coll Pharm, Dept Pharmacognosy, Abha, Saudi Arabia; [Siddiqua, Ayesha] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha, Saudi Arabia	King Khalid University; JSS Academy of Higher Education & Research; JSS College of Pharmacy, Mysuru; King Khalid University; King Khalid University; King Khalid University; King Khalid University	Begum, MY (corresponding author), King Khalid Univ, Coll Pharm, Dept Pharmaceut, Abha, Saudi Arabia.	yaminimp47@gmail.com	Alqahtani, Ali M/AAW-5226-2020; Osmani, Riyaz Ali/B-7455-2017; hani, umme/CAJ-4228-2022; Rahamathulla, Mohamed/ABC-7450-2021; hani, Umme/CAJ-4227-2022; Ghazwani, Mohammed/CDJ-7608-2022	Alqahtani, Ali M/0000-0002-2240-4757; Osmani, Riyaz Ali/0000-0002-2333-0817; Rahamathulla, Mohamed/0000-0001-8826-3718; 	King Khalid University [RGP.1/330/42]	King Khalid University	The grant was received by M.Yasmin Begum (The corresponding author). It was funded by the Deanship of Scientific Research through Research Group (Small) [Project number RGP.1/ 330/42] of King Khalid University, Abha-61421, Saudi Arabia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Begum MY., 2011, RES J PHARM TECHNOL, V4, P1766; Bhatia A, 2004, J PHARM PHARM SCI, V7, P252; Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495-200059040-00017; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Dave Vivek, 2019, Nano-Structures & Nano-Objects, V18, P43, DOI 10.1016/j.nanoso.2019.100288; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Er Y, 2009, J LIPOSOME RES, V19, P29, DOI 10.1080/08982100802673940; Flaten GE, 2006, EUR J PHARM SCI, V28, P336, DOI 10.1016/j.ejps.2006.03.008; GRAEME ML, 1966, J PHARMACOL EXP THER, V153, P373; Hathout RM, 2007, AAPS PHARMSCITECH, V8; Hoekman JD, 2014, J PHARM SCI-US, V103, P2231, DOI 10.1002/jps.24022; Immordino ML, 2006, INT J NANOMED, V1, P297; Jain SK, 2007, DRUG DELIV, V14, P327, DOI 10.1080/10717540601098740; Layek Buddhadev, 2010, Sci Pharm, V78, P507, DOI 10.3797/scipharm.0911-11; Manosroi A, 2004, INT J PHARMACEUT, V270, P279, DOI 10.1016/j.ijpharm.2003.10.031; Mohammed AR, 2004, INT J PHARMACEUT, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010; Nasr M, 2010, AAPS PHARMSCITECH, V11, P85, DOI 10.1208/s12249-009-9364-5; Okur NU, 2011, INT J PHARMACEUT, V416, P136, DOI 10.1016/j.ijpharm.2011.06.026; Pai RS., 2009, INT J PHARM SCI NANO, V1, P317; Paradkar AR, 2003, DRUG DEV IND PHARM, V29, P739, DOI 10.1081/DDC-120021773; Park KM, 1999, INT J PHARM, V181, P173, DOI 10.1016/S0378-5173(99)00029-0; Paulson SK, 2001, J PHARMACOL EXP THER, V297, P638; Paulson SK, 1999, BIOPHARM DRUG DISPOS, V20, P293, DOI 10.1002/(SICI)1099-081X(199909)20:6<293::AID-BDD188>3.0.CO;2-X; Ramana M. V., 2007, Indian Journal of Pharmaceutical Sciences, V69, P390; Rathod S, 2010, INDIAN J PHARM SCI, V72, P155, DOI 10.4103/0250-474X.65014; Saraswat AL, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101477; Segale L, 2015, J DRUG DELIV SCI TEC, V26, P35, DOI 10.1016/j.jddst.2015.02.001; Shakeel Faiyaz, 2008, Journal of Nanobiotechnology, V6, P8, DOI 10.1186/1477-3155-6-8; Shinde CG, 2016, RSC ADV, V6, P12913, DOI 10.1039/c5ra22672d; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022; Ventura CA, 2005, EUR J MED CHEM, V40, P624, DOI 10.1016/j.ejmech.2005.03.001; Vijayakumar MR, 2016, J DRUG DELIV SCI TEC, V33, P125, DOI 10.1016/j.jddst.2016.02.009; Walter MF, 2004, ATHEROSCLEROSIS, V177, P235, DOI 10.1016/j.atherosclerosis.2004.10.001; Zhang JA, 2005, EUR J PHARM BIOPHARM, V59, P177, DOI 10.1016/j.ejpb.2004.06.009	36	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0264518	10.1371/journal.pone.0264518	http://dx.doi.org/10.1371/journal.pone.0264518			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2K2KP	35472207	Green Published, gold			2023-01-03	WOS:000816171900019
J	Dalos, D; Dachs, T; Gatterer, C; Schneider, M; Binder, T; Bonderman, D; Hengstenberg, C; Panzer, S; Aschauer, S				Dalos, Daniel; Dachs, Theresa; Gatterer, Constantin; Schneider, Matthias; Binder, Thomas; Bonderman, Diana; Hengstenberg, Christian; Panzer, Simon; Aschauer, Stefan			Cardiac remodeling in ambitious endurance-trained amateur athletes older than 50 years-an observational study	PLOS ONE			English	Article							DIASTOLIC DYSFUNCTION; EUROPEAN ASSOCIATION; PHYSICAL-ACTIVITY; HEART; EXERCISE; ECHOCARDIOGRAPHY; METAANALYSIS; STRAIN; AGE; RECOMMENDATIONS	BackgroundData on cardiac remodeling in veteran athletes are conflicting but of clinical importance. MethodsSixty-nine clinically stable and healthy individuals >50 years were identified (median 55 (IQR 52-64), 26% female). Echocardiographic features were identified in individuals, who have performed endurance sports at 70% of their maximum heart rate for at least 1 hour 3 times/ week over the previous 5 years. ResultsMedian training time in all participants was 6 hours per week. Therefore, based on these 6 hours of weekly training, participants were grouped into 45 ambitious endurance-trained amateur athletes (EAA) and 24 recreationally active endurance-trained athletes (RAP) training >= 6 hours (6-10) and <6 hours (3.5-5), respectively. Left ventricular (LV) diameters were slightly larger in EAA than in RAP (27 mm/m(2) (25-28) vs. 25 mm/m(2) (24-27), p = 0.023) and EAA showed preserved diastolic function (p = 0.028) with lower E/E' ratio (7 (6-9) vs. 9 (7-10), p = 0.039). Interventricular septal thickness and relative wall thickness ratio were similar. Global right ventricular and LV strain were similar, but left atrial (LA) reservoir strain was higher in EAA than in RAP (27% (22-34) vs. 20% (15-29), p = 0.002). ConclusionsEndurance training in healthy athletes >50 years is not associated with chamber dilatation or LV hypertrophy. A weekly training duration of >= 6 hours seems beneficial to preserve diastolic function associated with an increased LA reservoir function.	[Dalos, Daniel; Dachs, Theresa; Gatterer, Constantin; Schneider, Matthias; Binder, Thomas; Bonderman, Diana; Hengstenberg, Christian; Aschauer, Stefan] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria; [Panzer, Simon] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Aschauer, S (corresponding author), Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria.	stefan.aschauer@meduniwien.ac.at		Schneider, Matthias/0000-0002-6320-3708; Dalos, Daniel/0000-0002-9597-5745; Dachs, Theresa-Marie/0000-0003-3468-7608; Hengstenberg, Christian/0000-0002-8284-2994				[Anonymous], 2021, Eur Heart J, V42, P548, DOI 10.1093/eurheartj/ehaa835; Baggish AL, 2011, CIRCULATION, V123, P2723, DOI 10.1161/CIRCULATIONAHA.110.981571; Banks L, 2020, J AM SOC ECHOCARDIOG, V33, P247, DOI 10.1016/j.echo.2019.09.014; Beaumont A, 2018, CURR CARDIOL REV, V14, P245, DOI 10.2174/1573403X14666180810155513; Beaumont A, 2017, SPORTS MED, V47, P1145, DOI 10.1007/s40279-016-0644-4; Biton Y, 2016, J AM COLL CARDIOL, V67, P303, DOI 10.1016/j.jacc.2015.10.076; Bohm P, 2016, CIRCULATION, V133, P1927, DOI 10.1161/CIRCULATIONAHA.115.020975; Carluccio Erberto, 2018, Circ Cardiovasc Imaging, V11, pe007696, DOI 10.1161/CIRCIMAGING.118.007696; Cuspidi C, 2019, CLIN CARDIOL, V42, P579, DOI 10.1002/clc.23180; D'Andrea A, 2013, INT J CARDIOL, V164, P48, DOI 10.1016/j.ijcard.2011.06.058; Dawes TJW, 2016, CIRC-CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.116.004712; DOUGLAS PS, 1992, J APPL PHYSIOL, V72, P1969, DOI 10.1152/jappl.1992.72.5.1969; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; Dunlay SM, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2017.65; Erz G, 2013, INT J CARDIOVAS IMAG, V29, P325, DOI 10.1007/s10554-012-0082-9; FLEG JL, 1995, JAMA-J AM MED ASSOC, V273, P1371, DOI 10.1001/jama.273.17.1371; FLEG JL, 1995, J APPL PHYSIOL, V78, P890, DOI 10.1152/jappl.1995.78.3.890; Grunig E, 2013, CIRC-CARDIOVASC IMAG, V6, P117, DOI 10.1161/CIRCIMAGING.112.978031; Hood S, 1999, BRIT J SPORT MED, V33, P239, DOI 10.1136/bjsm.33.4.239; Hotta K, 2017, J PHYSIOL-LONDON, V595, P3703, DOI 10.1113/JP274172; Jarasunas J, 2018, CARDIOVASC ULTRASOUN, V16, DOI 10.1186/s12947-018-0147-6; Lancellotti P, 2010, EUR J ECHOCARDIOGR, V11, P307, DOI 10.1093/ejechocard/jeq031; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; Martinez V, 2021, EUR J SPORT SCI, V21, P844, DOI 10.1080/17461391.2020.1789228; McDiarmid AK, 2016, CIRC-CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.115.003579; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Mor-Avi V, 2011, J AM SOC ECHOCARDIOG, V24, P277, DOI 10.1016/j.echo.2011.01.015; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; Nassenstein K, 2009, INT J CARDIOVAS IMAG, V25, P71, DOI 10.1007/s10554-008-9337-x; Naylor LH, 2008, SPORTS MED, V38, P69, DOI 10.2165/00007256-200838010-00006; Pluim BM, 1999, HEART, V81, P612, DOI 10.1136/hrt.81.6.612; Pluim BM, 2000, CIRCULATION, V101, P336, DOI 10.1161/01.CIR.101.3.336; Prasad A, 2007, AM J CARDIOL, V99, P1629, DOI 10.1016/j.amjcard.2007.01.050; ROESKE WR, 1976, CIRCULATION, V53, P286, DOI 10.1161/01.CIR.53.2.286; Santoro A, 2015, ECHOCARDIOGR-J CARD, V32, P920, DOI 10.1111/echo.12791; Santoro A, 2015, INT J CARDIOVAS IMAG, V31, P567, DOI 10.1007/s10554-015-0592-3; Teske AJ, 2009, AM J CARDIOL, V104, P1145, DOI 10.1016/j.amjcard.2009.05.066; Utomi V, 2013, HEART, V99, P1727, DOI 10.1136/heartjnl-2012-303465; Venckunas T, 2008, J SPORT SCI MED, V7, P151; Wasfy MM, 2016, CIRCULATION, V133, P2297, DOI 10.1161/CIRCULATIONAHA.116.018093; Whyte GP, 2004, INT J SPORTS MED, V25, P380, DOI 10.1055/s-2004-817827; Zilinski JL, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.114.002487	43	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	4							e0266951	10.1371/journal.pone.0266951	http://dx.doi.org/10.1371/journal.pone.0266951			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Y6SQ	35413088	gold, Green Published			2023-01-03	WOS:000790519000036
J	Saha, A; Marma, KKS; Rashid, A; Tarannum, N; Das, S; Chowdhury, T; Afrin, N; Chakraborty, P; Emran, M; Mehedi, HMH; Hussain, MI; Barua, A; Mistry, SK				Saha, Ayan; Marma, Kay Kay Shain; Rashid, Afrah; Tarannum, Nowshin; Das, Srabanty; Chowdhury, Tonmoy; Afrin, Nusrat; Chakraborty, Prashanta; Emran, Md; Mehedi, H. M. Hamidullah; Hussain, Mohammad Imdad; Barua, Ashim; Mistry, Sabuj Kanti			Risk factors associated with self-medication among the indigenous communities of Chittagong Hill Tracts, Bangladesh	PLOS ONE			English	Article							ANTIBIOTICS; STUDENTS; PREVALENCE; RESIDENTS; KNOWLEDGE	Background In developing countries like Bangladesh, self-medication has become a predicament associated with health risks and clinical complications. To date, no studies have been conducted on the practice of self-medication among the indigenous population living in Chittagong Hill Tract (CHT). Objectives This study was aimed to determine the prevalence of self-medication and analyzing the factors associated with it among the indigenous population in CHT. Methods This cross-sectional study was conducted from late October to early December 2020; among different indigenous group populations residing in the three districts of CHT aged 18 or more. A pre-tested and semi-structured questionnaire was developed to collect data on socio-demographic characteristics, health status, frequency of self-medication, reasons for self-medication in last one year, as well as other variables. Multivariate logistic regression was performed to assess associated factors with self-medication. Results A total of 1350 people from different indigenous populations were interviewed, among whom 49.9% practiced self-medication. The rate of self-prescribed antibiotics usage (80.9%) was significantly higher compared to other drugs. Self-prescribed medications were mostly used for diarrhea and food poisoning (60.6%), cough, cold and fever (51.4%), and headache (51.4%). A common source of self-prescribed medicines was community or retail pharmacy and the most reported reason for self-prescribed medication was the long-distance of healthcare facilities from home. Conclusion The prevalence of self-medication is substantially high among indigenous people and the effect is alarming. Particular concern is the misuse of antibiotics and analgesic drugs. Increasing awareness among the population of the negative effect of self-medication and implementation of proper policies and actions are urgently needed to prevent self-medication among indigenous population in Bangladesh.	[Saha, Ayan] East West Univ, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh; [Marma, Kay Kay Shain; Afrin, Nusrat] Univ Chittagong, Dept Pharm, Chattogram, Bangladesh; [Rashid, Afrah] Asian Univ Women, Dept Publ Hlth & Bioinformat, Chattogram, Bangladesh; [Tarannum, Nowshin] Univ Chittagong, Dept Microbiol, Chattogram, Bangladesh; [Das, Srabanty] Univ Chittagong, Dept Biochem & Mol Biol, Chattogram, Bangladesh; [Chowdhury, Tonmoy] Rangamati Med Coll, Rangamati, Bangladesh; [Chakraborty, Prashanta] Univ Chittagong, Dept Genet Engn & Biotechnol, Chattogram, Bangladesh; [Emran, Md] Univ Sci & Technol Chittagong, Dept Biochem & Biotechnol, Chattogram, Bangladesh; [Mehedi, H. M. Hamidullah] 250 Beded Gen Hosp, Dept Med, Chattogram, Bangladesh; [Hussain, Mohammad Imdad] Upazila Hlth Complex, Rowangchari, Bandarban, Bangladesh; [Barua, Ashim] Upazila Hlth Complex, Alikadam, Bandarban, Bangladesh; [Mistry, Sabuj Kanti] ARCED Fdn, Dhaka, Bangladesh; [Mistry, Sabuj Kanti] Univ New South Wales, Ctr Primary Hlth Care & Equ, Sydney, NSW, Australia; [Mistry, Sabuj Kanti] Daffodil Int Univ, Dept Publ Hlth, Dhaka, Bangladesh	East West University Bangladesh; University of Chittagong; Asian University for Women; University of Chittagong; University of Chittagong; University of Chittagong; University of Science & Technology Chittagong (USTC); University of New South Wales Sydney; Daffodil International University	Saha, A (corresponding author), East West Univ, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh.	ayan.saha.bd@gmail.com	Saha, Ayan/GZN-0133-2022	Tarannum, Nowshin/0000-0003-3897-4516; Marma, Kay Kay Shain/0000-0003-1383-8534; Rashid, Afrah/0000-0003-3488-0520; , Md. Emran/0000-0001-8938-0406	Chittagong University Research and Higher Study Society (CURHS)	Chittagong University Research and Higher Study Society (CURHS)	This paper is the outcome of one of the projects from the CURHS autumn internship 2020 program. The authors would like to appreciate Chittagong University Research and Higher Study Society (CURHS) for their help and support.	Abdi A, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0231-4; Agresti A., 2007, INTRO CATEGORICAL DA, V2nd; Akter S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237002; Al-Azzam Sayer I., 2007, International Journal of Occupational Medicine and Environmental Health, V20, P373, DOI 10.2478/v10001-007-0038-9; Alghanim S. A., 2011, Eastern Mediterranean Health Journal, V17, P409; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Aziz MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194240; Badiger S, 2012, AUSTRALAS MED J, V5, P217, DOI 10.4066/AMJ.2012.1007; Balamurugan E., 2011, British Journal of Medical Practitioners, V4, pa428; Banskota M, 2000, GROWTH POV ALL SUST; Behzadifar M, 2020, E MEDITERR HEALTH J, V26, P846, DOI 10.26719/emhj.20.052; Berzanskyte Ausra, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P246, DOI [10.2478/v10001-006-0030-9, 10.2478/v10001-006-0030.9]; Bishwajit Sutradhar K., 2014, ANN RES REV BIOL, V4, P1421, DOI [10.9734/ARRB/2014/8184, DOI 10.9734/ARRB/2014/8184]; Biswas M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-847; Conroy R., 2015, SAMPLE SIZE ROUGH GU; Donkor ES, 2012, INT J ENV RES PUB HE, V9, P3519, DOI 10.3390/ijerph9103519; Arrais PSD, 2016, REV SAUDE PUBL, V50, DOI [10.1590/s1518-8787.2016050006117, 10.1590/S1518-8787.2016050006117]; Durgawale PM., 2014, INT J SCI RES, V3, P211; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Fadare J. O., 2011, Journal of Public Health and Epidemiology, V3, P217; Faqihi AHMA, 2021, ANN PHARM FR, V79, P275, DOI 10.1016/j.pharma.2020.10.012; Fernando A D A, 2017, BMC Res Notes, V10, P257, DOI 10.1186/s13104-017-2579-8; Garofalo L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/580650; Garud SK., 2014, INT J SCI RES, V3, P2012; Ghumman SS, 2013, J PAK MED ASSOC, V63, P1210; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Gyawali S, 2015, J CLIN DIAGN RES, V9, pFC17, DOI 10.7860/JCDR/2015/16553.6988; Helal RM, 2017, J ENVIRON PUBLIC HEA, V2017, DOI 10.1155/2017/9145193; Horumpende PG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206623; Hossain S, 2018, 5 INT C NATURAL SCI, P70; Ira IJ, 2015, PHARMA INNOV, V4, P87; IWGIA. Bangladesh-IWGIA-International Work Group for Indigenous Affairs, 2020, IWG; Jafari Faranak, 2015, Glob J Health Sci, V7, P360, DOI 10.5539/gjhs.v7n2p360; Jalilian F, 2013, J RES HEALTH SCI, V13, P81; Jamhour A, 2017, AM J INFECT CONTROL, V45, P384, DOI 10.1016/j.ajic.2016.11.026; Jember E, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4195-2; Khan TA., 2014, J CONT MED DENT, V2, P65; Kumar N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072247; Lennox C, 2016, ROUT INT HANDB, P1; Lukovic JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114644; Marak A., 2016, INT J MED SCI PUBLIC, V5, P1134; Martins AP, 2002, PHARMACOEPIDEM DR S, V11, P409, DOI 10.1002/pds.711; Mok CZ, 2021, INT J PHARM PRACT, V29, P29, DOI 10.1111/ijpp.12660; Moonajilin MS, 2020, INT J PUBLIC HEAL RE, V10; Moonajilin MS, 2020, RISK MANAG HEALTHC P, V13, P743, DOI 10.2147/RMHP.S256272; Mortazavi SS, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0596-z; Nasir M., 2020, INT J BASIC CLIN PHA, V9, P1325, DOI DOI 10.18203/2319-2003.IJBCP20203522; Nepal G, 2018, CUREUS, V10, DOI 10.7759/cureus.2428; Ngo TT, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8734615; Nusair MB, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13665; Ocan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2109-3; Ocan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092323; Okyay RA, 2017, PEERJ, V5, DOI 10.7717/peerj.3990; Organization WH, 2000, WHOEDMQSM001; Paudel S, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08860-w; Pons ED, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189098; Seam MOR, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6010006; Selvaraj Kalaiselvi, 2014, Perspect Clin Res, V5, P32, DOI 10.4103/2229-3485.124569; Shankar P R, 2002, BMC Fam Pract, V3, P17, DOI 10.1186/1471-2296-3-17; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; Subashini N, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08622-8; Tabassum R, 2016, S E ASIA J PUBLIC HE, V6, P17, DOI [10.3329/seajph.v6i2.31831, DOI 10.3329/SEAJPH.V6I2.31831]; Ha TV, 2019, J MULTIDISCIP HEALTH, V12, P493, DOI 10.2147/JMDH.S211420; Wijesinghe Pushpa R, 2012, WHO South East Asia J Public Health, V1, P28, DOI 10.4103/2224-3151.206911; Zafar Syed Nabeel, 2008, J Pak Med Assoc, V58, P214; Zardosht M, 2016, GLOBAL J HLTH SCI, V8, P150, DOI [10.5539/gjhs.v8n11p150, DOI 10.5539/GJHS.V8N11P150]	66	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269622	10.1371/journal.pone.0269622	http://dx.doi.org/10.1371/journal.pone.0269622			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2RM	35696405	Green Published, gold			2023-01-03	WOS:000843575700038
J	Vassilopoulos, A; Mylonakis, E				Vassilopoulos, Athanasios; Mylonakis, Eleftherios			In patients with COVID-19 at risk for severe disease, nirmatrelvir plus ritonavir reduced hospitalization or death	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Vassilopoulos, Athanasios] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA; Brown Univ, Miriam Hosp, Alpert Med Sch, Providence, RI USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Miriam Hospital	Vassilopoulos, A (corresponding author), Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA.							COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; Owen DR, 2021, SCIENCE, V374, P1586, DOI 10.1126/science.abl4784	2	0	0	7	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2022	175	6					JC63	JC63		10.7326/J22-0038	http://dx.doi.org/10.7326/J22-0038		JUN 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3J5DE	35667068				2023-01-03	WOS:000809493500001
J	Xiao, L; Niu, LQ; Zhang, XM; Liu, XZ; Liu, XQ; Sun, CX; Yang, XK				Xiao, Lu; Niu, Liqing; Zhang, Xuemin; Liu, Xuezheng; Liu, Xinqiao; Sun, Chongxiang; Yang, Xiaokun			Comparative efficacy of Chinese herbal injections for treating severe pneumonia: A protocol for systematic review and Bayesian network meta-analysis of randomized controlled trials	PLOS ONE			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; XUEBIJING INJECTION; THORACIC-SOCIETY; CORTICOSTEROIDS; COVID-19; ADULTS	Background Severe pneumonia (SP) has a high mortality and is responsible for significant healthcare cost. Chinese herbal injections (CHIs) have been widely used in China as a novel and promising treatment option for SP. Therefore, this study will assess and rank the effectiveness of CHIs to provide more sights for the selection of SP treatment. Method Seven databases will be searched, including PubMed, the Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database, and the Chinese Scientific Journal Database (VIP) from their inception up to October, 2021. The literatures screening, data extraction and the quality assessment of included studies will be conducted independently by two reviewers. Then Bayesian network meta-analysis (NMA) will be performed by WinBUGS 14.0 and STATA 14.0 software. Surface under the cumulative ranking curve (SUCRA) probability values will be applied to rank the examined treatments. The risk of bias of each included study will be evaluated using the Revised Cochrane risk-of-bias tool for randomized trials (ROB 2). Publication bias will be reflected by a funnel plot. Results The results of this NMA will be disseminated through a peer-reviewed journal publication. Conclusion Our study findings maybe reveal which CHI or CHIs will be better in the treatment of SP and provide more therapy strategies for clinical practitioners and patients.	[Xiao, Lu; Niu, Liqing; Zhang, Xuemin; Liu, Xuezheng; Liu, Xinqiao; Sun, Chongxiang; Yang, Xiaokun] Tianjin Univ Tradit Chinese Med, Emergency Dept, Teaching Hosp 1, Tianjin, Tianjin Provinc, Peoples R China; [Xiao, Lu; Niu, Liqing; Zhang, Xuemin; Liu, Xuezheng; Liu, Xinqiao; Sun, Chongxiang; Yang, Xiaokun] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Tianjin Provinc, Peoples R China; [Xiao, Lu; Liu, Xuezheng; Liu, Xinqiao] Tianjin Univ Tradit Chinese Med, State Key Lab Multifract Tradit Chinese Med, Tianjin, Tianjin Provinc, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Liu, XQ (corresponding author), Tianjin Univ Tradit Chinese Med, Emergency Dept, Teaching Hosp 1, Tianjin, Tianjin Provinc, Peoples R China.; Liu, XQ (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Tianjin Provinc, Peoples R China.; Liu, XQ (corresponding author), Tianjin Univ Tradit Chinese Med, State Key Lab Multifract Tradit Chinese Med, Tianjin, Tianjin Provinc, Peoples R China.	13821150112@163.com	Zhang, Xuemin/HDN-2424-2022	Zhang, Xuemin/0000-0002-2473-5883; Niu, Liqing/0000-0002-3115-178X	National Program on Key Basic Research Project (973 Program) [2009CB522702]; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine [201928]	National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); First Teaching Hospital of Tianjin University of Traditional Chinese Medicine	This work is supported by the support program of National Program on Key Basic Research Project (973 Program, No.2009CB522702) and First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (No.201928). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliberti S, 2019, J INFECTION, V79, P300, DOI 10.1016/j.jinf.2019.07.004; Bi JR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165942; Brignardello-Petersen R, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3900; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chiavaroli L, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019438; Deng Z, 2021, CHIN J CLIN RATION D, V14, P71; [刁云锋 Diao Yunfeng], 2017, [中草药, Chinese Traditional and Herbal Drugs], V48, P1188; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Fan XC, 2018, HEBEI MED CHIN, V24, P1656, DOI [10.3969/j.issn.1006-6233.2018.10.018, DOI 10.3969/J.ISSN.1006-6233.2018.10.018]; Garnacho-Montero J, 2018, EXPERT REV ANTI-INFE, V16, P667, DOI 10.1080/14787210.2018.1512403; Garnacho-Montero J, 2010, SCAND J INFECT DIS, V42, P185, DOI 10.3109/00365540903418522; Guo H, 2020, ANN PALLIAT MED, V9, P3235, DOI 10.21037/apm-20-1478; Hansen V, 2016, JAMA-J AM MED ASSOC, V316, P2149, DOI 10.1001/jama.2016.12423; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2015, LANCET, V386, P628, DOI 10.1016/S0140-6736(15)61478-7; Huang XY, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153009; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Jin LR, 2020, REV ASSOC MED BRAS, V66, P771, DOI 10.1590/1806-9282.66.6.771; Lanks CW, 2019, MED CLIN N AM, V103, P487, DOI 10.1016/j.mcna.2018.12.008; Luo ZJ, 2021, EUR J INTEGR MED, V42, DOI 10.1016/j.eujim.2021.101305; Lv SJ, 2017, EUR J TRAUMA EMERG S, V43, P711, DOI 10.1007/s00068-016-0713-2; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; Mizgerd JP, 2017, CURR OPIN PULM MED, V23, P193, DOI [10.1097/MCP.0000000000000365, 10.1097/mcp.0000000000000365]; Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885; Prina E, 2015, LANCET, V386, P1097, DOI 10.1016/S0140-6736(15)60733-4; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Qi F, 2011, J TRADIT CHIN MED, V31, P46, DOI 10.1016/S0254-6272(11)60011-3; Qu J M, 2016, Zhonghua Jie He He Hu Xi Za Zhi, V39, P241, DOI 10.3760/cma.j.issn.1001-0939.2016.04.001; Restrepo MI, 2010, CHEST, V137, P552, DOI 10.1378/chest.09-1547; Riley RD, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3932; Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shi NN, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153367; Shim S, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017047; Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tomlinson A, 2019, EVID-BASED MENT HEAL, V22, P61, DOI 10.1136/ebmental-2019-300087; Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88; Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222; Wan YD, 2016, CHEST, V149, P209, DOI 10.1378/chest.15-1733; Welte T, 2016, MED KLIN-INTENSIVMED, V111, P279, DOI 10.1007/s00063-016-0165-9; Yang WF, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2231-8; Yang Z, 2014, BEIJING J TRADIT CHI, V33, P894, DOI DOI 10.16025/J.1674-1307.2014.12.004; Yuan Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.610745; Zhou DR, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024905	49	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2022	17	5							e0262776	10.1371/journal.pone.0262776	http://dx.doi.org/10.1371/journal.pone.0262776			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6F6EK	35604894	gold, Green Published			2023-01-03	WOS:000884151300001
J	Dorabawila, V; Hoefer, D; Bauer, UE; Bassett, MT; Lutterloh, E; Rosenberg, ES				Dorabawila, Vajeera; Hoefer, Dina; Bauer, Ursula E.; Bassett, Mary T.; Lutterloh, Emily; Rosenberg, Eli S.			Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter; Early Access								This database study examines vaccination for COVID-19 among children in New York after the emergence of the Omicron variant, including analysis of case rates and hospitalizations for COVID-19 disease.	[Dorabawila, Vajeera; Hoefer, Dina; Bauer, Ursula E.; Bassett, Mary T.; Lutterloh, Emily; Rosenberg, Eli S.] New York State Dept Hlth, Albany, NY 12237 USA	State University of New York (SUNY) System	Dorabawila, V (corresponding author), Bur Surveillance & Data Syst BSDS, Div Epidemiol, Corning Tower Room 754,Empire State Plaza, Albany, NY 12237 USA.	vajeera.dorabawila@health.ny.gov	Dorabawila, Vajeera/GNP-4756-2022					[Anonymous], DEMOGRAPHIC TRENDS C; Fowlkes AL, 2022, MMWR-MORBID MORTAL W, V71, P422, DOI [10.15585/mmwr.mm7111e1, 10.1101/2021.12.10.21267408v3]; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Reis B, 2021, NEW ENGL J MED, V385, P2101, DOI 10.1056/NEJMc2114290; Rosenberg ES, 2022, NEW ENGL J MED, V386, P116, DOI 10.1056/NEJMoa2116063; Walter EB, 2022, NEW ENGL J MED, V386, P35, DOI 10.1056/NEJMoa2116298	6	16	16	2	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.7319	http://dx.doi.org/10.1001/jama.2022.7319		MAY 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1F1GI	35559959	Bronze, Green Published			2023-01-03	WOS:000794922900003
J	Batista, AM; Gama, ZAD; Souza, D				Batista, Almaria Mariz; da Silva Gama, Zenewton Andre; Souza, Dyego			Validation of the QualiPresc instrument for assessing the quality of drug prescription writing in primary health care	PLOS ONE			English	Article							CONTENT VALIDITY; SAFETY; INDICATORS; AGREEMENT; INTERVENTIONS; FREQUENCY; EVENTS	Introduction Adverse events related to drug prescriptions are the main patient safety issue in primary care; however there is a lack of validated instruments for assessing the quality of prescription writing, which covers the prescriber, the patient and the drug information. Objective To develop and validate the QualiPresc instrument to assess and monitor the quality of drug prescriptions in primary care, accompanied by a self-instruction direction, with the goal of filling the gap in validated instruments to assess the quality of prescription writing. Methodology A validation study conducted in a municipality in Northeastern Brazil, based on prescriptions prepared in January 2021 by physicians assigned to 18 Basic Health Units and filed in 6 distribution/dispensing units. Four steps were covered: 1) Analysis of content validity of each indicator (relevance and adequacy); 2) Analysis of reliability via intra and inter-rater agreement of each indicator; 3) Analysis of the utility of each indicator; 4) Construction and analysis of the reliability of a weighted composite indicator based on effectiveness and safety scores for each indicator. Results Twenty-nine potential indicators were listed, but only 13 were approved for validity, reliability and usefulness. Twelve indicators were excluded because of validity (<90% validity index) and four because they were not useful in the context of the study. Three weighted composite indicators were tested, but only one was approved for reliability and usefulness. The validated instrument therefore contains 13 indicators and 1 weighted composite indicator. Conclusion This study demonstrates the validity, reliability and usefulness of QualiPresc for the evaluation of prescription writing in the context of primary care. Application to contexts such as secondary care and tertiary care requires cross-cultural adaptation and new content validity. Educators, managers and health care professionals can access QualiPresc online, free of charge, to assess performance and provide feedback involving drug prescribers.	[Batista, Almaria Mariz] Univ Fed Rio Grande do Norte, Escola Multicampi Ciencias Med, Caico, Brazil; [Batista, Almaria Mariz; Souza, Dyego] Univ Fed Rio Grande do Norte, Programa Posgrad Ciencias Saude, Natal, RN, Brazil; [da Silva Gama, Zenewton Andre; Souza, Dyego] Univ Fed Rio Grande do Norte, Dept Saude Colet, Natal, RN, Brazil; [Batista, Almaria Mariz] Univ Fed Rio Grande do Norte, Escola Multicampi Ciencias Med Rio Grande do Nort, Caico, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	Batista, AM (corresponding author), Univ Fed Rio Grande do Norte, Escola Multicampi Ciencias Med, Caico, Brazil.; Batista, AM (corresponding author), Univ Fed Rio Grande do Norte, Programa Posgrad Ciencias Saude, Natal, RN, Brazil.; Batista, AM (corresponding author), Univ Fed Rio Grande do Norte, Escola Multicampi Ciencias Med Rio Grande do Nort, Caico, RN, Brazil.	almariamariz@yahoo.com.br			Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study received financial support from the Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES).	Al-Worafi YM, 2018, MED PRIN PRACT, V27, P290, DOI 10.1159/000487307; Andersen M, 2006, BASIC CLIN PHARMACOL, V98, P314, DOI 10.1111/j.1742-7843.2006.pto_411.x; [Anonymous], 2021, B ISMP BRAS, V10, P1; [Anonymous], 2002, RESOLUCAO WHA55 18 A; Avery AJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588501; Avila Maria Laura, 2015, BMC Res Notes, V8, P612, DOI 10.1186/s13104-015-1561-6; BARBER N, 1995, BRIT MED J, V310, P923, DOI 10.1136/bmj.310.6984.923; Barclay M, 2019, BMJ QUAL SAF, V28, P338, DOI 10.1136/bmjqs-2018-007798; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bousquat A, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00037316, 10.1590/0102-311x00037316]; BRASIL. Ministerio da Saude, 2013, PROT SEG PRESCR US A; Brown CL, 2017, J AM MED INFORM ASSN, V24, P432, DOI 10.1093/jamia/ocw119; Cantrill JA, 1998, QUAL HEALTH CARE, V7, P130, DOI 10.1136/qshc.7.3.130; Cohen MR, 1999, MED ERRORS; Alexandre NMC, 2011, CIENC SAUDE COLETIVA, V16, P3061, DOI 10.1590/S1413-81232011000800006; da Silva EF, 1998, REV SAUDE PUBL, V32, P383, DOI 10.1590/S0034-89101998000400012; Dean B, 2000, QUAL HEALTH CARE, V9, P232, DOI 10.1136/qhc.9.4.232; Dreischulte Tobias, 2012, BMC Clin Pharmacol, V12, P5, DOI 10.1186/1472-6904-12-5; Duncan BB, 2004, MED AMBULATORIAL CON, V3; Dyasanoor S, 2016, J CLIN DIAGN RES, V10, pZC61, DOI 10.7860/JCDR/2016/18011.7472; European Medicine Agency, 2009, GUID READ LAB PACK L; Figueiras A, 2001, J EVAL CLIN PRACT, V7, P223, DOI 10.1046/j.1365-2753.2001.00234.x; IBGE. Instituto Brasileiro de Geografia e Estatistica, CENS DEM BRAS; Imran M, 2020, DARU, V28, P25, DOI 10.1007/s40199-018-00236-1; Joshi A, 2016, J CLIN DIAGN RES, V10, pFC1, DOI 10.7860/JCDR/2016/17896.7911; Lainer M, 2013, INT J QUAL HEALTH C, V25, P590, DOI 10.1093/intqhc/mzt043; Marchon SG, 2014, CAD SAUDE PUBLICA, V30, P1815, DOI 10.1590/0102-311X00114113; Medeiros SG, 2019, REV APS, V22, P423, DOI [10.34019/1809-8363.2019.v22.16743, DOI 10.34019/1809-8363.2019.V22.16743]; Meyer TA, 2000, AM J HEALTH-SYST PH, V57, pS18, DOI 10.1093/ajhp/57.suppl_4.S18; Montserrat-Capella D, 2015, INT J QUAL HEALTH C, V27, P52, DOI 10.1093/intqhc/mzu100; OECD. Organisation for Economic Co-operation and Development, 2018, EC PAT SAF PRIM AMB; Olaniyan Janice O, 2015, Int J Pharm Pract, V23, P3, DOI 10.1111/ijpp.12120; OPAS/OMS, 1995, PAP FARM AT SAL INF; Panesar S, 2008, PROSPERO, V2012; Panesar SS, 2016, BMJ QUAL SAF, V25, P544, DOI 10.1136/bmjqs-2015-004178; Pasquali L., 1998, REV PSIQUIATR CLIN, V25, P206; Pedroso ERP, 2007, BLACKBOOK CLIN MED, V1; Polit D.F., 2004, FUNDAMENTOS PESQUISA; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Prgomet M, 2017, J AM MED INFORM ASSN, V24, P413, DOI 10.1093/jamia/ocw145; Paumgartten FJR, 2020, CIENC SAUDE COLETIVA, V25, P3413, DOI 10.1590/1413-81232020259.16792020; Rosa MB, 2019, REV ASSOC MED BRAS, V65, P1349, DOI 10.1590/1806-9282.65.11.1349; Sarkar U, 2016, BMJ QUAL SAF, V25, P477, DOI 10.1136/bmjqs-2015-005006; Saturno-Hernandez PJ, 2015, METODOS HERRAMIENTAS; Silva Junior FC, 2019, INFARMA CIEN FARM, V31, ppp271, DOI [10.14450/2318-9312.v31.e4.a2019, DOI 10.14450/2318-9312.V31.E4.A2019]; Silva LSN, INFARMA CIEN FARM, V33, ppp167, DOI [10.14450/2318-9312.v33.e2.a2021, DOI 10.14450/2318-9312.V33.E2.A2021]; Neto JJS, 2016, CIENC SAUDE COLETIVA, V21, P2709, DOI 10.1590/1413-81232015219.16432016; Spencer R, 2014, BRIT J GEN PRACT, V64, pE181, DOI 10.3399/bjgp14X677806; The Heads of Medicines Agencies Co-ordination Group for Mutual Recognition and Decentralised Pro-cedures-Human, 2011, POS PAP US TEST PACK; The Joint Commission, FACTS OFF DO NOT US; Tully MP, 2006, INT J QUAL HEALTH C, V18, P87, DOI 10.1093/intqhc/mzi084; Varghese Naveen Jacob, 2018, J Nat Sci Biol Med, V9, P27, DOI 10.4103/jnsbm.JNSBM_108_17; Weldemariam DG, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05418-9; Wessell AM, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.034678; WHO. World Health Organization, 1993, INVESTIGATE DRUG USE; WHO. World Health Organization, 2012, SAF PRIM CAR GLOB CH; WHO. World Health Organization, 2010, MED RAT US MED; WHO. World Health Organization, 1994, GUIDE GOOD PRESCRIBI; WHO. World Health Organization, 2018, DEL QUAL HLTH SERV G; WILLIAMS PL, 1994, J ADV NURS, V19, P180, DOI 10.1111/j.1365-2648.1994.tb01066.x; World Health Organization, 2019, MENT HOLIST HLTH SOM; World Health Organization, 2017, MED HARM GLOB PAT SA	64	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2022	17	5							e0267707	10.1371/journal.pone.0267707	http://dx.doi.org/10.1371/journal.pone.0267707			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O1VP	35544534	gold, Green Published			2023-01-03	WOS:000818854500035
J	Li, T; Jiang, CC; Smith, FG				Li, Ting; Jiang, Chenchen; Smith, Fang Gao			Regional vs General Anesthesia and Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Li, Ting] Wenzhou Med Univ, Dept Anesthesiol & Perioperat Med, Affiliated Hosp 2, Wenzhou, Peoples R China; [Li, Ting; Jiang, Chenchen] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Jiang, Chenchen] Wenzhou Med Univ, Clin Res Unit, Affiliated Hosp 2, Wenzhou, Peoples R China; [Smith, Fang Gao] Univ Birmingham, Inst Inflammat & Aging, Birmingham, W Midlands, England	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; University of Birmingham	Smith, FG (corresponding author), Univ Birmingham, Birmingham Acute Care Res Ctr, Inst Inflammat & Ageing, Birmingham Univ Res Labs, Birmingham B15 2WB, W Midlands, England.	f.gaosmith@bham.ac.uk						GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Li T, 2022, JAMA-J AM MED ASSOC, V327, P50, DOI 10.1001/jama.2021.22647; National Institute for Health and Care Excellence, CG103 NICE; National Institute for Health Research Health Technology Assessment, DEV VAL 4AT NEW RAP; White SM, 2014, ANAESTHESIA, V69, P224, DOI 10.1111/anae.12542; Wildes TS, 2019, JAMA-J AM MED ASSOC, V321, P473, DOI 10.1001/jama.2018.22005	6	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2022	327	17					1708	1709						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1D3AC	35503348				2023-01-03	WOS:000793675300027
J	Squair, JW; Berney, M; Jimenez, MC; Hankov, N; Demesmaeker, R; Amir, S; Paley, A; Hernandez-Charpak, S; Dumont, G; Asboth, L; Allenbach, G; Becce, F; Schoettker, P; Wuerzner, G; Bally, JF; Courtine, G; Bloch, J				Squair, Jordan W.; Berney, Maxime; Jimenez, Mayte Castro; Hankov, Nicolas; Demesmaeker, Robin; Amir, Suje; Paley, Aurelie; Hernandez-Charpak, Sergio; Dumont, Gregory; Asboth, Leonie; Allenbach, Gilles; Becce, Fabio; Schoettker, Patrick; Wuerzner, Gregoire; Bally, Julien F.; Courtine, Gregoire; Bloch, Jocelyne			Implanted System for Orthostatic Hypotension in Multiple-System Atrophy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATERAL HORN CELLS; CATECHOLAMINERGIC NEURONS	Orthostatic hypotension is a cardinal feature of multiple-system atrophy. The upright posture provokes syncopal episodes that prevent patients from standing and walking for more than brief periods. We implanted a system to restore regulation of blood pressure and enable a patient with multiple-system atrophy to stand and walk after having lost these abilities because of orthostatic hypotension. This system involved epidural electrical stimulation delivered over the thoracic spinal cord with accelerometers that detected changes in body position.	[Squair, Jordan W.; Hankov, Nicolas; Demesmaeker, Robin; Amir, Suje; Paley, Aurelie; Hernandez-Charpak, Sergio; Dumont, Gregory; Asboth, Leonie; Courtine, Gregoire; Bloch, Jocelyne] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Ctr Neuroprosthet, Lausanne, Switzerland; [Squair, Jordan W.; Hankov, Nicolas; Demesmaeker, Robin; Amir, Suje; Paley, Aurelie; Hernandez-Charpak, Sergio; Dumont, Gregory; Asboth, Leonie; Courtine, Gregoire; Bloch, Jocelyne] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Brain Mind Inst, Sch Life Sci, Lausanne, Switzerland; [Squair, Jordan W.; Demesmaeker, Robin; Amir, Suje; Paley, Aurelie; Hernandez-Charpak, Sergio; Dumont, Gregory; Asboth, Leonie; Courtine, Gregoire; Bloch, Jocelyne] Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland; [Squair, Jordan W.; Courtine, Gregoire; Bloch, Jocelyne] Lausanne Univ Hosp CHUV, Serv Neurosurg, Lausanne, Switzerland; [Berney, Maxime; Wuerzner, Gregoire] Lausanne Univ Hosp CHUV, Serv Nephrol & Hypertens, Lausanne, Switzerland; [Jimenez, Mayte Castro; Bally, Julien F.] Lausanne Univ Hosp CHUV, Serv Neurol, Lausanne, Switzerland; [Becce, Fabio] Lausanne Univ Hosp CHUV, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland; [Schoettker, Patrick] Lausanne Univ Hosp CHUV, Serv Anesthesiol, Lausanne, Switzerland; [Squair, Jordan W.; Berney, Maxime; Hankov, Nicolas; Demesmaeker, Robin; Amir, Suje; Paley, Aurelie; Hernandez-Charpak, Sergio; Dumont, Gregory; Asboth, Leonie; Schoettker, Patrick; Courtine, Gregoire; Bloch, Jocelyne] Univ Lausanne UNIL, Defitech Ctr Intervent Neurotherapies Neurorestor, EPFL, CHUV,UNIL, Lausanne, Switzerland; [Allenbach, Gilles] CHU Vaudois, Dept Nucl Med & Mol Imaging, Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bloch, J (corresponding author), Dept Clin Neurosci, Serv Neurosurg, BH08-633,Rue Bugnon 46, CH-1011 Lausanne, Switzerland.; Courtine, G (corresponding author), Swiss Fed Inst Technol, Brain Mind Inst, Ctr Neuroprosthet B3 3, 9 Chemin Mines, CH-1202 Geneva, Switzerland.	gregoire.courtine@epfl.ch; jocelyne.bloch@chuv.ch	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; Castro-Jimenez, Mayte/0000-0003-4165-4804; Hernandez Charpak, Sergio Daniel/0000-0003-0477-8138; courtine, gregoire/0000-0002-5744-4142; Asboth, Leonie/0000-0003-2414-9574	Defitech Foundation	Defitech Foundation	Supported by the Defitech Foundation	Benarroch EE, 1998, ANN NEUROL, V43, P156, DOI 10.1002/ana.410430205; Claassen DO, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1129-x; Fanciulli A, 2015, NEW ENGL J MED, V372, P249, DOI 10.1056/NEJMra1311488; Figueroa JJ, 2014, MOVEMENT DISORD, V29, P1151, DOI 10.1002/mds.25927; GRAY F, 1988, ACTA NEUROPATHOL, V75, P513, DOI 10.1007/BF00687140; KATO S, 1995, J NEUROL SCI, V132, P216, DOI 10.1016/0022-510X(95)00155-U; Nishie M, 2004, ACTA NEUROPATHOL, V107, P292, DOI 10.1007/s00401-003-0811-1; O'Sullivan SS, 2008, BRAIN, V131, P1362, DOI 10.1093/brain/awn065; OPPENHEIMER DR, 1980, J NEUROL SCI, V46, P393, DOI 10.1016/0022-510X(80)90064-7; Rowald A., NAT MED; Schultz DM, 2012, PAIN PHYSICIAN, V15, P1; Squair JW, 2021, NATURE, V590, DOI 10.1038/s41586-020-03180-w; Stefanova N, 2009, LANCET NEUROL, V8, P1172, DOI 10.1016/S1474-4422(09)70288-1; Watanabe H, 2002, BRAIN, V125, P1070, DOI 10.1093/brain/awf117	14	6	6	8	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2022	386	14					1339	1344		10.1056/NEJMoa2112809	http://dx.doi.org/10.1056/NEJMoa2112809			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1T9JP	35388667				2023-01-03	WOS:000805040200009
J	Schreiber, K; Decouture, B; Lafragette, A; Chollet, S; Bruneau, M; Nicollet, M; Wittmann, C; Gadrat, F; Mansour, A; Forest-Villegas, P; Gauthier, O; Touzot-Jourde, G				Schreiber, Kevin; Decouture, Benoit; Lafragette, Audrey; Chollet, Stephane; Bruneau, Marine; Nicollet, Maxence; Wittmann, Catherine; Gadrat, Francis; Mansour, Alexandre; Forest-Villegas, Patricia; Gauthier, Olivier; Touzot-Jourde, Gwenola			A novel autotransfusion device saving erythrocytes and platelets used in a 72 h survival swine model of surgically induced controlled blood loss	PLOS ONE			English	Article							CELL TRANSFUSION; CARDIOPULMONARY BYPASS; COAGULATION; SALVAGE; PORCINE; COST; COAGULOPATHY; HEMORRHAGE; PRODUCTS; PROGRAM	Background The purpose of this study was to develop a swine model of surgically induced blood loss to evaluate the performances of a new autotransfusion system allowing red blood cells and platelets preservation while collecting, washing and concentrating hemorrhagic blood intraoperatively. Methods Two types of surgically induced blood loss were used in 12 minipigs to assess system performance and potential animal complications following autotransfusion: a cardiac model (cardiopulmonary bypass) and a visceral model (induced splenic bleeding). Animal clinical and hematological parameters were evaluated at different time-points from before bleeding to the end of a 72-hour post-transfusion period and followed by a post-mortem examination. System performances were evaluated by qualitative and quantitative parameters. Results All animals that received the autotransfusion survived. Minimal variations were seen on the red blood cell count, hemoglobin, hematocrit at the different sampling times. Coagulation tests failed to show any hypo or hypercoagulable state. Gross and histologic examination didn't reveal any thrombotic lesions. Performance parameters exceeded set objectives in both models: heparin clearance (>= 90%), final heparin concentration (<= 0.5 IU/mL), free hemoglobin washout (>= 90%) and hematocrit (between 45% and 65%). The device treatment rate of diluted blood was over 80 mL/min. Conclusions In the present study, both animal models succeeded in reproducing clinical conditions of perioperative cardiac and non-cardiac blood loss. Sufficient blood was collected to allow evaluation of autotransfusion effects on animals and to demonstrate the system performance by evaluating its capacity to collect, wash and concentrate red blood cells and platelets. Reinfusion of the treated blood, containing not only concentrated red blood cells but also platelets, did not lead to any postoperative adverse nor thrombogenic events. Clinical and comparative studies need to be conducted to confirm the clinical benefit of platelet reinfusion.	[Schreiber, Kevin; Lafragette, Audrey; Gauthier, Olivier; Touzot-Jourde, Gwenola] Oniris Nantes Atlantic Coll Vet Med Food Sci & En, Ctr Res & Preclin Invest, CRIP, Nantes, France; [Decouture, Benoit; Chollet, Stephane; Bruneau, Marine; Nicollet, Maxence; Wittmann, Catherine; Gadrat, Francis; Forest-Villegas, Patricia] I SEP, Nantes, France; [Mansour, Alexandre] Univ Rennes, Inserm CIC Ctr Invest Clin Rennes 1414, Dept Anesthesiol Crit Care Med & Perioperat Med, CHU Rennes, Rennes, France; [Gauthier, Olivier; Touzot-Jourde, Gwenola] Univ Nantes, ONIRIS, UMRS RMeS Regenerat Med & Skeleton 1229, INSERM, Nantes, France	Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; CHU Rennes; Universite de Rennes; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Touzot-Jourde, G (corresponding author), Oniris Nantes Atlantic Coll Vet Med Food Sci & En, Ctr Res & Preclin Invest, CRIP, Nantes, France.; Touzot-Jourde, G (corresponding author), Univ Nantes, ONIRIS, UMRS RMeS Regenerat Med & Skeleton 1229, INSERM, Nantes, France.	gwenola.touzot-jourde@oniris-nantes.fr		Touzot-Jourde, Gwenola/0000-0001-9176-0715	BPi France (French Public Bank for investments) [PSPC-402492]	BPi France (French Public Bank for investments)	The study was funded by BPi France (French Public Bank for investments) by the grant PSPC-402492 (BPI grants for structuring competitive research and development). The grant was awarded to the consortium Isep/Oniris/Universite ' de Rennes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Association of Blood Banks (AABB), 2021, STAND PER AUT BLOOD, V9th; Amin M, 2004, TRANSFUSION, V44, P1479, DOI 10.1111/j.1537-2995.2004.04065.x; [Anonymous], 2020, 109931 ISO; [Anonymous], 2017, 1099342017 ISO; Beckett Andrew, 2015, Can J Surg, V58, pS153; Biagini Silvana, 2014, Rev. bras. ter. intensiva, V26, P287, DOI 10.5935/0103-507X.20140040; Bode G, 2010, J PHARMACOL TOX MET, V62, P196, DOI 10.1016/j.vascn.2010.05.009; Boer C, 2018, J CARDIOTHOR VASC AN, V32, P88, DOI 10.1053/j.jvca.2017.06.026; Callum JL, 2014, TRANSFUSION, V54, P2344, DOI 10.1111/trf.12802; Carless PA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001888.pub3; Clemetson KJ, 2012, THROMB RES, V129, P220, DOI 10.1016/j.thromres.2011.11.036; Davidson AJ, 2017, J SURG RES, V218, P306, DOI 10.1016/j.jss.2017.06.045; De Somer F, 2019, PERFUSION-UK, V34, P318, DOI 10.1177/0267659118819927; Di Dedda U, 2018, CLIN HEMORHEOL MICRO, V70, P327, DOI 10.3233/CH-180391; EDQM, 2020, GUIDE PREPARATION US, V20th ed.; Filos KS, 1996, CRIT CARE MED, V24, P855, DOI 10.1097/00003246-199605000-00021; Freedman J, 2014, TRANSFUS APHER SCI, V50, P32, DOI 10.1016/j.transci.2013.12.010; GAYDOS LA, 1962, NEW ENGL J MED, V266, P905, DOI 10.1056/NEJM196205032661802; Gourlay T, 2018, J ROY ARMY MED CORPS, V164, P96, DOI 10.1136/jramc-2017-000789; Gregoretti S, 1996, TRANSFUSION, V36, P57, DOI 10.1046/j.1537-2995.1996.36196190516.x; HANNON JP, 1992, SWINE AS MODELS IN BIOMEDICAL RESEARCH, P197; Hofer J, 2016, CLIN APPL THROMB-HEM, V22, P505, DOI 10.1177/1076029616651146; Hofbauer N, 2016, J VET EMERG CRIT CAR, V26, P373, DOI 10.1111/vec.12472; Jain NC, 1993, ESSENTIALS VET HEMAT, P417; Kellett-Gregory LM, 2013, J VET EMERG CRIT CAR, V23, P82, DOI 10.1111/vec.12017; Kessler U, 2011, THROMB RES, V128, P477, DOI 10.1016/j.thromres.2011.03.013; KESTIN AS, 1993, BLOOD, V82, P107, DOI 10.1182/blood.V82.1.107.bloodjournal821107; Klein AA, 2018, ANAESTHESIA, V73, P1141, DOI 10.1111/anae.14331; Ledgerwood AM, 2012, J TRAUMA ACUTE CARE, V72, P1714, DOI 10.1097/TA.0b013e318245225c; Lelovas PP, 2014, J AM ASSOC LAB ANIM, V53, P432; Lemke M, 2016, HPB, V18, P428, DOI 10.1016/j.hpb.2016.02.002; Lu M, 2019, J BLOOD MED, V10, P37, DOI 10.2147/JBM.S166316; Mansour A, 2021, ANESTHESIOLOGY, V135, P246, DOI 10.1097/ALN.0000000000003820; Martin RCG, 2005, ANN SURG ONCOL, V12, P1017, DOI 10.1245/ASO.2005.12.018; McCrackin MA, 2016, SWINE IN THE LABORATORY: SURGERY, ANESTHESIA, IMAGING, AND EXPERIMENTAL TECHNIQUES, 3RD EDITION, P1; McQuilten ZK, 2018, TRANSFUS MED REV, V32, P6, DOI 10.1016/j.tmrv.2017.06.003; Meybohm P, 2020, VOX SANG, V115, P182, DOI 10.1111/vox.12873; Meybohm P, 2016, ANN SURG, V264, P203, DOI 10.1097/SLA.0000000000001747; Myers DD, 2016, SWINE IN THE LABORATORY: SURGERY, ANESTHESIA, IMAGING, AND EXPERIMENTAL TECHNIQUES, 3RD EDITION, P213; NAITO K, 1994, ARTIF ORGANS, V18, P7, DOI 10.1111/j.1525-1594.1994.tb03292.x; Naumenko Konstantin S, 2008, Interact Cardiovasc Thorac Surg, V7, P759, DOI 10.1510/icvts.2008.183582; Ni HY, 2003, TRANSFUS APHER SCI, V28, P257, DOI 10.1016/S1473-0502(03)00044-2; O'Brien SF, 2012, VOX SANG, V103, P83, DOI 10.1111/j.1423-0410.2012.01584.x; Olsen AK, 1999, SCAND J LAB ANIM SCI, V26, P214; Paparella D, 2016, SEMIN THROMB HEMOST, V42, P166, DOI 10.1055/s-0035-1569067; Patel NN, 2011, AM J PHYSIOL-RENAL, V301, pF605, DOI 10.1152/ajprenal.00145.2011; Pelagalli A, 2003, J COMP PATHOL, V128, P127, DOI 10.1053/jcpa.2002.0615; Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726; Samolyk KA, 2005, PERFUSION-UK, V20, P343, DOI 10.1191/0267659105pf831oa; Scott BH, 2008, ANN CARD ANAESTH, V11, P15, DOI 10.4103/0971-9784.38444; Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x; Sharma S, 2011, AM FAM PHYSICIAN, V83, P719; Shen SL, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0986-6; Sondeen JL, 2014, J AM ASSOC LAB ANIM, V53, P307; Spinella PC, 2016, CURR OPIN HEMATOL, V23, P536, DOI 10.1097/MOH.0000000000000284; Tretiak R, 1996, CAN MED ASSOC J, V154, P1501; VAGIANOS C, 1990, ACTA CHIR SCAND, V156, P121; Varghese S J, 2005, Med J Armed Forces India, V61, P316, DOI 10.1016/S0377-1237(05)80053-X; Velik-Salchner C, 2006, THROMB RES, V117, P597, DOI 10.1016/j.thromres.2005.05.015; Yarham G, 2011, PERFUSION-UK, V26, P263, DOI 10.1177/0267659111399951; Yoon C, 2014, J ARTIF ORGANS, V17, P118, DOI 10.1007/s10047-013-0745-x; Zhou J, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414-431X20165493, 10.1590/1414-431x20165493]	62	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2022	17	3							e0260855	10.1371/journal.pone.0260855	http://dx.doi.org/10.1371/journal.pone.0260855			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0K7DW	35324911	Green Published, gold			2023-01-03	WOS:000780951300007
J	Bradley, C; Malaia, EA; Siskind, JM; Wilbur, RB				Bradley, Chuck; Malaia, Evie A.; Siskind, Jeffrey Mark; Wilbur, Ronnie B.			Visual form of ASL verb signs predicts non- signer judgment of transitivity	PLOS ONE			English	Article							CLASSIFIER CONSTRUCTIONS; LANGUAGE; ICONICITY	Longstanding cross-linguistic work on event representations in spoken languages have argued for a robust mapping between an event's underlying representation and its syntactic encoding, such that-for example-the agent of an event is most frequently mapped to subject position. In the same vein, sign languages have long been claimed to construct signs that visually represent their meaning, i.e., signs that are iconic. Experimental research on linguistic parameters such as plurality and aspect has recently shown some of them to be visually universal in sign, i.e. recognized by non-signers as well as signers, and have identified specific visual cues that achieve this mapping. However, little is known about what makes action representations in sign language iconic, or whether and how the mapping of underlying event representations to syntactic encoding is visually apparent in the form of a verb sign. To this end, we asked what visual cues non-signers may use in evaluating transitivity (i.e., the number of entities involved in an action). To do this, we correlated non-signer judgments about transitivity of verb signs from American Sign Language (ASL) with phonological characteristics of these signs. We found that non-signers did not accurately guess the transitivity of the signs, but that non-signer transitivity judgments can nevertheless be predicted from the signs' visual characteristics. Further, non-signers cue in on just those features that code event representations across sign languages, despite interpreting them differently. This suggests the existence of visual biases that underlie detection of linguistic categories, such as transitivity, which may uncouple from underlying conceptual representations over time in mature sign languages due to lexicalization processes.	[Bradley, Chuck; Siskind, Jeffrey Mark; Wilbur, Ronnie B.] Purdue Univ, Dept Linguist, W Lafayette, IN 47907 USA; [Malaia, Evie A.] Univ Alabama, Dept Commun Disorders, Tuscaloosa, AL USA; [Siskind, Jeffrey Mark] Purdue Univ, Elmore Family Sch Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Siskind, Jeffrey Mark; Wilbur, Ronnie B.] Purdue Univ, Dept Speech Language & Hearing Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Alabama System; University of Alabama Tuscaloosa; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Bradley, C (corresponding author), Purdue Univ, Dept Linguist, W Lafayette, IN 47907 USA.	charles.roger.bradley@gmail.com	Malaia, Evguenia A/R-2606-2018	Malaia, Evguenia A/0000-0002-4700-0257; Bradley, Chuck/0000-0002-9695-1024	NSF [1734938-IIS, 1932547, 1522954IIS]; IARPA contract [D17PC00341]; NIH [108306]	NSF(National Science Foundation (NSF)); IARPA contract; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Preparation of the manuscript has been partially funded by NSF grant #1734938-IIS, "Neuroimaging to Advance Computer Vision, NLP, and AI" to JMS, EM, and RBW, NSF grant #1932547, "RF Sensing for Sign Language Driven Smart Environments" to EM, NSF grant #1522954IIS, "RobotSLANG: Simultaneous Localization, Mapping, and Language Acquisition" to JMS, IARPA contract #D17PC00341, "Intelligent Video Activity Detection and Recognition" from the Department of Interior/Interior Business Center (DOI/IBC) to JMS, and NIH grant #108306, "Computational methods for the study of American Sign Language nonmanuals using very large databases" to RBW. Any opinions, findings, views, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views, official policies, or endorsements, either expressed or implied, of the sponsors. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes, notwithstanding any copyright notation herein. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronoff M, 2003, PERSPECTIVES ON CLASSIFIER CONSTRUCTIONS IN SIGN LANGUAGES, P53; Baker Mark., 1997, ELEMENTS GRAMMAR, P73, DOI DOI 10.1007/978-94-011-5420-8_2; Battison R., 1978, LEXICAL BORROWING AM; BELLUGI U, 1976, ANN NY ACAD SCI, V280, P514, DOI 10.1111/j.1749-6632.1976.tb25514.x; Benedicto E, 2004, NAT LANG LINGUIST TH, V22, P743, DOI 10.1007/s11049-003-4698-2; Benedicto E, 2007, LINGUA, V117, P1202, DOI 10.1016/j.lingua.2005.06.012; Borstell C., 2017, THESIS STOCKHOLM U; Borstell C, 2019, OPEN LINGUIST, V5, P666, DOI 10.1515/opli-2019-0037; Brentari D, 2001, FOREIGN VOCABULARY IN SIGN LANGUAGES: CROSS-LINGUISTIC INVESTIGATION OF WORD FORMATION, P87; Brentari D., 1998, PROSODIC MODEL SIGN; Brentari D, 2017, LANG ACQUIS, V24, P283, DOI 10.1080/10489223.2016.1187614; Brentari D, 2015, TOP COGN SCI, V7, P95, DOI 10.1111/tops.12123; Brentari D, 2012, NAT LANG LINGUIST TH, V30, P1, DOI 10.1007/s11049-011-9145-1; Caselli NK, 2017, BEHAV RES METHODS, V49, P784, DOI 10.3758/s13428-016-0742-0; Cassell J., 1999, PRAGMATICS COGN, V7, P1, DOI 10.1075/pc.7.1.03cas; de Lint V, 2018, SIGN LANG LINGUIST, V21, P3, DOI 10.1075/sll.00011.lin; DOWTY D, 1991, LANGUAGE, V67, P547, DOI 10.2307/415037; Eccarius P, 2008, P 44 ANN M CHICAGO L, V2, P187; Eccarius P, 2007, LINGUA, V117, P1169, DOI 10.1016/j.lingua.2005.04.006; Fernald TB., 2000, SIGN LANG LINGUIST, V3, P3, DOI [10.1075/sll.3.1.03fer, DOI 10.1075/SLL.3.1.03FER]; FRISHBERG N, 1975, LANGUAGE, V51, P696, DOI 10.2307/412894; Frishberg N., 1973, MANUSCRIPT SALK I BI, V2000, P3; Gokgoz K., 2013, THESIS PURDUE U; Goldin-Meadow S, 2015, COGNITION, V136, P381, DOI 10.1016/j.cognition.2014.11.029; Hall ML, 2015, J MEM LANG, V81, P16, DOI 10.1016/j.jml.2014.12.003; Haspelmath M., 1993, CAUSATIVES TRANSITIV, P87, DOI [10.1075/slcs.23.05has, DOI 10.1075/SLCS.23.05HAS]; Haspelmath M, 2015, COMP HBK LINGUIST, V1, P131; Hassemer J, 2018, COGNITIVE SCI, V42, P3034, DOI 10.1111/cogs.12680; HOPPER PJ, 1980, LANGUAGE, V56, P251, DOI 10.2307/413757; Hout Angeliekvan., 2000, EVENTS GRAMMATICAL O, P239; Jackendoff R., 1993, KNOWLEDGE LANGUAGE, P31; Kayabasi D., 2020, TALK GIVEN FORMAL EX, P23; Kimmelman V, 2018, GLOSSA-UK, V3, DOI 10.5334/gjgl.494; Kimmelman Vadim, 2016, P 7 WORKSH REPR PROC, P117; Kohler W, 1929, GESTALT PSYCHOL INTR; Kuhn J, 2020, PSYARXIV, DOI [10.31234/osf.io/mkwaz, DOI 10.31234/OSF.IO/MKWAZ]; Lepic R., 2017, LOOKING WORDS STRUCT, P489, DOI DOI 10.5281/ZENODO.495463; Lepic R, 2019, GLOSSA-UK, V4, DOI 10.5334/gjgl.840; Lepic R, 2016, SIGN LANG LINGUIST, V19, P37, DOI 10.1075/sll.19.1.02lep; Levin B., 1993, ENGLISH VERB CLASSES; Levin Beth, 2005, ARGUMENT REALIZATION; Lockwood G, 2016, J EXP PSYCHOL LEARN, V42, P1274, DOI 10.1037/xlm0000235; Malaia E., 2013, STUDIES COMPOSITION, P231, DOI DOI 10.1007/978-94-007-5983-1_9; Malaia E, 2012, TELICITY CHANGE STAT, P122; Malaia E, 2018, LANG SPEECH, V61, P97, DOI 10.1177/0023830917708461; Malaia E, 2013, J SPEECH LANG HEAR R, V56, P1677, DOI 10.1044/1092-4388(2013/12-0257); Malaia E, 2012, LANG SPEECH, V55, P407, DOI 10.1177/0023830911422201; Malchukov A, 2015, COMP HBK LINGUIST, V1, P73; MARANTZ Alec P., 1984, NATURE GRAMMATICAL R; Marshall CR, 2015, TOP COGN SCI, V7, P61, DOI 10.1111/tops.12118; Meir I, 2001, SIGNED LANGUAGE, P74; Meir I, 2002, NAT LANG LINGUIST TH, V20, P413, DOI 10.1023/A:1015041113514; Meir I, 2013, COGN LINGUIST, V24, P309, DOI 10.1515/cog-2013-0010; MIRON MS, 1961, J ABNORM SOC PSYCH, V62, P623, DOI 10.1037/h0045212; Motamedi Y, 2019, COGNITION, V192, DOI 10.1016/j.cognition.2019.05.001; Napoli DJ., 2003, SIGN LANGUAGE LINGUI, V6, P123, DOI [10.1075/sll.6.2.03nap, DOI 10.1075/SLL.6.2.03NAP]; Nygaard LC, 2009, COGNITION, V112, P181, DOI 10.1016/j.cognition.2009.04.001; Occhino C, 2020, LANG COGN, V12, P114, DOI 10.1017/langcog.2020.1; Occhino C, 2017, GESTURE, V16, P99, DOI 10.1075/gest.16.1.04occ; Oomen M, 2017, SIGN LANG LINGUIST, V20, P55, DOI 10.1075/sll.20.1.03oom; Ortega G, 2019, COGNITION, V191, DOI 10.1016/j.cognition.2019.06.008; Ostling R, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00725; Papafragou A, 2015, CONCEPTUAL MIND: NEW DIRECTIONS IN THE STUDY OF CONCEPTS, P327; Patschke C., 1999, SIGN LANGUAGE LINGUI, V2, P3, DOI [DOI 10.1075/SLL.2.1.03WIL, 10.1075/sll.2.1.03wil]; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Perniss P, 2015, TOP COGN SCI, V7, P36, DOI 10.1111/tops.12122; Schlenker P, 2020, NAT LANG LINGUIST TH, V38, P887, DOI 10.1007/s11049-019-09460-z; Schlenker P, 2019, LINGUIST PHILOS, V42, P45, DOI 10.1007/s10988-018-9236-0; Schlenker P, 2018, THEOR LINGUIST, V44, P123, DOI 10.1515/tl-2018-0012; Schlenker P, 2018, NAT LANG LINGUIST TH, V36, P587, DOI 10.1007/s11049-017-9378-8; Schlenker P, 2016, NAT LANG LINGUIST TH, V34, P1067, DOI 10.1007/s11049-015-9323-7; Seabold S., 2010, P 9 PYTH SCI C, DOI 10.25080/MAJORA-92BF1922-011; Sehyr ZS, 2019, LANG COGN, V11, P208, DOI 10.1017/langcog.2019.18; Senghas A., 1997, P 21 ANN BOSTON U C, V2, P550; Siple Patricia, 1990, THEORETICAL ISSUES S, V1, P191, DOI DOI 10.1007/978-94-011-3468-2; Sler W., 2010, SIGN LANGUAGES CAMBR, P570; Strickland B, 2015, P NATL ACAD SCI USA, V112, P5968, DOI 10.1073/pnas.1423080112; Wilbur RB, 2003, CHIC LINGUIST SOC, V39, P354; Wilbur RB, 2008, SIGNS TIME SELECTED, P217; Wilbur RB, 2010, SIGN LANG LINGUIST, V13, P203, DOI 10.1075/sll.13.2.05wil; Wilbur RB, 2009, LANG SCI, V31, P325, DOI 10.1016/j.langsci.2008.12.017; Zacks JM, 2009, COGNITION, V112, P201, DOI 10.1016/j.cognition.2009.03.007; Zwitserlood I., 2003, THESIS U UTRECHT	83	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2022	17	2							e0262098	10.1371/journal.pone.0262098	http://dx.doi.org/10.1371/journal.pone.0262098			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0U7EE	35213558	gold, Green Published			2023-01-03	WOS:000787811000007
J	Li, HC; Jin, XJ; Herman, PM; Witt, CM; Chen, YY; Gang, WJ; Jing, XH; Song, P; Yang, LH; Ollendorf, D; Zhang, Y; Guyatt, G; Huang, LQ; Zhang, YQ				Li, Hongchao; Jin, Xuejing; Herman, Patricia M.; Witt, Claudia M.; Chen, Yingyao; Gang, Weijuan; Jing, Xianghong; Song, Ping; Yang, Longhui; Ollendorf, Dan; Zhang, Yuan; Guyatt, Gordon; Huang, Luqi; Zhang, Yu-Qing			Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LOW-BACK-PAIN; COST-EFFECTIVENESS; GUIDELINES; HEALTH; OSTEOARTHRITIS; TRIALS; GERAC		[Li, Hongchao] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China; [Li, Hongchao] China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing, Peoples R China; [Jin, Xuejing] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Herman, Patricia M.] RAND Corp, Santa Monica, CA 90406 USA; [Witt, Claudia M.] Univ Hosp Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland; [Witt, Claudia M.] Univ Zurich, Zurich, Switzerland; [Chen, Yingyao] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China; [Chen, Yingyao] Fudan Univ, Natl Hlth Commiss, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China; [Gang, Weijuan; Jing, Xianghong; Zhang, Yu-Qing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Gang, Weijuan; Jing, Xianghong; Huang, Luqi] China Acad Chinese Med Sci, China Ctr Evidence Based Tradit Chinese Med, Beijing, Peoples R China; [Song, Ping; Yang, Longhui; Huang, Luqi] China Acad Chinese Med Sci, Beijing, Peoples R China; [Ollendorf, Dan] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA; [Zhang, Yuan; Guyatt, Gordon; Zhang, Yu-Qing] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Guyatt, Gordon] McMaster Univ, Dept Med, Fac Hlth Sci, Hamilton, ON, Canada; [Zhang, Yu-Qing] China Acad Chinese Med Sci, Guanganmen Hosp, Ctr Evidence Based Integrat Med Clar Collaborat, Beijing, Peoples R China; [Zhang, Yu-Qing] Univ Nottingham, Ningbo Nottingham Grade Ctr, Ningbo, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; Beijing University of Chinese Medicine; RAND Corporation; University of Zurich; University Zurich Hospital; University of Zurich; Fudan University; Fudan University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Tufts Medical Center; McMaster University; McMaster University; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; University of Nottingham Ningbo China	Huang, LQ (corresponding author), China Acad Chinese Med Sci, China Ctr Evidence Based Tradit Chinese Med, Beijing, Peoples R China.; Huang, LQ (corresponding author), China Acad Chinese Med Sci, Beijing, Peoples R China.	huangluqi01@126.com	Jing, Xianghong/HHS-4003-2022; Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805	special purpose funds for the belt and road, China Academy of Chinese Medical Sciences, National Natural Science Foundation of China; National Center for Complementary and Integrative Health; Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine; Special Project of "Lingnan Modernization of Traditional Chinese Medicine" of the 2019 Guangdong Key Research and Development Program; Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine	special purpose funds for the belt and road, China Academy of Chinese Medical Sciences, National Natural Science Foundation of China; National Center for Complementary and Integrative Health; Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine; Special Project of "Lingnan Modernization of Traditional Chinese Medicine" of the 2019 Guangdong Key Research and Development Program; Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine	This article is part of a collection funded by the special purpose funds for the belt and road, China Academy of Chinese Medical Sciences, National Natural Science Foundation of China, the National Center for Complementary and Integrative Health, the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine, the Special Project of "Lingnan Modernization of Traditional Chinese Medicine" of the 2019 Guangdong Key Research and Development Program, and the Project of First Class Universities and High-level Dual Discipline for Guangzhou University of Chinese Medicine. The BMJ commissioned, peer reviewed, edited, and made the decision to publish. Kamran Abbasi was the lead editor for The BMJ. Yu-qing Zhang advised on commissioning for the collection, designed the topic of the series, and coordinated the author teams. Gordon Guyatt provided valuable advice and guidance.	Ambrosio EMM, 2012, COMPLEMENT THER MED, V20, P364, DOI 10.1016/j.ctim.2012.05.002; Beijing Municipal Bureau of Health Beijing Municipal Bureau of Finance., 1990, NOT REG PUBL FUND ME; Bleck R, 2021, ACUPUNCT MED, V39, P461, DOI 10.1177/0964528420964214; Borah BJ, 2017, COMPLEMENT THER MED, V31, P14, DOI 10.1016/j.ctim.2017.01.002; China National Healthcare Security Administration, WORK PLAN ADJ NAT RE; Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459; Cummings M, 2009, ACUPUNCT MED, V27, P26, DOI 10.1136/aim.2008.000281; Czarnawska-Iliev I, 2016, EUR J INTEGR MED, V8, P342, DOI 10.1016/j.eujim.2016.07.004; Database MC, 2020, DEC MEM AC CHRON LOW; Deng ZQ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-75; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Duarte RV, 2018, PAIN PRACT, V18, P666, DOI 10.1111/papr.12650; Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364; Giovanardi CM, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.576272; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Herman PM, 2020, SPINE, V45, P1383, DOI 10.1097/BRS.0000000000003539; Herman PM, 2019, SPINE, V44, P1456, DOI 10.1097/BRS.0000000000003097; Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Institute for Clinical and Economic Review, 2017, COGN MIND BOD THER C; Kim N, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-74; Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178; Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310; Mu JL, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013814; National Institute for Health and Care Excellence, 2021, CHRON PAIN PRIM SEC; Phillips Ceri J, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P591, DOI 10.1586/14737167.6.5.591; Reinhold T, 2008, EUR J HEALTH ECON, V9, P209, DOI 10.1007/s10198-007-0062-5; Reinhold T, 2013, ANN ALLERG ASTHMA IM, V111, P56, DOI 10.1016/j.anai.2013.04.008; Sa KN, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000779; Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005; Skelly A, 2018, AHRQ PUBLICATION, V209; Spackman E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113726; Stamuli E, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-149; Tedesco D, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.2872; Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005; WHO, 2013, WHO TRADITIONAL MED; Witt CM, 2008, CEPHALALGIA, V28, P334, DOI 10.1111/j.1468-2982.2007.01504.x; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Woods B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172749; Xu SB, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m697	40	2	2	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2022	376								e067477	10.1136/bmj-2021-067477	http://dx.doi.org/10.1136/bmj-2021-067477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1B5HI	35217521	hybrid, Green Published			2023-01-03	WOS:000792467400009
J	Sserwanja, Q; Mukunya, D; Nabachenje, P; Kemigisa, A; Kiondo, P; Wandabwa, JN; Musaba, MW				Sserwanja, Quraish; Mukunya, David; Nabachenje, Prossy; Kemigisa, Alleluyah; Kiondo, Paul; Wandabwa, Julius N.; Musaba, Milton W.			Continuum of care for maternal health in Uganda: A national cross-sectional study	PLOS ONE			English	Article							MORTALITY; BIRTH	Introduction A continuum of maternal care approach can reduce gaps and missed opportunities experienced by women and newborns. We determined the level of coverage and factors associated with the continuum of maternal care in Uganda. Methods We used weighted data from the Uganda Demographic and Health Survey (UDHS) 2016. We included 10,152 women aged 15 to 49 years, who had had a live birth within five years preceding the survey. Stratified two-stage cluster sampling design was used to select participants. Continuum of maternal care was considered when a woman had at least four antenatal care (ANC) visits, had delivered in a health facility and they had at least one postnatal check-up within six weeks. We conducted multivariable logistic regression analysis to determine factors associated with completion of the continuum of maternal care using SPSS version 25. Results The level of coverage of complete continuum of maternal care was 10.7% (1,091) (95% CI: 10.0-11.2). About 59.9% (6,080) (95% CI: 59.0-60.8) had four or more antenatal visits while 76.6% (7,780) (95% CI: 75.8-77.5) delivered in a health facility and 22.5% (2,280) (95% CI: 21.5-23.2) attended at least one postnatal care visit within six weeks. The following factors were associated with continuum of maternal care; initiating ANC in the first trimester (AOR 1.49, 95% CI: 1.23-1.79), having secondary level of education (AOR 1.60, 95% CI: 1.15-2.22) and tertiary level of education (AOR 2.08 95% CI: 1.38-3.13) compared to no formal education, being resident in Central Uganda (AOR 1.44, 95% CI:1.11-1.89), Northern Uganda (AOR 1.35, 95% CI: 1.06-1.71) and Western Uganda (AOR 0.61, 95% CI: 0.45-0.82) compared to Eastern Uganda, and exposure to newspapers and magazines. Conclusion The level of coverage of the complete continuum of maternal care was low and varied across regions. It was associated with easily modifiable factors such as early initiation of ANC, exposure to mass media and level of education. Interventions to improve utilisation of the continuum of maternal care should leverage mass media to promote services, especially among the least educated and the residents of Western Uganda.	[Sserwanja, Quraish] GOAL, Programs Dept, Khartoum, Sudan; [Mukunya, David] Busitema Univ, Dept Community & Publ Hlth, Mbale, Uganda; [Mukunya, David; Kemigisa, Alleluyah] Sanyu Africa Res Inst, Mbale, Uganda; [Nabachenje, Prossy] Busitema Univ, Dept Paediat & Child Hlth, Mbale, Uganda; [Kiondo, Paul] Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda; [Wandabwa, Julius N.; Musaba, Milton W.] Busitema Univ, Dept Obstet & Gynaecol, Mbale, Uganda	Makerere University	Musaba, MW (corresponding author), Busitema Univ, Dept Obstet & Gynaecol, Mbale, Uganda.	miltonmusaba@gmail.com		Sserwanja, Quraish/0000-0003-0576-4627; Musaba, Milton/0000-0003-4145-4044				Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; Ali B, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08480-4; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; [Anonymous], 2019, TRENDS MATERNAL MORT; Asp G, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.22904; Asratie MH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237980; Atukunda EC, 2020, J PREGNANCY, V2020, DOI 10.1155/2020/6596394; Babughirana G, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03385-x; Baqui AH, 2016, B WORLD HEALTH ORGAN, V94, P752, DOI 10.2471/BLT.15.160945; Benova L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3546-3; Bwalya BB, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1612-1; Camara BS, 2021, TROP MED INT HEALTH, V26, P1446, DOI 10.1111/tmi.13661; Chaka EE, 2019, INT J PREVENTIVE MED, V10, DOI 10.4103/ijpvm.IJPVM_26_19; De Graft-Johnson J., 2006, OPPOR AFRICAS NEWBOR; Devinit.org, 2021, POV UG NAT REG DAT T; Dey T, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004230; Ewunetie AA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1748-7; Group W., 2019, SO YOUR HOME IS BUIL, P41, DOI [10.1061/9780784415214.ch02, DOI 10.1061/9780784415214.CH02]; Haile D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0221670; Hamed A. F., 2018, International Journal of Medical Science and Public Health, V7, P417; Hanekom J., 2002, S AFRICAN J COMMUNIC, V28, P49, DOI [10.1080/02500160208537957, DOI 10.1080/02500160208537957]; Haws RA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S5; Hogberg U, 2005, SCAND J PUBLIC HEALT, V33, P409, DOI 10.1080/14034940500217037; Hosmer D.W., 2000, APPL LOGISTIC REGRES, V2nd; Iqbal S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2111-9; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Lincetto O., 2018, ANTENATAL CARE; Mbonye AK, 2007, INT J GYNECOL OBSTET, V96, P220, DOI 10.1016/j.ijgo.2006.12.017; Mbonye A K, 2001, Afr J Reprod Health, V5, P47, DOI 10.2307/3583322; Merdad L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189416; MOH, 2016, UG CLIN GUID 2016, P1; MoH Makerere University School of Public Health Health Systems 20/20, 2012, UG HLTH SYST ASS 201, P181; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Musaba Milton W, 2021, Matern Health Neonatol Perinatol, V7, P13, DOI 10.1186/s40748-021-00133-7; Mwangi W, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1803-4; Ndugga P, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02866-3; Oh J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036516; Okanlawon K., 2010, AFR J REPROD HEALTH, DOI [10.2307/41329750, DOI 10.2307/41329750]; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Osborn D, 2015, UNIVERSAL SUSTAINABL; Owili PO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3075-0; Paudel YR, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00242; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; PMNCH, 2014, PMNCH KNOWL SUMM 02; Rutaremwa G, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0943-8; Sacks E, 2017, MATERN CHILD HLTH J, V21, P599, DOI 10.1007/s10995-016-2144-4; Sacks E, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0042-7; Sakuma S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215635; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Shibanuma A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000786; Sialubanje C, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0051-6; Sserwanja Q, 2022, BMC WOMENS HEALTH, V22, DOI 10.1186/s12905-022-01594-4; Sserwanja Q, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-07179-5; Sserwanja Q, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-04080-1; Sserwanja Q, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905-021-01206-7; Sserwanja Q, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09775-2; Tamang TM, 2017, INT POP C; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Tetui M, 2012, PAN AFR MED J, V13; The Republic of Uganda, 2014, UG HOSP HLTH CTR IV, P224; The World Bank, 2020, NEW WORLD BANK COUNT; Uganda Bureau of Statistics, 2016, GOV UG UG DEM HLTH S, P625; Victoor A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-272; Waiswa Peter, 2008, BMC Pregnancy Childbirth, V8, P21, DOI 10.1186/1471-2393-8-21; WHO, 2013, WHO TRADITIONAL MED; World Health Organization, 2013, WHO WHO REC POSTN CA, P2; World Health Organization, 2014, EV NEWB ACT PLAN END, P12	67	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2022	17	2							e0264190	10.1371/journal.pone.0264190	http://dx.doi.org/10.1371/journal.pone.0264190			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ4EP	35202413	Green Published, gold			2023-01-03	WOS:000773224600025
J	Muhula, S; Gachohi, J; Kombe, Y; Karanja, S				Muhula, Samuel; Gachohi, John; Kombe, Yeri; Karanja, Simon			Interventions to improve early retention of patients in antiretroviral therapy programmes in sub-Saharan Africa: A systematic review	PLOS ONE			English	Review							VIRAL SUPPRESSION; FOLLOW-UP; CARE; IMPACT; INCOME; POSTPARTUM; MORTALITY; NIGERIA; ADULTS; RISK	Background Several interventions to improve long term retention (12 months and above) on treatment have been rigorously evaluated in Sub-Saharan Africa (SSA). However, research on interventions to improve retention of patients in the early stages of treatment (6 months) during this era of Universal Test and Treat has only recently emerged. The aim of this study is to systematically map evidence of interventions used to improve early retention of patients in antiretroviral therapy (ART) programmes in SSA. Methods We searched PubMed, EMBASE and Cochrane electronic databases to identify studies describing interventions aimed at improving early retention in ART treatment. We applied the methodological frameworks by Arksey and O'Malley (2005) and Levac et al. (2010). We also followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Interventions were categorized according to key broad areas in the existing literature. Results A total of 2,241 articles were identified of which 19 met the inclusion criteria and were eligible for this review, with the majority either being randomized control trials 32% (n = 6) or cohort studies 32% (n = 6). The studies reviewed were conducted in 11 SSA countries. The most common interventions described under key broad areas included: Health system interventions such as Universal Test-and-Treat, integration of ART initiation, HIV Testing and Counselling and Antenatal Care services and reduction of ART drug costs; Patient centered approaches such as fast track ART initiation, Differentiated Drug Delivery models and point of care HIV birth testing; Behavioral interventions and support through lay counselors, mentor mothers, nurse counselors and application of quality improvement interventions and financial incentives. Majority of the studies targeted the HIV positive adults and pregnant women. Conclusion With the introduction of Universal Test-and-Treat and same-day initiation of ART, findings suggest that adoption of policies that expand ART uptake with the goal of reducing HIV transmission at the population level, promoting patient centered approaches such as fast track ART initiation, Differentiated Service Delivery models and providing adequate support through Mentor Mothers, lay and nurse counselors may improve early retention in HIV care in SSA. However, these interventions have only been tested in few countries in the region which points to how hard evidence based HIV programming is. Further research investigating the impact of individual and a combination of interventions to improve early retention in HIV care, including for various groups at high risk of attrition, is warranted across SSA countries to fast track the achievement of 95-95-95 Joint United Nations Programme on HIV/AIDS (UNAIDS) targets by 2030.	[Muhula, Samuel; Gachohi, John; Karanja, Simon] Jomo Kenyatta Univ Agr & Technol, Sch Publ Hlth, Juja, Kenya; [Muhula, Samuel] Amref Hlth Africa, Nairobi, Kenya; [Kombe, Yeri] Kenya Govt Med Res Ctr, Nairobi, Kenya	Jomo Kenyatta University of Agriculture & Technology; African Medical & Research Foundation (AMREF); Kenya Medical Research Institute	Muhula, S (corresponding author), Jomo Kenyatta Univ Agr & Technol, Sch Publ Hlth, Juja, Kenya.; Muhula, S (corresponding author), Amref Hlth Africa, Nairobi, Kenya.	sam.muhula@gmail.com		Muhula, Samuel/0000-0001-7992-6532				Abrams EJ, 2019, AIDS, V33, P45, DOI 10.1097/QAD.0000000000002027; Ahmed I, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09887-9; [Anonymous], 2020, J INT AIDS SOC, V23, P1, DOI 10.1002/jia2.25547; [Anonymous], 2018, J Int AIDS Soc, V21 Suppl 6, pe25148, DOI 10.1002/jia2.25148; [Anonymous], 2007, NEWCASTLE OTTAWA SCA; Arnesen R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177168; Asieba IO, 2021, RES SOC ADMIN PHARM, V17, P842, DOI 10.1016/j.sapharm.2020.06.025; Chan AK, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20672; Churchill JPHTLJCDTJTEFR, MECIR STAND; Crawford TN, 2014, AIDS CARE, V26, P1393, DOI 10.1080/09540121.2014.920076; Data Extraction Forms, 2014, COCHRANE DEV PSYCHOS; Davey DJ, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25529; Fahey CA, 2020, LANCET HIV, V7, pE762, DOI 10.1016/S2352-3018(20)30230-7; Fayorsey RN, 2019, JAIDS-J ACQ IMM DEF, V80, P56, DOI 10.1097/QAI.0000000000001882; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Frijters EM, 2020, AIDS, V34, P1261, DOI 10.1097/QAD.0000000000002523; Graves JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192068; Hassan F, 2021, GLOB PUBLIC HEALTH, V16, P201, DOI 10.1080/17441692.2020.1839927; Herce ME, 2020, LANCET HIV, V7, pE807, DOI 10.1016/S2352-3018(20)30188-0; Hoffman RM, 2021, LANCET GLOB HEALTH, V9, pE628, DOI 10.1016/S2214-109X(21)00039-5; Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073; Ibrahim M, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25111; Izudi J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1524016; Khumalo Philisiwe Ntombenhle, 2020, J Acquir Immune Defic Syndr, V84 Suppl 1, pS22, DOI 10.1097/QAI.0000000000002380; Kim MH, 2015, JAIDS-J ACQ IMM DEF, V68, pE77, DOI 10.1097/QAI.0000000000000517; Kiragga AN, 2016, JAIDS-J ACQ IMM DEF, V72, pE32, DOI 10.1097/QAI.0000000000001002; Li Zihao, 2019, MMWR Morb Mortal Wkly Rep, V68, P267, DOI 10.15585/mmwr.mm6811e1; Long L, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25640; Mody A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002574; Moges NA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05168-3; Mosoko JJ, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-32; National Centre for AIDS and STD Control, 2020, RETENTION HIV CARE N; Onoya D, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25652; Oyeledun B, 2017, JAIDS-J ACQ IMM DEF, V75, pS156, DOI [10.1097/QAI.0000000000001363, 10.1097/qai.0000000000001363]; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n160; Sam-Agudu NA, 2017, JAIDS-J ACQ IMM DEF, V75, pS173, DOI [10.1097/QAI.0000000000001346, 10.1097/qai.0000000000001346]; Sande O, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08721-6; Schmitz K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211439; Siegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Stevens WS, 2017, JAIDS-J ACQ IMM DEF, V76, P65, DOI 10.1097/QAI.0000000000001456; UNAIDS, 2015, UNDERSTANDING FAST T; UNAIDS, 2020, UNAIDS DAT 2019; Wilkinson LS, 2015, TROP MED INT HEALTH, V20, P365, DOI 10.1111/tmi.12434; World Bank, 2019, POP TOT SUBS AFR; World Bank, 2020, DATA; Zerbe A, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05470-5	47	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2022	17	2							e0263663	10.1371/journal.pone.0263663	http://dx.doi.org/10.1371/journal.pone.0263663			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S0NR	35139118	gold, Green Published			2023-01-03	WOS:000821499100041
J	Javier, R; Wang, WX; Drumm, M; McCortney, K; Sarkaria, JN; Horbinski, C				Javier, Rodrigo; Wang, Wenxia; Drumm, Michael; McCortney, Kathleen; Sarkaria, Jann N.; Horbinski, Craig			The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma	PLOS ONE			English	Article							KETONE-BODIES; MUTATIONS; CANCER; METABOLISM; TUMORS; BRAIN	Infiltrative gliomas are the most common neoplasms arising in the brain, and remain largely incurable despite decades of research. A subset of these gliomas contains mutations in isocitrate dehydrogenase 1 (IDH1(mut)) or, less commonly, IDH2 (together called "IDHmut"). These mutations alter cellular biochemistry, and IDHmut gliomas are generally less aggressive than IDH wild-type (IDHwt) gliomas. Some preclinical studies and clinical trials have suggested that various forms of a ketogenic diet (KD), characterized by low-carbohydrate and high-fat content, may be beneficial in slowing glioma progression. However, adherence to a strict KD is difficult, and not all studies have shown promising results. Furthermore, no study has yet addressed whether IDHmut gliomas might be more sensitive to KD. The aim of the current study was to compare the effects of a unrestricted, cycling KD (weekly alternating between KD and standard diet) in preclinical models of IDHwt versus IDHmut gliomas. In vitro, simulating KD by treatment with the ketone body beta-hydroxybutyrate had no effect on the proliferation of patient-derived IDHwt or IDHmut glioma cells, either in low or normal glucose conditions. Likewise, an unrestricted, cycling KD had no effect on the in vivo growth of patient-derived IDHwt or IDHmut gliomas, even though the cycling KD did result in persistently elevated circulating ketones. Furthermore, this KD conferred no survival benefit in mice engrafted with Sleeping-Beauty transposase-engineered IDHmut or IDHwt glioma. These data suggest that neither IDHwt nor IDHmut gliomas are particularly responsive to an unrestricted, cycling form of KD.	[Javier, Rodrigo; Wang, Wenxia; Drumm, Michael; McCortney, Kathleen; Horbinski, Craig] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Javier, Rodrigo; Wang, Wenxia; Drumm, Michael; McCortney, Kathleen; Horbinski, Craig] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Northwestern Med Malnati Brain Tumor Inst, Chicago, IL 60611 USA; [Sarkaria, Jann N.] Mayo Clin, Rochester, MN USA; [Horbinski, Craig] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Mayo Clinic; Northwestern University; Feinberg School of Medicine	Horbinski, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.; Horbinski, C (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Northwestern Med Malnati Brain Tumor Inst, Chicago, IL 60611 USA.; Horbinski, C (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA.	craig.horbinski@northwestern.edu		Horbinski, Craig/0000-0001-8340-9992	Northwestern University SPORE in Brain Tumor Research [P50CA221747]; Lou and Jean Malnati Brain Tumor Institute;  [R01NS102669];  [R01NS117104];  [R01NS118039]	Northwestern University SPORE in Brain Tumor Research; Lou and Jean Malnati Brain Tumor Institute; ; ; 	This work was supported by R01NS102669 (CH), R01NS117104 (CH), R01NS118039 (CH), the Northwestern University P50CA221747 SPORE in Brain Tumor Research, and the Lou and Jean Malnati Brain Tumor Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahab MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036197; Biedermann J, 2019, CANCERS, V11, DOI 10.3390/cancers11122028; Brouns F, 2018, EUR J NUTR, V57, P1301, DOI 10.1007/s00394-018-1636-y; Burnet NG, 2005, BRIT J CANCER, V92, P241, DOI 10.1038/sj.bjc.6602321; Chung HY, 2017, J CANCER PREV, V22, P127, DOI 10.15430/JCP.2017.22.3.127; Ciusani E, 2021, NUTR CANCER, V73, P2315, DOI 10.1080/01635581.2020.1822423; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; De Feyter HM, 2016, NEURO-ONCOLOGY, V18, P1079, DOI 10.1093/neuonc/now088; Fack F, 2017, EMBO MOL MED, V9, P1681, DOI 10.15252/emmm.201707729; Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254; Foppiani A, 2021, NUTR CANCER, V73, P1004, DOI 10.1080/01635581.2020.1779759; Fu XD, 2015, CELL METAB, V22, P508, DOI 10.1016/j.cmet.2015.06.009; Gano LB, 2014, J LIPID RES, V55, P2211, DOI 10.1194/jlr.R048975; Garrett M, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0177-4; Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Horbinski C, 2013, ACTA NEUROPATHOL, V125, P621, DOI 10.1007/s00401-013-1106-9; Izquierdo-Garcia JL, 2015, CANCER RES, V75, P2999, DOI 10.1158/0008-5472.CAN-15-0840; Izquierdo-Garcia JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108289; Jensen Mette Munk, 2008, BMC Med Imaging, V8, P16, DOI 10.1186/1471-2342-8-16; Khurshed M, 2017, ONCOTARGET, V8, P49165, DOI 10.18632/oncotarget.17106; Klement RJ, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-1337-2; Martin-McGill KJ, 2020, J NEURO-ONCOL, V147, P213, DOI 10.1007/s11060-020-03417-8; Miyata S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46217-5; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Nunez FJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1427; Ohka F, 2014, TUMOR BIOL, V35, P5911, DOI 10.1007/s13277-014-1784-5; Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perez A, 2021, CANCER REP-US, V4, DOI 10.1002/cnr2.1383; Porper K, 2021, J NEURO-ONCOL, V153, P487, DOI 10.1007/s11060-021-03786-8; Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108; Schreck KC, 2021, NEUROLOGY, V97, pE953, DOI 10.1212/WNL.0000000000012386; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Sperry J, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101453; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Unruh D., 2018, CLIN CANCER RES, V28, P1078; Vaubel RA, 2020, CLIN CANCER RES, V26, P1094, DOI 10.1158/1078-0432.CCR-19-0909; Waitkus MS, 2018, CANCER RES, V78, P36, DOI 10.1158/0008-5472.CAN-17-1352; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Wenger KJ, 2020, CANCERS, V12, DOI 10.3390/cancers12123549; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zhou LN, 2019, J PROTEOME RES, V18, P960, DOI 10.1021/acs.jproteome.8b00663; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5	45	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2022	17	2							e0257725	10.1371/journal.pone.0257725	http://dx.doi.org/10.1371/journal.pone.0257725			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1L0FO	35134075	gold, Green Published			2023-01-03	WOS:000798968600001
J	Rowald, A; Komi, S; Demesmaeker, R; Baaklini, E; Hernandez-Charpak, SD; Paoles, E; Montanaro, H; Cassara, A; Becce, F; Lloyd, B; Newton, T; Ravier, J; Kinany, N; D'Ercole, M; Paley, A; Hankov, N; Varescon, C; McCracken, L; Vat, M; Caban, M; Watrin, A; Jacquet, C; Bole-Feysot, L; Harte, C; Lorach, H; Galvez, A; Tschopp, M; Herrmann, N; Wacker, M; Geernaert, L; Fodor, I; Radevich, V; van den Keybus, K; Eberle, G; Pralong, E; Roulet, M; Ledoux, JB; Fornari, E; Mandija, S; Mattera, L; Martuzzi, R; Nazarian, B; Benkler, S; Callegari, S; Greiner, N; Fuhrer, B; Froeling, M; Buse, N; Denison, T; Buschman, R; Wende, C; Ganty, D; Bakker, J; Delattre, V; Lambert, H; Minassian, K; van den Berg, CAT; Kavounoudias, A; Micera, S; van de Ville, D; Barraud, Q; Kurt, E; Kuster, N; Neufeld, E; Capogrosso, M; Asboth, L; Wagner, FB; Bloch, J; Courtine, G				Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Paoles, Edoardo; Montanaro, Hazael; Cassara, Antonino; Becce, Fabio; Lloyd, Bryn; Newton, Taylor; Ravier, Jimmy; Kinany, Nawa; D'Ercole, Marina; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Caban, Miroslav; Watrin, Anne; Jacquet, Charlotte; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Pralong, Etienne; Roulet, Maxime; Ledoux, Jean-Baptiste; Fornari, Eleonora; Mandija, Stefano; Mattera, Loan; Martuzzi, Roberto; Nazarian, Bruno; Benkler, Stefan; Callegari, Simone; Greiner, Nathan; Fuhrer, Benjamin; Froeling, Martijn; Buse, Nik; Denison, Tim; Buschman, Rik; Wende, Christian; Ganty, Damien; Bakker, Jurriaan; Delattre, Vincent; Lambert, Hendrik; Minassian, Karen; van den Berg, Cornelis A. T.; Kavounoudias, Anne; Micera, Silvestro; van de Ville, Dimitri; Barraud, Quentin; Kurt, Erkan; Kuster, Niels; Neufeld, Esra; Capogrosso, Marco; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire			Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	NATURE MEDICINE			English	Article							PHYSIOLOGICAL NOISE; ELECTRICAL-STIMULATION; EPIDURAL STIMULATION; TENDON VIBRATION; MUSCLE; ACTIVATION; MECHANISMS; LOCOMOTION; RECOVERY; DEFICITS	Epidural electrical stimulation (EES) targeting the dorsal roots of lumbosacral segments restores walking in people with spinal cord injury (SCI). However, EES is delivered with multielectrode paddle leads that were originally designed to target the dorsal column of the spinal cord. Here, we hypothesized that an arrangement of electrodes targeting the ensemble of dorsal roots involved in leg and trunk movements would result in superior efficacy, restoring more diverse motor activities after the most severe SCI. To test this hypothesis, we established a computational framework that informed the optimal arrangement of electrodes on a new paddle lead and guided its neurosurgical positioning. We also developed software supporting the rapid configuration of activity-specific stimulation programs that reproduced the natural activation of motor neurons underlying each activity. We tested these neurotechnologies in three individuals with complete sensorimotor paralysis as part of an ongoing clinical trial (www.clinicaltrials.gov identifier NCT02936453). Within a single day, activity-specific stimulation programs enabled these three individuals to stand, walk, cycle, swim and control trunk movements. Neurorehabilitation mediated sufficient improvement to restore these activities in community settings, opening a realistic path to support everyday mobility with EES in people with SCI.	[Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Kinany, Nawa; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Greiner, Nathan; Fuhrer, Benjamin; Capogrosso, Marco; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Greiner, Nathan; Fuhrer, Benjamin; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Greiner, Nathan; Fuhrer, Benjamin; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Univ Lausanne UNIL, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Roulet, Maxime; Greiner, Nathan; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] EPFL CHUV UNIL, Defitech Ctr Intervent Neurotherapies NeuroRestor, Lausanne, Switzerland; [Paoles, Edoardo; D'Ercole, Marina; Caban, Miroslav; Watrin, Anne; Jacquet, Charlotte; Ganty, Damien; Bakker, Jurriaan; Delattre, Vincent; Lambert, Hendrik] ONWARD Med, Lausanne, Switzerland; [Montanaro, Hazael; Cassara, Antonino; Lloyd, Bryn; Newton, Taylor; Benkler, Stefan; Kuster, Niels; Neufeld, Esra] Fdn Res Informat Technol Soc, Zurich, Switzerland; [Montanaro, Hazael; Kuster, Niels; Neufeld, Esra] Swiss Fed Inst Technol, Dept Informat Technol & Elect Engn, Zurich, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Becce, Fabio; Ledoux, Jean-Baptiste; Fornari, Eleonora] CHUV UNIL, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland; [Kinany, Nawa; Caban, Miroslav; van de Ville, Dimitri] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Kinany, Nawa] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy; [Pralong, Etienne; Roulet, Maxime; Bloch, Jocelyne; Courtine, Gregoire] CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland; [Ledoux, Jean-Baptiste; Fornari, Eleonora] CHU Vaudois, MR Sect, Biomed Imaging Ctr, Lausanne, Switzerland; [Mandija, Stefano; Froeling, Martijn] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Mattera, Loan; Martuzzi, Roberto] Fdn Campus Biotech Geneve, Geneva, Switzerland; [Nazarian, Bruno] Aix Marseille Univ, CNRS, Inst Neurosci Timone, Marseille, France; [Callegari, Simone; Kuster, Niels; Neufeld, Esra] ZurichMedTech, Zurich, Switzerland; [Buse, Nik; Denison, Tim; Buschman, Rik] Medtronic, Minneapolis, MN USA; [Denison, Tim] Univ Oxford, Dept Engn Sci, Oxford, England; [Wende, Christian] Tech Univ Munich, Med Mat & Implants, Munich, Germany; [Minassian, Karen] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria; [Kavounoudias, Anne] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria; [van den Berg, Cornelis A. T.; Micera, Silvestro] Aix Marseille Univ, CNRS, Lab Neurosci Cognit, Marseille, France; [van den Berg, Cornelis A. T.; Micera, Silvestro] Ecole Polytech Fed Lausanne, Bertarelli Fdn, Translat Neuroengn, Ctr Neuroprosthet, Lausanne, Switzerland; [van den Berg, Cornelis A. T.; Micera, Silvestro] Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Bioengn, Lausanne, Switzerland; [van de Ville, Dimitri] Univ Geneva, Dept Radiol & Med Informat, Geneva, Switzerland; [Kurt, Erkan] Radboud Univ Nijmegen Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; [Capogrosso, Marco] Univ Fribourg, Dept Neurosci & Movement Sci, Fribourg, Switzerland; [Capogrosso, Marco] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wagner, Fabien B.] Univ Bordeaux, CNRS, UMR 5293, Inst Malad Neurodegenerat, Bordeaux, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Scuola Superiore Sant'Anna; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Utrecht University; Utrecht University Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Medtronic; University of Oxford; Technical University of Munich; Medical University of Vienna; Medical University of Vienna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva; Radboud University Nijmegen; University of Fribourg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bloch, J; Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), Univ Lausanne UNIL, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), EPFL CHUV UNIL, Defitech Ctr Intervent Neurotherapies NeuroRestor, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland.	jocelyne.bloch@chuv.ch; gregoire.courtine@epfl.ch	Wagner, Fabien/ABC-4084-2020; Froeling, Martijn/E-7865-2012; Becce, Fabio/I-6781-2019; Cassara, Antonino Mario/G-2498-2018	Wagner, Fabien/0000-0002-9582-6109; Froeling, Martijn/0000-0003-3841-0497; Becce, Fabio/0000-0001-8444-8504; Demesmaeker, Robin/0000-0003-0856-0929; Hernandez Charpak, Sergio Daniel/0000-0003-0477-8138; Rowald, Andreas/0000-0001-5493-195X; Asboth, Leonie/0000-0003-2414-9574; Minassian, Karen/0000-0003-4197-6141; Cassara, Antonino Mario/0000-0003-3375-7440; McCracken, Laura/0000-0003-1663-2558; Montanaro Ochoa, Hazael Fabrizio/0000-0002-5373-1646; Kuster, Niels/0000-0002-5827-3728; Baaklini, Edeny/0000-0003-0942-0768; Komi, Salif/0000-0002-2655-6213; courtine, gregoire/0000-0002-5744-4142; Barraud, Quentin/0000-0003-0894-1959	Wings for Life; Defitech Foundation; International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME; Panacee Foundation; Pictet Group Charitable Foundation; Firmenich Foundation; ONWARD Medical; European Union [785907]; RESTORE: Eurostars [E10889]; Swiss National Science Foundation (NCCR Robotics); European Research Council [ERC-2015-CoG HOW2WALKAGAIN 682999]; Commission of Technology and Innovation Innosuisse [CTI 41871.1 IP_LS, CTI 25761.1]; H2020-MSCACOFUND-2015 EPFL fellows program [665667]	Wings for Life; Defitech Foundation; International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME; Panacee Foundation; Pictet Group Charitable Foundation; Firmenich Foundation; ONWARD Medical; European Union(European Commission); RESTORE: Eurostars; Swiss National Science Foundation (NCCR Robotics)(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission); Commission of Technology and Innovation Innosuisse; H2020-MSCACOFUND-2015 EPFL fellows program	We thank our study participants for their commitment and trust. All participants gave their informed consent for publication of their images. We thank A. Curt for support; A. van der Kolk and F. Visser for support in imaging data collection and inspection; and many students, interns and former employees for various contributions, including R. Wang, C. Puffay, Y. L. R. Wan, I. Perret, E. Revol, M. Van Campenhoudt, I. Youssef,I. Turcu, F. Sellet, G. Carparelli, C. Moerman, D. Scherrer-Ma, F. Magaud, M. Damiani and N. Regazzi. Investigational implantable stimulators and paddle leads were donated by Medtronic and ONWARD Medical. This work was supported by Wings for Life, the Defitech Foundation, the International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME, the Panacee Foundation, the Pictet Group Charitable Foundation, the Firmenich Foundation, ONWARD Medical, European Union's Horizon 2020 (785907 Human Brain Project SGA2), RESTORE: Eurostars E10889, CONFIRM!: Eurostars E!12743, the Swiss National Science Foundation (NCCR Robotics), the European Research Council (ERC-2015-CoG HOW2WALKAGAIN 682999), the Commission of Technology and Innovation Innosuisse (CTI 41871.1 IP_LS and CTI 25761.1) and the H2020-MSCACOFUND-2015 EPFL fellows program (grant 665667 to F.B.W.).	Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Asboth L, 2018, NAT NEUROSCI, V21, P576, DOI 10.1038/s41593-018-0093-5; BAROLAT G, 1986, APPL NEUROPHYSIOL, V49, P307; Barra B., EPIDURAL ELECT STIMU, DOI [10.1101/2020.11.13.379750(2021, DOI 10.1101/2020.11.13.379750(2021]; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Benabid AL, 2019, LANCET NEUROL, V18, P1112, DOI 10.1016/S1474-4422(19)30321-7; Bonizzato M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05282-6; Brooks JCW, 2008, NEUROIMAGE, V39, P680, DOI 10.1016/j.neuroimage.2007.09.018; Capogrosso M, 2018, NAT PROTOC, V13, P2031, DOI 10.1038/s41596-018-0030-9; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Cappellini G, 2010, J NEUROPHYSIOL, V104, P3064, DOI 10.1152/jn.00318.2010; Chen CL, 2003, ARCH PHYS MED REHAB, V84, P1276, DOI 10.1016/S0003-9993(03)00200-4; Cohen-Adad J., 2009, NEUROIMAGE S1, V47, pS186; Courtine G, 2007, J NEUROPHYSIOL, V97, P772, DOI 10.1152/jn.00764.2006; Courtine G, 2019, NAT MED, V25, P898, DOI 10.1038/s41591-019-0475-6; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Darrow D, 2019, J NEUROTRAUM, V36, P2325, DOI 10.1089/neu.2018.6006; De Leener B, 2017, NEUROIMAGE, V145, P24, DOI 10.1016/j.neuroimage.2016.10.009; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Edgerton VR, 2011, EXPERT REV NEUROTHER, V11, P1351, DOI [10.1586/ern.11.129, 10.1586/ERN.11.129]; Eippert F, 2017, NEUROIMAGE, V154, P255, DOI 10.1016/j.neuroimage.2016.09.065; Formento E, 2018, NAT NEUROSCI, V21, P1728, DOI 10.1038/s41593-018-0262-6; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; Gill M, 2020, FRONT SYST NEUROSCI, V14, DOI 10.3389/fnsys.2020.569337; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Gomez-Perez SL, 2016, JPEN-PARENTER ENTER, V40, P308, DOI 10.1177/0148607115604149; Greiner N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20703-1; Gros C, 2019, NEUROIMAGE, V184, P901, DOI 10.1016/j.neuroimage.2018.09.081; Gros C, 2018, MED IMAGE ANAL, V44, P215, DOI 10.1016/j.media.2017.12.001; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Herman R, 2002, SPINAL CORD, V40, P65, DOI 10.1038/sj.sc.3101263; Herrity AN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26602-2; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kasper L, 2017, J NEUROSCI METH, V276, P56, DOI 10.1016/j.jneumeth.2016.10.019; Kavounoudias A, 2008, NEUROPSYCHOLOGIA, V46, P567, DOI 10.1016/j.neuropsychologia.2007.10.002; Kinany N, 2020, NEURON, V108, P424, DOI 10.1016/j.neuron.2020.07.024; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Kong YZ, 2012, NEUROIMAGE, V60, P1538, DOI 10.1016/j.neuroimage.2011.11.077; Landelle C, 2018, NEUROSCIENCE, V381, P91, DOI 10.1016/j.neuroscience.2018.04.015; Landelle C, 2020, NEUROIMAGE, V220, DOI 10.1016/j.neuroimage.2020.117056; Ditterline BEL, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.554018; Lempka SF, 2020, NEUROMODULATION, V23, P572, DOI 10.1111/ner.13037; Mignardot JB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3621; Minassian K, 2012, CLIN NEUROL NEUROSUR, V114, P489, DOI 10.1016/j.clineuro.2012.03.013; Minev IR, 2015, SCIENCE, V347, P159, DOI 10.1126/science.1260318; Molnar G, 2014, NEUROMODULATION, V17, P12, DOI 10.1111/ner.12171; Moraud EM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18293-y; Moraud EM, 2016, NEURON, V89, P814, DOI 10.1016/j.neuron.2016.01.009; Morse LR, 2021, J NEUROTRAUM, V38, P1251, DOI 10.1089/neu.2020.7174; Neufeld E, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0058; PierrotDeseilligny E, 2005, CIRCUITRY OF THE HUMAN SPINAL CORD: ITS ROLE IN MOTOR CONTROL AND MOVEMENT DISORDERS, P1, DOI 10.1017/CBO9780511545047; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Rattay F, 2003, NEUROMODULATION, V6, P42, DOI 10.1046/j.1525-1403.2003.03006.x; ROLL JP, 1982, EXP BRAIN RES, V47, P177; ROLL JP, 1989, EXP BRAIN RES, V76, P213; Schiavone G, 2020, ADV MATER, V32, DOI 10.1002/adma.201906512; Schirmer CM, 2011, J NEUROSURG-SPINE, V15, P64, DOI 10.3171/2011.2.SPINE1068; Shokur S, 2021, MED-CAMBRIDGE, V2, P912, DOI 10.1016/j.medj.2021.05.002; Soloukey S, 2021, NEUROMODULATION, V24, P779, DOI 10.1111/ner.13235; Squair JW, 2021, NATURE, V590, DOI 10.1038/s41586-020-03180-w; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325; Woolrich MW, 2004, NEUROIMAGE, V21, P1748, DOI 10.1016/j.neuroimage.2003.12.024; Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931; Yakovenko S, 2002, J NEUROPHYSIOL, V87, P1542, DOI 10.1152/jn.00479.2001	72	35	34	39	83	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					260	+		10.1038/s41591-021-01663-5	http://dx.doi.org/10.1038/s41591-021-01663-5		FEB 2022	41	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35132264				2023-01-03	WOS:000752184200001
J	Jithavech, P; Suwattananuruk, P; Hasriadi, C; Muangnoi, C; Thitikornpong, W; Towiwat, P; Vajragupta, O; Rojsitthisak, P				Jithavech, Ponsiree; Suwattananuruk, Piyapan; Hasriadi, Chawanphat; Muangnoi, Chawanphat; Thitikornpong, Worathat; Towiwat, Pasarapa; Vajragupta, Opa; Rojsitthisak, Pornchai			Physicochemical investigation of a novel curcumin diethyl gamma-aminobutyrate, a carbamate ester prodrug of curcumin with enhanced anti-neuroinflammatory activity	PLOS ONE			English	Article							ACID-CATALYZED HYDROLYSIS; IN-VITRO; SIGNALING PATHWAY; LC-MS/MS; IDENTIFICATION; STABILITY; DELIVERY; PLASMA; STABILIZATION; DISUCCINATE	Curcumin is a polyphenol compound that alleviates several neuroinflammation-related diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy and cerebral injury. However, the therapeutic efficacy of curcumin is limited by its poor physicochemical properties. The present study aimed to develop a new carrier-linked curcumin prodrug, curcumin diethyl gamma-aminobutyrate (CUR-2GE), with improved physicochemical and anti-neuroinflammatory properties. CUR-2GE was designed and synthesized by conjugating curcumin with gamma-aminobutyric acid ethyl ester (GE) via a carbamate linkage. The carbamate linkage was selected to increase stability at acidic pH while GE served as a promoiety for lipophilic enhancement. The synthesized CUR-2GE was investigated for solubility, partition coefficient, stability, and bioconversion. The solubility of CUR-2GE was less than 0.05 mu g/mL similar to that of curcumin, while the lipophilicity with log P of 3.57 was significantly increased. CUR-2GE was resistant to chemical hydrolysis at acidic pH (pH 1.2 and 4.5) as anticipated but rapidly hydrolyzed at pH 6.8 and 7.4. The incomplete hydrolysis of CUR-2GE was observed in simulated gastrointestinal fluids which liberated the intermediate curcumin monoethyl gamma-aminobutyric acid (CUR-1GE) and the parent curcumin. In plasma, CUR-2GE was sequentially converted to CUR-1GE and curcumin within 1 h. In lipopolysaccharide (LPS)-stimulated BV-2 microglial cells, CUR-2GE effectively attenuated the pro-inflammatory mediators by decreasing the secretion of nitric oxide and cytokines (TNF-alpha and IL-6) to a greater extent than curcumin due to an increase in cellular uptake. Altogether, the newly developed acid-stable CUR-2GE prodrug is a potential pre-clinical and clinical candidate for further evaluation on neuroprotective and anti-neuroinflammatory effects.	[Jithavech, Ponsiree; Suwattananuruk, Piyapan; Thitikornpong, Worathat; Towiwat, Pasarapa; Vajragupta, Opa; Rojsitthisak, Pornchai] Chulalongkorn Univ, Ctr Excellence Nat Prod Ageing & Chron Dis, Bangkok, Thailand; [Jithavech, Ponsiree; Thitikornpong, Worathat; Rojsitthisak, Pornchai] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Food & Pharmaceut Chem, Bangkok, Thailand; [Suwattananuruk, Piyapan; Hasriadi, Chawanphat] Chulalongkorn Univ, Fac Pharmaceut Sci, Pharmaceut Sci & Technol Program, Bangkok, Thailand; [Muangnoi, Chawanphat] Mahidol Univ, Inst Nutr, Cell & Anim Model Unit, Nakhon Pathom, Thailand; [Towiwat, Pasarapa] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacol & Physiol, Bangkok, Thailand; [Vajragupta, Opa] Chulalongkorn Univ, Fac Pharmaceut Sci, Res Affairs, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Mahidol University; Chulalongkorn University; Chulalongkorn University	Rojsitthisak, P (corresponding author), Chulalongkorn Univ, Ctr Excellence Nat Prod Ageing & Chron Dis, Bangkok, Thailand.; Rojsitthisak, P (corresponding author), Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Food & Pharmaceut Chem, Bangkok, Thailand.	pornchai.r@chula.ac.th		, Hasriadi/0000-0003-4063-3681; Thitikornpong, Worathat/0000-0002-3537-3646	Thailand Science Research and Innovation (TSRI) Fund, Chulalongkorn University [CU_FRB65_hea (56) _065_33_09]; Ratchadaphiseksomphot Endowment Fund for Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University [GCE 6503433003-1]; Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University	Thailand Science Research and Innovation (TSRI) Fund, Chulalongkorn University; Ratchadaphiseksomphot Endowment Fund for Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University; Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University	This research was supported by Thailand Science Research and Innovation (TSRI)Fund, Chulalongkorn University (CU_FRB65_hea(56)_065_33_09) (to P.R.), Ratchad aphiseksomphot Endowment Fund for Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University (GCE6503433003-1) (to P.R.),and the Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University(to P.J.).The funders had no role in study design, data collection and analysis,	Amrani F, 2015, RSC ADV, V5, P45068, DOI 10.1039/c5ra04251h; Arnott JA, 2012, EXPERT OPIN DRUG DIS, V7, P863, DOI 10.1517/17460441.2012.714363; Azzolini M, 2017, EUR J PHARM BIOPHARM, V115, P149, DOI 10.1016/j.ejpb.2017.02.017; Azzolini M, 2015, MOL PHARMACEUT, V12, P3441, DOI 10.1021/acs.molpharmaceut.5b00464; Bhuket PRN, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04561; Bhuket PRN, 2019, RSC ADV, V9, P4626, DOI 10.1039/c8ra08594c; Bhuket PRN, 2017, EUR J DRUG METAB PH, V42, P341, DOI 10.1007/s13318-016-0377-7; Bhuket PRN, 2016, J CHROMATOGR B, V1033, P301, DOI 10.1016/j.jchromb.2016.08.039; Boonstra E, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01520; Boonyasirisri P, 2015, J NANO RES-SW, V33, P60, DOI 10.4028/www.scientific.net/JNanoR.33.60; Byun JI, 2018, J CLIN NEUROL, V14, P291, DOI 10.3988/jcn.2018.14.3.291; Che PH, 2015, CHEM COMMUN, V51, P1077, DOI 10.1039/c4cc08467e; Chen CR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4028394; Jin CY, 2007, ACTA PHARMACOL SIN, V28, P1645, DOI 10.1111/j.1745-7254.2007.00651.x; Cianciulli A, 2016, INT IMMUNOPHARMACOL, V36, P282, DOI 10.1016/j.intimp.2016.05.007; Ngo DH, 2019, MOLECULES, V24, DOI 10.3390/molecules24152678; Dey A, 2011, J CHEM SCI, V123, P909; DITTERT LW, 1963, J PHARM SCI, V52, P852, DOI 10.1002/jps.2600520908; Fattorini G, 2020, GLIA, V68, P646, DOI 10.1002/glia.23745; Ghosh AK, 2015, J MED CHEM, V58, P2895, DOI 10.1021/jm501371s; Gomez C, 2019, MOLECULES, V24, DOI 10.3390/molecules24071388; Grynkiewicz G, 2012, ACTA BIOCHIM POL, V59, P201; Guzman-Martinez L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01008; Hatton GB, 2015, J PHARM SCI-US, V104, P2747, DOI 10.1002/jps.24365; Heger M, 2014, PHARMACOL REV, V66, P222, DOI 10.1124/pr.110.004044; Hepsomali P, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00923; Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092; Hussain SGM, 2020, J MOL LIQ, V317, DOI 10.1016/j.molliq.2020.113910; ICH, 2020, P INT C HARM ICH TEC, DOI [10.1021/acs.molpharmaceut.9b01062, DOI 10.1021/ACS.MOLPHARMACEUT.9B01062]; Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130; Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334; Jia SL, 2017, J CHROMATOGR A, V1521, P110, DOI 10.1016/j.chroma.2017.09.032; Kawano S, 2013, CHINESE CHEM LETT, V24, P685, DOI 10.1016/j.cclet.2013.05.006; Khan MA, 2015, PHARMACEUTICS, V7, P43, DOI 10.3390/pharmaceutics7020043; Kim MK, 2009, BIOORGAN MED CHEM, V17, P1164, DOI 10.1016/j.bmc.2008.12.043; Kunati SR, 2018, J PHARMACEUT BIOMED, V156, P189, DOI 10.1016/j.jpba.2018.04.034; Kus-Slowinska M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121238; Leng FD, 2021, NAT REV NEUROL, V17, P157, DOI 10.1038/s41582-020-00435-y; Leung MHM, 2009, LANGMUIR, V25, P5773, DOI 10.1021/la804215v; Limcharoen T, 2021, EUR J PHARMACOL, V899, DOI 10.1016/j.ejphar.2021.174008; Luckanagul JA, 2018, CARBOHYD POLYM, V181, P1119, DOI 10.1016/j.carbpol.2017.11.027; Mattarei A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15216; Mattarei A, 2015, MOLECULES, V20, P16085, DOI 10.3390/molecules200916085; MINELLI A, 1995, J NEUROSCI, V15, P7734, DOI 10.1523/jneurosci.15-11-07734.1995; Moraczewski AL, 1998, J ORG CHEM, V63, P7258, DOI 10.1021/jo980644d; Muangnoi C, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080373; Muangnoi C, 2018, BIOSCI BIOTECH BIOCH, V82, P1301, DOI 10.1080/09168451.2018.1462694; Mudie DM, 2010, MOL PHARMACEUT, V7, P1388, DOI 10.1021/mp100149j; Nielsen CU, 2012, EUR J PHARM BIOPHARM, V81, P458, DOI 10.1016/j.ejpb.2012.03.007; Norris GT, 2019, J EXP MED, V216, P60, DOI 10.1084/jem.20180199; OECD, 1995, TEST 107 PART COEFF; Pawar Yogesh B, 2012, Pharmaceutics, V4, P517, DOI 10.3390/pharmaceutics4040517; Po HN, 2001, J CHEM EDUC, V78, P1499, DOI 10.1021/ed078p1499; Pop E, 1999, J PHARM SCI-US, V88, P1156, DOI 10.1021/js990098j; Porro C, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8030051; Rahman SMH, 2009, INDIAN J PHARM SCI, V71, P139, DOI 10.4103/0250-474X.54280; Rakibe U, 2018, J PHARM ANAL, V8, P357, DOI 10.1016/j.jpha.2018.03.001; Rautio J, 2018, NAT REV DRUG DISCOV, V17, P559, DOI 10.1038/nrd.2018.46; Rojsitthisak PW W., 2014, EMERGING ROLE PAIN M, P103; Sar SK, 2007, ASIAN J CHEM, V19, P1358; Sar SK, 2006, J DISPER SCI TECHNOL, V27, P435, DOI 10.1080/01932690500357172; Savjani Ketan T, 2012, ISRN Pharm, V2012, P195727, DOI 10.5402/2012/195727; Sorasitthiyanukarn FN, 2021, CARBOHYD POLYM, V256, DOI 10.1016/j.carbpol.2020.117426; Sundaram JR, 2017, J ALZHEIMERS DIS, V60, P1429, DOI [10.3233/JAD-170093, 10.3233/jad-170093]; Tung Bui Thanh, 2016, Curr Drug Discov Technol, V13, P254; USP, 2015, DESCR SOL; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; WHO, QAS17699 WHO; Wichitnithad W, 2011, J PHARM SCI-US, V100, P5206, DOI 10.1002/jps.22716; Wichitnithad W, 2011, MOLECULES, V16, P1888, DOI 10.3390/molecules16021888; Wongsrisakul J, 2010, J HEALTH RES, V24, P175; Yang YW, 2007, EUR J PHARM BIOPHARM, V66, P260, DOI 10.1016/j.ejpb.2006.11.002; Yoshioka Y, 2010, J PHARMACOL SCI, V113, P153, DOI 10.1254/jphs.10060FP; Yu S, 2016, CELL STRESS CHAPERON, V21, P697, DOI 10.1007/s12192-016-0695-3	74	3	3	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265689	10.1371/journal.pone.0265689	http://dx.doi.org/10.1371/journal.pone.0265689			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0P4VV	35303012	Green Published, gold			2023-01-03	WOS:000784220200024
J	Kaso, AW; Agero, G; Hurissa, Z; Kaso, T; Ewune, HA; Hareru, HE; Hailu, A				Kaso, Abdene Weya; Agero, Gebi; Hurissa, Zewdu; Kaso, Taha; Ewune, Helen Ali; Hareru, Habtamu Endashaw; Hailu, Alemayehu			Survival analysis of COVID-19 patients in Ethiopia: A hospital-based study	PLOS ONE			English	Article							PROGNOSTIC-FACTORS	Background COVID-19 is a global public health problem causing high mortality worldwide. This study aimed to assess time to death and predictors of mortality among patients hospitalized for COVID-19 in the Arsi zone treatment center. Method We performed a retrospective observational cohort study using medical records of laboratory-confirmed COVID-19 cases hospitalized at Bokoji Hospital COVID-19 treatment center from 1st July 2020 to 5th March 2021. We extracted data on the patients' sociodemographic and clinical characteristics from medical records of hospitalized patients retrospectively. We carried out Kaplan Meier and Cox regression analysis to estimate survival probability and investigate predictors of COVID-19 death 5% level of significance. The Adjusted Hazard Ratio (aHR) with 95% Confidence Interval (CI) was estimated and interpreted for predictors of time to death in the final cox model. Result A total of 422 COVID-19 patients treated were analyzed, of these more than one tenth (11.14%) deaths, with a mortality rate of 6.35 cases per 1000 person-days. The majority (87.2%) of deaths occurred within the first 14 days of admission, with a median time-to-death of nine (IQR: 8-12) days. We found patients that age between 31 and 45 years (aHR = 2.55; 95% CI: (1.03, 6.34), older than 46 years (aHR = 2.59 (1.27, 5.30), chronic obstructive pulmonary disease (aHR = 4.60, 95%CI: (2.37, 8.91), Chronic kidney disease (aHR = 5.58, 95%CI: (1.70, 18.37), HIV/AIDS (aHR = 3.66, 95%CI: (1.20, 11.10), admission to the Intensive care unit(aHR = 7.44, 95%CI: (1.82, 30.42), and being on intranasal oxygen care (aHR = 6.27, 95%CI: (2.75, 4.30) were independent risk factors increasing risk of death from COVID-19 disease than their counterparts. Conclusion The risk of dying due to COVID-19 disease was higher among patients with HIV/AIDS, chronic obstructive pulmonary disease, and chronic kidney diseases. We also found that older people, those admitted to ICU, and patients who received intranasal oxygen care had a higher risk of dying due to COVID-19 disease. Therefore, close monitoring hospitalized patients that are old aged and those with comorbidities after hospitalization is crucial within the first ten days of admission.	[Kaso, Abdene Weya; Ewune, Helen Ali; Hareru, Habtamu Endashaw] Dilla Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dilla, Ethiopia; [Agero, Gebi] Arsi Univ, Coll Hlth Sci, Dept Publ Hlth, Assela, Ethiopia; [Hurissa, Zewdu] Arsi Univ, Coll Hlth Sci, Dept Internal Med, Assela, Ethiopia; [Kaso, Taha] Arsi Univ, Coll Hlth Sci, Dept Surg, Assela, Ethiopia; [Hailu, Alemayehu] Univ Bergen, Bergen Ctr Ethics & Prior Setting, Dept Global Publ Hlth & Primary Care, Bergen, Norway	Dilla University; University of Bergen	Agero, G (corresponding author), Arsi Univ, Coll Hlth Sci, Dept Publ Hlth, Assela, Ethiopia.	gebi.agero@yahoo.com		Endashaw Hareru, Habtamu/0000-0002-0591-0893; Hailu, Alemayehu/0000-0003-4872-8036				Abate SM., 2020, B WORLD HEALTH ORGAN; Altonen BL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243343; Alwafi H, 2021, J MULTIDISCIP HEALTH, V14, P839, DOI 10.2147/JMDH.S304788; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], 2020, RISK FACT COVID 19 M; [Anonymous], 2006, 4 D SAMPLE SIZE DETE; Bhandari S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.585850; Boari GEM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20203455; Byeon KH, 2021, INT J INFECT DIS, V105, P588, DOI 10.1016/j.ijid.2021.02.101; CDC A, 2022, AFR UN MEMB STAT REP; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; De Meester J, 2021, J AM SOC NEPHROL, V32, P385, DOI 10.1681/ASN.2020060875; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; ECDC, 2020, RAPID RISK ASSESSMEN; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Federal Democratic Republic of Ethiopia Ministry of Health, 2020, NAT COMPR COVID 19 M; FMOH, 2022, COV 19 DAIL SIT AN R; FMOH, 2021, NAT GUID INT COV 19; Gupta M, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00159-y; Hospital B, 2021, ANN WOR BAS OP PLANN; Hu L, 2020, CLIN INFECT DIS, V71, P2089, DOI 10.1093/cid/ciaa539; Martins PR, 2020, EUR J INTERN MED, V76, P97, DOI 10.1016/j.ejim.2020.04.043; Mi J, 2020, AM J TRANSL RES, V12, P6537; Public Health England, 2020, DISP RISK OUTC COVID; Salinas-Escudero G, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09721-2; Sousa GJB, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001405; Ssentongo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238215; Unhale S.S., 2020, WJPLS, V2020, P109; van Gerwen M, 2021, J MED VIROL, V93, P907, DOI 10.1002/jmv.26337; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; WHO, 2022, WHO COR COVID 19 DAS; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	34	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	5							e0268280	10.1371/journal.pone.0268280	http://dx.doi.org/10.1371/journal.pone.0268280			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6O8LJ	35533178	Green Published, gold			2023-01-03	WOS:000890490400010
J	Lyu, SH; Zhang, CSQ; Zhang, AL; Sun, JB; Xue, CC; Guo, XF				Lyu, Shaohua; Zhang, Claire Shuiqing; Zhang, Anthony Lin; Sun, Jingbo; Xue, Charlie Changli; Guo, Xinfeng			Migraine patients visiting Chinese medicine hospital: Protocol for a prospective, registry-based, real-world observational cohort study	PLOS ONE			English	Article							ANXIETY DISORDER; HEADACHE; PATHOPHYSIOLOGY; EPIDEMIOLOGY; DEPRESSION; GUIDELINES; INSOMNIA; VALIDITY; EVALUATE; QUALITY	Introduction & nbsp;Migraine is a disabling, recurrent headache disorder with complex comorbidities. Conventional treatments for migraine are unsatisfactory, with side effects and limited effectiveness. Chinese herbal medicine (CHM) has been used as an alternative or complementary treatment option for migraine in China. Currently, the existing evidence of benefit of CHM for migraine has been generated from randomised clinical trials using standardised intervention with a focus on internal validity hence with limited external validity. Moreover, CHM individualised intervention design, patients' preferences and concerns, and clinicians' experience are critical to clinical decision making and therapeutic success. This real-world observational study aims to gather practice-based evidence of effects and safety of CHM for migraine in the context of integrating Chinese medicine diagnostic procedures, patients' preferences and matters relevant to clinical decision making.& nbsp;Methods and analysis & nbsp;The study is being undertaken at the Guangdong Provincial Hospital of Chinese Medicine (GPHCM) from December 2020 to May 2022. We anticipate that approximately 400 adult migraineurs will be enrolled and observed on their migraine severity, analgesic consumption, quality of life, anxiety, depression and insomnia at baseline and then every four weeks over 12 weeks. Treatments, diagnostic information, and patient-reported most bothersome symptoms will be collected from patient clinical records. Patient's demographic data, preferences and concerns on CHM treatments will also be gathered at baseline and be analysed. Factors related to clinical outcomes will be explored with multiple correlation and multivariable regression analyses. Effects of CHM will be evaluated using generalised estimated equation, based on clinical outcome data.& nbsp;Discussion & nbsp;This study will provide comprehensive evidence of CHM for migraine in the context of evidence-based practice.	[Lyu, Shaohua; Sun, Jingbo; Xue, Charlie Changli; Guo, Xinfeng] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med & Guangdong Prov, Affiliated Hosp 2, Guangzhou, Peoples R China; [Lyu, Shaohua; Zhang, Claire Shuiqing; Zhang, Anthony Lin; Xue, Charlie Changli] RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia	Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT)	Xue, CC; Guo, XF (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med & Guangdong Prov, Affiliated Hosp 2, Guangzhou, Peoples R China.; Xue, CC (corresponding author), RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia.	charlie.xue@rmit.edu.au; guoxinfeng@gzucm.edu.cn		Guo, Xinfeng/0000-0003-2699-9740; Xue, Charlie/0000-0001-6937-9088	Guangzhou University of Chinese Medicine; High-level University Discipline Collaborative Innovation Team [2021xk84]; China-Australia International Research Centre for Chinese Medicine (CAIRCCM)-a joint initiative of RMIT University, Australia; Guangdong Provincial Academy of Chinese Medical Sciences, China	Guangzhou University of Chinese Medicine; High-level University Discipline Collaborative Innovation Team; China-Australia International Research Centre for Chinese Medicine (CAIRCCM)-a joint initiative of RMIT University, Australia; Guangdong Provincial Academy of Chinese Medical Sciences, China	This study was funded by Guangzhou University of Chinese Medicine "Double First-Class" and High-level University Discipline Collaborative Innovation Team in the form of a grant to JBS (No.2021xk84). The study was also funded by China-Australia International Research Centre for Chinese Medicine (CAIRCCM)-a joint initiative of RMIT University, Australia and the Guangdong Provincial Academy of Chinese Medical Sciences, China in the form of a grant to XFG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AM., 2018, NEUROLOGY, V90; Agrawal R., 1993, SIGMOD Record, V22, P207, DOI 10.1145/170036.170072; Alstadhaug K, 2007, HEADACHE, V47, P1184, DOI 10.1111/j.1526-4610.2007.00858.x; Alston C., 2012, COMMUNICATING PATIEN; Amoozegar F, 2017, INT REV PSYCHIATR, V29, P504, DOI 10.1080/09540261.2017.1326882; [Anonymous], GUANGDONG HOSP TRADI; [Anonymous], 2018, SIGN 155 PHARM MANAG; Ashina M, 2021, LANCET, V397, P1505, DOI 10.1016/S0140-6736(20)32342-4; Baghyahi SBA., 2013, EUR PSYCHIAT, V28, P1; Bigal ME, 2008, HEADACHE, V48, P1157, DOI 10.1111/j.1526-4610.2008.01217.x; Black N, 1996, BRIT MED J, V312, P1215; Camm AJ, 2018, OPEN HEART, V5, DOI 10.1136/openhrt-2018-000788; Cao H., 2004, BASIC THEORY TRADITI; Cao KG, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1321-8; Cephalalgia group Pain-Relieving Branch Chinese Medical Association, 2016, CHINESE J PAIN MED, V22; Clark M, 2017, HEADACHE, V57, P133; Dawes Martin, 2005, BMC Med Educ, V5, P1; Diener HC, 2016, NAT REV NEUROL, V12, P575, DOI 10.1038/nrneurol.2016.124; Fu CH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/967968; Gliklich RE, 2014, REGISTRIES EVALUATIN; Guo X., 2020, J HUN UNICHIN MED, V40, P440; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Ha H, 2019, AM FAM PHYSICIAN, V99, P17; Harden RN, 2005, J PAIN, V6, P364, DOI 10.1016/j.jpain.2005.01.350; Khattri Jai Bahadur, 2020, J Nepal Health Res Counc, V18, P82, DOI 10.33314/jnhrc.v18i1.2202; Kim J, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0756-8; Kip KE, 2001, J CLIN EPIDEMIOL, V54, P482, DOI 10.1016/S0895-4356(00)00310-3; Kozak HH, 2017, ACTA NEUROL BELG, V117, P111, DOI 10.1007/s13760-016-0723-1; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Li JH, 2015, COMPLEMENT THER MED, V23, P577, DOI 10.1016/j.ctim.2015.06.012; Lipton RB, 2013, HEADACHE, V53, P1300, DOI 10.1111/head.12154; Liu HW, 2018, CHIN J INTEGR MED, V24, P409, DOI 10.1007/s11655-017-2547-5; Liu Y., 2019, J EMERG TRADIT CHIN, V28, P1147; Liu Y., 2020, J EMERG TRADIT CHIN, V29, P46; Lu PH, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/6649331; Lu PH, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/8854772; Lyu SH, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/5181587; Martin BC, 2000, HEADACHE, V40, P204, DOI 10.1046/j.1526-4610.2000.00030.x; Mehta P, 2016, INVEST OPHTH VIS SCI, V57; Minen MT, 2016, J NEUROL NEUROSUR PS, V87, P741, DOI 10.1136/jnnp-2015-312233; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Oedegaard KJ, 2006, CEPHALALGIA, V26, P1, DOI 10.1111/j.1468-2982.2005.00974.x; Preedy VR., 2010, HDB DIS BURDENS QUAL; Probyn K, 2017, NEUROLOGY, V89, P291, DOI 10.1212/WNL.0000000000004112; Rains JC, 2018, HEADACHE, V58, P1074, DOI 10.1111/head.13357; Shan CS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00589; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Tassorelli C, 2018, CEPHALALGIA, V38, P815, DOI 10.1177/0333102418758283; Tfelt-Hansen P, 2012, CEPHALALGIA, V32, P6, DOI 10.1177/0333102411417901; Torta R, 2012, NEUROL SCI, V33, pS117, DOI 10.1007/s10072-012-1055-4; Vetvik KG, 2017, LANCET NEUROL, V16, P76, DOI 10.1016/S1474-4422(16)30293-9; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wang Y., 2021, J PRACT CHIN MED INT, V35, P112, DOI DOI 10.13729/J.ISSN.1671-7813.Z20200604; Yang YH, 2016, CEPHALALGIA, V36, P679, DOI 10.1177/0333102416638520; Yao CY, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1048-2; You X, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1907848; Young NP, 2019, HEADACHE, V59, P1042, DOI 10.1111/head.13543; Yu SY, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01117-2; Yu SY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2775-2; Yu SY, 2019, J ALTERN COMPLEM MED, V25, P1215, DOI 10.1089/acm.2018.0500; Zhao Y., 2019, WORL J INTEGR TRADIT, V14; Zhou L, 2013, AM J CHINESE MED, V41, P1011, DOI 10.1142/S0192415X13500687	64	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0265137	10.1371/journal.pone.0265137	http://dx.doi.org/10.1371/journal.pone.0265137			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3VR	35290411	gold, Green Published			2023-01-03	WOS:000799901400011
J	Miller, AE; Russell, E; Reisman, DS; Kim, HE; Dinh, V				Miller, Allison E.; Russell, Emily; Reisman, Darcy S.; Kim, Hyosub E.; Dinh, Vu			A machine learning approach to identifying important features for achieving step thresholds in individuals with chronic stroke	PLOS ONE			English	Article							COMMUNITY WALKING ACTIVITY; PHYSICAL-ACTIVITY; AMBULATORY ACTIVITY; PREDICTING HOME; SELF-EFFICACY; PEOPLE; PERFORMANCE; SPEED; ACCELEROMETER; POSTSTROKE	Background While many factors are associated with stepping activity after stroke, there is significant variability across studies. One potential reason to explain this variability is that there are certain characteristics that are necessary to achieve greater stepping activity that differ from others that may need to be targeted to improve stepping activity. Objective Using two step thresholds (2500 steps/day, corresponding to home vs. community ambulation and 5500 steps/day, corresponding to achieving physical activity guidelines through walking), we applied 3 different algorithms to determine which predictors are most important to achieve these thresholds. Methods We analyzed data from 268 participants with stroke that included 25 demographic, performance-based and self-report variables. Step 1 of our analysis involved dimensionality reduction using lasso regularization. Step 2 applied drop column feature importance to compute the mean importance of each variable. We then assessed which predictors were important to all 3 mathematically unique algorithms. Results The number of relevant predictors was reduced from 25 to 7 for home vs. community and from 25 to 16 for aerobic thresholds. Drop column feature importance revealed that 6 Minute Walk Test and speed modulation were the only variables found to be important to all 3 algorithms (primary characteristics) for each respective threshold. Other variables related to readiness to change activity behavior and physical health, among others, were found to be important to one or two algorithms (ancillary characteristics). Conclusions Addressing physical capacity is necessary but not sufficientto achieve important step thresholds, as ancillary characteristics, such as readiness to change activity behavior and physical health may also need to be targeted. This delineation may explain heterogeneity across studies examining predictors of stepping activity in stroke.	[Miller, Allison E.; Reisman, Darcy S.; Kim, Hyosub E.] Univ Delaware, Dept Biomech & Movement Sci Program, Newark, DE 19716 USA; [Russell, Emily; Dinh, Vu] Univ Delaware, Dept Math Sci, Newark, DE USA; [Reisman, Darcy S.; Kim, Hyosub E.] Univ Delaware, Dept Phys Therapy, Newark, DE USA	University of Delaware; University of Delaware; University of Delaware	Miller, AE (corresponding author), Univ Delaware, Dept Biomech & Movement Sci Program, Newark, DE 19716 USA.	amillers@udel.edu		Miller, Allison/0000-0003-3043-6852; Kim, Hyosub/0000-0003-0109-593X	National Institutes of Health [1R01HD086362-01A1, K12 HD055931]; Foundation for Physical Therapy Research; Promotion of Doctoral Studies II Scholarship; National Science Foundation [1934650, DMS-1951474]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for Physical Therapy Research; Promotion of Doctoral Studies II Scholarship; National Science Foundation(National Science Foundation (NSF))	This work was supported by the National Institutes of Health [1R01HD086362-01A1 (DSR), K12 HD055931 (HEK)]; the Foundation for Physical Therapy Research [Florence P. Kendall Doctoral Scholarship, Promotion of Doctoral Studies I Scholarship, Promotion of Doctoral Studies II Scholarship (AM)]; and the National Science Foundation [M3X award 1934650 (HEK), award DMS-1951474 (VD)]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguiar LT, 2020, DISABIL REHABIL, V42, P902, DOI 10.1080/09638288.2018.1511755; Andrews AW, 2010, J GERIATR PHYS THER, V33, P128, DOI 10.1097/JPT.0b013e3181eda321; Barclay R, 2015, CLIN REHABIL, V29, P509, DOI 10.1177/0269215514546769; Bell EJ, 2013, MED SCI SPORT EXER, V45, P901, DOI 10.1249/MSS.0b013e31827d87ec; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Bohannon R W, 1991, Int J Rehabil Res, V14, P246, DOI 10.1097/00004356-199109000-00010; Bowden MG, 2008, NEUROREHAB NEURAL RE, V22, P672, DOI 10.1177/1545968308318837; Brick TR, 2018, J GERONTOL B-PSYCHOL, V73, P113, DOI 10.1093/geronb/gbx008; Chen C., 2004, USING RANDOM FOREST; Danks KA, 2016, J NEUROL PHYS THER, V40, P232, DOI 10.1097/NPT.0000000000000143; de Man-van Ginkel JM, 2012, NURS RES, V61, P333, DOI 10.1097/NNR.0b013e31825d9e9e; Durcan S, 2016, DISABIL REHABIL, V38, P245, DOI 10.3109/09638288.2015.1035460; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Ezekiel L, 2019, ARCH PHYS MED REHAB, V100, P945, DOI 10.1016/j.apmr.2018.06.017; Fini NA, 2017, PHYS THER, V97, P707, DOI 10.1093/ptj/pzx038; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; French MA, 2016, TOP STROKE REHABIL, V23, P77, DOI 10.1080/10749357.2015.1110306; Fulk GD, 2017, STROKE, V48, P406, DOI 10.1161/STROKEAHA.116.015309; Fulk GD, 2014, PHYS THER, V94, P222, DOI 10.2522/ptj.20120525; Fulk GD, 2010, ARCH PHYS MED REHAB, V91, P1582, DOI 10.1016/j.apmr.2010.07.005; Handlery R, 2020, PHYS THER, V100, P807, DOI 10.1093/ptj/pzaa020; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holleran CL, 2020, J NEUROL PHYS THER, V44, P241, DOI 10.1097/NPT.0000000000000327; Hui J, 2018, PHYSIOTHER CAN, V70, P81, DOI 10.3138/ptc.2016-40.ep; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Klassen TD, 2017, STROKE, V48, P2614, DOI 10.1161/STROKEAHA.117.018175; Klassen TD, 2016, PHYS THER, V96, P355, DOI 10.2522/ptj.20140611; Krawczyk B, 2016, PROG ARTIF INTELL, V5, P221, DOI 10.1007/s13748-016-0094-0; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Lin CH, 2020, COMPUT METH PROG BIO, V190, DOI 10.1016/j.cmpb.2020.105381; Loprinzi PD, 2018, AM J HEALTH PROMOT, V32, P24, DOI 10.1177/0890117117720061; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Middleton A, 2016, AM J PHYS MED REHAB, V95, P475, DOI 10.1097/PHM.0000000000000488; Middleton A, 2016, J AGING PHYS ACTIV, V24, P214, DOI 10.1123/japa.2015-0104; Miller A, 2021, J NEUROL PHYS THER, V45, P28, DOI 10.1097/NPT.0000000000000345; Miller A, 2021, TOP STROKE REHABIL, V28, P161, DOI 10.1080/10749357.2020.1803571; Mulder M, 2019, ARCH PHYS MED REHAB, V100, P2113, DOI 10.1016/j.apmr.2019.04.017; Narayanan A, 2020, J PHYS ACT HEALTH, V17, P360, DOI 10.1123/jpah.2019-0088; Olsony RS, 2018, BIOCOMPUT-PAC SYM, P192; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pendlebury ST, 2012, STROKE, V43, P464, DOI 10.1161/STROKEAHA.111.633586; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Robinson CA, 2013, PHYS THER, V93, P620, DOI 10.2522/ptj.20110217; Rosenkranz RR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2539-y; Saint-Maurice PF, 2020, JAMA-J AM MED ASSOC, V323, P1151, DOI 10.1001/jama.2020.1382; Salbach NM, 2006, ARCH PHYS MED REHAB, V87, P1597, DOI 10.1016/j.apmr.2006.08.336; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; Stinear CM, 2017, ANN CLIN TRANSL NEUR, V4, P811, DOI 10.1002/acn3.488; Tessier A, 2008, ARCH PHYS MED REHAB, V89, P1276, DOI 10.1016/j.apmr.2007.11.049; Thilarajah S, 2018, ARCH PHYS MED REHAB, V99, P1876, DOI 10.1016/j.apmr.2017.09.117; Tozlu C, 2020, NEUROREHAB NEURAL RE, V34, P428, DOI 10.1177/1545968320909796; Tudor-Locke C, 2005, PREV MED, V40, P293, DOI 10.1016/j.ypmed.2004.06.003; Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-80; Willey JZ, 2017, INT J STROKE, V12, P197, DOI 10.1177/1747493016676614; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wright H, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1044-1	58	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0270105	10.1371/journal.pone.0270105	http://dx.doi.org/10.1371/journal.pone.0270105			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D4TG	35714133	gold, Green Submitted, Green Published			2023-01-03	WOS:000829295700024
J	Mwase-Musicha, L; Chipeta, MG; Stephenson, J; Hall, JA				Mwase-Musicha, Loveness; Chipeta, Michael G.; Stephenson, Judith; Hall, Jennifer A.			How do women prepare for pregnancy in a low-income setting? Prevalence and associated factors	PLOS ONE			English	Article							SYSTEMATIC ANALYSIS; MORTALITY	BackgroundDespite growing evidence of pregnancy preparation benefits, there is little knowledge on how women in developing countries prepare for pregnancy and factors influencing their preparedness for pregnancy. Here, we determine how women in Malawi prepare for pregnancy and factors associated with pregnancy preparation. MethodsWe used data from a previous cohort study comprising 4,244 pregnant mothers, recruited between March and December 2013 in Mchinji district, Malawi. Associations of pregnancy preparation with socio-demographic and obstetric factors were tested for using mixed effects ordinal regression, with the likelihood ratio and Wald's tests used for variable selection and independently testing the associations. ResultsMost mothers (63.9%) did not take any action to prepare for their pregnancies. For those who did (36.1%), eating more healthily (71.9%) and saving money (42.8%) were the most common forms of preparation. Mothers who were married (adjusted odds-ratio (AOR 7.77 (95% CI [5.31, 11.25]) or with no or fewer living children were more likely to prepare for pregnancy (AOR 4.71, 95% CI [2.89,7.61]. Mothers with a period of two to three years (AOR 2.51, 95% CI [1.47, 4.22]) or at least three years (AOR 3.67, 95%CI [2.18, 6.23]) between pregnancies were more likely to prepare for pregnancy than women with first pregnancy or shorter intervals. On the other hand, teenage and older (>= 35 years old) mothers were less likely to prepare for pregnancy (AOR 0.61, 95%CI [0.47, 0.80]) and AOR 0.49 95%CI [0.33, 0.73], respectively). ConclusionWhile preconception care may not be formally available in Malawi, our study has revealed that over a third of mothers took some action to prepare for pregnancy before conception. Although this leaves around two thirds of women who did not make any form of pregnancy preparation, our findings form a basis for future research and development of a preconception care package that suits the Malawian context.	[Mwase-Musicha, Loveness; Stephenson, Judith; Hall, Jennifer A.] UCL, EGA Inst Womens Hlth, London, England; [Mwase-Musicha, Loveness] Minist Hlth, Lilongwe, Malawi; [Chipeta, Michael G.] Univ Oxford, Big Data Inst, Oxford, England	University of London; University College London; University of Oxford	Mwase-Musicha, L; Hall, JA (corresponding author), UCL, EGA Inst Womens Hlth, London, England.; Mwase-Musicha, L (corresponding author), Minist Hlth, Lilongwe, Malawi.	lovemwanji@yahoo.com; jennifer.hall@ucl.ac.uk			Wellcome Trust Research Training Fellowship Award [097268/Z/11/Z]; Commonwealth Scholarship	Wellcome Trust Research Training Fellowship Award; Commonwealth Scholarship	The original cohort study was funded by a Wellcome Trust Research Training Fellowship Award to JAH (award number 097268/Z/11/Z). LMM was supported by a Commonwealth Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akombi BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177338; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Asiki G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0708-8; Bannink F, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.90.5338; Barrett G, 2004, J EPIDEMIOL COMMUN H, V58, P426, DOI 10.1136/jech.2003.014787; Dean S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001508; Dean SV, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S3-S2; Denktas S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-253; Dwyer-Lindgren L, 2019, NATURE, V570, P189, DOI 10.1038/s41586-019-1200-9; Hall JA., 2021, BMC RES NOTES, V14, P1; Hall J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-200; Hall JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165621; Hemsing N, 2017, SEX REPROD HEALTHC, V14, P24, DOI 10.1016/j.srhc.2017.08.004; Ignaszak-Kaus N, 2018, GINEKOL POL, V89, P74, DOI 10.5603/GP.a2018.0013; Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Londero AP, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2400-x; Ministry of Health (MOH), 2017, MALAWI HLTH SECTOR S; Munasinghe Sujeevani, 2006, Malawi Med J, V18, P160; National Statistical Office The DHS Program ICF, 2017, MAL DEM HLTH SURV 20, P1; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Thindwa D., 2019, PLOS ONE; Toivonen KI, 2017, PREV MED, V96, P1, DOI 10.1016/j.ypmed.2016.11.022; UNICEF, 2020, MAT NEWB HLTH COV DA; van den Broek NR, 2000, BRIT J OBSTET GYNAEC, V107, P445; Wado YD, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2204-z; World Health, 2012, M DEV GLOB CONS PREC, P78; World Health Organization, 2012, GLOB REG EST VIOL WO; Yeatman S, 2018, STUD FAMILY PLANN, V49, P213, DOI 10.1111/sifp.12060; Zuhlke L, 2016, CARDIOVASC J AFR, V27, P79, DOI 10.5830/CVJA-2016-017	30	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	3							e0263877	10.1371/journal.pone.0263877	http://dx.doi.org/10.1371/journal.pone.0263877			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1M3NO	35286337	gold, Green Published			2023-01-03	WOS:000799880200004
J	Kuehn, BM				Kuehn, Bridget M.			Medical Groups Defend Patient-Physician Relationship and Access to Adolescent Gender-Affirming Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2022	327	15					1432	1432						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	1C3PR	35353160				2023-01-03	WOS:000793035800007
J	Kuehn, BM				Kuehn, Bridget M.			Medical Groups Defend Patient-Physician Relationship and Access to Adolescent Gender-Affirming Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item; Early Access								This Medical News article discusses physicians' advocacy to protect patients and the patient-physician relationship amid efforts by politicians to limit access or criminalize gender-affirming care.											0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.4617	http://dx.doi.org/10.1001/jama.2022.4617		MAR 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0E9DJ	35353160				2023-01-03	WOS:000776972600002
J	Rubin, R				Rubin, Rita			Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	7	7	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2022	327	23					2281	2281		10.1001/jama.2022.9847	http://dx.doi.org/10.1001/jama.2022.9847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L3ZC	35727289				2023-01-03	WOS:000816956000005
J	Munoz-Vergara, D; Grabowska, W; Yeh, GY; Khalsa, SB; Schreiber, KL; Huang, CA; Zavacki, AM; Wayne, PM				Munoz-Vergara, Dennis; Grabowska, Weronika; Yeh, Gloria Y.; Khalsa, Sat Bir; Schreiber, Kristin L.; Huang, Christene A.; Zavacki, Ann Marie; Wayne, Peter M.			A systematic review of in vivo stretching regimens on inflammation and its relevance to translational yoga research	PLOS ONE			English	Review							SKELETAL-MUSCLE; MECHANICAL HYPERALGESIA; CONTRACTIONS; STRESS; INJURY; EXERCISE; RATS; INDIVIDUALS; PERFORMANCE; ADAPTATION	Objective To conduct a systematic review evaluating the impact of stretching on inflammation and its resolution using in vivo rodent models. Findings are evaluated for their potential to inform the design of clinical yoga studies to assess the impact of yogic stretching on inflammation and health. Methods Studies were identified using four databases. Eligible publications included English original peer-reviewed articles between 1900-May 2020. Studies included those investigating the effect of different stretching techniques administered to a whole rodent model and evaluating at least one inflammatory outcome. Studies stretching the musculoskeletal and integumentary systems were considered. Two reviewers removed duplicates, screened abstracts, conducted full-text reviews, and assessed methodological quality. Results Of 766 studies identified, 25 were included for synthesis. Seven (28%) studies had a high risk of bias in 3 out of 10 criteria. Experimental stretching protocols resulted in a continuum of inflammatory responses with therapeutic and injurious effects, which varied with a combination of three stretching parameters-duration, frequency, and intensity. Relative to injurious stretching, therapeutic stretching featured longer-term stretching protocols. Evidence of pro- and mixed-inflammatory effects of stretching was found in 16 muscle studies. Evidence of pro-, anti-, and mixed-inflammatory effects was found in nine longer-term stretching studies of the integumentary system. Conclusion Despite the overall high quality of these summarized studies, evaluation of stretching protocols paralleling yogic stretching is limited. Both injurious and therapeutic stretching induce aspects of inflammatory responses that varied among the different stretching protocols. Inflammatory markers, such as cytokines, are potential outcomes to consider in clinical yoga studies. Future translational research evaluating therapeutic benefits should consider in vitro studies, active vs. passive stretching, shorter-term vs. longer-term interventions, systemic vs. local effects of stretching, animal models resembling human anatomy, control and estimation of non-specific stresses, development of in vivo self-stretching paradigms targeting myofascial tissues, and in vivo models accounting for gross musculoskeletal posture.	[Munoz-Vergara, Dennis; Grabowska, Weronika; Wayne, Peter M.] Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; [Munoz-Vergara, Dennis; Yeh, Gloria Y.; Khalsa, Sat Bir; Wayne, Peter M.] Harvard Med Sch, Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02115 USA; [Yeh, Gloria Y.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02115 USA; [Khalsa, Sat Bir] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Schreiber, Kristin L.] Brigham & Womens Hosp, Harvard Med Sch, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Huang, Christene A.] Univ Colorado, Sch Med, Dept Surg, Denver, CO USA; [Zavacki, Ann Marie] Harvard Med Sch, Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Munoz-Vergara, D (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.; Munoz-Vergara, D (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02115 USA.	dmunozvergara@bwh.harvard.edu	Munoz-Vergara, Dennis/GXM-3268-2022	Grabowska, Weronika/0000-0001-9338-1188	National Center for Complementary and Integrative Health (NCCIH) [T32 AT00051]; NCCIH [K24AT009465, K24AT009282]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK044128]	National Center for Complementary and Integrative Health (NCCIH); NCCIH; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Financial support for the work was provided by grant T32 AT00051 from the National Center for Complementary and Integrative Health (NCCIH) to DMV, grant K24AT009282 from NCCIH to PMW, and grant R01DK044128 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to AMZ, grant K24AT009465 from NCCIH to GYY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. T32AT00051-https://www.nccih.nih.gov K24AT009282-https://www.nccih.nih.gov K24AT009465-https://www.nccih.nih.gov R01DK044128-https://www.niddk.nih.gov.	Alter MJ, 2004, SCI FLEXIBILITY; [Anonymous], 2010, YOGA BODY ORIGINS MO; Apostolopoulos N, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01128; Arendt-Nielsen L, 2011, BEST PRACT RES CL RH, V25, P209, DOI 10.1016/j.berh.2010.01.013; Baker BA, 2006, MED SCI SPORT EXER, V38, P463, DOI 10.1249/01.mss.0000191419.67030.69; Baker BA, 2007, MED SCI SPORT EXER, V39, P1275, DOI 10.1249/mss.0b013e3180686dc7; Baker BA, 2006, APPL PHYSIOL NUTR ME, V31, P167, DOI 10.1139/H05-009; Baker BA, 2008, APPL PHYSIOL NUTR ME, V33, P1181, DOI 10.1139/H08-110; Berrueta L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35364-w; Berrueta L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26198-7; Berrueta L, 2016, J CELL PHYSIOL, V231, P1621, DOI 10.1002/jcp.25263; Bishop JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147393; Bower JE, 2016, BRAIN BEHAV IMMUN, V51, P1, DOI 10.1016/j.bbi.2015.06.012; Brickson SL, 2014, BMC SPORTS SCI MED R, V6, DOI 10.1186/2052-1847-6-14; Chang Douglas G, 2016, J Orthop Rheumatol, V3, P1; Chen CH, 2011, MED SCI SPORT EXER, V43, P491, DOI 10.1249/MSS.0b013e3181f315ad; Chen N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5387258; Chu SY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09402-8; Clarke Tainya C, 2018, NCHS Data Brief, P1; Coleman K, 2013, ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE, P75, DOI 10.1016/B978-0-12-415894-8.00004-X; Corey SM, 2014, PSYCHONEUROENDOCRINO, V49, P260, DOI 10.1016/j.psyneuen.2014.07.012; Corey SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029831; Cramer H, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2612-7; Cramer H, 2015, AM J EPIDEMIOL, V182, P281, DOI 10.1093/aje/kwv071; Cramer H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075515; Cramer H, 2013, CLIN J PAIN, V29, P216, DOI 10.1097/AJP.0b013e318251026c; Cutlip RG, 2006, APPL PHYSIOL NUTR ME, V31, P573, DOI 10.1139/H06-033; Danhauer SC, 2019, CANCER-AM CANCER SOC, V125, P1979, DOI 10.1002/cncr.31979; de Vries RBM., 2015, EVID BASED PRECLIN M, V2, DOI [10.1002/ebm2.7, DOI 10.1002/EBM2.7]; Dessem D, 2010, PAIN, V149, P284, DOI 10.1016/j.pain.2010.02.022; DOUGLAS WR, 1972, SPACE LIFE SCI, V3, P226, DOI 10.1007/BF00928167; Ellenbroek B, 2016, DIS MODEL MECH, V9, P1079, DOI 10.1242/dmm.026120; Ellis R, 2018, J ULTRAS MED, V37, P2091, DOI 10.1002/jum.14560; Falkenberg RI, 2018, J BEHAV MED, V41, P467, DOI 10.1007/s10865-018-9914-y; Field T, 2016, COMPLEMENT THER CLIN, V24, P145, DOI 10.1016/j.ctcp.2016.06.005; Forn-Cuni G, 2017, SCI REP-UK, V7, DOI 10.1038/srep41905; Garcia TA, 2018, TISSUE CELL, V54, P120, DOI 10.1016/j.tice.2018.08.014; Geronilla KB, 2003, EUR J APPL PHYSIOL, V90, P144, DOI 10.1007/s00421-003-0849-8; Gluck MJ, 2018, J NEUROSCI METH, V303, P68, DOI 10.1016/j.jneumeth.2018.02.006; Gomarasca M, 2020, ADV CLIN CHEM, V94, P155, DOI 10.1016/bs.acc.2019.07.010; Grenier S., 2014, INT J PHYS MED REHAB, V02; Harkess KN, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.234; Hayashi K, 2017, EUR J PAIN, V21, P125, DOI 10.1002/ejp.909; Hirata K, 2020, MED SCI SPORT EXER, V52, P2179, DOI 10.1249/MSS.0000000000002360; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Hunt M, 2018, MINDFULNESS, V9, P512, DOI 10.1007/s12671-017-0793-z; Inami T., 2014, AM J SPORTS SCI MED, V2, P166; Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860; Kiecolt-Glaser JK, 2010, PSYCHOSOM MED, V72, P113, DOI 10.1097/PSY.0b013e3181cb9377; Kjaer M, 2006, J ANAT, V208, P445, DOI 10.1111/j.1469-7580.2006.00549.x; Knudson D., 2006, J EXERC SCI PHYSIOTH, V2, P3; Konrad A, 2014, CLIN BIOMECH, V29, P636, DOI 10.1016/j.clinbiomech.2014.04.013; Kurien BT, 2015, METHODS MOL BIOL, V1312, P17, DOI 10.1007/978-1-4939-2694-7_5; Langevin HM, 2018, AM J PHYS MED REHAB, V97, P187, DOI 10.1097/PHM.0000000000000824; Li FH, 2018, EXP GERONTOL, V113, P150, DOI 10.1016/j.exger.2018.10.006; Long R., 2006, KEY MUSCLES YOGA YOU, V3rd ed; Mao JR, 2002, PAIN, V97, P183, DOI 10.1016/S0304-3959(02)00109-4; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Mishra M, 2017, EXPERT REV PROTEOMIC, V14, P1037, DOI 10.1080/14789450.2017.1388167; Mousavi Hondori Hossein, 2014, J Med Eng, V2014, P846514, DOI 10.1155/2014/846514; Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009; Oh S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41480-y; Ozaki G, 2015, INT J MORPHOL, V33, P908, DOI 10.4067/S0717-95022015000300017; Pablos A, 2020, INT J MED SCI, V17, P71, DOI 10.7150/ijms.37981; Pascoe MC, 2015, J PSYCHIATR RES, V68, P270, DOI 10.1016/j.jpsychires.2015.07.013; Patel Shruti R, 2021, Glob Adv Health Med, V10, p2164956120984140, DOI 10.1177/2164956120984140; Pizza FX, 2002, J APPL PHYSIOL, V92, P1873, DOI 10.1152/japplphysiol.01055.2001; Qiao P, 2019, J INVEST DERMATOL, V139, P1470, DOI 10.1016/j.jid.2018.12.019; Rader EP, 2017, EXERC SPORT SCI REV, V45, P195, DOI 10.1249/JES.0000000000000123; Rader EP, 2015, EXP GERONTOL, V72, P138, DOI 10.1016/j.exger.2015.09.020; Ramos L, 2018, PHOTOMED LASER SURG, V36, P460, DOI 10.1089/pho.2018.4473; Rao Raghavendra M, 2008, Int J Yoga, V1, P11, DOI [10.4103/0973-6131.36795, 10.4103/0973-6131.36789]; Riley DA, 2012, PHYS MED REH CLIN N, V23, P51, DOI 10.1016/j.pmr.2011.11.006; Robison LS, 2018, PHYSIOL BEHAV, V194, P218, DOI 10.1016/j.physbeh.2018.06.002; Saper RB, 2017, ANN INTERN MED, V167, P85, DOI 10.7326/M16-2579; Shan SZ, 2017, MOL MED REP, V16, P4643, DOI 10.3892/mmr.2017.7209; Sherman KJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/143271; Sikdar S, 2014, EXERC SPORT SCI REV, V42, P126, DOI 10.1249/JES.0000000000000015; Smith CA, 2007, J APPL PHYSIOL, V102, P755, DOI 10.1152/japplphysiol.01503.2005; Sudo M, 2009, J PHYSIOL SCI, V59, P405, DOI 10.1007/s12576-009-0049-3; Telles S, 2021, COMPLEMENT THER MED, V57, DOI 10.1016/j.ctim.2020.102644; Uebelacker LA, 2017, COMPLEMENT THER MED, V34, P149, DOI 10.1016/j.ctim.2017.06.008; Vergara DM, 2020, AM J PHYS MED REHAB, V99, P1012, DOI 10.1097/PHM.0000000000001465; Vogt M, 2014, J APPL PHYSIOL, V116, P1446, DOI 10.1152/japplphysiol.00146.2013; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Weerapong P., 2004, PHYS THER REV, V9, P189, DOI [DOI 10.1179/108331904225007078, 10.1179/108331904225007078]; Wong VW, 2011, FASEB J, V25, P4498, DOI 10.1096/fj.10-178087; Wu WT, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/950519; Xia S, 2019, J MATER CHEM B, V7, P4638, DOI 10.1039/c9tb01039d; Xiong Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00124; Zhang YT, 2017, HONG KONG J OCCUP TH, V29, P1, DOI 10.1016/j.hkjot.2016.11.001; Zhou SB, 2013, STEM CELLS, V31, P2703, DOI 10.1002/stem.1479	93	0	0	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	6							e0269300	10.1371/journal.pone.0269300	http://dx.doi.org/10.1371/journal.pone.0269300			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Y2OK	36584117	Green Published, gold			2023-01-03	WOS:000843567600040
J	Rubin, R				Rubin, Rita			NewTest to Help Diagnose Alzheimer Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	7	7	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2022	327	23					2281	2281						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2L3ZC	35727289				2023-01-03	WOS:000816956000029
